PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Zeiger, RS; Dawson, C; Weiss, S				Zeiger, RS; Dawson, C; Weiss, S		Childhood Asthma Management Program Res Grp	Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma duration; asthma severity; lung function; asthma symptoms and medications; atopy; sex; IgE; skin prick tests; eosinophils	BRONCHIAL BIOPSY SPECIMENS; LOWER RESPIRATORY ILLNESS; LUNG-FUNCTION; PULMONARY-FUNCTION; INHALED CORTICOSTEROIDS; YOUNG-ADULTS; FOLLOW-UP; ATOPY; AGE; HYPERRESPONSIVENESS	Background: Many factors, including heredity, atopic status, and environment, have been implicated in the determination of asthma severity, Relatively little is known about the degree to which asthma duration influences asthma severity. Objective: The Childhood Asthma Management Program (CAMP), consisting of 1041 children (age 8.9 +/- 2.1 years at enrollment) with mild-to-moderate asthma, offers an opportunity to examine the relationship between asthma duration and asthma severity. Methods: By using the extensive CAMP baseline cross-sectional data on asthma duration, spirometry, bronchial responsiveness, symptomatology and markers of atopy, univariate and multivariate regression models were used to evaluate whether asthma duration is associated with asthma severity, Results: Duration of asthma in the study cohort from time of diagnosis until randomization into CAMP ranged from 0.3 to 12.1 years (mean, 5.0; SD, 2.7; median,4.8). Asthma duration is associated in univariate analyses both with lower levels of several lung functions (P<.001), including methacholine bronchial reactivity (natural log [In] FEV1PC20, mg/mL; r = -0.112), prebronchodilator and postbronchodilator percent predicted FEV1 (r= -0.176 and r = -0.130, respectively), and prebronchodilator and postbronchodilator FEV1/forced vital capacity (FVC) (%) (r = -0.237 and r= -0.211, respectively), as well as higher levels of symptoms (symptom scare: r = 0.117, P <.001) and borderline greater use of albuterol fur symptoms (r= 0.058, P =.064) during a 28-day screening period before randomization. Simple linear regression detected the following differences in lung functions per gear of asthma duration: In FEV1PC20, -0.050 mg/mL/y; prebronchodilator FEV1-0.907 percent predicted/y; and prebronchodilator FEV1/FVC, -0.729 percent predicted/y. After controlling for potential explanatory variably (atopy, Inflammatory markers, household Der p 1 levels, anti-inflammatory medication use, and clinical center), regression models revealed that the duration of asthma remained significantly and independently associated with In FEV1PC20 (P =.004) prebronchodilator percent predicted FEV1 (P =.043), and prebronchodilator and postbronchodilator FEV1/FVC (%) (P <.001), as well as being positively associated with mean daily symptom score (P <.001) and albuterol use for symptoms (P=.003) during a 28-day screening period. Duration was also found to be significantly associated with physician/nurse assessment of asthma severity and other historical measures-of medication use. Conclusions: These data demonstrate that asthma duration is associated with loner lung function, greater methacholine responsiveness, more asthma symptomatology, and greater use of as-needed albuterol, which are all measures of asthma severity As such, early diagnosis and intervention mag be necessary to ameliorate these adverse effects of persistent asthma.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; Johns Hopkins Sch Hyg & Publ Hlth, Baltimore, MD USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Kaiser Permanente; University of California System; University of California San Diego; Johns Hopkins University; Harvard University; Brigham & Women's Hospital	Zeiger, RS (corresponding author), Johns Hopkins Ctr Clin Trials, CAMP Coordinating Ctr, 615 N Wolfe St,Room 5010, Baltimore, MD 21205 USA.			Zeiger, Robert/0000-0001-5788-5063	DIVISION OF LUNG DISEASES [N01HR016045, N01HR016046, N01HR016044] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR-16045, N01-HR-16044, N01-HR-16046] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; *CAMP RES GROUP, IN PRESS J ASTHMA; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Childhood Asthma Management Program, 1994, CHILDH ASTHM MAN PRO; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; COULTAS DB, 1988, AM REV RESPIR DIS, V135, P1386; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; DJUKANOVIC R, 1995, INT ARCH ALLERGY IMM, V107, P389, DOI 10.1159/000237047; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; FRETTE C, 1991, AM REV RESPIR DIS, V143, P987, DOI 10.1164/ajrccm/143.5_Pt_1.987; GOLD DR, 1994, AM J RESP CRIT CARE, V149, P1198, DOI 10.1164/ajrccm.149.5.8173760; GOLD DR, 1989, AM REV RESPIR DIS, V140, P877, DOI 10.1164/ajrccm/140.4.877; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Hatcher L., 1994, STEP BY STEP APPROAC; HENDERSON FW, 1992, AM REV RESPIR DIS, V145, P283, DOI 10.1164/ajrccm/145.2_Pt_1.283; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KELLY WJW, 1990, J ALLERGY CLIN IMMUN, V85, P548, DOI 10.1016/0091-6749(90)90092-I; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MENSINGA TT, 1992, AM REV RESPIR DIS, V146, P638, DOI 10.1164/ajrccm/146.3.638; MOSFELDT LE, 1993, ALLERGY, V48, P267; *NAT ASTHM ED PREV, 1991, NHLBI PUBL; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; RUBINSTEIN A, 1997, LUNG BIOL HLTH DIS, V110, P703; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; SHERRILL D, 1992, PEDIATR PULM, V13, P78, DOI 10.1002/ppul.1950130204; SIEGEL SC, 1985, J ALLERGY CLIN IMMUN, V76, P1, DOI 10.1016/0091-6749(85)90795-X; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Sorva R, 1997, PEDIAT ALLERG IMM-UK, V8, P45, DOI 10.1111/j.1399-3038.1997.tb00142.x; Strachan D, 1996, EUR RESPIR J, V9, pS42; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; ULRIK CS, 1995, CLIN EXP ALLERGY, V25, P820, DOI 10.1111/j.1365-2222.1995.tb00024.x; Wahlgren DR, 1997, J ASTHMA, V34, P291, DOI 10.3109/02770909709067219; Wilson JW, 1998, CLIN EXP ALLERGY, V28, P534; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	48	146	150	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				376	387		10.1016/S0091-6749(99)70460-4	http://dx.doi.org/10.1016/S0091-6749(99)70460-4			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069869				2022-12-18	WOS:000079175700004
J	Polito, AJ; Proud, D				Polito, AJ; Proud, D			Epithelial cells as regulators of airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXPRESSION; ASTHMA	The past decade has seen major advances in our understanding of the metabolic and biochemical functions of the epithelial cell. As a result, the traditional view of the epithelium as a relatively passive physical barrier to the external environment has been superseded by the concept that the epithelial cell plays a key role in regulating airway inflammation, The epithelial cell exerts this modulatory effect in several ways, Epithelial cells can function to maintain mucosal integrity and to modulate local immune responses. They can also limit inflammatory processes by degrading, or inhibiting, proinflammatory mediators and proteins. However, the epithelium also responds to a range of stimuli by producing biologically active mediators that can influence airway inflammation. These include, but are not limited to, a broad range of cytokines and chemokines that can exert profound effects on inflammatory cells, as well as lipid and peptide mediators. This review will highlight some of these aspects of the role of the epithelium in regulating airway inflammation.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Proud, D (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; Erjefalt JS, 1997, THORAX, V52, P213, DOI 10.1136/thx.52.3.213; HARKONEN E, 1995, AM J RESP CELL MOL, V13, P109; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; Nguyen HH, 1998, J VIROL, V72, P4534, DOI 10.1128/JVI.72.5.4534-4536.1998; POLITO AJ, 1997, ASTHMA, P491; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Venge J, 1996, J ALLERGY CLIN IMMUN, V97, P1110, DOI 10.1016/S0091-6749(96)70265-8	11	146	164	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					714	718		10.1016/S0091-6749(98)70008-9	http://dx.doi.org/10.1016/S0091-6749(98)70008-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9867498	hybrid			2022-12-18	WOS:000077033400002
J	AKI, T; KODAMA, T; FUJIKAWA, A; MIURA, K; SHIGETA, S; WADA, T; JYO, T; MUROOKA, Y; OKA, S; ONO, K				AKI, T; KODAMA, T; FUJIKAWA, A; MIURA, K; SHIGETA, S; WADA, T; JYO, T; MUROOKA, Y; OKA, S; ONO, K			IMMUNOCHEMICAL CHARACTERIZATION OF RECOMBINANT AND NATIVE TROPOMYOSINS AS A NEW ALLERGEN FROM THE HOUSE-DUST MITE, DERMATOPHAGOIDES-FARINAE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MITE ALLERGEN; COMPLEMENTARY DNA; SEQUENCING; TROPOMYOSIN; DERMATOPHAGOIDES FARINAE	DER-F-II; ALPHA-TROPOMYOSIN; ESCHERICHIA-COLI; D-PTERONYSSINUS; MAJOR ALLERGEN; FECAL EXTRACT; P-II; MUSCLE; IDENTIFICATION; PURIFICATION	Background: Two predominant mite species, Dermatophagoides farinae and Dermatophagoides pteronyssinus, are responsible for the immediate hypersensitivity reaction. Although a large number of antigens and allergens was detected in a whole mite culture extract, only the major allergens of Der I and II groups have been extensively studied. Much information on other important allergens remains to be accumulated. Methods: A new allergen complementary DNA (cDNA) clone was isolated from a D. farinae protein cDNA library. The expression product of the cDNA and native tropomyosin from D. farinae were purified, characterized, and evaluated. Results: An amino acid sequence deduced from the cDNA clone revealed significant homology with tropomyosins conserved in a wide range of animals. The amino acid sequences of two fragments obtained by degradation of the purified protein with cyanogen bromide coincided completely with the corresponding portions of the deduced amino acid sequence. The native tropomyosin reacted with specific IgE in the 31 sera tested at a high frequency (80.6%), comparable to that of Der f I (90.3%) and Der f II (74.2%). Conclusions: The cloned cDNA encodes tropomyosin. The high binding response of specific IgE antibodies to recombinant and native tropomyosins demonstrates that mite tropomyosin is an additional important allergen in house dust mite.	HIROSHIMA UNIV,FAC ENGN,DEPT FERMENTAT TECHNOL,HIGASHIHIROSHIMA 724,JAPAN; FUMAKILLA LTD,DEV & ADM SECT,HIROSHIMA,JAPAN; HIROSHIMA PREFECTURAL HOSP,DEPT INTERNAL MED 3,HIROSHIMA,JAPAN	Hiroshima University			Aki, Tsunehiro/B-6719-2012; Fujikawa, Akihiro/K-9805-2015	Aki, Tsunehiro/0000-0001-9753-2043; Fujikawa, Akihiro/0000-0002-3950-0550				AKI T, 1994, INT ARCH ALLERGY IMM, V103, P357, DOI 10.1159/000236654; AKI T, 1994, INT ARCH ALLERGY IMM, V103, P349, DOI 10.1159/000236653; ANDO T, 1993, CLIN EXP ALLERGY, V23, P777, DOI 10.1111/j.1365-2222.1993.tb00366.x; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Baldo B.A., 1989, Advances in the Biosciences, V74, P13; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; EDMAN P, 1949, ARCH BIOCHEM, V22, P475; FINE RE, 1975, J MOL BIOL, V95, P447, DOI 10.1016/0022-2836(75)90202-8; HANKE PD, 1986, GENE, V45, P211, DOI 10.1016/0378-1119(86)90256-8; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; KI T, 1994, J BIOCH, V115, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE FR, 1989, J ALLERGY CLIN IMMUN, V87, P1035; LIND P, 1986, INT ARCH ALLER A IMM, V79, P60, DOI 10.1159/000233943; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SMITH WA, 1994, CLIN EXP ALLERGY, V24, P220, DOI 10.1111/j.1365-2222.1994.tb00223.x; SODEK J, 1978, J BIOL CHEM, V253, P1129; STEWART GA, 1992, IMMUNOLOGY, V75, P29; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P24; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; Tovey E.R., 1989, Advances in the Biosciences, V74, P33; TOVEY ER, 1987, ELECTROPHORESIS, V8, P452, DOI 10.1002/elps.1150080915; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; YAMAGUCHI T, 1944, JPN J ALLERGOL, V43, P701; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402, DOI 10.1159/000234724; YASUEDA H, 1993, CLIN EXP ALLERGY, V23, P384, DOI 10.1111/j.1365-2222.1993.tb00343.x; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757	39	146	156	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					74	83		10.1016/S0091-6749(95)70035-8	http://dx.doi.org/10.1016/S0091-6749(95)70035-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622766				2022-12-18	WOS:A1995RK38300010
J	ELWOOD, W; LOTVALL, JO; BARNES, PJ; CHUNG, KF				ELWOOD, W; LOTVALL, JO; BARNES, PJ; CHUNG, KF			CHARACTERIZATION OF ALLERGEN-INDUCED BRONCHIAL HYPERRESPONSIVENESS AND AIRWAY INFLAMMATION IN ACTIVELY SENSITIZED BROWN-NORWAY RATS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BROWN-NORWAY RATS; BRONCHIAL HYPERRESPONSIVENESS; ACTIVE SENSITIZATION; OVALBUMIN; BRONCHOALVEOLAR LAVAGE	GUINEA-PIGS; ANTIGEN CHALLENGE; INHALED ANTIGEN; LYMPHOCYTES-T; RESPONSES; ASTHMA; EXPOSURE; RESPONSIVENESS; METHACHOLINE; EOSINOPHIL	Bronchial responsiveness to inhaled acetylcholine (ACh) and inflammatory cell recruitment in bronchoalveolar lavage fluid (BALF) were studied in inbred Brown-Norway rats actively sensitized to, and later exposed to, ovalbumin (OA). We examined animals 21 days after initial sensitization at 18 to 24 hours, or 5 days after a single challenge, or after the last of seven repeated exposures administered every 3 days. BALF was examined as an index of inflammatory changes within the lung. Animals repeatedly exposed to OA aerosols had an increased baseline lung resistance and a significant increase in bronchial responsiveness to inhaled ACh compared to control animals at both 18 to 24 hours and 5 days after the last OA exposure. Sensitized animals receiving a single OA aerosol also demonstrated bronchial hyperresponsiveness (BHR) to inhaled ACh (p < 0.01) at 18 to 24 hours of a similar order as the multiple-exposed group. There was a significant increase in eosinophils, lymphocytes, and neutrophils in BALF at 18 to 24 hours but not at 5 days after single or multiple exposure to OA aerosol in the sensitized groups. Control animals demonstrated no changes in bronchial responsiveness, although a small but significant increase in inflammatory cells was observed compared to saline-only treated animals. There was a significant correlation between bronchial responsiveness and eosinophil counts in the BALF in the single allergen-exposed group (R(s) = 0.68; p < 0.05). We conclude that (1) BHR after allergen exposure in sensitized rats is associated with the presence of pulmonary inflammation but persists despite the regression of inflammatory cells in BALF after multiple OA exposures, and (2) this rat model has many characteristics of human allergen-induced BHR.	NATL HEART & LUNG INST,DEPT THORAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; ROYAL BROMPTON NATL HEART & LUNG HOSP,LONDON,ENGLAND	Imperial College London; Imperial College London			Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Lotvall, Jan/0000-0001-9195-9249; Barnes, Peter/0000-0002-5122-4018				ANDERSSON P, 1980, ALLERGY, V35, P65, DOI 10.1111/j.1398-9995.1980.tb01718.x; ANDREW DK, 1984, INT ARCH ALLER A IMM, V75, P208, DOI 10.1159/000233617; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BELLOFIORE S, 1988, J APPL PHYSIOL, V65, P1642, DOI 10.1152/jappl.1988.65.4.1642; BLYTHE S, 1986, AM REV RESPIR DIS, V134, P1246; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRODER I, 1982, CLIN IMMUNOL IMMUNOP, V14, P211; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; CHURCH MK, 1975, BRIT J PHARMACOL, V55, P423, DOI 10.1111/j.1476-5381.1975.tb06947.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JG, 1988, AM REV RESPIR DIS, V131, P373; DUNN CJ, 1988, AM REV RESPIR DIS, V137, P541, DOI 10.1164/ajrccm/137.3.541; EIDELMAN DH, 1988, AM REV RESPIR DIS, V137, P1033, DOI 10.1164/ajrccm/137.5.1033; FREW AJ, 1990, AM REV RESPIR DIS, V141, P407, DOI 10.1164/ajrccm/141.2.407; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GUNDEL RH, 1990, J APPL PHYSIOL, V68, P779, DOI 10.1152/jappl.1990.68.2.779; HIRSHMAN CA, 1985, J APPL PHYSIOL, V58, P485, DOI 10.1152/jappl.1985.58.2.485; HOLT PG, 1981, IMMUNOLOGY, V42, P409; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KALLOS P, 1984, INT ARCH ALLER A IMM, V73, P77, DOI 10.1159/000233441; KLEEBERGER SR, 1985, J APPL PHYSIOL, V59, P1866, DOI 10.1152/jappl.1985.59.6.1866; LANES S, 1986, J APPL PHYSIOL, V61, P864, DOI 10.1152/jappl.1986.61.3.864; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; PAUWELS R, 1979, IMMUNOLOGY, V36, P151; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; SEDGWICK JD, 1985, IMMUNOLOGY, V56, P635; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; VONNEERGAARD K, 1927, Z KLIN MED, V105, P51; WEGNER CD, 1991, J ALLERGY CLIN IMMUN, V87, P835, DOI 10.1016/0091-6749(91)90130-G	32	146	153	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					951	960		10.1016/0091-6749(91)90253-K	http://dx.doi.org/10.1016/0091-6749(91)90253-K			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744366	Bronze			2022-12-18	WOS:A1991GW26200017
J	SETTIPANE, GA; PUDUPAKKAM, RK; MCGOWAN, JH				SETTIPANE, GA; PUDUPAKKAM, RK; MCGOWAN, JH			CORTICOSTEROID EFFECT ON IMMUNOGLOBULINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RHODE ISL HOSP,DEPT PEDIAT,DIV ALLERGY,PROVIDENCE,RI 02902; BROWN UNIV,PROGRAM MED,PROVIDENCE,RI 02912	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	SETTIPANE, GA (corresponding author), RHODE ISL HOSP,DEPT MED,DIV ALLERGY,PROVIDENCE,RI 02902, USA.							BLUMBERG MZ, 1976, J ALLERGY CLIN IMMUN, V57, P493, DOI 10.1016/0091-6749(76)90066-X; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; CLAMAN HN, 1975, J ALLERGY CLIN IMMUN, V55, P145, DOI 10.1016/0091-6749(75)90010-X; CREAM JJ, 1968, BRIT J HAEMATOL, V15, P259, DOI 10.1111/j.1365-2141.1968.tb01537.x; ELLIOTT EV, 1968, IMMUNOLOGY, V15, P643; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; GERMUTH FG, 1951, J EXP MED, V94, P139, DOI 10.1084/jem.94.2.139; GRIGGS RC, 1972, J ALLERGY CLIN IMMUN, V49, P267, DOI 10.1016/0091-6749(72)90094-2; HUFFMAN PJ, 1969, J ALLERGY, V43, P170; KISHIMOTO T, 1976, J IMMUNOL, V117, P396; KUNIN CM, 1959, PEDIATRICS, V23, P54; MCMILLAN R, 1976, J IMMUNOL, V116, P1592; POSEY WC, 1977, MAR AM C ALL IMM; SEGAL S, 1972, SCIENCE, V175, P1126, DOI 10.1126/science.175.4026.1126; TAKATSU K, 1975, CELL IMMUNOL, V20, P276, DOI 10.1016/0008-8749(75)90105-7; TAKATSU K, 1976, J IMMUNOL, V116, P1257; WALDMANN TA, 1976, FED PROC, V35, P2067	17	146	148	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					162	166		10.1016/0091-6749(78)90101-X	http://dx.doi.org/10.1016/0091-6749(78)90101-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	681628				2022-12-18	WOS:A1978FP55400006
J	Panganiban, RP; Wang, YL; Howrylak, J; Chinchilli, VM; Craig, TJ; August, A; Ishmael, FT				Panganiban, Ronaldo P.; Wang, Yanli; Howrylak, Judie; Chinchilli, Vernon M.; Craig, Timothy J.; August, Avery; Ishmael, Faoud T.			Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic rhinitis; microRNA; biomarker; plasma; inflammation; posttranscriptional regulation	EXPRESSION; INFLAMMATION; POPULATION; DISEASE; AIRWAYS; CELLS; SERUM; FLUID; IL-13	Background: MicroRNAs (miRNAs) are emerging as important regulatory molecules that might be involved in the pathogenesis of various diseases. Circulating miRNAs might be noninvasive biomarkers to diagnose and characterize asthma and allergic rhinitis (AR). Objective: We sought to determine whether miRNAs are differentially expressed in the blood of asthmatic patients compared with those in the blood of nonasthmatic patients with AR and nonallergic nonasthmatic subjects. Furthermore, we sought to establish whether miRNAs could be used to characterize or subtype asthmatic patients. Methods: Expression of plasma miRNAs was measured by using real-time quantitative PCR in 35 asthmatic patients, 25 nonasthmatic patients with AR, and 19 nonallergic nonasthmatic subjects. Differentially expressed miRNAs were identified by using Kruskal-Wallis 1-way ANOVA with Bonferroni P value adjustment to correct for multiple comparisons. A random forest classification algorithm combined with a leave-one-out cross-validation approach was implemented to assess the predictive capacities of the profiled miRNAs. Results: We identified 30 miRNAs that were differentially expressed among healthy, allergic, and asthmatic subjects. These miRNAs fit into 5 different expression pattern groups. Among asthmatic patients, miRNA expression profiles identified 2 subtypes that differed by high or low peripheral eosinophil levels. Circulating miR-125b, miR-16, miR-299-5p, miR-126, miR-206, and miR-133b levels were most predictive of allergic and asthmatic status. Conclusions: Subsets of circulating miRNAs are uniquely expressed in patients with AR and asthmatic patients and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases.	[Panganiban, Ronaldo P.; Howrylak, Judie; Craig, Timothy J.; Ishmael, Faoud T.] Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Div Pulm Allergy & Crit Care Med, Hershey, PA 17033 USA; [Chinchilli, Vernon M.] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA; [Panganiban, Ronaldo P.; Wang, Yanli; Ishmael, Faoud T.] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; [August, Avery] Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY USA; [Wang, Yanli] Penn State Univ, Bioinformat & Genom Program, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ishmael, FT (corresponding author), Penn State Univ, Coll Med, 500 Univ Dr,H171, Hershey, PA 17033 USA.	fishmael@hmc.psu.edu			Doris Duke Charitable Foundation Clinical Scientist Development Award; National Institutes of Health [1K08HL114100-1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL114100] Funding Source: NIH RePORTER	Doris Duke Charitable Foundation Clinical Scientist Development Award(American Heart AssociationDoris Duke Charitable Foundation (DDCF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a Doris Duke Charitable Foundation Clinical Scientist Development Award and National Institutes of Health 1K08HL114100-1.	Andiappan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019719; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bachert C, 2004, IMMUNOL ALLERGY CLIN, V24, P19, DOI 10.1016/S0889-8561(03)00104-8; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Bousquet J, 2012, J ALLERGY CLIN IMMUN, V130, P1049, DOI 10.1016/j.jaci.2012.07.053; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Casolaro V, 2008, J ALLERGY CLIN IMMUN, V121, P853, DOI 10.1016/j.jaci.2007.12.1166; Chen RW, 2008, BLOOD, V112, P822, DOI 10.1182/blood-2008-03-142182; Chen X, 2012, TRENDS CELL BIOL, V22, P125, DOI 10.1016/j.tcb.2011.12.001; Chen X, 2012, PROTEIN CELL, V3, P28, DOI 10.1007/s13238-012-2003-z; Chung KF, 2011, CHEST, V139, P1470, DOI 10.1378/chest.10-1914; Collison A, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-29; Cortez MA, 2009, EXPERT OPIN BIOL TH, V9, P703, DOI [10.1517/14712590902932889, 10.1517/14712590902932889 ]; Cruz AA, 2007, ALLERGY, V62, P1, DOI 10.1111/j.1398-9995.2007.01551.x; Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Fan JS, 2011, J IMMUNOL, V186, P2482, DOI 10.4049/jimmunol.0903634; Feng CH, 2012, AM J RHINOL ALLERGY, V26, P187, DOI 10.2500/ajra.2012.26.3762; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hocking DC, 2002, CHEST, V122, p275S, DOI 10.1378/chest.122.6_suppl.275S; Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342; Ishmael FT, 2011, J AM OSTEOPATH ASSOC, V111, pS11; Jinek M, 2009, NATURE, V457, P405, DOI 10.1038/nature07755; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kampe M, 2012, INFLAMMATION, V35, P230, DOI 10.1007/s10753-011-9309-5; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Lu TX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059397; Lu TX, 2013, J IMMUNOL, V190, P1576, DOI 10.4049/jimmunol.1202897; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Nelson PT, 2008, BRAIN PATHOL, V18, P130, DOI 10.1111/j.1750-3639.2007.00120.x; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Panganiban RPL, 2012, AM J CLIN EXP IMMUNO, V1, P154; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Pinkerton M, 2013, J ALLERGY CLIN IMMUN, V132, P217, DOI 10.1016/j.jaci.2013.03.006; Pohlert T., PAIRWISE MULTIPLE CO; Prakash Ys, 2010, Expert Rev Respir Med, V4, P395, DOI 10.1586/ers.10.29; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Roff AN, 2014, AM J CLIN EXP IMMUNO, V3, P68; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Sarlus H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-99; Scuri Mario, 2010, Inflammation & Allergy Drug Targets, V9, P173; Shaaban R, 2007, AM J RESP CRIT CARE, V176, P659, DOI 10.1164/rccm.200703-427OC; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Team RDC, 2009, R LANG ENV STAT COMP; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vasudevan S, 2007, CELL, V128, P1105, DOI 10.1016/j.cell.2007.01.038; Vickers KC, 2012, CURR OPIN LIPIDOL, V23, P91, DOI 10.1097/MOL.0b013e328350a425; Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494; Zhu Weizhu, 2009, BMC Res Notes, V2, P89, DOI 10.1186/1756-0500-2-89	60	145	154	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1423	1432		10.1016/j.jaci.2016.01.029	http://dx.doi.org/10.1016/j.jaci.2016.01.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27025347	Bronze			2022-12-18	WOS:000376180200017
J	Cahill, KN; Bensko, JC; Boyce, JA; Laidlaw, TM				Cahill, Katherine N.; Bensko, Jillian C.; Boyce, Joshua A.; Laidlaw, Tanya M.			Prostaglandin D-2: A dominant mediator of aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; Samter triad; nasal polyps; asthma; prostaglandin D-2; thromboxane; aspirin desensitization; cysteinyl leukotrienes; urinary eicosanoids; eosinophils	CYSTEINYL LEUKOTRIENE RECEPTOR; SENSITIVE ASTHMA; INDUCED BRONCHOCONSTRICTION; MOLECULAR-CLONING; MAST-CELLS; EXPRESSION; CHALLENGE; SYNTHASE; DESENSITIZATION; IDENTIFICATION	Background: Aspirin desensitization followed by high-dose aspirin therapy is routinely performed for patients with aspirin-exacerbated respiratory disease (AERD). Little is known about the contributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the therapeutic benefit of high-dose aspirin therapy. Objective: We investigated differences in urinary eicosanoid metabolite levels and blood eosinophil counts in patients with AERD who tolerate and those who fail aspirin desensitization and also in patients with AERD who were successfully treated with high-dose aspirin therapy. Methods: Twenty-nine patients with AERD were stratified into those who tolerated aspirin desensitization (group I) and those who did not (group II). Urine was analyzed for eicosanoid metabolites at baseline, during aspirin reactions, and during high-dose aspirin therapy. Blood was analyzed for cell differentials at baseline and during aspirin therapy. Results: Basal prostaglandin D-2 metabolite (PGD-M; 13.6 +/- 2.7 vs 7.0 +/- 0.8 pmol/mg creatinine [Cr], P <.05) and thromboxane metabolite (TX-M; 1.4 +/- 0.3 vs 0.9 +/- 0.1 pmol/mg Cr, P <.01) levels were higher in group II than in group I. During aspirin reactions, PGD-M levels remained unchanged, whereas TX-M levels (0.7 +/- 0.1 pmol/mg Cr, P = .07) tended to decrease in group I. In contrast, PGD-M levels increased dramatically in group II (61.3 +/- 19.9 pmol/mg Cr, P <. 05), whereas TX-M levels did not change. The decrease in FEV1 inversely correlated with basal urinary levels of both leukotriene E-4 and PGD-M. Blood eosinophil and basophil levels increased and urinary PGD-M levels (2.2 +/- 0.8 pmol/mg Cr, P <.001) decreased on 2 months of high-dose aspirin therapy in group I. Conclusion: Failure to tolerate aspirin desensitization in a subset of patients with AERD is associated with prostaglandin D2 overproduction. The increase in blood eosinophil and basophil counts during high-dose aspirin therapy might reflect the functional consequences of decreased prostaglandin D2	[Cahill, Katherine N.; Bensko, Jillian C.; Boyce, Joshua A.; Laidlaw, Tanya M.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; [Cahill, Katherine N.; Boyce, Joshua A.; Laidlaw, Tanya M.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA USA; [Bensko, Jillian C.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA USA; [Cahill, Katherine N.; Boyce, Joshua A.; Laidlaw, Tanya M.] Brigham & Womens Hosp, Jeff & Penny Vinik Ctr Allerg Dis Res, Boston, MA 02115 USA	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Laidlaw, TM (corresponding author), Brigham & Womens Hosp, 1 Jimmy Fund Way,Smith Bldg,Room 626B, Boston, MA 02115 USA.	tlaidlaw@partners.org		Cahill, Katherine/0000-0002-8549-1835; Bensko, Jillian/0000-0002-0363-6093	National Institutes of Health [AI007306-27, U19 AI095219-01, 5U19AI070412-06, 153556/153044, K23HL111113-02]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117945, K23HL111113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078908, U19AI070412, R37AI052353, T32AI007306, U19AI095219] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants (National Institute of Allergy and Infectious Diseases: AI007306-27, U19 AI095219-01, and 5U19AI070412-06 with Opportunity Fund Subaward No. 153556/153044; and National Heart, Lung, Blood Institute: K23HL111113-02) and by generous contributions from the Vinik Family and the Kaye Family.	AWAD JA, 1993, J BIOL CHEM, V268, P4161; BEASLEY RCW, 1989, J APPL PHYSIOL, V66, P1685, DOI 10.1152/jappl.1989.66.4.1685; Benyahia C, 2012, PULM PHARMACOL THER, V25, P115, DOI 10.1016/j.pupt.2011.12.012; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Bochenek G, 2014, J ALLERGY CLIN IMMUN, V133, P98, DOI 10.1016/j.jaci.2013.07.004; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, P339, DOI 10.1016/j.jaci.2012.10.013; Cheng K, 2006, P NATL ACAD SCI USA, V103, P6682, DOI 10.1073/pnas.0601574103; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; HARDY CC, 1988, J APPL PHYSIOL, V64, P1567, DOI 10.1152/jappl.1988.64.4.1567; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Higashi N, 2012, ALLERGOL INT, V61, P393, DOI 10.2332/allergolint.11-RA-0403; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; JOHNSTON SL, 1992, BRIT J CLIN PHARMACO, V34, P402, DOI 10.1111/j.1365-2125.1992.tb05649.x; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; KUMLIN M, 1995, CLIN EXP ALLERGY, V25, P467, DOI 10.1111/j.1365-2222.1995.tb01079.x; Kupczyk M, 2010, RESP MED, V104, P1404, DOI 10.1016/j.rmed.2010.04.017; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Larsson AK, 2011, EUR J PHARMACOL, V669, P136, DOI 10.1016/j.ejphar.2011.07.046; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; Lynch KR, 1999, NATURE, V399, P789; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Mastalerz L, 2008, THORAX, V63, P27, DOI 10.1136/thx.2007.080903; MORROW JD, 1995, J INVEST DERMATOL, V104, P937, DOI 10.1111/1523-1747.ep12606209; MORROW JD, 1993, J CHROMATOGR-BIOMED, V612, P179, DOI 10.1016/0378-4347(93)80161-V; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; SLADEK K, 1993, EUR RESPIR J, V6, P391; Smith WL, 1997, ADV EXP MED BIOL, V400, P189; Song WL, 2012, J CLIN INVEST, V122, P1459, DOI 10.1172/JCI59262; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; Swierczynska-Krepa M, 2014, J ALLERGY CLIN IMMUN, V134, P883, DOI 10.1016/j.jaci.2014.02.041; Szczeklik A, 1998, AM J RESP CRIT CARE, V158, P1168, DOI 10.1164/ajrccm.158.4.9710043; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; SZCZEKLIK A, 1977, PHARMACOL RES COMMUN, V9, P415, DOI 10.1016/S0031-6989(77)80027-1; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688, DOI 10.1016/S1081-1206(10)61101-5; Woessner KM, 2002, ARTHRITIS RHEUM, V46, P2201, DOI 10.1002/art.10426; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yoshida S, 1998, ANN ALLERG ASTHMA IM, V80, P171, DOI 10.1016/S1081-1206(10)62951-1; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545	50	145	147	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					245	252		10.1016/j.jaci.2014.07.031	http://dx.doi.org/10.1016/j.jaci.2014.07.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25218285	Green Accepted			2022-12-18	WOS:000347298200029
J	Long, A; Rahmaoui, A; Rothman, KJ; Guinan, E; Eisner, M; Bradley, MS; Iribarren, C; Chen, H; Carrigan, G; Rosen, K; Szefler, SJ				Long, Aidan; Rahmaoui, Abdelkader; Rothman, Kenneth J.; Guinan, Eva; Eisner, Mark; Bradley, Mary S.; Iribarren, Carlos; Chen, Hubert; Carrigan, Gillis; Rosen, Karin; Szefler, Stanley J.			Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cancer; safety; anti-IgE; EXCELS; allergic asthma	SEVERE ALLERGIC-ASTHMA; SEVERE PERSISTENT ASTHMA; ANTI-IGE ANTIBODY; CANCER INCIDENCE; RISK; THERAPY; EXACERBATIONS; COHORT	Background: The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma (EXCELS) assessed the long-term safety of omalizumab in a clinical practice setting as part of a phase IV US Food and Drug Administration postmarketing commitment. Objective: We sought to evaluate long-term safety in omalizumab-treated and nonomalizumab-treated patients. Primary outcome measures focused on assessment of malignancies. Methods: EXCELS was a prospective observational cohort study in patients (>= 12 years of age) with moderate-to-severe allergic asthma. There were 2 cohorts: omalizumab (taking omalizumab at baseline) and nonomalizumab (no history of omalizumab treatment). Primary outcomes included all confirmed, incident, study-emergent primary malignancies (malignancies), including and excluding nonmelanoma skin cancer (NMSC); all malignancies were externally adjudicated. Results: The omalizumab cohort had a higher proportion of patients with severe asthma compared with the nonomalizumab cohort (50.0% vs 23.0%). Median follow-up was approximately 5 years for both cohorts. Crude malignancy rates were similar in the omalizumab and nonomalizumab cohorts, with a rate ratio of 0.84 (95% CI, 0.62-1.13) for all malignancies and 0.98 (95% CI, 0.71-1.36) for all malignancies excluding NMSC. Kaplan-Meier plots of time to first confirmed study-emergent primary malignancy were similar for the 2 treatment cohorts. Cox proportional hazards modeling, adjusting for confounders and risk factors, resulted in a hazard ratio (omalizumab vs nonomalizumab) of 1.09 (95% CI, 0.87-1.38) for all malignancies and 1.15 (95% CI, 0.83-1.59) for all malignancies excluding NMSC. Conclusion: Results from EXCELS suggest that omalizumab therapy is not associated with an increased risk of malignancy.	[Long, Aidan] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Long, Aidan] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Rahmaoui, Abdelkader; Eisner, Mark; Bradley, Mary S.; Chen, Hubert; Carrigan, Gillis; Rosen, Karin] Genentech Inc, South San Francisco, CA USA; [Rothman, Kenneth J.] RTI Hlth Solut, Res Triangle Pk, NC USA; [Guinan, Eva] Dana Farber Canc Inst, Boston, MA USA; [Iribarren, Carlos] Kaiser Permanente Med Care Program, Div Res, Oakland, CA USA; [Szefler, Stanley J.] Childrens Hosp, Denver, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Denver, CO 80202 USA	Harvard University; Massachusetts General Hospital; Harvard University; Roche Holding; Genentech; Research Triangle Institute; Harvard University; Dana-Farber Cancer Institute; Kaiser Permanente; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Long, A (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cox 201,55 Fruit St, Boston, MA 02114 USA.	aalong@mgh.harvard.edu		Szefler, Stanley/0000-0002-6911-3199; Chen, Hubert/0000-0002-6630-239X	Genentech, South San Francisco, California; Novartis Pharmaceuticals, East Hanover, New Jersey	Genentech, South San Francisco, California(Roche HoldingGenentech); Novartis Pharmaceuticals, East Hanover, New Jersey	Supported by Genentech, South San Francisco, California, and Novartis Pharmaceuticals, East Hanover, New Jersey.	Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Bousquet J, 2011, ALLERGY, V66, P671, DOI 10.1111/j.1398-9995.2010.02522.x; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse W, 2012, J ALLERGY CLIN IMMUN, V129, P983, DOI 10.1016/j.jaci.2012.01.033; Eisner M, 2012, EUR AC ALL CLIN IMM; Eisner M, 2011, EUR RESP J S55, V38; ERIKSSON NE, 1995, ALLERGY, V50, P718, DOI 10.1111/j.1398-9995.1995.tb01212.x; Fernandez C, 2005, P AM THORAC SOC, V2, pA359; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Ji J, 2009, BRIT J CANCER, V100, P829, DOI 10.1038/sj.bjc.6604890; KALLEN B, 1993, EUR RESPIR J, V6, P694; Long AA, 2012, AM J RESP CRIT CARE, V183, pA4492; Long AA, 2009, ANN ALLERG ASTHMA IM, V103, P212, DOI 10.1016/S1081-1206(10)60184-6; MILLS PK, 1992, AM J EPIDEMIOL, V136, P287, DOI 10.1093/oxfordjournals.aje.a116494; Niven R, 2008, RESP MED, V102, P1371, DOI 10.1016/j.rmed.2008.06.002; Novartis US Genentech, 2010, OM XOL PRESCR INF; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; VESTERINEN E, 1993, INT J EPIDEMIOL, V22, P976, DOI 10.1093/ije/22.6.976; Wang H, 2006, INT J CANCER, V119, P695, DOI 10.1002/ijc.21883	21	145	151	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					560	+		10.1016/j.jaci.2014.02.007	http://dx.doi.org/10.1016/j.jaci.2014.02.007			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24679845	hybrid			2022-12-18	WOS:000341372400007
J	Jin, CC; Flavell, RA				Jin, Chengcheng; Flavell, Richard A.			Innate sensors of pathogen and stress: Linking inflammation to obesity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pattern recognition receptor; obesity; microbiota; metabolic inflammation	TOLL-LIKE RECEPTORS; INDUCED INSULIN-RESISTANCE; DIET-INDUCED OBESITY; HIGH-FAT DIET; DEFICIENCY DECREASES ATHEROSCLEROSIS; PATTERN-RECOGNITION RECEPTORS; BETA-CELL DYSFUNCTION; WHITE ADIPOSE-TISSUE; GUT MICROBIOTA; NLRP3 INFLAMMASOME	Pathogen and nutrient response pathways are evolutionarily conserved and highly integrated to regulate metabolic and immune homeostasis. Excessive nutrients can be sensed by innate pattern recognition receptors as danger signals either directly or through production of endogenous ligands or modulation of intestinal microbiota. This triggers the activation of downstream inflammatory cascades involving nuclear factor kappa B and mitogen-activated protein kinase and ultimately induces the production of inflammatory cytokines and immune cell infiltration in various metabolic tissues. The chronic low-grade inflammation in the brain, islet, liver, muscle, and adipose tissue further promotes insulin resistance, energy imbalance, and impaired glucose/lipid metabolism, contributing to the metabolic complications of obesity, such as diabetes and atherosclerosis. In addition, innate pathogen receptors have now emerged as a critical link between the intestinal microbiota and host metabolism. In this review we summarize recent studies demonstrating the important roles of innate pathogen receptors, including Toll-like receptors, nucleotide oligomerization domain containing proteins, and inflammasomes in mediating the inflammatory response to metabolic stress in different tissues and highlight the interaction of innate pattern recognition receptors, gut microbiota, and nutrients during the development of obesity and related metabolic disorders.	[Jin, Chengcheng; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Flavell, Richard A.] Howard Hughes Med Inst, Chevy Chase, MD USA	Yale University; Howard Hughes Medical Institute	Flavell, RA (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 300 Cedar St,TAC S-569, New Haven, CT 06520 USA.	richard.flavell@yale.edu		Jin, Chengcheng/0000-0001-9207-3191	American Diabetes Association; Juvenile Diabetes Research Foundation; National Institutes of Health, CT Stem Cell Research Fund; Bill & Melinda Gates Foundation; Department of Defense; Blavatnik Family Foundation; Yale Cancer Center; ACR Research and Education Foundation	American Diabetes Association(American Diabetes Association); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); National Institutes of Health, CT Stem Cell Research Fund(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Department of Defense(United States Department of Defense); Blavatnik Family Foundation; Yale Cancer Center; ACR Research and Education Foundation	R. Flavell has consultant arrangements with Immungene, Tempero Pharmaceuticals, Ensemble Therapeutics, Symbiotix Biotherapies, Inc, Hatteras Venture Advisors IV, LLC, and Vaxinnate; has provided expert witness testimony for Robbins, Kaplan, Miller, & Ciresi on sequencing; has received grants from the American Diabetes Association, the Juvenile Diabetes Research Foundation, the National Institutes of Health, CT Stem Cell Research Fund, the Bill & Melinda Gates Foundation, the Department of Defense, the Blavatnik Family Foundation, the Yale Cancer Center, and the ACR Research and Education Foundation; and has received stock/stock options from L2 Diagnostics. C. Jin declares no relevant conflicts of interest.	Amar J, 2011, EMBO MOL MED, V3, P559, DOI 10.1002/emmm.201100159; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2011, ANN NUTR METAB, V58, P44, DOI 10.1159/000328042; Biswas A, 2013, INT IMMUNOL, V25, P207, DOI 10.1093/intimm/dxs116; Bjorkbacka H, 2004, NAT MED, V10, P416, DOI 10.1038/nm1008; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Caricilli AM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001212; Caricilli AM, 2008, J ENDOCRINOL, V199, P399, DOI 10.1677/JOE-08-0354; Clarke TB, 2010, NAT MED, V16, P228, DOI 10.1038/nm.2087; Coenen KR, 2009, DIABETOLOGIA, V52, P318, DOI 10.1007/s00125-008-1221-7; Dasu MR, 2010, DIABETES CARE, V33, P861, DOI 10.2337/dc09-1799; Davis JE, 2008, OBESITY, V16, P1248, DOI 10.1038/oby.2008.210; Davis JE, 2011, J NUTR BIOCHEM, V22, P136, DOI 10.1016/j.jnutbio.2009.12.008; De Nardo D, 2011, TRENDS IMMUNOL, V32, P373, DOI 10.1016/j.it.2011.05.004; den Dekker WK, 2010, ATHEROSCLEROSIS, V209, P314, DOI 10.1016/j.atherosclerosis.2009.09.075; Ding YL, 2012, ARTERIOSCL THROM VAS, V32, P1596, DOI 10.1161/ATVBAHA.112.249847; Dixon LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056100; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Donath MY, 2010, TRENDS ENDOCRIN MET, V21, P261, DOI 10.1016/j.tem.2009.12.010; Donath MY, 2009, PHYSIOLOGY, V24, P325, DOI 10.1152/physiol.00032.2009; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Eguchi K, 2012, CELL METAB, V15, P518, DOI 10.1016/j.cmet.2012.01.023; Ehses JA, 2010, DIABETOLOGIA, V53, P1795, DOI 10.1007/s00125-010-1747-3; Ehses JA, 2009, P NATL ACAD SCI USA, V106, P13998, DOI 10.1073/pnas.0810087106; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Erridge C, 2011, ATHEROSCLEROSIS, V216, P1, DOI 10.1016/j.atherosclerosis.2011.02.043; Erridge C, 2009, ARTERIOSCL THROM VAS, V29, P1944, DOI 10.1161/ATVBAHA.109.194050; Fischer H, 2007, CELL MICROBIOL, V9, P1239, DOI 10.1111/j.1462-5822.2006.00867.x; Fresno Manuel, 2011, Archives of Physiology and Biochemistry, V117, P151, DOI 10.3109/13813455.2011.562514; Gage J, 2012, CAN J CARDIOL, V28, P222, DOI 10.1016/j.cjca.2011.10.013; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Greiner T, 2011, TRENDS ENDOCRIN MET, V22, P117, DOI 10.1016/j.tem.2011.01.002; Gurcel L, 2006, CELL, V126, P1135, DOI 10.1016/j.cell.2006.07.033; Hanisch UK, 2008, TRENDS NEUROSCI, V31, P176, DOI 10.1016/j.tins.2008.01.005; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Himes RW, 2010, FASEB J, V24, P731, DOI 10.1096/fj.09-141929; Holland WL, 2011, J CLIN INVEST, V121, P1858, DOI 10.1172/JCI43378; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Jiang YG, 2012, BIOCHEM BIOPH RES CO, V425, P121, DOI 10.1016/j.bbrc.2012.07.011; Kanczkowski W, 2008, NEUROIMMUNOMODULAT, V15, P54, DOI 10.1159/000135624; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim F, 2007, CIRC RES, V100, P1589, DOI 10.1161/CIRCRESAHA.106.142851; Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013; Konner AC, 2011, TRENDS ENDOCRIN MET, V22, P16, DOI 10.1016/j.tem.2010.08.007; Kuo LH, 2011, DIABETOLOGIA, V54, P168, DOI 10.1007/s00125-010-1931-5; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Lee HM, 2013, DIABETES, V62, P194, DOI 10.2337/db12-0420; Li L, 2011, HEPATOLOGY, V54, P1620, DOI 10.1002/hep.24552; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Lundberg AM, 2013, CARDIOVASC RES; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Madan M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003204; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; Masters SL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001902; Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Menu P, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.18; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009; Miura K, 2010, GASTROENTEROLOGY, V139, P323, DOI 10.1053/j.gastro.2010.03.052; Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200; Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813; Orr JS, 2012, DIABETES, V61, P2718, DOI 10.2337/db11-1595; Osborn O, 2008, SWISS MED WKLY, V138, P665, DOI /aop/smw-aop12276; Pal D., 2012, NAT MED; Petnicki-Ocwieja T, 2009, P NATL ACAD SCI USA, V106, P15813, DOI 10.1073/pnas.0907722106; Poggi M, 2007, DIABETOLOGIA, V50, P1267, DOI 10.1007/s00125-007-0654-8; Purkayastha S, 2011, P NATL ACAD SCI USA, V108, P2939, DOI 10.1073/pnas.1006875108; Purohit J., 2012, OBESITY SILVER SPRIN; Radin MS, 2008, DIABETOLOGIA, V51, P336, DOI 10.1007/s00125-007-0861-3; Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765; Rivera CA, 2007, J HEPATOL, V47, P571, DOI 10.1016/j.jhep.2007.04.019; Rocha VZ, 2009, NAT REV CARDIOL, V6, P399, DOI 10.1038/nrcardio.2009.55; Saberi M, 2009, CELL METAB, V10, P419, DOI 10.1016/j.cmet.2009.09.006; Sartorius T, 2012, FASEB J, V26, P1799, DOI 10.1096/fj.11-191023; Schertzer JD, 2011, DIABETES, V60, P2206, DOI 10.2337/db11-0004; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Senn JJ, 2006, J BIOL CHEM, V281, P26865, DOI 10.1074/jbc.M513304200; Shao W, 2007, J BIOL CHEM, V282, P36321, DOI 10.1074/jbc.M708182200; Shechter R, 2013, SCI REP-UK, V3, DOI 10.1038/srep01254; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Spruss A, 2009, HEPATOLOGY, V50, P1094, DOI 10.1002/hep.23122; Stienstra R, 2011, P NATL ACAD SCI USA, V108, P15324, DOI 10.1073/pnas.1100255108; Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Suganami T, 2007, BIOCHEM BIOPH RES CO, V354, P45, DOI 10.1016/j.bbrc.2006.12.190; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tamrakar AK, 2010, ENDOCRINOLOGY, V151, P5624, DOI 10.1210/en.2010-0437; Tanti JF., 2012, FRONT ENDOCRINOL, V3, P181, DOI [DOI 10.3389/FENDO.2012.00181, 10.3389/fendo.2012.00181]; Thaler JP, 2010, FRONT NEUROENDOCRIN, V31, P79, DOI 10.1016/j.yfrne.2009.10.002; Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Usui F, 2012, BIOCHEM BIOPH RES CO, V425, P162, DOI 10.1016/j.bbrc.2012.07.058; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Vives-Pi M, 2003, CLIN EXP IMMUNOL, V133, P208, DOI 10.1046/j.1365-2249.2003.02211.x; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Youm YH, 2011, ENDOCRINOLOGY, V152, P4039, DOI 10.1210/en.2011-1326; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Zhao L, 2011, AM J PHYSIOL-ENDOC M, V301, pE587, DOI 10.1152/ajpendo.00709.2010; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831; Zorriila EP, 2007, P NATL ACAD SCI USA, V104, P11097, DOI 10.1073/pnas.0611523104	111	145	150	0	59	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					287	294		10.1016/j.jaci.2013.06.022	http://dx.doi.org/10.1016/j.jaci.2013.06.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23905917				2022-12-18	WOS:000322631700004
J	Savage, JH; Matsui, EC; Wood, RA; Keet, CA				Savage, Jessica H.; Matsui, Elizabeth C.; Wood, Robert A.; Keet, Corinne A.			Urinary levels of triclosan and parabens are associated with aeroallergen and food sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Triclosan; paraben; benzophenone; bisphenol A; endocrine-disrupting compound; aeroallergen; sensitization; food; allergy	ENDOCRINE-DISRUPTING CHEMICALS; BISPHENOL-A; PARASITE INFECTION; NATIONAL-HEALTH; ORAL PATHOGENS; AIR-POLLUTION; EXPOSURE; ASTHMA; CHILDHOOD; RISK	Background: Endocrine-disrupting compounds (EDCs) have immune-modulating effects. We were interested in determining their association with allergic sensitization. Objective: We sought to determine the association between EDCs and allergic sensitization and whether this relationship depends on the antimicrobial properties of the EDCs, sex, or both. Methods: Data were obtained from the 2005-2006 National Health and Nutrition Examination Survey in which urinary bisphenol A; triclosan; benzophenone-3; propyl, methyl, butyl, and ethyl parabens; and specific IgE levels were available for 860 children. Aeroallergen and food sensitizations were defined as having at least 1 positive (>= 0.35 kU/L) specific IgE level to an aeroallergen or a food. Logistic regression was used to determine the association of EDCs and sensitization. Analyses were adjusted for urinary creatinine level, age, sex, ethnicity, and poverty index ratio. Results: The odds of aeroallergen sensitization significantly increased with the level of the antimicrobial EDCs triclosan and propyl and butyl parabens (P <= .04). The odds of food sensitization significantly increased with the level of urinary triclosan among male subjects (odds ratio for third vs first tertiles, 3.9; P = .02 for trend). There was a significant interaction between sex and triclosan level, with male subjects being more likely to be food sensitized with exposure (P = .03). Similar associations were not identified for the nonantimicrobial EDCs bisphenol A and benzophenone-3 (P > .2). Conclusions: As a group, EDCs are not associated with allergen sensitization. However, levels of the antimicrobial EDCs triclosan and parabens were significantly associated with allergic sensitization. The potential role of antimicrobial EDCs in allergic disease warrants further study because they are commonly used in Western society. (J Allergy Clin Immunol 2012;130:453-60.)	[Savage, Jessica H.] Johns Hopkins Div Allergy & Clin Immunol, Baltimore, MD 21224 USA; [Matsui, Elizabeth C.; Wood, Robert A.; Keet, Corinne A.] Johns Hopkins Div Pediat Allergy & Immunol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Savage, JH (corresponding author), Johns Hopkins Div Allergy & Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	jessicahsavage@gmail.com		Matsui, Elizabeth/0000-0001-8134-5593; Keet, Corinne/0000-0002-6585-239X	National Institutes of Health [T32AI007056-31]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007056] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant T32AI007056-31.	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Ahluwalia SK, 2011, CURR OPIN ALLERGY CL, V11, P137, DOI 10.1097/ACI.0b013e3283445921; Allmyr M, 2006, SCI TOTAL ENVIRON, V372, P87, DOI 10.1016/j.scitotenv.2006.08.007; Arbes SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1169, DOI 10.1016/j.jaci.2006.07.029; Arbes SJ, 2011, J ALLERGY CLIN IMMUN, V127, P1119, DOI 10.1016/j.jaci.2011.03.023; Barr L, 2012, J APPL TOXICOL, V32, P219, DOI 10.1002/jat.1786; Barros SP, 2010, J CLIN PERIODONTOL, V37, P412, DOI 10.1111/j.1600-051X.2010.01548.x; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bredin J, 2005, J ANTIMICROB CHEMOTH, V55, P1013, DOI 10.1093/jac/dki110; Centers for Disease Control and Prevention NCfHS, NAT HLTH NUTR EX SUR; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; Crofton KM, 2007, ENVIRON TOXICOL PHAR, V24, P194, DOI 10.1016/j.etap.2007.04.008; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; Dann AB, 2011, J APPL TOXICOL, V31, P285, DOI 10.1002/jat.1660; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Elwood CN, 2007, J ENDOUROL, V21, P1217, DOI 10.1089/end.2007.9903; Gee RH, 2008, J APPL TOXICOL, V28, P78, DOI 10.1002/jat.1316; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Hengstler JG, 2011, CRIT REV TOXICOL, V41, P263, DOI 10.3109/10408444.2011.558487; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; McDonald KL, 2008, J ALLERGY CLIN IMMUN, V121, P626, DOI 10.1016/j.jaci.2007.11.034; Modeer T, 1996, J CLIN PERIODONTOL, V23, P927, DOI 10.1111/j.1600-051X.1996.tb00513.x; Mortimer K, 2008, J ASTHMA, V45, P874, DOI 10.1080/02770900802195722; Mortimer K, 2008, EPIDEMIOLOGY, V19, P550, DOI 10.1097/EDE.0b013e31816a9dcb; Mustafa M, 2000, J CLIN PERIODONTOL, V27, P733, DOI 10.1034/j.1600-051x.2000.027010733.x; Poimenova A, 2010, NEUROSCIENCE, V167, P741, DOI 10.1016/j.neuroscience.2010.02.051; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Russell AD, 2004, J ANTIMICROB CHEMOTH, V53, P693, DOI 10.1093/jac/dkh171; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schlumpf M, 2004, TOXICOLOGY, V205, P113, DOI 10.1016/j.tox.2004.06.043; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Sheng ZG, 2012, TOXICOL APPL PHARM, V259, P133, DOI 10.1016/j.taap.2011.12.018; Soni MG, 2005, FOOD CHEM TOXICOL, V43, P985, DOI 10.1016/j.fct.2005.01.020; Spycher BD, 2009, PEDIATRICS, V123, P944, DOI 10.1542/peds.2008-0115; Spycher BD, 2008, J ALLERGY CLIN IMMUN, V122, P656, DOI 10.1016/j.jaci.2008.06.037; Tyl RW, 2002, TOXICOL SCI, V68, P121, DOI 10.1093/toxsci/68.1.121; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105; Witorsch RJ, 2010, CRIT REV TOXICOL, V40, P1, DOI 10.3109/10408444.2010.515563; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Ye XY, 2006, J CHROMATOGR B, V844, P53, DOI 10.1016/j.jchromb.2006.06.037; Ziolkowska A, 2006, INT J MOL MED, V18, P1165; Zorrilla LM, 2009, TOXICOL SCI, V107, P56, DOI 10.1093/toxsci/kfn225	48	145	155	1	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					453	+		10.1016/j.jaci.2012.05.006	http://dx.doi.org/10.1016/j.jaci.2012.05.006			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22704536	Green Accepted			2022-12-18	WOS:000307002200027
J	Miajlovic, H; Fallon, PG; Irvine, AD; Foster, TJ				Miajlovic, Helen; Fallon, Padraic G.; Irvine, Alan D.; Foster, Timothy J.			Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Filaggrin; Staphylococcus aureus; colonization; skin; atopic dermatitis	CAUSE ICHTHYOSIS VULGARIS; OF-FUNCTION MUTATIONS; ATOPIC-DERMATITIS; STRATUM-CORNEUM; NASAL CARRIAGE; METHICILLIN-RESISTANT; BINDING PROTEIN; UROCANIC ACID; SKIN; SURFACE	Background: Colonization of the skin by Staphylococcus aureus in individuals with atopic dermatitis exacerbates inflammation. Atopic dermatitis is associated with loss-of-function mutations in the filaggrin (FLG) gene, accompanied by reduced levels of filaggrin breakdown products on the skin. Objective: To assess the affect of growth in the presence of the filaggrin breakdown products urocanic acid (UCA) and pyrrolidone carboxylic acid (PCA) on fitness of and protein expression by S aureus. Methods: S aureus was grown for 24 hours in the presence of UCA and PCA, and the density of the cultures was monitored by recording OD600 values. Cell wall extracts and secreted proteins of S aureus were isolated and analyzed by SDS-PAGE. Cell wall-associated proteins known to be involved in colonization and immune evasion including clumping factor B, fibronectin binding proteins, protein A, iron-regulated surface determinant A, and the serine-aspartate repeat proteins were examined by Western immunoblotting. Results: Acidification of growth media caused by the presence of UCA and PCA resulted in reduced growth rates and reduced final cell density of S aureus. At the lower pH, reduced expression of secreted and cell wall-associated proteins, including proteins involved in colonization (clumping factor B, fibronectin binding protein A) and immune evasion (protein A), was observed. Decreased expression of iron-regulated surface determinant A due to growth with filaggrin breakdown products appeared to be independent of the decreased pH. Conclusion: S aureus grown under mildly acidic conditions such as those observed on healthy skin expresses reduced levels of proteins that are known to be involved in immune evasion. (J Allergy Clin Immunol 2010;126:1184-90.)	[Miajlovic, Helen; Foster, Timothy J.] Trinity Coll Dublin, Moyne Inst Prevent Med, Dublin 2, Ireland; [Fallon, Padraic G.; Irvine, Alan D.] Trinity Coll Dublin, Inst Mol Med, Dublin 2, Ireland; [Fallon, Padraic G.; Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Crumlin, Ireland	Trinity College Dublin; Trinity College Dublin; National Children's Research Centre (NCRC)	Foster, TJ (corresponding author), Trinity Coll Dublin, Moyne Inst Prevent Med, Dublin 2, Ireland.	tfoster@tcd.ie	Irvine, Alan D/A-3982-2008; Fallon, Padraic/Y-2711-2019	Irvine, Alan D/0000-0002-9048-2044; Fallon, Padraic/0000-0002-8401-7293; Miajlovic, Helen/0000-0001-8854-4309	Health Research Board of Ireland; National Children's Research Centre; Wellcome Trust	Health Research Board of Ireland; National Children's Research Centre; Wellcome Trust(Wellcome TrustEuropean Commission)	Supported by the Health Research Board of Ireland.; Disclosure of potential conflict of interest: A. D. Irvine has received research support from the National Children's Research Centre, Wellcome Trust, and Health Research Board of Ireland. T. J. Foster has received research support from the Health Research Board of Ireland. H. Miajlovic and P. G. Fallon have declared that they have no conflict of interest.	Akiyama H, 2002, J DERMATOL, V29, P580, DOI 10.1111/j.1346-8138.2002.tb00183.x; Behne MJ, 2002, J BIOL CHEM, V277, P47399, DOI 10.1074/jbc.M204759200; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Clarke SR, 2008, INFECT IMMUN, V76, P1518, DOI 10.1128/IAI.01530-07; Clarke SR, 2007, CELL HOST MICROBE, V1, P199, DOI 10.1016/j.chom.2007.04.005; Clarke SR, 2009, INFECT IMMUN, V77, P2408, DOI 10.1128/IAI.01304-08; Clarke SR, 2006, J INFECT DIS, V193, P1098, DOI 10.1086/501471; Corrigan RM, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-22; Diep BA, 2008, J INFECT DIS, V197, P1523, DOI 10.1086/587907; Downer R, 2002, J BIOL CHEM, V277, P243, DOI 10.1074/jbc.M107621200; Eberlein-Konig B, 2000, ACTA DERM-VENEREOL, V80, P188; Gomez MI, 2004, NAT MED, V10, P842, DOI 10.1038/nm1079; Hartford OM, 2001, J BIOL CHEM, V276, P2466, DOI 10.1074/jbc.M007979200; HARTFORD OM, 1997, MOL MICROBIOL, V26, P1065; HAUSER C, 1985, DERMATOLOGICA, V170, P35, DOI 10.1159/000249493; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Jin T, 2004, J IMMUNOL, V172, P1169, DOI 10.4049/jimmunol.172.2.1169; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Krien PM, 2000, J INVEST DERMATOL, V115, P414, DOI 10.1046/j.1523-1747.2000.00083.x; Kumaran D, 2001, ACTA CRYSTALLOGR D, V57, P1270, DOI 10.1107/S0907444901011118; Ladhani S, 2003, FEMS IMMUNOL MED MIC, V39, P181, DOI 10.1016/S0928-8244(03)00225-6; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Mempel M, 1998, J INVEST DERMATOL, V111, P452, DOI 10.1046/j.1523-1747.1998.00293.x; O'Brien LM, 2002, CELL MICROBIOL, V4, P759, DOI 10.1046/j.1462-5822.2002.00231.x; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Palma M, 2001, J BIOL CHEM, V276, P31691, DOI 10.1074/jbc.M104554200; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Perkins S, 2001, J BIOL CHEM, V276, P44721, DOI 10.1074/jbc.M106741200; Rippke F, 2004, AM J CLIN DERMATOL, V5, P217, DOI 10.2165/00128071-200405040-00002; Safer D, 2007, P NATL ACAD SCI USA, V104, P1627, DOI 10.1073/pnas.0610193104; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; SasaiTakedatsu M, 1997, ALLERGY, V52, P1012, DOI 10.1111/j.1398-9995.1997.tb02423.x; Schlievert PM, 2008, CLIN INFECT DIS, V46, P1562, DOI 10.1086/586746; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Sieprawska-Lupa M, 2004, ANTIMICROB AGENTS CH, V48, P4673, DOI 10.1128/AAC.48.12.4673-4679.2004; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Terada M, 2006, P NATL ACAD SCI USA, V103, P8816, DOI 10.1073/pnas.0602900103; van den Akker ELT, 2006, J INFECT DIS, V194, P814, DOI 10.1086/506367; Weinrick B, 2004, J BACTERIOL, V186, P8407, DOI 10.1128/JB.186.24.8407-8423.2004; Wertheim HFL, 2008, PLOS MED, V5, P104, DOI 10.1371/journal.pmed.0050017; Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4; Zollner TM, 2000, CLIN EXP ALLERGY, V30, P994	47	145	156	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1184	U182		10.1016/j.jaci.2010.09.015	http://dx.doi.org/10.1016/j.jaci.2010.09.015			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21036388	Green Published, hybrid			2022-12-18	WOS:000284947800016
J	Douwes, J; van Strien, R; Doekes, G; Smit, J; Kerkhof, M; Gerritsen, J; Postma, D; Travier, N; Brunekreef, B				Douwes, Jeroen; van Strien, Rob; Doekes, Gert; Smit, Jet; Kerkhof, Marian; Gerritsen, Jorrit; Postma, Dirkje; Travier, Noernie; Brunekreef, Bert			Does early indoor microbial exposure reduce the risk of asthma? The Prevention and Incidence of Asthma and Mite Allergy birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; endotoxin; (1 -> 3)-beta-D-glucan; hygiene hypothesis; infant cohort study	HOUSE-DUST ENDOTOXIN; CHILDREN; ATOPY; SENSITIZATION; INFANCY; LIFE; POLYMORPHISM; WHEEZE; AIRWAY; CD14	Background: Exposure to microbial agents might inhibit the development of atopy and asthma. Objective: We measured the association between microbial exposure assessed at 3 months and the development of atopic sensitization and doctor-diagnosed (DD) asthma and wheeze in the first 4 years in a birth cohort study of children with atopic mothers. Methods: Endotoxin, fungal (1 -> 3)-beta-D-glucans, extracellular polysaccharides from the genera Penicillium and Aspergillus (EPS-Pen/Asp), and dust on living room floors were measured at 3 months of age. Serum IgE levels against common allergens were determined at 1 and 4 years, and questionnaire information about respiratory morbidity was collected yearly. Results: Microbial levels in mattresses were low and not associated with serum IgE levels, DD asthma, and wheeze. Floor levels of biocontaminants and dust, on the other hand, were inversely associated with DD asthma, being most pronounced for endotoxin (odds ratio [OR], 0.40; 95% CI, 0.210.77) and EPS-Pen/Asp (OR, 0.42; 95% CI, 0.18-0.99). Mutual adjustment for other exposures did not significantly after the results for endotoxin and only moderately affected the results for EPS-Pen/Asp. Persistent wheeze was also consistently less common in the high-exposure group, being significant only for EPS-PenlAsp (OR, 0.37; 95% CI, 0.15-0.96). Transient wheeze and wheeze in the past 12 months were also reduced, but effects were smaller and not significant. Relationships with serum-specific IgE levels, which could only be assessed in 41% at age 4 years, were less pronounced and statistically significant only for EPS-Pen/Asp. Conclusions: Early exposure to common microbial contaminants, including fungal agents, might protect against asthma. Clinical implications: Microbial exposure in early life might protect against asthma and might constitute a novel target for prevention.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Municipal Hlth Serv, Dept Environm Med, Amsterdam, Netherlands; Natl Inst Publ Hlth & Environm, RIVM, Bilthoven, Netherlands; Univ Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Epidemiol, Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Pulm Med, Groningen, Netherlands; Erasmus Univ, Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Utrecht University; Massey University; Netherlands National Institute for Public Health & the Environment; University of Groningen; University of Groningen; University of Groningen; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Utrecht University	Brunekreef, B (corresponding author), Univ Utrecht, Inst Risk Assessment Sci, POB 80178, NL-3508 TD Utrecht, Netherlands.	B.Brunekreef@iras.uu.nl	Kerkhof, Marjan/A-8846-2008	Travier, Noemie/0000-0001-5228-7769; Douwes, Jeroen/0000-0003-3599-4036; brunekreef, bert/0000-0001-9908-0060				ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763, DOI 10.1128/AEM.61.5.1763-1769.1995; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176, DOI 10.1128/AEM.62.9.3176-3182.1996; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hastie T.J., 1990, GEN ADDITIVE MODELS, V43; Institute of Medicine (US) Committee on Damp Indoor Spaces and Health, 2004, DAMP IND SPAC HLTH; Jain VV, 2004, EXPERT OPIN BIOL TH, V4, P1533, DOI 10.1517/14712598.4.9.1533; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Singh J, 2005, J ALLERGY CLIN IMMUN, V115, P330, DOI 10.1016/j.jaci.2004.11.021; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	30	145	147	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1067	1073		10.1016/j.jaci.2006.02.002	http://dx.doi.org/10.1016/j.jaci.2006.02.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675334				2022-12-18	WOS:000237436300014
J	Meltzer, EO; Bachert, C; Staudinger, H				Meltzer, EO; Bachert, C; Staudinger, H			Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute rhinosinusitis; amoxicillin; intranasal corticosteroid; mometasone furoate; symptoms	SEASONAL ALLERGIC RHINITIS; ACUTE BACTERIAL RHINOSINUSITIS; ORAL ANTIBIOTIC-THERAPY; ACUTE SINUSITIS; GENERAL-PRACTICE; CONTROLLED TRIAL; ADULTS; MANAGEMENT; DIAGNOSIS; ADJUNCT	Background: Intranasal corticosteroids used with antibiotics are known to improve rhinosinusitis symptoms compared with antibiotic therapy alone. However, the efficacy of intranasal corticosteroid monotherapy for acute, uncomplicated rhinosinusitis is not established. Objectives: To evaluate efficacy and safety of mometasone furoate nasal spray (MFNS) versus amoxicillin and placebo in patients with acute, uncomplicated rhinosinusitis. Methods: In this double-blind, double-dummy trial, subjects (>= 12 years; N = 981) were randomized to MFNS 200 mu g once daily or twice daily for 15 days, amoxicillin 500 mg 3 times daily for 10 days, or respective placebo. Follow-up was 14 days. The primary efficacy endpoint was mean AM/PM major symptom score over the treatment phase. Secondary efficacy endpoints included total symptom score. Safety assessments included disease recurrence during follow-up and adverse event monitoring. Results: Mometasone furoate nasal spray 200 Kg twice daily was significantly superior to placebo (P < .001) and amoxicillin (P = .002) at improving major symptom score. Starting on day 2, MFNS 200 mu g twice daily improved total symptom score throughout treatment versus amoxicillin (P = .012) and placebo (P < .001). Global response to treatment was significantly greater with MFNS 200 mu g twice daily versus amoxicillin (P = .013) and placebo (P = .001). Although significantly superior to placebo, MFNS 200 mu g once daily was not superior to amoxicillin for the primary or secondary efficacy endpoints. All treatments were well tolerated with a similar incidence of adverse events. Conclusion: In patients with acute, uncomplicated rhinosinusitis, MFNS 200 mu g twice daily produced significant symptom improvements versus amoxicillin and placebo, without predisposing the patient to disease recurrence or bacterial infection.	Allergy & Asthma Med Grp & Res Ctr, San Diego, CA 92123 USA; State Univ Ghent Hosp, Dept Ear Nose & Throat, B-9000 Ghent, Belgium; Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA	Ghent University; Ghent University Hospital; Merck & Company; Schering Plough Corporation	Meltzer, EO (corresponding author), Allergy & Asthma Med Grp & Res Ctr, 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.	eomeltzer@aol.com	Bachert, Claus/J-8825-2012					Anon JB, 2004, OTOLARYNG HEAD NECK, V130, P1, DOI 10.1016/j.otohns.2003.12.003; Bachert C, 2003, ALLERGY, V58, P176, DOI 10.1034/j.1398-9995.2003.02172.x; Barlan IB, 1997, ANN ALLERG ASTHMA IM, V78, P598, DOI 10.1016/S1081-1206(10)63223-1; Berkowitz RB, 1999, ALLERGY ASTHMA PROC, V20, P167, DOI 10.2500/108854199778553037; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; Bucher HC, 2003, ARCH INTERN MED, V163, P1793, DOI 10.1001/archinte.163.15.1793; Casale TB, 1999, ALLERGY ASTHMA PROC, V20, P193, DOI 10.2500/108854199778553046; Corey J P, 2000, Ear Nose Throat J, V79, P690; Davies RJ, 1997, CLIN THER, V19, P27; de Ferranti SD, 1998, BMJ-BRIT MED J, V317, P632, DOI 10.1136/bmj.317.7159.632; Dolor RJ, 2001, JAMA-J AM MED ASSOC, V286, P3097, DOI 10.1001/jama.286.24.3097; Felmingham D, 2002, J ANTIMICROB CHEMOTH, V50, P1, DOI 10.1093/jac/dkf807; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hickner JM, 2001, ANN INTERN MED, V134, P498, DOI 10.7326/0003-4819-134-6-200103200-00017; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V106, P630, DOI 10.1067/mai.2000.109056; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V89, P271, DOI 10.1016/S1081-1206(10)61954-0; Osguthorpe JD, 2001, AM FAM PHYSICIAN, V63, P69; ROPER PUBLIC AFFAIRS GROUP OF NOP WORLD, 2004, IMP NAS CONG ALL RHI; Scheid DC, 2004, AM FAM PHYSICIAN, V70, P1697; Schenkel E, 2003, EXPERT OPIN PHARMACO, V4, P1579, DOI 10.1517/14656566.4.9.1579; Spector S L, 1998, J Allergy Clin Immunol, V102, pS107; Stalman W, 1997, BRIT J GEN PRACT, V47, P794; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; WILLIAMS JW, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000243	25	145	161	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1289	1295		10.1016/j.jaci.2005.08.044	http://dx.doi.org/10.1016/j.jaci.2005.08.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337461				2022-12-18	WOS:000235687000020
J	Norjavaara, E; de Verdier, MG				Norjavaara, E; de Verdier, MG			Normal pregnancy outcomes in a population-based study including 2968 pregnant women exposed to budesonide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled corticosteroids; budesonide; pregnancy; growth	CONGENITAL ADRENAL-HYPERPLASIA; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; ASTHMA; CORTICOSTEROIDS; THERAPY; MALFORMATIONS; HYPERTENSION; SAFETY; TYPE-2; FETAL	Background: Inhaled corticosteroids are recommended as first-line therapy for pregnant women with moderate to severe asthma, although the effects on pregnancy outcome are uncertain. A low compliance with the recommendations might lead to inadequate control of asthma, which has been associated with adverse outcomes both for the mother and the infant. Objective: To investigate whether the reported use of inhaled budesonide (Pulmicort) during pregnancy influences birth outcome. Methods: Data were derived from the Swedish Medical Birth Register, which includes 99% of births in Sweden. During 1995 to 1998, 293,948 newborn infants were identified. Pregnancy outcomes were compared for mothers in Sweden reporting asthma medication usage with those reporting no asthma medication usage. Results: The 2968 mothers who reported use of inhaled budesonide during early pregnancy gave birth to infants of normal gestational age, birth weight, and length, with no increased rate of stillbirths or multiple births. The rate of caesarean births was higher among mothers who used asthma medication during their pregnancy than among the control group. Conclusions: The use of inhaled budesonide in Sweden is not linked with any clinically relevant effects associated with pregnancy outcome.	AstraZeneca Molndal, SE-43183 Molndal, Sweden; AstraZeneca Molndal, Lund, Sweden; Univ Gothenburg, Sahlgrenska Univ Hosp Ostra, Queen Silvia Childrens Hosp, Goteborg Paediat Growth Res Ctr, Gothenburg, Sweden	AstraZeneca; AstraZeneca; Queen Silvia Children's Hospital; Sahlgrenska University Hospital; University of Gothenburg	Norjavaara, E (corresponding author), AstraZeneca Molndal, SE-43183 Molndal, Sweden.			Norjavaara, Ensio/0000-0003-0415-4843				AUSHUS RJ, 2001, ENDOCRINOLOGY, P1616; BAXTER H, 1950, McGill Med J, V19, P245; Callaghan ML, 2000, ANN ALLERG ASTHMA IM, V84, P475, DOI 10.1016/S1081-1206(10)62505-7; Carlson AD, 1999, J STEROID BIOCHEM, V69, P19, DOI 10.1016/S0960-0760(99)00059-X; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Czeizel AE, 1997, TERATOLOGY, V56, P335, DOI 10.1002/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO;2-W; Dombrowski MP, 1997, OBSTET GYN CLIN N AM, V24, P559, DOI 10.1016/S0889-8545(05)70322-3; DUPONT E, 1991, ENDOCRINOLOGY, V129, P2687, DOI 10.1210/endo-129-5-2687; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; ERICSON A, 1999, SWEDISH MED PRODUCTS, V1, P8; Forest MG, 1998, TRENDS ENDOCRIN MET, V9, P284, DOI 10.1016/S1043-2760(98)00067-8; Jadad AR, 2000, LANCET, V355, P119, DOI 10.1016/S0140-6736(99)02542-8; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Kallen B, 1999, OBSTET GYNECOL, V93, P392, DOI 10.1016/S0029-7844(98)00454-2; Lajic S, 1998, J CLIN ENDOCR METAB, V83, P3872, DOI 10.1210/jc.83.11.3872; LangleyEvans SC, 1997, CLIN SCI, V93, P423, DOI 10.1042/cs0930423; Lipworth BJ, 2000, DRUG SAFETY, V23, P11, DOI 10.2165/00002018-200023010-00002; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; MOLITH ME, 2001, ENDOCRINOLOGY, P2489; *NIH NAT HEART LUN, 1993, NIH PUBL; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; ROBERT E, 1994, RISK SAFETY MED, V6, P78; Rodriguez-Pinilla E, 1998, TERATOLOGY, V58, P2, DOI 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4; Schardein J. L., 2000, CHEM INDUCED BIRTH D; Schatz M, 1999, J ALLERGY CLIN IMMUN, V103, pS330, DOI 10.1016/S0091-6749(99)70258-7; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Seckl JR, 1997, STEROIDS, V62, P89, DOI 10.1016/S0039-128X(96)00165-1; STENIUSAARNIALA B, 1995, CHEST, V107, P642, DOI 10.1378/chest.107.3.642; Stewart PM, 1995, J STEROID BIOCHEM, V55, P465, DOI 10.1016/0960-0760(95)00195-6; WALKER BE, 1965, SCIENCE, V149, P862, DOI 10.1126/science.149.3686.862	32	145	148	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					736	742		10.1067/mai.2003.1340	http://dx.doi.org/10.1067/mai.2003.1340			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704351	Bronze			2022-12-18	WOS:000182258500011
J	McHugh, RS; Shevach, EM				McHugh, RS; Shevach, EM			The role of suppressor T cells in regulation of immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						CD4(+) CD25(+) T cells; immunoregulation; tolerance; autoimmunity; tumor immunity; chronic infection; allergy; immunotherapy	GROWTH-FACTOR-BETA; IN-VIVO; AUTOIMMUNE-DISEASE; SELF-TOLERANCE; TRANSPLANTATION TOLERANCE; INTESTINAL INFLAMMATION; IMMUNOREGULATORY CELLS; ANTITUMOR IMMUNITY; EFFECTOR FUNCTION; TUMOR REJECTION	Suppressor T cells play important roles in the regulation of immune responses and the mediation of dominant immunologic tolerance. Studies of suppressor T-cell function have been hampered until their recent identification as a minor fraction (approximately 10%) of CD4(+) T cells that coexpress CD25. CD4(+)CD25(+) T cells have been shown to play a critical role in the prevention of organ-specific autoimmunity and allograft rejection. Because tumor antigens are self-antigens, it is not surprising that CD4(+)CD25(+) T cells also inhibit the induction of tumor immunity. The spectrum of activity of CD4(+)CD25(+) cells extends to non-self-antigens, including infectious agents. Indeed, T cell-mediated suppression might be responsible for the low level of chronic infection seen with many pathogens. Interestingly, however, this persistent level of infection might be beneficial to the host and needed for maintenance of immunologic memory. Although CD4(+)CD25(+) T cells are capable of inhibiting T(H)2 responses, their role in the suppression of allergic responses has not been firmly established. Depending on the desired immune response, enhancement or restraint of suppressor T-cell function might be required. Therefore immunologic or pharmacologic manipulation of regulatory T-cell populations represents an important future approach to immunotherapy of a wide range of immune responses.	NIAID, Cellular Immunol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Shevach, EM (corresponding author), NIAID, Cellular Immunol Sect, Immunol Lab, NIH, 9000 Rockville Pike,Bldg 10,Rm 11N311, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000224, Z01AI000224] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aranda R, 1997, J IMMUNOL, V158, P3464; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; AWWAD M, 1989, CANCER RES, V49, P1649; AWWAD M, 1988, CANCER IMMUNOL IMMUN, V26, P55; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; BELKAID Y, 2002, IN PRESS NATURE; BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; BURSUKER I, 1985, CANCER IMMUNOL IMMUN, V19, P215; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Coutinho A, 2001, IMMUNOL REV, V182, P89, DOI 10.1034/j.1600-065X.2001.1820107.x; Dieckmann D, 2002, J EXP MED, V196, P247, DOI 10.1084/jem.20020642; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; Geissler M, 2001, GASTROENTEROLOGY, V121, P931, DOI 10.1053/gast.2001.28019; Graca L, 2002, J EXP MED, V195, P1641, DOI 10.1084/jem.20012097; Graca L, 2002, J IMMUNOL, V168, P5558, DOI 10.4049/jimmunol.168.11.5558; Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HALL BM, 1985, J EXP MED, V162, P1683, DOI 10.1084/jem.162.5.1683; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789; Hori S, 2002, EUR J IMMUNOL, V32, P1282, DOI 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#; Iwashiro M, 2001, P NATL ACAD SCI USA, V98, P9226, DOI 10.1073/pnas.151174198; Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080; KOJIMA A, 1976, LAB INVEST, V34, P601; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; MacDonald AJ, 2002, J INFECT DIS, V185, P720, DOI 10.1086/339340; Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; McHugh RS, 2002, J IMMUNOL, V168, P5979, DOI 10.4049/jimmunol.168.12.5979; McHugh RS, 2001, MICROBES INFECT, V3, P919, DOI 10.1016/S1286-4579(01)01453-8; MOHLER KM, 1989, TRANSPLANTATION, V47, P625, DOI 10.1097/00007890-198904000-00013; NISHIZUK.Y, 1969, SCIENCE, V166, P753, DOI 10.1126/science.166.3906.753; NORTH RJ, 1982, J EXP MED, V155, P1063, DOI 10.1084/jem.155.4.1063; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Onizuka S, 1999, CANCER RES, V59, P3128; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; ROTHS JB, 1992, J CLIN INVEST, V90, P673, DOI 10.1172/JCI115910; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Sanchez-Fueyo A, 2002, J IMMUNOL, V168, P2274, DOI 10.4049/jimmunol.168.5.2274; Seddon B, 1999, J EXP MED, V189, P877, DOI 10.1084/jem.189.5.877; Seddon B, 1999, J EXP MED, V189, P279, DOI 10.1084/jem.189.2.279; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; Shimizu J, 1999, J IMMUNOL, V163, P5211; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Steitz J, 2001, CANCER RES, V61, P8643; Stephens LA, 2000, J IMMUNOL, V165, P3105, DOI 10.4049/jimmunol.165.6.3105; Suri-Payer E, 2001, J AUTOIMMUN, V16, P115, DOI 10.1006/jaut.2000.0473; Suri-Payer E, 1999, EUR J IMMUNOL, V29, P669, DOI 10.1002/(SICI)1521-4141(199902)29:02<669::AID-IMMU669>3.0.CO;2-J; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Suto A, 2001, AM J RESP CRIT CARE, V164, P680, DOI 10.1164/ajrccm.164.4.2010170; Taguchi O, 1996, EUR J IMMUNOL, V26, P1608, DOI 10.1002/eji.1830260730; TAGUCHI O, 1994, IMMUNOLOGY, V82, P365; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; Taylor PA, 2001, J EXP MED, V193, P1311, DOI 10.1084/jem.193.11.1311; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Zelenika D, 2002, J IMMUNOL, V168, P1069, DOI 10.4049/jimmunol.168.3.1069; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	78	145	164	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					693	702		10.1067/mai.2002.129339	http://dx.doi.org/10.1067/mai.2002.129339			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417876				2022-12-18	WOS:000179082500002
J	Pochard, P; Gosset, P; Grangette, C; Andre, C; Tonnel, AB; Pestel, J; Mercenier, A				Pochard, P; Gosset, P; Grangette, C; Andre, C; Tonnel, AB; Pestel, J; Mercenier, A			Lactic acid bacteria inhibit T(H)2 cytokine production by mononuclear cells from allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; type 2 cytokine; lactic acid bacteria; immunomodulation; superantigen; dust mite	INTERLEUKIN-12 IL-12; PROBIOTICS; LACTOBACILLI; CHILDHOOD; RESPONSES; MICE	Background: Among factors potentially involved in the increased prevalence of allergic diseases, modification of the intestinal bacteria flora or lack of bacterial stimulation during childhood has been proposed. Lactic acid bacteria (LAB) present in fermented foods or belonging to the natural intestinal microflora were shown to exert beneficial effects on human health. Recent reports have indicated their capacity to reduce allergic symptoms. Objective: The purpose of this investigation was to determine the effect of LAB on the production of type 2 cytokines, which characterize allergic diseases. Methods: PBMCs from patients allergic to house dust mite versus those from healthy donors were stimulated for 48 hours with the related Dermatophagoides pteronyssinus allergen or with a staphylococcal superantigen. The effect of LAB preincubation was assessed by measuring the type 2 cytokine production by means of specific ELISA. Results: The tested gram-positive LAB were shown to inhibit the secretion of T(H)2 cytokines (IL-4 and IL-5). This effect was dose dependent and was observed irrespective of the LAB strain used. No significant inhibition was induced by the control, gram-negative Escherichia coli TG1. Interestingly, LAB reduced the T(H)2 cytokine production from allergic PBMCs specifically restimulated with the related allergen. The inhibition mechanism was shown to be dependent on antigen-presenting cells (ie, monocytes) and on the involvement of IL-12 and IFN-gamma. Conclusion: The tested LAB strains were demonstrated to exhibit an anti-T(H)2 activity, and thus different, strains of this family might be useful in the prevention of allergic diseases.	Inst Pasteur, INSERM U 416, F-59019 Lille, France; Inst Biol, Lab Bacteriol Ecosyst, Lille, France; Stallergenes SA, Antony, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Stallergenes Greer	Pestel, J (corresponding author), Inst Pasteur, INSERM U 416, 1 Rue Prof Calmette,BP 425,IFR 17, F-59019 Lille, France.		Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429; Pochard, Pierre/0000-0002-5608-7286				Bengmark S, 2001, CURR OPIN CLIN NUTR, V4, P571, DOI 10.1097/00075197-200111000-00019; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bjorksten B, 1997, CLIN REV ALLERG IMMU, V15, P125, DOI 10.1007/BF02826583; Bjorksten B, 1999, ALLERGY, V54, P17, DOI 10.1111/j.1398-9995.1999.tb04383.x; Cameron SB, 2001, EUR CYTOKINE NETW, V12, P210; Drouault S, 2001, VET RES, V32, P101, DOI 10.1051/vetres:2001115; Fooks LJ, 1999, INT DAIRY J, V9, P53, DOI 10.1016/S0958-6946(99)00044-8; Hessle C, 2000, INFECT IMMUN, V68, P3581, DOI 10.1128/IAI.68.6.3581-3586.2000; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Julge K, 1997, ACTA PAEDIATR, V86, P1188, DOI 10.1111/j.1651-2227.1997.tb14842.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kopp-Hoolihan L, 2001, J AM DIET ASSOC, V101, P229, DOI 10.1016/S0002-8223(01)00060-8; Lee YK, 2000, APPL ENVIRON MICROB, V66, P3692, DOI 10.1128/AEM.66.9.3692-3697.2000; Maassen CBM, 1998, VET QUART, V20, pS81; Marteau PR, 2001, AM J CLIN NUTR, V73, p430S, DOI 10.1093/ajcn/73.2.430s; MARTINEZ FD, 1999, LANCET S2, V354; Matsuzaki T, 2000, IMMUNOL CELL BIOL, V78, P67, DOI 10.1046/j.1440-1711.2000.00887.x; Matsuzaki T, 1998, J DAIRY SCI, V81, P48, DOI 10.3168/jds.S0022-0302(98)75549-3; Miettinen M, 2000, J IMMUNOL, V164, P3733, DOI 10.4049/jimmunol.164.7.3733; Miettinen M, 1998, INFECT IMMUN, V66, P6058, DOI 10.1128/IAI.66.12.6058-6062.1998; Muller-Alouf H., 1999, Immunology Letters, V69, P33; Murch SH, 2001, LANCET, V357, P1057, DOI 10.1016/S0140-6736(00)04305-1; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Ouwehand AC, 1999, INT DAIRY J, V9, P43, DOI 10.1016/S0958-6946(99)00043-6; Robinson DS, 1996, CHEM IMMUNOL, V63, P187; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458	27	145	161	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					617	623		10.1067/mai.2002.128528	http://dx.doi.org/10.1067/mai.2002.128528			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373271				2022-12-18	WOS:000178501900013
J	SWEET, JM; STEVENSON, DD; SIMON, RA; MATHISON, DA				SWEET, JM; STEVENSON, DD; SIMON, RA; MATHISON, DA			LONG-TERM EFFECTS OF ASPIRIN DESENSITIZATION - TREATMENT FOR ASPIRIN-SENSITIVE RHINOSINUSITIS-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN W248,DEPT BASIC & CLIN RES,DIV ALLERGY & IMMUNOL,10666 N TORREY PINES RD,LA JOLLA,CA 92037	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00833] Funding Source: Medline; NIAID NIH HHS [AI-10386] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARM JP, 1988, J ALLERGY CLIN IMMUN, V83, P187; BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; LOCKEY RF, 1978, HOSP PRACT, V13, P129, DOI 10.1080/21548331.1978.11707389; LOCKEY RF, 1973, ANN INTERN MED, V78, P57, DOI 10.7326/0003-4819-78-1-57; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; MATHIEU D, 1983, UROL RADIOL, V5, P17, DOI 10.1007/BF02926763; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; NAEIJE N, 1984, ANN ALLERGY, V53, P262; NELSON RP, 1986, NEW ENGL REG ALLERGY, V7, P117; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; STEVENSON DD, 1987, J ALLERGY CLIN IMMUN, V80, P788, DOI 10.1016/S0091-6749(87)80266-X; STEVENSON DD, 1986, NEW ENGL REG ALLERGY, V7, P101; SZCZEKLIK A, 1978, THORAX, V33, P664, DOI 10.1136/thx.33.5.664; Widal M, 1922, PRESSE MED, V30, P189; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P400	20	145	145	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				59	65		10.1016/0091-6749(90)90222-P	http://dx.doi.org/10.1016/0091-6749(90)90222-P			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299107				2022-12-18	WOS:A1990CM37800010
J	SPANER, D; DOLOVICH, J; TARLO, S; SUSSMAN, G; BUTTOO, K				SPANER, D; DOLOVICH, J; TARLO, S; SUSSMAN, G; BUTTOO, K			HYPERSENSITIVITY TO NATURAL LATEX	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TORONTO,DEPT MED,202 ST CLAIR AVE W,TORONTO M4V 1R2,ONTARIO,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA	University of Toronto; McMaster University				Tarlo, Susan/0000-0002-4746-5310				AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; Cronin E., 1980, RUBBER CONTACT DERMA, P714; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P33, DOI 10.1111/j.1600-0536.1980.tb03887.x; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; KLEINHANS D, 1984, CONTACT DERMATITIS, V10, P124, DOI 10.1111/j.1600-0536.1984.tb00363.x; Kopman A, 1983, Duodecim, V99, P221; LEYNADIER F, 1988, PRESSE MED, V17, P390; MEDING B, 1984, CONTACT DERMATITIS, V10, P52, DOI 10.1111/j.1600-0536.1984.tb00071.x; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; TAYLOR JS, 1986, CONTACT DERMATITIS, P603; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; 1983, BLUE BOOK 1983, P576	15	145	145	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1135	1137		10.1016/0091-6749(89)90457-0	http://dx.doi.org/10.1016/0091-6749(89)90457-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2525140				2022-12-18	WOS:A1989AC23500019
J	Guttman-Yassky, E; Thaci, D; Pangan, AL; Hong, HCH; Papp, KA; Reich, K; Beck, LA; Mohamed, MEF; Othman, AA; Anderson, JK; Gu, YH; Teixeira, HD; Silverberg, JI				Guttman-Yassky, Emma; Thaci, Diamant; Pangan, Aileen L.; Hong, H. Chih-ho; Papp, Kim A.; Reich, Kristian; Beck, Lisa A.; Mohamed, Mohamed-Eslam F.; Othman, Ahmed A.; Anderson, Jaclyn K.; Gu, Yihua; Teixeira, Henrique D.; Silverberg, Jonathan I.			Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; randomized clinical trial; eczema; efficacy; Janus kinase; placebo-controlled; upadacitinib; safety	ACTIVATION; DUPILUMAB; FEATURES; BURDEN; AD	Background: Atopic dermatitis is a chronic inflammatory skin disease characterized by pruritic skin lesions. Objective: We sought to evaluate the safety and efficacy of multiple doses of the selective Janus kinase 1 inhibitor upadacitinib in patients with moderate to severe atopic dermatitis. Methods: In the 16-week, double-blind, placebo-controlled, parallel-group, dose-ranging portion of this 88-week trial in 8 countries (ClinicalTrials.gov, NCT02925117; ongoing, not recruiting), adults with moderate to severe disease and inadequate control by topical treatment were randomized 1:1:1:1, using an interactive response system and stratified geographically, to once-daily upadacitinib oral monotherapy 7.5, 15, or 30 mg or placebo. The primary end point was percentage improvement in Eczema Area and Severity Index from baseline at week 16. Efficacy was analyzed by intention-to-treat in all randomized patients. Safety was analyzed in all randomized patients who received study medication, based on actual treatment. Results: Patients (N = 167) enrolled from November 21, 2016, to April 20, 2017. All were randomized and analyzed for efficacy (each upadacitinib group, n = 42; placebo, n = 41); 166 were analyzed for safety (each upadacitinib group, n = 42; placebo, n = 40). The mean (SE) primary efficacy end point was 39% (6.2%), 62% (6.1%), and 74% (6.1%) for the upadacitinib 7.5-, 15-, and 30-mg groups, respectively, versus 23% (6.4%) for placebo (P = .03, <.001, and <.001). Serious adverse events occurred in 4.8% (2 of 42), 2.4% (1 of 42), and 0% (0 of 42) of upadacitinib groups (vs 2.5% [1 of 40] for placebo). Conclusions: A dose-response relationship was observed for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit. Dose-limiting toxicity was not observed.	[Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, 5 East 98th St, New York, NY 10029 USA; [Thaci, Diamant] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany; [Pangan, Aileen L.; Anderson, Jaclyn K.; Teixeira, Henrique D.] AbbVie Inc, Immunol Clin Dev, N Chicago, IL USA; [Hong, H. Chih-ho] Univ British Columbia & Prob Med Res, Dept Dermatol & Skin Sci, Surrey, BC, Canada; [Papp, Kim A.] Prob Med Res & K Papp Clin Res, Waterloo, ON, Canada; [Reich, Kristian] Univ Med Ctr Hamburg Eppendorf, Translat Res Inflammatory Skin Dis, Inst Hlth Serv Res Dermatol & Nursing, Hamburg, Germany; [Reich, Kristian] Skinflammat Ctr, Hamburg, Germany; [Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14642 USA; [Mohamed, Mohamed-Eslam F.; Othman, Ahmed A.] AbbVie Inc, Clin Pharmacol & Pharmacometr, N Chicago, IL USA; [Gu, Yihua] AbbVie Inc, Data & Stat Sci, N Chicago, IL USA; [Silverberg, Jonathan I.] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA	Icahn School of Medicine at Mount Sinai; University of Lubeck; AbbVie; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Rochester; AbbVie; AbbVie; George Washington University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, 5 East 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org	silverberg, jonathan/ABH-2765-2021; Thaci, Diamant/AAE-7310-2022	silverberg, jonathan/0000-0003-3686-7805; Othman, Ahmed/0000-0002-4937-2775; Mohamed, Mohamed-Eslam/0000-0003-0959-2025	AbbVie Inc	AbbVie Inc(AbbVie)	AbbVie Inc funded the study, contributed to the design of the study, and was involved in the collection, analysis, and interpretation of the data and in the writing, review, and approval of the publication.	[Anonymous], 2017, BMJ, V357, DOI [DOI 10.1136/BMJ.J1415, 10.1136/bmj.j2212, DOI 10.1136/BMJ.J2212]; Bao L, 2013, JAK STAT; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Boguniewicz M, 2018, ANN ALLERG ASTHMA IM, V120, P10, DOI 10.1016/j.anai.2017.10.039; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Cotter DG, 2018, J AM ACAD DERMATOL, V78, pS53, DOI 10.1016/j.jaad.2017.12.019; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; Drucker AM, 2017, ALLERGY ASTHMA PROC, V38, P3, DOI 10.2500/aap.2017.38.4005; Guttman-Yassky E, 2019, J AM ACAD DERMATOL, V80, P913, DOI 10.1016/j.jaad.2018.01.018; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Kim JP, 2016, J AM ACAD DERMATOL, V75, P681, DOI 10.1016/j.jaad.2016.05.028; Lee HH, 2019, J AM ACAD DERMATOL, V80, P1526, DOI 10.1016/j.jaad.2018.05.1241; Mohamed MEF, 2019, CLIN PHARM DRUG DEV, V8, P208, DOI 10.1002/cpdd.462; Mohamed MEF, 2016, CLIN PHARMACOKINET, V55, P1547, DOI 10.1007/s40262-016-0419-y; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Norman P, 2014, EXPERT OPIN INV DRUG, V23, P1067, DOI 10.1517/13543784.2014.918604; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Parmentier JM, 2018, BMC RHEUMATOL, V2, DOI 10.1186/s41927-018-0031-x; Silverberg JI, 2017, DERMATOL CLIN, V35, P283, DOI 10.1016/j.det.2017.02.002; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wollenberg A, 2018, J EUR ACAD DERMATOL, V32, P850, DOI 10.1111/jdv.14888	26	144	150	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					877	884		10.1016/j.jaci.2019.11.025	http://dx.doi.org/10.1016/j.jaci.2019.11.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31786154	hybrid			2022-12-18	WOS:000518756700025
J	Sullivan, PW; Ghushchyan, VH; Globe, G; Schatz, M				Sullivan, Patrick W.; Ghushchyan, Vahram H.; Globe, Gary; Schatz, Michael			Oral corticosteroid exposure and adverse effects in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral corticosteroids; adverse effects; severe asthma; burst therapy	DOSE-RESPONSE RELATIONSHIP; INHALED CORTICOSTEROIDS; UNITED-STATES; COMPLICATIONS; EVENTS	Background: Significant adverse effects (AEs) have been associated with continuous exposure to oral corticosteroids (OCSs). The potential association with intermittent exposure is unknown. Objective: We sought to assess the association between OCSs and AEs based on the number of OCS prescriptions. Methods: This was a retrospective cohort study of asthmatic patients 18 years and older in the 2000-2014 MarketScan data set. Propensity score matching was used at baseline (12 months before the index date: first OCS use). Logistic regression was used to examine the association between OCSs and new incident AEs (either combined or individual) controlling for covariates. Follow-up continued for 24 months minimum and 10 years maximum after the index date. Results: There were 72,063 and 156,373 subjects in the OCS and no OCS cohorts, respectively. Subjects taking 4 or more OCS (1-3) prescriptions within the year had 1.29 (1.04) times the odds of experiencing a new AE within the year. Each year of exposure to 4 or more OCS prescriptions (current and past) resulted in 1.20 times the odds of having an AE in the current year. Exposure to 4 or more prescriptions was associated with significantly greater odds of AEs for osteoporosis, hypertension, obesity, type 2 diabetes, gastrointestinal ulcers/bleeds, fractures, and cataracts (odds, 1.21-1.44 depending on the AE). Conclusion: Although previous research has documented the deleterious effect of continuous OCS exposure in patients with severe asthma, our results suggest that each OCS prescription might result in a cumulative burden on current and future health regardless of dose and duration. OCS-sparing strategies are extremely important to improve patient outcomes.	[Sullivan, Patrick W.] Regis Univ, Sch Pharm, 3333 Regis Blvd,H-28, Denver, CO 80221 USA; [Ghushchyan, Vahram H.] Univ Colorado Aurora, Dept Clin Pharm, Ctr Pharmaceut Outcomes Res, Aurora, CO USA; [Ghushchyan, Vahram H.] Amer Univ Armenia, Yerevan, Armenia; [Globe, Gary] Amgen Inc, Thousand Oaks, CA USA; [Schatz, Michael] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA	Regis University; University of Colorado System; University of Colorado Anschutz Medical Campus; American University of Armenia; Amgen; Kaiser Permanente	Sullivan, PW (corresponding author), Regis Univ, Sch Pharm, 3333 Regis Blvd,H-28, Denver, CO 80221 USA.	psulliva@regis.edu			Amgen	Amgen(Amgen)	Supported by Amgen.	Braunstahl GJ, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-47; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Fardet L, 2007, DRUG SAFETY, V30, P861, DOI 10.2165/00002018-200730100-00005; Global Initiative for Asthma (GINA) National Heart Lung and Blood Institute (NHLBI), 2012, GLOB STRAT ASTHM MAN; Lefebvre P, 2015, J ALLERGY CLIN IMMUN, V136, P1488, DOI 10.1016/j.jaci.2015.07.046; Leone FT, 2003, CHEST, V124, P2329, DOI 10.1378/chest.124.6.2329; Leuven E, 2003, STAT SOFTWARE COMPON; Matsumoto H, 2001, CHEST, V120, P1468, DOI 10.1378/chest.120.5.1468; RUBIN DB, 1980, BIOMETRICS, V36, P293, DOI 10.2307/2529981; Sarnes E, 2011, CLIN THER, V33, P1413, DOI 10.1016/j.clinthera.2011.09.009; Shah M, 2013, CLIN THER, V35, P486, DOI 10.1016/j.clinthera.2013.03.001; Sullivan PW, 2006, MED DECIS MAKING, V26, P410, DOI 10.1177/0272989X06290495; Sullivan PW, 2015, J ASTHMA, V52, P669, DOI 10.3109/02770903.2015.1004683; Weatherall M, 2008, CLIN EXP ALLERGY, V38, P1451, DOI 10.1111/j.1365-2222.2008.03029.x; Weatherall M, 2009, RESPIROLOGY, V14, P983, DOI 10.1111/j.1440-1843.2009.01589.x; Zeiger RS, 2015, J ALLER CL IMM-PRACT, V3, P986, DOI 10.1016/j.jaip.2015.06.016	16	144	146	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					110	+		10.1016/j.jaci.2017.04.009	http://dx.doi.org/10.1016/j.jaci.2017.04.009			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28456623	Bronze			2022-12-18	WOS:000419312200017
J	Bergmann, KC; Demoly, P; Worm, M; Fokkens, WJ; Carrillo, T; Tabar, AI; Nguyen, H; Montagut, A; Zeldin, RK				Bergmann, Karl-Christian; Demoly, Pascal; Worm, Margitta; Fokkens, Wytske J.; Carrillo, Teresa; Tabar, Ana I.; Nguyen, Helene; Montagut, Armelle; Zeldin, Robert K.			Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; double-blind; placebo-controlled; sublingual immunotherapy tablets; house dust mite	DOUBLE-BLIND; PERENNIAL RHINITIS; CLINICAL-TRIALS; IMMUNOTHERAPY; ASTHMA; ORGANIZATION; TOLERABILITY; MONTELUKAST; LORATADINE; CHILDREN	Background: Preliminary studies have suggested the efficacy of sublingual tablets of house dust mite (HDM) extracts in adults with allergic rhinitis. Objectives: We sought to assess the efficacy and safety of 2 doses of HDM sublingual tablets over 1 treatment year and the subsequent immunotherapy-free year. Methods: Adults with HDM-associated allergic rhinitis were randomized in a double-blind, placebo-controlled study to receive 500 index of reactivity (IR) tablets, 300IR tablets, or placebo administered once daily for 1 year and were followed for the subsequent year. The primary efficacy variable was the Average Adjusted Symptom Score over the year 1 primary period (ie, October 1 to December 31). Symptoms and rescue medication scores, onset of action, patient-reported outcomes, and safety were secondary variables. The same end points were evaluated during the immunotherapy-free year. The primary efficacy end point was analyzed by using analysis of covariance. Results: Five hundred nine participants were randomized, and 427 continued in the immunotherapy-free year. Both the 500IR and 300IR HDM sublingual tablets significantly reduced mean Average Adjusted Symptom Scores compared with placebo by -20.2% (P = .0066) and -17.9% (P = .0150), respectively. Efficacy of both doses was maintained during the treatment-free follow-up phase. The onset of action was at 4 months. Participants' global evaluation of treatment success was significantly higher in the 500IR and 300IR groups compared with the placebo group (P = .0206 and P = .0001, respectively). Adverse events were generally application-site reactions. There were no reports of anaphylaxis. Conclusions: Twelve months of treatment with 500IR and 300IR sublingual tablets of HDM allergen extracts was efficacious and well tolerated. Efficacy was maintained during the treatment-free follow-up year.	[Bergmann, Karl-Christian; Worm, Margitta] Charite, Allergy Ctr Charite, D-10117 Berlin, Germany; [Demoly, Pascal] CHU Montpellier, Dept Allergol, Montpellier, France; [Fokkens, Wytske J.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Carrillo, Teresa] Hosp Univ Gran Canaria Dr Negrin, Dept Allergol, Las Palmas Gran Canaria, Spain; [Tabar, Ana I.] Compleio Hosp Navarra, Dept Allergy, Pamplona, Spain	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universite de Montpellier; CHU de Montpellier; University of Amsterdam; Academic Medical Center Amsterdam; Servicio Navarro de Salud - Osasunbidea	Bergmann, KC (corresponding author), Charite, Allergy Ctr Charite, Dept Dermatol & Allergy, Campus Mitte,Luisenstr 2-5, D-10117 Berlin, Germany.	karlchristianbergmann@googlemail.com	Fokkens, Wytske WJ/ABF-2185-2020; Bergmann, Karl-Christian/AAA-4104-2019; Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964; Worm, Margitta/0000-0002-3449-1245; Bergmann, Karl-Christian/0000-0002-0306-9922	Stallergenes S.A.	Stallergenes S.A.	Supported by Stallergenes S.A.	Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet PJ, 2011, J ALLERGY CLIN IMMUN, V127, P49, DOI 10.1016/j.jaci.2010.09.017; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Canonica GW, 2011, J ALLERGY CLIN IMMUN, V127, P44, DOI 10.1016/j.jaci.2010.09.037; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; del Cuvillo A, 2011, J INVEST ALLERG CLIN, V21, P40; Demoly P, 2008, J ALLERGY CLIN IMMUN, V121, pS128, DOI 10.1016/j.jaci.2007.12.509; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Eifan AO, 2011, CURR OPIN ALLERGY CL, V11, P586, DOI 10.1097/ACI.0b013e32834cb994; Fernandez-Caldas E, 2006, CURR ALLERGY ASTHM R, V6, P413, DOI 10.1007/s11882-996-0015-6; Grouin JM, 2011, CLIN EXP ALLERGY, V41, P1282, DOI 10.1111/j.1365-2222.2011.03700.x; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; MOSBECH H, 1985, ALLERGY, V40, P81, DOI 10.1111/j.1398-9995.1985.tb02665.x; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592, DOI 10.1016/S1081-1206(10)61891-1; Passalacqua G, 2011, IMMUNOL ALLERGY CLIN, V31, P265, DOI 10.1016/j.iac.2011.03.002; Pawankar R, 2011, WAO WHITE BOOK ALLER; Rachelefsky GS, 1999, ANN ALLERG ASTHMA IM, V82, P296, DOI 10.1016/S1081-1206(10)62612-9; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; RoweJones JM, 1997, ALLERGY, V52, P20, DOI 10.1111/j.1398-9995.1997.tb04818.x; Solari Jose E Gereda, 2006, Allergol Immunopathol (Madr), V34, P102; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tabar AI, 2011, J ALLERGY CLIN IMMUN, V127, P57, DOI 10.1016/j.jaci.2010.10.025; Tahamiler R, 2008, ORL-J OTO-RHIN-LARYN, V70, P144, DOI 10.1159/000124286; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Yukselen A, 2012, INT ARCH ALLERGY IMM, V157, P288, DOI 10.1159/000327566	32	144	145	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1608	+		10.1016/j.jaci.2013.11.012	http://dx.doi.org/10.1016/j.jaci.2013.11.012			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24388010				2022-12-18	WOS:000336672500013
J	Baines, KJ; Simpson, JL; Wood, LG; Scott, RJ; Fibbens, NL; Powell, H; Cowan, DC; Taylor, DR; Cowan, JO; Gibson, PG				Baines, Katherine J.; Simpson, Jodie L.; Wood, Lisa G.; Scott, Rodney J.; Fibbens, Naomi L.; Powell, Heather; Cowan, Douglas C.; Taylor, D. Robin; Cowan, Jan O.; Gibson, Peter G.			Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inflammatory phenotypes; gene expression; induced sputum; neutrophils; eosinophils	LEYDEN CRYSTAL PROTEIN; NEUTROPHILS; GALECTIN-10; ACTIVATION; SUBTYPES; CELLS; TRIAL	Background: Airway inflammation is associated with asthma exacerbation risk, treatment response, and disease mechanisms. Objective: This study aimed to identify and validate a sputum gene expression signature that discriminates asthma inflammatory phenotypes. Methods: An asthma phenotype biomarker discovery study generated gene expression profiles from induced sputum of 47 asthmatic patients. A clinical validation study (n = 59 asthmatic patients) confirmed differential expression of key genes. A 6-gene signature was identified and evaluated for reproducibility (n = 30 asthmatic patients and n = 20 control subjects) and prediction of inhaled corticosteroid (ICS) response (n = 71 asthmatic patients). Receiver operating characteristic curves were calculated, and area under the curve (AUC) values were reported. Results: From 277 differentially expressed genes between asthma inflammatory phenotypes, we identified 23 genes that showed highly significant differential expression in both the discovery and validation populations. A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1 beta (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P<.0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8). The 6-gene signature predicted ICS response (>12% change in FEV1; AUC, 91.5%). ICS treatment reduced the expression of CLC, CPA3, and DNASE1L3 in patients with eosinophilic asthma. Conclusions: A sputum gene expression signature of 6 biomarkers reproducibly and significantly discriminates inflammatory phenotypes of asthma and predicts ICS treatment response. This signature has the potential to become a useful diagnostic tool to assist in the clinical diagnosis and management of asthma.	[Baines, Katherine J.; Simpson, Jodie L.; Wood, Lisa G.; Fibbens, Naomi L.; Powell, Heather; Gibson, Peter G.] Univ Newcastle, Hunter Med Res Inst, Prior Res Ctr Asthma & Resp Dis, New Lambton Hts, Australia; [Baines, Katherine J.; Simpson, Jodie L.; Wood, Lisa G.; Fibbens, Naomi L.; Powell, Heather; Gibson, Peter G.] John Hunter Hosp, Dept Resp & Sleep Med, New Lambton Hts, Australia; [Scott, Rodney J.] Univ Newcastle, Hunter Med Res Inst, Prior Res Ctr Informat Based Med, New Lambton Hts, Australia; [Cowan, Jan O.; Gibson, Peter G.] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand	Hunter Medical Research Institute; University of Newcastle; John Hunter Hospital; Hunter Medical Research Institute; University of Newcastle; University of Otago	Baines, KJ (corresponding author), Hunter Med Res Inst, Level 2 West,Locked Bag 1000, New Lambton, NSW 2305, Australia.	katherine.baines@newcastle.edu.au	SIMPSON, JODIE LOUISE/G-7639-2013; BAINES, KATHERINE JOANNE/G-7654-2013; Wood, Lisa G/G-7068-2013; gibson, peter/G-6194-2014; Scott, Rodney/B-2827-2013	SIMPSON, JODIE LOUISE/0000-0002-3626-680X; BAINES, KATHERINE JOANNE/0000-0002-4240-6581; Wood, Lisa/0000-0002-0941-9225; gibson, peter/0000-0001-5865-489X; Cowan, Douglas/0000-0001-7297-9041; Scott, Rodney/0000-0001-7724-3404	John Hunter Hospital Charitable Trust, University of Newcastle; Hunter Medical Research Institute; NHMRC; John Hunter Hospital Charitable Trust; National Health and Medical Research Council; NSA; LLC; GlaxoSmithKline; Aerocrine; Australian government NHMRC; AstraZeneca; Boehringer Ingelheim	John Hunter Hospital Charitable Trust, University of Newcastle; Hunter Medical Research Institute; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); John Hunter Hospital Charitable Trust; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); NSA(National Security Agency); LLC; GlaxoSmithKline(GlaxoSmithKline); Aerocrine; Australian government NHMRC(National Health and Medical Research Council (NHMRC) of Australia); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim)	Supported by the John Hunter Hospital Charitable Trust, University of Newcastle. The Hunter Medical Research Institute provided research grants to support the laboratory testing, and NHMRC and Asthma CRC supported the patient recruitment and sample collection.; K. J. Baines has received research support from the Hunter Medical Research Institute Project Grant, the NHMRC Project Grant, and the John Hunter Hospital Charitable Trust. J. L. Simpson has received research support from the Hunter Medical Research Institute and John Hunter Hospital Charitable Trust and the National Health and Medical Research Council, has received travel support from the University of Newcastle, and is employed by the Australian Respiratory Council and the National Health and Medical Research Council Centre for Respiratory and Sleep Medicine. L. G. Wood has received research support from NSA, LLC and has received payment for lectures from GlaxoSmithKline. D. R. Taylor has received consulting fees and travel support from Aerocrine. P. G. Gibson has received grants from the Australian government NHMRC and has received payment for lectures from AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim. The rest of the authors declare that they have no relevant conflicts of interest.	ACKERMAN SJ, 1982, J EXP MED, V155, P1597, DOI 10.1084/jem.155.6.1597; Al-Mayouf SM, 2011, NAT GENET, V43, P1186, DOI 10.1038/ng.975; Baines KJ, 2010, EUR RESPIR J, V35, P522, DOI 10.1183/09031936.00027409; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Chua JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042549; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Devouassoux G, 2008, ALLERGY, V63, P125, DOI 10.1111/j.1398-9995.2007.01558.x; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; DVORAK AM, 1988, BLOOD, V72, P150; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Konrad FM, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/740987; Kubach J, 2007, BLOOD, V110, P1550, DOI 10.1182/blood-2007-01-069229; Nagrete-Garcia MC, 2012, THESCIENTIFICWORLDJO, V2012; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Saffar AS, 2011, CURR DRUG TARGETS, V12, P556; Silverman RA, 2012, RESP MED, V106, P1096, DOI 10.1016/j.rmed.2012.04.002; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Strandberg K, 2010, PULM PHARMACOL THER, V23, P316, DOI 10.1016/j.pupt.2010.03.004; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P285, DOI 10.1016/j.jaci.2009.10.026; Trivedi NN, 2010, AM J RESP CELL MOL, V42, P257, DOI 10.1165/rcmb.2009-0324RT; Wadsworth SJ, 2013, CURR ALLERGY ASTHM R, V13, P118, DOI 10.1007/s11882-012-0325-9; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	32	144	152	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					997	1007		10.1016/j.jaci.2013.12.1091	http://dx.doi.org/10.1016/j.jaci.2013.12.1091			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24582314				2022-12-18	WOS:000333531700007
J	Kwan, A; Church, JA; Cowan, MJ; Agarwal, R; Kapoor, N; Kohn, DB; Lewis, DB; McGhee, SA; Moore, TB; Stiehm, ER; Porteus, M; Aznar, CP; Currier, R; Lorey, F; Puck, JM				Kwan, Antonia; Church, Joseph A.; Cowan, Morton J.; Agarwal, Rajni; Kapoor, Neena; Kohn, Donald B.; Lewis, David B.; McGhee, Sean A.; Moore, Theodore B.; Stiehm, E. Richard; Porteus, Matthew; Aznar, Constantino P.; Currier, Robert; Lorey, Fred; Puck, Jennifer M.			Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; newborn screening; T-cell receptor excision circle; T-cell lymphopenia; DiGeorge syndrome	RECEPTOR EXCISION CIRCLE; POPULATION; SPECTRUM; TRANSPLANTATION; IDENTIFICATION; DISORDERS; MUTATION	Background: Assay of T-cell receptor excision circles (TRECs) in dried blood spots obtained at birth permits population-based newborn screening (NBS) for severe combined immunodeficiency (SCID). Objective: We sought to report the first 2 years of TREC NBS in California. Methods: Since August 2010, California has conducted SCID NBS. A high-throughput TREC quantitative PCR assay with DNA isolated from routine dried blood spots was developed. Samples with initial low TREC numbers had repeat DNA isolation with quantitative PCR for TRECs and a genomic control, and immunophenotyping was performed within the screening program for infants with incomplete or abnormal results. Outcomes were tracked. Results: Of 993,724 infants screened, 50 (1/19,900 [0.005%]) had significant T-cell lymphopenia. Fifteen (1/66,250) required hematopoietic cell or thymus transplantation or gene therapy; these infants had typical SCID (n = 11), leaky SCID or Omenn syndrome (n = 3), or complete DiGeorge syndrome (n = 1). Survival to date in this group is 93%. Other T-cell lymphopenic infants had variant SCID or combined immunodeficiency (n = 6), genetic syndromes associated with T-cell impairment (n = 12), secondary T-cell lymphopenia (n = 9), or preterm birth (n = 8). All T-cell lymphopenic infants avoided live vaccines and received appropriate interventions to prevent infections. TREC test specificity was excellent: only 0.08% of infants required a second test, and 0.016% required lymphocyte phenotyping by using flow cytometry. Conclusions: TREC NBS in California has achieved early diagnosis of SCID and other conditions with T-cell lymphopenia, facilitating management and optimizing outcomes. Furthermore, NBS has revealed the incidence, causes, and follow-up of T-cell lymphopenia in a large diverse population.	[Kwan, Antonia; Cowan, Morton J.; Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Kwan, Antonia; Cowan, Morton J.; Puck, Jennifer M.] UCSF Benioff Childrens Hosp, San Francisco, CA USA; [Church, Joseph A.; Kapoor, Neena] Univ So Calif, Dept Pediat, Los Angeles, CA 90089 USA; [Church, Joseph A.; Kapoor, Neena] Childrens Hosp Los Angeles, Los Angeles, CA USA; [Agarwal, Rajni; Lewis, David B.; McGhee, Sean A.; Porteus, Matthew] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA; [Agarwal, Rajni; Lewis, David B.; McGhee, Sean A.; Porteus, Matthew] Lucille Packard Childrens Hosp, Palo Alto, CA USA; [Kohn, Donald B.; Moore, Theodore B.; Stiehm, E. Richard] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Kohn, Donald B.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90024 USA; [Aznar, Constantino P.; Currier, Robert; Lorey, Fred] Calif Dept Publ Hlth, Genet Dis Screening Program, Richmond, CA USA	University of California System; University of California San Francisco; University of Southern California; Children's Hospital Los Angeles; Stanford University; Lucile Packard Children's Hospital (LPCH); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; California Department of Public Health	Puck, JM (corresponding author), Univ Calif San Francisco, Box 0519,513 Parnassus Ave,HSE 301A, San Francisco, CA 94143 USA.	puckj@peds.ucsf.edu	Kohn, Donald/N-5085-2016	Kohn, Donald/0000-0003-1840-6087; Currier, Robert/0000-0001-9168-5604	Eunice Kennedy Shriver Institute of Child Health and Development [HHSN267200603430C]; Jeffrey Modell Foundation; Perkin Elmer Genetics; Primary Immune Deficiency Treatment Consortium; NIH Office of Rare Disease Research of the National Center for Advancing Translational Sciences (NCATS) [R13 AI094943]; NCATS [1UL1 RR024131, RO3 HD 060311, RO1 AI 078248]; HCA International Foundation; Baxter; National Institutes of Health (NIH); NIH [AI U54 082973]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD060311] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973, R01AI078248, N01AI030070, R13AI094943, R01AI105776] Funding Source: NIH RePORTER	Eunice Kennedy Shriver Institute of Child Health and Development; Jeffrey Modell Foundation; Perkin Elmer Genetics; Primary Immune Deficiency Treatment Consortium; NIH Office of Rare Disease Research of the National Center for Advancing Translational Sciences (NCATS); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); HCA International Foundation; Baxter; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Support for the initial phase of CA SCID screening was provided by contract HHSN267200603430C to New York State from the Eunice Kennedy Shriver Institute of Child Health and Development, the Jeffrey Modell Foundation, and Perkin Elmer Genetics. Analysis of SCID cases was supported by the Primary Immune Deficiency Treatment Consortium, NIH AI U54 082973, with case development criteria facilitated by NIH R13 AI094943 from the NIH Office of Rare Disease Research of the National Center for Advancing Translational Sciences (NCATS). J.M.P. received NIH support from NCATS 1UL1 RR024131 (UCSF CTSI), RO3 HD 060311 and RO1 AI 078248. A.K. was supported by an HCA International Foundation Travelling Scholarship.; A. Kwan has received a grant for a traveling fellowship from HCA International Foundation. S. A. McGhee has received payment for lectures including service on speakers' bureaus from Baxter. R. Currier is a member of the board for and has received reimbursement for travel to meetings from Newborn Screening Translational Research Network Steering Committee, is employed by the California Department of Public Health, has patents (planned, pending or issued) for multi-analyte interpretation tool in R4S website. E. R. Stiehm has consultant arrangements with UpToDate, has provided expert testimony for the US Department of Justice, and has received payment for lectures including service on speakers' bureaus. M. Porteus has received grants from the National Institutes of Health (NIH). C. P. Aznar has received grants from the Jeffrey Modell Foundation and the NIH, and has received support for travel to meetings for the study or other purposes from the Centers for Disease Control and Prevention/Association of Public Health Laboratories. F. Lorey is employed by the California Department of Public Health. J. M. Puck has received grants from the NIH and the Jeffrey Modell Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Adeli MM, 2010, PEDIATRICS, V126, pE465, DOI 10.1542/peds.2009-3659; Baumgart KW, 1997, J ALLERGY CLIN IMMUN, V100, P415, DOI 10.1016/S0091-6749(97)70257-4; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Chan A, 2011, CLIN IMMUNOL, V138, P3, DOI 10.1016/j.clim.2010.09.010; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Chan K, 2011, MOL GENET METAB, V104, P383, DOI 10.1016/j.ymgme.2011.07.007; Chase NM, 2011, ANN NY ACAD SCI, V1238, P99, DOI 10.1111/j.1749-6632.2011.06241.x; Chen XH, 2005, BLOOD, V105, P886, DOI 10.1182/blood-2004-04-1405; Comeau AM, 2010, J INHERIT METAB DIS, V33, pS273, DOI 10.1007/s10545-010-9103-9; Di Mascio M, 2006, J VIROL, V80, P2665, DOI 10.1128/JVI.80.6.2665-2674.2006; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FASTH A, 1982, J CLIN IMMUNOL, V2, P86, DOI 10.1007/BF00916891; Gruber TA, 2009, PEDIATR TRANSPLANT, V13, P244, DOI 10.1111/j.1399-3046.2008.00970.x; Hale JE, 2010, J ALLERGY CLIN IMMUN, V126, P1073, DOI 10.1016/j.jaci.2010.08.043; HAYAKAWA H, 1981, J CLIN IMMUNOL, V1, P31, DOI 10.1007/BF00915474; Hazenberg MD, 2000, NAT MED, V6, P1036, DOI 10.1038/79549; Howell R.R., REPORT NEWBORN SCREE; Kuo CY, 2013, J ALLERGY CLIN IMMUN; Mallott J, 2013, J CLIN IMMUNOL, V33, P540, DOI 10.1007/s10875-012-9846-1; McDonald-McGinn D.M., 1999, 22Q11 2 DELETION SYN; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Noordzij JG, 2002, BLOOD, V100, P2145; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Puck JM, 1997, HUM GENET, V99, P628, DOI 10.1007/s004390050418; Railey MD, 2009, J PEDIAT, V155; Ridanpaa M, 2002, EUR J HUM GENET, V10, P439, DOI 10.1038/sj.ejhg.5200824; RYSER O, 1988, J CLIN IMMUNOL, V8, P479, DOI 10.1007/BF00916954; Sobacchi C, 2006, HUM MUTAT, V27, P1174, DOI 10.1002/humu.20408; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; Stray-Pedersen A, 2000, J CLIN IMMUNOL, V20, P477, DOI 10.1023/A:1026416017763; Suliaman Fawzi, 2006, Pediatric Asthma Allergy & Immunology, V19, P14, DOI 10.1089/pai.2006.19.14; Verbsky J, 2012, J ALLERGY CLIN IMMUN, V129, P622, DOI 10.1016/j.jaci.2011.12.004; Verbsky JW, 2012, J CLIN IMMUNOL, V32, P82, DOI 10.1007/s10875-011-9609-4; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Watson MS, 2006, GENET MED, V8, p1S, DOI 10.1097/01.gim.0000223891.82390.ad	37	144	152	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					140	U245		10.1016/j.jaci.2013.04.024	http://dx.doi.org/10.1016/j.jaci.2013.04.024			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23810098	Green Accepted			2022-12-18	WOS:000321052300019
J	Calderon, MA; Casale, TB; Togias, A; Bousquet, J; Durham, SR; Demoly, P				Calderon, Moises A.; Casale, Thomas B.; Togias, Alkis; Bousquet, Jean; Durham, Stephen R.; Demoly, Pascal			Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Specific immunotherapy; allergic rhinitis; allergic asthma; allergens	POLLEN-INDUCED RHINOCONJUNCTIVITIS; TERM CLINICAL-EFFICACY; SUBLINGUAL IMMUNOTHERAPY; DOUBLE-BLIND; SYMPTOMATIC TREATMENT; ECONOMIC-EVALUATION; PEDIATRIC-PATIENTS; RHINITIS; SAFETY; ASTHMA	Allergen-specific immunotherapy (SIT) is an etiology-based treatment for respiratory and Hymenoptera-allergic diseases. Although introduced a century ago, SIT was not widely accepted for many years until its efficacy in the treatment of both allergic rhinoconjunctivitis and allergic asthma was demonstrated in appropriate double-blind, placebo-controlled trials and its mechanism of action was better understood. The indications for allergen-specific immunotherapy have been specified in consensus reports. Allergen-specific immunotherapy is primarily targeted to benefit patients with Hymenoptera allergy or severe upper and mild to moderate lower allergic respiratory diseases that are poorly controlled by pharmacologic treatments or who are unable or unwilling to use the latter. Several recent developments have helped to reinforce the position of SIT in the overall therapeutic management of respiratory allergies: (1) improvement in the quality of allergen extracts as a result of standardization, (2) better understanding of SIT's mechanism of action, (3) the introduction of sublingual tablets and their rigorous registration as pharmaceutical therapies by regulatory agencies, and (4) rationalization of prescribing patterns. There is a requirement for additional well designed, well executed, randomized trials in adults and children with allergic rhinitis and asthma, with a special focus on optimal patient selection, dosage, and treatment duration. In this review, the authors put into perspective current international expert recommendations on the use of SIT (in relation to levels of clinical evidence) and analyze what is needed for the future. (J Allergy Clin Immunol 2011;127:30-8.)	[Calderon, Moises A.; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, NHLI, Royal Brompton Hosp, London SW3 6LY, England; [Casale, Thomas B.] Creighton Univ, Omaha, NE 68178 USA; [Togias, Alkis] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Bousquet, Jean] CESP INSERM, Villejuif, France; [Bousquet, Jean; Demoly, Pascal] Univ Hosp Montpellier, Hop Arnaud Villeneuve, Dept Allergy, Montpellier, France; [Bousquet, Jean; Demoly, Pascal] INSERM, U657, F-75654 Paris 13, France	Imperial College London; Royal Brompton Hospital; Creighton University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Calderon, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, NHLI, Dovehouse St, London SW3 6LY, England.	m.calderon@imperial.ac.uk	Bousquet, Jean/O-4221-2019; Demoly, Pascal/Y-9938-2019; Casale, Thomas B/K-4334-2013	Demoly, Pascal/0000-0001-7827-7964; Casale, Thomas B/0000-0002-3149-7377	Creighton University from Schering-Plough; Stallergenes; Imperial College; ALK from ALK-Abello; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Creighton University from Schering-Plough; Stallergenes; Imperial College; ALK from ALK-Abello; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	M. A. Calderon and A. Togias declare no relevant conflicts of interest. T. B. Casale is on an advisory board for Stallergenes, has received research support (via Creighton University) from Schering-Plough and Stallergenes, and is on the board of directors of the World Allergy Organization. J. Bousquet has received honoraria for scientific and advisory boards, lectures during meetings, and/or press conferences from Stallergenes, Actelion, Almirall, Astra-Zeneca, Chiesi, GSK, Merck, MSD, Novartis, OM Pharma, Sanofi Aventis, Schering-Plough, Teva, and Uriach. S. R. Durham has given lectures and consulted for ALK-Abello, has consulted for Schering-Plough (now Merck), has received research support (via Imperial College) from ALK-Abello, and is a member of the World Allergy Organization and the European Academy of Allergy and Clinical Immunology's subcommittees on immunotherapy. P. Demoly has received speaker honoraria and consulting fees from ALK and Stallergenes and research support from Stallergenes.	Abramson MJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001186, DOI 10.1002/14651858.CD001186]; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; [Anonymous], 1997, ALL PROD, P1063; [Anonymous], 1992, ALLERGY S, V47, pS1; [Anonymous], 1995, STRUCTURE CONTENT CL; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Berto P, 2006, ANN ALLERG ASTHMA IM, V97, P615, DOI 10.1016/S1081-1206(10)61090-3; Berto P, 2008, CURR OPIN ALLERGY CL, V8, P585, DOI 10.1097/ACI.0b013e32831411e9; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2007, EUR RESPIR J, V29, P233, DOI 10.1183/09031936.00138606; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon Moises A, 2008, Clin Allergy Immunol, V21, P359; Calderon MA, 2008, DRUG TODAY, V44, P31; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Chanez P, 1996, ALLERGY, V51, P850; Compalati E, 2009, ALLERGY, V64, P1570, DOI 10.1111/j.1398-9995.2009.02129.x; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Cox L, 2007, ANN ALLERG ASTHMA IM, V98, P416, DOI 10.1016/S1081-1206(10)60755-7; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; Demoly Pascal, 2008, Clin Allergy Immunol, V21, P527; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Didier A, 2009, ALLERGY, V64, P166, DOI 10.1111/j.1398-9995.2008.01767.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; EMEA, 2008, GUID CLIN DEV PROD S; Esch Robert E, 2003, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P17; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Horak F, 2009, J ALLERGY CLIN IMMUN, V124, P471, DOI 10.1016/j.jaci.2009.06.006; International rhinitis management working group, 1994, ALLERGY S, V49, pS1, DOI [10.1111/j.1398-9995.1994.tb00765.x, DOI 10.1111/J.1398-9995.1994.TB00765.X]; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lowdermilk C, 1914, J AMER MED ASSOC, V63, P141; Malling H, 1988, ALLERGY S6, V43, P9; Malling HJ, 2009, CLIN EXP ALLERGY, V39, P387, DOI 10.1111/j.1365-2222.2008.03152.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 2009, J ALLERGY CLIN IMMUN, V123, P763, DOI 10.1016/j.jaci.2008.12.013; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Noon L, 1911, LANCET, V1, P1572; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Omnes L F, 2007, Eur Ann Allergy Clin Immunol, V39, P148; Patel P, 2006, EXPERT REV VACCINES, V5, P617, DOI 10.1586/14760584.5.5.617; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Rak S, 2007, QUAL LIFE RES, V16, P191, DOI 10.1007/s11136-006-9110-3; Sander I, 2009, ALLERGY, V64, P1486, DOI 10.1111/j.1398-9995.2009.02040.x; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x; Scadding G, 2009, J ASTHMA, V46, P322, DOI 10.1080/02770900902785729; Schadlich PK, 2000, PHARMACOECONOMICS, V17, P37, DOI 10.2165/00019053-200017010-00003; Senti G, 2009, CLIN EXP ALLERGY, V39, P562, DOI 10.1111/j.1365-2222.2008.03191.x; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; [No title captured]	86	144	157	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					30	38		10.1016/j.jaci.2010.08.024	http://dx.doi.org/10.1016/j.jaci.2010.08.024			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	20965551				2022-12-18	WOS:000285917300004
J	Gonzalez-Perez, A; Aponte, Z; Vidaurre, CF; Rodriguez, LAG				Gonzalez-Perez, Antonio; Aponte, Zuleika; Vidaurre, Carlos Fernandez; Garcia Rodriguez, Luis Alberto			Anaphylaxis epidemiology in patients with and patients without asthma: A United Kingdom database review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; anaphylaxis; epidemiology	POPULATION; EMERGENCY; SEVERITY; ALLERGY; FOOD	Background: There are currently limited data regarding the epidemiology of anaphylaxis. Objective: To estimate the incidence of anaphylaxis from all causes, to explore the variety of diagnoses that may predispose to an anaphylactic episode, and to estimate the rate of recurrence of anaphylaxis in patients with no asthma, nonsevere asthma, and severe asthma. Methods: The Health Improvement Network database provided data on individuals 10 to 79 years old who had been enrolled for at least 1 year with a general practitioner in the United Kingdom and had at least 1 health contact in the year before entering the study. Results: Anaphylaxis incidence rates (per 100,000 person-years) were 21.28 (95% CI, 17.64-25.44) and 50.45 (95% CI, 44.67-56.76) in the no asthma and overall asthma cohorts, respectively. Risk of anaphylaxis was greater in the nonsevere asthma (relative risk, 2.07; 95% CI, 1.65-2.60) and severe asthma (relative risk, 3.29; 95% CI, 2.47-3.47) subgroups compared with the no asthma cohort. The incidence rate of anaphylaxis was higher in women than men (22.65 vs 19.56 per 100,000 person-years). Within the overall asthma population, patients at significantly increased risk of anaphylaxis included those with allergic rhinitis or atopic dermatitis, and current users of antihistamines, oral steroids, or antibiotics (compared with nonusers). Drug and food allergies were the most common known causes of anaphylaxis. Conclusion: Patients with asthma have a greater risk of anaphylaxis than those without asthma, and the risk is greater in severe than nonsevere asthma. Women are at higher risk of anaphylaxis than men, especially those with severe asthma. (J Allergy Clin Immunol 2010;125:1098-104.)	[Gonzalez-Perez, Antonio; Garcia Rodriguez, Luis Alberto] Ctr Espanol Invest Farmacoepidemiol, Madrid 28004, Spain; [Gonzalez-Perez, Antonio] Dept Genom Estruct, Seville, Spain; [Aponte, Zuleika] Novartis Farmaceut SA, Barcelona, Spain; [Vidaurre, Carlos Fernandez] Novartis Pharmaceut, E Hanover, NJ USA	Novartis; Novartis	Rodriguez, LAG (corresponding author), Ctr Espanol Invest Farmacoepidemiol, Almirante 28,2, Madrid 28004, Spain.	lagarcia@ceife.es	Gonzalez-Perez, Antonio/A-5247-2010; González-Pérez, Antonio/AAY-4179-2021; rodriguez, luis a garcia/B-1980-2010	Gonzalez-Perez, Antonio/0000-0001-9771-5982; González-Pérez, Antonio/0000-0001-9771-5982; 	Novartis Pharma AG; AstraZeneca	Novartis Pharma AG; AstraZeneca(AstraZeneca)	Supported by Novartis Pharma AG.; Disclosure of potential conflict of interest: L. A. G. Rodriguez receives research support from AstraZeneca. The rest of the authors have declared that they have no conflict of interest.	Bansal PJ, 2005, ANN ALLERG ASTHMA IM, V94, P55, DOI 10.1016/S1081-1206(10)61286-0; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Lewis JD, 2007, PHARMACOEPIDEM DR S, V16, P393, DOI 10.1002/pds.1335; LIEBERMAN P, 2003, MIDDLETONS ALLERGY P, P1497; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; VANDERKLAUW MM, 1993, BRIT J CLIN PHARMACO, V35, P400; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	23	144	149	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1098	1104		10.1016/j.jaci.2010.02.009	http://dx.doi.org/10.1016/j.jaci.2010.02.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392483				2022-12-18	WOS:000277686700020
J	Varshney, P; Steele, PH; Vickery, BP; Bird, JA; Thyagarajan, A; Scurlock, AM; Perry, TT; Jones, SM; Burks, AW				Varshney, Pooja; Steele, Pamela H.; Vickery, Brian P.; Bird, J. Andrew; Thyagarajan, Ananth; Scurlock, Amy M.; Perry, Tamara T.; Jones, Stacie M.; Burks, A. Wesley			Adverse reactions during peanut oral immunotherapy home dosing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN		[Varshney, Pooja; Steele, Pamela H.; Vickery, Brian P.; Bird, J. Andrew; Thyagarajan, Ananth; Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Scurlock, Amy M.; Perry, Tamara T.; Jones, Stacie M.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72205 USA	Duke University; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Varshney, P (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.	wesley.burks@duke.edu		Bird, John/0000-0003-3772-6078; Vickery, Brian/0000-0002-7243-5543	NIAID NIH HHS [T32 AI007062-28A2, R01 AI068074-03, T32 AI007062-30, R01 AI068074, T32 AI007062-31, T32 AI007062-29, R01 AI068074-02, R01 AI068074-01A1, T32 AI007062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062, R01AI068074] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x	6	144	146	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1351	1352		10.1016/j.jaci.2009.09.042	http://dx.doi.org/10.1016/j.jaci.2009.09.042			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19913285	Green Accepted			2022-12-18	WOS:000273071500030
J	Bryant-Stephens, T				Bryant-Stephens, Tyra			Asthma disparities in urban environments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; disparities; children; community-based; asthma morbidity; asthma interventions	INNER-CITY CHILDREN; COCKROACH ALLERGEN; HEALTH DISPARITIES; MANAGEMENT PROGRAM; AFRICAN-AMERICAN; CONTROLLED-TRIAL; CARE; EDUCATION; OUTCOMES; QUALITY	Asthma continues to disproportionately affect minority and low-income groups, with African American and Latino children who live in low-socioeconomic-status urban environments experiencing higher asthma morbidity and mortality than white children. This uneven burden in asthma morbidity has been ever increasing despite medical advancement. Many factors have contributed to these disparities in the areas of health care inequities, which result in inadequate treatment; poor housing, which leads to increased exposure to asthma allergens; and social and psychosocial stressors, which are often unappreciated. Interventions to reduce individual areas of disparities have had varying successes. Because asthma is a complex disease that affects millions of persons, multifaceted comprehensive interventions that combine all evidence-based successful strategies are essential to finally closing the gap in asthma morbidity. (J Allergy Clin Immunol 2009;123:1199-206.)	Univ Penn, Childrens Hosp Philadelphia, Community Asthma Prevent Program, Dept Gen Pediat,Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Bryant-Stephens, T (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Community Asthma Prevent Program, Dept Gen Pediat,Sch Med, 3535 Market St,Suite 1032, Philadelphia, PA 19104 USA.	stephenst@email.chop.edu						AKINBAMI LJ, 1980, STATE CHILDHOOD ASTH; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Bartholomew LK, 2006, J SCHOOL HEALTH, V76, P283; Bloomberg GR, 2005, IMMUNOL ALLERGY CLIN, V25, P83, DOI 10.1016/j.iac.2004.09.001; Bryant-Stephens T, 2004, J NATL MED ASSOC, V96, P954; Bryant-Stephens T, 2008, J NATL MED ASSOC, V100, P306, DOI 10.1016/S0027-9684(15)31243-8; Cabana MD, 2006, PEDIATRICS, V117, P2149, DOI 10.1542/peds.2005-1055; Canino G, 2008, J ALLERGY CLIN IMMUN, V121, P665, DOI 10.1016/j.jaci.2007.10.022; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Chinn S, 1999, THORAX, V54, P469; CHRISTIAANSE ME, 1989, J DEV BEHAV PEDIATR, V10, P75; Clark NM, 2000, EUR RESPIR J, V16, P15, DOI 10.1034/j.1399-3003.2000.16a04.x; Cloutier MM, 2008, ANN ALLERG ASTHMA IM, V100, P545, DOI 10.1016/S1081-1206(10)60058-0; Coffman JM, 2008, PEDIATRICS, V121, P575, DOI 10.1542/peds.2007-0113; Curtin-Brosnan J, 2008, ANN ALLERG ASTHMA IM, V101, P517, DOI 10.1016/S1081-1206(10)60291-8; de Oliveira MA, 1999, EUR RESPIR J, V14, P908, DOI 10.1034/j.1399-3003.1999.14d30.x; Diette GB, 2007, CHEST, V132, p802S, DOI 10.1378/chest.07-1909; Eggleston PA, 2007, CHEST, V132, p782S, DOI 10.1378/chest.07-1906; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Ford ES, 2004, J ASTHMA, V41, P327, DOI 10.1081/JAS-120026090; Fox P, 2007, PEDIATRICS, V120, pE902, DOI 10.1542/peds.2006-1805; Friedman AR, 2006, HEALTH PROMOT PRACT, V7, pS140, DOI 10.1177/1524839906287058; Gendo K, 2003, ANN ALLERG ASTHMA IM, V91, P251, DOI 10.1016/S1081-1206(10)63526-0; Gerald LB, 2006, J SCHOOL HEALTH, V76, P291, DOI 10.1111/j.1746-1561.2006.00114.x; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Gotzsche PC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001187.pub3; Greek AA, 2006, J ASTHMA, V43, P61, DOI 10.1080/02770900500448639; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Hardie GE, 2000, CHEST, V117, P935, DOI 10.1378/chest.117.4.935; Haselkorn T, 2008, ANN ALLERG ASTHMA IM, V101, P256, DOI 10.1016/S1081-1206(10)60490-5; HOWDENCHAPMAN P, 2008, BMJ-BRIT MED J, V33, P208; *I MED REP, 2003, UN TREATM CONFR ETH; Institute of Medicine, 2001, CROSSING QUALITY CHA; Johnson RL, 2004, AM J PUBLIC HEALTH, V94, P2084, DOI 10.2105/AJPH.94.12.2084; Kamble S, 2009, J ASTHMA, V46, P73, DOI 10.1080/02770900802503107; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Lee Jung-Ahn, 2006, Korean Journal of Internal Medicine, V21, P33; Levy Jonathan I, 2004, Environ Health, V3, P13, DOI 10.1186/1476-069X-3-13; Levy M, 2006, J SCHOOL HEALTH, V76, P320, DOI 10.1111/j.1746-1561.2006.00120.x; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Magzamen S, 2008, J SCHOOL HEALTH, V78, P655, DOI 10.1111/j.1746-1561.2008.00362.x; MATHER M, KIDS COUNT      0206; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; MCMANUS MA, 1993, PEDIATRICS, V91, P1040; Mitchell DK, 2005, J ASTHMA, V42, P425, DOI 10.1081/JAS-200067936; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murray MD, 1997, J CLIN EPIDEMIOL, V50, P167, DOI 10.1016/S0895-4356(96)00333-2; *NAT HEART LUNG BL, 2007, NAT ASTHM ED PROGR E; *OFF ACT CTR MED M, NAT HLTH EXP FOR SUM; Okelo SO, 2007, J GEN INTERN MED, V22, P976, DOI 10.1007/s11606-007-0209-1; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-1291OC; Peters JL, 2007, J ASTHMA, V44, P455, DOI 10.1080/02770900701421971; Pilotto LS, 2004, INT J EPIDEMIOL, V33, P208, DOI 10.1093/ije/dyh018; Riekert KA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e214; Robinson LD, 2008, J NATL MED ASSOC, V100, P892, DOI 10.1016/S0027-9684(15)31401-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SAENZ R, NEW ORLEANS SOCIAL E; Saha S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/archinte.159.9.997; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Shields AE, 2007, CHEST, V132, p818S, DOI 10.1378/chest.07-1903; Shone LP, 2003, PEDIATRICS, V112, pE521; Simons E, 2007, J URBAN HEALTH, V84, P577, DOI 10.1007/s11524-007-9205-3; Smith LA, 2008, PEDIATRICS, V122, P760, DOI 10.1542/peds.2007-2750; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; Szilagyi PG, 2004, PEDIATRICS, V113, pE395, DOI 10.1542/peds.113.5.e395; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1; Wright RJ, 2007, CHEST, V132, p757S, DOI 10.1378/chest.07-1904	74	144	144	2	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1199	1206		10.1016/j.jaci.2009.04.030	http://dx.doi.org/10.1016/j.jaci.2009.04.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19501229				2022-12-18	WOS:000266799100007
J	Nakae, S; Ho, LH; Yu, M; Monteforte, R; Iikura, M; Suto, H; Galli, SJ				Nakae, Susumu; Ho, Lien H.; Yu, Mang; Monteforte, Rossella; Iikura, Motoyasu; Suto, Hajime; Galli, Stephen J.			Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and T(H)2 cytokine production in an asthma model in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperreactivity; asthma; cytokines; mast cells; TNF	TUMOR-NECROSIS-FACTOR; FC-EPSILON-RI; FACTOR-ALPHA; DEFICIENT MICE; ALLERGIC INFLAMMATION; REFRACTORY ASTHMA; IMMUNE-RESPONSES; KIT-LIGAND; IN-VIVO; MOUSE	Background: Mast cells, IgE, and TNF, which have been implicated in human atopic asthma, contribute significantly to the allergic airway inflammation induced by ovalbumin (OVA) challenge in mice sensitized with OVA without alum. However, it is not clear to what extent mast cells represent a significant source of TNF in this mouse model. Objective: We investigated the importance of mast cell-derived TNF in a mast cell-dependent model of OVA-induced airway hyperreactivity (AHR) and allergic airway inflammation. Methods: Features of this model of airway inflammation were analyzed in C57BL/6J-wild-type mice, mast cell-deficient C57BL/6J-Kit(W-sh/W-sh) mice, and C57BL/6J Kit(W-sh/W-sh) mice that had been systemically engrafted with bone marrow-derived cultured mast cells from C57BL/6J-wild-type or C57BL/6J-TNF-/- mice. Results: Ovalbumin-induced AHR and airway inflammation were significantly reduced in mast cell-deficient Kit(W-sh/W-sh) mice versus wild-type mice. By contrast, Kit(W-sh/W-sh) mice that had been engrafted with wild-type but not with TNF-/- bone marrow-derived cultured mast cells exhibited responses very similar to those observed in wild-type mice. Mast cells and mast cell-derived TNF were not required for induction of OVA-specific memory T cells in the sensitization phase, but significantly enhanced lymphocyte recruitment and T(H)2 cytokine production in the challenge phase. Conclusion: Mast cell-derived TNF contributes significantly to the pathogenesis of mast cell-dependent and IgE-dependent, OVA-induced allergic inflammation and AHR in mice, perhaps in part by enhancing lymphocyte recruitment and T(H)2 cytokine production. Clinical implications: Our findings in mice support the hypothesis that mast cell-derived TNF can promote allergic inflammation and AHR in asthma.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Juntendo Univ, Sch Med, Atopy Allergy Res Ctr, Tokyo 113, Japan	Stanford University; Juntendo University	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067674, P50HL067674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023990, R01AI023990] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA072074, CA72074] Funding Source: Medline; NHLBI NIH HHS [P50 HL067674, HL67674] Funding Source: Medline; NIAID NIH HHS [R01 AI070813, AI070813, AI23990, R01 AI023990] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Boyce JA, 2005, J EXP MED, V201, P1869, DOI 10.1084/jem.20050584; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; Brewer JM, 1999, J IMMUNOL, V163, P6448; Broide DH, 2001, AM J RESP CELL MOL, V24, P304, DOI 10.1165/ajrcmb.24.3.4071; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; Erzurum SC, 2006, NEW ENGL J MED, V354, P754, DOI 10.1056/NEJMe058266; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Halasz A, 2002, RESP MED, V96, P262, DOI 10.1053/rmed.2001.1256; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hu ZQ, 1997, BLOOD, V89, P526, DOI 10.1182/blood.V89.2.526; Hultner L, 2000, J IMMUNOL, V164, P5556, DOI 10.4049/jimmunol.164.11.5556; Kanehiro A, 2001, AM J RESP CRIT CARE, V164, P2229, DOI 10.1164/ajrccm.164.12.2012059; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; Korner H, 1997, EUR J IMMUNOL, V27, P2600, DOI 10.1002/eji.1830271020; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Laan M, 1999, J IMMUNOL, V162, P2347; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; Marone G, 2005, ADV IMMUNOL, V88, P97, DOI 10.1016/S0065-2776(05)88004-6; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Mayr SI, 2002, J IMMUNOL, V169, P2061, DOI 10.4049/jimmunol.169.4.2061; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Moffatt JD, 2005, PHARMACOL THERAPEUT, V107, P343, DOI 10.1016/j.pharmthera.2005.03.007; Nakae S, 2006, J IMMUNOL, V176, P2238, DOI 10.4049/jimmunol.176.4.2238; Nakae S, 2005, P NATL ACAD SCI USA, V102, P6467, DOI 10.1073/pnas.0501912102; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Nakae S, 2007, J ALLERGY CLIN IMMUN, V119, P680, DOI 10.1016/j.jaci.2006.11.701; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Rudmann DG, 2000, AM J PHYSIOL-LUNG C, V279, pL1047, DOI 10.1152/ajplung.2000.279.6.L1047; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Stassen M, 2001, J IMMUNOL, V166, P4391, DOI 10.4049/jimmunol.166.7.4391; Stassen M, 2000, J IMMUNOL, V164, P5549, DOI 10.4049/jimmunol.164.11.5549; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Varga SM, 2002, J IMMUNOL METHODS, V262, P111, DOI 10.1016/S0022-1759(02)00014-5; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wright HV, 2006, J IMMUNOL, V176, P2114, DOI 10.4049/jimmunol.176.4.2114; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175	56	144	149	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					48	55		10.1016/j.jaci.2007.02.046	http://dx.doi.org/10.1016/j.jaci.2007.02.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17482668				2022-12-18	WOS:000248066400007
J	Asero, R; Tedeschi, A; Coppola, R; Griffini, S; Paparella, P; Riboldi, P; Marzano, AV; Fanoni, D; Cugno, M				Asero, Riccardo; Tedeschi, Alberto; Coppola, Raffaella; Griffini, Samantha; Paparella, Paolo; Riboldi, Piersandro; Marzano, Angelo V.; Fanoni, Daniele; Cugno, Massimo			Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; coagulation; thrombin; D-dimer; factor VII	CHRONIC IDIOPATHIC URTICARIA; ANTI-IGE AUTOANTIBODIES; FC-EPSILON-RI; HISTAMINE-RELEASE; AUTOLOGOUS SERUM; MAST-CELLS; THROMBIN; PROTHROMBIN; WARFARIN; GENERATION	Background: In patients with chronic urticaria (CU), plasma shows signs of thrombin generation and autologous plasma skin tests score positive in as many as 95% of cases. Objective: To evaluate the initiators of blood coagulation that lead to thrombin generation and fibrinolysis in CU. Methods: Activated factor VII, activated factor XII, fragment F1+2, and D-dimer plasma levels were measured in 37 patients with CU and 37 controls. Skin specimens from 10 patients with CU and 10 controls were tested for tissue factor immunohistochemically. Results: Mean F1+2 levels were higher in patients than controls (2.54 [SD 2.57] nmol/L vs 0.87 [0.26] nmol/L; P < .001); disease activity was moderate or severe in 9 of 11 (82%) and 9 of 26 (35%) patients showing high or normal F1+2 levels, respectively (P < .025). Mean D-dimer plasma levels were higher in patients than controls (329 [188] ng/mL vs 236 [81] ng/mL; P < .01); disease activity was moderate or severe in 6 of 8 (75%) and 11 of 29 (38%) showing elevated or normal plasma D-dimer levels (P = NS). Factor VIIa levels were higher in patients than controls (2.86 ng/ mL [0.66] vs 1.97 ng/mL [0.65]; P < .001). Activated factor VII and F1+2 levels were correlated (r = 0.529; P = .008). Tissue factor reactivity was observed only in CU skin specimens. Conclusion: The extrinsic pathway of clotting cascade is activated in CU. Disease severity is associated with the activation of the coagulation cascade. Clinical implications: The involvement of the coagulation pathway in CU opens new perspectives for a better understanding of the pathogenesis and, possibly, for the treatment of this disease.	Clin San Carlo, Ambulatorio Allergol, I-20037 Paderno Dugnano, MI, Italy; Fdn IRCCS, Osped Maggiore Policlin Mangiagalli & Regina Elen, Unia Operat Allergol & Immunol Clin, Milan, Italy; Ctr Emofilia & Trombosi A Bianchi Bonomi, Milan, Italy; Univ Milan, Dipartimento Med Interna, I-20122 Milan, Italy; Clin San Carlo, Lab Anal, I-20037 Paderno Dugnano, MI, Italy; IRCCS, Ist Auxol, Unita Allergol Immunol Clin & Reumatol, Milan, Italy; Univ Milan, Osped Maggiore Policlin Mangiagalli & Regina Elen, Ist Sci Dermatol, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Istituto Auxologico Italiano; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Asero, R (corresponding author), Clin San Carlo, Ambulatorio Allergol, Via Osped 21, I-20037 Paderno Dugnano, MI, Italy.	r.asero@libero.it	Cugno, Massimo/K-8106-2016; meroni, pier luigi/K-8473-2016	Cugno, Massimo/0000-0002-9918-0763; meroni, pier luigi/0000-0002-3394-1451				Asero R, 2001, CLIN EXP ALLERGY, V31, P1105, DOI 10.1046/j.1365-2222.2001.01131.x; Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; BERTHJONES J, 1988, BRIT MED J, V297, P1382, DOI 10.1136/bmj.297.6660.1382; BORK K, 1984, ARCH DERMATOL RES, V276, P375, DOI 10.1007/BF00413358; Chua SL, 2005, BRIT J DERMATOL, V153, P216, DOI 10.1111/j.1365-2133.2005.06694.x; Cirino G, 1996, J EXP MED, V183, P821, DOI 10.1084/jem.183.3.821; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; Coppola R, 1996, BLOOD COAGUL FIBRIN, V7, P530, DOI 10.1097/00001721-199607000-00004; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DUVALL LA, 1986, SOUTHERN MED J, V79, P389, DOI 10.1097/00007611-198603000-00039; Fagiolo U, 1999, J ALLERGY CLIN IMMUN, V103, P1143, DOI 10.1016/S0091-6749(99)70190-9; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Greaves MW, 1998, EXP DERMATOL, V7, P11, DOI 10.1111/j.1600-0625.1998.tb00296.x; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; HURSTING MJ, 1993, CLIN CHEM, V39, P583; KIDO H, 1985, BIOCHEM BIOPH RES CO, V132, P613, DOI 10.1016/0006-291X(85)91177-5; Kikuchi Y, 2002, J ALLERGY CLIN IMMUN, V109, P114, DOI 10.1067/mai.2002.120954; Luquin E, 2005, CLIN EXP ALLERGY, V35, P456, DOI 10.1111/j.1365-2222.2005.02212.x; NEWMAN DJ, 1992, ANN CLIN BIOCHEM, V29, P22, DOI 10.1177/000456329202900104; Parslew R, 2000, CLIN EXP ALLERGY, V30, P1161; PELZER H, 1991, THROMB HAEMOSTASIS, V65, P153; RAZIN E, 1984, J IMMUNOL, V133, P3282; Sabroe RA, 2002, J ALLERGY CLIN IMMUN, V110, P492, DOI 10.1067/mai.2002.126782; SCHAEFFER RC, 1993, AM J PHYSIOL, V264, pH1798, DOI 10.1152/ajpheart.1993.264.6.H1798; Vliagoftis H, 2002, J IMMUNOL, V169, P4551, DOI 10.4049/jimmunol.169.8.4551; WILDGOOSE P, 1992, BLOOD, V80, P25	31	144	146	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					705	710		10.1016/j.jaci.2006.08.043	http://dx.doi.org/10.1016/j.jaci.2006.08.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17204316	Bronze			2022-12-18	WOS:000244925000025
J	Novak, N; Valenta, R; Bohle, B; Laffer, S; Haberstok, J; Kraft, S; Bieber, T				Novak, N; Valenta, R; Bohle, B; Laffer, S; Haberstok, J; Kraft, S; Bieber, T			Fc epsilon RI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; antigen presentation; IgE; skin; inflammation	MONOCYTE CHEMOATTRACTANT PROTEIN-1; PATCH TEST REACTIONS; ATOPIC-DERMATITIS; ALLERGEN PRESENTATION; EXPRESSION; DISEASES; 3-ALPHA; GAMMA; IL-12; LEADS	Background: Atopic dermatitis (AD) is a biphasic inflammatory skin disease characterized by an initial phase predominated by T(H)2 cytokines, which switches into a second T(H)1-dominated chronic phase. Thus far, the small number of FcepsilonRI-bearing Langerhans cells (LCs) and inflammatory dendritic epidermal cells (IDECs) in the epidermis of patients with AD has hampered a detailed functional analysis and limited our knowledge of these dendritic cells (DCs). Objective: We studied FcepsilonRI-mediated mechanisms of LCs and IDECs with the help of a novel in vitro model. Methods: Langerhans cell-like dendritic cells (LC-DCs) and inflammatory dendritic epidermal cell-like dendritic cells (IDEC-DCs) bearing FcepsilonRI have been generated from monocytes of the same atopic donor and compared functionally with LCs and IDECs isolated from the skin of patients with AD. Results: We found that FcepsilonRI-activated LC-DCs release chemotactic signals, and supernatants of FcepsilonRI-activated LC-DCs increase the migratory capacity of precursor cells of IDECs and naive T cells in vitro. FcepsilonRI-activated IDEC-DCs produce high amounts of proinflammatory cytokines and chemokines and might thereby amplify the inflammatory immune reaction in patients with AD. Furthermore, FcepsilonRI-activated IDEC-DCs prime naive T cells into IFN-gamma-producing T cells and release IL-12 and IL-18, which together might lead to the switch of the initial T(H)2-type immune response into a response of the T(H)1 type in vivo. Conclusion: The present study provides evidence that FcepsilonRI-activated LC-DCs and IDEC-DCs contribute distinctly to the outcome of T-cell responses in vitro and might have implications for the biphasic nature of AD in vivo.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Univ Vienna, AKH, Dept Pathophysiol, Vienna, Austria; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	University of Bonn; University of Vienna; Harvard University; Beth Israel Deaconess Medical Center	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.			Valenta, Rudolf/0000-0001-5944-3365; Bohle, Barbara/0000-0002-5105-7985				BIRBECK MS, 1961, J INVEST DERMATOL, V37, P51, DOI 10.1038/jid.1961.80; BUCKLEY CC, 1992, J INVEST DERMATOL, V99, P184, DOI 10.1111/1523-1747.ep12616813; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Companjen AR, 2000, EUR CYTOKINE NETW, V11, P383; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; Hanifin JM, 1999, ARCH DERMATOL, V135, P1551, DOI 10.1001/archderm.135.12.1551; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Junghans V, 1998, J INVEST DERMATOL, V111, P1184, DOI 10.1046/j.1523-1747.1998.00409.x; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1998, J IMMUNOL, V161, P2731; Maurer D, 1997, ADV EXP MED BIOL, V417, P175; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2002, J INVEST DERMATOL, V119, P842, DOI 10.1046/j.1523-1747.2002.00102.x; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; Reich K, 2001, J IMMUNOL, V167, P6321, DOI 10.4049/jimmunol.167.11.6321; TAYLOR RS, 1991, J IMMUNOL, V147, P3794; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Wang GP, 2001, BIOCHEM J, V357, P233, DOI 10.1042/0264-6021:3570233; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P941, DOI 10.1067/mai.2000.109825; Yoshimura T, 1992, Cytokines, V4, P131	34	144	153	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					949	957		10.1016/j.jaci.2004.02.005	http://dx.doi.org/10.1016/j.jaci.2004.02.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131579				2022-12-18	WOS:000221269000019
J	Corren, J; Casale, T; Deniz, Y; Ashby, M				Corren, J; Casale, T; Deniz, Y; Ashby, M			Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; immunoglobulin E; omalizumab; exacerbation; hospitalization	EXACERBATIONS	Background: Prevention of serious asthma exacerbations is an important therapeutic goal in patients with asthma. Objective: The purpose of this study was to investigate the effect of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody, on the rate of serious exacerbations during long-term therapy. Methods: A pooled analysis was completed of 3 multicenter, randomized, double-blind, placebo-controlled phase III studies with omalizumab in adults/adolescents aged greater than or equal to12 years (n = 1071) and in children aged 6 to 12 years (n = 334) who required treatment with inhaled corticosteroids for allergic asthma. Rates of serious asthma exacerbations were computed and compared between omalizumab- and placebo-treated patients. Serious exacerbations were those leading to unscheduled outpatient visits, emergency room treatment, or hospitalization during 1 year of treatment. Results: In all, 767 patients were treated with omalizumab (at least 0.016 mg/kg/IgE [IU/mL], administered subcutaneously every 4 weeks). Another 638 patients were treated with placebo. The rate of unscheduled, asthma-related outpatient visits was lower for the omalizumab-treated patients than for the placebo treated patients (rate ratio [95 % CI], 0.60 [0.44,0.81]; P < .01), as were asthma-related emergency room visits (rate ratio [95% CI], 0.47 [0.24, 1.01]; P = .05). Importantly, hospitalizations for asthma were markedly reduced in patients receiving omalizumab (rate ratio [95% CI], 0.08 [0.00, 0.25]; P < .01). Conclusion; Omalizumab reduces the rate of serious asthma exacerbations and the need for unscheduled outpatient visits, emergency room treatment, and hospitalization in patients with moderate-to-severe allergic asthma.	Allergy Res Fdn Inc, Los Angeles, CA 90025 USA; Creighton Univ, Omaha, NE 68178 USA; Genentech Inc, San Francisco, CA 94080 USA	Creighton University; Roche Holding; Genentech	Corren, J (corresponding author), Allergy Res Fdn Inc, 1160 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.							Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; Easthope S, 2001, DRUGS, V61, P253, DOI 10.2165/00003495-200161020-00008; Efron B., 1994, MONOGR STAT APPL PRO, DOI DOI 10.1007/978-1-4899-4541-9; Fick R B Jr, 1999, Curr Opin Pulm Med, V5, P76, DOI 10.1097/00063198-199901000-00013; GREEN RM, 2002, BRIT MED J, V324, P1; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 1995, NIH PUBLICATION	15	144	149	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					87	90		10.1067/mai.2003.49	http://dx.doi.org/10.1067/mai.2003.49			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532101	Bronze			2022-12-18	WOS:000180465500013
J	Furlong, TJ; DeSimone, J; Sicherer, SH				Furlong, TJ; DeSimone, J; Sicherer, SH			Peanut and tree nut allergic reactions in restaurants and other food establishments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut; tree nut; allergy; restaurant	ANAPHYLACTIC REACTIONS; NATURAL-HISTORY	Background: The clinical features of food-allergic reactions in restaurants and other food establishments have not been studied. Of the registrants in the United States Peanut and Tree Nut Allergy Registry (PAR), 13.7% have reported reactions associated with such establishments. Objective: The purpose of this study was to determine the features of allergic reactions to peanut and tree nut in restaurant foods and foods purchased at other private establishments (eg, ice cream shops and bakeries). Methods: Telephone interviews were conducted through use of a structured questionnaire. Subjects/parental surrogates were randomly selected from among the 706 PAR registrants who reported a reaction in a restaurant or other food establishment. Results: Details were obtained for 156 episodes (29 first-time reactions) from 129 subjects/parental surrogates. Most reactions were caused by peanut (67%) or tree nut (24%); for some reactions (9%), the cause was a combination of peanut and another nut or was unknown. Symptoms began at a median of 5 minutes after exposure and were severe in 27% of reactions. Overall, 86% of reactions were treated (antihistamines, 86%; epinephrine, 40%). Establishments commonly cited were Asian food restaurants (19%), ice cream shops (14%), and bakeries/doughnut shops (13%). Among meal courses, desserts were a common cause (43%). Of 106 registrants with previously diagnosed allergy who ordered food specifically for ingestion by the allergic individual, only 45% gave prior notification about the allergy to the establishment. For 83 (78%) of these 106 reactions, someone in the establishment knew that the food contained peanut or tree nut as an ingredient; in 50% of these incidents, the food item was "hidden" (in sauces, dressings, egg rolls, etc), visual identification being prevented. In 23 (22%) of the 106 cases, exposures were reported from contamination caused primarily by shared cooking/serving supplies. In the remaining 21 subjects with previously diagnosed allergy, reactions resulted from ingestion of food not intended for them, ingestion of food selected from buffet/food bars, or skin contact/inhalation (residual food on tables, 2; peanut shells covering floors, 2; being within 2 feet of the cooking of the food, 1). Conclusions: Restaurants and other food establishments pose a number of dangers for peanut- and tree nut-allergic individuals, particularly with respect to cross-contamination and unexpected ingredients in desserts and Asian food. Failure to establish a clear line of communication between patron and establishment is a frequent cause of errors.	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY USA; Food Allergy & Anaphylaxis Network, Fairfax, VA USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIAID NIH HHS [K23 AI01709-01] Funding Source: Medline; NICHD NIH HHS [HD28822-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	10	144	146	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					867	870		10.1067/mai.2001.119157	http://dx.doi.org/10.1067/mai.2001.119157			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692117	Bronze			2022-12-18	WOS:000172523800032
J	Christodoulopoulos, P; Cameron, L; Durham, S; Hamid, Q				Christodoulopoulos, P; Cameron, L; Durham, S; Hamid, Q			Molecular pathology of allergic disease - II: Upper airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic rhinitis; chronic sinusitis; inflammation; cytokines; chemokines	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; MAJOR BASIC-PROTEIN; ENDOTHELIAL ADHESION MOLECULES; CHRONIC HYPERPLASTIC SINUSITIS; GRASS-POLLEN IMMUNOTHERAPY; NITRIC-OXIDE SYNTHASE; PHASE NASAL RESPONSES; NECROSIS-FACTOR-ALPHA; FC-EPSILON-RI	Allergic upper airway diseases such as allergic rhinitis and chronic sinusitis are an increasing problem. Although the pathogenesis remains elusive, an individual's genetic predisposition as well as exposure to the allergen are currently considered factors in their development. Clinical symptoms of sneezing, rhinorrhea, and congestion are primarily a consequence of granulocyte release of chemical mediators such as histamine, prostanoids, and leukotrienes as well as the infiltration of inflammatory cells, Observations subsequent to allergen provocation are comparable to natural exposure and as such much of our understanding of allergic responses is derived from this model, A prominence of CD4(+) T cells and eosinophils, synthesis and release of T(H)2 cytokines, and the coordinate expression of chemokines and adhesion molecules are all characteristic of the allergic response observed in rhinitis and sinusitis. Corticosteroids and immunotherapy target these inflammatory processes and have been observed to successfully reduce and shift the predominantly T(H)2 environment toward T(H)1 cytokine expression. As our understanding of the pathophysiologic features of allergic upper airway disease improves, as well as the relationship between their development and that of lower airway disease, new strategies of diagnosis and treatment will allow for more effective modulation of the allergic process and associated morbidity.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England	McGill University; Imperial College London; Royal Brompton Hospital	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; Arnal JF, 1997, CLIN EXP ALLERGY, V27, P358; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BEASLEY R, 1993, J ALLERGY CLIN IMMUN, V92, P148, DOI 10.1016/0091-6749(93)90097-Y; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BUSUTTIL A, 1977, J ANAT, V124, P445; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; Cendan E, 1994, Rev Prat, V44, P1825; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; Chakir J, 1996, LAB INVEST, V75, P735; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COTRAN RS, 1989, ROBBINS PATHOLOGIC B, P39; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; Davidsson Ake, 1994, Rhinology (Utrecht), V32, P184; DEL PG, 1988, J IMMUNOL, V140, P4193; DENBURG JA, 1985, BLOOD, V66, P312; Dewson G, 1999, AM J RESP CELL MOL, V20, P720, DOI 10.1165/ajrcmb.20.4.3453; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOLOVICH J, 1990, RHINITIS ASTHMA SIMI, P233; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; DURHAM SR, N ENGL J MED, V341, P468; Eidelman DH, 1996, AM J RESP CELL MOL, V15, P582, DOI 10.1165/ajrcmb.15.5.8918365; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; ERJEFALT I, 1991, CLIN EXP ALLERGY, V21, P217, DOI 10.1111/j.1365-2222.1991.tb00833.x; Ferguson E. A., 1997, Rhinology (Utrecht), V35, P120; Fischer A, 1996, AM J RESP CRIT CARE, V154, P209, DOI 10.1164/ajrccm.154.1.8680682; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Ghaffar O, 1998, OTOLARYNG HEAD NECK, V118, P504, DOI 10.1016/S0194-5998(98)70209-8; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; Ghaffar O, 1998, AM J RESP CELL MOL, V18, P706, DOI 10.1165/ajrcmb.18.5.3030; GHAFFAR O, 1999, IN PRESS CLIN EXP AL; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; HUGGINS KG, 1975, LANCET, V2, P148; Iciek LA, 1997, J IMMUNOL, V158, P4769; IGARASHI Y, 1992, FASEB J, V6, pA2005; IGARASHI Y, 1992, J ALLERGY CLIN IMMUN, P89; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Jahnke V, 1978, Acta Otorhinolaryngol Belg, V32, P48; JAHNSEN FL, 1995, AM J RESP CELL MOL, V12, P624, DOI 10.1165/ajrcmb.12.6.7539273; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; KALINER MA, 1991, AM REV RESPIR DIS, V144, pS52, DOI 10.1164/ajrccm/144.3_pt_2.S52; Kamil A, 1998, OTOLARYNG HEAD NECK, V118, P804, DOI 10.1016/S0194-5998(98)70273-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KERN EB, 1983, POSTGRAD MED, V74, P156, DOI 10.1080/00325481.1983.11698461; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; Kondo H, 1999, LARYNGOSCOPE, V109, P91, DOI 10.1097/00005537-199901000-00018; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873, DOI 10.1164/ajrccm.157.3.9610052; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569, DOI 10.1016/S0091-6749(97)70152-0; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; Li L, 1999, J IMMUNOL, V162, P2477; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; LUKACS NW, 1995, AM J RESP CELL MOL, V13, P1; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; MASUDA S, QUANTITATIVE HISTOCH; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MAYER M, 1993, ANAESTHESIST, V42, P592; MCDONALD DM, 1996, NEUROGENIC INFLAMMAT, P575; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; MELTZER EO, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02736.x; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; MINSHALL E, 1999, J ALLERGY CLIN IMMUN, V103, pA222; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MOY JN, 1990, J IMMUNOL, V145, P2626; Munoz-Bellido FJ, 1998, ALLERGY, V53, P420, DOI 10.1111/j.1398-9995.1998.tb03916.x; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; MYGIND N, 1997, ALLERGY ALLERGIC DIS, P1300; NACLERIO RM, 1994, J ALLERGY CLIN IMMUN, V94, P1303, DOI 10.1016/0091-6749(94)90346-8; Naclerio RM, 1997, ALLERGY, V52, P7, DOI 10.1111/j.1398-9995.1997.tb04816.x; NACLERIO RM, 1993, ANN ALLERGY, V71, P292; *NAT I ALL INF DIS, 1979, NIH PUBL; Oddera S, 1996, ALLERGY, V51, P100, DOI 10.1111/j.1398-9995.1996.tb04565.x; Ohashi Y, 1997, ANN OTO RHINOL LARYN, V106, P483; OHKAWARA Y, 1992, AM J RESP CELL MOL, V7, P385, DOI 10.1165/ajrcmb/7.4.385; OHNO I, 1995, AM J RESP CELL MOL, V13, P639, DOI 10.1165/ajrcmb.13.6.7576701; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1988, ANN ALLERGY, V60, P537; ORGEL HA, 1991, J ALLERGY CLIN IMMUN, V88, P257, DOI 10.1016/0091-6749(91)90336-M; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PUNNONEN J, 1995, J IMMUNOL, V155, P4248; Rajakulasingam K, 1997, AM J RESP CRIT CARE, V155, P696, DOI 10.1164/ajrccm.155.2.9032215; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; Rochester CL, 1996, J IMMUNOL, V156, P4449; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; Sanai A, 1999, ACTA OTO-LARYNGOL, V119, P473; Sanico AM, 1996, J ALLERGY CLIN IMMUN, V97, P992; SCADDING GK, 1995, CLIN EXP ALLERGY, V25, P737, DOI 10.1111/j.1365-2222.1995.tb00011.x; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SHALIT M, 1995, CELL IMMUNOL, V160, P50, DOI 10.1016/0008-8749(95)80008-7; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SOMASSE T, 1996, J EXP MED, V184, P473; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473; STELLATO C, 1995, J IMMUNOL, V155, P410; SVENSSON C, 1995, CLIN EXP ALLERGY, V25, P942, DOI 10.1111/j.1365-2222.1995.tb00396.x; Symon FA, 1999, EUR J IMMUNOL, V29, P1324, DOI 10.1002/(SICI)1521-4141(199904)29:04<1324::AID-IMMU1324>3.3.CO;2-U; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TEDESCHI A, 1994, EUR RESPIR J, V7, P1445, DOI 10.1183/09031936.94.07081445; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; TERADA N, 1994, J ALLERGY CLIN IMMUN, V94, P629, DOI 10.1016/0091-6749(94)90140-6; THOMAS LL, 1989, IMMUNOLOGY, V66, P611; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VOLOVITZ B, 1988, J ALLERGY CLIN IMMUN, V82, P414, DOI 10.1016/0091-6749(88)90000-0; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wardlaw AJ, 1996, ANN NY ACAD SCI, V796, P124, DOI 10.1111/j.1749-6632.1996.tb32574.x; WARREN WD, 1995, J IMMUNOL, V155, P5637; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; Wilson SJ, 1998, CLIN EXP ALLERGY, V28, P220; WILSON SJ, 1995, AM J RESP CRIT CARE, V151, pA563; Wright ED, 1998, J OTOLARYNGOL, V27, P281; Wright ED, 1999, CLIN EXP ALLERGY, V29, P1320; Wright ED, 1998, OTOLARYNG HEAD NECK, V118, P490, DOI 10.1016/S0194-5998(98)70207-4; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YING S, 1994, IMMUNOLOGY, V82, P200; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	164	144	145	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				211	223		10.1016/S0091-6749(00)90068-X	http://dx.doi.org/10.1016/S0091-6749(00)90068-X			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669839	Bronze			2022-12-18	WOS:000085402200003
J	Nelson, HS; Szefler, SJ; Jacobs, J; Huss, K; Shapiro, G; Sternberg, AL				Nelson, HS; Szefler, SJ; Jacobs, J; Huss, K; Shapiro, G; Sternberg, AL		Childhood Asthma Management Program Res Grp	The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood Asthma Management Program; environmental allergen sensitization; allergens; bronchial hyperresponsiveness; pulmonary; function; skin tests	HOUSE-DUST-MITE; AIRWAY RESPONSIVENESS; CHEMOTACTIC ACTIVITY; LOS-ALAMOS; NEW-MEXICO; HAY-FEVER; IMMUNOTHERAPY; CHILDREN; ATOPY; ANTIBODIES	Background: Sensitivity and exposure to indoor allergens constitutes a risk factor for the development and persistence of asthma in children. Objective: Our purpose was to evaluate the relationship between sensitivity and exposure to inhalant allergens and lung function and bronchial responsiveness in a group of children (n = 1041) aged 8.9 +/- 2.1 gears with mild to moderate asthma enrolled in the Childhood Asthma Management Program (CAMP). Methods: With use of the extensive CAMP baseline cross-sectional data on spirometry, bronchial responsiveness, allergen sensitivities, and household allergen levels, the relationship of sensitization and exposure to allergens to lung function and methacholine sensitivity was evaluated. Children who enrolled in CAMP stopped ail antiasthma medication except rescue use of albuterol and prednisone for exacerbations during the 5- to 16-week screening period. During the last 2 of these weeks they underwent spirometry and methacholine challenge. Indoor allergen exposures were determined from questionnaires completed by the parent. Household levels of indoor allergens (mite, cat, dog, cockroach, mold) were determined on house dust samples. Allergen sensitivity was determined by percutaneous skin testing with a standard battery of allergens plus locally important pollen and fungal spores. Lung function and bronchial hyperresponsiveness were compared for children sensitive and not sensitive to both indoor and outdoor allergens on skin testing and, if sensitive, for exposed and not exposed to the allergens to which they were positive on skin testing. Results: There was a strong direct correlation between increased sensitivity to inhaled methacholine and skin test sensitivity to tree, meed, Alternaria, cat, dog, and indoor molds. When the relationship was examined by stepwise regression, the skin test sensitivities showing the strongest associations with the concentration of methacholine that caused a 20% fall in FEV1 mere dog (P = .003), Alternaria (P = .01), and cat (P = .05). Children sensitive to any one of the aeroallergens tested were compared for the presence or absence of exposure to that allergen at the time that the methacholine challenge was performed. Those who were sensitive and exposed to weed and cat had greater methacholine sensitivity than those similarly sensitive but not exposed (P = .003 and P = .02, respectively). Conclusions: Sensitivity to dog or cat dander or Alternaria by skin testing was associated with increased bronchial responsiveness but not decreased lung function in children with mild to moderate asthma. These findings support the important role that sensitization to certain allergens plays in modulating bronchial responsiveness.	Nalt Jewish Med & Res Ctr, Denver, CO 80206 USA; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; Johns Hopkins Univ, Ctr Clin Trials, Baltimore, MD USA; NW Asthma & Allergy Ctr, Seattle, WA USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Nelson, HS (corresponding author), Nalt Jewish Med & Res Ctr, 1400 Jackson St,B104, Denver, CO 80206 USA.				NHLBI NIH HHS [N01-HR-16045, N01-HR-16044, N01-HR-16046] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016044, N01HR016046, N01HR016045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AER MON NETW, 1997, POLL SPOR REP; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILD ASTHM MAN P, 1997, CHILDH ASTHM MAN PRO; COULTAS DB, 1988, AM REV RESPIR DIS, V138, P1386, DOI 10.1164/ajrccm/138.6.1386; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; de Marco R, 1998, ALLERGY, V53, P673; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; HAMILTON S, 1992, NEW ENGL REV-MIDDLEB, V14, P96; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Omenaas E, 1996, EUR RESPIR J, V9, P919, DOI 10.1183/09031936.96.09050919; OMENAAS E, 1995, AM J RESP CRIT CARE, V152, P1158, DOI 10.1164/ajrccm.152.4.7551364; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1995, INT ARCH ALLERGY IMM, V107, P301, DOI 10.1159/000237008; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; *SAS I, 1989, SAS STAT US GUID VER, V1; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x	29	144	145	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				775	785		10.1016/S0091-6749(99)70287-3	http://dx.doi.org/10.1016/S0091-6749(99)70287-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518821	Bronze			2022-12-18	WOS:000083281200008
J	Wood, RA; Phipatanakul, W; Hamilton, RG; Eggleston, PA				Wood, RA; Phipatanakul, W; Hamilton, RG; Eggleston, PA			A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin tests; radioallergosorbent testing; cat allergy	RADIOALLERGOSORBENT; CHALLENGE	Background: Skin testing and RASTs are the most commonly used methods for the diagnosis of allergy. Questions remain, however, as to the accuracy of these tests, particularly with regard to the role of intradermal skin tests (IDSTs) in the evaluation of respiratory allergy. Objective: The purpose of this study was to determine the predictive value of skin prick tests (SPTs), IDSTs, and RASTs in the diagnosis of cat allergy. Methods: Patients were challenged with a well-characterized cat exposure model after evaluation by history, SPTs, IDSTs (if SPT results were negative), and RASTs. All patients were evaluated with respect to their upper respiratory responses, although only those patients with asthma were included in the analysis of lower airway responses, Challenge results were considered positive if the mean upper respiratory symptom score was 0.5 or more, the mean lower respiratory symptom score was 0.4 or more, or the maximum fall in FEV1 value was 15% or more. Results: One hundred twenty patients were evaluated. SPT values were positive in 81 patients; of the remaining 39 patients, IDST values were positive in 26 patients, RASTs were performed in 89 patients; the values were positive in 45 of 51 patients with a positive SPT value and were negative in all patients with a negative SPT value. When any positive challenge outcome was considered, positive challenge results were seen in 38 of 41 patients with a positive SPT score, in 10 of 39 patients with a negative SPT score, in 6 of 26 patients with a positive IDST score, in 4 of 13 patients with a negative IDST score, in 27 of 27 patients with a positive RAST score, and in 12 of 44 patients with a negative RAST score. Conclusion: Although both SPT and RAST values exhibited excellent efficiency in the diagnosis of cat allergy, IDST scores added little to the diagnostic evaluation.	Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Immunol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NIAID NIH HHS [AI07007] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JA, 1992, JAMA-J AM MED ASSOC, V268, P2845, DOI 10.1001/jama.1992.03490200097011; [Anonymous], 1993, J Allergy Clin Immunol, V92, P636; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FERGUSON AC, 1986, CAN MED ASSOC J, V134, P1365; GALEN RS, 1986, TXB CLIN CHEM, P394; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; OWNBY DR, 1986, AM J DIS CHILD, V140, P45, DOI 10.1001/archpedi.1986.02140150047031; PEPYS J, 1975, Clinical Allergy, V5, P431, DOI 10.1111/j.1365-2222.1975.tb01882.x; REDDY PM, 1978, J ALLERGY CLIN IMMUN, V61, P36, DOI 10.1016/0091-6749(78)90471-2; Sicherer SH, 1997, J ALLERGY CLIN IMMUN, V99, P798, DOI 10.1016/S0091-6749(97)80014-0; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x; WOOD RA, 1994, PROVOCATION TESTING, P369	18	144	152	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				773	779		10.1016/S0091-6749(99)70419-7	http://dx.doi.org/10.1016/S0091-6749(99)70419-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329809				2022-12-18	WOS:000080470200010
J	Foresi, A; Pelucchi, A; Gherson, G; Mastropasqua, B; Chiapparino, A; Testi, R				Foresi, A; Pelucchi, A; Gherson, G; Mastropasqua, B; Chiapparino, A; Testi, R			Once daily intranasal fluticasone propionate (200 mu g) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; allergic rhinitis; nasal lavage; bronchial responsiveness	BECLOMETHASONE DIPROPIONATE; DOUBLE-BLIND; SPRAY; EXPOSURE; ASTHMA; MULTICENTER; CHALLENGE; MUCOSA	Background: Fluticasone propionate aqueous nasal spray, a new topical corticosteroid, has been proved to be an effective treatment for seasonal allergic rhinitis. Objectives: We studied the effect of fluticasone propionate on nasal symptoms, circulating eosinophils, and nasal inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Moreover, we examined its efficacy in preventing the increase in bronchial responsiveness to methacholine (PD20) during the pollen season. Methods: We conducted a double-blind, placebo-controlled, parallel-group study in patients who had a history of allergic rhinitis in response to pollens of grass and Parietaria species and were living in northern Italy. After a run-in period of 2 weeks, 24 patients were treated with fluticasone propionate (200 mu g, once daily), and 26 patients received matched placebo for 6 weeks, starting from the beginning of the pollen season. Assessment of efficacy was based on scores of daily nasal symptoms. Nasal lavage was performed at the end of the season, and differential cell count was expressed as percent of total cells. PD20 methacholine was measured at the beginning and end of the season and after the season had ended. Results: Fluticasone propionate significantly reduced nasal obstruction, itching, and rhinorrhea. Eosinophils in blood (p<0.01) and nasal lavage (p<0.001) were also reduced. Moreover, fluticasone significantly attenuated the decrease in mean PD20 methacholine (from 1.95 to 0.89 mg) compared with placebo (from 1.38 to 0.37 mg; p<0.01). After the season, no difference in PD20 methacholine was found between treatment groups. Conclusions: The results of this study indicate that fluticasone propionate is effective in decreasing nasal symptoms and eosinophil inflammation in patients with seasonal allergic rhinitis after high-load pollen exposure. Our results also demonstrate that treatment with fluticasone propionate partially prevents the increase in bronchial responsiveness provoked by the inhalation of seasonal pollens in allergic rhinitis.	OSPED ARMANI, UNITA OPERAT FISIOPATOL RESP, TRENT, ITALY; GLAXO SPA, DIREZ MED, VERONA, ITALY	GlaxoSmithKline	Foresi, A (corresponding author), SERV FISIOPATOL RESP G CAMPARI, MODULO ALLERGOL & IMMUNOPATOL POLMONARE, VIALE MATTEOTTI 83, I-2099 SESTO SAN GIOVANNI, ITALY.							ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; BOUSQUET J, 1993, ALLERGY, V48, P327, DOI 10.1111/j.1398-9995.1993.tb02401.x; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BRYSON HM, 1992, DRUGS, V43, P760, DOI 10.2165/00003495-199243050-00009; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DOCKHORN RJ, 1993, AM J RHINOL, V7, P77, DOI 10.2500/105065893781976519; DOLOVICH J, 1990, RESP MED, V84, P31, DOI 10.1016/S0954-6111(08)80005-4; DOLOVICH J, 1994, ANN ALLERGY, V72, P435; GROSSMAN J, 1993, PEDIATRICS, V92, P594; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; KARLSSON G, 1991, CLIN EXP ALLERGY, V21, P705; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NATHAN RA, 1991, ANN ALLERGY, V67, P332; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RATNER PH, 1992, J ALLERGY CLIN IMMUN, V90, P285, DOI 10.1016/S0091-6749(05)80005-3; SCADDING GK, 1994, BRIT J CLIN PHARMACO, V38, P447, DOI 10.1111/j.1365-2125.1994.tb04381.x; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; THOMAS KE, 1990, RESP MED, V84, P33, DOI 10.1016/S0954-6111(08)80006-6; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9; VANBAVEL J, 1994, ARCH INTERN MED, V154, P2699, DOI 10.1001/archinte.1994.00420230086010; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184	31	144	150	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					274	282		10.1016/S0091-6749(96)70150-1	http://dx.doi.org/10.1016/S0091-6749(96)70150-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757203				2022-12-18	WOS:A1996VC99500005
J	Wennergren, G; Kristjansson, S; Strannegard, IL				Wennergren, G; Kristjansson, S; Strannegard, IL			Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in the prevalence of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; hospitalization; inhaled corticosteroids; health economy	CHILDREN; MORBIDITY; GROWTH	Background: During the past 15 years, the prevalence of asthma in children in Sweeden has doubled. However, since, 1985, antiyinflammatory treatment with inhaled steroids has increased continuously. Objective: The aim of this study was to analyze the net effect of these changes in terms of hospitalization of children for treatment of asthma. Methods: The numbers of hospital days, admissions, and individual patients admitted to the Children's Hospital in Goteborg because of acute asthma were recorded from 1985 through 1993. All the in-patient treatment of children is centralized at this hospital (i.e., the study was population-based). Goteborg has half a million inhabitants. Hospitalization policies were not altered during the study period. Results: In children aged 2 to 18 years, the number of hospital days per year gradually decreased to less than a third (r = 0.9; p < 0.001), and admissions decreased by 45% (r = 0.7; p < 0.05). The decrease in hospitalization was most marked in the group older than the age of 5 years in which hospital days were reduced to one fifth (r = 0.9; p < 0.0001) and admissions were halved (r = 0.8; p < 0.05). A decreasing trend in number of hospital days was also seen in the 2- to 5-year-old group. The number of individual patients admitted did not show a statistically significant decreasing trend. In children under the age of 2 years, the number of hospital days fluctuated, and there was no clear-cut change with time. Conclusion: Although increased concentration on the education of patents and patients may have been a contributing factor, the major reason for the decrease in hospitalization in the group of children aged 2 to 18 years is most probably antiinflammatory treatment with inhaled steroids. The results suggest that this is a very cost-effective therapeutic approach.			Wennergren, G (corresponding author), GOTHENBURG UNIV,OSTRA HOSP,DEPT PEDIAT,S-41685 GOTHENBURG,SWEDEN.							ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; Adelroth E, 1984, Lakartidningen, V81, P4285; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Ashkenazi S, 1993, Pediatr Allergy Immunol, V4, P93, DOI 10.1111/j.1399-3038.1993.tb00074.x; BERTOLIS P, 1994, J ALLERGY CLIN IMMUN, V93, P293; BRABACK L, 1988, ACTA PAEDIATR SCAND, V77, P826, DOI 10.1111/j.1651-2227.1988.tb10763.x; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; Bryan S, 1992, Pharmacoeconomics, V2, P207, DOI 10.2165/00019053-199202030-00004; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; Carlsen KH, 1994, EUR RESPIR REV, V4, P5; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CONNETT GJ, 1993, ARCH DIS CHILD, V69, P202, DOI 10.1136/adc.69.2.202; FRIDAY GA, 1988, PEDIATR CLIN N AM, V35, P1149; GERDTHAM UG, 1993, IMPACT INHALED CORTI; GOLDSTEIN RA, 1992, CHEST, V101, pS355, DOI 10.1016/S0012-3692(16)32931-2; GORBY R, 1994, J ALLERGY CLIN IMMUN, V93, P293; KEISTINEN T, 1993, THORAX, V48, P44, DOI 10.1136/thx.48.1.44; LARSSON L, 1994, THORAX, V49, P41, DOI 10.1136/thx.49.1.41; Lenny W, 1994, EUR RESPIR REV, V4, P49; Mellis C M, 1993, Pharmacoeconomics, V3, P205, DOI 10.2165/00019053-199303030-00004; PERSSON U, 1994, SOCIOECONOMIC COSTS; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 1992, ARCH DIS CHILD, V67, P240	27	144	145	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					742	748		10.1016/S0091-6749(96)80150-3	http://dx.doi.org/10.1016/S0091-6749(96)80150-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613629	Bronze			2022-12-18	WOS:A1996UA97500003
J	MOSIMANN, BL; WHITE, MV; HOHMAN, RJ; GOLDRICH, MS; KAULBACH, HC; KALINER, MA				MOSIMANN, BL; WHITE, MV; HOHMAN, RJ; GOLDRICH, MS; KAULBACH, HC; KALINER, MA			SUBSTANCE-P, CALCITONIN-GENE-RELATED PEPTIDE, AND VASOACTIVE-INTESTINAL-PEPTIDE INCREASE IN NASAL SECRETIONS AFTER ALLERGEN CHALLENGE IN ATOPIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEUROPEPTIDES; SUBSTANCE-P; CALCITONIN GENE RELATED PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE; ALLERGIC RHINITIS; NASAL SECRETION	ANGIOTENSIN-CONVERTING ENZYME; VASCULAR-PERMEABILITY; RESPIRATORY-TRACT; MAST-CELLS; NEUROPEPTIDES; CAPSAICIN; RHINITIS; RELEASE; MUCOSA; LUNG	Background: There is suggestive evidence that neuropeptides participate in allergic reactions. Substance P (SP) and calcitonin gene-related peptide (CGRP) are released by sensory nerves, whereas vasoactive intestinal peptide (VIP) is released mainly by parasympathetic nerves. Both sets of nerves are thought to be stimulated by allergic inflammation. The aim of this study was to assess nasal secretions to determine whether SP CGRP, and VIP were increased after allergen challenge. Methods: Eight patients with allergic rhinitis were challenged nasally with 1 mg histamine or increasing doses of allergen. Nasal lavages were collected into a cocktail of protease inhibitors in order to restrict neuropeptide degradation. Radioimmunoassay for SP CGRP, and VIP were performed on each sample. Results: All patients had immediate clinical reactions to both histamine and allergen challenges, and seven patients experienced a later allergic reaction. After histamine challenge, SP and CGRP did not increase significantly above baseline in the nasal lavages, whereas VIP did (p < 0.02). In contrast, SP, CGRP, and VIP all significantly increased immediately after allergen challenge and returned to baseline within 2 hours. At the clinical peak of the late allergic reaction, SP, but not CGRP or VIP was increased slightly but significantly (p < 0.01). Conclusions: Thus SP CGRP, and VIP are found in nasal secretions after allergen challenge, which confirms that neuropeptides are released in human beings during allergic reactions. The selective stimulation of VIP secretion by histamine challenge suggests that histamine-induced cholinergic reflexes induce the release of VIP. These data support the suggestion that neuropeptides may be partly responsible for some of the nasal symptoms of allergy.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11-C-205,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALI H, 1986, INT ARCH ALLER A IMM, V79, P413, DOI 10.1159/000234011; BARANIUK JN, 1990, AM J PHYSIOL, V258, pL81, DOI 10.1152/ajplung.1990.258.2.L81; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1990, IMMUNOL ALLERGY CLIN, V10, P383; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; CASALE TB, 1991, J ALLERGY CLIN IMMUN, V88, P1, DOI 10.1016/0091-6749(91)90292-V; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; HOLZER P, 1991, PHARMACOL REV, V43, P143; KOWALSKI ML, 1990, J IMMUNOL, V145, P1214; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; LAITINEN A, 1985, HISTOCHEMISTRY, V82, P313, DOI 10.1007/BF00494059; LAITINEN LA, 1987, AM REV RESPIR DIS S, V136, P59; LOWMAN MA, 1988, BRIT J PHARMACOL, V95, P121, DOI 10.1111/j.1476-5381.1988.tb16555.x; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; LUNDBERG JM, 1985, EUR J PHARMACOL, V108, P315, DOI 10.1016/0014-2999(85)90456-X; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P49, DOI 10.1111/j.1748-1716.1983.tb07304.x; LUNDBERG JM, 1988, AIRWAYS NEURAL CONTR, P417; LUNG MA, 1987, J PHYSIOL-LONDON, V386, P465, DOI 10.1113/jphysiol.1987.sp016545; MATRAN R, 1989, ACTA PHYSIOL SCAND, V135, P335, DOI 10.1111/j.1748-1716.1989.tb08585.x; NATHANSON I, 1983, J APPL PHYSIOL, V55, P1844, DOI 10.1152/jappl.1983.55.6.1844; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; OHKUBO K, 1992, J ALLERGY CLIN IMMUN, V89, P210; OHKUBO K, 1992, IN PRESS AM J RESPIR; PAUWELS RA, 1989, J ALLERGY CLIN IMMUN, V83, P24; Petersson G, 1990, AM J RHINOL, V4, P163; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; SAID SI, 1990, LIFE SCI, V47, pPL19, DOI 10.1016/0024-3205(90)90580-K; SERTL K, 1988, AM REV RESPIR DIS, V138, P151, DOI 10.1164/ajrccm/138.1.151; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; Stjarne P, 1991, AM J RHINOL ALLERGY, V5, P145, DOI [10.2500/105065891781874992, DOI 10.2500/105065891781874992]; TONNESEN P, 1988, ALLERGY, V43, P310, DOI 10.1111/j.1398-9995.1988.tb00906.x; TONNESEN P, 1987, ALLERGY, V42, P146, DOI 10.1111/j.1398-9995.1987.tb02373.x; WALKER KB, 1988, J CLIN IMMUNOL, V8, P108, DOI 10.1007/BF00917898; WHITE MV, 1989, BIOCH ACUTE ALLERGIC, P83	38	144	147	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				95	104		10.1016/0091-6749(93)90043-F	http://dx.doi.org/10.1016/0091-6749(93)90043-F			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	7687608	Bronze			2022-12-18	WOS:A1993LQ35300015
J	DEBLAY, F; HEYMANN, PW; CHAPMAN, MD; PLATTSMILLS, TAE				DEBLAY, F; HEYMANN, PW; CHAPMAN, MD; PLATTSMILLS, TAE			AIRBORNE DUST MITE ALLERGENS - COMPARISON OF GROUP II ALLERGENS WITH GROUP-I MITE ALLERGEN AND CAT-ALLERGEN FEL D I	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MITE ALLERGENS; AIRBORNE ALLERGENS; CAT ALLERGENS; GROUP II MITE ALLERGEN	HUMAN IGE ANTIBODIES; DER-F-I; HOUSE DUST; DERMATOPHAGOIDES-PTERONYSSINUS; P-I; CASCADE IMPACTOR; MAJOR ALLERGEN; MURINE IGG; ASTHMA; PURIFICATION	The form in which allergens become airborne is important because it may influence both symptoms caused by allergen exposure and methods used to reduce exposure. The group I allergens from dust mites only become airborne during disturbance and fall rapidly, which is in keeping with their being carried on fecal pellets. Their mean size is approximately 20-mu-m in diameter. By contrast, the cat-allergen Fel d I is airborne on particles varying from > 10 to < 2-mu-m in diameter, some of which remain airborne even without disturbance. A second group of mite allergens, molecular weight 14,000, are equally important and are associated predominantly with mite bodies. With a monoclonal antibody-based assay and a cascade impactor, we have investigated the form in which group II mite allergens become airborne. The results reveal that these allergens only become airborne during disturbance and that they fall within 15 minutes. However, the mean size of the particles carrying group II allergens appears to be slightly smaller than the mean size of particles carrying group I allergens. In addition, the quantities of group II allergen becoming airborne during disturbance (mean, 26 ng/m3) could not be explained by the quantity found in fecal particles. Thus, group II mite allergens become airborne in a form quite distinct from cat allergens and very similar to group I mite allergens; however, it appears unlikely that fecal particles are the main form in which group II allergens become airborne.	UNIV VIRGINIA, HLTH SCI CTR,DEPT MED,DIV ALLERGY & IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DIV ALLERGY & CLIN IMMUNOL, CHARLOTTESVILLE, VA 22903 USA	University of Virginia; University of Virginia				Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565, R29AI024261, R29AI024687] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24687, AI-24261, AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1966, HEALTH PHYS, V12, P173; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; EHNERT B, 1991, Journal of Allergy and Clinical Immunology, V87, P320, DOI 10.1016/0091-6749(91)92005-L; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; GRIFFITHS DA, 1971, J STORED PROD RES, V7, P1, DOI 10.1016/0022-474X(71)90032-4; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HOLCK A, 1986, ALLERGY, V41, P408, DOI 10.1111/j.1398-9995.1986.tb00320.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MURRAY AB, 1983, PEDIATRICS, V71, P418; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1991, PHARM PATHOPHYSIOLOG, P595; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SVARTENGREN M, 1987, EXP LUNG RES, V12, P75, DOI 10.3109/01902148709068815; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; Voorhorst R., 1969, HOUSE DUST ATOPY HOU; WALSHAW MJ, 1986, Q J MED, V58, P199; WHARTON GW, 1976, J MED ENTOMOL, V12, P577, DOI 10.1093/jmedent/12.6.577; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; 1988, J ALLERGY CLIN IMMUN, V82, P841	36	144	144	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					919	926		10.1016/0091-6749(91)90249-N	http://dx.doi.org/10.1016/0091-6749(91)90249-N			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744363				2022-12-18	WOS:A1991GW26200013
J	VALENTA, R; DUCHENE, M; VRTALA, S; BIRKNER, T; EBNER, C; HIRSCHWEHR, R; BREITENBACH, M; RUMPOLD, H; SCHEINER, O; KRAFT, D				VALENTA, R; DUCHENE, M; VRTALA, S; BIRKNER, T; EBNER, C; HIRSCHWEHR, R; BREITENBACH, M; RUMPOLD, H; SCHEINER, O; KRAFT, D			RECOMBINANT ALLERGENS FOR IMMUNOBLOT DIAGNOSIS OF TREE-POLLEN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						POLLEN ALLERGENS; INVITRO DIAGNOSIS; IGE; ALLERGY; PROFILIN	BETULA-VERRUCOSA; MESSENGER-RNA; BIRCH POLLEN; PROTEINS; GENES	Diagnosis of type I allergy essentially depends on the availability of defined allergens, which can be provided by recombinant deoxyribonucleic acid (DNA) technology. We have previously isolated the c(complementary)DNAs encoding the major birch-pollen allergen, Bet v I, and another allergen with a molecular weight of 14 kd that was identified as birch profilin and designated Bet v II. These cDNAs were isolated from a lambda gt11 expression library by screening with the serum IgE from allergic patients. To obtain expression in Escherichia coli of recombinant allergens without additional fused polypeptides, both cDNAs were inserted into the plasmid pKK223-3. E. coli cells expressing Bet v I and birch profilin (Bet v II) were used for the preparation of recombinant proteins. These proteins were tested for their IgE-binding properties on immunoblots with sera from 100 different birch pollen-allergic patients. All patients' sera, which reacted with the natural allergens, Bet v I and Bet v II, demonstrated an identical IgE-binding pattern to recombinant birch-pollen allergens. Recombinant allergens may therefore be useful for the setup of diagnostic tests that allow the discrimination of different IgE-binding patterns as well as for patient-tailored immunotherapy.	UNIV VIENNA,DEPT GEN & EXPTL PATHOL,WAHRINGERGURTEL 18-20,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST SPECIF PROPHYLAXIS & TROP MED,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MICROBIOL & GENET,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN CHEM,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DIAGNOST LAB,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna			Duchêne, Michael/G-6659-2019	Duchêne, Michael/0000-0003-1232-3600; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BREITENBACH M, 1990, EPITOPES ATOPIC ALLE, P57; BREITENEDER H, 1988, INT ARCH ALLER A IMM, V87, P19, DOI 10.1159/000234643; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; IPSEN H, 1990, EPITOPES ATOPIC ALLE, P3; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SAMBROOK J, 1989, MOL CLONING LABORATO, V17, P3; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P384, DOI 10.1159/000234373; THOMAS WR, 1990, EPITOPES ATOPIC ALLE, P77; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALENTA R, 1991, SCHWEIZ MED WOSCHENS, V121, P10; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	20	144	146	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					889	894		10.1016/0091-6749(91)90245-J	http://dx.doi.org/10.1016/0091-6749(91)90245-J			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744359				2022-12-18	WOS:A1991GW26200009
J	KANG, B; VELLODY, D; HOMBURGER, H; YUNGINGER, JW				KANG, B; VELLODY, D; HOMBURGER, H; YUNGINGER, JW			COCKROACH CAUSE OF ALLERGIC-ASTHMA - ITS SPECIFICITY AND IMMUNOLOGICAL PROFILE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUSH MED COLL,MT SINAI HOSP MED CTR,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,CHICAGO,IL 60612; MAYO GRAD SCH MED,ROCHESTER,MN 55901	Rush University; Mayo Clinic	KANG, B (corresponding author), MT SINAI HOSP,MED CTR,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,CHICAGO,IL 60608, USA.							AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1970, ANN ALLERGY, V28, P420; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; COLTEN HR, 1975, NEW ENGL J MED, V292, P1050, DOI 10.1056/NEJM197505152922003; CORNWELL PB, 1977, BRIT MED J, V1, P1159, DOI 10.1136/bmj.1.6069.1159-d; DAVIES RJ, 1974, PROGR IMMUNOLOGY 2, V4, P249; FINK JN, 1974, MED CLIN N AM, V58, P157, DOI 10.1016/S0025-7125(16)32185-X; GANDEVIA B, 1970, BRIT J IND MED, V27, P235; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; HOMBURGER HA, UNPUBLISHED; HUDSON G, 1968, Seminars in Hematology, V5, P166; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; KANG B, 1977, 1ST ANN M AM C ALL I; KANG B, ANN ALLERGY; KANG F, 1976, J ALLERGY CLINICAL I, V58, P357; MENDOZA J, 1970, ANN ALLERGY, V28, P159; ORANGE RP, 1971, 2ND INT S BIOCH AC A, P189; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROTH LM, 1951, MISCELLANEOUS SMITHS, V134, P1; SMITH DB, 1968, ANAL BIOCHEM, V22, P543, DOI 10.1016/0003-2697(68)90299-6; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1	28	144	147	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	2					80	86		10.1016/0091-6749(79)90196-9	http://dx.doi.org/10.1016/0091-6749(79)90196-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GJ748	83332				2022-12-18	WOS:A1979GJ74800004
J	Li, N; Georas, S; Alexis, N; Fritz, P; Xia, T; Williams, MA; Horner, E; Nel, A				Li, Ning; Georas, Steve; Alexis, Neil; Fritz, Patricia; Xia, Tian; Williams, Marc A.; Horner, Elliott; Nel, Andre			A work group report on ultrafine particles (American Academy of Allergy, Asthma & Immunology): Why ambient ultrafine and engineered nanoparticles should receive special attention for possible adverse health outcomes in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ambient ultrafine particles; engineered nanoparticles; particle deposition and distribution; allergic inflammation; asthma; lung inflammation; oxidative stress; effect on human health	PREDICTIVE TOXICOLOGICAL APPROACH; WALLED CARBON NANOTUBES; PARTICULATE MATTER; OXIDATIVE STRESS; AIR-POLLUTION; ZINC-OXIDE; LUNG-FUNCTION; EXPOSURE IMPLICATIONS; HUMAN MICROBIOME; DENDRITIC CELLS	Ultrafine particles (UFPs) are airborne particulates of less than 100 nm in aerodynamic diameter. Examples of UFPs are diesel exhaust particles, products of cooking, heating, and wood burning in indoor environments, and, more recently, products generated through the use of nanotechnology. Studies have shown that ambient UFPs have detrimental effects on both the cardiovascular and respiratory systems, including a higher incidence of atherosclerosis and exacerbation rate of asthma. UFPs have been found to alter in vitro and in vivo responses of the immune system to allergens and can also play a role in allergen sensitization. The inflammatory properties of UFPs can be mediated by a number of different mechanisms, including the ability to produce reactive oxygen species, leading to the generation of proinflammatory cytokines and airway inflammation. In addition, because of their small size, UFPs also have unique distribution characteristics in the respiratory tree and circulation and might be able to alter cellular function in ways that circumvent normal signaling pathways. Additionally, UFPs can penetrate intracellularly and potentially cause DNA damage. The recent advances in nanotechnology, although opening up new opportunities for the advancement of technology and medicine, could also lead to unforeseen adverse health effects in exposed human subjects. Further research is needed to clarify the safety of nanoscale particles, as well as the elucidation of the possible beneficial use of these particulates to treat disease.	[Li, Ning] Michigan State Univ, CVM, Dept Pathol & Diagnost Invest, E Lansing, MI 48824 USA; [Georas, Steve] Univ Rochester, Sch Med, Dept Med, Rochester, NY 14627 USA; [Alexis, Neil] Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC USA; [Fritz, Patricia] New York State Dept Hlth, Albany, NY 12237 USA; [Xia, Tian; Nel, Andre] Univ Calif Los Angeles, Dept Med, Div NanoMed, Los Angeles, CA 90024 USA; [Williams, Marc A.] US Army Publ Hlth Command, Hlth Effects Res Program, Toxicol Portfolio, Aberdeen Proving Ground, MD USA; [Horner, Elliott] UL Environm, Marietta, GA USA	Michigan State University; University of Rochester; University of North Carolina; University of North Carolina Chapel Hill; State University of New York (SUNY) System; University of California System; University of California Los Angeles; United States Department of Defense; United States Army	Nel, A (corresponding author), 10833 Le Conte Ave,52-175 CHS, Los Angeles, CA 90095 USA.; Li, N (corresponding author), 1129 Farm Lane B43, E Lansing, MI 48840 USA.	lining3@msu.edu; ANel@mednet.ucla.edu	Xiao, Jian/GYU-4351-2022; Nel, Andre E/J-2808-2012; xia, tian/C-3158-2013	xia, tian/0000-0003-0123-1305	NSF [DBI-1266377]; NIEHS [U19ES019528, P30 ES01247]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U19ES019528, P30ES001247] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants NSF DBI-1266377 (to A.N.), NIEHS U19ES019528 (to A.N.), and NIEHS P30 ES01247 (to S.G.).	Afshari A, 2005, INDOOR AIR, V15, P141, DOI 10.1111/j.1600-0668.2005.00332.x; Alberg T, 2014, J TOXICOL ENV HEAL A, V77, P281, DOI 10.1080/15287394.2013.863746; Alessandrini F, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-11; Alessandrini F, 2009, AM J RESP CRIT CARE, V179, P984, DOI 10.1164/rccm.200807-1061OC; American Conference of Governmental Industrial Hygienists, 2001, SILV COMP TLV CHEM S; [Anonymous], 2011, NAT NAN IN ENV HLTH; [Anonymous], 2014, MARKET RES REPORT GL, P150; Araujo JA, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-24; Arnold F, 2012, ENVIRON SCI TECHNOL, V46, P11227, DOI 10.1021/es302432s; Auffan M, 2009, NAT NANOTECHNOL, V4, P634, DOI 10.1038/nnano.2009.242; Avouris P, 2007, NAT NANOTECHNOL, V2, P605, DOI 10.1038/nnano.2007.300; Beck-Speier I, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-27; Bezemer GFG, 2011, J INNATE IMMUN, V3, P150, DOI 10.1159/000321725; Bhatt I, 2011, CHEMOSPHERE, V82, P308, DOI 10.1016/j.chemosphere.2010.10.011; Biswas SK, 2009, MOL ASPECTS MED, V30, P60, DOI 10.1016/j.mam.2008.07.001; Blank F, 2013, AM J RESP CELL MOL, V49, P67, DOI 10.1165/rcmb.2012-0387OC; Breysse PN, 2013, AIR QUAL ATMOS HLTH, V6, P333, DOI 10.1007/s11869-012-0181-8; Brouwer D, 2009, J NANOPART RES, V11, P1867, DOI 10.1007/s11051-009-9772-1; Chalupa DC, 2004, ENVIRON HEALTH PERSP, V112, P879, DOI 10.1289/ehp.6851; Chan JKW, 2013, AM J RESP CELL MOL, V48, P114, DOI 10.1165/rcmb.2012-0108OC; Chen EY, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-2; Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535; Cheng YH, 2010, SCI TOTAL ENVIRON, V409, P364, DOI 10.1016/j.scitotenv.2010.10.023; Cho HY, 2010, TOXICOL APPL PHARM, V244, P43, DOI 10.1016/j.taap.2009.07.024; Chung A, 2001, ENVIRON SCI TECHNOL, V35, P2184, DOI 10.1021/es001879l; de Haar C, 2008, J ALLERGY CLIN IMMUN, V121, P1246, DOI 10.1016/j.jaci.2008.01.010; De Volder MFL, 2013, SCIENCE, V339, P535, DOI 10.1126/science.1222453; Dennekamp M, 2001, OCCUP ENVIRON MED, V58, P511, DOI 10.1136/oem.58.8.511; Devlin RB, 2014, TOXICOL SCI, V140, P61, DOI 10.1093/toxsci/kfu063; Diaz-Robles LA, 2014, ENVIRON INT, V66, P174, DOI 10.1016/j.envint.2014.01.017; Du YF, 2013, BIOCHEM BIOPH RES CO, V436, P462, DOI 10.1016/j.bbrc.2013.05.127; Eder C, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-27; England G. C., 2004, DEV FINE PARTICULATE; Erdely A, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-53; Evans KA, 2014, ENVIRON RES, V129, P11, DOI 10.1016/j.envres.2013.12.001; Fine JM, 1997, J OCCUP ENVIRON MED, V39, P722, DOI 10.1097/00043764-199708000-00006; Fiorino DJ, 2010, VOLUNTARY INITIATIVE; Frampton MW, 2006, ENVIRON HEALTH PERSP, V114, P51, DOI 10.1289/ehp.7962; Frank B, 2013, ENVIRON SCI TECHNOL, V47, P3026, DOI 10.1021/es4003873; Frank B, 2013, ANGEW CHEM INT EDIT, V52, P2673, DOI 10.1002/anie.201206093; Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007; Glover RD, 2011, ACS NANO, V5, P8950, DOI 10.1021/nn2031319; Gong H, 2008, INHAL TOXICOL, V20, P533, DOI 10.1080/08958370801911340 ; Han JH, 2008, INHAL TOXICOL, V20, P741, DOI [10.1080/08958370801942238, 10.1080/08958370801942238 ]; Heal MR, 2012, CHEM SOC REV, V41, P6606, DOI 10.1039/c2cs35076a; Helland A, 2008, ENVIRON SCI TECHNOL, V42, P640, DOI 10.1021/es062807i; Hischier R, 2012, SCI TOTAL ENVIRON, V425, P271, DOI 10.1016/j.scitotenv.2012.03.001; Horner WE, 2013, ANN C AM ASS AER RES; Hughes LS, 1998, ENVIRON SCI TECHNOL, V32, P1153, DOI 10.1021/es970280r; Hussain S, 2011, EUR RESPIR J, V37, P299, DOI 10.1183/09031936.00168509; Inoue K, 2010, FREE RADICAL BIO MED, V48, P924, DOI 10.1016/j.freeradbiomed.2010.01.013; Ivask A, 2012, ENVIRON SCI TECHNOL, V46, P2398, DOI 10.1021/es203087m; Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804; Jeng HA, 2010, ENVIRON MONIT ASSESS, V169, P597, DOI 10.1007/s10661-009-1199-8; Ji Z, 2012, ACS NANO, V6, P5366, DOI 10.1021/nn3012114; Jin C, 2011, BIOL TRACE ELEM RES, V141, P3, DOI 10.1007/s12011-010-8707-0; Johnston HJ, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-33; Karottki DG, 2014, ENVIRON INT, V73, P372, DOI 10.1016/j.envint.2014.08.019; Kawanaka Y, 2009, ENVIRON SCI TECHNOL, V43, P6851, DOI 10.1021/es900033u; Klems JP, 2010, ENVIRON SCI TECHNOL, V44, P7903, DOI 10.1021/es102009e; Kumar Sushil, 2013, Reviews on Environmental Health, V28, P117, DOI 10.1515/reveh-2013-0008; Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243; Lee JH, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-1134-8; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2008, FREE RADICAL BIO MED, V44, P1689, DOI 10.1016/j.freeradbiomed.2008.01.028; Li N, 2010, AM J PHYSIOL-LUNG C, V299, pL374, DOI 10.1152/ajplung.00115.2010; Li N, 2009, ENVIRON HEALTH PERSP, V117, P1116, DOI 10.1289/ehp.0800319; Liu JY, 2010, ACS NANO, V4, P6903, DOI 10.1021/nn102272n; Liu Z, 2011, MATER TODAY, V14, P316, DOI 10.1016/S1369-7021(11)70161-4; Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074; McAuley TR, 2010, AEROSOL SCI TECH, V44, P1096, DOI 10.1080/02786826.2010.512026; Mercer RR, 2008, AM J PHYSIOL-LUNG C, V294, pL87, DOI 10.1152/ajplung.00186.2007; Mercer RR, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-38; Miller RJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030321, 10.1371/journal.pone.0033885]; Mitchell LA, 2009, NAT NANOTECHNOL, V4, P451, DOI [10.1038/nnano.2009.151, 10.1038/NNANO.2009.151]; Moller W, 2008, AM J RESP CRIT CARE, V177, P426, DOI 10.1164/rccm.200602-301OC; Mostofsky E, 2012, AM J EPIDEMIOL, V176, P317, DOI 10.1093/aje/kws018; Mullins BJ, 2016, ENVIRON TOXICOL, V31, P44, DOI 10.1002/tox.22020; Murr LE, 2009, ATMOS ENVIRON, V43, P2683, DOI 10.1016/j.atmosenv.2009.03.002; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Nel A, 2013, ACCOUNTS CHEM RES, V46, P607, DOI 10.1021/ar300022h; Noble CA, 2003, ATMOS ENVIRON, V37, P827, DOI 10.1016/S1352-2310(02)00935-4; Norton SK, 2012, J ALLERGY CLIN IMMUN, V130, P761, DOI 10.1016/j.jaci.2012.04.023; Nowack B, 2013, NANOTOXICOLOGY, V7, P1152, DOI 10.3109/17435390.2012.711863; Nygaard UC, 2009, TOXICOL SCI, V109, P113, DOI 10.1093/toxsci/kfp057; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Olsen Y, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-112; Olvera HA, 2013, J EXPO SCI ENV EPID, V23, P289, DOI 10.1038/jes.2012.119; Osmond MJ, 2010, NANOTOXICOLOGY, V4, P15, DOI 10.3109/17435390903502028; Ostro B, 2015, ENVIRON HEALTH PERSP, V123, P549, DOI 10.1289/ehp.1408565; Pakkanen TA, 2001, ATMOS ENVIRON, V35, P4593, DOI 10.1016/S1352-2310(01)00167-4; Panzer AR, 2015, CURR OPIN RHEUMATOL, V27, P373, DOI 10.1097/BOR.0000000000000191; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Riiser A, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0102-0; Rossi EM, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-35; Ruuskanen J, 2001, ATMOS ENVIRON, V35, P3729, DOI 10.1016/S1352-2310(00)00373-3; Ryman-Rasmussen JP, 2009, NAT NANOTECHNOL, V4, P747, DOI [10.1038/nnano.2009.305, 10.1038/NNANO.2009.305]; Ryman-Rasmussen JP, 2009, AM J RESP CELL MOL, V40, P349, DOI 10.1165/rcmb.2008-0276OC; Samet JM, 2007, INHAL TOXICOL, V19, P29, DOI 10.1080/08958370701492706; Samet JM, 2009, AM J RESP CRIT CARE, V179, P1034, DOI 10.1164/rccm.200807-1043OC; Samuelsen M, 2009, SCAND J IMMUNOL, V69, P421, DOI 10.1111/j.1365-3083.2009.02244.x; Schaumann F, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0039-3; Semmler-Behnke M, 2007, ENVIRON HEALTH PERSP, V115, P728, DOI 10.1289/ehp.9685; Shi HB, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-15; Shvedova AA, 2008, AM J RESP CELL MOL, V38, P579, DOI 10.1165/rcmb.2007-0255OC; Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1; Song S, 2013, SCI TOTAL ENVIRON, V458, P408, DOI 10.1016/j.scitotenv.2013.04.011; Stephanie V, 2011, INHAL TOXICOL, V23, P627, DOI 10.3109/08958378.2011.599445; Terzano C, 2010, EUR REV MED PHARMACO, V14, P809; US EPA, 2009, INT SCI ASS PART MAT; von Garnier C, 2005, J IMMUNOL, V175, P1609, DOI 10.4049/jimmunol.175.3.1609; Vora R, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/s12989-014-0031-y; Wahlin P, 2001, ATMOS ENVIRON, V35, pS63; Wallace L, 2005, ATMOS ENVIRON, V39, P5777, DOI 10.1016/j.atmosenv.2005.03.050; Wallace L, 2011, J EXPO SCI ENV EPID, V21, P20, DOI 10.1038/jes.2009.59; Walling BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080283; Wang X, 2015, SMALL, V11, P5079, DOI 10.1002/smll.201500906; Wang X, 2015, ACS NANO, V9, P3032, DOI 10.1021/nn507243w; Wang X, 2014, SMALL, V10, P385, DOI 10.1002/smll.201301597; Wang X, 2012, NANO LETT, V12, P3050, DOI 10.1021/nl300895y; Wang X, 2011, ACS NANO, V5, P9772, DOI 10.1021/nn2033055; Wang XJ, 2013, INT J NANOMED, V8, P1733, DOI 10.2147/IJN.S44211; Wang ZL, 2004, J PHYS-CONDENS MAT, V16, pR829, DOI 10.1088/0953-8984/16/25/R01; Waring MS, 2008, ATMOS ENVIRON, V42, P5003, DOI 10.1016/j.atmosenv.2008.02.011; Weibel E, 2008, FISHERMANS PULMONARY; Weissenberg A, 2010, FREE RADICAL BIO MED, V49, P597, DOI 10.1016/j.freeradbiomed.2010.05.011; WILSON WE, 1977, JAPCA J AIR WASTE MA, V27, P46, DOI 10.1080/00022470.1977.10470391; Wiseman CLS, 2009, SCI TOTAL ENVIRON, V407, P2493, DOI 10.1016/j.scitotenv.2008.12.057; Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k; Xia T, 2009, ANNU REV PUBL HEALTH, V30, P137, DOI 10.1146/annurev.publhealth.031308.100155; Zhang HY, 2012, ACS NANO, V6, P4349, DOI 10.1021/nn3010087; Zhu YF, 2002, ATMOS ENVIRON, V36, P4323, DOI 10.1016/S1352-2310(02)00354-0	135	143	143	2	49	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					386	396		10.1016/j.jaci.2016.02.023	http://dx.doi.org/10.1016/j.jaci.2016.02.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27130856	Green Accepted, Bronze			2022-12-18	WOS:000380835800007
J	Tsitsiou, E; Williams, AE; Moschos, SA; Patel, K; Rossios, C; Jiang, XY; Adams, OD; Macedo, P; Booton, R; Gibeon, D; Chung, KF; Lindsay, MA				Tsitsiou, Eleni; Williams, Andrew E.; Moschos, Sterghios A.; Patel, Ketan; Rossios, Christos; Jiang, Xiaoying; Adams, Oona-Delpuech; Macedo, Patricia; Booton, Richard; Gibeon, David; Chung, Kian Fan; Lindsay, Mark A.			Transcriptome analysis shows activation of circulating CD8(+) T cells in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; CD8(+) T cells; transcriptome; long noncoding RNA; microRNA	NONCODING RNAS; MESSENGER-RNA; EXPRESSION; MICRORNAS; LUNG; PROTEIN; YKL-40; PATHOPHYSIOLOGY; IDENTIFICATION; INFLAMMATION	Background: Although previous studies have implicated tissue CD4(+) T cells in the development and maintenance of the inflammatory response in asthmatic patients, little is known about the role of CD8(+) T cells. There is now accumulating evidence that microRNAs and other noncoding RNAs are important regulators of T-cell function. Objectives: We sought to use transcriptomics to determine the activation state of circulating CD4(+) and CD8(+) T cells in patients with nonsevere and severe asthma. Methods: mRNA and noncoding RNA expression in circulating T cells was measured by means of microarray, quantitative real-time PCR, or both. Results: Comparison of mRNA expression showed widespread changes in the circulating CD8(+) but not CD4(+) T cells from patients with severe asthma. No changes were observed in the CD4(+) and CD8(+) T cells in patients with nonsevere asthma versus those in healthy control subjects. Bioinformatics analysis showed that the changes in CD8(+) T-cell mRNA expression were associated with multiple pathways involved in T-cell activation. As with mRNAs, we also observed widespread changes in expression of noncoding RNA species, including natural antisense, pseudogenes, intronic long noncoding RNAs (lncRNAs), and intergenic lncRNAs in CD8(+) T cells from patients with severe asthma. Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells. Conclusions: Severe asthma is associated with the activation of circulating CD8(+) T cells but not CD4(+) T cells. This response is correlated with the downregulation of miR-146a/b and miR-28-5p, as well as changes in the expression of multiple species of IncRNA that might regulate CD8(+) T-cell function. (J Allergy Clin Immunol 2012; 129: 95-103.)	[Tsitsiou, Eleni; Jiang, Xiaoying; Booton, Richard; Lindsay, Mark A.] Univ Manchester, Fac Med & Human Sci, Resp Res Grp, Manchester M13 9PL, Lancs, England; [Tsitsiou, Eleni; Jiang, Xiaoying; Booton, Richard; Lindsay, Mark A.] Univ S Manchester Hosp, Facil Resp Med, Natl Inst Hlth Res Translat Res, Manchester, Lancs, England; [Williams, Andrew E.; Rossios, Christos; Macedo, Patricia; Gibeon, David; Chung, Kian Fan; Lindsay, Mark A.] Imperial Coll, Natl Heart & Lung Inst, London, England; [Williams, Andrew E.; Rossios, Christos; Macedo, Patricia; Gibeon, David; Chung, Kian Fan; Lindsay, Mark A.] Royal Brompton Natl Inst Hlth Res, Biomed Res Unit, London, England; [Moschos, Sterghios A.; Patel, Ketan; Adams, Oona-Delpuech] Pfizer Global Res & Dev, Sandwich, Kent, England; [Lindsay, Mark A.] Univ Bath, Dept Pharm & Pharmacol, Bath, Avon, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Imperial College London; Pfizer; University of Bath	Lindsay, MA (corresponding author), Univ Bath, Dept Pharm & Pharmacol, Claverton Down, Bath BA2 7AY, Avon, England.	m.a.lindsay@bath.ac.uk	Moschos, Sterghios/AAD-8848-2022; Chung, Kian Fan/I-8456-2019; Patel, Ketan/AAB-9932-2019; Chung, Kian Fan/B-1872-2012	Moschos, Sterghios/0000-0001-6038-3785; Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Lindsay, Mark/0000-0003-4807-5506; Booton, Richard/0000-0003-4512-2899; Rossios, Christos/0000-0003-3470-3233	National Institute for Health Research (NIHR); Asthma UK [07/015]; Wellcome Trust [076111, 085935]; NIHR Royal Brompton Respiratory Biomedical Research Unit; Chinese Overseas Study Scholarship; Miltenyi Biotech and Caliper Life Sciences; Medical Research Council UK; Medical Research Council [G0801056B, G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Asthma UK; Wellcome Trust(Wellcome TrustEuropean Commission); NIHR Royal Brompton Respiratory Biomedical Research Unit; Chinese Overseas Study Scholarship; Miltenyi Biotech and Caliper Life Sciences; Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by a National Institute for Health Research (NIHR) Translational Research Facility Grant (to E. T. and R. B.), Asthma UK (07/015 to A. E. W.), the Wellcome Trust (076111 to M. A. L. and 085935 to K. F. C.), the NIHR Royal Brompton Respiratory Biomedical Research Unit (to K. F. C.), and a Chinese Overseas Study Scholarship (to X.J.).; S. A. Moschos has received travel grants from Miltenyi Biotech and Caliper Life Sciences. K. F. Chung is a consultant for Gilead, is on the advisory board for Merck and GlaxoSmithKline, and has received research support from the Medical Research Council UK, Asthma UK, and the Wellcome Trust. The rest of the authors have declared that they have no conflict of interest.	Alevizos I, 2010, NAT REV RHEUMATOL, V6, P391, DOI 10.1038/nrrheum.2010.81; Bargagli E, 2011, INFLAMMATION, V34, P85, DOI 10.1007/s10753-010-9210-7; Bartlett NW, 2009, CURR OPIN ALLERGY CL, V9, P395, DOI 10.1097/ACI.0b013e32833066fa; Boyd JH, 2008, CIRC RES, V102, P1239, DOI 10.1161/CIRCRESAHA.107.167544; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Chung KF, 1999, EUR RESPIR J, V13, P1198; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Curtale G, 2010, BLOOD, V115, P265, DOI 10.1182/blood-2009-06-225987; Durrant DM, 2010, IMMUNOL INVEST, V39, P526, DOI 10.3109/08820131003615498; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hamzaoui A, 2005, MEDIAT INFLAMM, P160, DOI 10.1155/MI.2005.160; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Huang K, 2009, J INT MED RES, V37, P18, DOI 10.1177/147323000903700102; Jia H, 2010, RNA, V16, P1478, DOI 10.1261/rna.1951310; Johansen JS, 2007, EXPERT OPIN THER TAR, V11, P219, DOI 10.1517/14728222.11.2.219; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Lasa A, 2008, ANN HEMATOL, V87, P205, DOI 10.1007/s00277-007-0388-1; Lee CG, 2010, ALLERGY ASTHMA IMMUN, V2, P20, DOI 10.4168/aair.2010.2.1.20; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Lindsay MA, 2008, TRENDS IMMUNOL, V29, P343, DOI 10.1016/j.coph.2009.05.003; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Maarsingh H, 2009, BRIT J PHARMACOL, V158, P652, DOI 10.1111/j.1476-5381.2009.00374.x; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Monticelli S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r71; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Opgen-Rhein R, 2007, STAT APPL GENET MOL, V6, DOI 10.2202/1544-6115.1252; Perera C, 2010, IMMUNOL CELL BIOL, V88, P41, DOI 10.1038/icb.2009.88; Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689; Perry MM, 2009, FEBS LETT, V583, P3349, DOI 10.1016/j.febslet.2009.09.038; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Robinson DS, 2010, J ALLERGY CLIN IMMUN, V126, P1081, DOI 10.1016/j.jaci.2010.06.025; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Sato T, 2010, AM J RESP CRIT CARE, V182, P1020, DOI 10.1164/rccm.201001-0055OC; Schaller MA, 2005, EUR J IMMUNOL, V35, P2061, DOI 10.1002/eji.200425715; Strimmer K, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-303; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tsitsiou E, 2009, CURR OPIN PHARMACOL, V9, P514, DOI 10.1016/j.coph.2009.05.003; Williams AE, 2007, DEV DYNAM, V236, P572, DOI 10.1002/dvdy.21047; Ying S, 1997, J IMMUNOL, V158, P3539	45	143	157	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					95	103		10.1016/j.jaci.2011.08.011	http://dx.doi.org/10.1016/j.jaci.2011.08.011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21917308	Green Submitted, Green Accepted			2022-12-18	WOS:000298634000012
J	Senti, G; Graf, N; Haug, S; Ruedi, N; von Moos, S; Sonderegger, T; Johansen, P; Kundig, TM				Senti, Gabriela; Graf, Nicole; Haug, Susanne; Rueedi, Nadine; von Moos, Seraina; Sonderegger, Theodor; Johansen, Pal; Kuendig, Thomas M.			Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen-specific immunotherapy; patch; grass pollen allergy; rhinoconjunctivitis; randomized clinical trial	EXPERIMENTAL TUMOR IMMUNOPROPHYLAXIS; PERCUTANEOUS PEPTIDE IMMUNIZATION; GRASS-POLLEN IMMUNOTHERAPY; DISRUPTED MURINE SKIN; CPG-OLIGODEOXYNUCLEOTIDES; SUBLINGUAL IMMUNOTHERAPY; PROTEIN ANTIGENS; LANGERHANS CELLS; DENDRITIC CELLS; DOUBLE-BLIND	Background: Subcutaneous allergen-specific immunotherapy is an effective treatment of IgE-mediated allergies, but it requires repeated allergen injections with a risk of systemic allergic reactions. Transcutaneous immunotherapy may improve patient compliance and safety. Objective: To assess the safety and efficacy of epicutaneous allergen immunotherapy. Methods: This monocentric, placebo-controlled, double-blind trial was conducted from March 2006 to December 2007 at the University Hospital Zurich. Thirty-seven adult patients with positive skin prick and nasal provocation tests to grass pollen were randomized to receive patches containing either allergen (n = 21) or placebo (n = 16). Treatment took place before and during the pollen season 2006, and follow-up visits took place before (n = 26) and after the pollen season 2007 (n = 30). The primary outcome measures were nasal provocation tests. Results: Allergen-treated patients showed significantly decreased scores in nasal provocation tests in the first (P < .001) and second year (P = .003) after treatment. In contrast, placebo-treated patients had decreased scores in the first treatment year, 2006 (P = .03), but the effect diminished in the second year (P = .53). Although improvement of nasal provocation test scores was not significantly better in the verum versus placebo group, the overall treatment success was rated significantly higher by the allergen-treated group than by the placebo group (2006, P = .02; 2007, P = .005). No severe adverse events were observed. Occurrence of eczema after allergen patch applications proved stimulation of specific T-cell responses, but was noted as an adverse effect of the treatment. Conclusion: Epicutaneous allergen immunotherapy is a promising strategy to treat allergies and merits further investigation. (J Allergy Clin Immunol 2009;124:997-1002.)	[Senti, Gabriela; Haug, Susanne; Rueedi, Nadine; Johansen, Pal; Kuendig, Thomas M.] Univ Zurich Hosp, Unit Expt Immunotherapy, Zurich, Switzerland; [Senti, Gabriela; Graf, Nicole; von Moos, Seraina] Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland; [Sonderegger, Theodor] Univ Hosp, Galen Dept, Zurich, Switzerland; [Sonderegger, Theodor] Canton Zurich, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Kundig, TM (corresponding author), Gloriastr 31, CH-8091 Zurich, Switzerland.	thomas.kuendig@usz.ch	Senti, Gabriela/Y-1019-2019; Johansen, Pål/A-1403-2013	Senti, Gabriela/0000-0002-9066-8383; Johansen, Pål/0000-0002-5055-6299	University of Zurich	University of Zurich	This study was investigator-initiated, and the allergen patch was manufactured by the hospital pharmacy. However, a patent that belongs to the University of Zurich has been licensed by a company (Allergy Innovations, Munich, Germany), which then partially funded the trial under a clinical trial agreement with the University of Zurich. Funding was independent of the study outcome.	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; BERGSTRESSER PR, 1980, J INVEST DERMATOL, V74, P77, DOI 10.1111/1523-1747.ep12519909; Bins AD, 2005, NAT MED, V11, P899, DOI 10.1038/nm1264; BLAMOUTIER P, 1959, J PRESSE MED, V67, P2299; CAMP R, 1990, J INVEST DERMATOL, V94, P735, DOI 10.1111/1523-1747.ep12874591; Celluzzi CM, 1997, J INVEST DERMATOL, V108, P716, DOI 10.1111/1523-1747.ep12292095; Corsini E, 2000, TOXICOLOGY, V142, P203, DOI 10.1016/S0300-483X(99)00145-6; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EICHENBERGER H, 1966, ACTA ALLERGOL, V21, P261, DOI 10.1111/j.1398-9995.1966.tb03112.x; Frech SA, 2008, LANCET, V371, P2019, DOI 10.1016/S0140-6736(08)60839-9; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225; HAUSER C, 1986, J IMMUNOL, V136, P3317; Inoue J, 2005, J CONTROL RELEASE, V108, P294, DOI 10.1016/j.jconrel.2005.08.014; Inoue J, 2007, VACCINE, V25, P1007, DOI 10.1016/j.vaccine.2006.09.075; Kenney RT, 2004, J INFECT DIS, V190, P774, DOI 10.1086/422694; Klimuk SK, 2004, J INVEST DERMATOL, V122, P1042, DOI 10.1111/j.0022-202X.2004.22411.x; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Partidos CD, 2001, VACCINE, V19, P2708, DOI 10.1016/S0264-410X(00)00507-7; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Pierson-Mullany LK, 2000, ANN ALLERG ASTHMA IM, V84, P241, DOI 10.1016/S1081-1206(10)62761-5; Roeder E, 2008, PEDIAT ALLERG IMM-UK, V19, P197, DOI 10.1111/j.1399-3038.2007.00648.x; ROMANI N, 1989, J EXP MED, V169, P1169, DOI 10.1084/jem.169.3.1169; Senti G, 2007, ANN ALLERG ASTHMA IM, V98, P134, DOI 10.1016/S1081-1206(10)60685-0; Seo N, 2000, P NATL ACAD SCI USA, V97, P371, DOI 10.1073/pnas.97.1.371; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Takigawa M, 2001, ANN NY ACAD SCI, V941, P139; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wang BH, 2002, J IMMUNOL, V168, P3303, DOI 10.4049/jimmunol.168.7.3303; Zhao YL, 2006, VACCINE, V24, P1282, DOI 10.1016/j.vaccine.2005.09.035; 2005, EPIDEMIOLOGY SURVEYS	35	143	151	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					997	1002		10.1016/j.jaci.2009.07.019	http://dx.doi.org/10.1016/j.jaci.2009.07.019			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19733905				2022-12-18	WOS:000272108000018
J	Horak, F; Zieglmayer, P; Zieglmayer, R; Lemell, P; Devillier, P; Montagut, A; Melac, M; Galvain, S; Jean-Alphonse, S; Van Overtvelt, L; Moingeon, P; Le Gall, M				Horak, Friedrich; Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Devillier, Philippe; Montagut, Armelle; Melac, Michel; Galvain, Sylvie; Jean-Alphonse, Stephanie; Van Overtvelt, Laurence; Moingeon, Philippe; Le Gall, Martine			Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Grass pollen; tablets; sublingual immunotherapy; allergen challenge chamber; Vienna Challenge Chamber	GRASS-POLLEN; RHINITIS; EXPOSURE; EFFICACY; PLACEBO; SYMPTOMS; RHINOCONJUNCTIVITIS; SAFETY; FLOW	Background: The efficacy and safety of a 5-grass-pollen sublingual immunotherapy (SLIT) tablet (Stallergenes SA, Antony, France) have been evaluated in clinical studies during the pollen season. The allergen challenge chamber (ACC) has been developed as a pharmacodynamic assessment tool to control the environmental allergens and to avoid all problems associated with unpredictable pollen seasons. Objective: We sought to evaluate the onset of action and efficacy of 300-IR (index of reactivity) SLIT tablets by using an ACC. Methods: Patients with grass pollen-induced rhinoconjunctivitis were randomized into the active or placebo groups. A standardized allergen challenge with grass pollen and symptom evaluation every 15 minutes was performed at baseline, 1 week, and 1, 2, and 4 months of treatment. The primary end point was the average rhinoconjunctivitis total symptom score (ARTSS). Allergen-specific basophil activation, T-cell proliferation, and plasmatic IgE and IgG responses were assessed before and after treatment. Results: In the intention-to-treat population (n = 89) a significant treatment effect was achieved after the first month (P = .0042) and second month (P = .0203) and was maintained through to the fourth month (P = .0007). In the active group the ARTSS (means +/- SDs) decreased at each challenge: week 1, 7.40 +/- 2.682; month 1, 5.89 +/- 2.431; month 2, 5.09 +/- 2.088; and month 4, 4.85 +/- 1.999. An improvement (vs placebo) of 29.3% for the mean ARTSS ( median, 33.3%) was observed at end point. Furthermore, the induction of grass pollen allergen specific IgGs was associated with clinical response. The most frequent adverse reactions were local: oral pruritus, ear pruritus, and throat irritation. Conclusions: In this ACC study the 300-IR 5-grass-pollen SLIT tablets had a significant effect on rhinoconjunctivitis symptoms (vs placebo) from the first month of treatment onward. (J Allergy Clin Immunol 2009;124:471-7.)	[Horak, Friedrich] Med Univ Vienna, ENT Dept, Vienna, Austria; [Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick] Allergy Ctr Vienna W, Dept Vienna Challenge Chamber, Vienna, Austria; [Devillier, Philippe] Univ Versailles St Quentin, Foch Hosp, UPRES EA 220, Suresnes, France; [Montagut, Armelle] Delta Consultants, Meylan, France; [Melac, Michel; Galvain, Sylvie; Jean-Alphonse, Stephanie; Van Overtvelt, Laurence; Moingeon, Philippe; Le Gall, Martine] Stallergenes SA, Antony, France	Medical University of Vienna; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Stallergenes Greer	Horak, F (corresponding author), AKH, Univ Klin, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	friedrich.horak@vienna.at	Zieglmayer, Petra/AAG-1006-2020; m, m/GZB-2153-2022	Lemell, Patrick/0000-0003-0262-4047	GlaxoSmithKline; Oxagen; Allergy Therapeutics; Altana-Nycomed; Boehringer-Ingelheim; Schering-Plough; Pierre Fabre; Servier; Novartis	GlaxoSmithKline(GlaxoSmithKline); Oxagen; Allergy Therapeutics; Altana-Nycomed; Boehringer-Ingelheim(Boehringer Ingelheim); Schering-Plough(Merck & CompanySchering Plough Corporation); Pierre Fabre; Servier(Servier); Novartis(Novartis)	F. Horak has received honoraria for lectures from Allergy Therapeutics, UCB, Schering-Plough, and Stallergenes and has received research support from GlaxoSmithKline, Oxagen, and Allergy Therapeutics. P. Devillier has received consulting fees from Stallergenes and has received research grants from Altana-Nycomed, Boehringer-Ingelheim, Schering-Plough, Pierre Fabre, Servier, and Novartis. The rest of the authors have declared that they have no conflict of interest.	ALVAREZCUESTA E, 2006, ALLERGY S82, V61, pS1; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; Didier A, 2009, ALLERGY, V64, P166, DOI 10.1111/j.1398-9995.2008.01767.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74, DOI 10.1016/S1081-1206(10)63483-7; DOYLE WJ, 1995, ANN ALLERG ASTHMA IM, V74, P171; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; European Medicines Agency, 2008, GUID CLIN DEV PROD S; Gomes DD, 2008, RHINOLOGY, V46, P276; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Horak F, 2003, ALLERGY, V58, P481, DOI 10.1034/j.1398-9995.2003.00148.x; Horak F, 2009, CLIN EXP ALLERGY, V39, P394, DOI 10.1111/j.1365-2222.2008.03153.x; HORAK F, 1987, WIEN KLIN WOCHENSCHR, V99, P509; Jaeger S., 2008, Clinical and Experimental Allergy Reviews, V8, P2, DOI 10.1111/j.1472-9733.2008.00125.x; Krug N, 2003, CLIN EXP ALLERGY, V33, P1667, DOI 10.1111/j.1365-2222.2003.01810.x; Nathan Robert A, 2005, J Allergy Clin Immunol, V115, pS442, DOI 10.1016/j.jaci.2004.12.015; Stuebner P, 2006, ANN ALLERG ASTHMA IM, V96, P37, DOI 10.1016/S1081-1206(10)61038-1; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zieglmayer P, 2008, CURR MED RES OPIN, V24, P1833, DOI 10.1185/03007990802155792	21	143	146	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					471	U126		10.1016/j.jaci.2009.06.006	http://dx.doi.org/10.1016/j.jaci.2009.06.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19647862				2022-12-18	WOS:000274315900011
J	Ebner, S; Nguyen, VA; Forstner, M; Wang, YH; Wolfram, D; Liu, YJ; Romani, N				Ebner, Susanne; Nguyen, Van Anh; Forstner, Markus; Wang, Yui-Hsi; Wolfram, Dolores; Liu, Yong-Jun; Romani, Nikolaus			Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; dendritic cells; Langerhans cells; thymic stromal lymphopoietin	ACTIVATION-REGULATED CHEMOKINE; HUMAN DENDRITIC CELLS; MACROPHAGE-DERIVED CHEMOKINE; ATOPIC SKIN INFLAMMATION; FC-EPSILON-RI; CONTACT HYPERSENSITIVITY; ALLERGIC INFLAMMATION; MONOCLONAL-ANTIBODY; SERUM THYMUS; IN-VIVO	Background: Thymic stromal lymphopoietin (TSLP) endows human CD11c(+) dendritic cells (DCs) from peripheral blood with the capacity to induce proallergic T cells. TSLP is present at high levels in the epidermis of atopic dermatitis where it appears to trigger emigration of epidermal Langerhans cells (LCs); however, nothing else is known about the influence of TSLP on LCs. Objective: Effects of TSLP on human epidermal LCs were investigated. Methods: LCs were isolated by trypsinization from healthy human skin, highly enriched by immunomagnetic techniques (via CD1a) and cultured for 2 days. Additionally, migratory LCs were obtained by emigration from epidermal sheets for 3 days. Results: The addition of TSLP promoted survival and maturation of LCs obtained by trypsinization, as indicated by their increased expression of CD83, CD86, and high levels of MHC 11. TSLP markedly increased numbers of migratory LCs. Allogeneic naive CD4(+) T cells, cocultured with migratory TSLP-LCs produced less IFN-gamma and IL-10 and more IL-4, IL-5, IL-13, and TNF-alpha. Finally, TSLP-LCs secreted markedly more of the T(H)2 T-cell-attracting chemokine CCL17/thymus and activation-regulated chemokine. Conclusion: These cytokine patterns correspond to those described for TSLP-treated blood DCs. They highlight a direct effect of TSLP on epidermal LCs. Clinical implications: Our data emphasize a critical role for LCs in the triggering of atopic dermatitis. Furthermore, they underscore the interest in TSLP as a potential therapeutic target in atopic diseases.	Innsbruck Med Univ, Dept Dermatol, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Venereol, Innsbruck, Austria; Innsbruck Med Univ, Dept Plast & Reconstruct Surg, Innsbruck, Austria; Kompetenzzentrum Med Tirol, Innsbruck, Austria; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Ctr Canc Immunol Res, Houston, TX 77030 USA	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; University of Texas System; UTMD Anderson Cancer Center	Romani, N (corresponding author), Innsbruck Med Univ, Dept Dermatol, Anichstr 35, A-6020 Innsbruck, Austria.	nikolaus.romani@i-med.ac.at		Wolfram, Dolores/0000-0003-0920-7211; Romani, Nikolaus/0000-0003-1614-9128; Ebner, Susanne/0000-0002-0394-9620				Artis D, 1999, J EXP MED, V190, P953, DOI 10.1084/jem.190.7.953; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Bernardini G, 1998, EUR J IMMUNOL, V28, P582, DOI 10.1002/(SICI)1521-4141(199802)28:02<582::AID-IMMU582>3.0.CO;2-A; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chen L, 2004, CLIN EXP IMMUNOL, V138, P375, DOI 10.1111/j.1365-2249.2004.02649.x; Ebner S, 1998, IMMUNOBIOLOGY, V198, P568, DOI 10.1016/S0171-2985(98)80079-X; Gilliet M, 2003, J EXP MED, V197, P1059, DOI 10.1084/jem.20030240; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0; HAUSER C, 1989, EUR J IMMUNOL, V19, P245, DOI 10.1002/eji.1830190205; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Iwasaki M, 2003, J ALLERGY CLIN IMMUN, V112, P134, DOI 10.1067/mai.2003.1554; Jahnz-Rozyk K, 2005, ALLERGY, V60, P685, DOI 10.1111/j.1398-9995.2005.00774.x; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kissenpfennig A, 2006, TRENDS IMMUNOL, V27, P132, DOI 10.1016/j.it.2006.01.003; KOCH F, 1992, J INVEST DERMATOL, V99, P803, DOI 10.1111/1523-1747.ep12614764; LENZ A, 1993, J CLIN INVEST, V92, P2587, DOI 10.1172/JCI116873; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; LIU YJ, 2006, ANN REV IMMUNOL 1127; Novak N, 2005, J AM ACAD DERMATOL, V53, pS171, DOI 10.1016/j.jaad.2005.04.060; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Romani N, 2003, APMIS, V111, P725, DOI 10.1034/j.1600-0463.2003.11107805.x; ROMANI N, 2006, HDB DENDRITIC CELLS, P73; ROMANI N, 1997, WEIRS HDB EXPT IMMUN; Romani N, 2006, IMMUNOL LETT, V106, P119, DOI 10.1016/j.imlet.2006.05.010; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; SILBERBERG I, 1976, J INVEST DERMATOL, V66, P210, DOI 10.1111/1523-1747.ep12482139; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stary G, 2005, INT ARCH ALLERGY IMM, V138, P278, DOI 10.1159/000088865; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Stumbles PA, 2003, APMIS, V111, P741, DOI 10.1034/j.1600-0463.2003.11107806.x; TOEWS GB, 1980, J IMMUNOL, V124, P445; Valladeau J, 1999, EUR J IMMUNOL, V29, P2695, DOI 10.1002/(SICI)1521-4141(199909)29:09<2695::AID-IMMU2695>3.3.CO;2-H; Van Rijt LS, 2005, CLIN EXP ALLERGY, V35, P1125, DOI 10.1111/j.1365-2222.2005.02321.x; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zingoni A, 1998, J IMMUNOL, V161, P547	48	143	147	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					982	990		10.1016/j.jaci.2007.01.003	http://dx.doi.org/10.1016/j.jaci.2007.01.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17320941				2022-12-18	WOS:000245729500030
J	Bousquet, J; Jacquot, W; Vignola, AM; Bachert, C; Van Cauwenberge, P				Bousquet, J; Jacquot, W; Vignola, AM; Bachert, C; Van Cauwenberge, P			Allergic rhinitis: A disease remodeling the upper airways?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; rhinitis; remodeling; endoderm; ectoderm; smooth muscle	BRONCHOALVEOLAR LAVAGE FLUID; NECROSIS-FACTOR-ALPHA; NERVE GROWTH-FACTOR; C-ERBB RECEPTORS; NASAL-MUCOSA; BASEMENT-MEMBRANE; NONASTHMATIC SUBJECTS; ASTHMA; EXPRESSION; INFLAMMATION	The nasal and bronchial mucosa present similarities and differences. Remodeling is defined as "model again or differently, reconstruct" and is present in the airways of most if not all asthmatic patients. Even though inflammation is similar in allergic rhinitis and asthma, the pathologic extent of nasal remodeling in patients with rhinitis seems to be far less extensive than that in the bronchi of asthmatic patients. Epithelial damage is only minimal, and the reticular basement membrane does not appear to be largely pseudothickened. Moreover, the demonstration of fibrogenic growth factors in the nasal mucosa of patients with allergic rhinitis is lacking because of the paucity of studies. The reasons why remodeling appears to be less extensive in the nasal mucosa than in the bronchial mucosa are still unclear, but 2 hypotheses can be put forward. On one hand, the cytokine production of smooth muscle cells might partly explain differences in remodeling of the 2 sites of the airways. On the other hand, the genes of the embryologic differentiation might persist in the nose and bronchi or might be re-expressed in asthma and rhinitis. Because the nose is of ectodermal origin and the bronchi of endodermal origin, these genes might also govern remodeling patterns. More studies are urgently required to better characterize nasal remodeling in patients with rhinitis. A better understanding of nasal and bronchial remodeling might help to identify new pathways and new therapeutic strategies to reduce long-term remodeling in asthma.	Hop Arnaud de Villeneuve, Univ Hosp, Clin Malad Resp, Montpellier, France; Hop Arnaud de Villeneuve, INSERM, U454, Montpellier, France; Univ Palermo, Ist Fisiopatol Resp, Palermo, Italy; CNR, Palermo, Italy; Univ Ghent, ENT Dept, B-9000 Ghent, Belgium	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; University of Palermo; Consiglio Nazionale delle Ricerche (CNR); Ghent University	Bousquet, J (corresponding author), Hop Arnaud de Villeneuve, Clin Malad Resp, F-34295 Montpellier 5, France.		Bachert, Claus/J-8825-2012; Bousquet, Jean/O-4221-2019					Abrams Don-Carlos, 1997, Rhinology (Utrecht), V35, P22; Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; Amin K, 2001, J ALLERGY CLIN IMMUN, V107, P249, DOI 10.1067/mai.2001.112266; Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR; Bachler M, 2001, MECH DEVELOP, V100, P313, DOI 10.1016/S0925-4773(00)00518-9; Baldwin Lindsay, 2002, Paediatr Respir Rev, V3, P315, DOI 10.1016/S1526054202002610; Bavbek S, 1996, J INVEST ALLERG CLIN, V6, P172; Benson M, 2002, ACTA OTO-LARYNGOL, V122, P202, DOI 10.1080/00016480252814234; Benson M, 2002, CYTOKINE, V18, P20, DOI 10.1006/cyto.2002.1012; Black JL, 2000, AM J RESP CRIT CARE, V161, pS207, DOI 10.1164/ajrccm.161.supplement_2.a1q4-12; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63, DOI 10.1164/ajrccm.164.supplement_2.2106059; Bonini S, 2002, ALLERGY, V57, P13, DOI 10.1034/j.1398-9995.57.s72.3.x; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Bousquet J, 2000, ALLERGY, V55, P1194, DOI 10.1034/j.1398-9995.2000.00923.x; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Carayol N, 2002, EUR RESPIR J, V20, P1430, DOI 10.1183/09031936.02.00013602; Carayol N, 2002, AM J RESP CELL MOL, V26, P341, DOI 10.1165/ajrcmb.26.3.4684; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Chakir J, 1996, LAB INVEST, V75, P735; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Chung KF, 2000, EUR RESPIR J, V15, P438, DOI 10.1034/j.1399-3003.2000.15.02.x; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Erel F, 2000, J INVEST ALLERG CLIN, V10, P14; Frieri M, 2001, ALLERGY ASTHMA PROC, V22, P167, DOI 10.2500/108854101778148692; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Gluck U, 2000, ORL J OTO-RHINO-LARY, V62, P68, DOI 10.1159/000027720; Hocking DC, 2002, CHEST, V122, p275S, DOI 10.1378/chest.122.6_suppl.275S; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; Ishii J, 2000, Arerugi, V49, P1156; James Alan L, 2002, Curr Allergy Asthma Rep, V2, P166, DOI 10.1007/s11882-002-0012-3; Jeffery PK, 1996, EUR RESPIR J, V9, P1583, DOI 10.1183/09031936.96.09081583; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; KARLSSON G, 1989, ORL J OTO-RHINO-LARY, V51, P171, DOI 10.1159/000276053; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kitaoka H, 1996, ANAT REC, V244, P207; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Laliberte F, 2000, ALLERGY, V55, P718, DOI 10.1034/j.1398-9995.2000.00649.x; Lam SM, 1999, LARYNGOSCOPE, V109, P1119, DOI 10.1097/00005537-199907000-00021; LARSEN WJ, 2001, HUMAN EMBRYOLOGY, P351; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136, DOI 10.1164/ajrccm.151.1.7812543; Low RB, 1999, CURR TOPICS PATHOL, V93, P19; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324, DOI 10.1164/ajrccm.160.1.9808087; McKay KO, 2002, MED J AUSTRALIA, V177, pS45; Mina M, 2001, CRIT REV ORAL BIOL M, V12, P276, DOI 10.1177/10454411010120040101; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; Mori S, 2000, CLIN EXP ALLERGY, V30, P1637; Panettieri Reynold A. Jr., 2002, Journal of Allergy and Clinical Immunology, V110, pS269, DOI 10.1067/mai.2002.129429; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Polosa R, 2000, J ALLERGY CLIN IMMUN, V106, P1124; Redington AE, 2001, J ALLERGY CLIN IMMUN, V107, P384, DOI 10.1067/mai.2001.112268; Sanai A, 1999, ACTA OTO-LARYNGOL, V119, P473; Sanico AM, 1999, INT ARCH ALLERGY IMM, V118, P154, DOI 10.1159/000024054; Shaida A, 2001, J ALLERGY CLIN IMMUN, V108, P791, DOI 10.1067/mai.2001.119024; Shapiro SD, 2002, NEW ENGL J MED, V347, P936, DOI 10.1056/NEJMcibr022144; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Solway J, 2000, AM J RESP CRIT CARE, V161, pS164, DOI 10.1164/ajrccm.161.supplement_2.a1q4-3; TALAAT MA, 1991, J ASTHMA, V28, P117, DOI 10.3109/02770909109082736; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; van Toorenenbergen AW, 1999, ALLERGY, V54, P293, DOI 10.1034/j.1398-9995.1999.00028.x; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P505, DOI 10.1164/ajrccm.157.2.9703070; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Watanabe K, 1998, ANN OTO RHINOL LARYN, V107, P564, DOI 10.1177/000348949810700704; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255	75	143	164	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					43	49		10.1016/j.jaci.2003.09.047	http://dx.doi.org/10.1016/j.jaci.2003.09.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713906				2022-12-18	WOS:000187837900005
J	Litonjua, AA; Milton, DK; Celedon, JC; Ryan, L; Weiss, ST; Gold, DR				Litonjua, AA; Milton, DK; Celedon, JC; Ryan, L; Weiss, ST; Gold, DR			A longitudinal analysis of wheezing in young children: The independent effects of early life exposure to house dust endotoxin, allergens, and pets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; allergens; domestic animals; wheeze; asthma	HAY-FEVER; ASTHMA; RISK; SENSITIZATION; INHALATION; DECREASES; COCKROACH; PROTECT; INFANCY; ROLES	Background: It has been postulated that exposure to bacterial endotoxins and animals early in life might confer protection against the development of asthma and allergies. Objective: We investigated the longitudinal effects of exposure to house dust endotoxin (HDE), allergen levels, and the presence of a dog in the home on wheezing in young children over a 4-year period. Methods: Two hundred twenty-six children younger than 5 years were followed for 4 years. Endotoxin and allergen levels were measured from house dust collected at baseline. Longitudinal associations were investigated by using a proportional hazards technique that allowed for multiple outcomes per subject. Results: Exposure to high concentrations of HDE of greater than the median level was associated with an increased risk for wheezing over the period of observation (multivariate relative risk, 1.52; 95% CI, 1.07-2.14), but this risk rapidly decreased over time (P for trend = .005). Exposure to cockroach allergen was associated with increased risk for wheezing, whereas exposure to cat allergen and the presence of a dog in the home were both associated with decreased risk for wheezing. The risks associated with cockroach allergen, cat allergen, and dog did not change over the period of observation. Conclusion: The negative associations between exposures to dogs and cat allergen and wheeze appear to be independent of the effects of endotoxin and suggest that separate mechanisms might mediate the effects of HDE exposure and pet exposure on the developing immune system.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute	Litonjua, AA (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Ryan, Louise M/A-4562-2009; Milton, Donald K/G-3286-2010	Ryan, Louise M/0000-0001-5957-2490; Milton, Donald K/0000-0002-0550-7834; Litonjua, Augusto/0000-0003-0422-5875	NHLBI NIH HHS [K08 HL-03870] Funding Source: Medline; NIAID NIH HHS [R01 AI/EHS-35786] Funding Source: Medline; NIEHS NIH HHS [R01 ES-07036] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007036] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Keman S, 1998, INT ARCH OCC ENV HEA, V71, P131, DOI 10.1007/s004200050260; LE JM, 1986, J IMMUNOL, V136, P4525; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059, DOI 10.1152/jappl.1989.66.3.1059; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P443; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; Silva JRL, 2000, TOXICOLOGY, V152, P31; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Therneau TM, 2000, STAT BIOL HEALTH; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	33	143	143	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					736	742		10.1067/mai.2002.128948	http://dx.doi.org/10.1067/mai.2002.128948			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417882				2022-12-18	WOS:000179082500008
J	Beasley, R				Beasley, R			The burden of asthma with specific reference to the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; beta-agonists; inhaled corticosteroids	CHANGING PATTERNS; PREVALENCE; TRENDS; MORTALITY; CHILDREN; HOSPITALIZATION; ASSOCIATION; MORBIDITY; HEALTH; EPIDEMIOLOGY	During the second half of the 20th century, the increasing prevalence, morbidity, economic burden, and, in some countries, mortality from asthma have generated worldwide concern. The prevalence in the United States and other English-speaking countries is higher than that in most other countries, but worldwide variations cannot be explained by current knowledge of recognized risk or protective factors. According to hospital admission rates, asthma morbidity rates have also risen throughout the world during the past 40 years. These trends are likely due to many different factors, including an increase in the prevalence of severe asthma. Asthma mortality rates gradually declined in the United States during the 1960s and 1970s but have exhibited a substantial, progressive increase during the past 20 years. This trend stands in contrast to those in most other western countries, where asthma mortality rates have generally been decreasing during the 1990s. In both western and developing countries, the considerable economic burden of asthma disproportionately affects individuals with severe disease. This observation illustrates the potential for reducing the costs associated with asthma through management approaches that have been proven to reduce morbidity and mortality.	Wellington Sch Med, Dept Med, Wellington, New Zealand	University of Otago	Beasley, R (corresponding author), Wellington Sch Med, Dept Med, POB 7343, Wellington, New Zealand.		Beasley, Richard/AAH-3908-2019	Beasley, Richard/0000-0003-0337-406X				Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beasley R, 1998, FATAL ASTHMA, P13; Burney P, 1996, EUR RESPIR J, V9, P687; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURNEY PGJ, 1993, P R COLL PHYSICIANS, V23, P595; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Farber HJ, 1997, ANN ALLERG ASTHMA IM, V78, P265, DOI 10.1016/S1081-1206(10)63179-1; *GALX WELLC INC, 1998, ASTHM AM LANDM SURV; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; *GLAX CAN, 1993, COSTS AD ASTHM CAN; Goldman M, 2000, J ALLERGY CLIN IMMUN, V105, P71, DOI 10.1016/S0091-6749(00)90180-5; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HSIEH HH, 1992, PROGR ALLERGOLOGY CL, V2, P235; HUNT L W, 1989, American Review of Respiratory Disease, V139, pA486; Jarvis D, 2000, ASTHMA RHINITIS, P17; Katz Y, 2000, J ALLERGY CLIN IMMUN, V106, P782, DOI 10.1067/mai.2000.110469; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; *LUNG ASTHM INF AG, 1995, 951 DEP PUBL HLTH SE; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; McFadden ER, 1997, ANN INTERN MED, V127, P142, DOI 10.7326/0003-4819-127-2-199707150-00009; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; *NAT ASTHM CAMP, 1992, REP COST ASTHM AUSTR; *NAT HEART LUNG BL, 1994, NIH PUBL, pCH8; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; PEARCE N, 2000, ASTHMA RHINITIS, P56; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1995, J INVEST ALLERG CLIN, V5, P66; Sly RM, 2000, J ALLERGY CLIN IMMUN, V106, P782, DOI 10.1067/mai.2000.110470; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; STOLLEY PD, 1978, PREV MED, V7, P519, DOI 10.1016/0091-7435(78)90265-7; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; WEISS KB, 1990, JAMA-J AM MED ASSOC, V164, P1683; Weiss KB, 2000, ASTHMA RHINITIS, P1786; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WILLIAMS MH, 1989, NEW ENGL J MED, V320, P1015; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	51	143	156	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5		S			S482	S489		10.1067/mai.2002.122716	http://dx.doi.org/10.1067/mai.2002.122716			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	554QH	11994720				2022-12-18	WOS:000175747400002
J	Koppelman, GH; Stine, OC; Xu, JF; Howard, TD; Zheng, SQL; Kauffman, HF; Bleecker, ER; Meyers, DA; Postma, DS				Koppelman, GH; Stine, OC; Xu, JF; Howard, TD; Zheng, SQL; Kauffman, HF; Bleecker, ER; Meyers, DA; Postma, DS			Genome-wide search for atopy susceptibility genes in Dutch families with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics of atopy; asthma; specific IgE; eosinophils; genoine-wide search	LINKAGE ANALYSIS; CHROMOSOME 5Q31-Q33; MITE SENSITIZATION; FOUNDER POPULATION; UNDERLYING ASTHMA; ALLERGY; MARKERS; SCREEN; LOCUS; HYPERRESPONSIVENESS	Background: Atopy is a phenotype associated with asthma that has a heritable component. However, the role of atopy-susceptibility genes in the development and expression of asthma and allergic disorders is not understood. Objective: We sought to study the familial aggregation and co-occurrence of atopic phenotypes within family members of patients with asthma and to identify chromosomal regions that may contain genes that regulate different atopic phenotypes. Methods: In 200 families (n = 1174) ascertained through a proband with asthma, genome-wide screen and linkage analysis was performed for the following atopic phenotypes: (1) specific IgE to common aeroallergens (Phadiatop assay); (2) specific IgE to Der p 1; (3) positive skin test responses to house dust mite; (4) positive skin test responses to 1 or more of 16 allergens; and (5) peripheral blood eosinophils. Results were compared with the linkage results for total serum IgE levels. Results: There was clear familial aggregation of atopy. A high total serum IgE level in combination with a positive Phadiatop result or a normal total IgE level in combination with a negative Phadiatop result was found in 56.1% of the probands and 66.9% of the offspring. Several chromosomal regions that showed evidence for linkage to an atopic phenotype (ie, 2q, 6p, 7q, and 13q) also showed evidence of linkage with total serum IgE (Xu et al. Am J Hum Genet 2000;67:1163-73). Specific regions of interest for atopic traits were also detected on chromosomes 11q, 17q, and 22q. Conclusions: Atopic phenotypes show familial aggregation, although family members may differ in expression of atopy. Specific chromosomal regions appear to be important in susceptibility to different phenotypes of atopic responsiveness.	Beatrixoord, Dept Pulm Rehabil, Haren, Netherlands; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Groningen Hosp, Dept Allergol, Groningen, Netherlands; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Wake Forest Univ, Sch Med, Ctr Human Genomics, Winston Salem, NC 27109 USA	University of Groningen; University of Groningen; University of Groningen; University System of Maryland; University of Maryland Baltimore; Wake Forest University	Postma, DS (corresponding author), Univ Groningen, Dept Pulmonol, POB 30-001, NL-9700 RB Groningen, Netherlands.		Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066393, R01HL048341] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P41 RR03655] Funding Source: Medline; NHLBI NIH HHS [R01HL66393, R01HL48341] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Amelung PJ, 1998, CLIN EXP ALLERGY, V28, P397; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BURNEY PGJ, 1997, ASTHMA, P35; Clarke JR, 2000, AM J RESP CRIT CARE, V162, P2188, DOI 10.1164/ajrccm.162.6.9904057; COOKSON WOCM, 1989, LANCET, V1, P1292; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Fryer AA, 2000, GENES IMMUN, V1, P509, DOI 10.1038/sj.gene.6363717; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kjellman NIM, 1999, PEDIATR ALLERGY IMMU, V10, P11; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Koppelman GH, 2000, ASTHMA, P146; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; MARSHALL E, 1994, SCIENCE, V264, P1524, DOI 10.1126/science.8202702; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Strauch K, 2000, AM J HUM GENET, V66, P1945, DOI 10.1086/302911; VANCAMP G, 1997, TRENDS GENET, V13, P82; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201	34	143	152	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					498	506		10.1067/mai.2002.122235	http://dx.doi.org/10.1067/mai.2002.122235			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897998				2022-12-18	WOS:000174586400018
J	Kikuchi, Y; Kaplan, AP				Kikuchi, Y; Kaplan, AP			A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; basophils; histamine release; complement; IgE receptor; alpha subunit	FC-EPSILON-RI; AUTOANTIBODIES; EOSINOPHILS; RECEPTOR	Background: Histamine release in chronic urticaria is initiated by cross-linking of the a subunit of FcepsilonRI by means of IgG antibody, followed by complement activation. Objective: We sought to. further elucidate the mechanism by which complement augments histamine release and to assess the role of C5a. Methods: We first quantitated the ability of purified C5a to initiate basophil histamine release and to be inhibited by antibody directed to the C5a receptor. Using this antibody, we quantitated its ability to inhibit histamine release induced by sera from patients with chronic urticaria. We also compared the ability of normal serum, C5-depleted serum, and C5-depleted serum after reconstitution with C5 to augment histamine release by IgG isolated from patients with chronic urticaria. Results: As the concentration of C5a was increased up to 50 ng/mL, the percentage of histamine release increased and reached a plateau of 40% to 50%; this was inhibited by antibody to the C5a receptor. Preincubation of basophils with antibody to the C5a receptor inhibited basophil histamine release from 15 sera tested, with a range of 4% to 39%. Histamine release caused by patient IgG was augmented when normal serum was added but not when C5-depleted serum was substituted for normal serum. Augmentation of histamine release by patient IgG was again obtained when CS-depleted serum was reconstituted with C5. Conclusion: Our conclusion is that pathogenic IgG cross-links the IgE receptor directly to cause histamine release, and activation is augmented by complement. C5a is the complement agonist that is responsible for the augmented histamine release.	Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Allergy & Clin Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Konishi MUSC Inst Inflammat Res, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med, Div Pulm Allergy, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA.							Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; FREW AJ, 1988, J IMMUNOL, V141, P4158; GORSKI JP, 1979, P NATL ACAD SCI USA, V76, P5299, DOI 10.1073/pnas.76.10.5299; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KAPLAN AP, 1999, INFLAMMATION BASIC P, P915; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Ying S, 1999, J IMMUNOL, V163, P3976	14	143	150	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					114	118		10.1067/mai.2002.120954	http://dx.doi.org/10.1067/mai.2002.120954			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799375				2022-12-18	WOS:000173739300018
J	Arkwright, PD; David, TJ				Arkwright, PD; David, TJ			Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mycobacterium vaccae; atopic dermatitis; atopy; T(H)2	BCG VACCINATION; IMMUNOTHERAPY; TUBERCULOSIS; OVALBUMIN; TRIAL	Background: Although a doubling in the prevalence of atopic disease, including atopic dermatitis, in the Western world over the last few generations has been paralleled by a marked reduction in infectious diseases, especially tuberculosis, it is unclear whether this increase in atopy is causally related to reduced exposure to mycobacteria. Objectives: The aim of this study was to determine whether administration of mycobacterial antigens to atopic individuals might ameliorate their disease. Methods: Forty-one children aged 5 to 18 years with moderate-to-severe atopic dermatitis were enrolled in a randomized, double-blind, placebo-controlled trial, where they were given either one intradermal injection of killed Mycobacterium vaccae (SRL 172) or buffer solution (placebo). Changes in skin surface area affected by dermatitis and dermatitis severity score were assessed before treatment and at 1 and 3 months after treatment. Results: Children treated with SRL 172 showed a mean 48% (95% CI, 32%-65%) reduction in surface area affected by dermatitis compared with a mean 4% (95% CI, -29% to 22%) reduction for the placebo group (P < .001) and a median 68% (interquartile range, 46%-85%) reduction in dermatitis severity score compared with 18% (interquartile range, -2% to 34%) for the placebo group (P < .01) at 3 months after treatment. There were no untoward effects of the treatment, apart from a local reaction in 13 of the 21 children, which occurred 1 month after SRL 172 administration and settled spontaneously. Conclusion: SRL 172 was associated with an improvement in the severity of the dermatitis in children with moderate-to-severe disease.	Univ Manchester, Booth Hall Childrens Hosp, Acad Unit Child Hlth, Manchester M9 7AA, Lancs, England	Royal Manchester Children's Hospital; University of Manchester	Arkwright, PD (corresponding author), Univ Manchester, Booth Hall Childrens Hosp, Acad Unit Child Hlth, Charlestown Rd, Manchester M9 7AA, Lancs, England.		Arkwright, Peter/C-5149-2012	Arkwright, Peter/0000-0002-7411-5375				Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; DAVID TJ, 1984, BRIT J DERMATOL, V111, P597, DOI 10.1111/j.1365-2133.1984.tb06630.x; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hrouda D, 1998, BRIT J UROL, V82, P568; Johnson D, 1999, VACCINE, V17, P2583, DOI 10.1016/S0264-410X(99)00055-9; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Maraveyas A, 1999, ANN ONCOL, V10, P817, DOI 10.1023/A:1008307821189; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Schaible UE, 2000, J IMMUNOL, V164, P4843, DOI 10.4049/jimmunol.164.9.4843; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stead WW, 1997, CLIN CHEST MED, V18, P65, DOI 10.1016/S0272-5231(05)70356-7; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Tocque K, 1998, AM J RESP CRIT CARE, V158, P484, DOI 10.1164/ajrccm.158.2.9709125; Tukenmez F, 1999, PEDIATR ALLERGY IMMU, V10, P107, DOI 10.1034/j.1399-3038.1999.00029.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wang CC, 1998, IMMUNOLOGY, V93, P307	20	143	146	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					531	534		10.1067/mai.2001.113081	http://dx.doi.org/10.1067/mai.2001.113081			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240956				2022-12-18	WOS:000167793300017
J	Kankaanranta, H; Lindsay, MA; Giembycz, MA; Zhang, XZ; Moilanen, E; Barnes, PJ				Kankaanranta, H; Lindsay, MA; Giembycz, MA; Zhang, XZ; Moilanen, E; Barnes, PJ			Delayed eosinophil apoptosis in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						albuterol; apoptosis; asthma; eosinophil; fenoterol; GM-CSF; IL-5; salmeterol	HUMAN-BLOOD EOSINOPHILS; PROGRAMMED CELL-DEATH; IN-VITRO; GM-CSF; SURVIVAL; MACROPHAGES; ALBUTEROL; AGONISTS; PROLONG; IL-5	Background: Eosinophilic inflammation of the airways is a key characteristic of asthma, A defect in apoptosis might contribute to the chronic tissue eosinophilia associated with asthma. Objective: Our purpose was to examine whether the rate of apoptosis differs between peripheral blood eosinophils from asthmatic patients and healthy volunteers, Methods: Peripheral blood was obtained from volunteers with asthma and from control volunteers. Eosinophils were isolated by CD16-negative selection to >99% purity and were cultured for 48 hours, The number of apoptotic eosinophils in the culture was assessed by flow cytometric analysis of relative DNA content in propidium iodide-stained cells. Eosinophil apoptosis is expressed as apoptosis index (number of apoptotic cells/total number of cells). Results: Eosinophils From asthmatic patients not taking steroid medication survived longer (apoptosis index 0.25) than those of healthy control subjects (apoptosis index 0.40, P < .05). In contrast, the rate of apoptosis in eosinophils from patients concurrently taking steroids (apoptosis index 0.46) is higher than that of those not using steroids (P < .01) and not different from that of healthy subjects. To assess whether endogenous IL-3, IL-5, and CM-CSF production contributes to the delayed eosinophil apoptosis, the effects of the corresponding neutralizing antibodies were studied on eosinophil longevity. Neutralization of GM-CSF, but not of IL-3 or IL-5, increased slightly but significantly (P < .01) the rate of apoptosis in eosinophils obtained from patients with asthma, To assess whether beta(2)-agonist medication could contribute to the observed differences, we determined the in vitro effects of albuterol, Fenoterol, and salmeterol on eosinophil apoptosis, All beta(2)-agonists inhibited eosinophil apoptosis by 12% to 19%, A possibility existed that a prior in vivo exposure to IL-5, GM-CSF, or beta(2)-agonists would explain the observed difference. To study this, eosinophils were incubated with GM-CSF, IL-5, and albuterol for 2 to 3 hours, followed by washout of the added compounds, and were subsequently cultured for 48 hours. However, an exposure to GM-CSF (7 pmol/L) or IL-5 (10 pmol/L) for 15 to 180 minutes was not a sufficient signal to prevent eosinophil apoptosis, In contrast, exposure to albuterol (100 nmol/L) for 120 minutes was sufficient to induce a significant (P < .05) decrease in eosinophil apoptosis, Conclusions: The results suggest that eosinophil apoptosis is delayed in asthma, This delay may be partly explained by production of GM-CSF, The in vitro effects of beta(2)-agonists suggest that beta(2)-agonist use might contribute to the prolonged eosinophil survival through inhibition of apoptosis and thus may worsen eosinophilia in asthmatic patients, Use of inhaled glucocorticoids seems to totally reverse the delayed eosinophil apoptosis in asthma.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England; Tampere Univ, Sch Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland	Imperial College London; Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Kankaanranta, Hannu/0000-0001-5258-0906; Barnes, Peter/0000-0002-5122-4018; Lindsay, Mark/0000-0003-4807-5506				Adkins JC, 1997, DRUGS, V54, P331, DOI 10.2165/00003495-199754020-00011; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; Evans DJ, 1996, EUR RESPIR J, V9, P703, DOI 10.1183/09031936.96.09040703; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Hallsworth MP, 1996, BRIT J PHARMACOL, V117, P79, DOI 10.1111/j.1476-5381.1996.tb15157.x; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Haslett C, 1997, BRIT MED BULL, V53, P669; HOCHHAUS G, 1992, INT J CLIN PHARM TH, V30, P342; JONKMAN JHG, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1133; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; KANKAANRANTA H, IN PRESS METHODS MOL; MURPHY S, 1997, NIH PUBL; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nielson CP, 1998, AM J RESP CRIT CARE, V157, P184, DOI 10.1164/ajrccm.157.1.9704070; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; POWELL ML, 1986, J CLIN PHARMACOL, V26, P643, DOI 10.1002/j.1552-4604.1986.tb02965.x; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Simon HU, 1997, J IMMUNOL, V158, P3902; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SPRY CJF, 1993, IMMUNOPHARMACOLOGY E, P1; STERN M, 1992, J IMMUNOL, V148, P3543; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P482, DOI 10.1111/j.1365-2222.1997.tb00735.x; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	28	143	158	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				77	83						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887309				2022-12-18	WOS:000088393300011
J	STOOP, AE; VANDERHEIJDEN, HAMD; BIEWENGA, J; VANDERBAAN, S				STOOP, AE; VANDERHEIJDEN, HAMD; BIEWENGA, J; VANDERBAAN, S			EOSINOPHILS IN NASAL POLYPS AND NASAL-MUCOSA - AN IMMUNOHISTOCHEMICAL STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NASAL POLYPS; NASAL MUCOSA; EOSINOPHILS; CORTICOSTEROIDS; ENDOSCOPIC SINUS SURGERY; ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EOSINOPHILIC CATIONIC PROTEIN; MAJOR BASIC PROTEIN	NONLYMPHOID CELLS; ASTHMA; GRANULOCYTES; LYMPHOCYTES; NEUTROPHILS; GENERATION; RECEPTORS; RHINITIS; STEROIDS	Immunohistochemical staining was performed at the time of endoscopic sinus surgery (ESS), after 6 months, and after 1 year on nasal polyps and biopsy specimens of the macroscopically unaffected mucosa of the middle and inferior turbinate bones of 46 patients with nasal polyps. During the follow-up period the patients were treated with topical corticosteroids. At time of ESS significantly more BMK13+ and EG1+ (pan eosinophil markers) and EG2+ (activation marker) eosinophils were found in the polyps than in the macroscopically unaffected mucosa of the middle and inferior turbinate bones of the patients. In the middle and inferior turbinate bones of 10 healthy subjects no EG2+ (activated) eosinophils were detected, whereas low-to-moderate numbers of BMK13+ and EG1+ eosinophils were seen in these specimens. This emphasizes that eosinophils play a role in the pathogenesis of nasal polyps. Compared with numbers at ESS, after 6 months and 1 year of follow-up, lower numbers of BMK13+, EG1+ and especially of EG2+ eosinophils were found in recurrences of polyps and in the macroscopically unaffected mucosa of the middle and inferior turbinate bones of the patients. The decrease in number of EG2+ (activated) eosinophils is an indication of a reduced local inflammatory reaction, and could be an important factor in postponement of recurrences of nasal polyps.	FREE UNIV AMSTERDAM,FAC MED,DEPT CELL BIOL,1007 MC AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	STOOP, AE (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.							BRUIJNZEEL PLB, 1989, INT ARCH ALLER A IMM, V90, P57, DOI 10.1159/000235077; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DINGSOR G, 1985, Rhinology (Utrecht), V23, P49; DRETTNER B, 1982, Rhinology (Utrecht), V20, P149; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; FUKUDA T, 1989, J ALLERGY CLIN IMMUN, V83, P369, DOI 10.1016/0091-6749(89)90120-6; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HARTWIG S, 1988, J LARYNGOL OTOL, V102, P148, DOI 10.1017/S0022215100104372; Henocq E, 1988, Prog Biochem Pharmacol, V22, P141; KARLSSON G, 1982, Rhinology (Utrecht), V20, P144; KITA H, 1991, J ALLERGY CLIN IMMUN, V87, P70, DOI 10.1016/0091-6749(91)90214-9; KLOPROGGE E, 1989, J ALLERGY CLIN IMMUN, V83, P393, DOI 10.1016/0091-6749(89)90124-3; LAMAS A M, 1990, Journal of Allergy and Clinical Immunology, V85, P282; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MIADONNA A, 1991, Journal of Allergy and Clinical Immunology, V87, P146, DOI 10.1016/0091-6749(91)91312-H; OGAWA H, 1986, ACTA OTOLARYNGOL S S, V430, P12; OGINO S, 1986, ACTA OTOLARYNGOL S S, V430, P21; PECH A, 1983, J FR OTORHINOLARYNG, V32, P371; PETERS MS, 1988, BLOOD, V71, P780; PETERSON AP, 1981, J ALLERGY CLIN IMMUN, V68, P212, DOI 10.1016/0091-6749(81)90186-X; SCHAUER U, 1989, INT ARCH ALLER A IMM, V90, P201, DOI 10.1159/000235025; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; STOOP AE, 1989, J ALLERGY CLIN IMMUN, V84, P734, DOI 10.1016/0091-6749(89)90302-3; STOOP AE, 1991, J ALLERGY CLIN IMMUN, V87, P470, DOI 10.1016/0091-6749(91)90004-8; TANIGUCHI N, 1985, ALLERGY, V40, P571, DOI 10.1111/j.1398-9995.1985.tb00884.x; VIROLAINEN E, 1980, Rhinology (Utrecht), V18, P9; WALLEN N D, 1991, Journal of Allergy and Clinical Immunology, V87, P173, DOI 10.1016/0091-6749(91)91423-Q; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; WINQVIST I, 1982, IMMUNOLOGY, V47, P531	32	143	156	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					616	622		10.1016/0091-6749(93)90267-J	http://dx.doi.org/10.1016/0091-6749(93)90267-J			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436776				2022-12-18	WOS:A1993KN54800009
J	Yang, JM; Koh, HY; Moon, SY; Yoo, IK; Ha, EK; You, S; Kim, SY; Yon, DK; Lee, SW				Yang, Jee Myung; Koh, Hyun Yong; Moon, Sung Yong; Yoo, In Kyung; Ha, Eun Kyo; You, Seulgi; Kim, So Young; Yon, Dong Keon; Lee, Seung Won			Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; asthma; allergic rhinitis; atopic dermatitis	TYPE-2 INFLAMMATION; ASTHMA; DISEASE	Background: There is inconclusive and controversial evidence of the association between allergic diseases and the risk of adverse clinical outcomes of coronavirus disease 2019 (COVID-19). Objective: We sought to determine the association of allergic disorders with the likelihood of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result and with clinical outcomes of COVID-19 (admission to intensive care unit, administration of invasive ventilation, and death). Methods: A propensity-score-matched nationwide cohort study was performed in South Korea. Data obtained from the Health Insurance Review & Assessment Service of Korea from all adult patients (age, >20 years) who were tested for SARS-CoV-2 in South Korea between January 1, 2020, and May 15, 2020, were analyzed. The association of SARS-CoV-2 test positivity and allergic diseases in the entire cohort (n = 219,959) and the difference in clinical outcomes of COVID-19 were evaluated in patients with allergic diseases and SARS-CoV-2 positivity (n = 7,340). Results: In the entire cohort, patients who underwent SARS-CoV-2 testing were evaluated to ascertain whether asthma and allergic rhinitis were associated with an increased likelihood of SARS-CoV-2 test positivity. After propensity score matching, we found that asthma and allergic rhinitis were associated with worse clinical outcomes of COVID-19 in patients with SARS-CoV-2 test positivity. Patients with nonallergic asthma had a greater risk of SARS-CoV-2 test positivity and worse clinical outcomes of COVID-19 than patients with allergic asthma. Conclusions: In a Korean nationwide cohort, allergic rhinitis and asthma, especially nonallergic asthma, confers a greater risk of susceptibility to SARS-CoV-2 infection and severe clinical outcomes of COVID-19.	[Yang, Jee Myung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea; [Koh, Hyun Yong] Harvard Med Sch, Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Moon, Sung Yong; Lee, Seung Won] Sejong Univ, Coll Software Convergence, Dept Data Sci, 209 Neungdong Ro, Seoul 05006, South Korea; [Yoo, In Kyung] CHA Univ, CHA Bundang Med Ctr, Sch Med, Dept Gastroenterol, Seongnam, South Korea; [Ha, Eun Kyo] Hallym Univ, Kangnam Sacred Heart Hosp, Coll Med, Dept Pediat, Seoul, South Korea; [You, Seulgi] Ajou Univ, Ajou Univ Hosp, Sch Med, Dept Radiol, Suwon, South Korea; [Kim, So Young] CHA Univ, CHA Bundang Med Ctr, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Seongnam, South Korea; [Yon, Dong Keon] Republ Korea Armed Forces, Armed Force Med Command, 81 Saemaeul Ro 177, Seongnam 463040, South Korea; [Yon, Dong Keon] CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Pediat, Seongnam, South Korea	University of Ulsan; Asan Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Sejong University; Pochon Cha University; Hallym University; Ajou University; Ajou University Hospital; Pochon Cha University; Pochon Cha University	Lee, SW (corresponding author), Sejong Univ, Coll Software Convergence, Dept Data Sci, 209 Neungdong Ro, Seoul 05006, South Korea.; Yon, DK (corresponding author), Republ Korea Armed Forces, Armed Force Med Command, 81 Saemaeul Ro 177, Seongnam 463040, South Korea.	yonkkang@gmail.com; swlsejong@sejong.ac.kr	Lee, Seung Won/GQQ-7259-2022; Lee, Seung Won/AAK-9460-2021; Koh, Hyun Yong/AAX-4374-2020; Yon, Dong Keon/M-1264-2017	Lee, Seung Won/0000-0001-5632-5208; Lee, Seung Won/0000-0001-5632-5208; Koh, Hyun Yong/0000-0002-3995-4341; Yon, Dong Keon/0000-0003-1628-9948	National Research Foundation of Korea - Korean government [NRF2019R1G1A109977912]	National Research Foundation of Korea - Korean government(National Research Foundation of KoreaKorean Government)	This work was supported by the National Research Foundation of Korea grant funded by the Korean government (grant no. NRF2019R1G1A109977912). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.	Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117; Almeida AN, 2017, STUD AGRIC ECON, V119, P107, DOI 10.7896/j.1703; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9; Calverley PMA, 2017, AM J RESP CRIT CARE, V195, P1088, DOI 10.1164/rccm.201701-0114ED; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Ha Jihyun, 2020, Clin Exp Pediatr, V63, P278, DOI 10.3345/cep.2019.01291; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024; Jung CR, 2019, J ALLERGY CLIN IMMUN, V143, P2254, DOI 10.1016/j.jaci.2019.03.024; Kim HJ, 2019, J ALLERGY CLIN IMMUN, V144, P1004, DOI 10.1016/j.jaci.2019.06.024; Kimura H, 2020, J ALLERGY CLIN IMMUN, V146, P80, DOI 10.1016/j.jaci.2020.05.004; Koh HY, 2019, J ALLER CL IMM-PRACT, V7, P2912, DOI 10.1016/j.jaip.2019.05.015; Lee SW, 2019, J ALLERGY CLIN IMMUN, V144, P1542, DOI 10.1016/j.jaci.2019.08.037; Lee SW, SEVERE CLIN OUTCOMES, DOI 10.1136/gutjnl-2020-322248; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415; Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621; Park Su Eun, 2020, Clin Exp Pediatr, V63, P119, DOI [10.14776/piv.2020.27.e9, 10.3345/cep.2020.00493]; Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975; Roumie CL, 2019, JAMA-J AM MED ASSOC, V322, P1167, DOI 10.1001/jama.2019.13206; Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324; Woo A, 2021, J ALLERGY CLIN IMMUN, V147, P135, DOI 10.1016/j.jaci.2020.04.041; World Health Organization, 2020, COR DIS 2019 COVID 1, V72; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001	39	142	148	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					790	798		10.1016/j.jaci.2020.08.008	http://dx.doi.org/10.1016/j.jaci.2020.08.008			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32810517	Green Published, Bronze			2022-12-18	WOS:000582395800009
J	Kabashima, K; Furue, M; Hanifin, JM; Pulka, G; Wollenberg, A; Galus, R; Etoh, T; Mihara, R; Nakano, M; Ruzicka, T				Kabashima, Kenji; Furue, Masutaka; Hanifin, Jon M.; Pulka, Grazyna; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Nakano, Miwa; Ruzicka, Thomas			Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Monoclonal antibody; IL-31; IL-31 receptor; atopic dermatitis; pruritus; nemolizumab	NATIONAL-HEALTH; SKIN BARRIER; RECEPTOR; IL-31; GUIDELINES; MANAGEMENT; PLACEBO; ECZEMA; CARE; INTERLEUKIN-31	Background: Nemolizumab, an anti-IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986933). Objective: We sought to assess the long-term efficacy and safety of nemolizumab injected subcutaneously every 4 weeks (Q4W) or every 8 weeks (Q8W) in a 52-week, double-blind extension (part B). Methods: During part B, patients continued the previous nemolizumab dose (0.1, 0.5, or 2.0 mg/kg Q4W or 2.0 mg/kg Q8W). Part B end points included percentage improvement from baseline in pruritus visual analog scale and dermatitis scores (including the Eczema Area and Severity Index). Results: Overall, 216 of 264 patients completed part A, and 191 entered part B; 131 completed part B. In 153 patients randomized to nemolizumab in part A, improvement from baseline in pruritus visual analog scale score was maintained/increased from weeks 12 to 64, with greatest improvement in the 0.5-mg/kg Q4W group (percentage change from baseline at week 64: -73.0, -89.6, -74.7, and -79.1 in the 0.1-, 0.5-, and 2.0-mg/kg Q4W and 2.0-mg/kg Q8W groups, respectively). Improvement from baseline in dermatitis scores was also maintained/increased to week 64 (percentage change in Eczema Area and Severity Index score: -68.5, -75.8, -78.9, and -69.3 in the 0.1-, 0.5-, and 2.0-mg/kg Q4W and 2.0-mg/kg Q8W groups, respectively). Over 64 weeks, 83% to 89% had 1 or more adverse events, with no new safety concerns identified. Conclusion: Nemolizumab for up to 64 weeks was efficacious and overall well tolerated in patients with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy.	[Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Furue, Masutaka] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Fukuoka, Japan; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Pulka, Grazyna] Jagiellonian Univ, Coll Med, Sch Med, Krakow, Poland; [Wollenberg, Andreas; Ruzicka, Thomas] Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergol, Munich, Germany; [Galus, Ryszard] Med Univ Warsaw, Dept Histol & Embryol, Warsaw, Poland; [Etoh, Takafumi] Tokyo Teishin Hosp, Dept Dermatol, Tokyo, Japan; [Mihara, Ryosuke; Nakano, Miwa] Chugai Pharmaceut, Clin Sci & Strategy Dept, Tokyo, Japan	Kyoto University; Kyushu University; Oregon Health & Science University; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Munich; Medical University of Warsaw; Chugai Pharmaceutical Co., Ltd.; Roche Holding	Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawahara, Kyoto 6068507, Japan.	kaba@kuhp.kyoto-u.ac.jp			Chugai Pharmaceutical	Chugai Pharmaceutical	We thank the patients for participating in the trial; the study investigators and project team members at Chugai Pharmaceutical, especially Keiko Hirokawa, Yasue Koyano, and Michiaki Tanaka, for their expert discussion on analysis planning and data interpretation and Nobuhiko Ishizuka for project management; Alyson Bexfield, PhD, Caudex, Oxford, United Kingdom, for medical writing and editorial assistance; and Marika Ogasawara, McCann Complete Medical, for project management, which was funded by Chugai Pharmaceutical.r Supported by Chugai Pharmaceutical. The trial was designed by Chugai Pharmaceutical with input from the first three and last authors. Data were gathered and analyzed by Chugai Pharmaceutical. The first draft was prepared by the authors with professional medical writing and editorial assistance provided by Alyson Bexfield, PhD, of Caudex, funded by Chugai Pharmaceutical.	Basra MKA, 2015, DERMATOLOGY, V230, P27, DOI 10.1159/000365390; Bilsborough J, 2010, J IMMUNOL, V185, P6023, DOI 10.4049/jimmunol.0902769; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Carr WW, 2013, PEDIATR DRUGS, V15, P303, DOI 10.1007/s40272-013-0013-9; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chrostowska-Plak D, 2013, J EUR ACAD DERMATOL, V27, pE239, DOI 10.1111/j.1468-3083.2012.04578.x; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Egawa G, 2016, J ALLERGY CLIN IMMUN, V138, P350, DOI 10.1016/j.jaci.2016.06.002; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; European Medicines Agency, 2017, DUP DUP 300 MG SOL; Feld M, 2016, J ALLERGY CLIN IMMUN, V138, P500, DOI 10.1016/j.jaci.2016.02.020; Food and Drug Administration, 2017, DUP DUP INJ PRESCR I; Hanel KH, 2016, J IMMUNOL, V196, P3233, DOI 10.4049/jimmunol.1402943; Kato A, 2014, J DERMATOL SCI, V74, P229, DOI 10.1016/j.jdermsci.2014.02.009; Kido-Nakahara M, 2015, ACTA DERM-VENEREOL, V95, P345, DOI 10.2340/00015555-1972; Langenbruch A, 2014, J EUR ACAD DERMATOL, V28, P719, DOI 10.1111/jdv.12154; Nemoto O, 2016, BRIT J DERMATOL, V174, P296, DOI 10.1111/bjd.14207; NICE, 2007, CLIN GUID; Nomura T, 2016, J ALLERGY CLIN IMMUN, V138, P1548, DOI 10.1016/j.jaci.2016.10.004; Perrigoue JG, 2007, J EXP MED, V204, P481, DOI 10.1084/jem.20061791; Perrigoue JG, 2009, J IMMUNOL, V182, P6088, DOI 10.4049/jimmunol.0802459; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1176, DOI 10.1111/j.1468-3083.2012.04636.x; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Saito S, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0194-9; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Whiteley J, 2016, CURR MED RES OPIN, V32, P1645, DOI 10.1080/03007995.2016.1195733; Wollenberg A, 2016, J EUR ACAD DERMATOL, V30, P729, DOI 10.1111/jdv.13599	30	142	150	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1121	+		10.1016/j.jaci.2018.03.018	http://dx.doi.org/10.1016/j.jaci.2018.03.018			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29753033	Green Published, hybrid			2022-12-18	WOS:000446327300013
J	Kull, I; Melen, E; Alm, J; Hallberg, J; Svartengren, M; van Hage, M; Pershagen, G; Wickman, M; Bergstrom, A				Kull, Inger; Melen, Erik; Alm, Johan; Hallberg, Jenny; Svartengren, Magnus; van Hage, Marianne; Pershagen, Goran; Wickman, Magnus; Bergstrom, Anna			Breast-feeding in relation to asthma, lung function, and sensitization in young schoolchildren	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Breast-feeding; asthma; sensitization; lung function; infant feeding; prevention; BAMSE	ALLERGIC DISEASES; ATOPIC DISEASE; CHILDHOOD; RISK; CHILDREN; WHEEZE; PREVENTION; DURATION; INFANTS; SEX	Background: The evidence from previous studies on beneficial effects of breast-feeding in relation to development of asthma is conflicting. Objective: To investigate the relation between breast-feeding and asthma and/or sensitization during the first 8 years of life. Method: In a birth cohort, children were followed up to 8 years by questionnaires at ages 2 months and 1, 2, 4, and 8 years to collect information on exposures and health effects. Determination of serum IgE antibodies to common inhalant and food allergens was performed at 4 and 8 years. Longitudinal analyses were applied by using general estimated equations. The study population consisted of 3825 children (93% of the original cohort), of whom 2370 gave blood and 2564 performed lung function measurements at 8 years. Results: Children exclusively breast-fed 4 months or more had a reduced risk of asthma during the first 8 years of life (adjusted odds ratio [OR], 0.63; 95% CI, 0.50-0.78) compared with children breast-fed less than 4 months. At 8 years, reduced risks of sensitization (adjusted OR, 0.79; 95% CI, 0.64-0.99) and asthma in combination with sensitization (adjusted OR, 0.59; 95% CI, 0.37-0.93) were seen among children exclusively breast-fed 4 months or more. This group also had a significantly better lung function measured with peak expiratory flow. Conclusion: Breast-feeding for 4 months or more seems to reduce the risk of asthma up to 8 years. At this age, a reduced risk was observed particularly for asthma combined with sensitization. Furthermore, breast-feeding seems to have a beneficial effect on lung function. (J Allergy Clin Immunol 2010;125:1013-9.)	[Kull, Inger; Melen, Erik; Pershagen, Goran; Wickman, Magnus; Bergstrom, Anna] Karolinska Inst, Inst Environm Med, SE-17176 Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Ctr Allergy Res, SE-17176 Stockholm, Sweden; [Svartengren, Magnus] Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Alm, Johan; Hallberg, Jenny; Wickman, Magnus] Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; [Alm, Johan] Soder Sjukhuset, Dept Clin Sci & Educ, Karolinska Inst, Stockholm, Sweden; [van Hage, Marianne] Karolinska Inst & Univ Hosp, Clin Immunol & Allergy Unit, Dept Med Solna, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska University Hospital	Kull, I (corresponding author), Karolinska Inst, Inst Environm Med, Norrbacka 3rd Level, SE-17176 Stockholm, Sweden.	inger.kull@ki.se	Svartengren, Magnus/AAM-7777-2021; van Hage, Marianne/A-9678-2017	Svartengren, Magnus/0000-0002-8165-7236; van Hage, Marianne/0000-0003-3091-1596; Kull, Inger/0000-0001-6096-3771; Alm, Johan/0000-0002-9062-4479; Pershagen, Goran/0000-0002-9701-1130	Swedish Asthma and Allergy Association's Research Foundation; Vardal Foundation for Health Care Sciences and Allergy Research; Swedish Heart and Lung Foundation, the Swedish Research Council; Stockholm County Council	Swedish Asthma and Allergy Association's Research Foundation; Vardal Foundation for Health Care Sciences and Allergy Research; Swedish Heart and Lung Foundation, the Swedish Research Council(Swedish Research CouncilSwedish Heart-Lung Foundation); Stockholm County Council(Stockholm County Council)	Supported by the Swedish Asthma and Allergy Association's Research Foundation, the Vardal Foundation for Health Care Sciences and Allergy Research, the Swedish Heart and Lung Foundation, the Swedish Research Council, and the Stockholm County Council.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Balding DJ, 2004, APPL LONGITUDINAL AN; Burgess SW, 2006, PEDIATRICS, V117, pE787, DOI 10.1542/peds.2005-1753; Duncan JM, 2008, CURR OPIN ALLERGY CL, V8, P398, DOI 10.1097/ACI.0b013e32830d82ed; Elliott L, 2008, J ALLERGY CLIN IMMUN, V122, P49, DOI 10.1016/j.jaci.2008.04.001; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Guilbert TW, 2007, AM J RESP CRIT CARE, V176, P843, DOI 10.1164/rccm.200610-1507OC; Hallberg J, 2006, ACTA PAEDIATR, V95, P1191, DOI 10.1080/08035250600584794; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; Kramer MS, 2007, BMJ-BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2005, J ALLERGY CLIN IMMUN, V116, P657, DOI 10.1016/j.jaci.2005.04.028; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Kurukulaaratchy RJ, 2006, ANN ALLERG ASTHMA IM, V97, P84, DOI 10.1016/S1081-1206(10)61375-0; Lodge CJ, 2008, AM J RESP CRIT CARE, V178, P994, DOI 10.1164/ajrccm.178.9.994a; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Mai XM, 2007, J ALLERGY CLIN IMMUN, V120, P551, DOI 10.1016/j.jaci.2007.05.004; Mandhane PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1359, DOI 10.1016/j.jaci.2007.01.043; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nagel G, 2009, EUR RESPIR J, V33, P993, DOI 10.1183/09031936.00075708; Oddy Wendy H, 2003, J Hum Lact, V19, P250, DOI 10.1177/0890334403255516; ODDY WH, 2003, J HUM LACT, V19, P62; Ogbuanu IU, 2009, THORAX, V64, P62, DOI 10.1136/thx.2008.101543; Ostblom E, 2008, CLIN EXP ALLERGY, V38, P1325, DOI 10.1111/j.1365-2222.2008.03010.x; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Quanjer PH, 1997, PEDIATR PULM, V24, P2, DOI 10.1002/(SICI)1099-0496(199707)24:1<2::AID-PPUL2>3.0.CO;2-S; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Rothman K., 1998, MODERN EPIDEMIOLOGY; SCHOLTENS S, 2008, BREASTFEEDING OVERWE; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Thomsen SF, 2006, ALLERGY ASTHMA PROC, V27, P110; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033	38	142	146	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1013	1019		10.1016/j.jaci.2010.01.051	http://dx.doi.org/10.1016/j.jaci.2010.01.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392479				2022-12-18	WOS:000277686700009
J	Krause, S; Reese, G; Randow, S; Zennaro, D; Quaratino, D; Palazzo, P; Ciardiello, MA; Petersen, A; Becker, WM; Mari, A				Krause, Susanne; Reese, Gerald; Randow, Stefanie; Zennaro, Danila; Quaratino, Donato; Palazzo, Paola; Ciardiello, Maria Antonietta; Petersen, Arnd; Becker, Wolf-Meinhard; Mari, Adriano			Lipid transfer protein (Ara h 9) as a new peanut allergen relevant for a Mediterranean allergic population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ara h 9; peanut allergy; lipid transfer protein; isoform; allergen	IN-VITRO DIAGNOSIS; MAJOR ALLERGEN; RECOMBINANT ALLERGENS; CHERRY ALLERGY; STABILITY; DIGESTION; FOOD; NITROCELLULOSE; SENSITIZATION; PURIFICATION	Background: Nonspecific lipid transfer proteins (LTPs) represent potent pollen and food allergens. However, the allergenic properties of peanut LTP have not been studied. Objective: To identify LTP in peanut extract using sera from subjects with peanut allergy and Pro p 3-sensitized subjects from Southern Europe, clone and express this protein, and obtain information on the importance as allergen for these selected patients. Methods: Peanut LTP (Ara h 9) was cloned and sequenced by using a combination of bioinformatic and molecular biology tools (PCR, immunoblotting, Basic Local Alignment Search Tool [BLAST] searches). The immunologic properties of Ara h 9, Ara h 1, Ara h 2, and Ara h 3 were studied by using sera from subjects with peanut and peach allergy from Italy by immunoblotting and allergen microarray technology. Results: Two Ara It 9 isoforms-Ara h 9.01 and Ara h 9.02-were cloned and expressed. Ara h 9 represented a minor allergen for subjects with peanut allergy. However, including Ara h 9 as single component for serologic detection of sensitization to peanut by component-resolved diagnosis seems crucial, because the frequency of sensitization to the classic major peanut allergens Ara h 1, Ara h 2, and Ara h 3 was low in these patients from Southern Europe. Conclusion: Ara h 9 is a new member of the LTP allergen family that seems to play an important role in peanut allergy for patients from the Mediterranean area. (J Allergy Clin Immunol 2009;124:771-8.)	[Krause, Susanne; Petersen, Arnd; Becker, Wolf-Meinhard] Res Ctr Borstel, D-23845 Borstel, Germany; [Reese, Gerald; Randow, Stefanie] Paul Ehrlich Inst, D-6070 Langen, Germany; [Zennaro, Danila; Quaratino, Donato; Palazzo, Paola; Mari, Adriano] IDI IRCCS, Ctr Clin & Expt Allergol, Rome, Italy; [Ciardiello, Maria Antonietta] CNR, Inst Prot Biochem, Naples, Italy	Forschungszentrum Borstel; Paul Ehrlich Institute; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Petersen, A (corresponding author), Res Ctr Borstel, Pk Allee 22, D-23845 Borstel, Germany.	apetersen@fz-borstel.de			"Sparkassenstiftung Sudholstein," Bad Segeberg, Germany	"Sparkassenstiftung Sudholstein," Bad Segeberg, Germany	Susanne Krause received support for her PhD thesis from the "Sparkassenstiftung Sudholstein," Bad Segeberg, Germany.	[Anonymous], 1994, B WORLD HEALTH ORGAN, V72, P797; Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boldt A, 2005, PROTEOMICS, V5, P675, DOI 10.1002/pmic.200401150; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Duffort OA, 2002, J AGR FOOD CHEM, V50, P7738, DOI 10.1021/jf0258398; Edman P, 1970, Mol Biol Biochem Biophys, V8, P211; Fernandez-Rivas M, 2003, J ALLERGY CLIN IMMUN, V112, P789, DOI 10.1016/S0091-6749(03)02016-5; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Gaier S, 2008, MOL NUTR FOOD RES, V52, pS220, DOI 10.1002/mnfr.200700274; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; Mills ENC, 2008, CURR OPIN ALLERGY CL, V8, P249, DOI 10.1097/ACI.0b013e3282ffb123; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; PETERSEN A, 1992, INT ARCH ALLERGY IMM, V98, P105, DOI 10.1159/000236172; Riecken S, 2008, BIOL CHEM, V389, P415, DOI 10.1515/BC.2008.038; Salcedo G, 2007, BBA-MOL CELL BIOL L, V1771, P781, DOI 10.1016/j.bbalip.2007.01.001; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Suhr M, 2004, MOL NUTR FOOD RES, V48, P390, DOI 10.1002/mnfr.200400028; Van Boxtel EL, 2006, J AGR FOOD CHEM, V54, P7180, DOI 10.1021/jf061433+; van Ree R, 2002, BIOCHEM SOC T, V30, P910, DOI 10.1042/BST0300910; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; Zuidmeer L, 2007, CURR OPIN ALLERGY CL, V7, P269, DOI 10.1097/ACI.0b013e32814a5401	30	142	145	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					771	778		10.1016/j.jaci.2009.06.008	http://dx.doi.org/10.1016/j.jaci.2009.06.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19665774				2022-12-18	WOS:000270802800023
J	Mauad, T; Bel, EH; Sterk, PJ				Mauad, Thais; Bel, Elisabeth H.; Sterk, Peter J.			Asthma therapy and airway remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; therapy; remodeling; corticosteroids; leukotriene receptor antagonist; airway; basement membrane; smooth muscle; epithelium; extracellular matrix	RETICULAR BASEMENT-MEMBRANE; ENDOTHELIAL GROWTH-FACTOR; SUBEPITHELIAL COLLAGEN DEPOSITION; SMOOTH-MUSCLE PROLIFERATION; BRONCHIAL THERMOPLASTY; IN-VITRO; MATRIX METALLOPROTEINASES; INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; MONOCLONAL-ANTIBODY	Asthma is characterized by variable degrees of chronic inflammation and structural alterations in the airways. The most prominent abnormalities include epithelial denudation, goblet cell metaplasia, subepithelial thickening, increased airway smooth muscle mass, bronchial gland enlargement, angiogenesis, and alterations in extracellular matrix components, involving large and small airways. Chronic inflammation is thought to initiate and perpetuate cycles of tissue injury and repair in asthma, although remodeling may also occur in parallel with inflammation. In the absence of definite evidence on how different remodeling features affect lung function in asthma, the working hypothesis should be that structural alterations can lead to the development of persistent airway hyperresponsiveness and fixed airway obstruction. It is still unanswered whether and when to begin treating patients with asthma to prevent or reverse deleterious remodeling, which components of remodeling to target, and how to monitor remodeling. Consequently, efforts are being made to understand better the effects of conventional anti-inflammatory therapies, such as glucocorticosteroids, on airway structural changes. Animal models, in vitro studies, and some clinical studies have advanced present knowledge on the cellular and molecular pathways involved in airway remodeling. This has encouraged the development of biologicals aimed to target various components of airway remodeling. Progress in this area requires the explicit linking of modern structure-function analysis with innovative biopharmaceutical approaches.	Univ Amsterdam, Acad Med Ctr, Dept Resp Dis, NL-1100 DE Amsterdam, Netherlands; Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil	University of Amsterdam; Academic Medical Center Amsterdam; Universidade de Sao Paulo	Sterk, PJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Resp Dis, F5-259,POB 22700, NL-1100 DE Amsterdam, Netherlands.	p.j.sterk@amc.nl	Sterk, P.J./AAK-8175-2020; Mauad, Thais/G-1254-2012	Mauad, Thais/0000-0002-3354-1466				Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; Ammit Alaina J, 2003, Prog Cell Cycle Res, V5, P49; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Belvisi MG, 2004, BIODRUGS, V18, P211, DOI 10.2165/00063030-200418040-00001; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bergeron C, 2007, EUR RESPIR J, V29, P596, DOI 10.1183/09031936.00019906; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Black JL, 2003, RESP PHYSIOL NEUROBI, V137, P339, DOI 10.1016/S1569-9048(03)00157-5; Bonacci JV, 2006, PULM PHARMACOL THER, V19, P32, DOI 10.1016/j.pupt.2005.02.011; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648, DOI 10.1164/ajrccm.153.5.8630616; Brackel HJL, 2000, AM J RESP CRIT CARE, V162, P896, DOI 10.1164/ajrccm.162.3.9905034; Brown RH, 2005, EUR RESPIR J, V26, P277, DOI 10.1183/09031936.05.00006605; Bruce C, 2005, TOXICOL APPL PHARM, V205, P126, DOI 10.1016/j.taap.2004.10.005; Burgess JK, 2006, J ALLERGY CLIN IMMUN, V118, P649, DOI 10.1016/j.jaci.2006.05.019; Camateros P, 2007, AM J RESP CRIT CARE, V175, P1241, DOI 10.1164/rccm.200701-054OC; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689, DOI 10.1164/ajrccm.155.2.9032214; Cazes E, 2001, J IMMUNOL, V167, P5329, DOI 10.4049/jimmunol.167.9.5329; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; Chetta A, 2007, PULM PHARMACOL THER, V20, P1, DOI 10.1016/j.pupt.2005.10.009; Cho JY, 2005, J ALLERGY CLIN IMMUN, V116, P1116, DOI 10.1016/j.jaci.2005.08.015; Cho JY, 2004, AM J RESP CELL MOL, V30, P651, DOI 10.1165/rcmb.2003-0066OC; Christie PE, 2004, EUR RESPIR J, V24, P107, DOI 10.1183/09031936.04.00013303; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; CHUNG KF, 1990, EUR RESPIR J, V3, P329; Cox G, 2006, AM J RESP CRIT CARE, V173, P965, DOI 10.1164/rccm.200507-1162OC; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Cox PG, 2004, EUR RESPIR J, V24, P659, DOI 10.1183/09031936.04.00054604; Das AM, 2006, CURR PHARM DESIGN, V12, P3233, DOI 10.2174/138161206778194097; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Jong PA, 2005, EUR RESPIR J, V26, P140, DOI 10.1183/09031936.05.00007105; de Kluijver J, 2005, CLIN EXP ALLERGY, V35, P1361, DOI 10.1111/j.1365-2222.2005.02334.x; Demedts IK, 2005, CURR OPIN PHARMACOL, V5, P257, DOI 10.1016/j.coph.2004.12.005; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dolhnikoff M, 1999, AM J RESP CRIT CARE, V160, P1750, DOI 10.1164/ajrccm.160.5.9812040; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; ERJEFALT JS, 1995, THORAX, V50, P785, DOI 10.1136/thx.50.7.785; Fanucchi MV, 2004, AM J RESP CRIT CARE, V170, P1153, DOI 10.1164/rccm.200404-533OC; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Feltis BN, 2007, THORAX, V62, P314, DOI 10.1136/thx.2006.069229; FEMANDES DJ, 2006, CURR DRUG TARGETS, V7, P567; Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fouty B, 2006, EUR RESPIR J, V27, P1160, DOI 10.1183/09031936.06.00078605; Fredberg JJ, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-2; *GLOB IN ASTH, 2006, GLOB STR ASTH MAN PR; Goldsmith AM, 2007, AM J PHYSIOL-LUNG C, V292, pL99, DOI 10.1152/ajplung.00269.2006; Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC; Greenlee KJ, 2007, PHYSIOL REV, V87, P69, DOI 10.1152/physrev.00022.2006; Gunst SJ, 2003, J APPL PHYSIOL, V95, P413, DOI 10.1152/japplphysiol.00277.2003; Halayko AJ, 2006, CURR DRUG TARGETS, V7, P525, DOI 10.2174/138945006776818728; Hasegawa M, 2006, AM J RESP CRIT CARE, V173, P1309, DOI 10.1164/rccm.200601-037OC; Hashimoto M, 2005, CHEST, V127, P965, DOI 10.1378/chest.127.3.965; Hendeles Leslie, 2004, Paediatr Respir Rev, V5 Suppl A, pS107, DOI 10.1016/S1526-0542(04)90020-6; Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501-088OC; Hirst SJ, 2000, EUR RESPIR J, V16, P159, DOI 10.1034/j.1399-3003.2000.16a28.x; Hoshino M, 2005, ALLERGY, V60, P1394, DOI 10.1111/j.1398-9995.2005.00897.x; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 2001, CLIN EXP ALLERGY, V31, P722, DOI 10.1046/j.1365-2222.2001.01071.x; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Huang J, 1999, AM J RESP CRIT CARE, V160, P725, DOI 10.1164/ajrccm.160.2.9809040; Huang YC, 2005, ANN ALLERG ASTHMA IM, V95, P443, DOI 10.1016/S1081-1206(10)61170-2; James A, 2005, CLIN EXP ALLERGY, V35, P703, DOI 10.1111/j.1365-2222.2005.02270.x; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Jeffery P, 2003, AM J RESP CRIT CARE, V168, pS1, DOI 10.1164/rccm.200202-150WS; Jeffery P, 2001, PEDIATR PULM, P3; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111; Karras JG, 2007, AM J RESP CELL MOL, V36, P276, DOI 10.1165/rcmb.2005-0456OC; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; Kelly MM, 2006, CHEST, V130, P741, DOI 10.1378/chest.130.3.741; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; Kraft M, 2001, J ALLERGY CLIN IMMUN, V107, P602, DOI 10.1067/mai.2001.113760; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289, DOI 10.1165/ajrcmb.22.3.3690; Kumar RK, 2003, J PHARMACOL EXP THER, V307, P349, DOI 10.1124/jpet.103.053819; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1987, AM REV RESPIR DIS, V135, pS67; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; LAURENT GJ, 1986, THORAX, V41, P418, DOI 10.1136/thx.41.6.418; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Lee SY, 2006, J ALLERGY CLIN IMMUN, V117, P597, DOI 10.1016/j.jaci.2005.11.008; LEE SY, 2006, PULM PHARM THER 1020; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Leung SY, 2006, J PHARMACOL EXP THER, V319, P586, DOI 10.1124/jpet.106.109314; Leung SY, 2005, J ALLERGY CLIN IMMUN, V115, P989, DOI 10.1016/j.jaci.2005.01.036; Liu YC, 1998, BRIT J PHARMACOL, V124, P563, DOI 10.1038/sj.bjp.0701886; Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; Matsushita MD, 2005, J PATHOL, V207, P102, DOI 10.1002/path.1818; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Mendes ES, 2004, AM J RESP CRIT CARE, V169, P1131, DOI 10.1164/rccm.200311-1544OC; Mendes ES, 2003, EUR RESPIR J, V21, P989, DOI 10.1183/09031936.03.00072402; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; Miller JD, 2005, CHEST, V127, P1999, DOI 10.1378/chest.127.6.1999; Miller M, 2006, AM J PHYSIOL-LUNG C, V290, pL162, DOI 10.1152/ajplung.00252.2005; Mitzner W, 2004, AM J RESP CRIT CARE, V169, P787, DOI 10.1164/rccm.200312-1636PP; Muz MH, 2006, EXP MOL MED, V38, P109, DOI 10.1038/emm.2006.14; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; O'Byrne PM, 2006, CHEST, V130, P244, DOI 10.1378/chest.130.1.244; Oda N, 1999, LIFE SCI, V65, P763, DOI 10.1016/S0024-3205(99)00303-3; Oddera S, 2002, INT ARCH ALLERGY IMM, V129, P152, DOI 10.1159/000065877; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117, DOI 10.1164/ajrccm.164.1.2006003; PANETTIERI A, 2004, P AM THORAC SOC, V1, P231; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Pini L, 2007, EUR RESPIR J, V29, P71, DOI 10.1183/09031936.00047905; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Roberts C R, 1998, Can Respir J, V5, P48; ROCHE WR, 1989, LANCET, V1, P520; Rogers DF, 2006, ANN MED, V38, P116, DOI 10.1080/07853890600585795; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Seow CY, 2000, J APPL PHYSIOL, V88, P527, DOI 10.1152/jappl.2000.88.2.527; Shaw RJ, 2002, RESP MED, V96, P67, DOI 10.1053/rmed.2001.1216; Shiba K, 2002, CHEST, V122, P1622, DOI 10.1378/chest.122.5.1622; Silvestri M, 2001, EUR RESPIR J, V18, P139, DOI 10.1183/09031936.01.00067901; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Southam DS, 2007, J ALLERGY CLIN IMMUN, V119, P848, DOI 10.1016/j.jaci.2006.12.623; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Tamaoki J, 2000, LANCET, V356, P273, DOI 10.1016/S0140-6736(00)02501-0; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; Todorova L, 2006, AM J RESP CELL MOL, V34, P92, DOI 10.1165/rcmb.2005-0048OC; Trifilieff A, 2002, BRIT J PHARMACOL, V135, P1655, DOI 10.1038/sj.bjp.0704616; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Vanacker NJ, 2002, EUR RESPIR J, V20, P873, DOI 10.1183/09031936.02.02562001; Vanacker NJ, 2002, CLIN EXP ALLERGY, V32, P914, DOI 10.1046/j.1365-2222.2002.01394.x; Vanacker NJ, 2001, AM J RESP CRIT CARE, V163, P674, DOI 10.1164/ajrccm.163.3.2004160; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Vlahos R, 2003, PULM PHARMACOL THER, V16, P171, DOI 10.1016/S1094-5539(02)00183-9; Wadsworth SJ, 2006, J CLIN IMMUNOL, V26, P376, DOI 10.1007/s10875-006-9029-z; Ward C, 2005, CLIN EXP ALLERGY, V35, P1565, DOI 10.1111/j.1365-2222.2005.02365.x; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Ward C, 2001, AM J RESP CRIT CARE, V164, P1718, DOI 10.1164/ajrccm.164.9.2102039; Wegmann M, 2007, AM J RESP CELL MOL, V36, P61, DOI 10.1165/rcmb.2006-0188OC; Wen LP, 1997, AM J PHYSIOL-LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Yano Y, 2006, BIOCHEM BIOPH RES CO, V341, P684, DOI 10.1016/j.bbrc.2006.01.018; Youn CJ, 2004, J IMMUNOL, V173, P7556, DOI 10.4049/jimmunol.173.12.7556	162	142	149	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					997	1009		10.1016/j.jaci.2007.06.031	http://dx.doi.org/10.1016/j.jaci.2007.06.031			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17681364				2022-12-18	WOS:000250973400002
J	Williamson, MP; McCormick, TG; Nance, CL; Shearer, WT				Williamson, Mike P.; McCormick, Theron G.; Nance, Christina L.; Shearer, William T.			Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV-1; gp120; CD4; EGCG; NMR; STD; flow cytometry	(-)-EPIGALLOCATECHIN GALLATE; NMR-SPECTROSCOPY; LIGAND-BINDING; GP120 BINDING; ENTRY; PREVENTION; CANCER; IDENTIFICATION; INFECTION; DISEASE	Background: The green tea flavonoid, epigallocatechin gallate (EGCG), has been proposed to have an anti-HIV-1 effect by preventing the binding of HIV-1 glycoprotein (gp) 120 to the CD4 molecule on T cells. Objective: To demonstrate that EGCG binds to the CD4 molecule at the gp120 attachment site and inhibits gp120 binding at physiologically relevant levels, thus establishing EGCG as a potential therapeutic treatment for HIV-1 infection. Methods: Nuclear magnetic resonance spectroscopy was used to examine the binding of EGCG and control, (-)-catechin, to CD4-IgG(2) (PRO 542 (R)). Gp120 binding to human CD4(+) T cells was analyzed by flow cytometry. Results: Addition of CD4 to EGCG produced a linear decrease in nuclear magnetic resonance signal intensity from EGCG but not from the control, (-)-catechin. In saturation transfer difference experiments, addition of 5.8 mu mol/L CD4 to 310 mu mol/L EGCG produced strong saturation at the aromatic rings of EGCG, but identical concentrations of (-)-catechin produced much smaller effects, implying EGCG/CD4 binding strong enough to reduce gp120/CD4 binding substantially. Molecular modeling studies suggested a binding site for EGCG in the D1 domain of CD4, the pocket that binds gp120. Physiologically relevant concentrations of EGCG (0.2 mu mol/L) inhibited binding of gp120 to isolated human CD4(+) T cells. Conclusion: We have demonstrated clear evidence of high-affinity binding of EGCG to the CD4 molecule with a K-d of approximately 10 nmol/L and inhibition of gp120 binding to human CD4(+) T cells. Clinical implications: Epigallocatechin gallate has potential use as adjunctive therapy in HIV-1 infection.	Texas Childrens Hosp, Dept Allergy & Immunol, Houston, TX 77030 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; University of Sheffield; Baylor College of Medicine	Nance, CL (corresponding author), Texas Childrens Hosp, Dept Allergy & Immunol, 6621 Fannin,MC FC3300-01, Houston, TX 77030 USA.	clnance@texaschildrenshospital.org		Williamson, Mike/0000-0001-5572-1903; Shearer, William/0000-0002-2483-2130	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072705, R01HL079533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027551, U01AI041089, P30AI036211] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0188] Funding Source: Medline; NHLBI NIH HHS [HL079533, HL72705] Funding Source: Medline; NIAID NIH HHS [AI41089, AI36211, AI27551] Funding Source: Medline; NICHD NIH HHS [HD41983] Funding Source: Medline; PHS HHS [RAT003084A] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BEHR M, 1997, NATURE, V389, P134; Beliveau R, 2004, LANCET, V364, P1021, DOI 10.1016/S0140-6736(04)17076-1; Benie AJ, 2003, J AM CHEM SOC, V125, P14, DOI 10.1021/ja027691e; Charlton AJ, 2002, J AGR FOOD CHEM, V50, P1593, DOI 10.1021/jf010897z; Charlton AJ, 2002, J AM CHEM SOC, V124, P9899, DOI 10.1021/ja0126374; D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215; Deana R, 2003, THROMB HAEMOSTASIS, V89, P866, DOI 10.1055/s-0037-1613474; Fassina G, 2002, AIDS, V16, P939, DOI 10.1097/00002030-200204120-00020; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Hamza A, 2006, J PHYS CHEM B, V110, P2910, DOI 10.1021/jp0550762; Jacobson JM, 2004, ANTIMICROB AGENTS CH, V48, P423, DOI 10.1128/AAC.48.2.423-429.2004; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; Jobstl E, 2004, BIOMACROMOLECULES, V5, P942, DOI 10.1021/bm0345110; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; Lipton SA, 2004, NATURE, V428, P473, DOI 10.1038/428473a; Liu SW, 2005, BBA-GEN SUBJECTS, V1723, P270, DOI 10.1016/j.bbagen.2005.02.012; Ludwig A, 2004, BIOCHEM BIOPH RES CO, V316, P659, DOI 10.1016/j.bbrc.2004.02.099; Machius M, 2003, CURR OPIN NEPHROL HY, V12, P431, DOI 10.1097/00041552-200307000-00012; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Nakachi K, 2000, BIOFACTORS, V13, P49, DOI 10.1002/biof.5520130109; Nakane H, 1989, Nucleic Acids Symp Ser, P115; Nance CL, 2005, CLIN IMMUNOL, V115, pS245; Nance CL, 2003, J ALLERGY CLIN IMMUN, V112, P851, DOI 10.1016/j.jaci.2003.08.048; *NCI DCPC, 1996, J CELL BIOCHEM, V26, P236; Patterson LJ, 2001, BIOCHEM BIOPH RES CO, V285, P639, DOI 10.1006/bbrc.2001.5227; Sakata R, 2004, J HEPATOL, V40, P52, DOI 10.1016/S0168-8278(03)00477-X; Wang YC, 2002, AMINO ACIDS, V22, P131, DOI 10.1007/s007260200002; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9; Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.2634931100	36	142	158	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1369	1374		10.1016/j.jaci.2006.08.016	http://dx.doi.org/10.1016/j.jaci.2006.08.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157668				2022-12-18	WOS:000242880300026
J	Zock, JP; Heinrich, J; Jarvis, D; Verlato, G; Norback, D; Plana, E; Sunyer, J; Chinn, S; Olivieri, M; Soon, A; Villani, S; Ponzio, M; Dahlman-Hoglund, A; Svanes, C; Luczynska, C				Zock, Jan-Paul; Heinrich, Joachim; Jarvis, Deborah; Verlato, Giuseppe; Norback, Dan; Plana, Estel; Sunyer, Jordi; Chinn, Susan; Olivieri, Mario; Soon, Argo; Villani, Simona; Ponzio, Michela; Dahlman-Hoglund, Anna; Svanes, Cecilie; Luczynska, Christina		Indoor Working Grp European Comm	Distribution and determinants of house dust mite allergens in Europe: the European Community Respiratory Health Survey II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; allergens; housing; risk factors; geographic; ECRHS	ASTHMA; PREVALENCE; DER-P-1; HOMES; EXPOSURE	Background: Several studies in European homes have described allergen levels from the house dust mite species Dermatophagoides pteronyssinus and to a lesser extent Dermatophagoides farinae, but geographic comparisons of exposure levels and risk factors have been hampered by a lack of standardized methods. Objective: To study the distribution and determinants of the major house dust mite allergens Der p 1 and Der f 1 in 10 European countries using a common protocol. Methods: During home visits with 3580 participants of the European Community Respiratory Health Survey II from 22 study centers, mattress dust was sampled and analyzed for Der p 1, Der f 1, and Der 2 allergen. Information on housing characteristics was obtained by both observations and interview. Results: Der 1 and Der 2 allergens were detectable (>= 0.1 mu g/g) in 68% and 53% of the samples, respectively. Large differences in allergen levels between study centers were observed, and geographic patterns for Der p 1 and Der f 1 were different. Low winter temperatures reduced Der p 1 rather than Der f 1. Important risk factors for high allergen levels included an older mattress, a lower floor level of the bedroom, limited ventilation of the bedroom, and dampness for Der p 1 but not for Der f 1. Conclusion: There are large qualitative and quantitative differences of house dust mite allergen levels in Europe, which can partly be explained by geographic and housing characteristics. Clinical implications: Mite allergen exposure may be reduced by replacing the mattress regularly and increasing ventilation of the bedroom, particularly in winter.	Municipal Inst Med Res, Ctr Res Environm Epidemiol, Barcelona, Spain; Inst Epidemiol, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; Univ London Imperial Coll Sci & Technol, Resp Epidemiol & Publ Hlth Grp, Natl Heart & Lung Inst, London, England; Univ Verona, Dept Med & Publ Hlth, I-37100 Verona, Italy; Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England; Univ Verona, Unit Occupat Med, I-37100 Verona, Italy; Univ Tartu, Dept Publ Hlth, EE-50090 Tartu, Estonia; Univ Pavia, Dept Hlth Sci, Sect Epidemiol & Med Stat, I-27100 Pavia, Italy; Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden; Univ Bergen, Dept Thorac Med, Inst Med, Bergen, Norway	Imperial College London; University of Verona; Uppsala University; University of London; King's College London; University of Verona; University of Tartu; University of Pavia; Sahlgrenska University Hospital; University of Bergen	Zock, JP (corresponding author), IMIM, Dr Aiguader 80, E-08003 Barcelona, Spain.	jpzock@imim.es	Jarvis, Deborah/E-6494-2011; Svanes, Cecilie/N-7556-2017; Rolla, Giovanni/C-9901-2009; Sánchez-Ramos, José Luis/G-1259-2011; Zock, Jan-Paul/P-5034-2018; Heinrich, Joachim/N-1720-2013; Burgos, Felip/E-5734-2015; Sunyer, Jordi/G-6909-2014; Ciccone, Giovannino/K-3136-2016; Bono, Roberto/J-8954-2012; Corsico, Angelo Guido/AAC-8138-2019; SESM, SESM/C-1440-2008	Svanes, Cecilie/0000-0001-8512-5192; Rolla, Giovanni/0000-0001-5997-7172; Sánchez-Ramos, José Luis/0000-0001-7187-9989; Zock, Jan-Paul/0000-0002-2941-6259; Heinrich, Joachim/0000-0002-9620-1629; Burgos, Felip/0000-0002-4938-4581; Sunyer, Jordi/0000-0002-2602-4110; Ciccone, Giovannino/0000-0001-7644-9574; Bono, Roberto/0000-0002-2471-6594; Corsico, Angelo Guido/0000-0002-8716-4694; Jarvis, Deborah/0000-0002-1753-3896; Bjornsson, Eythor/0000-0003-1186-8473; Plana, Estel/0000-0001-8675-7503; ROMANO, Canzio/0000-0001-5294-9793; /0000-0003-2517-6515; Burney, Peter/0000-0001-8635-5678; Grassi, Mario/0000-0001-6612-8566; Norback, Dan/0000-0002-5174-6668; Cerveri, Isa/0000-0003-0337-043X	NHLBI NIH HHS [R01 HL62633-01] Funding Source: Medline; NIEHS NIH HHS [5P30 ES07048] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Arlian LG, 2003, IMMUNOL ALLERGY CLIN, V23, P443, DOI 10.1016/S0889-8561(03)00005-5; Bleda Hernández M. J., 2002, Gac Sanit, V16, P188; Brunekreef B, 2005, ALLERGY, V60, P1083, DOI 10.1111/j.1398-9995.2005.00881.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P461, DOI 10.1046/j.1365-2222.1999.00513.x; El Sharif N, 2004, ALLERGY, V59, P623, DOI 10.1111/j.1398-9995.2004.00441.x; Gehring U, 2005, ALLERGY, V60, P1079, DOI 10.1111/j.1398-9995.2005.00872.x; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; Luczynska C, 1998, CLIN EXP ALLERGY, V28, P1201, DOI 10.1046/j.1365-2222.1998.00410.x; Macan J, 2003, ALLERGY, V58, P780, DOI 10.1034/j.1398-9995.2003.00210.x; Melki IS, 2004, J EPIDEMIOL COMMUN H, V58, P476, DOI 10.1136/jech.2003.012690; Mihrshahi S, 2002, ALLERGY, V57, P137, DOI 10.1034/j.1398-9995.2002.5720999.x; Moscato G, 2000, ALLERGY, V55, P873, DOI 10.1034/j.1398-9995.2000.00584.x; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V105, pS628, DOI 10.1067/mai.2000.106154; O'Connor GT, 2005, J ALLERGY CLIN IMMUN, V116, P26, DOI 10.1016/j.jaci.2005.02.013; Recer GM, 2004, CLIN EXP ALLERGY, V34, P268, DOI 10.1111/j.1365-2222.2004.01863.x; Schei MA, 2002, ALLERGY, V57, P538, DOI 10.1034/j.1398-9995.2002.23433.x; Sidenius KE, 2002, ANN AGR ENV MED, V9, P33; Simpson A, 2001, CLIN EXP ALLERGY, V31, P803, DOI 10.1046/j.1365-2222.2001.01110.x; van Strien RT, 2004, ALLERGY, V59, P645, DOI 10.1111/j.1398-9995.2004.00470.x; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; Warner A, 1998, ALLERGY, V53, P698, DOI 10.1111/j.1398-9995.1998.tb03956.x; Wickens K, 2004, PEDIAT ALLERG IMM-UK, V15, P55, DOI 10.1046/j.0905-6157.2003.00100.x; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383	29	142	152	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					682	690		10.1016/j.jaci.2006.04.060	http://dx.doi.org/10.1016/j.jaci.2006.04.060			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950288				2022-12-18	WOS:000240649000022
J	Simon, D; Marti, H; Heer, P; Simon, HU; Braathen, LR; Straumann, A				Simon, D; Marti, H; Heer, P; Simon, HU; Braathen, LR; Straumann, A			Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Bern, Dept Dermatol, CH-3010 Bern, Switzerland; Swiss Trop Inst, CH-4002 Basel, Switzerland; Kantonsspital Olten, Dept Gastroenterol, Olten, Switzerland; Univ Bern, Dept Pharmacol, Bern, Switzerland	University of Bern; University of Basel; Swiss Tropical & Public Health Institute; Kantonsspital Olten; University of Bern	Simon, D (corresponding author), Univ Bern, Dept Dermatol, Freiburgstr, CH-3010 Bern, Switzerland.		Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Straumann A, 2004, ALLERGY, V59, P15, DOI 10.1046/j.1398-9995.2003.00382.x; VITELLAS KM, 1993, RADIOLOGY, V186, P789, DOI 10.1148/radiology.186.3.8430189; WUETHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149	10	142	147	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1090	1092		10.1016/j.jaci.2005.01.017	http://dx.doi.org/10.1016/j.jaci.2005.01.017			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867873				2022-12-18	WOS:000229055100031
J	Scheurer, S; Lauer, I; Foetisch, K; Moncin, MSM; Retzek, M; Hartz, C; Enrique, E; Lidholm, J; Cistero-Bahima, A; Vieths, S				Scheurer, S; Lauer, I; Foetisch, K; Moncin, MSM; Retzek, M; Hartz, C; Enrique, E; Lidholm, J; Cistero-Bahima, A; Vieths, S			Strong allergenicity of Pru av 3, the lipid transfer protein from cherry, is related to high stability against thermal processing and digestion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lipid transfer protein; nsLTP; food allergy; Pru av 1; Pru av 3; Pru av 4; stability; pepsin digestion; thermal treatment; histamine release	POSITIVE DOUBLE-BLIND; PLANT-DERIVED FOODS; IN-VITRO; MAJOR ALLERGEN; RECOMBINANT ALLERGENS; PAN-ALLERGEN; DIAGNOSIS; IGE; THAUMATIN; RESISTANT	Background: Nonspecific lipid transfer proteins (nsLTPs) have been identified as major fruit allergens in patients from the Mediterranean area. Sensitization to nsLTPs is accompanied by severe reactions, possibly because of specific biophysical and biochemical properties of this allergen family. Objective: To assess the protein stability and allergenic potency of nsLTP from fruits in comparison with birch pollen-related allergens from the same allergenic source. Methods: Stability of natural and recombinant cherry allergens Pru av 3 (nsLTP), Pru av 1 (Bet v 1 homologue), and Pro av 4 (profilin) to pepsin digestion and to thermal processing and stability of allergens in skin prick test reagents was investigated by immunoblotting and/or circular dichroism spectroscopy. Moreover, allergenicity of processed and fresh fruits in regard to Pru av 1 and Pru av 3 was analyzed by histamine release assays. Results: Lipid transfer proteins showed the highest resistance to digestion by pepsin (rPru av 3>> rPru av 1 > rPru av 4). Immunologically active Pro av 3 was detectable after 2 hours of digestion by pepsin, whereas IgE reactivity of Pru av I and Pro av 4 was abolished within less than 60 minutes. In contrast with Pru av 1, IgE reactivity to nsLTPs was not diminished in thermally processed fruits, and secondary structures of purified Pro av 3 were more resistant to heating. Moreover, nsLTPs were stable components in skin prick test reagents. Histamine release assays confirmed the strong allergenicity of nsLTPs, which was not affected by protease treatment or thermal processing of fruits. Conclusion: In contrast with birch pollen-related allergens, nsLTPs are highly stable to pepsin treatment and thermal processing and show higher allergenic potency. Therefore, nsLTPs have the potential to act as true food allergens, probably eliciting severe systemic reactions by reaching the intestinal mucosa in an intact and fully active form.	Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany; Hosp Gen Castellon, Secc Alergia, Castellon de La Plana, Spain; Inst Univ Dexeus, Barcelona, Spain; Pharmacia Diagnost AB, S-75182 Uppsala, Sweden	Paul Ehrlich Institute; Pfizer; Pharmacia Corporation	Scheurer, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	Schst@pei.de	Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X; Lidholm, Jonas/0000-0002-7779-3411				Akkerdaas JH, 2003, INT ARCH ALLERGY IMM, V132, P132, DOI 10.1159/000073714; Asero R, 2003, J ALLERGY CLIN IMMUN, V112, P1009, DOI 10.1016/S0091-6749(03)02006-2; Asero R, 2001, INT ARCH ALLERGY IMM, V124, P67, DOI 10.1159/000053671; Asero R, 2001, ANN ALLERG ASTHMA IM, V87, P65, DOI 10.1016/S1081-1206(10)62325-3; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Ballmer-Weber BK, 2002, ALLERGY, V57, P873, DOI 10.1034/j.1398-9995.2002.23541.x; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; Budde IK, 2001, INT ARCH ALLERGY IMM, V126, P277, DOI 10.1159/000049524; Duffort OA, 2002, J AGR FOOD CHEM, V50, P7738, DOI 10.1021/jf0258398; *FAO WHO CONS, 2001, EV ALL GEN MOD FOODS; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Garcia-Casado G, 2001, J ALLERGY CLIN IMMUN, V108, P647, DOI 10.1067/mai.2001.118793; GRUBER P, 2004, IN PRESS J AGR FOOD; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Kaneko R, 2001, BIOSCI BIOTECH BIOCH, V65, P409, DOI 10.1271/bbb.65.409; Lindorff-Larsen K, 2001, FEBS LETT, V488, P145, DOI 10.1016/S0014-5793(00)02424-8; Murtagh GJ, 2003, CLIN EXP ALLERGY, V33, P1147, DOI 10.1046/j.1365-2222.2003.01736.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pastorello EA, 2003, J ALLERGY CLIN IMMUN, V112, P775, DOI 10.1016/S0091-6749(03)01942-0; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; van Ree R, 2002, BIOCHEM SOC T, V30, P910, DOI 10.1042/BST0300910; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Vieths S, 1999, EUR FOOD RES TECHNOL, V209, P379, DOI 10.1007/s002170050513	32	142	146	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					900	907		10.1016/j.jaci.2004.06.017	http://dx.doi.org/10.1016/j.jaci.2004.06.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480332				2022-12-18	WOS:000224439100026
J	Rueff, F; Wenderoth, A; Przybilla, B				Rueff, F; Wenderoth, A; Przybilla, B			Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hymenoptera venom allergy; venom immunotherapy; sting challenge; treatment failure; venom dose	YELLOW JACKET VENOM; ANAPHYLACTIC REACTIONS; DIAGNOSIS; WASP; TRYPTASE	Background: Up to 20% of patients allergic to Hymenoptera venom are not protected by conventional venom immunotherapy (VIT) with 100 mug of any single venom. Objective: We sought to evaluate the efficacy of an increased venom dose in patients allergic to Hymenoptera venom still reacting systemically to a sting challenge despite immunotherapy with 100 mug of venom every 4 weeks. Methods: In this retrospective study patients were included who still had reacted systemically to a sting challenge with a living bee or wasp despite VIT with a maintenance dose of 100 mug every 4 weeks. The maintenance dose was increased to 150 or 200 mug every 4 weeks, and a second sting challenge was performed. If a patient reacted again, the dose was further increased. Baseline mast-cell tryptase levels were assessed by using a fluoroenzyme immunoassay in stored patient sera. Results: While receiving a maintenance dose of 100 mug of venom every 4 weeks for 7 to 38 months, 18 patients reacted systemically to a bee sting and 22 reacted to a wasp sting. After an increase of the maintenance dose to 150 mug, 2 of 4 patients allergic to bee venom (BV) and 6 of 6 patients allergic to yellow jacket venom (YJV) no longer reacted systemically to the sting challenge. The respective rates of full protection were 13 of 14 and 15 of 16 in patients with an increase of the maintenance dose to 200 mug from the start. Of those 4 individuals not protected by the first dose increase, one patient allergic to BV (prior dose of 150 mug) and one patient allergic to YJV (prior dose of 200 mug) did not react systemically to a further sting challenge while receiving 200 mug of BV or 250 mug of YJV, respectively. One patient allergic to BV who had a systemic reaction to the sting challenge while receiving 150 mug was not protected after a dose increase to 200 mug; she later received a dose of 400 mug of BV, and no further sting challenge was performed. The patient allergic to BV who still reacted systemically after a first dose increase to 200 mug was a female patient with urticaria pigmentosa. She had repeated systemic adverse reactions to further BV immunotherapy, necessitating discontinuation of the treatment; however, she tolerated well VIT with 200 mug of YJV. In all other patients, no unusual adverse reactions to the increased venom doses were observed. Baseline serum tryptase levels were elevated: above 13.5 mug/L (95th percentile in normal subjects) in 9 (28.1%) of 32 patients. Conclusions: The majority of patients allergic to Hymenoptera venom who still reacted systemically to a sting challenge despite VIT with a dose of 1001 mug every 4 weeks can be fully protected by an increased maintenance dose. This dose increase is well tolerated by most patients. The rather high proportion of patients with elevated baseline serum tryptase levels necessitates further investigation of a possible association between mastocytosis and treatment failure of conventionally dosed VIT.	Univ Munich, Klin & Poliklin Dermatol & Allergol, D-80337 Munich, Germany	University of Munich	Rueff, F (corresponding author), Univ Munich, Klin & Poliklin Dermatol & Allergol, Frauenlobstr 9-11, D-80337 Munich, Germany.							Biedermann T, 1999, BRIT J DERMATOL, V141, P1110, DOI 10.1046/j.1365-2133.1999.03214.x; BOUSQUET J, 1988, ANN ALLERGY, V61, P63; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; FINDLAY SR, 1977, J ALLERGY CLIN IMMUN, V60, P230, DOI 10.1016/0091-6749(77)90135-X; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GRANT JA, 1983, J ALLERGY CLIN IMMUN, V72, P399, DOI 10.1016/0091-6749(83)90506-7; KORS JW, 1993, J INTERN MED, V233, P255, DOI 10.1111/j.1365-2796.1993.tb00984.x; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; MOSBECH H, 1983, ALLERGY, V38, P195, DOI 10.1111/j.1398-9995.1983.tb01606.x; MOSBECH H, 1986, ALLERGY, V41, P95, DOI 10.1111/j.1398-9995.1986.tb00284.x; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller UR., 1990, INSECT STING ALLERGY; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; PRICE LA, 1987, J ALLERGY CLIN IMMUN, V79, P407, DOI 10.1016/0091-6749(87)90162-X; PRZYBILLA B, 1987, DEUT MED WOCHENSCHR, V112, P416, DOI 10.1055/s-2008-1068068; PRZYBILLA B, 1986, ALLERGOLOGIE, V9, pS2; PRZYBILLA B, 1991, NEW TRENDS ALLERGY, V3, P335; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; RING J, 1977, LANCET, V1, P466; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0	28	142	146	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1027	1032		10.1067/mai.2001.119154	http://dx.doi.org/10.1067/mai.2001.119154			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742283				2022-12-18	WOS:000172938400021
J	Ying, S; Humbert, M; Meng, Q; Pfister, R; Menz, G; Gould, HJ; Kay, AB; Durham, SR				Ying, S; Humbert, M; Meng, Q; Pfister, R; Menz, G; Gould, HJ; Kay, AB; Durham, SR			Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucose in atonic and nonatopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic asthma; nonatopic asthma; local IgE; IL-4	ALLERGEN-INDUCED RHINITIS; INFLAMMATORY CELL NUMBER; MESSENGER-RNA; MAST-CELLS; NASAL-MUCOSA; IN-VIVO; AIRWAY INFLAMMATION; INTRINSIC ASTHMA; LYMPHOCYTES-T; ATOPIC ASTHMA	Background: The demonstration of epsilon germline gene (C epsilon) transcripts and mature mRNA for the epsilon heavy chain gene (I epsilon) in the nasal mucosa suggested that IgE synthesis may occur in allergic rhinitis. Objective: In view of our previous demonstration of increases in IL-4 mRNA(+) cells in asthmatic subjects, we assessed whether local IgE synthesis may also be a feature of bronchial asthma. Methods: Fiberoptic bronchoscopic mucosa biopsy specimens were obtained from 9 atopic asthmatic subjects and 10 nonatopic normal (intrinsic) control subjects. To control for atopy, we also studied 9 nonatopic asthmatic subjects and 10 atopic nonasthmatic control subjects. Tissue was processed for immunohistochemistry for B cells (CD20) and in situ hybridization for I epsilon and C epsilon RNA(+) cells and IL-4 mRNA(+) cells. Results: B-cell numbers in the bronchial mucosa were similar for asthmatic subjects compared with control subjects, whereas significantly higher numbers of I epsilon RNA(+) (P =.02 and P =.04, respectively), C epsilon RNA(+) (P =.01 and P =.03, respectively), and IL-4 mRNA(+) (P =.001 and P =.001, respectively) cells were observed in atopic asthmatic subjects and nonatopic asthmatic subjects, respectively, but not in atopic control subjects compared with nonatopic control subjects. In asthmatic subjects there H ere significant correlations between I epsilon RNA(+) tells (r = 0.53, P =.02) and CE RNA+ cells (r = 0.48, P = .05) when compared with the number of IL-4 mRNA(+) cells. Conclusion: Increases in I epsilon and C epsilon RNA(+) cells, but not B-cell numbers, in the bronchial mucosa provide evidence for local IgE synthesis in both atopic and nonatopic asthma. These changes appear to relate to asthma rather than atopy per se and, at least in part, may be under the regulation of IL-4.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England; Kings Coll London, Randall Inst, London WC2R 2LS, England; Hochgebirgsklin, Davos Wolgang, Switzerland; Kings Coll London, Randall Inst, London WC2R 2LS, England	Imperial College London; University of London; King's College London; University of London; King's College London	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.			Gould, Hannah/0000-0003-0411-688X; Humbert, Marc/0000-0003-0703-2892				AGRESTI A, 1997, MOL MECH IGE REGULAT, P179; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Ghaffar O, 1998, AM J RESP CELL MOL, V18, P706, DOI 10.1165/ajrcmb.18.5.3030; GILLON J, 1981, IMMUNOL TODAY, V2, P80, DOI 10.1016/0167-5699(81)90035-9; GODARD P, 1997, CLIN ASTHMA REV, V1, P19; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HUGGINS KG, 1975, LANCET, V2, P618; Humbert M, 1996, THORAX, V51, P664, DOI 10.1136/thx.51.7.664; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; KENTEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P6661, DOI 10.1073/pnas.79.21.6661; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Richmond I, 1996, AM J RESP CRIT CARE, V153, P899, DOI 10.1164/ajrccm.153.3.8630570; SENSI LG, 1994, CLIN EXP ALLERGY, V24, P377, DOI 10.1111/j.1365-2222.1994.tb00250.x; Sont JK, 1997, EUR RESPIR J, V10, P2602, DOI 10.1183/09031936.97.10112602; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; WUETHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149; YING S, 1994, IMMUNOLOGY, V82, P200	41	142	146	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					686	692		10.1067/mai.2001.114339	http://dx.doi.org/10.1067/mai.2001.114339			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295659				2022-12-18	WOS:000168190100022
J	Leonard, WJ; Lin, JX				Leonard, WJ; Lin, JX			Cytokine receptor signaling pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						cytokine; cytokine receptor; IL-2; STAT proteins; Jak kinases; XSCID	SEVERE COMBINED IMMUNODEFICIENCY; HUMAN INTERLEUKIN-2 RECEPTOR; DEFECTIVE LYMPHOID DEVELOPMENT; PROTEIN-TYROSINE-PHOSPHATASE; MICE LACKING JAK3; T-CELL LINE; IL-2 RECEPTOR; GAMMA-CHAIN; BETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE	Cytokines represent a diverse group of molecules that transmit intercellular signals. These signals may either be autocrine (where the same cell both produces the cytokine and responds to it) or paracrine (where the cytokine is made by one cell and acts on another). Both these situations can occur simultaneously. Cytokines use multiple signaling pathways. This review will focus on signaling by type I cytokines and in particular on signaling by the IL-2 family of cytokines, as an illustrative example. The major signaling pathway that mill be discussed is the Jak-STAT pathway, although other pathways will also be reviewd. The Jak-STAT pathway is a very rapid cytosol-to-nuclear signaling pathway that underscores how quickly extra-cellular signals ran be transmitted to the nucleus. Aspects related to cytokine redundancy, pleiotropy, and specificity will be discussed.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252, Bethesda, MD 20892 USA.		Leonard, Warren/AAA-1397-2022					Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Akaishi H, 1998, INT IMMUNOL, V10, P1747, DOI 10.1093/intimm/10.11.1747; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; COHEN S, 1974, CELL IMMUNOL, V12, P150, DOI 10.1016/0008-8749(74)90066-5; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVIES DR, 1995, FASEB J, V9, P50, DOI 10.1096/fasebj.9.1.7821759; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; John S, 1999, MOL CELL BIOL, V19, P1910; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kagami S, 2000, BLOOD, V95, P1370, DOI 10.1182/blood.V95.4.1370.004k29_1370_1377; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Kovanen PE, 1999, CURR BIOL, V9, pR899, DOI 10.1016/S0960-9822(00)80079-2; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard W.J., 1999, FUNDAMENTAL IMMUNOLO, Vfourth, P741; Leonard WJ, 1996, ANNU REV MED, V47, P229; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lischke A, 1998, J BIOL CHEM, V273, P31222, DOI 10.1074/jbc.273.47.31222; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOWIN B, 1994, P NATL ACAD SCI USA, V91, P11571, DOI 10.1073/pnas.91.24.11571; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; MERIDA I, 1991, J IMMUNOL, V147, P2202; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Puel A, 2000, IMMUNOL ALLERGY CLIN, V20, P51, DOI 10.1016/S0889-8561(05)70133-8; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; *STAT, 1996, CELL, V84, P331; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Turkson J, 1999, MOL CELL BIOL, V19, P7519; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Yu CR, 1999, J IMMUNOL, V162, P2785; Zhang J, 1999, J EXP MED, V190, P1297, DOI 10.1084/jem.190.9.1297; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	112	142	169	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					877	888		10.1067/mai.2000.106899	http://dx.doi.org/10.1067/mai.2000.106899			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808165				2022-12-18	WOS:000087185000003
J	Nakamura, Y; Ghaffar, O; Olivenstein, R; Taha, RA; Soussi-Gounni, A; Zhang, DH; Ray, A; Hamid, Q				Nakamura, Y; Ghaffar, O; Olivenstein, R; Taha, RA; Soussi-Gounni, A; Zhang, DH; Ray, A; Hamid, Q			Gene expression of the GATA-3 transcription factor is increased in atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; GATA-3; T lymphocytes; IL-5; eosinophils	NF-KAPPA-B; COLONY-STIMULATING FACTOR; ALLERGEN-INDUCED RHINITIS; T-CELL CLONE; MESSENGER-RNA; GLUCOCORTICOID RECEPTOR; AIRWAYS HYPERREACTIVITY; HUMAN INTERLEUKIN-5; EOSINOPHIL FUNCTION; LUNG DAMAGE	Background: High expression of IL-5 by T cells in the airways of asthmatic individuals is believed to play a fundamental role in the eosinophilia associated with this disease. Recently, the transcription factor GATA-3 was shown to be critical for IL-5 gene expression in T-H2 cells in vitro. Objective: Our aim was to examine the expression of GATA-3 mRNA and its colocalization within the airways of asthmatic and nonasthmatic individuals. Methods: We investigated the association between GATA-3 gene expression, airway inflammatory cells, and IL-5 gene expression in bronchoalveolar lavage fluid and bronchial biopsy specimens from atopic asthmatic subjects (n = 10) and normal control subjects (n = 10). Results: We report that GATA-3 mRNA expression is significantly increased in the airways of asthmatic subjects compared with those of normal control subjects (P < .001). Numbers of cells expressing GATA-3 transcripts correlated significantly with reduced airway caliber (P < .05) and airways hyperresponsiveness (P < .05) in asthmatic subjects. Colocalization studies showed that the majority (approximately 60% to 90%) of GATA-3 mRNA(+) cells in asthmatic airways were CD3(+) T cells, with smaller contributions from major basic protein(+) eosinophils and tryptase(+) mast cells. The density of GATA-3 mRNA+ cells correlated significantly with the numbers of cells expressing IL-5 mRNA (P < .001, r = 0.879 for bronchoalveolar lavage fluid; P < .05, r = 0.721 for biopsy specimens). Furthermore, double in situ hybridization demonstrated that approximately 76% of GATA-3 mRNA(+) cells coexpressed IL-5 mRNA and that 91% of IL-5 mRNA(+) cells coexpressed GATA-3 mRNA. Conclusion: The results of this study provide the first evidence of increased GATA-3 gene expression in association with IL-5 mRNA+ cells in asthmatic airways. These findings support a causal association between augmented GATA-3 expression and dysregulated IL-5 expression in atopic asthma.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Dept Med, Montreal, PQ H2X 2P2, Canada; McGill Univ, Dept Pathol, Montreal, PQ H2X 2P2, Canada; Yale Univ, Sch Med, Dept Med, Pulm & Crit Care Sect, New Haven, CT USA	McGill University; McGill University; McGill University; Yale University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Gounni, Abdelilah Soussi/AAH-3456-2020; Nakamura, Yutaka/AAE-1546-2019	Nakamura, Yutaka/0000-0001-8717-1475; Gounni, Abdelilah/0000-0003-1265-6560; Soussi Gounni, Abdelilah/0000-0002-7282-0388				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Bottomly K, 1989, Semin Immunol, V1, P21; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CALHOUN WJ, 1991, ANN NY ACAD SCI, V629, P62; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17, DOI 10.1165/ajrcmb.17.1.2696; GIAID A, 1989, HISTOCHEMISTRY, V93, P191, DOI 10.1007/BF00315974; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; Lee HJ, 1998, J IMMUNOL, V160, P2343; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; Taha RA, 1997, AM J RESP CRIT CARE, V155, P1135, DOI 10.1164/ajrccm.155.3.9116999; Umland SP, 1998, AM J RESP CELL MOL, V18, P631, DOI 10.1165/ajrcmb.18.5.3046; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; ZON LI, 1993, BLOOD, V81, P3234	47	142	167	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				215	222		10.1016/S0091-6749(99)70493-8	http://dx.doi.org/10.1016/S0091-6749(99)70493-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949310				2022-12-18	WOS:000078630100006
J	Gall, H; Kaufmann, R; Kalveram, CM				Gall, H; Kaufmann, R; Kalveram, CM			Adverse reactions to local anesthetics: Analysis of 197 cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						local anesthetics; adverse drug reactions; hypersensitivity	HISTORY; ALLERGY; INTOLERANCE; SENSITIVITY; PRILOCAINE; CHALLENGE	Background: Adverse drug reactions to local anesthetics are frequently reported. However, little is known about the underlying mechanisms. Therefore we investigated 177 patients a history of 197 events after application of these drugs. Methods: The diagnostic approach included prick and intracutaneous tests, provocative challenge tests with causative and unrelated local anesthetics, and in selected cases, radioimmunoassays to detect specific IgE. In addition, tests were performed with preservatives, including sodium metabisulfite and parahydroxybenzoic acid ester. Results: Results of prick and intracutaneous tests with local anesthetics were all negative. Only three patients reacted after subcutaneous challenge with the causative drug (local anesthetics of the amide type) Although one patient showed a delayed-type response to mepivacaine, two patients had immediate-type reactions to articaine and lidocaine. However,; in both cases no specific IgE could be detected. In five patients with positive skill test reactions to preservatives, challenge test results remained negative. Conclusions: Two immediate-type reactions were not IgE-mediated. In only one of 197 reported adverse reactions were we able to prove delayed-type allergic response. Therefore true allergic reactions caused by local anesthetics are extremely rare.	UNIV ULM, DEPT DERMATOL, D-89081 ULM, GERMANY; UNIV FRANKFURT, DEPT DERMATOL, FRANKFURT, GERMANY; LAB KALVERAM, MUNSTER, GERMANY	Ulm University; Goethe University Frankfurt								CAWSON RA, 1983, BRIT DENT J, V154, P253, DOI 10.1038/sj.bdj.4805046; CHANDLER MJ, 1987, J ALLERGY CLIN IMMUN, V79, P883, DOI 10.1016/0091-6749(87)90236-3; CURLEY RK, 1986, ARCH DERMATOL, V122, P924, DOI 10.1001/archderm.122.8.924; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; DOOMSGOOSSENS A, 1989, CONTACT DERMATITIS, V20, P124, DOI 10.1111/j.1600-0536.1989.tb03120.x; Escolano F, 1990, Rev Esp Anestesiol Reanim, V37, P172; FISHER MM, 1984, ANAESTH INTENS CARE, V12, P325, DOI 10.1177/0310057X8401200406; FULCHER DA, 1990, ASIAN PAC J ALLERGY, V8, P133; GALL H, 1992, ALLERGOLOGIE, V15, P89; Huwyler T, 1990, Schweiz Monatsschr Zahnmed, V100, P751; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P339, DOI 10.1016/0091-6749(78)90057-X; KLEIN CE, 1991, CONTACT DERMATITIS, V25, P45, DOI 10.1111/j.1600-0536.1991.tb01772.x; LANE CG, 1951, JAMA-J AM MED ASSOC, V146, P717, DOI 10.1001/jama.1951.03670080025007; Le Sellin J, 1986, Allerg Immunol (Paris), V18, P35; MCCAUGHEY W, 1992, DRUG SAFETY, V7, P178, DOI 10.2165/00002018-199207030-00003; RING J, 1981, ALLERGOLOGIE, V4, P174; RUZICKA T, 1987, J AM ACAD DERMATOL, V16, P1202, DOI 10.1016/S0190-9622(87)70158-3; SCHATZ M, 1984, J ALLERGY CLIN IMMUN, V74, P606, DOI 10.1016/0091-6749(84)90114-3; SCHWARTZ HJ, 1985, J ALLERGY CLIN IMMUN, V75, P525, DOI 10.1016/S0091-6749(85)80027-0; SIMON RA, 1984, J ALLERGY CLIN IMMUN, V74, P623, DOI 10.1016/0091-6749(84)90116-7	20	142	145	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					933	937		10.1016/S0091-6749(96)80067-4	http://dx.doi.org/10.1016/S0091-6749(96)80067-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655888				2022-12-18	WOS:A1996UG08600007
J	TOMASSINI, M; TSICOPOULOS, A; TAI, PC; GRUART, V; TONNEL, AB; PRIN, L; CAPRON, A; CAPRON, M				TOMASSINI, M; TSICOPOULOS, A; TAI, PC; GRUART, V; TONNEL, AB; PRIN, L; CAPRON, A; CAPRON, M			RELEASE OF GRANULE PROTEINS BY EOSINOPHILS FROM ALLERGIC AND NONALLERGIC PATIENTS WITH EOSINOPHILIA ON IMMUNOGLOBULIN-DEPENDENT ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHILS; FC RECEPTORS; IMMUNOGLOBULIN ISOTYPES; EOSINOPHIL PEROXIDASE; EOSINOPHIL CATIONIC PROTEIN	CATIONIC PROTEIN; BLOOD EOSINOPHILS; BRONCHIAL-ASTHMA; CELL-DENSITY; MONOCLONAL-ANTIBODIES; HYPODENSE EOSINOPHILS; SCHISTOSOMA-MANSONI; EFFECTOR FUNCTION; IGE ANTIBODIES; PEROXIDASE EPO	The release of eosinophil peroxidase (EPO) and eosinophil cationic protein (ECP) was evaluated after incubation of eosinophils (EOSs) from allergic subjects with the specific allergen or with anti-IgE monoclonal antibodies (MAbs). High levels of EPO could be released after addition of the specific allergen (and not unrelated ones) or anti-IgE MAb. Moreover, EPO release with the two stimuli was significantly correlated both in allergic and in nonallergic patients. In the same supernatants, another granule protein, ECP, could not be detected, suggesting a lack of correlation between EPO and ECP release after IgE-dependent stimulation. However, when EOSs with surface-IgA antibodies were incubated with anti-IgA MAb, both EPO and ECP were released. In contrast, incubation of EOSs with anti-IgG MAb induced mainly the release of ECP and not EPO. These results indicate that pharmacologically active mediators can be released by EOSs from allergic and nonallergic patients on immunoglobulin-dependent activation. The results also confirm the hypothesis of a selective release of the various granule proteins and raise the question of transduction signals delivered by the three Fc receptors (Fc-epsilon-R, FC-alpha-R, and FC-gamma-R) present on human EOSs.	INST PASTEUR, CTR IMMUNOL & BIOL PARASITAIRE,CNRS,U624,INSERM, U167,UNITE MIXTE, F-59019 LILLE, FRANCE; ST GEORGE HOSP, SCH MED, CARDIOVASC IMMUNOL RES GRP, LONDON, ENGLAND	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; St Georges University London			Tsicopoulos, Anne/C-2260-2019; Capron, monique/Z-2207-2019	Tsicopoulos, Anne/0000-0002-1579-2763; Capron, monique/0000-0001-5625-5158				ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CAPRON M, 1985, J IMMUNOL, V134, P3013; CAPRON M, 1987, J IMMUNOL, V139, P2059; CAPRON M, 1989, CLIN EXP ALLERGY, V19, P3; CAPRON M, 1988, CR ACAD SCI III-VIE, V307, P397; CAPRON M, 1989, INT ARCH ALLER A IMM, V88, P54, DOI 10.1159/000234748; CAPRON M, 1984, J IMMUNOL, V132, P462; CAPRON M, 1989, CHEM IMMUNOL, V47, P128; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; FISCHER E, 1986, CELL IMMUNOL, V97, P297, DOI 10.1016/0008-8749(86)90400-4; FRICK WE, 1988, J ALLERGY CLIN IMMUN, V82, P119, DOI 10.1016/0091-6749(88)90061-9; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; FUKUDA T, 1989, J ALLERGY CLIN IMMUN, V83, P369, DOI 10.1016/0091-6749(89)90120-6; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GRUART V, 1989, J IMMUNOL, V142, P4416; HALLGREN R, 1989, AM J MED, V86, P56, DOI 10.1016/0002-9343(89)90230-1; HOFFMAN RA, 1981, INT J IMMUNOPHARMACO, V3, P249, DOI 10.1016/0192-0561(81)90018-7; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KAUFFMAN HF, 1987, J ALLERGY CLIN IMMUN, V79, P611, DOI 10.1016/S0091-6749(87)80157-4; KHALIFE J, 1985, J IMMUNOL, V134, P1968; KHALIFE J, 1986, J IMMUNOL, V137, P1659; MOQBEL R, 1990, IMMUNOLOGY, V69, P435; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; RAMESH KS, 1987, BIOCHIM BIOPHYS ACTA, V923, P241, DOI 10.1016/0304-4165(87)90009-2; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SPRY CJF, 1988, EOSINOPHILS COMPREHE, P131; TAI PC, 1986, CLIN EXP IMMUNOL, V63, P728; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; VADAS MA, 1979, J IMMUNOL, V122, P1228; VANDERVORST E, 1988, INT ARCH ALLER A IMM, V87, P281, DOI 10.1159/000234686; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WHITEHEAD TP, 1983, NATURE, V305, P158, DOI 10.1038/305158a0; WINQVIST I, 1984, IMMUNOLOGY, V51, P1; WINQVIST I, 1982, IMMUNOLOGY, V47, P531	48	142	142	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				365	375		10.1016/0091-6749(91)90099-A	http://dx.doi.org/10.1016/0091-6749(91)90099-A			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890265	Bronze			2022-12-18	WOS:A1991GG12600031
J	BORK, K; WITZKE, G				BORK, K; WITZKE, G			LONG-TERM PROPHYLAXIS WITH C1-INHIBITOR (C1 INH) CONCENTRATE IN PATIENTS WITH RECURRENT ANGIOEDEMA CAUSED BY HEREDITARY AND ACQUIRED C1-INHIBITOR DEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BORK, K (corresponding author), UNIV MAINZ,DEPT DERMATOL,LANGENBECKSTR 1,D-6500 MAINZ,FED REP GER.		Bork, Konrad/AAE-4985-2022	Bork, Konrad/0000-0002-6084-4577				AGOSTONI A, 1980, ANN ALLERGY, V44, P299; ALSENZ J, 1987, J IMMUNOL METHODS, V96, P107, DOI 10.1016/0022-1759(87)90373-5; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; BERGAMASCHINI L, 1983, ALLERGY, V38, P81; BORK K, 1987, DEUT MED WOCHENSCHR, V112, P503, DOI 10.1055/s-2008-1068084; BORK K, 1984, DEUT MED WOCHENSCHR, V35, P1331; Brackertz D, 1975, CLIN ALLERGY, V1, P89; CURD JG, 1983, MOL IMMUNOL, V19, P1365; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1985, J CLIN INVEST, V75, P124, DOI 10.1172/JCI111664; DONALDSON VH, 1969, J CLIN INVEST, V48, P642, DOI 10.1172/JCI106022; DONALDSON VH, 1977, T ASSOC AM PHYSICIAN, V40, P174; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FUHGE P, 1986, BEHRING I MITT, V79, P164; GADEK JE, 1980, NEW ENGL J MED, V6, P542; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; HEINZ HP, 1983, LAB MED, V9, P320; Hilfenhaus J., 1988, Behring Institut Mitteilungen, V82, P82; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; KODAMA J, 1984, BLUT, V49, P405, DOI 10.1007/BF00319889; LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1; Mauler R, 1987, Dev Biol Stand, V67, P337; MELAMED J, 1986, J ALLERGY CLIN IMMUN, V77, P322; RAPP HJ, 1970, MOL BASIS COMPLEMENT, P97; RONNEBERGER H, 1986, TRENDS PHARMACOL SCI, V7, P130, DOI 10.1016/0165-6147(86)90286-5; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P640, DOI 10.1016/0091-6749(85)90087-9	28	142	146	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					677	682		10.1016/0091-6749(89)90082-1	http://dx.doi.org/10.1016/0091-6749(89)90082-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2926086				2022-12-18	WOS:A1989T859600016
J	PEARCE, FL; BEFUS, AD; BIENENSTOCK, J				PEARCE, FL; BEFUS, AD; BIENENSTOCK, J			MUCOSAL MAST-CELLS .3. EFFECT OF QUERCETIN AND OTHER FLAVONOIDS ON ANTIGEN-INDUCED HISTAMINE-SECRETION FROM RAT INTESTINAL MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT PATHOL,HOST RESISTANCE PROGRAMME,HAMILTON L8N 3Z5,ONTARIO,CANADA; UNIV LONDON UNIV COLL,DEPT CHEM,LONDON WC1E 6BT,ENGLAND	McMaster University; University of London; University College London			Befus, Dean/C-5561-2009	Befus, Dean/0000-0002-1611-2897				ASSEM ESK, 1973, BRIT J PHARMACOL, V48, P337; BARRETT KE, 1982, AGENTS ACTIONS, V12, P186, DOI 10.1007/BF01965141; BEFUS AD, 1979, IMMUNOLOGY, V38, P95; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BENNETT JP, 1981, ARZNEIMITTEL-FORSCH, V31-1, P433; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; CHURCH MK, 1981, BRIT J PHARMACOL, V74, pP979; ENNIS M, 1981, NATURE, V289, P186, DOI 10.1038/289186a0; ENNIS M, 1980, EUR J PHARMACOL, V66, P339, DOI 10.1016/0014-2999(80)90466-5; FEWTRELL CMS, 1977, BIOCHIM BIOPHYS ACTA, V469, P52, DOI 10.1016/0005-2736(77)90325-X; FOREMAN JC, 1977, BRIT J PHARMACOL, V59, pP473; GARLAND LG, 1978, HDB EXPT PHARM, V50, P467; KAMIMIERCZAK W, 1978, PROG ALLERGY, V24, P295; LEWIS RA, 1975, J IMMUNOL, V114, P87; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MIDDLETON E, 1982, BIOCHEM PHARMACOL, V31, P1449, DOI 10.1016/0006-2952(82)90044-2; MIDDLETON E, 1981, J IMMUNOL, V127, P546; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PEARCE FL, 1977, AGENTS ACTIONS, V7, P45, DOI 10.1007/BF01964880; PEARCE FL, 1983, TRENDS PHARMACOL SCI, V4, P165, DOI 10.1016/0165-6147(83)90345-0; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PEARCE FL, 1982, KLIN WOCHESCHR, V60, P694; PEARCE FL, BIOCH PHARM, V31, P2247; Selye H, 1965, MAST CELLS; SULLIVAN TJ, 1976, AM J PATHOL, V85, P437; WHITE JR, 1982, IMMUNOLOGY, V46, P361	26	142	152	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					819	823		10.1016/0091-6749(84)90453-6	http://dx.doi.org/10.1016/0091-6749(84)90453-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6202731				2022-12-18	WOS:A1984SV82900009
J	BORUM, P				BORUM, P			NASAL METHACHOLINE CHALLENGE - TEST FOR THE MEASUREMENT OF NASAL REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BORUM, P (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT EAR NOSE & THROAT,OTOPATHOL LAB,DK-2100 COPENHAGEN O,DENMARK.							ANGGARD A, 1974, ACTA OTO-LARYNGOL, V78, P98, DOI 10.3109/00016487409126332; ANGGARD A, 1974, ACTA OTO-LARYNGOL, V77, P131, DOI 10.3109/00016487409124608; BORUM P, 1978, Rhinology (Utrecht), V16, P225; BRYAN W T, 1959, Trans Am Acad Ophthalmol Otolaryngol, V63, P613; CAUNA N, 1972, J NEUROCYTOL, V1, P49, DOI 10.1007/BF01098645; ECCLES R, 1973, J PHYSIOL-LONDON, V230, P213, DOI 10.1113/jphysiol.1973.sp010184; GIRARD JP, 1974, REV FR ALLERGOL, V14, P175, DOI 10.1016/S0335-7457(74)80037-7; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; Mygind N, 1978, NASAL ALLERGY; MYGIND N, 1978, RHINOLOGY, V16, P1; OKUDA M, 1977, ORL DIGEST, V39, P22; ROSE B, 1971, IMMUNOLOGICAL DISEAS, P859; SPEKTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308; Starr I, 1933, AM J MED SCI, V186, P313, DOI 10.1097/00000441-193309000-00001; STURGESS J, 1972, CLIN SCI, V43, P533, DOI 10.1042/cs0430533; TOS M, 1977, ACTA OTO-LARYNGOL, V83, P498, DOI 10.3109/00016487709128878; 1967, MANUAL PHYSICIANS	18	142	142	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					253	257		10.1016/0091-6749(79)90109-X	http://dx.doi.org/10.1016/0091-6749(79)90109-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	429703				2022-12-18	WOS:A1979GR84200005
J	JENNE, JW; CHICK, TW; STRICKLAND, RD; WALL, FJ				JENNE, JW; CHICK, TW; STRICKLAND, RD; WALL, FJ			SUBSENSITIVITY OF BETA RESPONSES DURING THERAPY WITH A LONG-ACTING BETA-2 PREPARATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,PULM DIS SECT,ALBUQUERQUE,NM 87108; UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87106	University of New Mexico								AVNER BP, IN PRESS; Bollinger A., 1936, MED J AUST, V2, P818; CONNOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; HURST A, 1973, ANN ALLERGY, V31, P460; JENNE JW, TO BE PUBLISHED; KAHN CR, 1973, J BIOL CHEM, V248, P244; KEBABIAN JW, 1975, P NATL ACAD SCI USA, V72, P3735, DOI 10.1073/pnas.72.9.3735; Kendall M. G., 1962, RANK CORRELATION MET; LIN CL, TO BE PUBLISHED; MICKEY J, 1975, J BIOL CHEM, V250, P5727; MORRIS HG, 1976, J ALLERGY CLIN IMMUN, V57, P264; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V53, P98; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P1945, DOI 10.1073/pnas.72.5.1945; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; NELSON HS, IN PRESS; OSER BL, 1965, HAWKS PHYSL CHEM, P1052; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER SS, 1968, LANCET, V2, P426; RANDOLPH TG, 1944, AM J CLIN PATHOL, V8, P48; SCHACK JA, 1949, J PHARMACOL EXP THER, V97, P283; SPAULDING AS, 1975, J ALLERGY CLIN IMMUN, V55, P97; STEINER AL, 1969, P NATL ACAD SCI USA, V64, P367, DOI 10.1073/pnas.64.1.367; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; TROUT DL, 1960, J LIPID RES, V1, P199; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1	25	142	142	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					383	390		10.1016/0091-6749(77)90023-9	http://dx.doi.org/10.1016/0091-6749(77)90023-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	192771	Bronze			2022-12-18	WOS:A1977DF21500009
J	SPECTOR, SL; KATZ, FH; FARR, RS				SPECTOR, SL; KATZ, FH; FARR, RS			TROLEANDOMYCIN - EFFECTIVENESS IN STEROID-DEPENDENT ASTHMA AND BRONCHITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT MED,SECT CLIN IMMUNOL ALLERGY & CHEST DIS,3800 E COLFAX AVE,DENVER,CO 80206; UNIV COLORADO,MED CTR,DENVER,CO	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BRONSKY EA, 1970, DOUBLE BLIND CROSSOV; CELMER WD, 1958, ANTIBIOTICS ANNUAL, P476; ELSHABOURY AH, 1973, BMJ-BRIT MED J, V2, P85, DOI 10.1136/bmj.2.5858.85; ENGEL MF, 1963, SOUTHERN MED J, V56, P1279, DOI 10.1097/00007611-196311000-00017; FOLTZ EL, 1959, ANTIBIOTIC THERAPY S, P39; FOX JL, 1961, PENN MED J, V64, P634; GILBERT FI, 1962, JAMA-J AM MED ASSOC, V182, P1048; ISENBERG H, 1959, ANTIBIOTICS ANNUAL 1, P284; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; JENKINS JS, 1967, BRIT MED J, V2, P205, DOI 10.1136/bmj.2.5546.205; KATZ FH, 1967, J CLIN INVEST, V46, P1768, DOI 10.1172/JCI105667; KATZ FH, 1968, ACTA ENDOCRINOL-COP, V58, P664, DOI 10.1530/acta.0.0580664; LEMING BH, 1959, ANTIBIOTICS ANN 1958, P418; MADDREY WC, 1973, ANN INTERN MED, V79, P1, DOI 10.7326/0003-4819-79-1-1; MOSS JD, 1972, AM REV RESPIR DIS, V106, P849, DOI 10.1164/arrd.1972.106.6.849; PETERSON RE, 1956, J CLIN INVEST, V35, P552, DOI 10.1172/JCI103308; ROBINSON MM, 1962, AM J MED SCI, V243, P502, DOI 10.1097/00000441-196204000-00012; ROSS S, 1968, PEDIATR CLIN N AM, V15, P119; SELENKE W, 1969, J ALLERGY, V43, P156; SHUBIN H, 1958, ANTIBIOTICS ANNUAL 1, P679; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WEINER ALFRED, 1962, JOUR NEW DRUGS, V2, P307, DOI 10.1177/009127006200200507; 1962, AM REV RESPIR DIS, V85, P762	25	142	143	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	6					367	379		10.1016/0091-6749(74)90027-X	http://dx.doi.org/10.1016/0091-6749(74)90027-X			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U9288					2022-12-18	WOS:A1974U928800005
J	Rubner, FJ; Jackson, DJ; Evans, MD; Gangnon, RE; Tisler, CJ; Pappas, TE; Gern, JE; Lemanske, RF				Rubner, Frederick J.; Jackson, Daniel J.; Evans, Michael D.; Gangnon, Ronald E.; Tisler, Christopher J.; Pappas, Tressa E.; Gern, James E.; Lemanske, Robert F., Jr.			Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; respiratory syncytial virus; allergic sensitization; asthma	RESPIRATORY-SYNCYTIAL-VIRUS; VIRAL-INFECTIONS; PERSISTENT ASTHMA; CHILDHOOD ASTHMA; 1ST YEAR; AGE 13; PATTERNS; INFANCY; BRONCHIOLITIS; ILLNESSES	Background: Early life rhinovirus (RV) wheezing illnesses and aeroallergen sensitization increase the risk of asthma at school age. Whether these remain risk factors for the persistence of asthma out to adolescence is not established. Objective: We sought to define the relationships among specific viral illnesses and the type and timing of aeroallergen sensitization with the persistence of asthma into adolescence. Methods: A total of 217 children were followed prospectively from birth to age 13 years. The etiology and timing of viral wheezing illnesses during the first 3 years of life were assessed along with patterns of allergen sensitization. The associations between viral wheezing illnesses, presence and pattern of aeroallergen sensitization, and asthma diagnosis at age 13 years were evaluated. Results: When adjusted for all viral etiologies, wheezing with RV (odds ratio = 3.3; 95% CI, 1.5-7.1), but not respiratory syncytial virus (odds ratio = 1.0; 95% CI, 0.4-2.3), was associated with asthma at age 13 years. Age of aeroallergen sensitization also influenced asthma risk; 65% of children sensitized by age 1 year had asthma at age 13 years, compared with 40% of children not sensitized at age 1 year but sensitized by age 5 years, and 17% of children not sensitized at age 5 years. Early life aeroallergen sensitization and RV wheezing had additive effects on asthma risk at adolescence. Conclusions: In a high-risk birth cohort, the persistence of asthma at age 13 years was most strongly associated with outpatient wheezing illnesses with RV and aeroallergen sensitization in early life.	[Rubner, Frederick J.; Jackson, Daniel J.; Tisler, Christopher J.; Pappas, Tressa E.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; [Rubner, Frederick J.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Evans, Michael D.; Gangnon, Ronald E.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA; [Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, DJ (corresponding author), 600 Highland Ave,K4-936 CSC, Madison, WI 53792 USA.	djj@medicine.wisc.edu		Gangnon, Ronald/0000-0003-2587-6714; Evans, Michael/0000-0001-7449-3993	National Institutes of Health, National Heart, Lung, and Blood Institute [PO1 HL70381]; National Center for Advancing Translational Sciences [UL1TR000427]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER	National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the National Institutes of Health, National Heart, Lung, and Blood Institute (grant no. PO1 HL70381) and the National Center for Advancing Translational Sciences (grant no. UL1TR000427).	[Anonymous], 2018, FLEXIBLE IMPUTATION; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jackson DJ, 2010, IMMUNOL ALLERGY CLIN, V30, P513, DOI 10.1016/j.iac.2010.08.004; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2004, J ALLERGY CLIN IMMUN, V114, P1023, DOI 10.1016/j.jaci.2004.08.031; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; O'Brian AL, 2012, J ALLERGY CLIN IMMUN, V129, P1162, DOI 10.1016/j.jaci.2011.11.046; Rubin DB, 2004, MULTIPLE IMPUTATION; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162	29	141	145	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					501	507		10.1016/j.jaci.2016.03.049	http://dx.doi.org/10.1016/j.jaci.2016.03.049			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27312820	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000397002400016
J	Zhang, Y; Yu, XM; Ichikawa, M; Lyons, JJ; Datta, S; Lamborn, IT; Jing, H; Kim, ES; Biancalana, M; Wolfe, LA; DiMaggio, T; Matthews, HF; Kranick, SM; Stone, KD; Holland, SM; Reich, DS; Hughes, JD; Mehmet, H; McElwee, J; Freeman, AF; Freeze, HH; Su, HC; Milner, JD				Zhang, Yu; Yu, Xiaomin; Ichikawa, Mie; Lyons, Jonathan J.; Datta, Shrimati; Lamborn, Ian T.; Jing, Huie; Kim, Emily S.; Biancalana, Matthew; Wolfe, Lynne A.; DiMaggio, Thomas; Matthews, Helen F.; Kranick, Sarah M.; Stone, Kelly D.; Holland, Steven M.; Reich, Daniel S.; Hughes, Jason D.; Mehmet, Huseyin; McElwee, Joshua; Freeman, Alexandra F.; Freeze, Hudson H.; Su, Helen C.; Milner, Joshua D.			Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; immune deficiency; hyper-IgE; neurocognitive impairment; phosphoglucomutase 3; glycosylation; allergy; autoimmunity	CONGENITAL DISORDERS; NUCLEOTIDE SUGARS; STAT3 MUTATIONS; O-GLCNACYLATION; DOCK8; HEALTHY	Background: Identifying genetic syndromes that lead to significant atopic disease can open new pathways for investigation and intervention in allergy. Objective: We sought to define a genetic syndrome of severe atopy, increased serum IgE levels, immune deficiency, autoimmunity, and motor and neurocognitive impairment. Methods: Eight patients from 2 families with similar syndromic features were studied. Thorough clinical evaluations, including brain magnetic resonance imaging and sensory evoked potentials, were performed. Peripheral lymphocyte flow cytometry, antibody responses, and T-cell cytokine production were measured. Whole-exome sequencing was performed to identify disease-causing mutations. Immunoblotting, quantitative RTPCR, enzymatic assays, nucleotide sugar, and sugar phosphate analyses, along with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry of glycans, were used to determine the molecular consequences of the mutations. Results: Marked atopy and autoimmunity were associated with increased T(H)2 and T(H)17 cytokine production by CD4(+) T cells. Bacterial and viral infection susceptibility were noted along with T-cell lymphopenia, particularly of CD8(+) T cells, and reduced memory B-cell numbers. Apparent brain hypomyelination resulted in markedly delayed evoked potentials and likely contributed to neurologic abnormalities. Disease segregated with novel autosomal recessive mutations in a single gene, phosphoglucomutase 3 (PGM3). Although PGM3 protein expression was variably diminished, impaired function was demonstrated by decreased enzyme activity and reduced uridine diphosphate-N-acetyl-D-glucosamine, along with decreased O- and N-linked protein glycosylation in patients' cells. These results define a new congenital disorder of glycosylation. Conclusions: Autosomal recessive hypomorphic PGM3 mutations underlie a disorder of severe atopy, immune deficiency, autoimmunity, intellectual disability, and hypomyelination.	[Zhang, Yu; Lamborn, Ian T.; Jing, Huie; Kim, Emily S.; DiMaggio, Thomas; Su, Helen C.] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; [Yu, Xiaomin; Lyons, Jonathan J.; Datta, Shrimati; Stone, Kelly D.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Biancalana, Matthew; Matthews, Helen F.] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; [Holland, Steven M.; Freeman, Alexandra F.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Ichikawa, Mie; Freeze, Hudson H.] Sanford Burnham Med Res Inst, La Jolla, CA USA; [Wolfe, Lynne A.] NHGRI, Undiagnosed Dis Program, Bethesda, MD 20892 USA; [Kranick, Sarah M.] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA; [Reich, Daniel S.] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA; [Hughes, Jason D.; Mehmet, Huseyin; McElwee, Joshua] Merck & Co Inc, Merck Res Labs, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Sanford Burnham Prebys Medical Discovery Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Merck & Company	Milner, JD (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10CRC,Rm 5W-3940,10 Ctr Dr, Bethesda, MD 20892 USA.	hsu@niaid.nih.gov; jdmilner@niaid.nih.gov	Su, Helen C/H-9541-2015; Reich, Daniel S./E-5701-2010	Su, Helen C/0000-0002-5582-9110; Reich, Daniel S./0000-0002-2628-4334; Lyons, Jonathan/0000-0002-2346-8189; Biancalana, Matthew/0000-0002-1078-1838; Freeze, Hudson/0000-0001-6316-0501	Intramural Research Programs of the National Institutes of Allergy and Infectious Diseases; National Human Genome Research Institute; National Institute of Neurological Diseases and Stroke; National Institutes of Health; Rocket Fund; R01DK55615; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001059, ZIAAI001192, ZIAAI000647, ZIAAI001098, ZIAAI001099, ZIAAI000646, ZIAAI001183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK099551, R01DK055615] Funding Source: NIH RePORTER	Intramural Research Programs of the National Institutes of Allergy and Infectious Diseases; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute of Neurological Diseases and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rocket Fund; R01DK55615; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the Intramural Research Programs of the National Institutes of Allergy and Infectious Diseases, the National Human Genome Research Institute, and the National Institute of Neurological Diseases and Stroke, all at the National Institutes of Health. H. H. F. and M. I. were supported by R01DK55615 and the Rocket Fund.	BUCKLEY RH, 1972, PEDIATRICS, V49, P59; DAVIS SD, 1966, LANCET, V1, P1013; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Foster Barbara, 2007, Curr Protoc Immunol, VChapter 6, DOI 10.1002/0471142735.im0624s78; Greig KT, 2007, MOL CELL BIOL, V27, P5849, DOI 10.1128/MCB.00802-07; HALLETT M, 1979, NEUROLOGY, V29, P1107, DOI 10.1212/WNL.29.8.1107; Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511; Hay BN, 2004, AM J MED GENET A, V125A, P145, DOI 10.1002/ajmg.a.20595; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Huck K, 2009, CLIN IMMUNOL, V131, P50, DOI 10.1016/j.clim.2008.11.008; Kranz C, 2007, AM J MED GENET A, V143A, P1371, DOI 10.1002/ajmg.a.31791; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Mariappa D, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002335; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Nakajima K, 2010, GLYCOBIOLOGY, V20, P865, DOI 10.1093/glycob/cwq044; Rabina J, 2001, GLYCOCONJUGATE J, V18, P799, DOI 10.1023/A:1021107602535; Renner ED, 2007, NEW ENGL J MED, V357, P1667, DOI 10.1056/NEJMc076367; Sassi A, 2014, J ALLERGY CLIN IMMUN, V133, P1410, DOI 10.1016/j.jaci.2014.02.025; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Siegel AM, 2013, J ALLERGY CLIN IMMUN, V132, P1388, DOI 10.1016/j.jaci.2013.08.045; Westphal V, 2001, MOL GENET METAB, V73, P77, DOI 10.1006/mgme.2001.3161; Wolfe LA, 2013, DEV DISABIL RES REV, V17, P211, DOI 10.1002/ddrr.1115; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	24	141	145	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1400	U658		10.1016/j.jaci.2014.02.013	http://dx.doi.org/10.1016/j.jaci.2014.02.013			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24589341	Green Accepted			2022-12-18	WOS:000335450700023
J	Marciano, BE; Huang, CY; Joshi, G; Rezaei, N; Carvalho, BC; Allwood, Z; Ikinciogullari, A; Reda, SM; Gennery, A; Thon, V; Espinosa-Rosales, F; Al-Herz, W; Porras, O; Shcherbina, A; Szaflarska, A; Kilic, S; Franco, JL; Raccio, ACG; Roxo, P; Esteves, I; Galal, N; Grumach, AS; Al-Tamemi, S; Yildiran, A; Orellana, JC; Yamada, M; Morio, T; Liberatore, D; Ohtsuka, Y; Lau, YL; Nishikomori, R; Torres-Lozano, C; Mazzucchelli, JTL; Vilela, MMS; Tavares, FS; Cunha, L; Pinto, JA; Espinosa-Padilla, SE; Hernandez-Nieto, L; Elfeky, RA; Ariga, T; Toshio, H; Dogu, F; Cipe, F; Formankova, R; Nunez-Nunez, ME; Bezrodnik, L; Marques, JG; Pereira, MI; Listello, V; Slatter, MA; Nademi, Z; Kowalczyk, D; Fleisher, TA; Davies, G; Neven, B; Rosenzweig, SD				Marciano, Beatriz E.; Huang, Chiung-Yu; Joshi, Gyan; Rezaei, Nima; Carvalho, Beatriz Costa; Allwood, Zoe; Ikinciogullari, Aydan; Reda, Shereen M.; Gennery, Andrew; Thon, Vojtech; Espinosa-Rosales, Francisco; Al-Herz, Waleed; Porras, Oscar; Shcherbina, Anna; Szaflarska, Anna; Kilic, Sebnem; Franco, Jose L.; Gomez Raccio, Andrea C.; Roxo, Persio, Jr.; Esteves, Isabel; Galal, Nermeen; Grumach, Anete Sevciovic; Al-Tamemi, Salem; Yildiran, Alisan; Orellana, Julio C.; Yamada, Masafumi; Morio, Tomohiro; Liberatore, Diana; Ohtsuka, Yoshitoshi; Lau, Yu-Lung; Nishikomori, Ryuta; Torres-Lozano, Carlos; Mazzucchelli, Juliana T. L.; Vilela, Maria M. S.; Tavares, Fabiola S.; Cunha, Luciana; Pinto, Jorge A.; Espinosa-Padilla, Sara E.; Hernandez-Nieto, Leticia; Elfeky, Reem A.; Ariga, Tadashi; Toshio, Heike; Dogu, Figen; Cipe, Funda; Formankova, Renata; Enriqueta Nunez-Nunez, M.; Bezrodnik, Liliana; Marques, Jose Goncalo; Pereira, Maria I.; Listello, Viviana; Slatter, Mary A.; Nademi, Zohreh; Kowalczyk, Danuta; Fleisher, Thomas A.; Davies, Graham; Neven, Benedicte; Rosenzweig, Sergio D.			BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; severe combined immunodeficiency; vaccine; BCG; mycobacteria; newborn screening; hematopoietic stem cell transplant; immune reconstitution syndrome	BACILLUS-CALMETTE-GUERIN; CENTRAL-NERVOUS-SYSTEM; IMMUNOCOMPROMISED CHILDREN; TUBERCULOUS MENINGITIS; VACCINES	Background: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected. Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (<= 3 1 month) showed an increased prevalence of complications (P = 5.006) and death caused by BCG-associated complications (P < .0001). The odds of experiencing complications among patients with T-cell numbers of 250/mu L or less at diagnosis was 2.1 times higher (95% CI, 1.4-3.4 times higher; P = .001) than among those with T-cell numbers of greater than 250/mL. BCG-associated complications were reported in 2 of 78 patients who received antimycobacterial therapy while asymptomatic, and no deaths caused by BCG-associated complications occurred in this group. In contrast, 46 BCG-associated deaths were reported among 160 patients treated with antimycobacterial therapy for a symptomatic BCG infection (P < .0001). Conclusions: BCG vaccine has a very high rate of complications in patients with SCID, which increase morbidity and mortality rates. Until safer and more efficient antituberculosis vaccines become available, delay in BCG vaccination should be considered to protect highly vulnerable populations from preventable complications.	[Marciano, Beatriz E.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Huang, Chiung-Yu; Joshi, Gyan] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA; [Rezaei, Nima] Univ Tehran Med Sci, Pediat Ctr Excellence, Childrens Med Ctr Hosp, Tehran, Iran; [Carvalho, Beatriz Costa; Mazzucchelli, Juliana T. L.; Vilela, Maria M. S.; Tavares, Fabiola S.] Univ Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil; [Allwood, Zoe; Davies, Graham] Great Ormond St Hosp Sick Children, Dept Immunol, London, England; [Ikinciogullari, Aydan; Dogu, Figen; Cipe, Funda] Ankara Univ, Sch Med, Dept Pediat Immunol & Allergy, TR-06100 Ankara, Turkey; [Reda, Shereen M.; Elfeky, Reem A.] Ain Shams Univ, Dept Pediat Allergy & Immunol, Childrens Hosp, Cairo, Egypt; [Gennery, Andrew; Slatter, Mary A.; Nademi, Zohreh] Great North Childrens Hosp, Paediat Immunol Dept, Newcastle Upon Tyne, Tyne & Wear, England; [Thon, Vojtech] Masaryk Univ, Dept Clin Immunol & Allergy, Fac Med, St Annes Univ Hosp, Brno, Czech Republic; [Espinosa-Rosales, Francisco; Espinosa-Padilla, Sara E.; Hernandez-Nieto, Leticia] Natl Inst Pediat, Mexico City, DF, Mexico; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Al Sabah Hosp, Kuwait, Kuwait; [Porras, Oscar] Natl Childrens Hosp Dr Carlos Saenz Herrera, Dept Immunol & Rheumatol, San Jose, Costa Rica; [Shcherbina, Anna] Ctr Pediat Hematol Oncol & Immunol, Dept Clin Immunol, Moscow, Russia; [Szaflarska, Anna; Kowalczyk, Danuta] Childrens Univ Hosp, Dept Clin Immunol & Transplantol, Krakow, Poland; [Kilic, Sebnem] Uludag Univ, Fac Med, Pediat Immunol Div, Bursa, Turkey; [Franco, Jose L.] Univ Antioquia, Primary Immunodeficiency Grp, Medellin, Colombia; [Gomez Raccio, Andrea C.; Bezrodnik, Liliana] Childrens Hosp Ricardo Gutierrez, Immunol Unit, Buenos Aires, DF, Argentina; [Roxo, Persio, Jr.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-05508 Sao Paulo, Brazil; [Esteves, Isabel; Marques, Jose Goncalo] Hosp Santa Maria, Primary Immunodeficiency Ctr, Lisbon Acad Ctr, Lisbon, Portugal; [Galal, Nermeen] Cairo Univ, Santo Andre, SP, Brazil; [Grumach, Anete Sevciovic] ABC, Fac Med, Sao Paulo, Brazil; [Al-Tamemi, Salem] Sultan Qaboos Univ Hosp, Dept Child Hlth, Muscat, Oman; [Yildiran, Alisan] Ondokuz Mayis Univ, Dept Pediat Immunol, Atakum, Samsun, Turkey; [Orellana, Julio C.; Pereira, Maria I.; Listello, Viviana] Santisima Trinidad Childrens Hosp, Div Allergy & Clin Immunol, Cordoba, Argentina; [Yamada, Masafumi; Ariga, Tadashi] Hokkaido Univ, Dept Pediat, Grad Sch Med, Sapporo, Hokkaido, Japan; [Morio, Tomohiro] Tokyo Med & Dent Univ, Tokyo, Japan; [Liberatore, Diana] Italian Hosp, Buenos Aires, DF, Argentina; [Ohtsuka, Yoshitoshi] Hyogo Coll Med, Nishinomiya, Hyogo, Japan; [Lau, Yu-Lung] Univ Hong Kong, Dept Pediat & Adolescent Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Nishikomori, Ryuta; Toshio, Heike] Kyoto Univ Hosp, Dept Pediat, Kyoto, Japan; [Torres-Lozano, Carlos; Enriqueta Nunez-Nunez, M.] Western Natl Med Ctr, Dept Clin Immunol & Allergol, Guadalajara, Jalisco, Mexico; [Cunha, Luciana; Pinto, Jorge A.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil; [Formankova, Renata] Charles Univ Prague, Prague, Czech Republic; [Formankova, Renata] Univ Hosp Motol, Prague, Czech Republic; [Fleisher, Thomas A.] NIH, Serv Immunol, DLM CC, Bethesda, MD 20892 USA; [Neven, Benedicte] Hop Necker Enfants Malad, Immunol Hematol & Rheumatol Serv, Paris, France; [Rosenzweig, Sergio D.] NIAID, Primary Immunodeficiency Clin, LHD, NIH, Bethesda, MD 20892 USA; [Rosenzweig, Sergio D.] NIAID, Infect Dis Susceptibil Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Tehran University of Medical Sciences; Universidade Federal de Sao Paulo (UNIFESP); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Ankara University; Egyptian Knowledge Bank (EKB); Ain Shams University; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Al Sabah Hospital; Kuwait University; Uludag University; Universidad de Antioquia; Hospital de Ninos Doctor Ricardo Gutierrez; Universidade de Sao Paulo; Universidade de Lisboa; Hospital Santa Maria; Faculdade de Medicina do ABC; Sultan Qaboos University; Ondokuz Mayis University; Hokkaido University; Tokyo Medical & Dental University (TMDU); Hospital Italiano de Buenos Aires; Hyogo College of Medicine; University of Hong Kong; Kyoto University; Universidade Federal de Minas Gerais; Charles University Prague; Motol University Hospital; National Institutes of Health (NIH) - USA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rosenzweig, SD (corresponding author), NIH, Serv Immunol, DLM CC, 10 Ctr Dr,Bldg 10,2C410F, Bethesda, MD 20892 USA.	srosenzweig@cc.nih.gov	Grumach, Anete S/I-3430-2014; Kilic, Sara Sebnem/AAH-1658-2021; Nishikomori, Ryuta/N-4039-2018; Dogu, Figen/AAI-1316-2020; Al-Tamemi, Salem/T-7687-2017; Carvalho, Beatriz/GXA-0720-2022; FRANCO, JOSE/AAK-1590-2020; Pinto, Jorge A/D-1743-2014; İkinciogullari, Aydan/AAQ-3841-2020; Vilela, Maria Marluce S/G-3916-2013; Nishikomori, Ryuta/AAM-5771-2020; Rezaei, Nima/B-4245-2008; Roxo-Junior, Pérsio/E-3133-2012; Lau, Yu Lung/C-4322-2009	Nishikomori, Ryuta/0000-0002-9407-6158; Dogu, Figen/0000-0002-7869-4941; Al-Tamemi, Salem/0000-0002-7232-2629; FRANCO, JOSE/0000-0001-5664-6415; Pinto, Jorge A/0000-0003-2987-3238; İkinciogullari, Aydan/0000-0003-1145-0843; Nishikomori, Ryuta/0000-0002-9407-6158; Rezaei, Nima/0000-0002-3836-1827; Roxo-Junior, Persio/0000-0001-6318-4132; Hernandez-Nieto, Leticia/0000-0001-5305-8888; Lau, Yu Lung/0000-0002-4780-0289; Grumach, Anete/0000-0002-9803-0309; kilic, sara sebnem/0000-0001-8571-2581; Morio, Tomohiro/0000-0002-9259-1025	Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Disease; European Community [201549 (EURO-PADnet HEALTH-F2-2008-201549)]; Tehran University Med Sci; American Academy of Allergy, Asthma & Immunology (AAAAI) Young Investigator Award; EURO-PADnet HEALTH [F2-2008-201549]; Baxter; Kedrion; Grifols; SHIRE; CSL; Japan Science and Technology Agency; Ministry of Education, Culture, and Sport; Ministry of Health, Labour, and Welfare in Japan; Abbvie; CSL Behring; Chugai Pharmaceutical; Meiji Pharmaceuticals; Teijin Pharma; Toray Medical; InPractice; UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001122] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Disease; European Community(European Commission); Tehran University Med Sci; American Academy of Allergy, Asthma & Immunology (AAAAI) Young Investigator Award; EURO-PADnet HEALTH; Baxter; Kedrion; Grifols; SHIRE; CSL; Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Ministry of Education, Culture, and Sport; Ministry of Health, Labour, and Welfare in Japan(Ministry of Health, Labour and Welfare, Japan); Abbvie(AbbVie); CSL Behring; Chugai Pharmaceutical; Meiji Pharmaceuticals; Teijin Pharma; Toray Medical; InPractice; UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Disease. V. T. was supported by the European Community's Seventh Framework Program FP7/2007-2013 under grant agreement no. 201549 (EURO-PADnet HEALTH-F2-2008-201549).; N. Rezaei is employed by and has received research support from Tehran University Med Sci, has received royalties from Springer, and has been supported by an American Academy of Allergy, Asthma & Immunology (AAAAI) Young Investigator Award. B. Costa Carvalho has received payment for development of educational presentations from the Federal University of Sao Paulo (FAPESP) and has received travel support from Octapharma. V. Thon has received research support from EURO-PADnet HEALTH (F2-2008-201549). J. L. Franco has received consultancy fees from Baxter and Kedrion and has received lecture fees from Grifols. A. Sevciovic Grumach is a board member for Latin American Society for Immunodeficiencies and has received consultancy fees and lecture fees from SHIRE and CSL. T. Morio has received grant-in-aids for scientific research from the Japan Science and Technology Agency; the Ministry of Education, Culture, and Sport; and the Ministry of Health, Labour, and Welfare in Japan and has received lecture fees from Abbvie, CSL Behring, Chugai Pharmaceutical, Meiji Pharmaceuticals, Teijin Pharma, and Toray Medical. S. D. Rosenzweig has received consultancy fees from InPractice and UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; [Anonymous], 2013, VACCINES; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Chien Y-H, J FORMOSAN MED ASS; COMSTOCK GW, 1994, CLIN INFECT DIS, V19, P528, DOI 10.1093/clinids/19.3.528; DOERR CA, 1995, J PEDIATR-US, V127, P27, DOI 10.1016/S0022-3476(95)70252-0; Farinha NJ, 2000, J INFECTION, V41, P61, DOI 10.1053/jinf.2000.0692; FINE PEM, 1995, CLIN INFECT DIS, V20, P11, DOI 10.1093/clinids/20.1.11; Gantzer A, 2013, J CUTAN PATHOL, V40, P30, DOI 10.1111/cup.12048; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; GONZALEZ B, 1989, PEDIATR INFECT DIS J, V8, P201; Ho MM, 2008, VACCINE, V26, P4754, DOI 10.1016/j.vaccine.2008.06.026; Kanegae MPP, 2011, REV BRASIL ALERG IMU, V34, P1; Koppel A, 2010, J TROP PEDIATRICS, V56, P280, DOI 10.1093/tropej/fmp115; Lee LV, 2000, BRAIN DEV-JPN, V22, P469, DOI 10.1016/S0387-7604(00)00190-X; Lotte A, 1988, Bull Int Union Tuberc Lung Dis, V63, P47; MILSTIEN JB, 1990, B WORLD HEALTH ORGAN, V68, P93; Paganini H, 2000, SCAND J INFECT DIS, V32, P41, DOI 10.1080/00365540050164209; Parida SK, 2010, CURR OPIN IMMUNOL, V22, P374, DOI 10.1016/j.coi.2010.04.006; ROMANUS V, 1993, ACTA PAEDIATR, V82, P1043, DOI 10.1111/j.1651-2227.1993.tb12808.x; Satwani P, 2005, BIOL NEONATE, V88, P214, DOI 10.1159/000087585; Sharma AA, 2012, CLIN IMMUNOL, V145, P61, DOI 10.1016/j.clim.2012.08.006; Shefer Abigail, 2011, Morbidity and Mortality Weekly Report, V60, P1; Talbot EA, 1997, CLIN INFECT DIS, V24, P1139, DOI 10.1086/513642; van Well Gijs T J, 2009, Pediatrics, V123, pe1, DOI 10.1542/peds.2008-1353; Yao CM, 2013, J CLIN IMMUNOL, V33, P526, DOI 10.1007/s10875-012-9854-1; Yaramis A, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e49	28	141	156	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1134	1141		10.1016/j.jaci.2014.02.028	http://dx.doi.org/10.1016/j.jaci.2014.02.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24679470	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-18	WOS:000333531700025
J	Allen, KJ; Remington, BC; Baumert, JL; Crevel, RWR; Houben, GF; Brooke-Taylor, S; Kruizinga, AG; Taylor, SL				Allen, Katrina J.; Remington, Benjamin C.; Baumert, Joseph L.; Crevel, Rene W. R.; Houben, Geert F.; Brooke-Taylor, Simon; Kruizinga, Astrid G.; Taylor, Steve L.			Allergen reference doses for precautionary labeling (VITAL 2.0): Clinical implications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; allergen thresholds; peanut; egg; cow's milk; soy; hazelnut; precautionary labeling	COWS MILK ALLERGY; ORAL TOLERANCE INDUCTION; MEDIATED FOOD ALLERGY; SEVERE PEANUT ALLERGY; FAILURE TIME DATA; DOUBLE-BLIND; RISK-ASSESSMENT; HYDROLYSATE FORMULA; YOUNG-CHILDREN; CHALLENGES	Background: There has been a dramatic proliferation of precautionary labeling by manufacturers to mitigate the perceived risk from low-level contamination from allergens in food. This has resulted in a significant reduction in choice of potentially safe foods for allergic consumers. Objectives: We aimed to establish reference doses for 11 commonly allergenic foods to guide a rational approach by manufacturers based on all publically available valid oral food challenge data. Methods: Reference doses were developed from statistical dose-distribution modeling of individual thresholds of patients in a dataset of more than 55 studies of clinical oral food challenges. Sufficient valid data were available for peanut, milk, egg, and hazelnut to allow assessment of the representativeness of the data used. Results: The data were not significantly affected by the heterogeneity of the study methodology, including little effect of age on results for those foods for which sufficient numbers of adult challenge data were available (peanut and hazelnut). Thus by combining data from all studies, the eliciting dose for an allergic reaction in 1% of the population estimated for the following were 0.2 mg of protein for peanut, 0.1 mg for cow's milk, 0.03 mg for egg, and 0.1 mg for hazelnut. Conclusions: These reference doses will form the basis of the revised Voluntary Incidental Trace Allergen Labeling (VITAL) 2.0 thresholds now recommended in Australia. These new levels will enable manufacturers to apply credible precautionary labeling and provide increased consumer confidence in their validity and reliability, as well as improving consumer safety.	[Allen, Katrina J.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Remington, Benjamin C.; Baumert, Joseph L.; Taylor, Steve L.] Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA; [Crevel, Rene W. R.] Unilever, Safety & Environm Assurance Ctr, Bedford, England; [Houben, Geert F.; Kruizinga, Astrid G.] TNO, NL-3700 AJ Zeist, Netherlands; [Brooke-Taylor, Simon] Allergen Bur Australia, Hobart, Tas, Australia	Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; University of Nebraska System; University of Nebraska Lincoln; Unilever; Netherlands Organization Applied Science Research	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Taylor, Steve L./V-1341-2019; Allen, Katrina/I-4361-2018	Allen, Katrina/0000-0002-1921-4493; Remington, Benjamin/0000-0001-5450-8334; Houben, Geert/0000-0001-7261-3912	Dutch Ministry of Health; Allergen Bureau of Australia; Victorian Government's Operational Infrastructure Support Program, Australia; Food Allergy Research & Resource Program (FARRP), University of Nebraska, Lincoln, Nebraska	Dutch Ministry of Health; Allergen Bureau of Australia; Victorian Government's Operational Infrastructure Support Program, Australia; Food Allergy Research & Resource Program (FARRP), University of Nebraska, Lincoln, Nebraska	This study was conducted within the framework of the Food Safety Knowledge Development program of TNO, with financial support from the Dutch Ministry of Health, the Allergen Bureau of Australia (www.allergenbureau.net), the Victorian Government's Operational Infrastructure Support Program, Australia, and the Food Allergy Research & Resource Program (FARRP), University of Nebraska, Lincoln, Nebraska. K. J. A. is a Charles and Sylvia Viertel Senior Medical Research Fellow.	Anagnostou K, 2009, CLIN EXP ALLERGY, V39, P1954; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; Australian Allergen Bureau, SUMM VITAL SCI EXP P; Baehler P, 1996, CLIN EXP ALLERGY, V26, P254, DOI [10.1046/j.1365-2222.1996.d01-310.x, 10.1111/j.1365-2222.1996.tb00089.x]; Baker SS, 2000, PEDIATRICS, V106, P346; Benhamou AH, 2008, PEDIATR ALLERGY IMMU, V19, P173, DOI 10.1111/j.1399-3038.2007.00602.x; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Buchanan R, 2008, J FOOD PROTECT, V71, P1043; Caminiti L, 2009, ALLERGY ASTHMA PROC, V30, P443, DOI 10.2500/aap.2009.30.3221; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Crevel RWR, 2008, ALLERGY, V63, P597, DOI 10.1111/j.1398-9995.2008.01636.x; Crevel RWR, 2007, FOOD CHEM TOXICOL, V45, P691, DOI 10.1016/j.fct.2006.09.005; Crotty MP, 2010, J ALLERGY CLIN IMMUN, V125, P935, DOI 10.1016/j.jaci.2009.12.003; de Blok BMJ, 2007, ALLERGY, V62, P733, DOI 10.1111/j.1398-9995.2006.01303.x; Devenney I, 2006, ACTA PAEDIATR, V95, P1133, DOI 10.1080/08035250500516672; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; ELLIS MH, 1991, J PEDIATR-US, V118, P74, DOI 10.1016/S0022-3476(05)81849-9; Fiocchi A, 2003, CLIN EXP ALLERGY, V33, P1576, DOI 10.1046/j.1365-2222.2003.01781.x; Fleming F., 2010, Allergen management in the food industry, P453, DOI 10.1002/9780470644584.ch16; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; Ford LS, 2010, J ALLERGY CLIN IMMUN, V126, P384, DOI 10.1016/j.jaci.2010.05.034; Gendel SM, 2012, REGUL TOXICOL PHARM, V63, P279, DOI 10.1016/j.yrtph.2012.04.007; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; HILL DJ, 1984, CLIN REV ALLERG, V2, P125; HOST A, 1988, ALLERGY, V43, P113, DOI 10.1111/j.1398-9995.1988.tb00404.x; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Kleinman REBS., 1991, PEDIAT ALLERG IMM-UK, V2, P146, DOI [DOI 10.1111/J.1399-3038.1991.TB00200.X, 10.1111/j.1399-3038.1991.tb00200.x]; Lam HY, 2008, CLIN EXP ALLERGY, V38, P995, DOI 10.1111/j.1365-2222.2008.02968.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Madsen CB, 2012, CLIN EXP ALLERGY, V42, P30, DOI 10.1111/j.1365-2222.2011.03868.x; Madsen CB, 2009, FOOD CHEM TOXICOL, V47, P480, DOI 10.1016/j.fct.2008.12.001; Morisset M, 2007, Eur Ann Allergy Clin Immunol, V39, P12; Morisset M, 2003, CLIN EXP ALLERGY, V33, P1046, DOI 10.1046/j.1365-2222.2003.01734.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; NORGAARD A, 1992, ALLERGY, V47, P503, DOI 10.1111/j.1398-9995.1992.tb00673.x; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Orhan F, 2009, CLIN EXP ALLERGY, V39, P1027, DOI 10.1111/j.1365-2222.2009.03263.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Patriarca G, 2006, DIGEST DIS SCI, V51, P471, DOI 10.1007/s10620-006-3157-4; Patriarca G, 2002, INT J IMMUNOPATH PH, V15, P53, DOI 10.1177/039463200201500107; Pele M, 2007, FOOD ADDIT CONTAM A, V24, P1334, DOI 10.1080/02652030701458113; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Pieretti MM, 2009, J ALLERGY CLIN IMMUN, V124, P337, DOI 10.1016/j.jaci.2009.05.032; Remington B, 2010, J ALLERGY CLIN IMMUN, V125, pAB218, DOI 10.1016/j.jaci.2009.12.852; Roches AD, 2006, ALLERGY, V61, P900, DOI 10.1111/j.1398-9995.2006.01134.x; Rolinck-Werninghaus C, 2012, ALLERGY, V67, P951, DOI 10.1111/j.1398-9995.2012.02838.x; SAS, 2012, SAMPL 24980 NONP EST; SAYLOR JD, 1991, J PEDIATR-US, V118, P71, DOI 10.1016/S0022-3476(05)81848-7; Sheth SS, 2010, ANN ALLERG ASTHMA IM, V104, P60, DOI 10.1016/j.anai.2009.11.008; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; So Y, 2010, P SAS GLOB FOR 2010; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Sun JG, 2005, SCAND J STAT, V32, P49, DOI 10.1111/j.1467-9469.2005.00414.x; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; Turner PJ, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6180; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wood RA, 2003, PEDIATRICS, V111, P1631; Zhao Q, 2004, STAT MED, V23, P1621, DOI 10.1002/sim.1746; Zurzolo GA, 2012, CURR ALLERGY ASTHM R, V12, P292, DOI 10.1007/s11882-012-0263-6	70	141	145	4	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					156	164		10.1016/j.jaci.2013.06.042	http://dx.doi.org/10.1016/j.jaci.2013.06.042			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23987796				2022-12-18	WOS:000329105700022
J	Tan, BK; Chandra, RK; Pollak, J; Kato, A; Conley, DB; Peters, AT; Grammer, LC; Avila, PC; Kern, RC; Stewart, WF; Schleimer, RP; Schwartz, BS				Tan, Bruce K.; Chandra, Rakesh K.; Pollak, Jonathan; Kato, Atsushi; Conley, David B.; Peters, Anju T.; Grammer, Leslie C.; Avila, Pedro C.; Kern, Robert C.; Stewart, Walter F.; Schleimer, Robert P.; Schwartz, Brian S.			Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epidemiology; incidence; sinusitis; nasal polyps; risk factors; asthma; rhinitis; nested case-control study; antibiotics; diagnosis	NOCTURNAL GASTROESOPHAGEAL-REFLUX; ALLERGIC RHINITIS; PULMONARY-DISEASE; CHRONIC SINUSITIS; UNITED-STATES; NASAL POLYPS; PREVALENCE; ADULTS; EPIDEMIOLOGY; PERSPECTIVES	Background: Chronic rhinosinusitis (CRS) is a prevalent condition with underexplored risk factors. Objectives: We sought to determine CRS incidence and evaluate associations with a range of premorbid medical conditions for chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP) using real-world clinical practice data. Methods: Electronic health records data from 446,480 Geisinger Clinic primary care patients were used for a retrospective longitudinal cohort study for data from 2001-2010. By using logistic regression, newly diagnosed CRS cases between 2007 and 2009 were compared with frequency-matched control subjects on premorbid factors in the immediate (0-6 months), intermediate (7-24 months), and entire observed timeframes before diagnosis. Results: The average incidence of CRS was 83 +/- 13 CRSwNP cases per 100,000 person-years and 1048 +/- 78 CRSsNP cases per 100,000 person-years. Between 2007 and 2009, 595 patients with incident CRSwNP and 7523 patients with incident CRSsNP were identified and compared with 8118 control subjects. Compared with control subjects and patients with CRSsNP, patients with CRSwNP were older and more likely to be male. Before diagnosis, patients with CRS had a higher prevalence of acute rhinosinusitis, allergic rhinitis, chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep apnea, anxiety, and headaches (all P <.001). Patients with CRSsNP had a higher premorbid prevalence of infections of the upper and lower airway, skin/soft tissue, and urinary tract (all P <.001). In the immediate and intermediate timeframes analyzed, patients with CRS had more outpatient encounters and antibiotic prescriptions (P <.001), but guideline-recommended diagnostic testing was performed in a minority of cases. Conclusions: Patients who are given a diagnosis of CRS have a higher premorbid prevalence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infections of the respiratory system and some nonrespiratory sites, which results in higher antibiotic, corticosteroid, and health care use. The use of guideline-recommended diagnostic testing for confirmation of CRS remains poor.	[Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA; [Kato, Atsushi; Peters, Anju T.; Grammer, Leslie C.; Avila, Pedro C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Pollak, Jonathan; Schwartz, Brian S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; [Stewart, Walter F.; Schwartz, Brian S.] Geisinger Hlth Syst, Ctr Hlth Res, Danville, PA USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Geisinger Health System	Tan, BK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, 676 N St Clair,Suite 1325, Chicago, IL 60611 USA.	btan@nmff.org		Kato, Atsushi/0000-0001-9144-3138; Chandra, Rakesh/0000-0002-3612-0026; Grammer, Leslie/0000-0001-6860-2014	National Institutes of Health [K23DC012067, R01 HL068546, R01 HL078860, R01 AI072570]; National Institutes of Health (NIH); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by National Institutes of Health grants K23DC012067 (to B.K.T.), R01 HL068546, R01 HL078860, and R01 AI072570, as well as the Ernest S. Bazley Trust (to R.P.S.).; Disclosure of potential conflict of interest: B. K. Tan has been supported by one or more grants from the National Institutes of Health (NIH), has received one or more grants from or has one or more grants pending with the Triological Society, and has received one or more payments for travel/accommodations/meeting expenses from the Foundation for Innovation, Education, and Research in Otorhinolaryngology. J. Pollak is employed by Johns Hopkins Bloomberg School of Public Health. A. T. Peters has provided expert testimony regarding Stevens-Johnson syndrome and has received one or more payments for lecturing from or is on the speakers' bureau for Baxter. R. P. Schleimer has been supported by one or more grants from the NIH and has consultancy arrangements with Intersect ENT, GlaxoSmithKline, and Allakos. B. S. Schwartz has been supported by one or more grants from Northwestern University. The rest of the authors declare that they have no relevant conflicts of interest.	Baroody FM, 2008, J ALLERGY CLIN IMMUN, V121, P1126, DOI 10.1016/j.jaci.2008.02.010; Braunstahl Gert-Jan, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P176, DOI 10.1097/01.moo.0000193186.15440.39; Braunstahl Gert-Jan, 2009, Proc Am Thorac Soc, V6, P652, DOI 10.1513/pats.200906-052DP; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Chen Y, 2003, LARYNGOSCOPE, V113, P1199, DOI 10.1097/00005537-200307000-00016; COSTA PT, 1987, J PERS, V55, P299, DOI 10.1111/j.1467-6494.1987.tb00438.x; de Loos DAED, 2013, LARYNGOSCOPE, V123, P57, DOI 10.1002/lary.23671; DiBaise JK, 2006, DIS ESOPHAGUS, V19, P419, DOI 10.1111/j.1442-2050.2006.00616.x; El-Serag HB, 2001, GASTROENTEROLOGY, V121, P1294, DOI 10.1053/gast.2001.29545; ElSerag HB, 1997, GASTROENTEROLOGY, V113, P755, DOI 10.1016/S0016-5085(97)70168-9; Emilsson OI, 2012, EUR RESP J; Emilsson OI, 2012, RESP MED, V106, P459, DOI 10.1016/j.rmed.2011.12.004; Eross E, 2007, HEADACHE, V47, P213, DOI 10.1111/j.1526-4610.2006.00688.x; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gelincik A, 2008, ANN ALLERG ASTHMA IM, V101, P18, DOI 10.1016/S1081-1206(10)60829-0; Gislason T, 2002, CHEST, V121, P158, DOI 10.1378/chest.121.1.158; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Howren MB, 2011, J PERS SOC PSYCHOL, V100, P182, DOI 10.1037/a0021715; Hsueh WD, 2012, INT FORUM ALLERGY RH; James KM, 2012, J ALLERGY CLIN IMMUN, V130, P343, DOI 10.1016/j.jaci.2012.05.056; Joe SA, 2008, OTOLARYNG CLIN N AM, V41, P297, DOI 10.1016/j.otc.2007.11.001; Johansson L, 2003, ANN OTO RHINOL LARYN, V112, P625, DOI 10.1177/000348940311200709; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Marple BF, 2010, AM J RHINOL ALLERGY, V24, P249, DOI 10.2500/ajra.2010.24.3499; Mattos JL, 2011, INT FORUM ALLERGY RH, V1, P3, DOI 10.1002/alr.20003; Mehle ME, 2008, HEADACHE, V48, P67, DOI [10.1111/j.1526-4610.2007.00811.x, 10.1111/j.1526-4610.2007.00811]; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Min YG, 1996, EUR ARCH OTO-RHINO-L, V253, P435; del Castillo FM, 2009, J INVEST ALLERG CLIN, V19, P110; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Pleis John R, 2009, Vital Health Stat 10, P1; Rank MA, 2010, J ALLERGY CLIN IMMUN, V126, P168, DOI 10.1016/j.jaci.2010.03.041; Reh DD, 2009, AM J RHINOL ALLERGY, V23, P562, DOI 10.2500/ajra.2009.23.3377; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Roumie CL, 2005, J GEN INTERN MED, V20, P697, DOI 10.1111/j.1525-1497.2005.0148.x; Ryan MN, 2008, CURR OPIN OTOLARYNGO, V16, P231, DOI 10.1097/MOO.0b013e3282fdc3c5; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Smith WM, 2009, OTOLARYNG HEAD NECK, V141, P347, DOI 10.1016/j.otohns.2009.05.021; Stankiewicz JA, 2002, AM J RHINOL, V16, P199, DOI 10.1177/194589240201600404; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Tan BK, 2011, INT FORUM ALLERGY RH, V1, P88, DOI 10.1002/alr.20025; Tan BK, 2011, INT FORUM ALLERGY RH, V1, P229, DOI 10.1002/alr.20044; Tan BK, 2010, CURR OPIN OTOLARYNGO, V18, P21, DOI 10.1097/MOO.0b013e3283350053; Thomas Mike, 2008, Prim Care Respir J, V17, P79, DOI 10.3132/pcrj.2008.00029; Tomassen Peter, 2011, Proc Am Thorac Soc, V8, P115, DOI 10.1513/pats.201005-036RN; Walker C, 1998, AVIAT SPACE ENVIR MD, V69, P952; WATSON D, 1984, PSYCHOL BULL, V96, P465, DOI 10.1037/0033-2909.96.3.465; Wetherell JL, 2001, PSYCHOL AGING, V16, P187, DOI 10.1037//0882-7974.16.2.187; Wigton RS, 2008, J GEN INTERN MED, V23, P1615, DOI 10.1007/s11606-008-0707-9	53	141	145	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1350	1360		10.1016/j.jaci.2013.02.002	http://dx.doi.org/10.1016/j.jaci.2013.02.002			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23541327	Green Accepted, Bronze			2022-12-18	WOS:000318912200012
J	Soller, L; Ben-Shoshan, M; Harrington, DW; Fragapane, J; Joseph, L; St Pierre, Y; Godefroy, SB; La Vieille, S; Elliott, SJ; Clarke, AE				Soller, Lianne; Ben-Shoshan, Moshe; Harrington, Daniel W.; Fragapane, Joseph; Joseph, Lawrence; St Pierre, Yvan; Godefroy, Samuel B.; La Vieille, Sebastien; Elliott, Susan J.; Clarke, Ann E.			Overall prevalence of self-reported food allergy in Canada	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Soller, Lianne; Fragapane, Joseph; Joseph, Lawrence; St Pierre, Yvan; Clarke, Ann E.] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Dept Med, Montreal, PQ, Canada; [Ben-Shoshan, Moshe] McGill Univ, Ctr Hlth, Div Pediat Allergy & Clin Immunol, Dept Pediat, Montreal, PQ, Canada; [Clarke, Ann E.] McGill Univ, Ctr Hlth, Div Allergy & Clin Immunol, Dept Med, Montreal, PQ, Canada; [Harrington, Daniel W.] Univ Toronto, Dept Geog, Toronto, ON M5S 1A1, Canada; [Joseph, Lawrence] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; [Godefroy, Samuel B.; La Vieille, Sebastien] Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada; [Elliott, Susan J.] Univ Waterloo, Fac Appl Hlth Sci, Waterloo, ON N2L 3G1, Canada	McGill University; McGill University; McGill University; University of Toronto; McGill University; Health Canada; University of Waterloo	Soller, L (corresponding author), McGill Univ, Ctr Hlth, Div Clin Epidemiol, Dept Med, Montreal, PQ, Canada.	liannesoller@gmail.com	La Vieille, Sébastien/AAC-5087-2019; Soller, Lianne/AGR-7219-2022	La Vieille, Sebastien/0000-0001-5368-1266				Bahna SL, 2002, ANN ALLERG ASTHMA IM, V89, P56, DOI 10.1016/S1081-1206(10)62124-2; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; de Boissieu D, 2009, ARCH PEDIATRIE, V16, P873, DOI 10.1016/S0929-693X(09)74186-7; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; LEUNG RC, 1994, MED J AUSTRALIA, V161, P418, DOI 10.5694/j.1326-5377.1994.tb127522.x; Pawlinska-Chmara R, 2008, J PHYSIOL PHARMACOL, V59, P549; Rivas MF, 2009, J INVESTIG ALLERGOL, V19, P8; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	11	141	145	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					986	988		10.1016/j.jaci.2012.06.029	http://dx.doi.org/10.1016/j.jaci.2012.06.029			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22867693				2022-12-18	WOS:000309594800021
J	Soto-Quiros, M; Avila, L; Platts-Mills, TAE; Hunt, JF; Erdman, DD; Carper, H; Murphy, DD; Odio, S; James, HR; Patrie, JT; Hunt, W; O'Rourke, AK; Davis, MD; Steinke, JW; Lu, XY; Kennedy, J; Heymann, PW				Soto-Quiros, Manuel; Avila, Lydiana; Platts-Mills, Thomas A. E.; Hunt, John F.; Erdman, Dean D.; Carper, Holliday; Murphy, Deborah D.; Odio, Silvia; James, Hayley R.; Patrie, James T.; Hunt, William; O'Rourke, Ashli K.; Davis, Michael D.; Steinke, John W.; Lu, Xiaoyan; Kennedy, Joshua; Heymann, Peter W.			High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute asthma; dust mite-specific IgE; emergency department visits; viral respiratory tract infections; rhinovirus strain C; total serum IgE; inhaled allergens; exhaled nitric oxide	HUMAN METAPNEUMOVIRUS INFECTION; EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; RESPIRATORY VIRUSES; VIRAL-INFECTIONS; COSTA-RICA; EXACERBATIONS; SENSITIZATION; PREVALENCE; ADMISSION	Background: The relevance of allergic sensitization, as judged by titers of serum IgE antibodies, to the risk of an asthma exacerbation caused by rhinovirus is unclear. Objective: We sought to examine the prevalence of rhinovirus infections in relation to the atopic status of children treated for wheezing in Costa Rica, a country with an increased asthma burden. Methods: The children enrolled (n = 287) were 7 through 12 years old. They included 96 with acute wheezing, 65 with stable asthma, and 126 nonasthmatic control subjects. PCR methods, including gene sequencing to identify rhinovirus strains, were used to identify viral pathogens in nasal washes. Results were examined in relation to wheezing, IgE, allergen-specific IgE antibody, and fraction of exhaled nitric oxide levels. Results: Sixty-four percent of wheezing children compared with 13% of children with stable asthma and 13% of nonasthmatic control subjects had positive test results for rhinovirus (P < .001 for both comparisons). Among wheezing subjects, 75% of the rhinoviruses detected were group C strains. High titers of IgE antibodies to dust mite allergen (especially Dermatophagoides species) were common and correlated significantly with total IgE and fraction of exhaled nitric oxide levels. The greatest risk for wheezing was observed among children with titers of IgE antibodies to dust mite of 17.5 IU/mL or greater who tested positive for rhinovirus (odds ratio for wheezing, 31.5; 95% CI, 8.3-108; P < .001). Conclusions: High titers of IgE antibody to dust mite allergen were common and significantly increased the risk for acute wheezing provoked by rhinovirus among asthmatic children. (J Allergy Clin Immunol 2012;129:1499-505.)	[Hunt, John F.; Carper, Holliday; Murphy, Deborah D.; Davis, Michael D.; Heymann, Peter W.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; [Platts-Mills, Thomas A. E.; Hunt, John F.; Carper, Holliday; Murphy, Deborah D.; James, Hayley R.; Patrie, James T.; Hunt, William; O'Rourke, Ashli K.; Davis, Michael D.; Steinke, John W.; Kennedy, Joshua; Heymann, Peter W.] Univ Virginia, Sch Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; [Erdman, Dean D.; Lu, Xiaoyan] Ctr Dis Control & Prevent, Atlanta, GA USA; [Soto-Quiros, Manuel; Avila, Lydiana; Odio, Silvia] Hosp Nacl Ninos Dr Carlos Saenz Herrera, San Jose, Costa Rica	University of Virginia; University of Virginia; Centers for Disease Control & Prevention - USA	Heymann, PW (corresponding author), Univ Virginia, Sch Med, Dept Pediat, POB 800386, Charlottesville, VA 22908 USA.	PWH5A@virginia.edu	Kennedy, Josh/P-1869-2019; Avila, Lydiana/D-5638-2015	Avila, Lydiana/0000-0002-9579-1591; Platts-Mills, Thomas/0000-0002-1263-329X	Cove Point Foundation; National Institutes of Health [R01 AI020565, U19 AI070364]; University of Virginia Children's Hospital; Phadia/Thermo Fisher; Medtronic; University of Virginia; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070364, U01AI100799, R01AI020565] Funding Source: NIH RePORTER	Cove Point Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Virginia Children's Hospital; Phadia/Thermo Fisher; Medtronic(Medtronic); University of Virginia; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Cove Point Foundation, National Institutes of Health grants R01 AI020565 and U19 AI070364, and the University of Virginia Children's Hospital Research Fund.; T. A. E. Platts-Mills has consultant arrangements with IBT/Viracor Labs and has received research support and honorarium from Phadia/Thermo Fisher. J. W. Steinke has received payment as a Board Review Course Speaker for the American Academy of Allergy, Asthma & Immunology; has received research support from the National Institutes of Health and Medtronic; and is the AIR Committee Chair for the American Academy of Allergy, Asthma & Immunology. J. Kennedy has received research support from the National Institutes of Health and the University of Virginia. P. W. Heymann has received research support from the National Institutes of Health, the Cove Point Foundation, and the University of Virginia Children's Hospital. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1995, NORM AT INT SAL PRIM, P13; ARRUDA E, 1993, MOL CELL PROBE, V7, P373, DOI 10.1006/mcpr.1993.1055; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Celedon JC, 2001, CHEST, V120, P785, DOI 10.1378/chest.120.3.785; Crane J, 2012, PEDIAT ALLERG IMM-UK, V23, P59, DOI 10.1111/j.1399-3038.2011.01227.x; Dare RK, 2007, J INFECT DIS, V196, P1321, DOI 10.1086/521308; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Hasegawa S, 2011, ALLERGY, V66, P1618, DOI 10.1111/j.1398-9995.2011.02725.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Iwane MK, 2011, J INFECT DIS, V204, P1702, DOI 10.1093/infdis/jir634; Jackson DJ, 2009, J ALLERGY CLIN IMMUN, V124, P949, DOI 10.1016/j.jaci.2009.07.024; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Khetsuriani N, 2008, EMERG INFECT DIS, V14, P1793, DOI 10.3201/eid1411.080386; Kodani M, 2011, J CLIN MICROBIOL, V49, P2175, DOI 10.1128/JCM.02270-10; Matthew J, 2009, ITAL J PEDIATR, V35, DOI 10.1186/1824-7288-35-16; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Soto-Quiros ME, 2002, PEDIAT ALLERG IMM-UK, V13, P342, DOI 10.1034/j.1399-3038.2002.02035.x; Soto-Quiros ME, 1998, ALLERGY, V53, P499, DOI 10.1111/j.1398-9995.1998.tb04087.x; Spanier AJ, 2008, PEDIATR PULM, V43, P576, DOI 10.1002/ppul.20816; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; Volovitz B, 2007, RESP MED, V101, P685, DOI 10.1016/j.rmed.2006.10.009; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Williams JV, 2005, J ALLERGY CLIN IMMUN, V115, P1311, DOI 10.1016/j.jaci.2005.02.001; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	34	141	149	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1499	+		10.1016/j.jaci.2012.03.040	http://dx.doi.org/10.1016/j.jaci.2012.03.040			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22560151	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000304764600009
J	Salo, PM; Arbes, SJ; Crockett, PW; Thorne, PS; Cohn, RD; Zeldin, DC				Salo, Paeivi M.; Arbes, Samuel J.; Crockett, Patrick W.; Thorne, Peter S.; Cohn, Richard D.; Zeldin, Darryl C.			Exposure to multiple indoor allergens in US homes and its relationship to asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; indoor exposure; asthma; allergy	HOUSE-DUST MITE; INNER-CITY CHILDREN; 1ST NATIONAL-SURVEY; ALTERNARIA-ALTERNATA; MOUSE ALLERGEN; ENVIRONMENTAL INTERVENTION; COCKROACH ALLERGEN; UNITED-STATES; DOG ALLERGEN; SENSITIZATION	Background: The National Survey of Lead and Allergens in Housing was the first population-based study to measure indoor allergen levels in US homes. Objective: We characterized the overall burden to multiple allergens and examined whether increased allergen levels were associated with occupants' asthma status. Methods: This cross-sectional study surveyed a nationally representative sample of 831 housing units in 75 different locations throughout the United States. Information was collected by means of questionnaire and environmental assessment. Allergen concentrations in dust samples were assessed by using immunoassays. The following cutoff points were used to define increased allergen levels: 10 mu g/g for Der p 1, Der f 1, and Can f 1; 8 mu g/g for Fel d 1; 8 U/g for Bla g 1; 1.6 mu g/g for mouse urinary protein; and 7 mu g/g for Alternaria alternata antigens. Allergen burden was considered high when 4 or more allergens exceeded increased levels in any of the sampling locations. Results: Exposure to multiple allergens was common in US homes. Of the surveyed homes, 51.5% had at least 6 detectable allergens and 45.8% had at least 3 allergens exceeding increased levels. Race, income, housing type, absence of children, and presence of smokers, pets, cockroaches, rodents, and mold/moisture-related problems were independent predictors of high allergen burden. Among atopic subjects, high allergen burden increased the odds of having asthma symptoms (odds ratio, 1.81; 95% CI, 1.04-3.15). Conclusion: Increased allergen levels in the home are associated with asthma symptoms in allergic individuals.	[Salo, Paeivi M.; Zeldin, Darryl C.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA; [Arbes, Samuel J.] Rho Inc, Chapel Hill, NC USA; [Crockett, Patrick W.; Cohn, Richard D.] Constella Grp LLC, Durham, NC USA; [Thorne, Peter S.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rho; University of Iowa	Zeldin, DC (corresponding author), NIEHS, NIH, 111 Alexander Dr,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Thorne, Peter/0000-0002-5045-0929	Intramural NIH HHS [Z01 ES025041-10] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025041] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Barnes C, 2006, ANN ALLERG ASTHMA IM, V97, P350, DOI 10.1016/S1081-1206(10)60800-9; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Cho SH, 2006, SCI TOTAL ENVIRON, V371, P31, DOI 10.1016/j.scitotenv.2006.09.001; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; *COMM DAMP IND SPA, 2004, DAMP IND SPAC HLTH; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Elliott L, 2007, ENVIRON HEALTH PERSP, V115, P215, DOI 10.1289/ehp.9412; Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Institute of Medicine (US) Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V105, pS628, DOI 10.1067/mai.2000.106154; Perry TT, 2006, ANN ALLERG ASTHMA IM, V97, P628, DOI 10.1016/S1081-1206(10)61092-7; Peters JL, 2007, J URBAN HEALTH, V84, P185, DOI 10.1007/s11524-006-9146-2; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527; 2005, TOBACCO USE ADULTS U; 2000, SELF REPORTED ASTHMA	39	141	146	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					678	684		10.1016/j.jaci.2007.12.1164	http://dx.doi.org/10.1016/j.jaci.2007.12.1164			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18255132	Green Accepted			2022-12-18	WOS:000253918900021
J	de Marco, R; Locatelli, F; Cerveri, I; Bugiani, M; Marinoni, A; Giammanco, G				de Marco, R; Locatelli, F; Cerveri, I; Bugiani, M; Marinoni, A; Giammanco, G		Italian Study Asthma Young Adults	Incidence and remission of asthma: A retrospective study on the natural history of asthma in Italy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma incidence; asthma remission; persistence of asthma	RESPIRATORY HEALTH SURVEY; AGE; CHILDHOOD; SYMPTOMS; INCREASE; SMOKING	Background: The knowledge of the natural history of asthma from birth to adulthood could provide important clues for its cause and for the understanding of epidemiologic findings. Objective: This study is aimed at assessing the incidence and remission of asthma from birth to the age of 44 years by using data from 18,873 subjects involved in a large, nationally representative, cross-sectional study carried out in Italy from 1998 through 2000. Methods: The onset of asthma was defined as the age at the first attack, and remission was considered present when a subject was neither under treatment nor had experienced an asthma attack in the last 24 months. Person-years and survival techniques were used for the analysis. Results: The average annual incidence rate for the 1953 to 2000 period was 2.56/1000 persons per year. Incidence peaked in boys less than 10 years of age (4.38/1000 persons per year) and in women 30 years of age or older (3.1/1000 persons per year) and showed a generational increase (incident rate ratio = 2.63 and 95% CI = 2.20-3.12 for 1974-1979 vs 1953-1958 birth cohort). The overall remission rate was 45.8% (41.6% in women and 49.5% in men, P < .001). Asthmatic patients in remission had an earlier age at onset (7.8 vs 15.9 years, P < .001) and a shorter duration of the disease (5.6 vs 16.1 years, P < .001) than patients with current asthma. The probability of remission was strongly (P < .001) and inversely related to the age at onset (62.8% and 15.0% in the <10- and greater than or equal to20-years age-at-onset groups, respectively). Conclusion: With respect to its natural history, asthma presents 2 different forms: early-onset asthma, which occurs early in childhood, affects mainly boys, and has a good prognosis, and late-onset asthma, which generally occurs during or after puberty, mainly affects women, and has a poor prognosis. The minority of patients with early-onset asthma who do not remit represents more than 35% of patients with current asthma in the general young adult population.	Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Inst Biol 2, I-37134 Verona, Italy; Univ Catania, Inst Hyg & Prevent Med, Catania, Italy; Univ Pavia, Dept Appl Hlth Sci, I-27100 Pavia, Italy; Natl Hlth Serv, CPA, Resp Med Unit, Turin, Italy; Univ Pavia, IRCCS San Matteo, Inst Resp Dis, I-27100 Pavia, Italy	University of Verona; University of Catania; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia	de Marco, R (corresponding author), Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, Inst Biol 2, Strada Le Grazie 8, I-37134 Verona, Italy.		de Marco, Roberto/A-5470-2008; Bono, Roberto/J-8954-2012; faustini, massimo/K-6595-2017; SESM, SESM/C-1440-2008; Bucca, Caterina/C-9886-2009; Verlato, Giovanna/H-2202-2018; Pistelli, Francesco/Y-8270-2019; Struzzo, Pierluigi/I-7502-2012; Carolei, Adriana/AAQ-7656-2021	Bono, Roberto/0000-0002-2471-6594; faustini, massimo/0000-0003-2182-1003; Bucca, Caterina/0000-0002-9941-9236; Grassi, Mario/0000-0001-6612-8566; Corsico, Angelo Guido/0000-0002-8716-4694; /0000-0003-2517-6515; perfetti, luca/0000-0001-7646-8214; Verlato, Giovanna/0000-0003-4613-7427; Pistelli, Francesco/0000-0001-5612-6364; Struzzo, Pierluigi/0000-0003-0570-3103; Cerveri, Isa/0000-0003-0337-043X; Montomoli, Cristina/0000-0002-8526-5846; Carolei, Adriana/0000-0002-5254-8532; LOCATELLI, Francesca/0000-0001-9190-7190				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; Burney P, 1996, EUR RESPIR J, V9, P687; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; de Marco R, 1999, EUR RESPIR J, V14, P1044, DOI 10.1183/09031936.99.14510449; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; DEMARCO R, 2001, EUR RESPIR J, V18, pS110; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Grol MH, 1996, ALLERGY, V51, P855; Huovinen E, 1999, CHEST, V115, P928, DOI 10.1378/chest.115.4.928; Jarvis D, 1998, EUR RESPIR J, V11, P651; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Martinez FD, 1999, ALLERGY, V54, P24, DOI 10.1111/j.1398-9995.1999.tb04384.x; Marubini E, 1995, ANAL SURVIVAL DATA C; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Pagano R, 1998, TUMORI, V84, P456, DOI 10.1177/030089169808400404; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, P1107, DOI 10.1164/ajrccm.164.7.2107130b; Ronmark E, 1999, THORAX, V54, P611, DOI 10.1136/thx.54.7.611; Sears MR, 1998, CLIN EXP ALLERGY, V28, P82; Sears MR, 2000, CLIN CHEST MED, V21, P315, DOI 10.1016/S0272-5231(05)70269-0; *STAT CORP, 1997, STAT STAT SOFTW REL; STEWART W, 1989, J CLIN EPIDEMIOL, V42, P869, DOI 10.1016/0895-4356(89)90100-5; Strachan DP, 1996, BRIT MED J, V312, P1195; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; Toren K, 1999, INT J TUBERC LUNG D, V3, P192; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	31	141	141	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					228	235	UNSP 1/81/125600	10.1067/mai.2002.125600	http://dx.doi.org/10.1067/mai.2002.125600			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170262	Bronze			2022-12-18	WOS:000177509800006
J	Oettgen, HC; Geha, RS				Oettgen, HC; Geha, RS			IgE regulation and roles in asthma pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IgE; asthma; allergy; IL-4; IL-4 receptor; IL-13; CD40; CD40 ligand	NF-KAPPA-B; EOSINOPHILIC AIRWAY INFLAMMATION; CLASS SWITCH RECOMBINATION; CELL-DEFICIENT MICE; LOW-AFFINITY RECEPTOR; EPSILON-GERMLINE TRANSCRIPTS; X-LINKED IMMUNODEFICIENCY; CYTIDINE DEAMINASE AID; NK1.1(+) T-CELLS; CD40 LIGAND	Asthma and the predisposition to produce IgE are inherited as linked traits in families. In patients IgE levels correlate with asthma severity and bronchial hyperresponsiveness. The concept that IgE plays a critical role in asthma pathogenesis has driven the development of IgE blockers, which are currently being introduced into clinical use. This review focuses on the mechanisms whereby IgE participates both in immediate hypersensitivity responses in the airways and in the induction of chronic allergic bronchial inflammation. The molecular genetic events that give rise to IgE production by B cells and the cellular and cytokine factors that support IgE production in the bronchial mucosal microenvironment are discussed. It is clear that much remains to be learned regarding the roles of IgE in asthma and the genetic and environmental influences that lead to its production. Over the next few years, the emerging experience with anti-IgE in patients mill provide a more complete understanding of the mechanisms whereby IgE contributes to disease, as well as the therapeutic potential of its inhibition.	Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Oettgen, HC (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Enders 8,320 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031541, U01AI031541, R01AI031136] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31136, AI-31541] Funding Source: Medline; ASC OASH HHS [AS-47714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ASC OASH HHS		Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Adra CN, 1998, CLIN GENET, V54, P362; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Annunziato F, 1998, EUR CYTOKINE NETW, V9, P12; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Avni O, 2000, CURR OPIN IMMUNOL, V12, P654, DOI 10.1016/S0952-7915(00)00158-8; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CEMADAS M, 1999, AM J RESP CELL MOL B, V20, P1; Chen CL, 2000, J IMMUNOL, V165, P5418, DOI 10.4049/jimmunol.165.10.5418; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Christie G, 1997, EUR J IMMUNOL, V27, P3228, DOI 10.1002/eji.1830271221; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FARIS M, 1993, T ASSOC AM PHYSICIAN, V106, P187; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; Gustavsson S, 2000, J IMMUNOL, V164, P3990, DOI 10.4049/jimmunol.164.8.3990; GUSTAVSSON S, 1994, J IMMUNOL, V152, P4793; Haczku A, 1997, AM J RESP CRIT CARE, V156, P1945, DOI 10.1164/ajrccm.156.6.9701087; Haczku A, 2000, AM J RESP CRIT CARE, V161, P952, DOI 10.1164/ajrccm.161.3.9905046; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674, DOI 10.1165/ajrcmb.16.6.9191469; HAMS DP, 2000, NAT IMMUNOL, V1, P475; Harris MB, 1999, MOL CELL BIOL, V19, P7264; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; HOK PG, 1994, J IMMUNOL, V153, P256; Hoshino T, 1999, J IMMUNOL, V162, P5070; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; Iciek LA, 1997, J IMMUNOL, V158, P4769; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; JUNG CM, 1995, J ALLERGY CLIN IMMUN, V95, P77, DOI 10.1016/S0091-6749(95)70155-9; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; Kisselgof AB, 1998, INT IMMUNOL, V10, P1377, DOI 10.1093/intimm/10.9.1377; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83, DOI 10.1159/000236807; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lantz CS, 1997, J IMMUNOL, V158, P2517; LEE WT, 1987, J IMMUNOL, V139, P1191; LEE WT, 1986, J IMMUNOL, V136, P4573; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; MacLean JA, 1999, AM J RESP CELL MOL, V20, P379, DOI 10.1165/ajrcmb.20.3.3291; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Mayer RJ, 2000, CLIN EXP ALLERGY, V30, P719; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Mehlhop PD, 2000, AM J RESP CELL MOL, V23, P646, DOI 10.1165/ajrcmb.23.5.3954; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; MELVIN AJ, 1995, EUR J IMMUNOL, V25, P426, DOI 10.1002/eji.1830250218; Messner B, 1997, J IMMUNOL, V159, P3330; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULLER K M, 1991, Journal of Dermatological Science, V2, P125, DOI 10.1016/0923-1811(91)90022-P; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Murphy KM, 1999, CURR TOP MICROBIOL, V238, P13; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; OKAYAMA Y, 1995, J IMMUNOL, V155, P1796; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; Peritt D, 1998, J IMMUNOL, V161, P5821; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Pritchard DI, 1997, PARASITOLOGY, V115, pS33, DOI 10.1017/S0031182097001996; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Riffo-Vasquez Y, 2000, CLIN EXP ALLERGY, V30, P728; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROLLING C, 1995, ONCOGENE, V10, P1757; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SADICK MD, 1986, J IMMUNOL, V136, P655; SADICK MD, 1987, J IMMUNOL, V139, P1303; Saini SS, 1999, J IMMUNOL, V162, P5624; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P333, DOI 10.1016/S0091-6749(05)80096-X; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SHERR E, 1989, J IMMUNOL, V142, P481; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; STAVNEZER J, 1991, NATURE, V351, P447, DOI 10.1038/351447b0; Stutz AM, 1999, J IMMUNOL, V163, P4383; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Thienes CP, 1997, J IMMUNOL, V158, P5874; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; UCHIBAYASHI N, 1989, J IMMUNOL, V142, P3901; van de Rijn M, 1998, J ALLERGY CLIN IMMUN, V102, P65, DOI 10.1016/S0091-6749(98)70056-9; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; Viola JPB, 1999, J CLIN IMMUNOL, V19, P98, DOI 10.1023/A:1020502516196; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; YOSHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P11931, DOI 10.1073/pnas.92.25.11931; YOUNG HA, 1994, J IMMUNOL, V153, P3603; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	145	141	145	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					429	440		10.1067/mai.2001.113759	http://dx.doi.org/10.1067/mai.2001.113759			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240941	Bronze			2022-12-18	WOS:000167793300002
J	Vliagoftis, A; Schwingshackl, A; Milne, CD; Duszyk, M; Hollenberg, MD; Wallace, JL; Befus, AD; Moqbel, R				Vliagoftis, A; Schwingshackl, A; Milne, CD; Duszyk, M; Hollenberg, MD; Wallace, JL; Befus, AD; Moqbel, R			Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inflammation; lung; matrix metalloproteinases; trypsin; corticosteroids	ENDOTHELIAL-CELLS; GELATINASE-A; IN-VITRO; RECEPTOR-2-ACTIVATING PEPTIDES; RECEPTOR DISTINCT; THROMBIN RECEPTOR; IV COLLAGENASE; EXPRESSION; INHIBITION; TRYPTASE	Background: Matrix metalloproteinases (MMPs) digest extracellular matrix components and might be important mediators of tissue remodeling. Proteinase activated receptor-2 (PAR-2) is expressed in a variety of cell types including epithelial cells. PAR-2 receptors are activated by serine proteases such as trypsin and mast cell tryptase and have been implicated in inflammation. Objective: To study the effects of PAR-2-mediated airway epithelial cell activation on the production of MMP-9. Methods: A specific PAR-2-activating peptide and trypsin were used to activate the human airway epithelial cell line A549 as well as primary cultures of small airway epithelial cells (SAEC). MMP-2 and MMP-9 messenger RNA and enzymatic activity were evaluated by RT-PCR and gelatin zymography; respectively. Results: PAR-2-activating peptides upregulated MMP-9 mRNA expression and release of MMP-9 enzymatic activity from airway epithelial cells but had no effect on MMP-2 production. Dexamethasone and budesonide (10(-6) to 10(-10) mmol) inhibited PAR-2-mediated MMP-9 release. Pretreatment with indomethacin indicated that MMP-9 release was not prostaglandin dependent. Inhibitors of the MAP kinase MEK-1, and NF kappa B showed that both pathways are important for PAR-2-mediated MMP-9 release. Trypsin, a physiologic PAR-2 activator, upregulated MMP-9 but also MMP-2 release from airway epithelial cells. Conclusion: PAR-2 receptors appear to play an important role in the regulation of MMP-9 release from airway epithelial cells. As such, these receptors may be critical elements in tissue remodeling in asthma and other inflammatory conditions in the airways.	Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Dept Physiol, Edmonton, AB T6G 2S2, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada	University of Alberta; University of Alberta; University of Calgary	Moqbel, R (corresponding author), Univ Alberta, Dept Med, Pulm Res Grp, 574 HMRC, Edmonton, AB T6G 2S2, Canada.		Befus, Dean/C-5561-2009; Vliagoftis, Harissis/C-6480-2013; Wallace, John/AAL-3763-2021; Hollenberg, Morley/AFV-6966-2022	Befus, Dean/0000-0002-1611-2897; Vliagoftis, Harissis/0000-0002-5029-855X; 				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DEVARAJAN P, 1992, J BIOL CHEM, V267, P25228; Duncan ME, 1998, EUR J BIOCHEM, V258, P37, DOI 10.1046/j.1432-1327.1998.2580037.x; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Fang KC, 1999, J IMMUNOL, V162, P5528; Fiedler MA, 1998, AM J RESP CELL MOL, V19, P259, DOI 10.1165/ajrcmb.19.2.3149; Gipson TS, 1999, J IMMUNOL, V162, P3653; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Howells GL, 1997, J CELL SCI, V110, P881; Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581; Johnson JL, 1998, ARTERIOSCL THROM VAS, V18, P1707, DOI 10.1161/01.ATV.18.11.1707; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; King C, 1998, J IMMUNOL, V161, P3645; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Kumagai K, 1999, J IMMUNOL, V162, P4212; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V97, P153, DOI 10.1016/S0091-6749(96)80215-6; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; LEPPERT D, 1995, J IMMUNOL, V154, P4379; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; Roy SS, 1998, BRIT J PHARMACOL, V123, P1434, DOI 10.1038/sj.bjp.0701726; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; SLEINHOFF M, 2000, NAT MED, V6, P151; Stanton H, 1998, J CELL SCI, V111, P2789; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; von Bredow DC, 1998, BIOCHEM J, V331, P965, DOI 10.1042/bj3310965; Yao PM, 1998, AM J RESP CELL MOL, V18, P813, DOI 10.1165/ajrcmb.18.6.2984; Yao PM, 1996, J BIOL CHEM, V271, P15580, DOI 10.1074/jbc.271.26.15580; Yasuoka S, 1997, AM J RESP CELL MOL, V16, P300, DOI 10.1165/ajrcmb.16.3.9070615; Zeng L, 1996, J BIOL CHEM, V271, P27744, DOI 10.1074/jbc.271.44.27744; Zhang J, 1998, BIOL REPROD, V59, P693, DOI 10.1095/biolreprod59.3.693; Zhang YH, 1998, J IMMUNOL, V161, P3071	52	141	151	1	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					537	545		10.1067/mai.2000.109058	http://dx.doi.org/10.1067/mai.2000.109058			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984375				2022-12-18	WOS:000089471900018
J	Kay, GG				Kay, GG			The effects of antihistamines on cognition and performance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB   11, 1999	WASHINGTON, D.C.			allergic rhinitis; antihistamines; functional capacity		Allergic diseases are responsible for substantially more disability than is generally realized. Allergic rhinitis alone results in 3.5 million lost workdays and 2 million missed school days in the United States each year. Comorbid conditions such as asthma and sinusitis can be disabling as well, resulting each year in more than 10 million missed school days and more than 73 million days of restricted activity, respectively. Antihistamines continue to be the mainstay of treatment for allergic disorders. In the case of the first-generation antihistamines, however, the treatment may well be worse than the disease. Although these agents are effective H-1-receptor antagonists, they are also highly lipophilic and readily cross the blood-brain barrier, causing considerable sedation. The second-generation agents are more lipophobic and possess different ionic charges than the first-generation antihistamines, As a result, they are far less likely to cross the blood-brain barrier and, for that reason, cause little if any sedation. In a recent comparative trial, subjects who were treated with the first-generation agent diphenhydramine were found to have significant performance deficits on tests of divided attention, working memory, vigilance, and speed. By contrast, subjects who were treated with the second-generation antihistamine loratadine performed as well as subjects who were treated with placebo. The sedative effects of the first-generation agents persist well into the next day and thus can potentially interfere with daytime performance and safety even when taken the night before. It is therefore recommended that patients whose occupations require vigilance, divided attention, or concentration receive only second-generation antihistamines.	Georgetown Univ, Sch Med, Dept Neuropsychol, Neuropsychol Div, Washington, DC 20007 USA	Georgetown University	Kay, GG (corresponding author), Georgetown Univ, Sch Med, Dept Neuropsychol, Neuropsychol Div, 3800 Reservoir Rd NW, Washington, DC 20007 USA.							American Academy of Allergy, 1998, TASK FORC ALL DIS PR, P1; Gilmore TM, 1996, AM J IND MED, V30, P234; HEATON RK, 1991, PSYCHOL ASSESSMENT R; Kay GG, 1997, AM J MANAG CARE, V3, P1843; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; OHANLON JF, 1998, J RESP DIR, V9, P512; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Warren RSH, 1981, ALCOHOL DRUGS TRAFFI, P203; YANAI K, 1995, BRIT J PHARMACOL, V116, P1649, DOI 10.1111/j.1476-5381.1995.tb16386.x	9	141	148	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S622	S627						6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	328QU	10856168				2022-12-18	WOS:000087862200006
J	Macfarlane, AJ; Kon, OM; Smith, SJ; Zeibecoglou, K; Khan, LN; Barata, LT; McEuen, AR; Buckley, MG; Walls, AF; Meng, Q; Humbert, M; Barnes, NC; Robinson, DS; Ying, S; Kay, AB				Macfarlane, AJ; Kon, OM; Smith, SJ; Zeibecoglou, K; Khan, LN; Barata, LT; McEuen, AR; Buckley, MG; Walls, AF; Meng, Q; Humbert, M; Barnes, NC; Robinson, DS; Ying, S; Kay, AB			Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; eosinophil; mast cell; skin; bronchial provocation	MAJOR BASIC-PROTEIN; PERIPHERAL-BLOOD BASOPHILS; IL-4 MESSENGER-RNA; ANTIGEN CHALLENGE; BRONCHIAL BIOPSIES; MEDIATOR RELEASE; EXPRESSION; IDENTIFICATION; INTERLEUKIN-4; IMMEDIATE	Background: Previous studies used indirect methods to identify basophils in the bronchi in asthma, and the numbers were not compared with eosinophils and mast cells. Furthermore, differences in basophil numbers between atopic and nonatopic asthma at baseline and between late-phase skin and asthmatic reactions have not been previously documented. Objective: The basophil granule-specific mAb BB1 was used to identify basophils in (1) bronchial biopsy specimens from atopic asthmatic subjects and nonatopic asthmatic subjects and control subjects, (2) biopsy specimens from atopic asthmatic subjects before and after inhalational allergen challenge, and (3) late-phase skin reactions. Basophil numbers were compared with EG2(+) eosinophils and tryptase(+) mast cells. Methods: Cells were enumerated in bronchial and skin biopsy specimens by means of immunohistochemistry with the alkaline phosphatase-antialkaline phosphatase method. Results: There were elevated numbers of basophils in baseline biopsy specimens in atopic asthmatic subjects compared with atopic control subjects or normal control subjects, although eosinophils and mast cells were 10-fold higher. There was an intermediate number of basophils in nonatopic asthmatic subjects. Basophils increased after allergen inhalation, but again basophils were less than 10% of eosinophils. In contrast, basophils in cutaneous late-phase reactions were approximately 40% of infiltrating eosinophils. The peak of basophil accumulation was at 24 hours, whereas maximal eosinophil infiltration occurred at 6 hours. One third of cutaneous basophils had morphologic appearances suggestive of degranulation. Conclusion: Numerous basophils infiltrated cutaneous late-phase reactions in atopic subjects. However, this cell was not prominent in bronchial biopsy specimens of asthmatic subjects, either at baseline or after allergen challenge.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO9 4XY, Hants, England; Hop Antoine Beclere, Serv Pneumol & Reanimat Resp, Clamart, France; London Chest Hosp, London E2 9JX, England	Imperial College London; University of Southampton; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; University of London; Queen Mary University London	Kay, AB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.			Humbert, Marc/0000-0003-0703-2892; Kon, Onn Min/0000-0003-2647-4688; Taborda Barata, Luis/0000-0001-6649-8890				ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; [Anonymous], 1991, J INVESTIG ALLERGOL, V1, P271; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BENTLEY AM, 1994, J INVEST ALLERG CLIN, V4, P222; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; DENBURG JA, 1994, J ALLERGY CLIN IMMUN, V94, P1135, DOI 10.1016/0091-6749(94)90321-2; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; FROESE A, 1980, Critical Reviews in Immunology, V1, P79; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Khan LN, 1999, J ALLERGY CLIN IMMUN, V103, pS47; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; Kon OM, 1998, ALLERGY, V53, P891, DOI 10.1111/j.1398-9995.1998.tb03997.x; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; Koshino T, 1996, J ASTHMA, V33, P89, DOI 10.3109/02770909609054536; Li HM, 1996, J IMMUNOL, V156, P4833; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MARUYAMA N, 1994, AM J RESP CRIT CARE, V150, P1086, DOI 10.1164/ajrccm.150.4.7921441; McEuen AR, 1999, LAB INVEST, V79, P27; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Ochensberger B, 1996, BLOOD, V88, P3028, DOI 10.1182/blood.V88.8.3028.bloodjournal8883028; OCHENSBERGER B, 1995, BLOOD, V86, P4039, DOI 10.1182/blood.V86.11.4039.bloodjournal86114039; SARMIENTO EU, 1995, J IMMUNOL, V155, P2211; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Ying S, 1997, J IMMUNOL, V158, P5050; Ying S, 1999, J IMMUNOL, V163, P3976; ZEIGER RS, 1993, J ALLERGY CLIN IMMUN, V91, P723, DOI 10.1016/0091-6749(93)90191-H	41	141	145	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				99	107		10.1016/S0091-6749(00)90184-2	http://dx.doi.org/10.1016/S0091-6749(00)90184-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629459				2022-12-18	WOS:000084992100014
J	Lerch, E; Muller, UR				Lerch, E; Muller, UR			Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hymenoptera venom allergy; honeybee venom; Vespula venom; venom immunotherapy; long-term protection	YELLOW JACKET VENOM; HYMENOPTERA VENOM; HONEYBEE VENOM; CHALLENGE; ALLERGY; HYPERSENSITIVITY; ANAPHYLAXIS; CHILDREN; SEVERITY; IGE	Background: Venom immunotherapy (VIT) protects most patients allergic to Hymenoptera stings while booster injections are continued. Few data on long-term protection after discontinuation of treatment are available. Objective: We sought to investigate protection from re-stings over a prolonged period after stopping VIT. Methods: Re-sting data were obtained from 200 of 322 patients in whom VIT had been stopped between 1988 and 1992 after a duration of at least 3 gears. The 25 (12.5%) patients who again developed systemic allergic reactions were compared with 50 matched patients without re-sting reactions. Clinical data and diagnostic parameters (i.e., skin sensitivity and specific IgE and IgG) mere studied. Results: Of the 25 patients who had re-sting reactions, 19 had been treated with bee venom (relapse rate, 15.8%), and six had been treated with Vespula venom (relapse rate, 7.5%). About half of the re-sting reactions occurred on the first resting after stopping VIT. Most of these reactions were mild, whereas the majority of reactions occurring after repeated re-stings were severe. When re-sting reactions were related to the total re-stings per year, an accumulation of sting reactions was observed in years 3 to 5 after stopping VIT, Patients with re-sting reactions had been receiving VIT for a significantly shorter duration (43.35 months) than those with continued protection (54.65 months) (p < 0.01). Of the diagnostic parameters, only a negative intracutaneous skin test at 10(-3) gm/L predicted long-term protection reliably, Conclusion: Venom immunotherapy of 3 to 5 years duration induces long-term protection in most patients. In rare occasions severe re-sting reactions may, however, occur, especially after repeated re-stings.	Zieglerspital Bern, Div Internal Med, CH-3007 Bern, Switzerland		Muller, UR (corresponding author), Zieglerspital Bern, Div Internal Med, CH-3007 Bern, Switzerland.							BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; GOLDEN D B K, 1991, Journal of Allergy and Clinical Immunology, V87, P237, DOI 10.1016/0091-6749(91)91675-J; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; GOLDEN DBK, 1997, J ALLERGY CLIN IMMUN, V99, P377; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; MULLER U, 1993, ALLERGY          S14, V48, P36; Muller UR., 1990, INSECT STING ALLERGY; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1991, J ALLERGY CLIN IMMUN, V87, P618, DOI 10.1016/0091-6749(91)90378-2; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; SACHS L, 1978, ANGEWANDTE STAT STAT, P94; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889	25	141	141	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					606	612		10.1016/S0091-6749(98)70167-8	http://dx.doi.org/10.1016/S0091-6749(98)70167-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600496				2022-12-18	WOS:000073697400007
J	Busse, WW; Chervinsky, P; Condemi, J; Lumry, WR; Petty, TL; Rennard, S; Townley, RG				Busse, WW; Chervinsky, P; Condemi, J; Lumry, WR; Petty, TL; Rennard, S; Townley, RG			Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting of the American-Academy-of-Allergy-and-Immunology	MAR, 1994	ANAHEIM, CALIFORNIA	Amer Acad Allergy & Immunol		asthma; budesonide; inhalation; glucocorticosteroids; Turbuhaler	LONG-TERM TREATMENT; BECLOMETHASONE DIPROPIONATE; INHALED CORTICOSTEROIDS; BRONCHIAL-ASTHMA; MODERATE; EFFICACY; AEROSOL; HYPERRESPONSIVENESS; THERAPY	Background: Airway inflammation is a hallmark of asthma, therefore current treatment recommendations include the use of inhaled glucocorticosteroids (GCS). However, there is little evidence that the effects of inhaled GCS are dose dependent. Objectives: The objective of this study was to assess the efficacy and safety of a second-generation GCS, budesonide, delivered by Turbuhaler, in adults with chronic asthma. Methods: In a 12-week, randomized, double-blind, multi-center, parallel-group study, 473 subjects 18 to 70 years of age received either placebo or budesonide (200, 400, 800, or 1600 mu g total daily dose) administered twice daily. Primary efficacy end points were mean change from baseline for FEV1 and morning peak expiratory flow. Safety was assessed by reported adverse events and by a cosyntropin-stimulation test. Results: The mean baseline FEV1 was 63% to 66% of predicted normal value between groups. All doses of budesonide were more effective than placebo (p < 0.001). The mean changes in morning peak expiratory flow were 12, 22, 27, and 30 L/min in the 200, 400, 800, and 1600 mu g budesonide total daily dose groups, respectively, and -27 L/min for the placebo group. A statistically significant dose-response effect for the mean change from baseline over the 12-week study was seen for both morning peak expiratory flow and FEV1. Budesonide-treated subjects also demonstrated significant reduction in asthma symptoms and bronchodilator use compared with placebo. There were no clinically significant differences in treatment-related adverse experiences among groups. Conclusions: Budesonide administered by Turbuhaler exhibited a dose response and was effective at low doses. It was well tolerated and significantly more effective than placebo.	Univ Hosp CSC, Madison, WI USA; New England Res Ctr, N Dartmouth, MA USA; Genessee Valley Med Ctr, Rochester, NY USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Healthone Ctr Hlth Sci, Denver, CO USA; Univ Nebraska Hosp, Omaha, NE USA; Creighton Univ, Ctr Allerg Dis, Omaha, NE 68178 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Nebraska System; University of Nebraska Medical Center; Creighton University	Busse, WW (corresponding author), Univ Wisconsin, Sch Med, Madison, WI 53792 USA.							BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BOE J, 1989, ALLERGY, V44, P349, DOI 10.1111/j.1398-9995.1989.tb00457.x; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; ELLULMICALLEF R, 1983, BRIT J CLIN PHARMACO, V15, P419, DOI 10.1111/j.1365-2125.1983.tb01524.x; GADDIE J, 1973, LANCET, V2, P280; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; JACKSON C, 1995, BRIT J GEN PRACT, V45, P683; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAURSEN LC, 1986, EUR J RESPIR DIS, V68, P19; MOLEMA J, 1989, EUR RESPIR J, V2, P308; MORRIS JF, 1988, CHEST, V93, P123, DOI 10.1378/chest.93.1.123; NOONAN MJ, 1996, J ALLERGY CLIN IMMUN, V97, pP251; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TUKIAINEN P, 1987, EUR J RESPIR DIS, V70, P239; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317	24	141	145	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				457	463		10.1016/S0091-6749(98)70353-7	http://dx.doi.org/10.1016/S0091-6749(98)70353-7			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564797				2022-12-18	WOS:000073113500006
J	DURHAM, SR; LOEGERING, DA; DUNNETTE, S; GLEICH, GJ; KAY, AB				DURHAM, SR; LOEGERING, DA; DUNNETTE, S; GLEICH, GJ; KAY, AB			BLOOD EOSINOPHILS AND EOSINOPHIL-DERIVED PROTEINS IN ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	Imperial College London; Mayo Clinic								ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; CROMWELL O, 1986, HDB EXPT IMMUNOLOGY, V4, pCH127; Dacie JV., 1984, PRACTICAL HAEMATOLOG, V6, P42; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUNNILL MS, 1978, ALLERGY PRINCIPLES P, P678; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GLEICH GJ, 1986, 12 P INT C ALL CLIN, P124; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; HORN BR, 1975, NEW ENGL J MED, V292, P2252; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; JUNIPER FE, 1981, J ALLERGY CLIN IMMUN, V68, P347; KAY AB, 1971, J IMMUNOL, V107, P899; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; LOWELL FC, 1967, J AMER MED ASSOC, V202, P875, DOI 10.1001/jama.202.9.875; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	26	141	141	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				931	936		10.1016/0091-6749(89)90391-6	http://dx.doi.org/10.1016/0091-6749(89)90391-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2480971				2022-12-18	WOS:A1989CG29300012
J	MICHEL, L; DEVOS, C; RIHOUX, JP; BURTIN, C; BENVENISTE, J; DUBERTRET, L				MICHEL, L; DEVOS, C; RIHOUX, JP; BURTIN, C; BENVENISTE, J; DUBERTRET, L			INHIBITORY EFFECT OF ORAL CETIRIZINE ON INVIVO ANTIGEN-INDUCED HISTAMINE AND PAF-ACETHER RELEASE AND EOSINOPHIL RECRUITMENT IN HUMAN-SKIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP HENRI MONDOR,SERV DERMATOL,INSERM,U312,F-94010 CRETEIL,FRANCE; UNION CHIM BELGE,PHARMACEUT SECTOR,BRAINE ALLEUD,BELGIUM; INSERM,U200,F-92140 CLAMART,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UCB Pharma SA; Institut National de la Sante et de la Recherche Medicale (Inserm)			Michel, Laurence/E-8605-2017					ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BENVENISTE J, 1974, NATURE, V249, P581, DOI 10.1038/249581a0; BENYON RC, 1987, J IMMUNOL, V138, P861; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; COYLE AG, 1987, CLIN RES, V35, P254; DEVOS C, 1987, ANN ALLERGY, V59, P278; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOUGLAS WW, 1970, PHARM BASIS THERAPEU; DUBERTRET L, 1982, J INVEST DERMATOL, V79, P74, DOI 10.1111/1523-1747.ep12500028; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; GLEICH GG, 1986, B EUR PHYSIOPATH RES, V22, P62; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; HENOCQ E, 1986, LANCET, V1, P1378; HORNER FA, 1968, ANN ALLERGY, V26, P107; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; JOUVINMARCHE E, 1984, FED PROC, V43, P1924; JUHLIN L, 1987, J ALLERGY CLIN IMMUN, V80, P599, DOI 10.1016/0091-6749(87)90014-5; LEBEL B, 1983, ANAL BIOCHEM, V133, P16, DOI 10.1016/0003-2697(83)90217-8; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; LEVINE BB, 1968, J CLIN INVEST, V47, P556, DOI 10.1172/JCI105752; Lewis T., 1927, BLOOD VESSELS HUMAN; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1984, ASTHMA PHYSL IMMUNOP, P1; MATTHEWS CNA, 1979, BRIT J DERMATOL, V101, P57, DOI 10.1111/j.1365-2133.1979.tb15293.x; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; ODONNELL MC, 1983, J IMMUNOL, V123, P2925; OFLAHERTY JT, 1983, CLIN REV ALLERG, V1, P353; REBUCK JW, 1955, ANN NY ACAD SCI, V59, P757, DOI 10.1111/j.1749-6632.1955.tb45983.x; RIHOUX JP, 1987, ANN ALLERGY, V59, P235; ROCKLIN RE, 1982, IMMUNOPHARMACOLOGY, P49; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SPRY CJF, 1985, IMMUNOL TODAY, V6, P332, DOI 10.1016/0167-5699(85)90130-6; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; VALONE F, 1987, J ALLERGY CLIN IMMUN, V79, P248; VARGAFTIG BB, 1987, BRIT MED BULL, V43, P312, DOI 10.1093/oxfordjournals.bmb.a072185; Walker I C, 1917, J Med Res, V35, P487; WARDLAW AJ, 1986, J ALLERGY CLIN IMMUN, V77, P236; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WASSERMAN SI, 1983, BIOCH PHYSL SKIN, V2, P878; WEI YF, 1986, J IMMUNOL, V137, P1993; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; WELLER PF, 1983, IMMUNOBIOLOGY EOSINO, P145; WILCOXON F, 1945, BIOMETRICS, V1, P800	51	141	141	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					101	109		10.1016/0091-6749(88)90058-9	http://dx.doi.org/10.1016/0091-6749(88)90058-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	2899102				2022-12-18	WOS:A1988P400400017
J	ELIASSON, O; SCHERZER, HH; DEGRAFF, AC				ELIASSON, O; SCHERZER, HH; DEGRAFF, AC			MORBIDITY IN ASTHMA IN RELATION TO THE MENSTRUAL-CYCLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CONNECTICUT,HARTFORD HOSP,CTR HLTH,DEPT MED,HARTFORD,CT 06112; NEW BRITAIN GEN HOSP,DEPT MED,NEW BRITAIN,CT 06050	Hartford Hospital; University of Connecticut								AOYAMA Y, 1965, JPN J ALLERGY, V14, P583; BARKMAN RP, 1981, MED J AUSTRALIA, V1, P316; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; BUDOFF PW, 1982, NEW ENGL J MED, V307, P714, DOI 10.1056/NEJM198209163071203; CHIRAY M, 1940, PRESSE MED, V16, P201; Claude F., 1938, PRESSE MED, V38, P755; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DALTON K, 1984, PREMENSTRUAL SYNDROM, P46; DOWNIE J, 1974, J PHYSIOL-LONDON, V236, P465, DOI 10.1113/jphysiol.1974.sp010446; ELIASSON O, 1985, American Review of Respiratory Disease, V131, pA41; Eliasson O, 1984, Conn Med, V48, P777; FERRIS BG, 1978, AM REV RESPIR DIS S, V118, P10; GILANTE SA, 1981, PRIMER BIOSTATISTICS, P87; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HETZEL MR, 1981, THORAX, V36, P481, DOI 10.1136/thx.36.7.481; KOULLAPIS EN, 1980, ACTA ENDOCRINOL-COP, V93, P123, DOI 10.1530/acta.0.0930123; REES L, 1963, J PSYCHOSOM RES, V7, P191, DOI 10.1016/0022-3999(63)90003-5; REINBERG A, 1974, CHRONOBIOLOGICAL ASP, P305; SIEGEL S, 1956, NONPARAMETRIC STAT, P202; VIJAYAKUMAR R, 1981, AM J OBSTET GYNECOL, V141, P313; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WOOD C, 1980, BRIT J OBSTET GYNAEC, V87, P627, DOI 10.1111/j.1471-0528.1980.tb05018.x; WULFSOHN N. L., 1964, S AFRICAN MED JOUR, V38, P173; 1962, AM REV RESPIR DIS, V85, P762; 1979, SAS USERS GUIDE, P183	27	141	144	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				87	94		10.1016/0091-6749(86)90328-3	http://dx.doi.org/10.1016/0091-6749(86)90328-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3944377	Bronze			2022-12-18	WOS:A1986AZD3600016
J	SULLIVAN, TJ; YECIES, LD; SHATZ, GS; PARKER, CW; WEDNER, HJ				SULLIVAN, TJ; YECIES, LD; SHATZ, GS; PARKER, CW; WEDNER, HJ			DESENSITIZATION OF PATIENTS ALLERGIC TO PENICILLIN USING ORALLY-ADMINISTERED BETA-LACTAM ANTIBIOTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235; WASHINGTON UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,ST LOUIS,MO 63130; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63130; SUNY STONY BROOK,DEPT INTERNAL MED,STONY BROOK,NY 11794	University of Texas System; University of Texas Dallas; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	SULLIVAN, TJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SECT,DALLAS,TX 75235, USA.				NIAID NIH HHS [K07-AI-00414] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1971, N ENGL J MED, V185, P22; AHLSTEDT S, 1980, CRC CRIT R TOXICOL, V1, P219; BALME HW, 1954, BRIT MED J, V1, P500, DOI 10.1136/bmj.1.4860.500; BASOMBA A, 1978, CLIN ALLERGY, V8, P341, DOI 10.1111/j.1365-2222.1978.tb00469.x; BECK CA, 1953, JAMA-J AM MED ASSOC, V153, P1170, DOI 10.1001/jama.1953.02940300028009; CHIARAMONTE JS, 1978, ANN ALLERGY, V41, P111; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P782; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P798; DEHAAN P, 1979, ALLERGY, V34, P111; DELAGE C, 1972, Journal of Forensic Sciences, V17, P525; FELLNER MJ, 1970, J ALLERGY, V45, P55, DOI 10.1016/0021-8707(70)90017-1; GILLMAN S A, 1972, Clinical Allergy, V2, P63, DOI 10.1111/j.1365-2222.1972.tb01268.x; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREEN GR, 1967, ANN INTERN MED, V67, P235, DOI 10.7326/0003-4819-67-2-235; GRIECO MH, 1964, ANN INTERN MED, V60, P204, DOI 10.7326/0003-4819-60-2-204; HERMAN R, 1979, CUTIS, V24, P232; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; KRAFT D, 1976, BRIT J DERMATOL, V94, P593, DOI 10.1111/j.1365-2133.1976.tb05156.x; KRAPIN D, 1962, NEW ENGL J MED, V267, P820, DOI 10.1056/NEJM196210182671607; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1967, ANN NY ACAD SCI, V145, P298, DOI 10.1111/j.1749-6632.1967.tb50227.x; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; LEVINE BB, 1976, MANUAL CLIN IMMUNOLO, P637; LEVINE BB, 1973, J INFECT DIS, V128, P364; LEVINE MI, 1960, J ALLERGY, V31, P487, DOI 10.1016/0021-8707(60)90082-4; MASON L H, 1957, Can Med Assoc J, V76, P958; Miller RR, 1976, DRUG EFFECTS HOSPITA; ODONNOVAN WJ, 1946, LANCET, V2, P444; PARKER CW, 1967, METHODS IMMUNOLOGY I, V1, P133; PARKER CW, 1972, CRC CRIT R TOXICOL, V1, P161; PARKER CW, 1980, CLIN IMMUNOLOGY, P1208; PARKER CW, 1980, CLIN IMMUNOLOGY, P1219; PARKER CW, 1979, NIH79387 PUBL, P508; PEDERSEN.J, 1969, ACTA ALLERGOL, V24, P333, DOI 10.1111/j.1398-9995.1969.tb03748.x; REISMAN RE, 1962, J ALLERGY, V33, P178, DOI 10.1016/0021-8707(62)90007-2; ROBERTS AE, 1953, AMA ARCH IND HYG OCC, V8, P340; SPARK RP, 1971, AM J CLIN PATHOL, V56, P407; SPATH P, 1979, ALLERGY, V34, P405, DOI 10.1111/j.1398-9995.1979.tb02010.x; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2; ZAR JH, BIOSTATISTICAL ANAL, P262	42	141	142	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					275	282		10.1016/S0091-6749(82)80004-3	http://dx.doi.org/10.1016/S0091-6749(82)80004-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	7061769				2022-12-18	WOS:A1982NF69700004
J	Mullins, RJ; Dear, KBG; Tang, MLK				Mullins, Raymond James; Dear, Keith B. G.; Tang, Mimi L. K.			Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; anaphylaxis; epidemiology	FOOD-INDUCED ANAPHYLAXIS; UNITED-STATES; PEANUT ALLERGY; RISK-FACTORS; INFANTS; PREVALENCE; CHILDREN; EPIDEMIOLOGY; CHILDHOOD; PATTERNS	Background: Studies from the United Kingdom, the United States, and Australia have reported increased childhood food allergy and anaphylaxis prevalence in the 15 years after 1990. Objective: We sought to examine whether childhood food allergy/anaphylaxis prevalence has increased further since 2004-2005. Methods: We examined hospital anaphylaxis admission rates between 2005-2006 and 2011-2012 and compared findings with those from 1998-1999 to 2004-2005. Results: Overall population food-related anaphylaxis admission rates (per 10 5 population per year) increased from 5.6 in 2005-2006 to 8.2 in 2011-2012 (a 1.5-fold increase over 7 years). The highest rates occurred in children aged 0 to 4 years (21.7 in 2005-2006 and 30.3 in 2011-2012, a 1.4-fold increase), but the greatest proportionate increase occurred in those aged 5 to 14 years (5.8-12.1/10(5) population/y, respectively, a 2.1-fold increase) compared with those aged 15 to 29 years and 30 years or older (a 1.5- and 1.3-fold increase, respectively). Not only did absolute food-related anaphylaxis admissions increase, but the modeled year-on-year rate of increase in overall food-related anaphylaxis admissions also increased over time from an additional 0.35 per 10(5) population/y in 1998-1999 (all ages) to 0.49 in 2004-2005 and 0.63 in 2011-2012 (P < .001). Conclusions: Food-related anaphylaxis has increased further in all age groups since 2004-2005. Although the major burden falls on those aged 0 to 4 years, there is preliminary evidence for a recent acceleration in incidence rates in those aged 5 to 14 years. This contrasts with the previous decade in which the greatest proportionate increase was in those aged 0 to 4 years. These findings suggest a possible increasing burden of disease among adolescents and adults who carry the highest risk for fatal anaphylaxis.	[Mullins, Raymond James] John James Med Ctr, Canberra, ACT, Australia; [Mullins, Raymond James] Australian Natl Univ Canberra, Sch Med, Canberra, ACT, Australia; [Mullins, Raymond James] Univ Canberra, Hlth Sci, Canberra, ACT 2601, Australia; [Dear, Keith B. G.] Univ Durham, Duke Global Hlth Inst, Durham DH1 3HP, England; [Dear, Keith B. G.] Duke Kunshan Univ, Kunshan, Jiangsu, Peoples R China; [Tang, Mimi L. K.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia	Australian National University; University of Canberra; Durham University; Duke Kunshan University; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne	Mullins, RJ (corresponding author), John James Med Ctr, 175 Strickland Crescent, Deakin, ACT 2600, Australia.	rmullins@allergycapital.com.au	Mullins, Raymond James/H-8013-2019; Tang, Mimi/ABD-8350-2020	Mullins, Raymond James/0000-0002-0267-1591; Tang, Mimi/0000-0002-3839-5293; Dear, Keith/0000-0002-0788-7404	Deerfield; GLG Group; Danone Nutricia	Deerfield; GLG Group; Danone Nutricia(Danone Nutricia)	M. L. K. Tang is a board member for the Nestle Nutrition Institute and Danone Nutricia, has received consultancy fees from Deerfield and GLG Group, has received lecture fees from Danone Nutricia, has a patent for a novel treatment for food allergy (pending in the United States, awarded in the European Union, and granted in Australia and New Zealand), and has received travel support from WISC 2014. The rest of the authors declare that they have no relevant conflicts of interest.	Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; Allen KJ, 2012, IMMUNOL ALLERGY CLIN, V32, P35, DOI 10.1016/j.iac.2011.11.008; Bendiks M, 2013, CURR ALLERGY ASTHM R, V13, P487, DOI 10.1007/s11882-013-0382-8; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; [Department of Human Services Australian Government], PHARM BEN SCHEM IT R; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Jackson K, 2013, BFI FILM CLASSICS, P1, DOI 10.1007/978-1-84457-702-6; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Koplin JJ, 2012, ALLERGY, V67, P1415, DOI 10.1111/all.12015; Kotz D, 2011, J ALLERGY CLIN IMMUN, V127, P623, DOI 10.1016/j.jaci.2010.11.021; Lieberman JA, 2011, CURR OPIN ALLERGY CL, V11, P236, DOI 10.1097/ACI.0b013e3283464cf0; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Luccioli S, 2014, PEDIATRICS, V134, pS21, DOI 10.1542/peds.2014-0646E; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; Mullins RJ, 2010, CLIN EXP ALLERGY, V40, P1523, DOI 10.1111/j.1365-2222.2010.03573.x; Mullins RJ, 2007, MED J AUSTRALIA, V186, P618, DOI 10.5694/j.1326-5377.2007.tb01077.x; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; National Hospital Database Principle Diagnosis Cubes, NAT HOSP DAT PRINC D; Nocerino R, 2015, J ALLERGY CLIN IMMUN, V135, P833, DOI 10.1016/j.jaci.2014.12.1912; Norizoe C, 2014, PEDIATR INT, V56, P6, DOI 10.1111/ped.12207; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Patel DA, 2011, J ALLERGY CLIN IMMUN, V128, P110, DOI 10.1016/j.jaci.2011.03.013; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Robertson CF, 2004, MED J AUSTRALIA, V180, P273, DOI 10.5694/j.1326-5377.2004.tb05924.x; Rudders SA, 2014, J ALLERGY CLIN IMMUN, V134, P960, DOI 10.1016/j.jaci.2014.06.018; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; WHO, 2014, INT STAT CLASS DIS R; Zakariaeeabkoo R, 2014, CLIN BIOCHEM, V47, P804, DOI 10.1016/j.clinbiochem.2014.01.033	38	140	144	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					367	375		10.1016/j.jaci.2015.05.009	http://dx.doi.org/10.1016/j.jaci.2015.05.009			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26187235	Bronze			2022-12-18	WOS:000359004900018
J	Orange, JS; Glessner, JT; Resnick, E; Sullivan, KE; Lucas, M; Ferry, B; Kim, CE; Hou, CP; Wang, FX; Chiavacci, R; Kugathasan, S; Sleasman, JW; Baldassano, R; Perez, EE; Chapel, H; Cunningham-Rundles, C; Hakonarson, H				Orange, Jordan S.; Glessner, Joseph T.; Resnick, Elena; Sullivan, Kathleen E.; Lucas, Mary; Ferry, Berne; Kim, Cecilia E.; Hou, Cuiping; Wang, Fengxiang; Chiavacci, Rosetta; Kugathasan, Subra; Sleasman, John W.; Baldassano, Robert; Perez, Elena E.; Chapel, Helen; Cunningham-Rundles, Charlotte; Hakonarson, Hakon			Genome-wide association identifies diverse causes of common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; common variable immunodeficiency; antibody deficiency; genetics; genome-wide association; copy number variation; immunodiagnostics	DEFICIENCY; MUTATIONS; SUSCEPTIBILITY; MACROPHAGES; MANAGEMENT; DISORDERS; UPDATE; LIGAND; GENE; ICOS	Background: Common variable immunodeficiency (CVID) is a heterogeneous immune defect characterized by hypogammaglobulinemia, failure of specific antibody production, susceptibility to infections, and an array of comorbidities. Objective: To address the underlying immunopathogenesis of CVID and comorbidities, we conducted the first genome-wide association and gene copy number variation (CNV) study in patients with CVID. Methods: Three hundred sixty-three patients with CVID from 4 study sites were genotyped with 610,000 single nucleotide polymorphisms (SNPs). Patients were divided into a discovery cohort of 179 cases in comparison with 1,917 control subjects and a replication cohort of 109 cases and 1,114 control subjects. Results: Our analyses detected strong association with the MHC region and association with a disintegrin and metalloproteinase (ADAM) genes (P combined = 1.96 x 10(-7)) replicated in the independent cohort. CNV analysis defined 16 disease-associated deletions and duplications, including duplication of origin recognition complex 4L (ORC4L) that was unique to 15 cases (P = 8.66 x 10(-16)), as well as numerous unique rare intraexonic deletions and duplications suggesting multiple novel genetic causes of CVID. Furthermore, the 1,000 most significant SNPs were strongly predictive of the CVID phenotype by using a Support Vector Machine algorithm with positive and negative predictive values of 1.0 and 0.957, respectively. Conclusion: Our integrative genome-wide analysis of SNP genotypes and CNVs has uncovered multiple novel susceptibility loci for CVID, both common and rare, which is consistent with the highly heterogeneous nature of CVID. These results provide new mechanistic insights into immunopathogenesis based on these unique genetic variations and might allow for improved diagnosis of CVID based on accurate prediction of the CVID clinical phenotypes by using our Support Vector Machine model. (J Allergy Clin Immunol 2011;127:1360-7.)	[Hakonarson, Hakon] Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Ctr Appl Genom, Philadelphia, PA 19104 USA; [Orange, Jordan S.; Sullivan, Kathleen E.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Allergy & Immunol,Philadelphia Res Inst, Philadelphia, PA 19104 USA; [Resnick, Elena; Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, New York, NY USA; [Lucas, Mary; Ferry, Berne; Chapel, Helen] Univ Oxford, Nuffield Dept Med, Oxford, England; [Lucas, Mary; Ferry, Berne; Chapel, Helen] Oxford Radcliffe Hosp, Oxford, England; [Kugathasan, Subra] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Kugathasan, Subra] Childrens Hlth Care Atlanta, Atlanta, GA USA; [Sleasman, John W.; Perez, Elena E.] Univ S Florida, Div Allergy Immunol & Rheumatol, Dept Pediat, St Petersburg, FL 33701 USA; [Baldassano, Robert] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Gastroenterol,Dept Pediat, Philadelphia, PA 19104 USA; [Hakonarson, Hakon] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Genet,Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Icahn School of Medicine at Mount Sinai; University of Oxford; University of Oxford; Emory University; Children's Healthcare of Atlanta (CHOA); State University System of Florida; University of South Florida; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Hakonarson, H (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Ctr Appl Genom, Room 1216E,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	charlotte.cunningham-rundles@mssm.edu; hakonarson@email.chop.edu		orange, jordan/0000-0001-7117-7725; Sullivan, Kathleen/0000-0003-4018-1646; Glessner, Joseph/0000-0001-5131-2811	Children's Hospital of Philadelphia; Cotswold Foundation; Jeffrey Modell foundation; National Institutes of Health (NIH) [AI-079731]; NIHR Oxford Biomedical Research Centre; Baxter Healthcare; Talecris; Primary Immunodeficiency Association; European Commission for EU [201549]; NIH [5R03AI083904, AI-101093, AI-467320, AI-48693]; NIAID [03-22]; David S Gottesman Immunology Chair; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); Florida Department of Health; National Oceanic Atmospheric Administration; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R18AI048693, R03AI083904, R21AI079731, R21AI101093, P01AI061093] Funding Source: NIH RePORTER	Children's Hospital of Philadelphia; Cotswold Foundation; Jeffrey Modell foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Baxter Healthcare; Talecris; Primary Immunodeficiency Association; European Commission for EU; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); David S Gottesman Immunology Chair; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Florida Department of Health; National Oceanic Atmospheric Administration(National Oceanic Atmospheric Admin (NOAA) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Children's Hospital of Philadelphia support was from the Children's Hospital of Philadelphia Institutional Development Award to the Center for Applied Genomics, which funded all genotyping (to H.H.); a Research Development Award from the Cotswold Foundation (to H.H.); the Jeffrey Modell foundation (to J.S.O.); and National Institutes of Health (NIH) grant AI-079731 (to J.S.O.). Oxford support was from the NIHR Oxford Biomedical Research Centre, Baxter Healthcare (general support to the department not specific to this project), Talecris (general support to the department not specific to this project), and the Jeffrey Modell Foundation for unrestricted gifts; the Primary Immunodeficiency Association for the Centre of Excellence award; and the European Commission for EU 7th FP EURO-PADnet number 201549. University of South Florida support was from NIH grant 5R03AI083904 (to E.E.P.). Mount Sinai support was from NIH grants, AI-101093, AI-467320, AI-48693, NIAID Contract 03-22, and the David S Gottesman Immunology Chair (all to C.C.-R.).; Disclosure of potential conflict of interest: J. S. Orange has consultant arrangements with Talecris Biotherapeutics, Baxter Health, CSL Behring, and IBT Reference Labs; is a speaker for Baxter Health; receives research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); is an Elected Officer of the American Academy of Allergy, Asthma & Immunology (AAAAI); and is on the advisory board for the Immune Deficiency Foundation. K. E. Sullivan receives research support from the NIH and is a consultant for the Immune Deficiency Foundation. J. W. Sleasman receives research support from the NIH, the Florida Department of Health, and the National Oceanic Atmospheric Administration. E. E. Perez has consultant arrangements with Baxter and CSL Behring. The rest of the authors have declared that they have no conflict of interest.	Bacchelli C, 2007, CLIN EXP IMMUNOL, V149, P401, DOI 10.1111/j.1365-2249.2007.03461.x; Badour K, 2007, P NATL ACAD SCI USA, V104, P1593, DOI 10.1073/pnas.0610543104; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Boon ACM, 2009, J VIROL, V83, P10417, DOI 10.1128/JVI.00514-09; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; BROADLEY KN, 1989, LAB INVEST, V61, P571; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Cherkassky V, 1997, IEEE Trans Neural Netw, V8, P1564, DOI 10.1109/TNN.1997.641482; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Foerster C, 2010, J IMMUNOL, V184, P7305, DOI 10.4049/jimmunol.1000434; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hsu CW, 2003, PRACTICAL GUIDE SUPP; Imielinski M, 2009, NAT GENET, V41, P1335, DOI 10.1038/ng.489; Kanegane H, 2007, GENES IMMUN, V8, P663, DOI 10.1038/sj.gene.6364431; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; OLERUP O, 1992, P NATL ACAD SCI USA, V89, P10653, DOI 10.1073/pnas.89.22.10653; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Radojkovic M, 2009, AM J MED SCI, V338, P527, DOI 10.1097/MAJ.0b013e3181b7f17c; Rioux JD, 2009, P NATL ACAD SCI USA, V106, P18680, DOI 10.1073/pnas.0909307106; Saltis M, 2007, J IMMUNOL, V178; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Sheikh-Hamad D, 2010, AM J PHYSIOL-RENAL, V298, pF248, DOI 10.1152/ajprenal.00260.2009; Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399-0039.2004.00327.x; Thickett KM, 2002, QJM-INT J MED, V95, P655, DOI 10.1093/qjmed/95.10.655; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; VOLANAKIS JE, 1992, J CLIN INVEST, V89, P1914, DOI 10.1172/JCI115797; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wei Z, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000678; Yong PL, 2010, PEDIAT ALLERG IMM-UK, V21, P852, DOI 10.1111/j.1399-3038.2010.01004.x; Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001	42	140	142	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1360	U79		10.1016/j.jaci.2011.02.039	http://dx.doi.org/10.1016/j.jaci.2011.02.039			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21497890	Bronze, Green Accepted			2022-12-18	WOS:000291048500006
J	Kumagai, Y; Akira, S				Kumagai, Yutaro; Akira, Shizuo			Identification and functions of pattern-recognition receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pattern-recognition receptor; Toll-like receptor; RIG-I-like receptor; Nod-like receptor; C-type lectin receptor; systems biology	PLASMACYTOID DENDRITIC CELLS; DEPENDENT VIRAL RECOGNITION; ADAPTIVE IMMUNE-RESPONSES; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; RIG-I; NLRP3 INFLAMMASOME; INNATE IMMUNITY; ALVEOLAR MACROPHAGES; ANTIVIRAL RESPONSES	Since the identification of Toll-like receptors, our knowledge about pattern-recognition receptors (PRRs) has increased rapidly. Classes of PRRs that have been recently discovered include RIG-I like receptors, Nod-like receptors, and C-type lectin receptors. Recent studies have started to clarify the molecular basis of PRR-ligand interactions, yet the numbers PRRs and their ligands continue to increase. New technologies have elucidated the network regulation of immune responses the cellular and in vivo levels. We review the most recent discoveries about PRRs and their ligands, their roles in intracellular and in vivo regulation of immune responses, and the systems biology of innate immunity. (J Allergy Clin Immunol 2010;125:985-92.)	[Akira, Shizuo] Osaka Univ, Host Def Lab, WPI Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Global COE Program, Frontier Med Underlying Organelle Network Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Akira, S (corresponding author), Osaka Univ, Host Def Lab, WPI Immunol Frontier Res Ctr, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	sakira@biken.osaka-u.ac.jp	Kumagai, Yutaro/L-7732-2018; Akira, Shizuo/C-3134-2009	Kumagai, Yutaro/0000-0002-5039-3979; 				Ablasser A, 2009, NAT IMMUNOL, V10, P1065, DOI 10.1038/ni.1779; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Amit I, 2009, SCIENCE, V326, P257, DOI 10.1126/science.1179050; Anderson P, 2008, NAT IMMUNOL, V9, P353, DOI 10.1038/ni1584; Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Bhoj VG, 2008, P NATL ACAD SCI USA, V105, P14046, DOI 10.1073/pnas.0804717105; Bryant C, 2009, TRENDS CELL BIOL, V19, P455, DOI 10.1016/j.tcb.2009.06.002; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Chiu YH, 2009, CELL, V138, P576, DOI 10.1016/j.cell.2009.06.015; Choi MK, 2009, P NATL ACAD SCI USA, V106, P17870, DOI 10.1073/pnas.0909545106; Coban C, 2010, CELL HOST MICROBE, V7, P50, DOI 10.1016/j.chom.2009.12.003; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fukui R, 2009, J EXP MED, V206, P1339, DOI 10.1084/jem.20082316; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Griffith JW, 2009, J IMMUNOL, V183, P5208, DOI 10.4049/jimmunol.0713552; Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965; Haas T, 2008, IMMUNITY, V28, P315, DOI 10.1016/j.immuni.2008.01.013; Hao SL, 2009, NAT IMMUNOL, V10, P281, DOI 10.1038/ni.1699; Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Ishii KJ, 2008, NATURE, V451, P725, DOI 10.1038/nature06537; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Joly S, 2009, J IMMUNOL, V183, P3578, DOI 10.4049/jimmunol.0901323; Jones MR, 2009, NAT CELL BIOL, V11, P1157, DOI 10.1038/ncb1931; Jung A, 2008, J VIROL, V82, P196, DOI 10.1128/JVI.01640-07; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Kang JY, 2009, IMMUNITY, V31, P873, DOI 10.1016/j.immuni.2009.09.018; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Koyama S, 2007, J IMMUNOL, V179, P4711, DOI 10.4049/jimmunol.179.7.4711; Kumagai Y, 2007, IMMUNITY, V27, P240, DOI 10.1016/j.immuni.2007.07.013; Kumagai Y, 2009, J IMMUNOL, V182, P3960, DOI 10.4049/jimmunol.0804315; Kumar H, 2009, J IMMUNOL, V183, P8061, DOI 10.4049/jimmunol.0902477; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee HK, 2007, SCIENCE, V315, P1398, DOI 10.1126/science.1136880; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Litvak V, 2009, NAT IMMUNOL, V10, P437, DOI 10.1038/ni.1721; Liu L, 2008, SCIENCE, V320, P379, DOI 10.1126/science.1155406; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Matsumoto F, 2008, BIOCHEM BIOPH RES CO, V367, P693, DOI 10.1016/j.bbrc.2007.12.130; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013; Nilsson R, 2006, GENOMICS, V88, P133, DOI 10.1016/j.ygeno.2006.03.022; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824; Pribul PK, 2008, J VIROL, V82, P4441, DOI 10.1128/JVI.02541-07; Ramsey SA, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000021; Rivera R, 2007, VIROLOGY, V363, P48, DOI 10.1016/j.virol.2007.01.033; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Robinson MJ, 2009, J EXP MED, V206, P2037, DOI 10.1084/jem.20082818; Sabbah A, 2009, NAT IMMUNOL, V10, P1073, DOI 10.1038/ni.1782; SAITOH T, 2009, P NATL ACAD SCI US; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Satoh T, 2010, P NATL ACAD SCI USA, V107, P1512, DOI 10.1073/pnas.0912986107; Schlee M, 2009, IMMUNITY, V31, P25, DOI 10.1016/j.immuni.2009.05.008; Sepulveda FE, 2009, IMMUNITY, V31, P737, DOI 10.1016/j.immuni.2009.09.013; Shaw MH, 2009, NAT IMMUNOL, V10, P1267, DOI 10.1038/ni.1816; Shio MT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000559; Tabeta K, 2006, NAT IMMUNOL, V7, P156, DOI 10.1038/ni1297; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; van de Veerdonk FL, 2009, CELL HOST MICROBE, V5, P329, DOI 10.1016/j.chom.2009.02.006; Venkataraman T, 2007, J IMMUNOL, V178, P6444, DOI 10.4049/jimmunol.178.10.6444; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Yamasaki S, 2009, P NATL ACAD SCI USA, V106, P1897, DOI 10.1073/pnas.0805177106; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	83	140	146	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					985	992		10.1016/j.jaci.2010.01.058	http://dx.doi.org/10.1016/j.jaci.2010.01.058			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392481				2022-12-18	WOS:000277686700005
J	Savage, JH; Kaeding, AJ; Matsui, EC; Wood, RA				Savage, Jessica H.; Kaeding, Allison J.; Matsui, Elizabeth C.; Wood, Robert A.			The natural history of soy allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Soy; soy allergy; food allergy; IgE; tolerance; natural history	COWS MILK ALLERGY; FOOD ALLERGY; IGE CONCENTRATIONS; ATOPIC-DERMATITIS; CHILDREN; HYPERSENSITIVITY; WHEAT	Background: Soy allergy is very common, affecting approximately 0.4% of children. It is generally thought that the majority of children with soy allergy develop tolerance in early childhood; however, this has not been examined in a large cohort with soy allergy. Objective: We sought to describe the natural history of soy allergy and identify predictors of oral tolerance/outgrowing soy allergy. Methods: The records of patients with soy allergy seen in a tertiary referral clinic were reviewed. Data collected included soy allergy related symptoms, history of other food allergies and atopic diseases, soy-specific IgE levels, peanut-specific IgE levels, and food challenge results. Results: One hundred thirty-three patients were studied (96 male and 37 female patients). Eighty-five (64%) had asthma, 95 (71%) had allergic rhinitis, and 108 (85%) had atopic dermatitis. Eighty-eight percent had concomitant peanut allergy. The median age at the initial visit was 1 year (range, 2 months to 17.5 years); the median duration of follow-up was 5 years (range, 1-19 years). Kaplan-Meier analysis predicted resolution of soy allergy in 25% by age 4 years, 45% by age 6 years, and 69% by age 10 years. By age 6 years, 59% of children with a peak soy IgE level of less than 5 kU/L, 53% of children with a peak s-IgE level of 5 to 9.9 kU/L, 45% of children with a peak s-IgE level of 10 to 49.9 kU/L, and 18% of children with a peak s-IgE level of greater than 50 kU/L had outgrown soy allergy (P < .01 for trend). Conclusions: In this referral population approximately 50% of children with soy allergy outgrew their allergy by age 7 years. Absolute soy IgE levels were useful predictors of outgrowing soy allergy. (J Allergy Clin Immunol 2010;125:683-6.)	[Savage, Jessica H.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA; [Kaeding, Allison J.; Matsui, Elizabeth C.; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593	National Institutes of Health	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Disclosure of potential conflict of interest: J. H. Savage, E. C. Matsui, and R. A. Wood have received research support from the National Institutes of Health. A. J. Kaeding has declared that she has no conflict of interest.	Ballmer-Weber BK, 2008, CURR OPIN ALLERGY CL, V8, P270, DOI 10.1097/ACI.0b013e3282ffb157; Bruno G, 1997, PEDIAT ALLERG IMM-UK, V8, P190, DOI 10.1111/j.1399-3038.1997.tb00159.x; Keet CA, 2009, ANN ALLERG ASTHMA IM, V102, P410, DOI 10.1016/S1081-1206(10)60513-3; Klemola T, 2002, J PEDIATR-US, V140, P219, DOI 10.1067/mpd.2002.121935; Komata Takatsugu, 2009, Allergology International, V58, P599, DOI 10.2332/allergolint.09-OA-0096; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Wood RA, 2003, PEDIATRICS, V111, P1631	14	140	148	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					683	686		10.1016/j.jaci.2009.12.994	http://dx.doi.org/10.1016/j.jaci.2009.12.994			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226303				2022-12-18	WOS:000275883200026
J	Holloway, JW; Yang, IA; Holgate, ST				Holloway, John W.; Yang, Ian A.; Holgate, Stephen T.			Genetics of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Heritability; genetics; genetic testing; pharmacogenetics; epigenetics	GENOME-WIDE ASSOCIATION; IMPROVED LUNG-FUNCTION; OF-FUNCTION MUTATIONS; DUST-MITE EXPOSURE; SERUM IGE LEVELS; FILAGGRIN MUTATIONS; IMMUNOGLOBULIN-E; POSITIONAL CLONING; SEQUENCE VARIANTS; ORMDL3 EXPRESSION	Allergic diseases are complex genetic diseases resulting from the effect of multiple genetic and interacting environmental factors on their pathophysiology. Recent years have seen considerable progress in unraveling the contribution of these factors to an individual subject's susceptibility to, subsequent development of, and severity of disease. This has resulted in increasing insight into novel areas of allergic disease pathophysiology, for example the significant role played by locally acting tissue susceptibility factors like epithelial/epidermal barrier function and remodeling, such as filaggrin, ADAM33, and GSDML/ORMDL3, in patients with atopic dermatitis and asthma. Furthermore, studies of gene-environment interactions and Mendelian randomization approaches have led to increased insight into the importance of environmental triggers for allergic disease. Studies of the timing of action of genetic variants in determining disease susceptibility have highlighted the importance of in utero development and early life in determining susceptibility to allergic disease. In the future, genetic discoveries in allergic disease will potentially lead to better endophenotyping, prognostication, prediction of treatment response, and insights into molecular pathways to develop more targeted therapy for these conditions. (J Allergy Clin Immunol 2010;125:S81-94.)	[Holloway, John W.; Holgate, Stephen T.] Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Immun, Southampton SO16 6YD, Hants, England; [Holloway, John W.] Southampton Gen Hosp, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England; [Yang, Ian A.] Univ Queensland, Dept Thorac Med, Prince Charles Hosp, Brisbane, Qld, Australia; [Yang, Ian A.] Univ Queensland, Sch Med, Brisbane, Qld, Australia	University of Southampton; University of Southampton; Prince Charles Hospital; University of Queensland; University of Queensland	Holloway, JW (corresponding author), Southampton Gen Hosp, Sch Med, Div MP810 3, Southampton SO16 6YD, Hants, England.	J.W.Holloway@southampton.ac.uk	Yang, Ian A/B-9609-2008; Holloway, John W/B-5424-2009	Yang, Ian A/0000-0001-8338-1993; Holloway, John W/0000-0001-9998-0464	MRC [G0400473, G0800766, G19/34] Funding Source: UKRI; Medical Research Council [G0800766, G19/34, G0400473] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, P1391, DOI 10.1016/j.jaci.2009.03.014; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Benn CS, 2001, CLIN EXP ALLERGY, V31, P1862, DOI 10.1046/j.1365-2222.2001.01128.x; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bierbaum S, 2005, AM J RESP CRIT CARE, V172, P1505, DOI 10.1164/rccm.200506-890OC; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Blakey JD, 2009, THORAX, V64, P381, DOI 10.1136/thx.2008.102053; Bleecker ER, 2006, J ALLERGY CLIN IMMUN, V118, P809, DOI 10.1016/j.jaci.2006.06.036; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Breton CV, 2009, AM J RESP CRIT CARE, V179, P601, DOI 10.1164/rccm.200809-1384OC; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Busse WW, 2008, AM J RESP CRIT CARE, V178, P1002, DOI 10.1164/rccm.200708-1200OC; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Choi JH, 2004, ANN ALLERG ASTHMA IM, V93, P293, DOI 10.1016/S1081-1206(10)61504-9; COOKSON WOCM, 1989, LANCET, V1, P1292; Daley D, 2009, HUM GENET, V125, P445, DOI 10.1007/s00439-009-0643-8; Denham S, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-38; Dezateux C, 1997, BRIT MED BULL, V53, P40; Dijkstra A, 2008, J ALLERGY CLIN IMMUN, V121, P1510, DOI 10.1016/j.jaci.2008.04.015; Duroudier NP, 2009, ALLERGY, V64, P823, DOI 10.1111/j.1398-9995.2009.02015.x; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; HANSON B, 1991, AM J HUM GENET, V48, P873; Hawkins GA, 2008, PHARMACOGENOMICS, V9, P349, DOI 10.2217/14622416.9.3.349; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Henrichsen CN, 2009, HUM MOL GENET, V18, pR1, DOI 10.1093/hmg/ddp011; Hersh CP, 2007, AM J RESP CRIT CARE, V176, P849, DOI 10.1164/rccm.200704-592OC; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, CATALOG PUBLISHED GE; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holloway JW, 2008, NEW ENGL J MED, V359, P2043, DOI 10.1056/NEJMe0807576; Holloway JW, 2008, J ALLERGY CLIN IMMUN, V121, P573, DOI 10.1016/j.jaci.2008.01.007; Holloway JW, 2007, CURR OPIN ALLERGY CL, V7, P69, DOI 10.1097/ACI.0b013e328013d51b; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Islam T, 2009, THORAX, V64, P197, DOI 10.1136/thx.2008.099366; Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kim SH, 2009, CLIN EXP ALLERGY, V39, P203, DOI 10.1111/j.1365-2222.2008.03117.x; Kim Y, 2007, GENES IMMUN, V8, P369, DOI 10.1038/sj.gene.6364394; Klotsman M, 2007, PHARMACOGENET GENOM, V17, P189, DOI 10.1097/FPC.0b013e3280120043; Koppelman GH, 2008, EUR RESPIR J, V32, P775, DOI 10.1183/09031936.00093608; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; Leung TF, 2009, ALLERGY, V64, P621, DOI 10.1111/j.1398-9995.2008.01873.x; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Lima JJ, 2009, CURR OPIN PULM MED, V15, P57, DOI 10.1097/MCP.0b013e32831da8be; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; London SJ, 2009, ANNU REV PUBL HEALTH, V30, P55, DOI 10.1146/annurev.publhealth.031308.100151; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lucas JS, 2004, AM J RESP CRIT CARE, V170, P534, DOI 10.1164/rccm.200311-1583OC; Lyssenko V, 2008, NEW ENGL J MED, V359, P2220, DOI 10.1056/NEJMoa0801869; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McCarthy MI, 2008, HUM MOL GENET, V17, pR156, DOI 10.1093/hmg/ddn289; Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Narayan KMV, 2009, NEW ENGL J MED, V360, P1360, DOI 10.1056/NEJMc082624; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2001, Curr Allergy Asthma Rep, V1, P174, DOI 10.1007/s11882-001-0085-4; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Obermayer-Pietsch BM, 2004, J BONE MINER RES, V19, P42, DOI 10.1359/JBMR.0301207; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Presland RB, 2004, J INVEST DERMATOL, V123, P603, DOI 10.1111/j.0022-202X.2004.23226.x; Pykalainen M, 2005, J ALLERGY CLIN IMMUN, V115, P80, DOI 10.1016/j.jaci.2004.10.006; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Salam MT, 2009, J ALLERGY CLIN IMMUN, V123, P596, DOI 10.1016/j.jaci.2008.12.020; Salter HH, 1860, ASTHMA ITS PATHOLOGY; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Schroer KT, 2009, J PEDIATR-US, V154, P401, DOI 10.1016/j.jpeds.2008.08.040; SCHROER KT, 2008, J PEDIAT, V154, pE1; Sharma S, 2009, AM J RESP CRIT CARE, V179, P356, DOI 10.1164/rccm.200808-1268OC; Sheehan NA, 2008, PLOS MED, V5, P1205, DOI 10.1371/journal.pmed.0050177; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Skadhauge LR, 1999, EUR RESPIR J, V13, P8, DOI 10.1183/09031936.99.13100899; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Smith GD, 2005, BMJ-BRIT MED J, V330, P1076, DOI 10.1136/bmj.330.7499.1076; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Sutherland TE, 2009, CLIN EXP ALLERGY, V39, P943, DOI 10.1111/j.1365-2222.2009.03243.x; SUTTNER K, 2009, J ALLERGY CLIN IMMUN, V123, pE1; Suttner K, 2009, J ALLERGY CLIN IMMUN, V123, P1062, DOI 10.1016/j.jaci.2009.02.025; Tantisira KG, 2009, PHARMACOGENET GENOM, V19, P244, DOI 10.1097/FPC.0b013e328326e0b1; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Yang IA, 2008, THORAX, V63, P555, DOI 10.1136/thx.2007.079426; Yang IA, 2007, CLIN EXP ALLERGY, V37, P1264, DOI 10.1111/j.1365-2222.2007.02798.x; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; 1000 GENOMES DEEP CA	138	140	149	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S81	S94		10.1016/j.jaci.2009.10.071	http://dx.doi.org/10.1016/j.jaci.2009.10.071			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176270				2022-12-18	WOS:000280170600008
J	Schlievert, PM; Strandberg, KL; Lin, YC; Peterson, ML; Leung, DYM				Schlievert, Patrick M.; Strandberg, Kristi L.; Lin, Ying-Chi; Peterson, Marnie L.; Leung, Donald Y. M.			Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; Staphylococcus aureus; superantigens; cytolysins; methicillin resistance	TOXIC-SHOCK-SYNDROME; PANTON-VALENTINE LEUKOCIDIN; RECEPTOR BETA-CHAIN; 3-DIMENSIONAL STRUCTURE; ANTIMICROBIAL PEPTIDES; ALPHA-HEMOLYSIN; INFECTIONS; SKIN; ENTEROTOXIN; EXOTOXIN	Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains have emerged as serious health threats in the last 15 years. They are associated with large numbers of atopic dermatitis skin and soft tissue infections, but when they originate from skin and mucous membranes, have the capacity to produce sepsis and highly fatal pulmonary infections characterized as necrotizing pneumonia, purpura fulminans, and postviral toxic shock syndrome. This review is a discussion of the emergence of 3 major CA-MRSA organisms, designated CA-MRSA USA400, followed by USA300, and most recently USA200. CA-MRSA USA300 and USA400 isolates and their methicillin-sensitive counterparts (community-associated methicillin-sensitive S aureus) typically produce highly inflammatory cytolysins alpha-toxin, gamma-toxin, delta-toxin (as representative of the phenol soluble modulin family of cytolysins), and Panton Valentine leukocidin. USA300 isolates produce the superantigens enterotoxin-like Q and a highly pyrogenic deletion variant of toxic shock syndrome toxin 1 (TSST-1), whereas USA400 isolates produce the superantigens staphylococcal enterotoxin B or staphylococcal enterotoxin C. USA200 CA-MRSA isolates produce small amounts of cytolysins but produce high levels of TSST-1. In contrast, their methicillin-sensitive S aureus counterparts produce various cytolysins, apparently in part dependent on the niche occupied in the host and levels of TSST-1 expressed. Significant differences seen in production of secreted virulence factors by CA-MRSA versus hospital-associated methicillin-resistant S aureus and community-associated methicillin-sensitive S aureus strains appear to be a result of the need to specialize as the result of energy drains from both virulence factor production and methicillin resistance. (J Allergy Clin Immunol 2010;125:39-49.)	[Schlievert, Patrick M.; Strandberg, Kristi L.] Univ Minnesota, Dept Microbiol, Sch Med, Minneapolis, MN 55455 USA; [Lin, Ying-Chi; Peterson, Marnie L.] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; National Jewish Health	Schlievert, PM (corresponding author), Univ Minnesota, Dept Microbiol, Sch Med, 420 Delaware St SE, Minneapolis, MN 55455 USA.	schli001@umn.edu	Lin, Ying-Chi/V-7851-2019	Lin, Ying-Chi/0000-0003-0335-3402; Schlievert, Patrick/0000-0001-8314-9369	National Institutes of Health [R01 AI74283, R01 AI73366, R01 AR41256, R01 U54-AI57153, N01 AI40029]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029, R01AI073366, U54AI057153, R01AI074283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health grants R01s AI74283, AI73366, and AR41256; U54-AI57153 (Great Lakes Regional Center of Excellence in Biodefense and Emerging Infectious Diseases, where P.M.S. is a member); and contract N01 AI40029 to D.Y.M.L.	ALTEMEIER WA, 1983, ARCH SURG-CHICAGO, V118, P281; ALTEMEIER WA, 1981, SURG GYNECOL OBSTET, V153, P481; ALTEMEIER WA, 1982, ANN INTERN MED, V96, P978, DOI 10.7326/0003-4819-96-6-978; Assimacopoulos AP, 2009, CLIN INFECT DIS, V48, P612, DOI 10.1086/597009; BARSUMIAN EL, 1978, INFECT IMMUN, V22, P681, DOI 10.1128/IAI.22.3.681-688.1978; Bartlett AH, 2008, J INFECT DIS, V198, P1529, DOI 10.1086/592758; BERGDOLL MS, 1988, METHOD ENZYMOL, V165, P324; BERGDOLL MS, 1984, LANCET, V2, P691; BERGVELD P, 1981, SENSOR ACTUATOR, V1, P17, DOI 10.1016/0250-6874(81)80004-2; BETLEY MJ, 1984, P NATL ACAD SCI-BIOL, V81, P5179, DOI 10.1073/pnas.81.16.5179; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Brosnahan AJ, 2009, J IMMUNOL, V182, P2364, DOI 10.4049/jimmunol.0803283; Brosnahan AJ, 2008, BIOCHEMISTRY-US, V47, P12995, DOI 10.1021/bi801468w; Brown EL, 2009, CLIN MICROBIOL INFEC, V15, P156, DOI 10.1111/j.1469-0691.2008.02648.x; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025; CRASS BA, 1986, J CLIN MICROBIOL, V23, P1138, DOI 10.1128/JCM.23.6.1138-1139.1986; Davis CC, 2003, AM J OBSTET GYNECOL, V189, P1785, DOI 10.1016/S0002-9378(03)00873-1; DAVIS JP, 1980, NEW ENGL J MED, V303, P1429, DOI 10.1056/NEJM198012183032501; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Diep BA, 2008, TRENDS MICROBIOL, V16, P361, DOI 10.1016/j.tim.2008.05.002; Diep BA, 2008, ANN INTERN MED, V148, P249, DOI 10.7326/0003-4819-148-4-200802190-00204; Diep BA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003198; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Dragneva Y, 2001, INFECT IMMUN, V69, P2630, DOI 10.1128/IAI.69.4.2630-2635.2001; Dufour P, 2002, CLIN INFECT DIS, V35, P819, DOI 10.1086/342576; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; Fey PD, 2003, ANTIMICROB AGENTS CH, V47, P196, DOI 10.1128/AAC.47.1.196-203.2003; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Giantonio BJ, 1997, J CLIN ONCOL, V15, P1994, DOI 10.1200/JCO.1997.15.5.1994; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Hongo I, 2009, J INFECT DIS, V200, P715, DOI 10.1086/605332; HOVDE CJ, 1994, MOL MICROBIOL, V13, P897, DOI 10.1111/j.1365-2958.1994.tb00481.x; Hunt C, 1999, JAMA-J AM MED ASSOC, V282, P1123; Huseby M, 2007, J BACTERIOL, V189, P8719, DOI 10.1128/JB.00741-07; Ito Teruyo, 2007, V391, P87; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Kaneko J, 2004, BIOSCI BIOTECH BIOCH, V68, P981, DOI 10.1271/bbb.68.981; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; KONIG B, 1995, J INFECT DIS, V171, P607, DOI 10.1093/infdis/171.3.607; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Labandeira-Rey M, 2007, SCIENCE, V315, P1130, DOI 10.1126/science.1137165; Ladhani S, 2001, CLIN MICROBIOL INFEC, V7, P301, DOI 10.1046/j.1198-743x.2001.00258.x; LEE PK, 1991, J INFECT DIS, V164, P711, DOI 10.1093/infdis/164.4.711; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Liu GY, 2005, J EXP MED, V202, P209, DOI 10.1084/jem.20050846; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V257, P1053, DOI 10.1001/jama.257.8.1053; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Monti G, 1996, DERMATOLOGY, V193, P83, DOI 10.1159/000246218; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x; O'Gara JP, 2007, FEMS MICROBIOL LETT, V270, P179, DOI 10.1111/j.1574-6968.2007.00688.x; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; O'Riordan K, 2004, CLIN MICROBIOL REV, V17, P218, DOI 10.1128/CMR.17.1.218-234.2004; OREILLY M, 1990, MOL MICROBIOL, V4, P1947, DOI 10.1111/j.1365-2958.1990.tb02044.x; Parsonnet J, 1998, INT C S SERIES ROYAL, V229, P15; Peterson ML, 2005, INFECT IMMUN, V73, P2164, DOI 10.1128/IAI.73.4.2164-2174.2005; Pragman AA, 2004, FEMS IMMUNOL MED MIC, V42, P147, DOI 10.1016/j.femsim.2004.05.005; Pragman AA, 2004, J BACTERIOL, V186, P2430, DOI 10.1128/JB.186.8.2430-2438.2004; Pragman AA, 2007, J BACTERIOL, V189, P7515, DOI 10.1128/JB.00547-07; REINGOLD AL, 1982, ANN INTERN MED, V96, P871, DOI 10.7326/0003-4819-96-6-871; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schlievert PM, 2008, CLIN INFECT DIS, V46, P1562, DOI 10.1086/586746; Schlievert PM, 2007, BIOCHEMISTRY-US, V46, P14349, DOI 10.1021/bi701202w; Schlievert PM, 2007, ANTIMICROB AGENTS CH, V51, P3056, DOI 10.1128/AAC.01295-06; Schlievert PM, 2009, J INFECT DIS, V200, P676, DOI 10.1086/605333; SCHLIEVERT PM, 1982, INFECT IMMUN, V36, P123, DOI 10.1128/IAI.36.1.123-128.1982; SCHLIEVERT PM, 1982, ANN INTERN MED, V96, P937, DOI 10.7326/0003-4819-96-6-937; SCHLIEVERT PM, 1981, J INFECT DIS, V143, P509, DOI 10.1093/infdis/143.4.509; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P236, DOI 10.1093/infdis/147.2.236; SCHLIEVERT PM, 1986, LANCET, V1, P1149; Schlievert PM, 2000, INFECT IMMUN, V68, P3630, DOI 10.1128/IAI.68.6.3630-3634.2000; Schlievert PM, 2004, J CLIN MICROBIOL, V42, P2875, DOI 10.1128/JCM.42.6.2875-2876.2004; SHANDS KN, 1980, NEW ENGL J MED, V303, P1436, DOI 10.1056/NEJM198012183032502; TODD J, 1978, LANCET, V2, P1116; Vandenesch F, 2003, EMERG INFECT DIS, V9, P978; Voyich JM, 2006, J INFECT DIS, V194, P1761, DOI 10.1086/509506; Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656; Wardenburg JB, 2008, J INFECT DIS, V198, P1166, DOI 10.1086/592053; Wardenburg JB, 2008, J EXP MED, V205, P287, DOI 10.1084/jem.20072208; Wardenburg JB, 2007, NAT MED, V13, P1405, DOI 10.1038/nm1207-1405; WATSON DW, 1960, J EXP MED, V111, P255, DOI 10.1084/jem.111.2.255; Yarwood JM, 2003, J CLIN INVEST, V112, P1620, DOI 10.1172/JCI200320442; Yarwood JM, 2001, J BACTERIOL, V183, P1113, DOI 10.1128/JB.183.4.1113-1123.2001; 2003, MMWR MORB MORTAL WKL, V52, P992	97	140	148	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					39	49		10.1016/j.jaci.2009.10.039	http://dx.doi.org/10.1016/j.jaci.2009.10.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109735	Green Accepted			2022-12-18	WOS:000273660500004
J	Glasser, R; Navid, F; Schuller, W; Jantschitsch, C; Harder, J; Schroder, JM; Schwarz, A; Schwarz, T				Glaesser, Regine; Navid, Fatemeh; Schuller, Winfried; Jantschitsch, Christian; Harder, Juergen; Schroeder, Jens M.; Schwarz, Agatha; Schwarz, Thomas			UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						UV radiation; immunosuppression; adaptive immune response; innate immune response; antimicrobial peptides; skin; keratinocytes	NORMAL HUMAN SKIN; ULTRAVIOLET-RADIATION; ATOPIC-DERMATITIS; PSORIASIN S100A7; GENE-EXPRESSION; MESSENGER-RNA; T-CELLS; INNATE; PHOTOTHERAPY; INFECTION	Background: Suppression of the adaptive immune system by UV radiation plays an important role in photocarcinogenesis. Exacerbation of skin infections has been proposed as a further consequence of UV-induced immunosuppression. Clinically bacterial infections are not a problem. For defense against bacteria, the innate immune response including the release of antimicrobial peptides is much more relevant than the adaptive immune response. Keratinocytes; have the capacity to release antimicrobial peptides. Objective: We asked whether UV radiation induces antimicrobial peptides in vitro and in vivo. Methods: Antimicrobial peptide expression by normal human keratinocytes was measured by real-time PCR and fluorescence-activated cell sorting analysis. Biopsies taken from human volunteers and skin explants were studied with immunohistochemistry. Results: Real-time PCR of normal human keratinocytes revealed a dose-dependent increase of human beta-defensin-2, -3, ribonuclease 7, and psoriasin (S100A7) after UV radiation. This was confirmed at the protein level by intracellular fluorescence-activated cell sorting and in vitro immunofluorescence analysis. Immunohistochemistry of biopsies taken from healthy volunteers exposed to different UV radiation doses revealed enhanced epidermal expression of antimicrobial peptides after UV exposure. This was also confirmed by exposing human skin explants to UV radiation. Conclusion: UV radiation exerts diverse effects on the immune system, suppressing the adaptive but inducing the innate immune response. This may explain why T-cell-mediated immune reactions are suppressed on UV exposure but not host defense reactions against bacterial attacks. (J Allergy Clin Immunol 2009;123:1117-23.)	[Glaesser, Regine; Navid, Fatemeh; Schuller, Winfried; Jantschitsch, Christian; Harder, Juergen; Schroeder, Jens M.; Schwarz, Agatha; Schwarz, Thomas] Univ Kiel, Dept Dermatol & Allergol, D-24105 Kiel, Germany	University of Kiel	Schwarz, T (corresponding author), Univ Kiel, Dept Dermatol & Allergol, Schittenhelmstr 7, D-24105 Kiel, Germany.	tschwarz@dermatology.uni-kiel.de	Harder, Jürgen/B-3162-2010; Schwarz, Thomas/A-9148-2010; Gläser, Regine/B-3168-2010	Harder, Jurgen/0000-0002-4075-4603	German Research Foundation [SFB 617, A21]; Federal Ministry of Education and Research	German Research Foundation(German Research Foundation (DFG)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	Supported by grants front the German Research Foundation (SFB 617, A21) to T.S. and from the Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, SkinSlaph) to R.G.	Braff MH, 2006, CURR TOP MICROBIOL, V306, P91; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHAPMAN RS, 1995, PHOTOCHEM PHOTOBIOL, V61, P223; Di Nuzzo S, 2000, PHOTOCHEM PHOTOBIOL, V72, P374; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gambichler T, 2006, BRIT J DERMATOL, V155, P1275, DOI 10.1111/j.1365-2133.2006.07481.x; Glaser R, 2009, J INVEST DERMATOL, V129, P641, DOI 10.1038/jid.2008.268; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Harder J, 2007, J ENDOTOXIN RES, V13, P317, DOI 10.1177/0968051907088275; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Jiang SJ, 2006, J DERMATOL SCI, V44, P29, DOI 10.1016/j.jdermsci.2006.05.012; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Lee PL, 2008, PHOTOCHEM PHOTOBIOL, V84, P1528, DOI 10.1111/j.1751-1097.2008.00380.x; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mallbris L, 2005, J INVEST DERMATOL, V125, P1072, DOI 10.1111/j.0022-202X.2005.23872.x; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Norval M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1495, DOI 10.1562/2006-07-28-IR-987; Reddy KVR, 2004, INT J ANTIMICROB AG, V24, P536, DOI 10.1016/j.ijantimicag.2004.09.005; RUNGER TM, 2008, DERMATOLOGY, P1321; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schittek Birgit, 2008, Infectious Disorders - Drug Targets, V8, P135; Schroder JM, 2006, CELL MOL LIFE SCI, V63, P469, DOI 10.1007/s00018-005-5364-0; SCHWARZ T, 2008, DERMATOLOGY, P63; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Schwarz Thomas, 2005, Keio Journal of Medicine, V54, P165, DOI 10.2302/kjm.54.165; Seo SJ, 2001, J DERMATOL SCI, V27, P183, DOI 10.1016/S0923-1811(01)00135-9; Silva SH, 2006, J EUR ACAD DERMATOL, V20, P1114, DOI 10.1111/j.1468-3083.2006.01748.x; Sorensen O, 1997, BLOOD, V90, P2796; Termorshuizen F, 2002, INT IMMUNOPHARMACOL, V2, P263, DOI 10.1016/S1567-5769(01)00178-3; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Weichenthal M, 2005, PHOTODERMATOL PHOTO, V21, P260, DOI 10.1111/j.1600-0781.2005.00173.x; Wollenberg A, 2007, CLIN REV ALLERG IMMU, V33, P35, DOI 10.1007/s12016-007-0032-9; YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877	42	140	142	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1117	1123		10.1016/j.jaci.2009.01.043	http://dx.doi.org/10.1016/j.jaci.2009.01.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19342087				2022-12-18	WOS:000266309400021
J	Garvey, LH; Kroigaard, M; Poulsen, LK; Skov, PS; Mosbech, H; Venemalm, L; Degerbeck, F; Husum, B				Garvey, Lene Heise; Kroigaard, Mogens; Poulsen, Lars K.; Skov, Per Stahl; Mosbech, Holger; Venemalm, Lennart; Degerbeck, Fredrik; Husum, Bent			IgE-mediated allergy to chlorhexidine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chlorhexidine; anaphylaxis; allergy; specific IgE; skin prick testing; intradermal testing; histamine release; anesthesia; drug allergy	HAPTENIC DRUG CHLORHEXIDINE; ANAPHYLAXIS; HYPERSENSITIVITY; ANTIBODIES; IMMEDIATE; DERMATITIS; TRYPTASE	Background: Investigations at the Danish Anesthesia Allergy Centre have included testing for allergy to chlorhexidine since 1999. Objective: To investigate whether measurement of IgE and histamine release confirm an IgE-mediated mechanism for chlorhexidine allergy. Methods: Twenty-two patients with clinical history suggestive of chlorhexidine allergy were included. Skin tests with chlorhexidine and tryptase measurements were performed during initial investigations. Sera were analyzed retrospectively for IgE and histamine release (passive sensitization) to chlorhexidine. Results: Twelve patients were skin test positive and 10 were skin test negative. Of the skin test-positive patients, 11 of 12 had IgE to chlorhexidine and 7 of 11 had a positive histamine release test. None of the skin test-negative patients had specific IgE or positive histamine release to chlorhexidine. Skin test-positive patients had higher median age (64 vs 49 y) and were mainly male (11/12 vs 6/10). In both groups, 8 patients had hypotension, but bronchospasm mainly appeared in skin test-negative patients (1/12 vs 6/10). Reactions occurred more often during urologic surgery in skin test-positive patients (5/12 vs 0/10). Baseline tryptase was higher in skin test-positive patients (median, 11.5 vs 3.7 mu g/L), and 6 of 7 patients had elevated IgE to chlorhexidine in serum at the time of reaction. Conclusion: This study confirms that chlorhexidine allergy is IgE-mediated and that measurement of specific IgE and histamine release are good adjuncts to skin testing in patients with clinical history suggesting chlorhexidine allergy. Clinical implications: IgE and histamine release can be used to support the diagnosis of allergy to chlorhexidine.	Univ Copenhagen Hosp, Danish Anaesthesia Allergy Ctr, Rigshosp, Dept Anaesthesia, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Allergy Clin, DK-2100 Copenhagen, Denmark; Reference Lab, Copenhagen, Denmark; Phadia AB, Uppsala, Sweden; Malarinvest AB, Uppsala, Sweden	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Thermo Fisher Scientific; Phadia	Garvey, LH (corresponding author), Univ Copenhagen Hosp, Danish Anaesthesia Allergy Ctr, Rigshosp, Dept Anaesthesia, 4231 Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	lene@heisegarvey.dk	Husum, Bent/AAH-7518-2021; Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X				Aalto-Korte K, 2006, CONTACT DERMATITIS, V55, P173, DOI 10.1111/j.1600-0536.2006.00900.x; Baldo BA, 2001, CURR OPIN ALLERGY CL, V1, P327, DOI 10.1097/01.all.0000011034.96839.aa; BERGQVISTKARLSSON A, 1988, CONTACT DERMATITIS, V18, P84, DOI 10.1111/j.1600-0536.1988.tb02745.x; Blanca M, 1996, CLIN EXP ALLERGY, V26, P335; CALNAN CD, 1962, P ROY SOC MED, V55, P39, DOI 10.1177/003591576205500111; CHEUNG J, 1985, ANAESTH INTENS CARE, V13, P429, DOI 10.1177/0310057X8501300419; Deliargyris EN, 2005, ATHEROSCLEROSIS, V178, P381, DOI 10.1016/j.atherosclerosis.2004.09.008; Dirks CG, 2005, J ALLERGY CLIN IMMUN, V115, P1321, DOI 10.1016/j.jaci.2005.03.027; Ebo DG, 1998, J ALLERGY CLIN IMMUN, V101, P128, DOI 10.1016/S0091-6749(98)70205-2; Ebo DG, 2006, CONTACT DERMATITIS, V55, P301, DOI 10.1111/j.1600-0536.2006.00924.x; Garvey Lene Heise, 2004, Ugeskr Laeger, V166, P382; Garvey LH, 2001, ACTA ANAESTH SCAND, V45, P1204, DOI 10.1034/j.1399-6576.2001.451005.x; Garvey LH, 2001, ACTA ANAESTH SCAND, V45, P1290, DOI 10.1034/j.1399-6576.2001.451020.x; Heinemann C, 2002, EXOG DERMATOLOGY, V1, P186; Krautheim AB, 2004, CONTACT DERMATITIS, V50, P113, DOI 10.1111/j.0105-1873.2004.00308.x; Lauerma AI, 2001, CONTACT DERMATITIS, V44, P59; LAYTON GT, 1987, CLIN EXP IMMUNOL, V69, P157; LAYTON GT, 1987, MOL IMMUNOL, V24, P133, DOI 10.1016/0161-5890(87)90085-X; LAYTON GT, 1989, CLIN EXP ALLERGY, V19, P307, DOI 10.1111/j.1365-2222.1989.tb02388.x; MOSBECH H, 1986, CLIN ALLERGY, V16, P433, DOI 10.1111/j.1365-2222.1986.tb01978.x; OHTOSHI T, 1986, CLIN ALLERGY, V16, P155, DOI 10.1111/j.1365-2222.1986.tb00759.x; Pham NH, 2000, CLIN EXP ALLERGY, V30, P1001; REVELLE LK, 1995, J AGR FOOD CHEM, V43, P1299, DOI 10.1021/jf00053a032; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; *SFAR, 2002, ANN FR ANESTH S, V21, P7; Thune Per, 1998, Tidsskrift for den Norske Laegeforening, V118, P3295; Untersmayr E, 2005, J ALLERGY CLIN IMMUN, V115, P377, DOI 10.1016/j.jaci.2004.10.029	27	140	143	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					409	415		10.1016/j.jaci.2007.04.029	http://dx.doi.org/10.1016/j.jaci.2007.04.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17559915				2022-12-18	WOS:000248654900029
J	Blanchard, C; Wang, N; Rothenberg, ME				Blanchard, Carine; Wang, Ning; Rothenberg, Marc E.			Eosinophilic esophagitis: Pathogenesis, genetics, and therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophilic esophagitis; eosinophils; eosinophil-associated gastrointestinal disorder; allergy; eotaxin	ALLERGIC ESOPHAGITIS; PATCH TESTS; SKIN PRICK; CHILDREN; DYSPHAGIA; MUCOSA; INFILTRATION; POPULATION; EXPRESSION; EOTAXIN-3	Eosinophilic esophagitis (EE) is a recently recognized disorder characterized by the accumulation of eosinophils in the esophagus. Symptoms of EE frequently mimic those of - gastroesophageal reflux disease, but the 2 diseases are quite distinct in terms of the histopathology and response to therapy. We demonstrate that EE involves the interplay of numerous genes, especially the eosinophil chemoattractant eotaxin-3, allowing molecular distinction from other forms of esophagitis and consideration of targeted therapeutic intervention.	Univ Cincinnati, Coll Med, Childrens Hosp, Ctr Med,Div Allergy & Immunol,Dept Pediat, Cincinnati, OH 45221 USA; Univ Cincinnati, Coll Med, Childrens Hosp, Ctr Med,Div Human Genet,Dept Pediat, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Childrens Hosp, Div Allergy & Immunol, Ctr Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org			NIAID NIH HHS [R01 AI45898] Funding Source: Medline; NIDDK NIH HHS [R21 DK074626-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK074626] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Attwood SEA, 2003, GUT, V52, P181, DOI 10.1136/gut.52.2.181; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Chae SC, 2005, IMMUNOGENETICS, V56, P760, DOI 10.1007/s00251-004-0746-2; Dahms BB, 2004, PEDIATR DEVEL PATHOL, V7, P5, DOI 10.1007/s10024-003-0203-5; Dahshan A, 2000, J CLIN GASTROENTEROL, V31, P213, DOI 10.1097/00004836-200010000-00005; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fox VL, 2002, GASTROINTEST ENDOSC, V56, P260, DOI 10.1067/mge.2002.126390; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gawrieh Samer, 2004, Curr Gastroenterol Rep, V6, P189, DOI 10.1007/s11894-004-0004-7; Justinich CJ, 1997, J PEDIATR GASTR NUTR, V25, P194, DOI 10.1097/00005176-199708000-00011; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; KONIKOFF MR, 2006, IN PRESS GASTROENTER; KONIKOFF MR, 2006, CLIN GASTROENTE 1021; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras CA, 2004, CURR OPIN PEDIATR, V16, P560, DOI 10.1097/01.mop.0000141071.47572.eb; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Malerba G, 2000, AM J RESP CRIT CARE, V162, P1587, DOI 10.1164/ajrccm.162.4.9909031; Markowitz JE, 2003, GASTROENTEROL CLIN N, V32, P949, DOI 10.1016/S0889-8553(03)00047-5; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; MUELLER S, 2006, J CLIN PATHOL; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1016/S1542-3565(04)00240-X; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Ober C, 2005, J ALLERGY CLIN IMMUN, V116, P274, DOI 10.1016/j.jaci.2005.04.039; Onbasi K, 2005, CLIN EXP ALLERGY, V35, P1423, DOI 10.1111/j.1365-2222.2005.02351.x; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Parfitt JR, 2006, MODERN PATHOL, V19, P90, DOI 10.1038/modpathol.3800498; Patel SM, 2005, GASTROINTEST ENDOSC, V61, P165, DOI 10.1016/S0016-5107(04)02459-9; PENROSE L S, 1953, Acta Genet Stat Med, V4, P257; Rolland AMGASAS, 2004, J PEDIATR GASTR NUTR, V39, P373, DOI 10.1097/00005176-200410000-00013; Ronkainen J, 2006, GASTROENTEROLOGY, V130, pA575; Rothenberg MA, 2001, J ALLERGY CLIN IMMUN, V108, P891, DOI 10.1067/mai.2001.120095; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; STEIN ML, 2006, IN PRESS J ALLERGY C; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2005, INFLAMM BOWEL DIS, V11, P720, DOI 10.1097/01.MIB.0000172557.39767.53; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; TOTTRUP A, 1989, DIGEST DIS SCI, V34, P1894, DOI 10.1007/BF01536708; Vasilopoulos S, 2002, GASTROINTEST ENDOSC, V55, P99, DOI 10.1067/mge.2002.118645; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003	49	140	150	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1054	1059		10.1016/j.jaci.2006.07.038	http://dx.doi.org/10.1016/j.jaci.2006.07.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088129				2022-12-18	WOS:000244282300009
J	Wright, RJ				Wright, RJ			Stress and atopic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; atopy; psychological stress; oxidative stress; psychoneuroimmunology; genetics	GENETIC-VARIATION; MATERNAL STRESS; EXPOSURE; ASTHMA; NEUROPLASTICITY; SUSCEPTIBILITY; NEUROENDOCRINE; POLYMORPHISMS; PERSPECTIVE; PHENOTYPES	Evidence linking psychological stress to the expression of asthma and atopy continues to grow. Examining the underlying molecular mechanisms linking stress to asthma and other allergic phenomena is an active area of research. Evidence is reviewed for the influence of stress on neuroimmunoregulation and oxidative stress pathways, which, in turn, may affect biological hypersensitivity to environmental stimuli characteristic of atopic disorders. Critical periods of development, including in utero environment, are underscored. The role of genetics and gene-by-environment interactions is also discussed.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Wright, RJ (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	rosalind.wright@channing.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072494, R01HL064108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010932] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL64108, U01 HL072494] Funding Source: Medline; NIEHS NIH HHS [R01 ES10932] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barker D J, 2001, Med Health Care Philos, V4, P31, DOI 10.1023/A:1009934412988; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BIENENSTOCK J, 2003, AUTONOMIC NEUROIMMUN; Bonham AC, 2004, PULM PHARMACOL THER, V17, P453, DOI 10.1016/j.pupt.2004.09.008; Buske-Kirschbaum A, 2004, PSYCHONEUROENDOCRINO, V29, P705, DOI 10.1016/S0306-4530(03)00100-8; Chen CY, 2003, J APPL PHYSIOL, V94, P819, DOI 10.1152/japplphysiol.00552.2002; Chen CY, 2001, J ALLERGY CLIN IMMUN, V108, P557; Child F, 2003, RESP MED, V97, P1247, DOI 10.1016/S0954-6111(03)00250-6; Chrousos GP, 1996, AM J RESP CRIT CARE, V154, pS39, DOI 10.1164/ajrccm/154.2_Pt_2.S39; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Cohen S, 1996, ANNU REV PSYCHOL, V47, P113, DOI 10.1146/annurev.psych.47.1.113; Cohen S, 2003, BRAIN BEHAV IMMUN, V17, P407, DOI 10.1016/S0889-1591(03)00110-7; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214; Cohen Sheldon, 1995, MEASURING STRESS GUI, P3; Dantzer R, 2004, BRAIN BEHAV IMMUN, V18, P1, DOI 10.1016/j.bbi.2003.09.008; Donaldson K, 2000, Respir Res, V1, P12, DOI 10.1186/rr5; Essex MJ, 2002, BIOL PSYCHIAT, V52, P776, DOI 10.1016/S0006-3223(02)01553-6; FUKATA J, 1994, J ENDOCRINOL INVEST, V17, P141, DOI 10.1007/BF03347705; Glosli H, 2002, FASEB J, V16, P1450, DOI 10.1096/fj.01-0948fje; Gluckman PD, 2005, EARLY HUM DEV, V81, P51, DOI 10.1016/j.earlhumdev.2004.10.003; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Kelley KW, 2004, BRAIN BEHAV IMMUN, V18, P95, DOI 10.1016/j.bbi.2003.10.003; Lazarus R.S., 1984, STRESS APPRAISAL; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Meaney MJ, 2005, TRENDS NEUROSCI, V28, P456, DOI 10.1016/j.tins.2005.07.006; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Osler W, 1892, PRINCIPLES PRACTICE; Pike JL, 1997, PSYCHOSOM MED, V59, P447, DOI 10.1097/00006842-199707000-00015; Rich EL, 2005, AM J PHYSIOL-REG I, V288, pR1628, DOI 10.1152/ajpregu.00484.2004; Seckl JR, 1997, STEROIDS, V62, P89, DOI 10.1016/S0039-128X(96)00165-1; Shanks N, 2001, J CLIN INVEST, V108, P1567, DOI 10.1172/JCI14592; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P885, DOI 10.1210/jc.80.3.885; Theoharides TC, 2004, TRENDS PHARMACOL SCI, V25, P563, DOI 10.1016/j.tips.2004.09.007; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; UNDEM BJ, 2000, J ALLERGY CLIN IMMUN, V106, P213; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Wamboldt MZ, 2003, J ALLERGY CLIN IMMUN, V111, P509, DOI 10.1067/mai.2003.140; Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wu Z, 2004, CLIN EXP IMMUNOL, V135, P194, DOI 10.1111/j.1365-2249.2003.02372.x; Wust S, 2004, ANN NY ACAD SCI, V1032, P52, DOI 10.1196/annals.1314.005; Wust S, 2004, J CLIN ENDOCR METAB, V89, P565, DOI 10.1210/jc.2003-031148; Zhou JF, 2000, BIOMED ENVIRON SCI, V13, P44	47	140	147	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1301	1306		10.1016/j.jaci.2005.09.050	http://dx.doi.org/10.1016/j.jaci.2005.09.050			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337463	Bronze			2022-12-18	WOS:000235687000022
J	Ponikau, JU; Sherris, DA; Kita, H; Kern, EB				Ponikau, JU; Sherris, DA; Kita, H; Kern, EB			Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	17th Congress of the European-Rhinological-Society	JUN 25-29, 2000	BARCELONA, SPAIN	European Rhinol Soc		eosinophils; antifungal; chronic sinusitis; nasal polyps; rhinosinusitis	ALLERGIC FUNGAL SINUSITIS; EOSINOPHIL	Background: Chronic rhinosinusitis (CRS) is the most common chronic disease that is frequently refractory to treatment. Objective: We sought to establish the safety and demonstrate the clinical efficacy of intranasal antifungal drug therapy in patients with CRS in a pilot trial. Methods: A prospective open-label trial used amphotericin B as a medical treatment in 51 randomly selected patients with CRS. The antifungal agent was applied intranasally as 20 mL of a 100 mug/mL solution twice daily. The outcome was measured by using their symptoms and by using an endoscopic scoring system in all patients. In addition, pretreatment and posttreatment coronal computed tomographic scans of the nose and sinuses were available for evaluation in 13 patients. Results: By using amphotericin B, improvement of sinusitis symptoms was observed in 38 (75%) of 51 patients. Endoscopically, 18 (35%) of 51 patients became disease free, and an additional 20 (39%) of 51 had improvement of at least one stage (P < .001). No effect was seen in 13 (25%) of 51 patients. The available computed tomographic scans before and after treatment demonstrated a significant reduction in the inflammatory mucosa thickening that had occluded the paranasal sinuses (P < .0001 in maxillary sinus). Conclusion: This open-label pilot trial demonstrates that direct mucoadministration of an antifungal drug appears to be both safe and effective in the treatment of patients with CRS. Therefore controlled and blinded trials are indicated to clarify the novel role of intranasal antifungal drugs in the treatment of CRS.	Mayo Clin & Mayo Fdn, Div Allerg Dis, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol Head & Neck Surg, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Ponikau, JU (corresponding author), Mayo Clin & Mayo Fdn, Dept Otorhinolaryngol Head & Neck Surg, 200 1st St SW, Rochester, MN 55905 USA.				NIAID NIH HHS [AI50494, AI49235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049235, P01AI050494] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FRIEDMAN WH, 1995, OTOLARYNG HEAD NECK, V112, P210, DOI 10.1016/S0194-5998(95)70238-5; Garbutt JM, 2001, PEDIATRICS, V107, P619, DOI 10.1542/peds.107.4.619; Hamilos DL, 2000, J ALLERGY CLIN IMMUN, V106, P213, DOI 10.1067/mai.2000.109269; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Heatley DG, 2001, OTOLARYNG HEAD NECK, V125, P44, DOI 10.1067/mhn.2001.115909; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Kaliner MA, 1997, OTOLARYNG HEAD NECK, V116, pS1; Kondo H, 1999, LARYNGOSCOPE, V109, P91, DOI 10.1097/00005537-199901000-00018; Kupferberg SB, 1997, OTOLARYNG HEAD NECK, V117, P35, DOI 10.1016/S0194-5998(97)70203-1; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT, V10; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Shoseyov D, 1998, J ALLERGY CLIN IMMUN, V101, P602, DOI 10.1016/S0091-6749(98)70166-6; Ward GW, 1999, J ALLERGY CLIN IMMUN, V104, P541, DOI 10.1016/S0091-6749(99)70321-0	15	140	152	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					862	866		10.1067/mai.2002.130051	http://dx.doi.org/10.1067/mai.2002.130051			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464951				2022-12-18	WOS:000179777400007
J	Gergen, PJ; Mortimer, KM; Eggleston, PA; Rosenstreich, D; Mitchell, H; Ownby, D; Kattan, M; Baker, D; Wright, EC; Slavin, R; Malveaux, F				Gergen, PJ; Mortimer, KM; Eggleston, PA; Rosenstreich, D; Mitchell, H; Ownby, D; Kattan, M; Baker, D; Wright, EC; Slavin, R; Malveaux, F			Results of the National Cooperative Inner-City Asthma Study (NCICAS) environmental intervention to reduce cockroach allergen exposure in inner-city homes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		cockroach; Bla g 1; intervention	DUST; CHILDREN	Background: Cockroach allergen is important in asthma. Practical methods to reduce exposure are needed. Objective: We sought to evaluate the effectiveness of house cleaning and professional extermination on lowering cockroach antigen Levels in inner-city dwellings. Methods: As part of the National Cooperative Inner-City Asthma Study intervention, 265 of 331 families with asthmatic children who had positive skin test responses to cockroach allergen consented to a professional home extermination with 2 applications of a cockroach insecticide (Abamectin, Avert) combined with directed education on cockroach allergen removal. On a random subset of 48 homes undergoing cockroach extermination in the intervention group, Bla g 1 was measured in settled dust from the kitchen, bedroom, and TV/living room. The first sample was collected 1 week before extermination, with additional samples after the exterminations at approximately 2, 6, and 12 months after the first sample. Self-reported problems with cockroaches were collected at baseline and after 12 months of follow-up in both the intervention and control group. Results: The geometric mean kitchen lever of Bla g 1 decreased at 2 months (33.6 U/g) relative to preextermination levels (68.7 U/g, P < .05). The percent of kitchens with over 8 U/g of Bla 1 followed a similar pattern, but only the decrease from preextermination to 6-month levels was significant (86.8% vs 64.3%, P < .05). By the 12-month visit, the allergen burden had returned to or exceeded baseline levels. Except for an increase in the bedroom at 2 months (8.9 U/g vs 11.1 U/g, P < .05), no other significant change was seen. Only about 50% of the families followed the cleaning instructions; no greater effect was found in these homes. Self-reported problems with cockroaches showed no difference between the intervention and control group after I year of follow-up. Conclusions: Despite a significant, but short-lived, decrease the cockroach allergen burden remained well above levels previously found to be clinically significant.	NIAID, NIH, Bethesda, MD 20892 USA; New England Res Inst, Watertown, MA 02172 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Albert Einstein Coll Med, Dept Med, Div Allergy & Immunol, Bronx, NY 10467 USA; Rho Inc, Chapel Hill, NC USA; Henry Ford Hosp, Div Allergy, Detroit, MI 48202 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Univ Calif Irvine, Ctr Environm & Occupat Hlth, Irvine, CA 92717 USA; St Louis Univ, Sch Med, Dept Med, Div Allergy & Immunol, St Louis, MO 63104 USA; Howard Univ, Coll Med, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); HealthCore, Inc; Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine; Rho; Henry Ford Health System; Henry Ford Hospital; Icahn School of Medicine at Mount Sinai; University of California System; University of California Irvine; Saint Louis University; Howard University	Gergen, PJ (corresponding author), AHCPR, Ctr Primary Care & Res, Suite 201,Rm 204,6010 Execut Blvd, Rockville, MD 20852 USA.				NIAID NIH HHS [AI-30756, AI-30752, UO1 AI-30751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030752, U01AI030751, U01AI030756] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERKOWITZ RB, 1992, J ALLERGY CLIN IMMUN, V90, P979, DOI 10.1016/0091-6749(92)90471-D; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1993, INSIGHTS ALLERGY, V8, P1; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; MENDOZA J, 1970, ANN ALLERGY, V28, P1529; Mollet JA, 1997, J MED ENTOMOL, V34, P307, DOI 10.1093/jmedent/34.3.307; MURRAY AB, 1983, PEDIATRICS, V71, P418; PATTERSON R S, 1989, Journal of Agricultural Entomology, V6, P37; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART S, 1995, J ALLERGY CLIN IMMUN, V87, P505; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; Williams LW, 1998, J ALLERGY CLIN IMMUN, V101, pS156; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7	20	140	141	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				501	506		10.1016/S0091-6749(99)70477-X	http://dx.doi.org/10.1016/S0091-6749(99)70477-X			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069886	Bronze			2022-12-18	WOS:000079175700021
J	Matricardi, PM; Franzinelli, F; Franco, A; Caprio, G; Murru, F; Cioffi, D; Ferrigno, L; Palermo, A; Ciccarelli, N; Rosmini, F				Matricardi, PM; Franzinelli, F; Franco, A; Caprio, G; Murru, F; Cioffi, D; Ferrigno, L; Palermo, A; Ciccarelli, N; Rosmini, F			Sibship size, birth order, and atopy in 11,371 Italian young men	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; epidemiology; family; siblings; specific IgE; Italy; infections; risk factors	HAY-FEVER; SENSITIZATION; PREVALENCE; ALLERGY	Background: Having a low number of siblings and a low birth order has been reported to be a relevant risk factor for development of atopic diseases and skin sensitization to common inhalants, Although the inverse association of atopy with sibship size has been confirmed repeatedly, the association with birth order has provided conflicting results. This possibly is due to the relatively small size of the population sample examined. Objective: The objective of this study was to investigate the relation between sibship size, birth order, and atopy in a very large population sample, highly homogeneous for age and sex. Methods: This was a retrospective survey of 11,371 Italian young men, 18 to 21 years old, all candidates for enrollment in the Italian Air Force. Demographic data had been collected by a standard questionnaire. Specific IgE fur locally relevant airborne allergens had been tested by a multi-RAST assay (CAP-Phadiatop). Results: The prevalence of atopy (defined as a high level of specific IgE against inhalants [cut-point >1.2 log RU]) was inversely related to the total number of siblings (25% in those with no siblings and 9% in those with five or more siblings), with a mean of a 3% decrease in prevalence for each added sibling. This relation persisted after adjustment for relevant variables such as father's education and rural and southern residence. An independent association between birth order and atopy was also observed because the decrease in atopy prevalence with increasing numbers of older siblings was significantly steeper than that found with the number of younger siblings (X-2 = 179, df = 1, p < 0.0001). Conclusions: In a very large and homogeneous population sample of a Mediterranean country, not only sibship size but also birth order was significantly associated with atopy. This observation further highlights the role of family structure in the development of atopy and supports the hypothesis that cross-infections acquired early in infancy or in later childhood might prevent development of atopy later in life.	Div Area Studi Ric & Sperimentaz, Lab Immunol & Allergol, Aeroporto Prat Mare, I-00040 Rome, Italy; Ist Med Legale AM Aldo di Loreto, Napoli, Italy; Ist Super Sanita, Lab Epidemiol, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Matricardi, PM (corresponding author), Div Area Studi Ric & Sperimentaz, Lab Immunol & Allergol, Aeroporto Prat Mare, I-00040 Rome, Italy.							Brown MA, 1997, CLIN EXP ALLERGY, V27, P4, DOI 10.1046/j.1365-2222.1997.d01-430.x; Dean A. G., 1990, EPI INFO VERSION 5 W; ENGELMAN L, 1990, BMDP STATISTICAL SOF, V2, P1013; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; LENFANT C, 1995, NIH PUBLICATION; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; PASQUINI P, 1984, INT J EPIDEMIOL, V13, P83, DOI 10.1093/ije/13.1.83; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; STRACHAN DP, 1994, THORAX, V49, pP1053; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132	22	140	144	0	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				439	444		10.1016/S0091-6749(98)70350-1	http://dx.doi.org/10.1016/S0091-6749(98)70350-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564794				2022-12-18	WOS:000073113500002
J	FAHY, JV; LIU, J; WONG, H; BOUSHEY, HA				FAHY, JV; LIU, J; WONG, H; BOUSHEY, HA			ANALYSIS OF CELLULAR AND BIOCHEMICAL-CONSTITUENTS OF INDUCED SPUTUM AFTER ALLERGEN CHALLENGE - A METHOD FOR STUDYING ALLERGIC AIRWAY INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ALLERGEN; INDUCED SPUTUM; EOSINOPHILS; NEUTROPHILS; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE; TRYPTASE; MUCIN-LIKE GLYCOPROTEIN	BRONCHOALVEOLAR LAVAGE; ASTHMATIC REACTIONS; HEALTHY-SUBJECTS; MAST-CELLS; PERMEABILITY; SECRETION; TRACHEA; HISTAMINE; RESPONSES; RELEASE	To determine whether analysis of the constituents of induced sputum permits detection of changes provoked by aerosolized antigen challenge, we performed sputum induction (20-minute inhalation of aerosolized 3% saline solution) before and after aerosolized allergen challenge in eight subjects with asthma. Total cell counts and cell differentials of nonsquamous cells in induced sputum samples were determined after the samples were homogenized in dithiothreitol. Centrifugation of the entire homogenized sputum sample yielded supernatant that could be analyzed for biochemical constituents. We found that the median percentage of eosinophils and neutrophils in induced sputum samples was significantly higher 4 hours after allergen challenge than at baseline (12% vs 0.5%, p < 0.05; 30.5% vs 7.5%, p < 0.05) and remained high 24 hours after challenge. Median levels of eosinophil cationic protein and histamine in induced sputum supernatants were significantly higher 4 hours after challenge than at baseline (151.3 vs 39.8 ng/ml, p < 0.05; 19.4 vs 8.8 mu g, p < 0.05) and remained significantly higher 24 hours after challenge. Tryptase was detectable in sputum from seven of the subjects, and in these subjects, we found a trend toward an increase in median tryptase levels 4 hours after allergen challenge (4.4 vs 22 U/L, p = 0.09). We conclude that analysis of induced sputum after aerosolized allergen challenge reveals changes in inflammatory cells and markers similar to those reported in bronchoalveolar lavage fluid and that sputum induction is a useful noninvasive method for studying allergic airway inflammation in asthma.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 24136, HL07185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DEFEBACH ME, 1989, J APPL PHYSIOL, V66, P1309; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1132, DOI 10.1164/ajrccm/147.5.1132; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; FREW AJ, 1989, INT ARCH ALLER A IMM, V88, P63, DOI 10.1159/000234750; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MIADONNA A, 1988, Respiration, V54, P78; PHIPPS RJ, 1983, J APPL PHYSIOL, V55, P1593, DOI 10.1152/jappl.1983.55.5.1593; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; SALOMONSSON P, 1992, AM REV RESPIR DIS, V146, P1535, DOI 10.1164/ajrccm/146.6.1535; SHEINMAN BD, 1986, BMJ-BRIT MED J, V292, P857, DOI 10.1136/bmj.292.6524.857; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; TABACHNIK E, 1992, J APPL PHYSIOL, V73, P695, DOI 10.1152/jappl.1992.73.2.695; UMENO E, 1990, J CLIN INVEST, V85, P1905, DOI 10.1172/JCI114652; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	23	140	145	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1031	1039		10.1016/S0091-6749(94)70052-4	http://dx.doi.org/10.1016/S0091-6749(94)70052-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006308				2022-12-18	WOS:A1994NT17200012
J	GRIFFIN, E; HAKANSSON, L; FORMGREN, H; JORGENSEN, K; PETERSON, C; VENGE, P				GRIFFIN, E; HAKANSSON, L; FORMGREN, H; JORGENSEN, K; PETERSON, C; VENGE, P			BLOOD EOSINOPHIL NUMBER AND ACTIVITY IN RELATION TO LUNG-FUNCTION IN PATIENTS WITH ASTHMA AND WITH EOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CATIONIC PROTEIN; BRONCHIAL-ASTHMA; SERUM; CHALLENGE; COUNTS; INJURY	Blood eosinophil count, serum concentrations of eosinophil cationic protein (ECP), eosinophil protein X (EPX), myeloperoxidase (MPO), and peak expiratory flow (PEF) rate were studied in 23 patients with severe labile asthma characterized by eosinophilia at the start and end of a treatment period of 5 weeks. The mean blood eosinophil count was 808 x 10(6)/L at the start of the treatment period. Serum ECP and EPX were significantly raised compared with that of the references, whereas the mean serum MPO level was normal. The mean PEF was significantly and negatively correlated to both blood eosinophil count and serum ECP and EPX, but the predominant correlation was that between blood eosinophil count and PEF. At the end of the treatment period, PEF had increased and the blood eosinophil count and serum ECP and EPX were reduced when these values were compared with the values at the start of the treatment period. There was a significant and negative correlation of mean PEF to serum ECP but not to the blood eosinophil count. In individual subjects, the decreases in the blood eosinophil counts and serum EPX were significantly correlated to the individual increases of mean PEF. In conclusion, the present investigation indicates that in patients with asthma and pronounced eosinophilia, the lung function of the patients was principally related to the number of circulating eosinophils, whereas, when their eosinophilia was reduced to moderate levels, the patient's lung function was closer related to the activity of the eosinophils.	UNIV HOSP UPPSALA, DEPT CLIN CHEM, INFLAMMAT RES LAB, S-75185 UPPSALA, SWEDEN; ARE HOSP, ASTHMA & ALLERGY CLIN, ARE, SWEDEN	Uppsala University; Uppsala University Hospital								AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DAHL R, 1978, ALLERGY, V33, P152, DOI 10.1111/j.1398-9995.1978.tb01526.x; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GRIFFIN E, IN PRESS ALLERGY; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; OLOFSSON T, 1977, SCAND J HAEMATOL, V18, P73; PETERSON CGB, 1983, IMMUNOLOGY, V50, P19; PETERSON CGB, 1987, BIOCHEM J, V245, P781, DOI 10.1042/bj2450781; PETERSON CGB, 1987, EOSINOPHIL GRANULE P, P74; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SCHATZ M, 1982, ARCH INTERN MED, V142, P1515, DOI 10.1001/archinte.142.8.1515; SPRY CIF, 1988, EOSINOPHILS COMPREHE, P40; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; VENGE P, 1989, European Respiratory Journal, V2, p430S; VENGE P, 1988, INT ARCH ALLER A IMM, V87, P306, DOI 10.1159/000234690; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VENGE P, UNPUB ECP SERUM EXER; VENGE P, 1983, IMMUNOBIOLOGY EOSINO, P164	24	140	140	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					548	557		10.1016/0091-6749(91)90014-F	http://dx.doi.org/10.1016/0091-6749(91)90014-F			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1847158				2022-12-18	WOS:A1991EX98700013
J	ROTH, T; ROEHRS, T; KOSHOREK, G; SICKLESTEEL, J; ZORICK, F				ROTH, T; ROEHRS, T; KOSHOREK, G; SICKLESTEEL, J; ZORICK, F			SEDATIVE EFFECTS OF ANTIHISTAMINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ROTH, T (corresponding author), HENRY FORD HOSP,CTR SLEEP DISORDERS & RES,2921 W GRAND BLVD,DETROIT,MI 48202, USA.							BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; CARSKADON M, 1982, SLEEP, V5, P367; CARSKADON MA, 1979, PERCEPT MOTOR SKILL, V48, P495, DOI 10.2466/pms.1979.48.2.495; DEMENT W, 1981, ACTUALITIES MED EXPT, P47; LUMLEY M, 1986, PSYCHOPHYSIOLOGY, V23, P403, DOI 10.1111/j.1469-8986.1986.tb00653.x; Rechtshaffen A, 1968, NIH PUBLICATION; RICHARDSON GS, 1982, SLEEP, V5, pS82, DOI 10.1093/sleep/5.S2.S82; ROEHRS TA, 1984, SLEEP, V7, P137, DOI 10.1093/sleep/7.2.137; SCHWARTZ JC, 1982, PHARM HISTAMINE RECE, P351; SEIDEL WF, 1984, SCIENCE, V224, P1262, DOI 10.1126/science.6729454; VERHAEGEN P, 1981, P NATIONAL I OCCUPAT, P335; WADA H, 1985, FRONTIERS HISTAMINE, P225; ZORICK F, 1982, SLEEP, V5, pS165, DOI 10.1093/sleep/5.S2.S165	13	140	141	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					94	98		10.1016/S0091-6749(87)80197-5	http://dx.doi.org/10.1016/S0091-6749(87)80197-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	2885356				2022-12-18	WOS:A1987J219400015
J	SUNDIN, B; LILJA, G; GRAFFLONNEVIG, V; HEDLIN, G; HEILBORN, H; NORRLIND, K; PEGELOW, KO; LOWENSTEIN, H				SUNDIN, B; LILJA, G; GRAFFLONNEVIG, V; HEDLIN, G; HEILBORN, H; NORRLIND, K; PEGELOW, KO; LOWENSTEIN, H			IMMUNOTHERAPY WITH PARTIALLY PURIFIED AND STANDARDIZED ANIMAL DANDER EXTRACTS .1. CLINICAL-RESULTS FROM A DOUBLE-BLIND-STUDY ON PATIENTS WITH ANIMAL DANDER ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SACHS UNIV HOSP,STOCKHOLM,SWEDEN; DANDERYD UNIV HOSP,STOCKHOLM,SWEDEN; UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK	Danderyds Hospital; University of Copenhagen	SUNDIN, B (corresponding author), HUDDINGE UNIV HOSP,DEPT MED,ALLERGOL SECT,S-14186 HUDDINGE,SWEDEN.							AAS K, 1982, ALLERGY, V37, P1, DOI 10.1111/j.1398-9995.1982.tb04111.x; AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; BROWN FR, 1968, ANN ALLERGY, V26, P305; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FROSTAD AB, 1980, ALLERGY, V35, P81, DOI 10.1111/j.1398-9995.1980.tb01722.x; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KRAEPELIEN S, 1977, RAPPORT FRAU EXPERTG; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; LOWENSTEIN H, 1980, 1ST P INT P EHRL SEM, P122; Lowenstein H, 1983, 11 P INT C ALL CLIN, P545; LOWENSTEIN H, 1985, ALLERGY, V40, P435; LUTSKY I, 1983, 11 P INT C ALL CLIN, P449; MURRAY, 1983, J ALLERGY CLIN IMMUN, V72, P145; NELSON HS, 1980, ANN ALLERGY, V45, P333; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1983, 11 P INT C ALL CLIN, P455; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P553, DOI 10.1111/j.1398-9995.1982.tb02340.x; OSTERBALLE O, 1981, ALLERGY, V36, P183, DOI 10.1111/j.1398-9995.1981.tb01834.x; PEGELOW KO, 1984, ALLERGY, V39, P275, DOI 10.1111/j.1398-9995.1984.tb00864.x; RANSOM JH, 1971, ANN ALLERGY, V29, P635; RUDOLPH R, 1983, 11 P INT C ALL CLIN, P437; SCHWARTZ B, 1984, Journal of Allergy and Clinical Immunology, V73, P156; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TUFT L, 1967, AM J MED SCI, V253, P19, DOI 10.1097/00000441-196701000-00005; TUFT L, 1976, ANN ALLERGY, V36, P165; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x	42	140	145	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					478	487		10.1016/0091-6749(86)90183-1	http://dx.doi.org/10.1016/0091-6749(86)90183-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	3950252				2022-12-18	WOS:A1986A536700012
J	AYARS, GH; ALTMAN, LC; GLEICH, GJ; LOEGERING, DA; BAKER, CB				AYARS, GH; ALTMAN, LC; GLEICH, GJ; LOEGERING, DA; BAKER, CB			EOSINOPHIL MEDIATED AND EOSINOPHIL GRANULE MEDIATED PNEUMOCYTE INJURY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT MED,DIV ALLERGY & INFECT DIS,RM-13,SEATTLE,WA 98195; MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55901	University of Washington; University of Washington Seattle; Mayo Clinic								AYARS GH, 1984, AM REV RESPIR DIS, V130, P964; BUTTERWORTH AE, 1981, NEW ENGL J MED, V304, P154, DOI 10.1056/NEJM198101153040305; COGEN RB, 1981, J PERIODONTOL, V52, P668, DOI 10.1902/jop.1981.52.11.668; DAVID JR, 1980, AM J TROP MED HYG, V29, P842, DOI 10.4269/ajtmh.1980.29.842; DAVIS WB, 1984, J CLIN INVEST, V74, P269, DOI 10.1172/JCI111411; DIEM K, 1975, SIGNIFICANCE LIMITS, P32; DOBBS LG, 1980, BIOCHIM BIOPHYS ACTA, V618, P510, DOI 10.1016/0005-2760(80)90270-2; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FISHER AB, 1980, J APPL PHYSIOL, V49, P743, DOI 10.1152/jappl.1980.49.4.743; FOX B, 1980, THORAX, V35, P570, DOI 10.1136/thx.35.8.570; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1974, J EXP MED, V140, P313, DOI 10.1084/jem.140.2.313; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; HENDERSON WR, 1983, AM J PATHOL, V111, P341; HOGG JC, 1983, ALLERGY PRINCIPLES P, P833; KAZWA JW, 1980, EOSINOPHIL HLTH DISE, P321; KLEBANOFF SJ, 1980, EOSINOPHIL HLTH DISE, P261; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LIEBOW AA, 1969, MEDICINE, V48, P251, DOI 10.1097/00005792-196907000-00001; MASON RJ, 1977, FED PROC, V36, P2697; MASON RJ, 1977, AM REV RESPIR DIS, V115, P1015; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; PARILLO JE, 1978, ANN INTERN MED, V89, P167; SCHATZ M, 1981, MED CLIN N AM, V65, P1055, DOI 10.1016/S0025-7125(16)31489-4; SCHATZ M, 1982, ARCH INTERN MED, V142, P1515, DOI 10.1001/archinte.142.8.1515; SNYDERMAN K, 1972, BIOL ACTIVITIES COMP, P117; TAUBMAN SB, 1975, LAB INVEST, V32, P555; TAUBMAN SB, 1974, P SOC EXP BIOL MED, V145, P952; VADAS MA, 1979, J IMMUNOL, V122, P1228; VANDELLEN RG, 1981, MAYO CLIN PROC, V56, P395; Weller P F, 1979, Adv Immunol, V27, P339, DOI 10.1016/S0065-2776(08)60264-3	34	140	141	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					595	604		10.1016/0091-6749(85)90781-X	http://dx.doi.org/10.1016/0091-6749(85)90781-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	4056248				2022-12-18	WOS:A1985ATH6600012
J	MOORE, VL; FINK, JN; BARBORIAK, JJ; RUFF, LL; SCHLUETER, DP				MOORE, VL; FINK, JN; BARBORIAK, JJ; RUFF, LL; SCHLUETER, DP			IMMUNOLOGICAL EVENTS IN PIGEON BREEDERS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN, DEPT MED, ALLERGY SECT, MILWAUKEE, WI 53201 USA; MED COLL WISCONSIN, DEPT MED, MED CHEST SECT, MILWAUKEE, WI 53201 USA; MED COLL WISCONSIN, DEPT PHARMACOL, MILWAUKEE, WI 53201 USA; VET ADM HOSP, RES SERV, WOOD, WI 53193 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin								BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BERRENS L, 1972, INT ARCH ALLER A IMM, V43, P327, DOI 10.1159/000230848; BERRENS L, 1972, INT ARCH ALLER A IMM, V43, P289, DOI 10.1159/000230843; BUECHNER HA, 1958, AM J MED, V25, P234, DOI 10.1016/0002-9343(58)90030-5; CAMPBELL DH, 1970, METHODS IMMUNOLOGY, V2; DICKIE HA, 1958, JAMA-J AM MED ASSOC, V167, P1069, DOI 10.1001/jama.1958.02990260011004; DIXON FJ, 1971, IMMUNOBIOLOGY; EDWARDS JH, 1969, P SOC EXP BIOL MED, V132, P907; EDWARDS JH, 1970, IMMUNOLOGY, V19, P729; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; FAUX J A, 1971, Clinical Allergy, V1, P149, DOI 10.1111/j.1365-2222.1971.tb03014.x; FINK JN, 1970, J ALLERGY, V46, P156, DOI 10.1016/0021-8707(70)90094-8; FINK JN, 1971, J ALLERGY CLIN IMMUN, V48, P179, DOI 10.1016/0091-6749(71)90014-5; FINK JN, 1968, J LAB CLIN MED, V71, P20; FINK JN, 1969, J LAB CLIN MED, V74, P325; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; FINK JN, 1971, ANN INTERN MED, V74, P80, DOI 10.7326/0003-4819-74-1-80; GALINDO B, 1970, J IMMUNOL, V105, P227; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; HENSLEY GT, 1969, ARCH PATHOL, V87, P572; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P276, DOI 10.1016/0091-6749(72)90026-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PARISH WE, 1970, LANCET, V2, P591; Pepys J, 1970, Rev Fr Allergol, V10, P27, DOI 10.1016/S0035-2845(70)80006-3; Pepys J, 1969, HYPERSENSITIVITY DIS; ROCKLIN RE, 1970, J IMMUNOL, V104, P95; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SHELDON JM, 1967, MANUAL CLINICAL ALLE, V2; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; SPECTOR WG, 1969, J PATHOL, V98, P31, DOI 10.1002/path.1710980105	31	140	140	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	6					319	328		10.1016/0091-6749(74)90115-8	http://dx.doi.org/10.1016/0091-6749(74)90115-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T2239	4597344				2022-12-18	WOS:A1974T223900001
J	Fischer, A; Provot, J; Jais, JP; Alcais, A; Mahlaoui, N				Fischer, Alain; Provot, Johan; Jais, Jean-Philippe; Alcais, Alexandre; Mahlaoui, Nizar		CEREDIH French PID Study Grp	Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiencies; autoimmunity; inflammation	FRENCH NATIONAL REGISTRY; DISEASES; EPIDEMIOLOGY; PREVALENCE; CHILDREN; INSIGHTS; FRANCE; CELLS	Background: Primary immunodeficiencies (PIDs) are inherited diseases associated with a considerable increase in susceptibility to infections. It is known that PIDs can also predispose to cancer and immune diseases, including allergy, autoimmunity, and inflammation. Objective: We aimed at determining the incidence of autoimmunity and inflammation in patients with PIDs. Methods: We have retrospectively screened 2183 consecutive cases of PID in the Centre de Reference Deficits Immunitaires Hereditaires registry (CEREDIH; the French national PID registry) for the occurrence of autoimmunity and inflammation. Results: One or more autoimmune and inflammatory complications were noted in 26.2% of patients, with a risk of onset throughout the patient's lifetime. The risk of autoimmune cytopenia was at least 120 times higher than in the general population, the risk of inflammatory bowel disease in children was 80 times higher, and the risk of other autoimmune manifestations was approximately 10 times higher. Remarkably, all types of PIDs were associated with a risk of autoimmune and inflammatory complications, although the greatest risk was associated with T-cell PIDs and common variable immunodeficiency. The occurrence of autoimmune disease is a negative prognostic factor for survival. Conclusions: Our results provide the basis for a detailed prospective evaluation of autoimmunity and inflammation in the context of PIDs, with a view to accurately assessing these risks and describing the possible effect of medical intervention.	[Fischer, Alain; Provot, Johan; Jais, Jean-Philippe; Alcais, Alexandre; Mahlaoui, Nizar; CEREDIH French PID Study Grp] Ctr Reference Deficits Immunitaires Hereditaires, Paris, France; [Fischer, Alain; Mahlaoui, Nizar] Hop Univ Necker Enfants Malad, AP HP, Unite Immunohematol & Rhumatol Pediat, Paris, France; [Fischer, Alain; Jais, Jean-Philippe; Alcais, Alexandre; Mahlaoui, Nizar] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Fischer, Alain] INSERM, UMR 1163, Paris, France; [Fischer, Alain] Coll France, Paris, France; [Jais, Jean-Philippe] Univ Paris 05, INSERM, UMRS 1138, Team 22, Paris, France; [Jais, Jean-Philippe] Hop Necker Enfants Malad, AP HP, Biostat Unit, Paris, France; [Alcais, Alexandre; Mahlaoui, Nizar] INSERM, UMR 1163, Lab Human Genet Infect Dis, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fischer, A (corresponding author), Inst Imagine, 24 Blvd Montparnasse, F-75015 Paris, France.	alain.fischer@inserm.fr	Héritier, Sébastien/D-8139-2017; MAHLAOUI, Nizar/AAH-6103-2020; Lefèvre, Guillaume/I-7168-2018; Lecuit, Marc/M-4126-2019; Rieux-Laucat, Frédéric/A-7916-2017; HACHULLA, ERIC/R-8488-2018; Mahlaoui, Nizar/J-7928-2017; Lecuit, Marc/J-4073-2013; Alcais, Alexandre/J-5882-2017; schleinitz, nicolas/AAL-6751-2020; Moshous, Despina/B-7507-2017; Magerus-Chatinet, Aude/I-6245-2017	Héritier, Sébastien/0000-0003-0384-6370; MAHLAOUI, Nizar/0000-0002-0030-8094; Lefèvre, Guillaume/0000-0002-9427-7267; Lecuit, Marc/0000-0002-4491-1063; Rieux-Laucat, Frédéric/0000-0001-7858-7866; HACHULLA, ERIC/0000-0001-7432-847X; Mahlaoui, Nizar/0000-0002-0030-8094; Lecuit, Marc/0000-0002-4491-1063; Alcais, Alexandre/0000-0002-1012-2226; schleinitz, nicolas/0000-0001-9449-3392; Provot, Johan/0000-0002-2044-4210; Moshous, Despina/0000-0001-6719-3693; BEAUSSANT COHEN, Sarah/0000-0002-5591-9730; Magerus-Chatinet, Aude/0000-0001-7365-699X; bonnotte, bernard/0000-0002-1098-4598; LE MOIGNE, Emmanuelle/0000-0001-5103-2406; Korganow, Anne-Sophie/0000-0002-1664-6311; Jeziorski, Eric/0000-0003-0318-3044; Humbert, Sebastien/0000-0003-0454-0840	French Association of Patients with Primary Immunodeficiencies (IRIS); French Ministry of Health; LFB; GlaxoSmithKline; CSL Behring; Baxalta; Octapharma; Binding Site; patient association AT-Europe; patient association Trophee Guillaume	French Association of Patients with Primary Immunodeficiencies (IRIS); French Ministry of Health; LFB; GlaxoSmithKline(GlaxoSmithKline); CSL Behring; Baxalta; Octapharma; Binding Site; patient association AT-Europe; patient association Trophee Guillaume	CEREDIH is supported by the French Association of Patients with Primary Immunodeficiencies (IRIS) and is funded by the French Ministry of Health. It additionally received unrestricted educational grants from LFB, GlaxoSmithKline, CSL Behring, Baxalta, Octapharma, Binding Site, and the patient associations AT-Europe and Trophee Guillaume.	Aladjidi N, 2011, HAEMATOL-HEMATOL J, V96, P655, DOI 10.3324/haematol.2010.036053; Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021; Bodemer C, 2014, CLIN MICROBIOL INFEC, V20, pO656, DOI 10.1111/1469-0691.12573; Cooper GS, 2009, J AUTOIMMUN, V33, P197, DOI 10.1016/j.jaut.2009.09.008; Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5; Danner S, 2006, J RHEUMATOL, V33, P1377; de Jesus AA, 2015, ANNU REV IMMUNOL, V33, P823, DOI 10.1146/annurev-immunol-032414-112227; Eaton WW, 2007, J AUTOIMMUN, V29, P1, DOI 10.1016/j.jaut.2007.05.002; Edgar JDM, 2014, CLIN EXP IMMUNOL, V175, P68, DOI 10.1111/cei.12172; Flori NM, 1997, J CLIN IMMUNOL, V17, P333, DOI 10.1023/A:1027382916924; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Gower-Rousseau C, 2013, DIGEST LIVER DIS, V45, P89, DOI 10.1016/j.dld.2012.09.005; Grimbacher Bodo, 2016, J Allergy Clin Immunol, V137, P3, DOI 10.1016/j.jaci.2015.11.004; Hayter SM, 2012, AUTOIMMUN REV, V11, P754, DOI 10.1016/j.autrev.2012.02.001; Ji JG, 2016, J AUTOIMMUN, V69, P102, DOI 10.1016/j.jaut.2016.03.003; Jonkman-Berk BM, 2015, CLIN IMMUNOL, V156, P154, DOI 10.1016/j.clim.2014.10.003; Kirkpatrick P, 2007, J CLIN IMMUNOL, V27, P517, DOI 10.1007/s10875-007-9105-z; Kolhatkar NS, 2015, J EXP MED, V212, P1663, DOI 10.1084/jem.20150585; Magnani A, 2014, J ALLERGY CLIN IMMUN, V134, P655, DOI 10.1016/j.jaci.2014.04.014; Marschall K, 2015, CLIN EXP IMMUNOL, V182, P45, DOI 10.1111/cei.12661; Moulis G, 2014, BLOOD, V124, P3308, DOI 10.1182/blood-2014-05-578336; Notarangelo LD, 2013, ANNU REV IMMUNOL, V31, P195, DOI 10.1146/annurev-immunol-032712-095927; Peneau A, 2013, AM J GASTROENTEROL, V108, P1647, DOI 10.1038/ajg.2013.242; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; R-Core-Team, 2015, LANG ENV STAT COMP; Ramos-Casals M, 2015, AUTOIMMUN REV, V14, P670, DOI 10.1016/j.autrev.2015.03.008; Saifi M, 2015, IMMUNOL ALLERGY CLIN, V35, P731, DOI 10.1016/j.iac.2015.07.007; Shapira Y, 2010, J AUTOIMMUN, V34, pJ168, DOI 10.1016/j.jaut.2009.11.018; Shapiro RS, 2011, AM J HEMATOL, V86, P48, DOI 10.1002/ajh.21903; Suarez F, 2015, J CLIN ONCOL, V33, P202, DOI 10.1200/JCO.2014.56.5101; Tuano KS, 2015, J ALLERGY CLIN IMMUN, V135, P273, DOI 10.1016/j.jaci.2014.09.024; Warnatz K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00210	32	139	147	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1388	+		10.1016/j.jaci.2016.12.978	http://dx.doi.org/10.1016/j.jaci.2016.12.978			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28192146	Bronze			2022-12-18	WOS:000414304300018
J	Demoly, P; Emminger, W; Rehm, D; Backer, V; Tommerup, L; Kleine-Tebbe, J				Demoly, Pascal; Emminger, Waltraud; Rehm, Dorte; Backer, Vibeke; Tommerup, Lene; Kleine-Tebbe, Joerg			Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy; sublingual immunotherapy tablet; sublingual immunotherapy; allergen immunotherapy; allergy; allergic rhinitis; house dust mite; Rhinitis Quality of Life Questionnaire; rhinoconjunctivitis; total combined rhinitis score	IMMUNOTHERAPY TABLET; SUBLINGUAL IMMUNOTHERAPY; NORTH-AMERICAN; CLINICAL-TRIALS; RESPIRATORY ALLERGY; EFFICACY; SAFETY; ASTHMA; CHILDREN; STANDARDIZATION	Background: The SQ HDM SLIT-tablet (ALK) has been developed for treatment of house dust mite (HDM)-induced respiratory allergic disease. Objective: This trial investigated the efficacy and safety of the SQ HDM SLIT-tablet in adults with moderate-to-severe HDM-induced allergic rhinitis (AR). Methods: The trial was a randomized, double-blind, placebo-controlled phase III trial conducted in 12 European countries including 992 adults with moderate-to-severe HDM-induced AR despite treatment with pharmacotherapy. Subjects were randomized 1:1:1 to 1 year of daily treatment with placebo, 6 SQ-HDM, or 12 SQ-HDM. The primary end point was the total combined rhinitis score (ie, the sum of rhinitis symptom and medication scores) during the efficacy assessment period (approximately the last 8 weeks of the treatment period). Key secondary end points were rhinitis symptoms, medication scores, quality of life, and the combined rhinoconjunctivitis score. Results: Analysis of the primary end point (observed data) demonstrated absolute reductions in total combined rhinitis score of 1.18 (P=.002) and 1.22 (P=.001) compared with placebo for 6 SQ-HDM and 12 SQ-HDM, respectively. The statistically significant treatment effect was evident from 14 weeks of treatment onward. For all key secondary end points, efficacy was confirmed for 12 SQ-HDM, with statistically significant reductions of rhinitis symptoms and medication scores, improved quality of life, and a reduced combined rhinoconjunctivitis score in the efficacy assessment period compared with placebo. The treatment was well tolerated. Conclusion: The trial confirmed the efficacy and favorable safety profile of both 6 SQ-HDM and 12 SQ-HDM in adults with HDM-induced AR. The treatment effect was present from 14 weeks of treatment onward.	[Demoly, Pascal] Univ Hosp Montpellier, Hop Arnaud de Villeneuve, Div Allergy, Dept Pulmonol, F-34295 Montpellier 5, France; [Emminger, Waltraud] Allergy Outpatient Clin, Vienna, Austria; [Rehm, Dorte; Tommerup, Lene] ALK, Horsholm, Denmark; [Backer, Vibeke] Bispebjerg Hosp, Dept Resp Med, Copenhagen, Denmark; [Kleine-Tebbe, Joerg] Outpatient Clin & Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany; [Demoly, Pascal] Univ Paris 06, Sorbonne Univ, IPLESP, Equipe EPAR,UMR S 1136, F-75013 Paris, France	Universite de Montpellier; CHU de Montpellier; University of Copenhagen; Bispebjerg Hospital; UDICE-French Research Universities; Sorbonne Universite	Demoly, P (corresponding author), Univ Hosp Montpellier, Hop Arnaud de Villeneuve, Div Allergy, Dept Pulmonol, F-34295 Montpellier 5, France.	pascal.demoly@inserm.fr	Demoly, Pascal/Y-9938-2019; Backer, Vibeke/AAQ-9379-2021	Demoly, Pascal/0000-0001-7827-7964; Kleine-Tebbe, Joerg/0000-0002-2862-7353	ALK, Horsholm, Denmark	ALK, Horsholm, Denmark	Supported by ALK, Horsholm, Denmark.	Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon MA, 2014, CLIN EXP ALLERGY, V44, P1228, DOI 10.1111/cea.12331; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Calderon MA, 2013, J ALLERGY CLIN IMMUN, V132, P1322, DOI 10.1016/j.jaci.2013.09.004; Calderon MA, 2012, J ALLERGY CLIN IMMUN, V129, P929, DOI 10.1016/j.jaci.2011.11.019; Canonica GW, 2007, ALLERGY, V62, P359, DOI 10.1111/j.1398-9995.2006.01277.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, WORLD ALLERGY ORGAN, V2, P233, DOI 10.1097/WOX.0b013e3181c6c379; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Creticos PS, 2013, J ALLERGY CLIN IMMUN, V131, P1342, DOI 10.1016/j.jaci.2013.03.019; del Cuvillo A, 2011, J INVEST ALLERG CLIN, V21, P40; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; *EMEA, 2008, CHMPEWP185042006 EME; ICH, 1996, ICH HARM TRIP GUID T; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Maloney J, 2014, ANN ALLERG ASTHMA IM, V112, P146, DOI 10.1016/j.anai.2013.11.018; Meier U, 2006, PHARM STAT, V5, P253, DOI 10.1002/pst.210; Mosbech H, 2014, J ALLERGY CLIN IMMUN, V34, P568; Mosbech H, 2015, ANN ALLERG ASTHMA IM, V114, P134, DOI 10.1016/j.anai.2014.11.015; Nelson H, 2013, ALLERGY, V68, P252, DOI 10.1111/all.12074; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Nolte H, 2013, ANN ALLERG ASTHMA IM, V110, P450, DOI 10.1016/j.anai.2013.03.013; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Pfaar O, 2011, IMMUNOL ALLERGY CLIN, V31, P289, DOI 10.1016/j.iac.2011.02.004; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Riechelmann H, 2010, AM J RHINOL ALLERGY, V24, pE104, DOI 10.2500/ajra.2010.24.3508; Rubin DB, 2004, MULTIPLE IMPUTATION; Valovirta E, 2008, CURR OPIN ALLERGY CL, V8, P1, DOI 10.1097/ACI.0b013e3282f3f42f; World Medical Association, 2008, DECL HELS ETH PRINC; Yukselen A, 2012, INT ARCH ALLERGY IMM, V157, P288, DOI 10.1159/000327566; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	38	139	140	1	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					444	+		10.1016/j.jaci.2015.06.036	http://dx.doi.org/10.1016/j.jaci.2015.06.036			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26292778	hybrid			2022-12-18	WOS:000369235500013
J	Czarnowicki, T; Esaki, H; Gonzalez, J; Malajian, D; Shemer, A; Noda, S; Talasila, S; Berry, A; Gray, J; Becker, L; Estrada, Y; Xu, H; Zheng, XZ; Suarez-Farinas, M; Krueger, JG; Paller, AS; Guttman-Yassky, E				Czarnowicki, Tali; Esaki, Hitokazu; Gonzalez, Juana; Malajian, Dana; Shemer, Avner; Noda, Shinji; Talasila, Sreya; Berry, Adam; Gray, Jayla; Becker, Lauren; Estrada, Yeriel; Xu, Hui; Zheng, Xiuzhong; Suarez-Farinas, Mayte; Krueger, James G.; Paller, Amy S.; Guttman-Yassky, Emma			Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA) 1 T(H)2/T(H)1 cell imbalance, whereas adults acquire CLA1(+) T(H)22/T(C)22 cell subsets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; T cell; cutaneous lymphocyte antigen; IL-13; IL-22; IFN-gamma; inducible costimulator; CD69; HLA-DR	CD8(+) T-CELLS; AGE-RELATED-CHANGES; FLOW CYTOMETRIC ANALYSIS; ALLERGIC CONTACT-DERMATITIS; INTERFERON-GAMMA; IFN-GAMMA; CYTOKINE PRODUCTION; ACTIVATION MARKER; SKIN BARRIER; IMMUNE DYSREGULATION	Background: Identifying differences and similarities between cutaneous lymphocyte antigen (CLA)(+) polarized T-cell subsets in children versus adults with atopic dermatitis (AD) is critical for directing new treatments toward children. Objective: We sought to compare activation markers and frequencies of skin-homing (CLA(+)) versus systemic (CLA(-)) "polar'' CD4 and CD8 T-cell subsets in patients with early pediatric AD, adults with AD, and control subjects. Methods: Flow cytometry was used to measure CD69/inducible costimulator/HLA-DR frequency in memory cell subsets, as well as IFN-gamma, IL-13, IL-9, IL-17, and IL-22 cytokines, defining T(H)1/cytotoxic T(T-C) 1, T(H)2/T(C)2, TH9/T(C)9, T(H)17/T(C)17, and T(H)22/T(C)22 populations in CD4 and CD8 cells, respectively. We compared peripheral blood from 19 children less than 5 years old and 42 adults with well-characterized moderate-to-severe AD, as well as age-matched control subjects (17 children and 25 adults). Results: Selective inducible costimulator activation (P <. 001) was seen in children. CLA(+)T(H)2 T cells were markedly expanded in both children and adults with AD compared with those in control subjects, but decreases in CLA(+)T(H)1 T-cell numbers were greater in children with AD (17% vs 7.4%, P = .007). Unlike in adults, no imbalances were detected in CLA(-) T cells from pediatric patients with AD nor were there altered frequencies of T(H)22 T cells within the CLA(+) or CLA(-) compartments. adults with AD hAD increased frequencies of IL-22-producing CD4 and CD8 T cells within the skin-homing population, compared with controls (9.5% vs 4.5% and 8.6% vs 2.4%, respectively; P <. 001), as well as increased HLA-DR activation (P < .01). Conclusions: These data suggest that T(H)2 activation within skin-homing T cells might drive AD in children and that reduced counterregulation by T(H)1 T cells might contribute to excess T(H)2 activation. T(H)22 "spreading'' of AD is not seen in young children and might be influenced by immune development, disease chronicity, or recurrent skin infections.	[Czarnowicki, Tali; Esaki, Hitokazu; Malajian, Dana; Noda, Shinji; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA; [Gonzalez, Juana] Rockefeller Univ, Translat Technol Core Lab, New York, NY 10021 USA; [Esaki, Hitokazu; Estrada, Yeriel; Xu, Hui; Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Malajian, Dana] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Talasila, Sreya; Berry, Adam; Gray, Jayla; Becker, Lauren; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Talasila, Sreya; Berry, Adam; Gray, Jayla; Becker, Lauren; Paller, Amy S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Shemer, Avner] Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org		Esaki, Hitokazu/0000-0002-3716-520X; Paller, Amy/0000-0001-6187-6549; Talasila, Sreya/0000-0001-8248-937X	NCATS NIH HHS [UL1 TR000043, UL1 TR001422, UL1TR0000] Funding Source: Medline; NCRR NIH HHS [UL1 RR024143, 5UL1RR024143-02] Funding Source: Medline; NIAMS NIH HHS [P30AR057216, P30 AR057216] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057216] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Agner T, 2010, BRIT J DERMATOL, V163, P1147, DOI 10.1111/j.1365-2133.2010.10114.x; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 1999, J IMMUNOL, V163, P466; Antunez C, 2004, Allergol Immunopathol (Madr), V32, P252, DOI 10.1157/13066301; Antunez C, 2006, PEDIAT ALLERG IMM-UK, V17, P166, DOI 10.1111/j.1399-3038.2006.00390.x; Antunez C, 2004, CLIN EXP ALLERGY, V34, P559, DOI 10.1111/j.1365-2222.2004.1933.x; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Beier KC, 2000, EUR J IMMUNOL, V30, P3707, DOI 10.1002/1521-4141(200012)30:12<3707::AID-IMMU3707>3.0.CO;2-Q; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Biedermann T, 2004, J INVEST DERM SYMP P, V9, P5, DOI 10.1111/j.1087-0024.2004.00829.x; BISELLI R, 1992, SCAND J IMMUNOL, V35, P439, DOI 10.1111/j.1365-3083.1992.tb02879.x; Black A, 2012, EUR J IMMUNOL, V42, P311, DOI 10.1002/eji.201141847; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 2001, PEDIAT ALLERG IMM-UK, V12, P216, DOI 10.1034/j.1399-3038.2001.012004216.x; Burr ML, 2013, BRIT J DERMATOL, V168, P1339, DOI 10.1111/bjd.12216; Campbell DE, 1999, CLIN EXP IMMUNOL, V115, P377; Carlsten C, 2013, ANN ALLERG ASTHMA IM, V110, P24, DOI 10.1016/j.anai.2012.10.005; Caruso A, 1997, CYTOMETRY, V27, P71, DOI 10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O; Chernyshov PV, 2009, J EUR ACAD DERMATOL, V23, P462, DOI 10.1111/j.1468-3083.2008.02909.x; Christensen KLY, 2009, CLIN INFECT DIS, V49, P1025, DOI 10.1086/605562; Clark RA, 2010, J INVEST DERMATOL, V130, P362, DOI 10.1038/jid.2009.247; Cossarizza A, 1996, MECH AGEING DEV, V86, P173, DOI 10.1016/0047-6374(95)01691-0; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Ferenczi K, 2000, J AUTOIMMUN, V14, P63, DOI 10.1006/jaut.1999.0343; Ferran M, 2013, EXP DERMATOL, V22, P439, DOI 10.1111/exd.12154; Ferran Marta, 2010, World Allergy Organ J, V3, P44, DOI 10.1097/WOX.0b013e3181d675f8; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Folster-Holst R, 2014, J EUR ACAD DERMATOL, V28, P5, DOI 10.1111/jdv.12481; Fuiano N, 2012, ALLERGOL INT, V61, P231, DOI 10.2332/allergolint.11-RA-0371; Gasparoni A, 2003, BIOL NEONATE, V84, P297, DOI 10.1159/000073638; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gonzalez-Amaro R, 2013, TRENDS MOL MED, V19, P625, DOI 10.1016/j.molmed.2013.07.006; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hennino A, 2007, J IMMUNOL, V178, P5571, DOI 10.4049/jimmunol.178.9.5571; Herberth G, 2010, PEDIAT ALLERG IMM-UK, V21, P5, DOI 10.1111/j.1399-3038.2009.00890.x; Higaki S, 1999, INT J DERMATOL, V38, P265, DOI 10.1046/j.1365-4362.1999.00686.x; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; HULSTAERT F, 1994, CLIN IMMUNOL IMMUNOP, V70, P152, DOI 10.1006/clin.1994.1023; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Jung T, 2003, INT ARCH ALLERGY IMM, V130, P143, DOI 10.1159/000069010; JUNG T, 1995, J ALLERGY CLIN IMMUN, V96, P515, DOI 10.1016/S0091-6749(95)70296-2; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Katsunuma T, 2004, INT ARCH ALLERGY IMM, V134, P240, DOI 10.1159/000078772; Kawamoto N, 2006, PEDIAT ALLERG IMM-UK, V17, P125, DOI 10.1111/j.1399-3038.2005.00363.x; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kidd Parris, 2003, Altern Med Rev, V8, P223; Kong HH, 2012, J INVEST DERMATOL, V132, P933, DOI 10.1038/jid.2011.417; Kopf M, 2000, J EXP MED, V192, P53, DOI 10.1084/jem.192.1.53; La Grutta S, 2005, ALLERGY, V60, P391, DOI 10.1111/j.1398-9995.2005.00733.x; Leonardi S, 2007, ALLERGY ASTHMA PROC, V28, P529, DOI 10.2500/aap2007.28.3038; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Liu J, 2014, J INVEST DERMATOL, V134, P1903, DOI 10.1038/jid.2014.61; Liu SY, 2012, P NATL ACAD SCI USA, V109, P4239, DOI 10.1073/pnas.1114981109; Lyons JJ, 2015, IMMUNOL ALLERGY CLIN, V35, P161, DOI 10.1016/j.iac.2014.09.008; Ma L, 2014, CLIN EXP IMMUNOL, V175, P25, DOI 10.1111/cei.12198; Machura E, 2007, EUR J PEDIATR, V166, P789, DOI 10.1007/s00431-006-0319-5; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; MAINO VC, 1995, CYTOMETRY, V20, P127, DOI 10.1002/cyto.990200205; McAdam AJ, 1998, IMMUNOL REV, V165, P231; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; MCDONAGH M, 1995, IMMUNOLOGY, V84, P514; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Nagaraja, 1996, PEDIATR DERMATOL, V13, P10, DOI 10.1111/j.1442-200X.1996.tb02838.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; PICKER LJ, 1990, AM J PATHOL, V136, P1053; Reddy M, 2004, J IMMUNOL METHODS, V293, P127, DOI 10.1016/j.jim.2004.07.006; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Saule P, 2006, MECH AGEING DEV, V127, P274, DOI 10.1016/j.mad.2005.11.001; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Schietinger A, 2014, TRENDS IMMUNOL, V35, P51, DOI 10.1016/j.it.2013.10.001; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seneviratne SL, 2007, QJM-INT J MED, V100, P19, DOI 10.1093/qjmed/hcl132; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Tesciuba AG, 2008, J IMMUNOL, V181, P1019, DOI 10.4049/jimmunol.181.2.1019; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; Thunberg S, 2010, ALLERGY, V65, P311, DOI 10.1111/j.1398-9995.2009.02218.x; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Toma T, 2005, PEDIATR INT, V47, P32, DOI 10.1111/j.1442-200x.2004.02004.x; Torres MJ, 1998, CLIN EXP ALLERGY, V28, P1264; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; von Kobyletzki LB, 2014, BRIT J DERMATOL, V170, pE52; Weerkamp F, 2005, J ALLERGY CLIN IMMUN, V115, P834, DOI 10.1016/j.jaci.2004.10.031; Werfel T, 1997, ALLERGY, V52, P465, DOI 10.1111/j.1398-9995.1997.tb01031.x; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	106	139	149	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					941	+		10.1016/j.jaci.2015.05.049	http://dx.doi.org/10.1016/j.jaci.2015.05.049			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26242300	Green Accepted			2022-12-18	WOS:000362976300013
J	Amano, W; Nakajima, S; Kunugi, H; Numata, Y; Kitoh, A; Egawa, G; Dainichi, T; Honda, T; Otsuka, A; Kimoto, Y; Yamamoto, Y; Tanimoto, A; Matsushita, M; Miyachi, Y; Kabashima, K				Amano, Wataru; Nakajima, Saeko; Kunugi, Hayato; Numata, Yasuharu; Kitoh, Akihiko; Egawa, Gyohei; Dainichi, Teruki; Honda, Tetsuya; Otsuka, Atsushi; Kimoto, Yukari; Yamamoto, Yasuo; Tanimoto, Atsuo; Matsushita, Mutsuyoshi; Miyachi, Yoshiki; Kabashima, Kenji			The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; filaggrin; signal transducer and activator of transcription 3; Janus kinase inhibitor; keratinocyte differentiation	ATOPIC-DERMATITIS; FILAGGRIN MUTATIONS; CORNIFIED ENVELOPE; JAK INHIBITOR; NC/NGA MICE; DIFFERENTIATION; RESPONSES; MODEL; STAT6; TH2	Background: Barrier disruption and the resulting continuous exposure to allergens are presumed to be responsible for the development of atopic dermatitis (AD). However, the mechanism through which skin barrier function is disrupted in patients with AD remains unclear. Objectives: Taking into account the fact that the T(H)2 milieu impairs keratinocyte terminal differentiation, we sought to clarify our hypothesis that the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a critical role in skin barrier function and can be a therapeutic target for AD. Methods: We analyzed the mechanism of keratinocyte differentiation using a microarray and small interfering RNA targeting STATs. We studied the effect of the JAK inhibitor JTE-052 on keratinocyte differentiation using the human skin equivalent model and normal human epidermal keratinocytes. We applied topical JAK inhibitor onto NC/Nga mice, dry skin model mice, and human skin grafted to immunocompromised mice. Results: IL-4 and IL-13 downregulated genes involved in keratinocyte differentiation. STAT3 and STAT6 are involved in keratinocyte differentiation and chemokine production by keratinocytes, respectively. Topical application of the JAK inhibitor suppressed STAT3 activation and improved skin barrier function, permitting increases in levels of terminal differentiation proteins, such as filaggrin, and natural moisturizing factors in models of AD and dry skin and in human skin. Conclusion: STAT3 signaling is a key element that regulates keratinocyte differentiation. The JAK inhibitor can be a new therapeutic tool for the treatment of disrupted barrier function in patients with AD.	[Amano, Wataru; Nakajima, Saeko; Kitoh, Akihiko; Egawa, Gyohei; Dainichi, Teruki; Honda, Tetsuya; Otsuka, Atsushi; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068507, Japan; [Amano, Wataru; Kunugi, Hayato; Numata, Yasuharu; Kimoto, Yukari; Yamamoto, Yasuo; Tanimoto, Atsuo; Matsushita, Mutsuyoshi] Japan Tobacco, Cent Pharmaceut Res Inst, Tokyo, Japan; [Kabashima, Kenji] Japan Sci & Technol Agcy, PRESTO, Saitama, Japan	Kyoto University; Japan Tobacco Inc.; Japan Science & Technology Agency (JST)	Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawaharamachi, Kyoto 6068507, Japan.	mutsuyoshi.matsushita@jt.com; kaba@kuhp.kyoto-u.ac.jp	Dainichi, Teruki/AAL-5400-2020; Nakajima, Saeko/AAB-1577-2021; Kabashima, Kenji/G-2521-2014	Dainichi, Teruki/0000-0002-9497-0029; Nakajima, Saeko/0000-0003-0831-1447; Tanimoto, Atsuo/0000-0002-5309-5192; Kabashima, Kenji/0000-0002-0773-0554; Egawa, Gyohei/0000-0002-6101-4719; Otsuka, Atsushi/0000-0001-7365-947X	Ministry of Education, Culture, Sports, Science, and Technology; Ministry of Health, Labour and Welfare; Precursory Research for Embryonic Science and Technology; Japan Tobacco; Grants-in-Aid for Scientific Research [15H05790] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Precursory Research for Embryonic Science and Technology; Japan Tobacco; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (to K.K.) and from the Ministry of Health, Labour and Welfare (to K.K.); Precursory Research for Embryonic Science and Technology (to K.K.); a Grant-in-Aid from the Japan Society for the Promotion of Science Fellows (to S.N.), and by Japan Tobacco.	Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashino S, 2014, J ALLERGY CLIN IMMUN, V133, P1162, DOI 10.1016/j.jaci.2013.10.036; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Egawa G, 2011, J INVEST DERMATOL, V131, P2178, DOI 10.1038/jid.2011.198; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Fukushi S, 2011, BRIT J DERMATOL, V165, P990, DOI 10.1111/j.1365-2133.2011.10498.x; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gareus R, 2007, NAT CELL BIOL, V9, P461, DOI 10.1038/ncb1560; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Harding Clive R, 2004, Dermatol Ther, V17 Suppl 1, P6, DOI 10.1111/j.1396-0296.2004.04S1001.x; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Heimall J, 2012, EXPERT REV CLIN IMMU, V8, P189, DOI [10.1586/ECI.11.100, 10.1586/eci.11.100]; Hirai T, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-3; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Madden KB, 2002, J IMMUNOL, V169, P4417, DOI 10.4049/jimmunol.169.8.4417; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Miyamoto T, 2002, JPN J PHARMACOL, V88, P285, DOI 10.1254/jjp.88.285; Moniaga Catharina Sagita, 2011, Inflammation & Allergy Drug Targets, V10, P477; Nakagawa R, 2011, J IMMUNOL, V187, P4611, DOI 10.4049/jimmunol.1100649; Nakajima S, 2010, J IMMUNOL, V184, P5595, DOI 10.4049/jimmunol.0903260; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Owczarek W, 2010, CYTOKINE, V50, P181, DOI 10.1016/j.cyto.2010.02.016; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Suto H, 1999, INT ARCH ALLERGY IMM, V120, P70, DOI 10.1159/000053599; Tanimoto A, 2015, INFLAMM RES, V64, P41, DOI 10.1007/s00011-014-0782-9; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Umeshita-Suyama R, 2000, INT IMMUNOL, V12, P1499, DOI 10.1093/intimm/12.11.1499; Vainchenker W, 2008, SEMIN CELL DEV BIOL, V19, P385, DOI 10.1016/j.semcdb.2008.07.002; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433	54	139	147	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					667	+		10.1016/j.jaci.2015.03.051	http://dx.doi.org/10.1016/j.jaci.2015.03.051			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26115905	Bronze			2022-12-18	WOS:000360913300019
J	Foster, JM; Usherwood, T; Smith, L; Sawyer, SM; Xuan, W; Rand, CS; Reddel, HK				Foster, Juliet M.; Usherwood, Tim; Smith, Lorraine; Sawyer, Susan M.; Xuan, Wei; Rand, Cynthia S.; Reddel, Helen K.			Inhaler reminders improve adherence with controller treatment in primary care patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Medication adherence; treatment effectiveness; intervention studies; antiasthmatic agents; asthma; ambulatory monitoring; health communication	CLUSTER RANDOMIZED-TRIALS; GENERAL-PRACTITIONERS; DEPRESSION SCALE; HOSPITAL ANXIETY; ADULTS; CORTICOSTEROIDS; EXACERBATIONS; RELIABILITY; STATEMENT; VALIDITY	Background: Poor adherence contributes to uncontrolled asthma. Pragmatic adherence interventions for primary care settings are lacking. Objective: To test the effectiveness of 2 brief general practitioner (GP)-delivered interventions for improving adherence and asthma control. Methods: In a 6-month cluster randomized 2 x 2 factorial controlled trial, with GP as unit of cluster, we compared inhaler reminders and feedback (IRF) and/or personalized adherence discussions (PADs) with active usual care alone; all GPs received action plan and inhaler technique training. GPs enrolled patients prescribed combination controller inhalers, with suboptimal Asthma Control Test (ACT) scores (ACT score <= 19). Inhaler monitors recorded fluticasone propionate/salmeterol adherence (covertly for non-IRF groups) and, in IRF groups, provided twice-daily reminders for missed doses, and adherence feedback. PAD GPs received communication training regarding adherence. Outcomes collected every 2 months included ACT scores (primary outcome) and severe exacerbations. Intention-to-treat mixed-model analysis incorporated cluster effect and repeated measures. Results: A total of 43 GPs enrolled 143 patients with moderate-severe asthma (mean age, 40.3 +/- 15.2 years; ACT score, 14.6 +/- 3.8; fluticasone propionate dose, 718 +/- 470 mu g). Over 6 months, adherence was significantly higher in the IRF group than in non-IRF groups (73% +/- 26% vs 46% +/- 28% of prescribed daily doses; P < .0001), but not between PAD and non-PAD groups. Asthma control improved overall (mean change in ACT score, 4.5 +/- 4.9; P < .0001), with no significant difference among groups (P = .14). Severe exacerbations were experienced by 11% of the patients in IRF groups and 28% of the patients in non-IRF groups (P = .013; after adjustment for exacerbation history; P = .06). Conclusions: Inhaler reminders offer an effective strategy for improving adherence in primary care compared with a behavioral intervention or usual care, although this may not be reflected in differences in day-to-day asthma control.	[Foster, Juliet M.; Reddel, Helen K.] Univ Sydney, Woolcock Inst Med Res, Clin Management Grp, Camperdown, NSW 2050, Australia; [Usherwood, Tim] Univ Sydney, Dept Gen Practice, Sydney Med Sch Westmead, Camperdown, NSW 2050, Australia; [Smith, Lorraine] Univ Sydney, Fac Pharm, Camperdown, NSW 2050, Australia; [Sawyer, Susan M.] Royal Childrens Hosp, Ctr Adolescent Hlth, Parkville, Vic, Australia; [Sawyer, Susan M.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Sawyer, Susan M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Xuan, Wei] Univ New S Wales, South Western Sydney Clin Sch, Ingham Inst Appl Med Res, Sydney, NSW, Australia; [Rand, Cynthia S.] Johns Hopkins Sch Med, Dept Pulm & Crit Care Med, Baltimore, MD USA	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; University of Sydney; Royal Children's Hospital Melbourne; University of Melbourne; Murdoch Children's Research Institute; Ingham Institute for Applied Medical Research; University of New South Wales Sydney; Johns Hopkins University; Johns Hopkins Medicine	Foster, JM (corresponding author), Univ Sydney, Woolcock Inst Med Res, Clin Management Grp, POB M77,Missenden Rd, Camperdown, NSW 2050, Australia.	j.m.foster@woolcock.org.au	Reddel, Helen/ABD-6338-2021; Reddel, Helen/AAC-3394-2020	Reddel, Helen/0000-0002-6695-6350; Foster, Juliet M/0000-0003-0780-6034; Smith, Lorraine/0000-0002-3499-1514	National Health and Medical Research Council of Australia [ID571053]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Funding for this study was provided by the National Health and Medical Research Council of Australia (ID571053). The Asthma Control Test was used with permission of GlaxoSmithKline and in accordance with conditions specified by GlaxoSmithKline under the terms of its license with the copyright holder, QualityMetric Incorporated. One month's supply of controller and 1 spacer per patient was provided by GlaxoSmithKline. SmartTrack devices were purchased from Nexus6 (Auckland, New Zealand). SIM cards for the remote upload of adherence data were provided by Vodaphone, New Zealand. None of the above bodies had any role in the design, conduct, analysis, or interpretation of the study, nor did they see the manuscript before submission. The authors alone are responsible for the content and writing of the article.	Ampon RD, 2009, MED J AUSTRALIA, V191, P319, DOI 10.5694/j.1326-5377.2009.tb02815.x; [Anonymous], 2011, AIHW ASTHM SER, V4; Asthma G., 2020, GLOB STRAT ASTHM MAN; Australian Bureau of Statistics, 2006, SOC IND AR; Basheti IA, 2007, J ALLERGY CLIN IMMUN, V119, P1537, DOI 10.1016/j.jaci.2007.02.037; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bosnic-Anticevich SZ, 2010, J ASTHMA, V47, P251, DOI 10.3109/02770900903580843; Boutron I, 2007, PLOS MED, V4, P370, DOI 10.1371/journal.pmed.0040061; Butler C.C., 2013, BMJ-BRIT MED J, V346; Butler CC, 1999, BRIT J GEN PRACT, V49, P611; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Carlton BG, 2005, J ASTHMA, V42, P529, DOI 10.1081/JAS-200067000; Charles T, 2007, J ALLERGY CLIN IMMUN, V119, P811, DOI 10.1016/j.jaci.2006.11.700; DiIorio C, 2008, AIDS CARE, V20, P273, DOI 10.1080/09540120701593489; Fenerty SD, 2012, PATIENT PREFER ADHER, V6, P127, DOI 10.2147/PPA.S26314; Fisher JD, 2006, HEALTH PSYCHOL, V25, P462, DOI 10.1037/0278-6133.25.4.462; FitzGerald JM, 2005, CLIN THER, V27, P393, DOI 10.1016/j.clinthera.2005.03.006; Foster JM, 2012, INTERN MED J, V42, pE136, DOI 10.1111/j.1445-5994.2011.02541.x; Foster JM, 2011, EUR RESPIR MONOGR, P28, DOI 10.1183/1025448x.10000710; Foster JM, 2012, J ASTHMA, V49, P657, DOI 10.3109/02770903.2012.684253; Goeman DP, 2005, MED J AUSTRALIA, V183, P457, DOI 10.5694/j.1326-5377.2005.tb07122.x; Hahn Seokyung, 2005, BMC Med Res Methodol, V5, P10, DOI 10.1186/1471-2288-5-10; Haynes RB, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub2; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Lehane E, 2007, INT J NURS STUD, V44, P1468, DOI 10.1016/j.ijnurstu.2006.07.010; Mahtani KR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005025.pub3; Marcus BH, 1997, PREV MED, V26, P382, DOI 10.1006/pmed.1997.0158; Mason VL, 2007, FAM PRACT, V24, P518, DOI 10.1093/fampra/cmm047; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Miller WR, 2001, BEHAV COGN PSYCHOTH, V29, P457, DOI 10.1017/S1352465801004064; Mora PA, 2011, PSYCHOL HEALTH, V26, P713, DOI 10.1080/08870446.2010.490585; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Council Australia, 2014, AUSTR ASTHM HDB; O'Connor J, 2008, PATIENT EDUC COUNS, V70, P111, DOI 10.1016/j.pec.2007.09.004; Patel M, 2012, J ALLERGY CLIN IMMUN, V130, P1420, DOI 10.1016/j.jaci.2012.06.037; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; Reddel H, 2012, AUST PRESCR, V35, P78, DOI 10.18773/austprescr.2012.035; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reiff-Hekking S, 2005, J GEN INTERN MED, V20, P7, DOI 10.1111/j.1525-1497.2005.21240.x; Roche N, 2013, LANCET RESP MED, V1, pE29, DOI 10.1016/S2213-2600(13)70199-1; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Smith L, 2013, RES SOC ADMIN PHARM, V9, P918, DOI 10.1016/j.sapharm.2013.02.002; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Toelle BG, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002171.PUB2; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zolnierek KBH, 2009, MED CARE, V47, P826, DOI 10.1097/MLR.0b013e31819a5acc	55	139	142	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1260	+		10.1016/j.jaci.2014.05.041	http://dx.doi.org/10.1016/j.jaci.2014.05.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AW1UG	25062783				2022-12-18	WOS:000346075400006
J	Amelink, M; de Groot, JC; de Nijs, SB; Lutter, R; Zwinderman, AH; Sterk, PJ; ten Brinke, A; Bel, EH				Amelink, Marijke; de Groot, Jantina C.; de Nijs, Selma B.; Lutter, Rene; Zwinderman, Aeilko H.; Sterk, Peter J.; ten Brinke, Anneke; Bel, Elisabeth H.			Severe adult-onset asthma: A distinct phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; adult onset; eosinophilia; sinus disease	AIR-FLOW LIMITATION; LUNG-FUNCTION; CLUSTER-ANALYSIS; RISK-FACTORS; FOLLOW-UP; STANDARDIZATION; OBESITY; QUESTIONNAIRE; INFLAMMATION; DISEASE	Background: Some patients with adult-onset asthma have severe disease, whereas others have mild transient disease. It is currently unknown whether patients with severe adult-onset asthma represent a distinct clinical phenotype. Objective: We sought to investigate whether disease severity in patients with adult-onset asthma is associated with specific phenotypic characteristics. Methods: One hundred seventy-six patients with adult-onset asthma were recruited from 1 academic and 3 nonacademic outpatient clinics. Severe refractory asthma was defined according to international Innovative Medicines Initiative criteria, and mild-to-moderate persistent asthma was defined according to Global Initiative for Asthma criteria. Patients were characterized with respect to clinical, functional, and inflammatory parameters. Unpaired t tests and chi(2) tests were used for group comparisons; both univariate and multivariate logistic regression were used to determine factors associated with disease severity. Results: Apart from the expected high symptom scores, poor quality of life, need for high-intensity treatment, low lung function, and high exacerbation rate, patients with severe adultonset asthma were more often nonatopic (52% vs 34%, P = .02) and had more nasal symptoms and nasal polyposis (54% vs 27%, P <= .001), higher exhaled nitric oxide levels (38 vs 27 ppb, P = .02) and blood neutrophil counts (5.3 vs 4.0 10(9)/L, P <= .001) and sputum eosinophilia (11.8% vs 0.8%, P <= .001). Multiple logistic regression analysis showed that increased blood neutrophil (odds ratio, 10.9; P = .002) and sputum eosinophil (odds ratio, 1.5; P = .005) counts were independently associated with severe adult-onset disease. Conclusion: The majority of patients with severe adult-onset asthma are nonatopic and have persistent eosinophilic airway inflammation. This suggests that severe adult-onset asthma has a distinct underlying mechanism compared with milder disease.	[Amelink, Marijke; de Nijs, Selma B.; Lutter, Rene; Sterk, Peter J.; Bel, Elisabeth H.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1100 DE Amsterdam, Netherlands; [de Groot, Jantina C.; ten Brinke, Anneke] Med Ctr Leeuwarden, Dept Resp Med, Amsterdam, Netherlands; [Zwinderman, Aeilko H.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Bioinformat & Biostat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Medical Center Leeuwarden; University of Amsterdam; Academic Medical Center Amsterdam	Amelink, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Resp Med, F5-260,POB 22700, NL-1100 DE Amsterdam, Netherlands.	M.Amelink@amc.nl	Sterk, P.J./AAK-8175-2020		Novartis; GlaxoSmithKline; Innovative Medicines Initiative by the European Union; European Federation of Pharmaceutical Industries and Associations; Boehringer Ingelheim	Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Innovative Medicines Initiative by the European Union; European Federation of Pharmaceutical Industries and Associations; Boehringer Ingelheim(Boehringer Ingelheim)	M. Amelink has received an unrestricted grant from Novartis. J. C. de Groot has received an unrestricted grant from GlaxoSmithKline. S. B. de Nijs has received an unrestricted grant from GlaxoSmithKline. P. J. Sterk has been supported by one or more grants from GlaxoSmithKline and has received a public-private grant from the Innovative Medicines Initiative by the European Union and the European Federation of Pharmaceutical Industries and Associations. A. ten Brinkel is a member of the Dutch Research Advisory Board of Novartis, has received an unrestricted research grant from GlaxoSmithKline, and has received payments for lectures on severe asthma from GlaxoSmithKline and Boehringer Ingelheim. E. H. Bel is a Board member for Novartis; has consultancy arrangements with Merck and Schering-Plough; has received one or more grants from or has one or more grants pending with EFPIA, Novartis, and GlaxoSmithKline; and has received one or more payments for lecturing from or is on the speakers' bureau for Nicomed, GlaxoSmithKline, and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Boorsma Martin, 2007, COPD, V4, P321, DOI 10.1080/15412550701597720; Dahlberg PE, 2009, CLIN EXP ALLERGY, V39, P1324, DOI 10.1111/j.1365-2222.2009.03322.x; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Fairs A, 2010, AM J RESP CRIT CARE, V182, P1362, DOI 10.1164/rccm.201001-0087OC; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hashimoto S, 2012, CLIN EXP ALLERGY, V42, P693, DOI 10.1111/j.1365-2222.2011.03936.x; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Jaakkola MS, 2006, J ALLERGY CLIN IMMUN, V117, P642, DOI 10.1016/j.jaci.2005.11.003; Jamrozik E, 2009, RESPIROLOGY, V14, P814, DOI 10.1111/j.1440-1843.2009.01562.x; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kunzli N, 2009, THORAX, V64, P664, DOI 10.1136/thx.2008.110031; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; National Institutes of Health National Heart Lung and Blood Institute, 2006, NAT HEART LUNG BLOOD; Papi A, 1998, CLIN EXP ALLERGY, V28, P174; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Romieu I, 2010, THORAX, V65, P292, DOI 10.1136/thx.2009.116079; Ronmark E, 2007, RESP MED, V101, P2370, DOI 10.1016/j.rmed.2007.06.011; Sideleva O, 2012, AM J RESP CRIT CARE, V186, P598, DOI 10.1164/rccm.201203-0573OC; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P749, DOI 10.1164/ajrccm.164.5.2009035; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; van Veen IH, 2009, J ALLERGY CLIN IMMUN, V124, P615, DOI 10.1016/j.jaci.2009.06.029; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046	42	139	144	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					336	341		10.1016/j.jaci.2013.04.052	http://dx.doi.org/10.1016/j.jaci.2013.04.052			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23806634				2022-12-18	WOS:000322631700010
J	Margolis, DJ; Apter, AJ; Gupta, J; Hoffstad, O; Papadopoulos, M; Campbell, LE; Sandilands, A; McLean, WHI; Rebbeck, TR; Mitra, N				Margolis, David J.; Apter, Andrea J.; Gupta, Jayanta; Hoffstad, Ole; Papadopoulos, Maryte; Campbell, Linda E.; Sandilands, Aileen; McLean, W. H. Irwin; Rebbeck, Tim R.; Mitra, Nandita			The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; filaggrin; epidemiology; genetic epidemiology; atopy	ICHTHYOSIS VULGARIS; PROTEIN FILAGGRIN; RARE MUTATIONS; CHILDREN; ASTHMA; ECZEMA; RISK; SKIN; PREDISPOSE; PREVALENT	Background: Atopic dermatitis (AD) is a common skin disease that is characterized by recurrent episodes of itching. Filaggrin (FLG) loss-of-function (FLG null) mutations have been associated with an increased risk of AD. Objective: We sought to evaluate the effect of individual FLG null mutations on the persistence of AD over time. Methods: We evaluated a multiyear prospective cohort study of children with AD with respect to FLG null mutations (R501X, 2282del4, R2447X, and S3247X). We evaluated the association of these mutations with the persistence of AD symptoms over time with respect to reports of no symptoms of AD and whether topical medication was needed for symptom resolution. Results: Eight hundred fifty-seven subjects were followed for 3684 person-years. One or more FLG null mutations were noted in 16.3% of subjects and specifically in 27.5% of white subjects and 5.8% of African American subjects. Subjects with an FLG null mutation were less likely (odds ratio [OR], 0.54; 95% CI, 0.41-0.71) to report that their skin was symptom free at any time compared with those without an FLG null mutation. The effect of these mutations was similar in white subjects (OR, 0.42; 95% CI, 0.31-0.57) and African-American subjects (OR, 0.53; 95% CI, 0.25-1.12; P = .62). Children with the R501X mutation (OR, 0.44; 95% CI, 0.22-0.88) were the least responsive to therapy. Conclusions: In a US cohort with AD, FLG null mutations were common. Children with FLG null mutations were more likely to have persistent AD. Although these mutations were more common in those of European ancestry, their effect on persistence was similar in those of African ancestry. Response to therapy was not uniform among children with FLG null mutations. (J Allergy Clin Immunol 2012; 130:912-7.)	[Margolis, David J.; Gupta, Jayanta; Hoffstad, Ole; Papadopoulos, Maryte; Rebbeck, Tim R.; Mitra, Nandita] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Margolis, David J.] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; [Apter, Andrea J.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Campbell, Linda E.; Sandilands, Aileen; McLean, W. H. Irwin] Univ Dundee, Div Mol Med, Coll Life Sci, Dundee DD1 4HN, Scotland	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Dundee	Margolis, DJ (corresponding author), 901 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	margo@mail.med.upenn.edu		McLean, William Henry Irwin/0000-0001-5539-5757	National Institute of Arthritis Musculoskeletal and Skin Diseases [R01-AR0056755]; Valeant Pharmaceuticals; National Institutes of Health (NIH); NIH; Wellcome Trust; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056755] Funding Source: NIH RePORTER	National Institute of Arthritis Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Valeant Pharmaceuticals; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by R01-AR0056755 from the National Institute of Arthritis Musculoskeletal and Skin Diseases and a grant from Valeant Pharmaceuticals for the Pediatric Eczema Elective Registry (PEER) study.; D.J. Margolis has received grants from the National Institutes of Health (NIH) and Valeant Pharmaceuticals and has consultant arrangements with Astellas. A.J. Apter and N. Mitra have received grants from the NIH. W.H.I. McLean has received grants from the Wellcome Trust. The rest of the authors declare that they have no relevant conflicts of interest.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Brown SJ, 2009, BRIT J DERMATOL, V161, P884, DOI 10.1111/j.1365-2133.2009.09339.x; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Burnett MS, 2006, AM J EPIDEMIOL, V163, P486, DOI 10.1093/aje/kwj057; Chen H, 2011, BRIT J DERMATOL, V165, P106, DOI 10.1111/j.1365-2133.2011.10331.x; Dean M, 2003, HUM MUTAT, V22, P261, DOI 10.1002/humu.10259; Fonacier LS, 2010, J ALLERGY CLIN IMMUN, V125, pS138, DOI 10.1016/j.jaci.2009.05.039; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; HOARE C, 2002, HEALTH TECHNOL ASSES, V4, P1; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kapoor R, 2009, PEDIATR DERMATOL, V26, P682, DOI 10.1111/j.1525-1470.2009.01013.x; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Margolis DJ, 2011, J INVEST DERMATOL, V131, P1765, DOI 10.1038/jid.2011.102; Norton HL, 2007, MOL BIOL EVOL, V24, P710, DOI 10.1093/molbev/msl203; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V126, P574, DOI 10.1016/j.jaci.2010.04.038; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reiner AP, 2007, HUM GENET, V121, P565, DOI 10.1007/s00439-007-0350-2; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Segre JA, 2006, J INVEST DERMATOL, V126, P1202, DOI 10.1038/sj.jid.5700367; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stefflova K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014495; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	36	139	143	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					912	917		10.1016/j.jaci.2012.07.008	http://dx.doi.org/10.1016/j.jaci.2012.07.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22951058	Green Accepted			2022-12-18	WOS:000309594800012
J	Eder, W; Klimecki, W; Yu, LZ; von Mutius, E; Riedler, J; Braun-Fahrlander, C; Nowak, D; Martinez, FD				Eder, W; Klimecki, W; Yu, LZ; von Mutius, E; Riedler, J; Braun-Fahrlander, C; Nowak, D; Martinez, FD		ALEX Study Team	Opposite effects of CD14/-260 on serum IgE levels in children raised in different environments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						serium IgE; CD14/-260; microbial exposure; gene-environment interaction	PROMOTER POLYMORPHISM; CD14 PROMOTER; C-159T POLYMORPHISM; ENDOTOXIN LEVELS; MATTRESS DUST; SOLUBLE CD14; ASTHMA; GENE; ASSOCIATION; EXPOSURE	Background: Most complex diseases are the result of interactions between polymorphisms in the genome and environmental exposures. Objective: We sought to investigate the previously reported association between a polymorphism in the promoter region of CD14 (CD14/-260C -> T) and serum IgE levels in relation to the environment to which children are exposed. Methods: In 624 children living in 2 rural communities in Europe, we compared total and specific serum IgE levels between the genotypes of CD14/-260 in relation to exposure to animals and in relation to house dust endotoxin. Results: We found that the C allele of CD14/-260 was associated with higher levels of both total and specific serum IgE to aeroallergens in children with regular contact with pets, whereas an association in the opposite direction was found in children with regular contact with stable animals. This modifying effect of animal exposure was not explained by levels of house dust endotoxin. However, in children with high levels of house dust endotoxin, the C allele was associated with less specific IgE, independently from animal exposure. Conclusion: Because CD14 is a pattern recognition receptor for microbial molecules, the results suggest that the type and concentrations of such molecules present in the environment strongly determine the direction of the association between CD14/-260 and serum markers of atopy.	Univ Arizona, Arizona Resp Ctr, Innate Immun Program Genom Applicat, Tucson, AZ 85724 USA; Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; Childrens Hosp, Salzburg, Austria; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Univ Munich, Inst & Outpatient Clin Occupat & Environm Med, Munich, Germany	University of Arizona; University of Munich; University of Basel; University of Munich	Martinez, FD (corresponding author), Univ Arizona, Arizona Resp Ctr, Innate Immun Program Genom Applicat, 1501 N Campbell Ave,POB 245030, Tucson, AZ 85724 USA.	fernando@arc.arizona.edu	riedler, josef/AAQ-4666-2020	von Mutius, Erika/0000-0002-8893-4515	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066800, P01HL067672, P50HL067672] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67672, HL66800] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMELUNG PJ, 2000, AM J RESP CRIT CARE, V161, pA927; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gao PS, 1999, CLIN GENET, V56, P164; Gehring U, 2004, INDOOR AIR, V14, P284, DOI 10.1111/j.1600-0668.2004.00244.x; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Karhukorpi J, 2002, CLIN EXP IMMUNOL, V128, P326, DOI 10.1046/j.1365-2249.2002.01837.x; Kedda MA, 2005, THORAX, V60, P211, DOI 10.1136/thx.2004.028449; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; LEWONTIN RC, 1994, AM J HUM GENET, V26, P400; Lotz S, 2004, J LEUKOCYTE BIOL, V75, P467, DOI 10.1189/jlb.0803360; Obana N, 2002, SCAND J GASTROENTERO, V37, P699, DOI 10.1080/00365520212504; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Remold SK, 2004, NAT GENET, V36, P423, DOI 10.1038/ng1324; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schlichting C., 1998, PHENOTYPIC EVOLUTION, P51; Schmitz G, 2002, CURR OPIN LIPIDOL, V13, P513, DOI 10.1097/00041433-200210000-00007; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; 2003, LANCET, V361, P357	30	139	140	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					601	607		10.1016/j.jaci.2005.05.003	http://dx.doi.org/10.1016/j.jaci.2005.05.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159630				2022-12-18	WOS:000235686500020
J	Friedlander, SL; Busse, WW				Friedlander, SL; Busse, WW			The role of rhinovirus in asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinovirus; asthma exacerbations; virology; cytokine response profiles; mechanisms of asthma	RESPIRATORY-INFECTIONS; LOWER AIRWAYS; NASAL-MUCOSA; ADULTS; INFLAMMATION; EPITHELIUM; FREQUENCY; COLDS; VIRUS; CELLS	Rhinoviruses are a major cause of asthma exacerbations in children and adults. With the use of sensitive RT-PCR methods, respiratory viruses are found in approximately 80% of wheezing episodes in children and in approximately one half of such episodes in adults. Rhinovirus; is a member of the family Picornaviridae, and acute rhinovirus infections occur predominantly in the upper airway. This virus has also been identified in the lower airway, and it might cause acute wheezing through the production of proinflammatory mediators with a resulting neutrophilic inflammatory response. Precisely how this process leads to increases in airway hyperresponsiveness and airway obstruction is not fully established. However, risk factors for wheezing with colds include asthma and atopy, extremes in age, and perhaps having a deficient T(H)1 response to rhinovirus. With the use of in vitro models and experimental inoculation studies, significant advances have led to a better understanding of the mechanisms by which rhinovirus infections cause asthma exacerbations. Advances in our understanding of this interaction might provide knowledge that could ultimately lead to specific treatment modalities to prevent and/or treat this significant burden of asthma exacerbations.	Univ Wisconsin, Dept Med, Div Allergy & Immunol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Dept Med, Div Allergy & Immunol, K4-912 CSC-9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997; Avila PC, 2000, J ALLERGY CLIN IMMUN, V105, P923, DOI 10.1067/mai.2000.106214; Brooks GD, 2003, AM J RESP CRIT CARE, V168, P1091, DOI 10.1164/rccm.200306-737OC; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Cardell LO, 1999, AM J RESP CRIT CARE, V160, P411, DOI 10.1164/ajrccm.160.2.9808117; Casasnovas JM, 2000, TRENDS MICROBIOL, V8, P251, DOI 10.1016/S0966-842X(00)01749-2; de Kluijver J, 2003, CLIN EXP ALLERGY, V33, P1415, DOI 10.1046/j.1365-2222.2003.01770.x; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 2003, J PEDIATR-US, V142, pS9, DOI 10.1067/mpd.2003.20; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 1999, CLIN MICROBIOL REV, V12, P9, DOI 10.1128/CMR.12.1.9; Gern JE, 2002, AM J MED, V112, p19S; Greenberg SB, 2003, ARCH INTERN MED, V163, P278, DOI 10.1001/archinte.163.3.278; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; GWALTNEY JM, 2005, MANDELL DOUGLAS BENN, P2185; Hakonarson H, 1999, AM J PHYSIOL-LUNG C, V277, pL13, DOI 10.1152/ajplung.1999.277.1.L13; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; Jarjour NN, 2000, J ALLERGY CLIN IMMUN, V105, P1169, DOI 10.1067/mai.2000.106376; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kaul P, 2000, J INFECT DIS, V181, P1885, DOI 10.1086/315504; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Smart JM, 2002, J ALLERGY CLIN IMMUN, V110, P450, DOI 10.1067/mai.2002.127283; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; WINTHER B, 1984, ACTA OTO-LARYNGOL, P19; Yamaya M, 2003, VIRAL IMMUNOL, V16, P99, DOI 10.1089/088282403322017857; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	33	139	144	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					267	273		10.1016/j.jaci.2005.06.003	http://dx.doi.org/10.1016/j.jaci.2005.06.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083778				2022-12-18	WOS:000235686400004
J	Schatz, M; Dombrowski, MP; Wise, R; Momirova, V; Landon, M; Mabie, W; Newman, RB; Hauth, JC; Lindheimer, M; Caritis, SN; Leveno, KJ; Meis, P; Miodovnik, M; Wapner, RJ; Paul, RH; Varner, MW; O'Sullivan, MJ; Thurnau, GR; Conway, DL				Schatz, M; Dombrowski, MP; Wise, R; Momirova, V; Landon, M; Mabie, W; Newman, RB; Hauth, JC; Lindheimer, M; Caritis, SN; Leveno, KJ; Meis, P; Miodovnik, M; Wapner, RJ; Paul, RH; Varner, MW; O'Sullivan, MJ; Thurnau, GR; Conway, DL			The relationship of asthma medication use to perinatal outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma medications; pregnancy; perinatal outcomes; prematurity; inhaled beta-agonists; inhaled corticosteroids; theophylline; oral corticosteroids	PREGNANCY; WOMEN; SEVERITY; GROWTH; THEOPHYLLINE; SAFETY	Background: Maternal asthma has been reported to increase the risk of preeclampsia, preterm deliveries, and lower-birth-weight infants, but the mechanisms of this effect are not defined. Objective: We sought to evaluate the relationship between the use of contemporary asthma medications and adverse perinatal outcomes. Methods: Asthmatic patients were recruited from the 16 centers of the National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network from December 1994 through February 2000. Gestational medication use was determined on the basis of patient history at enrollment and at monthly visits during pregnancy. Perinatal data were obtained at postpartum chart reviews. Perinatal outcome variables included gestational hypertension, preterm births, low-birth-weight infants, small-for-gestational-age infants, and major malformations. Results: The final cohort included 2123 asthmatic participants. No significant relationships were found between the use of inhaled beta-agonists (n = 1828), inhaled corticosteroids (n = 722), or theophylline (n = 273) and adverse perinatal outcomes. After adjusting for demographic and asthma severity covariates, oral corticosteroid use was significantly associated with both preterm birth at less than 37 weeks' gestation (odds ratio, 1.54; 95% CI, 1.02-2.33) and low birth weight of less than 2500 g (odds ratio, 1.80; 95% CI, 1.13-2.88). Conclusions: Use of inhaled beta-agonists, inhaled steroids, and theophylline do not appear to increase perinatal risks in pregnant asthmatic women. The mechanism of the association between maternal oral corticosteroid use and prematurity remains to be determined.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI USA; Johns Hopkins Univ, Dept Pulm Med, Baltimore, MD USA; George Washington Univ, Ctr Biostat, Washington, DC USA; Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA; Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA; Coll Med, Dept Obstet & Gynecol, Charleston, SC USA; Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Obstet & Gynecol, Pittsburgh, PA 15213 USA; Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75235 USA; Wake Forest Univ, Dept Obstet & Gynecol, Winston Salem, NC 27109 USA; Univ Cincinnati, Dept Obstet & Gynecol, Cincinnati, OH USA; Thomas Jefferson Univ, Dept Obstet & Gynecol, Philadelphia, PA 19107 USA; Univ So Calif, Dept Obstet & Gynecol, Los Angeles, CA USA; Univ Utah, Dept Obstet & Gynecol, Salt Lake City, UT USA; Univ Miami, Dept Obstet & Gynecol, Miami, FL 33152 USA; Univ Oklahoma, Dept Obstet & Gynecol, Oklahoma City, OK USA; Univ Texas, Dept Obstet & Gynecol, San Antonio, TX 78285 USA	Kaiser Permanente; Wayne State University; Johns Hopkins University; George Washington University; University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Birmingham; University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Wake Forest University; University System of Ohio; University of Cincinnati; Jefferson University; University of Southern California; Utah System of Higher Education; University of Utah; University of Miami; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Texas System	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org	/AAO-2076-2020; Varner, Michael/K-9890-2013	Wise, Robert/0000-0002-8353-2349; caritis, steve/0000-0002-2169-0712; Varner, Michael/0000-0001-9455-3973				Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; Briggs GG., 2008, DRUGS PREGNANCY LACT, P431; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; DOMBROWSKI MP, 1986, AM J OBSTET GYNECOL, V155, P265, DOI 10.1016/0002-9378(86)90804-5; Dombrowski MP, 2004, OBSTET GYNECOL, V103, P5, DOI 10.1097/01.AOG.0000103994.75162.16; Dombrowski MP, 2004, AM J OBSTET GYNECOL, V190, P737, DOI 10.1016/j.ajog.2003.09.071; ERICSON A, 1999, INFORMATION SWEDISH, V1, P8; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; LEHRER S, 1993, AM J OBSTET GYNECOL, V168, P1463, DOI 10.1016/S0002-9378(11)90782-0; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; ROMERO R, 2002, SEMIN NEONATOL, V7, P258; Schatz M, 2000, IMMUNOL ALLERGY CLIN, V20, P715, DOI 10.1016/S0889-8561(05)70179-X; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; Schatz M, 2003, J ALLERGY CLIN IMMUN, V112, P283, DOI 10.1067/mai.2003.1516; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Schatz M, 2001, SEMIN PERINATOL, V25, P145, DOI 10.1053/sper.2001.24569; STENIUSAARNIALA B, 1988, THORAX, V43, P12, DOI 10.1136/thx.43.1.12; 2002, J ALLERGY CLIN IMM S, V110, pS141	24	139	142	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1040	1045		10.1016/j.jaci.2004.03.017	http://dx.doi.org/10.1016/j.jaci.2004.03.017			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208581				2022-12-18	WOS:000222091000005
J	Anderson, SD; Holzer, K				Anderson, SD; Holzer, K			Exercise-induced asthma: Is it the right diagnosis in elite athletes?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						exercise-induced asthma; athletes; dehydration; airway injury; osmolarity	LEUKOTRIENE-RECEPTOR ANTAGONIST; NEUTROPHIL CHEMOTACTIC FACTOR; 4.5-PERCENT SODIUM-CHLORIDE; CROSS-COUNTRY SKIERS; INDUCED BRONCHOCONSTRICTION; BRONCHIAL HYPERRESPONSIVENESS; INDUCED BRONCHOSPASM; HYPERTONIC SALINE; MAST-CELLS; COLD-AIR	Exercise-induced asthma, as recognized in asthmatic subjects, is an exaggerated airway response to airway dehydration in the presence of inflammatory cells and their mediators. The airway narrowing is primarily caused by contraction of bronchial smooth muscle. The milder airway narrowing documented in response to exercise in elite athletes and otherwise healthy subjects may simply be the result of the physiologic responses and pathologic changes in airway cells arising from dehydration injury. These changes, which include excessive mucus production and airway edema, would serve both to cause cough and to amplify the narrowing effects of normal bronchial smooth muscle contraction, resulting in symptoms. These changes are more likely to occur in healthy subjects who exercise intensely for long periods of time breathing cold air, dry air, or both. Under these conditions, the ability to humidify inspired air may be overwhelmed, causing significant dehydration of the airway mucosa and an increase in osmolarity, even in small airways. In addition to dehydration injury, airway narrowing to pharmacologic and physical agents may occur as a result of injury caused by large volumes of air containing irritant gases, particulate matter, or allergens being inspired during exercise. As a result, the airways may become inflamed, and the airway smooth muscle may become more sensitive. These events could result in the same exaggerated airway response to dehydration, as documented in asthmatic subjects.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahran, Australia	University of Sydney; Florey Institute of Neuroscience & Mental Health	Anderson, SD (corresponding author), Royal Prince Alfred Hosp, Dept Resp Med, Level 9 Page Chest Pavil,Missenden Rd, Camperdown, NSW 2050, Australia.			Anderson, Sandra/0000-0002-6308-8770				Alton EWFW, 1996, AM J RESP CELL MOL, V14, P380, DOI 10.1165/ajrcmb.14.4.8600943; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; ANDERSON SD, 1994, CHEST, V105, P673, DOI 10.1378/chest.105.3.673; ANDERSON SD, 1985, CHEST, V87, pS191, DOI 10.1378/chest.87.5_Supplement.191S; Anderson SD, 1998, ASTHMA: BASIC MECHANISMS AND CLINICAL MANAGEMENT, 3RD EDITION, P569, DOI 10.1016/B978-012079027-2/50113-1; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; Anderson SD, 1996, J ALLERGY CLIN IMMUN, V98, pS124, DOI 10.1016/S0091-6749(96)80140-0; Anderson SD, 1999, EXERCISE-INDUCED ASTHMA AND SPORTS IN ASTHMA, P72; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; Anderson SD, 1997, ALLERGY ALLERGIC DIS, P692; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; ASSOULINE G, 1977, EUR J PHARMACOL, V44, P271, DOI 10.1016/0014-2999(77)90073-5; BACKER V, 1992, CLIN EXP ALLERGY, V22, P741, DOI 10.1111/j.1365-2222.1992.tb02813.x; BANNER AS, 1984, NEW ENGL J MED, V311, P883, DOI 10.1056/NEJM198410043111404; BARDAGI S, 1993, AM REV RESPIR DIS, V147, P1112, DOI 10.1164/ajrccm/147.5.1112; BIANCO S, 1988, LANCET, V2, P252; BOULET LP, 1989, J ALLERGY CLIN IMMUN, V83, P882, DOI 10.1016/0091-6749(89)90101-2; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120, DOI 10.1164/ajrccm.158.4.9802087; BRANNAN JD, 2000, EUR RESP J S; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURR ML, 1974, ARCH DIS CHILD, V49, P923, DOI 10.1136/adc.49.12.923; BURY TB, 1994, ALLERGY, V49, P605, DOI 10.1111/j.1398-9995.1994.tb00126.x; Carlsen KH, 1998, RESP MED, V92, P308, DOI 10.1016/S0954-6111(98)90114-7; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRIMI E, 1992, AM REV RESPIR DIS, V146, P507, DOI 10.1164/ajrccm/146.2.507; CUSTOVIC A, 1994, CHEST, V105, P1127, DOI 10.1378/chest.105.4.1127; Davis MS, 1999, EUR RESPIR J, V14, P57, DOI 10.1034/j.1399-3003.1999.14a11.x; DAVISKAS E, 1991, RESP PHYSIOL, V84, P115, DOI 10.1016/0034-5687(91)90023-C; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; duToit JI, 1997, ALLERGY ASTHMA PROC, V18, P7, DOI 10.2500/108854197778612817; Dwyer TM, 1997, AM J PHYSIOL-LUNG C, V272, pL1121, DOI 10.1152/ajplung.1997.272.6.L1121; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNEY MJB, 1990, AM REV RESPIR DIS, V141, P1151, DOI 10.1164/ajrccm/141.5_Pt_1.1151; FREED AN, 1989, J APPL PHYSIOL, V67, P1727, DOI 10.1152/jappl.1989.67.5.1727; FREED AN, 1994, AM J RESP CELL MOL, V11, P724, DOI 10.1165/ajrcmb.11.6.7946400; FREED AN, 1995, EUR RESPIR J, V8, P1770, DOI 10.1183/09031936.95.08101770; GARLAND A, 1995, J CLIN INVEST, V95, P2359, DOI 10.1172/JCI117928; GIESBRECHT GG, 1995, AVIAT SPACE ENVIR MD, V66, P890; Gschwentner M, 1996, J ALLERGY CLIN IMMUN, V98, pS98, DOI 10.1016/S0091-6749(96)80135-7; HABY MM, 1995, EUR RESPIR J, V8, P729; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634, DOI 10.1164/ajrccm.159.2.9712090; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125, DOI 10.1136/bjsm.32.2.125; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; ISHII Y, 1990, PROSTAGLANDINS, V39, P685, DOI 10.1016/0090-6980(90)90028-T; Jackson D M, 1989, Pulm Pharmacol, V2, P179, DOI 10.1016/0952-0600(89)90018-5; JACKSON DM, 1992, EUR J PHARMACOL, V221, P175, DOI 10.1016/0014-2999(92)90790-B; JONGEJAN RC, 1990, J APPL PHYSIOL, V68, P1568, DOI 10.1152/jappl.1990.68.4.1568; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; KARJALAINEN J, 1991, THORAX, V46, P100, DOI 10.1136/thx.46.2.100; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; KOSKELA H, 2000, IN PRESS CLIN EXP AL; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Leuppi JD, 1998, EUR RESPIR J, V12, P13, DOI 10.1183/09031936.98.12010013; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; MAKHDUM A, 1993, AGENTS ACTIONS, V38, pC191, DOI 10.1007/BF01996456; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCFADDEN ER, 1985, J CLIN INVEST, V76, P1007, DOI 10.1172/JCI112052; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; MOQBEL R, 1986, AM REV RESPIR DIS, V133, P609; MUNAKATA M, 1988, J APPL PHYSIOL, V64, P466, DOI 10.1152/jappl.1988.64.1.466; Nagakura T, 1998, CLIN EXP ALLERGY, V28, P181; NISH WA, 1992, ANN ALLERGY, V69, P239; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875, DOI 10.1152/jappl.1980.49.5.875; OMORI C, 1995, J APPL PHYSIOL, V78, P1043, DOI 10.1152/jappl.1995.78.3.1043; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; PAUL DW, 1993, INT J SPORTS MED, V14, P433, DOI 10.1055/s-2007-1021205; Pedersen KE, 1998, J APPL PHYSIOL, V84, P499, DOI 10.1152/jappl.1998.84.2.499; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; PISARRI TE, 1991, AM J PHYSIOL, V260, pH1522, DOI 10.1152/ajpheart.1991.260.5.H1522; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; PRAZMA J, 1994, J APPL PHYSIOL, V76, P2275, DOI 10.1152/jappl.1994.76.6.2275; Pribyl CR, 1996, CLIN J SPORT MED, V6, P232, DOI 10.1097/00042752-199610000-00005; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632, DOI 10.1164/ajrccm.150.6.7952626; RODWELL LT, 1993, THORAX, V48, P208, DOI 10.1136/thx.48.3.208; RODWELL LT, 1992, AM REV RESPIR DIS, V146, P1149, DOI 10.1164/ajrccm/146.5_Pt_1.1149; Ronsen O., 1995, European Respiratory Journal, V8, p473S; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; RUNDELL KW, 2000, IN PRESS MED SCI SPO; RUPP NT, 1993, ANN ALLERGY, V70, P339; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SATAKE T, 1981, ADV PHYSL SCI, V10, P369; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Shimizu T, 1997, AM J RESP CRIT CARE, V155, P170, DOI 10.1164/ajrccm.155.1.9001307; SINCLAIR DG, 1995, EUR RESPIR J, V8, P1314, DOI 10.1183/09031936.95.08081314; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SPOONER CH, 1998, NEDOCROMIL SODIUM SI, V3; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597, DOI 10.1164/ajrccm.158.2.9711012; UMENO E, 1990, J CLIN INVEST, V85, P1905, DOI 10.1172/JCI114652; VOY RO, 1984, MED SCI SPORTS EXERC, V18, P328; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WILLUMSEN NJ, 1994, J CLIN INVEST, V94, P779, DOI 10.1172/JCI117397; WILSON BA, 1994, EUR RESPIR J, V7, P2174, DOI 10.1183/09031936.94.07122174; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAGER D, 1991, AM REV RESPIR DIS, V143, pS52, DOI 10.1164/ajrccm/143.3_Pt_2.S52; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879; Zimmerman MP, 2000, J APPL PHYSIOL, V88, P425, DOI 10.1152/jappl.2000.88.2.425; ZWICK H, 1990, LUNG, V168, P111, DOI 10.1007/BF02719681	119	139	142	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					419	428		10.1067/mai.2000.108914	http://dx.doi.org/10.1067/mai.2000.108914			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984359	Bronze			2022-12-18	WOS:000089471900002
J	Daschner, A; Alonso-Gomez, A; Cabanas, R; Suarez-de-Parga, JM; Lopez-Serrano, MC				Daschner, A; Alonso-Gomez, A; Cabanas, R; Suarez-de-Parga, JM; Lopez-Serrano, MC			Gastroallergic anisakiasis: Borderline between food allergy and parasitic disease - Clinical and allergologic evaluation of 20 patients with confirmed acute parasitism by Anisakis simplex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anisakis simplex; gastric anisakiasis; specific IgE; urticaria; angioedema; anaphylaxis; food hypersensitivity; parasitic diseases; skin tests; gastroscopy	ACUTE GASTRIC ANISAKIASIS; IGE; URTICARIA; NEMATODES	Background: Human subjects can be parasitized by Anisakis simplex by eating raw or undercooked fish, Gastric anisakiasis is probably the most frequent clinical entity presenting with severe epigastric pain, vomiting, and diarrhea. In gastroallergic anisakiasis hypersensitivity symptoms predominate. Objective: We sought to describe clinical features, laboratory data, and gastroscopic findings in gastroallergic anisakiasis. Methods: We selected 40 patients presenting to the emergency department with an acute allergic reaction, and if we suspected acute parasitism by A simplex, a fiberoptic gastroscopy was performed. In 20 patients we could detect one or more nematodes; these patients are referred to as group A. Those in whom no worm could be found are referred to as group B (n = 20). A detailed history, clinical features, gastroscopic findings, laboratory data, and skin prick test responses were compared. Results: Long-time intervals of up to 26 hours between fish intake and onset of hypersensitivity symptoms were found (group A, 5.4 +/- 6.3 hours; group B, 5.3 +/- 2.6 hours). Patients in groups A and B did not differ with respect to allergic symptoms (urticaria, angioedema, erythema, bronchospasm, and anaphylaxis) or the mainly light abdominal symptoms (upper abdominal pain, nausea, vomiting, and diarrhea). No significant differences were found with respect to age, time interval between fish intake and onset of symptoms, white fell and eosinophil counts, specific IgE levels against A simplex, or total IgE levels. Conclusions: The peculiar sometimes long-time interval between fish intake and onset of allergic symptoms render the diagnosis difficult. An early gastroscopy can confirm the diagnosis and prevent complications. We suggest that gastroallergic anisakiasis be considered a distinct clinical entity in which the predominant symptoms are hypersensitivity symptoms and in which the correct diagnosis is not only important in the management of the acute reaction but also in the prevention of further allergic episodes.	Univ Hosp La Paz, Allergy Unit, Madrid, Spain; Univ Hosp La Paz, Gastroscopy Unit, Madrid, Spain	Hospital Universitario La Paz; Hospital Universitario La Paz	Daschner, A (corresponding author), C Altamirano 30,5 Izq, E-28008 Madrid, Spain.							AKAO N, 1990, J HELMINTHOL, V64, P310, DOI 10.1017/S0022149X00012359; Allen JE, 1996, INT ARCH ALLERGY IMM, V109, P3, DOI 10.1159/000237225; Alonso A, 1997, NEW ENGL J MED, V337, P350, DOI [10.1056/NEJM199707313370518, 10.1056/NEJM199707313370517]; ASAISHI K, 1980, Gastroenterologia Japonica, V15, P128; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; BIER JW, 1987, BAILLIERE CLIN TROP, V2, P723; BOUREE P, 1995, COMP IMMUNOL MICROB, V18, P75, DOI 10.1016/0147-9571(95)98848-C; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P417, DOI 10.1016/0091-6749(88)90185-6; CHENG TC, 1978, PARASITOLOGIA GEN SU, P649; Daschner A, 1998, BRIT J DERMATOL, V139, P822, DOI 10.1046/j.1365-2133.1998.02507.x; Daschner A, 1999, CLIN EXP ALLERGY, V29, P1260, DOI 10.1046/j.1365-2222.1999.00569.x; DASCHNER A., 1997, REV ESP ALERGOL IMMU, V12, P370; DASCHNER A, 1997, EMERGENCIAS, V9, P173; Deardorff T L, 1991, Hawaii Med J, V50, P9; DEARDORFF TL, 1988, J PARASITOL, V74, P600, DOI 10.2307/3282175; deCorres LF, 1996, J INVEST ALLERG CLIN, V6, P315; Del Pozo M. D., 1996, Allergy (Copenhagen), V51, P53; delPozo MD, 1996, J ALLERGY CLIN IMMUN, V97, P977, DOI 10.1016/S0091-6749(96)80073-X; GUTIERREZ JM, 1995, REV CLIN ESP, V195, P105; IKEDA K, 1989, GASTROINTEST ENDOSC, V35, P304, DOI 10.1016/S0016-5107(89)72797-8; ISHIZAKA T, 1976, J ALLERGY CLIN IMMUN, V58, P523, DOI 10.1016/0091-6749(76)90196-2; JARRETT E, 1980, NATURE, V283, P302, DOI 10.1038/283302a0; Kasuya S, 1992, Arerugi, V41, P106; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; KASUYA S, 1989, ACI NEWS, V1, P140; KLIKS MM, 1983, AM J TROP MED HYG, V32, P526, DOI 10.4269/ajtmh.1983.32.526; LEE TDG, 1995, J ALLERGY CLIN IMMUN, V95, P1246, DOI 10.1016/S0091-6749(95)70082-X; LUCAS SB, 1985, LANCET, V2, P843; MATSUOKA H, 1994, AM J TROP MED HYG, V51, P819, DOI 10.4269/ajtmh.1994.51.819; MorenoAncillo A, 1997, ANN ALLERG ASTHMA IM, V79, P246, DOI 10.1016/S1081-1206(10)63009-8; MUDRY J, 1986, GASTROEN CLIN BIOL, V10, P83; Muraoka A, 1996, DIGEST DIS SCI, V41, P2362, DOI 10.1007/BF02100128; ORECCHIA P, 1989, Parassitologia (Rome), V31, P37; PEREIRA MM, 1996, REV ESP ALERGOL IMMU, V11, P197; PETITHORY JC, 1992, PATHOL BIOL, V40, P47; Podolska Magdalena, 1996, Wiadomosci Parazytologiczne, V42, P197; SUGIMACHI K, 1985, JAMA-J AM MED ASSOC, V253, P1012, DOI 10.1001/jama.253.7.1012; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; Van Thiel P. H., 1960, Tropical and Geographical Medicine, V2, P97; VANTHIEL PH, 1962, PARASITOLOGY, V52, pP16; WARIN RP, 1974, UTRICARIA	41	139	145	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				176	181		10.1016/S0091-6749(00)90194-5	http://dx.doi.org/10.1016/S0091-6749(00)90194-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629469	Bronze			2022-12-18	WOS:000084992100024
J	Schwiebert, LA; Beck, LA; Stellato, C; Bickel, CA; Bochner, BS; Schleimer, RP				Schwiebert, LA; Beck, LA; Stellato, C; Bickel, CA; Bochner, BS; Schleimer, RP			Glucocorticosteroid inhibition of cytokine production: Relevance to antiallergic actions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; LEUKOCYTE ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL-CELLS; ANTI-INFLAMMATORY STEROIDS; HUMAN MAST-CELLS; HUMAN EOSINOPHILS; T-CELLS; BRONCHOALVEOLAR LAVAGE; AIRWAY INFLAMMATION		JOHNS HOPKINS UNIV, SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR, DIV CLIN IMMUNOL,DEPT MED, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine			Stellato, Cristiana/P-3001-2015	Stellato, Cristiana/0000-0002-1294-8355				ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BECK L, 1995, FASEB J, V9, pA804; BECK LA, IN PRESS J ALLERGY C; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BOCHNER BS, 1987, J IMMUNOL, V139, P2303; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOCHNER BS, 1994, BRIT MED J, V12, P295; BOCHNER BS, 1995, IN PRESS ALLERGY; BORISH L, 1992, J IMMUNOL, V149, P3078; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRATTSAND R, 1982, J STEROID BIOCHEM, V16, P779, DOI 10.1016/0022-4731(82)90035-8; BRATTSAND R, 1989, CLIN EXP ASPECTS, P17; BURGE PS, 1982, CLIN ALLERGY, V12, P523, DOI 10.1111/j.1365-2222.1982.tb02551.x; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; CHURCHILL L, 1992, IMMUNOLOGY, V75, P189; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DAHL R, 1982, EUR J RESPIR DIS, V63, P167; DESREUMAUX P, 1992, J EXP MED, V175, P293, DOI 10.1084/jem.175.1.293; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DURHAM SR, 1992, J IMMUNOL, V148, P2390; EBISAWA M, 1994, J IMMUNOL, V152, P4590; EBISAWA M, 1994, J IMMUNOL, V153, P2153; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; GILLIS S, 1979, J IMMUNOL, V123, P1632; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GUYRE PM, 1988, J STEROID BIOCHEM, V30, P89, DOI 10.1016/0022-4731(88)90080-5; HALLSWORTH MP, 1992, IMMUNOLOGY, V75, P382; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HERXHEIMER H, 1954, BMJ-BRIT MED J, V1, P184, DOI 10.1136/bmj.1.4855.184; HIRATA F, 1982, BIOCHEM BIOPH RES CO, V109, P223, DOI 10.1016/0006-291X(82)91588-1; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KAISER J, 1993, J PHARMACOL EXP THER, V267, P245; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KATO M, 1994, LUNG, V172, P113; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; LAMAS AM, 1991, J IMMUNOL, V147, P254; LAMAS AM, 1989, J IMMUNOL, V142, P3978; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; LIU MC, 1993, AM REV RESPIR DIS, V147, pA521; LIU MC, 1994, AM REV RESPIR DIS, V149, pA944; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MAZINGUE C, 1987, CLIN EXP IMMUNOL, V67, P587; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROLFE FG, 1992, IMMUNOLOGY, V77, P494; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; SCHLEIMER RP, 1992, MAST CELL HLTH DIS, P483; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; STARUCH MJ, 1985, J LEUKOCYTE BIOL, V37, P193, DOI 10.1002/jlb.37.2.193; STELLATO C, 1995, J IMMUNOL, V155, P410; STELLATO C, IN PRESS J ALLERGY C; SUR S, 1993, ALLERGY PRINCIPLES P, P169; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; TOBLER A, 1992, BLOOD, V79, P45; TOMIOKA K, 1993, J IMMUNOL, V151, P4989; WAHL SM, 1975, J IMMUNOL, V115, P476; WALLEN N, 1991, J IMMUNOL, V147, P3490; WALSH GM, 1991, J IMMUNOL, V146, P3419; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WEISSMANN G, 1962, J EXP MED, V116, P433, DOI 10.1084/jem.116.4.433; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	105	139	141	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	2	S			143	152		10.1016/S0091-6749(96)80214-4	http://dx.doi.org/10.1016/S0091-6749(96)80214-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT805	8568145	hybrid			2022-12-18	WOS:A1996TT80500001
J	PASTORELLO, EA; INCORVAIA, C; ORTOLANI, C; BONINI, S; CANONICA, GW; ROMAGNANI, S; TURSI, A; ZANUSSI, C				PASTORELLO, EA; INCORVAIA, C; ORTOLANI, C; BONINI, S; CANONICA, GW; ROMAGNANI, S; TURSI, A; ZANUSSI, C			STUDIES ON THE RELATIONSHIP BETWEEN THE LEVEL OF SPECIFIC IGE ANTIBODIES AND THE CLINICAL EXPRESSION OF ALLERGY .1. DEFINITION OF LEVELS DISTINGUISHING PATIENTS WITH SYMPTOMATIC FROM PATIENTS WITH ASYMPTOMATIC ALLERGY TO COMMON AEROALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AEROALLERGENS; SPECIFIC IGE; SYMPTOMATIC ALLERGY; ASYMPTOMATIC ALLERGY; CUTOFF	CAP SYSTEM; ASTHMA; SKIN; RHINITIS; TESTS; RAST	Background: The detection of specific IgE antibodies to environmental allergens does not always coincide with a diagnosis of clinically evident allergic disease, because some patients with positive skin and/or in vitro test results have no symptoms related to the allergen or allergens that induced the antibodies. Objective: In a multicenter study the optimal cutoff values for specific IgE antibody levels and skin test results that could discriminate between patients with symptomatic and those with asymptomatic allergy were determined. Methods: IgE antibodies specific for a panel of common aeroallergens were assayed with the Pharmacia CAP system (Pharmacia, Uppsala, Sweden) in two groups of patients, a group of 267 patients with symptomatic allergy and a group of 243 healthy, nonallergic control subjects. The cutoff values were established by receiver operating characteristic analysis. Results: A significantly higher mean specific IgE antibody value was found in patients with symptomatic allergy compared with patients with asymptomatic allergy (p < 0.001) and in patients with symptomatic allergy compared with healthy control subjects (p < 0.001). The optimal cap system cutoff value between patients with symptomatic and those with asymptomatic allergy was 11.7 kU/L and when seasonal allergens were compared with perennial allergens, the cutoffs were 10.8 kU/L and 8.4 kU/L, respectively. The optimal cutoff value for the skin prick test was a wheal area 32 mm(2) for seasonal allergens and 31 mm(2) for perennial allergens. The skin test had a lower diagnostic value (sum of sensitivity and specificity) than the CAP system Conclusions: Cutoff values for specific serum IgE antibody levels are likely to be useful in clinical practice to distinguish symptomatic from asympotomatic allergy in patients with positive skin test results.	OSPED NIGUARDA CA GRANDA,BIZZOZERO DIV GEN MED,MILAN,ITALY; UNIV ROMA LA SAPIENZA,DEPT INTERNAL MED 1,ANDREA CESALPINO FDN,ROME,ITALY; UNIV GENOA,SCI DEPT INTERNAL MED,CTR ALLERGY & CLIN IMMUNOL,GENOA,ITALY; UNIV FLORENCE,DEPT ALLERGY & CLIN IMMUNOL,FLORENCE,ITALY; UNIV BARI,DEPT ALLERGY & CLIN IMMUNOL,BARI,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Sapienza University Rome; University of Genoa; University of Florence; Universita degli Studi di Bari Aldo Moro	PASTORELLO, EA (corresponding author), UNIV MILAN,DEPT INTERNAL MED 1,CTR ALLERGY,PAD GRANELLI,VIA FRANCESCO SFORZA 35,I-20122 MILAN,ITALY.		canonica, giorgio walter/ABF-2037-2020; Bonini, Sergio/T-6594-2019; PASTORELLO, ELIDE ANNA/E-3897-2017	canonica, giorgio walter/0000-0001-8467-2557; Bonini, Sergio/0000-0003-0079-3031; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				ARMITAGE P, 1987, STATISTICAL METHODS; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CHAMBERS VV, 1958, J ALLERGY, V29, P249, DOI 10.1016/0021-8707(58)90009-1; DEBLAY F, 1993, J ALLERGY CLIN IMMUN, V92, P255, DOI 10.1016/0091-6749(93)90169-G; DREBORG S, 1989, ALLERGY S10, V44, P27; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; GERHARDT W, 1986, SCAND J CLIN LA S181, V46, P5; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; HOLGERSSON M, 1985, ALLERGY S4, V40, P64; HORAK F, 1985, ARCH OTORHINOLARYNGO, V242, P224; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; Naclerio RM, 1993, ALLERGY PRINCIPLES P, P595; NORMAN PS, 1973, MECHANISMS ALLERGY R, P151; OLLIER S, 1989, CLIN EXP ALLERGY, V19, P457, DOI 10.1111/j.1365-2222.1989.tb02414.x; Ownby DR, 1993, ALLERGY PRINCIPLES P, P1059; PASTORELLO EA, 1992, ALLERGY, V47, P463, DOI 10.1111/j.1398-9995.1992.tb00665.x; PASTORELLO EA, 1991, ANN ALLERGY, V67, P365; Swets J., 1982, EVALUATION DIAGNOSTI; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; YUNGINGER JW, 1985, ALLERGY, P112; 1992, J ALLERGY CLIN IMMUN, V90, P263; 1986, J ALLERGY CLIN IMMUN, V77, P651	26	139	144	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				580	587		10.1016/S0091-6749(95)70255-5	http://dx.doi.org/10.1016/S0091-6749(95)70255-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499673				2022-12-18	WOS:A1995TG52800002
J	VANREE, R; FERNANDEZRIVAS, M; CUEVAS, M; VANWIJNGAARDEN, M; AALBERSE, RC				VANREE, R; FERNANDEZRIVAS, M; CUEVAS, M; VANWIJNGAARDEN, M; AALBERSE, RC			POLLEN-RELATED ALLERGY TO PEACH AND APPLE - AN IMPORTANT ROLE FOR PROFILIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						POLLINOSIS; FRUIT ALLERGY; PROFILIN; CARBOHYDRATE; BET V I; CROSS-REACTIVITY	BIRCH POLLEN; VEGETABLE FOODS; GRASS-POLLEN; IDENTIFICATION; ANTIBODIES; IGE; SENSITIVITY; CELERY	Background: Birch pollinosis is often accompanied by allergy to fruits such as peach and apple. Bet v I is of major importance as cross-reactive allergen for this combined allergy. We studied a group of patients with combined grass pollinosis and fruit allergy from an area virtually without birch trees. Objective: The aim of this study was to investigate the possible involvement of profilin and carbohydrate groups as cross-reactive structures in pollen and fruits. Methods: RAST inhibition was performed to measure cross-reactive IgE to pollen and fruits. The presence of IgE against profilin was determined in a rast with purified grass profilin, and IgE against carbohydrate structures was determined in a RAST with proteinase K-digested grass pollen extract. The biologic activity of IgE in response to profilin was tested by in vitro histamine release and skin prick tests. Results: IgE against fruits was shown to be largely cross-reactive with grass pollen. The majority of the patients had IgE against profilin (12 of 16) and carbohydrate structures (9 of 10). Profilin was shown to have biologic activity, in both histamine release and skin prick tests. Conclusion: profilin is an important allergen for patients with combined grass pollen/fruit allergy in areas without birch trees.	UNIV AMSTERDAM,CENT LAB,RED CROSS BLOOD TRANSFUS SERV,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,CLIN & EXPTL IMMUNOL LAB,AMSTERDAM,NETHERLANDS; VIRGEN VALLE HOSP,ALLERGY SECT,TOLEDO,OH; HOSP RAMON Y CAJAL,DEPT IMMUNOL,MADRID,SPAIN	University of Amsterdam; University of Amsterdam; Hospital Universitario Ramon y Cajal								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; Malling HJ., 2003, ALLERGY, V48, P55; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; STAPEL SO, 1992, ALLERGY, V47, P30; SUBIZA J, 1992, CLIN EXP ALLERGY, V22, P540, DOI 10.1111/j.1365-2222.1992.tb00163.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VANREE R, 1991, J ALLERGY CLIN IMMUN, V87, P188; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x	21	139	140	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					726	734		10.1016/S0091-6749(95)70178-8	http://dx.doi.org/10.1016/S0091-6749(95)70178-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897156				2022-12-18	WOS:A1995QM01700013
J	LARSSON, S; SVEDMYR, N; THIRINGER, G				LARSSON, S; SVEDMYR, N; THIRINGER, G			LACK OF BRONCHIAL BETA ADRENOCEPTOR RESISTANCE IN ASTHMATICS DURING LONG-TERM TREATMENT WITH TERBUTALINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV GOTEBORG,RENSTROMSKA HOSP,LUNG CLIN,CLIN PHARMACOL LAB,S-40260 GOTEBORG,SWEDEN	University of Gothenburg								AYRES SM, 1974, AM J MED, V57, P183, DOI 10.1016/0002-9343(74)90442-2; CAPLIN I, 1969, ANN ALLERGY, V27, P65; COHEN BM, 1971, CLIN PHARMACOL THER, V12, P289; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; EISENSTADT WS, 1969, ANN ALLERGY, V27, P283; FLEISCH JH, 1972, J PHARMACOL EXP THER, V181, P425; FORMGREN H, 1976, SCAND J RESPER DIS, V57, P321; HUME K. M., 1957, THORAX, V12, P276, DOI 10.1136/thx.12.3.276; INMAN WHW, 1969, LANCET, V2, P279; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; LARSSON S, 1974, Scandinavian Journal of Respiratory Diseases Supplementum, V88, P54; LICHTERFELD A, 1974, EUR J CLIN PHARMACOL, V7, P347, DOI 10.1007/BF00558204; PUN LQ, 1971, EUR J PHARMACOL, V14, P140, DOI 10.1016/0014-2999(71)90207-X; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; SIMONSSON BG, 1976, SCAND J RESPIR DIS, V57, P252; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SVEDMYR N, 1971, POSTGRAD MED J, V47, P44; SVEDMYR N, 1974, Scandinavian Journal of Respiratory Diseases Supplementum, V88, P58; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; THIRINGER G, 1975, SCAND J RESPIR DIS, V56, P93; 1975, CHEST, V67, P583	21	139	139	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					93	100		10.1016/0091-6749(77)90209-3	http://dx.doi.org/10.1016/0091-6749(77)90209-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	188873				2022-12-18	WOS:A1977CV62200001
J	Sugita, K; Steer, CA; Martinez-Gonzalez, I; Altunbulakli, C; Morita, H; Castro-Giner, F; Kubo, T; Wawrzyniak, P; Ruckert, B; Sudo, K; Nakae, S; Matsumoto, K; O'Mahony, L; Akdis, M; Takei, F; Akdis, CA				Sugita, Kazunari; Steer, Catherine A.; Martinez-Gonzalez, Itziar; Altunbulakli, Can; Morita, Hideaki; Castro-Giner, Francesc; Kubo, Terufumi; Wawrzyniak, Paulina; Ruckert, Beate; Sudo, Katsuko; Nakae, Susumu; Matsumoto, Kenji; O'Mahony, Liam; Akdis, Mubeccel; Takei, Fumio; Akdis, Cezmi A.			Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate lymphoid cell; tight junction; bronchial epithelium; barrier; IL-13	INFLAMMATION; EXPRESSION; INTERLEUKINS; HOMEOSTASIS; MECHANISMS; REDUNDANCY; RECEPTORS; ALLERGENS; CYTOKINES; ROLES	Background: Bronchial epithelial barrier leakiness and type 2 innate lymphoid cells (ILC2s) have been separately linked to asthma pathogenesis; however, the influence of ILC2s on the bronchial epithelial barrier has not been investigated previously. Objective: We investigated the role of ILC2s in the regulation of bronchial epithelial tight junctions (TJs) and barrier function both in bronchial epithelial cells of asthmatic patients and healthy subjects and general innate lymphoid cell- and ILC2-deficient mice. Methods: Cocultures of human ILC2s and bronchial epithelial cells were used to determine transepithelial electrical resistance, paracellular flux, and TJ mRNA and protein expressions. The effect of ILC2s on TJs was examined by using a murine model of IL-33-induced airway inflammation in wild-type, recombination-activating gene 2 (Rag2)(-/-), Rag2(-/-), and Rora(sg/sg) mice undergoing bone marrow transplantation to analyze the in vivo relevance of barrier disruption by ILC2s. Results: ILC2s significantly impaired the epithelial barrier, as demonstrated by reduced transepithelial electrical resistance and increased fluorescein isothiocyanate-dextran permeability in air-liquid interface cultures of human bronchial epithelial cells. This was in parallel to decreased mRNAs and disrupted protein expression of TJ proteins and was restored by neutralization of IL-13. Intranasal administration of recombinant IL-33 to wild-type and Rag2(-/-) mice lacking T and B cells triggered TJ disruption, whereas Rag2(-/-) and Il2rg(-/-) Rora(sg/sg) mice undergoing bone marrow transplantation that lack ILC2s did not show any barrier leakiness. Direct nasal administration of IL-13 was sufficient to induce deficiency in the TJ barrier in the bronchial epithelium of mice in vivo. Conclusion: These data highlight an essential mechanism in asthma pathogenesis by demonstrating that ILC2s are responsible for bronchial epithelial TJ barrier leakiness through IL-13.	[Sugita, Kazunari; Altunbulakli, Can; Morita, Hideaki; Castro-Giner, Francesc; Kubo, Terufumi; Wawrzyniak, Paulina; Ruckert, Beate; O'Mahony, Liam; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Sugita, Kazunari; Altunbulakli, Can; Morita, Hideaki; Castro-Giner, Francesc; Kubo, Terufumi; Wawrzyniak, Paulina; Ruckert, Beate; O'Mahony, Liam; Akdis, Mubeccel; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Sugita, Kazunari] Tottori Univ, Fac Med, Dept Med Sensory & Motor Organs, Div Dermatol, Yonago, Tottori 6838504, Japan; [Steer, Catherine A.; Martinez-Gonzalez, Itziar; Takei, Fumio] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Steer, Catherine A.; Martinez-Gonzalez, Itziar; Takei, Fumio] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC, Canada; [Morita, Hideaki; Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Castro-Giner, Francesc] Univ Zurich, Funct Genom Ctr Zurich, Zurich, Switzerland; [Sudo, Katsuko] Tokyo Med Univ, Anim Res Ctr, Tokyo, Japan; [Nakae, Susumu] Univ Tokyo, Inst Med Sci, Ctr Expt Med & Syst Biol, Lab Syst Biol, Tokyo, Japan; [Nakae, Susumu] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Saitama, Japan	Swiss Institute of Allergy & Asthma Research; University of Zurich; Tottori University; University of British Columbia; British Columbia Cancer Agency; National Center for Child Health & Development - Japan; University of Zurich; Tokyo Medical University; University of Tokyo; Japan Science & Technology Agency (JST)	Sugita, K (corresponding author), Tottori Univ, Fac Med, Dept Med Sensory & Motor Organs, Div Dermatol, Yonago, Tottori 6838504, Japan.; Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos Pl, CH-7270 Davos, Switzerland.	sugita@med.tottori-u.ac.jp; akdisac@siaf.uzh.ch	Wawrzyniak, Paulina/HCG-8924-2022; Morita, Hideaki/ADL-2008-2022; Castro-Giner, Francesc/D-7992-2014; Morita, Hideaki/S-2214-2016; Akdis, Cezmi/AAV-4844-2020; O'Mahony, Liam/AAG-5838-2019; Wawrzyniak, Paulina/AAD-7265-2020; Wawrzyniak, Paulina/AAG-3548-2019	Castro-Giner, Francesc/0000-0001-6111-0754; Morita, Hideaki/0000-0003-0928-8322; Akdis, Cezmi/0000-0001-8020-019X; O'Mahony, Liam/0000-0003-4705-3583; Wawrzyniak, Paulina/0000-0001-9641-2103; Altunbulakli, Can/0000-0003-2264-7377; Takei, Fumio/0000-0002-3620-5046; Martinez Gonzalez, Itziar/0000-0002-1695-5691	Swiss National Science Foundation [310030_156823, 320030_140772]; Canadian Institute of Health Research [MOP-119324, MOP 126194]; PRESTO, the Japan Science and Technology Agency from the Japan Society for the Promotion of Science; National Center for Child Health and Development [26-9]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); PRESTO, the Japan Science and Technology Agency from the Japan Society for the Promotion of Science; National Center for Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Supported by Swiss National Science Foundation grants 310030_156823 and 320030_140772, the Canadian Institute of Health Research (MOP-119324 and MOP 126194), PRESTO, the Japan Science and Technology Agency (to S.N.) from the Japan Society for the Promotion of Science, and the Grant of National Center for Child Health and Development (#26-9; to K.M.).	Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029, DOI 10.1152/ajpcell.2001.281.6.C2029; Akdis CA, 2014, J CLIN INVEST, V124, P4678, DOI 10.1172/JCI78891; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Bando JK, 2015, NAT IMMUNOL, V16, P153, DOI 10.1038/ni.3057; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Dullaers M, 2016, J ALLERGY CLIN IMMUN; ELIA C, 1988, J SUBMICR CYTOL PATH, V20, P509; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Fanning AS, 2012, MOL BIOL CELL, V23, P577, DOI 10.1091/mbc.E11-09-0791; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Goto Y, 2014, SCIENCE, V345, P1310, DOI 10.1126/science.1254009; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hardyman MA, 2013, J ALLERGY CLIN IMMUN, V132, P665, DOI 10.1016/j.jaci.2013.03.005; Henriquez OA, 2013, INT FORUM ALLERGY RH, V3, P630, DOI 10.1002/alr.21168; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Holtzman MJ, 2012, J CLIN INVEST, V122, P2741, DOI 10.1172/JCI60325; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Karta MR, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0581-6; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li BWS, 2016, EUR J IMMUNOL, V46, P1392, DOI 10.1002/eji.201546119; Matter K, 2014, CELL, V157, DOI 10.1016/j.cell.2014.04.027; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Ozyigit LP, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0068-5; Peebles RS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005881; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Rankin LC, 2016, NAT IMMUNOL, V17, P179, DOI 10.1038/ni.3332; Ray A, 2016, J CLIN INVEST, V126, P2394, DOI 10.1172/JCI84144; Rezaee F, 2014, AM J RESP CELL MOL, V50, P857, DOI 10.1165/rcmb.2013-0541RT; Robinette ML, 2016, J ALLERGY CLIN IMMUN, V138, P1243, DOI 10.1016/j.jaci.2016.09.006; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saatian B, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24333; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Tan HTT, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0650-5; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Withers DR, 2016, NAT MED, V22, P319, DOI 10.1038/nm.4046; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040	66	138	147	3	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					300	+		10.1016/j.jaci.2017.02.038	http://dx.doi.org/10.1016/j.jaci.2017.02.038			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28392332	Bronze			2022-12-18	WOS:000419312200035
J	Noda, S; Krueger, JG; Guttman-Yassky, E				Noda, Shinji; Krueger, James G.; Guttman-Yassky, Emma			The translational revolution and use of biologics in patients with inflammatory skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; atopic dermatitis; eczema; biologics; IL-23; T(H)17; T(H)2; T(H)22	SEVERE ATOPIC-DERMATITIS; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; CRTH2 ANTAGONIST OC000459; PLACEBO-CONTROLLED TRIAL; GROWTH FACTOR-ALPHA; DOUBLE-BLIND; TH2 CYTOKINES; STRATUM-CORNEUM; DENDRITIC CELLS; TNF-ALPHA	Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation. Although T-cell infiltration characterizes both diseases, T-cell polarization differs. Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/T(H)17 polarized. In patients with AD, although therapeutic development is approximately a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (T(H)2, T(H)22, and IL-23/T(H)17). These clinical trials and subsequent molecular analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.	Rockefeller Univ, Lab Invest Dermatol, New York, NY USA; Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA	Rockefeller University; Icahn School of Medicine at Mount Sinai	Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Icahn Sch Med, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org			Amgen; Innovaderm; Kyowa; Serono; Biogen Idec; Delenex; AbbVie; Sanofi; Baxter; Xenoport; Kineta; Novartis; Pfizer; Janssen; Lilly; Merck; Kadmon; Dermira; Boehringer; BMS; Paraxel; Regeneron; Sanofi Aventis; MedImmune; Celgene; Steifel/GlaxoSmithKline; Celsus; Drais	Amgen(Amgen); Innovaderm; Kyowa; Serono(Merck & Company); Biogen Idec(Biogen); Delenex; AbbVie(AbbVie); Sanofi; Baxter; Xenoport; Kineta; Novartis(Novartis); Pfizer(Pfizer); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Lilly(Eli Lilly); Merck(Merck & Company); Kadmon; Dermira; Boehringer(Boehringer Ingelheim); BMS(Bristol-Myers Squibb); Paraxel; Regeneron(Regeneron); Sanofi Aventis(Sanofi-Aventis); MedImmune(AstraZenecaMedimmune); Celgene(Bristol-Myers SquibbCelgene Corporation); Steifel/GlaxoSmithKline; Celsus; Drais	J. G. Krueger reports grants paid to his institution from Amgen, Innovaderm, and Kyowa; he has received personal fees from Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Xenoport, and Kineta and has received personal fees during the conduct of this study from Novartis, Pfizer, Janssen, Lilly, Merck, Kadmon, Dermira, Boehringer, BMS, and Paraxel. E. Guttman-Yassky is a board member for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, and Leo Pharma; has received consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Steifel/GlaxoSmithKline, Celsus, BMS, Amgen, and Drais; and has received research support from Regeneron, Celgene, BMS, and Janssen. S. Noda declares no relevant conflicts of interest.	Abrahamsen H, 2004, J IMMUNOL, V173, P4847, DOI 10.4049/jimmunol.173.8.4847; Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Aufiero BM, 2006, J PHOTOCH PHOTOBIO B, V82, P132, DOI 10.1016/j.jphotobiol.2005.08.011; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Barrios JL, 2013, J AM ACAD DERMATOL, V69, P832, DOI 10.1016/j.jaad.2013.05.035; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Berardesca E, 2003, J AM ACAD DERMATOL, V48, pS139, DOI 10.1067/mjd.2003.273; Berardesca E, 1998, BRIT J DERMATOL, V139, P855; Bhattacharya T, 2014, JAMA DERMATOL, V150, P1232, DOI 10.1001/jamadermatol.2014.1674; Bice JB, 2014, ANN ALLERG ASTHMA IM, V112, P108, DOI 10.1016/j.anai.2013.12.013; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Bissonnette R, 2010, J AM ACAD DERMATOL, V62, P427, DOI 10.1016/j.jaad.2009.05.042; Buka RL, 2005, J AM ACAD DERMATOL, V53, P358, DOI 10.1016/j.jaad.2005.03.013; Chandran V, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0453-4; Chiricozzi A, 2013, EXPERT OPIN INV DRUG, V22, P993, DOI 10.1517/13543784.2013.806483; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; D'Amato G, 2014, MULTIDISCIP RESP MED, V9, DOI 10.1186/2049-6958-9-23; Danso MO, 2014, J INVEST DERMATOL, V134, P1941, DOI 10.1038/jid.2014.83; Davidovici BB, 2010, J INVEST DERMATOL, V130, P1785, DOI 10.1038/jid.2010.103; De Boever EH, 2014, J ALLERGY CLIN IMMUN, V133, P989, DOI 10.1016/j.jaci.2014.01.002; Dehesa L, 2012, J DRUGS DERMATOL, V11, P979; Dhingra N, 2013, J ALLERGY CLIN IMMUN, V132, P498, DOI 10.1016/j.jaci.2013.04.043; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Ellis CN, 2012, SEMIN CUTAN MED SURG, V31, pS18, DOI 10.1016/j.sder.2012.07.006; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1010/J.JACL2011.05.016; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Gelfand JM, 2007, ARCH DERMATOL, V143, P1493, DOI 10.1001/archderm.143.12.1493; Ghoreschi K, 2003, NAT MED, V9, P40, DOI 10.1038/nm804; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; GOTTLIEB AB, 1990, J INVEST DERMATOL, V95, pS18, DOI 10.1111/1523-1747.ep12505675; Gottlieb AB, 2002, ARCH DERMATOL, V138, P591, DOI 10.1001/archderm.138.5.591; Gottlieb AB, 2013, J DRUGS DERMATOL, V12, P888; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Harden JL, 2015, J ALLERGY CLIN IMMUN, V135, P553, DOI 10.1016/j.jaci.2014.05.046; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; Horak F, 2012, ALLERGY, V67, P1572, DOI 10.1111/all.12042; Hotze M, 2014, ALLERGY, V69, P132, DOI 10.1111/all.12234; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Hsu L, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/283617; Iyengar SR, 2013, INT ARCH ALLERGY IMM, V162, P89, DOI 10.1159/000350486; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Jang IG, 2000, J AM ACAD DERMATOL, V42, P1033, DOI 10.1016/S0190-9622(00)90300-1; Jensen JM, 2012, ALLERGY, V67, P413, DOI 10.1111/j.1398-9995.2011.02747.x; Jensen JM, 2009, J ALLERGY CLIN IMMUN, V123, P1124, DOI 10.1016/j.jaci.2009.03.032; Kallstrom E, 2002, EXP DERMATOL, V11, P556, DOI 10.1034/j.1600-0625.2002.110608.x; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Kavanaugh A, 2014, ANN RHEUM DIS, V73, P1020, DOI 10.1136/annrheumdis-2013-205056; KHANDKE L, 1991, ARCH DERMATOL, V127, P1172, DOI 10.1001/archderm.127.8.1172; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim DH, 2013, CLIN EXP DERMATOL, V38, P496, DOI 10.1111/j.1365-2230.2012.04438.x; Kim IH, 2012, AM J CLIN DERMATOL, V13, P365, DOI 10.2165/11633110-000000000-00000; Kono M, 2014, ALLERGY, V69, P537, DOI 10.1111/all.12369; Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008; Kothary N, 2011, J AM ACAD DERMATOL, V65, P546, DOI 10.1016/j.jaad.2010.05.033; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Krueger JG, 2012, NAT MED, V18, P1750, DOI 10.1038/nm.3025; KRUEGER JG, 1990, J INVEST DERMATOL, V94, pS135, DOI 10.1111/1523-1747.ep12876121; KRUEGER JG, 1995, J EXP MED, V182, P2057, DOI 10.1084/jem.182.6.2057; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; Kurd SK, 2009, J AM ACAD DERMATOL, V60, P218, DOI 10.1016/j.jaad.2008.09.022; Langan SM, 2012, J INVEST DERMATOL, V132, P556, DOI 10.1038/jid.2011.365; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Lee S, 2013, AM J TRANSPLANT, V13, P3223, DOI 10.1111/ajt.12500; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Moul DK, 2008, J AM ACAD DERMATOL, V58, P984, DOI 10.1016/j.jaad.2008.02.007; MUNRO CS, 1991, BRIT J DERMATOL, V124, P43; Nakajima K, 2011, J IMMUNOL, V186, P4481, DOI 10.4049/jimmunol.1000148; Nakajima S, 2014, J INVEST DERMATOL, V134, P2122, DOI 10.1038/jid.2014.51; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2010, J ALLERGY CLIN IMMUN, V125, P744, DOI 10.1016/j.jaci.2009.12.934; Noonan M, 2013, J ALLERGY CLIN IMMUN, V132, P567, DOI 10.1016/j.jaci.2013.03.051; Oh CJ, 2000, J AM ACAD DERMATOL, V42, P829, DOI 10.1067/mjd.2000.105948; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pelaia G, 2012, NAT REV DRUG DISCOV, V11, P958, DOI 10.1038/nrd3792; Pettipher R, 2012, J PHARMACOL EXP THER, V340, P473, DOI 10.1124/jpet.111.187203; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Rabenhorst A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0423-y; Reich K, 2012, J EUR ACAD DERMATOL, V26, P3, DOI 10.1111/j.1468-3083.2011.04410.x; Reich K, 2001, J INVEST DERMATOL, V116, P319, DOI 10.1046/j.1523-1747.2001.01248.x; Roekevisch E, 2014, J ALLERGY CLIN IMMUN, V133, P429, DOI 10.1016/j.jaci.2013.07.049; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Samrao A, 2012, ARCH DERMATOL, V148, P890, DOI 10.1001/archdermatol.2012.812; Samuelov L, 2014, J ALLERGY CLIN IMMUN, V134, P808, DOI 10.1016/j.jaci.2014.07.061; Sawada E, 2012, J DERMATOL SCI, V68, P25, DOI 10.1016/j.jdermsci.2012.07.004; Schafer P, 2012, BIOCHEM PHARMACOL, V83, P1583, DOI 10.1016/j.bcp.2012.01.001; Schmitt J, 2014, J ALLERGY CLIN IMMUN, V134, P800, DOI 10.1016/j.jaci.2014.07.043; Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320; Shlyankevich J, 2014, AM J MED, V127, P1148, DOI 10.1016/j.amjmed.2014.08.008; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Silverberg JI, 2014, DERMATITIS, V25, P107, DOI 10.1097/DER.0000000000000034; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Stern RS, 2004, J INVEST DERM SYMP P, V9, P136, DOI 10.1046/j.1087-0024.2003.09102.x; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Takiguchi R, 2007, J AM ACAD DERMATOL, V56, P222, DOI 10.1016/j.jaad.2006.08.031; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Trepicchio WL, 1999, J CLIN INVEST, V104, P1527, DOI 10.1172/JCI6910; Uchida T, 2002, INT IMMUNOL, V14, P1431, DOI 10.1093/intimm/dxf109; Vachiramon V, 2012, PEDIATR DERMATOL, V29, P395, DOI 10.1111/j.1525-1470.2012.01740.x; VALLAT VP, 1994, J EXP MED, V180, P283, DOI 10.1084/jem.180.1.283; Wang CQF, 2014, J INVEST DERMATOL, V134, P2990, DOI 10.1038/jid.2014.268; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Wolk K, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006245; Wolk K, 2009, EUR J IMMUNOL, V39, P3570, DOI 10.1002/eji.200939687; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Yang YW, 2011, BRIT J DERMATOL, V165, P1037, DOI 10.1111/j.1365-2133.2011.10494.x; Yawalkar N, 1998, J INVEST DERMATOL, V111, P1053, DOI 10.1046/j.1523-1747.1998.00446.x; Yeung H, 2013, JAMA DERMATOL, V149, P1173, DOI 10.1001/jamadermatol.2013.5015; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	154	138	145	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					324	336		10.1016/j.jaci.2014.11.015	http://dx.doi.org/10.1016/j.jaci.2014.11.015			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25541257				2022-12-18	WOS:000349372300003
J	Jones, SM; Burks, AW; Dupont, C				Jones, Stacie M.; Burks, A. Wesley; Dupont, Christophe			State of the art on food allergen immunotherapy: Oral, sublingual, and epicutaneous	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; immunotherapy; treatment; investigational	COWS MILK ALLERGY; DOUBLE-BLIND; TOLERANCE INDUCTION; IMMUNOLOGICAL CHANGES; DELIVERY-SYSTEM; DENDRITIC CELLS; INTACT SKIN; KIWI FRUIT; PEANUT; CHILDREN	IgE-mediated food allergy is a global health problem that affects millions of persons and affects every aspect of life for the patient. Developing effective treatment strategies to augment current practice standards of strict dietary avoidance of antigens and availability of self-injectable epinephrine has been a major focus of research teams, advocacy groups, funding agencies, and patients and their families. Significant progress has been made through the development of allergen-specific immunotherapy encompassing 3 major forms of treatment: oral, sublingual, and epicutaneous immunotherapy. These therapies are in various stages of clinical investigation, with some successes noted in clinical outcomes and modulation of immune mechanisms toward effective therapy. Here we review recent progress and areas of concern for the role of these forms of immunotherapy as an emerging treatment for food allergy.	[Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Burks, A. Wesley] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA; [Dupont, Christophe] Paris Descartes Univ, Necker Hosp, Dept Pediat, Paris, France	University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Jones, SM (corresponding author), 13 Childrens Way,Slot 512-13, Little Rock, AR 72202 USA.	jonesstaciem@uams.edu			National Institutes of Health (NIH); Food Allergy Research Education; National Peanut Board; Department of Defense; Abbott Nutrition International; Kentucky Society for Allergy, Asthma Immunology; New England Allergy Society; American College of Allergy, Asthma Immunology; Indiana University Medical School; Riley Children's Hospital; Spanish Society of Allergy & Clinical Immunology; Oregon Allergy, Asthma & Immunology Society; European Academy of Allergology and Clinical Immunology; American Academy of Allergy, Asthma Immunology; NIH; Wallace Research Foundation; Hycor Biomedical; Food Allergy Research and Education; Abbott Laboratories; Mylan Specialty; DBV Technologies; Danone Baby Nutrition; Nestle; Mead-Johnson; Pfizer; United Pharmaceuticals	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Research Education; National Peanut Board; Department of Defense(United States Department of Defense); Abbott Nutrition International; Kentucky Society for Allergy, Asthma Immunology; New England Allergy Society; American College of Allergy, Asthma Immunology; Indiana University Medical School; Riley Children's Hospital; Spanish Society of Allergy & Clinical Immunology; Oregon Allergy, Asthma & Immunology Society; European Academy of Allergology and Clinical Immunology; American Academy of Allergy, Asthma Immunology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wallace Research Foundation; Hycor Biomedical; Food Allergy Research and Education; Abbott Laboratories(Abbott Laboratories); Mylan Specialty; DBV Technologies; Danone Baby Nutrition(Danone Nutricia); Nestle(Nestle SA); Mead-Johnson; Pfizer(Pfizer); United Pharmaceuticals	S. M. Jones is on the Medical Advisory Board for Food Allergy Research & Education; is a National Advisory Board member for St Louis Children's Hospital Food Allergy Management and Education; has consulted for the Gerson Lehrman Group; has received research support from the National Institutes of Health (NIH), Food Allergy Research & Education, and the National Peanut Board; has a pending grant from the Department of Defense; has received payment for lectures from Abbott Nutrition International, the Kentucky Society for Allergy, Asthma & Immunology, the New England Allergy Society, the American College of Allergy, Asthma & Immunology, Indiana University Medical School and Riley Children's Hospital, the Spanish Society of Allergy & Clinical Immunology, the Oregon Allergy, Asthma & Immunology Society, and the European Academy of Allergology and Clinical Immunology; has received payment for manuscript preparation from the American Academy of Allergy, Asthma & Immunology; and is on the Arkansas Medicaid Drug Review Committee. A. W. Burks has received research support from the NIH, the Wallace Research Foundation, and Hycor Biomedical; has board memberships with the Academy of Allergy, Asthma & Immunology, the Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section of the NIH, the Food and Drug Administration Food Advisory committee, the Food Allergy & Anaphylaxis Network Research Advisory Board, and the Merck US Allergy Immunotherapy Allergist Advisory Board; has consultant arrangements with Dow AgroSciences, McNeill Nutritionals, Merck, Novartis Pharma AG, Sanofi Aventis US, Schering Plough, Unilever, ExploraMed Development, GLG Research, and Regeneron Pharmaceuticals; is employed by UNC Children's Hospital; has a pending grant from Food Allergy Research and Education; has received payment for lectures from Abbott Laboratories, Mylan Specialty, and the American College of Allergy, Asthma & Immunology; has various US patents related to peanut allergens and methods; has received payment for development of educational presentations from Current Views 2012; and is a minority stockholder in Allertein and Mastcell Pharmaceuticals. C. Dupont has received fees for participation in review activities from DBV Technologies; is a board member for Nutricia Baby Nutrition; is chairman of the scientific advisory board for DBV Technologies; has consultant arrangements with Sodilac; has received payment for lectures from Danone Baby Nutrition, Nestle, Mead-Johnson, Pfizer, and United Pharmaceuticals; has a patent through DBV Technologies; and has stock/stock options in DBV Technologies.	Agbotounoi W, 2012, J ALLERGY CLIN IMMUN, V131, pAB91; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Barbi E, 2012, EUR ANN ALLERGY CLIN, V44, P18; Benhamou PH, 2014, J ALLERGY CLIN IMM S, V133, pAB47; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; Dioszeghy V, 2012, J ALLERGY CLIN IMMUN, V129, pAB114, DOI 10.1016/j.jaci.2011.12.556; Dioszeghy V, 2014, J ALLERGY CLIN IMM S, V133, pAB48; Dioszeghy V, 2013, J ALLERGY CLIN IMMUN, V68, pS97; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Dupont C, 2014, J ALLERGY CLIN IMM S, V133, pAB102; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Fisher HR, 2011, ARCH DIS CHILD, V96, P259, DOI 10.1136/adc.2009.172460; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kerzl R, 2007, J ALLERGY CLIN IMMUN, V119, P507, DOI 10.1016/j.jaci.2006.09.041; Kim Edwin H, 2011, J Allergy Clin Immunol, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Martorell A, 2011, CLIN EXP ALLERGY, V41, P1297, DOI 10.1111/j.1365-2222.2011.03749.x; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Mondoulet L, 2011, INT ARCH ALLERGY IMM, V154, P299, DOI 10.1159/000321822; Mousallem T, 2012, CLIN EXP IMMUNOL, V167, P26, DOI 10.1111/j.1365-2249.2011.04499.x; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Novak N, 2010, CLIN EXP IMMUNOL, V161, P28, DOI 10.1111/j.1365-2249.2010.04162.x; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nurmatov U, 2014, BRIT J NUTR, V111, P12, DOI 10.1017/S0007114513002353; Pajno GB, 2011, CURR OPIN ALLERGY CL, V11, P560, DOI 10.1097/ACI.0b013e32834cd298; Pajno GB, 2010, ANN ALLERG ASTHMA IM, V105, P376, DOI 10.1016/j.anai.2010.03.015; Rodriguez-Perez N, 2008, ANN ALLERG ASTHMA IM, V101, P304, DOI 10.1016/S1081-1206(10)60496-6; Salmivesi S, 2013, ACTA PAEDIATR, V102, P172, DOI 10.1111/j.1651-2227.2012.02815.x; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Vazquez-Ortiz M, 2013, CLIN EXP ALLERGY, V43, P92, DOI 10.1111/cea.12012; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V126, pAB87; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, P576, DOI 10.1016/j.jaci.2010.12.1116; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Vickery BP, 2010, ANN ALLERG ASTHMA IM, V105, P444, DOI 10.1016/j.anai.2010.09.030; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Yeung JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009542.pub2	58	138	147	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					318	323		10.1016/j.jaci.2013.12.1040	http://dx.doi.org/10.1016/j.jaci.2013.12.1040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24636471				2022-12-18	WOS:000332397100003
J	Patel, DA; Holdford, DA; Edwards, E; Carroll, NV				Patel, Dipen A.; Holdford, David A.; Edwards, Eric; Carroll, Norman V.			Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; food anaphylaxis; economic burden; direct medical costs; indirect costs; cost of illness	EMERGENCY-DEPARTMENT VISITS; CHILDREN; COSTS; RHINITIS; ADULTS; ASTHMA; IMPACT	Background: Food allergy is reported to affect 4% to 6% of children and 1% to 2% of adults in the United States. Every year, allergic reactions result in visits to physicians, emergency departments, and hospitals. However, the economic burden of food-induced allergic reactions is unknown. Objective: We sought to estimate the direct medical costs and indirect costs of food-induced allergic reactions and anaphylaxis in the United States. Methods: Costs were estimated with a bottom-up approach from a societal perspective: the average cost of illness per patient was calculated and multiplied by reported prevalence estimates. Patients with an inpatient admission, emergency department admission, office-based physician visit, or outpatient visit for a food-induced allergic reaction were identified from a list of federally administered 2006 and 2007 databases by using International Classification of Diseases, ninth revision, codes. Indirect costs were quantified by estimating lost productivity in terms of lost earnings caused by absenteeism and mortality of patients or caregivers. Sensitivity analyses were conducted to measure the robustness of the estimates. Results: For 2007, direct medical costs were $225 million, and indirect costs were $115 million. Office visits accounted for 52.5% of costs, and the remainder was split between emergency visits (20%), inpatient hospitalizations (11.8%), outpatient visits (3.9%), ambulance runs (3%), and epinephrine devices (8.7%). Simulations from probabilistic sensitivity analyses suggested mean direct medical costs were $307 million and indirect costs were $203 million. Conclusions: The economic burden of allergic reactions caused by food and anaphylaxis was an estimated half a billion dollars in 2007. Ambulatory visits accounted for more than half of the costs. (J Allergy Clin Immunol 2011; 128: 110-5.)	[Holdford, David A.] Virginia Commonwealth Univ, Dept Pharm, Sch Pharm, Richmond, VA 23298 USA	Virginia Commonwealth University	Holdford, DA (corresponding author), Virginia Commonwealth Univ, Dept Pharm, Sch Pharm, McGuire Hall,Room 213,POB 980533,1112 E Clay St, Richmond, VA 23298 USA.	david.holdford@vcu.edu			Food Allergy and Anaphylaxis Network	Food Allergy and Anaphylaxis Network	Supported in part by the Food Allergy and Anaphylaxis Network.	Abed-Meraim F., 2003, PREVENTION EFFECTIVE, P187; Agency for Healthcare Research and Quality, 1998, HEALTHC COST UT PROJ; [Anonymous], 2010, CLIN LAB FEE SCHED; Berge JJ, 2000, HEPATOLOGY, V31, P469, DOI 10.1002/hep.510310229; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; BRANUM AM, 2008, 10 NAT CTR HLTH STAT; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Clark S, 2011, J ALLERGY CLIN IMMUN, V127, P682, DOI 10.1016/j.jaci.2010.10.040; Coyne KS, 2006, VALUE HEALTH, V9, P348, DOI 10.1111/j.1524-4733.2006.00124.x; *CTR MED MED SERV, 2010, HOSP OUTP PROSP PAYM, DOI DOI 10.1111/J.1524-4733.2006.00124.X; Davis Carla M, 2009, Curr Probl Pediatr Adolesc Health Care, V39, P236, DOI 10.1016/j.cppeds.2009.09.003; GOINGS G, 2009, EMPLOYMENT WARNINGS, DOI DOI 10.1016/J.ANNEPIDEM.2005.12.003; Gupta RS, 2009, ANN ALLERG ASTHMA IM, V103, P43, DOI 10.1016/S1081-1206(10)60142-1; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI [10.1146/annurev.nu.16.070196.001113, 10.1146/annurev.nutr.16.1.161]; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Segel J., COST ILLNESS STUDIES; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Simons FER, 2004, ALLERGY CLIN IMMUN S, P242; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211, DOI 10.1164/ajrccm.160.1.9811040; *THOMS HEALTHC, 2007, DRUG TOP RED BOOK; *US GOV ACC OFF, GAO07383, DOI DOI 10.1016/J.JACI.2003.10.053; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Williams RM, 1996, ANN EMERG MED, V28, P671, DOI 10.1016/S0196-0644(96)70092-6; Zaloshnja E, 2005, AM J PREV MED, V28, P88, DOI 10.1016/j.amepre.2004.09.016; 2008, RECORD, V20, P25	39	138	139	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					110	U187		10.1016/j.jaci.2011.03.013	http://dx.doi.org/10.1016/j.jaci.2011.03.013			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21489610	Bronze			2022-12-18	WOS:000292245600014
J	Mathias, RA; Grant, AV; Rafaels, N; Hand, T; Gao, L; Vergara, C; Tsai, YJ; Yang, M; Campbell, M; Foster, C; Gao, PS; Togias, A; Hansel, NN; Diette, G; Adkinson, NF; Liu, MC; Faruque, M; Dunston, GM; Watson, HR; Bracken, MB; Hoh, J; Maul, P; Maul, T; Jedlicka, AE; Murray, T; Hetmanski, JB; Ashworth, R; Ongaco, CM; Hetrick, KN; Doheny, KF; Pugh, EW; Rotimi, CN; Ford, J; Eng, C; Burchard, EG; Sleiman, PMA; Hakonarson, H; Forno, E; Raby, BA; Weiss, ST; Scott, AF; Kabesch, M; Liang, LM; Abecasis, G; Moffatt, MF; Cookson, WOC; Ruczinski, I; Beaty, TH; Barnes, KC				Mathias, Rasika A.; Grant, Audrey V.; Rafaels, Nicholas; Hand, Tracey; Gao, Li; Vergara, Candelaria; Tsai, Yuhjung J.; Yang, Mao; Campbell, Monica; Foster, Cassandra; Gao, Peisong; Togias, A.; Hansel, Nadia N.; Diette, Gregory; Adkinson, N. Franklin; Liu, Mark C.; Faruque, Mezbah; Dunston, Georgia M.; Watson, Harold R.; Bracken, Michael B.; Hoh, Josephine; Maul, Pissamai; Maul, Trevor; Jedlicka, Anne E.; Murray, Tanda; Hetmanski, Jacqueline B.; Ashworth, Roxann; Ongaco, Chrissie M.; Hetrick, Kurt N.; Doheny, Kimberly F.; Pugh, Elizabeth W.; Rotimi, Charles N.; Ford, Jean; Eng, Celeste; Burchard, Esteban G.; Sleiman, Patrick M. A.; Hakonarson, Hakon; Forno, Erick; Raby, Benjamin A.; Weiss, Scott T.; Scott, Alan F.; Kabesch, Michael; Liang, Liming; Abecasis, Goncalo; Moffatt, Miriam F.; Cookson, William O. C.; Ruczinski, Ingo; Beaty, Terri H.; Barnes, Kathleen C.			A genome-wide association study on African-ancestry populations for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genome-wide association study; ADRA1B; PRNP; DPP10; African ancestry; ethnicity; polymorphism; genetic association	CELLULAR PRION PROTEIN; AIRWAY HYPERRESPONSIVENESS; SUSCEPTIBILITY; SEARCH; GENE; LINKAGE; EXPRESSION; LOCI; INFERENCE; VARIANTS	Background: Asthma is a complex disease characterized by striking ethnic disparities not explained entirely by environmental, social, cultural, or economic factors. Of the limited genetic studies performed on populations of African descent, notable differences in susceptibility allele frequencies have been observed. Objectives: We sought to test the hypothesis that some genes might contribute to the profound disparities in asthma. Methods: We performed a genome-wide association study in 2 independent populations of African ancestry (935 African American asthmatic cases and control subjects from the Baltimore-Washington, DC, area and 929 African Caribbean asthmatic subjects and their family members from Barbados) to identify single-nucleotide polymorphisms (SNPs) associated with asthma. Results: A meta-analysis combining these 2 African-ancestry populations yielded 3 SNPs with a combined P value of less than 10(-5) in genes of potential biologic relevance to asthma and allergic disease: rs10515807, mapping to the alpha-1B-adrenergic receptor (ADRA1B) gene on chromosome 5q33 (3.57 x 10(-6)); rs6052761, mapping to the prion-related protein (PRNP) gene on chromosome 20pter-p12 (2.27 x 10(-6)); and rs1435879, mapping to the dipeptidyl peptidase 10 (DPP10) gene on chromosome 2q12.3-q14.2. The generalizability of these findings was tested in family and case-control panels of United Kingdom and German origin, respectively, but none of the associations observed in the African groups were replicated in these European studies. Evidence for association was also examined in 4 additional case-control studies of African Americans; however, none of the SNPs implicated in the discovery population were replicated. Conclusions: This study illustrates the complexity of identifying true associations for a complex and heterogeneous disease, such asthma, in admixed populations, especially populations of African descent. (J Allergy Clin Immunol 2010;125:336-46.)	[Mathias, Rasika A.] NHGRI, Inherited Dis Res Branch, NIH, Baltimore, MD USA; [Grant, Audrey V.; Rafaels, Nicholas; Hand, Tracey; Gao, Li; Vergara, Candelaria; Tsai, Yuhjung J.; Yang, Mao; Campbell, Monica; Foster, Cassandra; Gao, Peisong; Togias, A.; Adkinson, N. Franklin; Barnes, Kathleen C.] Johns Hopkins Univ, Div Clin Immunol & Allergy, Baltimore, MD USA; [Hansel, Nadia N.; Diette, Gregory; Liu, Mark C.; Barnes, Kathleen C.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Faruque, Mezbah; Dunston, Georgia M.] Harvard Univ, Natl Human Genome Ctr, Washington, DC USA; [Watson, Harold R.; Maul, Pissamai; Maul, Trevor] Univ W Indies, Cave Hill, Barbados; [Bracken, Michael B.; Hoh, Josephine] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Jedlicka, Anne E.; Murray, Tanda; Hetmanski, Jacqueline B.; Ford, Jean; Beaty, Terri H.; Barnes, Kathleen C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Ashworth, Roxann; Ongaco, Chrissie M.; Hetrick, Kurt N.; Doheny, Kimberly F.; Pugh, Elizabeth W.; Scott, Alan F.] Johns Hopkins Sch Med, Ctr Inherited Dis Res, Inst Med Genet, Baltimore, MD USA; [Eng, Celeste; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA; [Sleiman, Patrick M. A.; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA; [Forno, Erick; Raby, Benjamin A.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Forno, Erick; Raby, Benjamin A.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA; [Kabesch, Michael] Univ Munich, Univ Childrens Hosp, Munich, Germany; [Liang, Liming; Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Moffatt, Miriam F.; Cookson, William O. C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; NHGRI, Ctr Res Genom & Global Hlth, NIH, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins University; Harvard University; University West Indies Mona Jamaica; University West Indies Cave Hill Campus; Yale University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California San Francisco; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Michigan System; University of Michigan; Imperial College London; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute on Aging (NIA)	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 3A-62, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu	Abecasis, Goncalo R/B-7840-2010; Raby, Benjamin/AAK-3866-2021; Forno, Erick/I-1476-2019; Kabesch, Michael/GZM-1583-2022; Cookson, William/HHC-1790-2022; Kabesch, Michael/AAB-5701-2020	Forno, Erick/0000-0001-6497-9885; Abecasis, Goncalo/0000-0003-1509-1825	National Institutes of Health [HL087699, HL49611, AI50024, AI44840, HL075417, HL072433, AI41040, FS09606, RR03048]; US Environmental Protection Agency [83213901]; NIGMS [S06GM08015]; Wellcome Trust; Medical Research Council; French Ministry of Higher Education and Research; German Ministry of Education and Research (BMBF); National Genuine Research Network (NGFN); National Institutes of Health (National Human Genome Research Institute and National Heart, Lung, and Blood Institute, G. R. A.); European Commission; Mary Beryl Patch Turnbull Scholar Program; National Human Genome Research Institute, National Institutes of Health; National Institutes of Health; Pfizer; Centocor; Novartis; Centers for Medicine and Medicaid Services; Genentech; DFG; BMBF; European Union; GlaxoSmithKline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003048] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL075417, U01HL049612, R01HL087699, U01HL072433, R01HL088133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041040, U19AI077439, R01AI050024, R18AI044840, N01AI050024, R01AI044840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794, P01ES009606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005484] Funding Source: NIH RePORTER; Medical Research Council [G0801056B] Funding Source: researchfish	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); French Ministry of Higher Education and Research; German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); National Genuine Research Network (NGFN); National Institutes of Health (National Human Genome Research Institute and National Heart, Lung, and Blood Institute, G. R. A.)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); European Commission(European CommissionEuropean Commission Joint Research Centre); Mary Beryl Patch Turnbull Scholar Program; National Human Genome Research Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); Centocor; Novartis(Novartis); Centers for Medicine and Medicaid Services; Genentech(Roche HoldingGenentech); DFG(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); GlaxoSmithKline(GlaxoSmithKline); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by National Institutes of Health grants HL087699. HL49611 AI50024, AI44840, HL075417, HL072433, AI41040, FS09606. HL072433. and RR03048 and US Environmental Protection Agency 83213901, and NIGMS grant S06GM08015. The genome-wide genotyping of the European study was funded by the Wellcome Trust, the Medical Research Council, the French Ministry of Higher Education and Research, the German Ministry of Education and Research (BMBF). the National Genuine Research Network (NGFN). the National Institutes of Health (National Human Genome Research Institute and National Heart, Lung, and Blood Institute, G. R. A.), and the European Commission as part of GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community). K. C. B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program. R. A. M. was supported by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.; Disclosure of potential conflict of interest: R. A. Mathias, L. Gao, P. Gao. C. M. Ongaco, K. N. Hetrick K. F. Doheny. E. W. Pugh. A. F. Scott I. Ruczinski, T. H. Beaty, and K. C. Barnes have received research support from the National Institutes of Health. N. N. Hansel has received research support from Pfizer. N. F. Adkinson has equity ownership in AllerQuest LLC, has received research support front the National Institutes of Health, and hits provided expert testimony on the topic of drug hypersensitivity. M. C. Liu is a consultant for the Novartis Advisory Board and has received research support from Pfizer. Centocor, and Novartis. J. Ford is a consultant for GlaxoSmithKline and has received research support from the National Institutes of Health and the Centers for Medicine and Medicaid Services. B. A. Raby is the Section Editor for Up to Date and is air in-house lecturer for Novartis Pharmaceuticals. S.T. Weiss has received research support front Genentech. M. Kabesch has financial arrangements with Roxall, Glaxo Wellcome, Novartis, Sanofi Aventis. and Allergopharrna and has received research Support front DFG. BMBF. and the European Union. G. Abecasis has received research support front GlaxoSmithKline and the National Institutes of Health. The rest of the authors have declared they have no conflict of interest.	Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Asher MI, 1998, EUR RESPIR J, V12, P315; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136; Bonilla C, 2005, HUM GENET, V116, P402, DOI 10.1007/s00439-004-1251-2; Carr MJ, 2003, RESPIROLOGY, V8, P291, DOI 10.1046/j.1440-1843.2003.00473.x; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Chen Z, 2003, J IMMUNOL, V171, P3627, DOI 10.4049/jimmunol.171.7.3627; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Duffy DL, 2001, CURR OPIN ALLERGY CL, V1, P431, DOI 10.1097/01.all.0000011056.21466.49; Epstein MP, 2000, AM J HUM GENET, V67, P1219, DOI 10.1016/S0002-9297(07)62952-8; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; EXTON JH, 1979, J CYCLIC NUCL PROT, V5, P277; Falush D, 2003, GENETICS, V164, P1567; Ford JG, 2001, CHEST, V120, P1129, DOI 10.1378/chest.120.4.1129; Gorlov IP, 2008, AM J HUM GENET, V82, P100, DOI 10.1016/j.ajhg.2007.09.006; Gunderson KL, 2006, METHOD ENZYMOL, V410, P359, DOI 10.1016/S0076-6879(06)10017-8; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HORIUCHI M, 1995, J GEN VIROL, V76, P2583, DOI 10.1099/0022-1317-76-10-2583; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Isaacs JD, 2008, IMMUNOLOGY, V125, P313, DOI 10.1111/j.1365-2567.2008.02853.x; Kim BH, 2004, MOL BRAIN RES, V124, P40, DOI 10.1016/j.molbrainres.2004.02.005; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Li BS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000481; Li RL, 2001, CELL IMMUNOL, V207, P49, DOI 10.1006/cimm.2000.1751; Li Y, 2006, AM J HUM GENET S, VS79, P2290; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; Malerba G, 1999, CLIN EXP ALLERGY, V29, P27; Marsh DG, 1997, NAT GENET, V15, P389; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; Mazzoni IE, 2005, BIOCHEM CELL BIOL, V83, P644, DOI 10.1139/o05-058; McCormack JE, 2002, GENE, V288, P139, DOI 10.1016/S0378-1119(02)00466-3; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Pearson TA, 2008, JAMA-J AM MED ASSOC, V299, P1335, DOI 10.1001/jama.299.11.1335; Pritchard JK, 2000, GENETICS, V155, P945; Prusiner SB, 1996, COLD SPRING HARB SYM, V61, P473; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qi SY, 2003, BIOCHEM J, V373, P179, DOI 10.1042/BJ20021914; Ren XM, 2005, MOL CELL NEUROSCI, V29, P320, DOI 10.1016/j.mcn.2005.02.003; Schade J, 2008, J HISTOCHEM CYTOCHEM, V56, P147, DOI 10.1369/jhc.7A7319.2007; Shi T, 2006, MOL PHARMACOL, V70, P129, DOI 10.1124/mol.105.020735; Sleiman PMA, 2008, J ALLERGY CLIN IMMUN, V122, P1225, DOI 10.1016/j.jaci.2008.06.041; Thornton T, 2007, AM J HUM GENET, V81, P321, DOI 10.1086/519497; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; Tsai HJ, 2006, HUM GENET, V119, P547, DOI 10.1007/s00439-006-0169-2; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Zagha E, 2005, J BIOL CHEM, V280, P18853, DOI 10.1074/jbc.M410613200; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	64	138	142	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					336	346		10.1016/j.jaci.2009.08.031	http://dx.doi.org/10.1016/j.jaci.2009.08.031			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	19910028	Green Accepted			2022-12-18	WOS:000274764000008
J	Nathan, AT; Peterson, EA; Chakir, J; Wills-Karp, M				Nathan, Amy T.; Peterson, Elizabeth A.; Chakir, Jamila; Wills-Karp, Marsha			Innate immune responses of airway epithelium to house dust mite are mediated through beta-glucan-dependent pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; house dust mite; epithelium; dendritic cell; chemokine; pattern recognition; innate immunity	T-CELL RESPONSES; DERMATOPHAGOIDES-PTERONYSSINUS; DENDRITIC CELLS; RECEPTOR CCR6; ATOPIC ASTHMA; MOUSE LUNG; ALLERGEN; INFLAMMATION; ENDOTOXIN; CCL20	Background: House dust mite (HDM) induces allergic asthma in sensitized individuals, although the mechanisms by which HDM is sensed and recognized by the airway mucosa, leading to dendritic cell (DC) recruitment, activation, and subsequent T(H)2-mediated responses, are unknown. Objective: We sought to define the pathways by which HDM activates respiratory epithelium to induce allergic airway responses. Methods: Using a human airway epithelial cell line (16HBE14o-), we studied secretion of the DC chemokine CCL20 after exposure to HDM or other allergens, investigated components of the HDM responsible for the induction of chemokine release, and examined activation of signaling pathways. Central findings were also confirmed in primary human bronchial cells. Results: We demonstrate that exposure of airway epithelium to HDM results in specific and rapid secretion of CCL20, a chemokine attractant for immature DCs. The induction of CCL20 secretion is dose and time dependent and quite specific to HDM because other allergens, such as ragweed pollen and cockroach antigen, fail to significantly induce CCL20 secretion. Induction of CCL20 secretion is not protease or Toll-like receptor 2/4 dependent but, interestingly, relies on beta-glucan moieties within the HDM extract, as evidenced by the ability of other beta-glucans to competitively inhibit its secretion and by the fact that disruption of these structures by treatment of HDM with beta-glucanase significantly reduces subsequent chemokine secretion. Conclusion: Taken together, our results describe a novel mechanism for specific pattern recognition of HDM-derived beta-glucan moieties, which initiates allergic airway inflammation and, through recruitment of DCs, might link innate pattern recognition at the airway surface with adaptive immune responses. (J Allergy Clin Immunol 2009;123:612-8.)	[Nathan, Amy T.; Peterson, Elizabeth A.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Neonatol, Cincinnati, OH 45229 USA; [Wills-Karp, Marsha] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Immunobiol, Cincinnati, OH 45229 USA; [Chakir, Jamila] Laval Hosp, Res Ctr, Dept Med, Laval, PQ, Canada	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Nathan, AT (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Neonatol, 3333 Burnet Ave,MLC 7038, Cincinnati, OH 45229 USA.	Amy.Nathan@cchmc.org		Nathan, Amy/0000-0002-6401-3519	National Institutes of Health [P01 HL076383, R01 H667737]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383, R01HL067736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083315] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.W.-K. received grant support from the National Institutes of Health (P01 HL076383 and R01 H667737).	Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Chen JZ, 2007, MYCOL RES, V111, P635, DOI 10.1016/j.mycres.2007.02.011; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Finkelman FD, 2005, J IMMUNOL, V174, P4630, DOI 10.4049/jimmunol.174.8.4630; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Goulet F, 1996, AM J RESP CELL MOL, V15, P312, DOI 10.1165/ajrcmb.15.3.8810634; Grunstein MM, 2005, J ALLERGY CLIN IMMUN, V116, P94, DOI 10.1016/j.jaci.2005.03.046; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; Hodgson MJ, 2001, AM J IND MED, V39, P616, DOI 10.1002/ajim.1061; Holt PG, 2000, J AEROSOL MED, V13, P361, DOI 10.1089/jam.2000.13.361; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kondo S, 2004, INFLAMM RES, V53, P489, DOI 10.1007/s00011-004-1287-8; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Maruo K, 1997, J ALLERGY CLIN IMMUN, V100, P253, DOI 10.1016/S0091-6749(97)70233-1; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OBRIEN RM, 1994, CLIN EXP ALLERGY, V24, P737, DOI 10.1111/j.1365-2222.1994.tb00984.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sato T, 2006, J LEUKOCYTE BIOL, V80, P204, DOI 10.1189/jlb.0106069; Scapini P, 2002, EUR J IMMUNOL, V32, P3515, DOI 10.1002/1521-4141(200212)32:12<3515::AID-IMMU3515>3.0.CO;2-3; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Starner TD, 2003, AM J RESP CELL MOL, V29, P627, DOI 10.1165/rcmb.2002-0272OC; Sugita S, 2002, J IMMUNOL, V168, P5621, DOI 10.4049/jimmunol.168.11.5621; Tada R, 2006, BIOL PHARM BULL, V29, P240, DOI 10.1248/bpb.29.240; Thorley AJ, 2005, AM J RESP CELL MOL, V32, P262, DOI 10.1165/rcmb.2004-0196OC; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Van Asselt L, 1999, INDOOR BUILT ENVIRON, V8, P216, DOI 10.1159/000024644; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438, DOI 10.1164/ajrccm.164.8.2007121; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172, DOI 10.1080/00039899909602256; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wong CK, 2006, INT IMMUNOL, V18, P1327, DOI 10.1093/intimm/dxl065	41	138	139	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					612	618		10.1016/j.jaci.2008.12.006	http://dx.doi.org/10.1016/j.jaci.2008.12.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19178937	Green Accepted			2022-12-18	WOS:000264731200019
J	Martin, RJ; Szefler, SJ; King, TS; Kraft, M; Boushey, HA; Chinchilli, VM; Craig, TJ; DiMango, EA; Deykin, A; Fahy, JV; Israel, E; Lazarus, SC; Lemanske, RF; Leone, FT; Pesola, GR; Peters, SP; Sorkness, CA; Szwejbka, LA; Wechsler, ME				Martin, Richard J.; Szefler, Stanley J.; King, Tonya S.; Kraft, Monica; Boushey, Homer A.; Chinchilli, Vernon M.; Craig, Timothy J.; DiMango, Emily A.; Deykin, Aaron; Fahy, John V.; Israel, Elliot; Lazarus, Stephen C.; Lemanske, Robert F., Jr.; Leone, Frank T.; Pesola, Gene R.; Peters, Stephen P.; Sorkness, Christine A.; Szwejbka, Lisa A.; Wechsler, Michael E.		Natl Heart Lung Blood Inst Asthma	The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroids; predicting response; therapy; characteristics; biomarkers	SPUTUM EOSINOPHIL COUNTS; EXHALED NITRIC-OXIDE; ASTHMA CONTROL; BECLOMETHASONE; RESPONSIVENESS; FLUTICASONE; MONTELUKAST	Background: Although guidelines recommend anti-inflammatory therapy for persistent asthma, recent studies suggest that 25% to 35% of patients with asthma may not improve lung function with inhaled corticosteroids. Objective: To evaluate potential biomarkers of predicting short-term (6-week) response to inhaled corticosteroid with subsequent evaluation of responders and nonresponders to asthma control over a longer interval (16 additional weeks). Methods: Eighty-three subjects with asthma off steroid were enrolled in this multicenter study. Biomarkers and asthma characteristics were evaluated as predictors of inhaled corticosteroid response over a 6-week trial for changes in FEV1 and metbacholine PC20. After this, an additional 4-month trial evaluated asthma control. Results: Although multiple baseline predictors had significant correlations with improvements for short-term inhaled steroid success, the only strong correlations (r >= +/- 0.6) were albuterol reversibility (r = 0.83; P < .001), FEV1/forced vital capacity (r = -0.75; P < .001), and FEV1 % predicted (r = -0.71; P < .001). Dividing the subjects in the short-term inhaled steroid trial into responders (> 5% FEV1 improvement) and nonresponders (<= 5%) determined the longer-term need for steroids. For the nonresponders, asthma control remained unchanged whether inhaled corticosteroids were continued or were substituted with a placebo (P = .99). The good short-term responders maintained asthma control longer-term only if maintained on inhaled steroids (P = .007). Conclusion: The short-term response to inhaled corticosteroids with regard to FEV1 improvement predicts long-term asthma control. Clinical implications: The decision to use long-term inhaled steroids could be based on a short-term trial. Different therapeutic strategies would need to be established for nonresponders.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Penn State Univ, Coll Med, Hershey, PA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Wisconsin, Madison, WI USA; Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, New York, NY 10032 USA; Columbia Univ, New York, NY USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; Columbia University; Columbia University; Jefferson University; University of California System; University of California San Francisco	Martin, RJ (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St,J206, Denver, CO 80206 USA.	martinr@njc.org	Wechsler, Michael/B-3979-2013; Wechsler, Michael/AAC-5506-2019	Wechsler, Michael/0000-0003-3505-2946; Pesola, Gene/0000-0002-3909-8039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051845, K23HL004285, U10HL074073, U10HL051831, U10HL051834, U10HL051810, U10HL051843, U10HL056443, U10HL051823] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10 HL051843, HL051834, HL051843, U10 HL056443, U10 HL074073-03, HL051823, K23 HL004285, HL051845, HL04285, U10 HL051834, U10 HL051823, HL051810, HL051831, HL056443, U10 HL051831, U10 HL074073, U10 HL051845] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacci E, 2006, CHEST, V129, P565, DOI 10.1378/chest.129.3.565; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Brightling CE, 2006, CHEST, V129, P503, DOI 10.1378/chest.129.3.503; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Juniper EF, 2001, RESP MED, V95, P319, DOI 10.1053/rmed.2001.1034; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; *NAT ASTHM ED PREV, 1997, PUBL NIH NAT HEART L; *NIH NAT HEART LUN, 1995, PUBL NIH NAT HEART L; NOETHER GE, 1987, J AM STAT ASSOC, V82, P645, DOI 10.2307/2289477; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler SJ, 1999, J ALLERGY CLIN IMMUN, V103, P780, DOI 10.1016/S0091-6749(99)70420-3	23	138	145	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					73	80		10.1016/j.jaci.2006.10.035	http://dx.doi.org/10.1016/j.jaci.2006.10.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208587	Bronze, Green Accepted			2022-12-18	WOS:000243622200012
J	Bender, BG; Pedan, A; Varasteh, LT				Bender, Bruce G.; Pedan, Alex; Varasteh, Laleh T.			Adherence and persistence with fluticasone propionate/salmeterol combination therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; chronic obstructive pulmonary disease; adherence; persistence; fluticasone propionate; salmeterol; iuhaled corticosteroid	MEDICATION; ASTHMA; ADULTS	Background: Pharmacy database medication refill studies provide a panoramic view of medication-taking behavior in patients nationally. Objective: To investigate fluticasone propionate/salmeterol combination (FSC) adherence, including the factors associated with refill adherence in a large national pharmacy database. Methods: Adherence and persistence were documented for 12 months from date of initial FSC prescription in 5504 patients who filled their medication at a nationwide pharmacy chain. Results: On average, patients filled enough medication to cover 22.2% of days. More than half the patients filled a 30-day prescription only once over the 1-year interval. Higher adherence levels were associated with being male, being older than 35 years, having a comorbid disorder, a having a copay of $1.01 to $10, previous beta(2)-agonist use, and a prescription for higher-dose FSC. Conclusion: This pharmacy database study portrays medication adherence levels to be considerably lower than those reported in most clinical trials, suggests that most adults taking FSC obtain a single fill before abandoning their controller medication, and indicates a need for a reappraisal of current treatment guidelines and educational strategies for both providers and patients. Clinical implications: For many patients, filling of a controller medication is markedly discrepant with practice guidelines. Reappraisal of both the guidelines and strategies to implement them is in order.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bender, BG (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	benderb@njc.org						Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Barr RG, 2002, ARCH INTERN MED, V162, P1761, DOI 10.1001/archinte.162.15.1761; Bauman LJ, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e6; Beausoleil JL, 1997, PEDIATRICS, V99, P40, DOI 10.1542/peds.99.1.40; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Bloom BS, 1998, CLIN THER, V20, P671, DOI 10.1016/S0149-2918(98)80130-6; Grant RW, 2004, ARCH INTERN MED, V164, P2343, DOI 10.1001/archinte.164.21.2343; Klein J.P., 2003, SURVIVAL ANAL TECHNI; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; Stempel DA, 2004, CHEST, V126, P75, DOI 10.1378/chest.126.1.75; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; World Health Organization, 2003, ADHERENCE LONG TERM; 2003, DRUG BENEFIT TRENDS, V15, P4	16	138	141	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					899	904		10.1016/j.jaci.2006.07.002	http://dx.doi.org/10.1016/j.jaci.2006.07.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030244				2022-12-18	WOS:000241434200018
J	Chung, HL; Hwang, JB; Park, JJ; Kim, SG				Chung, HL; Hwang, JB; Park, JJ; Kim, SG			Expression of transforming growth factor beta 1, transforming growth factor type I and II receptors, and TNF-alpha in the mucosa of the small intestine in infants with food protein-induced enterocolitis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food protein-induced enterocolitis syndrome; transforming growth factor beta; transforming growthfactor beta receptors; TNF-alpha	EPITHELIAL BARRIER FUNCTION; NECROSIS-FACTOR-ALPHA; TGF-BETA; CLINICAL-FEATURES; MILK; LOCALIZATION; INTOLERANCE; CYTOKINE; DISEASE; CELLS	Background. TNF-alpha secreted by activated T cells is known to increase intestinal permeability whereas transforming growth factor (TGF) beta has the ability to protect the epithelial barrier. Objective: We determined the expression of TGF-beta1, its receptors, and TNF-alpha on the mucosa of small intestine to investigate their roles in the pathogenesis of food protein-induced enterocolitis syndrome (FPIES). Methods: Twenty-eight infants diagnosed with FPIES by means of clinical criteria and challenge test results were included. Immunohistochemical stains for TGF-beta1, type I and 2 TGF-beta receptors, and TNF-alpha on duodenal biopsy specimens were performed. Results: TGF-beta1 expression was generally depressed in patients. Expression of type I TGF-beta receptor was significantly lower in the patients who had villous atrophy compared with expression in those patients who did not (P < .001) and negatively correlated with the severity of atrophy (r = -0.59, P < .001). Expression of type 2 TGF-beta receptor showed no significant difference between the patients with or without villous atrophy. The immunoreactivity for both TGF-beta receptors on lamina proprial cells was slight or negative. TNF-alpha expression was detected on both epithelial and lamina proprial cells and was significantly greater in the patients who had villous atrophy compared with that in the patients who did not (P < .01). Conclusion: Our results suggest that decreased countering activity of TGF-beta1 against T-cell cytokines is implicated in the pathogenesis of FPIES. The significantly lower expression of type 1 TGF-beta receptor compared with type 2 receptor suggests the differential contribution of each receptor to the diverse biologic activities of TGF-beta in the intestinal epithelium.	Catholic Univ Taegu, Sch Med, Dept Pediat, Taegu 705034, South Korea; Catholic Univ Taegu, Sch Med, Dept Pathol, Taegu 705034, South Korea; Catholic Univ Taegu, Sch Med, Dept Clin Pathol, Taegu 705034, South Korea	Catholic University of Daegu; Catholic University of Daegu; Catholic University of Daegu	Chung, HL (corresponding author), Catholic Univ Taegu, Sch Med, Dept Pediat, 3056-6 Taemyung 4 Dong Namgu, Taegu 705034, South Korea.							ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Eskinazi R, 1998, GASTROENTEROLOGY, V114, P1211, DOI 10.1016/S0016-5085(98)70427-5; HEINO J, 1989, J BIOL CHEM, V264, P380; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Lionetti P, 1999, J PEDIATR GASTR NUTR, V29, P308, DOI 10.1097/00005176-199909000-00013; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Majamaa H, 1996, CLIN EXP ALLERGY, V26, P181, DOI 10.1111/j.1365-2222.1996.tb00078.x; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MURRAY KF, 1993, J PEDIATR-US, V122, P90, DOI 10.1016/S0022-3476(05)83495-X; OHTANI H, 1995, J GASTROENTEROL, V30, P76; Penttila IA, 1998, PEDIATR RES, V44, P524, DOI 10.1203/00006450-199810000-00010; Planchon S, 1999, J CELL PHYSIOL, V181, P55, DOI 10.1002/(SICI)1097-4652(199910)181:1<55::AID-JCP6>3.3.CO;2-D; PLANCHON SM, 1994, J IMMUNOL, V153, P5730; POWELL G K, 1986, Comprehensive Therapy, V12, P28; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; POWELL GK, 1976, J PEDIATR-US, V88, P840, DOI 10.1016/S0022-3476(76)81128-6; Roche JK, 2000, INFECT IMMUN, V68, P5635, DOI 10.1128/IAI.68.10.5635-5644.2000; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; Zhang MF, 1999, PEDIATR RES, V46, P657, DOI 10.1203/00006450-199912000-00017	25	138	145	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					150	154		10.1067/mai.2002.120562	http://dx.doi.org/10.1067/mai.2002.120562			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799382				2022-12-18	WOS:000173739300025
J	Szalai, C; Kozma, GT; Nagy, A; Bojszko, A; Krikovszky, D; Szabo, T; Falus, A				Szalai, C; Kozma, GT; Nagy, A; Bojszko, A; Krikovszky, D; Szabo, T; Falus, A			Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; polymorphism; chemokines; MCP-1; RANTES; eosinophils	MONOCYTE CHEMOATTRACTANT PROTEIN-1; CC-CHEMOKINES; MIP-1 ALPHA; RANTES; HYPERREACTIVITY; PROMOTER	Background: Chemokines play an important role in the pathophysiology of asthma and allergy. Recently, polymorphisms in the gene regulatory region of monocyte chemoattractant protein 1 (MCP-1) and in the promoter region of RANTES have been found; these polymorphisms increase the expression of the chemokines. Objective: We investigated whether the presence of the polymorphisms was associated with atopy or asthma and whether these alleles influenced the severity of asthma in affected individuals. Methods: Three groups of subjects-160 children with asthma (disease severity being classified according to the Global Initiative for Asthma guidelines, modified for children), 151 children with nonasthmatic but allergic phenotype, and 303 children without allergic or asthmatic disorders-were screened with a PCR-based assay for genotyping. Results: The frequency of the -2518G polymorphism in the gene regulatory region of MCP-I was significantly higher in asthmatic children than in controls (P < .001; odds ratio [OR] = 2.0 [1.4-2.6]) and nonasthmatic atopic children (P < .00 1; OR = 2.0 [1.4-2.9]). The MCP-1 G/G genotype correlated with asthma severity. In asthmatic children, the MCP-1 -2518G allele was also associated with an increased blood eosinophil level. The promoter polymorphisms in the RANTES gene did not have a detectable effect on the susceptibility to asthma or allergy or on the blood eosinophil count. Conclusion: In this cohort of children, there are associations between carrying G at -2518 of the MCP-1 gene regulatory region and the presence of asthma as well as between asthma severity and homozygosity for the G allele. In asthmatic children, the MCP-1-2518G polymorphism correlated with increased eosinophil levels. This variant of MCP-1 might belong to the predictor gene set for asthma.	Heim Pal Pediat Hosp, H-1958 Budapest, Hungary; Hungarian Acad Sci, Mol Immunol Res Grp, H-1525 Budapest, Hungary; Semmelweis Univ, Dept Genet Cells & Immunobiol, H-1085 Budapest, Hungary; Budai Childrens Hosp, Budapest, Hungary; Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary	Hungarian Academy of Sciences; Semmelweis University; Semmelweis University	Szalai, C (corresponding author), Heim Pal Pediat Hosp, POB 66, H-1958 Budapest, Hungary.		Szalai, Csaba/A-2041-2008	Falus, Andras/0000-0002-6843-6789				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Barnes Kathleen C., 2000, Journal of Allergy and Clinical Immunology, V106, pS192; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Campbell EM, 1999, J IMMUNOL, V163, P2160; Duffy DL, 1998, AM J RESP CRIT CARE, V157, P840, DOI 10.1164/ajrccm.157.3.9702070; Folkard SG, 1997, EUR RESPIR J, V10, P2097, DOI 10.1183/09031936.97.10092097; Gangur V, 1999, INT ARCH ALLERGY IMM, V118, P387, DOI 10.1159/000024144; Gangur V, 2000, ANN ALLERG ASTHMA IM, V84, P569, DOI 10.1016/S1081-1206(10)62403-9; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gutierrez-Ramos JC, 1999, IMMUNOL TODAY, V20, P500, DOI 10.1016/S0167-5699(99)01522-4; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Karpus WJ, 1997, J LEUKOCYTE BIOL, V62, P681, DOI 10.1002/jlb.62.5.681; Liu HL, 1999, P NATL ACAD SCI USA, V96, P4581, DOI 10.1073/pnas.96.8.4581; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NELSON PJ, 1993, J IMMUNOL, V151, P2601; *NHLBI WHO WORKSH, 1995, PUBL NHLBI WHO; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; SYLVESTER I, 1993, J IMMUNOL, V151, P3292; Szalai C, 2001, ATHEROSCLEROSIS, V158, P233, DOI 10.1016/S0021-9150(01)00423-3; Teran LM, 1996, J IMMUNOL, V157, P1806; UEDA A, 1994, J IMMUNOL, V153, P2052; WUTHRICH B, 1981, CLIN ALLERGY, V11, P147, DOI 10.1111/j.1365-2222.1981.tb01578.x	34	138	148	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					375	381		10.1067/mai.2001.117930	http://dx.doi.org/10.1067/mai.2001.117930			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544456				2022-12-18	WOS:000171215400008
J	Howarth, PH; Stern, MA; Roi, L; Reynolds, R; Bousquet, J				Howarth, PH; Stern, MA; Roi, L; Reynolds, R; Bousquet, J			Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; efficacy; safety; fexofenadine hydrochloride; cetirizine; total symptom score; antihistamine; once daily	TORSADE-DE-POINTES; 2ND-GENERATION ANTIHISTAMINES; TERFENADINE; MODEL	Background: Fexofenadine hydrochloride (HCl) is a new HI antihistamine used twice daily in some countries. Objective: A multicenter, double-blind, parallel-group, placebo-controlled trial compared the efficacy and safety of fexofenadine HCl (120 and 180 mg administered once daily) and cetirizine (10 mg once daily) in the treatment of seasonal allergic rhinitis, Methods: After a 3- to 5-day run-in period, patients meeting entrance criteria were randomized to receive placebo, fexofenadine HCl 120 mg once daily, fexofenadine HCl 180 mg once daily, or cetirizine 10 mg once daily (active control) for 2 weeks, Eight hundred twenty-one patients comprised the intention-to-treat population and 722 patients completed the study, Symptom assessments were conducted 12 hours after the dose for the previous 12 hours and again at 24 hours after the dose for the previous 12 hours. In addition, assessment was made immediately before dosing in the morning for the previous 30 minutes. Total symptom score was calculated as the sum of scores for the 4 individual symptoms: (1) sneezing, (2) rhinorrhea, (3) itchy nose, palate, or throat, and (4) itchy, watery, or red eyes; the nasal congestion score was also recorded. Results: Both doses of fexofenadine HCl were superior to placebo in reducing the total symptom score. Efficacy was maintained for the entire dosing interval (ie, for 24 hours). There were no differences in efficacy between the 2 doses of fexofenadine HCl or between either dose of fexofenadine HCl and cetirizine, There was no major side effect, but the combined incidence of drowsiness or fatigue was greater with cetirizine (9%) than with placebo (4%) (P = .07) or fexofenadine (4%) (P = .02), Conclusions: Once-daily fexofenadine is thus a valuable addition to the nonsedating group of H-1 receptor antagonists currently available for the treatment of seasonal allergic rhinitis.	Southampton Gen Hosp, Resp Cell & Mol Biol Div, Southampton SO16 6YD, Hants, England; Leicester Gen Hosp, Dept Clin Immunol, Leicester LE5 4PW, Leics, England; Hoechst Marion Roussel, Denham, England; Hoechst Marion Roussel, Kansas City, MO USA; Hop Arnaud de Villeneuve, CHU Montpellier, Montpellier, France	University of Southampton; University Hospitals of Leicester NHS Trust; Leicester General Hospital; Universite de Montpellier; CHU de Montpellier	Howarth, PH (corresponding author), Southampton Gen Hosp, Resp Cell & Mol Biol Div, Level D,Ctr Block, Southampton SO16 6YD, Hants, England.		Bousquet, Jean/O-4221-2019	Howarth, Peter/0000-0003-0619-7927				Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443, DOI 10.1016/S1081-1206(10)63041-4; Bousquet J, 1996, INT ARCH ALLERGY IMM, V110, P207, DOI 10.1159/000237289; Bronsky EA, 1998, ALLERGY ASTHMA PROC, V19, P135, DOI 10.2500/108854198778604112; CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; CRAFT TM, 1986, BRIT MED J, V292, P660, DOI 10.1136/bmj.292.6521.660; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P159; Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P153; HOWARTH P H, 1991, Journal of Allergy and Clinical Immunology, V87, P151, DOI 10.1016/0091-6749(91)91333-O; HOWARTH PH, 1991, CLIN EXP ALLERGY, V21, P3, DOI 10.1111/j.1365-2222.1991.tb01751.x; HOWARTH PH, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb02734.x; KEMP JP, 1985, ANN ALLERGY, V54, P502; Lippert Christina, 1995, Pharmaceutical Research (New York), V12, pS390; Pratt CM, 1997, ALLERGY S37, V52, P67; RAMPE D, 1993, MOL PHARMACOL, V44, P1240; Russell T, 1998, CLIN PHARMACOL THER, V64, P612, DOI 10.1016/S0009-9236(98)90052-2; Simons FER, 1997, ANN ALLERG ASTHMA IM, V79, P530, DOI 10.1016/S1081-1206(10)63061-X; SIMONS FER, 1993, ANN ALLERGY, V71, P592; Tanner LA, 1999, AM J MANAG CARE, V5, pS235; WEINBERGER M, 1979, CURR MED RES OPIN, V6, P116, DOI 10.1185/03007997909115919; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532	22	138	140	1	11	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					927	933		10.1016/S0091-6749(99)70070-9	http://dx.doi.org/10.1016/S0091-6749(99)70070-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550734	Bronze			2022-12-18	WOS:000083778400012
J	Borish, L; Rosenwasser, LJ				Borish, L; Rosenwasser, LJ			Update on cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							TUMOR-NECROSIS-FACTOR; HISTAMINE-RELEASING FACTORS; COLONY-STIMULATING FACTOR; T-CELL CLONES; INTERLEUKIN-1 RECEPTOR ANTAGONIST; INTERFERON-GAMMA-PRODUCTION; MURINE BONE-MARROW; HUMAN B-CELLS; IGE SYNTHESIS; GROWTH-FACTOR				Borish, L (corresponding author), UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.							ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; AKINA S, 1993, ADV IMMUNOL, V54, P1; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; AURON PE, 1987, J IMMUNOL, V138, P1447; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BELLONE G, 1994, J IMMUNOL, V153, P930; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BHATIA A, 1992, BLOOD S, V80, pA410; BORISH L, 1993, J ALLERGY CLIN IMMUN, V92, P123, DOI 10.1016/0091-6749(93)90046-I; BRESSLER RB, 1989, J IMMUNOL, V143, P135; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; BRUNDA MJ, 1994, J LEUKOCYTE BIOL, V55, P280; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CHEN WF, 1991, J IMMUNOL, V147, P528; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; DELPRETE G, 1993, J IMMUNOL, V150, P353; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DENBURG JA, 1991, BLOOD, V77, P1462; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ENK AH, 1993, J IMMUNOL, V151, P2390; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FENTON MJ, 1992, J IMMUNOL, V149, P1283; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GAUCHAT JF, 1992, J IMMUNOL, V148, P2291; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; GRANT JA, 1991, J ALLERGY CLIN IMMUN, V88, P683, DOI 10.1016/0091-6749(91)90170-S; HATEKEYAMA M, 1991, SCIENCE, V252, P1523; HATEKEYAMA M, 1985, NATURE, V318, P467; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HENNEY CS, 1981, NATURE, V291, P335, DOI 10.1038/291335a0; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; HSEIH CS, 1993, SCIENCE, V260, P547; HSU DH, 1992, INT IMMUNOL, V4, P563, DOI 10.1093/intimm/4.5.563; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P2271, DOI 10.1002/eji.1830241002; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; KIRSHENBAUM AS, 1989, J IMMUNOL, V142, P2424; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KOIKE M, 1994, INT ARCH ALLERGY IMM, V104, P1, DOI 10.1159/000236702; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KUNA P, 1993, J IMMUNOL, V150, P1932; KUNA P, 1991, J IMMUNOL, V147, P1920; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MALKOVSKY M, 1987, NATURE, V325, P262, DOI 10.1038/325262a0; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MERBERG DM, 1992, IMMUNOL TODAY, V13, P77, DOI 10.1016/0167-5699(92)90140-3; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; MOSER R, 1992, J IMMUNOL, V149, P1432; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OHISSON K, 1990, NATURE, V348, P550; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PAUL WE, 1991, BLOOD, V77, P1859; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; RALPH P, 1992, J IMMUNOL, V148, P808; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TAKATSU K, 1992, CURR OPIN IMMUNOL, V4, P299, DOI 10.1016/0952-7915(92)90080-X; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VERCELLI D, 1993, SPRINGER SEMIN IMMUN, V15, P5; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELDMANN B, 1994, NATURE, V370, P434; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388; YSSEL H, 1992, J IMMUNOL, V149, P2378; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	120	138	154	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					719	733		10.1016/S0091-6749(96)80146-1	http://dx.doi.org/10.1016/S0091-6749(96)80146-1			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613627	Bronze			2022-12-18	WOS:A1996UA97500001
J	BOUSQUET, J; BECKER, WM; HEJJAOUI, A; CHANAL, I; LEBEL, B; DHIVERT, H; MICHEL, FB				BOUSQUET, J; BECKER, WM; HEJJAOUI, A; CHANAL, I; LEBEL, B; DHIVERT, H; MICHEL, FB			DIFFERENCES IN CLINICAL AND IMMUNOLOGICAL REACTIVITY OF PATIENTS ALLERGIC TO GRASS POLLENS AND TO MULTIPLE-POLLEN SPECIES .2. EFFICACY OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, SPECIFIC IMMUNOTHERAPY WITH STANDARDIZED EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; IMMUNOBLOT; GRASS POLLEN; NASAL CHALLENGE; SKIN TESTS; SYMPTOM SCORES	HIGH-MOLECULAR-WEIGHT; HAY-FEVER; NASAL CHALLENGE; RAGWEED-POLLEN; MEDITERRANEAN AREA; RUSH IMMUNOTHERAPY; NITROCELLULOSE; SAFETY; ANTIBODIES; RADIOIMMUNOASSAY	The IgE response of patients only allergic to grass pollens differs from response of patients allergic to multiple-pollen species. The IgE immunoblots to orchard-grass pollens confirmed that polysensitized patients had more proteins revealed than patients only allergic to grass pollens. To determine if both groups of patients present a different response toward specific immunotherapy (IT), a double-blind, placebo-controlled study was performed in 70 patients. Patients receiving the active treatment had a rush IT with either a standardized orchard grass-pollen extract or with a standardized mixed-pollen extract prepared, depending on the sensitivity of the patients. The maintenance dose was defined as that dose effective in grass-pollen IT in previous experiments. The same equipotent maintenance dose was administered for all pollen species. Symptom-medication scores during the pollen season and nasal challenge with orchard grass-pollen grains demonstrated that grass pollen-allergic patients had a significantly improved efficacy by comparison to placebo treatment, whereas polysensitized patients had a nonsignificant improvement. Serum grass-pollen IgG was significantly increased after IT in both treated groups. This study demonstrate that the response toward specific IT differs in patients only allergic to grass pollens by comparison to polysensitizied patients.	FORSCHUNGSINST BORSTEL,W-2061 BORSTEL,GERMANY; INSERM,U58,F-34100 MONTPELLIER,FRANCE	Forschungszentrum Borstel; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	BOUSQUET, J (corresponding author), CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BERG T, 1980, INT ARCH ALLER A IMM, V63, P266, DOI 10.1159/000232636; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1985, 3RD P P EHRL SEM REG, P291; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; COUR P, 1973, POLLEN SPORES, V16, P103; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; DREBORG S, 1986, HDB EXPT IMMUNOLOGY, V1; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; FRANKLAND AW, 1954, LANCET, V1, P1055; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P195, DOI 10.1016/0091-6749(85)90701-8; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V78, P1180, DOI 10.1016/0091-6749(86)90269-1; GRAMMER LC, 1989, J ALLERGY CLIN IMMUN, V83, P750, DOI 10.1016/0091-6749(89)90010-9; HAAS H, 1986, INT ARCH ALLER A IMM, V79, P434, DOI 10.1159/000234014; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HEJJAOUI A, 1985, J ALLERGY CLIN IMMUN, V75, P164, DOI 10.1016/0091-6749(85)90372-0; IRANDER K, 1979, ACTA OTOLARYNGOL S, V360, P24; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MUTHIAH R, 1990, Journal of Allergy and Clinical Immunology, V85, P151; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NORDVALL SL, 1978, INT ARCH ALLER A IMM, V67, P132; NORMAN PS, 1981, PROG ALLERGY, V32, P318; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; PUTTONEN E, 1981, INT ARCH ALLER A IMM, V64, P157, DOI 10.1159/000232687; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SINGH MB, 1985, INT ARCH ALLER A IMM, V78, P300, DOI 10.1159/000233901; TURKELTAUB PC, 1986, J ALLERGY CLIN IMMUN, V77, P211; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; 1980, GUIDELINES REGISTRAT	52	138	139	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					43	53		10.1016/0091-6749(91)90299-4	http://dx.doi.org/10.1016/0091-6749(91)90299-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071784				2022-12-18	WOS:A1991FY20400005
J	FITZSIMONS, R; GREENBERGER, PA; PATTERSON, R				FITZSIMONS, R; GREENBERGER, PA; PATTERSON, R			OUTCOME OF PREGNANCY IN WOMEN REQUIRING CORTICOSTEROIDS FOR SEVERE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; BAIRD D, 1968, COMBINED TXB OBSTETR, P287; BENSON RC, 1982, OBSTET GYNECOL, P682; BERNSTEIN IL, 1983, ALLERGY PRINCIPLES P, P916; GIESLER CF, 1984, GYNECOLOGY OBSTETRIC, P8; GILMAN AG, 1980, PHARM BASIS THERAPEU, P1490; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421, DOI 10.1016/0002-9378(70)90371-6; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; GREENBERGER PA, 1980, ALLERGIC DISEASES DI, P279; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P388; LOEVY H, 1968, ANAT REC, V160, P386; MISENHIMER HR, 1972, INVEST RADIOL, V7, P496, DOI 10.1097/00004424-197211000-00005; MOYA F, 1965, AM J OBSTET GYNECOL, V91, P76, DOI 10.1016/0002-9378(65)90589-2; ROLF BB, 1966, AM J OBSTET GYNECOL, V95, P339, DOI 10.1016/0002-9378(66)90109-8; SCHATZ M, 1975, JAMA-J AM MED ASSOC, V233, P804, DOI 10.1001/jama.233.7.804; THOMPSON JF, 1982, OBSTETRICS GYNECOLOG, P286; WARELL DW, 1968, LANCET, V1, P117; WULF KH, 1972, RESPIRATORY GAS EXCH, P505; YACKEL DB, 1966, AM J OBSTET GYNECOL, V96, P985, DOI 10.1016/0002-9378(66)90444-3	20	138	138	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					349	353		10.1016/S0091-6749(86)80088-4	http://dx.doi.org/10.1016/S0091-6749(86)80088-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734287				2022-12-18	WOS:A1986D726100018
J	BERG, TLO; JOHANSSON, SG				BERG, TLO; JOHANSSON, SG			ALLERGY DIAGNOSIS WITH RADIOALLERGOSORBENT TEST - COMPARISON WITH RESULTS OF SKIN AND PROVOCATION TESTS IN AN UNSELECTED GROUP OF CHILDREN WITH ASTHMA AND HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP UPPSALA, DEPT PEDIAT, S-75014 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, BLOOD CTR, S-75014 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; AAS K, 1973, CLIN ALLERGY, V3, P481, DOI 10.1111/j.1365-2222.1973.tb01355.x; Bennich H, 1971, Adv Immunol, V13, P1; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; BERG TG, TO BE PUBLISHED; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; Johansson S G, 1972, Prog Clin Immunol, V1, P157; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; WIDE L, 1973, CLIN ALLERGY, V3, P583, DOI 10.1111/j.1365-2222.1973.tb03063.x; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1971, EXCERPTA MEDICA  251, P85	13	138	138	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	4					209	221		10.1016/0091-6749(74)90063-3	http://dx.doi.org/10.1016/0091-6749(74)90063-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3236	4411916				2022-12-18	WOS:A1974U323600003
J	Busse, W; Chupp, G; Nagase, H; Albers, FC; Doyle, S; Shen, Q; Bratton, DJ; Gunsoy, NB				Busse, William; Chupp, Geoffrey; Nagase, Hiroyuki; Albers, Frank C.; Doyle, Scott; Shen, Qin; Bratton, Daniel J.; Gunsoy, Necdet B.			Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Benralizumab; indirect treatment comparison; mepolizumab; network meta-analysis; reslizumab; severe eosinophilic asthma	DOUBLE-BLIND; MEPOLIZUMAB; BENRALIZUMAB; METAANALYSIS; MULTICENTER; EFFICACY; RESLIZUMAB; VERSIONS; SIROCCO; DISEASE	Background: Three anti-IL-5 pathway-directed therapies are approved for use in patients with severe eosinophilic asthma (SEA); however, no head-to-head comparison data are available. Objective: We sought to compare the efficacy of licensed doses of mepolizumab, benralizumab, and reslizumab in patients with SEA, according to baseline blood eosinophil counts. Methods: This indirect treatment comparison (ITC) used data from a Cochrane review and independent searches. Eligible studies were randomized controlled trials in patients aged 12 years or greater with SEA. End points included annualized rate of clinically significant exacerbations and change from baseline in Asthma Control Questionnaire score and FEV1. An ITC was performed in patients with Asthma Control Questionnaire scores of 1.5 or greater and stratified by baseline blood eosinophil count. Results: Eleven studies were included. All treatments significantly reduced the rate of clinically significant exacerbations and improved asthma control versus placebo in all blood eosinophil count subgroups. Mepolizumab reduced clinically significant exacerbations by 34% to 45% versus benralizumab across subgroups (rate ratio >= 400 cells/mu L: 0.55 [95% CI, 0.35-0.87]; >= 300 cells/mu L: 0.61 [95% CI, 0.37-0.99]; and >= 150 cells/mu L: 0.66 [95% CI, 0.49-0.89]; all P <.05) and by 45% versus reslizumab in the 400 cells/mu L or greater subgroup (rate ratio, 0.55 [95% CI, 0.36-0.85]; P =.007). Asthma control was significantly improved with mepolizumab versus benralizumab (all subgroups: P <.05) and versus reslizumab in the 400 cells/mu L or greater subgroup (P =.004). Benralizumab significantly improved lung function versus reslizumab in the 400 cells/mu L or greater subgroup (P =.025). Conclusions: This ITC of the licensed doses suggests that mepolizumab was associated with significantly greater improvements in clinically significant exacerbations and asthma control compared with reslizumab or benralizumab in patients with similar blood eosinophil counts.	[Busse, William] Univ Wisconsin, Dept Med Allergy Pulm & Crit Care Med, Madison, WI USA; [Chupp, Geoffrey] Yale Univ, Internal Med, New Haven, CT USA; [Nagase, Hiroyuki] Teikyo Univ, Sch Med, Div Resp Med & Allergol, Dept Med, Tokyo, Japan; [Albers, Frank C.] GlaxoSmithKline, Resp Med Franchise, Res Triangle Pk, NC USA; [Doyle, Scott; Gunsoy, Necdet B.] GlaxoSmithKline, Value Evidence & Outcomes, Brentford, England; [Shen, Qin] GlaxoSmithKline, Analyt & Innovat, Value Evidence & Outcomes, Upper Providence, PA USA; [Bratton, Daniel J.] GlaxoSmithKline, Clin Stat, Stockley Pk, Uxbridge, Middx, England	University of Wisconsin System; University of Wisconsin Madison; Yale University; Teikyo University; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Busse, W (corresponding author), Ctr Clin Sci, 600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu	Nagase, Hiroyuki/Y-4367-2019	Nagase, Hiroyuki/0000-0002-0296-5901	GlaxoSmithKline	GlaxoSmithKline(GlaxoSmithKline)	Editorial support (in the form of writing assistance, including development of the initial draft from the study report, assembling tables and figures, collating authors comments, grammatical editing, and referencing) was provided by Natasha Dean, MSc, and Elizabeth Hutchinson, PhD, CMPP, at Fishawack Indicia Ltd, UK, and was funded by GlaxoSmithKline.	Albers FC, 2017, J ALLERGY CLIN IMMUN, V140, P1464, DOI 10.1016/j.jaci.2017.06.010; [Anonymous], 2018, FASENRA BENRALIZUMAB; [Anonymous], 2016, CINQAIR RESLIZUMAB U; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bjermer L, 2016, CHEST, V150, P789, DOI 10.1016/j.chest.2016.03.032; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Brusselle G, 2017, PULM PHARMACOL THER, V43, P39, DOI 10.1016/j.pupt.2017.01.011; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Cabon Y, 2017, CLIN EXP ALLERGY, V47, P129, DOI 10.1111/cea.12853; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X; Corren J, 2016, CHEST, V150, P799, DOI 10.1016/j.chest.2016.03.018; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Farne HA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub3; FitzGerald JM, 2018, LANCET RESP MED, V6, P51, DOI 10.1016/S2213-2600(17)30344-2; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; Jansen JP, 2011, VALUE HEALTH, V14, P417, DOI 10.1016/j.jval.2011.04.002; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; LOPEZ AF, 1986, J EXP MED, V163, P1085, DOI 10.1084/jem.163.5.1085; Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Phillipo DM, 2016, 18 NICE DSU U BRIST; Rucker G, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0060-8; Wyrwich KW, 2011, RESP MED, V105, P698, DOI 10.1016/j.rmed.2010.11.004; Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005; Zeiger RS, 2016, J ALLER CL IMM-PRACT, V4, P120, DOI 10.1016/j.jaip.2015.08.003	32	137	140	3	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					190	+		10.1016/j.jaci.2018.08.031	http://dx.doi.org/10.1016/j.jaci.2018.08.031			31	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30205189	hybrid			2022-12-18	WOS:000454918300025
J	Barzaghi, F; Hernandez, LCA; Neven, B; Ricci, S; Kucuk, ZY; Bleesing, JJ; Nademi, Z; Slatter, MA; Ulloa, ER; Shcherbina, A; Roppelt, A; Worth, A; Silva, J; Aiuti, A; Murguia-Favela, L; Speckmann, C; Carneiro-Sampaio, M; Fernandes, JF; Baris, S; Ozen, A; Karakoc-Aydiner, E; Kiykim, A; Schulz, A; Steinmann, S; Notarangelo, LD; Gambineri, E; Lionetti, P; Shearer, WT; Forbes, LR; Martinez, C; Moshous, D; Blanche, S; Fisher, A; Ruemmele, FM; Tissandier, C; Ouachee-Chardin, M; Rieux-Laucat, F; Cavazzana, M; Qasim, W; Lucarelli, B; Albert, MH; Kobayashi, I; Alonso, L; De Heredia, CD; Kanegane, H; Lawitschka, A; Seo, JJ; Gonzalez-Vicent, M; Diaz, MA; Goyal, RK; Sauer, MG; Yesilipek, A; Kim, M; Yilmaz-Demirdag, Y; Bhatia, M; Khlevner, J; Padilla, EJR; Martino, S; Montin, D; Neth, O; Molinos-Quintana, A; Valverde-Fernandez, J; Broides, A; Pinsk, V; Ballauf, A; Haerynck, F; Bordon, V; Dhooge, C; Garcia-Lloret, ML; Bredius, RG; Kalwak, K; Haddad, E; Seidel, MG; Duckers, G; Pai, SY; Dvorak, CC; Ehl, S; Locatelli, F; Goldman, F; Gennery, AR; Cowan, MJ; Roncarolo, MG; Bacchetta, R				Barzaghi, Federica; Hernandez, Laura Cristina Amaya; Neven, Benedicte; Ricci, Silvia; Kucuk, Zeynep Yesim; Bleesing, Jack J.; Nademi, Zohreh; Slatter, Mary Anne; Ulloa, Erlinda Rose; Shcherbina, Anna; Roppelt, Anna; Worth, Austen; Silva, Juliana; Aiuti, Alessandro; Murguia-Favela, Luis; Speckmann, Carsten; Carneiro-Sampaio, Magda; Fernandes, Juliana Folloni; Baris, Safa; Ozen, Ahmet; Karakoc-Aydiner, Elif; Kiykim, Ayca; Schulz, Ansgar; Steinmann, Sandra; Notarangelo, Lucia Dora; Gambineri, Eleonora; Lionetti, Paolo; Shearer, William Thomas; Forbes, Lisa R.; Martinez, Caridad; Moshous, Despina; Blanche, Stephane; Fisher, Alain; Ruemmele, Frank M.; Tissandier, Come; Ouachee-Chardin, Marie; Rieux-Laucat, Frederic; Cavazzana, Marina; Qasim, Waseem; Lucarelli, Barbarella; Albert, Michael H.; Kobayashi, Ichiro; Alonso, Laura; De Heredia, Cristina Diaz; Kanegane, Hirokazu; Lawitschka, Anita; Seo, Jong Jin; Gonzalez-Vicent, Marta; Diaz, Miguel Angel; Goyal, Rakesh Kumar; Sauer, Martin G.; Yesilipek, Akif; Kim, Minsoo; Yilmaz-Demirdag, Yesim; Bhatia, Monica; Khlevner, Julie; Padilla, Erick J. Richmond; Martino, Silvana; Montin, Davide; Neth, Olaf; Molinos-Quintana, Agueda; Valverde-Fernandez, Justo; Broides, Arnon; Pinsk, Vered; Ballauf, Antje; Haerynck, Filomeen; Bordon, Victoria; Dhooge, Catharina; Garcia-Lloret, Maria Laura; Bredius, Robbert G.; Kalwak, Krzysztof; Haddad, Elie; Seidel, Markus Gerhard; Duckers, Gregor; Pai, Sung-Yun; Dvorak, Christopher C.; Ehl, Stephan; Locatelli, Franco; Goldman, Frederick; Gennery, Andrew Richard; Cowan, Mort J.; Roncarolo, Maria-Grazia; Bacchetta, Rosa		PIDTC; IEWP; European Soc Blood Marrow	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IPEX; primary immune deficiency; FOXP3; Treg cells; hematopoietic stem cell transplantation; immunosuppression; rapamycin; enteropathy; neonatal diabetes; genetic autoimmunity	X-LINKED SYNDROME; STEM-CELL TRANSPLANTATION; REGULATORY T-CELLS; IMMUNE DYSREGULATION; POLYENDOCRINOPATHY; ENTEROPATHY; IMMUNODYSREGULATION; ENGRAFTMENT; MUTATIONS; SIROLIMUS	Background: Immunodysregulation polyendocrinopathy enteropathy x-linked(IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (IS), have not been thoroughly examined. Objective: This analysis sought to evaluate disease onset, progression, and long-term outcome of the 2 main treatments in long-term IPEX survivors. Methods: Clinical histories of 96 patients with a genetically proven IPEX syndrome were collected from 38 institutions worldwide and retrospectively analyzed. To investigate possible factors suitable to predict the outcome, an organ involvement (OI) scoring system was developed. Results: We confirm neonatal onset with enteropathy, type 1 diabetes, and eczema. In addition, we found less common manifestations in delayed onset patients or during disease evolution. There is no correlation between the site of mutation and the disease course or outcome, and the same genotype can present with variable phenotypes. HSCT patients (n = 58) had a median follow-up of 2.7 years (range, 1 week-15 years). Patients receiving chronic IS (n 5 34) had a median follow-up of 4 years (range, 2 months-25 years). The overall survival after HSCT was 73.2% (95% CI, 59.4-83.0) and after IS was 65.1% (95% CI, 62.8-95.8). The pretreatment OI score was the only significant predictor of overall survival after transplant (P = .035) but not under IS. Conclusions: Patients receiving chronic IS were hampered by disease recurrence or complications, impacting long-term.disease-free survival. When performed in patients with a low OI score, HSCT resulted in disease resolution with better quality of life, independent of age, donor source, or conditioning regimen.	[Barzaghi, Federica; Aiuti, Alessandro] Ist Ricovero & Cura Carattere Sci San Raffaele Sc, Pediat Immunohematol & Bone Marrow Transplant Uni, San Raffaele Telethon Inst Gene Therapy, Milan, Italy; [Hernandez, Laura Cristina Amaya; Roncarolo, Maria-Grazia; Bacchetta, Rosa] Stanford Univ, Sch Med, Dept Pediat, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA 94305 USA; [Neven, Benedicte; Moshous, Despina; Blanche, Stephane; Fisher, Alain] Paris Descartes Univ, Necker Enfants Malades Univ Hosp, Sorbonne Paris Cite, Paediat Immunol Haematol & Rheumatol Dept, Paris, France; [Ruemmele, Frank M.; Tissandier, Come] Paris Descartes Univ, Necker Enfants Malades Univ Hosp, Sorbonne Paris Cite, Pediat Gastroenterol Unit, Paris, France; [Cavazzana, Marina] Paris Descartes Univ, Necker Enfants Malades Univ Hosp, Sorbonne Paris Cite, Biotherapy Dept, Paris, France; [Ouachee-Chardin, Marie] Robert Debre Hosp, AP HP, Hematol Unit, Paris, France; [Ricci, Silvia] Univ Florence, Dept NEUROFARBA, Anna Meyer Childrens Hosp, Sect Childs Hlth,Pediat Immunol, Florence, Italy; [Gambineri, Eleonora] Univ Florence, Dept NEUROFARBA, Anna Meyer Childrens Hosp,Sect Childs Hlth, Dept Hematol Oncol,Bone Marrow Transplant BMT Uni, Florence, Italy; [Lionetti, Paolo] Univ Florence, Dept NEUROFARBA, Anna Meyer Childrens Hosp,Sect Childs Hlth, Gastroenterol Unit,Sect Childs Hlth, Florence, Italy; [Kucuk, Zeynep Yesim; Bleesing, Jack J.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Nademi, Zohreh; Slatter, Mary Anne; Gennery, Andrew Richard] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Nademi, Zohreh; Slatter, Mary Anne; Gennery, Andrew Richard] Great North Childrens Hosp, Childrens Bone Marrow Transplant Unit, Newcastle Upon Tyne, Tyne & Wear, England; [Ulloa, Erlinda Rose; Pai, Sung-Yun] Boston Childrens Hosp, Pediat, Boston, MA USA; [Shcherbina, Anna; Roppelt, Anna] Res & Clin Ctr Pediat Hematol Oncol & Immunol, Dept Immunol, Moscow, Russia; [Worth, Austen] Great Ormond St Hosp Sick Children, Dept Immunol & Gene Therapy, London, England; [Silva, Juliana] Great Ormond St Hosp Sick Children, Dept Stem Cell Transplantat, London, England; [Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy; [Murguia-Favela, Luis] Hosp Sick Children, Dept Pediat, Div Clin Immunol & Allergy, Toronto, ON, Canada; [Speckmann, Carsten] Univ Freiburg, Fac Med, Dept Pediat & Adolescent Med, Freiburg, Germany; [Speckmann, Carsten; Ehl, Stephan] Univ Freiburg, Fac Med, Ctr Chron Immunodeficiency Med Ctr, Freiburg, Germany; [Carneiro-Sampaio, Magda] Univ Sao Paulo, Fac Med, Dept Pediat, Inst Crianca, Sao Paulo, Brazil; [Fernandes, Juliana Folloni] Univ Sao Paulo, Fac Med, Stem Cell Transplantat Unit, Inst Crianca, Sao Paulo, Brazil; Hosp Albert Einstein, Sao Paulo, Brazil; [Baris, Safa; Ozen, Ahmet; Karakoc-Aydiner, Elif; Kiykim, Ayca] Marmara Univ, Pediat Allergy & Immunol, Istanbul, Turkey; [Schulz, Ansgar; Steinmann, Sandra] Univ Med Ctr, Dept Pediat, Ulm, Germany; [Notarangelo, Lucia Dora] Spedali Civil Brescia, Childrens Hosp, Pediat Oncohematol & Bone Marrow Transplant BMT, Brescia, Italy; [Shearer, William Thomas; Forbes, Lisa R.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Immunol Allergy Rheumatol, Houston, TX 77030 USA; [Martinez, Caridad] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat Hematol & Oncol, Houston, TX 77030 USA; [Rieux-Laucat, Frederic] INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmune Dis, Paris, France; [Qasim, Waseem] UCL, Great Ormond St Inst Child Hlth, London, England; [Lucarelli, Barbarella; Locatelli, Franco] Univ Pavia, Ist Ricovero & Cura Carattere Sci, Bambino Gesu Childrens Hosp, Dept Pediat Hematol Oncol, Rome, Italy; [Albert, Michael H.] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Pediat Hematol Oncol, Munich, Germany; [Kobayashi, Ichiro] KKR Sapporo Med Ctr, Ctr Pediat Allergy & Rheumatol, Sapporo, Hokkaido, Japan; [Alonso, Laura; De Heredia, Cristina Diaz] Hosp Univ Vall DHebron, Paediat Haematol & Oncol, Barcelona, Spain; [Kanegane, Hirokazu] Tokyo Med & Dent Univ, Pediat & Dev Biol, Tokyo, Japan; [Lawitschka, Anita] Med Univ Vienna, St Anna Childrens Hosp, Vienna, Austria; [Seo, Jong Jin] Univ Ulsan, Coll Med, Pediat, Seoul, South Korea; [Seo, Jong Jin] Asan Med Ctr, Seoul, South Korea; [Gonzalez-Vicent, Marta; Diaz, Miguel Angel] Childrens Univ Hosp Nino Jesus, Dept Pediat, Hematopoiet Stem Cell Transplantat Unit, Madrid, Spain; [Goyal, Rakesh Kumar] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Dept Pediat,Div Blood & Marrow Transplantat & Cel, Pittsburgh, PA 15260 USA; [Sauer, Martin G.] Hannover Med Sch, Dept Pediat Hematol & Oncol, Hannover, Germany; [Yesilipek, Akif] Medicalpk Hosp Goztepe, Pediat Stem Cell Transplantat Unit, Antalya, Turkey; [Yesilipek, Akif] Antalya Hosp, Antalya, Turkey; [Kim, Minsoo; Yilmaz-Demirdag, Yesim] Columbia Med Ctr, Pediat Allergy Immunol & Rheumatol, New York, NY USA; [Bhatia, Monica] Columbia Med Ctr, Pediat Hematol Oncol & Stem Cell Transplantat, New York, NY USA; [Khlevner, Julie] Columbia Med Ctr, Pediat Gastroenterol Hepatol & Nutr, New York, NY USA; [Padilla, Erick J. Richmond] Natl Childrens Hosp, Pediat Endocrinol, San Jose, CA USA; [Martino, Silvana; Montin, Davide] Univ Turin, Regina Margherita Childrens Hosp, Dept Paediat Infect Dis, Div Rheumatol & Immunol, Turin, Italy; [Neth, Olaf] Univ Seville, CSIC, Mixed Unit Res,Dept Paediat Infect Dis Rheumatol, UMR,Hosp Univ Virgen del Rocio,Inst Biomed Sevill, Seville, Spain; [Molinos-Quintana, Agueda] Univ Seville, CSIC, Mixed Unit Res,Dept Pediat Hematol, UMR,Hosp Univ Virgen del Rocio,Inst Biomed Sevill, Seville, Spain; [Valverde-Fernandez, Justo] Univ Seville, CSIC, Mixed Unit Res,Dept Paediatirc Gastroenterol, UMR,Hosp Univ Virgen del Rocio,Inst Biomed Sevill, Seville, Spain; [Broides, Arnon] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Univ, Med Ctr,Pediat Immunol Clin, Beer Sheva, Israel; [Pinsk, Vered] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Univ, Pediat Ambulatory Care Unit,Med Ctr, Beer Sheva, Israel; [Ballauf, Antje; Duckers, Gregor] Helios Childrens Hosp, Dept Pediat, Krefeld, Germany; [Haerynck, Filomeen; Bordon, Victoria; Dhooge, Catharina] Ghent Univ Hosp, Ctr Primary Immunodeficiencies, Dept Pediat, Ghent, Belgium; [Garcia-Lloret, Maria Laura] Univ Calif Los Angeles, Sch Med, Div Pediat Allergy Immunol & Rheumatol, Los Angeles, CA 90024 USA; [Bredius, Robbert G.] Leiden Univ, Med Ctr, Pediat Immunol Infect & Stem Cell Transplantat SC, Leiden, Netherlands; [Kalwak, Krzysztof] Wroclaw Med Univ, Dept Pediat Hematol, Oncol & Bone Marrow Transplant BMT Unit, Wroclaw, Poland; [Haddad, Elie] Univ Montreal, St Justine Hosp, Dept Pediat, Montreal, PQ, Canada; [Seidel, Markus Gerhard] Med Univ Graz, Res Unit Pediat Hematol & Immunol, Div Pediat Hematol Oncol, Graz, Austria; [Pai, Sung-Yun] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA; [Dvorak, Christopher C.; Cowan, Mort J.] Univ Calif San Francisco, Pediat Allergy Immunol & Bone Marrow Transplant, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Goldman, Frederick] Univ Alabama Birmingham, Pediat, Birmingham, AL USA	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Stanford University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Cincinnati Children's Hospital Medical Center; Newcastle University - UK; Harvard University; Boston Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Vita-Salute San Raffaele University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Freiburg; University of Freiburg; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Hospital Israelita Albert Einstein; Marmara University; Ulm University; Hospital Spedali Civili Brescia; Baylor College of Medicine; Baylor College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; IRCCS Bambino Gesu; University of Pavia; University of Munich; Hospital Universitari Vall d'Hebron; Tokyo Medical & Dental University (TMDU); Medical University of Vienna; Saint Anna Children's Hospital; University of Ulsan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hannover Medical School; Columbia University; Columbia University; Columbia University; A.O.U. Citta della Salute e della Scienza di Torino; University of Turin; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ghent University; Ghent University Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Wroclaw Medical University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Medical University of Graz; Harvard University; Dana-Farber Cancer Institute; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham	Bacchetta, R (corresponding author), Stanford Univ, Div Stem Cell Transplantat & Regenerat Med, Dept Pediat, 265 Campus Dr,Lokey Stem Cell G3015, Stanford, CA 94305 USA.	roasb@stanford.edu	Ricci, Silvia/K-2737-2018; Diaz, Miguel/M-8029-2018; Bredius, Robbert/AAF-2592-2019; Bordon, Victoria/AAJ-7451-2020; Lucarelli, Barbarella/AAB-5245-2020; Haerynck, Filomeen/AAD-6761-2020; Lionetti, Paolo/AAC-2626-2019; Haddad, Elie/AAQ-4971-2020; Amaya, Laura/AAP-3040-2020; Baris, Safa/AAH-1932-2019; Sampaio, Magda/AAU-6748-2020; Silva, Clovis Artur Almeida/J-3640-2017; Pai, Sung-Yun/AAH-7762-2019; Gambineri, Eleonora/J-8747-2016; Rieux-Laucat, Frédéric/A-7916-2017; Ozen, Ahmet/R-6749-2017; Neth, Olaf/F-1167-2015; Moshous, Despina/B-7507-2017; ricci, silvia/AAA-5030-2019; Dvorak, Christopher C/AAX-1630-2020; KIYKIM, Ayca/J-6400-2017; Ehl, Stephan/AAM-6006-2020; perez, miguel/GXF-5077-2022; Diaz de Heredia, Cristina/G-4016-2016; AIUTI, Alessandro/K-3918-2016; Seidel, Markus G/N-9951-2017	Ricci, Silvia/0000-0001-7140-1694; Diaz, Miguel/0000-0001-5286-1329; Baris, Safa/0000-0002-4730-9422; Sampaio, Magda/0000-0002-1924-4043; Pai, Sung-Yun/0000-0002-0158-8147; Gambineri, Eleonora/0000-0002-4676-6541; Rieux-Laucat, Frédéric/0000-0001-7858-7866; Ozen, Ahmet/0000-0002-9065-1901; Neth, Olaf/0000-0001-5018-0466; Moshous, Despina/0000-0001-6719-3693; Dvorak, Christopher C/0000-0002-6146-3952; KIYKIM, Ayca/0000-0001-5821-3963; Diaz de Heredia, Cristina/0000-0001-8086-296X; Haddad, Elie/0000-0003-2446-6879; Amaya, Laura/0000-0002-8742-9111; Murguia-Favela, Luis/0000-0001-6893-3366; Montin, Davide/0000-0001-8953-2182; AIUTI, Alessandro/0000-0002-5398-1717; Haerynck, Filomeen/0000-0001-9161-7361; KALWAK, KRZYSZTOF/0000-0003-1174-5799; QASIM, WASEEM/0000-0001-8353-4494; GONZALEZ VICENT, MARTA/0000-0002-4845-5616; Bacchetta, Rosa/0000-0002-0606-6268; Seidel, Markus G/0000-0003-0981-8661; Bredius, Robbert/0000-0001-8151-1539	Telethon [Tele10-A4]; Jeffrey Modell Foundation Travel Award; Italian Network for Primary Immunodeficiencies (IPINET); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973, R13AI094943] Funding Source: NIH RePORTER; National Institute for Health Research [RP-2014-05-007] Funding Source: researchfish	Telethon(Fondazione Telethon); Jeffrey Modell Foundation Travel Award; Italian Network for Primary Immunodeficiencies (IPINET); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute for Health Research(National Institute for Health Research (NIHR))	This work has been supported by Telethon (Tele10-A4 to R.B.), the Jeffrey Modell Foundation Travel Award to F.B., and a generous gift to the Stanford Center for Genetic Immune Diseases.r We are grateful to Robertson Parkman, for his thoughtful comments and revisions. We thank Ken Weinberg for critical revision and Rajni Agarwal-Hashmi and Maria Ester Bernardo for helping with transplanted patients' stratification. We thank Alessandro Ambrosi for his contribution in the initial statistical analysis and the Italian Network for Primary Immunodeficiencies (IPINET) for support. We sincerely thank all the patients and families for their participation and trust.	Apperley J, 2012, EBMT HDB HAEMATOPOIE; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Bacchetta R, 2018, ANN NY ACAD SCI, V1417, P5, DOI 10.1111/nyas.13011; Barzaghi F, 2012, J AUTOIMMUN, V38, P49, DOI 10.1016/j.jaut.2011.12.009; Barzaghi F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00211; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bin Dhuban K, 2015, CURR OPIN ALLERGY CL, V15, P525, DOI 10.1097/ACI.0000000000000214; Bindl L, 2005, J PEDIATR-US, V147, P256, DOI 10.1016/j.jpeds.2005.04.017; Burroughs LM, 2010, J ALLERGY CLIN IMMUN, V126, P1000, DOI 10.1016/j.jaci.2010.05.021; d'Hennezel E, 2012, J MED GENET, V49, P291, DOI 10.1136/jmedgenet-2012-100759; De Benedetti F, 2006, CLIN GASTROENTEROL H, V4, P653, DOI 10.1016/j.cgh.2005.12.014; Gambineri Eleonora, 2008, J Allergy Clin Immunol, V122, P1105, DOI 10.1016/j.jaci.2008.09.027; Iizuka-Koga M, 2017, J AUTOIMMUN, V83, P113, DOI 10.1016/j.jaut.2017.07.002; Kasow KA, 2011, CLIN IMMUNOL, V141, P169, DOI 10.1016/j.clim.2011.07.005; Kinnunen T, 2013, BLOOD, V121, P1595, DOI 10.1182/blood-2012-09-457465; Kucuk ZY, 2016, J ALLERGY CLIN IMMUN, V137, P953, DOI 10.1016/j.jaci.2015.09.030; Lucas KG, 2007, BONE MARROW TRANSPL, V39, P55, DOI 10.1038/sj.bmt.1705542; Mazzolari E, 2005, BONE MARROW TRANSPL, V35, P1033, DOI 10.1038/sj.bmt.1704954; Nademi Z, 2014, BONE MARROW TRANSPL, V49, P310, DOI 10.1038/bmt.2013.181; Passerini L, 2011, J ALLERGY CLIN IMMUN, V128, P1376, DOI 10.1016/j.jaci.2011.09.010; POWELL BR, 1982, J PEDIATR-US, V100, P731, DOI 10.1016/S0022-3476(82)80573-8; Rao A, 2007, BLOOD, V109, P383, DOI 10.1182/blood-2006-05-025072; Seidel MG, 2016, J CLIN IMMUNOL, V36, P6, DOI 10.1007/s10875-015-0218-5; Seidel MG, 2009, BLOOD, V113, P5689, DOI 10.1182/blood-2009-02-206359; Sheikine Y, 2015, PEDIATR NEPHROL, V30, P1197, DOI 10.1007/s00467-015-3102-x; Shin CR, 2012, BONE MARROW TRANSPL, V47, P1428, DOI 10.1038/bmt.2012.31; Slatter MA, 2015, BONE MARROW TRANSPL, V50, P1536, DOI 10.1038/bmt.2015.171; Taddio A, 2007, EUR J PEDIATR, V166, P1195, DOI 10.1007/s00431-006-0395-6; Veys P, 2011, PEDIATRIC REP, V3, P28, DOI 10.4081/pr.2011.s2.e11; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Yong PL, 2008, J CLIN IMMUNOL, V28, P581, DOI 10.1007/s10875-008-9196-1; Zama D, 2014, ITAL J PEDIATR, V40, DOI 10.1186/s13052-014-0068-4	34	137	145	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1036	+		10.1016/j.jaci.2017.10.041	http://dx.doi.org/10.1016/j.jaci.2017.10.041			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29241729	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000426974800024
J	Kim, RY; Horvat, JC; Pinkerton, JW; Starkey, MR; Essilfie, AT; Mayall, JR; Nair, PM; Hansbro, NG; Jones, B; Haw, TJ; Sunkara, KP; Nguyen, TH; Jarnicki, AG; Keely, S; Mattes, J; Adcock, IM; Foster, PS; Hansbro, PM				Kim, Richard Y.; Horvat, Jay C.; Pinkerton, James W.; Starkey, Malcolm R.; Essilfie, Ama T.; Mayall, Jemma R.; Nair, Prema M.; Hansbro, Nicole G.; Jones, Bernadette; Haw, Tatt Jhong; Sunkara, Krishna P.; Thi Hiep Nguyen; Jarnicki, Andrew G.; Keely, Simon; Mattes, Joerg; Adcock, Ian M.; Foster, Paul S.; Hansbro, Philip M.			MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; corticosteroids; airway hyperresponsiveness; miR-21; PI3 kinase; histone deacetylase 2; Chlamydia; species; Haemophilus influenzae; influenza; respiratory syncytial virus	OBSTRUCTIVE PULMONARY-DISEASE; ALLERGIC AIRWAYS DISEASE; REGULATORY T-CELLS; INFLUENZA-VIRUS INFECTION; RESPIRATORY-INFECTION; INFLAMMATORY RESPONSES; BACTERIAL-INFECTION; NEUTROPHILIC ASTHMA; IMMUNE-RESPONSE; TENSIN HOMOLOG	[GRAPHICS] Background: Severe steroid-insensitive asthma is a substantial clinical problem. Effective treatments are urgently required, however, their development is hampered by a lack of understanding of the mechanisms of disease pathogenesis. Steroid-insensitive asthma is associated with respiratory tract infections and noneosinophilic endotypes, including neutrophilic forms of disease. However, steroid-insensitive patients with eosinophil-enriched inflammation have also been described. The mechanisms that underpin infection-induced, severe steroid-insensitive asthma can be elucidated by using mouse models of disease. Objective: We sought to develop representative mouse models of severe, steroid-insensitive asthma and to use them to identify pathogenic mechanisms and investigate new treatment approaches. Methods: Novel mouse models of Chlamydia, Haemophilus influenzae, influenza, and respiratory syncytial virus respiratory tract infections and ovalbumin-induced, severe,steroid-insensitive allergic airway disease (SSIAAD) in BALB/c mice were developed and interrogated. Results: Infection induced increases in the levels of microRNA (miRNA)-21 (miR-21) expression in the lung during SSIAAD, whereas expression of the miR-21 target phosphatase and tensin homolog was reduced. This was associated with an increase in levels of phosphorylated Akt, an indicator of phosphoinositide 3-kinase (PI3K) activity, and decreased nuclear histone deacetylase (HDAC) 2 levels. Treatment with an miR-21-specific antagomir (Ant-21) increased phosphatase and tensin homolog levels. Treatment with Ant-21, or the pan-PI3K inhibitor LY294002, reduced PI3K activity and restored HDAC2 levels. This led to suppression of airway hyperresponsiveness and restored steroid sensitivity to allergic airway disease. These observations were replicated with SSIAAD associated with 4 different pathogens. Conclusion: We identify a previously unrecognized role for an miR-21/PI3K/HDAC2 axis in SSIAAD. Our data highlight miR-21 as a novel therapeutic target for the treatment of this form of asthma.	[Kim, Richard Y.; Horvat, Jay C.; Pinkerton, James W.; Starkey, Malcolm R.; Essilfie, Ama T.; Mayall, Jemma R.; Nair, Prema M.; Hansbro, Nicole G.; Jones, Bernadette; Haw, Tatt Jhong; Sunkara, Krishna P.; Thi Hiep Nguyen; Jarnicki, Andrew G.; Keely, Simon; Mattes, Joerg; Foster, Paul S.; Hansbro, Philip M.] Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, Newcastle, England; [Kim, Richard Y.; Horvat, Jay C.; Pinkerton, James W.; Starkey, Malcolm R.; Essilfie, Ama T.; Mayall, Jemma R.; Nair, Prema M.; Hansbro, Nicole G.; Jones, Bernadette; Haw, Tatt Jhong; Sunkara, Krishna P.; Thi Hiep Nguyen; Jarnicki, Andrew G.; Keely, Simon; Mattes, Joerg; Foster, Paul S.; Hansbro, Philip M.] Univ Newcastle, Callaghan, NSW, Australia; [Adcock, Ian M.] Imperial Coll London, Natl Heart & Lung Inst, Airways Dis Sect, London, England	University of Newcastle; Imperial College London	Hansbro, PM (corresponding author), Univ Newcastle, Prior Res Ctr Hlth Lungs, Callaghan, NSW 2308, Australia.; Hansbro, PM (corresponding author), Univ Newcastle, Hunter Med Res Inst, Callaghan, NSW 2308, Australia.	Philip.Hansbro@newcastle.edu.au	Keely, Simon/AAV-9973-2020; Hansbro, Phil/G-7486-2013; Essilfie, Ama/GLS-9794-2022; Foster, Paul/G-5057-2013; MATTES, JOERG/M-5179-2019; Adcock, Ian/L-3217-2019	Keely, Simon/0000-0002-1248-9590; Hansbro, Phil/0000-0002-4741-3035; Jones-Freeman, Bernadette/0000-0003-4613-7865; , Paul/0000-0002-0827-8299; /0000-0003-2315-7089; Adcock, Ian/0000-0003-2101-8843; Horvat, Jay/0000-0002-8526-0631; Essilfie, Ama-Tawiah/0000-0003-0443-9005; Sunkara, Krishna/0000-0003-3412-0708; Starkey, Malcolm/0000-0002-7359-7464; Mayall, Jemma/0000-0002-0915-5020; Kim, Richard/0000-0002-8709-5270	National Health and Medical Research Council of Australia; University of Newcastle; Asthma Foundation New South Wales; Rebecca Cooper Medical Research Foundation; Medical Research Council [G1001367, G1000758] Funding Source: researchfish; MRC [G1001367] Funding Source: UKRI	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Newcastle; Asthma Foundation New South Wales; Rebecca Cooper Medical Research Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by grants and fellowships from the National Health and Medical Research Council of Australia, the University of Newcastle, the Asthma Foundation New South Wales, and the Rebecca Cooper Medical Research Foundation.	Adcock IM, 2008, CURR ALLERGY ASTHM R, V8, P171, DOI 10.1007/s11882-008-0028-4; Adcock IM, 2004, CURR OPIN PHARMACOL, V4, P257, DOI 10.1016/j.coph.2004.02.001; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; Al-Garawi AA, 2009, J IMMUNOL, V182, P3095, DOI 10.4049/jimmunol.0802837; Asquith KL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001339; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Barends M, 2002, CLIN EXP ALLERGY, V32, P463, DOI 10.1046/j.1365-2222.2002.01317.x; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Beckett EL, 2013, J ALLERGY CLIN IMMUN, V131, P752, DOI 10.1016/j.jaci.2012.11.053; Beckett EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039460; Cantrell DA, 2001, J CELL SCI, V114, P1439; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Cho YS, 2005, CLIN EXP ALLERGY, V35, P1625, DOI 10.1111/j.1365-2222.2005.02391.x; Coombes BK, 2002, CELL MICROBIOL, V4, P447, DOI 10.1046/j.1462-5822.2002.00203.x; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; Ehrhardt C, 2006, CELL MICROBIOL, V8, P1336, DOI 10.1111/j.1462-5822.2006.00713.x; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Essilfie AT, 2015, THORAX, V70, P458, DOI 10.1136/thoraxjnl-2014-206067; Essilfie AT, 2012, THORAX, V67, P588, DOI 10.1136/thoraxjnl-2011-200160; Essilfie AT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002244; Foster PS, 2013, IMMUNOL REV, V253, P198, DOI 10.1111/imr.12058; Fung KY, 2013, SCIENCE, V339, P1088, DOI 10.1126/science.1233321; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Hallstrand TS, 2014, CLIN IMMUNOL, V151, P1, DOI 10.1016/j.clim.2013.12.003; Hansbro NG, 2008, PHARMACOL THERAPEUT, V117, P313, DOI 10.1016/j.pharmthera.2007.11.002; Hansbro PM, 2014, J BIOL CHEM, V289, P18214, DOI 10.1074/jbc.M114.548594; Hansbro PM, 2011, BRIT J PHARMACOL, V163, P81, DOI 10.1111/j.1476-5381.2011.01219.x; Hansbro PM, 2004, PHARMACOL THERAPEUT, V101, P193, DOI 10.1016/j.pharmthera.2003.10.007; Haylock-Jacobs S, 2011, J AUTOIMMUN, V36, P278, DOI 10.1016/j.jaut.2011.02.006; Horvat JC, 2007, AM J RESP CRIT CARE, V176, P556, DOI 10.1164/rccm.200607-1005OC; Horvat JC, 2010, J IMMUNOL, V184, P4159, DOI 10.4049/jimmunol.0902287; Horvat JC, 2010, J ALLERGY CLIN IMMUN, V125, P617, DOI 10.1016/j.jaci.2009.10.018; Horvat JC, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Hsu ACY, 2015, AM J RESP CRIT CARE, V191, P1012, DOI 10.1164/rccm.201501-0188OC; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2001, FASEB J, V15, pA473; Ito K, 2006, THESCIENTIFICWORLDJO, V6, P1750, DOI 10.1100/tsw.2006.274; Jayaram L, 2005, EUR RESPIR J, V25, P41, DOI 10.1183/09031936.04.00008104; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Li JJ, 2010, J IMMUNOL, V185, P4401, DOI 10.4049/jimmunol.1001039; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Lu TX, 2013, J ALLERGY CLIN IMMUN, V132, P3, DOI 10.1016/j.jaci.2013.04.039; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Marti-Lliteras P, 2009, INFECT IMMUN, V77, P4232, DOI 10.1128/IAI.00305-09; Marwick John A, 2010, Ther Adv Respir Dis, V4, P19, DOI 10.1177/1753465809352792; Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Newcomb DC, 2008, AM J RESP CRIT CARE, V177, P1111, DOI 10.1164/rccm.200708-1243OC; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Patel KK, 2010, PEDIATR INFECT DIS J, V29, P1093, DOI 10.1097/INF.0b013e3181eaebdc; Petersen BC, 2014, J LEUKOCYTE BIOL, V95, P809, DOI 10.1189/jlb.0913482; Plank M, 2013, CLIN EXP ALLERGY, V43, P981, DOI [10.1111/cea.12135, 10.1111/cea.12170]; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Roy S, 2009, CARDIOVASC RES, V82, P21, DOI 10.1093/cvr/cvp015; Sawant DV, 2013, MOL IMMUNOL, V54, P435, DOI 10.1016/j.molimm.2013.01.006; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; Starkey MR, 2014, MUCOSAL IMMUNOL, V7, P478, DOI 10.1038/mi.2013.65; Starkey MR, 2013, MUCOSAL IMMUNOL, V6, P569, DOI 10.1038/mi.2012.99; Starkey MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042588; Starkey MR, 2013, CURR OPIN PHARMACOL, V13, P337, DOI 10.1016/j.coph.2013.03.005; Tay HL, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004549; Thorburn AN, 2013, J IMMUNOL, V191, P4112, DOI 10.4049/jimmunol.1201232; Thorburn AN, 2012, J IMMUNOL, V188, P4611, DOI 10.4049/jimmunol.1101299; Thorburn AN, 2010, AM J RESP CELL MOL, V43, P511, DOI 10.1165/rcmb.2009-0342TR; To Y, 2010, AM J RESP CRIT CARE, V182, P897, DOI 10.1164/rccm.200906-0937OC; Trevor JL, 2014, ALLERGY, V69, P817, DOI 10.1111/all.12412; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Wang W, 2010, CURR DRUG TARGETS, V11, P957, DOI 10.2174/138945010791591412; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wark PAB, 2002, EUR RESPIR J, V20, P834, DOI 10.1183/09031936.02.00192002; White ES, 2006, AM J RESP CRIT CARE, V173, P112, DOI 10.1164/rccm.200507-1058OC; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Wood LG, 2010, FREE RADICAL RES, V44, P146, DOI 10.3109/10715760903362576; Yang M, 2012, J LEUKOCYTE BIOL, V91, P557, DOI 10.1189/jlb.0711357	81	137	142	2	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					519	532		10.1016/j.jaci.2016.04.038	http://dx.doi.org/10.1016/j.jaci.2016.04.038			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27448447	Bronze, Green Submitted			2022-12-18	WOS:000397002400018
J	Elkaim, E; Neven, B; Bruneau, J; Mitsui-Sekinaka, K; Stanislas, A; Heurtier, L; Lucas, CL; Matthews, H; Deau, MC; Sharapova, S; Curtis, J; Reichenbach, J; Glastre, C; Parry, DA; Arumugakani, G; McDermott, E; Kilic, SS; Yamashita, M; Moshous, D; Lamrini, H; Otremba, B; Gennery, A; Coulter, T; Quinti, I; Stephan, JL; Lougaris, V; Brodszki, N; Barlogis, V; Asano, T; Galicier, L; Boutboul, D; Nonoyama, S; Cant, A; Imai, K; Picard, C; Nejentsev, S; Molina, TJ; Lenardo, M; Savic, S; Cavazzana, M; Fischer, A; Durandy, A; Kracker, S				Elkaim, Elodie; Neven, Benedicte; Bruneau, Julie; Mitsui-Sekinaka, Kanako; Stanislas, Aurelie; Heurtier, Lucie; Lucas, Carrie L.; Matthews, Helen; Deau, Marie-Celine; Sharapova, Svetlana; Curtis, James; Reichenbach, Janine; Glastre, Catherine; Parry, David A.; Arumugakani, Gururaj; McDermott, Elizabeth; Kilic, Sara Sebnem; Yamashita, Motoi; Moshous, Despina; Lamrini, Hicham; Otremba, Burkhard; Gennery, Andrew; Coulter, Tanya; Quinti, Isabella; Stephan, Jean-Louis; Lougaris, Vassilios; Brodszki, Nicholas; Barlogis, Vincent; Asano, Takaki; Galicier, Lionel; Boutboul, David; Nonoyama, Shigeaki; Cant, Andrew; Imai, Kohsuke; Picard, Capucine; Nejentsev, Sergey; Molina, Thierry Jo; Lenardo, Michael; Savic, Sinisa; Cavazzana, Marina; Fischer, Alain; Durandy, Anne; Kracker, Sven			Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: A cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; phosphoinositide 3-kinase; p85 alpha; p110 delta; activated phosphoinositide 3-kinase delta syndrome; p110 delta-activating mutations causing senescent T cells; lymphadenopathy; and immunodeficiency; hyper-IgM; adenopathy; immunodeficiency; antibody deficiency	HUMAN IMMUNODEFICIENCY; MUTATIONS; KINASE; CELLS	Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) 2 (p110 delta-activating mutations causing senescent T cells, lymphadenopathy, and immunodeficiency [PASLI]-R1), a recently described primary immunodeficiency, results from autosomal dominant mutations in PIK3R1, the gene encoding the regulatory subunit (p85 alpha, p55 alpha, and p50 alpha) of class IA phosphoinositide 3-kinases. Objectives: We sought to review the clinical, immunologic, and histopathologic phenotypes of APDS2 in a genetically defined international patient cohort. Methods: The medical and biological records of 36 patients with genetically diagnosed APDS2 were collected and reviewed. Results: Mutations within splice acceptor and donor sites of exon 11 of the PIK3R1 gene lead to APDS2. Recurrent upper respiratory tract infections (100%), pneumonitis (71%), and chronic lymphoproliferation (89%, including adenopathy [75%], splenomegaly [43%], and upper respiratory tract lymphoid hyperplasia [48%]) were the most common features. Growth retardation was frequently noticed (45%). Other complications were mild neurodevelopmental delay (31%); malignant diseases (28%), most of them being B-cell lymphomas; autoimmunity (17%); bronchiectasis (18%); and chronic diarrhea (24%). Decreased serum IgA and IgG levels (87%), increased IgM levels (58%), B-cell lymphopenia (88%) associated with an increased frequency of transitional B cells (93%), and decreased numbers of naive CD4 and naive CD8 cells but increased numbers of CD8 effector/memory T cells were predominant immunologic features. The majority of patients (89%) received immunoglobulin replacement; 3 patients were treated with rituximab, and 6 were treated with rapamycin initiated after diagnosis of APDS2. Five patients died from APDS2-related complications. Conclusion: APDS2 is a combined immunodeficiency with a variable clinical phenotype. Complications are frequent, such as severe bacterial and viral infections, lymphoproliferation, and lymphoma similar to APDS1/PASLI-CD. Immunoglobulin replacement therapy, rapamycin, and, likely in the near future, selective phosphoinositide 3-kinase delta inhibitors are possible treatment options.	[Elkaim, Elodie; Neven, Benedicte; Moshous, Despina] Necker Childrens Hosp, AP HP, Dept Pediat Immunol Hematol & Rheumatol, Paris, France; [Elkaim, Elodie; Neven, Benedicte; Heurtier, Lucie; Deau, Marie-Celine; Moshous, Despina; Lamrini, Hicham; Picard, Capucine; Cavazzana, Marina; Fischer, Alain; Durandy, Anne; Kracker, Sven] INSERM UMR1163, Paris, France; [Bruneau, Julie; Mitsui-Sekinaka, Kanako; Heurtier, Lucie; Deau, Marie-Celine; Moshous, Despina; Lamrini, Hicham; Picard, Capucine; Molina, Thierry Jo] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Bruneau, Julie; Molina, Thierry Jo] Hop Necker Enfants Malad, AP HP, Dept Pathol, Paris, France; [Mitsui-Sekinaka, Kanako; Imai, Kohsuke] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Stanislas, Aurelie; Cavazzana, Marina] Necker Childrens Hosp, AP HP, Ctr Invest Clin Integre Biotherapies, Dept Biotherapie, Paris, France; [Lucas, Carrie L.; Matthews, Helen; Lenardo, Michael] NIAID, Lab Immunol Mol Dev, Immune Syst Sect, NIAID Clin Genom Program,NIH, Bethesda, MD USA; [Sharapova, Svetlana] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Minsk, BELARUS; [Curtis, James; Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge, England; [Reichenbach, Janine] Univ Zurich, Univ Childrens Hosp Zurich, Competence Ctr Appl Biotechnol & Mol Med, Div Immunol,Childrens Res Ctr, Zurich, Switzerland; [Reichenbach, Janine] Univ Zurich, Swiss Ctr Regenerat Med, Zurich, Switzerland; [Glastre, Catherine] Ctr Hosp Annecy Genevois, Serv Pediat, Metz Tessy, France; [Parry, David A.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Ctr Genom & Expt Med, Edinburgh, Midlothian, Scotland; [Arumugakani, Gururaj] St James Univ Hosp, Dept Clin Immunol & Allergy, Leeds, W Yorkshire, England; [McDermott, Elizabeth] Nottingham Univ Hosp, Nottingham, England; [Kilic, Sara Sebnem] Uludag Univ, Fac Med, Pediat Immunol Div, Bursa, Turkey; [Yamashita, Motoi; Imai, Kohsuke] Tokyo Med & Dent Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Yamashita, Motoi] Tokyo Med & Dent Univ, Sch Med, Dept Dev Biol, Tokyo, Japan; [Otremba, Burkhard] Oncol Practice Oldenburg Delmenhorst, Oldenburg, Germany; [Gennery, Andrew] Great North Childrens Hosp, Inst Cellular Med, Paediat Immunol Dept, Newcastle Upon Tyne, Tyne & Wear, England; [Coulter, Tanya] St James Hosp, Trinity Coll Dublin, Sch Med, Dept Immunol, Dublin, Ireland; [Coulter, Tanya] Our Ladys Childrens Hosp Crumlin, Dept Pediat Immunol & Infect Dis, Dublin, Ireland; [Quinti, Isabella] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Stephan, Jean-Louis] Hop Nord St Etienne, Dept Pediat, St Etienne, France; [Lougaris, Vassilios] Univ Brescia, Spedali Civili Brescia, Pediat Clin & Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, Brescia, Italy; [Brodszki, Nicholas] Skane Univ Hosp, Childrens Hosp, Lund, Sweden; [Barlogis, Vincent] Serv Hematol Pediat, Marseille, France; [Asano, Takaki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan; [Galicier, Lionel; Boutboul, David] Univ Paris Diderot, Hop St Louis, AP HP, Dept Clin Immunol, Paris, France; [Picard, Capucine] Hop Necker Enfants Malad, Hop Paris, AP HP, Ctr Primary Immunodeficiencies, Paris, France; [Savic, Sinisa] St James Univ Hosp, NIHR LMBRU, Leeds, W Yorkshire, England; [Savic, Sinisa] St James Univ Hosp, LIRMM, Leeds, W Yorkshire, England; [Fischer, Alain] Coll France, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; National Defense Medical College - Japan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Cambridge; University Children's Hospital Zurich; University of Zurich; University of Zurich; Centre Hospitalier Annecy Genevois; University of Edinburgh; Saint James's University Hospital; Nottingham University Hospital NHS Trust; University of Nottingham; Uludag University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Newcastle University - UK; Trinity College Dublin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Sapienza University Rome; CHU de St Etienne; Hospital Spedali Civili Brescia; University of Brescia; Lund University; Skane University Hospital; Hiroshima University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Saint James's University Hospital; Saint James's University Hospital; UDICE-French Research Universities; PSL Research University Paris; College de France	Kracker, S (corresponding author), Imagine Inst, INSERM U1163, 24 Blvd Montparnasse, F-75015 Paris, France.	sven.kracker@inserm.fr	Kilic, Sara Sebnem/AAH-1658-2021; Imai, Kohsuke/Q-2602-2015; Reichenbach, Janine/U-2171-2018; Kracker, Sven/H-3681-2017; Savic, Sinisa/Q-6217-2019; Moshous, Despina/B-7507-2017; Sharapova, Svetlana/ABF-3330-2020; Durandy, Anne/H-7475-2017; Heurtier, Lucie/H-2889-2017; lamrini, hicham/H-7004-2017; Molina, Thierry/ABA-5214-2020; Asano, Takaki/AAC-7757-2022; Yamashita, Motoi/ABB-5789-2021	Imai, Kohsuke/0000-0003-2132-8403; Reichenbach, Janine/0000-0002-9008-1312; Kracker, Sven/0000-0003-4543-8236; Savic, Sinisa/0000-0001-7910-0554; Moshous, Despina/0000-0001-6719-3693; Durandy, Anne/0000-0001-7706-8466; Heurtier, Lucie/0000-0002-2284-6774; lamrini, hicham/0000-0002-3193-0273; Molina, Thierry/0000-0002-3929-9754; Asano, Takaki/0000-0003-1424-2433; Cavazzana, Marina/0000-0002-0264-0891; Arumugakani, Gururaj/0000-0002-3561-2424; DEAU, Marie-Celine/0000-0003-3954-0584; kilic, sara sebnem/0000-0001-8571-2581; BOUTBOUL, David/0000-0002-5006-8279; Parry, David/0000-0003-0376-7736; Lucas, Carrie/0000-0002-5754-0820; Bruneau, Julie/0000-0001-5519-8489	European Union's 7th RTD Framework Programme (ERC advanced grant PID-IMMUNE) [249816]; French Agence Nationale de la Recherche, "Investments for the Future'' program [ANR-10-IAHU-01]; Institut National de la Sante et de la Recherche Medicale; Fondation pour la Recherche Medicale [ING20130526624]; la Ligue Contre le Cancer (Comite de Paris); Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH); Agence Nationale de la Recherche [ANR-15-CE15-0020]; Gebert Ruf Stiftung program "Rare Diseases-New Approaches'' [GRS-046/10]; EU-FP7 [CELL-PID HEALTH-261387]; Zurich Centre for Integrative Human Physiology (ZIHP); Gottfried und Julia Bangerter-Rhyner-Stiftung; Rossi Stiftung; European Research Council [260477]; EU FP7 [261441]; National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre; MEXT/JSPS; Ministry of Health Labor and Welfare; Ministry of Defense; Japan Agency for Medical Research and Development, AMED; National Institute for Health Research-Leeds Musculoskeletal Biomedical Research Unit (and Leeds Teaching Hospitals Charitable Foundation); National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland; Intramural Research Program of the National Institutes of Health/National Institute of Allergy and Infectious Diseases; Postdoctoral Research Associate (PRAT) Fellowship, National Institute of General Medical Sciences(NIGMS)/NIH; EU-FP7 NET4CGD; MRC [MR/M012328/2, MR/M012328/1] Funding Source: UKRI; Medical Research Council [MR/M012328/1, MR/M012328/2] Funding Source: researchfish	European Union's 7th RTD Framework Programme (ERC advanced grant PID-IMMUNE); French Agence Nationale de la Recherche, "Investments for the Future'' program(French National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); la Ligue Contre le Cancer (Comite de Paris); Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH); Agence Nationale de la Recherche(French National Research Agency (ANR)); Gebert Ruf Stiftung program "Rare Diseases-New Approaches''; EU-FP7(European Commission); Zurich Centre for Integrative Human Physiology (ZIHP); Gottfried und Julia Bangerter-Rhyner-Stiftung; Rossi Stiftung; European Research Council(European Research Council (ERC)European Commission); EU FP7(European Commission); National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); MEXT/JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Defense; Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); National Institute for Health Research-Leeds Musculoskeletal Biomedical Research Unit (and Leeds Teaching Hospitals Charitable Foundation); National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland; Intramural Research Program of the National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Postdoctoral Research Associate (PRAT) Fellowship, National Institute of General Medical Sciences(NIGMS)/NIH; EU-FP7 NET4CGD; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	A.F., A.D., and S.K. are supported by the European Union's 7th RTD Framework Programme (ERC advanced grant PID-IMMUNE contract 249816). A.F., A.D., M.C., and S.K. are supported by a government grant managed by the French Agence Nationale de la Recherche as part of the "Investments for the Future'' program (ANR-10-IAHU-01). S.K. is a researcher at the Centre National de la Recherche Scientifique-CNRS (France). A.F., A.D., M.C., and S.K. are supported by the Institut National de la Sante et de la Recherche Medicale. S.K. is also supported by the Fondation pour la Recherche Medicale (grant no. ING20130526624), la Ligue Contre le Cancer (Comite de Paris), the Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH), and the Agence Nationale de la Recherche (ANR-15-CE15-0020 [ANR-PIKimun]). J.R. is supported by the Gebert Ruf Stiftung program "Rare Diseases-New Approaches'' (grant no. GRS-046/10), EU-FP7 CELL-PID HEALTH-2010-261387 and EU-FP7 NET4CGD, as well as the Zurich Centre for Integrative Human Physiology (ZIHP), the Gottfried und Julia Bangerter-Rhyner-Stiftung, and the Rossi Stiftung. S. Nejentsev is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science (095198/Z/10/Z) and is also supported by the European Research Council Starting grant 260477, the EU FP7 collaborative grant 261441 (PEVNET project), and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. S. Nonoyama is partially supported by grants from MEXT/JSPS, Ministry of Health Labor and Welfare, Ministry of Defense, and the Practical Research for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development, AMED. S.S. is supported by grants from National Institute for Health Research-Leeds Musculoskeletal Biomedical Research Unit (and Leeds Teaching Hospitals Charitable Foundation). T.C. is supported by National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland. M.L., C.L.L., and H.M. are supported by the Intramural Research Program of the National Institutes of Health/National Institute of Allergy and Infectious Diseases. C.L.L. was also supported by the Postdoctoral Research Associate (PRAT) Fellowship, National Institute of General Medical Sciences(NIGMS)/NIH.	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Augustine JJ, 2007, DRUGS, V67, P369, DOI 10.2165/00003495-200767030-00004; Chudasama KK, 2013, AM J HUM GENET, V93, P150, DOI 10.1016/j.ajhg.2013.05.023; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Dyment DA, 2013, AM J HUM GENET, V93, P158, DOI 10.1016/j.ajhg.2013.06.005; Gaulard P, 2011, SEMIN DIAGN PATHOL, V28, P202, DOI 10.1053/j.semdp.2011.03.003; Kracker S, 2014, J ALLERGY CLIN IMMUN, V134, P233, DOI 10.1016/j.jaci.2014.02.020; Kuhlen M, 2016, CLIN IMMUNOL, V162, P27, DOI 10.1016/j.clim.2015.10.008; Lougaris V, 2015, CLIN IMMUNOL, V159, P33, DOI 10.1016/j.clim.2015.04.014; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Okkenhaug K, 2013, ANNU REV IMMUNOL, V31, P675, DOI 10.1146/annurev-immunol-032712-095946; Omori SA, 2006, IMMUNITY, V25, P545, DOI 10.1016/j.immuni.2006.08.015; Sander S, 2015, IMMUNITY, V43, P1075, DOI 10.1016/j.immuni.2015.10.021; Thauvin-Robinet C, 2013, AM J HUM GENET, V93, P141, DOI 10.1016/j.ajhg.2013.05.019; Urick ME, 2011, CANCER RES, V71, P4061, DOI 10.1158/0008-5472.CAN-11-0549	18	137	142	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					210	+		10.1016/j.jaci.2016.03.022	http://dx.doi.org/10.1016/j.jaci.2016.03.022			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27221134	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000379659100023
J	Hinks, TSC; Zhou, XY; Staples, KJ; Dimitrov, BD; Manta, A; Petrossian, T; Lum, PY; Smith, CG; Ward, JA; Howarth, PH; Walls, AF; Gadola, SD; Djukanovic, R				Hinks, Timothy S. C.; Zhou, Xiaoying; Staples, Karl J.; Dimitrov, Borislav D.; Manta, Alexander; Petrossian, Tanya; Lum, Pek Y.; Smith, Caroline G.; Ward, Jon A.; Howarth, Peter H.; Walls, Andrew F.; Gadola, Stephan D.; Djukanovic, Ratko			Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; T lymphocytes; cytokines; mast cells; phenotype; endotype; regulatory T; T(H)17; T(H)2; mucosal-associated invariant T-cell	AIRWAY INFLAMMATION; MAST-CELLS; MONOCLONAL-ANTIBODY; CLUSTER-ANALYSIS; IDENTIFICATION; EOSINOPHILS; HYPERRESPONSIVENESS; EXACERBATIONS; ACTIVATION; OMALIZUMAB	Background: Asthma is a chronic inflammatory disease involving diverse cells and mediators whose interconnectivity and relationships to asthma severity are unclear. Objective: We performed a comprehensive assessment of T(H)17 cells, regulatory T cells, mucosal-associated invariant T (MAIT) cells, other T-cell subsets, and granulocyte mediators in asthmatic patients. Methods: Sixty patients with mild-to-severe asthma and 24 control subjects underwent detailed clinical assessment and provided induced sputum, endobronchial biopsy, bronchoalveolar lavage, and blood samples. Adaptive and invariant T-cell subsets, cytokines, mast cells, and basophil mediators were analyzed. Results: Significant heterogeneity of T-cell phenotypes was observed, with levels of IL-13-secreting T cells and type 2 cytokines increased at some, but not all, asthma severities. T(H)17 cells and gamma d-17 cells, proposed drivers of neutrophilic inflammation, were not strongly associated with asthma, even in severe neutrophilic forms. MAIT cell frequencies were strikingly reduced in both blood and lung tissue in relation to corticosteroid therapy and vitamin D levels, especially in patients with severe asthma in whom bronchoalveolar lavage regulatory T-cell numbers were also reduced. Bayesian network analysis identified complex relationships between pathobiologic and clinical parameters. Topological data analysis identified 6 novel clusters that are associated with diverse underlying disease mechanisms, with increased mast cell mediator levels in patients with severe asthma both in its atopic (type 2 cytokine-high) and nonatopic forms. Conclusion: The evidence for a role for T(H)17 cells in patients with severe asthma is limited. Severe asthma is associated with a striking deficiency of MAIT cells and high mast cell mediator levels. This study provides proof of concept for disease mechanistic networks in asthmatic patients with clusters that could inform the development of new therapies.	[Hinks, Timothy S. C.; Zhou, Xiaoying; Staples, Karl J.; Ward, Jon A.; Howarth, Peter H.; Walls, Andrew F.; Gadola, Stephan D.; Djukanovic, Ratko] Univ Southampton, Fac Med, Sir Henry Wellcome Labs, Clin & Expt Sci, Southampton SO16 6YD, Hants, England; [Hinks, Timothy S. C.; Dimitrov, Borislav D.; Ward, Jon A.; Howarth, Peter H.; Djukanovic, Ratko] Univ Southampton, Fac Med, Southampton Univ Hosp, NIHR Southampton Resp Biomed Res Unit, Southampton SO16 6YD, Hants, England; [Dimitrov, Borislav D.; Smith, Caroline G.] Univ Southampton, Fac Med, Southampton Univ Hosp, Primary Care & Populat Sci, Southampton SO16 6YD, Hants, England; [Manta, Alexander] MantaMat UG, Geretsried, England; [Petrossian, Tanya; Lum, Pek Y.] Ayasdi, Palo Alto, CA USA; [Gadola, Stephan D.] Novartis, Novartis Inst Biomed Res, Basel, Switzerland	University of Southampton; University of Southampton; University of Southampton; Novartis	Djukanovic, R (corresponding author), Univ Southampton, Fac Med, Sir Henry Wellcome Labs, Clin & Expt Sci,Southampton Univ Hosp, Southampton SO16 6YD, Hants, England.	r.djukanovic@soton.ac.uk	Dimitrov, Borislav D/A-1246-2010	Dimitrov, Borislav D/0000-0002-5896-2072; Petrossian, Tanya/0000-0002-1205-9144; Ward, Jon/0000-0002-9278-0002; Walls, Andrew/0000-0003-4803-4595; Hinks, Timothy/0000-0003-0699-2373; Howarth, Peter/0000-0003-0619-7927; Zhou, Xiaoying/0000-0002-6756-5917; Staples, Karl/0000-0003-3844-6457; Djukanovic, Ratko/0000-0001-6039-5612	Wellcome Trust Clinical Research Fellowship [088365/z/09/z]; NIHR Southampton Respiratory Biomedical Research Unit; Medical Research Council [G0500729]; Asthma UK [06/026, 08/026]; Foundation for the Study of Infant Death [254]; National Institute for Health Research through the Primary Care Research Network; National Institute for Health Research through Academic Clinical Fellowship; Academy of Medical Sciences (AMS) [AMS-SGCL11-Hinks] Funding Source: researchfish; Medical Research Council [G0800649, G0900453, G0400473] Funding Source: researchfish; National Institute for Health Research [H039, NF-SI-0514-10085, ACF-2006-26-005] Funding Source: researchfish; MRC [G0800649, G0500729, G0900453, G0400473] Funding Source: UKRI	Wellcome Trust Clinical Research Fellowship(Wellcome Trust); NIHR Southampton Respiratory Biomedical Research Unit; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Foundation for the Study of Infant Death; National Institute for Health Research through the Primary Care Research Network; National Institute for Health Research through Academic Clinical Fellowship; Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a Wellcome Trust Clinical Research Fellowship (088365/z/09/z; to T.S.C.H.). Infrastructure support was funded by the NIHR Southampton Respiratory Biomedical Research Unit. X.Z. was supported by the Medical Research Council (G0500729), Asthma UK (06/026), and the Foundation for the Study of Infant Death (254). K.J.S. was supported by a project grant from Asthma UK (08/026). We acknowledge the support of the National Institute for Health Research through the Primary Care Research Network and through an Academic Clinical Fellowship awarded (to T.S.C.H.).	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Auffray C, 2010, CHEST, V137, P1410, DOI 10.1378/chest.09-1850; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brusselle GG, 2013, NAT MED, V19, P977, DOI 10.1038/nm.3300; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102; Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Garcia G, 2013, CHEST, V144, P411, DOI 10.1378/chest.12-1961; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; Global Initiative for Asthma (GIFA), 2012, GLOB STRAT ASTHM MAN; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; Mamessier E, 2008, ALLERGY, V63, P1202, DOI 10.1111/j.1398-9995.2008.01687.x; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Meierovics A, 2013, P NATL ACAD SCI USA, V110, pE3119, DOI 10.1073/pnas.1302799110; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Reshef DN, 2011, SCIENCE, V334, P1518, DOI 10.1126/science.1205438; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Staples KJ, 2012, J ALLERGY CLIN IMMUN, V130, P1404, DOI 10.1016/j.jaci.2012.07.023; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110	48	137	139	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					323	333		10.1016/j.jaci.2015.01.014	http://dx.doi.org/10.1016/j.jaci.2015.01.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25746968	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000359004900013
J	Keet, CA; McCormack, MC; Pollack, CE; Peng, RD; McGowan, E; Matsui, EC				Keet, Corinne A.; McCormack, Meredith C.; Pollack, Craig E.; Peng, Roger D.; McGowan, Emily; Matsui, Elizabeth C.			Neighborhood poverty, urban residence, race/ethnicity, and asthma: Rethinking the inner-city asthma epidemic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inner-city asthma; childhood asthma; urban/rural; neighborhood; race/ethnicity	PUERTO-RICAN CHILDREN; CHILDHOOD ASTHMA; UNITED-STATES; SOCIOECONOMIC-STATUS; INFECTIOUS-DISEASES; CHANGING PATTERNS; HISPANIC CHILDREN; RISK-FACTORS; GALA II; PREVALENCE	Background: Although it is thought that inner-city areas have a high burden of asthma, the prevalence of asthma in inner cities across the United States is not known. Objective: We sought to estimate the prevalence of current asthma in US children living in inner-city and non-inner-city areas and to examine whether urban residence, poverty, or race/ethnicity are the main drivers of asthma disparities. Methods: The National Health Interview Survey 2009-2011 was linked by census tract to data from the US Census and the National Center for Health Statistics. Multivariate logistic regression models adjusted for sex; age; race/ethnicity; residence in an urban, suburban, medium metro, or small metro/rural area; poverty; and birth outside the United States, with current asthma and asthma morbidity as outcome variables. Inner-city areas were defined as urban areas with 20% or more of households at below the poverty line. Results: We included 23,065 children living in 5,853 census tracts. The prevalence of current asthma was 12.9% in inner-city and 10.6% in non-inner-city areas, but this difference was not significant after adjusting for race/ethnicity, region, age, and sex. In fully adjusted models black race, Puerto Rican ethnicity, and lower household income but not residence in poor or urban areas were independent risk factors for current asthma. Household poverty increased the risk of asthma among non-Hispanics and Puerto Ricans but not among other Hispanics. Associations with asthma morbidity were very similar to those with prevalent asthma. Conclusions: Although the prevalence of asthma is high in some inner-city areas, this is largely explained by demographic factors and not by living in an urban neighborhood.	[Keet, Corinne A.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA; [McCormack, Meredith C.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Pollack, Craig E.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA; [McGowan, Emily] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [McGowan, Emily] Johns Hopkins Bloomberg Sch Publ Hlth, Grad Program Clin Invest, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Keet, CA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ckeet1@jhmi.edu		Keet, Corinne/0000-0002-6585-239X; Pham, Hewlett/0000-0003-0330-6104; Matsui, Elizabeth/0000-0001-8134-5593; Ayers, Andrew/0000-0001-5305-7156; McCormack, Meredith/0000-0003-1702-3201; Koehl, Rachelle/0000-0002-7797-7456	National Institute of Environmental Health Sciences [P50ES015903, P01ES018176, P01ES018181, R01ES019560]; US Environmental Protection Agency [R832139, RD83451501, R21HL117772]; National Institute of Allergy and Infectious Diseases [R01AI070630, U01AI083238, T32AI007007, K23AI103187, R21AI107085]; National Cancer Institute [K07CA151910]; NATIONAL CANCER INSTITUTE [K07CA151910] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI107085, T32AI007007, K24AI114769, U01AI083238, R01AI070630, K23AI103187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181, P50ES015903, K24ES021098, R01ES019560, P01ES018176, R01ES023447] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency(United States Environmental Protection Agency); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Environmental Health Sciences (P50ES015903, P01ES018176, P01ES018181, and R01ES019560), the US Environmental Protection Agency (R832139, STAR Grant RD83451501, and R21HL117772), the National Institute of Allergy and Infectious Diseases (R01AI070630, U01AI083238, T32AI007007, K23AI103187, and R21AI107085), and the National Cancer Institute (K07CA151910). The findings and conclusions in this article are those of the author or authors and do not necessarily represent the views of the Centers for Disease Control, the National Center for Health Statistics, or the Research Data Center.	Ahluwalia IB, 2012, J HUM LACT, V28, P167, DOI 10.1177/0890334412438403; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; [Anonymous], 2011, MULTIPLE IMPUTATION; [Anonymous], 2012, NHIS SURV DESCR 2011; [Anonymous], 2010, NHIS SURV DESCR 2009; [Anonymous], 2011, NHIS SURV DESCR 2010; BOOTH S, 1965, ARCH ENVIRON HEALTH, V10, P152, DOI 10.1080/00039896.1965.10663974; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Bryant-Stephens T, 2012, J ASTHMA, V49, P581, DOI 10.3109/02770903.2012.690476; Buescher P A, 1999, Matern Child Health J, V3, P211, DOI 10.1023/A:1022377405914; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Choudhry Shweta, 2007, Proc Am Thorac Soc, V4, P226, DOI 10.1513/pats.200701-029AW; Claudio L, 2006, ANN EPIDEMIOL, V16, P332, DOI 10.1016/j.annepidem.2005.06.046; CRAIN EF, 1994, PEDIATRICS, V94, P356; Crump C, 1999, Ethn Health, V4, P29; Duncan C, 1998, SOC SCI MED, V46, P97, DOI 10.1016/S0277-9536(97)00148-2; Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807; Gerbasi TR, 2000, PEDIATRICS, V105, P1171, DOI 10.1542/peds.105.5.1171; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Gold DR, 2005, J ALLERGY CLIN IMMUN, V116, P38, DOI 10.1016/j.jaci.2005.04.033; Gupta RS, 2008, J ALLERGY CLIN IMMUN, V121, P639, DOI 10.1016/j.jaci.2007.11.036; Howell AJ, 2014, J URBAN AFF, V36, P79, DOI 10.1111/juaf.12030; Ingram Deborah D, 2012, Vital Health Stat 2, P1; Jargowsky PA, 2013, CONCENTRATION POVERT; Kaplan RC, 2014, AM J PREV MED, V46, P496, DOI 10.1016/j.amepre.2014.01.014; Kneebone E., 2012, ATLANTIC MAGAZI 0920; Kumar R, 2013, J ALLERGY CLIN IMMUN, V132, P896, DOI 10.1016/j.jaci.2013.02.046; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; Moorman JE, 2013, MMWR-MORBID MORTAL W, V62, P93; Mosnaim GS, 2007, J ALLERGY CLIN IMMUN, V120, P1160, DOI 10.1016/j.jaci.2007.08.040; Mvula M, 2005, J ASTHMA, V42, P9, DOI 10.1081/JAS-200044746; NEGY C, 1992, HISPANIC J BEHAV SCI, V14, P248, DOI 10.1177/07399863920142004; Rastogi SJ, 2011, BLACK POPULATION; Rubin DB, 1987, MULTIPLE IMPUTATION, p[xxix, 258], DOI DOI 10.1002/9780470316696; Sampson RJ, 2008, P NATL ACAD SCI USA, V105, P845, DOI 10.1073/pnas.0710189104; Shalowitz MU, 2007, AMBUL PEDIATR, V7, P271, DOI 10.1016/j.ambp.2007.03.004; Shaw RJ, 2013, AM J PUBLIC HEALTH, V103, P1052, DOI 10.2105/AJPH.2012.300985; Thakur N, 2013, AM J RESP CRIT CARE, V188, P1202, DOI 10.1164/rccm.201306-1016OC; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; Wiey JF, 2014, J NUTR, V144, P305, DOI 10.3945/jn.113.182592; Wright RJ, 2007, CHEST, V132, p757S, DOI 10.1378/chest.07-1904	50	137	138	1	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					655	662		10.1016/j.jaci.2014.11.022	http://dx.doi.org/10.1016/j.jaci.2014.11.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CD4PF	25617226	Green Accepted			2022-12-18	WOS:000351065000008
J	Gittler, JK; Krueger, JG; Guttman-Yassky, E				Gittler, Julia K.; Krueger, James G.; Guttman-Yassky, Emma			Atopic dermatitis results in intrinsic barrier and immune abnormalities: Implications for contact dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; allergic contact dermatitis; contact hypersensitivity; irritant contact dermatitis; epidermal barrier; immune activation; T(H)2; T(H)17	EPIDERMAL LANGERHANS CELLS; DERMAL DENDRITIC CELLS; SODIUM LAURYL SULFATE; FC-EPSILON-RI; PATCH TEST CONCENTRATIONS; CYTOKINE GENE-EXPRESSION; ANTIGEN-PRESENTING CELLS; HIGH-AFFINITY RECEPTOR; TUMOR-NECROSIS-FACTOR; ALLERGY CLIN IMMUNOL	Atopic dermatitis (AD), as well as irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD), are common skin diseases. These diseases are characterized by skin inflammation mediated by activated innate immunity or acquired immune mechanisms. Although AD, ICD, and ACD can be encountered in pure forms by allergists and dermatologists, patients with AD often present with increased frequency of ICD and ACD. Although a disturbed barrier alone could potentiate immune reactivity in patients with AD through increased antigen penetration, additional immune mechanisms might explain the increased susceptibility of atopic patients to ICD and ACD. This review discusses cellular pathways associated with increased skin inflammation in all 3 conditions and presents mechanisms that might contribute to the increased rate of ICD and ACD in patients with AD. (J Allergy Clin Immunol 2013;131:300-13.)	[Gittler, Julia K.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Gittler, Julia K.; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA; [Guttman-Yassky, Emma] Mt Sinai Sch Med, Dept Dermatol, New York, NY 10029 USA	Yeshiva University; Albert Einstein College of Medicine; Rockefeller University; Icahn School of Medicine at Mount Sinai	Guttman-Yassky, E (corresponding author), Mt Sinai Sch Med, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	eguttman@rockefeller.edu			National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [5UL1RR024143-02]; NIH Roadmap for Medical Research; Dermatology Foundation Physician Scientist Career Development Award; Centercore; Eli Lilly; Pfizer; Amgen; Merck; Dermatology Foundation; Regeneron; Stiefel; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation Physician Scientist Career Development Award; Centercore; Eli Lilly(Eli Lilly); Pfizer(Pfizer); Amgen(Amgen); Merck(Merck & Company); Dermatology Foundation; Regeneron(Regeneron); Stiefel; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	J.G.K. was supported in part by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award.; J. G. Krueger has received consultancy fees from Centercore, Eli Lilly, and Pfizer and has received research support from Amgen, Centercore, Eli Lilly, Merck, and Pfizer. E. Guttman-Yassky has received research support from the Dermatology Foundation to Mount Sinai School of Medicine and has received consultancy fees from Regeneron, Merck, Pfizer, and Stiefel. J. K. Gittler declares that she has no relevant conflicts of interest.	Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; ALLENBY CF, 1989, CONTACT DERMATITIS, V20, P185, DOI 10.1111/j.1600-0536.1989.tb04655.x; ALLENBY CF, 1993, CONTACT DERMATITIS, V28, P129, DOI 10.1111/j.1600-0536.1993.tb03371.x; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Balato A, 2011, CLIN DERMATOL, V29, P24, DOI 10.1016/j.clindermatol.2010.07.003; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Basketter D, 2008, SKIN PHARMACOL PHYS, V21, P191, DOI 10.1159/000135635; Belhadjali H, 2008, CONTACT DERMATITIS, V58, P188, DOI [10.1111/j.1600-0536.2007.01248.x, 10.1111/j.1600-0536.2007.01238.x]; Belsito DV, 2005, J AM ACAD DERMATOL, V53, P303, DOI 10.1016/j.jaad.2005.02.045; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; BIEBER T, 1992, J INVEST DERMATOL, V99, pS10, DOI 10.1111/1523-1747.ep12668204; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Bonneville M, 2007, J INVEST DERMATOL, V127, P1430, DOI 10.1038/sj.jid.5700726; Brasch J, 1996, CONTACT DERMATITIS, V35, P17, DOI 10.1111/j.1600-0536.1996.tb02260.x; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Clayton TH, 2006, BRIT J DERMATOL, V154, P114, DOI 10.1111/j.1365-2133.2005.06845.x; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Cumberbatch M, 2002, TOXICOL APPL PHARM, V182, P126, DOI 10.1006/taap.2002.9442; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; DaSilva SC, 2012, ARCH DERMATOL RES, V304, P65, DOI 10.1007/s00403-011-1168-2; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Jongh CM, 2006, BRIT J DERMATOL, V154, P651, DOI 10.1111/j.1365-2133.2005.06989.x; de Waard-van der Spek FB, 2009, DERMATOLOGY, V218, P119, DOI 10.1159/000165629; Dickel H, 2003, J INVEST DERMATOL, V121, P37, DOI 10.1046/j.1523-1747.2003.12323.x; DIELI F, 1994, J IMMUNOL, V152, P2698; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; diNardo A, 1996, CONTACT DERMATITIS, V35, P86, DOI 10.1111/j.1600-0536.1996.tb02296.x; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Dotterud LK, 2007, CONTACT DERMATITIS, V56, P10, DOI 10.1111/j.1600-0536.2007.00980.x; Dubrac S, 2010, IMMUNOL CELL BIOL, V88, P400, DOI 10.1038/icb.2010.33; Elbe-Burger A, 2002, J INVEST DERMATOL, V118, P767, DOI 10.1046/j.1523-1747.2002.01753.x; Elias PM, 2009, CURR ALLERGY ASTHM R, V9, P265, DOI [10.1007/s11882-009-0037-y, 10.1097/ACI.0b013e32832e7d36]; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; ELSNER P, 1993, ACTA DERM-VENEREOL, V73, P214; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fartasch M, 1998, J Investig Dermatol Symp Proc, V3, P121; FARTASCH M, 1992, ACTA DERM-VENEREOL, P26; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1010/J.JACL2011.05.016; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Fukunaga A, 2008, J IMMUNOL, V180, P3057, DOI 10.4049/jimmunol.180.5.3057; Ghadially R, 1998, Am J Contact Dermat, V9, P162, DOI 10.1016/S1046-199X(98)90019-7; GRUBAUER G, 1989, J LIPID RES, V30, P323; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HAUSER C, 1989, EUR J IMMUNOL, V19, P245, DOI 10.1002/eji.1830190205; He DG, 2006, J IMMUNOL, V177, P6852, DOI 10.4049/jimmunol.177.10.6852; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Heine G, 2004, CONTACT DERMATITIS, V51, P111, DOI 10.1111/j.0105-1873.2004.00411.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Herro Elise M, 2011, J Clin Aesthet Dermatol, V4, P39; Holzmann S, 2004, J INVEST DERMATOL, V122, P1165, DOI 10.1111/j.0022-202X.2004.22520.x; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Igyarto BZ, 2009, J IMMUNOL, V183, P5085, DOI 10.4049/jimmunol.0901884; IKARASHI Y, 1993, CONTACT DERMATITIS, V29, P128, DOI 10.1111/j.1600-0536.1993.tb03509.x; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Ishikawa J, 2010, J INVEST DERMATOL, V130, P2511, DOI 10.1038/jid.2010.161; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kaplan DH, 2010, TRENDS IMMUNOL, V31, P446, DOI 10.1016/j.it.2010.08.006; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; KAPSENBERG ML, 1992, J INVEST DERMATOL, V98, P59, DOI 10.1111/1523-1747.ep12494841; Katoh N, 1997, ACTA DERM-VENEREOL, V77, P365; Kim DW, 2006, INT J DERMATOL, V45, P698, DOI 10.1111/j.1365-4632.2005.02644.x; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Koenders MI, 2005, AM J PATHOL, V167, P141, DOI 10.1016/S0002-9440(10)62961-6; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; LAMMINTAUSTA K, 1992, CONTACT DERMATITIS, V26, P234, DOI 10.1111/j.1600-0536.1992.tb00235.x; Landeck L, 2011, INT J DERMATOL, V50, P806, DOI 10.1111/j.1365-4632.2010.04754.x; Larsen JM, 2009, J ALLERGY CLIN IMMUN, V123, P486, DOI 10.1016/j.jaci.2008.09.036; Lee GR, 2004, INT IMMUNOL, V16, P1155, DOI 10.1093/intimm/dxh117; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Loffler H, 1999, CONTACT DERMATITIS, V40, P239, DOI 10.1111/j.1600-0536.1999.tb06056.x; Lutz MB, 2010, IMMUNOL CELL BIOL, V88, P381, DOI 10.1038/icb.2010.17; Lutz MB, 1996, EUR J IMMUNOL, V26, P586, DOI 10.1002/eji.1830260313; Lutz MB, 1996, IMMUNOBIOLOGY, V195, P431, DOI 10.1016/S0171-2985(96)80014-3; MAGNUSSON B, 1970, Odontologisk Revy, V21, P287; Matsui K, 2002, CLIN EXP ALLERGY, V32, P783, DOI 10.1046/j.1365-2222.2002.01357.x; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1996, J IMMUNOL, V157, P607; MCLELLAND J, 1991, ARCH DERMATOL, V127, P1016, DOI 10.1001/archderm.127.7.1016; McPherson T, 2010, BRIT J DERMATOL, V163, P544, DOI 10.1111/j.1365-2133.2010.09866.x; Metwally Shereen S, 2004, Egypt J Immunol, V11, P171; Milingou M, 2010, PEDIATR DERMATOL, V27, P255, DOI 10.1111/j.1525-1470.2010.01128.x; Minang JT, 2005, SCAND J IMMUNOL, V62, P289, DOI 10.1111/j.1365-3083.2005.01673.x; Mittermann I, 2004, CURR OPIN ALLERGY CL, V4, P367, DOI 10.1097/00130832-200410000-00007; Molin S, 2011, J INVEST ALLERG CLIN, V21, P472; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Mori T, 2008, J INVEST DERMATOL, V128, P1719, DOI 10.1038/jid.2008.5; Mortz CG, 1999, CONTACT DERMATITIS, V41, P121, DOI 10.1111/j.1600-0536.1999.tb06102.x; MULLER KM, 1993, J IMMUNOL, V150, P5576; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; NASSIF A, 1994, ARCH DERMATOL, V130, P1402, DOI 10.1001/archderm.130.11.1402; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; NICKOLOFF BJ, 1994, CLIN IMMUNOL IMMUNOP, V73, P63, DOI 10.1006/clin.1994.1170; Niiyama S, 2010, INT ARCH ALLERGY IMM, V153, P303, DOI 10.1159/000314372; Nishijima T, 1997, J INVEST DERMATOL, V109, P175, DOI 10.1111/1523-1747.ep12319282; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Noordegraaf M, 2010, J INVEST DERMATOL, V130, P2752, DOI 10.1038/jid.2010.223; Nosbaum A, 2009, EUR J DERMATOL, V19, P325, DOI 10.1684/ejd.2009.0686; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; Novak N, 2008, DRUG NEWS PERSPECT, V21, P158, DOI 10.1358/dnp.2008.21.3.1203412; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Onoue A, 2009, EXP DERMATOL, V18, P1036, DOI 10.1111/j.1600-0625.2009.00899.x; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Partidos CD, 2005, CELL MOL LIFE SCI, V62, P1418, DOI 10.1007/s00018-005-4529-1; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Poulin LF, 2007, J EXP MED, V204, P3119, DOI 10.1084/jem.20071724; PROBST P, 1995, CELL IMMUNOL, V165, P134, DOI 10.1006/cimm.1995.1196; Proksch E, 1996, BRIT J DERMATOL, V134, P630, DOI 10.1046/j.1365-2133.1996.66828.x; Proksch E, 1997, ACTA DERM-VENEREOL, V77, P102; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; Ptak W, 2002, INT ARCH ALLERGY IMM, V128, P8, DOI 10.1159/000057998; Ricciardi L, 2009, CONTACT DERMATITIS, V60, P57, DOI 10.1111/j.1600-0536.2008.01454.x; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; ROSKOS KV, 1992, DRUG AGING, V2, P432, DOI 10.2165/00002512-199202050-00007; Rowe A, 1998, CONTACT DERMATITIS, V38, P36, DOI 10.1111/j.1600-0536.1998.tb05634.x; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmuth M, 2002, EXP DERMATOL, V11, P135, DOI 10.1034/j.1600-0625.2002.110205.x; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Seidenari S, 2005, PEDIATR DERMATOL, V22, P1, DOI 10.1111/j.1525-1470.2005.22100.x; Seneviratne SL, 2006, CLIN EXP DERMATOL, V31, P689, DOI 10.1111/j.1365-2230.2006.02172.x; Seyfarth F, 2011, CLIN DERMATOL, V29, P31, DOI 10.1016/j.clindermatol.2010.07.004; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; SHIMADA S, 1987, J IMMUNOL, V139, P2551; Smith HR, 2002, CLIN EXP DERMATOL, V27, P138, DOI 10.1046/j.1365-2230.2002.00997.x; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Strid J, 2006, IMMUNOLOGY, V119, P27, DOI 10.1111/j.1365-2567.2006.02401.x; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Szczepanik M, 2005, IMMUNOLOGY, V115, P42, DOI 10.1111/j.1365-2567.2005.02127.x; Tabata N, 1998, CONTACT DERMATITIS, V78, P244; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Torma H, 2006, TOXICOL IN VITRO, V20, P472, DOI 10.1016/j.tiv.2005.09.011; UDEY MC, 1991, J INVEST DERMATOL, V96, P950, DOI 10.1111/1523-1747.ep12475701; UEHARA M, 1989, ARCH DERMATOL, V125, P366, DOI 10.1001/archderm.125.3.366; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; VANDERVALK PGM, 1985, CLIN EXP DERMATOL, V10, P185; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Watanabe H, 2008, J IMMUNOL, V180, P5826, DOI 10.4049/jimmunol.180.9.5826; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Werfel T, 1997, J IMMUNOL, V158, P2500; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; WOOD LC, 1994, J INVEST DERMATOL, V103, P834, DOI 10.1111/1523-1747.ep12413597; Yamamoto M, 2011, J DERMATOL SCI, V61, P110, DOI 10.1016/j.jdermsci.2010.11.018; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Yokozeki H, 2000, J EXP MED, V191, P995, DOI 10.1084/jem.191.6.995; Yoshiiki Takashi, 1993, Journal of Dermatological Science, V5, P92, DOI 10.1016/0923-1811(93)90076-2; Yu Y, 2009, BLOOD, V114, P1026, DOI 10.1182/blood-2009-03-210153; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015; Zhao Y, 2009, BRIT J DERMATOL, V161, P1301, DOI 10.1111/j.1365-2133.2009.09400.x; Zug KA, 2008, ARCH DERMATOL, V144, P1329, DOI 10.1001/archderm.144.10.1329; Zug KA, 2009, DERMATITIS, V20, P149, DOI 10.2310/6620.2009.08097	185	137	141	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					300	313		10.1016/j.jaci.2012.06.048	http://dx.doi.org/10.1016/j.jaci.2012.06.048			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22939651	Bronze, Green Accepted			2022-12-18	WOS:000314661500005
J	Reponen, T; Lockey, J; Bernstein, DI; Vesper, SJ; Levin, L; Hershey, GKK; Zheng, S; Ryan, P; Grinshpun, SA; Villareal, M; LeMasters, G				Reponen, Tiina; Lockey, James; Bernstein, David I.; Vesper, Stephen J.; Levin, Linda; Hershey, Gurjit K. Khurana; Zheng, Shu; Ryan, Patrick; Grinshpun, Sergey A.; Villareal, Manuel; LeMasters, Grace			Infant origins of childhood asthma associated with specific molds	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; molds; speciation; infants; Environmental Relative Moldiness Index	QUANTITATIVE PCR ANALYSIS; RELATIVE MOLDINESS INDEX; HOUSE-DUST; 1ST YEAR; CHILDREN; HOME; EXPOSURE; PENICILLIUM; ANTIBODIES; ENDOTOXIN	Background: The specific cause or causes of asthma development must be identified to prevent this disease. Objective: Our hypothesis was that specific mold exposures are associated with childhood asthma development. Methods: Infants were identified from birth certificates. Dust samples were collected from 289 homes when the infants were 8 months of age. Samples were analyzed for concentrations of 36 molds that comprise the Environmental Relative Moldiness Index (ERMI) and endotoxin, house dust mite, cat, dog, and cockroach allergens. Children were evaluated at age 7 years for asthma based on reported symptoms and objective measures of lung function. Host, environmental exposure, and home characteristics evaluated included a history of parental asthma, race, sex, upper and lower respiratory tract symptoms, season of birth, family income, cigarette smoke exposure, air conditioning, use of a dehumidifier, presence of carpeting, age of home, and visible mold at age 1 year and child's positive skin prick test response to aeroallergens and molds at age 7 years. Results: Asthma was diagnosed in 24% of the children at age 7 years. A statistically significant increase in asthma risk at age 7 years was associated with high ERMI values in the child's home in infancy (adjusted relative risk for a 10-unit increase in ERMI value, 1.8; 95% CI, 1.5-2.2). The summation of levels of 3 mold species, Aspergillus ochraceus, Aspergillus unguis, and Penicillium variabile, was significantly associated with asthma (adjusted relative risk, 2.2; 95% CI, 1.8-2.7). Conclusion: In this birth cohort study exposure during infancy to 3 mold species common to water-damaged buildings was associated with childhood asthma at age 7 years. (J Allergy Clin Immunol 2012;130:639-44.)	[Reponen, Tiina; Lockey, James; Levin, Linda; Zheng, Shu; Ryan, Patrick; Grinshpun, Sergey A.; LeMasters, Grace] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Lockey, James; Bernstein, David I.; Villareal, Manuel] Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA; [Vesper, Stephen J.] US EPA, Cincinnati, OH 45268 USA; [Hershey, Gurjit K. Khurana; Ryan, Patrick] Cincinnati Childrens Hosp, Ctr Med, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; United States Environmental Protection Agency; Cincinnati Children's Hospital Medical Center	Reponen, T (corresponding author), Univ Cincinnati, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.	Tiina.Reponen@uc.edu	Ryan, Patrick/HDO-1133-2022; Ryan, Patrick H/L-7062-2015	Khurana Hershey, Gurjit/0000-0001-6663-977X; Grinshpun, Sergey/0000-0003-4339-927X	US Department of Housing and Urban Development [OHLHH0226-10]; National Institute of Environmental Health Sciences (NIEHS) [RO1 ES11170]; US Environmental Protection Agency (EPA) through its Office of Research and Development; US Housing and Urban Development; Mycometrics; EMSL; TestAmerica; Forensics Analytical; Roche; Aemtek; Microbial Insight; National Institute of Environmental Health Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011170] Funding Source: NIH RePORTER	US Department of Housing and Urban Development; National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency (EPA) through its Office of Research and Development(United States Environmental Protection Agency); US Housing and Urban Development; Mycometrics; EMSL; TestAmerica; Forensics Analytical; Roche(Roche Holding); Aemtek; Microbial Insight; National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by US Department of Housing and Urban Development grant no. OHLHH0226-10 and National Institute of Environmental Health Sciences (NIEHS) grant no. RO1 ES11170 awarded to the University of Cincinnati. The US Environmental Protection Agency (EPA), through its Office of Research and Development, partially funded and collaborated in the research described here. It has been subjected to the Agency's peer review and has been approved as an EPA publication. Mention of trade names or commercial products does not constitute endorsement or recommendation by the EPA for use. Commercial use of the Environmental Relative Moldiness Index technology can provide royalties to the EPA.; T. Reponen has received research support from US Housing and Urban Development. J. Lockey and G. LeMasters are involved in the Diesel, Allergens and Gene Interaction and Child Atopy study. S. J. Vesper has received royalties from Mycometrics, EMSL, TestAmerica, Forensics Analytical, Roche, Aemtek, and Microbial Insight. P. Ryan has received research support from the National Institute of Environmental Health Sciences. The rest of the authors declare that they have no relevant conflicts of interest.	Agarwal R, 2011, MED MYCOL, V49, pS150, DOI 10.3109/13693786.2010.504752; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Bundy KW, 2009, ANN ALLERG ASTHMA IM, V103, P26, DOI 10.1016/S1081-1206(10)60139-1; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Cho SH, 2006, SCI TOTAL ENVIRON, V371, P31, DOI 10.1016/j.scitotenv.2006.09.001; Cohen J., 1988, STAT POWER ANAL BEHA; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crawford C, 2009, AEROBIOLOGIA, V25, P147, DOI 10.1007/s10453-009-9120-z; Epstein TG, 2011, J PEDIATR-US, V158, P265, DOI 10.1016/j.jpeds.2010.07.026; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459, DOI 10.1046/j.1365-2222.1998.00255.x; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781, DOI 10.1289/ehp.021100781; Haugland R.A., 2002, U.S. Patent, Patent No. [6,387,652, 6387652]; Haugland RA, 2004, SYST APPL MICROBIOL, V27, P198, DOI 10.1078/072320204322881826; Haugland RA, 2002, J MICROBIOL METH, V50, P319, DOI 10.1016/S0167-7012(02)00037-4; Heinrich J, 2011, INT J HYG ENVIR HEAL, V214, P3, DOI 10.1016/j.ijheh.2010.08.009; HOLM S, 1979, SCAND J STAT, V6, P65; Hyvarinen A, 2006, INDOOR AIR, V16, P20, DOI 10.1111/j.1600-0668.2005.00392.x; Institute of Medicine National Academies of Science, 2004, DAMP IND SPAC HLTH, P355; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Meklin T, 2004, J ENVIRON MONITOR, V6, P615, DOI 10.1039/b400250d; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Reponen T, 2010, SCI TOTAL ENVIRON, V408, P5565, DOI 10.1016/j.scitotenv.2010.07.090; Rosenbaum PF, 2010, J EXPO SCI ENV EPID, V20, P503, DOI 10.1038/jes.2009.27; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; Salo PM, 2009, J ALLERGY CLIN IMMUN, V124, P185, DOI 10.1016/j.jaci.2009.05.012; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Schmechel D, 2008, J ALLERGY CLIN IMMUN, V121, P763, DOI 10.1016/j.jaci.2007.09.046; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; Vesper S, 2008, SCI TOTAL ENVIRON, V394, P192, DOI 10.1016/j.scitotenv.2008.01.031; Vesper S, 2007, J ENVIRON MONITOR, V9, P826, DOI 10.1039/b704359g; Vesper S, 2007, J OCCUP ENVIRON MED, V49, P829, DOI 10.1097/JOM.0b013e3181255e98; Vesper S, 2011, J ENVIRON PUBLIC HEA, V2011, DOI 10.1155/2011/242457; Vesper S, 2011, CRIT REV MICROBIOL, V37, P15, DOI 10.3109/1040841X.2010.506177; Vesper S, 2009, J URBAN HEALTH, V86, P850, DOI 10.1007/s11524-009-9384-1; Vesper SJ, 2006, J OCCUP ENVIRON MED, V48, P852, DOI 10.1097/01.jom.0000224736.52780.2f; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502; WHO Europe ( World Health Organization Europe), 2009, WHO GUID IND AIR QUA; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x	44	137	137	1	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					639	+		10.1016/j.jaci.2012.05.030	http://dx.doi.org/10.1016/j.jaci.2012.05.030			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22789397	Green Accepted			2022-12-18	WOS:000308463500010
J	Didier, A; Worm, M; Horak, F; Sussman, G; de Beaumont, O; Le Gall, M; Melac, M; Malling, HJ				Didier, Alain; Worm, Margitta; Horak, Friedrich; Sussman, Gordon; de Beaumont, Olivier; Le Gall, Martine; Melac, Michel; Malling, Hans-Jorgen			Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinoconjunctivitis; sublingual immunotherapy; grass pollen; allergen; pre- and coseasonal treatment	ALLERGIC RHINITIS; ORGANIZATION; SAFETY	Background: Seasonal allergic rhinoconjunctivitis affects millions of persons. The efficacy of allergen sublingual immunotherapy (SLIT) was demonstrated in previous short-term studies. Objectives: We sought to evaluate the sustained efficacy of 2 dosing regimens of a pre- and coseasonal treatment with 300 IR (index of reactivity) 5-grass-pollen SLIT tablets (Oralair) compared with placebo assessed by using the average adjusted symptom score (AAdSS) at season 3 in adults with grass pollen-induced rhinoconjunctivitis. Methods: Six hundred thirty-three patients were treated for either 2 or 4 months before and then during the grass pollen season with active or placebo treatment for 3 consecutive seasons. The primary outcome was the AAdSS, a symptom score adjusted for rescue medication use, after 3 consecutive treatment seasons. Secondary outcomes were symptoms and rescue medication score, quality-of-life, and safety assessments. Results: The mean AAdSS was reduced by 36.0% and 34.5% at season 3 in the 2- and 4-month pre- and coseasonal active treatment groups, respectively, compared with that in the placebo group (P < .0001 for both). Reductions were observed in total symptom scores and ISSs and the medication score, with a marked improvement in quality of life for both active groups compared with the placebo group at season 3. Most treatment-emergent adverse events were local reactions expected with SLIT, decreasing in number and intensity in each treatment season. Conclusions: Sustained efficacy of 2- and 4-month pre- and coseasonal treatment with the 300 IR tablet over 3 pollen seasons was demonstrated, with reduction in symptoms and rescue medication use. The treatment was well tolerated. Adverse events decreased in number and intensity over the 3 seasons. (J Allergy Clin Immunol 2011;128:559-66.)	[Didier, Alain] Rangueil Larrey Hosp, Dept Resp Dis, F-31059 Toulouse 9, France; [Malling, Hans-Jorgen] Natl Univ Hosp, Copenhagen, Denmark; [Worm, Margitta] Univ Med Berlin, Ctr Allerg, Charite, Berlin, Germany; [Horak, Friedrich] Allergy Ctr Vienna W, Vienna, Austria; [Sussman, Gordon] Univ Toronto, Toronto, ON M5S 1A1, Canada; [de Beaumont, Olivier; Le Gall, Martine; Melac, Michel] Stallergenes SA, Antony, France	CHU de Toulouse; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Toronto; Stallergenes Greer	Didier, A (corresponding author), Rangueil Larrey Hosp, Dept Resp Dis, 24 Chemin Pouvourville TSA 30030, F-31059 Toulouse 9, France.	didier.a@chu-toulouse.fr	m, m/GZB-2153-2022	Worm, Margitta/0000-0002-3449-1245	Venti RX; Calistoga; Stallergenes; Mast Cell Pharma; Novartis; Schering-Plough	Venti RX; Calistoga; Stallergenes; Mast Cell Pharma; Novartis(Novartis); Schering-Plough(Merck & CompanySchering Plough Corporation)	Supported by Stallergenes S.A.; Disclosure of potential conflict of interest: A. Didier is a consultant for AstraZeneca, Stallergenes, ALK-Abello, MSD, and GlaxoSmithKline. M. Worm is a consultant for and has received lecture honoraria from Stallergenes. F. Horak has received research support from Venti RX, Calistoga, and Stallergenes. G. Sussman is a medical advisor for King Pharma; has received research support from Mast Cell Pharma, Novartis, Schering-Plough, and Stallergenes; has provided legal consultation/expert witness testimony for the Canadian Transportation Agency on food allergies in commercial airline cabins; is an expert advisor for the Canadian Medical Protective Association regarding specific allergy legal claims; is a medical advisor for Anaphylaxis Canada and the Ontario Allergy Society; and is a professional partner of Discovery Research International. H.-J. Malling is a consultant for and has received research support from Stallergenes. The rest of the authors have declared that they have no conflict of interest.	Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; *COMM MED PROD HUM, 2008, CHMPEWP185042006 COM; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Grouin JM, 2011, CLIN EXP ALLERGY; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Rachelefsky GS, 1999, ANN ALLERG ASTHMA IM, V82, P296, DOI 10.1016/S1081-1206(10)62612-9; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, pe3; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Warner JO, 2006, INT ARCH ALLERGY IMM, V139, P166, DOI 10.1159/000090502	16	137	139	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					559	566		10.1016/j.jaci.2011.06.022	http://dx.doi.org/10.1016/j.jaci.2011.06.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21802126				2022-12-18	WOS:000294283400015
J	Sullivan, PW; Ghushchyan, VH; Slejko, JF; Belozeroff, V; Globe, DR; Lin, SL				Sullivan, Patrick W.; Ghushchyan, Vahram H.; Slejko, Julia F.; Belozeroff, Vasily; Globe, Denise R.; Lin, Shao-Lee			The burden of adult asthma in the United States: Evidence from the Medical Expenditure Panel Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Medical expenditures; productivity; insurance coverage; utilization outcomes; economic burden; cost analyses; insurance trends	INDIRECT COSTS; CARE	Background: It is important to have an accurate picture of the sources and extent of medical expenditures and productivity loss to understand the nature and scope of the burden of asthma in the United States (US). Objective: The current study aims to provide recent nationally representative estimates of direct and productivity-related costs attributable to asthma in adults in the US. Methods: The 2003 and 2005 Medical Expenditure Panel Surveys were used to estimate the effect of asthma on medical expenditures, use, productivity, and chronic comorbidity among adults (>= 18 years). Productivity-related outcome variables included employment, annual wages, missed work days, days spent sick in bed, and activity limitations. Multivariate regression was conducted, controlling for sociodemographics and comorbidity. Results: Of 47,033 adults, 2,003 reported asthma. Compared with those without, subjects with asthma were significantly less likely to be employed (odds ratio, 0.78), spent 1.4 more days sick in bed annually, and were significantly more likely to have activity limitations or to be unable to work. Adults with asthma incurred an additional $1,907 (2008 US dollars) annually and experienced higher health care use and comorbidity. The total national medical expenditure attributable to adult asthma was $18 billion. Adults with asthma were more likely to be covered by Medicaid (30%) than the general adult population (10%). The largest contributors to medical expenditures for adults with asthma were prescription drugs, followed by inpatient hospitalizations and home health care. Conclusions: In recent national data adult asthma is associated with a significant deleterious effect on direct and indirect costs in the US. (J Allergy Clin Immunol 2011;127:363-9.)	[Sullivan, Patrick W.] Regis Univ, Sch Pharm, Denver, CO 80221 USA; [Ghushchyan, Vahram H.; Slejko, Julia F.] Univ Colorado Denver, Pharmaceut Outcomes Res Program, Dept Clin Pharm, Denver, CO USA; [Lin, Shao-Lee] Amgen Inc, Clin Dev, Thousand Oaks, CA 91320 USA	Regis University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Amgen	Sullivan, PW (corresponding author), Regis Univ, Sch Pharm, 3333 Regis Blvd,H-28, Denver, CO 80221 USA.	psulliva@regis.edu	Slejko, Julia/M-9335-2019		Amgen, Inc.	Amgen, Inc.(Amgen)	Supported by a research grant from Amgen, Inc.	Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Birnbaum HG, 2002, J ALLERGY CLIN IMMUN, V109, P264, DOI 10.1067/mai.2002.121310; *BUR LAB STAT, PUBL DAT QUER CONS P; Cameron A., 1998, REGRESSION ANAL COUN; Chen H, 2007, J ALLERGY CLIN IMMUN, V120, P396, DOI 10.1016/j.jaci.2007.04.040; Cisternas MG, 2003, J ALLERGY CLIN IMMUN, V111, P1212, DOI 10.1067/mai.2003.1449; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Gendo K, 2003, ANN ALLERG ASTHMA IM, V91, P251, DOI 10.1016/S1081-1206(10)63526-0; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; HECKMAN JJ, 1976, ANN ECON SOC MEAS, V5, pR1; [Internet] Centers for Disease Control and Prevention, NAT HLTH INT SURV; Kamble S, 2009, J ASTHMA, V46, P73, DOI 10.1080/02770900802503107; Medical Expenditure Panel Survey, 2007, HC 097 2005 FULL YEA; National Institutes of Health, 1999, DAT FACT SHEET ASTHM; *NIH, 2007, MORB MORT 2007 CHART; *RTI INT, 2006, COST OF ILLN SUMM SE; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Yelin E, 2002, EUR RESPIR J, V19, P414, DOI 10.1183/09031936.02.00522001	22	137	138	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					363	U400		10.1016/j.jaci.2010.10.042	http://dx.doi.org/10.1016/j.jaci.2010.10.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281868				2022-12-18	WOS:000286808000008
J	Robinson, DS				Robinson, Douglas S.			The role of the T cell in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T lymphocyte; T(H)2; cytokine; regulatory T cell; asthma; natural killer T cell; gamma delta T cell	ALLERGIC AIRWAY INFLAMMATION; BRONCHOALVEOLAR LAVAGE FLUID; MESSENGER-RIBONUCLEIC-ACID; IN-VIVO; IMMUNE-RESPONSES; ATOPIC ASTHMA; EOSINOPHILIC BRONCHITIS; T(H)17 CELLS; TGF-BETA; INCREASED EXPRESSION	Since the initial detection of T(H)2 cytokines in asthmatic airways, our understanding of the complexity of T-cell subtypes and flexibility and of the potential role of airway structural cells in the immunopathology of asthma has increased. Cytokines derived from airway epithelium, including IL-25, IL-33, and thymic stromal lymphopoietin, might be important drivers of T(H)2-type inflammation in asthma. The balance between effector T(H)2 cells and suppressive regulatory T cells is skewed toward a proinflammatory T(H)2 response in atopy and asthma, and there is much interest in how to redress this equilibrium. Novel T-cell subsets, including T(H)17, T(H)9, and T(H)22, have been described, although their role in asthma remains unclear. Other T cells, including natural killer T cells, gamma delta T cells, and CD8 T cells, have also been implicated in asthma, although their importance remains to be confirmed. Therapeutic strategies aimed at T(H)2 cytokines are beginning to bear fruit in patients with asthma, although like many biologic agents, these might need specific targeting at subgroups of patients. Strategies directed specifically at the T cells are currently being evaluated, including novel forms of allergen immunotherapy. T cells remain an exciting potential target for new treatments in patients with asthma. (J Allergy Clin Immunol 2010; 126: 1081-91.)	[Robinson, Douglas S.] Labs Leti SL, Madrid 28760, Spain; [Robinson, Douglas S.] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, NHLI, London, England	Imperial College London	Robinson, DS (corresponding author), Labs Leti SL, Calle Sol 5, Madrid 28760, Spain.	dsrobinson@leti.com						Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; Amsen D, 2009, NAT REV IMMUNOL, V9, P116, DOI 10.1038/nri2488; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Boyman O, 2006, SCIENCE, V311, P1924, DOI 10.1126/science.1122927; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Busse WW, 2008, AM J RESP CRIT CARE, V178, P1002, DOI 10.1164/rccm.200708-1200OC; Casale TB, 2008, J ALLERGY CLIN IMMUN, V121, P288, DOI 10.1016/j.jaci.2007.11.040; CASOLARO V, 1993, J IMMUNOL, V151, P5563; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Commins SP, 2010, J ALLERGY CLIN IMMUN, V125, pS53, DOI 10.1016/j.jaci.2009.07.008; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Garcia-Robaina JC, 2006, J ALLERGY CLIN IMMUN, V118, P1026, DOI 10.1016/j.jaci.2006.07.043; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GIBSON PG, 1989, LANCET, V1, P1346; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hayashi T, 2007, P NATL ACAD SCI USA, V104, P18619, DOI 10.1073/pnas.0709261104; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kariyawasam HH, 2008, AM J RESP CRIT CARE, V177, P1074, DOI 10.1164/rccm.200709-1376OC; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kearley J, 2008, J ALLERGY CLIN IMMUN, V122, P617, DOI 10.1016/j.jaci.2008.05.048; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Kroczek R, 2005, J ALLERGY CLIN IMMUN, V116, P906, DOI 10.1016/j.jaci.2005.07.005; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Lahn M, 1999, NAT MED, V5, P1150, DOI 10.1038/13476; Leggat JA, 2008, J ALLERGY CLIN IMMUN, V122, P1014, DOI 10.1016/j.jaci.2008.08.011; Lei Z, 2008, ALLERGY, V63, P327, DOI 10.1111/j.1398-9995.2007.01566.x; Letourneau S, 2009, J ALLERGY CLIN IMMUN, V123, P758, DOI 10.1016/j.jaci.2009.02.011; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442; Lombardi V, 2010, J IMMUNOL, V184, P2107, DOI 10.4049/jimmunol.0901208; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Martin P, 2005, P NATL ACAD SCI USA, V102, P9866, DOI 10.1073/pnas.0501202102; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan RK, 2007, J IMMUNOL, V178, P8081, DOI 10.4049/jimmunol.178.12.8081; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Newcomb DC, 2009, J IMMUNOL, V182, P5317, DOI 10.4049/jimmunol.0803868; Nguyen XD, 2004, J ALLERGY CLIN IMMUN, V114, P296, DOI 10.1016/j.jaci.2004.04.048; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Provoost S, 2009, ALLERGY, V64, P1539, DOI 10.1111/j.1398-9995.2009.02056.x; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Semitekolou M, 2009, J EXP MED, V206, P1769, DOI 10.1084/jem.20082603; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Steenwinckel V, 2007, J IMMUNOL, V178, P3244, DOI 10.4049/jimmunol.178.5.3244; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Taher YA, 2008, J IMMUNOL, V180, P5211, DOI 10.4049/jimmunol.180.8.5211; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Urry Z, 2009, J CLIN INVEST, V119, P387, DOI 10.1172/JCI32354; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Van Overtvelt L, 2008, INT ARCH ALLERGY IMM, V145, P152, DOI 10.1159/000108140; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Vincenti F, 2008, J ALLERGY CLIN IMMUN, V121, P299, DOI 10.1016/j.jaci.2008.01.002; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson MS, 2008, J IMMUNOL, V181, P6942, DOI 10.4049/jimmunol.181.10.6942; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Ying S, 1997, J IMMUNOL, V158, P3539; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	113	137	158	3	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1081	1091		10.1016/j.jaci.2010.06.025	http://dx.doi.org/10.1016/j.jaci.2010.06.025			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20709383				2022-12-18	WOS:000284947800001
J	Caudri, D; Wijga, A; Schipper, CMA; Hoekstra, M; Postma, DS; Koppelman, GH; Brunekreef, B; Smit, HA; de Jongste, JC				Caudri, Daan; Wijga, Alet; Schipper, C. Maarten A.; Hoekstra, Maarten; Postma, Dirkje S.; Koppelman, Gerard H.; Brunekreef, Bert; Smit, Henriette A.; de Jongste, Johan C.			Predicting the long-term prognosis of children with symptoms suggestive of asthma at preschool age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; wheeze; cough; prognosis; prediction; longitudinal; birth cohort	CHILDHOOD; RISK; IMPUTATION; SEVERITY; ALLERGY; DISEASE; VALUES; MODELS; WHEEZE; YOUNG	Background: Clinicians have difficulty in diagnosing asthma in preschool children with suggestive symptoms. Objective: We sought to develop a clinical asthma prediction score for preschool children who have asthma-like symptoms for the first time. Methods: The Prevalence and Incidence of Asthma and Mite Allergy birth cohort followed 3,963 children for 8 years. Between 0 and 4 years of age, 2,171 (55%) children reported "wheezing," "coughing at night without a cold," or both. In these children possible predictor variables for asthma were assessed at the age respiratory symptoms were first reported. Asthma was defined as wheezing, inhaled steroid prescription, or a doctor's diagnosis of asthma at both age 7 and 8 years of age. Results: Eleven percent of children with symptoms at 0 to 4 years of age had asthma at 7 to 8 years of age. Eight clinical parameters independently predicted asthma at 7 to 8 years of age: male sex, postterm delivery, parental education and inhaled medication, wheezing frequency, wheeze/dyspnea apart from colds, respiratory infections, and eczema. In 72% of the cases, the model accurately discriminated between asthmatic and nonasthmatic children. A clinical risk score was developed (range, 0-55 points). Symptomatic children with a score of less than 10 points had a 3% risk, whereas children with a score of 30 points or greater had a 42% risk of asthma. Conclusion: A risk score based on 8 readily available clinical parameters at the time preschool children first reported asthma-like symptoms predicted the risk of asthma at 7 to 8 years of age. (J Allergy Clin Immunol 2009;124:903-10.)	[Caudri, Daan; de Jongste, Johan C.] Erasmus Univ, Dept Pediat Resp Med, Rotterdam, Netherlands; [Wijga, Alet; Smit, Henriette A.] Natl Inst Publ Hlth & Environm RIVM, Ctr Prevent & Hlth Serv Res, Bilthoven, Netherlands; [Schipper, C. Maarten A.] Natl Inst Publ Hlth & Environm, Expertise Ctr Methodol & Informat Serv, Bilthoven, Netherlands; [Hoekstra, Maarten] Wilhelmina Childrens Hosp, Ctr Paediat Allergol, Utrecht, Netherlands; [Postma, Dirkje S.; Koppelman, Gerard H.] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Erasmus University Rotterdam; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Wilhelmina Kinderziekenhuis; University of Groningen; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	de Jongste, JC (corresponding author), Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Resp Med, POB 2060, NL-3000 CB Rotterdam, Netherlands.	j.c.dejongste@erasmusmc.nl	Koppelman, Gerard/AAG-9187-2020	brunekreef, bert/0000-0001-9908-0060; Koppelman, Gerard/0000-0001-8567-3252	Netherlands Organisation for Health Research and Development; Netherlands Organisation for Scientific Research; Netherlands Asthma Fund; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare and Sport; Netherlands Organisation for Scientific Research (NWO)	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Asthma Fund; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare and Sport; Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	Supported by the Netherlands Organisation for Health Research and Development; the Netherlands Organisation for Scientific Research; the Netherlands Asthma Fund; the Netherlands Ministry of Spatial Planning, Housing, and the Environment; and the Netherlands Ministry of Health, Welfare and Sport. The salary of D. C. was paid by a "Toptalent" grant from Netherlands Organisation for Scientific Research (NWO).	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bernsen RMD, 2003, PEDIATR ALLERGY IMMU, V14, P464, DOI 10.1046/j.0905-6157.2003.00108.x; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Cesaroni G, 2003, EUR RESPIR J, V22, P619, DOI 10.1183/09031936.03.00091202; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Duran-Tauleria E, 1999, THORAX, V54, P476, DOI 10.1136/thx.54.6.476; Eysink PED, 2005, BRIT J GEN PRACT, V55, P125; Frank PI, 2008, BRIT MED J, V336, P1423, DOI 10.1136/bmj.39568.623750.BE; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Levy Mark L, 2006, Prim Care Respir J, V15, P20, DOI 10.1016/j.pcrj.2005.10.004; MACFARLANE PI, 1988, ARCH DIS CHILD, V63, P368, DOI 10.1136/adc.63.4.368; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; McKean M, 2000, Cochrane Database Syst Rev, pCD001107, DOI 10.1002/14651858.CD001107; Moons KGM, 2006, J CLIN EPIDEMIOL, V59, P1092, DOI 10.1016/j.jclinepi.2006.01.009; MurphyFilkins RL, 1996, CRIT CARE MED, V24, P1968, DOI 10.1097/00003246-199612000-00007; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; R Development Core Team, 2007, R LANG ENV STAT COMP; Remes ST, 2008, PEDIAT ALLERG IMM-UK, V19, P541, DOI 10.1111/j.1399-3038.2007.00707.x; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Tollanes MC, 2008, J PEDIATR-US, V153, P112, DOI 10.1016/j.jpeds.2008.01.029; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; VANBUUREN S, MICE MULTIVARIATE IM; Wever-Hess J, 1999, ACTA PAEDIATR, V88, P827, DOI 10.1080/08035259950168739; Zuidgeest MG, 2008, RESP MED, V102, P1446, DOI 10.1016/j.rmed.2008.04.003	29	137	146	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					903	910		10.1016/j.jaci.2009.06.045	http://dx.doi.org/10.1016/j.jaci.2009.06.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19665765	Bronze			2022-12-18	WOS:000272108000004
J	Sarin, S; Undem, B; Sanico, A; Togias, A				Sarin, Seema; Undem, Bradley; Sanico, Alvin; Togias, Alkis			The role of the nervous system in rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						neuroimmune interactions; nasal reflexes; nasal hyperresponsiveness; neurogenic inflammation; neuropeptides; nerve growth factor; capsaicin; nociception; allergic rhinins; nonallergic rhinitis	HUMAN NASAL-MUCOSA; SEASONAL ALLERGIC RHINITIS; COLD DRY AIR; NONINFECTIOUS PERENNIAL RHINITIS; VASOACTIVE-INTESTINAL-PEPTIDE; PRIMARY AFFERENT NEURONS; NECROSIS-FACTOR-ALPHA; GENE-RELATED PEPTIDE; MAJOR BASIC-PROTEIN; PIG ISOLATED AIRWAY	The nose provides defensive and homeostatic functions requiring rapid responses to physical and chemical stimuli. As a result, it is armed with a complex nervous system that includes sensory, parasympathetic, and sympathetic nerves. Sensory nerves transmit signals from the mucosa, generating sensations, such as pruritus; motor reflexes, such as sneezing; and parasympathetic and sympathetic reflexes that affect the glandular and vascular nasal apparatuses. Reflexes directed to the nose are also generated by inputs from other body regions. Hence all symptoms that constitute the nosologic entity of rhinitis can be triggered through neural pathways. In addition, neural signals generated in the nose can influence distal physiology, such as that of the bronchial tree and the cardiovascular system. Neural function can be chronically upregulated in the presence of mucosal inflammation, acutely with an allergic reaction, or even in the absence of inflammation, as in cases of nonallergic rhinitis. Upregulation of the nasal nervous system can occur at various levels of the reflex pathways, resulting in exaggerated responses (neural hyperresponsiveness), as well as in increased capacity for generation of neurogenic inflammation, a phenomenon that depends on the release of neuropeptides on antidromic stimulation of nociceptive sensory nerves. The molecular mechanisms of hyperresponsiveness are not understood, but several inflammatory products appear to be playing a role. Neurotrophins, such as the nerve growth factor, are prime candidates as mediators of neural hyperresponsiveness. The many interactions between the nervous and immune systems contribute to nasal physiology but also to nasal disease.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Div Resp & Crit Care Med, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Togias, A (corresponding author), NIAID, DAIT, Room 3060,6610 Rockledge Dr, Bethesda, MD 20817 USA.	a_togias@comcast.net						Ahern GP, 2005, J NEUROSCI, V25, P5109, DOI 10.1523/JNEUROSCI.0237-05.2005; ANGELL JE, 1969, P ROY SOC MED, V62, P1287, DOI 10.1177/003591576906201238; ANGELLJAMES JE, 1972, J PHYSIOL-LONDON, V220, P673; ANGGARD A, 1974, ACTA OTO-LARYNGOL, V78, P98, DOI 10.3109/00016487409126332; ANGGARD A, 1977, ACTA OTO-LARYNGOL, V83, P22, DOI 10.3109/00016487709128806; ANTON F, 1991, NEUROSCIENCE, V41, P617, DOI 10.1016/0306-4522(91)90354-Q; BALUK P, 1995, AM J PHYSIOL-LUNG C, V268, pL263, DOI 10.1152/ajplung.1995.268.2.L263; Baraniuk JN, 1999, AM J RESP CRIT CARE, V160, P655, DOI 10.1164/ajrccm.160.2.9805081; BARANIUK JN, 1992, J ALLERGY CLIN IMMUN, V90, P1045, DOI 10.1016/0091-6749(92)90121-H; BARANIUK JN, 1990, AM J RESP CELL MOL, V3, P165, DOI 10.1165/ajrcmb/3.2.165; BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1991, AM J PHYSIOL, V261, pL223, DOI 10.1152/ajplung.1991.261.4.L223; BARANIUK JN, 1990, J APPL PHYSIOL, V258, P81; BARNES P, 1993, EUR RESPIR J, V6, P378; BAROODY F, 2003, UPPER LOWER RESP DIS, P1; BAROODY FM, 1992, J ALLERGY CLIN IMMUN, V90, P373, DOI 10.1016/S0091-6749(05)80017-X; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; BATES J, 1971, J PHYSIOL-LONDON, V219, pP1; BEDARD PM, 1989, AM J RHINOL, V3, P211; Berger D, 1979, Rhinology, V17, P193; BERNSTEIN JM, 1991, OTOLARYNG HEAD NECK, V105, P596; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Blom HM, 1998, CLIN EXP ALLERGY, V28, P1351; Braat JPM, 1998, AM J RESP CRIT CARE, V157, P1748, DOI 10.1164/ajrccm.157.6.9701016; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CAUNA N, 1972, J NEUROCYTOL, V1, P49, DOI 10.1007/BF01098645; CAUNA N, 1970, ANN OTO RHINOL LARYN, V79, P443, DOI 10.1177/000348947007900303; CAUNA N, 1970, ANAT REC, V168, P9, DOI 10.1002/ar.1091680102; CAUNA N, 1982, NOSE, P44; Cervin A, 1999, AM J RESP CRIT CARE, V160, P1724, DOI 10.1164/ajrccm.160.5.9902102; Cho YS, 2003, J ALLERGY CLIN IMMUN, V112, P695, DOI 10.1016/S0091-6749(03)01784-6; Chuaychoo B, 2005, J ALLERGY CLIN IMMUN, V116, P325, DOI 10.1016/j.jaci.2005.04.005; Cook JA, 1996, CLIN OTOLARYNGOL, V21, P226, DOI 10.1111/j.1365-2273.1996.tb01730.x; CRUZ AA, 1992, AM REV RESPIR DIS, V146, P340, DOI 10.1164/ajrccm/146.2.340; Curatolo M, 2004, CLIN J PAIN, V20, P469, DOI 10.1097/00002508-200411000-00013; DAHLSTROEM A, 1965, Acta Otolaryngol, V59, P65, DOI 10.3109/00016486509128547; De Swert KO, 2006, EUR J PHARMACOL, V533, P171, DOI 10.1016/j.ejphar.2005.12.066; de Vries A, 2001, BRIT J PHARMACOL, V134, P771, DOI 10.1038/sj.bjp.0704310; deTineo ML, 2001, J ALLERGY CLIN IMMUN, V107, P194, DOI 10.1067/mai.2001.111927; Diemer FB, 1999, J ALLERGY CLIN IMMUN, V103, pS2; Dixon WE, 1903, J PHYSIOL-LONDON, V29, P97; Djouhri L, 2004, BRAIN RES REV, V46, P131, DOI 10.1016/j.brainresrev.2004.07.015; DOYLE WJ, 1994, J ALLERGY CLIN IMMUN, V93, P534, DOI 10.1016/0091-6749(94)90364-6; DRAY A, 1994, TRENDS PHARMACOL SCI, V15, P190, DOI 10.1016/0165-6147(94)90147-3; DRETTNER B, 1961, ACTA OTOLARYNOL S, V166, P3; ECCLES R, 1974, J PHYSIOL-LONDON, V238, P549, DOI 10.1113/jphysiol.1974.sp010542; ECCLES R, 1978, ACTA OTO-LARYNGOL, V86, P464, DOI 10.3109/00016487809107526; ECCLES R, 1983, EUR J RESPIR DIS, V64, P150; Eccles R., 1982, NOSE UPPER AIRWAY PH, P191; ELLIS JL, 1991, J PHYSIOL-LONDON, V436, P469, DOI 10.1113/jphysiol.1991.sp018561; ELLIS JL, 1992, J PHARMACOL EXP THER, V262, P646; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; EVERETT HC, 1964, NEUROLOGY, V14, P483, DOI 10.1212/WNL.14.5.483; Fajac I, 1995, ALLERGY, V50, P970, DOI 10.1111/j.1398-9995.1995.tb02509.x; Fang SY, 1998, ACTA OTO-LARYNGOL, V118, P398; Fang SY, 1998, CLIN EXP ALLERGY, V28, P228; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; FISCHER A, 1998, ACI INT, V10, P10; Fischer Laurent, 1993, Rhinology (Utrecht), V31, P11; Fischer-Colbrie R, 2005, CURR PROTEIN PEPT SC, V6, P373, DOI 10.2174/1389203054546334; FLISBERG K, 1962, Acta Otolaryngol, V55, P457, DOI 10.3109/00016486209127380; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739, DOI 10.1152/jappl.1996.81.4.1739; Fontanari P, 1997, EUR RESPIR J, V10, P2250, DOI 10.1183/09031936.97.10102250; FRYER AD, 1993, LIFE SCI, V52, P529, DOI 10.1016/0024-3205(93)90311-P; FRYER AD, 1984, BRIT J PHARMACOL, V83, P973, DOI 10.1111/j.1476-5381.1984.tb16539.x; FRYER AD, 2000, ALLERGY CLIN IMMUNOL, V12, P63; GEPPETTI P, 1988, BRIT J PHARMACOL, V93, P509, DOI 10.1111/j.1476-5381.1988.tb10305.x; Gooden Brett A., 1994, Integrative Physiological and Behavioral Science, V29, P6, DOI 10.1007/BF02691277; GRONBORG H, 1983, EUR J RESPIR DIS, V64, P406; Gungor A, 1999, OTOLARYNG HEAD NECK, V121, P585, DOI 10.1016/S0194-5998(99)70061-6; HALL LJ, 1968, ANN OTO RHINOL LARYN, V77, P1120, DOI 10.1177/000348946807700610; Hanazawa T, 1997, ACTA OTO-LARYNGOL, V117, P735, DOI 10.3109/00016489709113469; Heppt W, 2004, CLIN EXP ALLERGY, V34, P1105, DOI 10.1111/j.1365-2222.2004.01990.x; HOLZER P, 1991, PHARMACOL REV, V43, P143; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; Hua XY, 1996, J NEUROSCI, V16, P4742; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P1985, DOI 10.1164/ajrccm.161.6.9908051; ICHINOSE M, 1992, LANCET, V340, P1248, DOI 10.1016/0140-6736(92)92948-F; ISHII T, 1970, PRACT-OTO-RHINO-LARY, V32, P153; JACKSON RT, 1971, LARYNGOSCOPE, V81, P565, DOI 10.1288/00005537-197104000-00007; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; James DE, 1999, CLIN EXP ALLERGY, V29, P1309; JANCSO N, 1967, BRIT J PHARM CHEMOTH, V31, P138, DOI 10.1111/j.1476-5381.1967.tb01984.x; Jaradeh SS, 2000, LARYNGOSCOPE, V110, P1828, DOI 10.1097/00005537-200011000-00012; Johansson A, 2000, RESP MED, V94, P1119, DOI 10.1053/rmed.2000.0924; KALINER MA, 1992, J ALLERGY CLIN IMMUN, V90, P1044, DOI 10.1016/0091-6749(92)90120-Q; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; Kawarai M, 2001, EUR J PHARMACOL, V413, P255, DOI 10.1016/S0014-2999(01)00759-2; KAYSER R, 1889, Z OHRENHEILKD, V20, P96; KENINS P, 1981, NEUROSCI LETT, V25, P137, DOI 10.1016/0304-3940(81)90321-9; KEUNING J, 1968, INT RHINOL, V6, P98; KLAASSEN ABM, 1986, CELL TISSUE RES, V243, P655; Kobayashi H, 2002, BLOOD, V99, P2214, DOI 10.1182/blood.V99.6.2214; KONNO A, 1983, EUR J RESPIR DIS, V64, P97; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; KONNO A, 1997, J CLIN THER MED, V13, P1921; Korsgren M, 2005, ALLERGY, V60, P459, DOI 10.1111/j.1398-9995.2005.00713.x; Korsgren M, 2003, AM J RESP CRIT CARE, V167, P1504, DOI 10.1164/rccm.200212-1508OC; Koskela H, 1995, EUR RESPIR J, V8, P2088, DOI 10.1183/09031936.95.08122088; Kummer W, 1995, PULM PHARMACOL THER, V8, P169, DOI 10.1006/pulp.1995.1022; Lacroix JS, 1998, ACTA OTO-LARYNGOL, V118, P257; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; LACROIX JS, 1989, ACTA PHYSIOL SCAND, V136, P1; LEVI CR, 1990, AUST NZ J MED, V20, P578, DOI 10.1111/j.1445-5994.1990.tb01317.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LILLY CM, 1994, J CLIN INVEST, V93, P2667, DOI 10.1172/JCI117280; LISNEY SJW, 1989, NEWS PHYSIOL SCI, V4, P45; LITTELL NT, 1990, AM REV RESPIR DIS, V141, P580, DOI 10.1164/ajrccm/141.3.580; LUCIER GE, 1989, EXP NEUROL, V103, P83, DOI 10.1016/0014-4886(89)90189-1; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V115, P521, DOI 10.1111/j.1748-1716.1982.tb07116.x; LUNDBLAD L, 1985, EUR J PHARMACOL, V113, P461, DOI 10.1016/0014-2999(85)90098-6; LUNDBLAD L, 1983, ACTA PHYSIOL SCAND, V119, P7, DOI 10.1111/j.1748-1716.1983.tb07299.x; LUNDBLAD L, 1983, ACTA OTO-LARYNGOL, V96, P479, DOI 10.3109/00016488309132734; LUNDBLAD L, 1984, N-S ARCH PHARMACOL, V326, P254, DOI 10.1007/BF00505327; LUNDBLAD L, 1982, BRIT J PHARMACOL, V77, P378; MALM L, 1977, ACTA OTO-LARYNGOL, V83, P20, DOI 10.3109/00016487709128805; Malmstrom R E, 1997, Acta Physiol Scand Suppl, V636, P1; MARABINI S, 1988, REGUL PEPTIDES, V22, P121, DOI 10.1016/0167-0115(88)90341-2; MARABINI S, 1991, EUR ARCH OTO-RHINO-L, V248, P191; McAlexander MA, 1998, J PHARMACOL EXP THER, V285, P602; MCDONALD DM, 1988, J NEUROCYTOL, V17, P605, DOI 10.1007/BF01260989; MCDONALD DM, 1988, J NEUROCYTOL, V17, P583, DOI 10.1007/BF01260988; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; Moore KA, 2000, AM J RESP CRIT CARE, V161, P232, DOI 10.1164/ajrccm.161.1.9903091; Morice AH, 2004, EUR RESPIR J, V24, P481, DOI 10.1183/09031936.04.00027804; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; MULLINS RJ, 1989, J ALLERGY CLIN IMMUN, V83, P955, DOI 10.1016/0091-6749(89)90111-5; Myers AC, 2002, AM J PHYSIOL-LUNG C, V282, pL775, DOI 10.1152/ajplung.00353.2001; MYERS AC, 1991, J APPL PHYSIOL, V71, P970, DOI 10.1152/jappl.1991.71.3.970; NAKAJIMA N, 1994, AM J RESP CRIT CARE, V149, P694, DOI 10.1164/ajrccm.149.3.7509704; Nakaya M, 2002, ANN OTO RHINOL LARYN, V111, P593, DOI 10.1177/000348940211100705; Nathan Robert A, 2005, J Allergy Clin Immunol, V115, pS442, DOI 10.1016/j.jaci.2004.12.015; Nilsson G, 1997, EUR J IMMUNOL, V27, P2295, DOI 10.1002/eji.1830270925; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P583, DOI 10.1016/j.jaci.2005.11.049; Nockher WA, 2006, J ALLERGY CLIN IMMUN, V117, P67, DOI 10.1016/j.jaci.2005.08.029; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; NOMURA Y, 1972, ACTA OTO-LARYNGOL, V73, P493, DOI 10.3109/00016487209138970; Numata T, 2000, LARYNGOSCOPE, V110, P297, DOI 10.1097/00005537-200002010-00021; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; OKAYAMA M, 1993, AM J RESP CELL MOL, V8, P176, DOI 10.1165/ajrcmb/8.2.176; Okita W, 1998, ACTA OTO-LARYNGOL, P76; OKUDA M, 1983, ANN ALLERGY, V51, P51; PERNOW B, 1985, J IMMUNOL, V135, pS812; Peters-Golden M, 2006, CLIN EXP ALLERGY, V36, P689, DOI 10.1111/j.1365-2222.2006.02498.x; Philip G, 1996, AM J RESP CRIT CARE, V153, P1222, DOI 10.1164/ajrccm.153.4.8616545; PHILIP G, 1993, AM REV RESPIR DIS, V148, P1616, DOI 10.1164/ajrccm/148.6_Pt_1.1616; Piedimonte G, 2002, RESP RES, V3, DOI 10.1186/rr185; Plevkova J, 2004, J Physiol Pharmacol, V55 Suppl 3, P101; Plevkova J, 2004, RESP PHYSIOL NEUROBI, V142, P225, DOI 10.1016/j.resp.2004.06.006; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; Revington M, 1997, J PHYSIOL-LONDON, V505, P823, DOI 10.1111/j.1469-7793.1997.823ba.x; Riccio MM, 1996, J ALLERGY CLIN IMMUN, V97, P1252, DOI 10.1016/S0091-6749(96)70193-8; Riccio MM, 1996, J PHYSIOL-LONDON, V491, P499, DOI 10.1113/jphysiol.1996.sp021234; ROOKER DW, 1969, ANN OTO RHINOL LARYN, V78, P403, DOI 10.1177/000348946907800217; Sanico AM, 1998, CLIN EXP ALLERGY, V28, P92; Sanico AM, 1997, J ALLERGY CLIN IMMUN, V100, P632, DOI 10.1016/S0091-6749(97)70167-2; Sanico AM, 1998, J APPL PHYSIOL, V84, P537, DOI 10.1152/jappl.1998.84.2.537; Sanico AM, 1999, J APPL PHYSIOL, V86, P1202, DOI 10.1152/jappl.1999.86.4.1202; Sanico AM, 2000, AM J RESP CRIT CARE, V161, P1631, DOI 10.1164/ajrccm.161.5.9908028; Sanico AM, 1999, INT ARCH ALLERGY IMM, V118, P154, DOI 10.1159/000024054; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; SARIA A, 1988, REGUL PEPTIDES, V22, P167, DOI 10.1016/0167-0115(88)90387-4; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; Settipane RA, 2001, ANN ALLERG ASTHMA IM, V86, P494, DOI 10.1016/S1081-1206(10)62896-7; Shirasaki H, 2004, ACTA OTO-LARYNGOL, V124, P85, DOI 10.1080/03655230410017733; Shirasaki H, 1998, ACTA OTO-LARYNGOL, V118, P717; Shusterman DJ, 1998, J ALLERGY CLIN IMMUN, V101, P732, DOI 10.1016/S0091-6749(98)70302-1; Solomon A, 1998, J ALLERGY CLIN IMMUN, V102, P454, DOI 10.1016/S0091-6749(98)70135-6; STJARNE P, 1989, CELL TISSUE RES, V256, P439; Stjarne P, 1991, AM J RHINOL ALLERGY, V5, P145, DOI [10.2500/105065891781874992, DOI 10.2500/105065891781874992]; STOKSTED P, 1952, Acta Otolaryngol, V42, P175, DOI 10.3109/00016485209120341; STOKSTED P, 1953, Acta Otolaryngol Suppl, V109, P176; SUNG CP, 1991, CIRC RES, V68, P314, DOI 10.1161/01.RES.68.1.314; SVENSSON C, 1995, CLIN EXP ALLERGY, V25, P942, DOI 10.1111/j.1365-2222.1995.tb00396.x; Tai CF, 2002, CURR OPIN ALLERGY CL, V2, P11, DOI 10.1097/00130832-200202000-00003; Taylor-Clark TE, 2005, J ALLERGY CLIN IMMUN, V116, P1282, DOI 10.1016/j.jaci.2005.08.043; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P283, DOI 10.1016/0091-6749(88)90694-X; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS A, 1993, ALLERGIC NONALLERGIC, P159; Tortorolo L, 2005, AM J RESP CRIT CARE, V172, P233, DOI 10.1164/rccm.200412-1693OC; UDDMAN R, 1981, ACTA OTO-LARYNGOL, V91, P135, DOI 10.3109/00016488109138491; UDDMAN R, 1978, ACTA OTO-LARYNGOL, V86, P443, DOI 10.3109/00016487809124767; UMENO E, 1990, J APPL PHYSIOL, V69, P2131, DOI 10.1152/jappl.1990.69.6.2131; UNDEM BJ, 1991, INT ARCH ALLER A IMM, V94, P319, DOI 10.1159/000235394; UNDEM BJ, 1993, J AUTONOM NERV SYST, V44, P35, DOI 10.1016/0165-1838(93)90376-6; UNDEM BJ, 2000, J ALLERGY CLIN IMMUN, V106, P213; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; Van Rijswijk JB, 2003, ALLERGY, V58, P754, DOI 10.1034/j.1398-9995.2003.00203.x; VANWIJK RG, 1987, CLIN ALLERGY, V17, P563; WAGENMANN M, 1994, J ALLERGY CLIN IMMUN, V93, P594, DOI 10.1016/S0091-6749(94)70071-0; Wagner JA, 1996, J EXP MED, V183, P2417, DOI 10.1084/jem.183.6.2417; WALDEN SM, 1991, AM REV RESPIR DIS, V144, P642, DOI 10.1164/ajrccm/144.3_Pt_1.642; WALLOIS F, 1995, BRAIN RES, V687, P143, DOI 10.1016/0006-8993(95)00487-B; WALLOIS F, 1991, NEUROSCI LETT, V122, P145, DOI 10.1016/0304-3940(91)90843-I; Walsh MT, 2004, AM J RESP CELL MOL, V30, P333, DOI 10.1165/rcmb.2003-0188OC; Wang M, 2003, BRIT J PHARMACOL, V138, P145, DOI 10.1038/sj.bjp.0705020; WEINREICH D, 1987, J CLIN INVEST, V79, P1529, DOI 10.1172/JCI112984; Weinreich D, 1997, J NEUROSCI, V17, P7683; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; Woolf C J, 1994, Drugs, V47 Suppl 5, P1, DOI 10.2165/00003495-199400475-00003; Wu XQ, 2006, J ALLERGY CLIN IMMUN, V118, P428, DOI 10.1016/j.jaci.2006.04.037; Wuestenberg EG, 2004, AM J RHINOL, V18, P371, DOI 10.1177/194589240401800606; Xiang Z, 2000, CLIN EXP ALLERGY, V30, P1379, DOI 10.1046/j.1365-2222.2000.00906.x; YAMAGIWA M, 1990, AM REV RESPIR DIS, V141, P1050, DOI 10.1164/ajrccm/141.4_Pt_1.1050; YAN K, 1983, EUR J RESPIR DIS, V64, P105; Yao W, 1996, ANN NY ACAD SCI, V805, P784; ZEIGER RS, 1989, AM J RHINOL, V3, P113; Zhang JM, 2002, J NEUROPHYSIOL, V88, P1387, DOI 10.1152/jn.2002.88.3.1387	215	137	151	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					999	1014		10.1016/j.jaci.2006.09.013	http://dx.doi.org/10.1016/j.jaci.2006.09.013			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088122				2022-12-18	WOS:000244282300002
J	Yu, JW; Kagan, R; Verreault, N; Nicolas, N; Joseph, L; Pierre, YS; Clarke, A				Yu, Joyce W.; Kagan, Rhoda; Verreault, Nina; Nicolas, Nathalie; Joseph, Lawrence; Pierre, Yvan St.; Clarke, Ann			Accidental ingestions in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; accidental ingestion; treatment; peanut safe policies	SKIN PRICK TESTS; TREE-NUT-ALLERGY; NATURAL-HISTORY; HYPERSENSITIVITY REACTIONS; ANAPHYLACTIC REACTIONS; IGE CONCENTRATIONS; FOOD; PREVALENCE; RESOLUTION; CHALLENGE	Background: Accidental exposure to peanut has been reported to occur frequently. Total avoidance of peanut is difficult because of its widespread use, manufacturing and labeling errors, utensil contamination, and label misinterpretation. Objective: Given the apparent increased awareness of peanut allergy by both consumers and food manufacturers, we aimed to determine the current frequency of accidental exposures occurring in peanut allergic children in Quebec and to identify factors associated with exposure. Methods: The parents of children with peanut allergy diagnosed at the Montreal Children's Hospital completed questionnaires about accidental exposure to peanut occurring over the period of the preceding year. Logistic regression was used to identify associated factors. Results: Of 252 children, 62% were boys, with a mean age of 8.1 years (SD, 2.9). The mean age at diagnosis was 2.0 years (SD, 2.1). Thirty-five accidental exposures occurred in 29 children over a period of 244 patient-years, yielding an annual incidence rate of 14.3% (95% CI, 10.0% to 19.9%). Fifteen reactions were mild, 16 moderate, and 4 severe. Of 20 reactions that were moderate to severe, only 4 received epinephrine. Eighty percent of children attended schools prohibiting peanut, and only 1 accidental exposure occurred at school. No associated factors were identified. Conclusion: Accidental exposure to peanut occurs at a lower frequency than previously reported, but most reactions are managed inappropriately. Clinical implications: Enhanced awareness, access to safer environments, and good food manufacturing practices may have contributed to a lower incidence of inadvertent peanut exposure, but a further reduction and better education on allergy management are desirable.	McGill Univ, Div Clin Immunol & Allergy, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; McGill Univ, Div Pediat Allergy & Clin Immunol, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; McGill Univ, Div Clin Epidemiol, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University; McGill University; McGill University	Clarke, A (corresponding author), McGill Univ, Div Clin Immunol & Allergy, Ctr Hlth, 1650 Cedar Ave,L10-413, Montreal, PQ H3G 1A4, Canada.	ann.clarke@mcgill.ca						Al-Muhsen S, 2003, CAN MED ASSOC J, V168, P1279; Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Banerjee D. K., 2004, Journal of Allergy and Clinical Immunology, V113, pS152, DOI 10.1016/j.jaci.2003.12.556; Banerjee DK, 2006, J ALLERGY CLIN IMMUN, V117, pS36, DOI 10.1016/j.jaci.2005.12.146; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; *CAN FOOD INSP AG, 2004, UND ALL FOOD; *CAN FOOD INSP AG, 2005, FOOD ALL; *CAN FOOD INSP AG, 2001, NAT SECT ASS 2000 IM; *CAN SOC ALL CLIN, 2005, AN SCH OTH SETT 2005; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; McKenna C, 1997, ANN ALLERG ASTHMA IM, V79, P234, DOI 10.1016/S1081-1206(10)63008-6; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790, DOI 10.1001/archpedi.155.7.790; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schappi GF, 2001, ALLERGY, V56, P1216, DOI 10.1034/j.1398-9995.2001.00280.x; Sicherer SH, 2000, CURR OPIN PEDIATR, V12, P567, DOI 10.1097/00008480-200012000-00010; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P118, DOI 10.1016/j.jaci.2004.03.056; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350, DOI 10.1016/S1081-1206(10)62363-0; Simons E, 2005, ANN ALLERG ASTHMA IM, V95, P426, DOI 10.1016/S1081-1206(10)61166-0; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473, DOI 10.1016/S1081-1206(10)62574-4; Vadas P, 2003, J FOOD PROTECT, V66, P1932, DOI 10.4315/0362-028X-66.10.1932; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Vierk K, 2002, J ALLERGY CLIN IMMUN, V109, P1022, DOI 10.1067/mai.2002.124500	45	137	137	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					466	472		10.1016/j.jaci.2006.04.024	http://dx.doi.org/10.1016/j.jaci.2006.04.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890773				2022-12-18	WOS:000239877700024
J	Finn, A; Gross, G; van Bavel, J; Lee, T; Windom, H; Everhard, F; Fowler-Taylor, A; Liu, J; Gupta, N				Finn, A; Gross, G; van Bavel, J; Lee, T; Windom, H; Everhard, F; Fowler-Taylor, A; Liu, J; Gupta, N			Omalizumab improves asthma-related quality of life in patients with severe allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IGE; ANTIBODY; INFLAMMATION; INHIBITION	Background: We have previously shown that omalizumab, a recombinant humanized monoclonal anti-IgE antibody, reduces asthma exacerbations and decreases inhaled corticosteroid (ICS) requirement in patients with severe allergic asthma who were symptomatic despite moderate-to-high doses of Icss. Objective: The aim of the present study was to assess the effects of omalizumab on asthma-related quality of life (QOL). Methods: These analyses were part of a multicenter, 52-week, randomized, double-blind, placebo-controlled study assessing the efficacy, safety, and tolerability of subcutaneous omalizumab ( greater than or equal to0.016 mg/kg of IgE [in international unit per milliliter] per 4 weeks) in 525 adults with severe allergic asthma. A 16-week steroid-stable phase was followed by a 12-week steroid-reduction phase and a 24-week double-blind extension phase. The effect of treatment on asthma-related QOL was evaluated by using the Asthma Quality of Life Questionnaire (AQLQ) administered at baseline and at weeks 16, 28, and 52. Results: The 2 treatment groups were comparable in terms of baseline AQLQ scores. At weeks 16, 28, and 52, omalizumab treated patients demonstrated statistically significant improvements across all AQLQ domains, as well as in overall score. Moreover, a greater proportion of patients receiving omalizumab achieved a clinically meaningful improvement in asthma-related QOL during each phase of the study. Greater than 50% of both patients and investigators rated treatment similarly with omalizumab as excellent or good compared with less than 40% of placebo recipients. Conclusion: In patients requiring moderate-to-high doses of ICSs for severe allergic asthma, the measurably improved disease control afforded by add-on omalizumab therapy is paralleled by clinically meaningful improvements in asthma-related QOL. (J Allergy Clin Immunol 2003; 111:278-84.).	Novartis Pharmaceut, E Hanover, NJ 07936 USA; Natl Allergy Asthma & Urticaria Ctr, Charleston, SC USA; Dallas Allergy & Asthma Ctr, Dallas, TX USA; Allergy & Asthma Associates Res Dept, Austin, TX USA; Peachtree Allergy & Asthma Clin, Atlanta, GA USA; Asthma & Allergy Res Ctr, Sarasota, FL USA; Novartis Pharma AG, Basel, Switzerland	Novartis; Novartis	Gupta, N (corresponding author), Novartis Pharmaceut, 1 Hlth Plaza,Bldg 122-N208, E Hanover, NJ 07936 USA.							Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Easthope S, 2001, DRUGS, V61, P253, DOI 10.2165/00003495-200161020-00008; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Holt PG, 1999, NATURE, V402, pB12; Jardieu PM, 1999, INT ARCH ALLERGY IMM, V118, P112, DOI 10.1159/000024043; Juniper E.F., 1996, QUAL LIFE PHARAMACOE, P49; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; LAINER R, 2001, AM J RESP CRIT CARE, V163, pA858; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; *NAT ASTHM ED PREV, 1997, PUBL US DHHS; PRESTA LG, 1993, J IMMUNOL, V151, P2623; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P412, DOI 10.1159/000237058; Spector SL, 1999, ANN ALLERG ASTHMA IM, V83, P435, DOI 10.1016/S1081-1206(10)62848-7; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	21	137	145	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					278	284		10.1067/mai.2003.54	http://dx.doi.org/10.1067/mai.2003.54			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589345				2022-12-18	WOS:000180942700009
J	OSullivan, S; Dahlen, B; Dahlen, SE; Kumlin, M				OSullivan, S; Dahlen, B; Dahlen, SE; Kumlin, M			Increased urinary excretion of the prostaglandin D-2 metabolite 9 alpha,11 beta-prostaglandin F-2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urinary 9 alpha,11 beta-prostaglandin F-2; prostaglandin D-2; leukotrienes; enzyme immunoassay; mast cell; aspirin-induced asthma	BRONCHOALVEOLAR LAVAGE FLUID; SENSITIVE ASTHMATIC SUBJECTS; RECEPTOR ANTAGONIST MK-0679; LEUKOTRIENE-ANTAGONIST; ATOPIC ASTHMATICS; HUMAN EOSINOPHILS; NASAL SECRETIONS; RELEASE; GENERATION; ALLERGEN	Prostaglandin (PG)D-2 is a major product of arachidonic acid metabolism in pulmonary mast cells. We therefore attempted to determine whether measurement of the stable urinary metabolite of PGD(2), 9 alpha,11 beta-PGF(2), could serve as a marker of mast cell activation in the lungs. A commercially available enzyme immunoassay was validated and found to be specific and sensitive when applied to unpurified urine. There was no diurnal variation in the levels of 9 alpha,11 beta-PGF(2) in healthy volunteers. Morning baseline values of urinary 9 alpha,11 beta-PGF(2) were measured in three groups-healthy volunteers (n = 9), patients with atopic asthma (n = 14), and aspirin-intolerant patients with asthma (n = 12)-and found to be very similar, 54 +/- 9, 62 +/- 5, and 71 +/- 15 ng/mmol creatinine, respectively (means +/- SEM). Urinary excretion of 9 alpha,11 beta-PGF(2). In addition, challenge with a higher dose of aspirin produced an even greater increase in urinary 9 alpha,11 beta-PGF(2), supporting dose-dependent release of PGD(2) during aspirin-induced bronchoconstriction. In contrast, the postchallenge levels of urinary 9 alpha,11 beta-PGF(2) were not increased when bronchoconstriction was induced by histamine challenge in the aspirin-intolerant patients with asthma. The study confirms mast cell involvement in allergen-induced bronchoconstriction and provides novel data, which strongly support the hypothesis that pulmonary mast cells are activated during aspirin-induced airway obstruction. It is finally suggested that measurement of urinary 9 alpha,11 beta-PGF(2) with enzyme immunoassay may be used as a new noninvasive strategy to monitor mast cell activation in vivo.	KAROLINSKA HOSP, DEPT MED BIOCHEM & BIOPHYS, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT MED, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT PHYSIOL & PHARMACOL, S-10401 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	OSullivan, S (corresponding author), KAROLINSKA INST, INST ENVIRONM MED, ASTHMA & ALLERGY RES GRP, S-17177 STOCKHOLM, SWEDEN.							BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; BUTTERFIELD JH, 1995, MAYO CLIN PROC, V70, P481, DOI 10.4065/70.5.481; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN B, 1994, EUR RESPIR J, V7, P324, DOI 10.1183/09031936.94.07020324; DAHLEN B, 1993, THORAX, V48, P1205, DOI 10.1136/thx.48.12.1205; DAHLEN B, 1990, EUR RESPIR J, V3, P527; DAHLEN B, 1995, MANUAL ASTHMA MANAGE, P590; DAHLEN SE, 1995, AM J RESP CRIT CARE, V151, pA376; DAHLEN SE, 1983, ACTA PHYSL SCAND, V53, P589; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; FRIEDLAENDER S, 1947, ANN INTERN MED, V26, P734, DOI 10.7326/0003-4819-26-5-734; Granstrom E, 1987, PROSTAGLANDINS RELAT, P5; HAMRIN B, 1957, LANCET, V1, P867; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; KUMLIN M, 1995, CLIN EXP ALLERGY, V25, P467, DOI 10.1111/j.1365-2222.1995.tb01079.x; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LISTON TE, 1985, P NATL ACAD SCI USA, V82, P6030, DOI 10.1073/pnas.82.18.6030; LISTON TE, 1985, J BIOL CHEM, V260, P3172; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1989, PROSTAGLANDINS, V38, P263, DOI 10.1016/0090-6980(89)90088-9; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; OWEN WF, 1987, J IMMUNOL, V138, P532; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; PIPER PJ, 1982, BRIT J PHARMACOL, V77, P267, DOI 10.1111/j.1476-5381.1982.tb09295.x; PRADELLES P, 1990, METHOD ENZYMOL, V187, P24; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS LJ, 1983, CLIN RES, V31, pA165; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHULMAN ES, 1983, EUR J RESPIR DIS, V64, P53; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; SCHUMBERGER H, 1974, ACTA MED SCAND, V196, P451; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SLADEK K, 1993, EUR RESPIR J, V6, P391; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; TAYLOR IK, 1992, J APPL PHYSIOL, V73, P743, DOI 10.1152/jappl.1992.73.2.743; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELTMAN JK, 1978, ALLERGY, V33, P273, DOI 10.1111/j.1398-9995.1978.tb01548.x; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; YAMAMOTO H, 1994, AM J RESP CRIT CARE, V150, P254, DOI 10.1164/ajrccm.150.1.8025759	50	137	138	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					421	432		10.1016/S0091-6749(96)70167-7	http://dx.doi.org/10.1016/S0091-6749(96)70167-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757220				2022-12-18	WOS:A1996VC99500022
J	SIGURS, N; HATTEVIG, G; KJELLMAN, B; KJELLMAN, NIM; NILSSON, L; BJORKSTEN, B				SIGURS, N; HATTEVIG, G; KJELLMAN, B; KJELLMAN, NIM; NILSSON, L; BJORKSTEN, B			APPEARANCE OF ATOPIC DISEASE IN RELATION TO SERUM IGE ANTIBODIES IN CHILDREN FOLLOWED UP FROM BIRTH FOR 4 TO 15 YEARS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DISEASE; IGE ANTIBODIES TO FOODS AND INHALANTS; ATOPY PREDICTION	COMMON FOOD PROTEINS; COWS MILK; MATERNAL AVOIDANCE; ALLERGIC MANIFESTATIONS; INHALANT ALLERGENS; CLINICAL SYMPTOMS; INFANTS; LACTATION; EGGS; FISH	Background: Few studies have addressed the relationship between sensitization and the development of atopic disease over many years. Objective: To study the temporal relationship between the appearance of IgE antibodies in serum and atopic disease, we studied 324 children from three different groups, who were followed up prospectively from birth for 4, 12, and 15 years, respectively. Methods: Serum samples were obtained at various ages and analyzed for IgE antibodies against egg white, cow's milk, wheat, animal dander, house dust mite, birch and timothy with Phadebas PAST (Kabi Pharmacia Diagnostics AB, Uppsala, Sweden) or Pharmacia CAP system. In addition, a screening test for atopy, the Phadiatop Paediatric test (Kabi Pharmacia Diagnostics AB) was performed. Presence of atopic disease was assessed by means of clinical examination, interviews, and questionnaires. Results: In 135 children IgE antibodies were detected at least once to at least one allergen. Antibodies to egg white appeared in 46 children before or at 2 years of age: in 57% of them IgE antibodies to inhalants developed within the next 2 years, and in 19 of 25 (76%) IgE antibodies to inhalants developed before or at 12 to 15 years. Antibodies to inhalant allergens appeared in 55 children during the first 4 years of life and in 64 before 12 to 15 years. Among the former 48% and among the latter 32% had previously detectable egg white antibodies. Atopic disease appeared before or at age 4 years in 80% of the 40 children with IgE antibodies against egg white up to 9 months of age and in 69% of the 58 children who had a positive Phadiatop Paediatric test result in infancy. Conclusions: IgE antibodies in children are usually associated with current dr later topic disease. Sensitization to foods in infants is usually associated with appearance of IgE antibodies to inhalants later in life.	CENT HOSP SKOVDE,DEPT PEDIAT,SKOVDE,SWEDEN; LINKOPING UNIV HOSP,LINKOPING,SWEDEN; CENT HOSP BORAS,DEPT PEDIAT,BORAS,SWEDEN	Linkoping University				Nilsson, Lennart/0000-0002-5680-6367				BJORKSTEN B, 1982, INT ARCH ALLER A IMM, V69, P174, DOI 10.1159/000233167; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; FOUCARD T, 1984, ACTA PAEDIATR SCAND, V73, P577, DOI 10.1111/j.1651-2227.1984.tb09977.x; FOUCARD T, 1991, ALLERGY, V46, P20; FOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633, DOI 10.1111/j.1651-2227.1973.tb17078.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HATTEVIG G, 1990, J ALLERGY CLIN IMMUN, V85, P108, DOI 10.1016/0091-6749(90)90231-R; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HATTEVIG G, 1983, ACTA PAEDIATR SCAND, V72, P849, DOI 10.1111/j.1651-2227.1983.tb09828.x; HATTEVIG G, 1981, ACTA PAEDIATR SCAND, V70, P541, DOI 10.1111/j.1651-2227.1981.tb05737.x; HOCHREUTENER H, 1991, MONATSSCHR KINDERH, V139, P618; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; KJELLMAN B, 1986, ALLERGY, V41, P351, DOI 10.1111/j.1398-9995.1986.tb00312.x; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; KJELLMAN NIM, 1981, LANCET, V1, P993; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; KJELLMAN NIM, 1982, THEORETICAL CLIN ASP, P52; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P519; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P607; LILJA G, 1991, PEDIATR ALLERGY IMMU, V2, P6; LOFTUS BG, 1986, CLIN ALLERGY, V16, P257; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SIGURS N, 1992, PEDIATRICS, V89, P735; SIGURS N, 1990, PEDIAT ALLERGY IMMUN, V1, P74; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANTOORENENBERGEN AW, 1991, ALLERGY, V46, P180; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35	33	137	140	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					757	763		10.1016/0091-6749(94)90184-8	http://dx.doi.org/10.1016/0091-6749(94)90184-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930310				2022-12-18	WOS:A1994PM27300015
J	CARLSON, M; HAKANSSON, L; PETERSON, C; STALENHEIM, G; VENGE, P				CARLSON, M; HAKANSSON, L; PETERSON, C; STALENHEIM, G; VENGE, P			SECRETION OF GRANULE PROTEINS FROM EOSINOPHILS AND NEUTROPHILS IS INCREASED IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CATIONIC PROTEIN; PURIFICATION; SERUM; NEUROTOXIN; MEDICATION; PEROXIDASE; ACTIVATION; LEUKOCYTE	The activity of eosinophil and neutrophil granulocytes with respect to secretion of granule proteins was studied in 30 patients with asthma and with varying severity of their disease. Granulocytes were stimulated with serum-opsonized Sephadex particles, and the released amount of eosinophil cationic protein (ECP), eosinophil protein X (EPX), and myeloperoxidase was measured by means of specific radioimmunoassays. Eosinophils from patients with asthma released significantly more (p < 0.001) ECP and EPX after 20 minutes of incubation than cells from control subjects without asthma. The release of myeloperoxidase from neutrophils was also somewhat higher (p < 0.03). The serum concentrations of ECP and EPX were also significantly increased (p < 0.001) in the group with asthma. No significant relationships were found between clinical variables and the secretory activity of either eosinophils or neutrophils. We conclude that eosinophils and, to some extent, neutrophils from subjects with asthma have an increased propensity to release their granule proteins, which we suggest is a consequence of priming of these cells.	UNIV HOSP UPPSALA,DEPT LUNG MED,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	CARLSON, M (corresponding author), UNIV HOSP UPPSALA,DEPT CLIN CHEM,INFLAMMAT RES LAB,S-75185 UPPSALA,SWEDEN.							CAPRON M, 1989, EOSINOPHILS ASTHMA, P49; DAHL R, 1978, SCAND J RESPIR DIS, V59, P319; Dahl R, 1988, ASTHMA BASIC MECHANI, P115; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; EGESTEN A, 1986, J HISTOCHEM CYTOCHEM, V34, P1399, DOI 10.1177/34.11.3772075; FORSHAM PH, 1948, J CLIN ENDOCRINOL, V8, P15, DOI 10.1210/jcem-8-1-15; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V85, P743; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LEE TC, 1984, J BIOL CHEM, V259, P5526; OBERG G, 1983, BRIT J HAEMATOL, V55, P701, DOI 10.1111/j.1365-2141.1983.tb02853.x; OLOFSSON T, 1977, SCAND J HAEMATOL, V18, P73; OLSSON H, 1989, CELL SIGNAL, V1, P405, DOI 10.1016/0898-6568(89)90059-4; PETERSON CGB, 1983, IMMUNOLOGY, V50, P19; PETERSON CGB, 1988, EUR J HAEMATOL, V40, P415; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511, DOI 10.1016/S0889-8588(18)30545-8; SILBERSTEIN DS, 1989, J IMMUNOL, V143, P979; SLIFMAN NR, 1989, J IMMUNOL, V143, P2317; VENGE P, 1989, European Respiratory Journal, V2, p430S; VENGE P, 1988, INT ARCH ALLER A IMM, V87, P306, DOI 10.1159/000234690; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; Venge P, 1989, EOSINOPHILS ASTHMA, P163; Venge P., 1987, THESIS UPPSALA U UPP, P1; WINQVIST I, 1984, IMMUNOLOGY, V51, P1	28	137	138	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				27	33		10.1016/0091-6749(91)90209-7	http://dx.doi.org/10.1016/0091-6749(91)90209-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1846890	Bronze			2022-12-18	WOS:A1991EX98500004
J	ATKINS, PC; NORMAN, ME; ZWEIMAN, B				ATKINS, PC; NORMAN, ME; ZWEIMAN, B			ANTIGEN-INDUCED NEUTROPHIL CHEMOTACTIC ACTIVITY IN MAN - CORRELATION WITH BRONCHOSPASM AND INHIBITION BY DISODIUM-CROMOGLYCATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19174	University of Pennsylvania	ATKINS, PC (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19174, USA.							ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BHAT KN, 1976, J ALLERGY CLIN IMMUN, V58, P647; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; KALINER M, 1975, ANNU REV PHARMACOL, V15, P177, DOI 10.1146/annurev.pa.15.040175.001141; KILPATRICK SJ, 1973, STATISTICAL PRINCIPL, P155; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LAVIN N, 1976, J ALLERGY CLIN IMMUN, V57, P80, DOI 10.1016/0091-6749(76)90081-6; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROSENTHAL RR, 1975, INT ARCH ALLER A IMM, V49, P89, DOI 10.1159/000231381; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; TERR AI, 1974, TXB PULMONARY DISEAS, P423; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WEINER HM, 1976, J ALLERGY CLIN IMMUN, V57, P219; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; 1973, INTAL CROMOLYN SODIU, P42	17	137	137	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					149	155		10.1016/0091-6749(78)90099-4	http://dx.doi.org/10.1016/0091-6749(78)90099-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	98551				2022-12-18	WOS:A1978FP55400004
J	SETTIPANE, GA; PUDUPAKKAM, RK				SETTIPANE, GA; PUDUPAKKAM, RK			ASPIRIN INTOLERANCE .3. SUBTYPES, FAMILIAL OCCURRENCE, AND CROSS-REACTIVITY WITH TARTRAZINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROWN UNIV,DIV BIOL & MED SCI,PROVIDENCE,RI; RHODE ISLAND HOSP,DEPT MED,DIV ALLERGY,PROVIDENCE,RI	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; LOCKEY RF, 1973, ANN INTERN MED, V78, P57, DOI 10.7326/0003-4819-78-1-57; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; MILLER FF, 1971, ANN ALLERGY, V29, P263; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SPEER F, 1958, MANAGEMENT CHILDHOOD, P23; 1971, FOOD COLORS	12	137	137	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	3					215	221		10.1016/0091-6749(75)90092-5	http://dx.doi.org/10.1016/0091-6749(75)90092-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ290	1151014				2022-12-18	WOS:A1975AQ29000006
J	SPECTOR, SL; FARR, RS				SPECTOR, SL; FARR, RS			COMPARISON OF METHACHOLINE AND HISTAMINE INHALATIONS IN ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT MED,SECT ALLERGY CLIN IMMUNOL & CHEST,3800 E COLFAX AVE,DENVER,CO 80206; UNIV COLORADO,MED CTR,DENVER,CO	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ARKINS JA, 1968, J ALLERGY, V41, P209, DOI 10.1016/0021-8707(68)90043-9; AUSTEN KF, 1973, PHYSIOLOGY IMMUNOPHA; CHAI H, 1973, J ALLERGY CLIN IMMUN, V51, P94, DOI 10.1016/S0091-6749(73)80036-3; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; CURRY JJ, 1948, J ALLERGY, V19, P9, DOI 10.1016/0021-8707(48)90072-0; CUTHBERT MF, 1971, P ROY SOC MED, V64, P15, DOI 10.1177/003591577106400108; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; HERXHEIMER H, 1961, J PHYSIOL-LONDON, V158, pP38; HERXHEIMER H, 1955, J PHYSIOL-LONDON, V128, P435, DOI 10.1113/jphysiol.1955.sp005317; HERXHEIMER H, 1963, J PHYSIOL-LONDON, V165, pP78; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; MATHE AA, 1973, BRIT MED J, V1, P193, DOI 10.1136/bmj.1.5847.193; MATHISON DA, 1973, J ALLERGY CLIN IMMUN, V51, P94, DOI 10.1016/S0091-6749(73)80037-5; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; OUELLETTE JJ, 1967, J ALLERGY, V39, P234, DOI 10.1016/0021-8707(67)90016-0; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; REED CE, 1974, MED CLIN N AM, V58, P55, DOI 10.1016/S0025-7125(16)32176-9; SIMONSSO.BG, 1967, AM REV RESPIR DIS, V95, P873; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SPECTOR SL, 1974, MED CLIN N AM, V58, P71, DOI 10.1016/S0025-7125(16)32178-2; SPECTOR SL, UNPUBLISHED OBSERVAT; SPECTOR SL, IN PRESS; TIFFENEAU R, 1956, PRESSE MED, V64, P719; TIFFENEAU R, 1958, ACTA ALLERGOL     S5, P187; TOWNLEY RG, 1971, J ALLERGY, V47, P91; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1974, J ALLERGY CLIN IMMUN, V53, P107; TUCHINDA M, 1972, ANN ALLERGY, V43, P142; WARDLAW AC, 1970, INT ARCH ALLER A IMM, V38, P573, DOI 10.1159/000230313	31	137	138	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	4					308	316		10.1016/0091-6749(75)90105-0	http://dx.doi.org/10.1016/0091-6749(75)90105-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AS523	1176722	Bronze			2022-12-18	WOS:A1975AS52300008
J	Posa, D; Perna, S; Resch, Y; Lupinek, C; Panetta, V; Hofmaier, S; Rohrbach, A; Hatzler, L; Grabenhenrich, L; Tsilochristou, O; Chen, KW; Bauer, CP; Hoffman, U; Forster, J; Zepp, F; Schuster, A; Wahn, U; Keil, T; Lau, S; Vrtala, S; Valenta, R; Matricardi, PM				Posa, Daniela; Perna, Serena; Resch, Yvonne; Lupinek, Christian; Panetta, Valentina; Hofmaier, Stephanie; Rohrbach, Alexander; Hatzler, Laura; Grabenhenrich, Linus; Tsilochristou, Olympia; Chen, Kuan-Wei; Bauer, Carl-Peter; Hoffman, Ute; Forster, Johannes; Zepp, Fred; Schuster, Antje; Wahn, Ulrich; Keil, Thomas; Lau, Susanne; Vrtala, Susanne; Valenta, Rudolf; Matricardi, Paolo Maria			Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mite allergy; recombinant allergens; microarray; allergic rhinitis; asthma; birth cohort; children; component-resolved diagnostics; Dermatophagoides pteronyssinus; IgE; prediction	DERMATOPHAGOIDES-PTERONYSSINUS; MAJOR ALLERGEN; CRYSTAL-STRUCTURE; PHLEUM-PRATENSE; P-I; RECOMBINANT; BINDING; ASTHMA; SENSITIZATION; DIAGNOSIS	Background: The evolution of the IgE response to the numerous allergen molecules of Dermatophagoides pteronyssinus is still unknown. Objectives: We sought to characterize the evolutionary patterns of the IgE response to 12 molecules of D pteronyssinus from birth to adulthood and to investigate their determinants and clinical relevance. Methods: We investigated the clinical data and sera of 722 participants in the German Multicenter Allergy Study, a birth cohort started in 1990. Diagnoses of current allergic rhinitis (AR) related to mite allergy and asthma were based on yearly interviews at the ages of 1 to 13 years and 20 years. IgE to the extract and 12 molecules of D pteronyssinus were tested by means of ImmunoCAP and microarray technology, respectively, in sera collected at ages 1, 2, 3, 5, 6, 7, 10, 13, and 20 years. Exposure to mites at age 6 and 18 months was assessed by measuring Der p 1 weight/weight concentration in house dust. Results: One hundred ninety-one (26.5%) of 722 participants ever had IgE to D pteronyssinus extract (>= 0.35 kU(A)/L). At age 20 years, their IgE recognized most frequently Der p 2, Der p 1, and Der p 23 (group A molecules; prevalence, >40%), followed by Der p 5, Der p 7, Der p 4, and Der p 21 (group B molecules; prevalence, 15% to 30%) and Der p 11, Der p 18, clone 16, Der p 14, and Der p 15 (group C molecules; prevalence, <10%). IgE sensitization started almost invariably with group A molecules and expanded sequentially first to group B and finally to group C molecules. Early IgE sensitization onset, parental hay fever, and higher exposure to mites were associated with a broader polymolecular IgE sensitization pattern. Participants reaching the broadest IgE sensitization stage (ie, ABC) had significantly higher risk of miterelated AR and asthma than unsensitized participants. IgE to Der p 1 or Der p 23 at age 5 years or less predicted asthma at school age. Conclusions: Parental hay fever and early exposure to D pteronyssinus allergens promote IgE polysensitization to several D pteronyssinus molecules, which in turn predicts current miterelated AR and current/future asthma. These results might inspire predictive algorithms and prevention strategies against the progression of IgE sensitization to mites toward AR and asthma.	[Posa, Daniela; Perna, Serena; Hofmaier, Stephanie; Rohrbach, Alexander; Hatzler, Laura; Tsilochristou, Olympia; Wahn, Ulrich; Lau, Susanne; Matricardi, Paolo Maria] Charite, Dept Paediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Grabenhenrich, Linus] Charite, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Resch, Yvonne; Lupinek, Christian; Chen, Kuan-Wei; Vrtala, Susanne; Valenta, Rudolf; Matricardi, Paolo Maria] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Vrtala, Susanne; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Dev Allergen Chips, Vienna, Austria; [Panetta, Valentina] Laltrastatistica srl, Consultancy & Training, Biostat, Rome, Italy; [Bauer, Carl-Peter; Hoffman, Ute] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Forster, Johannes] St Josefs Hosp, Dept Pediat St Hedwig, Freiburg, Germany; [Zepp, Fred] Univ Med Mainz, Dept Pediat & Adolescent Med, Mainz, Germany; [Schuster, Antje] Heinrich Heine Univ, Dept Pediat, Dusseldorf, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of Vienna; Medical University of Vienna; Technical University of Munich; Johannes Gutenberg University of Mainz; Heinrich Heine University Dusseldorf; University of Wurzburg	Matricardi, PM (corresponding author), Charite, Dept Paediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de	Dramburg, Stephanie/AAM-8340-2020; Lupinek, Christian/I-3311-2019	Lupinek, Christian/0000-0002-8612-8245; Valenta, Rudolf/0000-0001-5944-3365; Hatzler, Laura/0000-0001-8795-6205; Tsilochristou, Olympia/0000-0002-4540-4602; Dramburg, Stephanie/0000-0002-9303-3260; Vrtala, Susanne/0000-0003-4250-8243; Grabenhenrich, Linus/0000-0002-9300-6625; Lau, Susanne/0000-0002-5189-4265; Chen, Kuan-Wei/0000-0001-5899-5766; Resch, Yvonne/0000-0002-7933-2547	Deutsche Forschungsgemeinschaft (DFG) [MA-4740/1-1]; Austrian Science Fund (FWF) [F4602, F4605]; Christian Doppler Research Association, Vienna, Austria; German Federal Ministry of Education and Research [07015633, 07 ALE 27, 01EE9405/5, 01EE9406]; German Research Foundation [KE 1462/2-1]; Clemens von Pirquet Foundation scholarship	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Christian Doppler Research Association, Vienna, Austria; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); Clemens von Pirquet Foundation scholarship	Supported by the Deutsche Forschungsgemeinschaft (DFG) MA-4740/1-1, in part by grants F4602 and F4605 of the Austrian Science Fund (FWF), and by the Christian Doppler Research Association, Vienna, Austria. The Multicenter Allergy Study was funded by grants from the German Federal Ministry of Education and Research (07015633, 07 ALE 27, 01EE9405/5, and 01EE9406) and the German Research Foundation (KE 1462/2-1). D.P. received a DAAD scholarship. O.T. received a Clemens von Pirquet Foundation scholarship.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Banerjee S, 2015, J INVEST DERMATOL, V135, P102, DOI 10.1038/jid.2014.271; Becker S, 2016, INT ARCH ALLERGY IMM, V170, P132, DOI 10.1159/000447694; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Casas L, 2015, ALLERGY, V70, P820, DOI 10.1111/all.12626; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Cui YB, 2010, J MED ENTOMOL, V47, P868, DOI 10.1603/ME09180; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Epton MJ, 1999, INT ARCH ALLERGY IMM, V120, P185, DOI 10.1159/000024266; Grabenhenrich LB, 2014, J ALLERGY CLIN IMMUN, V133, P979, DOI 10.1016/j.jaci.2013.11.035; Hales BJ, 2013, INT ARCH ALLERGY IMM, V160, P233, DOI 10.1159/000339760; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lee CS, 2004, CLIN EXP ALLERGY, V34, P354, DOI 10.1111/j.1365-2222.2004.01878.x; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Matricardi PM, 2016, CLIN EXP ALLERGY, V46, P664, DOI 10.1111/cea.12679; Matricardi PM, 2014, PEDIAT ALLERG IMM-UK, V25, P15, DOI 10.1111/pai.12200; Mills KL, 1999, INT ARCH ALLERGY IMM, V120, P100, DOI 10.1159/000024227; Mueller GA, 2016, CLIN EXP ALLERGY, V46, P365, DOI 10.1111/cea.12680; Mueller GA, 2010, J BIOL CHEM, V285, P25394, DOI 10.1074/jbc.M110.128306; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; O'Neil SE, 2006, CLIN EXP ALLERGY, V36, P831, DOI 10.1111/j.1365-2222.2006.02497.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Resch Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160641; Resch Y, 2015, J ALLERGY CLIN IMMUN, V136, P1083, DOI 10.1016/j.jaci.2015.03.024; Sastre J, 2010, CLIN EXP ALLERGY, V40, P1442, DOI 10.1111/j.1365-2222.2010.03585.x; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; Soh WT, 2015, INT ARCH ALLERGY IMM, V168, P150, DOI 10.1159/000442176; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1987, INT ARCH ALLER A IMM, V82, P444, DOI 10.1159/000234249; Takai T, 2005, BIOCHEM BIOPH RES CO, V328, P944, DOI 10.1016/j.bbrc.2005.01.051; Thomas WR, 2015, ALLERGOL INT, V64, P304, DOI 10.1016/j.alit.2015.05.004; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Vrtala S, 2014, METHODS, V66, P67, DOI 10.1016/j.ymeth.2013.07.034; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wang JY, 2013, ALLERGY ASTHMA IMMUN, V5, P68, DOI 10.4168/aair.2013.5.2.68; Weghofer M, 2008, ALLERGY, V63, P758, DOI 10.1111/j.1398-9995.2008.01647.x; Weghofer M, 2008, INT ARCH ALLERGY IMM, V147, P101, DOI 10.1159/000135696; Weghofer M, 2013, J IMMUNOL, V190, P3059, DOI 10.4049/jimmunol.1202288	53	136	140	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					541	+		10.1016/j.jaci.2016.08.014	http://dx.doi.org/10.1016/j.jaci.2016.08.014			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27793411	Bronze			2022-12-18	WOS:000397002400020
J	Sears, MR				Sears, Malcolm R.			Epidemiology of asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; exacerbations; seasonality; etiology; viral infection; prevention	RANDOMIZED CONTROLLED-TRIAL; OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION DECLINE; SPUTUM CELL COUNTS; UNITED-STATES; INHALED CORTICOSTEROIDS; EMERGENCY-DEPARTMENT; AIRWAY INFLAMMATION; INTERMITTENT ASTHMA; HOSPITAL ADMISSIONS	Exacerbations of asthma sufficient to require urgent medical intervention are often, but not always, associated with viral infection, especially rhinovirus, with significant interaction with allergen sensitization and exposure. Seasonal patterns of exacerbations are seen especially in children, and may be aggravated by lack of adequate maintenance anti-inflammatory drug treatment during the high-risk viral season most well described in the Northern Hemisphere after school return in September. Age and sex differences in the epidemiology of exacerbations remain less than fully explained, but hormonal influences are demonstrable. Frequent exacerbations may be an indication of greater severity of disease, significant comorbidities, or poor compliance with therapy. Recognizing risk factors for exacerbations and implementing appropriate long-term management strategies coupled with improved compliance should reduce morbidity and mortality associated with asthma exacerbations.	[Sears, Malcolm R.] McMaster Univ, Hamilton, ON L8N 4A6, Canada; [Sears, Malcolm R.] St Josephs Healthcare Hamilton, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada	McMaster University; McMaster University	Sears, MR (corresponding author), McMaster Univ, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	searsm@mcmaster.ca						Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Alvarez G G, 2005, Can Respir J, V12, P265; Atkinson RW, 2006, OCCUP ENVIRON MED, V63, P580, DOI 10.1136/oem.2005.024448; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barr RG, 2004, ARCH INTERN MED, V164, P379, DOI 10.1001/archinte.164.4.379; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P519, DOI 10.1016/j.jaci.2006.01.028; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Chen Y, 2003, J CLIN EPIDEMIOL, V56, P180, DOI 10.1016/S0895-4356(02)00593-0; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Contoli M, 2005, CLIN EXP ALLERGY, V35, P137, DOI 10.1111/j.1365-2222.2005.02163.x; D'silva L, 2007, RESP MED, V101, P2217, DOI 10.1016/j.rmed.2007.05.010; Dhuper S, 2003, CHEST, V124, P1880, DOI 10.1378/chest.124.5.1880; Dusser D, 2007, ALLERGY, V62, P591, DOI 10.1111/j.1398-9995.2007.01394.x; Federico MJ, 2007, J ALLERGY CLIN IMMUN, V119, P50, DOI 10.1016/j.jaci.2006.10.019; FitzGerald JM, 2006, THORAX, V61, P992, DOI 10.1136/thx.2005.045195; FitzGerald J Mark, 2006, Can Respir J, V13, P253; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Fleming DM, 2000, THORAX, V55, P662, DOI 10.1136/thorax.55.8.662; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; GREEN RM, 2002, BRIT MED J, V324, P1; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Johnson-Leger C, 2006, EXPERT OPIN BIOL TH, V6, P1, DOI 10.1517/14712598.6.1.1; Johnston Neil W, 2007, Proc Am Thorac Soc, V4, P591, DOI 10.1513/pats.200706-064TH; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kling S, 2005, CLIN EXP ALLERGY, V35, P672, DOI 10.1111/j.1365-2222.2005.02244.x; Ko FWS, 2007, CLIN EXP ALLERGY, V37, P1312, DOI 10.1111/j.1365-2222.2007.02791.x; Koga T, 2006, RESP MED, V100, P273, DOI 10.1016/j.rmed.2005.05.017; Krishnan V, 2006, AM J RESP CRIT CARE, V174, P633, DOI 10.1164/rccm.200601-007OC; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Lincoln D, 2006, PUBLIC HEALTH, V120, P854, DOI 10.1016/j.puhe.2006.05.015; Lister S, 2001, AUST NZ J PUBL HEAL, V25, P514, DOI 10.1111/j.1467-842X.2001.tb00315.x; MacFaul R, 2004, ARCH DIS CHILD, V89, P1158, DOI 10.1136/adc.2004.054130; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; McCoy L, 2005, J ASTHMA, V42, P757, DOI 10.1080/02770900500308189; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; O'Byrne P, 1996, CAN RESPIR J, V3, P169; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pendergraft TB, 2005, J ASTHMA, V42, P265, DOI 10.1081/JAS-200057893; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reddel HK, 2006, EUR RESPIR J, V28, P182, DOI 10.1183/09031936.06.00105305; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Schatz M, 2006, CHEST, V129, P50, DOI 10.1378/chest.129.1.50; Schatz M, 2006, J ALLERGY CLIN IMMUN, V118, P1048, DOI 10.1016/j.jaci.2006.07.057; Schokker S, 2008, PULM PHARMACOL THER, V21, P88, DOI 10.1016/j.pupt.2006.12.007; Sears MR, 2007, EUR RESPIR J, V30, P411, DOI 10.1183/09031936.00080007; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Silverman RA, 2005, ARCH PEDIAT ADOL MED, V159, P818, DOI 10.1001/archpedi.159.9.818; Singh AM, 2006, THORAX, V61, P809, DOI 10.1136/thx.2005.045179; Sly RM, 2004, ANN ALLERG ASTHMA IM, V92, P313, DOI 10.1016/S1081-1206(10)61568-2; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Tan KS, 1997, AM J RESP CRIT CARE, V155, P1273, DOI 10.1164/ajrccm.155.4.9105066; TAYLOR DR, 2008, EUR RESP J IN PRESS; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Trawick DR, 2001, CHEST, V119, P115, DOI 10.1378/chest.119.1.115; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Vrieze A, 2003, J ALLERGY CLIN IMMUN, V112, P271, DOI 10.1067/mai.2003.1676; Williams JV, 2005, J INFECT DIS, V192, P1149, DOI 10.1086/444392; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020	79	136	137	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					662	668		10.1016/j.jaci.2008.08.003	http://dx.doi.org/10.1016/j.jaci.2008.08.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014756				2022-12-18	WOS:000259989000005
J	Summers, CW; Pumphrey, RS; Woods, CN; McDowell, G; Pemberton, PW; Arkwright, PD				Summers, Colin W.; Pumphrey, Richard S.; Woods, Charlotte N.; McDowell, Garry; Pemberton, Philip W.; Arkwright, Peter D.			Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; tree nuts; peanut; atopy; asthma; ACE; aminopeptidase P; bradykinin; age	ANGIOTENSIN-CONVERTING-ENZYME; FATAL ALLERGIC REACTIONS; AMINOPEPTIDASE-P; HEREDITARY ANGIOEDEMA; FOOD ALLERGY; BRADYKININ; CHILDREN; EDEMA; PREVALENCE; INHIBITION	Background: Although acute allergic reactions after ingestion of peanuts and tree nuts are common, fatalities are rare. Other than patients with coexisting asthma, it is currently not possible to predict which patients are most likely to develop severe reactions. Objective: The aim of this study was to determine which clinical and laboratory parameters best predict the likelihood of severe allergic reactions. Methods: From 1992 to 2004, we collected detailed information on the clinical severity and allergy test results of 1094 patients with peanut and tree nut allergy attending a regional allergy center. In a subgroup of 122 patients, sera were assayed for activity of enzymes involved in the catabolism of bradykinin. Results: Severe pharyngeal edema was 3.8 (2.1-6.9) times more common in patients with severe rhinitis and 2.6 (1.8-3.7) more common after ingestion of tree nuts compared with peanuts. Patients with serum angiotensin-converting enzyme concentrations <37.0 mmol/L had a 9.6 (1.6-57)-fold risk of severe pharyngeal edema. Life-threatening bronchospasm was most likely in patients with severe asthma (relative risk, 6.8 [4.1-11.3]) and less so in patients with milder asthma (2.7 [1.7-4.0]). Altered levels of consciousness were more likely in patients with severe eczema (3.1 [1.1-8.4]). Conclusion: Severity of coexisting atopic diseases predicted which patients attending a tertiary referral clinic were most likely to develop life-threatening allergic reactions to peanuts and tree nuts. Patients with the lowest serum angiotensin-converting enzyme concentrations were more likely to develop life-threatening pharyngeal edema, suggesting that this complication may be partly mediated by bradykinin.	[Summers, Colin W.; Pumphrey, Richard S.; Woods, Charlotte N.; Arkwright, Peter D.] Univ Manchester, Dept Immunol, Manchester Royal Infirm, Manchester M13 9PL, Lancs, England; [Woods, Charlotte N.; Pemberton, Philip W.] Univ Manchester, Dept Clin Biochem, Manchester Royal Infirm, Manchester M13 9PL, Lancs, England	University of Manchester; University of Manchester	Arkwright, PD (corresponding author), Univ Manchester, Dept Immunol, Manchester Royal Infirm, Oxford Rd, Manchester M13 9PL, Lancs, England.	peter_arkwright@lineone.net	Arkwright, Peter/C-5149-2012	Arkwright, Peter/0000-0002-7411-5375; McDowell, Garry/0000-0002-2880-5236				Adam A, 2002, LANCET, V359, P2088, DOI 10.1016/S0140-6736(02)08914-6; Blais C, 2000, PEPTIDES, V21, P1903, DOI 10.1016/S0196-9781(00)00348-X; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Clark AT, 2007, ALLERGY, V62, P913, DOI 10.1111/j.1398-9995.2007.01447.x; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Davoren M, 2005, ARCH DIS CHILD, V90, P1084, DOI 10.1136/adc.2005.073817; Duan QL, 2005, AM J HUM GENET, V77, P617, DOI 10.1086/496899; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Kim KS, 2000, J PHARMACOL EXP THER, V292, P295; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; NHLBI, 2007, 3 NHLBI; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey Richard S H, 2004, Novartis Found Symp, V257, P116; Radauer C, 2007, J ALLERGY CLIN IMMUN, V120, P518, DOI 10.1016/j.jaci.2007.07.024; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SETTIPANE GA, 1989, ALLERGY PROC, V10, P271, DOI 10.2500/108854189778960036; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; SIMMONS WH, 1992, J BIOL CHEM, V267, P4897; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; STUDDY PR, 1983, J CLIN PATHOL, V36, P938, DOI 10.1136/jcp.36.8.938; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; TIRET L, 1992, AM J HUM GENET, V51, P197	32	136	141	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					632	638		10.1016/j.jaci.2007.12.003	http://dx.doi.org/10.1016/j.jaci.2007.12.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18207562				2022-12-18	WOS:000253918900014
J	Rasmussen, LM; Phanareth, K; Nolte, H; Backer, V				Rasmussen, LM; Phanareth, K; Nolte, H; Backer, V			Internet-based monitoring of asthma: A long-term, randomized clinical study of 300 asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; telemonitoring; telemedicine; Internet; outcome assessment; disease management; action plan; self-management	QUALITY-OF-LIFE; POPULATION; MANAGEMENT; OUTCOMES	Background: Experience from other fields of internal medicine shows that Internet-based technology can be used to monitor various diseases. The new technology handles complex calculation programs easily, and it is a unique way of communicating. These advantages might be used in optimizing the treatment for asthmatic subjects because undertreatment is a common problem found in European asthmatic subjects. Objective: We sought to investigate the outcome of monitoring and treatment using a physician-managed online interactive asthma monitoring tool and to assess whether the outcome differs from that of monitoring and treatment in an outpatient respiratory clinic or in primary care. Methods: Three hundred asthmatic subjects were randomized to 3 parallel groups in a 6-month prospective study: (1) Internet-based monitoring (n = 100); (2) specialist monitoring (n = 100); and (3) general practitioner (GP) monitoring (n = 100). All the patients were examined on entry into the study and after 6 months of treatment. Results: The treatment and monitoring with the Internet-based management tool lead to significantly better improvement in the Internet group than in the other 2 groups regarding asthma symptoms (Internet vs specialist: odds ratio of 2.64, P =.002; Internet vs GP: odds ratio of 3.26; P < .001), quality, of life (Internet vs specialist: odds ratio of 2.21, P = .03; Internet vs GP: odds ratio of 2.10, P = .04), lung function (Internet vs specialist: odds ratio of 3.26, P =.002; Internet vs GP: odds ratio of 4.86, P < .001), and airway responsiveness (Internet vs GP: odds ratio of 3.06, P = .02). Conclusion: When physicians and patients used an interactive Internet-based asthma monitoring tool, better asthma control was achieved.	Copenhagen Univ Hosp, HS Bispehjerg Hosp, Dept Internal Med 1, Resp & Allergy Res Unit, Copenhagen, Denmark; HS Frederiksberg Hosp, Dept Internal Med B, Copenhagen, Denmark	University of Copenhagen	Rasmussen, LM (corresponding author), Bispebjerg Hosp, Dept Internal Med, Resp & Allergy Res Unit, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark.	makowska@dadlnet.dk	Backer, Vibeke/I-9573-2014; Backer, Vibeke/AAQ-9379-2021	Backer, Vibeke/0000-0002-7806-7219; 				Anhoj J, 2004, J MED INTERNET RES, V6, P34, DOI 10.2196/jmir.6.3.e23; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Bateman ED, 2002, EUR RESPIR J, V20, P588, DOI 10.1183/09031936.02.00294702; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P514, DOI 10.1016/S0091-6749(96)70084-2; CHOWIENCZYK PJ, 1994, BRIT MED J, V309, P1618, DOI 10.1136/bmj.309.6969.1618; Demeris G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e6; Finkelstein J, 1998, ST HEAL T, V52, P272; Finkelstein J, 2000, CHEST, V117, P148, DOI 10.1378/chest.117.1.148; GIBSON PG, 2003, COCHRANE LIB; *GLOB IN ASTHM, 2000, WHO NHLBI WORKSH REP; GROTH S, 1986, B EUR PHYSIOPATH RES, V22, P35; Groth S, 1986, Ugeskr Laeger, V148, P3207; Guendelman S, 2002, ARCH PEDIAT ADOL MED, V156, P114, DOI 10.1001/archpedi.156.2.114; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Juniper EF, 1999, EUR RESPIR J, V14, P1038, DOI 10.1183/09031936.99.14510389; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Louis AA, 2003, EUR J HEART FAIL, V5, P583, DOI 10.1016/S1388-9842(03)00160-0; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; RASMUSSEN LM, 2002, C EUR RESP SOC STOCK; Reddel HK, 2002, BRIT MED J, V324, P146, DOI 10.1136/bmj.324.7330.146; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Winder JA, 2000, ANN ALLERG ASTHMA IM, V85, P467, DOI 10.1016/S1081-1206(10)62573-2; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	30	136	137	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1137	1142		10.1016/j.jaci.2005.03.030	http://dx.doi.org/10.1016/j.jaci.2005.03.030			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940125	Bronze			2022-12-18	WOS:000229815400005
J	Bochenek, G; Nagraba, K; Nizankowska, E; Szczeklik, A				Bochenek, G; Nagraba, K; Nizankowska, E; Szczeklik, A			A controlled study of 9 alpha,11 beta-PGF2 (a prostaglandin D-2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						prostaglandin D-2; 9 alpha,11 beta-PGF(2); mast cells; aspirin-induced asthma; tryptase; leukotriene E-4	MAST-CELL ACTIVATION; CORONARY-ARTERIES; RELEASE; HISTAMINE; ALLERGEN; AIRWAYS; LEUKOTRIENES; SPECTROMETRY; PROVOCATION; EXCRETION	Background: Prostaglandin D-2 (PGD(2)) is the predominant cyclooxygenase product of mast cells, the number of which is increased in bronchial asthma. Release of PGD2 might reflect mast cell activation and disordered function of the asthmatic lung. Objective: We sought to determine blood and urinary levels of 9alpha,11beta-PGF(2), a major stable PGD(2) metabolite in 2 well-defined phenotypes of asthma, aspirin-induced asthma (AIA) and aspirin-tolerant asthma (ATA), and in healthy control subjects and to study the effects of aspirin on PGD2 release. Methods: Using gas chromatography/mass spectrometry, we determined plasma and urinary concentrations of 9alpha,11beta-PGF(2) at baseline in 131 stable asthmatic patients, 65 of whom had AIA and 66 of whom had ATA. Fifty healthy nonatopic subjects served as the control group. The measurements were also performed after an aspirin challenge in 26 of 65 patients with AIA and in 24 of 50 control subjects. Results: At baseline, patients with AIA had significantly higher plasma levels of 9alpha,11beta-PGF(2) than either patients with ATA or healthy subjects. A similar significant elevation of serum tryptase was observed in patients with AIA compared with patients with ATA and control subjects. Mean urinary 9alpha,11beta-PGF(2) values did not differ among the 3 groups. In patients with AIA, as opposed to healthy subjects, aspirin challenge invariably precipitated a clinical reaction, accompanied in most patients by a further rise in plasma levels of PGD2 metabolite and tryptase. Conclusions: In stable AIA, though not in ATA, there is a steady release of PGD(2) into the blood, accompanied by the release of tryptase. Aspirin enhances this reaction in most patients. Release of bronchoconstrictive PGD(2) might contribute to the severe clinical course of AIA.	Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland	Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Skawinska 8, PL-31066 Krakow, Poland.							AWAD JA, 1994, J ALLERGY CLIN IMMUN, V93, P817, DOI 10.1016/0091-6749(94)90371-9; BAZANSOCHA S, 2001, POL ARCH MED WEWN, V55, P311; BEASLEY CRW, 1987, J CLIN INVEST, V79, P978, DOI 10.1172/JCI112909; BOCHENEK G, 2002, EUR RESPR J S, V20, pS424; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; FISHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Hartert TV, 2000, AM J RESP CRIT CARE, V162, P637, DOI 10.1164/ajrccm.162.2.9904038; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; KUEHL FA, 1984, BIOCHEM PHARMACOL, V33, P1, DOI 10.1016/0006-2952(84)90362-9; Laine P, 1999, CIRCULATION, V99, P361, DOI 10.1161/01.CIR.99.3.361; Laine P, 2000, CIRCULATION, V101, P1665; LISTON TE, 1985, J BIOL CHEM, V260, P3172; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Mita H, 2001, ALLERGY, V56, P1061; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; Nagakura T, 1998, CLIN EXP ALLERGY, V28, P181; NARUMIYA S, 1995, ADV PROSTAG THROMB L, V23, P17; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; O'Sullivan S, 1999, PROSTAG OTH LIPID M, V57, P149, DOI 10.1016/S0090-6980(98)00076-8; OBATA T, 1994, J CHROMATOGR B, V655, P173, DOI 10.1016/0378-4347(94)00100-6; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; ROBERTSON RM, 1985, CLIN RES, V33, pA221; Sampson AP, 1997, INT ARCH ALLERGY IMM, V113, P355, DOI 10.1159/000237600; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; Serhan CN, 2001, AM J RESP CELL MOL, V24, P658, DOI 10.1165/ajrcmb.24.6.f210; SLADEK K, 1993, EUR RESPIR J, V6, P391; SLADEK K, 1990, ADV PROSTAGLANDIN TH, P433; SMITH SJ, 2002, ACI INT, V14, P52; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Szczeklik A, 1998, AM J RESP CRIT CARE, V158, P1168, DOI 10.1164/ajrccm.158.4.9710043; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Taha R, 2000, AM J RESP CRIT CARE, V161, P636, DOI 10.1164/ajrccm.161.2.9811063; VANE JR, 1991, ASPIRIN OTHER SALICY, P35; WOODBAKER R, 1993, EUR RESPIR J, V6, P1138	42	136	138	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					743	749		10.1067/mai.2003.1387	http://dx.doi.org/10.1067/mai.2003.1387			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704352	Green Published			2022-12-18	WOS:000182258500012
J	Li, XM; Zhang, MF; Huang, CK; Srivastava, K; Teper, AA; Zhang, LB; Schofield, BH; Sampson, HA				Li, XM; Zhang, MF; Huang, CK; Srivastava, K; Teper, AA; Zhang, LB; Schofield, BH; Sampson, HA			Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut anaphylaxis; traditional Chinese medicine; IgE; mast cells; T(H)2 cytokines	RESPONSES; ASTHMA; IMMUNOTHERAPY; MICE; EXPRESSION; MEDICINE	Background: Peanut allergy is a major cause of fatal and near-fatal anaphylactic reactions to foods. There is no curative therapy for this condition. Traditional Chinese medicines have been reported to have antiallergic properties, which might be useful for treating peanut allergy. Objective: The purpose of this study was to investigate the effects of a Chinese herbal formula, FAHF-1, on peanut anaphylactic reactions in a mouse model of peanut allergy. Methods: Mice were sensitized with freshly ground whole peanut in the presence of cholera toxin and boosted 1 and 3 weeks later. FAHF-1 treatment was initiated 1 week later and continued for 7 weeks. After treatment, mice were challenged with peanut, and anaphylactic symptoms, body temperatures, and plasma histamine and IgE levels were measured. T-cell proliferative responses and cytokine production were also determined. Results: FAHF-1 completely blocked peanut-induced anaphylactic symptoms and markedly reduced mast cell degranulation and histamine release. Peanut-specific serum IgE levels were significantly reduced by 2 weeks of treatment at the time of challenge, and they remained lower 4 weeks after discontinuation of treatment. FAHF-1 significantly reduced peanut-induced lymphocyte proliferation is well as IL-4, IL-5, and IL-13 synthesis but not IFN-gamma synthesis. No toxic effects on liver or kidney functions were observed, nor was there any overall immune suppression. Conclusion: FAHF-1 protected peanut-sensitized mice from anaphylactic reactions and significantly reversed established IgE-niediated peanut allergy. This suggests that FAHF-1 might prove valuable for the treatment of peanut allergy.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Ctr Comparat Med & Surg, New York, NY 10029 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Li, XM (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43668] Funding Source: Medline; NIEHS NIH HHS [ES03819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bensky D, 1993, CHINESE HERBAL MED F, P21; BENSKY D, 1993, CHINESE HERBAL MED M, P513; Bielory L, 1999, J ASTHMA, V36, P1, DOI 10.3109/02770909909065150; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BURKS AW, 1991, ADV EXP MED BIOL, V289, P295; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Huang CK, 1999, J ALLERGY CLIN IMMUN, V103, pS238; Huang K, 1999, PHARM CHINESE HERBS, P118; HUANG KC, 1999, PHARM CHINESE HERBS, P485; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P660, DOI 10.1067/mai.2000.110102; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 1996, J IMMUNOL, V157, P3216; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; *NRC I LAB AN RES, 1996, GUID CAR US LAB AN; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; TASAKA K, 1988, AGENTS ACTIONS, V23, P153, DOI 10.1007/BF02142526; von Garnier C, 2000, EUR J IMMUNOL, V30, P1638, DOI 10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R; XIU SY, 1986, EXPT METHOD PHARM, P1184; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; Ziment I, 2000, J ALLERGY CLIN IMMUN, V106, P603, DOI 10.1067/mai.2000.109432	31	136	141	0	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					639	646						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590394	Bronze			2022-12-18	WOS:000171760300027
J	Wahn, U; von Mutius, E				Wahn, U; von Mutius, E			Childhood risk factors for atopy and the importance of early intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopy; prediction; prevention; epidemiology; atopic march; asthma	INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; HOUSE-DUST MITE; 1ST 6 YEARS; ALLERGIC SENSITIZATION; INHALANT ALLERGENS; DOMESTIC EXPOSURE; PARENTAL SMOKING; MATERNAL SMOKING; HAY-FEVER	The increasing prevalence of atopic diseases, particularly atopy-associated asthma, has become a major challenge for allergists and public health authorities in many countries. The understanding of the natural history of the atopic march, including the determinants that are modifiable and might become candidates for preventive intervention, is still very limited, Information provided by cross-sectional studies can only generate hypotheses, which need to be supported by prospective, longitudinal, cohort studies. Ultimately, it will depend on the results of well-controlled intervention studies to identify which nutritional, environmental, or lifestyle-related factors should be considered for early intervention and might be useful to reverse the epidemiologic trend.	Charite Humboldt Univ Berlin, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Dr Von Haunersches Kinderspital, Munich, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich	Wahn, U (corresponding author), Charite Humboldt Univ Berlin, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.							ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Asher MI, 1998, EUR RESPIR J, V12, P315; Baker SS, 2000, PEDIATRICS, V106, P346; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Becker AB, 2000, PEDIATR PULM, V30, P63, DOI 10.1002/1099-0496(200007)30:1<63::AID-PPUL10>3.0.CO;2-7; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; BERGMANN RL, IN PRESS CLIN EXP AL; Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Buhrer C, 1999, LANCET, V353, P1674, DOI 10.1016/S0140-6736(98)03975-0; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CARLSEN KCL, 1995, EUR RESPIR J, V8, P1148, DOI 10.1183/09031936.95.08071148; COOKSON WOCM, 1989, LANCET, V1, P1292; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Edenharter G, 1998, CLIN EXP ALLERGY, V28, P671; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Gutgesell C, 1999, CLIN EXP ALLERGY, V29, P920, DOI 10.1046/j.1365-2222.1999.00553.x; Halken S, 2000, ALLERGY, V55, P793, DOI 10.1034/j.1398-9995.2000.00117.x; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jung T, 1999, CLIN EXP ALLERGY, V29, P912; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Kulig M, 1999, ALLERGY, V54, P220, DOI 10.1034/j.1398-9995.1999.00753.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; MOLLER C, UNPUB POLLEN IMMUNOT; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Pohunek P, 1996, THORAX, V51, P615, DOI 10.1136/thx.51.6.615; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; RIEDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527, DOI 10.1016/0091-6749(88)90961-X; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shaheen SO, 1999, CLIN EXP ALLERGY, V29, P291; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977, DOI 10.1164/ajrccm.152.3.7663813; Upton MN, 2000, BMJ-BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806	79	136	141	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					567	574		10.1067/mai.2001.112943	http://dx.doi.org/10.1067/mai.2001.112943			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295640	Bronze			2022-12-18	WOS:000168190100001
J	Berlyne, GS; Parameswaran, K; Kamada, D; Efthimiadis, A; Hargreave, FE				Berlyne, GS; Parameswaran, K; Kamada, D; Efthimiadis, A; Hargreave, FE			A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exhaled nitric oxide; sputum; asthma; eosinophilic bronchitis	MILD ASTHMA; INHALED BUDESONIDE; LUNG-FUNCTION; INDEXES; HYPERRESPONSIVENESS; RECOMMENDATIONS; RESPONSIVENESS; EOSINOPHILS; BRONCHITIS; PREDNISONE	Background: Exhaled nitric oxide (ENO) has been proposed as a noninvasive marker of airway inflammation in asthma. Objective: We investigated the relationships among ENO, eosinophilic airway inflammation as measured by induced sputum, and physiologic parameters of disease severity (spirometry and methacholine PC20), We also examined the effect of corticosteroid treatment and atopy on ENO levels and eosinophil counts in induced sputum. Methods: Measurements were taken on one day in 22 healthy nonatopic subjects, 28 healthy atopic subjects, 38 asthmatic subjects not taking inhaled steroids, 35 asthmatic subjects taking inhaled steroids, and 8 subjects with eosinophilic bronchitis without asthma. Results: ENO levels showed significant hut weak correlations with eosinophil differential counts in the steroid-naive asthmatic and healthy atopic groups (r(s) < 0.05), ENO levels were significantly lower in the asthmatic subjects taking steroids compared with the asthmatic subjects not taking steroids, despite there being no difference in the sputum cell counts, and a tendency to increased airflow limitation, ENO levels and sputum eosinophil counts were equally good at differentiating from steroid-naive asthmatic subjects. ENO levels were consistently raised in subjects with eosinophilic bronchitis without asthma, Atopy had no effect on ENO levels in the healthy subjects. Conclusion: We conclude that ENO is likely to have limited utility as a surrogate clinical measurement for either the presence or severity of eosinophilic airway inflammation, except in steroid-naive subjects.	St Josephs Hosp, Dept Med, Asthma Res Grp, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Hamilton, ON, Canada	McGill University; McMaster University; McMaster University	Hargreave, FE (corresponding author), St Josephs Hosp, Firestone Reg Chest & Allergy Unit, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.							[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barnes PJ, 1996, THORAX, V51, P233, DOI 10.1136/thx.51.3.233; Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894, DOI 10.1164/ajrccm.157.3.9709064; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; GIBSON PG, 1989, LANCET, V1, P1346; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042, DOI 10.1164/ajrccm.158.4.9710091; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Juniper E, 1994, HISTAMINE METHACHOLI; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889, DOI 10.1164/ajrccm.151.6.7767536; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; KHARITONOV SA, 1995, EUR RESPIR J, V8, P135; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; Parameswaran K, 1998, EUR RESPIR J, V11, P1405, DOI 10.1183/09031936.98.11061405; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Pizzichini MMM, 1996, AM J RESP CRIT CARE, V154, P866, DOI 10.1164/ajrccm.154.4.8887576; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; SCHILLING J, 1994, EUR RESPIR J, V7, P467, DOI 10.1183/09031936.94.07030467; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Silkoff PE, 1998, AM J RESP CRIT CARE, V157, P1822, DOI 10.1164/ajrccm.157.6.9707159; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Taylor DA, 1998, THORAX, V53, P483, DOI 10.1136/thx.53.6.483; van Rensen ELJ, 1999, THORAX, V54, P403, DOI 10.1136/thx.54.5.403	35	136	142	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					638	644		10.1067/mai.2000.109622	http://dx.doi.org/10.1067/mai.2000.109622			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031333				2022-12-18	WOS:000089980600006
J	Rosi, E; Ronchi, MC; Grazzini, M; Duranti, R; Scano, G				Rosi, E; Ronchi, MC; Grazzini, M; Duranti, R; Scano, G			Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: Results of a factor analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; factor analysis; bronchial hyperresponsiveness; airway inflammation; induced sputum	OBSTRUCTIVE PULMONARY-DISEASE; MAST-CELLS; INFLAMMATION; EOSINOPHILS; RESPONSIVENESS; METHACHOLINE; HYPERREACTIVITY; MODEL	Background: Recent studies have shown weak associations among FEV1, bronchial hyperresponsiveness (BHR), sputum eosinophils, and sputum eosinophil cationic protein (ECP), suggesting that they are nonoverlapping quantities. The statistical method of factor analysis enables reduction of many parameters that characterize the disease to a few independent factors, with each factor grouping associated parameters. Objective: The purpose of this study was to demonstrate, by using factor analysis, that reversible airway obstruction, BHR, and eosinophilic inflammation of the bronchial tree, as assessed by cytologic and biochemical analysis of sputum, may be considered separate dimensions that characterize chronic bronchial asthma. Methods: Ninety-nine clinically stable patients with a previous diagnosis of asthma underwent spirometry, sputum induction, and histamine inhalation tests. Results: Most patients were nonobstructed (FEV1, 91% +/- 20%); a low level of bronchial reversibility (FEV1 increase after beta(2)-agonist, 7.8% +/- 9.2%) and BHR (histamine PC20FEV1 geometric mean, 0.98 mg/mL) were found. Sputum eosinophil differential count (12.4% +/- 17.7%) and sputum ECP (1305 +/- 3072 mu g/mL) were in the normal range of our laboratory in 38 and 22 patients, respectively. Factor analysis selected 3 different factors, explaining 74.8% of variability. Measurements of airway function and age loaded on factor I, PC20FEV1 and beta(2)-response loaded on factor II, and sputum ECP and eosinophils loaded on factor III. Additional post hoc factor analyses provided similar results when the sample was divided into 2 subgroups by randomization, presence of airway obstruction, degree of BHR, percentage of sputum eosinophils, or concentration of sputum ECP. Conclusions: We conclude that airway function, baseline BHR, and airway inflammation may be considered separate dimensions in the description of chronic asthma. Such evidence supports the utility of routine measurement of all these dimensions.	Univ Florence, Inst Internal med & Immunoallergol, Sect Resp Med, I-50134 Florence, Italy	University of Florence	Rosi, E (corresponding author), Univ Florence, Inst Internal med & Immunoallergol, Sect Resp Med, Vle Morgagni 85, I-50134 Florence, Italy.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; CLAMAN DM, 1994, J ALLERGY CLIN IMMUN, V94, P861, DOI 10.1016/0091-6749(94)90154-6; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V143, P1165, DOI 10.1164/ajrccm/143.5_Pt_1.1165; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; *EUR RESP SOC, 1993, EUR RESPIR J, V16, P1; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; FANELLI A, 1994, THORAX, V49, P639, DOI 10.1136/thx.49.7.639; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; IREDALE MJ, 1994, CLIN EXP ALLERGY, V24, P940, DOI 10.1111/j.1365-2222.1994.tb02725.x; JEFFERY PK, 1991, AM REV RESPIR DIS, V143, P1152, DOI 10.1164/ajrccm/143.5_Pt_1.1152; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922, DOI 10.1164/ajrccm/145.4_Pt_1.922; PIN I, 1993, EUR RESPIR J, V6, P1249; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; Ronchi MC, 1996, THORAX, V51, P1000, DOI 10.1136/thx.51.10.1000; Ronchi MC, 1997, EUR RESPIR J, V10, P1809, DOI 10.1183/09031936.97.10081809; SCANO G, 1980, ARCH ENVIRON HEALTH, V35, P360; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; VIRCHOW JC, 1992, AM REV RESPIR DIS, V146, P604, DOI 10.1164/ajrccm/146.3.604; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; [No title captured]	34	136	141	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				232	237		10.1016/S0091-6749(99)70496-3	http://dx.doi.org/10.1016/S0091-6749(99)70496-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949313	Bronze			2022-12-18	WOS:000078630100009
J	Ohtoshi, T; Takizawa, H; Okazaki, H; Kawasaki, S; Takeuchi, N; Ohta, K; Ito, K				Ohtoshi, T; Takizawa, H; Okazaki, H; Kawasaki, S; Takeuchi, N; Ohta, K; Ito, K			Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel exhaust particle; suspended particulate matter; cytokine; airway epithelial cell	IN-VITRO; IGE PRODUCTION; ADJUVANT ACTIVITY; HUMAN NEUTROPHIL; RELEASE; MICE; EXPRESSION; HISTAMINE; ANTIBODY; VIVO	Background: Epidemiologic and experimental studies suggest that air pollution such as diesel exhaust particles (DEPs), one of the important air pollutants, mag play a role in the increasing prevalence of allergic airway diseases. Objective: We studied the effect of suspended particulate matter (SPM) and its main component, DEPs, on the production of IL-8 and granulocyte-macrophage colony-stimulating factor (GM-CSF) by human aint ay epithelial cells in vitro. Methods: SPM obtained from high-volume air samplers and DEPs were added to cultured human nasal polyp-derived upper airway, normal bronchial, and transformed bronchial epithelial cells. Production of GM-CSF and IL-8 by airway epithelial cells was evaluated. Results: Nontoxic doses of DEPs showed a significant stimulatory effect on IL-8 and GM-CSF production by these three kinds of epithelial cells in a dose- and time-dependent fashion. SPM had a stimulatory effect on GM-CSF, but not IL-8, production. These effects were abrogated by treatment with a protein synthesis inhibitor, cycloheximide, suggesting that the process required a de novo protein synthesis. On the double-chamber plates, airway epithelial cells responded to DEPs only when they were stimulated from the apical sides, which can be a model for in vivo environments. Neither charcoal nor graphite showed such stimulatory effects, indicating that the activity of DEPs did not derive from their particulate nature. Benzo(a)pyrene, one of the main aromatic hydrocarbons contained in DEPs, showed a stimulatory effect on the release of the cytokines, and this organic substance might have a causative effect on of the potency of DEPs. Conclusion: We conclude that SPM and DEPs, its main component, might be important air pollutants in the activation of airway epithelial cells for the release of cytokines relevant to allergic airway inflammation.	Univ Tokyo, Sch Med, Dept Med & Phys Therapy, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Sch Med, Dept Otolaryngol, Bunkyo Ku, Tokyo 113, Japan; Teikyo Univ, Sch Med, Dept Internal Med, Tokyo 173, Japan	University of Tokyo; University of Tokyo; Teikyo University	Takizawa, H (corresponding author), Univ Tokyo, Sch Med, Dept Med & Phys Therapy, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.							ANDERSEN AA, 1966, AM IND HYG ASSOC J, V27, P160, DOI 10.1080/00028896609342810; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1994, CLIN EXP ALLERGY, V24, P187; Devalia JL, 1994, ACI NEWS, V6, P80; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; ERGER RA, 1995, AM J PHYSIOL-LUNG C, V268, pL117, DOI 10.1152/ajplung.1995.268.1.L117; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KANEKO S, 1980, OTORHINOLARYNGOLO S4, V23, P270; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MEDHURST AD, 1991, ANN NY ACAD SCI, V629, P419; MIZOHATA A, 1985, 26TH P C JAP SOC AIR, P133; MIZOHATA A, 1986, TAIKI OSEN GAKKAISHI, V21, P83; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NAKANO J, 1994, CLIN EXP ALLERGY, V24, P330, DOI 10.1111/j.1365-2222.1994.tb00243.x; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; REDDEL RR, 1988, CANCER RES, V48, P1904; *S COAST AIR QUAL, 1994, 2A S COAST AIR QUAL; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1, DOI 10.1159/000234990; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; TAKIZAWA H, 1993, CANCER RES, V53, P4175; TAKIZAWA H, 1992, BIOCHEM BIOPH RES CO, V187, P596, DOI 10.1016/0006-291X(92)91236-J; TAKIZAWA H, 1995, INT ARCH ALLERGY IMM, V108, P260, DOI 10.1159/000237162; VILLAR M, 1998, AM REV RESPIR DIS, V147, pA242; VOSTAL JJ, 1980, B NEW YORK ACAD MED, V56, P914	34	136	140	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				778	785		10.1016/S0091-6749(98)70307-0	http://dx.doi.org/10.1016/S0091-6749(98)70307-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648705	Bronze			2022-12-18	WOS:000074414200011
J	Sakaguchi, M; Nakayama, T; Inouye, S				Sakaguchi, M; Nakayama, T; Inouye, S			Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; food allergy; gelatin; IgE; vaccines	MEASLES-VACCINE; IGE; MUMPS	Background: Anaphylaxis to measles-mumps-rubella vaccines has been reported. We have suspected that most such reactions are caused by gelatin contained in the vaccines. Objective: To confirm the relation between systemic allergic reactions to vaccines and the presence of anti-gelatin IgE, we measured anti-gelatin IgE in children who demonstrated allergy to gelatin-containing vaccines. Furthermore, to clarify the relation between allergic reactions to gelatin in vaccines and foods, we surveyed the occurrence of allergic reactions to gelatin-containing foods in the same children. Methods: Serum samples were taken from 26 children who had systemic immediate-type reactions, including anaphylactic shock, to vaccines and the same number of children without allergic reactions. Specific IgE to gelatin in these samples was measured. We then surveyed whether these children had allergic reactions to gelatin-containing foods before and after vaccination. Results: Twenty-four of the 26 children with allergic reactions to vaccines had anti-gelatin IgE ranging from 1.2 to 250 Ua/ml. Seven had allergic reactions on ingestion of gelatin-containing foods. Of these; two had reactions before vaccination, and five had reactions after vaccination. All the control children without allergic reactions to vaccines had no anti-gelatin IgE. Conclusion: We reconfirmed a strong relationship between systemic immediate-type allergic reactions, including anaphylaxis, to vaccines and the presence of specific IgE to gelatin. Moreover, some of the children also had allergic reactions to food gelatin before or after vaccination.	KITASATO INST,DEPT VIROL,TOKYO 108,JAPAN		Sakaguchi, M (corresponding author), NATL INST HLTH,DEPT EPIDEMIOL,SHINJUKU KU,TOYAMA 1-23-1,TOKYO 162,JAPAN.		Inouye, Sharon/R-7216-2019					AUKRUST L, 1980, ALLERGY, V35, P581, DOI 10.1111/j.1398-9995.1980.tb01808.x; BUSINCO L, 1994, ANN ALLERGY, V92, P1; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; HASHIZUME S, 1994, CLIN VIROL, V22, P140; JANTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; POLLOCK TM, 1983, LANCET, V1, P753; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; SAKAGUCHI M, 1990, ALLERGY, V45, P309, DOI 10.1111/j.1398-9995.1990.tb00501.x; THURSTON A, 1987, J ROY COLL GEN PRACT, V37, P41; WAHL R, 1989, CLIN EXP ALLERGY, V19, P77, DOI 10.1111/j.1365-2222.1989.tb02348.x; ZIMMERMAN B, 1993, ALLERGY PRINCIPLES P, P1705	12	136	144	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1058	1061		10.1016/S0091-6749(96)80191-6	http://dx.doi.org/10.1016/S0091-6749(96)80191-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977505				2022-12-18	WOS:A1996WB37800009
J	REISMAN, RE				REISMAN, RE			NATURAL-HISTORY OF INSECT STING ALLERGY - RELATIONSHIP OF SEVERITY OF SYMPTOMS OF INITIAL STING ANAPHYLAXIS TO RESTING REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INSECT STING ANAPHYLAXIS; RESTINGS; NATURE OF SYMPTOMS		To examine the postulate that the nature of the symptoms of initial insect sting anaphylaxis is related to the risk and severity of subsequent sting reactions, the results of field re-stings were analyzed in 220 patients who had had venom anaphylaxis and did not receive venom immunotherapy. The incidence of a reaction after the first re-sting was 56% in the total group, was more frequent in adults (74%) than in children (40%), and was unrelated to the time interval since the initial sting reaction. When re-sting reactions did occur, the nature of the symptoms was similar to the symptoms of the initial sting reaction. Reactions to repeated re-stings tended to be similar. Overall, more severe reactions to re-stings occurred eventually in 24 patients. These observations confirm the frequent self-limiting course of insect sting allergy, especially in children, and the repetitive nature of specific anaphylactic symptoms, and the observations thus suggest that patients with mild to moderate anaphylactic symptoms probably do not require venom immunotherapy.	SUNY BUFFALO,SCH MED,DEPT PEDIAT,BUFFALO,NY 14260; SUNY BUFFALO,SCH MED,DIV ALLERGY,BUFFALO,NY 14260; SUNY BUFFALO,SCH MED,DEPT MED,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; Mueller H.L., 1990, INSECT STING ALLERGY; REISMAN RE, 1989, ALLERGY PROC, V10, P97, DOI 10.2500/108854189778960991; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VALENTINE MD, 1991, NEW ENGL J MED, V23, P1601; WOERMANN U, 1985, UNTERSUCHUNGER NATUR	9	136	136	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				335	339		10.1016/S0091-6749(05)80012-0	http://dx.doi.org/10.1016/S0091-6749(05)80012-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1345753				2022-12-18	WOS:A1992JP52000010
J	BROWN, MJ; CAUSON, R; LEE, TH				BROWN, MJ; CAUSON, R; LEE, TH			A NOVEL DOUBLE-ISOTOPE TECHNIQUE FOR THE ENZYMATIC ASSAY OF PLASMA HISTAMINE - APPLICATION TO ESTIMATION OF MAST-CELL ACTIVATION ASSESSED BY ANTIGEN CHALLENGE IN ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0HS,ENGLAND; ROYAL POSTGRAD MED SCH,INST CARDIOTHORAC,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London	BROWN, MJ (corresponding author), ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,DU CANE RD,LONDON W12 0HS,ENGLAND.			Lee, Tak/0000-0002-7554-4059				ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BROWN MJ, 1981, CLIN SCI, V61, P591, DOI 10.1042/cs0610591; BROWN MJ, 1980, ANAL BIOCHEM, V109, P142, DOI 10.1016/0003-2697(80)90022-6; BRUCE C, 1979, ANN CLIN BIOCHEM, V16, P259, DOI 10.1177/000456327901600166; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DENT C, 1979, AGENTS ACTIONS, V9, P34, DOI 10.1007/BF02024097; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; HARRIES MG, 1980, BRIT J IND MED, V37, P248; IND PW, AGENTS ACTIONS; MILLER RL, 1970, J PHARMACOL EXP THER, V175, P228; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3	14	136	139	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	1					20	24		10.1016/0091-6749(82)90082-3	http://dx.doi.org/10.1016/0091-6749(82)90082-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ377	7033328				2022-12-18	WOS:A1982MZ37700004
J	BAROR, O; NEUMAN, I; DOTAN, R				BAROR, O; NEUMAN, I; DOTAN, R			EFFECTS OF DRY AND HUMID CLIMATES ON EXERCISE-INDUCED ASTHMA IN CHILDREN AND PRE-ADOLESCENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WINGATE INST PHYS EDUC & SPORT,DEPT RES SPORTS MED,WINGATE 42902,ISRAEL; HASHARON HOSP,DEPT PEDIAT ALLERGY,PETAH TIKVA,ISRAEL	Rabin Medical Center								ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; ANDERSON SD, 1972, THESIS U LONDON; BADIEI B, 1975, ANN ALLERGY, V35, P32; Borg G., 1962, PHYS PERFORMANCE PER; BURR ML, 1974, ARCH DIS CHILD, V49, P923, DOI 10.1136/adc.49.12.923; CHEN WY, 1976, PHYSIOLOGIST, V19, P152; CHENEY FW, 1968, ANESTHESIOLOGY, V29, P1099, DOI 10.1097/00000542-196811000-00004; DAVIES RR, 1969, ACTA ALLERGOL, V24, P396, DOI 10.1111/j.1398-9995.1969.tb03754.x; EGGLESTON PA, 1975, PEDIATRICS, V56, P1; FITCH KD, 1976, ARCH DIS CHILD, V51, P190, DOI 10.1136/adc.51.3.190; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; FONTANA VJ, 1968, J ALLERGY, V45, P16; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; GODFREY S, 1975, J ALLERGY CLIN IMMUN, V56, P1, DOI 10.1016/0091-6749(75)90029-9; JONES RS, 1966, BRIT MED J, V2, P972, DOI 10.1136/bmj.2.5520.972; JOSENHANS WT, 1969, RESPIRATION, V26, P435, DOI 10.1159/000192624; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LEBOWITZ MD, 1974, AM REV RESPIR DIS, V109, P262; MCNEILL RS, 1966, Q J MED, V35, P55; MELVILLE GN, 1970, CAN J PHYSIOL PHARM, V48, P592, DOI 10.1139/y70-090; MILLER GJ, 1975, THORAX, V30, P306, DOI 10.1136/thx.30.3.306; PIERSON WE, 1975, PEDIATRICS, V56, P890; RODRIQUEZ GE, 1975, J ALLERGY CLIN IMMUN, V56, P1; SEABURY J, 1976, J ALLERGY CLIN IMMUN, V57, P174, DOI 10.1016/0091-6749(76)90037-3; SEABURY J, 1973, J ALLERGY CLIN IMMUN, V51, P161, DOI 10.1016/0091-6749(73)90021-3; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; WEINSTEIN RE, 1976, 32ND ANN M AM AC ALL; WELLS RE, 1960, NEW ENGL J MED, V263, P268, DOI 10.1056/NEJM196008112630602	30	136	137	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	3					163	168		10.1016/0091-6749(77)90119-1	http://dx.doi.org/10.1016/0091-6749(77)90119-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DU852	893875				2022-12-18	WOS:A1977DU85200003
J	SETTIPANE, GA; CHAFEE, FH; KLEIN, DE				SETTIPANE, GA; CHAFEE, FH; KLEIN, DE			ASPIRIN INTOLERANCE .2. PROSPECTIVE STUDY IN AN ATOPIC AND NORMAL POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RHODE ISLAND HOSP, DEPT MED, DIV ALLERGY, PROVIDENCE, RI USA; BROWN UNIV, DIV BIOL & MED SCI, PROVIDENCE, RI USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University								CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; Miller F F, 1967, J Okla State Med Assoc, V60, P122; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7	7	136	136	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	4					200	204		10.1016/0091-6749(74)90081-5	http://dx.doi.org/10.1016/0091-6749(74)90081-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S6732	4835733				2022-12-18	WOS:A1974S673200002
J	BAZARAL, M; HAMBURGER, RN				BAZARAL, M; HAMBURGER, RN			STANDARDIZATION AND STABILITY OF IMMUNOGLOBULIN E (IGE)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		BAZARAL M, 1971, J IMMUNOL, V107, P794; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; ROWE D S, 1970, Bulletin of the World Health Organization, V43, P609; ROWE DS, 1970, INT ARCH ALLER A IMM, V39, P1	5	136	136	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	3					189	+		10.1016/0091-6749(72)90113-3	http://dx.doi.org/10.1016/0091-6749(72)90113-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L8566	4622102				2022-12-18	WOS:A1972L856600007
J	White, KD; Chung, WH; Hung, SI; Mallal, S; Phillips, EJ				White, Katie D.; Chung, Wen-Hung; Hung, Shuen-Iu; Mallal, Simon; Phillips, Elizabeth J.			Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Abacavir; adverse drug reaction; allopurinol; altered peptide; carbamazepine; drug reaction with eosinophilia and systemic symptoms; hapten; heterologous immunity; human herpesvirus; human leukocyte antigen; major histocompatibility complex; p-i; pharmacogenetics; pharmacogenomics; Stevens-Johnson syndrome; T-cell receptor; toxic epidermal necrolysis	STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; CUTANEOUS ADVERSE-REACTIONS; HLA CLASS-I; IMPLEMENTATION CONSORTIUM GUIDELINES; INDUCED HYPERSENSITIVITY SYNDROME; GENOME-WIDE ASSOCIATION; INDUCED LIVER-INJURY; HLA-B-ASTERISK-1502 ALLELE; NEVIRAPINE HYPERSENSITIVITY	Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of preventable morbidity, mortality, and cost. Increasingly, genetic variation in the HLA loci is associated with risk of severe reactions, highlighting the importance of T-cell immune responses in the mechanisms of both B cell-mediated and primary T cell-mediated IM-ADRs. In this review we summarize the role of host genetics, microbes, and drugs in IM-ADR development; expand on the existing models of IM-ADR pathogenesis to address multiple unexplained observations; discuss the implications of this work in clinical practice today; and describe future applications for preclinical drug toxicity screening, drug design, and development.	[White, Katie D.; Mallal, Simon; Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Chung, Wen-Hung] Chang Gung Mem Hosp, Dept Dermatol, Keelung, Taiwan; [Chung, Wen-Hung] Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Dept Dermatol, Linkou, Taiwan; [Chung, Wen-Hung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Hung, Shuen-Iu] Natl Yang Ming Univ, Program Mol Med, Inst Pharmacol, Sch Med,Infect & Immun Res Ctr, Taipei 112, Taiwan; [Mallal, Simon; Phillips, Elizabeth J.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia	Vanderbilt University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University; Murdoch University	Phillips, EJ (corresponding author), Vanderbilt Univ, Med Ctr N, Div Infect Dis, Med Ctr, A-2200, Nashville, TN 37232 USA.	elizabeth.j.phillips@vanderbilt.edu	Hung, Shuen-Iu/ABB-2139-2021; Mallal, Simon Alexander/HDM-9561-2022	Hung, Shuen-Iu/0000-0001-6531-5538; Mallal, Simon Alexander/0000-0002-7036-1309	National Institutes of Health [P50GM115305]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Work reported in this article was supported in part by National Institutes of Health grant P50GM115305.	Aberg JA, 2009, CLIN INFECT DIS, V49, P651, DOI 10.1086/605292; Adam J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095339; Adam J, 2012, EUR J IMMUNOL, V42, P1706, DOI 10.1002/eji.201142159; Alfirevic A, 2006, PHARMACOGENOMICS, V7, P813, DOI 10.2217/14622416.7.6.813; Amir AL, 2010, BLOOD, V115, P3146, DOI 10.1182/blood-2009-07-234906; Amstutz U, 2013, CLIN PHARMACOL THER, V94, P142, DOI 10.1038/clpt.2013.55; An DM, 2010, EPILEPSY RES, V92, P226, DOI 10.1016/j.eplepsyres.2010.10.006; Aota N, 2009, AUTOIMMUN REV, V8, P488, DOI 10.1016/j.autrev.2009.02.029; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Becquement L, 2011, PHARMACOGENOMICS, V12, P113, DOI 10.2217/PGS.10.147; Bharadwaj M, 2012, ANNU REV PHARMACOL, V52, P401, DOI 10.1146/annurev-pharmtox-010611-134701; Broccolo F, 2013, SCI WORLD J, DOI 10.1155/2013/867389; Brook MO, 2006, TRANSPLANTATION, V82, P1, DOI 10.1097/01.tp.0000226082.17507.da; Burrows SR, 1999, IMMUNOL TODAY, V20, P203, DOI 10.1016/S0167-5699(98)01429-7; BYRNE JA, 1988, J IMMUNOL, V141, P3249; Carr DF, 2014, J ANTIMICROB CHEMOTH, V69, P3329, DOI 10.1093/jac/dku315; Carr DF, 2013, CLIN INFECT DIS, V56, P1330, DOI 10.1093/cid/cit021; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Caselli E, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002951; CHAN SH, 1989, DERMATOLOGICA, V179, P32, DOI 10.1159/000248097; Chang CC, 2011, INT J DERMATOL, V50, P221, DOI 10.1111/j.1365-4632.2010.04745.x; Chantarangsu S, 2011, CLIN INFECT DIS, V53, P341, DOI 10.1093/cid/cir403; Chantarangsu S, 2009, PHARMACOGENET GENOM, V19, P139, DOI 10.1097/FPC.0b013e32831d0faf; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Chung WH, 2015, ANN RHEUM DIS, V74, P2157, DOI 10.1136/annrheumdis-2014-205577; Chung WH, 2014, JAMA-J AM MED ASSOC, V312, P525, DOI 10.1001/jama.2014.7859; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Ciccacci C, 2013, EUR J CLIN PHARMACOL, V69, P1909, DOI 10.1007/s00228-013-1549-x; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Colf LA, 2007, CELL, V129, P135, DOI 10.1016/j.cell.2007.01.048; Curtsinger JM, 1998, J IMMUNOL, V160, P3236; Cutrell AG, 2004, ANN PHARMACOTHER, V38, P2171, DOI 10.1345/aph.1E202; D'Orsogna LJA, 2010, TRANSPL IMMUNOL, V23, P149, DOI 10.1016/j.trim.2010.06.008; D'Orsogna LJA, 2011, TRANSPLANTATION, V91, P494, DOI 10.1097/TP.0b013e318207944c; Dainichi T, 2007, DERMATOLOGY, V215, P86, DOI 10.1159/000102045; Daly AK, 2007, GASTROENTEROLOGY, V132, P272, DOI 10.1053/j.gastro.2006.11.023; Daly AK, 2012, DRUG METAB REV, V44, P116, DOI 10.3109/03602532.2011.605790; Daly AK, 2009, SEMIN LIVER DIS, V29, P400, DOI 10.1055/s-0029-1240009; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Descamps V, 2001, ARCH DERMATOL, V137, P301; Dickinson L, 2014, ANTIMICROB AGENTS CH, V58, P706, DOI 10.1128/AAC.02069-13; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Fernandez CA, 2014, BLOOD, V124, P1266, DOI 10.1182/blood-2014-03-563742; Ferrell PB, 2008, PHARMACOGENOMICS, V9, P1543, DOI 10.2217/14622416.9.10.1543; Gao SC, 2012, AIDS RES HUM RETROV, V28, P540, DOI [10.1089/aid.2011.0107, 10.1089/AID.2011.0107]; Gatanaga H, 2007, AIDS, V21, P264, DOI 10.1097/QAD.0b013e32801199d9; Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x; Genin E, 2014, PHARMACOGENOMICS J, V14, P281, DOI 10.1038/tpj.2013.40; Genin E, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-52; Goldkind L, 2006, PHARMACOEPIDEM DR S, V15, P213, DOI 10.1002/pds.1207; Grover S, 2014, PHARMACOGENET GENOM, V24, P94, DOI 10.1097/FPC.0000000000000021; Gueant JL, 2015, J ALLERGY CLIN IMMUN, V135, P253, DOI 10.1016/j.jaci.2014.07.047; Hakkarainen KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033236; Harding DJ, 2012, MED J AUSTRALIA, V197, P411, DOI 10.5694/mja12.10477; Hautekeete ML, 1999, GASTROENTEROLOGY, V117, P1181, DOI 10.1016/S0016-5085(99)70404-X; Hershfield MS, 2013, CLIN PHARMACOL THER, V93, P153, DOI 10.1038/clpt.2012.209; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hislop AD, 2007, ANNU REV IMMUNOL, V25, P587, DOI 10.1146/annurev.immunol.25.022106.141553; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; Hraber P, 2007, HEPATOLOGY, V46, P1713, DOI 10.1002/hep.21889; Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]; Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Ikeda H, 2010, EPILEPSIA, V51, P297, DOI 10.1111/j.1528-1167.2009.02269.x; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Jung JW, 2011, NEPHROL DIAL TRANSPL, V26, P3567, DOI 10.1093/ndt/gfr060; Kang HR, 2011, PHARMACOGENET GENOM, V21, P303, DOI 10.1097/FPC.0b013e32834282b8; Kaniwa N, 2010, EPILEPSIA, V51, P2461, DOI 10.1111/j.1528-1167.2010.02766.x; Kaniwa N, 2008, PHARMACOGENOMICS, V9, P1617, DOI 10.2217/14622416.9.11.1617; Kano Y, 2006, BRIT J DERMATOL, V155, P301, DOI 10.1111/j.1365-2133.2006.07238.x; Keane NM, 2014, AIDS, V28, P1891, DOI 10.1097/QAD.0000000000000345; Kearns GL, 1998, CLIN PHARMACOL THER, V63, P686, DOI 10.1016/S0009-9236(98)90093-5; Kim SH, 2011, EPILEPSY RES, V97, P190, DOI 10.1016/j.eplepsyres.2011.08.010; Kindmark A, 2008, PHARMACOGENOMICS J, V8, P186, DOI 10.1038/sj.tpj.6500458; Knowles SR, 1999, DRUG SAFETY, V21, P489, DOI 10.2165/00002018-199921060-00005; Ko TM, 2011, J ALLERGY CLIN IMMUN, V128, P1266, DOI 10.1016/j.jaci.2011.08.013; Komanduri KV, 2001, VIROLOGY, V279, P459, DOI 10.1006/viro.2000.0697; Kongkaew C, 2008, ANN PHARMACOTHER, V42, P1017, DOI 10.1345/aph.1L037; Kulkantrakorn K, 2012, PAIN PRACT, V12, P202, DOI 10.1111/j.1533-2500.2011.00479.x; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Leckband SG, 2013, CLIN PHARMACOL THER, V94, P324, DOI 10.1038/clpt.2013.103; Lee AY, 2004, EUR J CLIN PHARMACOL, V60, P155, DOI 10.1007/s00228-004-0753-0; Likanonsakul Sirirat, 2009, AIDS Res Ther, V6, P22, DOI 10.1186/1742-6405-6-22; Lin CH, 2015, J ALLERGY CLIN IMMUN, V135, P1063, DOI 10.1016/j.jaci.2014.09.041; Lin LC, 2009, KAOHSIUNG J MED SCI, V25, P82, DOI 10.1016/S1607-551X(09)70045-2; Lin YT, 2013, J EUR ACAD DERMATOL, V27, P356, DOI 10.1111/j.1468-3083.2011.04418.x; Lin Y.T., 2013, 8 INT C CUT ADV DRUG; Littera R, 2006, AIDS, V20, P1621, DOI 10.1097/01.aids.0000238408.82947.09; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Lucas A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117160; Lucena MI, 2011, GASTROENTEROLOGY, V141, P338, DOI 10.1053/j.gastro.2011.04.001; Macdonald WA, 2009, IMMUNITY, V31, P897, DOI 10.1016/j.immuni.2009.09.025; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; Martin AM, 2005, AIDS, V19, P97, DOI 10.1097/00002030-200501030-00014; Martin MA, 2012, CLIN PHARMACOL THER, V91, P734, DOI 10.1038/clpt.2011.355; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Mizumoto K, 2012, J DERMATOL, V39, P791, DOI 10.1111/j.1346-8138.2011.01421.x; Moss P, 2004, HUM IMMUNOL, V65, P456, DOI 10.1016/j.humimm.2004.02.014; Naisbitt DJ, 2001, BRIT J PHARMACOL, V133, P295, DOI 10.1038/sj.bjp.0704074; Niihara H, 2012, J DERMATOL, V39, P594, DOI 10.1111/j.1346-8138.2011.01457.x; Nikolich-Zugich J, 2004, NAT REV IMMUNOL, V4, P123, DOI 10.1038/nri1292; Norcross MA, 2012, AIDS, V26, pF21, DOI 10.1097/QAD.0b013e328355fe8f; O'Donohue J, 2000, GUT, V47, P717, DOI 10.1136/gut.47.5.717; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; Ozeki T, 2011, HUM MOL GENET, V20, P1034, DOI 10.1093/hmg/ddq537; Padovan E, 1996, EUR J IMMUNOL, V26, P42, DOI 10.1002/eji.1830260107; Park BK, 2001, TOXICOLOGY, V158, P11, DOI 10.1016/S0300-483X(00)00397-8; Pavlos R, 2015, ANNU REV MED, V66, P439, DOI 10.1146/annurev-med-050913-022745; Pavlos R, 2014, J ALLER CL IMM-PRACT, V2, P21, DOI 10.1016/j.jaip.2013.11.005; Pavlos R, 2012, PHARMACOGENOMICS, V13, P1285, DOI [10.2217/PGS.12.108, 10.2217/pgs.12.108]; Phillips EJ, 2005, AIDS, V19, P979, DOI 10.1097/01.aids.0000171414.99409.fb; Phillips EJ, 2002, AIDS, V16, P2223, DOI 10.1097/00002030-200211080-00017; Picard D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001116; Pichler W, 2002, ALLERGY, V57, P884, DOI 10.1034/j.1398-9995.2002.02161.x; Pichler Werner J, 2006, Allergol Int, V55, P17, DOI 10.2332/allergolint.55.17; Pichler Werner J., 2014, Current Immunology Reviews, V10, P7, DOI 10.2174/1573395510666140407212357; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Prugnolle F, 2005, CURR BIOL, V15, P1022, DOI 10.1016/j.cub.2005.04.050; Qutob N, 2012, IMMUNOGENETICS, V64, P165, DOI 10.1007/s00251-011-0576-y; Rauch A, 2006, CLIN INFECT DIS, V43, P99, DOI 10.1086/504874; Rauch A, 2008, ANTIVIR THER, V13, P1019; Rawlins M., 1977, TXB ADVERSE DRUG REA, P10; Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891; Reiser JB, 2002, IMMUNITY, V16, P345, DOI 10.1016/S1074-7613(02)00288-1; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Saag M, 2008, CLIN INFECT DIS, V46, P1111, DOI 10.1086/529382; SANDERS ME, 1989, EUR J IMMUNOL, V19, P803, DOI 10.1002/eji.1830190504; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2013, J ALLERGY CLIN IMMUN, V132, P756, DOI 10.1016/j.jaci.2013.04.013; Seishima M, 2006, BRIT J DERMATOL, V155, P344, DOI 10.1111/j.1365-2133.2006.07332.x; Sester M, 2002, J VIROL, V76, P3748, DOI 10.1128/JVI.76.8.3748-3755.2002; Shapiro M, 2001, AIDS Read, V11, P222; Shi YW, 2011, BASIC CLIN PHARMACOL, V109, P42, DOI 10.1111/j.1742-7843.2011.00681.x; Shiohara Tetsuo, 2006, Allergol Int, V55, P1, DOI 10.2332/allergolint.55.1; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Singer JB, 2010, NAT GENET, V42, P711, DOI 10.1038/ng.632; Somkrua R, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-118; Spraggs CF, 2011, J CLIN ONCOL, V29, P667, DOI 10.1200/JCO.2010.31.3197; Suh DC, 2000, ANN PHARMACOTHER, V34, P1373, DOI 10.1345/aph.10094; Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; Takahashi R, 2009, J IMMUNOL, V182, P8071, DOI 10.4049/jimmunol.0804002; Tassaneeyakul W, 2010, EPILEPSIA, V51, P926, DOI 10.1111/j.1528-1167.2010.02533.x; Tassaneeyakul W, 2009, PHARMACOGENET GENOM, V19, P704, DOI 10.1097/FPC.0b013e328330a3b8; Then SM, 2011, ASIAN PAC J ALLERGY, V29, P290; Thursz MR, 1997, NAT GENET, V17, P11, DOI 10.1038/ng0997-11; Tohyama M, 2007, BRIT J DERMATOL, V157, P934, DOI 10.1111/j.1365-2133.2007.08167.x; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; Vitezica ZG, 2008, AIDS, V22, P540, DOI 10.1097/QAD.0b013e3282f37812; von Greyerz S, 2001, INT IMMUNOL, V13, P877, DOI 10.1093/intimm/13.7.877; Wang Q, 2011, SEIZURE-EUR J EPILEP, V20, P446, DOI 10.1016/j.seizure.2011.02.003; Wei CY, 2012, J ALLERGY CLIN IMMUN, V129, P1562, DOI 10.1016/j.jaci.2011.12.990; Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x; Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820; White K.R., 2014, HDB PHARMACOGENOMICS, P437; Wu XT, 2010, EPILEPSY BEHAV, V19, P405, DOI 10.1016/j.yebeh.2010.08.007; Yin YY, 2009, IMMUNITY, V31, P849, DOI 10.1016/j.immuni.2009.12.002; Yip VL, 2012, CLIN PHARMACOL THER, V92, P757, DOI 10.1038/clpt.2012.189; Yuan J, 2011, AIDS, V25, P1271, DOI 10.1097/QAD.0b013e32834779df; Yun J, 2013, CLIN EXP ALLERGY, V43, P1246, DOI 10.1111/cea.12184; Yun J, 2014, J IMMUNOL, V192, P2984, DOI 10.4049/jimmunol.1302306; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zanni MP, 1998, INT IMMUNOL, V10, P507, DOI 10.1093/intimm/10.4.507; Zhang FR, 2013, NEW ENGL J MED, V369, P1620, DOI 10.1056/NEJMoa1213096; Zhang Y, 2011, EUR J CLIN PHARMACOL, V67, P885, DOI 10.1007/s00228-011-1009-4; Zhu J, 2007, J EXP MED, V204, P595, DOI 10.1084/jem.20061792; Zhu J, 2013, NATURE, V497, P494, DOI 10.1038/nature12110	180	135	143	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					219	235		10.1016/j.jaci.2015.05.050	http://dx.doi.org/10.1016/j.jaci.2015.05.050			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26254049	Green Accepted, Bronze			2022-12-18	WOS:000359004900001
J	Ferreira, MAR; Matheson, MC; Tang, CS; Granell, R; Ang, W; Hui, J; Kiefer, AK; Duffy, DL; Baltic, S; Danoy, P; Bui, M; Price, L; Sly, PD; Eriksson, N; Madden, PA; Abramson, MJ; Holt, PG; Heath, AC; Hunter, M; Musk, B; Robertson, CF; Le Souef, P; Montgomery, GW; Henderson, AJ; Tung, JY; Dharmage, SC; Brown, MA; James, A; Thompson, PJ; Pennell, C; Martin, NG; Evans, DM; Hinds, DA; Hopper, JL				Ferreira, Manuel A. R.; Matheson, Melanie C.; Tang, Clara S.; Granell, Raquel; Ang, Wei; Hui, Jennie; Kiefer, Amy K.; Duffy, David L.; Baltic, Svetlana; Danoy, Patrick; Bui, Minh; Price, Loren; Sly, Peter D.; Eriksson, Nicholas; Madden, Pamela A.; Abramson, Michael J.; Holt, Patrick G.; Heath, Andrew C.; Hunter, Michael; Musk, Bill; Robertson, Colin F.; Le Souef, Peter; Montgomery, Grant W.; Henderson, A. John; Tung, Joyce Y.; Dharmage, Shyamali C.; Brown, Matthew A.; James, Alan; Thompson, Philip J.; Pennell, Craig; Martin, Nicholas G.; Evans, David M.; Hinds, David A.; Hopper, John L.		Australian Asthma Genetics	Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; atopy; selection; genetic correlation; bivariate; single nucleotide polymorphism	GENE-EXPRESSION; SUSCEPTIBILITY LOCI; MULTIPLE-SCLEROSIS; POPULATION STRATIFICATION; TRANSCRIPTION FACTORS; JAPANESE POPULATION; ALLERGIC RHINITIS; METAANALYSIS; DISEASE; SP1	Background: To date, no genome-wide association study (GWAS) has considered the combined phenotype of asthma with hay fever. Previous analyses of family data from the Tasmanian Longitudinal Health Study provide evidence that this phenotype has a stronger genetic cause than asthma without hay fever. Objective: We sought to perform a GWAS of asthma with hay fever to identify variants associated with having both diseases. Methods: We performed a meta-analysis of GWASs comparing persons with both physician-diagnosed asthma and hay fever (n = 6,685) with persons with neither disease (n = 14,091). Results: At genome-wide significance, we identified 11 independent variants associated with the risk of having asthma with hay fever, including 2 associations reaching this level of significance with allergic disease for the first time: ZBTB10 (rs7009110; odds ratio [OR], 1.14; P = 4 x 10(-9)) and CLEC16A (rs62026376; OR, 1.17; P = 1 x 10(-8)). The rs62026376: C allele associated with increased asthma with hay fever risk has been found to be associated also with decreased expression of the nearby DEXI gene in monocytes. The 11 variants were associated with the risk of asthma and hay fever separately, but the estimated associations with the individual phenotypes were weaker than with the combined asthma with hay fever phenotype. A variant near LRRC32 was a stronger risk factor for hay fever than for asthma, whereas the reverse was observed for variants in/near GSDMA and TSLP. Single nucleotide polymorphisms with suggestive evidence for association with asthma with hay fever risk included rs41295115 near IL2RA (OR, 1.28; P = 5 x 10(-7)) and rs76043829 in TNS1 (OR, 1.23; P = 2 x 10(-6)). Conclusion: By focusing on the combined phenotype of asthma with hay fever, variants associated with the risk of allergic disease can be identified with greater efficiency.	[Ferreira, Manuel A. R.; Tang, Clara S.; Duffy, David L.; Montgomery, Grant W.; Martin, Nicholas G.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Matheson, Melanie C.; Bui, Minh; Dharmage, Shyamali C.; Hopper, John L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia; [Tang, Clara S.] Univ Hong Kong, Ctr Genom Sci, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [Tang, Clara S.] Univ Hong Kong, Ctr Genom Sci, Dept Surg & Med, Hong Kong, Hong Kong, Peoples R China; [Granell, Raquel; Henderson, A. John; Evans, David M.] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Ang, Wei; Pennell, Craig] Univ Western Australia, Sch Womens & Infants Hlth, Subiaco, WA, Australia; [Hui, Jennie] PathWest Lab Med Western Australia, Nedlands, WA, Australia; [Hui, Jennie; Hunter, Michael] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Hui, Jennie] Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA 6009, Australia; [Hui, Jennie; Hunter, Michael; Musk, Bill; James, Alan] Sir Charles Gairdner Hosp, Bussel Populat Med Res Fdn, Perth, WA, Australia; [Kiefer, Amy K.; Eriksson, Nicholas; Tung, Joyce Y.; Hinds, David A.] 23&Me, Mountain View, CA USA; [Baltic, Svetlana; Price, Loren; Thompson, Philip J.] Univ Western Australia, Lung Inst Western Australia, Perth, WA 6009, Australia; [Baltic, Svetlana; Price, Loren; Thompson, Philip J.] Univ Western Australia, Ctr Asthma Allergy & Resp Res, Perth, WA 6009, Australia; [Danoy, Patrick; Brown, Matthew A.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia; [Sly, Peter D.] Royal Childrens Hosp, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Madden, Pamela A.; Heath, Andrew C.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63130 USA; [Abramson, Michael J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Holt, Patrick G.] Univ Western Australia, Telethon Inst Child Hlth Res, Subiaco, WA, Australia; [Musk, Bill; James, Alan] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia; [Musk, Bill] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia; [Robertson, Colin F.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Le Souef, Peter] Princess Margaret Hosp Children, Sch Paediat & Child Hlth, Perth, WA, Australia; [James, Alan] West Australian Sleep Disorders Res Inst, Dept Pulm Physiol, Nedlands, WA, Australia; [Evans, David M.] Univ Bristol, Med Res Council MRC Ctr Causal Anal Translat Epid, Bristol BS8 1TH, Avon, England	QIMR Berghofer Medical Research Institute; University of Melbourne; University of Hong Kong; University of Hong Kong; University of Bristol; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Queensland; Royal Children's Hospital Brisbane; Washington University (WUSTL); Monash University; Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia; Murdoch Children's Research Institute; University of Western Australia; University of Bristol	Ferreira, MAR (corresponding author), Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Locked Bag 2000, Herston, Qld 4029, Australia.	manuel.ferreira@qimrberghofer.edu.au; j.hopper@unimelb.edu.au	Hui, Jennie/A-9543-2013; Matheson, Melanie C/O-4721-2015; Montgomery, Grant W/B-7148-2008; Granell, Raquel/AAY-4846-2020; Granell, Raquel/AAB-5256-2022; Hunter, Michael L/B-3213-2013; Abramson, Michael/AAQ-2671-2020; Pennell, Craig/ABD-6902-2020; Martin, Nicholas/R-9235-2019; Sly, Peter D/F-1486-2010; Le Souef, Peter N/H-5256-2014; Evans, David M/H-6325-2013; Ferreira, Manuel A R/D-3609-2013; Brown, Matthew A/E-5749-2010; Duffy, David L/B-7392-2013; Holt, Patrick G/H-1548-2011	Hui, Jennie/0000-0002-1653-2496; Matheson, Melanie C/0000-0002-5822-3499; Montgomery, Grant W/0000-0002-4140-8139; Granell, Raquel/0000-0002-4890-4012; Hunter, Michael L/0000-0001-6704-4815; Abramson, Michael/0000-0002-9954-0538; Pennell, Craig/0000-0002-0937-6165; Martin, Nicholas/0000-0003-4069-8020; Sly, Peter D/0000-0001-6305-2201; Evans, David M/0000-0003-0663-4621; Ferreira, Manuel A R/0000-0001-9059-1825; Brown, Matthew A/0000-0003-0538-8211; Duffy, David L/0000-0001-7227-632X; Holt, Patrick G/0000-0003-1193-0935; Flynn, Loren/0000-0001-5249-547X; Tang, Clara/0000-0003-0265-2638; Hinds, David/0000-0002-4911-803X; Le Souef, Peter/0000-0003-0930-1654; Baltic, Svetlana/0000-0002-3428-940X; Bui, Minh/0000-0002-9099-6870	Australian National Health and Medical Research Council (NHMRC) [241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498, 613627, 403981, 003209]; Australian Research Council [A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921]; FP-5 GenomEUtwin Project [QLG2-CT-2002-01254]; US National Institutes of Health [AA07728, AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, DA12854, MH66206]; Asthma Foundation in Tasmania; Asthma Foundation in Queensland; Asthma Foundation in Victoria; Clifford Craig Trust in Northern Tasmania; Lew Carty Foundation; Royal Hobart Research Foundation; University of Melbourne; Great Wine Estates of the Margaret River region of Western Australia; University of Western Australia (UWA); Raine Medical Research Foundation; UWA Faculty of Medicine, Dentistry and Health Sciences; Telethon Institute for Child Health Research; Women and Infants Research Foundation; Canadian Institutes of Health Research [MOP-82893]; National Heart, Lung, and Blood Institute of the National Institutes of Health [1R43HL115873-01]; MRC [MC_UU_12013/4] Funding Source: UKRI; Medical Research Council [MC_UU_12013/4, MC_PC_15018] Funding Source: researchfish; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013321, R01AA013326, P60AA011998, R01AA010249, R01AA014041, R01AA007535, K05AA017688, R37AA007728, R01AA007728, R01AA013320, P50AA011998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012854, R56DA012854] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); FP-5 GenomEUtwin Project; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma Foundation in Tasmania; Asthma Foundation in Queensland; Asthma Foundation in Victoria; Clifford Craig Trust in Northern Tasmania; Lew Carty Foundation; Royal Hobart Research Foundation; University of Melbourne(University of Melbourne); Great Wine Estates of the Margaret River region of Western Australia; University of Western Australia (UWA); Raine Medical Research Foundation; UWA Faculty of Medicine, Dentistry and Health Sciences; Telethon Institute for Child Health Research; Women and Infants Research Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Heart, Lung, and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by the Australian National Health and Medical Research Council (NHMRC; grants 241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498, 613627, 403981, and 003209); the Australian Research Council (grants A7960034, A79906588, A79801419, DP0770096, DP0212016, and DP0343921); the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254); the US National Institutes of Health (grants AA07728, AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, DA12854, and MH66206); Asthma Foundations in Tasmania, Queensland, and Victoria; the Clifford Craig Trust in Northern Tasmania; the Lew Carty Foundation; the Royal Hobart Research Foundation; the University of Melbourne; the Great Wine Estates of the Margaret River region of Western Australia; the University of Western Australia (UWA); Raine Medical Research Foundation; UWA Faculty of Medicine, Dentistry and Health Sciences; the Telethon Institute for Child Health Research; the Women and Infants Research Foundation; the Canadian Institutes of Health Research (MOP-82893); and the National Heart, Lung, and Blood Institute of the National Institutes of Health under grant no. 1R43HL115873-01.	Andiappan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019719; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Davison LJ, 2012, HUM MOL GENET, V21, P322, DOI 10.1093/hmg/ddr468; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Ding J, 2010, AM J HUM GENET, V87, P779, DOI 10.1016/j.ajhg.2010.10.024; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Evans S, 1996, EARLY HUM DEV, V45, P203, DOI 10.1016/0378-3782(96)01728-8; Fairfax BP, 2012, NAT GENET, V44, P502, DOI 10.1038/ng.2205; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Ferreira MAR, 2010, AM J HUM GENET, V86, P88, DOI 10.1016/j.ajhg.2009.12.008; Ferreira MAR, 2009, AM J HUM GENET, V85, P745, DOI 10.1016/j.ajhg.2009.10.005; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, CATALOG PUBLISHED GE; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hopper JL, 2012, J ALLERGY CLIN IMMUN, V130, P1117, DOI 10.1016/j.jaci.2012.08.003; Jin Y, 2010, NEW ENGL J MED, V362, P1686, DOI 10.1056/NEJMoa0908547; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Lasky-Su J, 2012, CLIN EXP ALLERGY, V42, P1724, DOI 10.1111/cea.12000; Leikfoss IS, 2013, GENES IMMUN, V14, P62, DOI 10.1038/gene.2012.52; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Li MX, 2012, HUM GENET, V131, P747, DOI 10.1007/s00439-011-1118-2; Mells GF, 2011, NAT GENET, V43, P329, DOI 10.1038/ng.789; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pe'er I, 2008, GENET EPIDEMIOL, V32, P381, DOI 10.1002/gepi.20303; Petukhova L, 2010, NATURE, V466, P113, DOI 10.1038/nature09114; Plagnol V, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002216; Ramasamy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044008; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Reich DE, 2001, GENET EPIDEMIOL, V20, P4, DOI 10.1002/1098-2272(200101)20:1<4::AID-GEPI2>3.0.CO;2-T; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Rimmer J, 2006, MED J AUSTRALIA, V185, P565, DOI 10.5694/j.1326-5377.2006.tb00693.x; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; Takahashi K, 2008, J BIOL CHEM, V283, P15134, DOI 10.1074/jbc.M800498200; Thomsen SF, 2006, CLIN EXP ALLERGY, V36, P1382, DOI 10.1111/j.1365-2222.2006.02512.x; Tillotson LG, 1999, J BIOL CHEM, V274, P8123, DOI 10.1074/jbc.274.12.8123; Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Tone M, 2002, J BIOL CHEM, V277, P8890, DOI 10.1074/jbc.M109889200; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Williams LA, 1997, BRIT MED J, V314, P1864, DOI 10.1136/bmj.314.7098.1864; Yang J, 2011, EUR J HUM GENET, V19, P807, DOI 10.1038/ejhg.2011.39; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693	65	135	139	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1564	1571		10.1016/j.jaci.2013.10.030	http://dx.doi.org/10.1016/j.jaci.2013.10.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24388013	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000336672500007
J	Noonan, M; Korenblat, P; Mosesova, S; Scheerens, H; Arron, JR; Zheng, Y; Putnam, WS; Parsey, MV; Bohen, SP; Matthews, JG				Noonan, Michael; Korenblat, Phillip; Mosesova, Sofia; Scheerens, Heleen; Arron, Joseph R.; Zheng, Yanan; Putnam, Wendy S.; Parsey, Merdad V.; Bohen, Sean P.; Matthews, John G.			Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; lebrikizumab; IL-13; type 2 inflammation; periostin; uncontrolled; antibody; FEV1	IL-13; PHENOTYPES; CORTICOSTEROIDS; INTERLEUKIN-13; INFLAMMATION; EXPRESSION; RESPONSES; BLOCKADE; RECEPTOR	Background: Asthma is a disease with marked heterogeneity in its clinical course and response to treatment. IL-13 is central to type 2 inflammation, which contributes to many key features of asthma. Lebrikizumab is an anti-IL-13 mAb previously reported to significantly improve lung function in patients with inadequately controlled asthma despite inhaled corticosteroid therapy, especially in periostin-high patients. Objective: This phase II study investigated the efficacy and safety of IL-13 blockade with different doses of lebrikizumab in asthmatic patients not receiving inhaled corticosteroids. Methods: Patients were randomized to receive 125, 250, or 500 mg of lebrikizumab or placebo subcutaneously monthly for 12 weeks with an 8-week follow-up period. The primary efficacy end point was the relative change in prebronchodilator FEV1 from baseline to week 12. Results: A total of 212 patients were randomized. The mean relative change in FEV1 was numerically higher in all lebrikizumab dose groups versus the placebo group, although the difference was neither statistically nor clinically significant. There were no meaningful differences in changes in FEV1 between the dose groups and the placebo group by the periostin subgroup. Lebrikizumab treatment was associated with a reduced risk of treatment failure at all doses versus placebo (P < .001), and results were similar by the periostin subgroup, with no apparent differences between doses of lebrikizumab. Lebrikizumab was generally well tolerated. Conclusion: Blocking IL-13, a single cytokine, in this population of asthmatic patients is insufficient to improve lung function. There is evidence that IL-13 blockade may improve disease control, as measured by prevention of protocol-defined treatment failure in these patients.	[Noonan, Michael] Allergy Associates Res, Portland, OR USA; [Korenblat, Phillip] Clin Res Ctr LLC, St Louis, MO USA; [Mosesova, Sofia; Scheerens, Heleen; Arron, Joseph R.; Zheng, Yanan; Putnam, Wendy S.; Bohen, Sean P.; Matthews, John G.] Genentech Inc, San Francisco, CA 94080 USA; [Parsey, Merdad V.] 3V Biosci, Menlo Pk, CA USA	Roche Holding; Genentech	Matthews, JG (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	matthews.john@gene.com		Arron, Joseph/0000-0001-7677-9979	F. Hoffmann-La Roche Ltd.; Clinical Research Center, LLC; Washington University School of Medicine (CME Allergy for the Practicing Physician, Program Director); American Association of Pharmaceutical Scientists	F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche); Clinical Research Center, LLC; Washington University School of Medicine (CME Allergy for the Practicing Physician, Program Director); American Association of Pharmaceutical Scientists	Supported by F. Hoffmann-La Roche Ltd.; P. Korenblat has been supported by one or more grants from Clinical Research Center, LLC; has consultancy arrangements with Targacept; is employed by Associated Specialists in Medicine, PC, and the Clinical Research Center, LLC; has received one or more payments from the Washington University School of Medicine (CME Allergy for the Practicing Physician, Program Director); and owns stock/stock options in Dendreon Corporation, Johnson & Johnson, GlaxoSmithKline, and Stereotaxis. S. Mosesova is employed by Genentech; has one or more patents (planned, pending, or issued) with Genentech and Roche; and owns stock/stock options in Roche. H. Scheerens has been provided with writing assistance, medicines, equipment, or administrative support by MTM; is employed by Genentech; has one or more patents (planned, pending, or issued) with Genentech and Roche; and owns stock/stock options in Roche. J. R. Arron is employed by Genentech, has one or more patents (planned, pending, or issued) with Genentech and Roche, and owns stock/stock options in Roche. Y. Zheng is employed by Genentech; has one or more patents (planned, pending, or issued) with Genentech and Roche; and owns stock/stock options in Roche. W. S. Putnam is employed by and owns stock/stock options in Genentech and has received one or more payments for travel/accommodations/meeting expenses from the American Association of Pharmaceutical Scientists. M. V. Parsey is employed by and owns stock/stock options in Genentech. S. P. Bohen has been provided with writing assistance, medicines, equipment, or administrative support by MTM and is employed by Genentech. J. G. Matthews has been provided with writing assistance, medicines, equipment, or administrative support by MTM; is employed by Genentech; has one or more patents (planned, pending, or issued) with Genentech and Roche; and owns stock/stock options in Roche. M. Noonan declares that he has no relevant conflicts of interest.	Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Berger WE, 2009, ALLERGY ASTHMA PROC, V30, P304, DOI 10.2500/aap.2009.30.3242; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hodsman P, 2013, BRIT J CLIN PHARMACO, V75, P118, DOI 10.1111/j.1365-2125.2012.04334.x; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Noonan MJ, 1998, EUR RESPIR J, V11, P1232, DOI 10.1183/09031936.98.11061232; Scheerens H, 2012, CLIN EXP ALLERGY, V127, pAB164; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Ultsch M, 2013, J MOL BIOL, V425, P1330, DOI 10.1016/j.jmb.2013.01.024; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.006	20	135	139	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					567	+		10.1016/j.jaci.2013.03.051	http://dx.doi.org/10.1016/j.jaci.2013.03.051			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23726041				2022-12-18	WOS:000323612000007
J	Corrigan, CJ; Wang, W; Meng, Q; Fang, CL; Eid, G; Caballero, MR; Lv, Z; An, YQ; Wang, YH; Liu, YJ; Kay, AB; Lee, TH; Ying, S				Corrigan, Chris J.; Wang, Wei; Meng, Qiu; Fang, Cailong; Eid, Ghada; Caballero, M. Rosario; Lv, Ze; An, Yunqing; Wang, Yui-Hsi; Liu, Yong-Jun; Kay, A. Barry; Lee, Tak H.; Ying, Sun			Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-25; IL-25 receptor; asthma; skin late-phase response; allergen challenge	THYMIC STROMAL LYMPHOPOIETIN; PROTEIN-KINASE; INTERLEUKIN-25; IL-17E; EOSINOPHILS; INFLAMMATION; CHEMOKINES; LUNG	Background: IL-25 is thought to participate in allergic inflammation by propagating T(H)2-type responses. Objective: To address the hypothesis that allergen provocation increases expression of IL-25 and its receptor IL-25R in the asthmatic bronchial mucosa and skin dermis of atopic subjects. Methods: Sequential single and double immunostaining was used to evaluate the numbers and phenotypes of IL-25 and IL-25R immunoreactive cells in bronchial biopsies from mild atopic subjects with asthma (n = 10) before and 24 hours after allergen inhalation challenge and skin biopsies from atopic subjects (n = 10) up to 72 hours after allergen subepidermal injection. Results: IL-25 immunoreactivity was expressed by a majority of epidermal cells in both organs at baseline and was not further augmented by challenge. IL-25R immunoreactive cells were rare in the epidermis before or after challenge. Allergen challenge was associated with significantly (P < .01) increased expression of IL-25 and IL-25R immunoreactivity in the submucosa of both organs. IL-25 immunoreactivity colocalized with eosinophils, mast cells, and endothelial cells, whereas IL-25R immunoreactivity colocalized with eosinophils, mast cells, endothelial cells, and T lymphocytes. In both organs, correlations were observed between increases in IL-25 expression and the magnitudes of the late-phase allergen-induced clinical responses. Conclusion: Allergen provocation induces functionally relevant, increased expression of IL-25 and its receptor in the asthmatic bronchial mucosa and dermis of sensitized atopic subjects. In addition to T cells, eosinophils, mast cells, and endothelial cells are potential sources and targets of IL-25 in the course of allergic inflammation. (J Allergy Clin Immunol 2011; 128: 116-24.)	[Corrigan, Chris J.; Meng, Qiu; Fang, Cailong; Eid, Ghada; Caballero, M. Rosario; Lee, Tak H.; Ying, Sun] Guys Hosp, Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, Div Asthma Allergy & Lung Biol, London SE1 9RT, England; [Wang, Wei; Lv, Ze; An, Yunqing] Capital Med Univ, Dept Immunol, Dept Resp Dis, Beijing, Peoples R China; [Wang, Yui-Hsi] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Liu, Yong-Jun] Univ Texas MD Anderson Canc Ctr, Dept Immunol & Ctr Canc Immunol Res, Houston, TX USA; [Kay, A. Barry] Univ London Imperial Coll Sci Technol & Med, Fac Med, London SW7 2AZ, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Capital Medical University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center; Imperial College London	Ying, S (corresponding author), Guys Hosp, Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, Div Asthma Allergy & Lung Biol, 5th Floor,Tower Wing, London SE1 9RT, England.	ying.sun@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Caballero, Maria Rosario/0000-0002-0702-043X; Corrigan, Chris/0000-0002-0706-6534	Dana Foundation; Asthma UK; Department of Health via the National Institute for Health Research (NIHR); NHS Foundation Trust; King's College London; King's College Hospital NHS Foundation Trust; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Dana Foundation; Asthma UK; Department of Health via the National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NHS Foundation Trust; King's College London; King's College Hospital NHS Foundation Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the Dana Foundation and Asthma UK. The authors also acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.	Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Benatar T, 2008, CANCER IMMUNOL IMMUN, V57, P1757, DOI 10.1007/s00262-008-0502-9; Cheung PFY, 2006, ALLERGY, V61, P878, DOI 10.1111/j.1398-9995.2006.01102.x; Claudio E, 2009, J IMMUNOL, V182, P1617, DOI 10.4049/jimmunol.182.3.1617; Corrigan CJ, 2009, ALLERGY, V64, P1014, DOI 10.1111/j.1398-9995.2009.01947.x; Corrigan CJ, 2011, P NATL ACAD SCI USA, V108, P1579, DOI 10.1073/pnas.1014241108; Dong C, 2008, IMMUNOL REV, V226, P80, DOI 10.1111/j.1600-065X.2008.00709.x; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Lajoie-Kadoch S, 2006, AM J PHYSIOL-LUNG C, V290, pL1238, DOI 10.1152/ajplung.00301.2005; Letuve S, 2006, J ALLERGY CLIN IMMUN, V117, P590, DOI 10.1016/j.jaci.2005.10.025; Pan GH, 2001, J IMMUNOL, V167, P6559, DOI 10.4049/jimmunol.167.11.6559; Phipps S, 2004, AM J RESP CELL MOL, V31, P626, DOI 10.1165/rcmb.2004-0193OC; Schneider E, 2010, EUR CYTOKINE NETW, V21, P142, DOI 10.1684/ecn.2010.0197; Sonobe Y, 2009, J BIOL CHEM, V284, P31834, DOI 10.1074/jbc.M109.025940; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Terrier B, 2010, BLOOD, V116, P4523, DOI 10.1182/blood-2010-02-267542; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wong CK, 2005, AM J RESP CELL MOL, V33, P186, DOI 10.1165/rcmb.2005-0034OC; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030; Yu HS, 2010, J KOREAN MED SCI, V25, P829, DOI 10.3346/jkms.2010.25.6.829	30	135	143	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					116	124		10.1016/j.jaci.2011.03.043	http://dx.doi.org/10.1016/j.jaci.2011.03.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21570719				2022-12-18	WOS:000292245600015
J	Saude, EJ; Skappak, CD; Regush, S; Cook, K; Ben-Zvi, A; Becker, A; Moqbel, R; Sykes, BD; Rowe, BH; Adamko, DJ				Saude, Erik J.; Skappak, Christopher D.; Regush, Shana; Cook, Kim; Ben-Zvi, Amos; Becker, Allan; Moqbel, Redwan; Sykes, Brian D.; Rowe, Brian H.; Adamko, Darryl J.			Metabolomic profiling of asthma: Diagnostic utility of urine nuclear magnetic resonance spectroscopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; inflammation; biomarkers; urine; NMR; metabolomics	RANDOMIZED CONTROLLED-TRIAL; EOSINOPHIL PROTEIN-X; N-METHYLHISTAMINE; HISTAMINE-RELEASE; NMR ANALYSIS; MANAGEMENT; CHILDREN; METABOLITES; MECHANISMS; BIOMARKERS	Background: The ability to diagnose and monitor asthma on the basis of noninvasive measurements of airway cellular dysfunction is difficult in the typical clinical setting. Objective: Metabolomics is the study of molecules created by cellular metabolic pathways. We hypothesized that the metabolic activity of children with asthma would differ from healthy children without asthma. Furthermore, children having an asthma exacerbation would be different compared with children with stable asthma in outpatient clinics. Finally, we hypothesized that H-1-nuclear magnetic resonance (NMR) would measure such differences using urine samples, one of the least invasive forms of biofluid sampling. Methods: Children (135 total, ages 4-16 years) were enrolled, having met the criteria of healthy controls (C), stable asthma in the outpatient clinic (AO), or unstable asthma in the emergency department (AED). Partial least squares discriminant analysis was performed on the NMR data to create models of separation (70 metabolites were measured/urine sample). Some NMR data were withheld from modeling to be run blindly to determine possible diagnostic accuracy. Results: On the basis of the model of AO versus C, 31 of 33 AO samples were correctly diagnosed with asthma (94% accuracy). Only 1 of 20 C samples was incorrectly labeled as asthma (5% misclassification). On the basis of the AO versus AED model, 31 of the 33 AO samples were correctly diagnosed as outpatient asthma (94% accurate). Conclusion: This is the first report suggesting that H-1-NMR analysis of human urine samples has the potential to be a useful clinical tool for physicians treating asthma. (J Allergy Clin Immunol 2011;127:757-64.)	[Adamko, Darryl J.] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB T6G 2S2, Canada; [Saude, Erik J.; Skappak, Christopher D.; Regush, Shana; Sykes, Brian D.; Rowe, Brian H.; Adamko, Darryl J.] Univ Alberta, Magnet Resonance Diagnost Ctr, Edmonton, AB T6G 2S2, Canada; [Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Edmonton, AB T6G 2S2, Canada; [Moqbel, Redwan; Adamko, Darryl J.] Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; [Saude, Erik J.; Sykes, Brian D.] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; [Ben-Zvi, Amos] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 2S2, Canada; [Rowe, Brian H.] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2S2, Canada; [Becker, Allan] Univ Manitoba, Dept Pediat, Winnipeg, MB R3T 2N2, Canada; [Moqbel, Redwan] Univ Manitoba, Dept Immunol, Winnipeg, MB R3T 2N2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Manitoba; University of Manitoba	Adamko, DJ (corresponding author), Univ Alberta, Fac Med & Dent, Dept Pediat, 550A HMRC, Edmonton, AB T6G 2S2, Canada.	dadamko@ualberta.ca			Sick Kids Foundation; AllerGen; Magnetic Resonance Diagnostic Centre (MRDC); Canadian Institutes for Health Research (CIHR); Genome Prairie; Genome Canada; AHFMR; Canadian National High Field NMR Centre; Natural Science and Engineering Research Council of Canada; University of Alberta Hospital Foundation; Alberta Science and Research Authority, and Western Economic Development; Government of Canada (Ottawa, Ontario); GlaxoSmithKline; MedImmune; Canadian Institutes of Health Research; Afexa; Merck	Sick Kids Foundation; AllerGen; Magnetic Resonance Diagnostic Centre (MRDC); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Genome Prairie; Genome Canada(Genome Canada); AHFMR(Alberta Heritage Foundation for Medical Research); Canadian National High Field NMR Centre; Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); University of Alberta Hospital Foundation(University of Alberta); Alberta Science and Research Authority, and Western Economic Development; Government of Canada (Ottawa, Ontario); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Afexa; Merck(Merck & Company)	Supported by the Sick Kids Foundation, AllerGen, the Magnetic Resonance Diagnostic Centre (MRDC), and the Canadian Institutes for Health Research (CIHR). The MRDC has received funding from CIHR, Genome Prairie, Genome Canada, an establishment grant from AHFMR, the Canadian National High Field NMR Centre, the Natural Science and Engineering Research Council of Canada, the University of Alberta Hospital Foundation, the Alberta Science and Research Authority, and Western Economic Development. D.J.A. was an AHFMR Clinical Investigator and R.M. an AHFMR Medical Scientist. B.H.R.'s research is supported by the 21st Century Research Chairs Program from the Government of Canada (Ottawa, Ontario).; R. Moqbel has a consultancy with GlaxoSmithKline. B. H. Rowe has received speaking fees and research support from GlaxoSmithKline; has received research support from MedImmune and the Canadian Institutes of Health Research; and is on the Canadian Thoracic Society Asthma Guidelines Committee. D. J. Adamko has received research support from Afexa and Merck. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 2007, 3 EXP PAN; Aragones J, 2009, CELL METAB, V9, P11, DOI 10.1016/j.cmet.2008.10.001; Azmi J, 2005, BIOMARKERS, V10, P401, DOI 10.1080/13547500500309259; Baker PRS, 2004, AM J PHYSIOL-CELL PH, V287, pC1359, DOI 10.1152/ajpcell.00238.2004; Becker A, 2005, CAN MED ASSOC J, V173, pS3; Beckwith-Hall BM, 1998, CHEM RES TOXICOL, V11, P260, DOI 10.1021/tx9700679; BEKIER E, 1974, INT ARCH ALLER A IMM, V47, P737, DOI 10.1159/000231265; BENEDICT JD, 1955, J CLIN INVEST, V34, P141, DOI 10.1172/JCI103057; Brightling Christopher E, 2005, Treat Respir Med, V4, P309, DOI 10.2165/00151829-200504050-00002; Brown RA, 2008, BRIT J PHARMACOL, V153, pS446, DOI 10.1038/bjp.2008.22; FITCH CD, 1964, J CLIN INVEST, V43, P444, DOI 10.1172/JCI104929; Fixman ED, 2007, EUR RESPIR J, V29, P379, DOI 10.1183/09031936.00053506; Forsythe Ian J, 2009, Curr Protoc Bioinformatics, VChapter 14, DOI 10.1002/0471250953.bi1408s25; Godet C, 2001, INTENSIVE CARE MED, V27; Gowda GAN, 2008, EXPERT REV MOL DIAGN, V8, P617, DOI 10.1586/14737159.8.5.617; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hargreave FE, 2007, CURR OPIN ALLERGY CL, V7, P102, DOI 10.1097/ACI.0b013e328013e3c2; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Kozyrskyj AL, 2009, ALLERGY, V64, P1185, DOI 10.1111/j.1398-9995.2009.02033.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kumps A, 2002, CLIN CHEM, V48, P708; Leipnitz G, 2008, J NEUROSCI RES, V86, P683, DOI 10.1002/jnr.21527; Lenz EM, 2004, J PHARMACEUT BIOMED, V36, P841, DOI 10.1016/j.jpba.2004.08.002; Nadel JA, 2000, TXB RESP MED; Nelson D.L., 2008, LEHNINGER PRINCIPLES; Nishiwaki F, 2000, BIOMED CHROMATOGR, V14, P184, DOI 10.1002/1099-0801(200005)14:3<184::AID-BMC970>3.0.CO;2-2; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909, DOI 10.4049/jimmunol.173.10.5909; Oka T, 2008, CIRC J, V72, P1359, DOI 10.1253/circj.72.1359; Pauly DF, 2003, AM J KIDNEY DIS, V41, pS35, DOI 10.1016/S0272-6386(03)00115-X; Saude EJ, 2004, MAGN RESON MED, V52, P807, DOI 10.1002/mrm.20242; Saude EJ, 2007, METABOLOMICS, V3, P439, DOI 10.1007/s11306-007-0091-1; Saude EJ, 2007, METABOLOMICS, V3, P19, DOI 10.1007/s11306-006-0042-2; Saude EJ, 2006, METABOLOMICS, V2, P113, DOI 10.1007/s11306-006-0023-5; Saude EJ, 2009, AM J RESP CRIT CARE, V179, P25, DOI 10.1164/rccm.200711-1716OC; Scichilone N, 2004, CLIN EXP ALLERGY, V34, P1168, DOI 10.1111/j.1365-2222.2004.02020.x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Severien C, 2000, EUR RESPIR J, V16, P588, DOI 10.1034/j.1399-3003.2000.16d03.x; Shockcor John P., 2002, Current Topics in Medicinal Chemistry, V2, P35, DOI 10.2174/1568026023394498; Skappak Ejs C, 2009, AM J RESP CRIT CARE, V179, pA2531; STEPHAN V, 1990, J ALLERGY CLIN IMMUN, V86, P862, DOI 10.1016/S0091-6749(05)80147-2; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Takei S, 1997, ANN ALLERG ASTHMA IM, V78, P492, DOI 10.1016/S1081-1206(10)63237-1; Tan P, 2009, EXPERT OPIN THER TAR; Taylor DR, 2008, POSTGRAD MED J, V84, P628, DOI 10.1136/pgmj.2008.069864; Wojnarowski C, 1999, CLIN EXP ALLERGY, V29, P926; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Xu EY, 2009, CURR OPIN DRUG DISC, V12, P40	47	135	142	2	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					757	U408		10.1016/j.jaci.2010.12.1077	http://dx.doi.org/10.1016/j.jaci.2010.12.1077			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377043	Bronze			2022-12-18	WOS:000288018400031
J	Worm, M; Lee, HH; Kleine-Tebbe, J; Hafner, RP; Laidler, P; Healey, D; Buhot, C; Verhoef, A; Maillere, B; Kay, AB; Larche, M				Worm, Margitta; Lee, Hae-Hyuk; Kleine-Tebbe, Joerg; Hafner, Roderick P.; Laidler, Paul; Healey, David; Buhot, Cecile; Verhoef, Adrienne; Maillere, Bernard; Kay, A. Barry; Larche, Mark			Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; allergy; T cell; epitope; peptide; MHC; immune tolerance; vaccine	FEL D 1; GRASS-POLLEN IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; LATE ASTHMATIC REACTIONS; T-CELL PEPTIDES; DOUBLE-BLIND; SEASONAL RHINOCONJUNCTIVITIS; FOLLOW-UP; CHILDREN; FEL-D-1	Background: Allergic sensitization to cat allergens is common and represents a major risk factor for asthma. Specific immunotherapy (SIT) is effective but cumbersome and associated with IgE-dependent adverse events. Immunotherapy targeting allergen-specific T cells, with synthetic peptides representing T-cell epitopes, might improve safety and reduce the duration of treatment. Objective: We sought to define major T-cell epitopes of Fel d 1 for peptide immunotherapy, generate a peptide vaccine, and evaluate its safety and tolerability in subjects with cat allergy. Methods: We determined the binding affinities of Fel d 1 peptides for 10 commonly expressed HLA-DR molecules. Functionally immunodominant peptides were identified by means of proliferation and cytokine secretion. Histamine-releasing activity was assessed, and a peptide vaccine was formulated. Safety and tolerability were evaluated in a dose-ranging phase IIa clinical trial. Results: MHC-binding sequences were identified throughout Fel d 1. Some regions contained multiple overlapping T-cell epitopes that bound multiple MHC molecules. Immunodominant sequences were identified on the basis of proliferative and cytokine (IFN-gamma, IL-10, and IL-13) responses. Cat allergen extract, but not peptides, induced histamine release in blood basophils. A single administration of peptide vaccine was safe and well tolerated. The dose of vaccine resulting in the greatest inhibition of the late-phase skin response to intradermal whole allergen challenge was 3 nmol. Conclusions: Fel d 1 contains multiple overlapping MHC-binding motifs. A peptide vaccine comprising the immunodominant regions of the allergen was safe and well tolerated when given to subjects with cat allergy as a single dose. The dose of vaccine resulting in the greatest reduction in late-phase skin response was defined for future clinical development. (J Allergy Clin Immunol 2011;127:89-97.)	[Worm, Margitta; Lee, Hae-Hyuk] Charite, Dept Dermatol Venerol & Allergol, D-13353 Berlin, Germany; [Kleine-Tebbe, Joerg] Allergy & Asthma Ctr Westend, Berlin, Germany; [Hafner, Roderick P.; Laidler, Paul] Circassia Ltd, Magdalen Ctr, Oxford, England; [Kay, A. Barry] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, Leukocyte Biol Sect, London, England; [Buhot, Cecile; Maillere, Bernard] CEA, Saclay, France; [Kay, A. Barry; Larche, Mark] MRC, London W1N 4AL, England; [Kay, A. Barry; Larche, Mark] Asthma UK Ctr Allerg Mech Asthma, London, England; [Larche, Mark] McMaster Univ, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Larche, Mark] McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON, Canada; [Larche, Mark] McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Imperial College London; CEA; University of London; King's College London; McMaster University; McMaster University; McMaster University	Larche, M (corresponding author), McMaster Univ, Canada Res Chair Allergy & Immune Tolerance, GSK Chair Lung Immunol, T2131-1,2nd Floor,Juravinski Tower,50 Charlton Av, Hamilton, ON L8N 4A6, Canada.	larche@mcmaster.ca		Hafner, Roderick/0000-0002-9082-733X; Worm, Margitta/0000-0002-3449-1245; Larche, Mark/0000-0002-1439-7593; Kleine-Tebbe, Joerg/0000-0002-2862-7353	Circassia Ltd.; Adiga Life Sciences	Circassia Ltd.; Adiga Life Sciences	Supported by Circassia Ltd.; R. P. Hafner and P. Laidler are employees of Circassia Ltd. A. B. Kay is a founder, stockholder, and consultant for Circassia Ltd. M. Larche is founder, stockholder, and consultant of Circassia Ltd and a founding scientist of Adiga Life Sciences and has received research support from both companies. The rest of the authors have declared that they have no conflict of interest.	Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Bateman EAL, 2008, CLIN EXP ALLERGY, V38, P1760, DOI 10.1111/j.1365-2222.2008.03098.x; Bateman EAL, 2006, J ALLERGY CLIN IMMUN, V118, P1350, DOI 10.1016/j.jaci.2006.07.040; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Carneiro R, 2004, J INVEST DERMATOL, V122, P927, DOI 10.1111/j.0022-202X.2004.22407.x; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; DES RA, 1997, J ALLERGY CLIN IMMUN, V99, P450; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P349, DOI 10.1067/mai.2001.117461; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Mark PG, 1996, CLIN EXP ALLERGY, V26, P1316, DOI 10.1111/j.1365-2222.1996.tb00529.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091; Peters B, 2007, NAT REV IMMUNOL, V7, P485, DOI 10.1038/nri2092; Peters B, 2006, PLOS COMPUT BIOL, V2, P574, DOI 10.1371/journal.pcbi.0020065; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Sarpong SB, 1998, ANN ALLERG ASTHMA IM, V80, P303, DOI 10.1016/S1081-1206(10)62973-0; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; Southwood S, 1998, J IMMUNOL, V160, P3363; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Texier C, 2000, J IMMUNOL, V164, P3177, DOI 10.4049/jimmunol.164.6.3177; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027	44	135	149	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					89	U169		10.1016/j.jaci.2010.11.029	http://dx.doi.org/10.1016/j.jaci.2010.11.029			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211644	Bronze			2022-12-18	WOS:000285917300013
J	Shek, LPC; Cabrera-Morales, EA; Soh, SE; Gerez, I; Ng, PZ; Yi, FC; Ma, S; Lee, BW				Shek, Lynette Pei-Chi; Cabrera-Morales, Elizabeth Ann; Soh, Shu E.; Gerez, Irvin; Ng, Pau Zhing; Yi, Fong Cheng; Ma, Stefan; Lee, Bee Wah			A population-based questionnaire survey on the prevalence of peanut, tree nut, and shellfish allergy in 2 Asian populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; tree nut allergy; shellfish allergy; food allergy; anaphylaxis; epinephrine autoinjectors; Singapore; Philippines; Asia	DUST-MITE FAUNA; FOOD ALLERGY; NATURAL-HISTORY; UNITED-KINGDOM; RISK-FACTORS; HONG-KONG; CHILDREN; ANAPHYLAXIS; HYPERSENSITIVITY; SENSITIZATION	Background: There has been a substantial increase in the prevalence of peanut and tree nut allergy in Western populations in the last 2 decades. However, there is an impression that peanut and tree nut allergy is relatively uncommon in Asia. Objective: To evaluate the prevalence of peanut, tree nut, and shellfish allergy in schoolchildren in 2 Asian countries (Singapore and Philippines). Methods: A structured written questionnaire was administered to local and expatriate Singapore (4-6 and 14-16 years old) and Philippine (14-16 years old) schoolchildren. Results: A total of 25,692 schoolchildren responded to the survey (response rate, 74.2%). Of these, 23,425 responses fell within the study protocol's 4 to 6 and 14 to 16 year age groups and were included in the analysis. The prevalence of convincing peanut and tree nut allergy were similar in both local Singapore (4-6 years, 0.64%, 0.28%; 14-16 years, 0.47%, 0.3%, respectively) and Philippine (14-16, 0.43%, 0.33%, respectively) schoolchildren, but was higher in the Singapore expatriates (4-6 years, 1.29%, 1.12%; 14-16 years, both 1.21%, respectively; 4-6 years, expatriates vs local Singaporeans: peanut, P = .019; tree nut, P = .0017; 14-16 years, P > .05). Conversely, shellfish allergy was more common in the local Singapore (4-6 years, 1.19%; 14-16 years, 5.23%) and Philippine (14-16 years, 5.12%) schoolchildren compared with expatriate children (4-6 years, 0.55%; 14-16 years, 0.96%; P < .001). When data were pooled, respondents born in Western countries were at higher risk of peanut (adjusted odds ratios [95% CIs]: 4-6 years, 3.47 [1.35-8.93]; 14-16 years, 5.56 [1.74-17.76]) and tree nut allergy (adjusted odds ratios [95% CIs]: 4-6 years, 10.40 [1.61-67.36]; 14-16 years, 3.53 [1.00-12.43]) compared with those born in Asia. Conclusion: This study substantiates the notion that peanut and tree nut allergy is relatively low in Asian children, and instead shellfish allergy predominates. Environmental factors that are yet to be defined are likely to contribute to these differences. (J Allergy Clin Immunol 2010;126:324-31.)	[Shek, Lynette Pei-Chi; Soh, Shu E.; Gerez, Irvin; Ng, Pau Zhing; Yi, Fong Cheng; Lee, Bee Wah] Natl Univ Hlth Syst, Singapore, Singapore; [Cabrera-Morales, Elizabeth Ann] Asian Hosp & Med Ctr, Manila, Philippines; [Ma, Stefan] Minist Hlth, Epidemiol & Dis Control Div, Singapore, Singapore	National University of Singapore; Ministry of Health-Singapore	Lee, BW (corresponding author), Natl Univ Singapore, Dept Pediat, Yong Loo Lin Sch Med, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.	paeleebw@nus.edu.sg	Shek, Lynette/D-8016-2015	Shek, Lynette/0000-0001-9064-8983	National University of Singapore [R-178-000-131-112]	National University of Singapore(National University of Singapore)	Supported by the National University of Singapore Academic Research Fund (R-178-000-131-112).	Baker SS, 2000, PEDIATRICS, V106, P346; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Chew FT, 1999, CLIN EXP ALLERGY, V29, P201, DOI 10.1046/j.1365-2222.1999.00493.x; Chew FT, 1999, ALLERGY, V54, P1150, DOI 10.1034/j.1398-9995.1999.00050.x; Chiang WC, 2007, CLIN EXP ALLERGY, V37, P1055, DOI 10.1111/j.1365-2222.2007.02752.x; Crespo JF, 2003, ALLERGY, V58, P98, DOI 10.1034/j.1398-9995.2003.02170.x; DAUL CB, 1990, J ALLERGY CLIN IMMUN, V86, P88, DOI 10.1016/S0091-6749(05)80127-7; Fleischer DM, 2007, CURR ALLERGY ASTHM R, V7, P175, DOI 10.1007/s11882-007-0018-y; Goh DLM, 1999, ALLERGY, V54, P84, DOI 10.1034/j.1398-9995.1999.00925.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Guilloux L, 1998, ALLERGY, V53, P151, DOI 10.1111/j.1398-9995.1998.tb03863.x; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Jirapongsananuruk O, 2007, ANN ALLERG ASTHMA IM, V98, P157, DOI 10.1016/S1081-1206(10)60689-8; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; KAJOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815, DOI 10.1111/j.1651-2227.1982.tb09525.x; Kandyil RM, 2009, PEDIAT ALLERG IMM-UK, V20, P408, DOI 10.1111/j.1399-3038.2009.00925.x; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; *LEAP STUD, LEAP STUD CLIN TRIAL; Leung TF, 2009, PEDIATR ALLERGY IMMU, V20, P339, DOI 10.1111/j.1399-3038.2008.00801.x; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; NG TP, 1994, THORAX, V49, P347, DOI 10.1136/thx.49.4.347; NG TP, 1994, INT J EPIDEMIOL, V23, P553, DOI 10.1093/ije/23.3.553; Pajno GB, 2002, J ALLERGY CLIN IMMUN, V109, P627, DOI 10.1067/mai.2002.122844; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SICHERER SH, 2007, J ALLERGY CLIN IMMUN, V491, P504; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P622, DOI 10.1016/S1081-1206(10)62289-2; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Tham EH, 2008, ALLERGY ASTHMA PROC, V29, P211, DOI 10.2500/aap.2008.29.3102; Thong B. Y. H., 2007, SMJ Singapore Medical Journal, V48, P236; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; Wang XS, 2004, ARCH DIS CHILD, V89, P423, DOI 10.1136/adc.2003.031112	40	135	140	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					324	U50		10.1016/j.jaci.2010.06.003	http://dx.doi.org/10.1016/j.jaci.2010.06.003			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624649	Bronze			2022-12-18	WOS:000281203800018
J	Gergen, PJ; Arbes, SJ; Calatroni, A; Mitchell, HE; Zeldin, DC				Gergen, Peter J.; Arbes, Samuel J., Jr.; Calatroni, Agustin; Mitchell, Herman E.; Zeldin, Darryl C.			Total IgE levels and asthma prevalence in the US population: Results from the National Health and Nutrition Examination Survey 2005-2006	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; prevalence; IgE; total; specific; atopy; nonatopic	SERUM IMMUNOGLOBULIN-E; SKIN-TEST REACTIVITY; BIRTH COHORT; ALLERGEN SENSITIZATION; NONALLERGIC ASTHMA; RISK-FACTORS; AGE; CHILDREN; ASSOCIATION; SMOKING	Background: The inability to measure IgE-based sensitivity to all allergens has limited our understanding of what portion of asthma is related to IgE. Total IgE measurement can potentially overcome this limitation. Objective: We sought to determine the association between total IgE levels and asthma. Methods: The National Health and Nutrition Examination Survey 2005-2006 examined a representative sample of the US population 6 years of age and older. Results: The median total IgE level was 40.8 kU/L (interquartile range, 15.5-114 kU/L). Total IgE levels varied with age, sex, race/ethnicity, serum cotinine level, body size, and socioeconomic status. The prevalence of current asthma was 8.8%. The prevalence of atopy was 42.5%, as defined by 15 specific IgEs. The adjusted odds ratio (OR) for asthma with a 10-fold increase in total IgE level was 2.18 (95% CI, 1.66-2.87). Total IgE level predicted asthma only among atopic subjects (OR, 2.41; 95% CI, 1.62-3.60) and not among nonatopic subjects (OR, 1.11; 95% CI, 0.72-1.71; interaction P = .005). Among atopic subjects, the association between total IgE level and asthma became stronger as the number of positive specific IgE test results increased. Asthma was present at even the lowest levels of total IgE, regardless of atopic status. Approximately 92% of atopic subjects were identified by 6 specific IgEs, but to increase the identification to more than 99% required 11 specific IgEs. Conclusion: Total IgE levels are associated with asthma only among persons who have positive results for at least 1 allergen-specific IgE. Asthma independent of IgE is not uncommon in the US population. The complete identification of atopic subjects in a population requires a large panel of allergen-specific IgEs. (J Allergy Clin Immunol 2009;124:447-53.)	[Gergen, Peter J.] NIAID, Asthma Allergy & Inflammat Branch, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Arbes, Samuel J., Jr.; Calatroni, Agustin; Mitchell, Herman E.] Rho Fed Syst Div Inc, Chapel Hill, NC USA; [Zeldin, Darryl C.] Natl Inst Environm Hlth Sci, Div Intramural Res, NIH, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Gergen, PJ (corresponding author), NIAID, Asthma Allergy & Inflammat Branch, Div Allergy Immunol & Transplantat, NIH, 6610 Rockledge Dr,Room 3067, Bethesda, MD 20892 USA.	pgergen@niaid.nih.gov	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	National Institutes of Health, National Institute of Environmental Health Sciences [Z01 ES025041-10]; National Institute of Allergy and Infectious Diseases [N01-AI-25482]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041, ZIAES025041] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01 ES025041-10), and National Institute of Allergy and Infectious Diseases under contract number N01-AI-25482.	Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Borish L, 2008, ANN ALLERG ASTHMA IM, V101, P1, DOI 10.1016/S1081-1206(10)60826-5; Boustiere C, 2007, ACTA ENDOSC, V37, P7, DOI 10.1007/BF02961812; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Garcia-Marcos L, 2005, PEDIAT ALLERG IMM-UK, V16, P471, DOI 10.1111/j.1399-3038.2005.00318.x; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; GRUNDBACHER FJ, 1985, J ALLERGY CLIN IMMUN, V75, P651, DOI 10.1016/0091-6749(85)90089-2; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Janson C, 2007, CLIN RESPIR J, V1, P16, DOI 10.1111/j.1752-699X.2007.00001.x; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kattan M, 2007, J ALLERGY CLIN IMMUN, V120, P618, DOI 10.1016/j.jaci.2007.05.014; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Lumley T., 2004, J STAT SOFTW, V9, P1, DOI [10.18637/jss.v009.i08, DOI 10.18637/JSS.V009.I08]; Nickel R, 2005, CLIN EXP ALLERGY, V35, P619, DOI 10.1111/j.1365-2222.2005.02237.x; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sapigni T, 1998, EUR RESPIR J, V11, P278, DOI 10.1183/09031936.98.11020278; Sarkar D, 2008, USE R, P1; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEKHON JS, MATCHING MULTIVARIAT; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; The R Development Core Team, R LANG ENV STAT COMP; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3; Wuthrich B, 1996, INT ARCH ALLERGY IMM, V111, P396, DOI 10.1159/000237398	34	135	140	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					447	453		10.1016/j.jaci.2009.06.011	http://dx.doi.org/10.1016/j.jaci.2009.06.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19647861	Green Accepted			2022-12-18	WOS:000274315900008
J	Julien, JY; Martin, JG; Ernst, P; Olivenstein, R; Hamid, Q; Lemiere, C; Pepe, C; Naor, N; Olha, A; Kimoff, RJ				Julien, Joanne Y.; Martin, James G.; Ernst, Pierre; Olivenstein, Ronald; Hamid, Qutayba; Lemiere, Catherine; Pepe, Carmela; Naor, Naftaly; Olha, Allen; Kimoff, R. John			Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sleep; sleep apnea; obstructive; dyspnea; paroxysmal; asthma	DAYTIME SLEEPINESS; NOCTURNAL ASTHMA; AIRWAY PRESSURE; HEALTH; QUESTIONNAIRE; INFLAMMATION; QUALITY; RISK	Background: Previous studies have suggested a link between obstructive sleep apnea and poor asthma control, which may be mediated through airway inflammation, obesity, and other mechanisms. Objective: To test the hypothesis that the prevalence and severity of sleep apnea is greater among patients with severe compared with moderate asthma and controls without asthma. Methods: Complete overnight home polysomnography was performed in 26 patients with severe asthma consecutively recruited to a difficult asthma program, 26 patients with moderate asthma, and 26 controls without asthma of similar age and body mass index. Flow rates and Juniper asthma control and quality of life questionnaires were also obtained. Results: Obstructive sleep apnea-hypopnea, defined by an Apnea-Hypopnea Index >= 15 events/h of sleep scored using Chicago criteria, was present in 23 of 26 (88%) patients with severe asthma, 15 of 26 (58%) patients with moderate asthma, and 8 of 26 (31%) controls without asthma (chi(2): P <.001). Using the more restrictive scoring criteria applied in the Wisconsin cohort study, Apnea-Hypopnea Index >= 5/h was present in 50% (severe), 23% (moderate), and 12% (control) of subjects (P =.007). Mean nocturnal arterial oxygen saturation was significantly lower in patients with severe asthma versus controls, and apnea-hypopnea severity measures were significantly worse for both asthmatic groups compared with controls. Among subjects with asthma, no significant correlations were identified between the severity of sleep-disordered breathing and asthma severity or control measures (FEV1, Juniper scores). Conclusions: Obstructive sleep apnea-hypopnea was significantly more prevalent among patients with severe compared with moderate asthma, and more prevalent for both asthma groups than controls without asthma. These observations suggest potential pathophysiologic interactions between obstructive sleep apnea-hypopnea and asthma severity and control. (J Allergy Clin Immunol 2009;124:371-6.)	[Kimoff, R. John] McGill Univ, Ctr Hlth, Div Resp, Montreal, PQ H3A 1A1, Canada; [Julien, Joanne Y.; Martin, James G.; Olivenstein, Ronald; Hamid, Qutayba; Lemiere, Catherine; Pepe, Carmela; Kimoff, R. John] McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 1A1, Canada; [Naor, Naftaly; Olha, Allen; Kimoff, R. John] McGill Univ, Ctr Hlth, Sleep Lab, Montreal, PQ H3A 1A1, Canada; [Lemiere, Catherine] Univ Montreal, Dept Pneumol, Hop Sacre Coeur, Montreal, PQ H3C 3J7, Canada	McGill University; McGill University; McGill University; Universite de Montreal	Kimoff, RJ (corresponding author), McGill Univ, Ctr Hlth, Div Resp, 687 Pine Ave W,Room L4-08, Montreal, PQ H3A 1A1, Canada.	john.kimoff@mcgill.ca		Martin, James/0000-0001-7574-5363	Edith Strauss Canada Foundation; McGill University Health Centre Research Institute; Fonds de la Recherche en Sante do Quebec; GlaxoSmithKline Canada Inc; CHEST Foundation; Fonds de la Recherche en Sante du Quebec	Edith Strauss Canada Foundation; McGill University Health Centre Research Institute; Fonds de la Recherche en Sante do Quebec; GlaxoSmithKline Canada Inc(GlaxoSmithKline); CHEST Foundation; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec)	Supported by grants from the Richard and Edith Strauss Canada Foundation, McGill University Health Centre Research Institute, and the Fonds de la Recherche en Sante do Quebec. J.Y.J. was a recipient of the Ann Woolcock Memorial Fellowship, was supported by GlaxoSmithKline Canada Inc, and is a CHEST Foundation Awardee. R.J.K. was a Clinical Research Scholar of the Fonds de la la Recherche en Sante du Quebec. Q.H. is a recipient of a Chercheur Nationale award from the Fonds de la Recherche en Sante du Quebec.	Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P1393, DOI 10.1016/j.jaci.2005.10.008; BONNET MH, 1992, SLEEP, V15, P526; Boulay ME, 2003, CURR OPIN ALLERGY CL, V3, P51, DOI 10.1097/01.all.0000053268.39029.19; Boyd JH, 2004, AM J RESP CRIT CARE, V170, P541, DOI 10.1164/rccm.200308-1100OC; CATTERALL JR, 1982, LANCET, V1, P301; Champagne K, 2009, EUR RESPIR J, V33, P559, DOI 10.1183/09031936.00122607; CHAN CS, 1988, AM REV RESPIR DIS, V137, P1502, DOI 10.1164/ajrccm/137.6.1502; Ciftci TU, 2005, RESP MED, V99, P529, DOI 10.1016/j.rmed.2004.10.011; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Gozal D, 2008, AM J RESP CRIT CARE, V177, P369, DOI 10.1164/rccm.200608-1190PP; GUILLEMINAULT C, 1988, EUR RESPIR J, V1, P902; Haxhiu MA, 2008, ADV EXP MED BIOL, V605, P469; Iber C, 2004, SLEEP, V27, P536, DOI 10.1093/sleep/27.3.536; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kales A, 1968, MANUAL STANDARDIZED; Lafond C, 2007, EUR RESPIR J, V29, P307, DOI 10.1183/09031936.00059706; Larsson LG, 2001, RESP MED, V95, P423, DOI 10.1053/rmed.2001.1054; Mastronarde JG, 2008, J ASTHMA, V45, P183, DOI 10.1080/02770900801890224; Mehra R, 2008, J ALLERGY CLIN IMMUN, V121, P1096, DOI 10.1016/j.jaci.2008.04.002; Payne RJ, 2006, OTOLARYNG HEAD NECK, V134, P836, DOI 10.1016/j.otohns.2006.01.012; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; PLOWMAN L, 1990, J APPL PHYSIOL, V68, P1555, DOI 10.1152/jappl.1990.68.4.1555; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Quan SF, 2002, SLEEP, V25, P843; Redline S, 1998, SLEEP, V21, P759; Redline S, 2000, AM J RESP CRIT CARE, V161, P369, DOI 10.1164/ajrccm.161.2.9904031; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; SNEDCOR G, 1980, STAT METHODS IOWA; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Teodorescu M, 2006, SLEEP MED, V7, P607, DOI 10.1016/j.sleep.2006.02.001; Teodorescu M, 2009, CHEST, V135, P1125, DOI 10.1378/chest.08-1273; Yigla M, 2003, J ASTHMA, V40, P865, DOI 10.1081/JAS-120023577; Younes M, 2004, AM J RESP CRIT CARE, V169, P623, DOI 10.1164/rccm.200307-1023OC; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	37	135	138	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					371	376		10.1016/j.jaci.2009.05.016	http://dx.doi.org/10.1016/j.jaci.2009.05.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19560194				2022-12-18	WOS:000268860400027
J	Fitzpatrick, AM; Teague, WG; Holguin, F; Yeh, M; Brown, LAS				Fitzpatrick, Anne M.; Teague, W. Gerald; Holguin, Fernando; Yeh, Mary; Brown, Lou Ann S.		Severe Asthma Res Program	Airway glutathione homeostasis is altered in children with severe asthma: Evidence for oxidant stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; glutathione; 8-isoprostanes; hydrogen peroxide; malondialdehyde; oxidative stress; redox potential	ANTIOXIDANT STATUS; OXIDATIVE STRESS; ALVEOLAR FLUID; HUMAN PLASMA; LUNG; INFLAMMATION; ASSOCIATION; DEFICIENCY; DECLINE; ATOPY	Background: Severe asthma is characterized by persistent airway inflammation and increased formation of reactive oxygen species. Objectives: Glutathione (GSH) is an important antioxidant in the epithelial lining fluid (ELF). We hypothesized that airway GSH homeostasis was altered in children with severe asthma and was characterized by decreased GSH and increased glutathione disulfide (GSSG) concentrations. Methods: Bronchoalveolar lavage was obtained from 65 children with severe asthma, including 35 children with baseline airway obstruction evidenced by FEV1 <80%. Control data were obtained from 6 children with psychogenic (habit) cough or vocal cord dysfunction undergoing diagnostic bronchoscopy and 35 healthy adult controls. GSH, GSSG, and other determinants of airway oxidative stress including glutathione S-transferase (GST), glutathione reductase (GR), glutathione peroxidase (GPx), malondialdehyde, 8-isoprostane, and H2O2 were measured in the ELF. The ELF redox potential was calculated from GSH and GSSG by using the Nernst equation. Results: Compared with controls, subjects with severe asthma had lower airway GSH with increased GSSG despite no differences in GST, GR, and GPx activities between groups. 4 This was accompanied by increased malondialdehyde, 8-isoprostane, and H2O2 concentrations in the ELF. GSH oxidation was most apparent in subjects with severe asthma with airway obstruction and was supported by an upward shift in the ELF GSH redox potential. Conclusion: Children with severe asthma have increased biomarkers of oxidant stress in the ELF that are associated with increased formation of GSSG and a shift in the GSH redox potential toward the more oxidized state. (J Allergy Clin Immunol 2009;123:146-52.)	[Fitzpatrick, Anne M.; Teague, W. Gerald; Yeh, Mary; Brown, Lou Ann S.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Holguin, Fernando] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Fitzpatrick, AM (corresponding author), 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Fitzpatrick, Anne/0000-0002-2933-5926	National Institutes of Health (NIH)/National Institute for Nursing Research (NINR) [KO1 NR010584]; NIH/National Center for Research Resources (NCRR) [K12 RR017643]; NIH/National Heart, Lung, and Blood Institute (NHLBI) Severe Asthma Research Program [RO1 HL69170]; American Nurses Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [K01NR010584] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute for Nursing Research (NINR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NIH/National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/National Heart, Lung, and Blood Institute (NHLBI) Severe Asthma Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Nurses Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Supported by the National Institutes of Health (NIH)/National Institute for Nursing Research (NINR) KO1 NR010584. NIH/National Center for Research Resources (NCRR) K12 RR017643, NIH/National Heart, Lung, and Blood Institute (NHLBI) Severe Asthma Research Program RO1 HL69170, and the American Nurses Foundation.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Beeh KM, 2002, EUR RESPIR J, V19, P1119, DOI 10.1183/09031936.02.00262402; BEHR J, 1995, EUR RESPIR J, V8, P1286, DOI 10.1183/09031936.95.08081286; BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174, DOI 10.1164/ajrccm/148.5.1174; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; Comhair SAA, 2005, AM J RESP CRIT CARE, V172, P306, DOI 10.1164/rccm.200502-180OC; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; Dauletbaev N, 2001, THORAX, V56, P13, DOI 10.1136/thorax.56.1.13; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Koike Y, 2007, AM J RESP CELL MOL, V37, P322, DOI 10.1165/rcmb.2006-0423OC; Mak JCW, 2004, J ALLERGY CLIN IMMUN, V114, P260, DOI 10.1016/j.jaci.2004.05.013; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moss M, 2000, AM J RESP CRIT CARE, V161, P414, DOI 10.1164/ajrccm.161.2.9905002; Nagai K, 2006, THORAX, V61, P496, DOI 10.1136/thx.2005.049148; *NAT HEART LUNG BL, 2002, NAEPP EXP PAN REP GU; Pacht ER, 1997, CHEST, V112, P785, DOI 10.1378/chest.112.3.785; Payne D, 2001, ARCH DIS CHILD, V84, P423, DOI 10.1136/adc.84.5.423; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; POTTER WZ, 1974, PHARMACOLOGY, V12, P129, DOI 10.1159/000136531; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4; Schmidt R, 2004, EUR RESPIR J, V24, P994, DOI 10.1183/09031936.04.00120703; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461, DOI 10.1164/ajrccm/147.6_Pt_1.1461; Yeh MY, 2007, AM J RESP CRIT CARE, V176, P270, DOI 10.1164/rccm.200611-1722OC	38	135	139	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					146	152		10.1016/j.jaci.2008.10.047	http://dx.doi.org/10.1016/j.jaci.2008.10.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130935	Green Accepted			2022-12-18	WOS:000262793900024
J	Admyre, C; Bohle, B; Johansson, SM; Focke-Tejkl, M; Valenta, R; Scheynius, A; Gabrielsson, S				Admyre, Charlotte; Bohle, Barbara; Johansson, Sara M.; Focke-Tejkl, Margarete; Valenta, Rudolf; Scheynius, Annika; Gabrielsson, Susanne			B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce T(H)2-like cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exosomes; Bet v 1; allergy; T cells; B cells	BIRCH POLLEN ALLERGEN; COMPLEX CLASS-II; DENDRITIC CELLS; MEMBRANE-VESICLES; ANTIGEN; MOLECULES; VACCINE; ACCUMULATION; STIMULATION; RELEASE	Background: Exosomes are vesicles of 30 to 100 nm produced by inward budding of endosomal compartments and are released by a range of different cell types. Exosomes from antigen-presenting cells carry immunorelevant molecules like MHC class I and II and costimulatory molecules and thus are suggested to have a role in immune modulation. Objective: To investigate the role of antigen-presenting cell derived exosomes in allergen presentation and T-cell stimulation. Methods: Exosomes were isolated from supernatants of B-cell lines derived from patients with birch pollen allergy. The exesomes were characterized with regard to the expression of surface molecules by flow cytometry. Moreover, exosomes were loaded with T-cell-activating peptides from the major birch allergen Bet v 1, and binding was tested with ELISA. Loaded exosomes were used for stimulation of Bet v 1-specific T-cell lines. Cell proliferation and cytokine production were assessed. Results: The exosomes had a phenotype typical of B cell-derived exosomes with expression of MHC, costimulatory molecules like CD86, tetraspanin proteins such as CD81, and CD19. Furthermore, B cell-derived exosomes bound Bet v 1-derived peptides and subsequently induced a dose-dependent T-cell proliferation. In addition to proliferation, T cells synthesized the cytokines IL-5 and IL-13 in response to peptide-loaded exosomes. Conclusion: These results demonstrate for the first time that exosomes isolated from B cells can present allergen-derived peptides and thereby induce T-cell proliferation and T(H)2-like cytokine production. Clinical implications: Our data suggest that exosomes from B lymphocytes are an immunostimulatory factor in allergic immune responses.	[Admyre, Charlotte; Johansson, Sara M.; Scheynius, Annika; Gabrielsson, Susanne] Karolinska Univ Hosp, Clin Allergy Res Unit, Dept Med, Karolinska Inst, S-17176 Stockholm, Sweden; [Bohle, Barbara; Focke-Tejkl, Margarete; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Vienna, Austria; [Bohle, Barbara; Focke-Tejkl, Margarete; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol, Div Immunopathol, Ctr Physiol & Pathophysiol, Vienna, Austria	Karolinska Institutet; Karolinska University Hospital; Medical University of Vienna; Medical University of Vienna	Admyre, C (corresponding author), Karolinska Univ Hosp, Clin Allergy Res Unit, Dept Med, Karolinska Inst, L2 04, S-17176 Stockholm, Sweden.	Charlotte.Admyre@ki.se	Gabrielsson, S./E-4145-2014	Gabrielsson, S./0000-0003-1771-1346; Valenta, Rudolf/0000-0001-5944-3365; Bohle, Barbara/0000-0002-5105-7985				Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; Admyre C, 2006, EUR J IMMUNOL, V36, P1772, DOI 10.1002/eji.200535615; Aline F, 2004, INFECT IMMUN, V72, P4127, DOI 10.1128/IAI.72.7.4127-4137.2004; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Chaput N, 2004, J IMMUNOL, V172, P2137, DOI 10.4049/jimmunol.172.4.2137; Clayton A, 2004, FASEB J, V18, P977, DOI 10.1096/fj.03-1094fje; Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5; Clayton A, 2003, EUR J IMMUNOL, V33, P522, DOI 10.1002/immu.200310028; Delcayre A, 2005, BLOOD CELL MOL DIS, V35, P158, DOI 10.1016/j.bcmd.2005.07.003; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; FISCHER GF, 1995, TISSUE ANTIGENS, V45, P143, DOI 10.1111/j.1399-0039.1995.tb02432.x; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Grayson MH, 2006, ANN ALLERG ASTHMA IM, V96, P643, DOI 10.1016/S1081-1206(10)61061-7; GRAYSON MH, 2006, ANN ALLERG ASTHMA IM, V96, P52; GRAYSON MH, 2006, ANN ALLERG ASTHMA IM, V96, P78; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hsu DH, 2003, J IMMUNOTHER, V26, P440, DOI 10.1097/00002371-200309000-00007; Hwang IY, 2003, P NATL ACAD SCI USA, V100, P6670, DOI 10.1073/pnas.1131852100; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Karlsson M, 2001, EUR J IMMUNOL, V31, P2892, DOI 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I; Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015; Kim SH, 2005, J IMMUNOL, V174, P6440, DOI 10.4049/jimmunol.174.10.6440; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Morse MA, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-9; Peche H, 2003, TRANSPLANTATION, V76, P1503, DOI 10.1097/01.TP.0000092494.75313.38; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Rialland P, 2006, BIOL CELL, V98, P491, DOI 10.1042/BC20060027; Rickert RC, 2005, CURR OPIN IMMUNOL, V17, P237, DOI 10.1016/j.coi.2005.03.001; Segura E, 2005, BLOOD, V106, P216, DOI 10.1182/blood-2005-01-0220; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Vincent-Schneider H, 2002, INT IMMUNOL, V14, P713, DOI 10.1093/intimm/dxf048; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	43	135	146	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1418	1424		10.1016/j.jaci.2007.06.040	http://dx.doi.org/10.1016/j.jaci.2007.06.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17868797				2022-12-18	WOS:000251653800026
J	Noga, O; Hanf, G; Brachmann, I; Klucken, AC; Kleine-Tebbe, J; Rosseau, S; Kunkel, G; Suttorp, N; Seybold, J				Noga, Oliver; Hanf, Gerald; Brachmann, Ilka; Klucken, Andrea C.; Kleine-Tebbe, Jorg; Rosseau, Simone; Kunkel, Gert; Suttorp, Norbert; Seybold, Joachim			Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						omalizumab; allergic asthma; asthma treatment; inflammation; anti-IgE; eosinophils; T-lymphocytes	COLONY-STIMULATING FACTOR; ANTI-IGE ANTIBODY; FC-EPSILON-RI; AIRWAY INFLAMMATION; IN-VITRO; INTERLEUKIN-5; MEDIATOR; RHINITIS	Background: Omalizumab is a recombinant monoclonal anti-IgE antibody with proven efficacy in allergic diseases and further anti-inflammatory potency in the treatment of asthma. Objectives: To explore the anti-inflammatory mechanism of omalizumab, we investigated the induction of immunologic changes leading to eosinophil apoptosis and examined T-lymphocyte cytokine profiles in patients with allergic asthma. Methods: Nineteen patients with allergic asthma were enrolled and received omalizumab at a dose of at least 0.016 mg/kg/IgE (IU/mL) every 4 weeks. Peripheral eosinophils and T-lymphocyte cytokine profiles were evaluated by fluorescence-activated cell sorting before treatment (baseline), at 12 weeks of treatment, and 12 weeks after discontinuation of treatment with omalizumab or placebo. Results: Markers of eosinophil apoptosis (Annexin V) were significantly increased in omalizumab recipients compared with placebo, whereas no changes in markers of necrosis (7-amino-actinomycin) or eosinophil activation CD69 or Fas receptor (CD95) were detected. GM-CSF+ lymphocytes were reduced in omalizumab recipients compared with placebo. Fewer IL-2(+) and IL-13(+) lymphocytes were evident in omalizumab recipients than in the placebo group. There were no significant differences in IL-5, IFN-gamma, or TNF-alpha between the omalizumab and placebo groups. Conclusion: These findings provide further evidence that omalizumab has additional anti-inflammatory activity demonstrated by induction of eosinophil apoptosis and downregulation of the inflammatory cytokines IL-2 and IL-13. Further studies are needed to determine the underlying mechanisms. Clinical implications: These findings support the critical role of IgE in the regulation of inflammation in allergic asthma: influencing the inflammation is the key to control the more severe type of asthma.	Charite Univ Med Berlin, Dept Internal Med Resp & Infect Dis, D-13353 Berlin, Germany; Charite Univ Med Berlin, Dept Internal Med, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Noga, O (corresponding author), Charite Univ Med Berlin, Dept Internal Med Resp & Infect Dis, Augustenburger Pl 1, D-13353 Berlin, Germany.	oliver.noga@charite.de	Rosseau, Simone/AAO-1201-2020	Suttorp, Norbert/0000-0002-3958-1151; Seybold, Joachim/0000-0003-1444-8976; Kleine-Tebbe, Joerg/0000-0002-2862-7353				Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; Buhl R, 2002, EUR RESPIR J, V20, P1088, DOI 10.1183/09031936.02.00016502; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Carulli G, 1998, CYTOMETRY, V34, P272, DOI 10.1002/(SICI)1097-0320(19981215)34:6<272::AID-CYTO5>3.0.CO;2-L; Conesa A, 2003, ALLERGY ASTHMA PROC, V24, P27; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hanf G, 2004, EUR RESPIR J, V23, P414, DOI 10.1183/09031936.04.00024504; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Kita H, 1999, J IMMUNOL, V162, P6901; Kopp MV, 2003, PEDIAT ALLERG IMM-UK, V14, P401, DOI 10.1034/j.1399-3038.2003.00068.x; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Park CS, 1998, EUR RESPIR J, V12, P872, DOI 10.1183/09031936.98.12040872; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Saini SS, 1999, J IMMUNOL, V162, P5624; SEDGWICK JB, 1995, J ALLERGY CLIN IMMUN, V96, P375, DOI 10.1016/S0091-6749(95)70057-9; SEHMI R, 1992, BLOOD, V79, P2952; Simon HU, 2003, EUR J IMMUNOL, V33, P834, DOI 10.1002/eji.200323727; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	29	135	144	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1493	1499		10.1016/j.jaci.2006.02.028	http://dx.doi.org/10.1016/j.jaci.2006.02.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751018				2022-12-18	WOS:000238332300045
J	Berry, MA; Parker, D; Neale, N; Woodman, L; Morgan, A; Monk, P; Bradding, P; Wardlaw, AJ; Pavord, ID; Brightling, CE				Berry, MA; Parker, D; Neale, N; Woodman, L; Morgan, A; Monk, P; Bradding, P; Wardlaw, AJ; Pavord, ID; Brightling, CE			Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-13; eosinophilic bronchitis; eosinophils; mast cells	AIRWAY SMOOTH-MUSCLE; MAST-CELLS; INTERLEUKIN-13; CYTOKINES	Background: Nonasthmatic eosinophilic bronchitis is a condition characterized by the presence of eosinophilic airway inflammation in the absence of airflow obstruction or airway hyperresponsiveness. In asthma, the T(H)2-type cytokine IL-13 has been implicated in the development of airway inflammation and hyperresponsiveness. Whether the expression of IL-13 is different between these 2 conditions is unknown. Objective: We sought to investigate whether IL-13 expression is increased in asthma compared with eosinophilic bronchitis. Methods: Sputum samples from subjects with mild asthma (n = 30) and eosinophilic bronchitis (n = 15) and normal controls (n = 16) were dialyzed, and IL-13 concentration was measured by ELISA. In a subgroup of these patients, IL-13 protein expression in bronchial biopsies was assessed by immunohistochemistry. Results: The concentration of sputum IL-13 was higher in patients with mild asthma than in normal controls (P = .03) and in patients with eosinophilic bronchitis (P = .03). The median (interquartile range) number of IL-13(+) cells/mm(2) submucosa was significantly higher in asthma 4 (8) than eosinophilic bronchitis 1.7 (1.9) and normal controls 0.5 (1.1; P = .004). Eighty-three percent of the cells expressing IL-13 in the submucosa were eosinophils, and 8% were mast cells. The median (interquartile range) proportion of eosinophils that expressed IL-13 was higher in the subjects with asthma, 16 (10)%, than those with eosinophilic bronchitis, 7 (3)% (P = .02). Conclusion: The increased expression of IL-13 in asthma compared with eosinophilic bronchitis supports the concept that IL-13 may play a critical role in the pathophysiology of asthma.	Univ Hosp Leicester, Inst Lung Hlth, Leicester LE3 9QP, Leics, England; Cambridge Antibody Technol, Cambridge, England	University Hospitals of Leicester NHS Trust; University of Leicester; AstraZeneca	Brightling, CE (corresponding author), Univ Hosp Leicester, Inst Lung Hlth, Groby Rd,Clin Sci Wing, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk		brightling, chris/0000-0002-9345-4903; Bradding, Peter/0000-0001-8403-0319; Wardlaw, Andrew/0000-0001-6583-0791; Pavord, Ian/0000-0002-4288-5973				Brightling CE, 2003, CLIN EXP ALLERGY, V33, P1711, DOI 10.1111/j.1365-2222.2003.01827.x; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; *BRIT THOR SOC BRO, 2001, THORAX, V56, P11; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V101, P320, DOI 10.1016/S0091-6749(98)70242-8; Grunstein MM, 2002, AM J PHYSIOL-LUNG C, V282, pL520, DOI 10.1152/ajplung.00343.2001; Hadjicharalambous C, 2004, J ALLERGY CLIN IMMUN, V113, P657, DOI 10.1016/j.jaci.2004.01.757; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Juniper E, 1994, HISTAMINE METHACHOLI; Kelly MM, 2001, EUR RESPIR J, V18, P685, DOI 10.1183/09031936.01.00098501; Komai-Koma M, 2001, CLIN EXP ALLERGY, V31, P1441, DOI 10.1046/j.1365-2222.2001.01174.x; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Li HM, 1996, J IMMUNOL, V156, P4833; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490	22	135	148	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1106	1109		10.1016/j.jaci.2004.08.032	http://dx.doi.org/10.1016/j.jaci.2004.08.032			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536417				2022-12-18	WOS:000225047800017
J	Burge, HA				Burge, HA			An update on pollen and fungal spore aerobiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						pollen; fungi; aerobiology; spores; allergen; immunodetection	IN-HOUSE DUST; THUNDERSTORM-ASSOCIATED ASTHMA; VOLATILE ORGANIC-COMPOUNDS; WATER-DAMAGED BUILDINGS; REPORTED HOME DAMPNESS; GRASS-POLLEN; STACHYBOTRYS-CHARTARUM; RESIDENTIAL CHARACTERISTICS; RESPIRATORY SYMPTOMS; INDOOR AIR	Changes in climate are altering pollen distribution. Predictive modeling can be used to forecast long- and short-term changes in pollen concentrations. Increasing evidence confirms the presence of pollen allergens on small, respirable particles in the air, explaining the occurrence of pollen-season increases in asthma. Like pollens, above ground indoor fungal aerosols primarily reflect outdoor concentrations. Basement spore concentrations might be higher and reflective of local sources. Fungal presence in the indoor or outdoor air can be monitored on an area basis or with personal monitors. The samples can be analyzed by means of microscopy, culture, DNA probes, HPLC, or immunodetection. Total fungal biomass can be estimated on the basis of measurements of ergosterol or glucan in environmental samples. Unfortunately, there are no generally accepted standards for interpretation of fungal levels in indoor or outdoor air. At present, the best approach to indoor fungal control is moisture control in the indoor environment. This will essentially prevent fungal growth, except from extraordinary events.	Harvard Univ, Sch Publ Hlth, Landmark Ctr, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health	Burge, HA (corresponding author), Harvard Univ, Sch Publ Hlth, Landmark Ctr, Room 404M W,401 Pk Dr,POB 15677, Boston, MA 02215 USA.							Ahearn DG, 1997, CURR MICROBIOL, V35, P305, DOI 10.1007/s002849900259; Aizenberg V, 2000, AM IND HYG ASSOC J, V61, P398, DOI 10.1080/15298660008984550; Aizenberg V, 2000, AIHAJ, V61, P855, DOI 10.1080/15298660008984598; Anderson W, 2001, QJM-MON J ASSOC PHYS, V94, P429, DOI 10.1093/qjmed/94.8.429; Bellin P, 2001, INDOOR AIR, V11, P65, DOI 10.1034/j.1600-0668.2001.011001065.x; Burge HA, 2000, CURR MICROBIOL, V40, P10, DOI 10.1007/s002849910003; Celenza A, 1996, BMJ-BRIT MED J, V312, P604; Charcosset JY, 2001, APPL ENVIRON MICROB, V67, P2051, DOI 10.1128/AEM.67.5.2051-2055.2001; Cruz-Perez P, 2001, MOL CELL PROBE, V15, P129, DOI 10.1006/mcpr.2001.0347; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; Dales RE, 1999, MYCOPATHOLOGIA, V147, P21, DOI 10.1023/A:1007096704217; Davidson AC, 1996, BRIT MED J, V312, P601; Davis MB, 2001, SCIENCE, V292, P673, DOI 10.1126/science.292.5517.673; Day JP, 2002, APPL ENVIRON MICROB, V68, P37, DOI 10.1128/AEM.68.1.37-45.2002; DE RW, 2002, J ECON ENTOMOL, V95, P36; Degaudenzi ME, 1999, PHYS REV E, V59, P6569, DOI 10.1103/PhysRevE.59.6569; Dharmage S, 1999, INDOOR AIR, V9, P188, DOI 10.1111/j.1600-0668.1999.t01-1-00005.x; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Elke K, 1999, J ENVIRON MONITOR, V1, P445, DOI 10.1039/a903034d; Emberlin J, 1999, CLIN EXP ALLERGY, V29, P347, DOI 10.1046/j.1365-2222.1999.00369.x; Engvall K, 2001, INT J TUBERC LUNG D, V5, P468; Etzel RA, 1998, ARCH PEDIAT ADOL MED, V152, P757; Fahlbusch B, 2001, ALLERGY, V56, P1081, DOI 10.1034/j.1398-9995.2001.00106.x; Fiorina A, 1998, J INVEST ALLERG CLIN, V8, P85; Fischer G, 1999, Schriftenr Ver Wasser Boden Lufthyg, V104, P183; Freye HB, 2001, ALLERGY ASTHMA PROC, V22, P239; Galan C, 2001, INT J BIOMETEOROL, V45, P8, DOI 10.1007/s004840000081; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459, DOI 10.1046/j.1365-2222.1998.00255.x; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P437, DOI 10.1016/0091-6749(94)90352-2; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; Geiser M, 2000, J ALLERGY CLIN IMMUN, V106, P92, DOI 10.1067/mai.2000.107753; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Hameed AAA, 2001, J ENVIRON MONITOR, V3, P206, DOI 10.1039/b007159p; Hauck BC, 1997, AM IND HYG ASSOC J, V58, P713, DOI 10.1202/0002-8894(1997)058<0713:FTONAS>2.0.CO;2; Hirsch T, 2000, ALLERGY, V55, P79, DOI 10.1034/j.1398-9995.2000.00250.x; Holmquist L, 2001, INDOOR AIR, V11, P241, DOI 10.1034/j.1600-0668.2001.110405.x; Inglis GD, 2002, CAN J MICROBIOL, V48, P60, DOI 10.1139/W01-130; James TY, 2001, MOL ECOL, V10, P471, DOI 10.1046/j.1365-294x.2001.01224.x; Kamata N, 2002, B ENTOMOL RES, V92, P119, DOI 10.1079/BER2002158; Karunasena E, 2001, MYCOPATHOLOGIA, V150, P91, DOI 10.1023/A:1010920611811; Kenny LC, 1999, ANN OCCUP HYG, V43, P393, DOI 10.1016/S0003-4878(99)00042-3; Kenny LC, 1998, AM IND HYG ASSOC J, V59, P831, DOI 10.1080/15428119891011009; Keshri G, 2002, J APPL MICROBIOL, V92, P165, DOI 10.1046/j.1365-2672.2002.01515.x; Khan ZU, 1999, MYCOPATHOLOGIA, V146, P25, DOI 10.1023/A:1007034703398; Kilpelainen M, 2001, THORAX, V56, P462, DOI 10.1136/thorax.56.6.462; KLIRONOMOS JN, 1946, REV CANADIENNE BOT, V75, P1670; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Korpi A, 1999, ARCH ENVIRON HEALTH, V54, P347, DOI 10.1080/00039899909602499; Laaidi K, 2001, INT J BIOMETEOROL, V45, P124, DOI 10.1007/s004840100096; Leenders ACAP, 1999, J CLIN MICROBIOL, V37, P1752, DOI 10.1128/JCM.37.6.1752-1757.1999; Levy JI, 1999, AM IND HYG ASSOC J, V60, P317, DOI 10.1080/00028899908984448; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P1724, DOI 10.1046/j.1365-2222.2000.00947.x; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72, DOI 10.1080/00039899709603804; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; MADELIN TM, 1992, J APPL BACTERIOL, V72, P400, DOI 10.1111/j.1365-2672.1992.tb01853.x; Mahieu LM, 2000, J HOSP INFECT, V45, P191, DOI 10.1053/jhin.2000.0773; MALMBERG P, 1993, CHEST, V103, P1202, DOI 10.1378/chest.103.4.1202; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Martinez Ordaz Veronica Araceli, 2002, Rev Alerg Mex, V49, P2; McGrath JJ, 1999, CURR MICROBIOL, V38, P33, DOI 10.1007/PL00006768; Mehta SK, 2000, AIHAJ, V61, P850, DOI 10.1080/15298660008984597; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; Newson R, 1997, THORAX, V52, P680, DOI 10.1136/thx.52.8.680; Nielsen KF, 1999, MYCOPATHOLOGIA, V145, P43, DOI 10.1023/A:1007038211176; Olsson M, 1998, J CLIN MICROBIOL, V36, P1737, DOI 10.1128/JCM.36.6.1737-1740.1998; Pasanen AL, 2000, INDOOR AIR, V10, P111, DOI 10.1034/j.1600-0668.2000.010002111.x; Pessi AM, 2002, APPL ENVIRON MICROB, V68, P963, DOI 10.1128/AEM.68.2.963-967.2002; Peteet D, 2000, P NATL ACAD SCI USA, V97, P1359, DOI 10.1073/pnas.97.4.1359; Pieckenstain FL, 2001, ANTON LEEUW INT J G, V80, P245, DOI 10.1023/A:1013021011328; RANTIOLEHTIMAKI A, 1989, ALLERGY, V44, P18, DOI 10.1111/j.1398-9995.1989.tb00440.x; Rautiala S, 1998, AM IND HYG ASSOC J, V59, P455, DOI 10.1080/15428119891010190; Razmovski V, 2000, J ALLERGY CLIN IMMUN, V105, P725, DOI 10.1067/mai.2000.105222; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; Roe JD, 2001, J EXPO ANAL ENV EPID, V11, P12, DOI 10.1038/sj.jea.7500147; Rylander R, 1999, ENVIRON HEALTH PERSP, V107, P501, DOI 10.1289/ehp.99107s3501; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; SNELLER MR, 1979, ANN ALLERGY, V43, P352; Spicer RC, 2000, AM IND HYG ASSOC J, V61, P362, DOI 10.1080/15298660008984544; Stazi MA, 2002, PEDIAT ALLERG IMM-UK, V13, P105, DOI 10.1034/j.1399-3038.2002.00070.x; Sterling DA, 1998, ANN ALLERG ASTHMA IM, V80, P279, DOI 10.1016/S1081-1206(10)62971-7; Su HJJ, 2001, ARCH ENVIRON HEALTH, V56, P144, DOI 10.1080/00039890109604066; Szponar B, 2000, INDOOR AIR, V10, P13; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; Takamura S, 2000, RRD PLASMAS, V1, P41; Thorn J, 2001, MEDIAT INFLAMM, V10, P173, DOI 10.1080/09629350124119; Thrane U, 2001, FEMS MICROBIOL LETT, V203, P249, DOI 10.1111/j.1574-6968.2001.tb10849.x; Tiffany JA, 2000, J ENVIRON HEALTH, V62, P9; Troutt C, 2001, INT J BIOMETEOROL, V45, P64, DOI 10.1007/s004840100087; Tuomi T, 2000, APPL ENVIRON MICROB, V66, P1899, DOI 10.1128/AEM.66.5.1899-1904.2000; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; Vesper S, 2000, J URBAN HEALTH, V77, P68, DOI 10.1007/BF02350963; Waghorn TS, 2002, VET PARASITOL, V104, P119, DOI 10.1016/S0304-4017(01)00629-X; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172, DOI 10.1080/00039899909602256; Ward MDW, 2000, TOXICOLOGY, V147, P133, DOI 10.1016/S0300-483X(00)00191-8; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279, DOI 10.1016/S1081-1206(10)62009-1; Wijnands LM, 2000, ALLERGY, V55, P856, DOI 10.1034/j.1398-9995.2000.00532.x; Wilkins CK, 1998, PHARMACOL TOXICOL, V83, P112, DOI 10.1111/j.1600-0773.1998.tb01453.x; Wilkins K, 2000, CHEMOSPHERE, V41, P437, DOI 10.1016/S0045-6535(99)00273-8; Williams RH, 2001, APPL ENVIRON MICROB, V67, P2453, DOI 10.1128/AEM.67.6.2453-2459.2001; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000; Wu PC, 2000, ENVIRON RES, V82, P253, DOI 10.1006/enrs.1999.4017; Zacharasiewicz A, 1999, WIEN KLIN WOCHENSCHR, V111, P882; Zhou G, 2000, MOL CELL PROBE, V14, P339, DOI 10.1006/mcpr.2000.0324; Zukowski K, 1998, Rocz Panstw Zakl Hig, V49, P67; Zukowski K, 1996, Rocz Panstw Zakl Hig, V47, P343	110	135	136	2	44	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					544	552		10.1067/mai.2002.128674	http://dx.doi.org/10.1067/mai.2002.128674			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373259				2022-12-18	WOS:000178501900001
J	Lack, G				Lack, G			Pediatric allergic rhinitis and comorbid disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; cough variant rhinitis; postnasal drip; sinusitis	INTERCELLULAR-ADHESION MOLECULE-1; EUSTACHIAN-TUBE OBSTRUCTION; NASAL EPITHELIAL-CELLS; OTITIS-MEDIA; POLLEN EXPOSURE; DOSE-RESPONSE; ASTHMA; CHILDREN; CHALLENGE; HISTAMINE	Allergic rhinitis (AR) is rarely found in isolation and needs to be considered in the context of systemic allergic disease associated with numerous comorbid disorders, including asthma, chronic middle ear effusions, sinusitis, lymphoid hypertrophy with obstructive sleep apnea, disordered sleep, and consequent behavioral and educational effects. The coexistence of AR and asthma is complex. First, the diagnosis of asthma may be confounded by symptoms of cough caused by rhinitis and postnasal drip. This may lead to either inaccurate diagnosis of asthma or inappropriate assessment of asthma severity with over treatment of the patient. The term "cough variant rhinitis" is therefore proposed to describe rhinitis that manifests itself primarily as cough that results from postnasal drip. AR, however, also has a causal role in asthma; it appears both to be responsible for exacerbating asthma and to have a role in its pathogenesis. Postnasal drip with nasopharyngeal inflammation leads to a number of other conditions. Thus sinusitis is a frequent extension of rhinitis and is one of the most frequently missed diagnoses In children. Allergen exposure in the nasopharynx with release of histamine and other mediators can cause Eustachian tube obstruction possibly leading to middle car effusions. Chronic allergic inflammation of the upper airway causes lymphoid hypertrophy with prominence of adenoidal and tonsillar tissue. This may be associated with poor appetite, poor growth, and obstructive sleep apnea. AR is therefore part of a spectrum of allergic disorders that can profoundly affect the well being and quality of life of a child. Prospective cohort studies are required to assess the disease burden caused by AR in childhood and to further assess the potential educational impairment that may result. Because AR is part of a systemic disease process, its management requires a coordinated approach rather than a fragmented, organ-based approach.	St Marys Hosp, Dept Pediat Allergy & Immunol, London W2 1NY, England	Imperial College London	Lack, G (corresponding author), St Marys Hosp, Dept Pediat Allergy & Immunol, Praed St, London W2 1NY, England.			Lack, Gideon/0000-0001-7350-4021				BAKER BM, 1982, ANN OTO RHINOL LARYN, V91, P277, DOI 10.1177/000348948209100310; Baram Y, 1998, NEURAL PROCESS LETT, V8, P1, DOI 10.1023/A:1009611427303; BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; Bernstein JM, 1996, OTOLARYNG HEAD NECK, V114, P562, DOI 10.1016/S0194-5998(96)70247-4; BLUESTONE CD, 1983, J ALLERGY CLIN IMMUN, V72, P242, DOI 10.1016/0091-6749(83)90027-1; CAUWENBERGE PV, 1997, EUR RESPIR REV, V7, P286; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; CIPRANDI G, 1994, J ALLERGY CLIN IMMUN, V94, P738, DOI 10.1016/0091-6749(94)90182-1; COREY JP, 1994, AM J OTOLARYNG, V15, P138, DOI 10.1016/0196-0709(94)90063-9; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; Faniran AO, 1998, ARCH DIS CHILD, V79, P411, DOI 10.1136/adc.79.5.411; FRIEDMAN RA, 1983, J ALLERGY CLIN IMMUN, V71, P442, DOI 10.1016/0091-6749(83)90459-1; GAMBLE J E, 1992, Ear Nose and Throat Journal, V71, P397; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; IRVIN CG, 1992, J ALLERGY CLIN IMMUN, V90, P521, DOI 10.1016/0091-6749(92)90179-6; KATO M, 1995, CLIN EXP ALLERGY, V25, P744, DOI 10.1111/j.1365-2222.1995.tb00012.x; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KNIGHT LC, 1992, CLIN OTOLARYNGOL, V17, P308, DOI 10.1111/j.1365-2273.1992.tb01002.x; Koskela H, 1995, EUR RESPIR J, V8, P2088, DOI 10.1183/09031936.95.08122088; Matsuzaki Z, 1996, IMMUNOLOGY, V88, P565, DOI 10.1046/j.1365-2567.1996.d01-687.x; McColley SA, 1997, CHEST, V111, P170, DOI 10.1378/chest.111.1.170; MIGLETS A, 1973, LARYNGOSCOPE, V83, P1355, DOI 10.1288/00005537-197309000-00001; MOGI G, 1992, ACTA OTO-LARYNGOL, P155; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; OSUR SL, 1989, ALLERGY PROC, V10, P133, DOI 10.2500/108854189778961071; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; SKONER DP, 1991, ANN ALLERGY, V67, P619; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Yumoto E, 1991, Nihon Jibiinkoka Gakkai Kaiho, V94, P534	39	135	144	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S9	S15		10.1067/mai.2001.115562	http://dx.doi.org/10.1067/mai.2001.115562			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	459BU	11449201	Bronze			2022-12-18	WOS:000170230600003
J	van Wetering, S; Sterk, PJ; Rabe, KF; Hiemstra, PS				van Wetering, S; Sterk, PJ; Rabe, KF; Hiemstra, PS			Defensins: Key players or bystanders in infection, injury, and repair in the lung?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						defensins; antimicrobial peptides; neutrophils; epithelial cells; infection; innate immunity; host defense; immune response; inflammatory lung disease	HUMAN NEUTROPHIL DEFENSINS; EPITHELIAL-CELLS; HUMAN BETA-DEFENSIN-1; CYSTIC-FIBROSIS; BETA-DEFENSIN; ALPHA-1-PROTEINASE INHIBITOR; ANTIBACTERIAL ACTIVITY; AIRWAY EPITHELIA; LAVAGE FLUID; PEPTIDE	Antimicrobial peptides have been identified as key elements in the innate host defense against infection. Recent studies have indicated that the activity of antimicrobial peptides may be decreased in cystic fibrosis, suggesting a major role for these peptides in host defense against infection. One of the most intensively studied classes of antimicrobial peptides are defensins, Defensins comprise a family of cationic peptides that in human subjects can be divided into the alpha- and beta-defensin subfamilies. The alpha-defensins are produced by neutrophils and intestinal Paneth's cells, whereas beta-defensins are mainly produced by epithelial cells. Although studies on beta-defensins have so far focused on their antimicrobial activity, studies on alpha-defensins have suggested a role of these peptides in inflammation, wound repair, and specific immune responses. alpha-Defensins, which accumulate in airway secretions of patients with various chronic inflammatory lung disorders, were shown to be cytotoxic toward airway epithelial cells and to induce chemokine secretion in several cell types. Furthermore, the capacity of alpha-defensins to promote bacterial adherence to epithelial cells in vitro further supports a role for these peptides in the pathogenesis of chronic obstructive pulmonary disease and cystic fibrosis, Increased numbers of neutrophils are also present in the airways of patients with asthma, suggesting that neutrophils are involved in the pathogenesis of this disease. Because defensins are able to induce histamine release by mast cells and increase the airway hyperresponsiveness to histamine, it is tempting to speculate that defensins may also contribute to the inflammatory processes in asthma, Besides these proinflammatory effects, alpha-defensins may also display anti-inflammatory activities, including regulation of complement activation and proteinase inhibitor secretion. Finally, defensins may be involved in wound repair because defensins increase epithelial cell proliferation. Thus recent defensin research has revealed potential links between the innate and acquired immune system.	Leiden Univ, Med Ctr, Dept Pulmonol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Wetering, S (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, Bldg 1,C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Rabe, Klaus F./AAW-6296-2021; Sterk, P.J./AAK-8175-2020; Hiemstra, Pieter S/K-8587-2018	Rabe, Klaus F./0000-0002-7020-1401; Hiemstra, Pieter S/0000-0002-0238-5982				Ashitani J, 1998, EUR RESPIR J, V11, P104, DOI 10.1183/09031936.98.11010104; Ashitani J, 1996, Nihon Kyobu Shikkan Gakkai Zasshi, V34, P1349; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; COYLE AJ, 1994, AM J RESP CRIT CARE, V150, pS63, DOI 10.1164/ajrccm/150.5_Pt_2.S63; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Effros R M, 1986, J Thorac Imaging, V1, P54, DOI 10.1097/00005382-198603000-00007; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Gorter AD, 1998, J INFECT DIS, V178, P1067, DOI 10.1086/515667; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hiemstra PS, 1998, EUR RESPIR J, V12, P1200, DOI 10.1183/09031936.98.12051200; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; HIGAZI AAR, 1995, J BIOL CHEM, V270, P9472, DOI 10.1074/jbc.270.16.9472; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hiratsuka T, 1998, BIOCHEM BIOPH RES CO, V249, P943, DOI 10.1006/bbrc.1998.9239; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LICHTENSTEIN AK, 1988, CELL IMMUNOL, V114, P104, DOI 10.1016/0008-8749(88)90258-4; Lillard JW, 1999, P NATL ACAD SCI USA, V96, P651, DOI 10.1073/pnas.96.2.651; LINZMEIER R, 1993, FEBS LETT, V321, P267, DOI 10.1016/0014-5793(93)80122-B; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Liu L, 1996, J INVEST MED, V44, pA294; Liu LD, 1997, GENOMICS, V43, P316, DOI 10.1006/geno.1997.4801; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; MORRISON HM, 1987, CLIN SCI, V72, P373, DOI 10.1042/cs0720373; MURPHY CJ, 1993, J CELL PHYSIOL, V155, P408, DOI 10.1002/jcp.1041550223; PALFREE RGE, 1993, MOL ENDOCRINOL, V7, P199, DOI 10.1210/me.7.2.199; PANYUTICH AV, 1995, AM J RESP CELL MOL, V12, P351, DOI 10.1165/ajrcmb.12.3.7873202; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; Paone G, 1999, AM J RESP CRIT CARE, V159, pA511; PAONE G, 1997, AM J RESP CRIT CARE, V155, P853; Quayle AJ, 1998, AM J PATHOL, V152, P1247; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; RAHMAN I, 1995, AM J PHYSIOL, V269, pL2859; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Soong LB, 1997, INFLAMM RES, V46, P98, DOI 10.1007/s000110050114; SPARKES RS, 1989, GENOMICS, V5, P240, DOI 10.1016/0888-7543(89)90052-9; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; TREFZ G, 1992, CLIN INVESTIGATOR, V70, P269; Valore E, 1996, J INVEST MED, V44, pA268; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; van den Berg RH, 1998, BLOOD, V92, P3898, DOI 10.1182/blood.V92.10.3898.422k03_3898_3903; VANGESSEL S, 1999, IN PRESS CLIN EXP AL; VANOVERVELD FJ, 1995, EUR RESPIR J, V6, pS534; VanWetering S, 1997, J LEUKOCYTE BIOL, V62, P217, DOI 10.1002/jlb.62.2.217; vanWetering S, 1997, AM J PHYSIOL-LUNG C, V272, pL888, DOI 10.1152/ajplung.1997.272.5.L888; VANWETERING S, 1998, AM J RESP CRIT CARE, V157, P570; Welling MM, 1998, J CLIN INVEST, V102, P1583, DOI 10.1172/JCI3664; WILDE CG, 1989, J BIOL CHEM, V264, P11200; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	57	135	142	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1131	1138		10.1016/S0091-6749(99)70004-7	http://dx.doi.org/10.1016/S0091-6749(99)70004-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588992	Bronze			2022-12-18	WOS:000084289200003
J	Tee, RD; Cullinan, P; Welch, J; Burge, PS; Newman-Taylor, AJ				Tee, RD; Cullinan, P; Welch, J; Burge, PS; Newman-Taylor, AJ			Specific IgE to isocyanates: A useful diagnostic role in occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						isocyanates; IgE; occupational asthma; bronchial provocation test	INHALATION CHALLENGE; ANTIBODIES; WORKERS; DISEASE; SERUM; MDI	Background: Isocyanates are the most frequent cause of occupational asthma in industrialized countries. Objective: We sought to investigate the utility of specific IgE measurement in the diagnosis of isocyanate-induced asthma. Methods: Fifty-eight of 101 patients referred for investigation were diagnosed as having isocyanate-induced occupational asthma by means of history, serial peak flow records, and bronchial provocation tests. Specific IgE antibodies to toluene diisocyanate:human serum albumin (HSA), diphenylmethane diisocyanate:HSA, and hexamethylene diisocyanate: HSA were measured in all patients by Phadebas RAST. Results: Twenty patients had a RAST ratio of 2 or greater to at least one isocyanate. Thirteen (28%) of the 46 patients with a positive provocation test response had a RAST ratio of 2 or greater, and nine (20%) had a RAST ratio of 3 or greater. Raising the RAST cut-off from 2 or greater to 3 or greater reduced its sensitivity but increased the specificity of the test to 100%. RAST measurement was most likely to be positive within 30 days of exposure. Serial measurements suggested that the half-life of the IgE antibodies was approximately 6 months. Evidence of cross-reactivity between isocyanate RAST responses was found in eight subjects. Conclusion: Specific IgE to isocyanates is a more specific than sensitive index of occupational asthma. With a RAST score of 3 or greater, it is wholly specific and therefore diagnostic of isocyanate-induced asthma. The sensitivity of specific IgE measurement is highest when blood is taken less than 30 days from last exposure, which is consistent with the observed half-life.	Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Environm & Occupat Med, London SW3 6LR, England; Birmingham Chest Clin, Birmingham, W Midlands, England	Imperial College London	Tee, RD (corresponding author), Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Environm & Occupat Med, Manresa Rd, London SW3 6LR, England.							BANKS DE, 1989, CHEST, V95, P414, DOI 10.1378/chest.95.2.414; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BAUR X, 1994, INT ARCH OCC ENV HEA, V66, P141, DOI 10.1007/BF00380772; Baur X, 1991, Clin Exp Allergy, V21 Suppl 1, P241, DOI 10.1111/j.1365-2222.1991.tb01735.x; BAUR X, 1990, LUNG S, P606; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P820, DOI 10.1016/0091-6749(89)90345-X; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; Butcher Brian T., 1993, P415; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128, DOI 10.1159/000237525; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P94, DOI 10.1016/S0091-6749(05)80128-9; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611, DOI 10.1164/ajrccm.149.3.8118626; KESKINEN H, 1988, CLIN ALLERGY, V18, P597, DOI 10.1111/j.1365-2222.1988.tb02911.x; LAGIER F, 1990, REV MAL RESPIR, V7, P337; LENKEI R, 1977, J IMMUNOL METHODS, V16, P23, DOI 10.1016/0022-1759(77)90036-9; LISS GM, 1988, J ALLERGY CLIN IMMUN, V82, P55, DOI 10.1016/0091-6749(88)90051-6; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; NEWMANTAYLOR AJ, 1981, OCCUPATIUONAL LUNG D, V18, P143; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; VANDENPLAS O, 1993, BRIT J IND MED, V50, P213; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9	25	135	135	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					709	715		10.1016/S0091-6749(98)70181-2	http://dx.doi.org/10.1016/S0091-6749(98)70181-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600510				2022-12-18	WOS:000073697400021
J	Metz, DP; Hingorani, M; Calder, VL; Buckley, RJ; Lightman, SL				Metz, DP; Hingorani, M; Calder, VL; Buckley, RJ; Lightman, SL			T-cell cytokines in chronic allergic eye disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; T lymphocytes; cytokines; mRNA; immunohistochemistry	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; OCULAR ALLERGY; ATOPIC KERATOCONJUNCTIVITIS; NASAL-MUCOSA; IL-4; TH1; INTERLEUKIN-5; CONJUNCTIVA; MECHANISMS	Background: The pathophysiology of chronic allergic eye disease cannot be explained by type I hypersensitivity alone, and T cell-mediated inflammation has been strongly implicated as a possible additional mechanism. Previous studies suggested that T-H2-like T cells play an important role in one form of chronic allergic eye disease. Objectives: This study examined the cytokine profile of T cells in different clinical groups of subjects with chronic allergic eye disease (i.e., vernal keratoconjunctivitis [VKC], atopic keratoconjunctivitis [AKC], and giant papillary conjunctivitis [GPC]) and normal control subjects. Methods: In situ hybridization was used to identify cytokine messenger RNA (mRNA), and two-color immunohistochemical analysis was used to demonstrate cytokine immunoreactivity localizing to T cells in the conjunctiva. Results: Allergic tissue expressed increased levels of mRNA for IL-3, IL-4, and IL-5 when compared with normal tissue. There was significantly greater IL-2 mRNA expression in subjects with AKC than in those with VKC (p = 0.004) and those with GPC (p = 0.02). Immunoreactivity for T-cell IL-5 was present more frequently in subjects with VKC (p = 0.004), GPC (p = 0.02), and AKC (p = 0.04) than in normal control subjects. However, T-cell IFN-gamma protein expression was greater in subjects with AKC than in subjects with VKC (p = 0.01), GPC (p = 0.01), and control subjects (p = 0.005). Conclusions: These results show a T-H2-like T-cell cytokine array in subjects with VKC and GPC but a shift in cytokine profile toward a T-H1-like pattern, potentially because of differences in chronicity of the disorders, in subjects with AKC. These important functional T-cell variations in chronic allergic eye conditions are likely to be important in understanding differences in clinical characteristics and therapeutic responses.	Inst Ophthalmol, London EC1V 9EL, England; Moorfields Eye Hosp, London, England	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Calder, VL (corresponding author), Inst Ophthalmol, Bath St, London EC1V 9EL, England.		Calder, Virginia/AAG-8278-2020	Calder, Virginia/0000-0003-1422-2926				ABELSON MB, 1993, SURV OPHTHALMOL, V38, P115, DOI 10.1016/0039-6257(93)90036-7; Akova Y A, 1994, Ocul Immunol Inflamm, V2, P125, DOI 10.3109/09273949409057069; ALLANSMITH MR, 1988, INT OPHTHALMOL CLIN, V28, P309, DOI 10.1097/00004397-198802840-00010; ALLANSMITH MR, 1988, CLIN ALLERGY, V18, P1, DOI 10.1111/j.1365-2222.1988.tb02837.x; BHAN AK, 1982, AM J OPHTHALMOL, V94, P205, DOI 10.1016/0002-9394(82)90076-9; BONINI S, 1993, ANN ALLERGY, V71, P296; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BUCKLEY RJ, 1981, T OPHTHAL SOC UK, V101, P234; BUCKLEY RJ, 1988, INT OPHTHALMOL CLIN, V28, P303, DOI 10.1097/00004397-198802840-00009; BUCKLEY RJ, 1988, CORNEA T WORLD C COR, V3, P435; DELPRETE G, 1994, LAB INVEST, V70, P299; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; DURHAM SR, 1992, J IMMUNOL, V148, P2390; EHLERS W H, 1992, CLAO Journal, V18, P117; FOSTER CS, 1990, OPHTHALMOLOGY, V97, P992; FOSTER CS, 1991, OPHTHALMOLOGY, V98, P1190; FOSTER CS, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb04250.x; FRIEDLAENDER MH, 1993, SURV OPHTHALMOL, V38, P105, DOI 10.1016/0039-6257(93)90035-6; GOLDING B, 1995, ANN NY ACAD SCI, V754, P126, DOI 10.1111/j.1749-6632.1995.tb44445.x; GREINER JV, 1985, ADV IMMUNOLOGY IMMUN, P302; GREINER JV, 1986, CLAO GUIDE BASIC SCI; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HAVENER W, 1980, PRINCIPLES PRACTICE, P756; HINGORANI M, 1995, DRUGS, V50, P208, DOI 10.2165/00003495-199550020-00002; Howard M, 1994, GUIDEBOOK CYTOKINES; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; JAY JL, 1981, BRIT J OPHTHALMOL, V65, P335, DOI 10.1136/bjo.65.5.335; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; KEMP M, 1994, APMIS, V102, P81, DOI 10.1111/j.1699-0463.1994.tb04850.x; LUQMAN M, 1991, EUR J IMMUNOL, V21, P17, DOI 10.1002/eji.1830210104; MAGGI E, 1991, J IMMUNOL, V146, P1169; Metz DP, 1996, J ALLERGY CLIN IMMUN, V98, P686, DOI 10.1016/S0091-6749(96)70103-3; Morgan G, 1971, Trans Ophthalmol Soc U K, V91, P467; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; ROMAGNANI S, 1991, INT ARCH ALLER A IMM, V94, P133, DOI 10.1159/000235344; Sander B, 1995, IMMUNOLOGY, V86, P512; SECCHI AG, 1990, AM J OPHTHALMOL, V110, P641, DOI 10.1016/S0002-9394(14)77061-8; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; TUFT SJ, 1991, OPHTHALMOLOGY, V98, P150; YUASA T, 1985, ADV IMMUNOLOGY IMMUN, P85	47	135	139	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				817	824		10.1016/S0091-6749(97)70279-3	http://dx.doi.org/10.1016/S0091-6749(97)70279-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438492	Bronze			2022-12-18	WOS:000071353600016
J	VANDERLINDEN, PWG; HACK, CE; STRUYVENBERG, A; VANDERZWAN, JK				VANDERLINDEN, PWG; HACK, CE; STRUYVENBERG, A; VANDERZWAN, JK			INSECT-STING CHALLENGE IN 324 SUBJECTS WITH A PREVIOUS ANAPHYLACTIC REACTION - CURRENT CRITERIA FOR INSECT-VENOM HYPERSENSITIVITY DO NOT PREDICT THE OCCURRENCE AND THE SEVERITY OF ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INSECT-STING CHALLENGE; HYMENOPTERA; IGE; IGG(4) SKIN TEST; ANAPHYLAXIS; IMMEDIATE HYPERSENSITIVITY	HONEY BEE VENOM; WASP VENOM; NATURAL-HISTORY; SKIN-TESTS; IMMUNOTHERAPY; IGG; HYMENOPTERA; ALLERGY; ANTIBODY; SENSITIVITY	Three hundred twenty-four patients with a history of yellow jacket- (n = 272) or honeybee- (n = 52) sting anaphylaxis were prospectively subjected to an in-hospital sting challenge. Plasma levels of specific IgE and IgG(4), skin venom tests, severity of previous reaction, sex, age, atopic constitution, histamine skin test results, location and number of previous stings, time interval between previous anaphylactic reaction and sting challenge, and time interval between sting challenge and onset of anaphylaxis were studied in relation to the clinical severity of a reaction after sting challenge. A recurrent anaphylactic reaction after sting challenge was observed in 25% of yellow jacket- and in 52% of honeybee-sensitive persons. The severity of this reaction correlated significantly with age and the time interval between sting challenge and onset of anaphylaxis only: older persons with faster reactions had more severe symptoms after sting challenge. None of the current criteria for insect-sting hypersensitivity (IgE, IgG(4), skin test) significantly related on an individual basis or in combinations to the reaction after sting challenge. We conclude chat the current criteria to assess insect-venom hypersensitivity do not relate to the occurrence and severity of anaphylactic symptoms after an insect-sting challenge.	UNIV UTRECHT HOSP, DEPT INTERNAL MED, UTRECHT, NETHERLANDS; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT AUTOIMMUNE DIS, AMSTERDAM, NETHERLANDS; EEMLAND HOSP, DEPT INTERNAL MED, AMERSFOORT, NETHERLANDS	Utrecht University; Utrecht University Medical Center			Levi, Marcel/AAZ-8559-2020					Aalberse R C, 1979, Monogr Allergy, V14, P29; AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; BARSELA S, 1983, J ALLERGY CLIN IMMUN, V72, P690, DOI 10.1016/0091-6749(83)90631-0; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; CHARPIN D, 1992, J ALLERGY CLIN IMMUN, V90, P331, DOI 10.1016/S0091-6749(05)80011-9; CLAYTON WF, 1985, CLIN ALLERGY, V15, P329, DOI 10.1111/j.1365-2222.1985.tb03000.x; FRANKEN HH, 1991, LANCET, V338, P1344, DOI 10.1016/0140-6736(91)92654-K; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; HAUK PJ, 1992, J ALLERGY CLIN IMMUN, V89, P291; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; KEMENY DM, 1989, INT ARCH ALLER A IMM, V88, P247, DOI 10.1159/000234799; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; LEVI R, 1988, CLIN IMMUNOLOGY, V1, P93; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; LOMNITZER R, 1988, CLIN ALLERGY, V18, P39, DOI 10.1111/j.1365-2222.1988.tb02841.x; Mueller H L, 1966, J Asthma Res, V3, P331; Mueller H.L., 1990, INSECT STING ALLERGY; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PRZYBILLA B, 1989, ALLERGOLOGIE, V12, P192; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P282, DOI 10.1016/S0091-6749(05)80004-1; REISMAN RE, 1987, ANN ALLERGY, V59, P429; REISMAN RE, 1981, J ALLERGY CLIN IMMUN, V68, P406, DOI 10.1016/0091-6749(81)90140-8; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; VALENTINE MD, 1987, JAMA-J AM MED ASSOC, V258, P2881, DOI 10.1001/jama.258.20.2881; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329	39	135	136	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					151	159		10.1016/0091-6749(94)90034-5	http://dx.doi.org/10.1016/0091-6749(94)90034-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064067	Bronze			2022-12-18	WOS:A1994PC92600003
J	MROZ, MM; KREISS, K; LEZOTTE, DC; CAMPBELL, PA; NEWMAN, LS				MROZ, MM; KREISS, K; LEZOTTE, DC; CAMPBELL, PA; NEWMAN, LS			REEXAMINATION OF THE BLOOD LYMPHOCYTE-TRANSFORMATION TEST IN THE DIAGNOSIS OF CHRONIC BERYLLIUM DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BERYLLIUM; CHRONIC BERYLLIUM DISEASE; LYMPHOCYTE TRANSFORMATION; STIMULATION INDEX; BRONCHOALVEOLAR LAVAGE	BRONCHOALVEOLAR LAVAGE; WORKERS	The T cell response to beryllium, measured in bronchoalveolar lavage by the lymphocyte transformation test (LTT), is a critical diagnostic test for discriminating between chronic beryllium disease (CBD) and other granulomatous diseases. We examined the sensitivity, reproducibility, and methods of a less invasive, peripheral blood LTT in 17 patients with CBD and in 18 beryllium-exposed control subjects. Ninety-four percent of CBD cases (16/17) had abnormal blood LTT results, and all 18 beryllium-exposed control subjects had normal blood LTT results. Split samples for 10 beryllium disease cases and eight control subjects demonstrated that the blood LTT was reproducible between two separate laboratories. The LTT was equally sensitive with 10% and 20% serum in the culture medium. We conclude that an abnormal blood LTT can be used to diagnose CBD in patients with compatible lung pathology.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV PULMONARY,1400 JACKSON ST,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV OCCUPAT & ENVIRONM MED,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV BASIC IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIEHS NIH HHS [ES-00173, ES-04843] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004843, K11ES000173] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARGON J, 1986, EUR J RESPIR DIS, V69, P211; CULLEN MR, 1987, AM REV RESPIR DIS, V135, P201; DEODHAR SD, 1973, CHEST, V63, P309, DOI 10.1378/chest.63.3.309; EPSTEIN PE, 1982, ANN INTERN MED, V97, P213, DOI 10.7326/0003-4819-97-2-213; Freiman D G, 1970, Hum Pathol, V1, P25, DOI 10.1016/S0046-8177(70)80003-X; KREISS K, 1989, J OCCUP ENVIRON MED, V31, P603, DOI 10.1097/00043764-198907000-00011; NEWMAN LS, 1989, AM REV RESPIR DIS, V139, P1479, DOI 10.1164/ajrccm/139.6.1479; OPPENHEIM JJ, 1980, MANUAL CLIN IMMUNOLO, P223; PREUSS OP, 1980, 8TH P INT C SARC OTH, P711; ROM WN, 1983, ARCH ENVIRON HEALTH, V38, P302, DOI 10.1080/00039896.1983.10544010; Rosner B, 1982, FUNDAMENTALS BIOSTAT; ROSSMAN MD, 1988, ANN INTERN MED, V108, P687, DOI 10.7326/0003-4819-108-5-687; SALTINI C, 1989, NEW ENGL J MED, V320, P1103, DOI 10.1056/NEJM198904273201702; STOKES RF, 1991, J OCCUP ENVIRON MED, V33, P23, DOI 10.1097/00043764-199101000-00009; WATTERS LC, 1987, AM REV RESPIR DIS, V135, P696; WILLIAMS WJ, 1983, THORAX, V38, P41, DOI 10.1136/thx.38.1.41; WILLIAMS WR, 1982, INT ARCH ALLER A IMM, V67, P175, DOI 10.1159/000233010	17	135	136	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					54	60		10.1016/0091-6749(91)90300-D	http://dx.doi.org/10.1016/0091-6749(91)90300-D			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071785	Bronze			2022-12-18	WOS:A1991FY20400006
J	BUTCHER, BT; SALVAGGIO, JE; WEILL, H; ZISKIND, MM				BUTCHER, BT; SALVAGGIO, JE; WEILL, H; ZISKIND, MM			TOLUENE DIISOCYANATE (TDI) PULMONARY-DISEASE - IMMUNOLOGICAL AND INHALATION CHALLENGE STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LOUISIANA STATE UNIV,MED CTR,NEW ORLEANS,LA 70122; TULANE UNIV,MED CTR,NEW ORLEANS,LA 70118	Louisiana State University System; Tulane University								ADAMS WGF, 1970, P ROY SOC MED, V63, P378, DOI 10.1177/003591577006300420; AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BICE DE, 1974, INT ARCH ALLER A IMM, V47, P54; BRUCKNER HC, 1968, ARCH ENVIRON HEALTH, V16, P619, DOI 10.1080/00039896.1968.10665117; BRUGSCH HG, 1963, NEW ENGL J MED, V268, P353, DOI 10.1056/NEJM196302142680705; BUTCHER B T, 1975, Clinical Allergy, V5, P33, DOI 10.1111/j.1365-2222.1975.tb01834.x; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DISCOMBE G, 1946, LANCET, V1, P195; FUCHS S, 1951, Arch Mal Prof, V12, P191; GLASS W I, 1964, N Z Med J, V63, P642; HILL, 1970, P ROY SOC MED, V63, P375; LAYTON LL, 1968, INT ARCH ALLER A IMM, V33, P417, DOI 10.1159/000230057; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MCKERROW, 1970, P ROY SOC MED, V63, P376; OVARY Z, 1963, J EXP MED, V117, P965; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; PETERS JM, 1970, P ROY SOC MED, V63, P372, DOI 10.1177/003591577006300417; SALVAGGIO JE, 1970, J ALLERGY, V46, P326, DOI 10.1016/0021-8707(70)90083-3; SCHEEL L D, 1964, Am Ind Hyg Assoc J, V25, P179, DOI 10.1080/00028896409342574; Stokinger H E, 1973, J Occup Med, V15, P564; SWEET L C, 1968, University of Michigan Medical Center Journal, V34, P27; TAYLOR G, 1970, P ROY SOC MED, V63, P379, DOI 10.1177/003591577006300421; Weill H, 1975, Environ Health Perspect, V11, P101	24	135	135	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					89	100		10.1016/0091-6749(76)90110-X	http://dx.doi.org/10.1016/0091-6749(76)90110-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	181412				2022-12-18	WOS:A1976BX74200010
J	SALVAGGIO, J; SEABURY, J; SCHOENHARDT, EA				SALVAGGIO, J; SEABURY, J; SCHOENHARDT, EA			NEW-ORLEANS ASTHMA .5. RELATIONSHIP BETWEEN CHARITY HOSPITAL ASTHMA ADMISSION RATES, SEMIQUANTITATIVE POLLEN AND FUNGAL SPORE COUNTS, AND TOTAL PARTICULATE AEROMETRIC SAMPLING DATA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GREENBURG L, 1964, ARCH ENVIRON HEALTH, V8, P642, DOI 10.1080/00039896.1964.10663734; Haldane JS, 1931, BRIT MED J, V1931, P366, DOI 10.1136/bmj.1.3660.366; HARRIS LEONARD H., 1939, JOUR ALLERGY, V10, P327, DOI 10.1016/S0021-8707(39)90147-4; HEIMANN H, 1963, ANN ALLERGY, V21, P396; Ingold C.T., 1965, SPORE LIBERATION, P210; KENLINE PA, 1966, ARCH ENVIRON HEALTH, V12, P295, DOI 10.1080/00039896.1966.10664376; LEWIS R, 1962, PUBLIC HEALTH REP, V77, P947, DOI 10.2307/4591673; LEWIS R, 1963, J La State Med Soc, V115, P300; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; PADY SM, 1967, J ALLERGY, V39, P302, DOI 10.1016/0021-8707(67)90094-9; REBHUN J, 1954, J ALLERGY, V25, P407, DOI 10.1016/0021-8707(54)90005-2; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P82, DOI 10.1016/0091-6749(71)90090-X; SALVAGGIO J, IN PRESS; SALVAGGIO JE, 1967, J ALLERGY, V39, P227, DOI 10.1016/0021-8707(67)90015-9; SCHOETTLIN EC, PUBLIC HEALTH REP, V76, P545; SCHRENK HH, 1948, 306 PUBL HEALTH B; SMITH RBW, 1964, ARCH ENVIRON HEALTH, V8, P805; SOLOMON WR, 1967, MANUAL CLINICAL ALLE, P427; STAKMAN EC, 1946, BOT REV, V12, P205, DOI 10.1007/BF02861523; WEILL H, 1964, JAMA-J AM MED ASSOC, V190, P811; WEILL H, 1965, ARCH ENVIRON HEALTH, V10, P148, DOI 10.1080/00039896.1965.10663973; WEILL H, 1964, ARCH ENVIRON HEALTH, V8, P184, DOI 10.1080/00039896.1964.10663650; WEILL H, 1965, 58 ANN M AIR POLL CO; ZEIDBERG LD, NASHVILLE AIR POLLUT; 1965, SAMPLING IDENTIFICAT; 1954, 95 MIN HEALTH REP	30	135	138	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	2					96	+		10.1016/0091-6749(71)90091-1	http://dx.doi.org/10.1016/0091-6749(71)90091-1			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K0446	5283607				2022-12-18	WOS:A1971K044600004
J	Yancey, SW; Keene, ON; Albers, FC; Ortega, H; Bates, S; Bleecker, ER; Pavord, I				Yancey, Steven W.; Keene, Oliver N.; Albers, Frank C.; Ortega, Hector; Bates, Stewart; Bleecker, Eugene R.; Pavord, Ian			Biomarkers for severe eosinophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; biomarkers; severe eosinophilic asthma	ANTI-IL-5 MEPOLIZUMAB THERAPY; OBSTRUCTIVE PULMONARY-DISEASE; SURROGATE END-POINTS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; SPUTUM EOSINOPHILIA; AIRWAY INFLAMMATION; PLACEBO; BENRALIZUMAB; MARKERS	The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available evidence and combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/mL or greater or a historical blood eosinophil threshold of 300 cells/mL or greater will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clinically significant reductions in the rate of exacerbations with mepolizumab treatment.	[Yancey, Steven W.; Ortega, Hector] GlaxoSmithKline, Resp Therapeut Area, Res Triangle Pk, NC USA; [Albers, Frank C.] GlaxoSmithKline, Resp Med Franchise, Res Triangle Pk, NC USA; [Keene, Oliver N.] GlaxoSmithKline, Clin Stat, Stockley Pk, Uxbridge, Middx, England; [Bates, Stewart] GlaxoSmithKline, Resp Discovery Med, Stevenage, Herts, England; [Bleecker, Eugene R.] Univ Arizona, Coll Med, Div Genet Genom & Personalized Med, Tucson, AZ USA; [Pavord, Ian] Univ Oxford, Resp Med Unit, Nuffield Dept Med, Oxford, England; [Pavord, Ian] Univ Oxford, Oxford Resp BRC, Nuffield Dept Med, Oxford, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Arizona; University of Oxford; University of Oxford	Yancey, SW (corresponding author), 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.	steve.w.yancey@gsk.com		Keene, Oliver/0000-0003-0016-9773; Ortega, Hector/0000-0002-2632-6370	GlaxoSmithKline; National Institute for Health Research [NF-SI-0510-10157] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); National Institute for Health Research(National Institute for Health Research (NIHR))	This article reports data from studies funded by GlaxoSmithKline.	Albers FC, 2017, J ASTHMA; Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; American Diabetes Association, 2015, Diabetes Care, V38 Suppl, pS8, DOI 10.2337/dc15-S005; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Austin D, 2016, AM J RESP CRIT CARE, V193; Austin D, 2016, EUR RESPIR J, V48, DOI 10.1183/13993003.congress-2016.PA1110; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Bousquet J, 2007, RESP MED, V101, P1483, DOI 10.1016/j.rmed.2007.01.011; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Chung KF, 2015, LANCET, V386, P1086, DOI 10.1016/S0140-6736(15)00157-9; Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X; Corren J, 2016, CHEST, V150, P799, DOI 10.1016/j.chest.2016.03.018; de Groote P, 2013, EUR HEART J, V34, P636, DOI 10.1093/eurheartj/ehs432; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Duffy MJ, 2017, EUR J CANCER, V75, P284, DOI 10.1016/j.ejca.2017.01.017; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fowler SJ, 2015, J ALLERGY CLIN IMMUN, V135, P822, DOI 10.1016/j.jaci.2014.09.034; Gaggin HK, 2013, BBA-MOL BASIS DIS, V1832, P2442, DOI 10.1016/j.bbadis.2012.12.014; Genentech, 2017, OM PRESCR INF; Ghazi A, 2012, EXPERT OPIN BIOL TH, V12, P113, DOI 10.1517/14712598.2012.642359; Gheorghiade M, 2011, J HEART LUNG TRANSPL, V30, P218, DOI 10.1016/j.healun.2010.08.027; GlaxoSmithKline, 2017, MEP PRESCR INF; GlaxoSmithKline, 2016, MEP SUMM PROD CHAR; Global Initiative For Asthma, 2017, GLOB STRAT ASTHM MAN; Goldman M, 2017, CURR MED RES OPIN, V33, P1605, DOI 10.1080/03007995.2017.1347091; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1111/j.1365-2222.1997.tb01211.x; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hansbro PM, 2011, BRIT J PHARMACOL, V163, P81, DOI 10.1111/j.1476-5381.2011.01219.x; Hart TK, 2001, J ALLERGY CLIN IMMUN, V108, P250, DOI 10.1067/mai.2001.116576; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Katz Lynn E, 2014, Ann Am Thorac Soc, V11, P531, DOI 10.1513/AnnalsATS.201310-354OC; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449, DOI 10.1164/ajrccm.155.2.9032177; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Korevaar DA, 2015, LANCET RESP MED, V3, P290, DOI 10.1016/S2213-2600(15)00050-8; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Lin CH, 2016, DRUG DES DEV THER, V10, P2369, DOI 10.2147/DDDT.S112208; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; Mckeon S, 2015, THORAX, V70, pA124, DOI 10.1136/thoraxjnl-2015-207770.235; Menzella F, 2016, THER ADV RESPIR DIS, V10, P534, DOI 10.1177/1753465816667659; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore KT, 2015, BRIT J CLIN PHARMACO, V79, P907, DOI 10.1111/bcp.12559; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Novartis, 2015, OM SUMM PROD CHAR; Ortega H, 2015, ANN AM THORAC SOC, V12, P1896, DOI 10.1513/AnnalsATS.201507-443LE; Ortega H, 2015, J ALLERGY CLIN IMMUN, V136, P825, DOI 10.1016/j.jaci.2015.05.039; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pletcher MJ, 2011, CIRCULATION, V123, P1116, DOI 10.1161/CIRCULATIONAHA.110.943860; Pouliquen IJ, 2015, INT J CLIN PHARM TH, V53, P1015, DOI 10.5414/CP202446; Prazma C, 2017, AM J RESP CRIT CARE, V195; Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7; Raterman HG, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3819; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Sacks DB, 2011, DIABETES CARE, V34, P1419, DOI 10.2337/dc11-9997; Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Teva, 2016, RESL SUMM PROD CHAR; Wagner JA, 2002, DIS MARKERS, V18, P41, DOI 10.1155/2002/929274; Wahn U, 2009, ALLERGY, V64, P1780, DOI 10.1111/j.1398-9995.2009.02119.x; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411; Yancey SW, 2017, J ALLERGY CLIN IMMUN, V139, P1167, DOI 10.1016/j.jaci.2016.08.008; Zeiger RS, 2014, J ALLER CL IMM-PRACT, V2, P741, DOI 10.1016/j.jaip.2014.06.005	76	134	138	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1509	1518		10.1016/j.jaci.2017.10.005	http://dx.doi.org/10.1016/j.jaci.2017.10.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	29221581	hybrid, Green Published			2022-12-18	WOS:000417206000004
J	Fremond, ML; Rodero, MP; Jeremiah, N; Belot, A; Jeziorski, E; Duffy, D; Bessis, D; Cros, G; Rice, GI; Charbit, B; Hulin, A; Khoudour, N; Caballero, CM; Bodemer, C; Fabre, M; Berteloot, L; Le Bourgeois, M; Reix, P; Walzer, T; Moshous, D; Blanche, SE; Fischer, A; Bader-Meunier, B; Rieux-Laucat, F; Crow, YJ; Neven, B				Fremond, Marie-Louise; Rodero, Mathieu Paul; Jeremiah, Nadia; Belot, Alexandre; Jeziorski, Eric; Duffy, Darragh; Bessis, Didier; Cros, Guilhem; Rice, Gillian I.; Charbit, Bruno; Hulin, Anne; Khoudour, Nihel; Caballero, Consuelo Modesto; Bodemer, Christine; Fabre, Monique; Berteloot, Laureline; Le Bourgeois, Muriel; Reix, Philippe; Walzer, Thierry; Moshous, Despina; Blanche, St Ephane; Fischer, Alain; Bader-Meunier, Brigitte; Rieux-Laucat, Frederic; Crow, Yanick Joseph; Neven, Benedicte			Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AICARDI-GOUTIERES SYNDROME		[Fremond, Marie-Louise; Cros, Guilhem; Moshous, Despina; Blanche, St Ephane; Fischer, Alain; Bader-Meunier, Brigitte; Neven, Benedicte] Hop Necker Enfants Malad, Pediat Hematol Immunol & Rheumatol Dept, Paris, France; [Fremond, Marie-Louise; Rodero, Mathieu Paul; Jeremiah, Nadia; Bodemer, Christine; Moshous, Despina; Blanche, St Ephane; Fischer, Alain; Bader-Meunier, Brigitte; Rieux-Laucat, Frederic; Crow, Yanick Joseph; Neven, Benedicte] Paris Descartes Univ, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Fremond, Marie-Louise; Rodero, Mathieu Paul; Crow, Yanick Joseph] INSERM, UMR 1163, Lab Neurogenet & Neuroinflammat, Paris, France; [Jeremiah, Nadia; Bader-Meunier, Brigitte; Rieux-Laucat, Frederic; Neven, Benedicte] INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmun, Paris, France; [Belot, Alexandre] Hosp Civils Lyon, Nephrol & Dermatol Dept, Pediat Rheumatol, Lyon, France; [Belot, Alexandre; Walzer, Thierry] Univ Lyon 1, Ecole Normale Super Lyon, INSERM, CIRI,U1111,CNRS,UMR5308, Lyon, France; [Jeziorski, Eric] Ctr Hosp Univ Montpellier, Dept Pediat, Montpellier, France; [Duffy, Darragh; Charbit, Bruno] INSERM, U1223, Lab Dendrit Cell Immunobiol, Paris, France; [Duffy, Darragh] Inst Pasteur, Ctr Translat Res, Paris, France; [Bessis, Didier] Ctr Hosp Univ Montpellier, Dept Dermatol, Montpellier, France; [Rice, Gillian I.; Crow, Yanick Joseph] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Med & Human Sci, Manchester Ctr Genom Med,Inst Human Dev, Manchester, Lancs, England; [Hulin, Anne; Khoudour, Nihel] Hop Univ Henri Mondor, Pharmacol & Toxicol Lab, Creteil, France; [Caballero, Consuelo Modesto] Hosp Univ Vall dHebron, Dept Pediat Rheumatol, Barcelona, Spain; [Bodemer, Christine] Hop Necker Enfants Malad, Dept Dermatol, Paris, France; [Fabre, Monique] Hop Necker Enfants Malad, Dept Pathol, Paris, France; [Berteloot, Laureline] Hop Necker Enfants Malad, Dept Pediat Radiol, Paris, France; [Le Bourgeois, Muriel] Hop Necker Enfants Malad, Dept Pediat Pneumol, Paris, France; [Reix, Philippe] Hosp Civils Lyon, Ctr Reference Mucoviscidose, Dept Pneumol, Lyon, France; [Reix, Philippe] Claude Bernard Lyon 1 Univ, Lyon, France; [Moshous, Despina] INSERM, UMR 1163, Lab Genome Dynam Immune Syst, Paris, France; [Fischer, Alain] INSERM, UMR 1163, Paris, France; [Fischer, Alain] Coll France, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Montpellier; CHU de Montpellier; University of Manchester; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Hospital Universitari Vall d'Hebron; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France	Neven, B (corresponding author), Hop Necker Enfants Malad, Pediat Hematol Immunol & Rheumatol Dept, Paris, France.; Neven, B (corresponding author), Paris Descartes Univ, Sorbonne Paris Cite, Inst Imagine, Paris, France.; Neven, B (corresponding author), INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmun, Paris, France.	benedicte.neven@aphp.fr	Rice, Gillian I/G-3128-2015; Crow, Yanick J/N-6120-2014; Hulin, Anne/AAA-4757-2022; Walzer, Thierry/L-9418-2014; Charbit, Bruno/AAI-9714-2021; Belot, Alexandre/C-7378-2013; Jeziorski, Eric/AAI-3530-2021; Rieux-Laucat, Frédéric/A-7916-2017; rodero, mathieu/C-8083-2011; Frémond, Marie-Louise/G-9371-2017; Moshous, Despina/B-7507-2017; Frémond, Marie-Louise/AAH-4266-2019	Rice, Gillian I/0000-0002-4223-0571; Crow, Yanick J/0000-0001-7211-7564; Walzer, Thierry/0000-0002-0857-8179; Charbit, Bruno/0000-0002-5478-482X; Belot, Alexandre/0000-0003-4902-5332; Jeziorski, Eric/0000-0003-0318-3044; Rieux-Laucat, Frédéric/0000-0001-7858-7866; rodero, mathieu/0000-0002-1300-0187; Frémond, Marie-Louise/0000-0002-2798-9141; Moshous, Despina/0000-0001-6719-3693; Frémond, Marie-Louise/0000-0002-2798-9141; Didier, Bessis/0000-0002-3815-5417; bader-meunier, brigitte/0000-0001-8476-8196				Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; Hornung T, 2014, NEW ENGL J MED, V371, P2537, DOI 10.1056/NEJMc1412997; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Loh ML, 2015, PEDIATR BLOOD CANCER, V62, P1717, DOI 10.1002/pbc.25575; Mostafavi S, 2016, CELL, V164, P564, DOI 10.1016/j.cell.2015.12.032; Munoz J, 2015, JAMA DERMATOL, V151, P872, DOI 10.1001/jamadermatol.2015.0251; Rice GI, 2013, LANCET NEUROL, V12, P1159, DOI 10.1016/S1474-4422(13)70258-8; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557; von Hofsten J, 2016, NEW ENGL J MED, V374, P296, DOI 10.1056/NEJMc1413918	10	134	138	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1752	1755		10.1016/j.jaci.2016.07.015	http://dx.doi.org/10.1016/j.jaci.2016.07.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27554814	Bronze, Green Submitted			2022-12-18	WOS:000390019300045
J	Tai, A; Tran, H; Roberts, M; Clarke, N; Gibson, AM; Vidmar, S; Wilson, J; Robertson, CF				Tai, Andrew; Tran, Haily; Roberts, Mary; Clarke, Nadeene; Gibson, Anne-Marie; Vidmar, Suzanna; Wilson, John; Robertson, Colin F.			Outcomes of childhood asthma to the age of 50 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; remission; lung function	1ST 6 YEARS; LUNG-FUNCTION; WHEEZY BRONCHITIS; NATURAL-HISTORY; FOLLOW-UP; CHILDREN; DECLINE; AIRWAY; LIFE; GENDER	Background: In 1964, The Melbourne Asthma Study was established to describe the spectrum and natural history of childhood asthma. Objective: To describe the clinical and lung function outcome of childhood asthma to the age of 50 years. Method: Subjects were invited to complete an interviewer-administered questionnaire, skin prick testing, and measurement of lung function from the age of 7 years to the age of 50 years at 7-year intervals. Results: Of 458 survivors (from the original 484 subjects at recruitment), 346 subjects (76%) participated, of whom, 197 completed lung function measurement. Asthma remission at the age of 50 years was 64% in those with wheezy bronchitis, 47% for those with persistent asthma, and 15% for those with severe asthma in childhood. Multivariable analysis identified severe asthma in childhood (odds ratio [OR] 11.9 [95% CI, 3.4-41.8]), female sex (OR 2.0 [95% CI, 1.1-3.6]), and childhood hay fever (OR 2.0 [95% CI, 1.0-4.0]) as risk factors for "current asthma" at age 50 years. There was no evidence of a difference in the rate of decline in FEV1 (mL/y, 95% CI) between the severe asthma group (15 mL/y [95% CI, 9-22 mL/y]) and all the other recruitment groups: control (16 mL/y [95% CI, 12-20 mL/y]), mild wheezy bronchitis (14 mL/y [95% CI, 8-19 mL/y]), wheezy bronchitis (16 mL/y [95% CI, 11-20 mL/y]), and persistent asthma (19 mL/y [95% CI, 13-24 mL/y]). Conclusion: The clinical and lung function outcome in adult life is strongly determined by asthma severity in childhood. The reduced lung function seen in adults is established in childhood and does not appear to decline more rapidly in adult years despite continuing symptoms.	[Tai, Andrew] Womens & Children Hosp, Dept Resp & Sleep Med, Adelaide, SA 5006, Australia; [Tran, Haily; Clarke, Nadeene; Gibson, Anne-Marie; Robertson, Colin F.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Roberts, Mary; Robertson, Colin F.] Royal Childrens Hosp Melbourne, Melbourne, Vic, Australia; [Vidmar, Suzanna] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Parkville, Vic, Australia; [Vidmar, Suzanna] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Wilson, John] Alfred Hosp, Dept Allergy Immunol & Resp Med, Prahran, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; Florey Institute of Neuroscience & Mental Health	Tai, A (corresponding author), Womens & Children Hosp, Dept Resp & Sleep Med, 72 King William Rd, Adelaide, SA 5006, Australia.	andrew.tai@health.sa.gov.au		Adams, Anne-Marie/0000-0003-0441-3796	National Medical Health Research Council, Australia	National Medical Health Research Council, Australia	This study was funded by the National Medical Health Research Council, Australia.	Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Burgess JA, 2011, THORAX, V66, P508, DOI 10.1136/thx.2010.146845; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Henderson J, 2004, Prim Care Respir J, V13, P138, DOI 10.1016/j.pcrj.2004.05.005; HIBBERT ME, 1989, PEDIATR PULM, V7, P101, DOI 10.1002/ppul.1950070209; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; Marossy AE, 2007, AM J RESP CRIT CARE, V175, P355, DOI 10.1164/rccm.200607-1023OC; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; OCONNOR GT, 1995, AM J RESP CRIT CARE, V152, P87, DOI 10.1164/ajrccm.152.1.7599868; Ordonez GA, 1998, ARCH DIS CHILD, V78, P143, DOI 10.1136/adc.78.2.143; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377, DOI 10.1164/ajrccm.151.5.7735588; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Tollefsen E, 2006, RESP MED, V100, P471, DOI 10.1016/j.rmed.2005.06.007; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; Woods SE, 2010, GENDER MED, V7, P109, DOI 10.1016/j.genm.2010.03.005	37	134	141	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1572	+		10.1016/j.jaci.2013.12.1033	http://dx.doi.org/10.1016/j.jaci.2013.12.1033			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24495434	Bronze			2022-12-18	WOS:000336672500008
J	Phillips, EJ; Chung, WH; Mockenhaupt, M; Roujeau, JC; Mallal, SA				Phillips, Elizabeth J.; Chung, Wen-Hung; Mockenhaupt, Maja; Roujeau, Jean-Claude; Mallal, Simon A.			Drug hypersensitivity: Pharmacogenetics and clinical syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	4th Drug Hypersensitivity Meeting (DHM4)	APR 22-25, 2010	Rome, ITALY	European Acad Allergy & Clinical Immunol (EAACI)		Drug hypersensitivity; drug reaction with eosinophilia and systemic symptoms; drug-induced hypersensitivity syndrome; Stevens-Johnson syndrome/toxic epidermal necrolysis; pharmacogenetics; severe cutaneous adverse reaction; abacavir; nevirapine; carbamazepine; allopurinol	STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; HLA-B REGION; HLA-B-ASTERISK-1502 ALLELE; GENETIC-VARIATIONS; JAPANESE PATIENTS; ASSOCIATION; CARBAMAZEPINE; ALLOPURINOL; MARKER	Severe cutaneous adverse reactions include syndromes such as drug reaction with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity syndrome (DIHS) and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). An important advance has been the discovery of associations between HLA alleles and many of these syndromes, including abacavir-associated hypersensitivity reaction, allopurinol-associated DRESS/DIHS and SJS/TEN, and SJS/TEN associated with aromatic amine anticonvulsants. These HLA associations have created the promise for prevention through screening and have additionally shed further light on the immunopathogenesis of severe cutaneous adverse reactions. The rollout of HLA-B*5701 into routine clinical practice as a genetic screening test to prevent abacavir hypersensitivity provides a translational roadmap for other drugs. Numerous hurdles exist in the widespread translation of several other drugs, such as carbamazepine, in which the positive predictive value of HLA-B*1502 is low and the negative predictive value of HLA-B*1502 for SJS/TEN might not be 100% in all ethnic groups. International collaborative consortia have been formed with the goal of developing phenotypic standardization and undertaking HLA and genome-wide analyses in diverse populations with these syndromes. (J Allergy Clin Immunol 2011;127:S60-6.)	[Phillips, Elizabeth J.; Mallal, Simon A.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia; [Phillips, Elizabeth J.; Mallal, Simon A.] Royal Perth Hosp, Dept Clin Immunol & lmmunogenet, Perth, WA, Australia; [Phillips, Elizabeth J.] Sir Charles Gairdner Hosp, Dept Clin Immunol Infect Dis & Clin Pharmacol Tox, Nedlands, WA 6009, Australia; [Phillips, Elizabeth J.] Univ Western Australia, Sch Pathol, Crawley, WA, Australia; [Phillips, Elizabeth J.] Univ Western Australia, Lab Med & Biomed Biomol & Chem Sci, Crawley, WA, Australia; [Chung, Wen-Hung] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Dermatol, Taipei, Taiwan; [Mockenhaupt, Maja] Univ Med Ctr, Dept Dermatol, Dokumentat Zentrum Schewerer Hautreaktionen dZh, Freiburg, Germany; [Roujeau, Jean-Claude] Univ Paris 12, Dept Dermatol, Creteil, France	Murdoch University; Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; Chang Gung Memorial Hospital; Chang Gung University; University of Freiburg; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Phillips, EJ (corresponding author), Murdoch Univ, Inst Immunol & Infect Dis, Discovery Way, Murdoch, WA 6150, Australia.	e.phillips@iiid.com.au	Mallal, Simon Alexander/HDM-9561-2022	Mallal, Simon Alexander/0000-0002-7036-1309; Hung, Shuen-Iu/0000-0001-6531-5538	NIAID NIH HHS [R01 AI060460, P30 AI110527, R01 AI060460-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Auquier-Dunant A, 2002, ARCH DERMATOL, V138, P1019, DOI 10.1001/archderm.138.8.1019; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; CHANG CC, 2008, P 7 AS OC EP C XIAM; Chantarangsu S, 2009, PHARMACOGENET GENOM, V19, P139, DOI 10.1097/FPC.0b013e32831d0faf; Chung WH, 2010, EXPERT OPIN DRUG SAF, V9, P15, DOI 10.1517/14740330903427969; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Dainichi T, 2007, DERMATOLOGY, V215, P86, DOI 10.1159/000102045; Gatanaga H, 2007, AIDS, V21, P264, DOI 10.1097/QAD.0b013e32801199d9; Gueant-Rodriguez RM, 2008, PHARMACOGENOMICS J, V8, P162, DOI 10.1038/sj.tpj.6500456; Gueant-Rodriguez RM, 2006, PHARMACOGENET GENOM, V16, P713, DOI 10.1097/01.fpc.0000230409.00276.44; Guglielmi L, 2006, ALLERGY, V61, P921, DOI 10.1111/j.1398-9995.2006.01067.x; Halevy S, 2008, J AM ACAD DERMATOL, V58, P25, DOI 10.1016/j.jaad.2007.08.036; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hughes AR, 2004, PHARMACOGENOMICS, V5, P203, DOI 10.1517/phgs.5.2.203.27481; Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]; Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Ikeda H, 2010, EPILEPSIA, V51, P297, DOI 10.1111/j.1528-1167.2009.02269.x; Jia Xiaoping, 2009, American Fisheries Society Annual Meeting; Kaniwa N, 2008, PHARMACOGENOMICS, V9, P1617, DOI 10.2217/14622416.9.11.1617; Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x; KARDAUN SH, 2010, EUR ANN ALLERGY CLIN, V42, P45; Kuehn BM, 2008, JAMA-J AM MED ASSOC, V300, P2845, DOI 10.1001/jama.2008.890; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; Littera R, 2006, AIDS, V20, P1621, DOI 10.1097/01.aids.0000238408.82947.09; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Lonjou C, 2006, PHARMACOGENOMICS J, V6, P265, DOI 10.1038/sj.tpj.6500356; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; Martin AM, 2005, AIDS, V19, P97, DOI 10.1097/00002030-200501030-00014; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Mockenhaupt Maja, 2007, P18, DOI 10.1159/000104186; *NCT, NCT00986063; Philips EJ, 2010, PHARMACOGENOMICS, V11, P973, DOI 10.2217/PGS.10.77; Phillips E, 2010, EUR ANN ALLERGY CLIN, V42, P48; Phillips EJ, 2005, AIDS, V19, P979, DOI 10.1097/01.aids.0000171414.99409.fb; Phillips EJ, 2002, AIDS, V16, P2223, DOI 10.1097/00002030-200211080-00017; Qiao HL, 2004, ALLERGY, V59, P1326, DOI 10.1111/j.1398-9995.2004.00625.x; Roujeau JC, 2005, TOXICOLOGY, V209, P123, DOI 10.1016/j.tox.2004.12.022; ROUJEAU JC, 1993, NEW ENGL J MED, V333, P1600; Saag M, 2008, CLIN INFECT DIS, V46, P1111, DOI 10.1086/529382; Shear NH, 2008, AIDS, V22, P999, DOI 10.1097/QAD.0b013e3282f7cb60; Sidoroff A, 2001, J CUTAN PATHOL, V28, P113, DOI 10.1034/j.1600-0560.2001.028003113.x; Tassaneeyakul W, 2009, PHARMACOGENET GENOM, V19, P704, DOI 10.1097/FPC.0b013e328330a3b8	47	134	142	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3		S			S60	S66		10.1016/j.jaci.2010.11.046	http://dx.doi.org/10.1016/j.jaci.2010.11.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	743NJ	21354501	Green Accepted			2022-12-18	WOS:000289024700002
J	Ronmark, E; Bjerg, A; Perzanowski, M; Platts-Mills, T; Lundback, B				Roenmark, Eva; Bjerg, Anders; Perzanowski, Matthew; Platts-Mills, Thomas; Lundbaeck, Bo			Major increase in allergic sensitization in schoolchildren from 1996 to 2006 in northern Sweden	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic sensitization; atopic disease; epidemiology; OLIN; school children; skin prick test	OBSTRUCTIVE LUNG-DISEASE; RISK-FACTORS; HAY-FEVER; PERTUSSIS VACCINATION; ATOPIC SENSITIZATION; LIFE-STYLE; ASTHMA; PREVALENCE; CHILDREN; CHILDHOOD	Background: Time trends for allergic sensitization are poorly known. Objective: To compare the trends in prevalence of allergic sensitization and associated risk factors in children. Methods: Two cohorts of children (age 7-8 years) were invited for skin prick tests (SPTs) 10 years apart, 1996 and 2006. The participation rates were 2148 (88%) and 1700 (90%), respectively. The methods were identical, and 10 common airborne allergens were used. An expanded International Study of Allergy and Asthma in Children questionnaire about symptoms and possible risk factors for allergic conditions was completed by the parents. Results: The prevalence of any positive SPT increased from 21 % in 1996 to 30 % in 2006 (P < .001). The pattern of sensitization remained similar, and sensitization to cat was most common both years, 13% and 19%, respectively. Sensitization to mites and mold was uncommon in both surveys. A family history of allergy was a significant risk factor for a positive SPT both years (odds ratio, 1.7). Factors that in 1996 had a protective effect, such as rural living and having several siblings, had lost this effect in 2006. The prevalence of most risk factors remained similar, but respiratory infections and smoking among parents decreased significantly. During the same period, there was no significant increase in the prevalence of current wheeze (11.9% to 12.4%, P = .636) or symptoms of rhinitis or eczema. Conclusion: The prevalence of allergic sensitization increased significantly from 1996 to 2006, whereas no increase in clinical symptoms was found. The parallel decrease in parental smoking and respiratory infections indicate a different influence of environmental factors on allergic sensitization and clinical symptoms, respectively. (J Allergy Clin Immunol 2009;124: 357-63.)	[Roenmark, Eva; Bjerg, Anders] Umea Univ, Dept Clin Med & Publ Hlth, SE-90185 Umea, Sweden; [Roenmark, Eva; Bjerg, Anders; Lundbaeck, Bo] Sunderby Cent Hosp Norrbotten, Dept Med, Lulea, Sweden; [Lundbaeck, Bo] Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med Resp Med & Allergol, Gothenburg, Sweden; [Perzanowski, Matthew] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA; [Lundbaeck, Bo] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Umea University; University of Gothenburg; Columbia University; University of Virginia	Ronmark, E (corresponding author), Umea Univ, Dept Clin Med & Publ Hlth, SE-90185 Umea, Sweden.	eva.ronmark@telia.com	Bjerg, Anders/GRR-3443-2022	Platts-Mills, Thomas/0000-0002-1263-329X	Swedish Heart-Lung Foundation; Swedish Foundation for Health Care Science and Allergy Research (Vardal); Swedish Asthma-Allergy Foundation, VisareNorr; US National Institute of Allergy and Infectious Disease [AI-20565, AI-34607]; GlaxoSmithKline World Wide Epidemiology; ALK; Phadia; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, U19AI034607, R01AI020565, U01AI034607, P01AI050989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014400] Funding Source: NIH RePORTER	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Foundation for Health Care Science and Allergy Research (Vardal); Swedish Asthma-Allergy Foundation, VisareNorr; US National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GlaxoSmithKline World Wide Epidemiology(GlaxoSmithKline); ALK; Phadia(Phadia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Swedish Heart-Lung Foundation, the Swedish Foundation for Health Care Science and Allergy Research (Vardal), the Swedish Asthma-Allergy Foundation, VisareNorr. Norrbotten's local health authorities. and the US National Institute of Allergy and Infectious Disease (AI-20565 and AI-34607). GlaxoSmithKline World Wide Epidemiology, ALK, and Phadia provided additional financial support.	Addo-Yobo EOD, 2007, PLOS MED, V4, P355, DOI 10.1371/journal.pmed.0040070; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Backlund AB, 2006, ALLERGY, V61, P549, DOI 10.1111/j.1398-9995.2006.01027.x; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Dreborg S, 2001, ALLERGY, V56, P359, DOI 10.1034/j.1398-9995.2001.056005359.x; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Krause TG, 2002, LANCET, V360, P691, DOI 10.1016/S0140-6736(02)09841-0; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; Maitra A, 2004, BRIT MED J, V328, P925, DOI 10.1136/bmj.38045.858889.EB; Majkowska-Wojciechowska BM, 2007, ALLERGY, V62, P1044, DOI 10.1111/j.1398-9995.2007.01457.x; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; Nilsson L, 2003, ARCH PEDIAT ADOL MED, V157, P1184, DOI 10.1001/archpedi.157.12.1184; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Riikjarv MA, 2000, EUR RESPIR J, V16, P86, DOI 10.1034/j.1399-3003.2000.16a15.x; Ronchetti R, 2001, ALLERGY, V56, P436, DOI 10.1034/j.1398-9995.2001.056005436.x; Ronmark E, 2003, J ALLERGY CLIN IMMUN, V112, P747, DOI 10.1016/S0091-6749(03)01866-9; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Ronmark E, 2003, PEDIAT ALLERG IMM-UK, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sub-committee on Skin tests of the European Academy of Allergy and Clinical Immunology, 1989, ALLERGY, V44, P1; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Thomsen SF, 2006, J ASTHMA, V43, P151, DOI 10.1080/02770900500499004; Toelle BG, 2004, BRIT MED J, V328, P386, DOI 10.1136/bmj.328.7436.386; von Hertzen L, 2007, ALLERGY, V62, P288, DOI 10.1111/j.1398-9995.2006.01281.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Zollner IK, 2005, THORAX, V60, P545, DOI 10.1136/thx.2004.029561	41	134	138	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					357	363		10.1016/j.jaci.2009.05.011	http://dx.doi.org/10.1016/j.jaci.2009.05.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19577282	Green Accepted			2022-12-18	WOS:000268860400025
J	Maestrelli, P; Boschetto, P; Fabbri, LM; Mapp, CE				Maestrelli, Piero; Boschetto, Piera; Fabbri, Leonardo M.; Mapp, Cristina E.			Mechanisms of occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Workplace exposure; asthma; airway hyperresponsiveness; antigen; chemical; genetics; mechanisms; inflammation	DIISOCYANATE-INDUCED ASTHMA; AIRWAYS DYSFUNCTION SYNDROME; ISOCYANATE-INDUCED ASTHMA; SERUM-ALBUMIN CONJUGATE; TUMOR-NECROSIS-FACTOR; GENE-ENVIRONMENT INTERACTIONS; LABORATORY-ANIMAL WORKERS; WESTERN RED CEDAR; HLA CLASS-II; TOLUENE DIISOCYANATE	Inhalation of agents in the workplace can induce asthma in a relatively small proportion of exposed workers. Like nonoccupational asthma, occupational asthma is probably the result of multiple genetic, environmental, and behavioral influences. It is important that occupational asthma be recognized clinically because it has serious medical and socioeconomic consequences. Environmental factors that can affect the initiation of occupational asthma include the intrinsic characteristics of causative agents as well as the influence of the level and route of exposure at the workplace. The identification of host factors, polymorphisms, and candidate genes associated with occupational asthma may improve our understanding of mechanisms involved in asthma. High-molecular-weight compounds from biological sources and low-molecular-weight chemicals cause occupational asthma after a latent period of exposure. Although the clinical, functional, and pathologic features of occupational asthma caused by low-molecular-weight agents resemble those of allergic asthma, the failure to detect specific IgE antibodies against most low-molecular-weight agents has resulted in a search for alternative or complementary physiopathologic mechanisms leading to airway sensitization. Recent advances have been made in the characterization of the immune response to low-molecular-weight agents. In contrast, the mechanism of the type of occupational asthma that occurs without latency after high-level exposure to irritants remains undetermined. (J Allergy Clin Immunol 2009;123:531-42.)	[Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Dept Oncol Hematol & Resp Dis, Policlin Modena, I-41100 Modena, Italy; [Maestrelli, Piero] Univ Padua, Dept Environm Med & Publ Hlth, I-35100 Padua, Italy; [Boschetto, Piera; Mapp, Cristina E.] Univ Ferrara, Dept Clin & Expt Med, Sect Hyg & Occupat Med, I-44100 Ferrara, Italy	Universita di Modena e Reggio Emilia; University of Padua; University of Ferrara	Fabbri, LM (corresponding author), Univ Modena & Reggio Emilia, Dept Oncol Hematol & Resp Dis, Policlin Modena, Largo Pozzo 71, I-41100 Modena, Italy.	leonardo.fabbri@unimore.it	Fabbri, Leonardo M/I-4055-2012; Boschetto, Piera/AAM-3247-2020	Fabbri, Leonardo M/0000-0001-8894-1689; Boschetto, Piera/0000-0003-3889-1681	Ministry of University and Scientific Research; University of Padova; University of Ferrara; Consorzio Ferrara Ricerche; Associazione per la Ricerca e Cara dell' Asma, Padova; Associazione per to Studio dei Tumori e delle Malattie Polmonari, Padova	Ministry of University and Scientific Research(Ministry of Education, Universities and Research (MIUR)); University of Padova; University of Ferrara; Consorzio Ferrara Ricerche; Associazione per la Ricerca e Cara dell' Asma, Padova; Associazione per to Studio dei Tumori e delle Malattie Polmonari, Padova	Supported by the Ministry of University and Scientific Research: University of Padova; University of Ferrara; Consorzio Ferrara Ricerche; the Associazione per la Ricerca e Cara dell' Asma, Padova; and the Associazione per to Studio dei Tumori e delle Malattie Polmonari, Padova.	Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Aul DJ, 1999, J ALLERGY CLIN IMMUN, V103, P749, DOI 10.1016/S0091-6749(99)70415-X; BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; Balmes JR, 2002, CLIN CHEST MED, V23, P727, DOI 10.1016/S0272-5231(02)00031-X; Ban M, 2006, TOXICOLOGY, V218, P39, DOI 10.1016/j.tox.2005.09.013; Bardana EJ, 2008, J ALLERGY CLIN IMMUN, V121, pS408, DOI 10.1016/j.jaci.2007.08.005; BAUR X, 1995, J ALLERGY CLIN IMMUN, V96, P489, DOI 10.1016/S0091-6749(95)70292-X; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; Beghe B, 2004, ALLERGY, V59, P61, DOI 10.1046/j.1398-9995.2003.00352.x; Bello D, 2008, ANN OCCUP HYG, V52, P117, DOI 10.1093/annhyg/mem066; BENAUCH GI, 2005, CRIT CARE MED, V33, pS102; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; Bernstein DI, 2006, ANN ALLERG ASTHMA IM, V97, P800, DOI 10.1016/S1081-1206(10)60972-6; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; Bernstein I. L., 2006, ASTHMA WORKPLACE, V3, P1; BERODE M, 1991, BIOCHEM INT, V24, P947; Berode M, 2005, INT ARCH OCC ENV HEA, V78, P158, DOI 10.1007/s00420-004-0568-4; BIAGINI RE, 1985, J ALLERGY CLIN IMMUN, V76, P794, DOI 10.1016/0091-6749(85)90750-X; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005; Casset A, 2006, ALLERGY, V61, P1344, DOI 10.1111/j.1398-9995.2006.01174.x; Ceyhan BB, 2004, J INVEST ALLERG CLIN, V14, P80; Chan-Yeung Moira, 2004, Can Respir J, V11, P21; Christiani DC, 2008, OCCUP ENVIRON MED, V65, P430, DOI 10.1136/oem.2007.033977; CLEARE MJ, 1976, CLIN ALLERGY, V6, P183, DOI 10.1111/j.1365-2222.1976.tb01897.x; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Cunningham AR, 2005, SAR QSAR ENVIRON RES, V16, P273, DOI 10.1080/10659360500036976; DEARMAN RJ, 1991, IMMUNOLOGY, V72, P563; Dearman RJ, 2000, J APPL TOXICOL, V20, P221, DOI 10.1002/(SICI)1099-1263(200005/06)20:3<221::AID-JAT651>3.0.CO;2-#; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Farrall M, 2004, HUM MOL GENET, V13, pR1, DOI 10.1093/hmg/ddh084; Feger U, 2007, BLOOD, V110, P568, DOI 10.1182/blood-2006-11-057125; Fent KW, 2008, J ENVIRON MONITOR, V10, P500, DOI 10.1039/b715605g; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; Frew A, 1998, J ALLERGY CLIN IMMUN, V101, P841, DOI 10.1016/S0091-6749(98)70313-6; Frew AJ, 2004, J ALLERGY CLIN IMMUN, V113, P1161, DOI 10.1016/j.jaci.2004.03.039; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; Hendrick DJ, 2002, DISORDERS AIRWAYS PA, P33; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Herrick CA, 2003, J ALLERGY CLIN IMMUN, V111, P1087, DOI 10.1067/mai.2003.1413; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Horne C, 2001, EUR RESPIR J, V15, P911; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499, DOI 10.1164/ajrccm.158.5.9803055; Jame AJ, 2007, CLIN EXP ALLERGY, V37, P880, DOI 10.1111/j.1365-2222.2007.02733.x; Jarvis J, 2005, OCCUP ENVIRON MED, V62, P243, DOI 10.1136/oem.2004.016402; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Jeal H, 2006, AM J RESP CRIT CARE, V174, P21, DOI 10.1164/rccm.200506-964OC; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; Jones MG, 2008, CURR OPIN ALLERGY CL, V8, P110, DOI 10.1097/ACI.0b013e3282f4b5f1; Jones MG, 2006, J ALLERGY CLIN IMMUN, V117, P663, DOI 10.1016/j.jaci.2005.09.053; Jones MG, 2004, CLIN EXP ALLERGY, V34, P812, DOI 10.1111/j.1365-2222.2004.1956.x; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611, DOI 10.1164/ajrccm.149.3.8118626; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; Kim SH, 2006, ALLERGY, V61, P891, DOI 10.1111/j.1398-9995.2006.01023.x; Kimber I, 2005, CURR OPIN ALLERGY CL, V5, P119, DOI 10.1097/01.all.0000162302.82233.93; Kimber I, 1997, CLIN REV ALLERG IMMU, V15, P145, DOI 10.1007/BF02826584; Kimber I, 2007, ATLA-ALTERN LAB ANIM, V35, P243, DOI 10.1177/026119290703500212; Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lee CT, 2005, TOXICOL APPL PHARM, V205, P53, DOI 10.1016/j.taap.2004.09.015; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; LeVan TD, 2005, AM J RESP CRIT CARE, V171, P773, DOI 10.1164/rccm.200404-530OC; Liu Q, 2003, ANN ALLERG ASTHMA IM, V90, P35, DOI 10.1016/S1081-1206(10)61647-X; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; MAESTRELLI P, 2006, ASTHMA WORKPLACE REL, V5, P109; Magnusson LL, 2006, OCCUP ENVIRON MED, V63, P640, DOI 10.1136/oem.2005.024422; Malo JL, 2004, CURR OPIN PULM MED, V10, P57, DOI 10.1097/00063198-200401000-00010; Malo JL, 2001, J ALLERGY CLIN IMMUN, V108, P317, DOI 10.1067/mai.2001.116432; Mamessier E, 2007, ALLERGY, V62, P162, DOI 10.1111/j.1398-9995.2006.01288.x; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Mapp CE, 2001, OCCUP ENVIRON MED, V58, P354, DOI 10.1136/oem.58.5.354; MAPP CE, 2009, CLIN EXP AL IN PRESS; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Matheson JM, 2002, AM J RESP CELL MOL, V27, P396, DOI 10.1165/rcmb.4614; Matsui EC, 2006, CLIN EXP ALLERGY, V36, P1097, DOI 10.1111/j.1365-2222.2006.02534.x; Matsui EC, 2005, CLIN EXP ALLERGY, V35, P1347, DOI 10.1111/j.1365-2222.2005.02331.x; Matsui EC, 2004, ANN ALLERG ASTHMA IM, V93, P171, DOI 10.1016/S1081-1206(10)61471-8; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; NIELSEN J, 1989, SCAND J WORK ENV HEA, V15, P154, DOI 10.5271/sjweh.1869; Nieuwenhuijsen MJ, 2003, OCCUP ENVIRON MED, V60, P104, DOI 10.1136/oem.60.2.104; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Pacheco K, 2008, J ALLERGY CLIN IMMUN, V122, P896, DOI 10.1016/j.jaci.2008.08.025; Park Hae Sim, 2002, Korean J Intern Med, V17, P249; Park Hae-Sim, 1996, Journal of Korean Medical Science, V11, P314; PARK HS, 1991, CLIN EXP ALLERGY, V21, P357, DOI 10.1111/j.1365-2222.1991.tb01668.x; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; Park HS, 2001, J KOREAN MED SCI, V16, P57, DOI 10.3346/jkms.2001.16.1.57; PEPYS J, 1979, CLIN ALLERGY, V9, P99, DOI 10.1111/j.1365-2222.1979.tb01528.x; Perfetti L, 2003, AM J IND MED, V44, P325, DOI 10.1002/ajim.10262; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516, DOI 10.1164/ajrccm.162.2.9909026; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prezant DJ, 2008, MT SINAI J MED, V75, P89, DOI 10.1002/msj.20028; Prezant DJ, 2008, LUNG, V186, pS94, DOI 10.1007/s00408-007-9051-9; Pronk A, 2006, OCCUP ENVIRON MED, V63, P624, DOI 10.1136/oem.2005.023226; Redlich CA, 2008, CURR OPIN ALLERGY CL, V8, P115, DOI 10.1097/ACI.0b013e3282f85a31; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.0.CO;2-4; Rizzo R, 2005, J ALLERGY CLIN IMMUN, V115, P508, DOI 10.1016/j.jaci.2004.11.031; Sastre J, 2003, EUR RESPIR J, V22, P364, DOI 10.1183/09031936.03.00045103; Seed MJ, 2008, CURR OPIN ALLERGY CL, V8, P103, DOI 10.1097/ACI.0b013e3282f4cadd; Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399-0039.2004.00327.x; Sigsgaard T, 2000, EUR RESPIR J, V16, P50, DOI 10.1034/j.1399-3003.2000.16a09.x; Son Minsik, 1998, Journal of Korean Medical Science, V13, P147; Tarlo SA, 2003, ANN ALLERG ASTHMA IM, V90, P19, DOI 10.1016/S1081-1206(10)61643-2; Tarlo SM, 2006, EUR RESPIR J, V27, P607, DOI 10.1183/09031936.06.00062105; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Taylor AJN, 2003, ANN ALLERG ASTHMA IM, V90, P24; Taylor AJN, 1999, AM J RESP CRIT CARE, V160, P435; Taylor AN, 2001, CURR OPIN ALLERGY CL, V1, P157, DOI 10.1097/01.all.0000011001.66699.9d; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; Tomita K, 2002, CLIN IMMUNOL, V102, P258, DOI 10.1006/clim.2001.5176; Valdar W, 2006, GENETICS, V174, P959, DOI 10.1534/genetics.106.060004; Vanoirbeek JAJ, 2004, TOXICOL SCI, V80, P310, DOI 10.1093/toxsci/kfh155; Vanoirbeek JAJ, 2008, J ALLERGY CLIN IMMUN, V121, P456, DOI 10.1016/j.jaci.2007.09.006; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9; Wikman H, 2002, PHARMACOGENETICS, V12, P227, DOI 10.1097/00008571-200204000-00007; Wisnewski AV, 2008, CLIN EXP ALLERGY, V38, P957, DOI 10.1111/j.1365-2222.2008.02982.x; Wisnewski AV, 2007, CURR OPIN ALLERGY CL, V7, P138, DOI 10.1097/ACI.0b013e3280895d22; Wisnewski AV, 2003, J ALLERGY CLIN IMMUN, V112, P538, DOI 10.1067/mai.2003.1713; Wisnewski AV, 2005, CLIN EXP ALLERGY, V35, P352, DOI 10.1111/j.1365-2222.2005.02185.x; Wisnewski AV, 2001, AM J RESP CELL MOL, V24, P332, DOI 10.1165/ajrcmb.24.3.4325; Wisnewski AV, 2000, AM J RESP CRIT CARE, V162, P2330, DOI 10.1164/ajrccm.162.6.2002086; Xue AL, 2005, CLIN IMMUNOL, V117, P302, DOI 10.1016/j.clim.2005.08.003; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39; Ye YM, 2006, CLIN EXP ALLERGY, V36, P1153, DOI 10.1111/j.1365-2222.2006.02547.x; Yokota K, 1998, CLIN EXP ALLERGY, V28, P694; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219, DOI 10.1164/ajrccm.151.1.7812558; Zhang XD, 1997, TOXICOLOGY, V118, P223, DOI 10.1016/S0300-483X(96)03605-0; Zock JP, 1996, CLIN EXP ALLERGY, V26, P542, DOI 10.1046/j.1365-2222.1996.d01-344.x	144	134	135	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					531	542		10.1016/j.jaci.2009.01.057	http://dx.doi.org/10.1016/j.jaci.2009.01.057			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281901				2022-12-18	WOS:000264731200008
J	Mainardi, T; Kapoor, S; Bielory, L				Mainardi, Timothy; Kapoor, Simi; Bielory, Leonard			Complementary and alternative medicine: Herbs, phytochemicals and vitamins and their immunologic effects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Complementary and alternative medicine; immunology; herbal medicines; vitamin; NIH-National Center for Complementary and Alternative Medicine; asthma; allergic rhinitis; atopic dermatitis	SEASONAL ALLERGIC RHINITIS; NF-KAPPA-B; COMMON VARIABLE IMMUNODEFICIENCY; PLACEBO-CONTROLLED TRIAL; ST-JOHNS-WORT; ATOPIC-DERMATITIS; DOUBLE-BLIND; SKIN-LESIONS; CHINESE MEDICINE; TYLOPHORA INDICA	Complementary and alternative medicines (CAMS) are used in more than 80% of the world's population and are becoming an increasing component of the US health care system, with more than 70% of the population using CAM at least once and annual spending reaching as much as $34 billion. Since the inception of the National Center for Complementary and Alternative Medicine, there has been an enormous increase in the number of basic science and therapy-based clinical trials exploring CAM. The subspecialty of allergy and immunology represents a particularly fertile area with a large number of CAM therapies that have been shown to affect the immune system. Recent work has uncovered potential biochemical mechanisms involved in the immunomodulatory pathway of many supplemental vitamins (A, D, and l:) that appear to affect the differentiation of CD4(+) cell T(H)1 and T(H)2 subsets. Other research has shown that herbs such as resveratrol, quercetin, and magnolol may affect transcription factors such as nuclear factor-kappa B and the signal transducer and activator of transcription/Janus kinase pathways with resultant changes in cytokines and inflammatory mediators. Clinically, there have been hundreds of trials looking at the effect of CAM on asthma, allergic rhinitis, and atopic dermatitis. This article reviews the history of CAM and its use among patients, paying special attention to new research focusing on herbals, phytochemicals, and vitamins and their potential interaction with the immune system. (J Allergy Clin Immunol 2009;123:283-94.)	[Bielory, Leonard] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med Pediat Ophthalmol & Visual Sci, Div Allergy Immunol & Rheumatol,Asthma & Allergy, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bielory, L (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med Pediat Ophthalmol & Visual Sci, Div Allergy Immunol & Rheumatol,Asthma & Allergy, 90 Bergen St,Suite 4700, Newark, NJ 07103 USA.	bielory@umdnj.edu						Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Arora P, 2002, PEDIATR ALLERGY IMMU, V13, P223, DOI 10.1034/j.1399-3038.2002.00010.x; Badar VA, 2005, J ETHNOPHARMACOL, V96, P445, DOI 10.1016/j.jep.2004.09.034; BADRIA FA, 2004, ALTERNATIVE COMPLEME, V10, P257; Barnes PatriciaM., 2002, COMPLEMENTARY ALTERN; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bernstein DI, 2002, ANN ALLERG ASTHMA IM, V88, P272, DOI 10.1016/S1081-1206(10)62008-X; BIELORY L, 1994, ANN ALLERGY, V73, P89; Bielory L, 1999, J ASTHMA, V36, P1, DOI 10.3109/02770909909065150; Bjelakovic G, 2007, JAMA-J AM MED ASSOC, V297, P842, DOI 10.1001/jama.297.8.842; Chen C, 2004, J NEUROL SCI, V217, P55, DOI 10.1016/j.jns.2003.08.012; Chen SC, 2006, BRIT J PHARMACOL, V148, P226, DOI 10.1038/sj.bjp.0706647; Cho SY, 2003, MOL CELL BIOCHEM, V243, P153, DOI 10.1023/A:1021624520740; Choi JJ, 2008, EXP BIOL MED, V233, P1026, DOI 10.3181/0801-RM-19; Choi MS, 2008, BIOL PHARM BULL, V31, P51, DOI 10.1248/bpb.31.51; Critchley JAJH, 2000, J CLIN PHARMACOL, V40, P462, DOI 10.1177/00912700022009224; Denny SI, 2003, CURR ALLERGY ASTHM R, V3, P130, DOI 10.1007/s11882-003-0025-6; Donsky Howard, 2007, Am J Ther, V14, P442, DOI 10.1097/MJT.0b013e31814002c1; DYKES MHM, 1975, JAMA-J AM MED ASSOC, V231, P1073, DOI 10.1001/jama.231.10.1073; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Fugh-Berman A, 2001, BRIT J CLIN PHARMACO, V52, P587, DOI 10.1046/j.0306-5251.2001.01469.x; Gabrielian E. S., 2004, Phytomedica, V5, P113; Gupta I, 1998, Eur J Med Res, V3, P511; GUPTA S, 1979, INDIAN J MED RES, V69, P981; Harik-Khan RI, 2004, AM J EPIDEMIOL, V159, P351, DOI 10.1093/aje/kwh053; Heimall J, 2004, CLIN REV ALLERG IMMU, V27, P93, DOI 10.1385/CRIAI:27:2:093; Hon KLE, 2007, BRIT J DERMATOL, V157, P357, DOI 10.1111/j.1365-2133.2007.07941.x; Hon KLE, 2006, ANN ACAD MED SINGAP, V35, P759; Hu GR, 2002, ANN ALLERG ASTHMA IM, V88, P478, DOI 10.1016/S1081-1206(10)62386-1; Ikeda Y, 2002, JPN J PHARMACOL, V90, P328, DOI 10.1254/jjp.90.328; Jackson CM, 2004, ANN ALLERG ASTHMA IM, V92, P250, DOI 10.1016/S1081-1206(10)61556-6; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Josling P, 2003, ADV THER, V20, P213, DOI 10.1007/BF02850092; Juergens UR, 2003, RESP MED, V97, P250, DOI 10.1053/rmed.2003.1432; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1038, DOI 10.1001/jama.231.10.1038; Kempna P, 2004, J BIOL CHEM, V279, P50700, DOI 10.1074/jbc.M410800200; Khayyal MT, 2003, FUND CLIN PHARMACOL, V17, P93, DOI 10.1046/j.1472-8206.2003.00117.x; Kim SH, 2007, FOOD CHEM TOXICOL, V45, P2138, DOI 10.1016/j.fct.2007.05.011; Kimata H, 2006, PEDIATR DERMATOL, V23, P386, DOI 10.1111/j.1525-1470.2006.00268.x; Klovekorn W, 2007, INT J CLIN PHARM TH, V45, P583; Kobayashi S, 2006, INT J MOL MED, V17, P511; LAU B H S, 1975, American Journal of Chinese Medicine, V3, P263, DOI 10.1142/S0192415X7500027X; Lee DKC, 2003, CLIN EXP ALLERGY, V33, P882, DOI 10.1046/j.1365-2222.2003.01705.x; Lee HS, 2006, BRIT J DERMATOL, V155, P33, DOI 10.1111/j.1365-2133.2006.07303.x; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Mao TK, 2005, J MED FOOD, V8, P27, DOI 10.1089/jmf.2005.8.27; Mathew K, 1974, ASPECTS ALLERGY APPL, V7, P166; Matsumoto T, 1998, EUR ARCH OTO-RHINO-L, V255, P359, DOI 10.1007/s004050050077; Mehendale SR, 2004, AM J CHINESE MED, V32, P1, DOI 10.1142/S0192415X04001680; Mellis CM, 2002, MED J AUSTRALIA, V177, pS78; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Mizuno Y, 2006, PEDIATR INT, V48, P261, DOI 10.1111/j.1442-200X.2006.02200.x; Moreira A, 2007, RESP MED, V101, P1123, DOI 10.1016/j.rmed.2006.11.015; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Myers SP, 2004, MED J AUSTRALIA, V181, P222, DOI 10.5694/j.1326-5377.2004.tb06244.x; Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002; Nja F, 2005, ACTA PAEDIATR, V94, P147, DOI 10.1080/08035250410023638; Ogden NS, 2005, CURR OPIN ALLERGY CL, V5, P179, DOI 10.1097/01.all.0000162312.64308.fc; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; RAM FS, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000993.PUB2; Resnick ES, 2008, CURR ALLERGY ASTHM R, V8, P118, DOI 10.1007/s11882-008-0021-y; Riccioni G, 2005, EXPERT OPIN INV DRUG, V14, P1145, DOI 10.1517/13543784.14.9.1145; Riccioni G, 2007, ANN CLIN LAB SCI, V37, P96; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; Ross AC, 2007, VITAM HORM, V75, P197, DOI 10.1016/S0083-6729(06)75008-7; Rouhi H., 2006, Pakistan Journal of Nutrition, V5, P373; Ruiz PA, 2007, J NUTR, V137, P1208, DOI 10.1093/jn/137.5.1208; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12; Saper RB, 2004, JAMA-J AM MED ASSOC, V292, P2868, DOI 10.1001/jama.292.23.2868; Saper RB, 2008, JAMA-J AM MED ASSOC, V300, P915, DOI 10.1001/jama.300.8.915; Saxena VS, 2004, INT J CLIN PHARM RES, V24, P79; SAXON A, 1993, IMMUNOLOGY, V80, P477; Schafer T, 2004, ANN ALLERG ASTHMA IM, V93, pS5, DOI 10.1016/S1081-1206(10)61481-0; Schaneberg BT, 2003, PHYTOCHEMISTRY, V62, P911, DOI 10.1016/S0031-9422(02)00716-1; Schapowal A, 2005, PHYTOTHER RES, V19, P530, DOI 10.1002/ptr.1705; Schempp CA, 2003, PHYTOMEDICINE, V10, P31, DOI 10.1078/1433-187X-00306; Schuster GU, 2008, J IMMUNOL, V180, P1834, DOI 10.4049/jimmunol.180.3.1834; Shin TY, 2005, TOXICOL APPL PHARM, V209, P255, DOI 10.1016/j.taap.2005.04.011; SHIVPURI DN, 1969, J ALLERGY, V43, P145, DOI 10.1016/S0021-8707(69)80005-5; SHIVPURI DN, 1972, ANN ALLERGY, V30, P407; Sidora-Arcoleo K, 2007, J ASTHMA, V44, P169, DOI 10.1080/02770900701209640; Srivastava K, 2004, J ALLERGY CLIN IMMUN, V113, P268, DOI 10.1016/j.jaci.2003.10.062; Stonemetz Diane, 2008, Holist Nurs Pract, V22, P171, DOI 10.1097/01.HNP.0000318026.45527.07; Studdert DM, 1998, JAMA-J AM MED ASSOC, V280, P1610, DOI 10.1001/jama.280.18.1610; Tan WF, 2003, EUR J PHARMACOL, V459, P255, DOI 10.1016/S0014-2999(02)02848-0; Theoharides TC, 2004, ANN ALLERG ASTHMA IM, V93, pS24, DOI 10.1016/S1081-1206(10)61484-6; Thien R, 2005, J ALLERGY CLIN IMMUN, V116, P683, DOI 10.1016/j.jaci.2005.05.013; Tse AKW, 2007, MOL IMMUNOL, V44, P2647, DOI 10.1016/j.molimm.2006.12.004; Ukawa Y, 2007, J NUTR SCI VITAMINOL, V53, P293, DOI 10.3177/jnsv.53.293; van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016/j.jsbmb.2005.06.002; Wagner JG, 2008, CLIN EXP ALLERGY, V38, P501, DOI 10.1111/j.1365-2222.2007.02855.x; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029; Wood B, 1997, NEW ZEAL MED J, V110, P420; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; World Health Organization, 2003, TRADITIONAL MED; Yang SH, 2008, J ETHNOPHARMACOL, V115, P104, DOI 10.1016/j.jep.2007.09.011; Yoshimura Mineka, 2007, Allergol Int, V56, P225, DOI 10.2332/allergolint.O-06-443; Youn HS, 2005, J IMMUNOL, V175, P3339, DOI 10.4049/jimmunol.175.5.3339; Zhang JG, 1997, CLIN EXP IMMUNOL, V107, P57, DOI 10.1046/j.1365-2249.1997.d01-893.x; Zhao Y, 2005, ANN ALLERG ASTHMA IM, V95, P79, DOI 10.1016/S1081-1206(10)61192-1; Zingg JM, 2007, VITAM HORM, V76, P393, DOI 10.1016/S0083-6729(07)76015-6; 2007, ALT MED REV, V12, P280	108	134	142	0	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					283	294		10.1016/j.jaci.2008.12.023	http://dx.doi.org/10.1016/j.jaci.2008.12.023			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203652				2022-12-18	WOS:000263495000001
J	Spergel, JM; Brown-Whitehorn, T; Beausoleil, JL; Shuker, M; Liacouras, CA				Spergel, Jonathan M.; Brown-Whitehorn, Terri; Beausoleil, Janet L.; Shuker, Michele; Liacouras, Chris A.			Predictive values for skin prick test and atopy patch test for eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ELIMINATION DIET; PREVALENCE		Childrens Hosp Philadelphia, Allergy Sect, Div Allergy & Immunol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Gastroenterol & Nutr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Spergel, JM (corresponding author), Childrens Hosp Philadelphia, Allergy Sect, Div Allergy & Immunol, Philadelphia, PA 19104 USA.	spergel@email.chop.edu		Spergel, Jonathan/0000-0002-4658-5353				Cherian S, 2006, ARCH DIS CHILD, V91, P1000, DOI 10.1136/adc.2006.100974; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; de Boissieu D, 2003, J PEDIATR-US, V142, P203, DOI 10.1067/mpd.2003.92; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.2324.x	9	134	138	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					509	511		10.1016/j.jaci.2006.11.016	http://dx.doi.org/10.1016/j.jaci.2006.11.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291865				2022-12-18	WOS:000244327900038
J	Nieuwenhuizen, N; Lopata, AL; Jeebhay, MLF; Herbert, DR; Robins, TG; Brombacher, F				Nieuwenhuizen, Natalie; Lopata, Andreas L.; Jeebhay, Mohamed F.; Herbert, De'Broski R.; Robins, Thomas G.; Brombacher, Frank			Exposure to the fish parasite Anisakis causes allergic airway hyperreactivity and dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anisakis; nematode; parasitc; gene-deficient mice; food allergy; dermatitis; asthma; occupational allergy; IL4; IL-13	LEISHMANIA-MAJOR INFECTION; FOOD ALLERGY; GASTROALLERGIC ANISAKIASIS; LARVAL ANTIGENS; SEAFOOD ALLERGY; UNITED-STATES; T-CELLS; SIMPLEX; ASTHMA; RESPONSES	Background: Several case reports show allergy and anaphylactic reactions to the fish parasite Anisakis in the domestic and occupational setting. Further research is needed on the prevalence and mechanisms of disease. Objective: To determine the prevalence of Anisakis sensitization and related symptoms among workers in 2 fish-processing factories, and to use gene-deficient mice to determine the working mechanisms of Anisakis allergy. Methods: A modified version of the European Community Respiratory Health Survey was used to interview 578 South African fish-processing workers. Sensitization to Anisakis, seafood, and common aeroallergens was determined by skin prick test. Lung function was measured by spirometry and methacholine challenge. Serum eicosapentaenoic acid levels were used as an index of seafood consumption. Sensitized wildtype, IL-4, or IL-4 receptor alpha-deficient mice were challenged orally with Anisakis extract. Allergic reactions, lung pathology, antibodies, cytokines, mast cell proteases, and histamine were evaluated. Results: The prevalence of sensitization to Anisakis was higher than the prevalence of sensitization to fish (8% vs 6%). Anisakis-specific IgE reactivity was associated with bronchial hyperreactivity and dermatitis, and significantly increased with fish consumption. In mice, Anisakis infective larvae (1,3) induced a striking T(H)2/type 2 response. Food-allergic-type reactions induced by oral challenge with Anisakis extract were absent in IL-4 receptor a knockout mice. Conclusion: Anisakis sensitization in fish-processing workers is associated with allergic symptoms and correlates with high levels of fish consumption. Anisakis proteins induce allergic reactions in sensitized mice by IL-4/IL-13-mediated mechanisms. Clinical implications: Anisakis allergy should be considered in fish-processing workers with allergic symptoms.	Univ Cape Town, Observ, Div Immunol, IIDMM,Fac Hlth Sci,Natl Hlth Lab Serv, ZA-7925 Cape Town, South Africa; Univ Cape Town, Occupat & Environm Hlth Res Unit, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa; Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	University of Cape Town; University of Cape Town; University of Michigan System; University of Michigan	Brombacher, F (corresponding author), Univ Cape Town, Observ, Div Immunol, IIDMM,Fac Hlth Sci,Natl Hlth Lab Serv, ZA-7925 Cape Town, South Africa.	fbrombac@mweb.co.za	Herbert, De'Broski/J-7357-2012; Lopata, Andreas/C-8160-2009; Nieuwenhuizen, Natalie/AAP-2400-2021; Lopata, Andreas L/C-3831-2012; Jeebhay, Mohamed/AAR-8346-2021; Lopata, Andreas L/O-2143-2017; Herbert, DeBroski/AAD-3035-2019	Herbert, De'Broski/0000-0002-2449-5365; Lopata, Andreas L/0000-0002-2940-9235; Jeebhay, Mohamed/0000-0001-6656-9193; Lopata, Andreas L/0000-0002-2940-9235; Herbert, DeBroski/0000-0002-2449-5365; Nieuwenhuizen, Natalie/0000-0001-5749-2462	PHS HHS [R01 F002304] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alonso-Gomez A, 2004, PARASITOL RES, V93, P378, DOI 10.1007/s00436-004-1085-9; Araujo MIAS, 2004, J INFECT DIS, V190, P1797, DOI 10.1086/425017; Armentia A, 1998, J ALLERGY CLIN IMMUN, V102, P831, DOI 10.1016/S0091-6749(98)70024-7; Audicana MT, 2002, TRENDS PARASITOL, V18, P20, DOI 10.1016/S1471-4922(01)02152-3; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; Brewer JM, 1999, J IMMUNOL, V163, P6448; Buhl R, 2005, CURR OPIN PULM MED, V11, P27; Caballero ML, 2004, PARASITOL RES, V93, P248, DOI 10.1007/s00436-004-1099-3; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Couture C, 2003, AM J SURG PATHOL, V27, P1167, DOI 10.1097/00000478-200308000-00017; Daschner A, 2002, PARASITE IMMUNOL, V24, P243, DOI 10.1046/j.1365-3024.2002.00458.x; Daschner A, 2001, ALLERGY, V56, P1003, DOI 10.1034/j.1398-9995.2001.00207.x; Davey G, 2005, CLIN EXP ALLERGY, V35, P301, DOI 10.1111/j.1365-2222.2005.02181.x; del Pozo V, 1999, J ALLERGY CLIN IMMUN, V104, P637, DOI 10.1016/S0091-6749(99)70336-2; Dominguez-Ortega J, 2001, INT ARCH ALLERGY IMM, V125, P86, DOI 10.1159/000053801; Falcao H, 2002, ALLERGY, V57, P44, DOI 10.1034/j.1398-9995.2002.13429.x; GarciaPalacios L, 1996, J HELMINTHOL, V70, P281, DOI 10.1017/S0022149X0001556X; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; IGLESIAS R, 1993, PARASITE IMMUNOL, V15, P243, DOI 10.1111/j.1365-3024.1993.tb00607.x; James JM, 2003, PEDIATRICS, V111, P1625; Jeebhay MF, 2004, OCCUP ENVIRON MED, V61, P471, DOI 10.1136/oem.2002.001099; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; Jung SK, 2000, J IMMUNOL, V165, P1491, DOI 10.4049/jimmunol.165.3.1491; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; Kimura S, 2001, Rinsho Byori, V49, P376; KLIKS MM, 1983, AM J TROP MED HYG, V32, P526, DOI 10.4269/ajtmh.1983.32.526; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Mohrs M, 2000, INFECT IMMUN, V68, P1773, DOI 10.1128/IAI.68.4.1773-1780.2000; Murase T, 1998, BLOOD, V92, P2182, DOI 10.1182/blood.V92.6.2182; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; OSHIMA T, 1987, PARASITOL TODAY, V3, P44, DOI 10.1016/0169-4758(87)90212-2; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Perteguer MJ, 2001, PARASITOL RES, V87, P396, DOI 10.1007/s004360000362; Pichler WJ, 1999, CLIN EXP ALLERGY, V29, P1161, DOI 10.1046/j.1365-2222.1999.00646.x; Ring Johannes, 2004, Novartis Found Symp, V257, P6; SAKANARI JA, 1990, PARASITOL TODAY, V6, P323, DOI 10.1016/0169-4758(90)90176-5; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Scala E, 2001, EUR J DERMATOL, V11, P249; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; VANTHIEL PH, 1966, TROP GEOGR MED, V18, P310; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yazdanbakhsh M, 2005, CURR OPIN ALLERGY CL, V5, P386, DOI 10.1097/01.all.0000182541.52971.eb; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	52	134	139	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1098	1105		10.1016/j.jaci.2005.12.1357	http://dx.doi.org/10.1016/j.jaci.2005.12.1357			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675338	Bronze			2022-12-18	WOS:000237436300018
J	Szczeklik, W; Sanak, M; Szczeklik, A				Szczeklik, W; Sanak, M; Szczeklik, A			Functional effects and gender association of COX-2 gene polymorphism G(-765)C in bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cyclooxygenase; bronchial asthma; aspirin; prostaglandins; genetic polymorphism; aspirin-induced asthma; gender	ARACHIDONIC-ACID; EPITHELIAL-CELLS; ASPIRIN; CYCLOOXYGENASE-2; EXPRESSION; SYNTHASE; PATHOGENESIS; CYCLO-OXYGENASE-2; INDUCTION; CYTOKINES	Background: Prostaglandins, generated via the COX pathways, are essential mediators of inflammation in bronchial asthma. The promoter polymorphism of COX-2 gene (G(-765)C), which might affect binding of transcription factors, has recently been described. Objective: To study distribution and function of the genetic COX-2 variant in patients with asthma compared with healthy controls. Methods: Three groups of adults were studied: (1) patients with aspirin-induced asthma (AIA; n = 112), (2) asthmatic patients who tolerated aspirin (ATA; n = 198), and (3) a random population sample from city of Krakow (n = 547). The COX-2 promoter region was genotyped for the G-765C polymorphism. Ex vivo production of prostaglandin E-2 and prostaglandin D-2 by peripheral blood monocytes was measured. Results: In the 2 asthmatic groups, the G-765C allele frequency was similar (AIA, 0.18; ATA, 0.19) and did not differ from that of controls (0.17). In asthmatic women, but not in men, CC homozygotes were overrepresented compared with controls (odds ratio, 3.08; 95% CI, 1.35-6.63; P = .01). There was no relationship between genotype and FEV1, serum IgE, blood eosinophil count, or duration of the disease. In AIA but not in ATA patients, CC homozygosity was associated with more severe course of the disease, as reflected by need for oral corticotherapy. Production of 2 Prostaglandins by monocytes was more than 10-fold higher in CC than in GG homozygotes, and the magnitude of this difference was not changed by LPS stimulation. Conclusion: In asthma, the COX-2(-765)C homozygosity is associated with female sex. The CC homozygosity has functional effects resulting in increased capacity of monocytes to produce Prostaglandins.	Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland	Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Ul Skawinska 8, PL-31066 Krakow, Poland.	mmszczek@cyf-kr.edu.pl	Szczeklik, Wojciech/N-8096-2014; Sanak, Marek/A-2115-2008; Sanak, Marek/AAV-1628-2021	Szczeklik, Wojciech/0000-0002-1349-1123; Sanak, Marek/0000-0001-7635-8103				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; BJOMSON CL, 2000, J GEND SPECIF MED, V3, P57; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; BOSCHETTO P, 2003, RESP DIS WOMEN EUROP, V8, P90; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Cipollone F, 2002, ARTERIOSCL THROM VAS, V22, P1516, DOI 10.1161/01.ATV.0000035402.68085.A0; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Demoly P, 1997, AM J RESP CRIT CARE, V155, P670, DOI 10.1164/ajrccm.155.2.9032211; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Fritsche E, 2001, J PHARMACOL EXP THER, V299, P468; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Kato M, 2001, J PHARM PHARMACOL, V53, P1679, DOI 10.1211/0022357011778070; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MIYAGI M, 1993, J PERIODONTOL, V64, P1075, DOI 10.1902/jop.1993.64.11.1075; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; Papafili A, 2002, ARTERIOSCL THROM VAS, V22, P1631, DOI 10.1161/01.ATV.0000030340.80207.C5; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Picado C, 1999, AM J RESP CRIT CARE, V160, P291, DOI 10.1164/ajrccm.160.1.9808048; Picado C, 2003, ALLERGY, V58, P122, DOI 10.1034/j.1398-9995.2003.23792.x; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Profita M, 2003, J ALLERGY CLIN IMMUN, V112, P709, DOI 10.1016/S0091-6749(03)01889-X; Schwab JM, 2003, PROSTAG LEUKOTR ESS, V69, P339, DOI 10.1016/j.plefa.2003.07.003; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2002, CLIN EXP ALLERGY, V32, P339, DOI 10.1046/j.1365-2222.2002.01333.x; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Taha R, 2000, AM J RESP CRIT CARE, V161, P636, DOI 10.1164/ajrccm.161.2.9811063; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Vane Jr, 1998, LUNG BIOL HEALTH DIS, V114, P1; Vigano T, 1997, AM J RESP CRIT CARE, V155, P864, DOI 10.1164/ajrccm.155.3.9117018; Vignola AM, 2003, ALLERGY, V58, P95, DOI 10.1034/j.1398-9995.2003.00103.x; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281	36	134	143	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					248	253		10.1016/j.jaci.2004.05.030	http://dx.doi.org/10.1016/j.jaci.2004.05.030			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316498	Green Published			2022-12-18	WOS:000223405600005
J	Orange, JS; Jain, A; Ballas, ZK; Schneider, LC; Geha, RS; Bonilla, FA				Orange, JS; Jain, A; Ballas, ZK; Schneider, LC; Geha, RS; Bonilla, FA			The presentation and natural history of immunodeficiency caused by nuclear factor kappa B essential modulator mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nuclear factor kappa B essential modulator; primary immunodeficiency; nuclear factor kappa B; innate immunity; ectodermal dysplasia; hypogammaglobulinemia; mycobacteria; natural killer cells; combined immunodeficiency	ANHIDROTIC ECTODERMAL DYSPLASIA; INCONTINENTIA PIGMENTI; IMMUNE-DEFICIENCY; CELL CYTOTOXICITY; MICE LACKING; ACTIVATION; PROTEIN; COLOCALIZES; LYMPHOCYTES; DISEASE	Background: An increasing number of rare genetic defects are associated with immunodeficiency and impaired ability to activate gene transcription through nuclear factor (NF) kappaB. Hypomorphic mutations in the NFkappaB essential modulator (NEMO) impair NFkappaB function and are linked to both immunodeficiency and ectodermal dysplasia (ED), as well as susceptibility to atypical mycobacterial infections. Objective: We sought to investigate the clinical and immunologic natural history of patients with NEMO mutation with immunodeficiency (NEMO-ID). Methods: Patients with severe bacterial infection and ED or unexplained mycobacterial sensitivity were evaluated for NEMO mutation. Laboratory investigations and clinical data were retrospectively and prospectively accumulated and reviewed. Results: We have given a diagnosis of NEMO-ID to 7 boys; 6 had ED, and 5 had gene mutations in the 10th exon of NEMO. Our resulting estimated incidence of NEMO-ID is 1:250,000 live male births. All patients had serious pyogenic bacterial illnesses early in life, and the median age of first infection was 8.1 months. Most boys had mycobacterial disease (median age, 84 months), and a minority had herpesviral infections. Initial immunologic assessments showed hypogammaglobulinemia (median IgG, 170 mg/dL) with variable IgM (median, 41 mg/dL) and IgA (median, 143 mg/dL) levels. Two patients had increased IgM levels, and 5 had increased IgA levels. All patients evaluated had normal lymphocyte subsets with impaired proliferative responses, specific antibody production, and natural killer cell function. Two patients died from complications of mycobacterial disease (ages 21 and 33 months). Conclusion: NEMO-ID is a combined immunodeficiency with early susceptibility to pyogenic bacteria and later susceptibility to mycobacterial infection. Specific features of particular NEMO mutations in these patients provide insight into the role of this gene in immune function.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; NIH, Bethesda, MD 20892 USA; Univ Iowa, Iowa City, IA USA	Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA; University of Iowa	Bonilla, FA (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.		Orange, Jordan S/D-5239-2009	orange, jordan/0000-0001-7117-7725; Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415	NCRR NIH HHS [M01 RR 02172] Funding Source: Medline; NIAID NIH HHS [AI 55602, AI 31541, AI 31136] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000924, K08AI055602, R01AI031136, U19AI031541, U01AI031541] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abinun M, 1996, EUR J PEDIATR, V155, P146, DOI 10.1007/s004310050395; Aradhya S, 2001, HUM MOL GENET, V10, P2171, DOI 10.1093/hmg/10.19.2171; Bardaro T, 2003, HUM MUTAT, V21, P8, DOI 10.1002/humu.10150; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; CHATILA T, 1989, NEW ENGL J MED, V320, P696, DOI 10.1056/NEJM198903163201104; CLARKE A, 1987, ARCH DIS CHILD, V62, P989, DOI 10.1136/adc.62.10.989; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; DAVIS JR, 1976, ACTA DERM-VENEREOL, V56, P115; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dupuis-Girod S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e97; Ezer S, 1999, HUM MOL GENET, V8, P2079, DOI 10.1093/hmg/8.11.2079; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gulino AV, 2003, CURR OPIN RHEUMATOL, V15, P422, DOI 10.1097/00002281-200307000-00009; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; HUNTLEY CC, 1981, CUTIS, V28, P417; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Mansour S, 2001, AM J MED GENET, V99, P172, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1155>3.0.CO;2-Y; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Orange JS, 2002, MICROBES INFECT, V4, P1545, DOI 10.1016/S1286-4579(02)00038-2; Orange JS, 2003, J CLIN INVEST, V112, P983, DOI 10.1172/JCI200319960; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; Schweizer P, 1999, KLIN PADIATR, V211, P459, DOI 10.1055/s-2008-1043834; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Smahi A, 2000, NATURE, V405, P466; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	36	134	141	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					725	733		10.1016/j.jaci.2004.01.762	http://dx.doi.org/10.1016/j.jaci.2004.01.762			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100680				2022-12-18	WOS:000220956600022
J	Langley, SJ; Goldthorpe, S; Craven, M; Morris, J; Woodcock, A; Custovic, A				Langley, SJ; Goldthorpe, S; Craven, M; Morris, J; Woodcock, A; Custovic, A			Exposure and sensitization to indoor allergens: Association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma severity and control; allergen exposure-sensitization; bronchial reactivity; lung function	DUST-MITE ANTIBODIES; RISK-FACTORS; ADULTS; CHILDREN; DECLINE; HYPERRESPONSIVENESS; AVOIDANCE; HISTAMINE	Background: Exposure to high levels of allergens in sensitized asthmatic patients causes worsening of pulmonary function in experimental studies. Chronic exposure to lower, naturally occurring levels of allergens might increase the severity of asthma. Objective: We sought to study the associations between sensitization and exposure to common indoor allergens (dust mite, cat; and dog) in the home on pulmonary function, exhaled nitric oxide (eNO), and airway reactivity in asthmatic patients. Methods: Dust samples were collected from the living room carpet and mattress of 311 subject's homes, and Der p 1, Fel d 1, and Can f 1 concentrations were measured by using ELISAs. Spirometry, nonspecific bronchial reactivity, and eNO were measured. Results: Subjects both sensitized and exposed to high levels of sensitizing allergen had significantly lower FEV1 percent predicted values (mean, 83.7% vs 89.3%; mean difference, 5.6%; 95% CI, 0.6% -10.6%; P = .03), higher eNO values (geometric mean [GM], 12.8 vs 8.7 ppb; GM ratio, 0.7; 95% CI, 0.5-0.8; P = .001), and more severe airways reactivity (PD20 GM, 0.25 vs 0.73 mg; GM ratio, 2.9; 95% CI, 1.6-5.0; P < .001) compared with subjects not sensitized and exposed. No significant effect of the interaction between sensitization and exposure was found for FEV1 percent predicted and eNO values. However, there was a significant effect of the interaction between sensitization and exposure to any allergen (P = .05) and between sensitization and exposure to cat allergen (P = .04) for nonspecific bronchial reactivity. Conclusion: Asthmatic subjects who are exposed in their homes to allergens to which they are sensitized have a more severe form of the disease.	Wythenshawe Hosp, NW Lung Ctr, Med Evaluat Unit, Manchester M23 9LT, Lancs, England; Wythenshawe Hosp, Dept Stat, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Langley, SJ (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Med Evaluat Unit, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Custovic A, 2001, CURR OPIN ALLERGY CL, V1, P133; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032, DOI 10.1164/ajrccm.158.4.9707143; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561, DOI 10.1164/ajrccm.153.2.8564098; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Henriksen AH, 2000, EUR RESPIR J, V15, P849, DOI 10.1034/j.1399-3003.2000.15e07.x; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Omenaas E, 1996, EUR RESPIR J, V9, P919, DOI 10.1183/09031936.96.09050919; OMENAAS E, 1995, AM J RESP CRIT CARE, V152, P1158, DOI 10.1164/ajrccm.152.4.7551364; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627, DOI 10.1164/ajrccm.161.2.9902094; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323, DOI 10.1016/S0091-6749(99)70031-X; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; SALOME CM, 1980, CLIN ALLERGY, V10, P541, DOI 10.1111/j.1365-2222.1980.tb02135.x; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45, DOI 10.1164/ajrccm.160.1.9809091; Sunyer J, 2000, INT J EPIDEMIOL, V29, P125, DOI 10.1093/ije/29.1.125; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; VILLAR MTA, 1995, AM J RESP CRIT CARE, V151, P656, DOI 10.1164/ajrccm/151.3_Pt_1.656; WOODFOLK JA, 1992, ANN ALLERGY, V69, P273; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	36	134	134	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					362	368		10.1067/mai.2003.1654	http://dx.doi.org/10.1067/mai.2003.1654			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897743	Bronze			2022-12-18	WOS:000184650600021
J	Pumphrey, RSH				Pumphrey, RSH			Fatal posture in anaphylactic shock	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HISTAMINE; CORONARY		St Marys Hosp, Manchester M13 0JH, Lancs, England	University of Manchester	Pumphrey, RSH (corresponding author), St Marys Hosp, Hathersage Rd, Manchester M13 0JH, Lancs, England.							Bautista E, 2002, INT ARCH ALLERGY IMM, V128, P151, DOI 10.1159/000059406; Boulain T, 2002, CHEST, V121, P1245, DOI 10.1378/chest.121.4.1245; Ceyhan C, 2001, INT J CARDIOL, V80, P251, DOI 10.1016/S0167-5273(01)00477-6; LEVINE HD, 1976, AM HEART J, V91, P365, DOI 10.1016/S0002-8703(76)80222-0; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Schiano P., 2002, Annales de Cardiologie et d'Angeiologie, V51, P382, DOI 10.1016/S0003-3928(02)00122-1; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; Tsuda A, 2001, ANESTH ANALG, V93, P1453, DOI 10.1097/00000539-200112000-00020; Vigorito C, 1997, INT J CLIN LAB RES, V27, P178, DOI 10.1007/BF02912454; VIGORITO C, 1987, J AM COLL CARDIOL, V10, P1207, DOI 10.1016/S0735-1097(87)80120-1	10	134	137	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					451	452		10.1067/mai.2003.1614	http://dx.doi.org/10.1067/mai.2003.1614			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897756				2022-12-18	WOS:000184650600034
J	Kabesch, M; Peters, W; Carr, D; Leupold, W; Weiland, SK; von Mutius, E				Kabesch, M; Peters, W; Carr, D; Leupold, W; Weiland, SK; von Mutius, E			Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopic dermatitis; allergic rhinitis; atopy; childhood; IgE; CARD15; NOD2; polymorphism; SNP	CROHNS-DISEASE; KAPPA-B; NOD2; SUSCEPTIBILITY; MONOCYTES; MUTATION; GENE	Background: Early exposure to microbial matter such as LPS may influence the development of asthma and allergies by activation of innate immunity pathways as indicated by studies in farming environments. Recently, polymorphisms in caspase recruitment domain containing protein 15 (CARD15), an intracellular LPS receptor protein, have been associated with Crohn's disease. Because these polymorphisms lead to changes in LPS recognition, they may affect the development of asthma and allergies. Objective: We genotyped a large population of German schoolchildren (N = 1872) from East and West Germany for 3 functional relevant CARD15 polymorphisms for their role in the development of asthma and allergy. Methods: By use of parental questionnaires, skin prick testing, pulmonary function tests, bronchial challenge tests, and measurements of serum IgE levels, children were phenotyped for the presence of atopic diseases. Genotyping was performed with PCR-based restriction enzyme assays. To assess associations between atopic phenotypes and genotypes standard statistical procedures were applied. Results: Children with the polymorphic allele C2722 had a more than 3-fold risk to develop allergic rhinitis (P < .001) and an almost 2-fold risk for atopic dermatitis (P < .05). Furthermore, the T2104 allele was associated with an almost 2-fold risk for allergic rhinitis (P < .05). When a C insertion at position 3020 was present, the risk of atopy increased by 50% (P < .05) and serum IgE levels were elevated (P < .01). Conclusion: The shared genetic background between Crohn's disease and atopy may indicate that an impaired recognition of microbial exposures results in an insufficient downregulation of excessive immune responses, giving rise to either T(H)2 dominated allergies or T(H)1 related Crohn's disease.	Univ Munich, Childrens Univ Hosp, D-80337 Munich, Germany; Univ Childrens Hosp, Dresden, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Kabesch, M (corresponding author), Univ Munich, Childrens Univ Hosp, Lindwurmstr 4, D-80337 Munich, Germany.		Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020	von Mutius, Erika/0000-0002-8893-4515				Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BERBIG B, 1991, ALLERGOLOGIE, V14, P51; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Ten RM, 1999, J ALLERGY CLIN IMMUN, V104, P376, DOI 10.1016/S0091-6749(99)70382-9; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x	16	134	135	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					813	817		10.1067/mai.2003.1336	http://dx.doi.org/10.1067/mai.2003.1336			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704363	Bronze			2022-12-18	WOS:000182258500023
J	Hemmer, W; Focke, M; Kolarich, D; Wilson, IBH; Altmann, F; Wohrl, S; Gotz, M; Jarisch, R				Hemmer, W; Focke, M; Kolarich, D; Wilson, IBH; Altmann, F; Wohrl, S; Gotz, M; Jarisch, R			Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alpha 1-3-fucose; carbohydrate epitopes; cross-reactive carbohydrate determinant; cross-reactive carbohydrate determinants; honeybee venom allergy; Hymenoptera venom allergy; N-linked glycans; oilseed rape; venom double positivity; yellow jacket venom allergy	IGE ANTIBODIES; CROSS-REACTIVITY; BEE-VENOM; LINKED CARBOHYDRATE; VEGETABLE FOODS; MAJOR ALLERGEN; WASP-VENOM; N-GLYCANS; POLLEN; PHOSPHOLIPASE-A2	Background: Up to 50% of patients with stinging-insect allergy have double-positive RAST results to honeybee and yellow jacket (YJ) venom. True double sensitization and crossreactivity through venom hyaluronidases are considered main reasons for this multiple reactivity. Objective: We investigated the role of antibodies against crossreactive carbohydrate determinants in venom double positivity. Methods: CAP inhibition experiments were performed with crude oilseed rape (OSR) and timothy grass pollen extracts and a neoglycoprotein construct displaying a MUXF glycan, as present in pineapple-stem bromelain (MUXF-BSA). CAP to OSR was used as a rough measure for carbohydrate-specific IgE in individual sera. Results: CAP results to OSR pollen were positive in 2 of 14 single-positive honeybee venom sera, 2 of 16 single-positive,YJ venom sera, and 33 (80.5%) of 41 double-positive sera (P<.00001, <chi>(2) test). CAP inhibition was performed in 16 selected patients with a CAP class of 3 or higher to both venoms. In 9 of 11 patients with a highly positive CAP result to OSR (CAP score to OSR > CAP score to second venom), pollen extracts, MUXF-BSA, or both were able to completely inhibit IgE binding to one of the venoms, whereas this was not them case in 5 patients with a negative or weakly positive CAP result to OSR (CAP score to OSR < CAP score to second venom). Conclusions: The data suggest that carbohydrate-specific IgE is a major cause for the double positivity to honeybee and YJ venom seen in patients with Hymenoptera allergy. Because these antibodies may have low clinical relevance, they may severely impede the correct diagnosis of Hymenoptera venom allergy.	FAZ Floridsdorf Allergy Ctr, A-1210 Vienna, Austria; Agr Univ Vienna, Inst Chem, A-1180 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna	Hemmer, W (corresponding author), FAZ Floridsdorf Allergy Ctr, Franz Jonas Pl 8-6, A-1210 Vienna, Austria.		Kolarich, Daniel/AAJ-3550-2020; Wilson, Iain/B-3326-2009; Wöhrl, Stefan/B-6954-2013; Kolarich, Daniel/B-6893-2012	Kolarich, Daniel/0000-0002-8452-1350; Wilson, Iain/0000-0001-8996-1518; Wöhrl, Stefan/0000-0002-6324-0007; Kolarich, Daniel/0000-0002-8452-1350; Altmann, Friedrich/0000-0002-0112-7877				AALBERSE RC, 1981, INT ARCH ALLER A IMM, V66, P259, DOI 10.1159/000232913; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; BROICHMANN PW, 1992, ALLERGOLOGIE, V15, P295; BULOW P, 1992, ALLERGOLOGIE, V15, P306; CHARPIN D, 1994, CLIN EXP ALLERGY, V24, P1010, DOI 10.1111/j.1365-2222.1994.tb02736.x; Egner W, 1998, CLIN EXP ALLERGY, V28, P26, DOI 10.1046/j.1365-2222.1998.00176.x; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; FISCHER H, 1994, ALLERGY CLIN IMMU S2, V6, P498; Focke M, 1998, INT ARCH ALLERGY IMM, V117, P105, DOI 10.1159/000023996; Fotisch K, 1998, ALLERGY, V53, P1043, DOI 10.1111/j.1398-9995.1998.tb03813.x; Hemmer W, 2000, ALLERGY, V55, P923, DOI 10.1034/j.1398-9995.2000.00671.x; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1994, J ALLERGY CLIN IMMUN, V93, P223; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; KUBELKA V, 1995, GLYCOCONJUGATE J, V12, P77, DOI 10.1007/BF00731872; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; MARZ L, 1983, TOXICON, V21, P893, DOI 10.1016/0041-0101(83)90080-6; MULLER U, 1977, CLIN ALLERGY, V7, P147, DOI 10.1111/j.1365-2222.1977.tb01435.x; REISMAN RE, 1987, INT ARCH ALLER A IMM, V82, P190, DOI 10.1159/000234185; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; Schafer T, 1996, ALLERGY, V51, P372; Schlenvoigt G, 1996, ALLERGOLOGIE, V19, P461; Straumann F, 2000, INT ARCH ALLERGY IMM, V123, P268, DOI 10.1159/000024453; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; WYPYCH JI, 1989, INT ARCH ALLER A IMM, V89, P60, DOI 10.1159/000234924	35	134	134	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1045	1052		10.1067/mai.2001.120013	http://dx.doi.org/10.1067/mai.2001.120013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742287				2022-12-18	WOS:000172938400025
J	Romano, A; Mayorga, C; Torres, MJ; Artesani, MC; Suau, R; Sanchez, F; Perez, E; Venuti, A; Blanca, M				Romano, A; Mayorga, C; Torres, MJ; Artesani, MC; Suau, R; Sanchez, F; Perez, E; Venuti, A; Blanca, M			Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; penicillins; cephalosporins; IgE response; and cross-reactivity	IGE ANTIBODIES; BETA-LACTAMS; PENICILLIN ALLERGY; GOOD TOLERANCE; HYPERSENSITIVITY; SPECIFICITIES; RECOGNITION; CEFUROXIME	Background: After penicillins, cephalosporins are the most important beta -lactams inducing IgE-mediated reactions, Responses may be selective or cross reactive with common beta -lactam determinants. Unlike determinants derived from benzylpenicillin, cephalosporin allergenic determinants have not been properly identified, even though a wide variety of these beta -lactams is currently used Objective: We sought to evaluate the IgE response in subjects with immediate allergic reactions to injectable cephalosporins and to assess their reactivity to different penicillins and cephalosporins. Methods: We studied 30 subjects with immediate reactions to one or more of the following cephalosporins: ceftriaxone, cefotaxime, ceftazidime, and cefuroxime. Skin tests and in vitro-specific IgE antibody assays were performed for major and minor determinants of penicillin G, amoxicillin, and ampicillin, as well as for the culprit cephalosporins. Responses to cephalosporins other than the culprit ones were also studied by using skin testing. Results: Twenty-six patients (group A, 86.7%) displayed skin test and RAST negativity to penicillin determinants and skin test positivity to cephalosporins, viith RAST confirmation in 9 patients, Four subjects (group B, 13.3 %) had a positive response to penicillin determinants, In group A two patterns of reactivity were observed: one characterized by a response only to the culprit cephalosporin (n = 15, 57.7%) and the other by positive responses to different cephalosporins, including the responsible cephalosporins (n = 11, 42.3%). Conclusion: Most patients with a history of immediate reactions to cephalosporins are sensitized to determinants generated only by cephalosporins (group A), although a small percentage react to penicillin determinants (group B), Some patients from group A responded only to the culprit cephalosporin, but others reacted to different cephalosporins. These findings can be explained in terms of either selective response to unique determinants or cross-reactivity.	CI Columbus, UCSC Allergy Unit, Dept Internal Med & Geriatr, Rome, Italy; IRCCS Oasi Maria SS, Troina, Italy; Carlos Haya Hosp, Res Unit Allerg Dis, Malaga, Spain; Univ Malaga, Fac Sci, Dept Organ Chem, E-29071 Malaga, Spain	IRCCS Oasi Maria SS; Hospital Carlos Haya; Universidad de Malaga	Romano, A (corresponding author), Complesso Integrato Columbus, Unita Allergol, Via G Moscati 31, I-00168 Rome, Italy.		Torres, Maria/GVU-3391-2022; Mayorga, Cristobalina/D-7167-2018; Romano, Antonino/D-3102-2017; Perez-Inestrosa, Ezequiel/H-9801-2015; Torres, María José/T-3518-2017; Mayorga, Lina/FBO-7730-2022	Mayorga, Cristobalina/0000-0001-8852-8077; Romano, Antonino/0000-0001-9742-9898; Perez-Inestrosa, Ezequiel/0000-0001-7546-5273; Torres, María José/0000-0001-5228-471X; 				ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; ASSEM ESK, 1974, IMMUNOLOGY, V27, P255; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; Baldo BA, 1999, CLIN EXP ALLERGY, V29, P744; BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; BATCHELOR FR, 1966, IMMUNOLOGY, V10, P21; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; BLANCA M, 1995, ALLERGY, V50, P777; BLANCA M, 1992, J IMMUNOL METHODS, V153, P99, DOI 10.1016/0022-1759(92)90311-G; BRAVO CM, 1995, ALLERGY, V50, P359, DOI 10.1111/j.1398-9995.1995.tb01160.x; Demoly P, 2000, ALLERGY, V55, P418, DOI 10.1034/j.1398-9995.2000.00605.x; DEWDNEY JM, 1977, ANTIGENS, V5, P73; HAMILTONMILLER JM, 1970, BIOCHEM J, V116, P371, DOI 10.1042/bj1160371; HARLE DG, 1990, INT ARCH ALLER A IMM, V92, P439, DOI 10.1159/000235177; IGEA JM, 1992, ANN ALLERGY, V68, P515; KRAFT D, 1977, CLIN ALLERGY, V7, P21, DOI 10.1111/j.1365-2222.1977.tb01420.x; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; Miranda A, 1996, J ALLERGY CLIN IMMUN, V98, P671, DOI 10.1016/S0091-6749(96)70101-X; MORENO F, 1995, INT ARCH ALLERGY IMM, V108, P74, DOI 10.1159/000237121; NAGAKURA N, 1990, INT ARCH ALLER A IMM, V93, P126, DOI 10.1159/000235291; ONG R, 1988, J ALLERGY CLIN IMMUN, V81, P222, DOI 10.1016/0091-6749(88)90452-6; Pham NH, 1996, J MOL RECOGNIT, V9, P287, DOI 10.1002/(SICI)1099-1352(199607)9:4<287::AID-JMR340>3.3.CO;2-C; Romano A, 1998, J ALLERGY CLIN IMMUN, V101, P564, DOI 10.1016/S0091-6749(98)70368-9; Romano A, 1999, J ALLERGY CLIN IMMUN, V104, P1113, DOI 10.1016/S0091-6749(99)70100-4; Romano A, 2000, ALLERGY, V55, P415, DOI 10.1034/j.1398-9995.2000.00589.x; ROMANO A, 1997, INT J IMMUNOPATHO S2, V10, P187; Sastre J, 1996, ALLERGY, V51, P383, DOI 10.1111/j.1398-9995.1996.tb04634.x; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x	29	134	137	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1177	1183						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112903				2022-12-18	WOS:000165930300022
J	Bochner, BS				Bochner, BS			Road signs guiding leukocytes along the inflammation superhighway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						eosinophils; lymphocytes; homing; recruitment; adhesion molecules; chemokines; skin; gastrointestinal tract; lung; lymph nodes	CELL-ADHESION MOLECULE-1; LYMPHOID-TISSUE CHEMOKINE; MONOCYTE CHEMOATTRACTANT PROTEIN-3; SKIN-ASSOCIATED CHEMOKINE; HIGH ENDOTHELIAL VENULES; MEMORY T-LYMPHOCYTES; HUMAN CC-CHEMOKINE; P-SELECTIN; HUMAN EOSINOPHILS; DIFFERENTIAL REGULATION	The term inflammation is used to describe the localized tissue changes, including leukocyte extravasation, that occur as part of the response to tissue damage, infection, or other immuno-logic responses, This carefully orchestrated series of events requires the existence of highly specific, regulated mechanisms For control of leukocyte recruitment and is dependent on both the inciting event and organ involved. This review summarizes recent developments in our understanding of how adhesion molecules and chemokines interact to facilitate tissue-specific and leukocyte subtype-specific influx during inflammation, Novel mechanisms believed to be responsible for capture and compartmentalization of B and T lymphocytes within lymph nodes are discussed, along with a description of adhesion molecule- and chemokine-mediated pathways that are believed to be involved in selective recruitment of lymphocytes and eosinophils to a variety of tissues, including the skin, gut, and lung. This growing knowledge and its potential importance provide enthusiasm for future anti-inflammatory therapies that target these recruitment pathways.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Dept Med,Div Clin Immunol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Bochner, BS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Dept Med,Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI45115, AI41472] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham WM, 1999, AM J RESP CRIT CARE, V159, P1205, DOI 10.1164/ajrccm.159.4.9806002; Agace WW, 2000, EUR J IMMUNOL, V30, P819, DOI 10.1002/1521-4141(200003)30:3<819::AID-IMMU819>3.0.CO;2-Y; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Arima M, 1999, AM J RESP CELL MOL, V21, P684, DOI 10.1165/ajrcmb.21.6.3671; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; Barnes PJ, 2000, J ALLERGY CLIN IMMUN, V106, P5, DOI 10.1067/mai.2000.107930; Beck LA, 1997, J IMMUNOL, V159, P2962; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BERMAN JS, 1990, AM J RESP CELL MOL, V3, P101, DOI 10.1165/ajrcmb/3.2.101; BOCHNER BS, 1994, J IMMUNOL, V152, P774; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, P527, DOI 10.1016/S0091-6749(99)70481-1; BOCHNER BS, 1999, ALLERGIC SKIN DIS MU, P87; BOCHNER BS, 1998, CELL ADHESION MOL MA, P113; BOCHNER BS, 1998, ALLERGY PRINCIPLES P, P94; BRISKIN M, 1997, ADHESION MOL ALLERGI, P105; Broide DH, 1998, BLOOD, V91, P2847, DOI 10.1182/blood.V91.8.2847.2847_2847_2856; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chung HL, 1999, J ALLERGY CLIN IMMUN, V103, P1195, DOI 10.1016/S0091-6749(99)70199-5; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; Cruikshank WW, 2000, J LEUKOCYTE BIOL, V67, P757, DOI 10.1002/jlb.67.6.757; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; Davenpeck KL, 2000, J ALLERGY CLIN IMMUN, V105, P769, DOI 10.1067/mai.2000.105121; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; de Vries IJM, 1998, J ALLERGY CLIN IMMUN, V102, P461, DOI 10.1016/S0091-6749(98)70136-8; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; Ebisawa M., 1997, ADHESION MOL ALLERGI, P173; Edwards BS, 2000, J IMMUNOL, V165, P404, DOI 10.4049/jimmunol.165.1.404; ERLE DJ, 1994, AM J RESP CELL MOL, V10, P237, DOI 10.1165/ajrcmb.10.3.7509610; ERLE DJ, 1994, J IMMUNOL, V153, P517; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; Fagarasan S, 2000, J EXP MED, V191, P1477, DOI 10.1084/jem.191.9.1477; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FOURNIER M, 1989, AM REV RESPIR DIS, V140, P737, DOI 10.1164/ajrccm/140.3.737; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GEORAS SN, 1993, BLOOD, V82, P2872; Gerwin N, 1999, IMMUNITY, V10, P9, DOI 10.1016/S1074-7613(00)80002-3; Ghaffar O, 2000, CHEMOKINES IN ALLERGIC DISEASE, P403; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Goto E, 2000, AM J RESP CELL MOL, V22, P405, DOI 10.1165/ajrcmb.22.4.3861; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HAMANN A, 1988, J IMMUNOL, V140, P693; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Kim CH, 1999, J LEUKOCYTE BIOL, V65, P6, DOI 10.1002/jlb.65.1.6; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Kitayama J, 1998, J CLIN INVEST, V101, P2017, DOI 10.1172/JCI2688; KNOL EF, 1994, J IMMUNOL, V153, P2161; Krug N, 2000, AM J RESP CRIT CARE, V162, P105, DOI 10.1164/ajrccm.162.1.9908055; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; Kuijpers TW, 1997, INT IMMUNOL, V9, P607, DOI 10.1093/intimm/9.4.607; LEUNG DYM, 1997, ADHESION MOL ALLERGI, P297; LEY K, 1991, BLOOD, V77, P2553; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Matsukura S, 1999, J IMMUNOL, V163, P6876; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Mochizuki M, 1998, J IMMUNOL, V160, P60; MONTEFORT S, 1997, ADHESION MOL ALLERGI, P315; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Murphy PM, 2000, CHEMOKINES IN ALLERGIC DISEASE, P53; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nakano H, 1997, EUR J IMMUNOL, V27, P215, DOI 10.1002/eji.1830270132; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; PABST R, 1990, AM J RESP CELL MOL, V3, P131, DOI 10.1165/ajrcmb/3.2.131; Pachynski RK, 1998, J IMMUNOL, V161, P952; Patel KD, 1998, BLOOD, V92, P3904, DOI 10.1182/blood.V92.10.3904.422k41_3904_3911; Patel KD, 1997, J IMMUNOL, V159, P4555; Pedersen KE, 1997, J PHARMACOL EXP THER, V281, P655; PICKER LJ, 1993, J IMMUNOL, V150, P1105; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Randolph DA, 1999, SCIENCE, V286, P2159, DOI 10.1126/science.286.5447.2159; RICHMOND I, 1993, THORAX, V48, P1130, DOI 10.1136/thx.48.11.1130; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; Rothenberg ME, 2000, CHEMOKINES IN ALLERGIC DISEASE, P151; RYAN GB, 1977, INFLAMMATION, P6; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sauty A, 1999, J IMMUNOL, V162, P3549; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHLOSBERG M, 1993, AM REV RESPIR DIS, V147, pA521; SCHLOSBERG M, 1994, AM J RESP CRIT CARE, V149, pA961; Schon MP, 1999, J IMMUNOL, V162, P6641; Schroder JM, 2000, CHEMOKINES IN ALLERGIC DISEASE, P453; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; Shahabuddin S, 2000, J IMMUNOL, V164, P3847, DOI 10.4049/jimmunol.164.7.3847; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; Shinkai A, 1999, J IMMUNOL, V163, P1602; SMINIA T, 1989, CRIT REV IMMUNOL, V9, P119; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Stellato C, 1999, J IMMUNOL, V163, P5624; STELLATO C, 1995, J IMMUNOL, V155, P410; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Suzuki A, 1996, BLOOD, V87, P3550, DOI 10.1182/blood.V87.9.3550.bloodjournal8793550; Tachimoto H, 2000, J IMMUNOL, V165, P2748, DOI 10.4049/jimmunol.165.5.2748; Tachimoto H, 2000, CHEM IMMUNOL, V76, P45; Taha RA, 2000, J ALLERGY CLIN IMMUN, V105, P1002, DOI 10.1067/mai.2000.106483; Teraki Y, 1997, J IMMUNOL, V159, P6018; Teran LM, 2000, IMMUNOL TODAY, V21, P235, DOI 10.1016/S0167-5699(00)01634-0; Vassileva G, 1999, J EXP MED, V190, P1183, DOI 10.1084/jem.190.8.1183; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Warnock RA, 2000, J EXP MED, V191, P77, DOI 10.1084/jem.191.1.77; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WERFEL S, 1995, J ALLERGY CLIN IMMUN, V96, P57, DOI 10.1016/S0091-6749(95)70033-1; Woltmann G, 2000, BLOOD, V95, P3146; Wurbel MA, 2000, EUR J IMMUNOL, V30, P262, DOI 10.1002/1521-4141(200001)30:1<262::AID-IMMU262>3.0.CO;2-0; YACYSHYN B, 1998, CELL ADHESION MOL MA, P149; Ying S, 1999, J IMMUNOL, V163, P6321; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; Ying S, 1999, J IMMUNOL, V163, P3976; Ying S, 2000, CHEMOKINES IN ALLERGIC DISEASE, P383; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zaballos A, 1999, J IMMUNOL, V162, P5671; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241; Zimmerman CN, 1999, EXPERT OPIN THER PAT, V9, P129, DOI 10.1517/13543776.9.2.129; Zingoni A, 1998, J IMMUNOL, V161, P547; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P104, DOI 10.1016/S0091-6749(97)70201-X	151	134	139	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					817	828		10.1067/mai.2000.110813	http://dx.doi.org/10.1067/mai.2000.110813			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080701				2022-12-18	WOS:000167865200003
J	Levings, MK; Roncarolo, MG				Levings, MK; Roncarolo, MG			T-regulatory 1 cells: A novel subset of CD4(+)T cells with immunoregulatory properties	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			Tr1 cells; anergy; peripheral tolerance; transplantation; inflammatory bowel disease	GROWTH-FACTOR-BETA; ANTIGEN-PRESENTING CELLS; IN-VIVO; STEM-CELLS; SUPPRESSOR CELLS; IMMUNE-RESPONSES; TRANSGENIC MICE; DOWN-REGULATION; HUMAN CHIMERA; INTERLEUKIN-10	Clonal deletion and clonal anergy are well established mechanisms of peripheral tolerance. A role has also been described for clonal suppression by regulatory cells in the induction of peripheral tolerance to a variety of antigens, However, it has been difficult to isolate regulatory cells and to define their mechanism of action. We have recently reported the in vitro generation and characterization of a novel subset of CD4(+) T cells that have regulatory properties and are able to suppress antigen-specific immune responses in vitro and in vivo. These T-regulatory 1 (Tr1) cells are defined by their unique profile of cytokine production and make high levels of IL-10 and TGF-beta, but no IL-4 or IL-2, The IL-10 and TGF-beta produced by these cells mediate the inhibition of primary naive T cells in vitro. There is also evidence that Tr1 cells exist in vivo, and we have documented the presence of high IL-10-producing CD4(+) T cells in patients with severe combined immunodeficiency who have received allogeneic stem-cell transplants, These findings support the notion that Tr1 cells are involved in the regulation of peripheral tolerance and that they could potentially be used as a cellular therapy to modulate immune responses in vivo.	San Raffaele Sci Inst, Telethon Inst Gene Therapy, I-20132 Milan, Italy	Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Roncarolo, MG (corresponding author), San Raffaele Sci Inst, Telethon Inst Gene Therapy, Via Olgettina 58, I-20132 Milan, Italy.			Levings, Megan/0000-0002-0305-5790	Telethon [TGT00Z04, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Asseman C, 1998, GUT, V42, P157, DOI 10.1136/gut.42.2.157; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; BACCHETTA R, 1990, J IMMUNOL, V144, P902; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BACCHETTA R, 1993, J CLIN INVEST, V91, P1067, DOI 10.1172/JCI116264; Baker KS, 1999, BONE MARROW TRANSPL, V23, P1123, DOI 10.1038/sj.bmt.1701780; Braunstein J, 1997, GUT, V41, P215, DOI 10.1136/gut.41.2.215; Bridoux F, 1997, J EXP MED, V185, P1769, DOI 10.1084/jem.185.10.1769; BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940; Buer J, 1998, J EXP MED, V187, P177, DOI 10.1084/jem.187.2.177; Chakraborty NG, 1999, J IMMUNOL, V162, P5576; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cua DJ, 1999, J EXP MED, V189, P1005, DOI 10.1084/jem.189.6.1005; DE WMR, 1991, J EXP MED, V174, P1209; DORF ME, 1984, ANNU REV IMMUNOL, V2, P127, DOI 10.1146/annurev.iy.02.040184.001015; Groux H, 1999, J IMMUNOL, V162, P1723; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Hagenbaugh A, 1997, J EXP MED, V185, P2101, DOI 10.1084/jem.185.12.2101; Han HS, 1996, J AUTOIMMUN, V9, P331, DOI 10.1006/jaut.1996.0045; HOLLER E, 1995, EUR J CANCER, V31A, P39; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Khoo UY, 1997, J IMMUNOL, V158, P3626; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LOMBARDI G, 1994, SCIENCE, V264, P1587, DOI 10.1126/science.8202711; MALEFYT RD, 1991, J EXP MED, V174, P915; Mason D, 1998, CURR OPIN IMMUNOL, V10, P649, DOI 10.1016/S0952-7915(98)80084-8; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Miller C, 1999, J EXP MED, V190, P53, DOI 10.1084/jem.190.1.53; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ozawa H, 1996, EUR J IMMUNOL, V26, P648, DOI 10.1002/eji.1830260321; Perrin GQ, 1999, BLOOD, V93, P208, DOI 10.1182/blood.V93.1.208.401k06_208_216; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; Rolland J, 1998, CURR OPIN IMMUNOL, V10, P640, DOI 10.1016/S0952-7915(98)80082-4; RONCAROLO MG, 1988, J EXP MED, V167, P1523, DOI 10.1084/jem.167.5.1523; RONCAROLO MG, 1991, BLOOD CELLS, V17, P391; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Sundstedt A, 1997, J IMMUNOL, V158, P180; Taams LS, 1999, J IMMUNOL, V162, P1974; Taams LS, 1998, EUR J IMMUNOL, V28, P2902, DOI 10.1002/(SICI)1521-4141(199809)28:09<2902::AID-IMMU2902>3.0.CO;2-B; Zeller JC, 1999, J IMMUNOL, V163, P3684	45	134	149	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S109	S112		10.1067/mai.2000.106635	http://dx.doi.org/10.1067/mai.2000.106635			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887343	Bronze			2022-12-18	WOS:000088482600016
J	Schubert, MS; Goetz, DW				Schubert, MS; Goetz, DW			Evaluation and treatment of allergic fungal sinusitis. I. Demographics and diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic mucin; antibodies, fungal; diagnosis; Deuteromycetes, fungi; fungus diseases; hypersensitivity, type I; IgE; prednisone; serodiagnosis; spores, fungal; rhinosinusitis; sinusitis; treatment outcome	ASPERGILLUS SINUSITIS; BRONCHOPULMONARY ASPERGILLOSIS; EXPERIENCE; MANAGEMENT; IGE	Background: Pew eases of allergic fungal sinusitis have been systematically evaluated to conclusively confirm working clinical, histopathologic, and serologic diagnostic criteria. Objectives: The objective of this study was to describe 67 consecutive cases of allergic fungal sinusitis, the largest number of cases Set published. Methods: Cases from 1 practice over 8 years were evaluated with a consistent protocol, including skin testing, serum chemistries and serologies, and surgical specimen analysis. Results: All patients were atopic (100%) and had nasal polyposis (100%). They tended to be young (33.3 +/- 13.1 years, mean +/- SEM), immunocompetent (92%; remaining 8% with low quantitative immunoglobulin but normal function), have slight female preponderance (58%), have a history of hypertrophic rhinosinusitis (100%), report nasal cast production (75%), and have developed their disease in the southwestern United States. Bipolaris spicifera was the most prevalent fungus involved (67%). Total serum IgE (mean 668 IU/mL) and fungal-specific Ige were generally elevated, whereas fungal-specific precipitins and specific IgE were generally negative despite positive fungal-specific immediate hypersensitivity skin tests. Conclusions: Patients with allergic fungal sinusitis tend to have elevated total serum IgE and fungal-specific IgG at diagnosis but not fungal-specific IgE or precipitins, Histopathologic criteria for allergic fungal sinusitis diagnosis are discussed. The southwestern United States appears to be a "hot spot" for the disease, particularly caused by B spicifera.	Wilford Hall USAF Med Ctr, Allergy Asthma Clin, Phoenix, AZ 85013 USA; Wilford Hall USAF Med Ctr, Dept Allergy Immunol, Phoenix, AZ 85013 USA		Schubert, MS (corresponding author), Wilford Hall USAF Med Ctr, Allergy Asthma Clin, 31 W Camelback Rd, Phoenix, AZ 85013 USA.							Bent JP, 1996, ALLERGY ASTHMA PROC, V17, P259, DOI 10.2500/108854196778662273; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; Chang WJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P767, DOI 10.1001/archopht.1996.01100130759031; CLEVELAND CH, 1992, PEDIATR ASTHMA ALLER, V6, P189, DOI 10.1089/pai.1992.6.189; CODY DT, 1994, LARYNGOSCOPE, V104, P1074, DOI 10.1288/00005537-199409000-00005; COREY JP, 1995, OTOLARYNG HEAD NECK, V113, P110, DOI 10.1016/S0194-5998(95)70153-2; DAGHISTANI KJ, 1992, J LARYNGOL OTOL, V106, P799, DOI 10.1017/S0022215100120912; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; FRENKEL L, 1987, PEDIATR INFECT DIS J, V6, P1130, DOI 10.1097/00006454-198706120-00012; GOLDSTEIN MF, 1985, J ALLERGY CLIN IMMUN, V76, P515, DOI 10.1016/0091-6749(85)90737-7; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P582; GREENBERGER PA, 1986, ANN ALLERGY, V56, P444; HARTWICK RW, 1991, ANN OTO RHINOL LARYN, V100, P427, DOI 10.1177/000348949110000515; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; Kinsella JB, 1996, CLIN OTOLARYNGOL, V21, P389, DOI 10.1046/j.1365-2273.1996.00807.x; Kupferberg SB, 1996, ARCH OTOLARYNGOL, V122, P1381, DOI 10.1001/archotol.1996.01890240087019; Lydiatt W M, 1994, Ear Nose Throat J, V73, P402; Mabry RL, 1995, OTOLARYNG HEAD NECK, V113, P721, DOI 10.1016/S0194-5998(95)70011-0; Manning SC, 1997, LARYNGOSCOPE, V107, P170, DOI 10.1097/00005537-199702000-00007; MANNING SC, 1993, LARYNGOSCOPE, V103, P717, DOI 10.1288/00005537-199307000-00002; Morpeth JF, 1996, ANN ALLERG ASTHMA IM, V76, P128, DOI 10.1016/S1081-1206(10)63411-4; NEUVONEN P, 1985, ALLERGY, V40, P208, DOI 10.1111/j.1398-9995.1985.tb00218.x; NORMAN PS, 1983, ALLERGY PRINCIPLES P; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; REILLY JS, 1990, OTOLARYNG HEAD NECK, V103, P856, DOI 10.1177/01945998901030S504; REINER A, 1978, ACTA OTO-LARYNGOL, V355, P1; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; Roth M, 1994, Ear Nose Throat J, V73, P928; SAKAKURA Y, 1985, CLIN OTOLARYNGOL, V10, P79, DOI 10.1111/j.1365-2273.1985.tb01171.x; SCHUBERT MS, 1992, ANN ALLERGY, V69, P231; Schwartz HJ, 1996, ANN ALLERG ASTHMA IM, V77, P500, DOI 10.1016/S1081-1206(10)63359-5; SHAW A, 1990, ANN ALLERGY, V64, P507; SHER TH, 1988, J ALLERGY CLIN IMMUN, V81, P844, DOI 10.1016/0091-6749(88)90940-2; Torres C, 1996, HUM PATHOL, V27, P793, DOI 10.1016/S0046-8177(96)90451-7; TRAVIS WD, 1991, HUM PATHOL, V22, P1240, DOI 10.1016/0046-8177(91)90106-Y; WASHBURN RG, 1988, MEDICINE, V67, P231, DOI 10.1097/00005792-198807000-00004; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261; WICKERN GM, 1993, PEDIATR ASTHMA ALLER, V7, P147, DOI 10.1089/pai.1993.7.147	38	134	144	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					387	394		10.1016/S0091-6749(98)70125-3	http://dx.doi.org/10.1016/S0091-6749(98)70125-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768578				2022-12-18	WOS:000076212800009
J	DARSOW, U; VIELUF, D; RING, J				DARSOW, U; VIELUF, D; RING, J			ATOPY PATCH TEST WITH DIFFERENT VEHICLES AND ALLERGEN CONCENTRATIONS - AN APPROACH TO STANDARDIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AEROALLERGENS; PATCH TEST; ATOPY PATCH TEST; STANDARDIZATION; ATOPIC ECZEMA	EPIDERMAL LANGERHANS CELLS; HOUSE DUST MITE; AEROALLERGEN CONTACT; DERMATITIS; ECZEMA; SKIN	Background: In some patients with atopic eczema, eczematous skin lesions can be induced by patch testing with aeroallergens. Methods: To establish a standardized system for the atopy patch tet (APT), 36 patients with atopic eczema, four patients with rhinoconjunctivitis and 10 healthy control subjects were epicutaneously tested with allergen extracts from house dust mite, cat dander, and grass pollen. APTs were performed on nonabraded, uninvolved skin with 1000 and 10,000 protein nitrogens units (PNU)/gm allergen in petrolatum or hydrogel. Reactions were evaluated after 48 and 72 hours and compared with skin prick and specific serum IgE (CAP-RAST; Pharmacia, Uppsala, Sweden). Results: After 48 hours, 57 clear-cut positive reactions with eczematous, often follicle-bound, appearance were diagnosed from a total of 432 test sites. Seventy-two percent of these positive reactions in patients with atopic eczema developed with 10,000 PNU/gm and 28% with 1000 PNU/gm. Sixty-seven percent of reactions were elicited with allergens in petrolatum versus 33% when hydrogel was used as vehicle. Allergen-specific concordances of APT (10,000 PNU/gm, petrolatum) ranged from 0.39 to 0.53 (prick tet) and 0.42 to 0.69 (CAP-RAST). In healthy control subjects and patients with rhinoconjunctivitis without atopic eczema, no clear-cut positive APT reaction was seen. Conclusions: Petrolatum as vehicle and an allergen concentration higher than 1000 PNU/gm may lead to improved APT results on unchanged skin. In the future, the clinical relevance of an IgE-mediated sensitization for eczematous skin lesions may be evaluated by the APT.	UNIV HAMBURG, HOSP EPPENDORF, DEPT DERMATOL & ALLERGOL, D-20246 HAMBURG, GERMANY	University of Hamburg			Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				ADINOFF AD, 1988, J ALLERGY CLIN IMMUN, V81, P736, DOI 10.1016/0091-6749(88)91047-0; BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BRUYNZEELKOOMEN CAFM, 1988, BRIT J DERMATOL, V118, P229, DOI 10.1111/j.1365-2133.1988.tb01779.x; CLARK RAF, 1989, J AM ACAD DERMATOL, V21, P863, DOI 10.1016/S0190-9622(89)70269-3; DARSOW U, 1993, J DERMATOL SCI, V6, P95; GONDO A, 1986, BRIT J DERMATOL, V115, P485, DOI 10.1111/j.1365-2133.1986.tb06243.x; IMAYAMA S, 1992, J AM ACAD DERMATOL, V27, P531, DOI 10.1016/0190-9622(92)70218-5; Jones TD, 1934, NEW ENGL J MED, V210, P120, DOI 10.1056/NEJM193401182100302; LANGELAND T, 1989, ACTA DERM-VENEREOL, P105; MAEDA K, 1992, Journal of Dermatological Science, V3, P73, DOI 10.1016/0923-1811(92)90038-D; MITCHELL EB, 1982, LANCET, V1, P127; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Rajka G., 1989, ESSENTIAL ASPECTS AT; RASP G, 1991, ALLERGOLOGIE, V14, P434; REITAMO S, 1989, ACTA DERM-VENEREOL, P119; RING J, 1991, INT ARCH ALLER A IMM, V94, P194, DOI 10.1159/000235361; RING J, 1989, J ALLERGY CLIN IMMUN, V83, P195; RING J, 1990, ANGEWANDTE ALLERGOLO; RUZICKA T, 1991, HDB ATOPIC ECZEMA; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Sager N, 1992, Z HAUTKRANKHEITEN, V67, P600; SEIDENARI S, 1992, ANN ALLERGY, V69, P201; Seifert H, 1987, DTSCH DERM, V35, P1204; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; TANAKA Y, 1990, Journal of Dermatological Science, V1, P361, DOI 10.1016/0923-1811(90)90593-3; VADER PCV, 1991, ACTA DERM-VENEREOL, V71, P301; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Vieluf D, 1993, ALLERGY J, V2, P9; VOCKS E, 1991, NEW TRENDS ALLERGY, V3, P230	31	134	137	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					677	684		10.1016/S0091-6749(95)70172-9	http://dx.doi.org/10.1016/S0091-6749(95)70172-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897150				2022-12-18	WOS:A1995QM01700007
J	DIAMANT, Z; TIMMERS, MC; VANDERVEEN, H; FRIEDMAN, BS; DESMET, M; DEPRE, M; HILLIARD, D; BEL, EH; STERK, PJ				DIAMANT, Z; TIMMERS, MC; VANDERVEEN, H; FRIEDMAN, BS; DESMET, M; DEPRE, M; HILLIARD, D; BEL, EH; STERK, PJ			THE EFFECT OF MK-0591, A NOVEL 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR, ON LEUKOTRIENE BIOSYNTHESIS AND ALLERGEN-INDUCED AIRWAY RESPONSES IN ASTHMATIC SUBJECTS IN-VIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; LEUKOTRIENES; ALLERGEN BRONCHIAL PROVOCATION TESTS; BRONCHIAL HYPERREACTIVITY	3-<1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL>-2,2.; LIQUID-CHROMATOGRAPHY; LUNG-FUNCTION; IMMEDIATE; HISTAMINE; CHALLENGE; RELEASE; BRONCHOCONSTRICTION; RADIOIMMUNOASSAY; RESPONSIVENESS	Background: The 5-lipoxygenase metabolites of arachidonic acid are likely to be involved in the pathophysiology of atopic asthma. We investigated the effect of pretreatment with MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on allergen-induced early asthmatic reactions (EARs) and late asthmatic reactions (LARs), and subsequent airway hyperresponsiveness to histamine. Methods: Eight atopic men with mild to moderate asthma aged 19 to 31 years, (forced expiratory volume in 1 second [FEV(1)] greater than or equal to 67% of predicted value, histamine provocative concentration causing a 20% fall in FEV(1) [PC20] <4 mg/ml) and documented EAR and LAR to house dust mite extract participated in a two-period double-blind placebo-controlled crossover study. During each study period histamine PC20 was measured 2 days before and 1 day after a standardized allergen inhalation challenge test. MK-0591 was administered in 3 oral doses of 250 mg each at 24, 12, and 1.5 hours before inhalation of allergen. Biochemical activity of MK-0591 was determined by calcium ionophore A-23187-stimulated leukotriene (LT)B-4 biosynthesis in whole blood ex vivo and by urinary LTE(4) excretion. Airway response to allergen was measured by FEV(1) (percent fall from baseline). The EAR (0 to 3 hours) and the LAR (3 to 8 hours) were expressed as corresponding areas under the time-response curves. Results: MK-0591 and placebo did not differ in their effects on prechallenge FEV(1) (p = 0.10). As compared with the value before pretreatment, MK-0591 blocked LTB(4) biosynthesis and LTE(4) excretion by a mean of 98% (range, 96% to 99%; p < 0.002) and 87% (range, 84% to 96%; p < 0.046), respectively, from 0 to 24 hours after allergen challenge. Both the EAR and the LAR were significantly reduced after administration of MK-0591 as compared with placebo with a mean inhibition of 79% (p = 0.011) and 39% (p = 0.010), respectively. Allergen-induced airway hyperresponsiveness was not significantly different between the two pretreatment periods (p = 0.37). Conclusions: In this study oral MK-0591 prevented leukotriene biosynthesis after allergen challenge in patients with mild to moderate asthma. The results of our study indicate that 5-lipoxygenase products play an important role during the EAR, whereas their contribution to the pathophysiology of the LAR seems to be of less importance.	MERCK RES LABS, RAHWAY, NJ USA; MERCK SHARP & DOHME RES LABS, BRUSSELS, BELGIUM; CATHOLIC UNIV LEUVEN, SCH MED, DEPT PHARMACOL, LOUVAIN, BELGIUM; CATHOLIC UNIV LEUVEN, SCH PHARM, LOUVAIN, BELGIUM	Merck & Company; KU Leuven; KU Leuven	DIAMANT, Z (corresponding author), UNIV LEIDEN HOSP, DEPT PULMONOL,LUNG FUNCT LAB,BLDG 1,C2P, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Sterk, P.J./AAK-8175-2020					AALBERS R, 1993, AM REV RESPIR DIS, V147, P76, DOI 10.1164/ajrccm/147.1.76; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BEL EH, 1987, AM REV RESPIR DIS, V136, P979, DOI 10.1164/ajrccm/136.4.979; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRIDEAU C, 1992, CAN J PHYSIOL PHARM, V70, P799, DOI 10.1139/y92-107; CAREY F, 1986, PROSTAG LEUKOTR ESS, V22, P57, DOI 10.1016/0262-1746(86)90022-3; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CHRISTIE PE, 1992, AM REV RESPIR DIS, V145, P1281, DOI 10.1164/ajrccm/145.6.1281; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; DWORSKI R, 1989, AM REV RESPIR DIS, V139, P46, DOI 10.1164/ajrccm/139.1.46; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; HUI KP, 1993, PULM PHARMACOL THER, V6, P3, DOI 10.1006/pulp.1993.1002; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; INMAN MD, 1993, AM REV RESPIR DIS, V147, pA20; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; KATZUNG BG, 1987, BASIC CLIN PHARM, P14; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KLINE WF, 1991, J PHARMACEUT BIOMED, V9, P511, DOI 10.1016/0731-7085(91)80255-8; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MANNING PJ, 1991, EUR RESPIR J, V4, P667; MENARD L, 1992, CAN J PHYSIOL PHARM, V70, P808, DOI 10.1139/y92-108; MULLER M, 1985, J CHROMATOGR, V343, P213, DOI 10.1016/S0378-4347(00)84589-2; OBYRNE PM, 1988, J ALLERGY CLIN IMMUN, V81, P119, DOI 10.1016/0091-6749(88)90230-8; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; SAMPSON AP, 1992, BRIT J CLIN PHARMACO, V33, P423, DOI 10.1111/j.1365-2125.1992.tb04062.x; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; STEVENS WHM, 1994, J APPL PHYSIOL, V76, P1583, DOI 10.1152/jappl.1994.76.4.1583; TAGARI P, 1989, CLIN CHEM, V35, P388; TANAKA W, 1992, 8TH INT C PROST REL; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450	43	134	139	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				42	51		10.1016/S0091-6749(95)70151-6	http://dx.doi.org/10.1016/S0091-6749(95)70151-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822663				2022-12-18	WOS:A1995QC31200007
J	COCKCROFT, DW; MURDOCK, KY; BERSCHEID, BA; GORE, BP				COCKCROFT, DW; MURDOCK, KY; BERSCHEID, BA; GORE, BP			SENSITIVITY AND SPECIFICITY OF HISTAMINE PC20 DETERMINATION IN A RANDOM SELECTION OF YOUNG COLLEGE-STUDENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRWAY RESPONSIVENESS; SENSITIVITY; SPECIFICITY; HISTAMINE INHALATION	BRONCHIAL HYPERRESPONSIVENESS; INHALED HISTAMINE; AUSTRALIAN SCHOOLCHILDREN; METHACHOLINE; POPULATION; RESPONSIVENESS; ASTHMA; HYPERREACTIVITY; REACTIVITY; RHINITIS	Histamine provocative concentration causing a 20% drop in FEV1 (PC20) was measured in 500, randomly selected, young (20 to 29 years) university students. Participation was 500/619, or 81%. In this population, by a research assistant-administered questionnaire, we identified 17 subjects with current asthma, 16 with asthma only on allergen exposure, 19 with past (more than 1 year ago) asthma, 158 with rhinitis (77 atopic and 81 nonatopic subjects), and 290 subjects with neither asthma nor rhinitis. Histamine airway hyperresponsiveness (PC20 less-than-or-equal-to 8 mg/ml) was observed in 58 subjects and included the 17 subjects with current asthma, 6/16 with asthma only on allergen exposure, 2/19 subjects with prevous asthma, 20/158 with rhinitis, and 13/290 subjects with neither asthma nor rhinitis. With "current symptomatic asthma" as the diagnosis and PC20 less-than-or-equal-to 8 mg/ml as the positive test, the sensitivity was 100%, the specificity was 93%, and the negative predictive value was 100%; the positive predictive value (for current symptoms of asthma) was only 29%. The strength of this test with a cutoff of 8 mg/ml is the high sensitivity, indicating that a PC20 > 8 mg/ml is likely to indicate that current asthma is not present. The weakness is the failure to predict current symptoms of asthma. As the cutoff is lowered, for example, to PC20, 1 mg/ml, the sensitivity falls to < 50% and the positive predictive value approaches 100%. These data indicate that a PC20 > 8 (or 16) mg/ml rules out current asthma in most instances, whereas a PC20 < 1 mg/ml is almost diagnostic of current asthma. Values between 1 and 8 mg/ml are intermediate in these regards.	ROYAL UNIV HOSP SASKATOON, SASKATOON, SASKATCHEWAN, CANADA	University of Saskatchewan								BRITTON J, 1988, EUR RESPIR J, V1, P478; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1982, THORAX, V37, P133, DOI 10.1136/thx.37.2.133; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1990, AM REV RESPIR DIS, V142, P497, DOI 10.1164/ajrccm/142.3.497; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GIBSON P G, 1988, Clinical and Investigative Medicine, V11, pC105; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; JENKINS CR, 1984, AM REV RESPIR DIS, V130, P879; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; POPA V, 1988, CHEST, V94, P466, DOI 10.1378/chest.94.3.466; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; Steel R.G., 1980, PRINCIPLES PROCEDURE, V2nd, P102; Steele RG, 1980, PRINCIPLES PROCEDURE, P495; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; WOOLCOCK AJ, 1985, AIRWAY RESPONSIVENES, P80; 1983, CAN MED ASSOC J, V129, P559	33	134	143	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				23	30		10.1016/S0091-6749(05)80037-5	http://dx.doi.org/10.1016/S0091-6749(05)80037-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730837				2022-12-18	WOS:A1992GZ90800003
J	LIND, P				LIND, P			PURIFICATION AND PARTIAL CHARACTERIZATION OF 2 MAJOR ALLERGENS FROM THE HOUSE DUST MITE DERMATOPHAGOIDES-PTERONYSSINUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALK RES GRP,COPENHAGEN,DENMARK		LIND, P (corresponding author), UNIV COPENHAGEN,PROT LAB,SIGURDSGADE 34,DK-2200 COPENHAGEN N,DENMARK.							BJERRUM OJ, 1979, PROTIDES BIOL FLUIDS, V27, P775; CHAKRABARTY S, 1981, INT ARCH ALLER A IMM, V66, P142, DOI 10.1159/000232813; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHAPMAN MD, 1982, 11 P INT C ALL CLIN, P531; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; POULSEN LK, 1985, ALLERGY, V40, P406; SCHAFERNIELSEN C, 1982, BIOCHIM BIOPHYS ACTA, V696, P323, DOI 10.1016/0167-4781(82)90064-1; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P259, DOI 10.1038/icb.1980.26; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; WAHN U, 1985, ALLERGY, V40, P383; WEEKE B, 1983, SCAND J IMMUNOL S10, V17, P265	20	134	139	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					753	761		10.1016/0091-6749(85)90682-7	http://dx.doi.org/10.1016/0091-6749(85)90682-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	2414353				2022-12-18	WOS:A1985AUU3400016
J	JACOBS, RL; FREEDMAN, PM; BOSWELL, RN				JACOBS, RL; FREEDMAN, PM; BOSWELL, RN			NON-ALLERGIC RHINITIS WITH EOSINOPHILIA (NARES SYNDROME) - CLINICAL AND IMMUNOLOGICAL PRESENTATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											JACOBS, RL (corresponding author), WILFORD HALL USAF MED CTR,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236, USA.							ANGGARD A, 1974, ACTA OTO-LARYNGOL, V78, P98, DOI 10.3109/00016487409126332; ANGGARD A, 1974, ACTA OTO-LARYNGOL, V77, P131, DOI 10.3109/00016487409124608; ARROYAVE CM, 1979, J ALLERGY CLIN IMMUN, V63, P276, DOI 10.1016/0091-6749(79)90113-1; BENNICH H, 1970, VOX SANG, V19, P1, DOI 10.1111/j.1423-0410.1970.tb01490.x; BHANDARI CM, 1976, ANN ALLERGY, V37, P280; BOSWELL RN, 1979, J ALLERGY CLIN IMMUN, V63, P202; CANNON DC, 1974, CLIN CHEM PRINCIPLES, P405; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHEVALIER JE, 1980, MAR REG M AM COLL PH; COCHRANE CG, 1973, ADV IMMUNOL, V16, P186; CONNELL JT, 1976, BRONCHIAL ASTHMA MEC, P481; COSTANZI JJ, 1969, J LAB CLIN MED, V74, P902; DAMAN L, 1978, J ALLERGY CLIN IMMUN, V61, P273, DOI 10.1016/0091-6749(78)90203-8; DEUSCHL H, 1976, INT ARCH ALLER A IMM, V52, P376, DOI 10.1159/000231704; DEUSCHL H, 1977, CLIN ALLERGY, V7, P195, DOI 10.1111/j.1365-2222.1977.tb01442.x; DIENSTAG JL, 1978, ANN INTERN MED, V89, P34, DOI 10.7326/0003-4819-89-1-34; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; FREDA A, 1980, MAR REG M AM COLL PH; HANSEL FK, 1953, CLIN ALLERGY; Hopper I, 1972, J Laryngol Otol, V86, P725; HORTON RJM, 1962, J ALLERGY, V33, P524; HUGGINS KG, 1975, LANCET, V2, P148; JACOBS RL, 1979, J ALLERGY CLIN IMMUN, V63, P202; JAFFE BF, 1977, OTOLARYNG CLIN N AM, V10, P81; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KNIGHT A, 1979, CLIN ALLERGY, V9, P159, DOI 10.1111/j.1365-2222.1979.tb01537.x; LEIFERMAN KM, 1975, J ALLERGY CLIN IMMUN, V56, P481, DOI 10.1016/0091-6749(75)90066-4; LORIN MI, 1972, J LAB CLIN MED, V80, P275; MALCOMSON K G, 1959, J Laryngol Otol, V73, P73, DOI 10.1017/S0022215100054980; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; MILLER RD, 1979, AM REV RESPIR DIS, V119, P229; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MULLARKEY MF, 1979, POSTGRAD MED, V65, P97, DOI 10.1080/00325481.1979.11715114; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; MYGIND N, 1972, ACTA ALLERGOL, V27, P372, DOI 10.1111/j.1398-9995.1972.tb01436.x; MYGIND N, 1975, INT ARCH ALLER A IMM, V49, P99, DOI 10.1159/000231383; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; PEARSON R S B, 1958, Acta Allergol, V12, P277; PELIKAN Z, 1970, ANN ALLERGY, V28, P548; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; RICHERSON HB, 1968, J ALLERGY, V41, P269, DOI 10.1016/0021-8707(68)90032-4; RITTER FN, 1978, ALLERGY PRINCIPLES P, P359; RYAN TJ, 1968, BRIT J DERMATOL, V80, P485, DOI 10.1111/j.1365-2133.1968.tb12334.x; SALVAGGIO J, 1973, J ALLERGY CLIN IMMUN, V51, P335, DOI 10.1016/0091-6749(73)90072-9; SEEBOHM PM, 1978, ALLERGY PRINCIPLES P, P868; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SOTER NA, 1977, J ALLERGY CLIN IMMUN, V59, P294, DOI 10.1016/0091-6749(77)90050-1; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; TADA T, 1970, Journal of Immunology, V104, P377; TENNENBAUM JI, 1972, ALLERGIC DISEASES DI, P161; TOS M, 1977, ACTA OTO-LARYNGOL, V83, P498, DOI 10.3109/00016487709128878; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WILLIAMS EO, 1949, BMJ-BRIT MED J, V2, P897, DOI 10.1136/bmj.2.4633.897; WILLIAMS RB, 1972, ANN ALLERGY, V30, P189; WOLF AF, 1973, ANN ALLERGY, V31, P300; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	58	134	142	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					253	262		10.1016/0091-6749(81)90019-1	http://dx.doi.org/10.1016/0091-6749(81)90019-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	7204783				2022-12-18	WOS:A1981LL69700002
J	Maes, T; Cobos, FA; Schleich, F; Sorbello, V; Henket, M; De Preter, K; Bracke, KR; Conickx, G; Mesnil, C; Vandesompele, J; Lahousse, L; Bureau, F; Mestdagh, P; Joos, GF; Ricciardolo, FLM; Brusselle, GG; Louis, R				Maes, Tania; Cobos, Francisco Avila; Schleich, Florence; Sorbello, Valentina; Henket, Monique; De Preter, Katleen; Bracke, Ken R.; Conickx, Griet; Mesnil, Claire; Vandesompele, Jo; Lahousse, Lies; Bureau, Fabrice; Mestdagh, Pieter; Joos, Guy F.; Ricciardolo, Fabio L. M.; Brusselle, Guy G.; Louis, Renaud			Asthma inflammatory phenotypes show differential microRNA expression in sputum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; microRNA; sputum; neutrophilic inflammation	EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; NLRP3 INFLAMMASOME; MIRNA EXPRESSION; CELLS; MIR-223; PROLIFERATION; INDUCTION; AIRWAYS	Background: Asthma is classified according to severity and inflammatory phenotype and is likely to be distinguished by specific microRNA (miRNA) expression profiles. Objective: We sought to associate miRNA expression in sputum supernatants with the inflammatory cell profile and disease severity in asthmatic patients. Methods: We investigated miRNA expression in sputum supernatants of 10 healthy subjects, 17 patients with mild-to-moderate asthma, and 9 patients with severe asthma using high-throughput, stem-loop, reverse transcriptase quantitative real-time PCR miRNA expression profiling (screening cohort, n = 36). Differentially expressed miRNAs were validated in an independent cohort (n = 60; 10 healthy subjects and 50 asthmatic patients). Cellular miRNA origin was examined by using in situ hybridization and reverse transcriptase quantitative real-time PCR. The functional role of miRNAs was assessed by using in silico analysis and in vitro transfecting miRNA mimics in human bronchial epithelial cells. Results: In 2 independent cohorts expression of miR-629-3p, miR-223-3p, and miR-142-3p was significantly upregulated in sputum of patients with severe asthma compared with that in healthy control subjects and was highest in patients with neutrophilic asthma. Expression of the 3 miRNAs was associated with sputum neutrophilia, and miR-223-3p and miR-142-3p expression was associated also with airway obstruction (FEV1/forced vital capacity). Expression of miR-629-3p was localized in the bronchial epithelium, whereas miR-223-3p and miR-142-3p were expressed in neutrophils, monocytes, and macrophages. Transfecting human bronchial epithelial cells with miR-629-3p mimic induced epithelial IL-8 mRNA and protein expression. IL-1 beta and IL-8 protein levels were significantly increased in sputum of patients with severe asthma and were positively associated with sputum neutrophilia. Conclusions: Expression of miR-223-3p, miR-142-3p, and miR-629-3p is increased in sputum of patients with severe asthma and is linked to neutrophilic airway inflammation, suggesting that these miRNAs contribute to this asthma inflammatory phenotype.	[Maes, Tania; Bracke, Ken R.; Conickx, Griet; Lahousse, Lies; Joos, Guy F.; Brusselle, Guy G.] Ghent Univ Hosp, Dept Resp Med, Blok B,Room 420,De Pintelaan 185, B-9000 Ghent, Belgium; [Cobos, Francisco Avila; De Preter, Katleen; Vandesompele, Jo; Mestdagh, Pieter] Univ Ghent, Ctr Med Genet, Liege, Belgium; [Schleich, Florence; Henket, Monique; Louis, Renaud] CHU Sart TilmanB35, Dept Resp Med, Liege, Belgium; [Sorbello, Valentina; Ricciardolo, Fabio L. M.] Univ Turin, Dept Clin & Biol Sci, I-10124 Turin, Italy; [Mesnil, Claire; Bureau, Fabrice] Univ Liege, GIGA Res Ctr, Dept Cellular & Mol Immunol, B-4000 Liege, Belgium; [Mesnil, Claire; Bureau, Fabrice] Univ Liege, Fac Vet Med, B-4000 Liege, Belgium	Ghent University; Ghent University Hospital; Ghent University; University of Turin; University of Liege; University of Liege	Maes, T (corresponding author), Ghent Univ Hosp, Dept Resp Med, Blok B,Room 420,De Pintelaan 185, B-9000 Ghent, Belgium.	Tania.Maes@UGent.be	Ricciardolo, F. L. M./K-5330-2018; Vandesompele, Jo/W-3411-2018; Lahousse, Lies/O-9426-2019; Cobos, Francisco Avila/N-7368-2019; Maes, Tania/M-8675-2016; Bracke, Ken R/GSN-7630-2022	Ricciardolo, F. L. M./0000-0003-1826-5018; Vandesompele, Jo/0000-0001-6274-0184; Lahousse, Lies/0000-0002-3494-4363; Cobos, Francisco Avila/0000-0002-8816-9243; Maes, Tania/0000-0002-3037-6928; Bracke, Ken R/0000-0001-5906-4605; Sorbello, Valentina/0000-0002-9098-8686; Brusselle, Guy/0000-0001-7021-8505; Joos, Guy/0000-0002-3149-9444; Conickx, Griet/0000-0002-9475-8749; Mestdagh, Pieter/0000-0001-7821-9684	Belgian Interuniversity Attraction Poles Program (IUAP) [P7/30]; Concerted Research Action of Ghent University, Belgium [BOF14-GOA-027]; Spearhead Immunology, Ghent University Hospital, Belgium; FWO Flanders [G.0A99.13, G.0319.11N]; Maro Fund of the King Baudouin Foundation	Belgian Interuniversity Attraction Poles Program (IUAP); Concerted Research Action of Ghent University, Belgium; Spearhead Immunology, Ghent University Hospital, Belgium(Ghent University); FWO Flanders(FWO); Maro Fund of the King Baudouin Foundation	Supported by the Belgian Interuniversity Attraction Poles Program (IUAP) P7/30, Concerted Research Action of Ghent University BOF14-GOA-027, Belgium; Spearhead Immunology, Ghent University Hospital, Belgium; FWO Flanders (G.0A99.13 and G.0319.11N); and the Maro Fund of the King Baudouin Foundation.	Alexis NE, 2014, CURR OPIN PULM MED, V20, P46, DOI 10.1097/MCP.0000000000000010; Allantaz F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029979; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Balamurugan K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2677; Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516; Brooks CR, 2013, CYTOM PART B-CLIN CY, V84B, P104, DOI 10.1002/cyto.b.21069; Carraro G, 2014, DEVELOPMENT, V141, P1272, DOI 10.1242/dev.105908; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Coldren CD, 2006, AM J PHYSIOL-LUNG C, V291, pL1267, DOI 10.1152/ajplung.00097.2006; D'haene Barbara, 2012, Methods Mol Biol, V822, P261, DOI 10.1007/978-1-61779-427-8_18; Delvaux M, 2004, THORAX, V59, P111, DOI 10.1136/thorax.2003.011130; Dorhoi A, 2013, J CLIN INVEST, V123, P4836, DOI 10.1172/JCI67604; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Eickmeier O, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/913135; Ezzie ME, 2012, THORAX, V67, P122, DOI 10.1136/thoraxjnl-2011-200089; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Haj-Salem I, 2015, ALLERGY, V70, P212, DOI 10.1111/all.12551; Haneklaus M, 2013, J INTERN MED, V274, P215, DOI 10.1111/joim.12099; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Ismail N, 2013, BLOOD, V121, P984, DOI 10.1182/blood-2011-08-374793; Jardim MJ, 2012, AM J RESP CELL MOL, V47, P536, DOI 10.1165/rcmb.2011-0160OC; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076; Lei Z, 2014, FASEB J, V28, P2696, DOI 10.1096/fj.13-247288; Lodish HF, 2008, NAT REV IMMUNOL, V8, P120, DOI 10.1038/nri2252; Ma J, 2015, ONCOTARGET, V6, P1740, DOI 10.18632/oncotarget.2714; Manise M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058388; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Oglesby IK, 2013, J IMMUNOL, V190, P3354, DOI 10.4049/jimmunol.1202960; Perry MM, 2014, AM J RESP CELL MOL, V50, P7, DOI 10.1165/rcmb.2013-0067OC; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Ricciardolo FLM, 2013, THORAX, V68, P803, DOI 10.1136/thoraxjnl-2012-202741; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Schleich FN, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-11; Seiscento M, 2010, INT J TUBERC LUNG D, V14, P1153; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Simpson LJ, 2014, NAT IMMUNOL, V15, P1162, DOI 10.1038/ni.3026; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Sun W, 2010, CELL RES, V20, P1158, DOI 10.1038/cr.2010.134; Van Pottelberge GR, 2011, AM J RESP CRIT CARE, V183, P898, DOI 10.1164/rccm.201002-0304OC; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Williams AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005889	48	133	138	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1433	1446		10.1016/j.jaci.2016.02.018	http://dx.doi.org/10.1016/j.jaci.2016.02.018			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27155035	Bronze, Green Submitted			2022-12-18	WOS:000376180200018
J	Czarnowicki, T; Gonzalez, J; Shemer, A; Malajian, D; Xu, H; Zheng, XZ; Khattri, S; Gilleaudeau, P; Sullivan-Whalen, M; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E				Czarnowicki, Tali; Gonzalez, Juana; Shemer, Avner; Malajian, Dana; Xu, Hui; Zheng, Xiuzhong; Khattri, Saakshi; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma			Severe atopic dermatitis is characterized by selective expansion of circulating T(H)2/T(C)2 and T(H)22/T(C)22, but not T(H)17/T(C)17, cells within the skin-homing T-cell population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; T cell; cutaneous lymphocyte antigen; IL-13; IL-22; IFN-gamma; skin infections	POSSIBLE PATHOGENIC ROLE; BLOOD MONONUCLEAR-CELLS; HUMAN B-CELLS; PERIPHERAL-BLOOD; INTERFERON-GAMMA; IFN-GAMMA; HOST-DEFENSE; TH17 CELLS; ANTIMICROBIAL PEPTIDES; STAPHYLOCOCCUS-AUREUS	Background: Past studies of blood T-cell phenotyping in patients with atopic dermatitis (AD) have provided controversial results and were mostly performed before the identification of T(H)9, T(H)17, and T(H)22 T-cell populations in human subjects. Objective: We sought to quantify T(H)1, T(H)2, T(H)9, T(H)17, and T(H)22 T-cell populations and corresponding CD8(+) T-cell subsets in both cutaneous lymphocyte antigen (CLA)-positive and CLA(-) T-cell subsets in patients with AD and control subjects. Methods: We studied 42 adults with severe AD (mean SCORAD score, 65) and 25 healthy subjects using an 11-color flow cytometric antibody panel. Frequencies of IFN-gamma-, IL-22-, IL-13-, IL-17-, and IL-9-producing CD4(+) and CD8(+) T cells were compared in CLA(-) and CLA(+) populations. Results: We measured increased T(H)2/T(C)2/IL-13(+) and T(H)22/T(C)22/IL-22(+) populations (P <.1) in patients with severe AD versus control subjects, with significant differences in CLA(+) T-cell numbers (P <.01). A significantly lower frequency of CLA(+) IFN-gamma-producing cells was observed in patients with AD, with no significant differences in CLA(-) T-cell numbers. The CLA(+) T(H)1/T(H)2 and T(C)1/T(C)2 ratio was highly imbalanced in patients withAD (10 vs 3 [P = .005] and 19 vs 7 [P < .001], respectively). Positive correlations were found between frequencies of IL-13- and IL-22- producing CD4(+) and CD8(+) T cells (r = 0.5 and 0.8, respectively; P < .0001), and frequencies of IL-13-producing CLA(+) cells were also correlated with IgE levels and SCORAD scores. Patients with AD with skin infections had higher CD4(+) IL-22(+) and IL-17(+) cell frequencies, which were highly significant among CLA(-) cells (IL-22: 3.7 vs 1.7 [P < .001] and IL-17: 1.7 vs 0.6 [P < .001]), with less significant effects among CLA(+) T cells (IL-22: 11 vs 7.5, P = .04). Conclusions: Severe AD is accompanied by expansion of skinhoming T(H)2/T(C)2 and T(H)22/T(C)22 subsets with lower T(H)1/T(C)1 frequencies. These data create a critical basis for studying alterations in immune activation in adults and pediatric patients with AD.	[Czarnowicki, Tali; Malajian, Dana; Xu, Hui; Zheng, Xiuzhong; Khattri, Saakshi; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10065 USA; [Gonzalez, Juana] Rockefeller Univ, Translat Technol Core Lab, New York, NY 10065 USA; [Suarez-Farinas, Mayte] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10065 USA; [Shemer, Avner] Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel; [Malajian, Dana] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA	Rockefeller University; Rockefeller University; Rockefeller University; Columbia University; Icahn School of Medicine at Mount Sinai	Czarnowicki, T (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA.	tczarnowic01@rockefeller.edu			National Center for Advancing Translational Science Award (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1 TR000043]; NCATS, NIH CTSA program [UL1TR0000]; American Dermatological Association Medical Student Fellowship; National Center for Research Resources (NCRR), NIH [5UL1RR024143-02]; NIH Road-map for Medical Research; Dermatology Foundation Physician Scientist Career Development Award	National Center for Advancing Translational Science Award (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program; NCATS, NIH CTSA program; American Dermatological Association Medical Student Fellowship; National Center for Research Resources (NCRR), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Road-map for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation Physician Scientist Career Development Award	T.C. was supported in part by grant no. UL1 TR000043 from the National Center for Advancing Translational Science Award (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. J.G. was supported in part by grant no. UL1TR0000 from the NCATS, NIH CTSA program. D.M. received funding from the American Dermatological Association Medical Student Fellowship. J.G.K. and M.S.-F. were supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the NIH, and the NIH Road-map for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award.	Agner T, 2010, BRIT J DERMATOL, V163, P1147, DOI 10.1111/j.1365-2133.2010.10114.x; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 1999, J IMMUNOL, V163, P466; Aleksza M, 2002, BRIT J DERMATOL, V147, P1135, DOI 10.1046/j.1365-2133.2002.05013.x; Antunez C, 2006, PEDIAT ALLERG IMM-UK, V17, P166, DOI 10.1111/j.1399-3038.2006.00390.x; Antunez C, 2004, CLIN EXP ALLERGY, V34, P559, DOI 10.1111/j.1365-2222.2004.1933.x; Antunez C, 2004, ALLERGOL IMMUNOPATHO, V32, P252; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Batista DI, 2014, J EUR ACAD DERMATOL; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Biedermann T, 2002, EUR J IMMUNOL, V32, P3171, DOI 10.1002/1521-4141(200211)32:11<3171::AID-IMMU3171>3.0.CO;2-4; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Ciprandi G, 2010, ANN ALLERG ASTHMA IM, V104, P180, DOI 10.1016/j.anai.2009.11.043; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; Di Cesare A, 2008, J INVEST DERMATOL, V128, P2569, DOI 10.1038/jid.2008.283; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Ferran Marta, 2010, World Allergy Organ J, V3, P44, DOI 10.1097/WOX.0b013e3181d675f8; Gao PS, 2012, J INVEST DERMATOL, V132, P650, DOI 10.1038/jid.2011.374; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hennino A, 2011, J ALLERGY CLIN IMMUN, V127, P1064, DOI 10.1016/j.jaci.2010.11.022; Higaki S, 1999, INT J DERMATOL, V38, P265, DOI 10.1046/j.1365-4362.1999.00686.x; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Jin W, 2013, EMERG MICROBES INFEC, P2; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; JUNG T, 1995, J ALLERGY CLIN IMMUN, V96, P515, DOI 10.1016/S0091-6749(95)70296-2; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Kalinke U, 2012, IMMUNOL CELL BIOL, V90, P505, DOI 10.1038/icb.2012.8; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; La Grutta S, 2005, ALLERGY, V60, P391, DOI 10.1111/j.1398-9995.2005.00733.x; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu SY, 2012, P NATL ACAD SCI USA, V109, P4239, DOI 10.1073/pnas.1114981109; Lonati A, 1999, CLIN EXP IMMUNOL, V115, P1; Ma L, 2014, CLIN EXP IMMUNOL, V175, P25, DOI 10.1111/cei.12198; Machura E, 2007, EUR J PEDIATR, V166, P789, DOI 10.1007/s00431-006-0319-5; MALEFYT RD, 1995, INT IMMUNOL, V7, P1405, DOI 10.1093/intimm/7.9.1405; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Nada HA, 2012, INT J INFECT DIS, V16, pE29, DOI 10.1016/j.ijid.2011.09.014; Nakagawa S, 1998, EXP DERMATOL, V7, P112, DOI 10.1111/j.1600-0625.1998.tb00310.x; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Pennino D, 2013, J ALLERGY CLIN IMMUN, V131, P562, DOI 10.1016/j.jaci.2012.09.036; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Sato A, 1998, J INVEST DERMATOL, V111, P1079, DOI 10.1046/j.1523-1747.1998.00454.x; Sato A, 1998, J INVEST DERMATOL, V110, P665; Savinko T, 2005, J IMMUNOL, V175, P8320, DOI 10.4049/jimmunol.175.12.8320; Scheynius A, 2014, EXP DERMATOL, V23, P2; Schmitt E, 2014, TRENDS IMMUNOL, V35, P61, DOI 10.1016/j.it.2013.10.004; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Stassen M, 2012, ANN NY ACAD SCI, V1247, P56, DOI 10.1111/j.1749-6632.2011.06351.x; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Teraki Y, 2000, BRIT J DERMATOL, V143, P373, DOI 10.1046/j.1365-2133.2000.03665.x; Teraki Y, 2013, J ALLERGY CLIN IMMUN, V132, P971, DOI 10.1016/j.jaci.2013.07.029; Wittkowski KM, 2004, STAT MED, V23, P1579, DOI 10.1002/sim.1778; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Xing JC, 2011, J ASTHMA, V48, P115, DOI 10.3109/02770903.2011.554944; Ying S, 2002, CLIN EXP ALLERGY, V32, P866, DOI 10.1046/j.1365-2222.2002.01376.x; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720	75	133	137	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					104	U215		10.1016/j.jaci.2015.01.020	http://dx.doi.org/10.1016/j.jaci.2015.01.020			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25748064				2022-12-18	WOS:000357542200012
J	Esaki, H; Ewald, DA; Ungar, B; Rozenblit, M; Zheng, XZ; Xu, H; Estrada, YD; Peng, XY; Mitsui, H; Litman, T; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E				Esaki, Hitokazu; Ewald, David A.; Ungar, Benjamin; Rozenblit, Mariya; Zheng, Xiuzhong; Xu, Hui; Estrada, Yeriel D.; Peng, Xiangyu; Mitsui, Hiroshi; Litman, Thomas; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma			Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; laser capture microdissection; IL-34; claudins 8 and 4; immune; barrier	TIGHT JUNCTIONS; LANGERHANS CELLS; HUMAN EPIDERMIS; CNS MYELIN; T-CELLS; SKIN; DIFFERENTIATION; PERMEABILITY; ACTIVATION; MECHANISMS	Background: The molecular signature of atopic dermatitis (AD) lesions is associated with T(H)2 and T(H)22 activation and epidermal alterations. However, the epidermal and dermal AD transcriptomes and their respective contributions to abnormalities in respective immune and barrier phenotypes are unknown. Objective: We sought to establish the genomic profile of the epidermal and dermal compartments of lesional and nonlesional AD skin compared with normal skin. Methods: Laser capture microdissection was performed to separate the epidermis and dermis of lesional and nonlesional skin from patients with AD and normal skin from healthy volunteers, followed by gene expression (microarrays and real-time PCR) and immunostaining studies. Results: Our study identified novel immune and barrier genes, including the IL-34 cytokine and claudins 4 and 8, and showed increased detection of key AD genes usually undetectable on arrays (ie, IL22, thymic stromal lymphopoietin [TSLP], CCL22, and CCL26). Overall, the combined epidermal and dermal transcriptomes enlarged the AD transcriptome, adding 674 upregulated and 405 downregulated differentially expressed genes between lesional and nonlesional skin to the AD transcriptome. We were also able to localize individual transcripts as primarily epidermal (defensin, beta 4A [DEFB4A]) or dermal (IL22, cytotoxic T-lymphocyte antigen 4 [CTLA4], and CCR7) and link their expressions to possible cellular sources. Conclusions: This is the first report that establishes robust epidermal and dermal genomic signatures of lesional and nonlesional AD skin and normal skin compared with whole tissues. These data establish the utility of laser capture microdissection to separate different compartments and cellular subsets in patients with AD, allowing localization of key barrier or immune molecules and enabling detection of gene products usually not detected on arrays.	[Esaki, Hitokazu; Ewald, David A.; Ungar, Benjamin; Rozenblit, Mariya; Zheng, Xiuzhong; Xu, Hui; Estrada, Yeriel D.; Peng, Xiangyu; Mitsui, Hiroshi; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA; [Esaki, Hitokazu; Ungar, Benjamin; Rozenblit, Mariya; Estrada, Yeriel D.; Peng, Xiangyu; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Ewald, David A.; Litman, Thomas] LEO Pharma, Mol Biomed, Ballerup, Denmark; [Ewald, David A.] Tech Univ Denmark, DTU Syst Biol, Ctr Microbial Biotechnol, DK-2800 Lyngby, Denmark	Rockefeller University; Icahn School of Medicine at Mount Sinai; LEO Pharma; Technical University of Denmark	Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Icahn Sch Med Mt Sinai, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org		Litman, Thomas/0000-0002-6068-901X; Ungar, Benjamin/0000-0003-0882-8163; Esaki, Hitokazu/0000-0002-3716-520X; Rozenblit, Mariya/0000-0002-8874-6688; Ewald, David Adrian/0000-0001-6620-2738	National Center for Research Resources (NCRR) [5UL1RR024143-02]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	J.G.K. and M.S.-F. were supported by grant 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Supported in part by grant no. UL1TR000043 from the National Center for Advancing Translational Sciences (NCATS, NIH Clinical and Translational Science Award [CTSA]) program. E. G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award and by Leo Pharma, and D. A. E. is a joint PhD student of Leo Pharma and DTU and partly funded by the Danish Ministry of Higher Education and Science.	Agrawal R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0433-9; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boedigheimer MJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-285; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Bronstein JM, 1997, J NEUROSCI RES, V50, P713, DOI 10.1002/(SICI)1097-4547(19971201)50:5<713::AID-JNR8>3.3.CO;2-Q; Chiricozzi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090284; DeCarlo K, 2011, METHODS MOL BIOL, V755, P1, DOI 10.1007/978-1-61779-163-5_1; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Espina V, 2006, NAT PROTOC, V1, P586, DOI 10.1038/nprot.2006.85; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Greter M, 2012, IMMUNITY, V37, P1050, DOI 10.1016/j.immuni.2012.11.001; Gulati N, 2013, J INVEST DERMATOL, V133, P2640, DOI 10.1038/jid.2013.190; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2013, EXPERT OPIN BIOL TH, V13, P549, DOI 10.1517/14712598.2013.758708; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hatano Y, 2005, J INVEST DERMATOL, V124, P786, DOI 10.1111/j.0022-202X.2005.23651.x; Hou JH, 2010, P NATL ACAD SCI USA, V107, P18010, DOI 10.1073/pnas.1009399107; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Juric M, 2013, INFLAMM BOWEL DIS, V19, P904, DOI 10.1097/MIB.0b013e3182813322; Kennedy-Crispin M, 2012, J INVEST DERMATOL, V132, P105, DOI 10.1038/jid.2011.262; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kitajiri S, 2004, HEARING RES, V187, P25, DOI 10.1016/S0378-5955(03)00338-1; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; Liu Angen, 2010, J Biomol Tech, V21, P120; Mitsui H, 2012, J INVEST DERMATOL, V132, P1615, DOI 10.1038/jid.2012.33; Ning H, 2013, ONCOTARGET, V4, P2237, DOI 10.18632/oncotarget.1357; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Onoue A, 2009, EXP DERMATOL, V18, P1036, DOI 10.1111/j.1600-0625.2009.00899.x; Radoja N, 2006, PHYSIOL GENOMICS, V27, P65, DOI 10.1152/physiolgenomics.00031.2006; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yuki T, 2013, J DERMATOL SCI, V69, P148, DOI 10.1016/j.jdermsci.2012.11.595	46	133	136	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					153	163		10.1016/j.jaci.2014.10.037	http://dx.doi.org/10.1016/j.jaci.2014.10.037			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25567045	Green Published, Green Accepted			2022-12-18	WOS:000347298200019
J	Nanzer, AM; Chambers, ES; Ryanna, K; Richards, DF; Black, C; Timms, PM; Martineau, AR; Griffiths, CJ; Corrigan, CJ; Hawrylowicz, CM				Nanzer, Alexandra M.; Chambers, Emma S.; Ryanna, Kimuli; Richards, David F.; Black, Cheryl; Timms, Peter M.; Martineau, Adrian R.; Griffiths, Christopher J.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.			Enhanced production of IL-17A in patients with severe asthma is inhibited by 1 alpha,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; vitamin D; IL-17A; steroid resistant; steroid sensitive; T(H)17; glucocorticoids	COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; VITAMIN-D LEVELS; RECEPTOR-BETA; AIRWAY HYPERRESPONSIVENESS; PROINFLAMMATORY CYTOKINES; INSENSITIVE ASTHMA; RESISTANT ASTHMA; EPITHELIAL-CELLS; LUNG-FUNCTION	Background: T(H)17 cells are proposed to play a role in the pathology of asthma, including steroid-resistant (SR) disease. We previously identified a steroid-enhancing function of vitamin D in patients with SR asthma in restoring the impaired response to steroids for production of the anti-inflammatory cytokine IL-10. Objective: We sought to investigate the production of the T(H)17-associated cytokines IL-17A and IL-22 in culture in patients with moderate-to-severe asthma defined on the basis of their clinical response to steroids and the susceptibility of this response to inhibition by steroids and the active form of vitamin D, 1 alpha,25-dihydroxyvitamin D3 (1,25[OH](2)D3). Methods: PBMCs were stimulated in culture with or without dexamethasone and 1,25(OH)(2)D3. A cytometric bead array, ELISA, and intracellular cytokine staining were used to assess cytokine production. The role of CD39 in inhibition of the T(H)17 response was studied by using quantitative real-time PCR, flow cytometry, and addition of the antagonist POM-1 to culture. Results: Asthmatic patients synthesized much higher levels of IL-17A and IL-22 than nonasthmatic control subjects, with patients with SR asthma expressing the highest levels of IL-17A. Glucocorticoids did not inhibit IL-17A cytokine expression in patients and enhanced production in cultures from control subjects. Treatment with 1,25(OH)(2)D3 with or without dexamethasone significantly reduced both IL-17A and IL-22 levels. An antagonist of the ectonucleotidase CD39 reversed 1,25(OH)(2)D3-mediated inhibition of the IL-17A response. Conclusion: Patients with severe asthma exhibit increased levels of T(H)17 cytokines, which are not inhibited by steroids. 1,25(OH)(2)D3 inhibits T(H)17 cytokine production in all patients studied, irrespective of their clinical responsiveness to steroids, identifying novel steroid-enhancing properties of vitamin D in asthmatic patients.	[Nanzer, Alexandra M.; Chambers, Emma S.; Ryanna, Kimuli; Richards, David F.; Black, Cheryl; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, MRC, London SE1 9RT, England; [Nanzer, Alexandra M.; Chambers, Emma S.; Ryanna, Kimuli; Richards, David F.; Black, Cheryl; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England; [Nanzer, Alexandra M.; Martineau, Adrian R.; Griffiths, Christopher J.] Univ London, Blizard Inst, Ctr Primary Care & Publ Hlth, London, England; [Timms, Peter M.] Homerton Univ NHS Fdn Trust, London, England	University of London; King's College London; University of London; King's College London; University of London	Hawrylowicz, CM (corresponding author), Kings Coll London, Guys Hosp, Dept Asthma Allergy & Resp Sci, 5th Floor Tower Wing, London SE1 9RT, England.	catherine.hawrylowicz@kcl.ac.uk	Chambers, Emma/AAI-3521-2021; Martineau, Adrian R/A-3083-2010; Hawrylowicz, Catherine/Q-8483-2017	Chambers, Emma/0000-0003-0990-8835; Corrigan, Chris/0000-0002-0706-6534; Hawrylowicz, Catherine/0000-0002-2337-7463	MRC; BSI International; MRC Clinical Research Training Fellowship; Novartis; Asthma UK; National Institutes of Health; Wellcome Trust; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; Asthma UK [08/019] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BSI International; MRC Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Novartis(Novartis); Asthma UK; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	E. S. Chambers has received an MRC Centenary Award and has received a BSI International Travel Grant. K. Ryanna has received an MRC Clinical Research Training Fellowship. C. J. Corrigan has received honoraria for consultancy from Meda and from Chiesi, has received one or more grants from or has one or more grants pending with and has received one or more payments for travel/accommodations/meeting expenses from Novartis, and has received honoraria for lectures from Allergy Therapeutics. C. M. Hawrylowicz has been supported by one or more grants from Asthma UK and has received an Ancillary grant from the National Institutes of Health, a Wellcome Trust Clinical Research Training Fellowship, and MRC PhD studentships. The rest of the authors declare that they have no relevant conflicts of interest.	Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Adcock IM, 2008, CURR ALLERGY ASTHM R, V8, P171, DOI 10.1007/s11882-008-0028-4; Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; Bhakta NR, 2011, IMMUNOL REV, V242, P220, DOI 10.1111/j.1600-065X.2011.01032.x; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Bush A, 2011, CURR OPIN ALLERGY CL, V11, P115, DOI 10.1097/ACI.0b013e32834487ae; Butler CA, 2012, THORAX, V67, P392, DOI 10.1136/thoraxjnl-2011-200760; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Chang H, 2006, J IMMUNOL, V177, P3635, DOI 10.4049/jimmunol.177.6.3635; Chang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012925; Chen K, 2011, IMMUNITY, V35, P997, DOI 10.1016/j.immuni.2011.10.018; Chung KF, 1999, EUR RESPIR J, V13, P1198; Corrigan Chris J, 2002, Am J Respir Med, V1, P47; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Damera G, 2009, BRIT J PHARMACOL, V158, P1429, DOI 10.1111/j.1476-5381.2009.00428.x; Dimeloe S, 2012, THORAX, V67, P574, DOI 10.1136/thoraxjnl-2011-200651; Dwyer KM, 2010, AM J TRANSPLANT, V10, P2410, DOI 10.1111/j.1600-6143.2010.03291.x; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Geboes L, 2009, ARTHRITIS RHEUM-US, V60, P390, DOI 10.1002/art.24220; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Gupta A, 2011, AM J RESP CRIT CARE, V184, P1342, DOI 10.1164/rccm.201107-1239OC; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757; Joshi S, 2011, MOL CELL BIOL, V31, P3653, DOI 10.1128/MCB.05020-11; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; KAM JC, 1993, J IMMUNOL, V151, P3460; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Mogil J, 2007, J AM ACAD NURSE PRAC, V19, P459, DOI 10.1111/j.1745-7599.2007.00247.x; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Nakagome K, 2011, J IMMUNOL, V187, P5077, DOI 10.4049/jimmunol.1001560; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Takei-Taniguchi R, 2012, J DERMATOL, V39, P625, DOI 10.1111/j.1346-8138.2011.01462.x; Tang J, 2009, J IMMUNOL, V182, P4624, DOI 10.4049/jimmunol.0801543; Urry Z, 2012, EUR J IMMUNOL, V42, P2697, DOI 10.1002/eji.201242370; Vazquez-Tello A, 2010, CLIN EXP ALLERGY, V40, P1312, DOI 10.1111/j.1365-2222.2010.03544.x; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Wu AC, 2012, AM J RESP CRIT CARE, V186, P508, DOI 10.1164/rccm.201202-0351OC; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519	49	133	139	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					297	+		10.1016/j.jaci.2013.03.037	http://dx.doi.org/10.1016/j.jaci.2013.03.037			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23683514	Green Submitted			2022-12-18	WOS:000322631700005
J	Olenec, JP; Kim, WK; Lee, WM; Vang, F; Pappas, TE; Salazar, LEP; Evans, MD; Bork, J; Roberg, K; Lemanske, RF; Gern, JE				Olenec, Jaime P.; Kim, Woo Kyung; Lee, Wai-Ming; Vang, Fue; Pappas, Tressa E.; Salazar, Lisa E. P.; Evans, Michael D.; Bork, Jack; Roberg, Kathleen; Lemanske, Robert F., Jr.; Gern, James E.			Weekly monitoring of children with asthma for infections and illness during common cold seasons	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; viral respiratory tract infection; human rhinovirus; allergic sensitization; wheezing; cold symptoms; illness	HUMAN RHINOVIRUS; HOSPITAL ADMISSIONS; SEPTEMBER EPIDEMIC; VIRAL-INFECTIONS; EXACERBATIONS; INFANTS; ATOPY	Background: Exacerbations of childhood asthma and rhinovirus infections both peak during the spring and fall, suggesting that viral infections are major contributors to seasonal asthma morbidity. Objectives: We sought to evaluate rhinovirus infections during peak seasons in children with asthma and to analyze relationships between viral infection and illness severity. Methods: Fifty-eight children aged 6 to 8 years with asthma provided 5 consecutive weekly nasal lavage samples during September and April; symptoms, medication use, and peak flow were recorded. Rhinoviruses were identified by using multiplex PCR and partial sequencing of viral genomes. Results: Viruses were detected in 36% to 50% of the specimens, and 72% to 99% of the viruses were rhinoviruses. There were 52 different strains (including 16 human rhinovirus C) among the 169 rhinovirus isolates; no strains were found in more than 2 collection periods, and all but 2 children had a respiratory tract infection. Virus-positive weeks were associated with greater cold and asthma symptom severity (P <.0001 and P = .0002, respectively). Furthermore, virus-positive illnesses had increased duration and severity of cold and asthma symptoms and more frequent loss of asthma control (47% vs 22%, P = .008). Although allergen-sensitized versus nonsensitized children had the same number of viral infections, the former had 47% more symptomatic viral illnesses (1.19 vs 0.81 per month, P = .03). Conclusions: Rhinovirus infections are nearly universal in children with asthma during common cold seasons, likely because of a plethora of new strains appearing each season. Illnesses associated with viruses have greater duration and severity. Finally, atopic asthmatic children experienced more frequent and severe virus-induced illnesses. (J Allergy Clin Immunol 2010;125:1001-6.)	[Olenec, Jaime P.; Kim, Woo Kyung; Lee, Wai-Ming; Vang, Fue; Pappas, Tressa E.; Salazar, Lisa E. P.; Bork, Jack; Roberg, Kathleen; Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA; [Olenec, Jaime P.; Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Dept Med, Madison, WI 53792 USA; [Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Kim, Woo Kyung] Inje Univ, Coll Med, Dept Pediat, Seoul, South Korea	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Inje University	Gern, JE (corresponding author), Univ Wisconsin, Dept Pediat, K4-918 CSC,600 Highland Ave, Madison, WI 53792 USA.	gern@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993	National Institutes of Health [R01 HL080072]; AstraZeneca; Merck; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca); Merck(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant R01 HL080072.; Disclosure of potential conflict of interest: R. F. Lemanske, Jr, has given lectures for Merck and AstraZeneca and has consulted for AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, International Meetings and Science, and Scienomics. J. E. Gem has stock options in EraGen Biosciences and 3V Biosciences, has consulted for 3V Biosciences and Synairgen, and has received research support from AstraZeneca and Merck. The rest of the authors have declared that they have no conflict of interest.	FOX JP, 1985, AM J EPIDEMIOL, V122, P830, DOI 10.1093/oxfordjournals.aje.a114166; Hayden FG, 2003, CLIN INFECT DIS, V36, P1523, DOI 10.1086/375069; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kistler AL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-40; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; *NIH NAT ASTHM ED, 2007, 3 US DEP HLTH HUM SE; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; POWELL KR, 1977, J INFECT DIS, V136, P109, DOI 10.1093/infdis/136.1.109; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8	19	133	137	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1001	1006		10.1016/j.jaci.2010.01.059	http://dx.doi.org/10.1016/j.jaci.2010.01.059			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392488	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000277686700007
J	Bager, P; Arnved, J; Ronborg, S; Wohlfahrt, J; Poulsen, LK; Westergaard, T; Petersen, HW; Kristensen, B; Thamsborg, S; Roepstorff, A; Kapel, C; Melbye, M				Bager, Peter; Arnved, John; Ronborg, Steen; Wohlfahrt, Jan; Poulsen, Lars K.; Westergaard, Tine; Petersen, Henning Willads; Kristensen, Bjarne; Thamsborg, Stig; Roepstorff, Allan; Kapel, Christian; Melbye, Mads			Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; Trichuris suis; randomized clinical trial; parasite; helminth; allergy; IgE; skin prick test; total histamine; eosinophils	REGULATORY T-CELLS; SCHISTOSOMA-MANSONI INFECTION; GRASS-POLLEN IMMUNOTHERAPY; SKIN-TEST REACTIVITY; AIRWAY INFLAMMATION; HELMINTH INFECTION; INTESTINAL HELMINTHS; PROTECTS MICE; MURINE MODEL; SUBLINGUAL IMMUNOTHERAPY	Background: Parasitic helminth infections can protect against allergic airway inflammation in experimental models and have been associated with a reduced risk of atopy and a reduced course of asthma in some observational studies. Although no clinical evidence exists to support the use of helminth therapy for allergic disease, the helminth Trichuris suis has demonstrated efficacy in, treatment of inflammatory bowel disease. Objective: To determine efficacy of helminth therapy for allergic rhinitis. Methods: We conducted a double-blind, placebo-controlled, parallel group trial in which 100 subjects age 18 to 65 years with grass pollen-induced allergic rhinitis were randomly assigned to ingest a total of 8 doses with 2500 live T suis ova or placebo with an interval of 21 days. The primary outcome was a change in mean daily total symptom score for runny, itchy, sneezing nose (maximum change, 9.0) or in percentage of well days during the grass pollen season. Results: Treatment with T suis ova (N = 49) compared with placebo (N = 47) caused transient diarrhea peaking at day 41 in 33% of participants (placebo, 2%), and increased eosinophil counts (P < .001) and T suis-specific IgE (P < .05), IgG (P < .001), IgG4 (P < .003), and IgA (P < .001), whereas there was no significant change in symptom scores (0.0; 95% CI, -0.5 to 0.4; P = .87), well days (3%; 95% CI, -9% to 14%; P = .63), total histamine (P = .44), grass-specific IgE (P = .76), or diameter of wheal reaction on skin prick testing with grass (P = .85) or 9 other allergens. Conclusion: Repeated treatment with the helminth T suis induced a substantial clinical and immunologic response as evidence of infection, but had no therapeutic effect on allergic rhinitis. (J Allergy Clin Immunol 2010;125:123-30.)	[Bager, Peter; Wohlfahrt, Jan; Westergaard, Tine; Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen C, Denmark; [Arnved, John; Ronborg, Steen] Pulmonol & Allergy Clin Copenhagen, Copenhagen, Denmark; [Poulsen, Lars K.] Natl Univ Hosp, Allergy Clin, Copenhagen, Denmark; [Petersen, Henning Willads] Univ Copenhagen, Fac Life Sci, Serv Pharm, Frederiksberg, Denmark; [Thamsborg, Stig; Roepstorff, Allan] Univ Copenhagen, Fac Life Sci, Dept Vet Dis Biol, Frederiksberg, Denmark; [Kapel, Christian] Univ Copenhagen, Fac Life Sci, Dept Agr & Ecol, Frederiksberg, Denmark; [Kristensen, Bjarne] Phadia ApS, Allerod, Denmark	Statens Serum Institut; University of Copenhagen; University of Copenhagen; University of Copenhagen	Bager, P (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen C, Denmark.	pbg@ssi.dk	Poulsen, Lars K/J-3065-2019; Bager, Peter/R-3310-2019; Kapel, Christian M. O./G-9168-2014	Poulsen, Lars K/0000-0002-1730-847X; Bager, Peter/0000-0002-3577-8459; Kapel, Christian M. O./0000-0002-9539-457X; melbye, mads/0000-0001-8264-6785	Danish Medical Research Council; TrygFonden for Health	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); TrygFonden for Health	Supported by unrestricted grants from the Danish Medical Research Council, TrygFonden for Health, A. P. Moller and Wife Chastine Mc-Kinney Moller's Foundation for the Progress of Medical Sciences, and Aase and Ejnar Danielsen's Foundation for Medical Sciences.	Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; BEER RJS, 1973, PARASITOLOGY, V67, P253, DOI 10.1017/S0031182000046497; BEER RJS, 1973, PARASITOLOGY, V67, P263, DOI 10.1017/S0031182000046503; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Burastero SE, 2008, ANN ALLERG ASTHMA IM, V100, P343, DOI 10.1016/S1081-1206(10)60597-2; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Committee for Medicinal Products for Human Use (CHMP), 2004, GUID CLIN DEV MED PR; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Croese J, 2006, GUT, V55, P136, DOI 10.1136/gut.2005.079129; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Dittrich AM, 2008, J IMMUNOL, V180, P1792, DOI 10.4049/jimmunol.180.3.1792; Elliott DE, 2004, EUR J IMMUNOL, V34, P2690, DOI 10.1002/eji.200324833; Elliott DE, 2003, AM J PHYSIOL-GASTR L, V284, pG385, DOI 10.1152/ajpgi.00049.2002; Fenoy I, 2009, CLIN EXP IMMUNOL, V155, P275, DOI 10.1111/j.1365-2249.2008.03813.x; Flohr C, 2009, CLIN EXP ALLERGY, V39, P20, DOI 10.1111/j.1365-2222.2008.03134.x; Flohr C, 2007, AM J TROP MED HYG, V76, P732, DOI 10.4269/ajtmh.2007.76.732; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; HARTMANN S, 2009, CLIN EXP ALLERGY; Jackson JA, 2009, IMMUNOLOGY, V126, P18, DOI 10.1111/j.1365-2567.2008.03010.x; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; Kringel H, 2007, PARASITE IMMUNOL, V29, P327, DOI 10.1111/j.1365-3024.2007.00943.x; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Linneberg A, 2007, CLIN EXP ALLERGY, V37, P1137, DOI 10.1111/j.1365-2222.2007.02760.x; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Mangan NE, 2006, J IMMUNOL, V176, P138, DOI 10.4049/jimmunol.176.1.138; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Medeiros M, 2004, PEDIAT ALLERG IMM-UK, V15, P142, DOI 10.1046/j.1399-3038.2003.00119.x; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Mortimer K, 2006, AM J TROP MED HYG, V75, P914, DOI 10.4269/ajtmh.2006.75.914; Nagler-Anderson C, 2006, CHEM IMMUNOL ALLERGY, V90, P1, DOI 10.1159/000088876; Ndiaye M, 2004, CLIN REV ALLERG IMMU, V26, P105, DOI 10.1007/s12016-004-0005-1; Oliveira RR, 2009, MICROBES INFECT, V11, P223, DOI 10.1016/j.micinf.2008.11.017; Pacifico LGG, 2009, INFECT IMMUN, V77, P98, DOI 10.1128/IAI.00783-07; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Schnoeller C, 2008, J IMMUNOL, V180, P4265, DOI 10.4049/jimmunol.180.6.4265; Schubert C, 2004, NAT MED, V10, P1271, DOI 10.1038/nm1204-1271; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; Smits HH, 2007, J ALLERGY CLIN IMMUN, V120, P932, DOI 10.1016/j.jaci.2007.06.009; Summers RW, 2005, INFLAMM BOWEL DIS, V11, P783, DOI 10.1097/01.MIB.0000179316.50002.f3; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI [10.1016/S0002-9270(03)00623-3, 10.1111/j.1572-0241.2003.07660.x]; Trujillo-Vargas CM, 2007, AM J RESP CRIT CARE, V175, P336, DOI 10.1164/rccm.200601-054OC; TURNER KJ, 1985, INT ARCH ALLER A IMM, V78, P329, DOI 10.1159/000233906; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; Wang CC, 2001, CLIN EXP ALLERGY, V31, P495, DOI 10.1046/j.1365-2222.2001.01044.x; Weinstock JV, 2009, INFLAMM BOWEL DIS, V15, P128, DOI 10.1002/ibd.20633; Weinstock JV, 2005, SPRINGER SEMIN IMMUN, V27, P249, DOI 10.1007/s00281-005-0209-3; Wickelgren I, 2004, SCIENCE, V305, P170, DOI 10.1126/science.305.5681.170; Wilson MS, 2006, CHEM IMMUNOL ALLERGY, V90, P176, DOI 10.1159/000088892; Wilson MS, 2004, CLIN REV ALLERG IMMU, V26, P35, DOI 10.1385/CRIAI:26:1:35; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; World Medical Association, 2008, DECL HELS ETH PRINC; Yang JH, 2007, IMMUNOLOGY, V120, P8, DOI 10.1111/j.1365-2567.2006.02472.x	62	133	136	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					123	130		10.1016/j.jaci.2009.08.006	http://dx.doi.org/10.1016/j.jaci.2009.08.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19800680				2022-12-18	WOS:000273660500014
J	Covar, RA; Szefler, SJ; Zeiger, RS; Sorkness, CA; Moss, M; Mauger, DT; Boehmer, SJ; Strunk, RC; Martinez, FD; Taussig, LM				Covar, Ronina A.; Szefler, Stanley J.; Zeiger, Robert S.; Sorkness, Christine A.; Moss, Mark; Mauger, David T.; Boehmer, Susan J.; Strunk, Robert C.; Martinez, Fernando D.; Taussig, Lynn M.		Childhood Asthma Res & Educ	Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; asthma; bronchial hyperresponsiveness; childhood asthma; exacerbations	EMERGENCY-DEPARTMENT VISITS; EXHALED NITRIC-OXIDE; RISK-FACTORS; CHILDHOOD ASTHMA; SPIROMETRY; SEVERITY; PATTERNS	Background: Asthma exacerbations are a common cause of critical illness in children. Objective: To determine factors associated with exacerbations in children with persistent asthma. Methods: Regression modeling was used to identify historical, phenotypic, treatment, and time-dependent factors associated with the occurrence of exacerbations, defined by need for oral corticosteroids or emergency or hospital care in the 48-week Pediatric Asthma Controller Trial study. Children age 6 to 14 years with mild-to-moderate persistent asthma were randomized to receive either fluticasone propionate 100 mu g twice daily (FP monotherapy), combination fluticasone 100 mu g AM and salmeterol twice daily, or montelukast 5 mg once daily. Results: Of the 285 participants randomized, 48% had 231 exacerbations. Using a multivariate analysis, which included numerous demographic, pulmonary, and inflammatory parameters, only a history of an asthma exacerbation requiring a systemic corticosteroid in the past year (odds ratio [OR], 2.10; P < .001) was associated with a subsequent exacerbation during the trial. During the trial, treatment with montelukast versus FP monotherapy (OR, 2.00; P = .005), season (spring, fall, or winter vs summer; P <= .001), and average seasonal 5% reduction in AM peak expiratory flow (OR, 1.21; P = .01) were each associated with exacerbations. Changes in worsening of symptoms, P-agonist use, and low peak expiratory flow track together before an exacerbation, but have poor positive predictive value of exacerbation. Conclusion: Children with mild-to-moderate persistent asthma with previous exacerbations are more likely to have a repeat exacerbation despite controller treatment. Inhaled corticosteroids are superior to montelukast at modifying the exacerbation risk. Available physiologic measures and biomarkers and diary card tracking are not reliable predictors of asthma exacerbations.	[Covar, Ronina A.; Szefler, Stanley J.; Taussig, Lynn M.] Univ Colorado, Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; [Covar, Ronina A.; Szefler, Stanley J.; Taussig, Lynn M.] Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA; [Zeiger, Robert S.; Sorkness, Christine A.; Moss, Mark] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Sorkness, Christine A.; Moss, Mark] Univ Wisconsin, Ctr Clin Sci, Madison, WI 53706 USA; [Mauger, David T.; Boehmer, Susan J.] Penn State Univ, Dept Publ Hlth Sci, University Pk, PA 16802 USA; [Strunk, Robert C.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721 USA	National Jewish Health; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Diego; Kaiser Permanente; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Washington University (WUSTL); University of Arizona	Covar, RA (corresponding author), Univ Colorado, Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	covarr@njc.org		Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; General Clinical Research Centers at Washington University School of medicine [M01 RR00036]; National Jewish Medical and Research Center [M01 RR00051]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064288, U10HL064305, U10HL064295, U10HL064287, U10HL064307, U10HL064313] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Centers at Washington University School of medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Jewish Medical and Research Center; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants 5U10HL064287. 5U10HL064288, 5U10HL064295, 5U10HL064307. 5U10HL064305. and 5U10HL064313 from the National Heart. Lung. and Blood Institute: General Clinical Research Centers at Washington University School of medicine (M01 RR00036): and National Jewish Medical and Research Center (M01 RR00051).	Brouwer AFJ, 2006, EUR RESPIR J, V28, P1131, DOI 10.1183/09031936.06.00118205; Buist AS, 2006, AM J RESP CRIT CARE, V174, P1075, DOI 10.1164/rccm.200510-1606OC; Farber HJ, 1998, J ASTHMA, V35, P95, DOI 10.3109/02770909809055410; Farber HJ, 1998, J ASTHMA, V35, P547, DOI 10.3109/02770909809048957; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173, DOI 10.1164/ajrccm.157.4.9708124; McCoy K, 2006, J ALLERGY CLIN IMMUN, V118, P1226, DOI 10.1016/j.jaci.2006.09.006; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pijnenburg MW, 2006, PEDIAT ALLERG IMM-UK, V17, P189, DOI 10.1111/j.1399-3038.2006.00394.x; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Reeves MJ, 2006, PEDIATRICS, V117, pS106, DOI 10.1542/peds.2005-2000H; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Silverman RA, 2005, ARCH PEDIAT ADOL MED, V159, P818, DOI 10.1001/archpedi.159.9.818; Silverman RA, 2003, ANN EMERG MED, V42, P577, DOI 10.1067/S0196-0644(03)00410-4; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100	20	133	133	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					741	747		10.1016/j.jaci.2008.08.021	http://dx.doi.org/10.1016/j.jaci.2008.08.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014765	Green Accepted			2022-12-18	WOS:000259989000018
J	Juhn, YJ; Kita, H; Yawn, BP; Boyce, TG; Yoo, KH; McGree, ME; Weaver, AL; Wollan, P; Jacobson, RM				Juhn, Young J.; Kita, Hirohito; Yawn, Barbara P.; Boyce, Thomas G.; Yoo, Kwang H.; McGree, Michaela E.; Weaver, Amy L.; Wollan, Peter; Jacobson, Robert M.			Increased risk of serious pneumococcal disease in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; invasive pneumococcal disease; epidemiology; risk; microbial infection; pneumococcal pneumonia; adults; Rochester Epidemiology Project	VACCINE; EPIDEMIOLOGY; COMMUNITY; PNEUMONIAE; CLEARANCE; RECORD; MICE	Background: Individuals with asthma have been reported to be at increased risk of invasive pneumococcal disease (IPD). These findings need to be confirmed in a different population-based study setting. Objective: We assessed whether serious pneumococcal disease (SPD), defined as an IPD, pneumococcal pneumonia, or both, was associated with asthma status. Methods: This is a retrospective case-control study using criteria-based methods for ascertaining SPD, as well as asthma. Subjects were residents of Rochester, Minnesota, who had SPD between 1964 and 1983 (the primarily pre-pneumococcal vaccine era) and their age-and sex-matched control subjects using 1:2 matching. Potential cases and control subjects were identified by using the Rochester Epidemiology project database and confirmed by medical record reviews. All cases and control subjects were merged with the database comprising the entire pool of Rochester residents with and without asthma between 1964 and 1983. Results: A total of 3941 records of potential patients with SPD were reviewed, and we identified 174 cases of SPD (51% male subjects and 94% white subjects). SPD was associated with a history of asthma among all ages (odds ratio, 2.4; 95% CI, 0.96.6; P = .09) and among adults (odds ratio, 6.7; 95% CI, 1.627.3; P = .01), controlling for high-risk conditions for IPD and smoking exposure. The population-attributable risk percentage was 17% in the adult population. Conclusion: Adults with asthma might be at increased risk of SPD.	[Juhn, Young J.] Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, Rochester, MN 55905 USA; [Yawn, Barbara P.; Wollan, Peter] Olmsted Med Ctr, Dept Res, Rochester, MN USA; [Yoo, Kwang H.] Konkuk Univ, Sch Med, Dept Internal Med, Seoul, South Korea; [McGree, Michaela E.; Weaver, Amy L.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA	Mayo Clinic; Olmsted Medical Center; Konkuk University; Konkuk University Medical Center; Mayo Clinic	Juhn, YJ (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu		Jacobson, Robert/0000-0002-6355-8752	National Institutes of Health [R01 AI 56133]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by a National Institutes of Health grant (R01 AI 56133) from the National Institute of Allergy and Infectious Diseases.	*AM AC PED, 2006, RED BOOK 2006; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; BEARD CM, 1992, J CLIN EPIDEMIOL, V45, P1013; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BUSSE WW, 1991, REV INFECT DIS, V13, pS477; *CDC, 1997, ACT BACT COR SURV RE; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1022; Chaplin DD, 2007, J ALLERGY CLIN IMMUN, V119, pS132, DOI 10.1016/j.jaci.2006.11.647; Chinn S, 2004, THORAX, V59, P646, DOI 10.1136/thx.2004.021642; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; Fischer JE, 1997, J VIROL, V71, P8672, DOI 10.1128/JVI.71.11.8672-8677.1997; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; Juhn YJ, 2006, ANN ALLERG ASTHMA IM, V97, P469, DOI 10.1016/S1081-1206(10)60937-4; Katusic SK, 1998, MAYO CLIN PROC, V73, P1053, DOI 10.4065/73.11.1053; Kelsey JL., 1996, METHODS OBSERVATIONA; KincyCain T, 1996, INFECT IMMUN, V64, P1437, DOI 10.1128/IAI.64.4.1437-1440.1996; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LAHOOD N, 1993, ANN ALLERGY, V70, P289; LEE HJ, 1995, VACCINE, V13, P1533, DOI 10.1016/0264-410X(95)00093-G; LETHBRIDGECEJKU M, 2005, VITAL HLTH STAT, V10, P1; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; TSIGRELIS C, 1999, 45 ANN INF DIS SOC A; *US BUR CENS, 1980, PHC802305 US BUR CEN; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; *WHO, 2005, N307 WHO; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	31	133	137	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					719	723		10.1016/j.jaci.2008.07.029	http://dx.doi.org/10.1016/j.jaci.2008.07.029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18790525	Green Accepted			2022-12-18	WOS:000259989000014
J	Golden, DBK				Golden, DBK			Insect sting allergy and venom immunotherapy: A model and a mystery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						venom immunotherapy; insect sting; Hymenoptera; anaphylaxis; immunotherapy	YELLOW JACKET VENOM; LARGE LOCAL REACTIONS; WHOLE-BODY EXTRACT; HYMENOPTERA VENOM; NATURAL-HISTORY; HONEYBEE VENOM; SKIN-TESTS; FOLLOW-UP; ANT VENOM; ANAPHYLAXIS	Whole-body extracts of Hymenoptera were used for diagnosis and treatment until controlled clinical trials proved them no better than placebo, whereas venom is 85% to 98% effective. Studies of natural history reveal why whole-body extracts were thought to work. The chance of future systemic reactions is low in large local reactors and in most children and varies between 20% and 70% in adults. Venom skin tests are most accurate, but RAST is an important complementary test. The degree of sensitivity on skin tests or RASTs does not reliably predict the severity of a sting reaction. Venom immunotherapy is recommended for patients at high risk for sting reactions. Rapid regimens are as safe as slower regimens. The recommended dose is 100 mu g, but some patients require higher doses for full protection. Venom immunotherapy is continued every 4 to 8 weeks for at least 5 years in most cases. Skin test results become negative in only 25% after 5 years of therapy but in 60% to 70% after 7 to 10 years. When treatment is stopped after 5 years or more, there is a 10% chance of systemic reaction to each future sting, but most reactions are mild. Some patients have a higher risk of relapse and should continue treatment for an extended period.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Golden, DBK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Blvd, Baltimore, MD 21224 USA.	dgolden1@jhmi.edu			NCRR NIH HHS [5M01-RR02719] Funding Source: Medline; NIAID NIH HHS [AI08270] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BENSON RL, 1930, J ALLERGY, V1, P105; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BIMBAUM J, 1993, CLIN EXP ALLERGY, V23, P226; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; Brown SGA, 2003, J ALLERGY CLIN IMMUN, V111, P187, DOI 10.1067/mai.2003.48; Cho YS, 2002, J ALLERGY CLIN IMMUN, V110, P54, DOI 10.1067/mai.2002.124890; DAY JH, 1986, J ALLERGY CLIN IMMUN, V77, P142; DAY JH, 1994, J ALLERGY CLIN IMMUN, V93, P691, DOI 10.1016/0091-6749(94)90249-6; Eberlein-Konig B, 2004, J INVEST ALLERG CLIN, V14, P10; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; Golden DB, 2004, ANAPHYLAXIS NOVARTIS, V257, P101; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, pS159; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, pS222; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; HAMILTON RG, 1993, J ALLERGY CLIN IMMUN, V92, P651, DOI 10.1016/0091-6749(93)90007-3; Hamilton RG, 2004, CURR OPIN ALLERGY CL, V4, P297, DOI 10.1097/01.all.0000136755.13077.b5; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hoffman DR, 2003, ALLERGY ASTHMA PROC, V24, P123; Hoffman DR, 2004, MONOGRAPH INSECT ALL, P37; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Insect Allergy Committee American Academy of Allergy, 1965, JAMA-J AM MED ASSOC, V193, P115; JUTEL M, 1995, J IMMUNOL, V154, P4187; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; King TP, 2001, J IMMUNOL, V166, P6057, DOI 10.4049/jimmunol.166.10.6057; Konno S., 2004, Journal of Allergy and Clinical Immunology, V113, pS215, DOI 10.1016/j.jaci.2004.01.224; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller UR, 2002, ALLERGY, V57, P570, DOI 10.1034/j.1398-9995.2002.02157.x; MULLER UR, 1986, J ALLERGY CLIN IMMUN, V78, P115, DOI 10.1016/0091-6749(86)90123-5; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V91, P1100, DOI 10.1016/0091-6749(93)90227-7; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Sainte-Laudy J, 2000, CLIN EXP ALLERGY, V30, P1166, DOI 10.1046/j.1365-2222.2000.00863.x; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SCHWARTZ H J, 1984, Journal of Allergy and Clinical Immunology, V73, P189; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOBOTKA A, 1974, J ALLERGY CLIN IMMUN, V53, P110; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; YUNGINGER J W, 1982, Journal of Allergy and Clinical Immunology, V69, P139; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	79	133	138	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					439	447		10.1016/j.jaci.2005.01.005	http://dx.doi.org/10.1016/j.jaci.2005.01.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753884	Bronze			2022-12-18	WOS:000227687000001
J	Stuck, BA; Czajkowski, J; Hagner, AE; Klimek, L; Verse, T; Hormann, K; Maurer, JT				Stuck, BA; Czajkowski, J; Hagner, AE; Klimek, L; Verse, T; Hormann, K; Maurer, JT			Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: A controlled clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; daytime sleepiness; quality of life; polysomnography	YOUNG-ADULTS; CHILDREN; APNEA; PREVALENCE; DISORDERS	Background: It has long been assumed that allergic rhinitis leads to daytime sleepiness and a deterioration of nocturnal sleep, yet systematic studies have only been rarely conducted in this field. Objective: The aim of the present study was to investigate the effects of seasonal allergic rhinitis on subjective and objective sleep patterns, quality of life, and daytime sleepiness in otherwise healthy subjects in comparison with nonallergic volunteers. Methods: Twenty-five patients with seasonal allergic rhinitis and 25 healthy volunteers were enrolled in this prospective, controlled clinical trial. Daytime sleepiness and quality of life were assessed with the help of questionnaires (Epworth Sleepiness Scale, SF-36); 2 consecutive nights of fully attended polysomnography were performed before and during the pollen season of 2002. Results: Statistically significant differences between groups were found in respect to changes in daytime sleepiness and selected parameters of quality of life. Impairment of daytime sleepiness and quality of life were related to the severity of the disease. Statistically significant differences were also found for selected parameters of the sleep studies, although the changes were only minimal, and all values were within normal ranges. Conclusion: Seasonal allergic rhinitis leads to increased daytime sleepiness, as well as to an impairment of quality of life, depending on the severity of the disease. Objective measurements revealed a statistically significant influence of seasonal allergic rhinitis on selected sleep parameters, but changes were not of clinical relevance. Daytime sleepiness seems to be related to the condition itself rather than to an impairment of nocturnal sleep.	Univ Hosp Mannheim, Dept Otorhinolaryngol Head & Neck Surg, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg	Stuck, BA (corresponding author), Univ Hosp Mannheim, Dept Otorhinolaryngol Head & Neck Surg, D-68135 Mannheim, Germany.							Anuntaseree W, 2001, PEDIATR PULM, V32, P222, DOI 10.1002/ppul.1112; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kramer MF, 2001, ACTA OTO-LARYNGOL, V121, P494, DOI 10.1080/000164801300366651; Kremer B, 2002, CLIN EXP ALLERGY, V32, P1310, DOI 10.1046/j.1365-2745.2002.01483.x; Krouse HJ, 2002, OTOLARYNG HEAD NECK, V126, P607, DOI 10.1067/mhn.2002.125300; Lack G, 2001, J ALLERGY CLIN IMMUN, V108, pS9, DOI 10.1067/mai.2001.115562; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391, DOI 10.1164/ajrccm.162.4.9912033; Majani G, 2001, ALLERGY, V56, P313, DOI 10.1034/j.1398-9995.2001.00852.x; McColley SA, 1997, CHEST, V111, P170, DOI 10.1378/chest.111.1.170; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; Rechtschaffen A, 1968, MANUAL STANDARIZED T; Settipane RA, 1999, ALLERGY ASTHMA PROC, V20, P209, DOI 10.2500/108854199778339053; Simons FER, 1996, ALLERGY ASTHMA PROC, V17, P185, DOI 10.2500/108854196778996895; Spaeth J, 1996, ALLERGY, V51, P893; Young T, 1997, J ALLERGY CLIN IMMUN, V99, pS757, DOI 10.1016/S0091-6749(97)70124-6	19	133	138	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					663	668		10.1016/j.jaci.2003.12.589	http://dx.doi.org/10.1016/j.jaci.2003.12.589			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100670				2022-12-18	WOS:000220956600012
J	Nickel, R; Beck, LA; Stellato, C; Schleimer, RP				Nickel, R; Beck, LA; Stellato, C; Schleimer, RP			Chemokines and allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic disease; angiogenesis; chemokine; chemotaxis; cytokines; eosinophil; glucocorticoids; hematopoieses; mediators; transendothelial migration	HUMAN CC-CHEMOKINE; MONOCYTE CHEMOATTRACTANT PROTEIN-1; FACTOR-KAPPA-B; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; MYELOID PROGENITOR CELLS; LUNG EPITHELIAL-CELLS; HUMAN T-LYMPHOCYTES; PLATELET FACTOR-IV; IN-VIVO; EOSINOPHIL RECRUITMENT	Understanding the chemokine network has become one of the great challenges for researchers interested in inflammatory mechanisms and inflammation-based diseases. The complexity and diversity of the system provide not only a daunting task for its comprehension but also numerous opportunities for development of new, targeted therapies. It is now certain that chemokines are involved as important mediators of allergic inflammation; the fine details and scope of their roles are now under investigation, Presumably, because of distinct pressures on the immune systems of people living in different geographic regions, genetic variation of ligands, receptors, and regulatory regions in the network have emerged. Establishing the roles of these polymorphisms in determining disease susceptibility or progression among individuals and in distinct ethnic groups will provide a basis for improved understanding and treatment of allergic diseases.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Nickel, R (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Room 3A62,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Stellato, Cristiana/P-3001-2015	Stellato, Cristiana/0000-0002-1294-8355	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045839] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI045839] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1994, J IMMUNOL, V152, P1298; Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Andrew DP, 1998, J IMMUNOL, V161, P5027; Bartels Joachim, 1997, Rhinology (Utrecht), V35, P171; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Beck L, 1998, J ALLERGY CLIN IMMUN, V101, pS36; Beck LA, 1997, J IMMUNOL, V159, P2962; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; BECK LA, 1999, J ALLERGY CLIN IMMUN, V103, pA433; Becker S, 1997, AM J PHYSIOL-LUNG C, V272, pL512, DOI 10.1152/ajplung.1997.272.3.L512; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Berkman N, 1996, IMMUNOLOGY, V87, P599, DOI 10.1046/j.1365-2567.1996.477579.x; BERKMAN N, 1995, AM J PHYSIOL-LUNG C, V269, pL443, DOI 10.1152/ajplung.1995.269.4.L443; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, P527, DOI 10.1016/S0091-6749(99)70481-1; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, pS114; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bonini JA, 1997, DNA CELL BIOL, V16, P1249, DOI 10.1089/dna.1997.16.1249; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Broxmeyer HE, 1996, J EXP MED, V184, P1825, DOI 10.1084/jem.184.5.1825; BROXMEYER HE, 1993, J IMMUNOL, V150, P3448; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chensue SW, 1999, J IMMUNOL, V163, P165; CHUNG KF, 1997, ASTHMA, P673; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Conroy DM, 1997, MEM I OSWALDO CRUZ, V92, P183, DOI 10.1590/S0074-02761997000800024; Cooper JAD, 1998, AM J RESP CELL MOL, V18, P521, DOI 10.1165/ajrcmb.18.4.2786; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DALY TJ, 1995, J BIOL CHEM, V270, P23282, DOI 10.1074/jbc.270.40.23282; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Daugherty BL, 1997, GENOMICS, V41, P294, DOI 10.1006/geno.1997.4626; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; DUNNILL MS, 1978, ALLERGY PRINCIPLES P, P678; EBISAWA M, 1994, J IMMUNOL, V153, P2153; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1997, GENOMICS, V41, P471, DOI 10.1006/geno.1997.4656; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10, DOI 10.1164/ajrccm/148.1.10; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; GRUNDBACHER FJ, 1985, J ALLERGY CLIN IMMUN, V75, P651, DOI 10.1016/0091-6749(85)90089-2; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hein H, 1997, BIOCHEM BIOPH RES CO, V237, P537, DOI 10.1006/bbrc.1997.7169; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Jahnsen FL, 1999, J IMMUNOL, V163, P1545; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kellermann SA, 1999, J IMMUNOL, V162, P3859; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; KHORRAM O, 1993, AM J OBSTET GYNECOL, V169, P1545, DOI 10.1016/0002-9378(93)90433-J; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873, DOI 10.1164/ajrccm.157.3.9610052; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V97, P153, DOI 10.1016/S0091-6749(96)80215-6; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lecomte-Raclet L, 1998, BLOOD, V91, P2772, DOI 10.1182/blood.V91.8.2772.2772_2772_2780; LEE SC, 1998, IN PRESS J IMMUNOL; LEVINE SJ, 1995, J INVEST MED, V43, P241; Li L, 1998, J IMMUNOL, V161, P3128; Li L, 1999, J IMMUNOL, V162, P2477; LIGGETT SB, 1996, GENETICS ASTHMA, P455; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Marsh DG, 1997, NAT GENET, V15, P389; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3; Matsukura S, 1999, J ALLERGY CLIN IMMUN, V103, pS202; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; MAZE R, 1992, J IMMUNOL, V149, P1004; Meng Q, 1999, J ALLERGY CLIN IMMUN, V103, pS54; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Miyamasu M, 1998, J ALLERGY CLIN IMMUN, V101, P75, DOI 10.1016/S0091-6749(98)70196-4; Mochizuki M, 1998, J IMMUNOL, V160, P60; Mochizuki M, 1997, J INVEST DERMATOL, V109, P412; Modi WS, 1998, GENOMICS, V47, P136, DOI 10.1006/geno.1997.5100; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1992, IMMUNOLOGY, V75, P674; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21, DOI 10.1016/S1081-1206(10)63365-0; NEOTE K, 1994, BLOOD, V84, P44; Nickel R, 1999, J ALLERGY CLIN IMMUN, V103, pS174; NICKEL RG, 1999, INPRESS DETERMINATIO; NIGGS RJB, 1997, J BIOL CHEM, V272, P32078; Nomiyama H, 1998, CYTOGENET CELL GENET, V81, P10, DOI 10.1159/000015000; Nomiyama H, 1998, GENOMICS, V49, P339, DOI 10.1006/geno.1998.5250; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ogata M, 1999, BLOOD, V93, P3225, DOI 10.1182/blood.V93.10.3225.410k25_3225_3232; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; ORKIN SH, 1992, BLOOD, V80, P575; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Peled A, 1998, BLOOD, V91, P1909, DOI 10.1182/blood.V91.6.1909.1909_1909_1916; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; Powell N, 1996, EUR RESPIR J, V9, P2454, DOI 10.1183/09031936.96.09122454; Quackenbush EJ, 1997, J LEUKOCYTE BIOL, V62, P661, DOI 10.1002/jlb.62.5.661; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; Sabroe I, 1998, J IMMUNOL, V161, P6139; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; Schleimer RP, 1998, ASTHMA AND ALLERGIC DISEASES, P337, DOI 10.1016/B978-012473340-4/50028-X; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; SELVAN RS, 1994, J BIOL CHEM, V269, P13893; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SLAVIN J, 1995, GROWTH FACTORS, V12, P151, DOI 10.3109/08977199509028961; SNOWDEN N, 1994, LANCET, V343, P547, DOI 10.1016/S0140-6736(94)91503-2; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; Stafford S, 1997, J IMMUNOL, V158, P4953; STELLATO C, 1995, J IMMUNOL, V155, P410; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Stellato C, 1998, J ALLERGY CLIN IMMUN, V101, pS230; STELLATO C, 1999, IN PRESS J IMMUNOL; STELLATO C, 1997, ASTHMA, P1569; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; Strieter RM, 1996, CHEMOKINES DIS, P195; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanaka Y, 1998, BLOOD, V91, P3909; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Teran LM, 1996, J IMMUNOL, V157, P1806; Teran LM, 1997, J ALLERGY CLIN IMMUN, V100, P499, DOI 10.1016/S0091-6749(97)70142-8; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TUNNACLIFFE A, 1992, BLOOD, V79, P2896; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VADDI K, 1994, J IMMUNOL, V153, P4721; Venge J, 1996, J ALLERGY CLIN IMMUN, V97, P1110, DOI 10.1016/S0091-6749(96)70265-8; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WEBER M, 1995, J IMMUNOL, V154, P4166; Weido AJ, 1996, ANN ALLERG ASTHMA IM, V77, P407, DOI 10.1016/S1081-1206(10)63340-6; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Wingett D, 1996, FEBS LETT, V398, P308, DOI 10.1016/S0014-5793(96)01238-0; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; Zhao J, 1998, J CELL BIOCHEM, V71, P36, DOI 10.1002/(SICI)1097-4644(19981001)71:1<36::AID-JCB4>3.0.CO;2-2; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P104, DOI 10.1016/S0091-6749(97)70201-X	204	133	138	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				723	742		10.1016/S0091-6749(99)70281-2	http://dx.doi.org/10.1016/S0091-6749(99)70281-2			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518815				2022-12-18	WOS:000083281200002
J	Dewar, JC; Wilkinson, J; Wheatley, A; Thomas, NS; Doull, I; Morton, N; Lio, P; Harvey, JF; Liggett, SB; Holgate, ST; Hall, IP				Dewar, JC; Wilkinson, J; Wheatley, A; Thomas, NS; Doull, I; Morton, N; Lio, P; Harvey, JF; Liggett, SB; Holgate, ST; Hall, IP			The glutamine 27 beta(2)-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta(2)-adrenoceptor polymorphism; IgE; asthma; atopy; chromosome 5q; genetics of asthma	BETA-ADRENOCEPTOR AGONISTS; BRONCHIAL-ASTHMA; GENETIC-ANALYSIS; RECEPTOR; RESPONSIVENESS; HISTAMINE; INVITRO; CELLS; ATOPY	Background: The beta(2)-adrenoceptor polymorphisms occurring at amino acid positions 16 (arginine to glycine) and 27 (glutamine to glutamate) are known to be functionally relevant and also disease-modifying in subjects with asthma. However, the contribution of these polymorphisms to the development of the asthmatic phenotype or other markers for allergic disease remains to be established. Objective: This large family study examines the contributions of these polymorphisms in determining the heritable component of markers for allergic disease in asthmatic families. Methods: Three hundred twenty-four individuals from 60 families multiplex for asthma selected by means of an asthmatic proband were characterized for the following markers of allergic disease: asthma, atopy, and serum IgE. The polymerase chain reaction was used to generate a 234 base pair fragment spanning the region of interest, and the beta(2)-adrenoceptor polymorphism was then defined by allele-specific oligonucleotide hybridization. Segregation analysis was then performed. Results: We found a significant association (p = 0.009) between the glutamine 27 beta(2)-adrenoceptor polymorphism and elevated levels of IgE, which was supported by the observation of linkage between IgE and beta(2)-adrenoceptor polymorphisms at locus 27 (p = 0.037), However, there was no association between either the arginine-glycine 16 or the glutamine-glutamate 27 beta(2)-adrenoceptor polymorphism and an increased risk of asthma or atopy per se. Conclusion: The glutamine 27 beta(2)-adrenoceptor polymorphism appears to contribute to IgE variability in families with asthma. However, it seems that although both amino acid 16 and 27 beta(2)-adrenoceptor polymorphisms are disease-modifying in subjects with asthma, they do not contribute markedly to the development of the asthmatic phenotype.	UNIV NOTTINGHAM HOSP,NATL ASTHMA CAMPAIGN,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND; PRINCESS ANNE HOSP,DEPT MED,SOUTHAMPTON,HANTS,ENGLAND; PRINCESS ANNE HOSP,CANC RES CAMPAIGN GENET EPIDEMIOL RES GRP,SOUTHAMPTON,HANTS,ENGLAND; UNIV CINCINNATI,DEPT PULM & CRIT CARE MED,CINCINNATI,OH	University of Nottingham; University System of Ohio; University of Cincinnati			Doull, Iolo/Y-6174-2019; liggett, stephen b/E-7453-2012	Hall, Ian/0000-0001-9933-3216; Henry, Amanda/0000-0001-6299-7676; Liggett, Stephen B./0000-0002-0128-3669				BACHELET M, 1991, J ALLERGY CLIN IMMUN, V88, P322, DOI 10.1016/0091-6749(91)90093-4; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669, DOI 10.1111/j.1365-2125.1986.tb02956.x; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; GUNNEBERG A, 1993, CLIN CHEM, V39, P2157; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Holroyd K, 1995, AM J RESP CRIT CARE, V151, pA673; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSH DG, 1990, GENETIC ENV FACTORS, P132; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; OCONNOR BJ, 1994, AM J RESP CRIT CARE, V150, P381, DOI 10.1164/ajrccm.150.2.8049819; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; REISHAUS E, 1993, AM J RESPIR CELL MOL, V8, P334; SVENTIVANYI A, 1968, J ALLERGY, V42, P203; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	27	133	149	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					261	265		10.1016/S0091-6749(97)70234-3	http://dx.doi.org/10.1016/S0091-6749(97)70234-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275150				2022-12-18	WOS:A1997XR35100019
J	FURIN, MJ; NORMAN, PS; CRETICOS, PS; PROUD, D; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM				FURIN, MJ; NORMAN, PS; CRETICOS, PS; PROUD, D; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM			IMMUNOTHERAPY DECREASES ANTIGEN-INDUCED EOSINOPHIL CELL-MIGRATION INTO THE NASAL CAVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; RAGWEED; ALLERGIC RHINITIS; AMB A-I; EOSINOPHILS	HAY-FEVER; RAGWEED POLLEN; CHALLENGE; INFLUX; PRETREATMENT; PROTEIN	We investigated the effect of immunotherapy (IT) on eosinophil (EOS) migration into the nasal cavity after nasal provocation with ragweed antigen and during seasonal exposure. In the first study, three groups of subjects participated: one group with no treatment (N = 19), one group with 10 months of IT, reaching maintenance at 2-mu-g of Amb a I (antigen E) (N = 15), and one group with 22 months of IT, reaching maintenance at 24-mu-g of Amb a I (N = 10). The percent of EOSs in nasal lavages performed during December before and 24 hours after nasal challenge with ragweed extract was determined. No significant difference between groups existed before challenge. The no-treatment group demonstrated a significant increase in the percent of EOSs from 26% to 69.5% (p < 0.008), whereas the treated groups demonstrated no significant change. In the second study, 45 patients were divided into four groups based on maintenance dose in micrograms of Amb a I and duration of treatment: (1) no treatment (N = 15), (2) 1 year at 2-mu-g (N = 13), (3) 2 years at 2-mu-g (N = 11), and (4) 3 years at 24-mu-g (N = 9). Nasal mucosal brushings were done during the ragweek season. A significantly smaller percentage of EOSs in 3-year IT-treated individuals was obtained compared to the control group (18 versus 8.4; p < 0.04). The smaller dose of IT, regardless of duration, did not reveal a reduction compared to that in the no-treatment group. These studies provide evidence that IT modifies the eosinophilic response to antigen exposure and demonstrate a parallel between in vivo provocation and seasonal exposure.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI004866, F32AI008290, R01AI031335, R01AI004866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31335, AI 04866, AI 08290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PIPKORN U, 1988, J IMMUNOL METHODS, V112, P37, DOI 10.1016/0022-1759(88)90030-0; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SLIFMAN NR, 1988, ALLERGY PRINCIPLES P, V1, P179; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, ALLERGY PRINCIPLES P, V2, P1327; WALDEN SM, 1988, J ALLERGY CLIN IMMUN, V81, P282, DOI 10.1016/0091-6749(88)90690-2	19	133	136	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					27	32		10.1016/0091-6749(91)90297-2	http://dx.doi.org/10.1016/0091-6749(91)90297-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071783				2022-12-18	WOS:A1991FY20400003
J	BURKS, AW; BROOKS, JR; SAMPSON, HA				BURKS, AW; BROOKS, JR; SAMPSON, HA			ALLERGENICITY OF MAJOR COMPONENT PROTEINS OF SOYBEAN DETERMINED BY ENZYME-LINKED IMMUNOSORBENT-ASSAY (ELISA) AND IMMUNOBLOTTING IN CHILDREN WITH ATOPIC-DERMATITIS AND POSITIVE SOY CHALLENGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARKANSAS MED SCI, DEPT PEDIAT, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS, DEPT FOOD SCI, FAYETTEVILLE, AR 72701 USA; JOHNS HOPKINS MED SCH, DEPT PEDIAT, BALTIMORE, MD USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Fayetteville; Johns Hopkins University; Johns Hopkins Medicine	BURKS, AW (corresponding author), ARKANSAS CHILDRENS HOSP, DEPT PEDIAT, 800 MARSHALL ST, LITTLE ROCK, AR 72202 USA.				NCRR NIH HHS [RR05350-24] Funding Source: Medline; NIAID NIH HHS [AI24439, AI00830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K07AI000830, R01AI024439] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JA, 1984, NIH842442 PUBL; ANET J, 1985, INT ARCH ALLER A IMM, V77, P364, DOI 10.1159/000233846; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BROOKS JR, 1985, J AM OIL CHEM SOC, V62, P1347, DOI 10.1007/BF02545956; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BURKS AW, UNPUB J FOOD SCI; Conover William Jay, 1998, PRACTICAL NONPARAMET, V350; COOK CD, 1960, NEW ENGL J MED, V263, P1076, DOI 10.1056/NEJM196011242632109; CUNNINGHAMRUNDLES C, 1979, J CLIN INVEST, V64, P272, DOI 10.1172/JCI109448; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; DUKE W. W., 1934, JOUR ALLERGY, V5, P300, DOI 10.1016/S0021-8707(34)90228-8; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; Hill Lewis Webb, 1942, JOUR ALLERGY, V13, P366, DOI 10.1016/S0021-8707(42)90293-4; JAKOBSSON I, 1979, ACTA PAEDIATR SCAND, V68, P853; KOSHIYAMA I, 1976, PHYTOCHEMISTRY, V15, P157, DOI 10.1016/S0031-9422(00)89075-5; MAROZ LA, 1980, NEW ENGL J MED, V302, P1126; MARTIN ME, 1984, PEDIATRICS, V73, P532; MATTHEWS TS, 1970, LANCET, V2, P893; MAY CD, 1980, ALLERGY, V35, P301, DOI 10.1111/j.1398-9995.1980.tb01771.x; MOREIRA MA, 1981, ARCH BIOCHEM BIOPHYS, V210, P633, DOI 10.1016/0003-9861(81)90230-7; NAISMITH WEF, 1955, BIOCHIM BIOPHYS ACTA, V16, P203, DOI 10.1016/0006-3002(55)90205-5; Nielsen N., 1985, NEW PROTEIN FOODS, P27; OSTERBALLE O, 1983, J ALLERGY CLIN IMMUN, V71, P40, DOI 10.1016/0091-6749(83)90545-6; RATNER B, 1955, AMA AM J DIS CHILD, V89, P187, DOI 10.1001/archpedi.1955.02050110229008; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SHATTUCKEIDENS DN, 1985, PLANT PHYSIOL, V78, P895; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; THANH VH, 1976, J AGR FOOD CHEM, V24, P1117, DOI 10.1021/jf60208a030; THEOBALD K, 1986, J ALLERGY CLIN IMMUN, V78, P470, DOI 10.1016/0091-6749(86)90035-7; WOLF WJ, 1956, ARCH BIOCHEM BIOPHYS, V63, P40, DOI 10.1016/0003-9861(56)90007-8; [No title captured]	35	133	140	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1135	1142		10.1016/0091-6749(88)90881-0	http://dx.doi.org/10.1016/0091-6749(88)90881-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379225				2022-12-18	WOS:A1988P002300011
J	MACHTINGER, S; MOSS, R				MACHTINGER, S; MOSS, R			COWS MILK ALLERGY IN BREAST-FED INFANTS - THE ROLE OF ALLERGEN AND MATERNAL SECRETORY IGA ANTIBODY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP STANFORD,520 SAND HILL RD,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,FAC PEDIAT,DIV ALLERGY PULM,STANFORD,CA 94305	Stanford University			Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				ATHERTON DJ, 1983, BRIT MED J, V287, P775, DOI 10.1136/bmj.287.6395.775; AVRAMEAS S, 1978, SCAND J IMMUNOL   S7, V8, P7; BAHNA SL, 1980, ALLERGIES MILK, P146; BJORKSTEN B, 1983, IMMUNOL TODAY, V4, P215, DOI 10.1016/0167-5699(83)90029-4; BROWN BW, 1977, STATISTICS BIOMEDICA, P310; CAMPBELL DH, 1970, METHOD IMMUNOL, P159; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CRUZ JR, 1981, J PEDIATR-US, V99, P600, DOI 10.1016/S0022-3476(81)80269-7; DONNALLY HH, 1930, J IMMUNOL, V19, P14; DUCHATEAU J, 1983, LANCET, V1, P413; EVANS RW, 1981, LANCET, V1, P340; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GERRARD JW, 1979, ANN ALLERGY, V42, P69; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; Hanson L. A., 1979, Immunology of breast milk, P145; HANSON LA, 1977, INT ARCH ALLER A IMM, V54, P457, DOI 10.1159/000231862; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; JAKOBSSON I, 1978, LANCET, V2, P437; JUTO P, 1980, CLIN ALLERGY, V10, P593, DOI 10.1111/j.1365-2222.1980.tb02141.x; KAPLAN MS, 1979, J ALLERGY CLIN IMMUN, V64, P122, DOI 10.1016/0091-6749(79)90045-9; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8, DOI 10.1159/000233582; KOVAR MG, 1984, PEDIATRICS, V74, P615; MCCLELLAND DBL, 1976, LANCET, V2, P1251; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; OGRA PL, 1983, ANN NY ACAD SCI, V409, P82, DOI 10.1111/j.1749-6632.1983.tb26861.x; RASMUSSEN JE, 1984, J ALLERGY CLIN IMMUN, V74, P772; SHACKS SJ, 1982, CLIN IMMUNOL ALLERGY, V2, P121; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; WALKER WA, 1982, CLIN IMMUNOL ALLERGY, V2, P15; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WELSH JK, 1979, J PEDIATR-US, V94, P1, DOI 10.1016/S0022-3476(79)80340-6	32	133	134	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					341	347		10.1016/S0091-6749(86)80115-4	http://dx.doi.org/10.1016/S0091-6749(86)80115-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3484762				2022-12-18	WOS:A1986A089900013
J	MILLER, DL; HIRVONEN, T; GITLIN, D				MILLER, DL; HIRVONEN, T; GITLIN, D			SYNTHESIS OF IGE BY HUMAN CONCEPTUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TURKU, SCH MED, DEPT OBSTET & GYNECOL, TURKU, FINLAND; UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA USA	University of Turku; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								AREY LB, 1954, DEVELOPMENTAL ANATOM; BAZARAL M, 1971, J IMMUNOL, V107, P794; COOPER MD, 1971, IMMUNOLOGIC INCOMPET; GITLIN D, 1969, J CLIN INVEST, V48, P1433, DOI 10.1172/JCI106109; GITLIN D, 1967, ACTA PAEDIATR SCAND, VS, P60; INGALL M, 1965, PEDIATRICS, V35, P108; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; JOHNASSON SGO, 1968, INT ARCH ALLERGY, V34, P1; MILLER D L, 1973, Federation Proceedings, V32, P1013; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; Patten B. M., 1968, HUMAN EMBRYOLOGY; ROWE DS, 1965, J EXP MED, V121, P185, DOI 10.1084/jem.121.1.185; SHEPARD TH, 1964, ANAT REC, V148, P123, DOI 10.1002/ar.1091480202; TADA T, 1970, Journal of Immunology, V104, P377; VANFURTH R, 1965, J EXP MED, V122, P1173, DOI 10.1084/jem.122.6.1173; WAGNER G, 1962, J OBSTET GYN BR COMM, V69, P131	17	133	134	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	3					182	188		10.1016/0091-6749(73)90035-3	http://dx.doi.org/10.1016/0091-6749(73)90035-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q7045	4737557				2022-12-18	WOS:A1973Q704500007
J	Khatri, S; Moore, W; Gibson, PG; Leigh, R; Bourdin, A; Maspero, J; Barros, M; Buhl, R; Howarth, P; Albers, FC; Bradford, ES; Gilson, M; Price, RG; Yancey, SW; Ortega, H				Khatri, Sumita; Moore, Wendy; Gibson, Peter G.; Leigh, Richard; Bourdin, Arnaud; Maspero, Jorge; Barros, Manuel; Buhl, Roland; Howarth, Peter; Albers, Frank C.; Bradford, Eric S.; Gilson, Martyn; Price, Robert G.; Yancey, Steven W.; Ortega, Hector			Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mepolizumab; severe eosinophilic asthma; long-term safety; extension study	DOUBLE-BLIND; SEVERE EXACERBATIONS; MONOCLONAL-ANTIBODY; LUNG-FUNCTION; PLACEBO; BENRALIZUMAB; MULTICENTER; EFFICACY; RECEPTOR; THERAPY	Background: Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. Objective: We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic asthma (SEA). Methods: COLUMBA (Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects, NCT01691859) was an open-label extension study in patients with SEA previously enrolled in DREAM (Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma, NCT01000506). Patients received 100 mg of subcutaneous mepolizumab every 4 weeks plus standard of care until a protocol-defined stopping criterion was met. Safety end points included frequency of adverse events (AEs), serious AEs, and AEs of special interest. Efficacy end points included annualized exacerbation rates, changes from baseline in Asthma Control Questionnaire 5 scores, and blood eosinophil counts. Immunogenicity was also assessed. Results: Overall, 347 patients were enrolled for an average of 3.5 years (maximum, 4.5 years; total exposure, 1201 patientyears). On-treatment AEs were reported in 94% of patients (exposure-adjusted rate, 3688 events/1000 patient-years). The most frequently reported on-treatment AEs were respiratory tract infection, headache, bronchitis, and asthma worsening. Seventy-nine (23%) patients experienced 1 or more ontreatment serious AEs; there were 6 deaths, none of which were assessed as related to mepolizumab. For patients with 156 weeks or greater enrollment, the exacerbation rate was 0.74 events/y (weeks 0-156), a 56% reduction from the off-treatment period between DREAM and COLUMBA. For all patients, at the first postbaseline assessment, the mean Asthma Control Questionnaire 5 score was reduced by 0.47 points, and blood eosinophil counts were reduced by 78%, with similar improvements maintained throughout the study. The immunogenicity profile (8% anti-drug antibodies) was consistent with previous studies. Conclusion: These data support the long-term safety and efficacy of mepolizumab in patients with SEA.	[Khatri, Sumita] Cleveland Clin Fdn, Resp Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Moore, Wendy] Wake Forest Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC USA; [Gibson, Peter G.] Univ Newcastle, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia; [Gibson, Peter G.] Univ Newcastle, Ctr Excellence Severe Asthma, Newcastle, NSW, Australia; [Leigh, Richard] Univ Calgary, Dept Med, Cumming Sch Med, Calgary, AB, Canada; [Leigh, Richard] Univ Calgary, Snyder Inst Chron Dis, Cumming Sch Med, Calgary, AB, Canada; [Bourdin, Arnaud] Univ Montpellier, Dept Resp Dis PhyMedExp, Montpellier, France; [Bourdin, Arnaud] CHU Montpellier, Hop Arnaud de Villeneuve, Montpellier, France; [Maspero, Jorge] Fdn Cidea Allergy & Resp Res Unit, Buenos Aires, DF, Argentina; [Barros, Manuel] Univ Valparaiso, Sch Med, Valparaiso, Chile; [Barros, Manuel] Hosp Carlos van Buren, Valparaiso, Chile; [Buhl, Roland] Mainz Univ Hosp, Dept Pulm, Mainz, Germany; [Howarth, Peter] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England; [Howarth, Peter] Southampton Gen Hosp, NIHR Resp Biomed Res Unit, Southampton, Hants, England; [Howarth, Peter] GSK House, Global Resp Franchise, Brentford, Middx, England; [Albers, Frank C.] GSK, Resp Med Franchise, Res Triangle Pk, NC USA; [Bradford, Eric S.; Yancey, Steven W.] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA; [Gilson, Martyn] GSK, Resp Res & Dev, Stockley Pk, Uxbridge, Middx, England; [Price, Robert G.] GSK, Clin Stat, Stevenage, Herts, England; [Ortega, Hector] GSK, Resp, Med Affairs, La Jolla, CA USA	Cleveland Clinic Foundation; Wake Forest University; University of Newcastle; University of Newcastle; University of Calgary; University of Calgary; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universidad de Valparaiso; University Hospital Mainz; University of Southampton; University of Southampton; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Ortega, H (corresponding author), 3013 Sci Pk Rd,Suite 200, San Diego, CA 92121 USA.	hortega@gossamerbio.com	; gibson, peter/G-6194-2014	Howarth, Peter/0000-0003-0619-7927; Price, Robert/0000-0001-6418-6818; gibson, peter/0000-0001-5865-489X	GlaxoSmithKline (GSK) [MEA115666, NCT01691859]	GlaxoSmithKline (GSK)(GlaxoSmithKline)	This study was funded by GlaxoSmithKline (GSK ID: MEA115666; ClinicalTrials.gov number: NCT01691859).	Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bjermer L, 2016, CHEST, V150, P789, DOI 10.1016/j.chest.2016.03.032; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; GlaxoSmithKline, CLIN STUD REG; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026; Howlader N, US CANC STAT REV 197; Howlader N, US SEER BREAST CANC; Howlader N, US SEER PROST CANC S; Iribarren C, 2017, J ALLERGY CLIN IMMUN, V139, P1489, DOI 10.1016/j.jaci.2016.07.038; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Leung E, 2017, EXPERT OPIN DRUG SAF, V16, P397, DOI 10.1080/14740338.2017.1286327; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; Lugogo N, 2016, CLIN THER, V38, P2058, DOI 10.1016/j.clinthera.2016.07.010; Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664; Murphy K, 2017, J ALLER CL IMM-PRACT, V5, P1572, DOI 10.1016/j.jaip.2017.08.024; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Ojanguren I, 2018, J ALLER CL IMM-PRACT, V6, P2151, DOI 10.1016/j.jaip.2018.04.014; Ortega H, 2018, ADV THER, V35, P1059, DOI 10.1007/s12325-018-0727-8; Ortega H, 2018, J ALLER CL IMM-PRACT, V6, P980, DOI 10.1016/j.jaip.2017.12.019; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Park HS, 2016, INT ARCH ALLERGY IMM, V169, P135, DOI 10.1159/000444799; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; US Food and Drug Administration, 2003, OM XOL PROD LAB; US Food and Drug Administration, RESL CINQ PRESCR INF; US Food and Drug Administration, BENR FAS PRESCR INF; Wenzel S, 2012, CLIN EXP ALLERGY, V42, P650, DOI 10.1111/j.1365-2222.2011.03929.x; Winthrop KL, 2015, ANN RHEUM DIS, V74, P2107, DOI 10.1136/annrheumdis-2015-207841; Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005	39	132	138	3	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1742	+		10.1016/j.jaci.2018.09.033	http://dx.doi.org/10.1016/j.jaci.2018.09.033			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30359681	hybrid, Green Submitted			2022-12-18	WOS:000466784600010
J	Edwards, MR; Strong, K; Cameron, A; Walton, RP; Jackson, DJ; Johnston, SL				Edwards, Michael R.; Strong, Katherine; Cameron, Aoife; Walton, Ross P.; Jackson, David J.; Johnston, Sebastian L.			Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Virus; allergic inflammation; interferon; asthma; T-H(2)	RESPIRATORY SYNCYTIAL VIRUS; INNATE IMMUNE-RESPONSES; BRONCHIAL EPITHELIAL-CELLS; CYTOKINE SIGNALING 1; PLASMACYTOID DENDRITIC CELLS; SEVERE EOSINOPHILIC ASTHMA; RHINOVIRUS-INDUCED ASTHMA; PLACEBO-CONTROLLED TRIAL; BLOOD MONONUCLEAR-CELLS; HOSPITAL ADMISSIONS	Viral respiratory tract infections are associated with asthma inception in early life and asthma exacerbations in older children and adults. Although how viruses influence asthma inception is poorly understood, much research has focused on the host response to respiratory viruses and how viruses can promote; or how the host response is affected by subsequent allergen sensitization and exposure. This review focuses on the innate interferon-mediated host response to respiratory viruses and discusses and summarizes the available evidence that this response is impaired or suboptimal. In addition, the ability of respiratory viruses to act in a synergistic or additive manner with T-H(2) pathways will be discussed. In this review we argue that these 2 outcomes are likely linked and discuss the available evidence that shows reciprocal negative regulation between innate interferons and T-H(2) mediators. With the renewed interest in anti-T-H(2) biologics, we propose a rationale for why they are particularly successful in controlling asthma exacerbations and suggest ways in which future clinical studies could be used to find direct evidence for this hypothesis.	[Edwards, Michael R.; Strong, Katherine; Cameron, Aoife; Walton, Ross P.; Jackson, David J.; Johnston, Sebastian L.] Imperial Coll London, COPD, Norfolk Pl, London W2 1PG, England; [Edwards, Michael R.; Strong, Katherine; Cameron, Aoife; Walton, Ross P.; Jackson, David J.; Johnston, Sebastian L.] Imperial Coll London, Natl Heart Lung Inst, Asthma Sect, Norfolk Pl, London W2 1PG, England; [Edwards, Michael R.; Strong, Katherine; Cameron, Aoife; Walton, Ross P.; Jackson, David J.; Johnston, Sebastian L.] MRC, London, England; [Edwards, Michael R.; Strong, Katherine; Cameron, Aoife; Walton, Ross P.; Jackson, David J.; Johnston, Sebastian L.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Jackson, David J.] Guys & St Thomass Hosp London, London, England	Imperial College London; Imperial College London; University of London; King's College London	Edwards, MR (corresponding author), Imperial Coll London, COPD, Norfolk Pl, London W2 1PG, England.; Edwards, MR (corresponding author), Imperial Coll London, Natl Heart Lung Inst, Asthma Sect, Norfolk Pl, London W2 1PG, England.	michael.edwards@imperial.ac.uk	Johnston, Sebastian Lennox/I-2423-2012; Jackson, David/AAG-8818-2020	Johnston, Sebastian Lennox/0000-0003-3009-9200; 	Centocor; GlaxoSmithKline; Chiesi; Boehringer Ingelheim; Novartis; Synairgen; Sanofi Pasteur; Aviragen; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish	Centocor; GlaxoSmithKline(GlaxoSmithKline); Chiesi(Chiesi Pharmaceuticals Inc); Boehringer Ingelheim(Boehringer Ingelheim); Novartis(Novartis); Synairgen; Sanofi Pasteur; Aviragen; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	M. R. Edwards is a member of the National Medical Research Council Singapore Expert Panel and has consultant arrangements with, holds shares in, and is Scientific Director for Therapeutic Frontiers. K. Strong is employed by Asthma UK and the Medical Research Council. R. P. Walton is a board member of and has consultant arrangements with Therapeutic Frontiers Ltd. S. L. Johnston has received grants from Centocor, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, and Synairgen; has received personal fees from Centocor, Sanofi Pasteur, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, Synairgen, and Aviragen; is co-owner of a patent with Sanofi Pasteur; is a shareholder in Synairgen; is director and shareholder in Therapeutic Frontiers; has a patent (Blair ED, Killington RA, Rowlands DJ, Clarke NJ, Johnston SL. Transgenic animal models of HRV with human ICAM-1 sequences. UK patent application no. 02 167 29.4 [July 18, 2002] and international patent application no. PCT/EP2003/007939 [July 17, 2003]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. UK patent application no. GB 0405634.7 [March 12, 2004]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-Beta for Anti-Virus Therapy for Respiratory Diseases. International patent application no. PCT/GB05/50031 [March 12, 2004]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. The use of Interferon Lambda for the treatment and prevention of virally-induced exacerbation in asthma and chronic pulmonary obstructive disease. UK patent application no. 0518425.4 [September 9, 2005]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. US patent application - 11/517,763, patent no. 7569216, National Phase of PCT/GB2005/050031 [August 4, 2009]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases. European patent no. 1734987 [May 5, 2010]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases [IFNb therapy]. Hong Kong patent no. 1097181 [August 31, 2010]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases [IFNb therapy]. Japanese patent no. 4807526 [August 26, 2011]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases. New Hong Kong-Divisional patent application no. 11100187.0 [January 10, 2011]), and licensed a patent (Burdin N, Almond J, Lecouturieir V, Girerd-Chambaz Y, Guy B, Bartlett N, et al. Induction of cross-reactive cellular response against rhinovirus antigens. European patent no. 13305152 [April 4, 2013]) pending. The rest of the authors declare that they have no relevant conflicts of interest.	Arden KE, 2010, J MED VIROL, V82, P1458, DOI 10.1002/jmv.21819; Baetz A, 2008, FASEB J, V22, P4296, DOI 10.1096/fj.08-116079; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Bartlett NW, 2012, EMBO MOL MED, V4, P1244, DOI 10.1002/emmm.201201650; Baturcam E, 2017, J INNATE IMMUN, V9, P52, DOI 10.1159/000449101; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Becker Y, 2006, VIRUS GENES, V33, P253, DOI 10.1007/s11262-006-0063-y; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Bergauer A, 2017, EUR RESP J, V49; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cakebread JA, 2011, J ALLERGY CLIN IMMUN, V127, P1148, DOI 10.1016/j.jaci.2011.01.023; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Contoli M, 2015, ALLERGY, V70, P910, DOI 10.1111/all.12627; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; da Silva J, 2017, CLIN EXP ALLERGY, V47, P313, DOI 10.1111/cea.12809; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Doran E, 2016, EUR RESPIR J, V48, P715, DOI 10.1183/13993003.00400-2015; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Edwards MR, 2012, NAT REV MICROBIOL, V10, P459, DOI 10.1038/nrmicro2801; Edwards S, 2013, J IMMUNOL, V190, P2585, DOI 10.4049/jimmunol.1200780; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fukuyama S, 2009, AM J RESP CRIT CARE, V179, P992, DOI 10.1164/rccm.200806-992OC; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gielen V, 2015, J ALLERGY CLIN IMMUN, V136, P177, DOI 10.1016/j.jaci.2014.11.039; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Globinska A, 2017, CLIN EXP IMMUNOL, V187, P100, DOI 10.1111/cei.12869; Gonem S, 2016, LANCET RESP MED, V4, P699, DOI 10.1016/S2213-2600(16)30179-5; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Hansel TT, 2017, EBIOMEDICINE, V19, P128, DOI 10.1016/j.ebiom.2017.03.033; Harada M, 2007, AM J RESP CELL MOL, V36, P491, DOI 10.1165/rcmb.2006-0090OC; Hatchwell L, 2015, THORAX, V70, P854, DOI 10.1136/thoraxjnl-2014-205465; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; Iikura K, 2011, INT ARCH ALLERGY IMM, V155, P27, DOI 10.1159/000327262; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kicic A, 2016, CLIN EXP ALLERGY, V46, P1441, DOI 10.1111/cea.12767; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Lin L, 2016, P AM THOR SOC C MAY, pA7870; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Lynch JP, 2016, J ALLERGY CLIN IMMUN, V138, P1326, DOI 10.1016/j.jaci.2016.02.039; Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moller-Larsen S, 2008, THORAX, V63, P1064, DOI 10.1136/thx.2007.094128; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Patel DA, 2014, J ALLERGY CLIN IMMUN, V134, P1402, DOI 10.1016/j.jaci.2014.07.013; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pettipher R, 2014, ALLERGY, V69, P1223, DOI 10.1111/all.12451; Pothlichet J, 2008, J IMMUNOL, V180, P2034, DOI 10.4049/jimmunol.180.4.2034; Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507; Proud D, 2008, AM J RESP CRIT CARE, V178, P962, DOI 10.1164/rccm.200805-670OC; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Rupani H, 2016, AM J RESP CRIT CARE, V194, P26, DOI 10.1164/rccm.201502-0280OC; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Sharma V, 2014, ALLERGY, V69, P1077, DOI 10.1111/all.12431; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Slater L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001178; Spann KM, 2014, THORAX, V69, P918, DOI 10.1136/thoraxjnl-2013-204908; Sparer TE, 1998, J EXP MED, V187, P1921, DOI 10.1084/jem.187.11.1921; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Tebbey PW, 1998, J EXP MED, V188, P1967, DOI 10.1084/jem.188.10.1967; Thomas BJ, 2009, AM J RESP CELL MOL, V41, P339, DOI 10.1165/rcmb.2008-0316OC; Uller L, 2010, THORAX, V65, P626, DOI 10.1136/thx.2009.125930; Wagener AH, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-9; Wang Q, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002070; Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104	96	132	135	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					909	920		10.1016/j.jaci.2017.07.025	http://dx.doi.org/10.1016/j.jaci.2017.07.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28987220	Green Published, hybrid			2022-12-18	WOS:000412172900002
J	Bellach, J; Schwarz, V; Ahrens, B; Trendelenburg, V; Aksunger, O; Kalb, B; Niggemann, B; Keil, T; Beyer, K				Bellach, Johanna; Schwarz, Veronika; Ahrens, Birgit; Trendelenburg, Valerie; Aksuenger, Oezlem; Kalb, Birgit; Niggemann, Bodo; Keil, Thomas; Beyer, Kirsten			Randomized placebo-controlled trial of hen's egg consumption for primary prevention in infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; hen's egg allergy; allergy prevention; atopic eczema; oral tolerance; randomized controlled trial; complementary feeding	CONSORT STATEMENT; FOOD ALLERGY; BIRTH COHORT; ANAPHYLAXIS; RISK; ALLERGENICITY; TRENDS; ECZEMA; WHITE; TIME	Background: Hen's egg is the most common cause of food allergy in early childhood. Objective: We investigated the efficacy and safety of early hen's egg introduction at age 4 to 6 months to prevent hen's egg allergy in the general population. Methods: This randomized, placebo-controlled trial included 4to 6-month-old infants who were not sensitized against hen's egg, as determined based on specific serum antibodies (IgE). These infants were randomized to receive either verum (egg white powder) or placebo (rice powder) added to the first weaning food 3 times a week under a concurrent egg-free diet from age 4 to 6 until 12 months. The primary outcome was sensitization to hen's egg (increased specific serum IgE levels) by age 12 months. Hen's egg allergy (secondary outcome) was confirmed by double-blind, placebo-controlled food challenges. Results: Among 406 screened infants, 23 (5.7%) had hen's egg-specific IgE before randomization. Seventeen of 23 underwent subsequent double-blind, placebo-controlled food challenges, and 16 were confirmed as allergic, including 11 with anaphylactic reactions. Of the 383 nonsensitized infants (56.7% male), 184 were randomized to verum and 199 to placebo. At 12 months of age, 5.6% of the children in the verum group were hen's egg sensitized versus 2.6% in the placebo group (primary outcome; relative risk, 2.20; 95% CI, 0.68-7.14; P = .24), and 2.1% were confirmed to have hen's egg allergy versus 0.6% in the placebo group (relative risk, 3.30; 95% CI, 0.35-31.32; P = .35). Conclusion: We found no evidence that consumption of hen's egg starting at 4 to 6 months of age prevents hen's egg sensitization or allergy. In contrast, it might result in frequent allergic reactions in the community considering that many 4-to 6-month-old infants were already allergic to hen's egg.	[Bellach, Johanna; Schwarz, Veronika; Ahrens, Birgit; Trendelenburg, Valerie; Aksuenger, Oezlem; Kalb, Birgit; Niggemann, Bodo; Beyer, Kirsten] Charite, Dept Paediat Pneumol & Immunol, Berlin, Germany; [Keil, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Beyer, Kirsten] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Icahn School of Medicine at Mount Sinai	Beyer, K (corresponding author), Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	kirsten.beyer@charite.de		Kalb, Birgit/0000-0002-3104-6736; Trendelenburg, Valerie/0000-0003-4401-5899	FAAN (Food Allergy & Anaphylaxis Network); pina e.V. (Prevention and Information Network for Allergy/Asthma, Germany)	FAAN (Food Allergy & Anaphylaxis Network); pina e.V. (Prevention and Information Network for Allergy/Asthma, Germany)	Supported by FAAN (Food Allergy & Anaphylaxis Network), and pina e.V. (Prevention and Information Network for Allergy/Asthma, Germany).	Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Altman DG, 2012, STAT MED, V31, P2985, DOI 10.1002/sim.5402; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Escudero C, 2013, PEDIAT ALLERG IMM-UK, V24, P263, DOI 10.1111/pai.12052; Fleischer DM, 2015, ALLERGY, V70, P1193, DOI 10.1111/all.12687; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Jitlal M, 2012, BRIT J CANCER, V107, P910, DOI 10.1038/bjc.2012.344; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; Muraro A, 2014, ALLERGY, V69, P590, DOI 10.1111/all.12398; Netting M, 2015, PEDIAT ALLERG IMM-UK, V26, P234, DOI 10.1111/pai.12365; Niggemann B, 2010, ALLERGY, V65, P2, DOI 10.1111/j.1398-9995.2009.02170.x; Niggemann B, 2012, J ALLERGY CLIN IMMUN, V130, P261, DOI 10.1016/j.jaci.2012.03.021; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V137, P1477, DOI 10.1016/j.jaci.2015.12.1322; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Prescott SL, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-21; Rudders SA, 2014, J ALLERGY CLIN IMMUN, V134, P960, DOI 10.1016/j.jaci.2014.06.018; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Schafer Torsten, 2014, Allergo J Int, V23, P186; Shin M, 2013, ALLERGY ASTHMA IMMUN, V5, P96, DOI 10.4168/aair.2013.5.2.96; Xepapadaki P, 2016, ALLERGY, V71, P350, DOI 10.1111/all.12801	27	132	136	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1591	+		10.1016/j.jaci.2016.06.045	http://dx.doi.org/10.1016/j.jaci.2016.06.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27523961	Bronze			2022-12-18	WOS:000400465300020
J	Ma, CS; Wong, N; Rao, G; Avery, DT; Torpy, J; Hambridge, T; Bustamante, J; Okada, S; Stoddard, JL; Deenick, EK; Pelham, SJ; Payne, K; Boisson-Dupuis, S; Puel, A; Kobayashi, M; Arkwright, PD; Kilic, SS; El Baghdadi, J; Nonoyama, S; Minegishi, Y; Mahdaviani, SA; Mansouri, D; Bousfiha, A; Blincoe, AK; French, MA; Hsu, P; Campbell, DE; Stormon, MO; Wong, M; Adelstein, S; Smart, JM; Fulcher, DA; Cook, MC; Phan, TG; Stepensky, P; Boztug, K; Kansu, A; Ikinciogullari, A; Baumann, U; Beier, R; Roscioli, T; Ziegler, JB; Gray, P; Picard, C; Grimbacher, B; Warnatz, K; Holland, SM; Casanova, JL; Uzel, G; Tangye, SG				Ma, Cindy S.; Wong, Natalie; Rao, Geetha; Avery, Danielle T.; Torpy, James; Hambridge, Thomas; Bustamante, Jacinta; Okada, Satoshi; Stoddard, Jennifer L.; Deenick, Elissa K.; Pelham, Simon J.; Payne, Kathryn; Boisson-Dupuis, Stephanie; Puel, Anne; Kobayashi, Masao; Arkwright, Peter D.; Kilic, Sara Sebnem; El Baghdadi, Jamila; Nonoyama, Shigeaki; Minegishi, Yoshiyuki; Mahdaviani, Seyed Alireza; Mansouri, Davood; Bousfiha, Aziz; Blincoe, Annaliesse K.; French, Martyn A.; Hsu, Peter; Campbell, Dianne E.; Stormon, Michael O.; Wong, Melanie; Adelstein, Stephen; Smart, Joanne M.; Fulcher, David A.; Cook, Matthew C.; Phan, Tri Giang; Stepensky, Polina; Boztug, Kaan; Kansu, Aydan; Ikinciogullari, Aydan; Baumann, Ulrich; Beier, Rita; Roscioli, Tony; Ziegler, John B.; Gray, Paul; Picard, Capucine; Grimbacher, Bodo; Warnatz, Klaus; Holland, Steven M.; Casanova, Jean-Laurent; Uzel, Gulbu; Tangye, Stuart G.			Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Follicular helper T cells; humoral immunity; primary immunodeficiencies; cytokine signaling	TRANSCRIPTION FACTOR STAT3; ANTIBODY-RESPONSES; HUMORAL IMMUNITY; IL-21 RECEPTOR; IFN-GAMMA; B-CELLS; DEFICIENCY; PHENOTYPE; AGAMMAGLOBULINEMIA; COMMITMENT	Background: Follicular helper T (T-FH) cells underpin T cell-dependent humoral immunity and the success of most vaccines. T-FH cells also contribute to human immune disorders, such as autoimmunity, immunodeficiency, and malignancy. Understanding the molecular requirements for the generation and function of T-FH cells will provide strategies for targeting these cells to modulate their behavior in the setting of these immunologic abnormalities. Objective: We sought to determine the signaling pathways and cellular interactions required for the development and function of T-FH cells in human subjects. Methods: Human primary immunodeficiencies (PIDs) resulting from monogenic mutations provide a unique opportunity to assess the requirement for particular molecules in regulating human lymphocyte function. Circulating follicular helper T (cT(FH)) cell subsets, memory B cells, and serum immunoglobulin levels were quantified and functionally assessed in healthy control subjects, as well as in patients with PIDs resulting from mutations in STAT3, STAT1, TYK2, IL21, IL21R, IL10R, IFNGR1/2, IL12RB1, CD40LG, NEMO, ICOS, or BTK. Results: Loss-of-function (LOF) mutations in STAT3, IL10R, CD40LG, NEMO, ICOS, or BTK reduced cT(FH) cell frequencies. STAT3 and IL21/R LOF and STAT1 gain-of-function mutations skewed cT(FH) cell differentiation toward a phenotype characterized by overexpression of IFN-gamma and programmed death 1. IFN-gamma inhibited cT(FH) cell function in vitro and in vivo, as corroborated by hypergammaglobulinemia in patients with IFNGR1/2, STAT1, and IL12RB1 LOF mutations. Conclusion: Specific mutations affect the quantity and quality of cT(FH) cells, highlighting the need to assess T-FH cells in patients by using multiple criteria, including phenotype and function. Furthermore, IFN-gamma functions in vivo to restrain T-FH cell-induced B-cell differentiation. These findings shed new light on T-FH cell biology and the integrated signaling pathways required for their generation, maintenance, and effector function and explain the compromised humoral immunity seen in patients with some PIDs.	[Ma, Cindy S.; Wong, Natalie; Rao, Geetha; Avery, Danielle T.; Torpy, James; Hambridge, Thomas; Deenick, Elissa K.; Pelham, Simon J.; Payne, Kathryn; Phan, Tri Giang; Tangye, Stuart G.] Garvan Inst Med Res, Immunol Res Program, Darlinghurst, NSW, Australia; [Ma, Cindy S.; Deenick, Elissa K.; Pelham, Simon J.; Phan, Tri Giang; Roscioli, Tony; Tangye, Stuart G.] UNSW Australia, St Vincents Clin Sch, Melbourne, Vic, Australia; [Bustamante, Jacinta; Boisson-Dupuis, Stephanie; Puel, Anne; Picard, Capucine; Casanova, Jean-Laurent] Univ Paris 05, Necker Med Sch, Inst IMAGINE, Lab Human Genet Infect Dis,Necker Branch,INSERMU1, Paris, France; [Bustamante, Jacinta; Picard, Capucine] Necker Hosp Sick Children, AP HP, Study Ctr Primary Immunodeficiencies, Paris, France; [Okada, Satoshi; Kobayashi, Masao] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan; [Stoddard, Jennifer L.] NIH, Ctr Clin, Bethesda, MD 20892 USA; [Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY 10021 USA; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester M13 9PL, Lancs, England; [Kilic, Sara Sebnem] Uludag Univ, Fac Med, Dept Pediat Immunol, Gorukle, Bursa, Turkey; [El Baghdadi, Jamila] Mil Hosp Mohamed V, Genet Unit, Rabat, Morocco; [Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Tokorozawa, Saitama 359, Japan; [Minegishi, Yoshiyuki] Univ Tokushima, Inst Genome Res, Div Mol Med, Tokushima, Japan; [Mahdaviani, Seyed Alireza; Mansouri, Davood] Shahid Beheshti Univ Med Sci, NRITLD, Pediat Resp Dis Res Ctr, Tehran, Iran; [Bousfiha, Aziz] King Hasan II Univ, Averroes Univ Hosp, Pediat Infect Dis Dept, Clin Immunol Unit, Casablanca, Morocco; [Blincoe, Annaliesse K.] Starship Childrens Hosp, Auckland, New Zealand; [French, Martyn A.] Royal Perth Hosp, Dept Clin Immunol, Perth, WA, Australia; [French, Martyn A.] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia; [Hsu, Peter; Campbell, Dianne E.; Stormon, Michael O.; Wong, Melanie] Childrens Hosp Westmead, Westmead, NSW, Australia; [Adelstein, Stephen] Royal Prince Alfred Hosp, Clin Immunol, Sydney, NSW, Australia; [Smart, Joanne M.] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Fulcher, David A.] Univ Sydney, Westmead Hosp, Dept Immunol, Sydney, NSW 2006, Australia; [Cook, Matthew C.] Australian Natl Univ, Sch Med, Canberra, ACT 0200, Australia; [Cook, Matthew C.] Australian Natl Univ, John Curtin Sch Med Res, Acton, ACT, Australia; [Cook, Matthew C.] Canberra Hosp, Dept Immunol, Acton, ACT, Australia; [Stepensky, Polina] Hebrew Univ Jerusalem, Med Ctr, Pediat Hematol Oncol & Bone Marrow Transplantat H, Jerusalem, Israel; [Boztug, Kaan] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria; [Boztug, Kaan] Med Univ Vienna, Dept Paediat & Adolescent Med, Vienna, Austria; [Kansu, Aydan] Ankara Univ, Sch Med, Dept Pediat Gastroenterol, TR-06100 Ankara, Turkey; [Ikinciogullari, Aydan] Ankara Univ, Sch Med, Dept Pediat Immunol & Allergy, TR-06100 Ankara, Turkey; [Baumann, Ulrich] Hannover Med Sch, Paediat Pulmonol Allergy & Neonatol, Hannover, Germany; [Beier, Rita] Univ Hosp Essen, Pediat Haematol & Oncol, Essen, Germany; [Roscioli, Tony] Kinghorn Ctr Clin Genom, Darlinghurst, NSW, Australia; [Roscioli, Tony] Sydney Childrens Hosp, Dept Med Genet, Randwick, NSW, Australia; [Ziegler, John B.; Gray, Paul] Sydney Childrens Hosp, Randwick, NSW, Australia; [Ziegler, John B.; Gray, Paul] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Grimbacher, Bodo; Warnatz, Klaus] Univ Freiburg, Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Holland, Steven M.; Uzel, Gulbu] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Hematol & Immunol Unit, Paris, France; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA	Garvan Institute of Medical Research; University of New South Wales Sydney; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Hiroshima University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Rockefeller University; Royal Manchester Children's Hospital; University of Manchester; Uludag University; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; National Defense Medical College - Japan; Tokushima University; Shahid Beheshti University Medical Sciences; Hassan II University of Casablanca; Ibn Rochd University Hospital Center of Casablanca; Starship Children's Hospital; Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Sydney; University of Sydney; Royal Children's Hospital Melbourne; University of Sydney; Australian National University; Australian National University; John Curtin School of Medical Research; Australian National University; Canberra Hospital; Hebrew University of Jerusalem; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Ankara University; Ankara University; Hannover Medical School; University of Duisburg Essen; University of New South Wales Sydney; University of Freiburg; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute	Tangye, SG (corresponding author), Garvan Inst Med Res, Immunol Res Program, Darlinghurst, NSW, Australia.	c.ma@garvan.org.au; s.tangye@garvan.org.au	Okada, Satoshi/B-8901-2011; Tangye, Stuart G/H-4023-2014; Boztug, Kaan/AAM-4161-2021; mansouri, davood/G-6471-2017; Warnatz, Klaus/AAD-3464-2022; Boisson-Dupuis, Stéphanie/I-2040-2017; Casanova, Jean-Laurent/I-3418-2017; Kilic, Sara Sebnem/AAH-1658-2021; mahdaviani, alireza/G-3256-2017; Deenick, Elissa/AAY-8998-2020; İkinciogullari, Aydan/AAQ-3841-2020; Cook, matthew/F-4151-2019; S, Cindy/B-2340-2012; Adelstein, Stephen/I-7936-2016; Bustamante, Jacinta/H-7877-2017; Boisson-Dupuis, Stephanie/AAF-5066-2021; Puel, Anne/H-7305-2017; Phan, Tri/G-3937-2012	Okada, Satoshi/0000-0002-4622-5657; Tangye, Stuart G/0000-0002-5360-5180; Boztug, Kaan/0000-0001-8387-9185; mansouri, davood/0000-0002-0564-8282; Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; mahdaviani, alireza/0000-0001-6224-4797; Deenick, Elissa/0000-0002-9271-0004; İkinciogullari, Aydan/0000-0003-1145-0843; Cook, matthew/0000-0002-3331-9363; S, Cindy/0000-0001-5387-8413; Adelstein, Stephen/0000-0001-7221-6298; Bustamante, Jacinta/0000-0002-3439-2482; Puel, Anne/0000-0003-2603-0323; Arkwright, Peter/0000-0002-7411-5375; Campbell, Dianne/0000-0002-0907-6963; kilic, sara sebnem/0000-0001-8571-2581; Gray, Paul/0000-0003-2057-3968; KANSU, AYDAN/0000-0002-3133-9846; Hambridge, Thomas/0000-0003-2600-7510; French, Martyn/0000-0002-4644-1982; Phan, Tri/0000-0002-4909-2984; Casanova, Jean-Laurent/0000-0002-7782-4169	Grants-in-Aid for Scientific Research [25293232] Funding Source: KAKEN; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCRR NIH HHS [5UL1RR024143, UL1 RR024143] Funding Source: Medline	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Arroyo-Villa I, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0500-6; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Boisson B, 2013, J CLIN INVEST, V123, P4781, DOI 10.1172/JCI71927; Bossaller L, 2006, J IMMUNOL, V177, P4927, DOI 10.4049/jimmunol.177.7.4927; Boswell KL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003853; Butler NS, 2012, NAT IMMUNOL, V13, P188, DOI 10.1038/ni.2180; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Choi JY, 2015, ARTHRITIS RHEUMATOL, V67, P988, DOI 10.1002/art.39020; Coffman RL, 2006, NAT IMMUNOL, V7, P539, DOI 10.1038/ni0606-539; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Cubas RA, 2013, NAT MED, V19, P494, DOI 10.1038/nm.3109; Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003; Frohlich A, 2007, BLOOD, V109, P2023, DOI 10.1182/blood-2006-05-021600; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Hams E, 2011, J IMMUNOL, V186, P5648, DOI 10.4049/jimmunol.1003161; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Herati RS, 2014, J IMMUNOL, V193, P3528, DOI 10.4049/jimmunol.1302503; Hussain R, 1999, IMMUNOLOGY, V98, P238; Kawamoto S, 2012, SCIENCE, V336, P485, DOI 10.1126/science.1217718; Khan AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6997; Kim CH, 2004, BLOOD, V104, P1952, DOI 10.1182/blood-2004-03-1206; Kim JR, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-3; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KING CL, 1993, J IMMUNOL, V151, P458; Le Coz C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075319; Lee CE, 2014, BLOOD, V124, P2964, DOI 10.1182/blood-2014-06-578542; Linterman MA, 2012, IMMUNOL REV, V247, P143, DOI 10.1111/j.1600-065X.2012.01121.x; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma CS, 2014, CURR OPIN PEDIATR, V26, P720, DOI 10.1097/MOP.0000000000000157; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Ma CS, 2009, IMMUNOL CELL BIOL, V87, P590, DOI 10.1038/icb.2009.64; Ma CS, 2005, J CLIN INVEST, V115, P1049, DOI 10.1172/JCI23139; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Marinova E, 2006, INT IMMUNOL, V18, P1337, DOI 10.1093/intimm/dxl066; Martini H, 2011, CLIN EXP IMMUNOL, V164, P381, DOI 10.1111/j.1365-2249.2011.04377.x; MILLER JFA, 1965, NATURE, V208, P1332, DOI 10.1038/2081332a0; Moens L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00065; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Pallikkuth S, 2012, BLOOD, V120, P985, DOI 10.1182/blood-2011-12-396648; Paulos CM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000448; Ray JP, 2014, IMMUNITY, V40, P367, DOI 10.1016/j.immuni.2014.02.005; Romberg N, 2013, J ALLERGY CLIN IMMUN, V131, P1691, DOI 10.1016/j.jaci.2013.01.004; Schmitt N, 2013, BLOOD, V121, P3375, DOI 10.1182/blood-2012-08-448902; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Spensieri F, 2013, P NATL ACAD SCI USA, V110, P14330, DOI 10.1073/pnas.1311998110; Stritesky GL, 2011, IMMUNITY, V34, P39, DOI 10.1016/j.immuni.2010.12.013; Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447; Terawaki S, 2011, J IMMUNOL, V186, P2772, DOI 10.4049/jimmunol.1003208; Wang CW, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-53; Wang J, 2013, CLIN EXP IMMUNOL, V174, P212, DOI 10.1111/cei.12162; Zhang SY, 2008, IMMUNOL REV, V226, P29, DOI 10.1111/j.1600-065X.2008.00698.x	61	132	137	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					993	+		10.1016/j.jaci.2015.05.036	http://dx.doi.org/10.1016/j.jaci.2015.05.036			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26162572	Bronze, Green Accepted			2022-12-18	WOS:000362976300018
J	Chan, TF; Ji, KM; Yim, AKY; Liu, XY; Zhou, JW; Li, RQ; Yang, KY; Li, J; Li, M; Law, PTW; Wu, YL; Cai, ZL; Qin, H; Bao, Y; Leung, RKK; Ng, PKS; Zou, J; Zhong, XJ; Ran, PX; Zhong, NS; Liu, ZG; Tsui, SKW				Chan, Ting-Fung; Ji, Kun-Mei; Yim, Aldrin Kay-Yuen; Liu, Xiao-Yu; Zhou, Jun-Wei; Li, Rui-Qi; Yang, Kevin Yi; Li, Jing; Li, Meng; Law, Patrick Tik-Wan; Wu, Yu-Lan; Cai, Ze-Lang; Qin, Hao; Bao, Ying; Leung, Ross Ka-Kit; Ng, Patrick Kwok-Shing; Zou, Ju; Zhong, Xiao-Jun; Ran, Pi-Xin; Zhong, Nan-Shan; Liu, Zhi-Gang; Tsui, Stephen Kwok-Wing			The draft genome, transcriptome, and microbiome of Dermatophagoides farinae reveal a broad spectrum of dust mite allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mite; allergen; genome; microbiome; transcriptome; proteome; ubiquinol-cytochrome c reductase binding protein; Der f 24; Enterobacter species	RNA-SEQ DATA; HOUSE-DUST; ENDOTOXIN EXPOSURE; SPLICE JUNCTIONS; IDENTIFICATION; SENSITIZATION; ANNOTATION; BACTERIA; IDENTITY; PROTEIN	Background: A sequenced house dust mite (HDM) genome would advance our understanding of HDM allergens, a common cause of human allergies. Objective: We sought to produce an annotated Dermatophagoides farinae draft genome and develop a combined genomic-transcriptomic-proteomic approach for elucidation of HDM allergens. Methods: A Dermatophagoides farinae draft genome and transcriptome were assembled with high-throughput sequencing, accommodating microbiome sequences. The allergen gene structures were validated by means of Sanger sequencing. The mite's microbiome composition was determined, and the predominant genus was validated immunohistochemically. The allergenicity of a ubiquinol-cytochrome c reductase binding protein homologue was evaluated with immunoblotting, immunosorbent assays, and skin prick tests. Results: The full gene structures of 20 canonical allergens and 7 noncanonical allergen homologues were produced. A novel major allergen, ubiquinol-cytochrome c reductase binding protein-like protein, was found and designated Der f 24. All 40 sera samples from patients with mite allergy had IgE antibodies against rDer f 24. Of 10 patients tested, 5 had positive skin reactions. The predominant bacterial genus among 100 identified species was Enterobacter (63.4%). An intron was found in the 13.8-kDa Dermatophagoides farinae bacteriolytic enzyme gene, indicating that it is of HDM origin. The Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed a phototransduction pathway in Dermatophagoides farinae, as well as thiamine and amino acid synthesis pathways, which is suggestive of an endosymbiotic relationship between Dermatophagoides farinae and its microbiome. Conclusion: An HDM genome draft produced from genomic, transcriptomic, and proteomic experiments revealed allergen genes and a diverse endosymbiotic microbiome, providing a tool for further identification and characterization of HDM allergens and development of diagnostics and immunotherapeutic vaccines.	[Chan, Ting-Fung; Yim, Aldrin Kay-Yuen; Law, Patrick Tik-Wan; Qin, Hao] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China; [Yim, Aldrin Kay-Yuen; Yang, Kevin Yi; Qin, Hao; Leung, Ross Ka-Kit; Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Hong Kong Bioinformat Ctr, Hong Kong, Hong Kong, Peoples R China; [Zhou, Jun-Wei; Yang, Kevin Yi; Leung, Ross Ka-Kit; Ng, Patrick Kwok-Shing; Tsui, Stephen Kwok-Wing] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Ji, Kun-Mei; Liu, Zhi-Gang] Shenzhen Univ, State Key Lab Resp Dis Allergy, Shenzhen, Peoples R China; [Liu, Xiao-Yu; Li, Rui-Qi; Li, Meng; Wu, Yu-Lan; Cai, Ze-Lang; Bao, Ying; Zou, Ju; Zhong, Xiao-Jun; Liu, Zhi-Gang] Shenzhen Univ, Shenzhen Key Lab Allergy & Immunol, Sch Med, Shenzhen, Peoples R China; [Li, Jing; Ran, Pi-Xin; Zhong, Nan-Shan] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Shenzhen University; State Key Laboratory of Respiratory Disease; Shenzhen University; Guangzhou Medical University; State Key Laboratory of Respiratory Disease	Zhong, NS (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.	nanshan@vip.163.com; lzg@szu.edu.cn; kwtsui@cuhk.edu.hk	Chan, TingFung/A-6161-2013; Yang, Kevin/AAA-2623-2021; Tsui, Stephen Kwok-Wing/E-4385-2015; Li, Meng/K-3172-2012	Chan, TingFung/0000-0002-0489-3884; Yang, Kevin/0000-0002-4200-745X; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Li, Meng/0000-0001-8675-0758	NSFC [81071388, 31328014, 3027122]; Guangdong-Hong Kong Technology Cooperation Foundation [2005A10905007]; China 863 Project Foundation [2006AA02A231]; China 973 Project Foundation [2009CB522100]; Chinese University of Hong Kong Focused Investment Funding; Hong Kong Research Grants Council [475113]; Shenzhen Science Foundation [JCYJ20120613113021045, JCYJ20130326112225593]; Guangdong Province NSF [2014566]	NSFC(National Natural Science Foundation of China (NSFC)); Guangdong-Hong Kong Technology Cooperation Foundation; China 863 Project Foundation(National High Technology Research and Development Program of China); China 973 Project Foundation; Chinese University of Hong Kong Focused Investment Funding; Hong Kong Research Grants Council(Hong Kong Research Grants Council); Shenzhen Science Foundation; Guangdong Province NSF	Supported by the NSFC (81071388; 31328014; 3027122), Guangdong-Hong Kong Technology Cooperation Foundation (2005A10905007), the China 863 (2006AA02A231) and 973 (2009CB522100) Project Foundations, the Chinese University of Hong Kong Focused Investment Funding, the Hong Kong Research Grants Council (475113), the Shenzhen Science Foundation (JCYJ20120613113021045; JCYJ20130326112225593) and the Guangdong Province NSF (no. 2014566).	An S, 2013, MOL CELL PROTEOMICS, V12, P1818, DOI 10.1074/mcp.M112.027136; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Au KF, 2010, NUCLEIC ACIDS RES, V38, P4570, DOI 10.1093/nar/gkq211; Chen KW, 2012, J ALLERGY CLIN IMMUN, V130, P435, DOI 10.1016/j.jaci.2012.05.035; Colloff M., 2009, DUST MITES, P84; Colloff MJ, 2009, DUST MITES, P273, DOI 10.1007/978-90-481-2224-0_7; Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610; Delgado J, 1997, CLIN EXP ALLERGY, V27, P640, DOI 10.1111/j.1365-2222.1997.tb01191.x; Erban T, 2008, EXP APPL ACAROL, V44, P199, DOI 10.1007/s10493-008-9138-x; Erban T, 2013, J MED ENTOMOL, V50, P931, DOI 10.1603/ME13027; Gastmeier P, 2009, ANTIMICROB AGENTS CH, V53, P2714, DOI 10.1128/AAC.01070-08; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gnerre S, 2011, P NATL ACAD SCI USA, V108, P1513, DOI 10.1073/pnas.1017351108; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Grbic M, 2011, NATURE, V479, P487, DOI 10.1038/nature10640; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Lagesen K, 2007, NUCLEIC ACIDS RES, V35, P3100, DOI 10.1093/nar/gkm160; Li RQ, 2010, GENOME RES, V20, P265, DOI 10.1101/gr.097261.109; Liu ZG, 2007, INT ARCH ALLERGY IMM, V144, P85, DOI 10.1159/000102619; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Majoros WH, 2004, BIOINFORMATICS, V20, P2878, DOI 10.1093/bioinformatics/bth315; Mathaba LT, 2002, FEMS IMMUNOL MED MIC, V33, P77, DOI 10.1111/j.1574-695X.2002.tb00576.x; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; MILLNER PD, 1982, APPL ENVIRON MICROB, V44, P355, DOI 10.1128/AEM.44.2.355-362.1982; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; Nembrini C, 2011, THORAX, V66, P755, DOI 10.1136/thx.2010.152512; Parra G, 2007, BIOINFORMATICS, V23, P1061, DOI 10.1093/bioinformatics/btm071; Pawankar R., 2011, WORLD ALLERGY ORG WA; PECOUD A, 1990, ALLERGY, V45, P386, DOI 10.1111/j.1398-9995.1990.tb00516.x; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; Sanders WE, 1997, CLIN MICROBIOL REV, V10, P220, DOI 10.1128/CMR.10.2.220; Shakib F, 2008, TRENDS IMMUNOL, V29, P633, DOI 10.1016/j.it.2008.08.007; Takai T, 2005, J ALLERGY CLIN IMMUN, V115, P555, DOI 10.1016/j.jaci.2004.11.024; Tategaki A., 2011, ACI INT S, V1, P74; Ter-Hovhannisyan V, 2008, GENOME RES, V18, P1979, DOI 10.1101/gr.081612.108; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Valerio CR, 2005, J ALLERGY CLIN IMMUN, V116, P1296, DOI 10.1016/j.jaci.2005.09.046; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Weghofer M, 2013, J IMMUNOL, V190, P3059, DOI 10.4049/jimmunol.1202288; Wu HQ, 2012, CHEM PHARM BULL, V60, P178, DOI 10.1248/cpb.60.178; Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107; Zhang YY, 2008, INT ARCH ALLERGY IMM, V146, P219, DOI 10.1159/000115890	46	132	145	2	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					539	548		10.1016/j.jaci.2014.09.031	http://dx.doi.org/10.1016/j.jaci.2014.09.031			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25445830	Green Published, hybrid			2022-12-18	WOS:000349372300028
J	Alexander, ES; Martin, LJ; Collins, MH; Kottyan, LC; Sucharew, H; He, H; Mukkada, VA; Succop, PA; Abonia, JP; Foote, H; Eby, MD; Grotjan, TM; Greenler, AJ; Dellon, ES; Demain, JG; Furuta, GT; Gurian, LE; Harley, JB; Hopp, RJ; Kagalwalla, A; Kaul, A; Nadeau, KC; Noel, RJ; Putnam, PE; von Tiehl, KF; Rothenberg, ME				Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Dellon, Evan S.; Demain, Jeffrey G.; Furuta, Glenn T.; Gurian, Larry E.; Harley, John B.; Hopp, Russell J.; Kagalwalla, Amir; Kaul, Ajay; Nadeau, Kari C.; Noel, Richard J.; Putnam, Philip E.; von Tiehl, Karl F.; Rothenberg, Marc E.			Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilia; food allergy; medical genetics; twins; immune system diseases; heritability; gene-environment interaction; drug hypersensitivity; gastrointestinal diseases; skin diseases	MISSING HERITABILITY; MOLECULAR CHARACTERIZATION; PROVIDES INSIGHT; LINKAGE ANALYSIS; CROHNS-DISEASE; EARLY-LIFE; ASSOCIATION; EXPRESSION; EXPOSURE; ANTIBIOTICS	Background: Eosinophilic esophagitis (EoE) is a chronic antigen-driven allergic inflammatory disease, likely involving the interplay of genetic and environmental factors, yet their respective contributions to heritability are unknown. Objective: To quantify the risk associated with genes and environment on familial clustering of EoE. Methods: Family history was obtained from a hospital-based cohort of 914 EoE probands (n = 2192 first-degree "Nuclear-Family" relatives) and an international registry of monozygotic and dizygotic twins/triplets (n = 63 EoE "Twins" probands). Frequencies, recurrence risk ratios (RRRs), heritability, and twin concordance were estimated. Environmental exposures were preliminarily examined. Results: Analysis of the Nuclear-Family-based cohort revealed that the rate of EoE, in first-degree relatives of a proband, was 1.8% (unadjusted) and 2.3% (sex-adjusted). RRRs ranged from 10 to 64, depending on the family relationship, and were higher in brothers (64.0; P = .04), fathers (42.9; P = .004), and males (50.7; P < .001) than in sisters, mothers, and females, respectively. The risk of EoE for other siblings was 2.4%. In the Nuclear-Family cohort, combined gene and common environment heritability was 72.0% 6 2.7% (P < .001). In the Twins cohort, genetic heritability was 14.5% +/- 4.0% (P < .001), and common family environment contributed 81.0% +/- 4% (P < .001) to phenotypic variance. Probandwise concordance in monozygotic co-twins was 57.9% +/- 9.5% compared with 36.4% +/- 9.3% in dizygotic co-twins (P = .11). Greater birth weight difference between twins (P = .01), breast-feeding (P = .15), and fall birth season (P = .02) were associated with twin discordance in disease status. Conclusions: EoE RRRs are increased 10- to 64-fold compared with the general population. EoE in relatives is 1.8% to 2.4%, depending on relationship and sex. Nuclear-Family heritability appeared to be high (72.0%). However, the Twins cohort analysis revealed a powerful role for common environment (81.0%) compared with additive genetic heritability (14.5%).	[Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; Mukkada, Vincent A.; Succop, Paul A.; Abonia, J. Pablo; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Lab Med, Cincinnati, OH USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Pathol, Cincinnati, OH 45229 USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Div Rheumatol, Cincinnati, OH 45229 USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol, Cincinnati, OH 45229 USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Hepatol & Nutr, Cincinnati, OH 45229 USA; [Alexander, Eileen S.; Martin, Lisa J.; Collins, Margaret H.; Kottyan, Leah C.; Sucharew, Heidi; He, Hua; Mukkada, Vincent A.; Abonia, J. Pablo; Foote, Heather; Eby, Michael D.; Grotjan, Tommie M.; Greenler, Alexandria J.; Harley, John B.; Kaul, Ajay; Putnam, Philip E.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Alexander, Eileen S.] Xavier Univ, Dept Hlth Serv Adm, Cincinnati, OH 45207 USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Esophageal Dis & Swallowing, Div Gastroenterol & Hepatol, Chapel Hill, NC USA; [Demain, Jeffrey G.] Allergy Asthma & Immunol Ctr Alaska, Anchorage, AK USA; [Furuta, Glenn T.] Univ Colorado, Sch Med, Digest Hlth Inst, Gastrointestinal Eosinophil Dis Program,Childrens, Aurora, CO USA; [Gurian, Larry E.] Ferrell Duncan Clin & CoxHlth, Springfield, MO USA; [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA; [Hopp, Russell J.] Creighton Univ, Dept Pediat, Div Allergy & Immunol, Omaha, NE 68178 USA; [Kagalwalla, Amir] Ann & Robert H Lurie Childrens Hosp Chicago, Div Gastroenterol Hepatol & Nutr, Chicago, IL USA; [Kagalwalla, Amir] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Nadeau, Kari C.] Stanford Med Sch, Stanford, CA USA; [Nadeau, Kari C.] Stanford Med Ctr, Div Allergy & Immunol, Stanford, CA USA; [Nadeau, Kari C.] Lucille Packard Childrens Hosp, Stanford, CA USA; [Noel, Richard J.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA; [Noel, Richard J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [von Tiehl, Karl F.] Huntington Mem Hosp, Pasadena, CA USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Xavier University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Creighton University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Stanford University; Stanford University; Lucile Packard Children's Hospital (LPCH); Children's Hospital of Wisconsin; Medical College of Wisconsin; University of Southern California; Huntington Memorial Hospital	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	Hopp, Russell/K-4578-2019; Sucharew, Heidi/M-4338-2015; Hopp, Russell/AAY-7626-2020; Martin, Lisa/E-2425-2016; Mukkada, Vincent/AAF-6995-2019; Kottyan, Leah C./H-3050-2019	Martin, Lisa/0000-0001-8702-9946; Mukkada, Vincent/0000-0003-4225-5506; Kottyan, Leah C./0000-0003-3979-2220; Alexander, Eileen/0000-0002-6548-489X; Abonia, Juan/0000-0003-3788-6485	Cincinnati Children's Division of Biostatistics and Epidemiology; University of Cincinnati Research Council; Campaign Urging Research for Eosinophilic Diseases (CURED); Food Allergy Research and Education (FARE); Buckeye Foundation; National Institutes of Health (NIH) [T32-ES10957]; NIEHS [P30-ES006096]; CTSA; NCATS; NCRR/NIH [UL1-RR026314-01]; UAB Section on Statistical Genetics [1R25GM093044-01];  [NIH-1K24DK100303]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR026314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, K24DK100303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957, P30ES006096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM093044] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001834] Funding Source: NIH RePORTER	Cincinnati Children's Division of Biostatistics and Epidemiology; University of Cincinnati Research Council; Campaign Urging Research for Eosinophilic Diseases (CURED); Food Allergy Research and Education (FARE); Buckeye Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); UAB Section on Statistical Genetics; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported in part by the: Frank C. Woodside, Dinsmore& Shohl Fellowship through Cincinnati Children's Division of Biostatistics and Epidemiology; University of Cincinnati Research Council; Campaign Urging Research for Eosinophilic Diseases (CURED); Food Allergy Research and Education (FARE); Buckeye Foundation; National Institutes of Health (NIH) grants: T32-ES10957 Molecular Epidemiology in Children's Environmental Health Fellowship 2011-2013; NIEHS P30-ES006096 Center for Environmental Genetics New Investigator Scholar and PI Mentee/Mentor; NIH 8 UL1-TR000077-04 Center for Clinical and Translational Science and Training, CTSA, NCATS Just in Time; CCTST REDCap UL1-RR026314-01 NCRR/NIH; 1R25GM093044-01 UAB Section on Statistical Genetics; NIH-1K24DK100303 (GTF). This work was completed in partial fulfillment of the Doctor of Philosophy degree in Epidemiology in the Department of Environmental Health, Division of Epidemiology and Biostatistics, University of Cincinnati College of Medicine.	Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Barker DJP, 2009, ANN HUM BIOL, V36, P445, DOI 10.1080/03014460902980295; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Boomsma DI, 2007, TWIN RES HUM GENET, V10, P267, DOI 10.1375/twin.10.2.267; Calkins K, 2011, CURR PROB PEDIATR AD, V41, P158, DOI 10.1016/j.cppeds.2011.01.001; Cherian S, 2006, ARCH DIS CHILD, V91, P1000, DOI 10.1136/adc.2006.100974; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P1283, DOI 10.1016/j.cgh.2008.10.005; Dellon ES, 2011, GASTROENTEROLOGY, V141, P1586, DOI 10.1053/j.gastro.2011.06.081; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809; Fillon SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042938; Furuta GT, 2013, GUT, V62, P1395, DOI 10.1136/gutjnl-2012-303171; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hurrell JM, 2012, AM J GASTROENTEROL, V107, P698, DOI 10.1038/ajg.2012.6; Hviid A, 2011, GUT, V60, P49, DOI 10.1136/gut.2010.219683; Iwanczak B, 2011, ADV MED SCI-POLAND, V56, P151, DOI 10.2478/v10039-011-0038-7; Jensen ET, 2013, J PEDIATR GASTR NUTR, V57, P67, DOI 10.1097/MPG.0b013e318290d15a; Kalach N, 2011, J PEDIATR GASTR NUTR, V52, P175, DOI 10.1097/MPG.0b013e3181e2ae00; Katzka DA, 2007, GASTROINTEST ENDOSC, V65, P335, DOI 10.1016/j.gie.2006.10.049; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Larsson H, 2011, OTOLARYNG HEAD NECK, V144, P186, DOI 10.1177/0194599810392655; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lim EJ, 2011, J BIOL CHEM, V286, P13193, DOI 10.1074/jbc.M110.210724; Lim E, 2014, J IMMUNOL, V192, P466, DOI 10.4049/jimmunol.1302454; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Malerba G, 2000, AM J RESP CRIT CARE, V162, P1587, DOI 10.1164/ajrccm.162.4.9909031; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marian AJ, 2012, CURR OPIN CARDIOL, V27, P197, DOI 10.1097/HCO.0b013e328352707d; Matoso A, 2013, MODERN PATHOL, V26, P665, DOI 10.1038/modpathol.2013.41; MCGUE M, 1992, SCHIZOPHRENIA BULL, V18, P171, DOI 10.1093/schbul/18.2.171; Meyer GW, 2005, GASTROINTEST ENDOSC, V61, P932, DOI 10.1016/S0016-5107(05)00508-0; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Moya J, 2004, PEDIATRICS, V113, P996; Mukkada VA, 2008, BEST PRACT RES CL GA, V22, P497, DOI 10.1016/j.bpg.2007.09.002; Muthen B, 2006, TWIN RES HUM GENET, V9, P313, DOI 10.1375/twin.9.3.313; Neale M. C, 1992, METHODOLOGY GENETIC, P35; NEALE MC, 2002, METHODOLOGY GENETIC; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Ooki Syuichi, 1993, Acta Geneticae Medicae et Gemellologiae, V42, P17; Patel SM, 2005, GASTROINTEST ENDOSC, V61, P165, DOI 10.1016/S0016-5107(04)02459-9; Peeters H, 1998, BEHAV GENET, V28, P159, DOI 10.1023/A:1021416112215; Prasad GA, 2009, CLIN GASTROENTEROL H, V7, P1055, DOI 10.1016/j.cgh.2009.06.023; Prescott CA, 2004, BEHAV GENET, V34, P17, DOI 10.1023/B:BEGE.0000009474.97649.2f; Rayapudi M, 2010, J LEUKOCYTE BIOL, V88, P337, DOI 10.1189/jlb.0110025; Reed T, 2005, TWIN RES HUM GENET, V8, P362, DOI 10.1375/1832427054936763; Rice TK, 2008, ADV GENET, V60, P35, DOI 10.1016/S0065-2660(07)00402-6; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Sealock RJ, 2010, ALIMENT PHARM THER, V32, P712, DOI 10.1111/j.1365-2036.2010.04411.x; Shaw SY, 2011, AM J GASTROENTEROL, V106, P2133, DOI 10.1038/ajg.2011.304; Shaw SY, 2010, AM J GASTROENTEROL, V105, P2687, DOI 10.1038/ajg.2010.398; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Soon IS, 2013, J PEDIATR GASTR NUTR, V57, P72, DOI 10.1097/MPG.0b013e318291fee2; Sorser SA, 2013, J GASTROENTEROL, V48, P81, DOI 10.1007/s00535-012-0608-x; Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998; van Dongen J, 2012, NAT REV GENET, V13, P640, DOI 10.1038/nrg3243; Virta L, 2012, AM J EPIDEMIOL, V175, P775, DOI 10.1093/aje/kwr400; Wang FY, 2007, J CLIN GASTROENTEROL, V41, P451, DOI 10.1097/01.mcg.0000248019.16139.67; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Zaitlen N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003520; Zink DA, 2007, GASTROINTEST ENDOSC, V65, P330, DOI 10.1016/j.gie.2006.07.021; Zuk O, 2012, P NATL ACAD SCI USA, V109, P1193, DOI 10.1073/pnas.1119675109	72	132	138	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1084	+		10.1016/j.jaci.2014.07.021	http://dx.doi.org/10.1016/j.jaci.2014.07.021			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25258143	Green Accepted, Green Published			2022-12-18	WOS:000344938900013
J	Lluis, A; Depner, M; Gaugler, B; Saas, P; Casaca, VI; Raedler, D; Michel, S; Tost, J; Liu, J; Genuneit, J; Pfefferle, P; Roponen, M; Weber, J; Braun-Fahrlander, C; Riedler, J; Lauener, R; Vuitton, DA; Dalphin, JC; Pekkanen, J; von Mutius, E; Schaub, B				Lluis, Anna; Depner, Martin; Gaugler, Beatrice; Saas, Philippe; Casaca, Vera Isabel; Raedler, Diana; Michel, Sven; Tost, Jorg; Liu, Jing; Genuneit, Jon; Pfefferle, Petra; Roponen, Marjut; Weber, Juliane; Braun-Fahrlaender, Charlotte; Riedler, Josef; Lauener, Roger; Vuitton, Dominique Angele; Dalphin, Jean-Charles; Pekkanen, Juha; von Mutius, Erika; Schaub, Bianca		Protection Against Allergy Study R	Increased regulatory T-cell numbers are associated with farm milk exposure and lower atopic sensitization and asthma in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopic sensitization; farming; FOXP3 demethylation; innate; milk; peripheral blood mononuclear cells; regulatory T cells	INVERSE ASSOCIATION; ALLERGIC DISEASES; CD127 EXPRESSION; LIFE-STYLE; CONSUMPTION; FOXP3; RISK; PROTECTION; RECEPTORS; CHILDREN	Background: European cross-sectional studies have suggested that prenatal and postnatal farm exposure decreases the risk of allergic diseases in childhood. Underlying immunologic mechanisms are still not understood but might be modulated by immune-regulatory cells early in life, such as regulatory T (Treg) cells. Objective: We sought to assess whether Treg cells from 4.5-year-old children from the Protection against Allergy: Study in Rural Environments birth cohort study are critical in the atopy and asthma-protective effect of farm exposure and which specific exposures might be relevant. Methods: From 1133 children, 298 children were included in this study (149 farm and 149 reference children). Detailed questionnaires until 4 years of age assessed farming exposures over time. Treg cells were characterized as upper 20% CD4(+)CD25(+) forkhead box protein 3 (FOXP3)(+) (intracellular) in PBMCs before and after stimulation (with phorbol 12-myristate 13-acetate/ionomycin or LPS), and FOXP3 demethylation was assessed. Atopic sensitization was defined by specific IgE measurements; asthma was defined by a doctor's diagnosis. Results: Treg cells were significantly increased in farm-exposed children after phorbol 12-myristate 13-acetate/ionomycin and LPS stimulation. Exposure to farm milk was defined as a relevant independent farm-related exposure supported by higher FOXP3 demethylation. Treg cell (upper 20% CD4(+)CD25(+), FOXP3(+) T cells) numbers were significantly negatively associated with doctor-diagnosed asthma (LPS stimulated: adjusted odds ratio, 0.26; 95% CI, 0.08-0.88) and perennial IgE (unstimulated: adjusted odds ratio, 0.21; 95% CI, 0.08-0.59). Protection against asthma by farm milk exposure was partially mediated by Treg cells. Conclusions: Farm milk exposure was associated with increased Treg cell numbers on stimulation in 4.5-year-old children and might induce a regulatory phenotype early in life, potentially contributing to a protective effect for the development of childhood allergic diseases.	[Lluis, Anna; Depner, Martin; Casaca, Vera Isabel; Raedler, Diana; Liu, Jing; Weber, Juliane; von Mutius, Erika; Schaub, Bianca] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp, D-80337 Munich, Germany; [Gaugler, Beatrice; Saas, Philippe] Univ Franche Comte, Univ Hosp Besancon, F-25030 Besancon, France; [Gaugler, Beatrice; Saas, Philippe] Univ Franche Comte, Plateforme Biomonitoring, EFS Bourgogne Franche Comte, INSERM,UMR1098,CIC BT506, F-25030 Besancon, France; [Michel, Sven] Univ Regensburg, Univ Childrens Hosp Eastern Bavaria KUNO, Dept Pediat Pneumol & Allergy, D-93053 Regensburg, Germany; [Tost, Jorg] CEA Inst Genom, Ctr Natl Genotypage, Lab Epigenet & Environm LEE, Evry, France; [Liu, Jing] JI LIN Univ, Dept Resp Med, Hosp 2, Changchun, Peoples R China; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Pfefferle, Petra] Univ Marburg, Dept Clin Chem & Mol Diagnost, D-35032 Marburg, Germany; [Roponen, Marjut] Univ Eastern Finland, Dept Environm Sci, Kuopio, Finland; [Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Hochgebirgklin Davos, Davos, Switzerland; [Vuitton, Dominique Angele; Dalphin, Jean-Charles] Univ Franche Comte, Res Unit Hlth & Rural Environm, Univ Hosp Besancon, F-25030 Besancon, France; [Pekkanen, Juha] Natl Inst Hlth & Welfare, Dept Environm Hlth, Kuopio, Finland; [Pekkanen, Juha] Univ Eastern Finland, Kuopio, Finland; Univ Utrecht, Div Environm Epidemiol, Inst Risk Assessment Sci IRAS, Utrecht, Netherlands	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; University of Regensburg; CEA; UDICE-French Research Universities; Universite Paris Saclay; Jilin University; Ulm University; Philipps University Marburg; University of Eastern Finland; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Universite de Franche-Comte; CHU Besancon; Finland National Institute for Health & Welfare; University of Eastern Finland; Utrecht University	Schaub, B (corresponding author), Ludwig Maximilians Univ Munchen, Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Bianca.Schaub@med.uni-muenchen.de	SAAS, Philippe/M-3550-2015; Saas, Philippe/M-9605-2019; Tost, Joerg/H-7129-2019; Schaub, Bianca/B-9935-2019; Gaugler-Verjus, Beatrice/M-3528-2018; Roponen, Marjut/C-2086-2017; Lauener, Roger P/O-8612-2016; Genuneit, Jon/I-9323-2012; Ege, Markus/C-1962-2012; Loss, Georg/F-1557-2013; Roduit, Caroline/S-4928-2017; riedler, josef/AAQ-4666-2020	Saas, Philippe/0000-0002-8857-9939; Tost, Joerg/0000-0002-2683-0817; Schaub, Bianca/0000-0003-1652-8873; Gaugler-Verjus, Beatrice/0000-0001-9434-7176; Roponen, Marjut/0000-0002-4442-9090; Lauener, Roger P/0000-0002-8412-606X; Genuneit, Jon/0000-0001-5764-1528; Ege, Markus/0000-0001-6643-3923; Loss, Georg/0000-0003-1090-812X; Michel, Sven/0000-0003-3604-3187; von Mutius, Erika/0000-0002-8893-4515	EFRAIM EU [FP7- KBBE-2007-1]; Bavarian Research Association; Marie Curie Grant [MEST-CT-2005-020524-GALTRAIN]; Comprehensive Pneumology Centre;  [SFB TR22]	EFRAIM EU; Bavarian Research Association; Marie Curie Grant(European Commission); Comprehensive Pneumology Centre; 	Supported by EFRAIM EU FP7- KBBE-2007-1, the Bavarian Research Association (to J.L.), SFB TR22 (to B.S. and A.L.), a Marie Curie Grant (MEST-CT-2005-020524-GALTRAIN; to A.L.), and the Comprehensive Pneumology Centre (to B.S.).	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Barnes M, 2001, CLIN EXP ALLERGY, V31, P1822, DOI 10.1046/j.1365-2222.2001.01240.x; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Basagana X, 2002, PEDIAT ALLERG IMM-UK, V13, P412, DOI 10.1034/j.1399-3038.2002.02081.x; Braun-Fahrlander C, 2011, CLIN EXP ALLERGY, V41, P29, DOI 10.1111/j.1365-2222.2010.03665.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Di Caro V, 2011, CLIN EXP IMMUNOL, V165, P60, DOI 10.1111/j.1365-2249.2011.04334.x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Gamborg M, 2009, AM J EPIDEMIOL, V169, P1167, DOI 10.1093/aje/kwp047; Herzum I, 2005, CLIN CHEM LAB MED, V43, P963, DOI 10.1515/CCLM.2005.165; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Liu J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013267; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Michel S, 2013, ALLERGY, V68, P355, DOI 10.1111/all.12097; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Perkin MR, 2007, CLIN EXP ALLERGY, V37, P627, DOI 10.1111/j.1365-2222.2007.02715.x; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Shevach EM, 2006, IMMUNITY, V25, P195, DOI 10.1016/j.immuni.2006.08.003; Simonetta F, 2010, EUR J IMMUNOL, V40, P2528, DOI 10.1002/eji.201040531; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x	39	132	137	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					551	+		10.1016/j.jaci.2013.06.034	http://dx.doi.org/10.1016/j.jaci.2013.06.034			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	23993223				2022-12-18	WOS:000332397100032
J	Kagalwalla, AF; Akhtar, N; Woodruff, SA; Rea, BA; Masterson, JC; Mukkada, V; Parashette, KR; Du, J; Fillon, S; Protheroe, CA; Lee, JJ; Amsden, K; Melin-Aldana, H; Capocelli, KE; Furuta, GT; Ackerman, SJ				Kagalwalla, Amir F.; Akhtar, Noorain; Woodruff, Samantha A.; Rea, Bryan A.; Masterson, Joanne C.; Mukkada, Vincent; Parashette, Kalyan R.; Du, Jian; Fillon, Sophie; Protheroe, Cheryl A.; Lee, James J.; Amsden, Katie; Melin-Aldana, Hector; Capocelli, Kelley E.; Furuta, Glenn T.; Ackerman, Steven J.			Eosinophilic esophagitis: Epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; esophagitis; epithelium; remodeling; fibrosis; mesenchymal; vimentin; cytokeratin	GROWTH-FACTOR-BETA; CONSENSUS RECOMMENDATIONS; PULMONARY-FIBROSIS; TUMOR PROGRESSION; ADULT PATIENTS; N-CADHERIN; TGF-BETA; CELLS; CHILDREN; EXPRESSION	Background: Mechanisms underlying esophageal remodeling with subepithelial fibrosis in subjects with eosinophilic esophagitis (EoE) have not been delineated. Objectives: We sought to explore a role for epithelial mesenchymal transition (EMT) in subjects with EoE and determine whether EMT resolves with treatment. Methods: Esophageal biopsy specimens from 60 children were immunostained for epithelial (cytokeratin) and mesenchymal (vimentin) EMT biomarkers, and EMT was quantified. Subjects studied had EoE (n = 517), indeterminate EoE (n = 515), gastroesophageal reflux disease (n = 7), or normal esophagus (n = 21). EMT was analyzed for relationships to diagnosis, eosinophil counts, and indices of subepithelial fibrosis, eosinophil peroxidase, and TGF-beta immunostaining. EMT was assessed in pretreatment and posttreatment biopsy specimens from 18 subjects with EoE treated with an elemental diet, 6-food elimination diet, or topical corticosteroids (n = 6 per group). Results: TGF-beta 1 treatment of esophageal epithelial cells in vitro for 24 hours induced upregulation of mesenchymal genes characteristic of EMT, including N-cadherin (3.3-fold), vimentin (2.1-fold), and fibronectin (7.5-fold). EMT in esophageal biopsy specimens was associated with EoE (or indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and was correlated to eosinophil counts (r = 0.691), eosinophil peroxidase (r = 0.738), and TGF-beta (r = 0.520) immunostaining and fibrosis (r = 0.644) indices. EMT resolved with EoE treatments that induced clinicopathologic remission with reduced eosinophil counts. EMT decreased significantly after treatment by 74.1% overall in the 18 treated subjects with EoE; pretreatment versus posttreatment EMT scores were 3.17 +/- 0.82 versus 0.82 +/- 0.39 (P <.001), with similar decreases within treatment groups. Pretreatment/posttreatment EMT was strongly correlated with eosinophil counts for combined (r = 0.804, P <.001) and individual treatment groups. Conclusions: EMT likely contributes to subepithelial fibrosis in subjects with EoE and resolves with treatments that decrease esophageal inflammation, and its resolution correlates with decreased numbers of esophageal eosinophils. (J Allergy Clin Immunol 2012;129:1387-96.)	[Akhtar, Noorain; Rea, Bryan A.; Parashette, Kalyan R.; Du, Jian; Ackerman, Steven J.] Univ Illinois, Dept Biochem & Mol Genet, Coll Med, Chicago, IL 60607 USA; Northwestern Univ, Chicago, IL 60611 USA; [Kagalwalla, Amir F.; Amsden, Katie] Childrens Mem Hosp, Dept Pediat, Chicago, IL 60614 USA; [Melin-Aldana, Hector] Childrens Mem Hosp, Dept Pathol, Chicago, IL 60614 USA; [Kagalwalla, Amir F.] John H Stroger Hosp Cook Cty, Dept Pediat, Chicago, IL USA; [Woodruff, Samantha A.; Masterson, Joanne C.; Mukkada, Vincent; Fillon, Sophie; Furuta, Glenn T.] Univ Colorado, Denver Sch Med, Dept Pediat, Mucosal Inflammat Program, Aurora, CO USA; [Capocelli, Kelley E.] Univ Colorado, Denver Sch Med, Dept Pathol, Aurora, CO USA; [Woodruff, Samantha A.; Masterson, Joanne C.; Mukkada, Vincent; Fillon, Sophie; Capocelli, Kelley E.; Furuta, Glenn T.] Childrens Hosp Colorado, Digest Hlth Inst, Sect Pediat Gastroenterol Hepatol & Nutr, Gastrointestinal Eosinophil Dis Program, Aurora, CO USA; [Protheroe, Cheryl A.; Lee, James J.] Mayo Clin Arizona, Dept Biochem & Mol Biol, Scottsdale, AZ USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; John H Stroger Junior Hospital Cook County; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; Mayo Clinic; Mayo Clinic Phoenix	Ackerman, SJ (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, Coll Med, MBRB 2074,MC669,900 S Ashland Ave, Chicago, IL 60607 USA.	sackerma@uic.edu	Mukkada, Vincent/AAF-6995-2019; Parashette, Kalyan Ray/Y-7621-2019	Mukkada, Vincent/0000-0003-4225-5506; Capocelli, Kelley/0000-0002-8256-2896	American Gastroenterological Association (AGA); National Institutes of Health (NIH) [R21AI079925]; UIC Department of Pediatrics; Mayo Foundation and its NIH [NCRR K26 RR0109709]; UIC COM; NIH/NCRR Colorado CTSI [UL1 RR025780]; Campaign Urging Research on Eosinophil Diseases; Buckeye Foundation; University of Illinois at Chicago Department of Pediatrics; Children's Hospital Colorado; Children's Memorial Hospital in Chicago; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI079925] Funding Source: NIH RePORTER	American Gastroenterological Association (AGA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UIC Department of Pediatrics; Mayo Foundation and its NIH; UIC COM; NIH/NCRR Colorado CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research on Eosinophil Diseases; Buckeye Foundation; University of Illinois at Chicago Department of Pediatrics; Children's Hospital Colorado; Children's Memorial Hospital in Chicago; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by a translational research award from the AGA (to S.J.A. and G.T.F.), National Institutes of Health (NIH) grant R21AI079925 (to G. T. F. and S.J.A.), unrestricted gifts from the Campaign Urging Research on Eosinophilic Diseases (CURED; to S.J.A., G.T.F., and A.F.K.) and the Buckeye Foundation (to A.F.K.), and research funds from the UIC Department of Pediatrics (to A. F. K. and S.J.A.) and the Mayo Foundation and its NIH grant NCRR K26 RR0109709 (J.J.L.). B.A.R. was supported in part by a Craig Medical Student Summer Research Fellowship from the UIC COM. The CURED and Buckeye Foundations did not play any role in development of the study or in the preparation of this manuscript aside from providing research funding. This project was also supported in part by NIH/NCRR Colorado CTSI grant UL1 RR025780 (to G.T.F., S.A.W., and J.C.M.). Its contents are the authors' sole responsibility and do not necessarily represent official NIH views. S.J.A. and G.T.F. are members of the Medical Advisory Panel of the American Partnership for Eosinophilic Diseases.; A. F. Kagalwalla is on the speakers' bureau for Abbott Nutrition and has received research support from the Campaign Urging Research on Eosinophil Diseases, the Buckeye Foundation, and the University of Illinois at Chicago Department of Pediatrics. G. T. Furuta has received research support from the American Gastroenterological Association. The rest of the authors declare that they have no relevant conflicts of interest.; We thank Wendy Moore, Zachary Robinson, and Mark Lovell at the Children's Hospital Colorado and associated nurses and histology laboratory staff at Children's Memorial Hospital in Chicago for their participation and support and Christine Jun, MD, at UIC COM for participation in preliminary development of the project and immunostaining methods for EMT.	Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2009, IMMUNOL ALLERGY CLIN, V29, P197, DOI 10.1016/j.iac.2008.10.003; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Bataille F, 2008, INFLAMM BOWEL DIS, V14, P1514, DOI 10.1002/ibd.20590; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384; Cho JY, 2004, AM J RESP CELL MOL, V30, P651, DOI 10.1165/rcmb.2003-0066OC; Dalby K, 2010, SCAND J GASTROENTERO, V45, P1029, DOI 10.3109/00365521.2010.487917; Feighery R, 2008, PROTEOM CLIN APPL, V2, P1110, DOI 10.1002/prca.200780148; Flier SN, 2010, J BIOL CHEM, V285, P20202, DOI 10.1074/jbc.M110.102012; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Galichon P, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-11; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kwiatek MA, 2011, GASTROENTEROLOGY, V140, P82, DOI 10.1053/j.gastro.2010.09.037; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007; Masterson J, 2007, CELLS TISSUES ORGANS, V185, P175, DOI 10.1159/000101318; Masterson JC, 2011, AM J PATHOL, V179, P2302, DOI 10.1016/j.ajpath.2011.07.039; Masterson JC, 2011, CELL SIGNAL, V23, P398, DOI 10.1016/j.cellsig.2010.10.010; Molloy EL, 2008, GROWTH FACTORS, V26, P12, DOI 10.1080/08977190801987166; Morrissey J, 2002, J AM SOC NEPHROL, V13, pS14; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Pegorier S, 2006, J IMMUNOL, V177, P4861, DOI 10.4049/jimmunol.177.7.4861; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; Rochester CL, 1996, J IMMUNOL, V156, P4449; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Sheppard D, 2005, CANCER METAST REV, V24, P395, DOI 10.1007/s10555-005-5131-6; Stevoff C, 2001, GASTROINTEST ENDOSC, V54, P373, DOI 10.1067/mge.2001.116569; Straumann A, 2012, ALLERGY, V67, P477, DOI 10.1111/j.1398-9995.2012.02787.x; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Straumann A, 2008, CLIN GASTROENTEROL H, V6, P598, DOI 10.1016/j.cgh.2008.02.003; Straumann A, 2011, CLIN GASTROENTEROL H, V9, P400, DOI 10.1016/j.cgh.2011.01.017; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Willis Brigham C, 2006, Proc Am Thorac Soc, V3, P377, DOI 10.1513/pats.200601-004TK; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	49	132	134	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1387	U299		10.1016/j.jaci.2012.03.005	http://dx.doi.org/10.1016/j.jaci.2012.03.005			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22465212	Green Accepted			2022-12-18	WOS:000303418000030
J	Thiel, J; Kimmig, L; Salzer, U; Grudzien, M; Lebrecht, D; Hagena, T; Draeger, R; Volxen, N; Bergbreiter, A; Jennings, S; Gutenberger, S; Aichem, A; Illges, H; Hannan, JP; Kienzler, AK; Rizzi, M; Eibel, H; Peter, HH; Warnatz, K; Grimbacher, B; Rump, JA; Schlesier, M				Thiel, Jens; Kimmig, Lucas; Salzer, Ulrich; Grudzien, Magdalena; Lebrecht, Dirk; Hagena, Tina; Draeger, Ruth; Voelxen, Nadine; Bergbreiter, Astrid; Jennings, Stephanie; Gutenberger, Sylvia; Aichem, Annette; Illges, Harald; Hannan, Jonathan P.; Kienzler, Anne-Kathrin; Rizzi, Marta; Eibel, Hermann; Peter, Hans-Hartmut; Warnatz, Klaus; Grimbacher, Bodo; Rump, Joerg-Andres; Schlesier, Michael			Genetic CD21 deficiency is associated with hypogammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD21; complement receptor; hypogammaglobulinemia; common variable immunodeficiency; B lymphocyte	EPSTEIN-BARR-VIRUS; COMMON VARIABLE IMMUNODEFICIENCY; COMPLEMENT RECEPTOR TYPE-2; FOLLICULAR DENDRITIC CELLS; LYMPHOCYTE-B RECEPTOR; PNEUMOCOCCAL POLYSACCHARIDES; CAPSULAR POLYSACCHARIDE; ANTIBODY-RESPONSE; C3D; CR-2	Background: Complement receptor 2 (CR2/CD21) is part of the B-cell coreceptor and expressed by mature B cells and follicular dendritic cells. CD21 is a receptor for C3d-opsonized immune complexes and enhances antigen-specific B-cell responses. Objective: Genetic inactivation of the murine CR2 locus results in impaired humoral immune responses. Here we report the first case of a genetic CD21 deficiency in human subjects. Methods: CD21 protein expression was analyzed by means of flow cytometry and Western blotting. CD21 transcripts were quantified by using real-time PCR. The CD21 gene was sequenced. Wild-type and mutant CD21 cDNA expression was studied after transfection of 293T cells. Binding of EBV-gp350 or C3d-containing immune complexes and induction of calcium flux in CD21-deficient B cells were analyzed by means of flow cytometry. Antibody responses to protein and polysaccharide vaccines were measured. Results: A 28-year-old man presented with recurrent infections, reduced class-switched memory B cells, and hypogammaglobulinemia. CD21 receptor expression was undetectable. Binding of C3d-containing immune complexes and EBV-gp350 to B cells was severely reduced. Sequence analysis revealed a compound heterozygous deleterious mutation in the CD21 gene. Functional studies with anti-immunoglobulin-and C3d-containing immune complexes showed a complete loss of costimulatory activity of C3d in enhancing suboptimal B-cell receptor stimulation. Vaccination responses to protein antigens were normal, but the response to pneumococcal polysaccharide vaccination was moderately impaired. Conclusions: Genetic CD21 deficiency adds to the molecular defects observed in human subjects with hypogammaglobulinemia. (J Allergy Clin Immunol 2012;129:801-10.)	[Thiel, Jens; Kimmig, Lucas; Salzer, Ulrich; Grudzien, Magdalena; Lebrecht, Dirk; Hagena, Tina; Draeger, Ruth; Voelxen, Nadine; Bergbreiter, Astrid; Jennings, Stephanie; Gutenberger, Sylvia; Kienzler, Anne-Kathrin; Rizzi, Marta; Eibel, Hermann; Peter, Hans-Hartmut; Warnatz, Klaus; Grimbacher, Bodo; Rump, Joerg-Andres; Schlesier, Michael] Univ Hosp Freiburg, Dept Rheumatol & Clin Immunol, D-79106 Freiburg, Germany; [Thiel, Jens; Salzer, Ulrich; Voelxen, Nadine; Bergbreiter, Astrid; Jennings, Stephanie; Gutenberger, Sylvia; Kienzler, Anne-Kathrin; Rizzi, Marta; Eibel, Hermann; Peter, Hans-Hartmut; Warnatz, Klaus; Schlesier, Michael] Univ Hosp Freiburg, Ctr Chron Immunodeficiency, D-79106 Freiburg, Germany; [Kienzler, Anne-Kathrin; Rizzi, Marta; Eibel, Hermann] Univ Hosp Freiburg, Clin Res Unit Rheumatol, D-79106 Freiburg, Germany; [Aichem, Annette] Univ Konstanz, Biotechnol Inst Thurgau, Kreuzlingen, Switzerland; [Illges, Harald] Univ Appl Sci, Dept Nat Sci Immunol & Cell Biol, Rheinbach, Germany; [Hannan, Jonathan P.] Univ Edinburgh, Inst Struct Biol & Mol Biol, Sch Biol Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Grimbacher, Bodo] Royal Free Hosp, Dept Clin Immunol, London, England; [Grimbacher, Bodo] UCL, London WC1E 6BT, England	University of Freiburg; University of Freiburg; University of Freiburg; University of Edinburgh; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London	Thiel, J (corresponding author), Univ Hosp Freiburg, Dept Rheumatol & Clin Immunol, Hugstetterstr 55, D-79106 Freiburg, Germany.	jens.thiel@uniklinik-freiburg.de	Rizzi, Marta/ABE-7264-2020; Warnatz, Klaus/AAD-3464-2022	Hannan, Jonathan/0000-0003-3318-2341; Kimmig, Lucas/0000-0001-8297-0278; Salzer, Ulrich/0000-0002-1769-1157; Rizzi, Marta/0000-0002-5153-6089; Kienzler, Anne-Kathrin/0000-0002-3082-9210	Deutsche Forschungsgemeinschaft (DFG) [SFB 620 C1, SFB 620 C2, SFB 620 C7]; European Union [CCI-01E O0803, LSHM-CT-2004-005264, HEALTH-F2-2008-201549]; Hans Hench foundation; Federal Ministry for Education and Research (BMBF)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); European Union(European Commission); Hans Hench foundation; Federal Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	Supported by the Deutsche Forschungsgemeinschaft (DFG) SFB 620 C1, SFB 620 C2 (U. S. and B. G.) and SFB 620 C7 (U. S.), by grant CCI-01E O0803 (K. W., H. E., and U. S.), by grants LSHM-CT-2004-005264 and EUROPADnet HEALTH-F2-2008-201549 of the European Union, and by a grant from the Hans Hench foundation.; K. Warnatz is a consultant for Medisys Health and has received research support from the Federal Ministry for Education and Research (BMBF). The rest of the authors declare that they have no relevant conflicts of interest.	Aghamohammadi A, 2008, INT ARCH ALLERGY IMM, V147, P87, DOI 10.1159/000135694; Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; Asokan R, 2006, J IMMUNOL, V177, P383, DOI 10.4049/jimmunol.177.1.383; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Barel M, 1998, MOL IMMUNOL, V35, P1025, DOI 10.1016/S0161-5890(98)00098-4; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Chen ZB, 2000, J IMMUNOL, V164, P4522, DOI 10.4049/jimmunol.164.9.4522; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; Crawford K, 2000, Rev Immunogenet, V2, P323; de Brouwer APM, 2006, MOL DIAGN THER, V10, P197; Fang YF, 1998, J IMMUNOL, V160, P5273; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; FUJISAKU A, 1989, J BIOL CHEM, V264, P2118; Gatto D, 2005, J EXP MED, V201, P993, DOI 10.1084/jem.20042239; Goldacker S, 2007, CLIN IMMUNOL, V124, P294, DOI 10.1016/j.clim.2007.04.011; GRIFFIOEN AW, 1991, INFECT IMMUN, V59, P1839, DOI 10.1128/IAI.59.5.1839-1845.1991; Isenman DE, 2010, J IMMUNOL, V184, P1946, DOI 10.4049/jimmunol.0902919; Janz A, 2000, J VIROL, V74, P10142, DOI 10.1128/JVI.74.21.10142-10152.2000; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Kulik L, 2011, MOL IMMUNOL, V48, P883, DOI 10.1016/j.molimm.2010.12.019; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; Lyubchenko T, 2005, J IMMUNOL, V174, P3264, DOI 10.4049/jimmunol.174.6.3264; Masilamani M, 2003, EUR J IMMUNOL, V33, P2391, DOI 10.1002/eji.200323843; MOLINA H, 1990, J IMMUNOL, V145, P2974; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; Pozdnyakova O, 2003, J IMMUNOL, V170, P84, DOI 10.4049/jimmunol.170.1.84; QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590, DOI 10.1128/CDLI.2.5.590-597.1995; Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003; Shaw CD, 2010, J MOL BIOL, V404, P697, DOI 10.1016/j.jmb.2010.10.005; Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118; Tew JG, 1997, IMMUNOL REV, V156, P39, DOI 10.1111/j.1600-065X.1997.tb00957.x; van Kessel DA, 2005, EUR RESPIR J, V25, P482, DOI 10.1183/09031936.05.00073204; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; WEIS JJ, 1988, J EXP MED, V167, P1047, DOI 10.1084/jem.167.3.1047; Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003; Young KA, 2007, J BIOL CHEM, V282, P36614, DOI 10.1074/jbc.M706324200	43	132	136	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					801	U299		10.1016/j.jaci.2011.09.027	http://dx.doi.org/10.1016/j.jaci.2011.09.027			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22035880				2022-12-18	WOS:000301189300028
J	Taubel, M; Rintala, H; Pitkaranta, M; Paulin, L; Laitinen, S; Pekkanen, J; Hyvarinen, A; Nevalainen, A				Taubel, Martin; Rintala, Helena; Pitkaranta, Miia; Paulin, Lars; Laitinen, Sirpa; Pekkanen, Juha; Hyvarinen, Anne; Nevalainen, Aino			The occupant as a source of house dust bacteria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbial markers; mattress dust; floor dust; indoor; microbial exposure; bacteria; sequencing; endotoxin; LPS; muramic acid	ENDOTOXIN EXPOSURE; SCHOOL-CHILDREN; FARM CHILDREN; BIRTH COHORT; DIVERSITY; CULTURE; RISK; DETERMINANTS; ENVIRONMENT; COMPONENTS	Background: Markers for microbial groups are commonly measured in house dust samples to assess indoor exposure to microbes in studies on asthma and allergy. However, little is known about the sources of different microbes. A better understanding of the nature and origin of microbes present in the immediate environment of human beings is crucial if one wants to elucidate protective as well as adverse effects on human health. Objective: To determine the extent to which the bacterial composition of mattress and floor dust reflects the presence of the human body in relation to other environmental sources. Methods: House dust and skin surface swab samples of occupants in 4 homes were collected and analyzed for their bacterial content, using a culture-independent methodology. Bacterial sequences analyzed from the different house dusts and skin surface swabs represented random samples of bacteria present in a given sample. Highly similar sequences were grouped to assess biodiversity and to draw conclusions about the sources of bacteria. Results: The bacterial flora in the house dust samples was found to be highly diverse and dominated by gram-positive bacteria. To a considerable extent, the presence of different bacterial groups was attributed to human sources. In the individuals' mattress dust samples, 69% to 88% of the bacterial sequences analyzed were associated with human origins. The respective percentages for the individual floor dusts ranged from 45% to 55%. Conclusion: Our study indicates that human-derived bacteria account for a large part of the mainly gram-positive bacterial content in house dust. (J Allergy Clin Immunol 2009;124:834-40.)	[Taubel, Martin; Rintala, Helena; Pekkanen, Juha; Hyvarinen, Anne; Nevalainen, Aino] Natl Inst Hlth & Welf, Dept Environm Hlth, FIN-70701 Kuopio, Finland; [Pitkaranta, Miia; Paulin, Lars] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; [Laitinen, Sirpa] Finnish Inst Occupat Hlth, Kuopio, Finland; [Pekkanen, Juha] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Helsinki; Finnish Institute of Occupational Health; University of Eastern Finland	Taubel, M (corresponding author), Natl Inst Hlth & Welf, Dept Environm Hlth, POB 95, FIN-70701 Kuopio, Finland.	martin.taubel@thl.fi	Täubel, Martin/P-7059-2019	Täubel, Martin/0000-0001-8082-1041; Pitkaranta, Miia/0000-0003-2552-8154; Hyvarinen, Anne/0000-0002-2823-0866	Academy of Finland [106103, 111177]	Academy of Finland(Academy of Finland)	Supported by the Academy of Finland with grant nos. 106103 and 111177.	Abraham JH, 2005, ENVIRON HEALTH PERSP, V113, P1516, DOI 10.1289/ehp.7632; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andersson AM, 1999, J APPL MICROBIOL, V86, P622, DOI 10.1046/j.1365-2672.1999.00706.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bouillard L, 2005, ANN AGR ENV MED, V12, P187; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Dekio I, 2005, J MED MICROBIOL, V54, P1231, DOI 10.1099/jmm.0.46075-0; EVANS CA, 1976, J CLIN MICROBIOL, V3, P576; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Giovannangelo M, 2007, INDOOR AIR, V17, P70, DOI 10.1111/j.1600-0668.2006.00461.x; Horak B, 1996, ANN ALLERG ASTHMA IM, V76, P41, DOI 10.1016/S1081-1206(10)63405-9; Hyvarinen A, 2006, INDOOR AIR, V16, P20, DOI 10.1111/j.1600-0668.2005.00392.x; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; Lappalainen MHJ, 2008, CLIN EXP ALLERGY, V38, P1483, DOI 10.1111/j.1365-2222.2008.03054.x; Lee L, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-27; Pakarinen J, 2008, ENVIRON MICROBIOL, V10, P3317, DOI 10.1111/j.1462-2920.2008.01723.x; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JH, 2004, APPL ENVIRON MICROB, V70, P262, DOI 10.1128/aEM.70.1.262-267.2004; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Rintala H, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-56; Saraf A, 1997, APPL ENVIRON MICROB, V63, P2554, DOI 10.1128/AEM.63.7.2554-2559.1997; Schloss PD, 2006, APPL ENVIRON MICROB, V72, P6773, DOI 10.1128/AEM.00474-06; Schloss PD, 2005, APPL ENVIRON MICROB, V71, P1501, DOI 10.1128/AEM.71.3.1501-1506.2005; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Wintzingerode F, 1997, FEMS MICROBIOL REV, V21, P213; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; Zhao ZH, 2008, PEDIAT ALLERG IMM-UK, V19, P455, DOI 10.1111/j.1399-3038.2007.00664.x	31	132	133	2	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					834	840		10.1016/j.jaci.2009.07.045	http://dx.doi.org/10.1016/j.jaci.2009.07.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767077	Bronze			2022-12-18	WOS:000270802800031
J	Traidl-Hoffmann, C; Jakob, T; Behrendt, H				Traidl-Hoffmann, Claudia; Jakob, Thilo; Behrendt, Heidrun			Determinants of allergenicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; structure; intrinsic function; pollen-associated lipid mediators; adjuvant	HOUSE-DUST MITE; SERUM IGE LEVELS; DIESEL EXHAUST PARTICLES; CD4(+)CD25(+) T-CELLS; AMINO-ACID-SEQUENCE; DER-P-I; DENDRITIC CELLS; PROTEOLYTIC ACTIVITY; MAJOR ALLERGEN; BIRCH POLLEN	The question "What makes an allergen an allergen?" has puzzled generations of researchers, and we still do not have a conclusive answer. Despite increasing knowledge about the molecular and functional characteristics of allergens that have been identified, we still do not fully understand why some proteins are clinically relevant allergens and most are not. Different approaches have been taken to identify the structural and functional features of allergens, aiming at developing methods to predict allergenicity and thus to identify allergens. However, none of these methods has allowed a reliable discrimination between allergenic and nonallergenic compounds on its own. This review sums up diverse determinants that contribute to the phenomenon of allergenicity and outlines that in addition to the structure and function of the allergen, factors derived from allergen carriers, the environment, and the susceptible individual are of importance. (J Allergy Clin Immunol 2009;123:558-66.)	[Traidl-Hoffmann, Claudia; Behrendt, Heidrun] Tech Univ Munich, Div Environm Dermatol & Allergy, Helmholtz Ctr Munich TUM, ZAUM Ctr Allergy & Environm,Dept Dermatol & Aller, D-80802 Munich, Germany; [Jakob, Thilo] Univ Med Ctr Freiburg, Allergy Res Grp, Dept Dermatol, Freiburg, Germany	Technical University of Munich; University of Freiburg	Traidl-Hoffmann, C (corresponding author), Tech Univ Munich, Div Environm Dermatol & Allergy, Helmholtz Ctr Munich TUM, ZAUM Ctr Allergy & Environm,Dept Dermatol & Aller, Biedersteinerstr 29, D-80802 Munich, Germany.	traidl-hoffmann@lrz.tum.de; thilo.jakob@uniklinik-freiburg.de	Jakob, Thilo/J-1621-2012	Traidl-Hoffmann, Claudia/0000-0001-5085-5179	German Ministry of Research and Science; University of Freiburg Medical Faculty; Landesstifung Baden Wuettemberg	German Ministry of Research and Science; University of Freiburg Medical Faculty; Landesstifung Baden Wuettemberg	Disclosure of potential conflict of interest: T. Jakob receives grant support from the German Ministry of Research and Science, the University of Freiburg Medical Faculty, and the Landesstifung Baden Wuettemberg and is a member of the Executive Committee for the European Academy of Allergy and Clinical Immunology and a board member for the European Immunodermatology Society. The rest of the authors have declared that they have no conflict of interest.	Aalberse RC, 2006, CHEM IMMUNOL ALLERGY, V91, P134; Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Aalberse RC, 2006, MOL NUTR FOOD RES, V50, P625, DOI 10.1002/mnfr.200500270; Akdis CA, 2006, CURR OPIN IMMUNOL, V18, P718, DOI 10.1016/j.coi.2006.09.016; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akkoc T, 2008, J ALLERGY CLIN IMMUN, V121, P652, DOI 10.1016/j.jaci.2007.12.1171; Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Antens CJM, 2006, CLIN EXP ALLERGY, V36, P1525, DOI 10.1111/j.1365-2222.2006.02603.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; Behrendt H, 1999, INT ARCH ALLERGY IMM, V118, P414, DOI 10.1159/000024151; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Blaser K, 1996, ADV EXP MED BIOL, V409, P295; Blaser K, 1998, INT ARCH ALLERGY IMM, V117, P1, DOI 10.1159/000023984; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; Buters JTM, 2008, INT ARCH ALLERGY IMM, V145, P122, DOI 10.1159/000108137; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cortes L, 2006, J ALLERGY CLIN IMMUN, V118, P878, DOI 10.1016/j.jaci.2006.05.029; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; De Groot J, 2007, BIOTECHNOL BIOENG, V97, P735, DOI 10.1002/bit.21264; Deb R, 2007, J BIOL CHEM, V282, P36808, DOI 10.1074/jbc.M702336200; Dharajiya N, 2007, J ALLERGY CLIN IMMUN, V119, P646, DOI 10.1016/j.jaci.2006.11.634; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Emanuelsson C, 2007, MOL IMMUNOL, V44, P3256, DOI 10.1016/j.molimm.2007.01.019; Franze T, 2005, ENVIRON SCI TECHNOL, V39, P1673, DOI 10.1021/es0488737; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; Furmonaviciene R, 2005, BIOINFORMATICS, V21, P4201, DOI 10.1093/bioinformatics/bti700; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; GILFILLAN AM, 2008, IMMUNOL RES; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Gruijthuijsen YK, 2006, INT ARCH ALLERGY IMM, V141, P265, DOI 10.1159/000095296; Gutermuth J, 2007, J ALLERGY CLIN IMMUN, V120, P293, DOI 10.1016/j.jaci.2007.03.017; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Holloway JW, 2007, CURR OPIN ALLERGY CL, V7, P69, DOI 10.1097/ACI.0b013e328013d51b; Horner AA, 2006, J ALLERGY CLIN IMMUN, V117, P1133, DOI 10.1016/j.jaci.2006.02.035; Ichikawa K, 2001, CLIN EXP ALLERGY, V31, P1279, DOI 10.1046/j.1365-2222.2001.01169.x; Jankovic D, 2006, CHEM IMMUNOL ALLERGY, V90, P65, DOI 10.1159/000088881; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kaiser L, 2003, INT ARCH ALLERGY IMM, V132, P25, DOI 10.1159/000073261; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kauffman Henk F, 2006, Clin Mol Allergy, V4, P5, DOI 10.1186/1476-7961-4-5; Kikuchi Y, 2006, J IMMUNOL, V177, P1609, DOI 10.4049/jimmunol.177.3.1609; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Li YJ, 2008, CLIN IMMUNOL, V128, P366, DOI 10.1016/j.clim.2008.05.005; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Mariani V, 2007, J IMMUNOL, V178, P7623, DOI 10.4049/jimmunol.178.12.7623; McCloskey N, 2007, J BIOL CHEM, V282, P24083, DOI 10.1074/jbc.M703195200; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meno K, 2005, J IMMUNOL, V175, P3835, DOI 10.4049/jimmunol.175.6.3835; Mogensen JE, 2007, BIOCHEMISTRY-US, V46, P3356, DOI 10.1021/bi062058h; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; Ng N, 2006, J ALLERGY CLIN IMMUN, V117, P1074, DOI 10.1016/j.jaci.2006.03.025; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Ozdemir C, 2006, CLIN EXP ALLERGY, V36, P960, DOI 10.1111/j.1365-2222.2006.02515.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Platts-Mills TAE, 2004, SPRINGER SEMIN IMMUN, V25, P271, DOI 10.1007/s00281-003-0149-8; Plotz SG, 2004, J ALLERGY CLIN IMMUN, V113, P1152, DOI 10.1016/j.jaci.2004.03.011; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Riedl MA, 2005, J IMMUNOL, V174, P7440, DOI 10.4049/jimmunol.174.11.7440; Ring J, 2001, CURR OPIN IMMUNOL, V13, P701, DOI 10.1016/S0952-7915(01)00282-5; Sackesen C, 2005, ALLERGY, V60, P1485, DOI 10.1111/j.1398-9995.2005.00874.x; SARFATI M, 1992, IMMUNOLOGY, V76, P662; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Shibata Y, 2000, J IMMUNOL, V164, P1314, DOI 10.4049/jimmunol.164.3.1314; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Silvanovich A, 2006, TOXICOL SCI, V90, P252, DOI 10.1093/toxsci/kfj068; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tai HY, 2006, ALLERGY, V61, P382, DOI 10.1111/j.1398-9995.2005.00958.x; Takai T, 2005, INT ARCH ALLERGY IMM, V137, P194, DOI 10.1159/000086331; Thunberg S, 2007, CLIN EXP ALLERGY, V37, P1127, DOI 10.1111/j.1365-2222.2007.02739.x; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Vercelli D, 2006, CURR OPIN IMMUNOL, V18, P733, DOI 10.1016/j.coi.2006.09.002; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Williams MA, 2007, J ALLERGY CLIN IMMUN, V119, P488, DOI 10.1016/j.jaci.2006.10.022; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zeller S, 2008, INT ARCH ALLERGY IMM, V145, P87, DOI 10.1159/000108133; Zhang J, 2007, ALLERGY, V62, P1302, DOI 10.1111/j.1398-9995.2007.01492.x	122	132	134	0	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					558	566		10.1016/j.jaci.2008.12.003	http://dx.doi.org/10.1016/j.jaci.2008.12.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19152966				2022-12-18	WOS:000264731200011
J	Basheti, IA; Reddel, HK; Armour, CL; Bosnic-Anticevich, SZ				Basheti, Iman A.; Reddel, Helen K.; Armour, Carol L.; Bosnic-Anticevich, Sinthia Z.			Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							QUALITY-OF-LIFE; ADULTS		Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; Woolcock Inst Med Res, Camperdown, NSW, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research	Basheti, IA (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.	ebasheti@pharm.usyd.edu.au	Bosnic-Anticevich, Sinthia/AAD-2526-2021; Basheti, Iman/Q-8917-2017; Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021	Bosnic-Anticevich, Sinthia/0000-0001-5077-8329; Basheti, Iman/0000-0002-8460-1158; Reddel, Helen/0000-0002-6695-6350; Armour, Carol/0000-0002-2930-2227				Basheti Iman A, 2005, Respir Care, V50, P617; Fink James B, 2005, Respir Care, V50, P1360; Giraud V, 2002, EUR RESPIR J, V19, P246, DOI 10.1183/09031936.02.00218402; Katz PP, 2002, ANN ALLERG ASTHMA IM, V89, P251, DOI 10.1016/S1081-1206(10)61951-5; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; *NAT ASTHM ED PREV, 1997, GUIDELINES DIAGNOSIS; REDDEL HK, 1995, AM J RESP CRIT CARE, V151, P1320, DOI 10.1164/ajrccm.151.5.7735580; van der Palen J, 1998, J ASTHMA, V35, P147, DOI 10.3109/02770909809068202	8	132	145	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1537	1538		10.1016/j.jaci.2007.02.037	http://dx.doi.org/10.1016/j.jaci.2007.02.037			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17433831				2022-12-18	WOS:000247232800033
J	Alexis, NE; Lay, JC; Zeman, K; Bennett, WE; Peden, DB; Soukup, JM; Devlin, RB; Becker, S				Alexis, NE; Lay, JC; Zeman, K; Bennett, WE; Peden, DB; Soukup, JM; Devlin, RB; Becker, S			Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PM(2.5-1)0; airway macrophages; TNF-alpha; mCD14; eotaxin	ALVEOLAR MACROPHAGE RESPONSES; DIESEL EXHAUST PARTICLES; POLLUTION PARTICLES; INSOLUBLE COMPONENTS; ATOPIC ASTHMATICS; ENDOTOXIN; EXPOSURE; INFLAMMATION; DEPOSITION; ULTRAFINE	Background: In vitro, endotoxin on coarse fraction particulate matter (PM2.5-10) accounts for the majority of the ability of PM2.5-10 to induce cytokine responses from alveolar macrophages. Objective: We examined in vivo whether inhaled PM2.5-10 from local ambient air induce inflammatory and immune responses in the airways of healthy human beings and whether biologic material on PM2.5-10 accounts for these effects. Methods: On 3 separate visits, 9 healthy subjects inhaled nebulized saline (0.9%, control), PM2.5-10 collected from local ambient air that was heated to inactivate biological material (PM2.5-10-), or nonheated PM (PM2.5-10+)- PM2.5-10 deposition (similar to 0.65 mg/subject) targeted the bronchial airways (confirmed by using radiolabeled aerosol), and induced sputum was obtained 2 to 3 hours postinhalation for analysis of cellular and biochemical markers of inflammation and innate immune function. Results: Inhaled PM2.5-10+ induced elevated inflammation (% PMNs, macrophage mRNA TNF-alpha), increased eotaxin, upregulated immune surface phenotypes on macrophages (mCD14, CD11b, HLA-DR), and increased phagocytosis (monocytes) versus saline (P < .05). Biological inactivation of PM2.5-10 (PM2.5-10-) had no effect on neutrophilia but significantly (P < .05) attenuated mRNA TNF-alpha, eotaxin levels, cell surface marker responses, and phagocytosis. Conclusion: Biological components of PM2.5-10 are not necessary to induce neutrophil responses but are essential in mediating macrophage responses. The ability Of PM2.5-10 to activate monocytic cells and potentially skew the airways toward an allergic phenotype by enhancing eotaxin levels may enhance responses to allergens or bacteria in individuals with allergy. Clinical implications: PM2.5-10 might enhance the response of individuals with allergy to airborne bacteria.	Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Alexis, NE (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.	Neil_Alexis@med.unc.edu	Lay, John/A-6380-2012	Peden, David/0000-0003-4526-4627	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624, R01HL066559] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 66559, R01HL-62624, R01 HL066559-04, R01 HL066559, R01 HL062624-06, R01 HL062624] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert I, 2005, INT J FOOD MICROBIOL, V100, P197, DOI 10.1016/j.ijfoodmicro.2004.10.016; Alexis N, 2000, CLIN IMMUNOL, V97, P21, DOI 10.1006/clim.2000.4911; Alexis N, 2002, CLIN IMMUNOL, V104, P217, DOI 10.1006/clim.2002.5236; Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; Alexis NE, 2001, AM J RESP CRIT CARE, V164, P1964, DOI 10.1164/ajrccm.164.10.2104051; Becker S, 2005, ENVIRON HEALTH PERSP, V113, P1032, DOI 10.1289/ehp.7996; Becker S, 2003, J TOXICOL ENV HEAL A, V66, P847, DOI 10.1080/15287390306381; Becker S, 2003, EXP LUNG RES, V29, P29, DOI 10.1080/01902140303762; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Becker Susanne, 2005, Toxicol Appl Pharmacol, V207, P269, DOI 10.1016/j.taap.2005.01.023; Bennett WD, 2002, J AEROSOL MED, V15, P179, DOI 10.1089/089426802320282301; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; BOVALLIUS A, 1978, APPL ENVIRON MICROB, V35, P1231, DOI 10.1128/AEM.35.6.1231-1232.1978; Conroy DM, 1997, MEM I OSWALDO CRUZ, V92, P183, DOI 10.1590/S0074-02761997000800024; Daniels AU, 2000, J BIOMED MATER RES, V49, P469, DOI 10.1002/(SICI)1097-4636(20000315)49:4<469::AID-JBM5>3.3.CO;2-1; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Eldridge MW, 2000, J TOXICOL ENV HEAL A, V61, P27, DOI 10.1080/00984100050116762; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; Ichinose T, 1998, TOXICOL SCI, V44, P70, DOI 10.1093/toxsci/44.1.70; ILOWITE JS, 1989, ARCH ENVIRON HEALTH, V44, P267, DOI 10.1080/00039896.1989.9935893; Imrich A, 2000, TOXICOL APPL PHARM, V167, P140, DOI 10.1006/taap.2000.9002; Kim CS, 1996, J APPL PHYSIOL, V81, P2203, DOI 10.1152/jappl.1996.81.5.2203; Kitchens RL, 2000, CHEM IMMUNOL, V74, P61; Landmann R, 2000, MICROBES INFECT, V2, P295, DOI 10.1016/S1286-4579(00)00298-7; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Pope C. A., 1998, AIR POLLUTION HLTH, P673; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; Roos-Engstrand E, 2005, EUR RESPIR J, V25, P797, DOI 10.1183/09031936.05.00078804; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096	32	132	135	0	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1396	1403		10.1016/j.jaci.2006.02.030	http://dx.doi.org/10.1016/j.jaci.2006.02.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751003	Bronze			2022-12-18	WOS:000238332300029
J	Meltzer, EO; Berkowitz, RB; Grossbard, EB				Meltzer, EO; Berkowitz, RB; Grossbard, EB			An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; most cell inhibition; R112; park study; mast cell mediators; Syk-kinase	NASAL SPRAY; LORATADINE; OUTDOOR; ONSET	Background: R112 inhibits Syk kinase, a transducer of signaling through the Fc is an element of receptor of mast cells, blocking mast cell responses to allergic stimuli. Objective: Examine the efficacy and safety of intranasal R112 in volunteers with symptomatic seasonal allergic rhinitis compared with a placebo in a park setting. Methods: In this double-blind, placebo-controlled study of 319 volunteers with seasonal allergic rhinitis, 160 were randomized to intranasal R112 and 159 to a vehicle control during 2 days at 2 separate locations in spring 2004. Subjects were evaluated for symptoms of allergic rhinitis (ie, sneezes, runny nose/sniffles, itchy nose, stuffy nose) on the basis of a possible maximum score of 32 for the Global Symptom Complex (GSC) scale. The primary outcome evaluated was the difference in the reduction in GSC (area under the curve over a period of 8 hours) from baseline between R112 and vehicle placebo. Results: At baseline, the combined GSC was similar to 18/32 and equal between treatment groups. After 8 hours (dosing 3 mg/nostril every 4 hours X 2), R112 significantly reduced the GSC compared with placebo (7 vs 5.4 units, respectively; P = .0005). Each individual symptom combined to form the GSC was also significantly improved in the R112 group compared with control (P < .05). As early as 45 minutes after dosing, R112 showed a significant improvement in symptoms over placebo, and the duration of action exceeded 4 hours. Adverse effects were indistinguishable between the groups and clinically insignificant. Conclusion: Intranasal R112 was effective in this park study and is a promising new treatment for seasonal allergic rhinitis.	Allergy & Asthma Med Grp & Res Ctr, San Diego, CA 92123 USA; Rx Res, Woodstock, GA USA; Rigel Pharmaceut, San Francisco, CA USA		Meltzer, EO (corresponding author), Allergy & Asthma Med Grp & Res Ctr, 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.	eomeltzer@aol.com						Berger WE, 1999, ANN ALLERG ASTHMA IM, V82, P535, DOI 10.1016/S1081-1206(10)63161-4; Berkowitz RB, 1999, ALLERGY ASTHMA PROC, V20, P167, DOI 10.2500/108854199778553037; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Chervinsky P, 2001, J ALLERGY CLIN IMMUN, V107, pS156; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P474, DOI 10.1016/S1081-1206(10)63154-7; Guyer B., 2004, Journal of Allergy and Clinical Immunology, V113, pS28, DOI 10.1016/j.jaci.2003.12.058; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; Meltzer EO, 2001, ANN ALLERG ASTHMA IM, V86, P286, DOI 10.1016/S1081-1206(10)63300-5; Niimi T, 2001, J MED CHEM, V44, P4737, DOI 10.1021/jm010313k; *US DEP HHS, 2000, GUID IND ALL RHIN CL; Wong BR, 2004, EXPERT OPIN INV DRUG, V13, P743, DOI 10.1517/13543784.13.7.743	11	132	153	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					791	796		10.1016/j.jaci.2005.01.040	http://dx.doi.org/10.1016/j.jaci.2005.01.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806000				2022-12-18	WOS:000228373400019
J	Carter, MC; Perzanowski, MS; Raymond, A; Platts-Mills, TAE				Carter, MC; Perzanowski, MS; Raymond, A; Platts-Mills, TAE			Home intervention in the treatment of asthma among inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen avoidance; dust mite; children; inner city	HOUSE-DUST MITE; COCKROACH ALLERGEN; BRONCHIAL HYPERREACTIVITY; INDOOR ALLERGENS; CAT ALLERGEN; RISK-FACTORS; EXPOSURE; SENSITIZATION; AVOIDANCE; MORBIDITY	Background: In Atlanta, as in other major urban areas of the United States, asthma is a leading cause of school absenteeism, emergency department use, and hospitalization. Recent guidelines for asthma management recommend reducing exposure to relevant allergens, but neither the feasibility nor the efficacy of this form of treatment has been established for children living in poverty. Objective: We sought to investigate allergen avoidance as a treatment for asthma among inner-city children. Methods: One hundred four children with asthma living in the city of Atlanta were enrolled into a controlled trial of avoidance without being skin tested. The children were randomized to an active avoidance group, a placebo avoidance group, and a second control group for which no house visits occurred until the end of the first year. Avoidance included bed and pillow covers, hot washing of bedding, and cockroach bait. Eighty-five children completed the study, and the outcome was measured as unscheduled clinic visits, emergency department visits, and hospitalization for asthma, as well as changes in mite and cockroach allergen levels. Results: There was a significant decrease in acute visits for asthma among children whose homes were visited (P <.001). However, there was no significant difference between the active and placebo homes either in the effect on asthma visits or in allergen concentrations. When the children with mite allergy were considered separately, there was a significant correlation between decreased mite allergen and change in acute visits (P <.01). The avoidance measures for cockroach allergen appeared to be ineffective, and the changes observed did not correlate with changes in visits. Conclusions: Applying allergen avoidance as a treatment for asthma among children living in poverty is difficult because of multiple sensitivities and problems applying the protocols in this environment. The current results demonstrate that home visiting positively influences the management of asthma among families living in poverty. Furthermore, the results for children with mite allergy strongly suggest that decreasing relevant allergen exposure should be an objective of treatment in this population.	Emory Univ, Dept Family Med, Atlanta, GA 30322 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Emory University; University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565, P01AI050989] Funding Source: NIH RePORTER; NIAID NIH HHS [1P01 AI50989, AI-20565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Celano M, 1998, J PEDIATR PSYCHOL, V23, P345, DOI 10.1093/jpepsy/23.6.345; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Hayden ML, 1997, ANN ALLERG ASTHMA IM, V79, P437, DOI 10.1016/S1081-1206(10)63040-2; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Mollet JA, 1997, J MED ENTOMOL, V34, P307, DOI 10.1093/jmedent/34.3.307; *NIH, 1997, NIH PUBL; PARSONS HM, 1974, SCIENCE, V183, P922, DOI 10.1126/science.183.4128.922; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Piacentini GL, 1996, J ALLERGY CLIN IMMUN, V97, P1079, DOI 10.1016/S0091-6749(96)70261-0; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Redline S, 1996, PEDIATR PULM, V21, P203; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; WEISS KB, 1990, AM J EPIDEMIOL, V132, pS107; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Yoos H L, 1997, J Pediatr Health Care, V11, P66	37	132	133	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					732	737		10.1067/mai.2001.119155	http://dx.doi.org/10.1067/mai.2001.119155			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692097				2022-12-18	WOS:000172523800012
J	Kazemi-Shirazi, L; Pauli, G; Purohit, A; Spitzauer, S; Froschl, R; Hoffmann-Sommergruber, K; Breiteneder, H; Scheiner, O; Kraft, D; Valenta, R				Kazemi-Shirazi, L; Pauli, G; Purohit, A; Spitzauer, S; Froschl, R; Hoffmann-Sommergruber, K; Breiteneder, H; Scheiner, O; Kraft, D; Valenta, R			Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; pollen allergy; cross-reactivity; recombinant allergens	CROSS-REACTIVE ALLERGEN; BIRCH POLLEN; MAJOR ALLERGEN; IMMUNOLOGICAL RELATIONSHIP; VEGETABLE FOODS; TREE POLLEN; IDENTIFICATION; ANTIBODIES; PROFILIN; BET-V-1	Background: Type I allergic symptoms in the oropharyngeal mucosa upon contact with plant-derived food in patients with pollen allergies have been termed oral allergy syndrome (OAS). IgE cross-reactivity between pollen and food allergens represents the molecular basis for this phenomenon. The sensitizing allergen source (pollen or plant Toed) in OAS is a controversial issue. Objective:We sought to determine the primary sensitizing molecules in patients with GAS. Methods: We used recombinant birch pollen (rBet v 1 and rBet v 2) and plant food allergens (apple, rMal d 1; celery, rApi g 1; and carrot, rDau c 1), as well as natural pollen (birch and timothy grass) and plant food (apple, peach, kiwi, hazelnut, celery, and carrot) allergens, to identify cross-reactive allergens by using qualitative immunoblot inhibitions. In addition, we determined the percentage of plant food-specific IgE that can be preadsorbed with recombinant and natural pollen allergens by quantitative RAST inhibitions by using sera from 71 patients with GAS. Results: Preincubation of sera with recombinant and natural pollen allergens led to an almost complete inhibition of IgE binding to plant food allergens in Western blots, as well as in RAST inhibition experiments. In contrast, recombinant plant food allergens poorly inhibited IgE binding to Eet v 1. Conclusion: Most IgE epitopes in plant food recognized by patients with OAS are resembled by pollen allergens. Thus pollen allergens may be responsible for the elicitation and maintenance of GAS.	Univ Vienna, Inst Gen & Expt Pathol, Vienna, Austria; Univ Vienna, Dept Internal Med 4, Div Gastroenterol & Hepatol, Vienna, Austria; Univ Vienna, Clin Inst Med & Chem Lab Diagnost, AKH, Vienna, Austria; Univ Strasbourg, Hosp Civil, Serv Pneumol, Strasbourg, France; Univ Strasbourg, Hosp Civil, INSERM, U425, Strasbourg, France	University of Vienna; University of Vienna; University of Vienna; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp, Inst Gen & Expt Pathol, Med Sch,Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.			Valenta, Rudolf/0000-0001-5944-3365; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Altman DR, 1996, J ALLERGY CLIN IMMUN, V97, P1247, DOI 10.1016/S0091-6749(96)70192-6; ANDERSEN KE, 1978, CONTACT DERMATITIS, V4, P73, DOI 10.1111/j.1600-0536.1978.tb03739.x; Asero R, 1996, J ALLERGY CLIN IMMUN, V97, P611, DOI 10.1016/S0091-6749(96)70306-8; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; Bischoff SC, 1997, GUT, V40, P745, DOI 10.1136/gut.40.6.745; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Etesamifar M, 1998, ALLERGOLOGIE, V21, P451; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; HALEMPURO L, 1985, ALLERGY, V40, P264; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V101, P531, DOI 10.1016/S0091-6749(98)70360-4; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; *ROYAL COLL PHYS R, 1995, CLIN EXP ALLERGY, V25, P586; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Werfel T, 1999, INT ARCH ALLERGY IMM, V118, P230, DOI 10.1159/000024081	42	132	134	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				116	125		10.1016/S0091-6749(00)90186-6	http://dx.doi.org/10.1016/S0091-6749(00)90186-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629461				2022-12-18	WOS:000084992100016
J	Brockow, K; Kiehn, M; Riethmuller, C; Vieluf, D; Berger, J; Ring, J				Brockow, K; Kiehn, M; Riethmuller, C; Vieluf, D; Berger, J; Ring, J			Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hymenoptera venom allergy; immunotherapy; adverse reactions; pretreatment; prophylaxis; terfenadine; ranitidine; antihistamines; H-1/H-2-antagonists	ANAPHYLACTOID REACTIONS; H2-RECEPTOR ANTAGONISTS; THERAPEUTIC EFFICACY; DOUBLE-BLIND; TERFENADINE; VENOMS; PREMEDICATION; ANESTHESIA; IMMEDIATE; SEVERITY	Background: Some clinical studies suggest that a combination of an H-1-and H-2-antagonist may be effective in the prophylaxis of allergic reactions, Objective: The efficacy of pretreatment with an H-1/H-2-antagonist combination, H-1-antagonist alone, or placebo in the prophylaxis of local and systemic adverse reactions to specific immunotherapy with Hymenoptera venom,vas compared, Methods: In a prospective, randomized, double-blind, placebo-controlled study, 121 patients with Hymenoptera venom allergy were treated with rush immunotherapy and pretreatment with one of the following: 120 mg of terfenadine plus 300 mg of ranitidine, 120 mg of terfenadine alone, or placebo, The incidence of unwanted systemic adverse and local reactions was recorded for up to 50 weeks. Results: In seven patients (6%), six in the placebo group and one in the terfenadine group, systemic side effects required cessation of therapy (p = 0.005), Subjective symptoms occurred in four patients (10%) in the terfenadine plus ranitidine group and in three patients (7%) in the terfenadine group, Regarding local reactions, significantly fewer patients treated with a combination of terfenadine and ranitidine and with terfenadine alone as compared with placebo had severe local symptoms of erythema (29%, 29%, and 49%), edema (24%, 18%, and 41%), and pruritus (13%, 11%, and 31%) at week 1 (p < 0.05), This therapeutic benefit was limited to the first 4 weeks of treatment, Treatment with a combination of terfenadine and ranitidine was not superior to treatment with terfenadine alone, Conclusions: Pretreatment with H-1-antihistamines with or without H-2-antihistamines significantly reduced local and systemic adverse reactions to immunotherapy with Hymenoptera venom and may therefore be helpful in the management of immunotherapy.	UNIV HAMBURG,HOSP EPPENDORF,DEPT DERMATOL,HAMBURG,GERMANY; UNIV HAMBURG,HOSP EPPENDORF,INST MATH & COMP SCI MED,HAMBURG,GERMANY	University of Hamburg; University of Hamburg	Brockow, K (corresponding author), TECH UNIV MUNICH,KLIN & POLIKLIN DERMATOL & ALLERGOL BIEDERSTEIN,D-80802 MUNICH,GERMANY.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				BERCHTOLD E, 1991, CLIN EXP ALLERGY, V22, P59; DEWECK AL, 1993, INT ARCH ALLERGY IMM, V101, P326, DOI 10.1159/000236472; DORSCH W, 1982, AGENTS ACTIONS, V12, P113, DOI 10.1007/BF01965120; Herman D., 1996, Allergy (Copenhagen), V51, P68; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LIEBERMAN P, 1990, J ALLERGY CLIN IMMUN, V86, P684, DOI 10.1016/S0091-6749(05)80241-6; LORENZ W, 1985, NEW ENGL REG ALLERGY, V6, P174; LORENZ W, 1980, AGENTS ACTIONS, V10, P114, DOI 10.1007/BF02024192; MATLOFF SM, 1993, ALLERGY PROC, V14, P347, DOI 10.2500/108854193778774001; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; MULLER U, 1993, ALLERGY, V48, P37; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; PAUL E, 1986, EUR J CLIN PHARMACOL, V31, P277, DOI 10.1007/BF00981123; PELICAN Z, 1990, LATE PHASE ALLERGIC, P521; PRZYBILLA B, 1987, DEUT MED WOCHENSCHR, V112, P416, DOI 10.1055/s-2008-1068068; RING J, 1985, INT ARCH ALLER A IMM, V78, P9, DOI 10.1159/000233854; RING J, 1977, LANCET, V1, P466; RING J, 1990, CLIN EXP ALLERGY, V20, P43, DOI 10.1111/j.1365-2222.1990.tb02460.x; ROCKLIN RE, 1982, IMMUNOPHARMACOLOGY, P49; Schafer T, 1996, ALLERGY, V51, P372; SETIPANE GA, 1994, ALLERGY PROC, V15, P69; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; WRIGHT DN, 1990, ALLERGY PROC, V11, P23, DOI 10.2500/108854190778999474	23	132	136	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					458	463		10.1016/S0091-6749(97)70135-0	http://dx.doi.org/10.1016/S0091-6749(97)70135-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338537	Bronze			2022-12-18	WOS:A1997YA52900005
J	Matsukura, S; Kokubu, F; Noda, H; Tokunaga, H; Adachi, M				Matsukura, S; Kokubu, F; Noda, H; Tokunaga, H; Adachi, M			Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-6; IL-8; RANTES; influenza virus; airway inflammation	RESPIRATORY SYNCYTIAL VIRUS; TUMOR-NECROSIS-FACTOR; CYTOKINE PRODUCTION; HUMAN EOSINOPHILS; LYMPHOCYTES-T; INFECTION; LINE; INTERLEUKIN-8; MODULATION; NASAL	Bronchial epithelial cells ave primary sites of airway viral infection, and these cells may play an important role in the pathogenesis of respiratory diseases. It has recently been reported that bronchial epithelial cells express RANTES. RANTES attracts monocytes, T cells, eosinophils, and basophils; it can also activate eosinophils. To determine whether viral infection induces RANTES expression on bronchial epithelial cells, we infected a bronchial epithelial cell line, NCI-H292 with influenza virus A (H3N2). We then examined the concentration of RANTES in the culture medium of infected cells by ELISA and assessed expression of the gene for RANTES by the reverse-transcriptase polymerase chain reaction. We also investigated the concentrations of IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor in the medium of infected cells, because some virus infections have been reported to induce expression of these cytokines on bronchial epithelial cells, but there are few data concerning influenza virus infection. Small amounts of IL-6 and IL-8 were detected in the medium of uninfected cells. RANTES was not detected in the medium of uninfected cells. After influenza virus infection, significant amounts of IL-6, IL-8, and RANTES were released into the culture medium of infected cells, and RANTES messenger RNA was detected from infected cells. Granulocyte-macrophage colony-stimulating factor was not detected in the medium of uninfected and infected cells. These results suggest that influenza virus infection may stimulate production of IL-6, IL-8, and RANTES from human bronchial epithelial cells and that these cytokines may contribute to the pathogenesis of airway inflammatory diseases caused by influenza virus infection.			Matsukura, S (corresponding author), SHOWA UNIV,SCH MED,DEPT INTERNAL MED 1,SHINAGAWA KU,1-5-8 HATANODAI,TOKYO 142,JAPAN.							ALAM R, 1993, J IMMUNOL, V150, P3442; ARNOLD R, 1994, IMMUNOLOGY, V82, P126; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BECKER S, 1992, AM J RESP CELL MOL, V6, P369, DOI 10.1165/ajrcmb/6.4.369; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; CARNEY DN, 1985, CANCER RES, V45, P2913; CASTELLS E, 1990, ARCH VIROL, V115, P277, DOI 10.1007/BF01310536; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; DAVIES RJ, 1995, INT ARCH ALLERGY IMM, V107, P428, DOI 10.1159/000237068; Devalia J. L., 1994, European Respiratory Journal, V7, p98S; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; HELLE M, 1989, J IMMUNOL, V142, P4335; HENNET T, 1992, J IMMUNOL, V149, P932; HUGEL DW, 1979, AM REV RESPIR DIS, V120, P393; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KWON OJ, 1995, AM J RESP CELL MOL, V12, P488, DOI 10.1165/ajrcmb.12.5.7537968; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; NELSON PJ, 1993, J IMMUNOL, V151, P2601; NOAH TL, 1993, AM J PHYSIOL, V265, pL472, DOI 10.1152/ajplung.1993.265.5.L472; NOAH TL, 1995, J INFECT DIS, V171, P584, DOI 10.1093/infdis/171.3.584; PHAL HL, 1995, J VIROL, V69, P1480; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; STELLATO C, 1995, J IMMUNOL, V155, P410; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; VERHOEYEN M, 1980, NATURE, V286, P771, DOI 10.1038/286771a0; WALSH JJ, 1960, ARCH INTERN MED, V108, P376	31	132	140	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1080	1087		10.1016/S0091-6749(96)80195-3	http://dx.doi.org/10.1016/S0091-6749(96)80195-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977509				2022-12-18	WOS:A1996WB37800013
J	MALTBY, NH; TAYLOR, GW; RITTER, JM; MOORE, K; FULLER, RW; DOLLERY, CT				MALTBY, NH; TAYLOR, GW; RITTER, JM; MOORE, K; FULLER, RW; DOLLERY, CT			LEUKOTRIENE-C4 ELIMINATION AND METABOLISM IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,DUCANE RD,LONDON W12 0NN,ENGLAND; UNIV LONDON KINGS COLL HOSP,LIVER UNIT,LONDON SE5 8RX,ENGLAND	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				Taylor, Graham/0000-0002-9672-8463				BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; DENZLINGER C, 1986, J BIOL CHEM, V261, P5601; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P939, DOI 10.1016/0091-6749(89)90109-7; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HEAVEY DJ, 1987, PROSTAG OTH LIPID M, V33, P693, DOI 10.1016/0090-6980(87)90035-9; HENDERSON WR, 1983, J BIOL CHEM, V258, P3522; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; MALTBY NH, 1989, CLIN EXP ALLERGY, V19, P33, DOI 10.1111/j.1365-2222.1989.tb02340.x; OKUBO T, 1987, INT ARCH ALLER A IMM, V84, P149, DOI 10.1159/000234414; ORNING L, 1985, BIOCHEM BIOPH RES CO, V130, P214, DOI 10.1016/0006-291X(85)90404-8; ORNING L, 1987, EUR J BIOCHEM, V170, P77, DOI 10.1111/j.1432-1033.1987.tb13669.x; RICHMOND R, 1987, J CHROMATOGR-BIOMED, V417, P241, DOI 10.1016/0378-4347(87)80117-2; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; STENE DO, 1988, J BIOL CHEM, V263, P2773; TAYLOR GW, 1989, LANCET, V1, P584; VERHAGEN J, 1987, BIOCHEM BIOPH RES CO, V148, P864, DOI 10.1016/0006-291X(87)90955-7; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626	18	132	134	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				3	9		10.1016/0091-6749(90)90214-O	http://dx.doi.org/10.1016/0091-6749(90)90214-O			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299103				2022-12-18	WOS:A1990CM37800002
J	Pretolani, M; Bergqvist, A; Thabut, G; Dombret, MC; Knapp, D; Hamidi, F; Alavoine, L; Taille, C; Chanez, P; Erjefalt, JS; Aubier, M				Pretolani, Marina; Bergqvist, Anders; Thabut, Gabriel; Dombret, Marie-Christine; Knapp, Dominique; Hamidi, Fatima; Alavoine, Loubna; Taille, Camille; Chanez, Pascal; Erjefalt, Jonas S.; Aubier, Michel			Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Refractory asthma; asthma control; airway smooth muscle; airway remodeling; epithelium neuroendocrine cells; mucosal nerves; bronchial epithelium	AIRWAY SMOOTH-MUSCLE; DOUBLE-BLIND; SAFETY; PHENOTYPES; LUNG; QUESTIONNAIRE; MULTICENTER; MECHANISMS; REDUCTION; DISEASE	Background: The effectiveness of bronchial thermoplasty (BT) has been reported in patients with severe asthma, yet its effect on different bronchial structures remains unknown. Objective: We sought to examine the effect of BT on bronchial structures and to explore the association with clinical outcome in patients with severe refractory asthma. Methods: Bronchial biopsy specimens (n = 300) were collected from 15 patients with severe uncontrolled asthma before and 3 months after BT. Immunostained sections were assessed for airway smooth muscle (ASM) area, subepithelial basement membrane thickness, nerve fibers, and epithelial neuroendocrine cells. Histopathologic findings were correlated with clinical parameters. Results: BT significantly improved asthma control and quality of life at both 3 and 12 months and decreased the numbers of severe exacerbations and the dose of oral corticosteroids. At 3 months, this clinical benefit was accompanied by a reduction in ASM area (median values before and after BT, respectively: 19.7% [25th-75th interquartile range (IQR), 15.9% to 22.4%] and 5.3% [25th-75th IQR], 3.5% to 10.1%, P < .001), subepithelial basement membrane thickening (4.4 mu m [25th-75th IQR, 4.0-4.7 mu m] and 3.9 mu m [25th-75th IQR, 3.7-4.6 mu m], P = 0.02), submucosal nerves (1.0 parts per thousand [25th-75th IQR, 0.7-1.3 parts per thousand] immunoreactivity and 0.3 parts per thousand [25th-75th IQR, 0.1-0.5 parts per thousand] immunoreactivity, P < .001), ASM-associated nerves (452.6 [25th-75th IQR, 196.0-811.2] immunoreactive pixels per mm(2) and 62.7 [25th-75th IQR, 0.0-230.3] immunoreactive pixels per mm(2), P = .02), and epithelial neuroendocrine cells (4.9/mm(2) [25th-75th IQR, 0-16.4/mm(2)] and 0.0/mm(2) [25th-75th IQR, 0-0/mm(2)], P = .02). Histopathologic parameters were associated based on Asthma Control Test scores, numbers of exacerbations, and visits to the emergency department (all P < .02) 3 and 12 months after BT. Conclusion: BT is a treatment option in patients with severe therapy-refractory asthma that downregulates selectively structural abnormalities involved in airway narrowing and bronchial reactivity, particularly ASM, neuroendocrine epithelial cells, and bronchial nerve endings.	[Pretolani, Marina; Thabut, Gabriel; Dombret, Marie-Christine; Knapp, Dominique; Hamidi, Fatima; Taille, Camille; Aubier, Michel] INSERM, UMR1152, Physiopathol & Epidemiol Resp Dis, Paris, France; [Pretolani, Marina; Thabut, Gabriel; Dombret, Marie-Christine; Knapp, Dominique; Hamidi, Fatima; Taille, Camille; Aubier, Michel] Paris Diderot Univ, Fac Med, Bichat Campus, Paris, France; [Pretolani, Marina; Thabut, Gabriel; Dombret, Marie-Christine; Knapp, Dominique; Hamidi, Fatima; Taille, Camille; Aubier, Michel] Univ Sorbonne Paris Cite, INFLAMEX, Lab Excellence, Paris, France; [Pretolani, Marina; Thabut, Gabriel; Dombret, Marie-Christine; Knapp, Dominique; Hamidi, Fatima; Taille, Camille; Aubier, Michel] DHU FIRE, Paris, France; [Bergqvist, Anders; Thabut, Gabriel; Erjefalt, Jonas S.] Lund Univ, Unit Airway Inflammat, Lund, Sweden; [Thabut, Gabriel] Bichat Claude Bernard Univ Hosp, Dept Pneumol B, Paris, France; [Dombret, Marie-Christine; Taille, Camille; Aubier, Michel] Bichat Claude Bernard Univ Hosp, Dept Pneumol A, Paris, France; [Alavoine, Loubna] Bichat Claude Bernard Univ Hosp, Clin Invest Ctr, Paris, France; [Thabut, Gabriel; Dombret, Marie-Christine; Knapp, Dominique; Taille, Camille; Aubier, Michel] AP HP, Paris, France; [Chanez, Pascal] APHM Aix Marseille Univ, INSERM, U1067, Marseille, France; [Chanez, Pascal] APHM Aix Marseille Univ, CNRS, UMR7733, Dept Resp Dis, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Lund University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Aubier, M (corresponding author), Hop Bichat Claude Bernard, Serv Pneumol A, 46 Rue Henri Huchard, F-75018 Paris, France.	michel.aubier@aphp.fr	Taille, Camille/J-3751-2017; Pretolani, Marina/G-6643-2017	Erjefalt, Jonas/0000-0002-6716-3010; chanez, pascal/0000-0003-4059-0917	Boston Scientific, Marlborough, Mass	Boston Scientific, Marlborough, Mass	Supported in part by Boston Scientific, Marlborough, Mass.	Adriaensen D, 2004, CURR OPIN PHARMACOL, V4, P207, DOI 10.1016/j.coph.2004.01.010; Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bergqvist A, 2015, CLIN SCI, V128, P47, DOI 10.1042/CS20140309; Bergqvist A, 2013, AM J RESP CRIT CARE, V188, P1475, DOI 10.1164/rccm.201308-1444LE; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; Brightling CE, 2012, CLIN EXP ALLERGY, V42, P638, DOI 10.1111/j.1365-2222.2011.03917.x; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Chakir J, 2015, ANN AM THORAC SOC, V12, P1612, DOI 10.1513/AnnalsATS.201504-208OC; Chung Kian Fan, 2013, Ann Am Thorac Soc, V10 Suppl, pS109, DOI 10.1513/AnnalsATS.201304-087AW; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Danek CJ, 2004, J APPL PHYSIOL, V97, P1946, DOI 10.1152/japplphysiol.01282.2003; Denner DR, 2015, ANN AM THORAC SOC, V12, P1302, DOI 10.1513/AnnalsATS.201502-082OC; Dombret MC, 2014, EUR RESPIR REV, V23, P510, DOI 10.1183/09059180.00005114; Hambly N, 2014, CURR OPIN PULM MED, V20, P87, DOI 10.1097/MCP.0000000000000007; Hirota N, 2013, CHEST, V144, P1026, DOI 10.1378/chest.12-3073; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Lee LY, 2014, COMPR PHYSIOL, V4, P287, DOI 10.1002/cphy.c130020; Linnoila RI, 2006, LAB INVEST, V86, P425, DOI 10.1038/labinvest.3700412; Miller JD, 2005, CHEST, V127, P1999, DOI 10.1378/chest.127.6.1999; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Mori M, 2013, THORAX, V68, P521, DOI 10.1136/thoraxjnl-2012-202879; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Pavord ID, 2013, ANN ALLERG ASTHMA IM, V111, P402, DOI 10.1016/j.anai.2013.05.002; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pretolani M, 2014, AM J RESP CRIT CARE, V190, P1452, DOI 10.1164/rccm.201407-1374LE; van der Velden VHJ, 1999, NEUROIMMUNOMODULAT, V6, P145, DOI 10.1159/000026376; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Wahidi MM, 2012, AM J RESP CRIT CARE, V185, P709, DOI 10.1164/rccm.201105-0883CI; Wechsler ME, 2013, J ALLERGY CLIN IMMUN, V132, P1295, DOI 10.1016/j.jaci.2013.08.009; Weichselbaum M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-115; Wener RRL, 2013, EUR RESPIR REV, V22, P227, DOI 10.1183/09059180.00001913; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678	36	131	138	2	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1176	1185		10.1016/j.jaci.2016.08.009	http://dx.doi.org/10.1016/j.jaci.2016.08.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27609656				2022-12-18	WOS:000398771800013
J	Elias, PM; Wakefield, JS				Elias, Peter M.; Wakefield, Joan S.			Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antimicrobial peptides; atopic dermatitis; barrier function; ceramides; cytokines; filaggrin; kallikreins; lamellar bodies; lipid composition; pH; serine protease inhibitors; T(H)2 cells	STRATUM-CORNEUM MOISTURIZATION; MAMMALIAN EPIDERMAL BARRIER; SERINE-PROTEASE ACTIVITY; OF-FUNCTION MUTATIONS; FILAGGRIN MUTATIONS; ICHTHYOSIS VULGARIS; CERAMIDE DEFICIENCY; LIPID ORGANIZATION; PERMEABILITY; GENE	I review how diverse inherited and acquired abnormalities in epidermal structural and enzymatic proteins converge to produce defective permeability barrier function and antimicrobial defense in patients with atopic dermatitis (AD). Although best known are mutations in filaggrin (FLG), mutations in other member of the fused S-100 family of proteins (ie, hornerin [hrn] and filaggrin 2 [flg-2]); the cornified envelope precursor (ie, SPRR3); mattrin, which is encoded by TMEM79 and regulates the assembly of lamellar bodies; SPINK5, which encodes the serine protease inhibitor lymphoepithelial Kazal-type trypsin inhibitor type 1; and the fatty acid transporter fatty acid transport protein 4 have all been linked to AD. Yet these abnormalities often only predispose to AD; additional acquired stressors that further compromise barrier function, such as psychological stress, low ambient humidity, or high-pH surfactants, often are required to trigger disease. T(H)2 cytokines can also compromise barrier function by downregulating expression of multiple epidermal structural proteins, lipid synthetic enzymes, and antimicrobial peptides. All of these inherited and acquired abnormalities converge on the lamellar body secretory system, producing abnormalities in lipid composition, secretion, and/or extracellular lamellar membrane organization, as well as antimicrobial defense. Finally, I briefly review therapeutic options that address this new pathogenic paradigm.	Univ Calif San Francisco, Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Elias, PM (corresponding author), Vet Adm Med Ctr, Dermatol Serv 190, 4150 Clement St, San Francisco, CA 94121 USA.	eliasp@derm.ucsf.edu			National Institutes of Health [AR019098]; Medical Research Service, Department of Veterans Affairs; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061106, R01AR019098] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Service, Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health grant AR019098 and by the Medical Research Service, Department of Veterans Affairs. These contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Arthritis and Musculoskeletal and Skin Diseases or NIH.	Aberg KM, 2008, J INVEST DERMATOL, V128, P917, DOI 10.1038/sj.jid.5701099; Altemus M, 2001, J INVEST DERMATOL, V117, P309, DOI 10.1046/j.1523-1747.2001.01373.x; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Arikawa J, 2002, J INVEST DERMATOL, V119, P433, DOI 10.1046/j.1523-1747.2002.01846.x; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Braff MH, 2005, J INVEST DERMATOL, V124, P394, DOI 10.1111/j.0022-202X.2004.23443.x; Brandner JM, 2002, EUR J CELL BIOL, V81, P253, DOI 10.1078/0171-9335-00244; Breiden B, 2014, BBA-MOL CELL BIOL L, V1841, P441, DOI 10.1016/j.bbalip.2013.08.010; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Celli A, 2012, EXP DERMATOL, V21, P798, DOI 10.1111/j.1600-0625.2012.01573.x; Choi EH, 2005, J INVEST DERMATOL, V124, P587, DOI 10.1111/j.0022-202X.2005.23589.x; Choi EH, 2006, AM J PHYSIOL-REG I, V291, pR1657, DOI 10.1152/ajpregu.00010.2006; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Demerjian M, 2009, EXP DERMATOL, V18, P643, DOI 10.1111/j.1600-0625.2009.00841.x; Denda M, 1998, BRIT J DERMATOL, V138, P780; Denda M, 2000, AM J PHYSIOL-REG I, V278, pR367, DOI 10.1152/ajpregu.2000.278.2.R367; Di Nardo A, 1998, ACTA DERM-VENEREOL, V78, P27; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Elias P M, 1998, J Investig Dermatol Symp Proc, V3, P87; Elias P M, 1999, Am J Contact Dermat, V10, P119, DOI 10.1016/S1046-199X(99)90054-4; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Elias PM, 2007, SEMIN IMMUNOPATHOL, V29, P3, DOI 10.1007/s00281-007-0060-9; Elias PM, 2012, J INVEST DERMATOL, V132, P2131, DOI 10.1038/jid.2012.246; Elias PM, 2011, CLIN REV ALLERG IMMU, V41, P282, DOI 10.1007/s12016-010-8231-1; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; ELIAS PM, 1991, ADV LIPID RES, V24, P1; ELIAS PM, 1977, J INVEST DERMATOL, V69, P535, DOI 10.1111/1523-1747.ep12687968; Elias PM, 1996, ARCH DERMATOL, V132, P1505, DOI 10.1001/archderm.132.12.1505; Elias PM, 2013, EXPERT REV DERMATOL, V8, P27; Elias PM, 2010, ICHTHYOSES CLIN BIOC, P144; Epstein TG, 2012, ANN ALLERG ASTHMA IM, V108, P145, DOI 10.1016/j.anai.2012.01.004; Feingold KR, 2014, BBA-MOL CELL BIOL L, V1841, P280, DOI 10.1016/j.bbalip.2013.11.007; Feingold KR, 2012, J INVEST DERMATOL, V132, P1951, DOI 10.1038/jid.2012.177; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garg A, 2001, ARCH DERMATOL, V137, P53; Ghadially R, 1996, J INVEST DERMATOL, V107, P558, DOI 10.1111/1523-1747.ep12582813; Greisenegger EK, 2013, EUR J DERMATOL, V23, P142, DOI 10.1684/ejd.2013.1955; GRUBAUER G, 1989, J LIPID RES, V30, P89; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hachem JP, 2006, J INVEST DERMATOL, V126, P1609, DOI 10.1038/sj.jid.5700288; Hachem JP, 2006, J INVEST DERMATOL, V126, P2074, DOI 10.1038/sj.jid.5700351; Hachem JP, 2010, J INVEST DERMATOL, V130, P500, DOI 10.1038/jid.2009.249; Hachem JP, 2003, J INVEST DERMATOL, V121, P345, DOI 10.1046/j.1523-1747.2003.12365.x; Hatano Y, 2013, EXP DERMATOL, V22, P30, DOI 10.1111/exd.12047; Hatano Y, 2009, J INVEST DERMATOL, V129, P1824, DOI 10.1038/jid.2008.444; Henry J, 2011, FASEB J, V25, P1567, DOI 10.1096/fj.10-168658; Hon KL, 2013, AM J CLIN DERMATOL, V14, P389, DOI 10.1007/s40257-013-0033-9; Hoste E, 2011, J INVEST DERMATOL, V131, P2233, DOI 10.1038/jid.2011.153; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Imokawa G, 2009, J DERMATOL SCI, V55, P1, DOI 10.1016/j.jdermsci.2009.04.006; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ishikawa J, 2010, J INVEST DERMATOL, V130, P2511, DOI 10.1038/jid.2010.161; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Janssens M, 2011, J INVEST DERMATOL, V131, P2136, DOI 10.1038/jid.2011.175; Jeon SK, 2008, J INVEST DERMATOL, V128, P1930, DOI 10.1038/jid.2008.13; Jungersted JM, 2010, ALLERGY, V65, P911, DOI 10.1111/j.1398-9995.2010.02326.x; Kato JS, 2003, J INVEST DERMATOL, V120, P456, DOI 10.1046/j.1523-1747.2003.12053.x; Kelsell DP, 2011, J INVEST DERMATOL, V131, P1593, DOI 10.1038/jid.2011.92; Khnykin D, 2012, J AM ACAD DERMATOL, V66, P606, DOI 10.1016/j.jaad.2011.04.014; Kita K, 2002, BIOCHEM J, V362, P619, DOI 10.1042/0264-6021:3620619; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; Kurahashi R, 2008, J INVEST DERMATOL, V128, P1329, DOI 10.1038/sj.jid.5701138; Langan SM, 2013, J INVEST DERMATOL, V133, P1706, DOI 10.1038/jid.2013.128; Lee SE, 2010, YONSEI MED J, V51, P808, DOI 10.3349/ymj.2010.51.6.808; Lin TK, 2012, J INVEST DERMATOL, V132, P2430, DOI 10.1038/jid.2012.173; Loiseau N, 2013, J DERMATOL SCI, V72, P296, DOI 10.1016/j.jdermsci.2013.08.003; Macheleidt O, 2002, J INVEST DERMATOL, V119, P166, DOI 10.1046/j.1523-1747.2002.01833.x; Makino T, 2003, J HISTOCHEM CYTOCHEM, V51, P485, DOI 10.1177/002215540305100410; Makino T, 2001, J BIOL CHEM, V276, P47445, DOI 10.1074/jbc.M107512200; Man MQ, 2008, J INVEST DERMATOL, V128, P79, DOI 10.1038/sj.jid.5701011; Marenholz I, 2011, J INVEST DERMATOL, V131, P1644, DOI 10.1038/jid.2011.90; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; Ny A, 2004, ACTA DERM-VENEREOL, V84, P18, DOI 10.1080/0001555031004924; NylanderLundqvist E, 1996, J IMMUNOL, V157, P1699; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ohnishi Y, 1999, CLIN DIAGN LAB IMMUN, V6, P101, DOI 10.1128/CDLI.6.1.101-104.1999; Oren A, 2003, EXP MOL PATHOL, V74, P180, DOI 10.1016/S0014-4800(02)00023-0; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park YH, 2012, J INVEST DERMATOL, V132, P476, DOI 10.1038/jid.2011.333; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Presland R. B., 2006, SKIN BARRIER, P111; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Rawlings AV, 2005, J INVEST DERMATOL, V124, P1099, DOI 10.1111/j.1523-1747.2005.23726.x; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; Rodriguez-Martin M, 2011, J INVEST DERMATOL, V131, P2263, DOI 10.1038/jid.2011.210; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; Ross-Hansen K, 2014, J INVEST DERMATOL, V134, P1164, DOI 10.1038/jid.2013.445; Sakai T, 2014, J DERMATOL SCI, V74, P222, DOI 10.1016/j.jdermsci.2014.01.012; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Sawada E, 2012, J DERMATOL SCI, V68, P25, DOI 10.1016/j.jdermsci.2012.07.004; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schmuth M, 2001, J INVEST DERMATOL, V117, P837, DOI 10.1046/j.0022-202x.2001.01471.x; SCHURER NY, 1991, ADV LIPID RES, V24, P27; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Stout TE, 2014, J INVEST DERMATOL, V134, P423, DOI 10.1038/jid.2013.284; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Taieb A, 1999, CONTACT DERMATITIS, V41, P177, DOI 10.1111/j.1600-0536.1999.tb06125.x; Tawada C, 2014, J INVEST DERMATOL, V134, P712, DOI 10.1038/jid.2013.364; Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069; Thyssen JP, 2013, BRIT J DERMATOL, V168, P1155, DOI 10.1111/bjd.12219; Thyssen JP, 2014, J ALLERGY CLIN IMMUN; Toulza E, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r107; Voegeli R, 2009, BRIT J DERMATOL, V161, P70, DOI 10.1111/j.1365-2133.2009.09142.x; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Wood LC, 1997, EXP DERMATOL, V6, P98, DOI 10.1111/j.1600-0625.1997.tb00154.x; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Wu ZH, 2009, J INVEST DERMATOL, V129, P1446, DOI 10.1038/jid.2008.370; Wu ZH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005227; Ye J, 1999, J INVEST DERMATOL, V112, P543	131	131	134	2	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					781	U369		10.1016/j.jaci.2014.05.048	http://dx.doi.org/10.1016/j.jaci.2014.05.048			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25131691	Green Accepted			2022-12-18	WOS:000343155700002
J	Keet, CA; Seopaul, S; Knorr, S; Narisety, S; Skripak, J; Wood, RA				Keet, Corinne A.; Seopaul, Shannon; Knorr, Sarah; Narisety, Satya; Skripak, Justin; Wood, Robert A.			Long-term follow-up of oral immunotherapy for cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Keet, Corinne A.; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21205 USA; [Keet, Corinne A.; Seopaul, Shannon; Knorr, Sarah; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Narisety, Satya] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, Div Allergy & Immunol, Newark, NJ 07103 USA; [Skripak, Justin] ENT & Allergy Associates, Hoboken, NJ USA	Johns Hopkins University; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Keet, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21205 USA.	ckeet1@jhmi.edu		Keet, Corinne/0000-0002-6585-239X	NIAID NIH HHS [1K23AI103187, K23 AI103187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI103187] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Meglio P, 2008, PEDIAT ALLERG IMM-UK, V19, P412, DOI 10.1111/j.1399-3038.2007.00670.x; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Wasserman RL, 2011, J ALLERGY CLIN IMMUN, V127, P290, DOI 10.1016/j.jaci.2010.08.052	7	131	131	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					737	739		10.1016/j.jaci.2013.05.006	http://dx.doi.org/10.1016/j.jaci.2013.05.006			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23806635	Green Accepted			2022-12-18	WOS:000323612000027
J	Beeh, KM; Kanniess, F; Wagner, F; Schilder, C; Naudts, I; Hammann-Haenni, A; Willers, J; Stocker, H; Mueller, P; Bachmann, MF; Renner, WA				Beeh, Kai-Michael; Kanniess, Frank; Wagner, Frank; Schilder, Cordula; Naudts, Ingomar; Hammann-Haenni, Anya; Willers, Joerg; Stocker, Hans; Mueller, Philipp; Bachmann, Martin F.; Renner, Wolfgang A.			The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Persistent allergic asthma; Toll-like receptor 9; virus-like particle; immune modulator; clinical trial	PLASMACYTOID DENDRITIC CELLS; CPG OLIGODEOXYNUCLEOTIDES; CONTROL QUESTIONNAIRE; IMMUNOTHERAPY; ADJUVANT; VACCINE; SAFETY; TRIAL; IMMUNOGENICITY; EXACERBATIONS	Background: Allergen-specific T(H)2 responses contribute to the development of allergic asthma. Their increase may be due to a reduced early exposure to environmental pathogens, which induces a T(H)1 response, and thereby suppresses the allergic T(H)2 response. QbG10 (bacteriophage Qbeta-derived virus-like particle with CpG-motif G10 inside), a novel Toll-like receptor 9 agonist packaged into virus-like particles, was designed to stimulate the immune system toward a T(H)1-mediated protective response. Objective: We examined clinical efficacy, safety, and tolerability of QbG10 with patient-reported and objective clinical outcome parameters in patients with mild-to-moderate persistent allergic asthma. Methods: In this proof-of-concept parallel-group, double-blind, randomized trial, 63 asthmatic patients followed conversion to a standardized inhaled steroid and were treated with 7 injections of either QbG10 or placebo. Incorporating a controlled steroid withdrawal, the effects on patient-reported (day- and nighttime asthma symptoms, salbutamol usage, and 7-item-Asthma Control Questionnaire scores) and objective clinical outcome measures (FEV1, fraction of exhaled nitric oxide, and blood eosinophils) were assessed over 12 weeks (ClinicalTrials.gov number, NCT00890734). Results: All patient-reported parameters improved overall between week 0 and 12 in QbG10-treated patients (n=33) despite steroid withdrawal, compared with deteriorations observed under placebo (n=30, P<.05). At week 12, two thirds of the QbG10-treated patients had their asthma "well controlled'' (Asthma Control Questionnaire score <= 0.75) compared with one third under placebo. FEV1 had worsened to a clinically significant extent in patients on placebo, while it remained stable in QbG10 patients. Adverse events were mostly injection site reactions occurring after QbG10 administration. Conclusion: Treatment with QbG10 may contribute to continued asthma control during steroid reduction in patients on moderate or high-dose inhaled steroids. (J Allergy Clin Immunol 2013;131:866-74.)	[Beeh, Kai-Michael] Insaf Resp Res Inst, Wiesbaden, Germany; [Kanniess, Frank] KLB Healthres Lubeck, Lubeck, Germany; [Wagner, Frank] Charite Res Org, Berlin, Germany; [Schilder, Cordula] Hlth Ctr Schilder, Eisenach, Germany; [Naudts, Ingomar] Praxis Rodgau, Rodgau, Germany; [Hammann-Haenni, Anya; Willers, Joerg; Stocker, Hans; Mueller, Philipp; Bachmann, Martin F.; Renner, Wolfgang A.] Cytos Biotechnol AG, CH-8952 Schlieren, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Mueller, P (corresponding author), Cytos Biotechnol AG, Wagistr 25, CH-8952 Schlieren, Switzerland.	philipp.mueller@cytos.com	Kanniess, Frank/AAJ-1137-2020; Stoecker, Horst/F-8382-2012	Stoecker, Horst/0000-0002-3282-3664	Cytos Biotechnology AG; Novartis; Boehringer Ingelheim; AstraZeneca; GlaxoSmithKline; Revotar Biopharmaceuticals; Almirall; Takeda	Cytos Biotechnology AG; Novartis(Novartis); Boehringer Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Revotar Biopharmaceuticals; Almirall(Almirall); Takeda(Takeda Pharmaceutical Company Ltd)	Cytos Biotechnology AG funded this study.; K.-M. Beeh has received consulting and lecture fees from Novartis, Boehringer Ingelheim, and AstraZeneca; has received research support from GlaxoSmithKline, Revotar Biopharmaceuticals, and Almirall; and has received lecture fees from Takeda. The rest of the authors declare that they have no relevant conflicts of interest.	Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Barnes PJ, 2001, EUR RESPIR J, V18, p67S, DOI 10.1183/09031936.01.00229901; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Belda Jose, 2006, Can Respir J, V13, P129; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P85; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Carpentier A, 2006, NEURO-ONCOLOGY, V8, P60, DOI 10.1215/S1522851705000475; Casale TB, 2011, J ALLERGY CLIN IMMUN, V127, P8, DOI 10.1016/j.jaci.2010.10.034; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cooper CL, 2004, VACCINE, V22, P3136, DOI 10.1016/j.vaccine.2004.01.058; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Friedberg JW, 2005, BLOOD, V105, P489, DOI 10.1182/blood-2004-06-2156; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Halperin SA, 2003, VACCINE, V21, P2461, DOI 10.1016/S0264-410X(03)00045-8; Hofmann MA, 2008, J IMMUNOTHER, V31, P520, DOI 10.1097/CJI.0b013e318174a4df; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Kanniess F, 2002, EUR RESPIR J, V20, P1080, DOI 10.1183/09031936.02.00304202; Klimek L, 2011, CLIN EXP ALLERGY, V41, P1305, DOI 10.1111/j.1365-2222.2011.03783.x; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; KURAMOTO E, 1992, JPN J CANCER RES, V83, P1128, DOI 10.1111/j.1349-7006.1992.tb02734.x; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Onyirimba F, 2003, ANN ALLERG ASTHMA IM, V90, P411, DOI 10.1016/S1081-1206(10)61825-X; Parker JM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-14; Roussel L, 2011, J ALLERGY CLIN IMMUN, V127, P1632, DOI 10.1016/j.jaci.2011.03.034; Senti G, 2009, CLIN EXP ALLERGY, V39, P562, DOI 10.1111/j.1365-2222.2008.03191.x; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Speiser DE, 2010, J IMMUNOTHER, V33, P848, DOI 10.1097/CJI.0b013e3181f1d614; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Tattersfield Anne E, 2004, Proc Am Thorac Soc, V1, P171, DOI 10.1513/pats.200402-016MS; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x	45	131	137	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					866	874		10.1016/j.jaci.2012.12.1561	http://dx.doi.org/10.1016/j.jaci.2012.12.1561			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23384679				2022-12-18	WOS:000315587800031
J	Calderon, MA; Cox, L; Casale, TB; Moingeon, P; Demoly, P				Calderon, Moises A.; Cox, Linda; Casale, Thomas B.; Moingeon, Philippe; Demoly, Pascal			Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen immunotherapy; polysensitization; monosensitization; polyallergic; subcutaneous immunotherapy; sublingual immunotherapy; safety; efficacy	SUBLINGUAL IMMUNOTHERAPY; EFFICACY; SENSITIZATION; EXTRACT; SAFETY; POPULATION; CHILDHOOD; STABILITY; PATTERNS; TABLETS	In allergen immunotherapy there is debate as to whether polysensitized patients are best treated with many allergens simultaneously (chosen according to the sensitization profile, a predominantly North American approach) or a single allergen (chosen according to the most clinically problematic allergy, a predominantly European approach). In patients seeking treatment for moderate-to-severe respiratory allergies, polysensitization is more prevalent (range, 50% to 80%) than monosensitization in both the United States and Europe. Safe, effective, single-allergen preparations will most likely have been tested in polysensitized patients. In robust, large-scale clinical trials of grass pollen sublingual tablets, polysensitized patients benefited at least as much from allergen immunotherapy as monosensitized patients. A recent review of multiallergen immunotherapy concluded that simultaneous delivery of multiple unrelated allergens can be clinically effective but that there was a need for additional investigation of therapy with more than 2 allergen extracts (particularly in sublingual allergen immunotherapy). More work is also required to determine whether single-allergen and multiallergen immunotherapy protocols elicit distinct immune responses in monosensitized and polysensitized patients. Sublingual and subcutaneous multiallergen immunotherapy in polysensitized patients requires more supporting data to validate its efficacy in practice. (J Allergy Clin Immunol 2012;129:929-34.)	[Calderon, Moises A.] Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England; [Casale, Thomas B.] Creighton Univ, Div Allergy & Immunol, Dept Med, Omaha, NE 68178 USA; [Demoly, Pascal] Univ Hosp Montpellier, INSERM U657, Dept Pneumol, Allergy Div,Hop Arnaud de Villeneuve, Montpellier, France	Imperial College London; Royal Brompton Hospital; Creighton University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Calderon, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, Natl Heart & Lung Inst, Royal Brompton Hosp, Dovehouse St, London, England.	m.calderon@imperial.ac.uk	Cox, Linda/AAP-1697-2021; Demoly, Pascal/Y-9938-2019; Casale, Thomas B/K-4334-2013	Cox, Linda/0000-0002-5258-6870; Demoly, Pascal/0000-0001-7827-7964; Casale, Thomas B/0000-0002-3149-7377	Stallergenes; Novartis; Merck/Schering-Plough; ALK-Abello	Stallergenes; Novartis(Novartis); Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); ALK-Abello	M. A. Calderon receives honoraria for consulting and lectures from ALK-Abello and Stallergenes, receives honoraria for lectures from Merck, and is the Chair of the Immunotherapy Group for the European Academy of Allergy and Clinical Immunology (EAACI). L. Cox has consultant arrangements with Stallergenes, Genentech/Novartis, and ISTA; is on the speaker's bureau for Phadia; receives research support from Stallergenes and Novartis; is secretary/treasurer for the American Academy of Allergy, Asthma & Immunology (AAAAI); is on the board of directors for the American Board of Allergy and Immunology (ABAI); and is a member of the Joint Task Force on Practice Parameters. T. B. Casale is on the advisory board for Stallergenes, receives research support from Stallergenes and Merck/Schering-Plough, and is executive vice president of the AAAAI. P. Moingeon is an employee of Stallergenes SA. P. Demoly is on advisory boards for Stallergenes and ALK-Abello; is on the speaker's bureau for Stallergenes, ALK-Abello, Merck/Schering-Plough, AstraZeneca, and GlaxoSmithKline; has consultant arrangements with Therabel and Crucell; receives research support from Stallergenes and ALK-Abello; and is Vice President of the EAACI.	Agostinis F, 2008, ALLERGY, V63, P1637, DOI 10.1111/j.1398-9995.2008.01742.x; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bar-On ES, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005530.pub2; Barth C, 2010, EUR ARCH OTO-RHINO-L, V267, P1873, DOI 10.1007/s00405-010-1262-7; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Bousquet PJ, 2010, ANN EPIDEMIOL, V20, P797, DOI 10.1016/j.annepidem.2010.05.012; Calderon M, 2010, ALLERGY, V65, P420, DOI 10.1111/j.1398-9995.2009.02292.x; Ciprandi G, 2010, J INVEST ALLERG CLIN, V20, P274; Ciprandi G, 2010, INT J IMMUNOPATH PH, V23, P637, DOI 10.1177/039463201002300227; Ciprandi G, 2009, J BIOL REG HOMEOS AG, V23, P165; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; Craig TJ, 2008, J ALLERGY CLIN IMMUN, V121, P671, DOI 10.1016/j.jaci.2007.12.1153; de Jong AB, 2011, PEDIAT ALLERG IMM-UK, V22, P166, DOI 10.1111/j.1399-3038.2010.00993.x; Didier A, 2010, REV FR ALLERGOL, V50, P426, DOI 10.1016/j.reval.2010.07.001; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Emminger W, 2009, J ALLERGY CLIN IMMUN, V123, pS75, DOI 10.1016/j.jaci.2008.12.257; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Kim KW, 2006, J KOREAN MED SCI, V21, P1012, DOI 10.3346/jkms.2006.21.6.1012; Limb SL, 2006, INT ARCH ALLERGY IMM, V140, P245, DOI 10.1159/000093250; Malling HJ, 2009, CLIN EXP ALLERGY, V39, P387, DOI 10.1111/j.1365-2222.2008.03152.x; Mari A, 2006, INT ARCH ALLERGY IMM, V141, P57, DOI 10.1159/000094254; Nelson HS, 2009, J ALLERGY CLIN IMMUN, V123, P763, DOI 10.1016/j.jaci.2008.12.013; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; PENE J, 1994, IMMUNOLOGY, V81, P58; Plunkett G, 2008, CURR OPIN OTOLARYNGO, V16, P285, DOI 10.1097/MOO.0b013e3282ff62b0; Prigione I, 2010, ALLERGY, V65, P740, DOI 10.1111/j.1398-9995.2009.02285.x; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x	30	131	138	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					929	934		10.1016/j.jaci.2011.11.019	http://dx.doi.org/10.1016/j.jaci.2011.11.019			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22244595	Bronze			2022-12-18	WOS:000302144600006
J	Arshad, SH; Bateman, B; Sadeghnejad, A; Gant, C; Matthews, SM				Arshad, Syed Hasan; Bateman, Belinda; Sadeghnejad, Alireza; Gant, Carole; Matthews, Sharon M.			Prevention of allergic disease during childhood by allergen avoidance: The Isle of Wight prevention study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergy; asthma; rhinitis; atopic dermatitis; food allergy; prevention; diet; house dust mite; randomized controlled trial	HOUSE-DUST MITE; BIRTH-COHORT; ASTHMA; EXPOSURE; INFANCY; SENSITIZATION; RISK; AGE; OUTCOMES; ATOPY	Background: Early life allergen exposure may increase the risk of childhood allergy, but the protective effect of reduction in allergen exposure remains uncertain. Objective: To evaluate the effect of reduction in food and house dust mite (HDM) allergen exposure in infancy in preventing asthma and allergy. Methods: Infants, at higher risk because of family predisposition, were recruited prenatally and randomized to prophylactic (n = 58) and control (n = 62) groups. Prophylactic group infants were either breast-fed with mother on a low allergen diet or given an extensively hydrolyzed formula. Exposure to HDM was reduced by the use of an acaricide and mattress covers. The control group followed standard advice. Development of allergic diseases and sensitization to common allergens (atopy) was assessed blindly at ages 1, 2, 4, and 8 years in all 120 children. Results: Repeated measurement analysis, adjusted for all relevant confounding variables, confirmed a preventive effect on asthma: adjusted odds ratio (OR), 0.24; 95% CI, 0.09-0.66; P = .005; atopic dermatitis, OR, 0.23; Cl, 0.08-0.64; P = .005; rhinitis, OR, 0.42; CI, 0.19-0.92; P = .03; and atopy, OR, 0.13; Cl, 0.05-0.32; P < .001. The protective effect was primarily observed in the subgroup of children with persistent disease (symptoms at all visits) and in those with evidence of allergic sensitization. Conclusion: Allergic diseases can be reduced, for at least the first 8 years of life, by combined food and HDM allergen avoidance in infancy. Clinical implications: Strict food and HDM allergen avoidance should be considered for prevention of allergy in high-risk infants.	St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, Wales; Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27109 USA	Wake Forest University	Arshad, SH (corresponding author), St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, Wales.	sha@soton.ac.uk						Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; Hide D W, 1994, Pediatr Allergy Immunol, V5, P61, DOI 10.1111/j.1399-3038.1994.tb00351.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; HOST A, 1994, PEDIATR ALLERGY IMMU, V5, P5; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; KRAMER MS, 2001, COCHRANE LIB, V1, P133; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stokes M., 2001, CATEGORICAL DATA ANA; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	30	131	137	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					307	313		10.1016/j.jaci.2006.12.621	http://dx.doi.org/10.1016/j.jaci.2006.12.621			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291851				2022-12-18	WOS:000244327900006
J	Kushnir-Sukhov, NM; Brown, JM; Wu, YL; Kirshenbaum, A; Metcalfe, DD				Kushnir-Sukhov, Nataliya M.; Brown, Jared M.; Wu, Yalin; Kirshenbaum, Arnold; Metcalfe, Dean D.			Human mast cells are capable of serotonin synthesis and release	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MASTOCYTOSIS		NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kushnir-Sukhov, NM (corresponding author), NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA.	nkushnir@niaid.nih.gov	Kushnir, Nataliya/AAR-4704-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000513] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ARZT ES, 1988, J CLIN IMMUNOL, V8, P513, DOI 10.1007/BF00916958; Enomoto U, 1999, CLIN EXP DERMATOL, V24, P16; INOUE H, 1995, JPN J PHARMACOL, V69, P61, DOI 10.1254/jjp.69.61; Jernej B, 2000, PSYCHIAT RES, V94, P153, DOI 10.1016/S0165-1781(00)00129-3; Joint Task Force on Practice Parameters, 2000, Ann Allergy Asthma Immunol, V85, P521; KUSHNIRSUKHOV NM, 2007, IN PRESS J IMMUNOL; Lesurtel M, 2006, SCIENCE, V312, P104, DOI 10.1126/science.1123842; MORISHIMA T, 1970, TOHOKU J EXP MED, V102, P121, DOI 10.1620/tjem.102.121; Siddiqui EJ, 2005, ONCOL REP, V14, P1593; WEITZMAN G, 1985, INT ARCH ALLER A IMM, V77, P189, DOI 10.1159/000233782	10	131	137	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					498	499		10.1016/j.jaci.2006.09.003	http://dx.doi.org/10.1016/j.jaci.2006.09.003			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291861				2022-12-18	WOS:000244327900031
J	Vercelli, D				Vercelli, D			Genetics, epigenetics, and the environment: Switching, buffering, releasing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics; epigenetics; environment; IgE; innate immunity	SERUM IGE LEVELS; SOLUBLE CD14 LEVELS; HYGIENE HYPOTHESIS; PROMOTER POLYMORPHISMS; ALLERGIC DISEASE; DNA METHYLATION; ASTHMA; CHILDREN; ATOPY; LIPOPOLYSACCHARIDE	Increasing evidence suggests that the interactions between genes and environment might play a critical role in the pathogenesis of complex diseases, such as asthma, that exhibit a heritable component but do not follow Mendel's laws. Gene-environment interactions are extremely complex and not linear, such that the same genetic variants might be associated with opposite phenotypes in different environments. This is particularly evident for innate immunity genes, which operate at the interface between the immune system and the pathogen world. This article examines gene-environment interactions by using CD14 as a model and argues that the conflicting results of epidemiologic studies on CD14*C-159T result from differences in environmental conditions essential to modulate CD14 gene expression. Furthermore, on the basis of how rapidly environmental changes have affected the incidence of immune diseases, I argue that a full understanding of gene-environment interactions requires that epigenetic as well as classical genetic mechanisms be taken into account. Recent data about the effect of diet on gene methylation and the release of hidden genetic variation by impairment of heat shock protein 90-mediated buffering systems offer eloquent examples of how epigenetic mechanisms might affect gene-environment interactions.	Arizona Hlth Sci Ctr, Arizona Resp Ctr, Funct Genom Lab, Tucson, AZ 85724 USA; Univ Arizona, Coll Med, Dept Cell Biol, Tucson, AZ 85721 USA	University of Arizona Health Sciences; University of Arizona	Vercelli, D (corresponding author), Arizona Hlth Sci Ctr, Arizona Resp Ctr, Funct Genom Lab, Rm 2349,1501 N Campbell Ave, Tucson, AZ 85724 USA.				NHLBI NIH HHS [HL67672, HL66803, HL66391] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066391, U01HL066803, P01HL067672, P50HL067672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMELUNG PJ, 2000, AM J RESP CRIT CARE, V161, pA927; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Buckova D, 2003, ALLERGY, V58, P1023, DOI 10.1034/j.1398-9995.2003.00271.x; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; EDER W, 2003, AM J RESP CRIT CARE, V167, pA943; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; Heinzmann A, 2003, EUR J IMMUNOGENET, V30, P345, DOI 10.1046/j.1365-2370.2003.00414.x; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones CA, 2002, J ALLERGY CLIN IMMUN, V109, P858, DOI 10.1067/mai.2002.123535; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Lewontin R, 2000, TRIPLE HELIX; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; McIntire JJ, 2003, NATURE, V425, P576, DOI 10.1038/425576a; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MILLAR SE, 1995, DEVELOPMENT, V121, P3223; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Petronis A, 2001, TRENDS GENET, V17, P142, DOI 10.1016/S0168-9525(00)02213-7; Pigliucci M, 2002, NATURE, V417, P598, DOI 10.1038/417598a; Pigliucci M, 2003, CELL CYCLE, V2, P34, DOI 10.4161/cc.2.1.274; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sangster TA, 2003, CELL CYCLE, V2, P166; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; STERN D, 2003, IN PRESS NOVARTIS FD; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vercelli D, 2002, J ALLERGY CLIN IMMUN, V109, P14, DOI 10.1067/mai.2002.121015; Vercelli D, 2003, CURR OPIN ALLERGY CL, V3, P343, DOI 10.1097/01.all.0000092603.76804.e4; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; XU J, 1995, AM J HUM GENET, V57, P425; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	49	131	138	1	30	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					381	386		10.1016/j.jaci.2004.01.752	http://dx.doi.org/10.1016/j.jaci.2004.01.752			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007332				2022-12-18	WOS:000220144200002
J	Dales, RE; Cakmak, S; Judek, S; Dann, T; Coates, F; Brook, JR; Burnett, RT				Dales, RE; Cakmak, S; Judek, S; Dann, T; Coates, F; Brook, JR; Burnett, RT			Influence of outdoor aeroallergens on hospitalization for asthma in Canada	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; fungus; pollen; air pollution; epidemiology	INHALED ALLERGEN; AIRWAY RESPONSE; OZONE EXPOSURE; POLLEN	Background: The risk of hospitalization for asthma caused by outdoor aeroallergens is largely unknown. Objective: The objective of this study was to determine the association between changes in outdoor aeroallergens and hospitalizations for asthma from the Pacific coast to the Atlantic coast of Canada. Methods: A daily time series analysis was done to test the association between daily changes in aeroallergens and daily changes in hospitalizations for asthma during a 7-year period between 1993 and 2000 in 10 of the largest cities in Canada. Results were adjusted for long-term trends, day of the week, climate, and air pollution. Results: A daily increase, equivalent to the mean value of each allergen, was associated with the following percentage increase in asthma hospitalizations: 3.3% (95% CI, 2.3 to 4.1) for basidiomycetes, 3.1 % (95 % CI, 2.8 to 5.7) for ascomycetes, 3.2% (95% CI, 1.6 to 4.8) for deuteromycetes, 3.0% (95% CI, 1.1 to 4.9) for weeds, 2.9 % (95 % CI, 0.9 to 5.0) for trees, and 2.0% (95% CI, 1.1 to 2.8) for grasses. After accounting for the independent effects of trees and ozone, the combination of the 2 was associated with an additional 0.22% increase in admissions averaged across cities (P < .05). Conclusion: These findings provide evidence for the hypothesis that aeroallergens are an important cause of severe asthma morbidity across Canada,, and in some situations there might be a modest synergistic adverse effect of ozone and aeroallergens combined.	Univ Ottawa, Ottawa, ON K1N 6N5, Canada; Ottawa Hlth Res Inst, Ottawa, ON, Canada; Hlth Canada, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Health Canada	Dales, RE (corresponding author), Ottawa Gen Hosp, Gen Campus,501 Smyth Rd,Box 211, Ottawa, ON K1H 8L6, Canada.			Cakmak, Sabit/0000-0001-9921-2107				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568, DOI 10.1164/ajrccm.155.2.9032196; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; Guarro J, 2000, ATLAS CLIN FUNGI, P1, DOI DOI 10.1093/ANNHYG/MEG032; Hastie T. J, 1990, GEN ADDICTIVE MODELS; Hoek G, 1997, ARCH ENVIRON HEALTH, V52, P455, DOI 10.1080/00039899709602224; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33, DOI 10.1164/ajrccm.160.1.9808119; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P1724, DOI 10.1046/j.1365-2222.2000.00947.x; Lierl MB, 2003, ANN ALLERG ASTHMA IM, V90, P28, DOI 10.1016/S1081-1206(10)63610-1; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P246; MCCALLAGH P, 1989, GEN LINEAR MODELS; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PLATTSMILLS T, 1999, ASTHAM LINK ENV IMMU; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schappi GF, 1999, ALLERGY, V54, P478, DOI 10.1034/j.1398-9995.1999.00838.x; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Vagaggini B, 2002, AM J RESP CRIT CARE, V166, P1073, DOI 10.1164/rccm.2201013; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4	23	131	132	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					303	306		10.1016/j.jaci.2003.11.016	http://dx.doi.org/10.1016/j.jaci.2003.11.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767446	Bronze			2022-12-18	WOS:000188885700019
J	Werner, M; Topp, R; Wimmer, K; Richter, K; Bischof, W; Wjst, M; Heinrich, J				Werner, M; Topp, R; Wimmer, K; Richter, K; Bischof, W; Wjst, M; Heinrich, J			TLR4 gene variants modify endotoxin effects on asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; TLR4; gene polymorphism; asthma; ECRHS	HOUSE-DUST ENDOTOXIN; TOLL-LIKE RECEPTOR-4; RESPIRATORY SYMPTOMS; INNATE IMMUNITY; EXPOSURE; LIPOPOLYSACCHARIDE; CD14; SENSITIZATION; INHALATION; RESPONSES	Background: Environmental exposure to endotoxin might have a crucial role in immune maturation and development of asthma. Objective: The aim of this study was to investigate whether the effect of endotoxin concentration in settled house dust on asthma is modified by the presence of variation in the TLR4 gene. Methods: We performed a cross-sectional study within the German follow-up of the European Community Respiratory Health Survey. Multivariate logistic regression analysis and nonparametric effect estimates (S-Plus) were applied to examine the association between endotoxin exposure and diagnosed asthma, related clinical symptoms, and bronchial hyperreactivity (BHR) stratified for noncarriers and carriers of G299/1399 polymorphism in the TLR4 gene. Results: In the noncarrier group (n = 279), the prevalence of asthma was significantly increased with elevated endotoxin levels in house dust with adjusted odds ratio 6.24 (95% CI, 1.33-29.17) in the second tertile, and 4.54 (95% CI, 0.94-21.96) in the third tertile compared with the lowest endotoxin fertile. The carriers of the polymorphisms (n = 55) showed a nonsignificant trend to have a lower risk of asthma (crude odds ratio, 0.67; 95% CI, 0.06-8.06 for the second tertile and 1.33; 95% CI, 0.17-10.58 for the third tertile). We found a similar association for wheeze and endotoxin exposure that was also attenuated in subjects with G299/1399 polymorphisms. Conclusions: The G299/1399 polymorphisms were associated with a modified response to endotoxin, but the functional relationship still needs clarification.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Grosshansdorf Hosp, Pulm Res Inst, Ctr Pneumol & Thorac Surg, Grosshansdorf, Germany; Univ Jena, Inst Occupat Social & Environm Med, Erfurt, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Grosshansdorf Hospital; Friedrich Schiller University of Jena	Heinrich, J (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Heinrich, Joachim/N-1720-2013	Heinrich, Joachim/0000-0002-9620-1629				Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Bischof W, 2002, INDOOR AIR, V12, P2, DOI 10.1034/j.1600-0668.2002.120102.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chinn S, 2002, THORAX, V57, P393, DOI 10.1136/thorax.57.5.393; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Douwes J, 1997, INT J OCCUP ENV HL S, V3, P26; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736, DOI 10.1152/ajplung.1996.270.5.L736; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924, DOI 10.1164/ajrccm.159.3.9804024; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; O'Neill LAJ, 2002, TRENDS IMMUNOL, V23, P296, DOI 10.1016/S1471-4906(02)02222-6; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; SANDSTROM T, 1992, EUR RESPIR J, V5, P992	37	131	142	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					323	330		10.1067/mai.2003.1648	http://dx.doi.org/10.1067/mai.2003.1648			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897738	Bronze			2022-12-18	WOS:000184650600016
J	Liu, AH; Murphy, JR				Liu, AH; Murphy, JR			Hygiene hypothesis: Fact or fiction?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hygiene; allergy; atopy; asthma; autoimmunity; childhood; endotoxin; epidemiology type 1diabetes; celiac disease; inflammatory bowel disease; rheumatoid arthritis; microbiology	HOUSE-DUST ENDOTOXIN; DAY-CARE ATTENDANCE; ATOPIC DISEASE; CHILDHOOD ASTHMA; UNITED-STATES; SCHOOL-AGE; EARLY-LIFE; EXPOSURE; CHILDREN; RISK	The hygiene hypothesis of asthma and allergy has recently received a swell of popularity and published supporting evidence, and has been extended to autoimmune conditions of childhood. Broadly stated, naturally occurring infections and microbial exposures might essentially immunize against the development of asthma and allergic and autoimmune diseases. If true, then reductions in nature's immunotherapy over the past century might be a major factor in the global increase of these conditions (eg, the higher prevalence of asthma and allergies in urban metropolitan areas compared with rural and farm communities) and might lead to new therapies for these conditions. Although such a unifying hypothesis has great appeal, currently it is only speculation about what might be at the end of the investigative road. How close are the current studies to establishing a causal relationship between microbial exposures and a reduction in allergic, asthmatic, and autoimmune disease prevalence? A systematic epidemiologic appraisal of the current hygiene hypothesis evidence can provide a critical analysis of what is currently known and an investigative blueprint for future studies that can ultimately prove causation and improve recommendations, interventions, and therapies. (J Allergy Clin Immunol 2003;111:471-8.).	Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Dept Pediat, Boulder, CO 80309 USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Dept Prevent Med & Biometr, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Liu, AH (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, 1400 Jackson St K1023, Denver, CO 80206 USA.				NCRR NIH HHS [5 MO1 RR00051] Funding Source: Medline; NHLBI NIH HHS [HL36577,, HL-04272, 1NO1-HR-16048, HL 51834] Funding Source: Medline; NHLBI NIH HHS [K23-HL-0472] Funding Source: Medline; NICHD NIH HHS [1-U01-HD37237] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Ball TM, 2002, ARCH PEDIAT ADOL MED, V156, P121, DOI 10.1001/archpedi.156.2.121; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; FEDERICO MJ, IN PRESS PEDIAT CLIN; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; HURWITZ ES, 1991, PEDIATRICS, V87, P62; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LOUHIALA PJ, 1995, AM J PUBLIC HEALTH, V85, P1109, DOI 10.2105/AJPH.85.8_Pt_1.1109; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Salvi SS, 2001, AM J RESP CRIT CARE, V164, P1343, DOI 10.1164/ajrccm.164.8.2103080; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; SHEIKH A, IN PRESS J ALLERGY C; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; WALD ER, 1991, J PEDIATR-US, V118, P509, DOI 10.1016/S0022-3476(05)83370-0; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	41	131	138	1	43	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					471	478		10.1067/mai.2003.172	http://dx.doi.org/10.1067/mai.2003.172			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642824				2022-12-18	WOS:000181639500005
J	Ortolani, C; Ballmer-Weber, BK; Hansen, KS; Ispano, M; Wuthrich, B; Bindslev-Jensen, C; Ansaloni, R; Vannucci, L; Pravettoni, V; Scibilia, J; Poulsen, LK; Pastorello, EA				Ortolani, C; Ballmer-Weber, BK; Hansen, KS; Ispano, M; Wuthrich, B; Bindslev-Jensen, C; Ansaloni, R; Vannucci, L; Pravettoni, V; Scibilia, J; Poulsen, LK; Pastorello, EA			Hazelnut allergy: A double-blind, placebo-controlled food challenge multicenter study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; hypersensitivity; oral allergy syndrome; double-blind; placebo-controlled food challenge; hazelnut allergy	HYPERSENSITIVITY; CHILDREN; PEANUT; APPLE	Background: Tree nuts are a common cause of food allergy in Europe. However, few studies deal with real food allergy to hazelnuts in subjects believed to be allergic to this food. Objective: We sought to select subjects with a history of allergic reactions on ingestion of hazelnut and determine how many of these have true allergy by means of the double-blind, placebo-controlled food challenge (DBPCFC), Methods: Eighty-six subjects with a history of symptoms after hazelnut ingestion were recruited from 3 allergy centers (Milan, Zurich, and Copenhagen). All subjects underwent skin prick tests (SPTs) with aeroallergens and hazelnut, as well as having their specific hazelnut IgE levels determined. Diagnosis of clinical relevant food allergy Mas made on the basis of the DBPCFC. Results: Sixty-seven (77.9%) of 86 subjects had a positive DBPCFC result: 8 were placebo responders, and II were non-responders. Of the 11 nonresponders, 4 had positive open-challenge test results. Of the DBPCFC-positive subjects, 87% also had positive skin test responses to birch pollen extract. Specific IgE determination for hazelnut ((positive CAP response 0.7 kU/L, [ie, class 2]) showed a sensitivity of 0.75, a positive predictive value (PPV) of 0.92, a specificity of 0.16, and a negative predictive value (NPV) of 0.05. Skin tests with commercial hazelnut extract produced a sensitivity of 0.89, a PPV of 0.92, a specificity of 0.05, and an NPV of 0.05, Skin tests with natural food produced a sensitivity of 0.88, a PPV of 0.94, a specificity of 0.27, and an NPV of 0.15. Conclusion: This study shows that hazelnut is an allergenic source that can cause real food allergy, as confirmed by DBPCFC. Skin and IgE tests demonstrated reasonable sensitivity and PPV but a very lon specificity and NP); thus implying that these should not be used to validate the diagnosis of food allergy to hazelnut.	AO Niguarda Hosp, UO Med Gen 1, Milan, Italy; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Natl Univ Hosp, Allergy Unit, Copenhagen, Denmark; Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark; Univ Milan, Ist Med Interna Malattie Infett & Immunol, Milan, Italy	University of Zurich; University Zurich Hospital; University of Southern Denmark; Odense University Hospital; University of Milan	Ortolani, C (corresponding author), Osped Niguarda Ca Granda, UO Med Gen Bizzozero 1, Piazza Osped Maggiore 3, I-20162 Milan, Italy.		Bindslev-Jensen, Carsten/H-1877-2011; SCIBILIA, GIUSEPPE/AAC-9673-2022; Poulsen, Lars K/J-3065-2019; PASTORELLO, ELIDE ANNA/E-3897-2017	Bindslev-Jensen, Carsten/0000-0002-8940-038X; SCIBILIA, GIUSEPPE/0000-0002-5452-4024; Poulsen, Lars K/0000-0002-1730-847X; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				[Anonymous], 1995, REP FAO TECHN CONS F; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; Bousquet J, 1998, ALLERGY, V53, P3, DOI 10.1111/j.1398-9995.1998.tb04987.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; deGroot H, 1996, ALLERGY, V51, P712; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Eriksson N., 1986, NORDIC AEROBIOLOGY, P66; Etesamifar M, 1998, ALLERGOLOGIE, V21, P451; Ewan PW, 1996, BRIT MED J, V312, P1074; Goldstein Laurence, 1987, PRINCIPLES INTERNAL, P5; HOFER T, 1985, SCHWEIZ MED WSCHR, V115, P1437; HOFFMANNSOMMERG.K, 1996, ADV EXPT MED BIOL, P219; Malmheden-Yman I., 1994, Food and Agricultural Immunology, V6, P167, DOI 10.1080/09540109409354827; MUHLEMANN RJ, 1991, SCHWEIZ MED WSCHR, V121, P1696; Noe D, 1998, ALLERGY, V53, P75, DOI 10.1111/j.1398-9995.1998.tb04967.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Ortolani C, 1999, ALLERGY, V54, P27, DOI 10.1034/j.1398-9995.1999.00913.x; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Sampson HA, 1993, ALLERGY PRINCIPLES P, VII, P1661; Steinman HA, 1996, J ALLERGY CLIN IMMUN, V98, P241, DOI 10.1016/S0091-6749(96)70146-X; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	25	131	137	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					577	581		10.1067/mai.2000.103052	http://dx.doi.org/10.1067/mai.2000.103052			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719310				2022-12-18	WOS:000088946700027
J	Holgate, ST				Holgate, ST			Genetic and environmental interaction in allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; genetics; IL-4 and IL-13; IL-4 and IL-13 receptors; leukotrienes	SERUM IGE LEVELS; LEUKOTRIENE C-4 SYNTHASE; GENOME-WIDE SEARCH; CYTOKINE PRODUCTION; IMMUNOGLOBULIN-E; LUNG-FUNCTION; PROMOTER; LINKAGE; CHILDREN; FAMILIES	Asthma is an inflammatory disorder of the airways involving coordinate up-regulation of T(H)2-type cytokines encoded in a cluster on chromosome 5q(31-33) on T Cells and inflammatory cells. There is also a requirement for local airway susceptibility factors that, together with T(H)2 polarization, results in hyperresponsiveness, variable airflow obstruction, and, over time, remodeling of the airway wall, Asthma has strong genetic and environmental components that interact both in the induction and subsequent expression of the disease phenotypes, Multiple genes are involved and probably interact. Whole genome screens are beginning to identify gene-rich regions of special relevance to asthma and atopy, although a novel disease-related gene has yet to be discovered from these. By contrast, there are a plethora of candidate genes whose function in relation to disease pathophysiologic mechanisms and response to treatment are known, Two examples are polymorphisms involving IL-4 receptors and the enzymes controlling cysteinyl Leukotriene production, Abnormal signaling between the epithelium, which is in contact with the environment, and the underlying (mgo)fibroblasts and dendritic cells indicating reactivation of the epithelial mesenchymal trophic unit, which is involved in fetal lung development and branching, provide a basis for asthma that encapsulates both T(H)2 polarization and airway wall remodeling.	Southampton Gen Hosp, Resp Cell & Mol Biol Div, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Southampton Gen Hosp, Resp Cell & Mol Biol Div, Level D,Ctr Block, Southampton SO16 6YD, Hants, England.							Anto J.M., 1998, EUROPIAN RESP J, V8, P159; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; BRITTON JR, 1995, AM J RESP CRIT CARE, V151, P1383, DOI 10.1164/ajrccm.151.5.7735589; Broughton KS, 1997, AM J CLIN NUTR, V65, P1011, DOI 10.1093/ajcn/65.4.1011; BRUNEKREEF B, 1998, EUR RESPIR REV, V8, P131; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Calder PC, 1997, ANN NUTR METAB, V41, P203, DOI 10.1159/000177997; Cook DG, 1997, THORAX, V52, P628, DOI 10.1136/thx.52.7.628; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dahlen SE, 1998, LUNG BIOL HEALTH DIS, V117, P679; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; DIZIER MH, 1995, GENET EPIDEMIOL, V12, P93, DOI 10.1002/gepi.1370120109; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; EVANS MJ, IN PRESS AM J RESP C; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GERRARD JW, 1976, ANN ALLERGY, V36, P10; HANSON B, 1991, AM J HUM GENET, V48, P873; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P449, DOI 10.1016/S0091-6749(98)70134-4; HODGE L, 1997, EUR RESPIR J, V11, P261; Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; HOLGATE ST, 1998, EUR RESPIR REV, V8, P1007; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Holt PG, 1999, CLIN EXP ALLERGY, V29, P8, DOI 10.1046/j.1365-2222.1999.00003.x-i2; HOPP RJ, 1988, ANN ALLERGY, V61, P184; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475; Krishna M. T., 1998, Reviews on Environmental Health, V13, P59; Kruse S, 1999, IMMUNOLOGY, V96, P365; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; Lee TH, 1998, J ROY COLL PHYS LOND, V32, P56; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lynch KR, 1999, NATURE, V399, P789; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Marsh DG, 1997, NAT GENET, V15, P389; MARTINEZ F, 1998, CLIN EXP ALLERGY   S, V28, P12; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; MEYERS DA, 1991, GENET EPIDEMIOL, V8, P351, DOI 10.1002/gepi.1370080507; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Richter LM, 1998, S AFR J PSYCHOL, V28, P1; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; SAMPSON AP, 1999, IN PRESS THORAX S; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154; Skadhauge LR, 1999, EUR RESPIR J, V13, P8, DOI 10.1183/09031936.99.13100899; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Strachan DP, 1999, ALLERGY, V54, P7, DOI 10.1111/j.1398-9995.1999.tb04381.x; THIEN FCK, 1993, AM REV RESPIR DIS, V147, P1138, DOI 10.1164/ajrccm/147.5.1138; THIEN FCK, 1992, J ALLERGY CLIN IMMUN, V89, P829, DOI 10.1016/0091-6749(92)90438-8; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401, DOI 10.1164/ajrccm.151.5.7735592; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45; Wang HY, 1999, J IMMUNOL, V162, P4385; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; WUTHRICH B, 1981, CLIN ALLERGY, V11, P147, DOI 10.1111/j.1365-2222.1981.tb01578.x; Zhang S, 1996, J PATHOL, V180, P95	72	131	143	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1139	1146		10.1016/S0091-6749(99)70005-9	http://dx.doi.org/10.1016/S0091-6749(99)70005-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588993	Bronze, Green Published			2022-12-18	WOS:000084289200004
J	Villaran, C; O'Neill, SJ; Helbling, A; van Noord, JA; Lee, TH; Chuchalin, AG; Langley, SJ; Gunawardena, KA; Suskovic, S; Laurenzi, M; Jasan, J; Menten, J; Leff, JA				Villaran, C; O'Neill, SJ; Helbling, A; van Noord, JA; Lee, TH; Chuchalin, AG; Langley, SJ; Gunawardena, KA; Suskovic, S; Laurenzi, M; Jasan, J; Menten, J; Leff, JA		Montelukast Salmeterol Exercise Study Grp	Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tolerance; tachyphylaxis; leukotrienes; montelukast; salmeterol; exercise-induced asthma	LEUKOTRIENE-RECEPTOR ANTAGONIST; DOUBLE-BLIND TRIAL; 14-YEAR-OLD CHILDREN; INDUCED BRONCHOSPASM; MILD ASTHMA; TOLERANCE; PROTECTION; METHACHOLINE; INHIBITION	Background: Montelukast, a leukotriene receptor antagonist, and salmeterol, a long-acting beta(2)-receptor agonist, each have demonstrated benefits in the treatment of exercise-induced bronchoconstriction (EIB) in short-term studies. Direct comparisons between these agents in long-term studies are limited. Objective: We sought to compare montelukast and salmeterol in the long-term treatment of EIB. Methods: One hundred ninety-seven patients with mild asthma and a postexercise fall in FEV1 of at least 18% were randomized (double-blind) to receive montelukast 10 mg once daily or salmeterol 50 mu g twice daily for 8 weeks. Exercise challenge was repeated at day 3, week 4, and week 8 after randomization near the end of the dosing interval for both drugs. The primary efficacy endpoint was the maximal percent fall in postexercise FEV1 at week 8. Results: Montelukast was effective in treating EIB without inducing tolerance and provided superior (P less than or equal to .001) protection than salmeterol at weeks 4 and 8, with comparable protection at day 3. The frequency of respiratory clinical adverse events (P = .046) and discontinuations because of clinical adverse events (P = .052) were less with montelukast. Conclusion: The effect of montelukast was greater than that of salmeterol in the chronic treatment of EIB over a period of 8 weeks in patients with mild asthma as demonstrated by effect size, maintenance of effect, and fewer respiratory clinical adverse events during the study period. Montelukast may be a better alternative to salmeterol as a controller agent for the chronic treatment of EIB.	Merck & Co Inc, Whitehouse Stn, NJ 08889 USA; Clin Ricardo Palma, Lima, Peru; Beaumont Hosp, Dublin 9, Ireland; Univ Bern, Allergol Immunol Policlin, Bern, Switzerland; Hosp Wever & Gregorius, Heerlen, Netherlands; Guys Hosp, Dept Allergy & Resp Med, London SE1 9RT, England; Res Inst Pulm, Moscow, Russia; Wythenshawe Hosp, N W Lung Res Ctr, Manchester, England; Inst Lung Dis & TB Golnik, Ljubljana, Slovenia; Merck & Co Inc, Whitehouse Stn, NJ USA	Merck & Company; University of Bern; Guy's & St Thomas' NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University Clinic Golnik; Merck & Company	Leff, JA (corresponding author), Merck & Co Inc, One Merck Dr,POB 100,WS2BC-25, Whitehouse Stn, NJ 08889 USA.		Goriachkina, Ludmila/J-8799-2014; Lee, Tak/AAA-9526-2020; Cucalin, Aleksandr/P-5678-2018	Goriachkina, Ludmila/0000-0002-5138-1240; Lee, Tak/0000-0002-7554-4059; Cucalin, Aleksandr/0000-0002-6808-5528				Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; ANDERSON SD, 1985, CHEST, V87, pS191, DOI 10.1378/chest.87.5_Supplement.191S; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Booth H, 1996, THORAX, V51, P1100, DOI 10.1136/thx.51.11.1100; Bray GA, 1999, DIABETES CARE, V22, P623; Bronsky EA, 1997, CLIN PHARMACOL THER, V62, P556, DOI 10.1016/S0009-9236(97)90051-5; DENTE FL, 1997, AM J RESP CRIT CARE, V155, pA344; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; Drotar DE, 1998, ANN ALLERG ASTHMA IM, V80, P31, DOI 10.1016/S1081-1206(10)62935-3; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V63, P104, DOI 10.1016/0091-6749(79)90199-4; FREEZER NJ, 1995, EUR RESPIR J, V8, P1488; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Knorr B. A., 1997, European Respiratory Journal Supplement, V10, p219S; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MCFADDEN ER, 1987, CHEST, V91, pS151, DOI 10.1378/chest.91.6.151S; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; PIZZICHINI E, IN PRESS EUR RESP RE; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Reiss T. F., 1997, European Respiratory Journal Supplement, V10, p437S; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; TURPIN JA, 1998, AM J RESP CRIT CARE, V157, pA456; WILLIAMS J, 1996, AM J RESP CRIT CAR S, V153, pA803; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342; YATES DH, 1995, AM J RESP CRIT CARE, V152, P1170, DOI 10.1164/ajrccm.152.4.7551366	34	131	136	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				547	553		10.1016/S0091-6749(99)70322-2	http://dx.doi.org/10.1016/S0091-6749(99)70322-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482826				2022-12-18	WOS:000082870000014
J	Abuaf, N; Rajoely, B; Ghazouani, E; Levy, DA; Pecquet, C; Chabane, H; Leynadier, F				Abuaf, N; Rajoely, B; Ghazouani, E; Levy, DA; Pecquet, C; Chabane, H; Leynadier, F			Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						myorelaxant drugs; anaphylactic reactions; drug allergy; basophils; surface molecules; flow cytometry	CROSS-REACTIVITY; DRUGS; IGE; RADIOIMMUNOASSAY; ANAPHYLAXIS; PLATELETS; ANTIBODY	Background: Anaphylactic reactions during anesthesia are mainly the result of muscle-relaxant (MR) drugs. Skin tests, serologic detection of specific IgE, and in vitro leukocyte histamine release are used to investigate MR allergy. Objective: We describe a new assay that is based on the detection, by flow cytometry of the altered expression of plasma membrane molecules of MR-activated basophils. Methods: For this assay, which we have named the BASIC assay, basophils are incubated in vitro with MR, after which they are fixed and then triple labeled with fluorescein-conjugated anti-CD63, tandem dye R-phycoerythrin-cyanin 5.1 conjugated anti-CD45, and R-phycoerythrin conjugated anti-IgE. The resulting Basophils' Altered Surface Immunofluorescence is detected by flow Cytometry (BASIC). Results: Forty-one patients who had an allergic reaction during general anesthesia and 23 control subjects without such a history were studied. All included subjects' basophils were tested in the BASIC assay with at least 4 MR: suxamethonium, gallamine, vecuronium, and pancuronium. After reaction of the basophils of the MR-allergic patients with MRs, increased surface expression of CD63 and CD45 and decreased expression of IgE were detected. Increased expression of CD63 was observed most frequently and it was stronger than the alteration of the 2 other markers. Cross-reactivity between MRs commonly occurred. MRs diluted 10(-1) activate the basophils of the control subjects, suggesting that at relatively high concentrations MRs are also nonspecific basophil activators. Conclusion: In the diagnosis of MR allergy, the BASIC assay has a good specificity but a low sensitivity, and it correlates strongly with skin test results. It is currently appraised for the diagnosis of anaphylactic reaction induced by other classes of drugs.	Univ Paris 06, Ctr Hosp Univ St Antoine, Hop Rothschild Assistance Publ, Serv Immunol & Hematol Biol, Paris, France; Univ Paris 06, Ctr Hosp Univ St Antoine, Hop Rothschild Assistance Publ, Serv Med Interne & Allergol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Abuaf, N (corresponding author), Hop Rothschild, Serv Immunol & Hematol, 33 Blvd Picpus, F-75571 Paris 12, France.			Abuaf, Nisen/0000-0002-1277-0593				Altin JG, 1997, IMMUNOL CELL BIOL, V75, P430, DOI 10.1038/icb.1997.68; BALDO BA, 1983, MOL IMMUNOL, V20, P1393, DOI 10.1016/0161-5890(83)90171-2; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; BALDO BA, 1994, CHEM RES TOXICOL, V7, P703, DOI 10.1021/tx00042a001; BOCHNER BS, 1989, J IMMUNOL, V142, P3180; BOCHNER BS, 1991, J IMMUNOL, V146, P2367; GANE P, 1993, CYTOMETRY, V14, P344, DOI 10.1002/cyto.990140316; GANE P, 1995, CYTOMETRY, V19, P361, DOI 10.1002/cyto.990190411; GUEANT JL, 1991, ALLERGY, V46, P452; HALONEN M, 1975, J IMMUNOL, V115, P519; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Leynadier F., 1996, Journal of Allergy and Clinical Immunology, V97, P344, DOI 10.1016/S0091-6749(96)80865-7; LEYNADIER F, 1991, INT ARCH ALLER A IMM, V94, P349, DOI 10.1159/000235400; MATA E, 1992, ALLERGY, V47, P471, DOI 10.1111/j.1398-9995.1992.tb00667.x; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; Moneret-Vautrin D A, 1985, Ann Fr Anesth Reanim, V4, P186, DOI 10.1016/S0750-7658(85)80198-2; Moneret-Vautrin D A, 1987, Ann Fr Anesth Reanim, V6, P352, DOI 10.1016/S0750-7658(87)80059-X; PORRI F, 1995, ALLERGY, V50, P374, DOI 10.1111/j.1398-9995.1995.tb01164.x; REID TMS, 1992, MONOGR ALLERGY, V30, P162	19	131	135	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				411	418		10.1016/S0091-6749(99)70386-6	http://dx.doi.org/10.1016/S0091-6749(99)70386-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452764				2022-12-18	WOS:000082364800035
J	Hermes, B; Prochazka, AK; Haas, N; Jurgovsky, K; Sticherling, M; Henz, BM				Hermes, B; Prochazka, AK; Haas, N; Jurgovsky, K; Sticherling, M; Henz, BM			Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urticaria; IL-3; TNF; IL-8; cytokines; mast cells; endothelial cells; keratinocytes	COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; DELAYED PRESSURE URTICARIA; MESSENGER-RNA EXPRESSION; MAST-CELLS; P-SELECTIN; ACTIVATING-FACTOR; DIFFERENT FORMS; ATOPIC SUBJECTS; NASAL-MUCOSA	Background: Although mast cells are known to secrete a broad spectrum of proinflammatory and immunomodulatory cytokines, the role of these molecules in mast cell-dependent cutaneous inflammation is not clear. Objective: We decided to study biopsy specimens from lesional and nonlesional skin of patients with acute, chronic recurrent, delayed pressure, and cold urticaria; from fleeting wheals of prick test reactions to allergens; and from normal skin of nonallergic subjects. Methods: Cryostat sections were stained by immunohistochemistry with antibodies against IL-3, IL-8, TNF-alpha, and mast cell-specific tryptase. In serial sections with tryptase and each cytokine, reactivity of mast cells was studied as well. Results: Compared with normal skin and prick test reactions, immunoreactivity for TNF-alpha and IL-3 was significantly increased on endothelial and perivascular cells of the upper dermis in all urticaria lesions, In nonlesional skin comparable upregulation was noted on endothelial cells and for TNF-alpha on perivascular cells of patients with delayed pressure urticaria. In addition, TNF-alpha was expressed throughout the epidermis in lesional and nonlesional skin of patients with all types of urticaria, but not in normal control subjects. Sequential biopsy specimens from patients with cold urticaria shelved upregulation of TNF-alpha and IL-3 on endothelial cells 30 minutes after elicitation of lesions with an ice cube. In contrast to these findings, epidermal immunoreactivity, as well as endothelial and perivascular cell expression of IL-8, were only slightly altered in urticaria compared with normal skin. In sequentially stained sections, few tryptase-positive mast cells reacted to TNF-alpha, few reacted to IL-3 in pressure urticaria only, and practically none stained for IL-8. Conclusion: These findings suggest that the cytokines studied here are involved in the pathology of urticaria, possibly by inducing subthreshold inflammation in endothelial cells of uninvolved skin.	Humboldt Univ, Charite, Dept Dermatol, D-13344 Berlin, Germany; Neukolln Hosp, Berlin, Germany; Univ Hosp, Kiel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Schleswig Holstein University Hospital	Henz, BM (corresponding author), Humboldt Univ, Charite, Dept Dermatol, Campus Virchow Klinikum,Augustenburgerpl 1, D-13344 Berlin, Germany.							Algermissen B, 1994, Exp Dermatol, V3, P290, DOI 10.1111/j.1600-0625.1994.tb00291.x; BARLOW RJ, 1994, BRIT J DERMATOL, V131, P341, DOI 10.1111/j.1365-2133.1994.tb08521.x; Becherel PA, 1997, J IMMUNOL, V159, P5761; Becherel PA, 1997, MOL MED, V3, P686, DOI 10.1007/BF03401707; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRESSLER RB, 1995, IMMUNOL ALLERGY CLIN, V15, P659; CZARNETZKI BM, 1989, J INVEST DERMATOL, V93, P471, DOI 10.1111/1523-1747.ep12284036; Douglass J, 1996, CLIN EXP ALLERGY, V26, P1371, DOI 10.1046/j.1365-2222.1996.d01-291.x; DURHAM SR, 1992, J IMMUNOL, V148, P2390; ERGER RA, 1995, AM J PHYSIOL-LUNG C, V268, pL117, DOI 10.1152/ajplung.1995.268.1.L117; GABOURY JP, 1995, J IMMUNOL, V154, P804; Haas N, 1996, INT ARCH ALLERGY IMM, V109, P177, DOI 10.1159/000237217; HAAS N, 1995, ARCH DERMATOL RES, V287, P180, DOI 10.1007/BF01262329; HAAS N, 1995, BRIT J DERMATOL, V133, P48; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; Haas N, 1998, INT ARCH ALLERGY IMM, V115, P210, DOI 10.1159/000023902; HENZ BM, 1997, URTICARIA CLIN DIAGN; HORSMANHEIMO L, 1994, BRIT J DERMATOL, V131, P348, DOI 10.1111/j.1365-2133.1994.tb08522.x; Kano Y, 1998, ARCH DERMATOL, V134, P62, DOI 10.1001/archderm.134.1.62; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KhewGoodall Y, 1996, BLOOD, V87, P1432, DOI 10.1182/blood.V87.4.1432.bloodjournal8741432; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LAWLOR F, 1993, BRIT J DERMATOL, V128, P500, DOI 10.1111/j.1365-2133.1993.tb00225.x; Lippert U, 1998, J IMMUNOL, V161, P2600; LUGER TA, 1997, SKIN IMMUNE SYSTEM, P271; MacLeod JDA, 1997, CLIN EXP ALLERGY, V27, P1328; Miyamasu M, 1997, ALLERGY, V52, P317, DOI 10.1111/j.1398-9995.1997.tb00997.x; Moller A, 1998, IMMUNOLOGY, V93, P289; MOLLER A, 1993, J IMMUNOL, V151, P3261; Okada S, 1997, AM J RESP CELL MOL, V16, P455, DOI 10.1165/ajrcmb.16.4.9115757; Park HS, 1997, EUR RESPIR J, V10, P1476, DOI 10.1183/09031936.97.10071476; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; SCHADENDORF D, 1991, J INVEST DERMATOL, V97, P549, DOI 10.1111/1523-1747.ep12481884; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SCHRODER JM, 1995, CLIN DERMATOL, V13, P137, DOI 10.1016/0738-081X(95)93820-E; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; STICHERLING M, 1991, J INVEST DERMATOL, V96, P26, DOI 10.1111/1523-1747.ep12514689; THORLACIUS H, 1994, BIOCHEM BIOPH RES CO, V203, P1043, DOI 10.1006/bbrc.1994.2287; Toppe E, 1998, BRIT J DERMATOL, V138, P248; VANOVERVELD FJ, 1991, CLIN EXP ALLERGY, V21, P711; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Yousefi S, 1997, INT ARCH ALLERGY IMM, V112, P9, DOI 10.1159/000237424; Zuberbier T, 1997, INT ARCH ALLERGY IMM, V114, P86, DOI 10.1159/000237648	48	131	138	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				307	314		10.1016/S0091-6749(99)70506-3	http://dx.doi.org/10.1016/S0091-6749(99)70506-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949323	Bronze			2022-12-18	WOS:000078630100019
J	Cicardi, M; Castelli, R; Zingale, LC; Agostoni, A				Cicardi, M; Castelli, R; Zingale, LC; Agostoni, A			Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: Comparison of treated and untreated patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DANAZOL; EDEMA		UNIV MILAN,IST MED INTERNA,OSPED MAGGIORE,IST RICOVERA & CURA CARATTERE SCI,I-20122 MILAN,ITALY	University of Milan			cicardi, marco/K-9219-2016; Castelli, Roberto/ABC-9973-2020; Zingale, Lorenza Chiara/AAB-8598-2020	cicardi, marco/0000-0003-1251-225X; Zingale, Lorenza Chiara/0000-0001-8577-7449; castelli, roberto/0000-0003-3976-7690				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CICARDI M, 1991, J ALLERGY CLIN IMMUN, V87, P768, DOI 10.1016/0091-6749(91)90120-D; CICARDI M, 1983, J ALLERGY CLIN IMMUN, V72, P294, DOI 10.1016/0091-6749(83)90034-9; CICARDI M, 1995, TRANSFUSION, V35, P209, DOI 10.1046/j.1537-2995.1995.35395184276.x; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; HOOGERBRUGGE N, 1995, J INTERN MED, V237, P603; KAHN H, 1991, ARCH PATHOL LAB MED, V115, P1054; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; STEWART JM, 1995, BIOPOLYMERS, V37, P143, DOI 10.1002/bip.360370208; ZURLO JJ, 1990, FERTIL STERIL, V54, P64	11	131	134	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					194	196		10.1016/S0091-6749(97)70095-2	http://dx.doi.org/10.1016/S0091-6749(97)70095-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042044	Bronze			2022-12-18	WOS:A1997WH83100007
J	VANDERLINDEN, PWG; HACK, CE; POORTMAN, J; VIVIEKIPP, YC; STRUYVENBERG, A; VANDERZWAN, JK				VANDERLINDEN, PWG; HACK, CE; POORTMAN, J; VIVIEKIPP, YC; STRUYVENBERG, A; VANDERZWAN, JK			INSECT-STING CHALLENGE IN 138 PATIENTS - RELATION BETWEEN CLINICAL SEVERITY OF ANAPHYLAXIS AND MAST-CELL ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANAPHYLAXIS; IMMEDIATE HYPERSENSITIVITY; HYMENOPTERA VENOM; INSECT STING; MAST CELL; TRYPTASE; HISTAMINE; PROSTAGLANDIN-D2	TRYPTASE; VENOM; HISTAMINE; HYPERSENSITIVITY; SENSITIVITY; MECHANISMS; MEDIATOR; IGE	One hundred thirty-eight patients with a previous anaphylactic reaction to a yellow jacket or a honeybee sting, as well as eight volunteers, were subjected to an in-hospital sting challenge. Plasma levels of histamine, tryptase, and prostaglandin D2 (PGD2) during sting challenge were studied in relation to clinical symptoms. Prechallenge levels (mean +/- SD) of histamine, tryptase, and PGD2 were 2 +/- 1 nmol/L, 0.3 +/- 0.3 U/L, and 320 +/- 223 ng/L, respectively. In the volunteers and in none except for one of the nonreacting patients, these levels did not change significantly after challenge. In contrast, mean increases in the group of 18 patients with a mild reaction were significant for histamine and tryptase at one or more time points after the challenge. (Five patients demonstrated no increase in histamine; nine demonstrated no increase in tryptase.) Except for histamine levels in one patient, these increases were considerably more in all 17 patients with a severe reaction, starting from the first anaphylactic symptoms. Fifteen minutes later, peak values were reached of 1275 +/- 2994 nmol of histamine per liter (range, 3 to 12800 nmol/L; median, 11 nmol/L) and 406 +/- 1062 U of tryptase per liter (range, 1.8 to 4400 U/L; median, 17 U/L). This rise in levels inversely correlated with the mean arterial pressure. Plasma levels of PGD2 in severely reacting patients did not differ significantly from those in patients with a mild or no reaction. In conclusion, only 28% of patients with a history of Hymenoptera anaphylaxis developed an anaphylactic reaction after an in-hospital challenge. The clinical severity of these reactions correlated with the level of systemically released, preformed histamine and tryptase, but not of PGD2.	LICHTENBERG HOSP, DEPT CLIN CHEM, 3818 ES AMERSFOORT, NETHERLANDS; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT AUTOIMMUNE DIS, AMSTERDAM, NETHERLANDS; UNIV UTRECHT HOSP, DEPT INTERNAL MED, 3511 GV UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center	VANDERLINDEN, PWG (corresponding author), LICHTENBERG HOSP, DEPT INTERNAL MED, UTRECHTSWEG 160, 3818 ES AMERSFOORT, NETHERLANDS.		Levi, Marcel/AAZ-8559-2020					ALTER SC, 1989, PROVOCATIVE CHALLENG, P167; ATKINS PC, 1990, J ALLERGY CLIN IMMUN, V86, P360, DOI 10.1016/S0091-6749(05)80099-5; BENYON RC, 1989, CLIN EXP ALLERGY, V19, P375, DOI 10.1111/j.1365-2222.1989.tb02402.x; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; CLAYTON WF, 1985, CLIN ALLERGY, V15, P329, DOI 10.1111/j.1365-2222.1985.tb03000.x; DELBALZO U, 1988, J PHARMACOL EXP THER, V246, P911; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LEVI R, 1988, HUMAN INFLAMMATORY D, V1, P93; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; LOMNITZER R, 1988, CLIN ALLERGY, V18, P39, DOI 10.1111/j.1365-2222.1988.tb02841.x; MILLER JS, 1989, CURR OPIN IMMUNOL, V1, P637, DOI 10.1016/0952-7915(89)90033-2; Mueller H L, 1966, J Asthma Res, V3, P331; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PAVEK K, 1982, KLIN WOCHENSCHR, V60, P941, DOI 10.1007/BF01716952; POITIER P, 1902, CR SOC BIOL, V54, P170; RATNOFF OD, 1983, BLOOD, V61, P132; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1987, ANN ALLERGY, V59, P429; SCHELLENBERG RR, 1991, J ALLERGY CLIN IMMUN, V87, P499, DOI 10.1016/0091-6749(91)90008-C; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANE JR, 1990, NEW ENGL J MED, V323, P27; VOGT W, 1986, Complement, V3, P177; WASSERMAN SI, 1990, J ALLERGY CLIN IMMUN, V86, P590, DOI 10.1016/S0091-6749(05)80221-0; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4	35	131	131	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					110	118		10.1016/S0091-6749(06)80017-5	http://dx.doi.org/10.1016/S0091-6749(06)80017-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629497				2022-12-18	WOS:A1992JE25500013
J	TOOGOOD, JH; BASKERVILLE, J; JENNINGS, B; LEFCOE, NM; JOHANSSON, SA				TOOGOOD, JH; BASKERVILLE, J; JENNINGS, B; LEFCOE, NM; JOHANSSON, SA			BIOEQUIVALENT DOSES OF BUDESONIDE AND PREDNISONE IN MODERATE AND SEVERE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO, DEPT STAT & ACTUARIAL SCI, STATLAB, LONDON N6A 3K7, ONTARIO, CANADA; AB DRACO, S-22101 LUND, SWEDEN	Western University (University of Western Ontario)	TOOGOOD, JH (corresponding author), VICTORIA HOSP, ALLERGY CLIN, DEPT MED, 375 S ST, LONDON N6A 4G5, ONTARIO, CANADA.							ADELROTH E, 1985, ALLERGY, V40, P58, DOI 10.1111/j.1398-9995.1985.tb04155.x; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; BARAN D, 1987, BRIT J DIS CHEST, V81, P170, DOI 10.1016/0007-0971(87)90135-5; BLACK R L, 1957, J Chronic Dis, V5, P751, DOI 10.1016/0021-9681(57)90082-6; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CHESNEY RW, 1978, AM J DIS CHILD, V132, P768, DOI 10.1001/archpedi.1978.02120330040010; CRILLY RG, 1983, INT C S SERIES, V55, P153; CROMPTON GK, 1987, BRIT MED J, V294, P123, DOI 10.1136/bmj.294.6564.123-a; EBDEN P, 1984, LANCET, V2, P576; EKENSTAM EA, 1986, ANN RHEUM DIS, V45, P484, DOI 10.1136/ard.45.6.484; GAMBERTOGLIO JG, 1980, J CLIN ENDOCR METAB, V51, P561, DOI 10.1210/jcem-51-3-561; GENNARI C, 1984, HORM RES, V20, P13, DOI 10.1159/000179970; GORDON ACH, 1987, EUR J RESPIR DIS, V71, P10; GRANT IWB, 1983, BRIT MED J, V286, P644, DOI 10.1136/bmj.286.6365.644-e; GREENBERGER PA, 1982, CLIN ALLERGY, V12, P363, DOI 10.1111/j.1365-2222.1982.tb02540.x; GRIECO MH, 1978, ARCH INTERN MED, V138, P1337, DOI 10.1001/archinte.138.9.1337; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762; KOZOWER M, 1974, J CLIN ENDOCR METAB, V38, P407, DOI 10.1210/jcem-38-3-407; LEKKERKE.JF, 1972, ACTA ENDOCRINOL-COP, V69, P488, DOI 10.1530/acta.0.0690488; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; MAUNSELL K, 1968, BMJ-BRIT MED J, V1, P661, DOI 10.1136/bmj.1.5593.661; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; NEWMAN SP, 1983, STEROIDS ASTHMA REAP, P210; PEDERSEN S, 1987, EUR J CLIN PHARMACOL, V31, P579, DOI 10.1007/BF00606634; PRAHL P, 1987, ALLERGY, V42, P541, DOI 10.1111/j.1398-9995.1987.tb00379.x; RAISZ LG, 1988, NEW ENGL J MED, V318, P818; REES HA, 1962, BMJ-BRIT MED J, P1575, DOI 10.1136/bmj.1.5292.1575; REID DM, 1982, BMJ-BRIT MED J, V285, P330, DOI 10.1136/bmj.285.6338.330; REID DM, 1986, BMJ-BRIT MED J, V293, P1463, DOI 10.1136/bmj.293.6560.1463; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P379, DOI 10.1016/0091-6749(80)90117-7; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; SMYLLIE HC, 1968, THORAX, V23, P571, DOI 10.1136/thx.23.6.571; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; TOOGOOD JH, 1988, AM REV RESPIR DIS, V138, P57, DOI 10.1164/ajrccm/138.1.57; TOOGOOD JH, 1973, CHEST, V63, P881, DOI 10.1378/chest.63.6.881; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, 1985, BRONCHIAL ASTHMA MEC, P698; TOOGOOD JH, 1984, ANN R COLL PHYS SURG, V17, P297; TUKIAINEN P, 1987, EUR J RESPIR DIS, V70, P239	44	131	132	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				688	700		10.1016/0091-6749(89)90297-2	http://dx.doi.org/10.1016/0091-6749(89)90297-2			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2681331	Bronze			2022-12-18	WOS:A1989CA31400006
J	Egawa, G; Kabashima, K				Egawa, Gyohei; Kabashima, Kenji			Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; barrier function; stratum corneum; corneocytes; cornified envelope; tight junction; filaggrin; lipid	OF-FUNCTION MUTATIONS; SPINK5 GENE POLYMORPHISMS; GENOME-WIDE ASSOCIATION; STRATUM-CORNEUM; EPIDERMAL BARRIER; ICHTHYOSIS VULGARIS; PREDISPOSING FACTOR; MOLECULAR ANALYSIS; TRANSGLUTAMINASE 1; FUNCTION VARIANTS	Atopic dermatitis (AD) is the most common inflammatory skin disease in the industrialized world and has multiple causes. Over the past decade, data from both experimental models and patients have highlighted the primary pathogenic role of skin barrier deficiency in patients with AD. Increased access of environmental agents into the skin results in chronic inflammation and contributes to the systemic "atopic (allergic) march.'' In addition, persistent skin inflammation further attenuates skin barrier function, resulting in a positive feedback loop between the skin epithelium and the immune system that drives pathology. Understanding the mechanisms of skin barrier maintenance is essential for improving management of AD and limiting downstream atopic manifestations. In this article we review the latest developments in our understanding of the pathomechanisms of skin barrier deficiency, with a particular focus on the formation of the stratum corneum, the outermost layer of the skin, which contributes significantly to skin barrier function.	[Egawa, Gyohei; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Kabashima, Kenji] ASTAR, Biopolis, Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Biopolis, Inst Med Biol, Singapore, Singapore; [Kabashima, Kenji] Japan Sci & Technol Agcy, PRESTO, Saitama, Japan	Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Japan Science & Technology Agency (JST)	Egawa, G; Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawahara, Kyoto 6068507, Japan.	gyohei@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	; Kabashima, Kenji/G-2521-2014	Egawa, Gyohei/0000-0002-6101-4719; Kabashima, Kenji/0000-0002-0773-0554	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [15H05790] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Aho S, 2004, MOL CELL BIOL, V24, P6410, DOI 10.1128/MCB.24.14.6410-6418.2004; Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; BLATTNER RJ, 1967, J PEDIATR-US, V70, P997, DOI 10.1016/S0022-3476(67)80277-4; Bognar P, 2014, J INVEST DERMATOL, V134, P105, DOI 10.1038/jid.2013.307; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; Carregaro F, 2013, ARCH DERMATOL RES, V305, P857, DOI 10.1007/s00403-013-1415-9; Cascella R, 2011, J INVEST DERMATOL, V131, P982, DOI 10.1038/jid.2010.398; Cassidy AJ, 2005, AM J HUM GENET, V77, P909, DOI 10.1086/497707; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chidgey M, 2001, J CELL BIOL, V155, P821, DOI 10.1083/jcb.200105009; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Juanes S, 2009, J INVEST DERMATOL, V129, P1429, DOI 10.1038/jid.2008.410; Deraison C, 2007, MOL BIOL CELL, V18, P3607, DOI 10.1091/mbc.E07-02-0124; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Djian P, 2000, J CELL BIOL, V151, P381, DOI 10.1083/jcb.151.2.381; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Eckert RL, 2005, J INVEST DERMATOL, V124, P481, DOI 10.1111/j.0022-202X.2005.23627.x; Eckl KM, 2009, J INVEST DERMATOL, V129, P1421, DOI 10.1038/jid.2008.409; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Elias PM, 2009, CURR ALLERGY ASTHM R, V9, P265, DOI [10.1007/s11882-009-0037-y, 10.1097/ACI.0b013e32832e7d36]; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gibbs NK, 2008, PHOTOCH PHOTOBIO SCI, V7, P655, DOI 10.1039/b717398a; Grether-Beck S, 2012, J INVEST DERMATOL, V132, P1561, DOI 10.1038/jid.2012.42; Hachem JP, 2005, J INVEST DERMATOL, V125, P510, DOI 10.1111/j.0022-202X.2005.23838.x; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Hoffman EP, 2011, AM J PATHOL, V179, P12, DOI 10.1016/j.ajpath.2011.03.050; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Hoste E, 2011, J INVEST DERMATOL, V131, P2233, DOI 10.1038/jid.2011.153; Hou MH, 2013, EXP DERMATOL, V22, P210, DOI 10.1111/exd.12102; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Iwai I, 2012, J INVEST DERMATOL, V132, P2215, DOI 10.1038/jid.2012.43; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kalinin A, 2001, J CELL SCI, V114, P3069; Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kelsell DP, 2005, AM J HUM GENET, V76, P794; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kim H, 2012, BRIT J NUTR, V108, P1726, DOI 10.1017/S0007114511007306; Kirschner N, 2010, EUR J CELL BIOL, V89, P839, DOI 10.1016/j.ejcb.2010.07.010; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Krieg P, 2014, BBA-MOL CELL BIOL L, V1841, P390, DOI 10.1016/j.bbalip.2013.08.005; Krieg P, 2013, J INVEST DERMATOL, V133, P172, DOI 10.1038/jid.2012.250; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Laiho E, 1997, AM J HUM GENET, V61, P529, DOI 10.1086/515498; Leclerc EA, 2009, J CELL SCI, V122, P2699, DOI 10.1242/jcs.050302; Lee JH, 2011, J ALLERGY CLIN IMMUN, V128, P1326, DOI 10.1016/j.jaci.2011.06.036; Levin Jacquelyn, 2013, J Clin Aesthet Dermatol, V6, P37; Levin Jacquelyn, 2013, J Clin Aesthet Dermatol, V6, P16; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; Lieden A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049694; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; LYNCH FW, 1945, ARCH DERMATOL SYPH, V51, P129, DOI 10.1001/archderm.1945.01510200053009; Maatta A, 2001, MOL CELL BIOL, V21, P7047, DOI 10.1128/MCB.21.20.7047-7053.2001; Malik V, 2010, ANN NEUROL, V67, P771, DOI 10.1002/ana.22024; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Masukawa Y, 2008, J LIPID RES, V49, P1466, DOI 10.1194/jlr.M800014-JLR200; Matsui T, 2015, INT IMMUNOL, V27, P269, DOI 10.1093/intimm/dxv013; Matsui T, 2011, EMBO MOL MED, V3, P320, DOI 10.1002/emmm.201100140; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Nachat R, 2005, J INVEST DERMATOL, V124, P384, DOI 10.1111/j.0022-202X.2004.23568.x; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Nakamizo S, 2015, SEMIN IMMUNOPATHOL, V37, P73, DOI 10.1007/s00281-014-0452-6; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Otberg N, 2008, BRIT J CLIN PHARMACO, V65, P488, DOI 10.1111/j.1365-2125.2007.03065.x; Otsuka A, 2014, J ALLERGY CLIN IMMUN, V133, P139, DOI 10.1016/j.jaci.2013.07.027; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Rippke F, 2004, AM J CLIN DERMATOL, V5, P217, DOI 10.2165/00128071-200405040-00002; Ruiz P, 1998, TRENDS CARDIOVAS MED, V8, P97, DOI 10.1016/S1050-1738(97)00141-2; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sasaki T, 2014, J DERMATOL SCI, V76, P10, DOI 10.1016/j.jdermsci.2014.06.004; Sasaki T, 2013, J ALLERGY CLIN IMMUN, V132, P1111, DOI 10.1016/j.jaci.2013.08.027; Saunders SP, 2016, J ALLERGY CLIN IMMUN, V137, P482, DOI 10.1016/j.jaci.2015.06.045; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Seltmann J, 2015, J ALLERGY CLIN IMMUN, V135, P1659, DOI 10.1016/j.jaci.2015.01.048; Sevilla LM, 2007, J CELL BIOL, V179, P1599, DOI 10.1083/jcb.200706187; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Sklyarova T, 2008, J INVEST DERMATOL, V128, P1375, DOI 10.1038/sj.jid.5701189; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Stefansson K, 2006, BIOL CHEM, V387, P761, DOI 10.1515/BC.2006.095; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thawer-Esmail F, 2014, J ALLERGY CLIN IMMUN, V133, P280, DOI 10.1016/j.jaci.2013.09.053; Vasilopoulos Y, 2011, J DERMATOL SCI, V61, P131, DOI 10.1016/j.jdermsci.2010.11.013; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x; Yanagi T, 2010, AM J PATHOL, V177, P106, DOI 10.2353/ajpath.2010.091120; Yang T, 2004, GENE DEV, V18, P2354, DOI 10.1101/gad.1232104; Yokouchi M, 2015, J DERMATOL SCI, V77, P28, DOI 10.1016/j.jdermsci.2014.11.007; Zhang C, 2012, CELLS TISSUES ORGANS, V196, P431, DOI 10.1159/000336268; Zhao LP, 2012, J EUR ACAD DERMATOL, V26, P572, DOI 10.1111/j.1468-3083.2011.04120.x	110	130	140	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					350	+		10.1016/j.jaci.2016.06.002	http://dx.doi.org/10.1016/j.jaci.2016.06.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27497277	Bronze			2022-12-18	WOS:000380835800003
J	Savenije, OE; John, JMM; Granell, R; Kerkhof, M; Dijk, FN; de Jongste, JC; Smit, HA; Brunekreef, B; Postma, DS; Van Steen, K; Henderson, J; Koppelman, GH				Savenije, Olga E.; John, Jestinah M. Mahachie; Granell, Raquel; Kerkhof, Marjan; Dijk, F. Nicole; de Jongste, Johan C.; Smit, Henriette A.; Brunekreef, Bert; Postma, Dirkje S.; Van Steen, Kristel; Henderson, John; Koppelman, Gerard H.			Association of IL33-IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL33-IL1RL1 pathway; asthma; wheezing phenotypes; children; IL1RL1; IL33; Avon Longitudinal Study of Parents and Children study; Prevalence and Incidence of Asthma and Mite Allergy study	GENOME-WIDE ASSOCIATION; 1ST 6 YEARS; GENETIC-VARIATION; BIRTH COHORT; DISEASE; ATOPY; IL-33; LIFE	Background: Genome-wide association studies identified IL33 and IL-1 receptor-like 1 (IL1RL1)/IL18R1 as asthma susceptibility loci. IL33 and IL1RL1 constitute a single ligand-receptor pathway. Objective: In 2 birth cohorts, the Prevalence and Incidence of Asthma and Mite Allergy (PIAMA) study and Avon Longitudinal Study of Parents and Children (ALSPAC), we analyzed associations of longitudinal wheezing phenotypes and asthma with single nucleotide polymorphisms (SNPs) of 8 genes encoding IL-33, IL1RL1, its coreceptor IL1RAcP, its adaptors myeloid differentiation primary response gene 88 (MyD88) and Toll-IL-11 receptor domain containing adaptor protein (TIRAP), and the downstream IL-1 receptor-associated kinase 1, IL-1 receptor-associated kinase 4, and TNF receptor-associated factor 6 (TRAF6). Furthermore, we investigated whether SNPs in this pathway show replicable evidence of gene-gene interaction. Methods: Ninety-four SNPs were investigated in 2007 children in the PIAMA study and 7247 children in ALSPAC. Associations with wheezing phenotypes and asthma at 8 years of age were analyzed in each cohort and subsequently meta-analyzed. Gene-gene interactions were assessed through model-based multifactor dimensionality reduction in the PIAMA study, and gene-gene interactions of 10 SNP pairs were further evaluated. Results: Intermediate-onset wheeze was associated with SNPs in several genes in the IL33-IL1RL1 pathway after applying multiple testing correction in the meta-analysis: 2 IL33 SNPs (rs4742170 and rs7037276), 1 IL-1 receptor accessory protein (IL1RAP) SNP (rs10513854), and 1 TRAF6 SNP (rs5030411). Late-onset wheeze was associated with 2 IL1RL1 SNPs (rs10208293 and rs13424006), and persistent wheeze was associated with 1 IL33 SNP (rs1342326) and 1 IL1RAP SNP (rs9290936). IL33 and IL1RL1 SNPs were nominally associated with asthma. Three SNP pairs showed interaction for asthma in the PIAMA study but not in ALSPAC. Conclusions: IL33-IL1RL1 pathway polymorphisms are associated with asthma and specific wheezing phenotypes; that is, most SNPs are associated with intermediate-onset wheeze, a phenotype closely associated with sensitization. We speculate that IL33-IL1RL1 pathway polymorphisms affect development of wheeze and subsequent asthma through sensitization in early childhood.	[Savenije, Olga E.; Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, GRIAC Res Inst, NL-9700 RB Groningen, Netherlands; [Savenije, Olga E.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Beatrix Childrens Hosp,GRIAC Res Inst, NL-9700 RB Groningen, Netherlands; [John, Jestinah M. Mahachie; Van Steen, Kristel] Univ Liege, Inst Montefiore, Syst & Modeling Unit, B-4000 Liege, Belgium; [John, Jestinah M. Mahachie; Van Steen, Kristel] Univ Liege, GIGA R, B-4000 Liege, Belgium; [Granell, Raquel; Henderson, John] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Dijk, F. Nicole; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp,GRIAC Res Inst, NL-9700 RB Groningen, Netherlands; [de Jongste, Johan C.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Resp Med, Rotterdam, Netherlands; [Smit, Henriette A.; Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, GRIAC Res Inst, NL-9700 RB Groningen, Netherlands	University of Groningen; University of Groningen; University of Liege; University of Liege; University of Bristol; University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Utrecht University; Utrecht University Medical Center; Utrecht University; University of Groningen	Koppelman, GH (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, POB 30-001, NL-9700 RB Groningen, Netherlands.	g.h.koppelman@umcg.nl	Koppelman, Gerard/AAG-9187-2020; Granell, Raquel/AAY-4846-2020; Granell, Raquel/AAB-5256-2022	Granell, Raquel/0000-0002-4890-4012; Koppelman, Gerard/0000-0001-8567-3252; Van Steen, Kristel/0000-0001-9868-5033; brunekreef, bert/0000-0001-9908-0060	Gratama Foundation [10.21]; Dutch Asthma Foundation [3.4.01.26, 3.2.06.022, 3.2.09.081JU]; ZonMw Netherlands [912-03-031]; ministry of the environment; ZonMw AGIKO-fund [92003555]; Welcome Trust [092731]; Interuniversity Attraction Poles Programme; Belgian State Science Policy Office; IST Programme of the European Community under the PASCAL2 Network of Excellence (Pattern Analysis, Statistical Modelling and Computational Learning) [IST-2007-216886]; Medical Research Council [MC_PC_15018, G9815508] Funding Source: researchfish	Gratama Foundation; Dutch Asthma Foundation; ZonMw Netherlands(Netherlands Organization for Health Research and DevelopmentNetherlands Government); ministry of the environment(Ministry of the Environment, Japan); ZonMw AGIKO-fund; Welcome Trust(Wellcome Trust); Interuniversity Attraction Poles Programme(Belgian Federal Science Policy Office); Belgian State Science Policy Office(Belgian Federal Science Policy Office); IST Programme of the European Community under the PASCAL2 Network of Excellence (Pattern Analysis, Statistical Modelling and Computational Learning); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The PIAMA study was supported by the Gratama Foundation (grant 10.21), the Dutch Asthma Foundation (grants 3.4.01.26, 3.2.06.022, and 3.2.09.081JU), the ZonMw Netherlands (grant 912-03-031), and the ministry of the environment. O.E.S. was supported by a ZonMw AGIKO-fund (grant 92003555). The UK Medical Research Council and the Welcome Trust (grant reference 092731) and the University of Bristol provide core support for ALSPAC. J.M.M.J. and K. V. S. acknowledge research opportunities offered by the Belgium Network DYSCO (Dynamical Systems, Control, and Optimization), which is funded by the Interuniversity Attraction Poles Programme and initiated by the Belgian State Science Policy Office. Their work was also supported by in part by the IST Programme of the European Community under the PASCAL2 Network of Excellence (Pattern Analysis, Statistical Modelling and Computational Learning), IST-2007-216886.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Calle ML, 2008, STAT MED, V27, P6532, DOI 10.1002/sim.3431; Chapuis J, 2009, MOL PSYCHIATR, V14, P1004, DOI 10.1038/mp.2009.10; Collins SA, 2013, PEDIATR PULM, V48, P683, DOI 10.1002/ppul.22766; Dijk FN, 2013, CURR OPIN ALLERGY CL, V13, P193, DOI 10.1097/ACI.0b013e32835eb707; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Ho JE, 2013, J CLIN INVEST, V123, P4208, DOI 10.1172/JCI67119; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Kimman TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003665; Koppelman GH, 2006, CURR ALLERGY ASTHM R, V6, P103, DOI 10.1007/s11882-006-0047-y; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Paternoster L, 2011, HUM MOL GENET, V20, P4069, DOI 10.1093/hmg/ddr309; Pinard R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-216; Ramasamy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044008; Reijmerink NE, 2010, ALLERGY, V65, P199, DOI 10.1111/j.1398-9995.2009.02111.x; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Sakashita M, 2008, CLIN EXP ALLERGY, V38, P1875, DOI 10.1111/j.1365-2222.2008.03114.x; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Savenije OEM, 2011, J ALLERGY CLIN IMMUN, V127, P750, DOI 10.1016/j.jaci.2010.12.014; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Spycher BD, 2012, J ALLERGY CLIN IMMUN, V130, P503, DOI 10.1016/j.jaci.2012.06.002; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Van Steen K, 2012, BRIEF BIOINFORM, V13, P1, DOI 10.1093/bib/bbr012; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Wijga AH, 2013, INT J EPIDEMIOL; Zhao J, 2012, NAT IMMUNOL, V13, P651, DOI 10.1038/ni.2341	37	130	132	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					170	177		10.1016/j.jaci.2013.12.1080	http://dx.doi.org/10.1016/j.jaci.2013.12.1080			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24568840	Green Accepted			2022-12-18	WOS:000338930300022
J	Haldar, P; Brightling, CE; Singapuri, A; Hargadon, B; Gupta, S; Monteiro, W; Bradding, P; Green, RH; Wardlaw, AJ; Ortega, H; Pavord, ID				Haldar, Pranabashis; Brightling, Christopher E.; Singapuri, Amisha; Hargadon, Beverley; Gupta, Sumit; Monteiro, William; Bradding, Peter; Green, Ruth H.; Wardlaw, Andrew J.; Ortega, Hector; Pavord, Ian D.			Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INHALED CORTICOSTEROIDS; SPUTUM		[Haldar, Pranabashis; Brightling, Christopher E.; Singapuri, Amisha; Hargadon, Beverley; Gupta, Sumit; Monteiro, William; Bradding, Peter; Green, Ruth H.; Wardlaw, Andrew J.] Glenfield Gen Hosp, Inst Lung Hlth, Leicester LE3 9QP, Leics, England; [Haldar, Pranabashis; Brightling, Christopher E.; Gupta, Sumit; Bradding, Peter; Wardlaw, Andrew J.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Ortega, Hector] GlaxoSmithKline, Resp Therapeut Area Unit, R&D, Res Triangle Pk, NC USA; [Pavord, Ian D.] Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Leicester; GlaxoSmithKline; University of Oxford	Haldar, P (corresponding author), Glenfield Gen Hosp, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.	ian.pavord@ndm.ox.ac.uk		Wardlaw, Andrew/0000-0001-6583-0791; Haldar, Pranabashis/0000-0002-1572-5421; brightling, chris/0000-0002-9345-4903; Pavord, Ian/0000-0002-4288-5973; Bradding, Peter/0000-0001-8403-0319	National Institute for Health Research [CL-2012-11-002, NF-SI-0510-10157, NF-SI-0512-10030] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Kim YJ, 2004, J ALLERGY CLIN IMMUN, V114, P1449, DOI 10.1016/j.jaci.2004.08.027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Lupinek C, 2013, METHODS         1022, DOI [10.1016/j.ymeth.2013.10.008, DOI 10.1016/J.YMETH.2013.10.008.[]; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pizzichini MMM, 1999, EUR RESPIR J, V13, P15, DOI 10.1183/09031936.99.13101599; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033	11	130	133	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					921	+		10.1016/j.jaci.2013.11.026	http://dx.doi.org/10.1016/j.jaci.2013.11.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24418480				2022-12-18	WOS:000332397600049
J	Wark, PAB; Bucchieri, F; Johnston, SL; Gibson, PG; Hamilton, L; Mimica, J; Zummo, G; Holgate, ST; Attia, J; Thakkinstian, A; Davies, DE				Wark, Peter A. B.; Bucchieri, Fabio; Johnston, Sebastian L.; Gibson, Peter G.; Hamilton, Lynnsey; Mimica, Joanna; Zummo, Giovanni; Holgate, Stephen T.; Attia, John; Thakkinstian, Ammarin; Davies, Donna E.			IFN-gamma-induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinovirus; airway inflammation	BRONCHIAL EPITHELIAL-CELLS; VIRUS-INDUCED ASTHMA; RANDOMIZED CONTROLLED-TRIAL; AIRWAY SMOOTH-MUSCLE; CHEMOKINE RECEPTOR; VIRAL-INFECTIONS; IN-VITRO; T-CELLS; EXPRESSION; INFLAMMATION	Background: Rhinovirus-induced acute asthma is the most frequent trigger for asthma exacerbations. Objective: We assessed which inflammatory mediators were released from bronchial epithelial cells (BECs) after infection with rhinovirus and then determined whether they were also present in subjects with acute virus-induced asthma, with the aim to identify a biomarker or biomarkers for acute virus-induced asthma. Methods: BECs were obtained from bronchial brushings of steroidnaive asthmatic subjects and healthy nonatopic control subjects. Cells were infected with rhinovirus 16. Inflammatory mediators were measured by means of flow cytometry with a cytometric bead array. Subjects with acute asthma and virus infection were recruited; they were characterized clinically by using lung function tests and had blood taken to measure the inflammatory mediators identified as important by the BEC experiments. Results: IFN-gamma-induced protein 10 (IP-10) and RANTES were released in the greatest quantities, followed by IL-6, IL-8, and TNF-alpha. Dexamethasone treatment of BECs only partially suppressed IP-10 and TNF-alpha but was more effective at suppressing RANTES, IL-6, and IL-8. In acute clinical asthma serum IP-10 levels were increased to a greater extent in those with acute virus-induced asthma (median of 604 pg/mL compared with 167 pg/mL in those with non-virus-induced acute asthma, P <.01). Increased serum IP-10 levels were predictive of virus-induced asthma (odds ratio, 44.3 [95 % CI, 3.9-100.3]). Increased serum IP-10 levels were strongly associated with more severe airflow obstruction (r = -0.8; P <.01). Conclusions: IP-10 release is specific to acute virus-induced asthma. Clinical implications: Measurement of serum IP-10 could be used to predict a viral trigger to acute asthma.	Univ Southampton, Brooke Labs, Southampton SO9 5NH, Hants, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, London, England; Univ Palermo, Div Human Anat, Dept Expt Med, I-90133 Palermo, Italy; Univ Newcastle, John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia; Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia; Mahidol Univ, Clin Epidemiol Unit, Bangkok 10700, Thailand	University of Southampton; Imperial College London; University of Palermo; John Hunter Hospital; University of Newcastle; University of Newcastle; Mahidol University		peter.wark@hnehealth.nsw.gov.au	Johnston, Sebastian Lennox/I-2423-2012; Wark, Peter/G-7037-2013; Attia, John R/F-5376-2013; Davies, Donna E/H-2993-2012; Bucchieri, Fabio/F-8877-2012; Thakkinstian, Ammarin/J-4788-2019; gibson, peter/G-6194-2014	Johnston, Sebastian Lennox/0000-0003-3009-9200; Wark, Peter/0000-0001-5676-6126; Attia, John R/0000-0001-9800-1308; BUCCHIERI, Fabio/0000-0002-0209-8668; gibson, peter/0000-0001-5865-489X; Davies, Donna/0000-0002-5117-2991	Medical Research Council [G0400503B] Funding Source: researchfish; MRC [G0501506] Funding Source: UKRI; Medical Research Council [G0501506] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179, DOI 10.1165/ajrcmb.27.2.4699; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Garrett J, 1998, ARCH DIS CHILD, V79, P12, DOI 10.1136/adc.79.1.12; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jacoby DB, 2002, JAMA-J AM MED ASSOC, V287, P755, DOI 10.1001/jama.287.6.755; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Konno S, 2002, AM J RESP CELL MOL, V26, P594, DOI 10.1165/ajrcmb.26.5.4438; Lagging M, 2006, HEPATOLOGY, V44, P1617, DOI 10.1002/hep.21407; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Nanki T, 2000, INT IMMUNOL, V12, P1659, DOI 10.1093/intimm/12.12.1659; National Heart Lung and Blood Institute World Health Organization, 1995, GLOB STRAT ASTHM MAN, P1; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Rabin RL, 1999, J IMMUNOL, V162, P3840; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Rodrigo GJ, 2000, CHEST, V118, P1547, DOI 10.1378/chest.118.6.1547; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Sedgwick JB, 2002, J ALLERGY CLIN IMMUN, V110, P752, DOI 10.1067/mai.2002.128581; Silvestri M, 2006, CLIN EXP ALLERGY, V36, P1373, DOI 10.1111/j.1365-2222.2006.02502.x; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Tan JQ, 2000, J IMMUNOL, V165, P1548, DOI 10.4049/jimmunol.165.3.1548; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; Thomas MS, 2002, J IMMUNOL, V169, P7045, DOI 10.4049/jimmunol.169.12.7045; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Yuan YH, 2001, INFLAMM BOWEL DIS, V7, P281, DOI 10.1097/00054725-200111000-00001; Zhang Y, 2004, J VIROL, V78, P11061, DOI 10.1128/JVI.78.20.11061-11069.2004	43	130	133	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					586	593		10.1016/j.jaci.2007.04.046	http://dx.doi.org/10.1016/j.jaci.2007.04.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17628646	Green Published, Bronze			2022-12-18	WOS:000249505400017
J	Ballmer-Weber, BK; Holzhauser, T; Scibilia, J; Mittag, D; Zisa, G; Ortolani, C; Oesterballe, M; Poulsen, LK; Vieths, S; Bindslev-Jensen, C				Ballmer-Weber, Barbara K.; Holzhauser, Thomas; Scibilia, Joseph; Mittag, Diana; Zisa, Guliana; Ortolani, Claudio; Oesterballe, Morten; Poulsen, Lars K.; Vieths, Stefan; Bindslev-Jensen, Carsten			Clinical characteristics of soybean allergy in Europe: A double-blind, placebo-controlled food challenge study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; double-blind; placebo-controlled food challenge; threshold dose; soy allergy; diagnosis; soy allergens	PEANUT ALLERGY; SOY ALLERGY; ATOPIC-DERMATITIS; BIRCH POLLEN; CHILDREN; ANAPHYLAXIS; PROTEIN; TOO	Background: Soybean is a relevant allergenic food, but little is known about individual threshold doses in soy allergy. Objective: We sought to determine the clinical characteristics of soy allergy in Europe, including a dose-response curve. Methods: Patients with a history of soy allergy underwent a titrated, double-blind, placebo-controlled food challenge. A statistical model was used to calculate the risk of allergic consumers to experience an allergic reaction to soy. Sera were analyzed for specific IgE to soy, peanut, Bet v 1, and Gly m 4. Results: All patients but one responded primarily with subjective symptoms to the challenge followed by objective symptoms in 11 subjects, ranging from rhinitis up to a decrease in blood pressure. Cumulative threshold doses for allergic reactions ranged from 10 mg to 50 g for subjective symptoms and from 454 mg to 50 g for objective symptoms. The pattern of IgE reactivity against proteins with molecular weights of between approximately 10 and 70 kd was highly individual among the patients and did not correlate with the severity of symptoms. Conclusions: When data are fitted by using a normal distribution statistical model, they predict that 1% of patients with soy allergy would react subjectively and objectively with 0.21 and 37.2 mg of soy protein, respectively. Clinical implications: Both the clinical and immunologic basis of soy allergy in Europe are highly complex, which affects the diagnosis of soy allergy and the advice given to patients with soy allergy in regard to risk management.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Paul Ehrlich Inst, Div Allergol, D-6070 Langen, Germany; Osped Niguarda Ca Granda, Azienda Ospidaliera, Milan, Italy; Odense Univ Hosp, Dept Dermatol, Allergy Ctr, DK-5000 Odense, Denmark; Natl Univ Hosp, Allergy Clin, Copenhagen, Denmark	University of Zurich; University Zurich Hospital; Paul Ehrlich Institute; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Southern Denmark; Odense University Hospital	Ballmer-Weber, BK (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.	barbara.ballmer@usz.ch	SCIBILIA, GIUSEPPE/AAC-9673-2022; Bindslev-Jensen, Carsten/H-1877-2011; Poulsen, Lars K/J-3065-2019; Holzhauser, Thomas/ABD-5038-2020	SCIBILIA, GIUSEPPE/0000-0002-5452-4024; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Poulsen, Lars K/0000-0002-1730-847X; Holzhauser, Thomas/0000-0002-7818-7261				[Anonymous], 1993, ALLERGY S, V48, P48; BESLER M, 2000, INTERNET S FOOD A S3, V2, P1; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bindslev-Jensen C, 2002, ALLERGY, V57, P741, DOI 10.1034/j.1398-9995.2002.23797.x; Cianferoni A, 2001, ANN ALLERG ASTHMA IM, V87, P27, DOI 10.1016/S1081-1206(10)62318-6; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; GONZALEZ R, 1992, CLIN EXP ALLERGY, V22, P748, DOI 10.1111/j.1365-2222.1992.tb02814.x; Grimshaw KEC, 2003, CLIN EXP ALLERGY, V33, P1581, DOI 10.1046/j.1365-2222.2003.01795.x; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Magnolfi CF, 1996, ANN ALLERG ASTHMA IM, V77, P197, DOI 10.1016/S1081-1206(10)63255-3; MEILGAARD M, 1991, SENSORY EVALUATION T, P4280; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Ogawa T, 2000, J NUTR SCI VITAMINOL, V46, P271, DOI 10.3177/jnsv.46.271; Rihs HP, 1999, J ALLERGY CLIN IMMUN, V104, P1293, DOI 10.1016/S0091-6749(99)70027-8; *ROMPP CHEM LEX, 1995, THIEME, P4197; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Steinman HA, 1996, J ALLERGY CLIN IMMUN, V98, P241, DOI 10.1016/S0091-6749(96)70146-X; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; van Odijk J, 2005, ALLERGY, V60, P602, DOI 10.1111/j.1398-9995.2005.00666.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; Zeiger RS, 1999, J PEDIATR-US, V134, P614, DOI 10.1016/S0022-3476(99)70249-0	27	130	132	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1489	1496		10.1016/j.jaci.2007.01.049	http://dx.doi.org/10.1016/j.jaci.2007.01.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17379287				2022-12-18	WOS:000247232800026
J	Carter, MC; Robyn, JA; Bressler, PB; Walker, JC; Shapiro, GG; Metcalfe, DD				Carter, Melody C.; Robyn, Jamie A.; Bressler, Peter B.; Walker, John C.; Shapiro, Gail G.; Metcalfe, Dean D.			Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									NIAID, NIH, Lab Allerg Dis, Bethesda, MD 20892 USA; Carolina Allergy & Asthma, Chapel Hill, NC USA; Univ Washington, Childrens Hosp, NW Allery & Asthma Ctr, Richland, WA USA; Reg Med Ctr, Richland, WA USA; Univ Washington, Sch Med, NW Allergy & Asthma Ctr, Seattle, WA 98195 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington; University of Washington Seattle	Carter, MC (corresponding author), NIAID, NIH, Lab Allerg Dis, Bethesda, MD 20892 USA.	mcarter@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000513, Z01AI000249] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; MacGlashan DW, 1997, INT ARCH ALLERGY IMM, V113, P45; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Robyn J, 2006, ADV IMMUNOL, V89, P169, DOI 10.1016/S0065-2776(05)89005-4	4	130	130	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1550	1551		10.1016/j.jaci.2007.03.032	http://dx.doi.org/10.1016/j.jaci.2007.03.032			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17481708	Bronze			2022-12-18	WOS:000247232800039
J	Vachier, I; Bonnans, C; Chavis, C; Farce, M; Godard, P; Bousquet, J; Chanez, P				Vachier, I; Bonnans, C; Chavis, C; Farce, M; Godard, P; Bousquet, J; Chanez, P			Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lipoxins; asthma; induced sputum; LTB4; IL-8	HUMAN ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; INDUCED SPUTUM; LIPOXINS; ACID; GLUCOCORTICOIDS; EICOSANOIDS; EXPRESSION; 15(S)-HETE; SERIES	Background: Lipoxins and 15-epi-lipoxins are lipid mediators that modulate leukocyte trafficking and promote the inflammation resolution. They are produced by different enzymatic pathways. Patients with severe asthma present ongoing airway inflammation despite chronic long-term treatment including oral glucocorticoids. Objectives: The aim of this study was to assess the presence of proinflammatory and anti-inflammatory mediators in the supernatants of induced sputum. Methods: Induced sputum supernatants were collected from 10 normal subjects; 12 subjects with mild, 15 with moderate, and 24 with severe asthma; and 13 patients with chronic obstructive pulmonary disease. First, we validated the measurements of IL-8, leukotriene B-4, lipoxin A(4), and 15-epi-lipoxin A(4) in these samples. Then we measured these mediators by using immunoenzymatic methods. Results: IL-8 levels were highly increased in patients with severe asthma (P <.0001), and leukotriene B-4 levels were significantly increased in patients with severe asthma and patients with chronic obstructive pulmonary disease. Lipoxin A(4) was significantly increased in the supernatant obtained from patients with mild asthma (P <.0001), whereas 15-epi-lipoxin A(4) levels were higher in patients with severe asthma (P =.05). More interestingly, we found a positive correlation between the level of lipoxin A(4) and IL-8 in patients with mild asthma. Conclusion: These results indicate that induced sputum is a suitable method to assess lipoxin and 15-epi-lipoxin measurements in bronchi. The mechanisms involved in the synthesis of these 2 eicosanoid mediators would be helpful to understand better the imbalance between proinflammatory and anti-inflammatory mediators occurring in severe asthma. Lipoxin production involves interaction between lipoxygenases, whereas 15-epi-lipoxin production might involve CytP450 activity.	CHU, Clin Mal Resp, Montpellier, France	Universite de Montpellier; CHU de Montpellier	Chanez, P (corresponding author), Hop Arnaud Villeneuve, 371 Av Doyen Gaston Giraud, F-34295 Montpellier 5, France.	chanez@montp.insenn.fr	Bousquet, Jean/O-4221-2019; Vachier, Isabelle/AAV-5731-2020	Vachier, Isabelle/0000-0003-2730-5165; chanez, pascal/0000-0003-4059-0917				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; BORGEAT P, 1990, CLIN BIOCHEM, V23, P459, DOI 10.1016/0009-9120(90)90272-V; Bylund J, 1998, ANAL BIOCHEM, V265, P55, DOI 10.1006/abio.1998.2897; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CHAVIS C, 1992, EICOSANOIDS, V5, P203; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; DYKEWICZ MS, 1986, ARCH INTERN MED, V146, P2369, DOI 10.1001/archinte.146.12.2369; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7, DOI 10.1164/ajrccm.162.1.9911032; Godson C, 2000, Curr Opin Investig Drugs, V1, P380; Hukkanen J, 2002, CRIT REV TOXICOL, V32, P391, DOI 10.1080/20024091064273; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170; Kelly MM, 2002, EUR RESPIR J, V20, p24S, DOI 10.1183/09031936.02.00002402; Kips JC, 1998, EUR RESPIR J, V11, p9S; LEE TH, 1990, AM REV RESPIR DIS, V141, P1453, DOI 10.1164/ajrccm/141.6.1453; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Pauwels R, 2001, EUR RESPIR J, V18, P901, DOI 10.1183/09031936.01.0027401; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 2002, EUR RESPIR J, V20, p9S, DOI 10.1183/09031936.02.00000902; Pizzichini MMM, 1999, EUR RESPIR J, V13, P15, DOI 10.1183/09031936.99.13101599; Profita M, 2000, AM J PHYSIOL-CELL PH, V279, pC1249, DOI 10.1152/ajpcell.2000.279.4.C1249; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413, DOI 10.1152/ajplung.1993.264.4.L413; Romano M, 2002, LAB INVEST, V82, P1253, DOI 10.1097/01.LAB.0000028823.53486.4A; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; SERHAN CN, 1994, LIPID MEDIATORS ALLE, P65; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; STEINHILBER D, 1989, FEBS LETT, V255, P143, DOI 10.1016/0014-5793(89)81078-6; Taha R, 2000, AM J RESP CRIT CARE, V161, P636, DOI 10.1164/ajrccm.161.2.9811063; Teran LM, 1996, AM J RESP CRIT CARE, V154, P469, DOI 10.1164/ajrccm.154.2.8756824; Vachier I, 2001, J ALLERGY CLIN IMMUN, V107, P824, DOI 10.1067/mai.2001.113868; Vrugt B, 1999, EUR RESPIR J, V13, P1245, DOI 10.1183/09031936.99.13612539; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; *WHO NHLBI, 2002, PUBLICATION WHO NHLB; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	43	130	136	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					55	60		10.1016/j.jaci.2004.09.038	http://dx.doi.org/10.1016/j.jaci.2004.09.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637547				2022-12-18	WOS:000226267000007
J	Fleischer, DM; Conover-Walker, MK; Christie, L; Burks, AW; Wood, RA				Fleischer, DM; Conover-Walker, MK; Christie, L; Burks, AW; Wood, RA			Peanut allergy: Recurrence and its management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; recurrence; food challenge; RAST; food hypersensitivity		Background: Although peanut allergy may recur, the frequency with which this occurs is unknown. Objective: The goals of this study were to determine the rate of peanut allergy recurrence, identify risk factors for recurrent peanut allergy, and develop specific recommendations for the treatment of patients with resolved peanut allergy. Methods: Children who outgrew peanut allergy were evaluated with questionnaires, skin tests, and peanut-specific IgE levels. Patients were invited to undergo a double-blind, placebo-controlled food challenge (DBPCFC) unless the history of a possible recurrence reaction was so convincing that a challenge would be potentially dangerous. Results: Sixty-eight patients were evaluated. Forty-seven patients continued to tolerate peanut, of whom 34 ingested concentrated peanut products at least once per month and 13 ate peanut infrequently or in limited amounts but passed a DBPCFC. The status of 18 patients was indeterminate because they ate peanut infrequently or in limited amounts and declined to have a DBPCFC. After excluding 12 patients originally diagnosed with peanut allergy based solely on a positive skin prick test or peanut-specific IgE level, 3 of 15 patients who consumed peanut infrequently (P = .025). The recurrence rate was 7.9 (95% CI, 1.7% to 21.4%). Conclusion: Children who outgrow peanut allergy are at risk for recurrence, and this risk is significantly higher for patients who continue largely to avoid peanut after resolution of their allergy. On the basis of these findings, we now recommend that patients eat peanut frequently and carry epinephrine indefinitely until they have demonstrated ongoing peanut tolerance.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD USA; Univ Arkansas Med Sci Hosp, Dept Pediat, Little Rock, AR USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; Duke Univ, Sch Med, Dept Pediat, Durham, NC 27706 USA	Johns Hopkins University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Duke University	Wood, RA (corresponding author), Johs Hopkins Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu			NCRR NIH HHS [M01 RR 000052, M01 RR 14288] Funding Source: Medline; NIAID NIH HHS [T32 AI 07007] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052, M01RR014288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, pS92, DOI 10.1016/S0091-6749(02)81378-1; Factor J. M., 2003, Journal of Allergy and Clinical Immunology, V111, pS275, DOI 10.1016/S0091-6749(03)80989-2; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Kerr P. E., 2004, Journal of Allergy and Clinical Immunology, V113, pS151, DOI 10.1016/j.jaci.2003.12.548; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129	8	130	133	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1195	1201		10.1016/j.jaci.2004.08.035	http://dx.doi.org/10.1016/j.jaci.2004.08.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536431				2022-12-18	WOS:000225047800041
J	Pullerits, T; Praks, L; Ristioja, V; Lotvall, J				Pullerits, T; Praks, L; Ristioja, V; Lotvall, J			Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; glucocorticoids; antileukotriene; anti-histamine; mucosal inflammation	INTRANASAL FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR ANTAGONIST; SEGMENTAL ANTIGEN CHALLENGE; GRASS-POLLEN; 5-LIPOXYGENASE INHIBITOR; CORTICOSTEROIDS; INFLAMMATION; LORATADINE; PLACEBO; EOSINOPHILS	Background: Allergic rhinitis requires active intervention for symptom relief. A combination of antileukotriene and antihistamine drugs has been suggested to provide additive treatment benefits for patients with allergic rhinitis. Objective: We evaluated how such a combination treatment would affect symptoms and local mucosal eosinophilia in comparison with a nasal glucocorticoid. Methods: In a double-blind, randomized study 62 patients ith grass pollen-induced allergic rhinitis received a nasal glucocorticoid (fluticasone propionate aqueous nasal spray [FPANS], 200 mug/d), an antileukotriene (montelukast, 10 mg/d), a combination of montelukast with an antihistamine (loratadine, 10 mg/d), or placebo throughout the season. Cromoglycate eyedrops and a limited amount of loratadine were allowed as rescue medication for severe symptoms. Patients recorded their symptoms for nasal blockage, itching, rhinorrhea, and sneezing. Before and during the season, nasal biopsy specimens were obtained from patients for evaluation of local eosinophilic inflammation. Results: During the peak season, both FPANS and combined montelukast-loratadine were significantly more effective than placebo and montelukast alone for daytime symptom prevention. For nighttime symptoms, FPANS was significantly more effective compared with all other treatments, whereas combined montelukast-loratadine and montelukast alone did not provide significant symptom prevention compared with placebo. The pollen-induced increase in the numbers of epithelial eosinophils was significantly lower for FPANS-treated patients compared with that seen in all other treatment groups. Conclusion: In patients with seasonal allergic rhinitis, intranasal glucocorticoids are more effective than an antileukotriene drug or combined antileukotriene-antihistamine for the reduction of pollen-induced nasal eosinophilic inflammation and for control of nasal symptoms.	Gothenburg Univ, Dept Resp Med & Allergol, Lung Pharmacol Grp, Inst Internal Med, S-41346 Gothenburg, Sweden; Univ Tartu, Lung Clin, EE-50090 Tartu, Estonia; Univ Tartu, Otorhinolaryngol Clin, EE-50090 Tartu, Estonia	University of Gothenburg; University of Tartu; University of Tartu	Pullerits, T (corresponding author), Gothenburg Univ, Dept Resp Med & Allergol, Lung Pharmacol Grp, Inst Internal Med, Guldhedsgatan 10A, S-41346 Gothenburg, Sweden.			Lotvall, Jan/0000-0001-9195-9249				BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, P1381, DOI 10.1164/ajrccm.157.5.9609014; DARNELL R, 1994, CLIN EXP ALLERGY, V24, P1144, DOI 10.1111/j.1365-2222.1994.tb03320.x; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Foresi A, 2000, ALLERGY, V55, P12, DOI 10.1034/j.1398-9995.2000.055suppl62012.x; Hasday JD, 2000, AM J RESP CRIT CARE, V161, P1229, DOI 10.1164/ajrccm.161.4.9904026; Howarth PH, 1997, ALLERGY, V52, P12, DOI 10.1111/j.1398-9995.1997.tb04878.x; Jacobson MR, 1999, CLIN EXP ALLERGY, V29, P1347; Jordana G, 1996, J ALLERGY CLIN IMMUN, V97, P588, DOI 10.1016/S0091-6749(96)70303-2; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lis K, 2001, J ALLERGY CLIN IMMUN, V107, pS158; Meltzer E O, 1997, J Allergy Clin Immunol, V99, pS805; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; OKUDA M, 1988, ANN ALLERGY, V60, P537; Pullerits T, 2000, CLIN EXP ALLERGY, V30, P1469, DOI 10.1046/j.1365-2222.2000.00993.x; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814, DOI 10.1164/ajrccm.159.6.9810016; Reicin A, 2000, ARCH INTERN MED, V160, P2481, DOI 10.1001/archinte.160.16.2481; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Stempel DA, 1998, AM J MANAG CARE, V4, P89; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802	26	130	139	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					949	955		10.1067/mai.2002.124467	http://dx.doi.org/10.1067/mai.2002.124467			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063523	Bronze			2022-12-18	WOS:000176442700009
J	Golden, DBK; Kagey-Sobotka, A; Norman, PS; Hamilton, RG; Lichtenstein, LM				Golden, DBK; Kagey-Sobotka, A; Norman, PS; Hamilton, RG; Lichtenstein, LM			Insect sting allergy with negative venom skin test responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin test; insect venom; RAST; insect sting; Hymenoptera; anaphylaxis	HYMENOPTERA VENOMS; DIAGNOSTIC METHODS; NATURAL-HISTORY; IMMUNOTHERAPY; HYPERSENSITIVITY; ANAPHYLAXIS; SENSITIVITY; SEVERITY; CHALLENGE; SYMPTOMS	Background: In our 1976 controlled venom immunotherapy trial, 33% of 182 patients with a history of systemic reactions to insect stings were excluded because of negative venom skin test responses, There have been reports of patients with negative skin test responses who have had severe reactions to subsequent stings, Objective: Our aim is to increase awareness about the patient with a negative skin test response and insect sting allergy and to determine the frequency and significance of negative skin test responses in patients with a history of systemic reactions to insect stings. Methods: We prospectively examined the prevalence of negative venom skin test responses in patients with 3 history of systemic reactions to stings, In patients who gave informed consent, we analyzed the outcome of retesting and sting challenge. Results: Of 307 patients with positive histories screened for our sting challenge study, 208 (68%) had positive venom skin test responses (up to 1 mug/mL concentration), and 99 (32%) had negative venom skin test responses. In 36 (36%) of the 99 patients with negative skin test responses, the venom RAST result was a low positive (1-3 ng/mL), or repeat venom skin test responses were positive; another 7 (7%) patients had high venom-specific IgE antibody levels (4-243 ng/mL), Notably, 56 (57%) of 99 patients with positive histories and negative skin test responses had negative RAST results, In patients with positive skin test responses, sting challenges were performed in 141 of 196 patients, with 30 systemic reactions. Sting challenges were performed on 37 of 43 patients with negative skin test responses and positive venom-specific IgE and in 14 of 56 patients with negative skin test responses and negative RAST results. There were 11 patients with negative skin test responses who had systemic reactions to the challenge sting: 2 had negative RAST results, and 9 had positive RAST results at 1 ng/mL, The frequency of systemic reaction was 21% in patients with positive skin test responses and 22% in patients with negative skin test responses (24% in those with positive RAST results and 14% in those with negative RAST results); Conclusions: Venom skin test responses can be negative in patients who will subsequently experience another systemic sting reaction. Venom skin test responses are negative in many patients with a history of systemic allergic reactions to insect stings and may be associated with positive serologic test responses for venom-specific IgE antibodies (sometimes strongly positive results). Venom skin test responses should be repeated when negative, along with a serologic IgE antivenom test. Better diagnostic skin test reagents are urgently needed.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Golden, DBK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Blvd, Baltimore, MD 21224 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1-RR02719] Funding Source: Medline; NIAID NIH HHS [AI08270] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; DAY JH, 1986, J ALLERGY CLIN IMMUN, V77, P142; DAY JH, 1994, J ALLERGY CLIN IMMUN, V93, P691, DOI 10.1016/0091-6749(94)90249-6; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, pS376, DOI 10.1016/S0091-6749(00)91527-6; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, pS159; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MULLER U, 1993, ALLERGY, V48, P37; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; Portnoy J M, 1999, J Allergy Clin Immunol, V103, P963, DOI 10.1016/S0091-6749(99)70450-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SELCOW JE, 1980, J ALLERGY CLIN IMMUN, V65, P400, DOI 10.1016/0091-6749(80)90220-1; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889	28	130	132	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					897	901		10.1067/mai.2001.114706	http://dx.doi.org/10.1067/mai.2001.114706			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344359	Bronze			2022-12-18	WOS:000168812300020
J	Kikly, KK; Bochner, BS; Freeman, SD; Tan, KB; Gallagher, KT; D'Alessio, KJ; Holmes, SD; Abrahamson, JA; Erickson-Miller, CL; Murdock, PR; Tachimoto, H; Schleimer, RP; White, JR				Kikly, KK; Bochner, BS; Freeman, SD; Tan, KB; Gallagher, KT; D'Alessio, KJ; Holmes, SD; Abrahamson, JA; Erickson-Miller, CL; Murdock, PR; Tachimoto, H; Schleimer, RP; White, JR			Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; basophil; mast cell; allergy; cell surface molecule	NATURAL-KILLER-CELLS; ACID-BINDING SITE; IMMUNOGLOBULIN SUPERFAMILY; SIALOADHESIN FAMILY; CD22; ACTIVATION; MOLECULES; RECEPTOR; PROTEIN; CD33	Background: Eosinophils, basophils, and mast cells are believed to be the central tenet cells in allergic conditions including allergic rhinitis, asthma, and eczema. The molecular mechanisms underlying the recruitment of these cells to sites of allergic inflammation are poorly understood. Objectives: Our aim was to identify a common adhesion molecule that could potentially be responsible for mediating the recruitment of the allergic cell types to the lungs and other sites of allergy. Methods: We have cloned a sialoadhesin molecule from a human eosinophil library with the use of expressed sequence tag technology and characterized its expression on allergic cells by the use of flow cytometry and specific mAbs. Results: With the use of expressed sequence tag sequencing, we have identified a novel siglec molecule, SAF-2. SAF-2 has homology with other sialoadhesin family members (CD33 and siglec-5) and belongs to a subgroup of the Ig superfamily. SAF-2 is a 431-amino acid protein composed of 3 Ig domains with a 358-amino acid extracellular domain and a 47-amino acid tail. SAF-2 is highly restricted to eosinophils, basophils, and mast cells. Antibodies to SAF-2 do not modulate Ca++ mobilization or chemotaxis of human eosinophils induced by eotaxin. Conclusion: SAF-2 is a highly restricted sialoadhesin molecule, which may be useful in the detection and/or modulation of allergic cells.	SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Microbial & Cell Culture Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Virol & Host Def, King Of Prussia, PA 19406 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA; Inst Mol Med, Dept Cell Adhes, Oxford, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Johns Hopkins University; University of Oxford	Kikly, KK (corresponding author), SmithKline Beecham Pharmaceut, Dept Immunol, 709 Swedeland Rd,Mailcode UW2101, King Of Prussia, PA 19406 USA.			Freeman, Sylvie/0000-0003-1869-180X; White, John R/0000-0003-2998-1626				Barnes YC, 1999, BLOOD, V93, P1245, DOI 10.1182/blood.V93.4.1245.404k09_1245_1252; Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; BOCHNER BS, 1989, J IMMUNOL METHODS, V125, P265, DOI 10.1016/0022-1759(89)90102-6; BOCHNER BS, 1998, ALLERGY PRINCIPLES P, P94; BODGER MP, 1987, BLOOD, V69, P1414; COLLINS SJ, 1987, BLOOD, V70, P1233; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; GUO CB, 1992, BLOOD, V79, P708; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Lajaunias F, 1999, IMMUNOGENETICS, V49, P991, DOI 10.1007/s002510050584; Macphee CH, 1998, J IMMUNOL, V161, P6273; Matsumoto K, 1998, AM J RESP CELL MOL, V18, P860, DOI 10.1165/ajrcmb.18.6.3159; MAYUMI M, 1992, LEUKEMIA LYMPHOMA, V7, P243, DOI 10.3109/10428199209053629; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Razi N, 1998, P NATL ACAD SCI USA, V95, P7469, DOI 10.1073/pnas.95.13.7469; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAITO H, 1986, BLOOD, V67, P50; Saito H, 1996, J IMMUNOL, V157, P343; Sgroi D, 1996, J BIOL CHEM, V271, P18803, DOI 10.1074/jbc.271.31.18803; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; SUR S, 1993, ALLERGY PRINCIPLES P, P169; Tachimoto H, 1997, INT ARCH ALLERGY IMM, V113, P293, DOI 10.1159/000237578; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; ZOLA H, 1987, MONOCLONAL ANTIBODIE	38	130	140	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1093	1100		10.1067/mai.2000.107127	http://dx.doi.org/10.1067/mai.2000.107127			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856141				2022-12-18	WOS:000087781800008
J	FISCHER, AR; ROSENBERG, MA; LILLY, CM; CALLERY, JC; RUBIN, P; COHN, J; WHITE, MV; IGARASHI, Y; KALINER, MA; DRAZEN, JM; ISRAEL, E				FISCHER, AR; ROSENBERG, MA; LILLY, CM; CALLERY, JC; RUBIN, P; COHN, J; WHITE, MV; IGARASHI, Y; KALINER, MA; DRAZEN, JM; ISRAEL, E			DIRECT EVIDENCE FOR A ROLE OF THE MAST-CELL IN THE NASAL RESPONSE TO ASPIRIN IN ASPIRIN-SENSITIVE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPIRIN; ASTHMA; MAST CELL; LEUKOTRIENES; ZILEUTON	ARACHIDONIC-ACID METABOLITES; URINARY LEUKOTRIENE-E4; PEPTIDE LEUKOTRIENE; LYSINE-ASPIRIN; RELEASE; HISTAMINE; SECRETIONS; TRYPTASE; ANTAGONIST; CHALLENGE	Background: A subset of patients with asthma experience adverse nasoocular reactions after ingestion of aspirin or agents that inhibit cyclooxygenase. Recent evidence has implicated the leukotrienes in the nasoocular reaction, but the cellullar sources and mechanism of activation are unknown. We used nasal lavage,vith and without a 5-lipoxygenase inhibitor, zileuton, to define the role of leukotrienes and to profile nasal cellular activation during this reaction. Methods: A group of eight patients with asthma shown to have adverse reactions to aspirin documented by a 15% or greater den ease in forced expiratory volume in 1 second, accompanied by an elevation in urinary leukotriene E(4) after ingestion of aspirin, received aspirin or placebo in a study with a crossover design. Nasal symptoms and nasal tryptase, histamine, leukotriene, and eosinophil cationic protein levels were evaluated. Serum tryptase and urinary histamine levels were also assessed. Subjects were then randomized to receive a week of treatment with zileuton or placebo according to a double-blind, crossover design followed by aspirin challenge and measurement of the same mediators. Results: Aspirin ingestion produced a marked increase in nasal symptoms from a baseline symptom score of 21 +/- 0.7 to a maximum of 8.4 +/- 1.2 (p < 0.0007). Aspirin ingestion produced a mean maximal increase in nasal tryptase of 3.5 +/- 26 ng/ml, whereas placebo ingestion produced a mean maximum increase of 0.1 +/- 0.2 ng/ml (p < 0.05, aspirin vs placebo). Mean maximal nasal histamine increased 1.73 +/- 1.26 ng/ml versus 0.08 +/- 0.08 ng/ml sm baseline (p < 0.05, aspirin vs placebo). Aspirin produced a mean maximal increase in nasal leukotriene value of 152 pg/ml versus a 16 pg/ml decrease after placebo ingestion (p < 0.05). Zileuton treatment blacked the increase in nasal symptoms after aspirin ingestion (maximum nasal symptom score of 1.6 +/- 0.6 with zileuton vs 5.5 +/- 0.9 with placebo [p < 0.0053]). It also blocked the rise in nasal tryptase (p = 0.011) and nasal leukotriene (p < 0.05) levels after aspirin ingestion. Zileluton treatment had no significant effect on the recovery of nasal histamine. Conclusion: The increase in nasal symptoms in aspirin-sensitive patients with asthma after aspirin ingestion is associated with increases in nasal tryptase, histamine, and cysteinyl leukotriene levels. This mediator profile is consistent with mast cell activation during the nasal response to aspirin and suggests that 5-lipoxygenase products are essential for the nasal response to aspirin.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RESP,BOSTON,MA 02115; HARVARD UNIV,COMBINED PROGRAM PULM & CRIT CARE MED,BOSTON,MA 02115; LONGWOOD AREA ADULT ASTHMA CTR,BOSTON,MA; ABBOTT LABS,ABBOTT PK,IL; NIAID,ALLERG DIS SECT,BETHESDA,MD 20892	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Abbott Laboratories; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR01032-17] Funding Source: Medline; NHLBI NIH HHS [HL-T32-07633] Funding Source: Medline; NIAID NIH HHS [AI-U01-31599] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DELANEY JC, 1983, CLIN ALLERGY, V13, P247, DOI 10.1111/j.1365-2222.1983.tb02595.x; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; EGGLESTON PA, 1990, AM REV RESPIR DIS, V141, P960, DOI 10.1164/ajrccm/141.4_Pt_1.960; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; HENDRSON WR, 1992, 8TH INT C PROST REL, P372; HOOVER RL, 1984, P NATL ACAD SCI-BIOL, V81, P2191, DOI 10.1073/pnas.81.7.2191; IGARASHI Y, 1992, J ALLERGY CLIN IMMUN, V89, P1085, DOI 10.1016/0091-6749(92)90292-A; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; KAWABORI S, 1992, AM J RESP CELL MOL, V6, P37, DOI 10.1165/ajrcmb/6.1.37; KNAPP HR, 1992, J LAB CLIN MED, V119, P48; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; KOWALSKI ML, 1993, J ALLERGY CLIN IMMUN, V91, P580, DOI 10.1016/0091-6749(93)90264-G; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OLSSON I, 1977, LAB INVEST, V36, P493; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; RUBIN P, 1991, AGENT ACTION SUPPL, V35, P103; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1992, AM REV RESPIR DIS, V145, pS18, DOI 10.1164/ajrccm/145.2_Pt_2.S18; Shore S, 1989, LUNG CELL BIOL, P1011; SLADEK K, 1993, EUR RESPIR J, V6, P391; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1980, ALLERGY, V35, P421, DOI 10.1111/j.1398-9995.1980.tb01788.x; SZMIDT M, 1981, AGENTS ACTIONS, V11, P105, DOI 10.1007/BF01991472; TAKASAKA T, 1986, ACTA OTOLARYNGOL S S, V430, P39; Yamashita T, 1989, Rhinol Suppl, V8, P15	39	130	130	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				1046	1056		10.1016/0091-6749(94)90123-6	http://dx.doi.org/10.1016/0091-6749(94)90123-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798537				2022-12-18	WOS:A1994PY23000013
J	VANMETRE, TE; MARSH, DG; ADKINSON, NF; KAGEYSOBOTKA, A; KHATTIGNAVONG, A; NORMAN, PS; ROSENBERG, GL				VANMETRE, TE; MARSH, DG; ADKINSON, NF; KAGEYSOBOTKA, A; KHATTIGNAVONG, A; NORMAN, PS; ROSENBERG, GL			IMMUNOTHERAPY FOR CAT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,ALLERGY CLIN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine					NCRR NIH HHS [RR 00722] Funding Source: Medline; NIAID NIH HHS [AI08270, R01-AI 18374] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270, R01AI018374] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO; ANDERSON MC, 1981, J IMMUNOL, V127, P972; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; LINDGREN BW, 1968, STATISTICAL THEORY, P437; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; LOWENSTEIN H, 1980, REGULATORY CONTROL S, P75; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; Siegel S., 1956, NONPARAMETRIC STAT B; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1968, J ALLERGY, V41, P195, DOI 10.1016/0021-8707(68)90042-7; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; 1983, J AM VET MED ASSOC, V183, P841	29	130	133	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1055	1068		10.1016/0091-6749(88)90144-3	http://dx.doi.org/10.1016/0091-6749(88)90144-3			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	2462581				2022-12-18	WOS:A1988R631100015
J	RYAN, G; LATIMER, KM; JUNIPER, EF; ROBERTS, RS; HARGREAVE, FE				RYAN, G; LATIMER, KM; JUNIPER, EF; ROBERTS, RS; HARGREAVE, FE			EFFECT OF BECLOMETHASONE DIPROPIONATE ON BRONCHIAL RESPONSIVENESS TO HISTAMINE IN CONTROLLED NONSTEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,50 CHARLTON AVE E,HAMILTON L8N 4A6,ONTARIO,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McGill University; McMaster University; McMaster University; McMaster University								ALTOUNYAN REC, 1969, DISODIUM CROMOGLYCAT, P47; ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; ARKINS JA, 1968, J ALLERGY, V41, P209, DOI 10.1016/0021-8707(68)90043-9; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1980, J ALLERGY CLIN IMMUN, V66, P458, DOI 10.1016/0091-6749(80)90006-8; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HORTON DJ, 1978, AM REV RESPIR DIS, V117, P1029; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KALINER M, 1983, ASTHMA, V3; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P209; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; TIFFENEAU R., 1959, ACTA ALLERGOL, V14, P416, DOI 10.1111/j.1398-9995.1959.tb02857.x; TIFFENEAU R, 1956, PRESSE MED, V64, P719; VALLIERES M, 1977, AM REV RESPIR DIS, V115, P867; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P162	32	130	130	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					25	30		10.1016/0091-6749(85)90007-7	http://dx.doi.org/10.1016/0091-6749(85)90007-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	3881501				2022-12-18	WOS:A1985ABF2600003
J	SECHER, C; KIRKEGAARD, J; BORUM, P; MAANSSON, A; OSTERHAMMEL, P; MYGIND, N				SECHER, C; KIRKEGAARD, J; BORUM, P; MAANSSON, A; OSTERHAMMEL, P; MYGIND, N			SIGNIFICANCE OF H-1 AND H-2 RECEPTORS IN THE HUMAN NOSE - RATIONALE FOR TOPICAL USE OF COMBINED ANTIHISTAMINE PREPARATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN,RIGSHOSP,DEPT EAR NOSE & THROAT,OTOPATHOL LAB,DK-2100 COPENHAGEN O,DENMARK	Rigshospitalet; University of Copenhagen								BLEECKER ER, 1979, J ALLERGY CLIN IMMUN, V64, P597, DOI 10.1016/0091-6749(79)90020-4; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; Bradshaw J., 1979, BRIT J PHARMACOL, V66, P464; Broms P, 1979, Acta Otolaryngol Suppl, V360, P22; CONNELL JT, 1979, ANN ALLERGY, V42, P278; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KIRKEGARD J, UNPUB BR J DIS CHEST; KIRKEGARD J, UNPUB ALLERGY; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; MATSON CJ, 1978, ARCH INT PHARMACOD T, V232, P68; MATSON CJ, 1978, ARCH INT PHARMACOD T, V237, P68; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; WIDDICOMBE JG, 1977, RESPIRATORY DEFENS 2, P593; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P273	16	130	133	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					211	218		10.1016/0091-6749(82)90044-6	http://dx.doi.org/10.1016/0091-6749(82)90044-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	6179976				2022-12-18	WOS:A1982PG38400009
J	Lanternier, F; Mandaviani, SA; Barbati, E; Chaussade, H; Koumar, Y; Levy, R; Denis, B; Brunel, AS; Martin, S; Loop, M; Peeters, J; de Selys, A; Vanclaire, J; Vermylen, C; Nassogne, MC; Chatzis, O; Liu, LY; Migaud, M; Pedergnana, V; Desoubeaux, G; Jouvion, G; Chretien, F; Darazam, IA; Schaffer, AA; Netea, MG; De Bruycker, JJ; Bernard, L; Reynes, J; Amazrine, N; Abel, L; Van der Linden, D; Harrison, T; Picard, C; Lortholary, O; Mansouri, D; Casanova, JL; Puel, A				Lanternier, Fanny; Mandaviani, Seyed Alireza; Barbati, Elisa; Chaussade, Helene; Koumar, Yatrika; Levy, Romain; Denis, Blandine; Brunel, Anne-Sophie; Martin, Sophie; Loop, Michele; Peeters, Julie; de Selys, Ariel; Vanclaire, Jean; Vermylen, Christiane; Nassogne, Marie-Cecile; Chatzis, Olga; Liu, Luyan; Migaud, Melanie; Pedergnana, Vincent; Desoubeaux, Guillaume; Jouvion, Gregory; Chretien, Fabrice; Darazam, Ilad Alavi; Schaeffer, Alejandro A.; Netea, Mihai G.; De Bruycker, Jean J.; Bernard, Louis; Reynes, Jacques; Amazrine, Noureddine; Abel, Laurent; Van der Linden, Dimitri; Harrison, Tom; Picard, Capucine; Lortholary, Olivier; Mansouri, Davood; Casanova, Jean-Laurent; Puel, Anne			Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inborn error of immunity; primary immunodeficiency; invasive fungal diseases; inherited CARD9 deficiency; central nervous system; colitis; Candida species; human	CHRONIC MUCOCUTANEOUS CANDIDIASIS; HYPER-IGE SYNDROME; CHRONIC GRANULOMATOUS-DISEASE; CENTRAL-NERVOUS-SYSTEM; FUNGAL-INFECTIONS; CEREBRAL CANDIDIASIS; CEREBROSPINAL-FLUID; IL-17 IMMUNITY; INBORN-ERRORS; MASS LESION	Background: Invasive infections of the central nervous system (CNS) or digestive tract caused by commensal fungi of the genus Candida are rare and life-threatening. The known risk factors include acquired and inherited immunodeficiencies, with patients often displaying a history of multiple infections. Cases of meningoencephalitis, colitis, or both caused by Candida species remain unexplained. Objective: We studied 5 previously healthy children and adults with unexplained invasive disease of the CNS, digestive tract, or both caused by Candida species. The patients were aged 39, 7, 17, 37, and 26 years at the time of infection and were unrelated, but each was born to consanguineous parents of Turkish (2 patients), Iranian, Moroccan, or Pakistani origin. Meningoencephalitis was reported in 3 patients, meningoencephalitis associated with colitis was reported in a fourth patient, and the fifth patient had colitis only. Methods: Inherited caspase recruitment domain family, member 9 (CARD9) deficiency was recently reported in otherwise healthy patients with other forms of severe disease caused by Candida, Trichophyton, Phialophora, and Exophiala species, including meningoencephalitis but not colitis caused by Candida and Exophiala species. Therefore we sequenced CARD9 in the 5 patients. Results: All patients were found to be homozygous for rare and deleterious mutant CARD9 alleles: R7OW and Q289* for the 3 patients with Candida albicans induced meningoencephalitis, R35Q for the patient with meningoencephalitis and colitis caused by Candida glabrata, and Q295* for the patient with Candida albicans induced colitis. Regardless of their levels of mutant CARD9 protein, the patients' monocyte-derived dendritic cells responded poorly to CARD9-dependent fungal agonists (curdlan, heat-killed Calbicans, Saccharomyces cerevisiae, and Exophiala dermatitidis). Conclusion: Invasive infections of the CNS or digestive tract caused by Candida species in previously healthy children and even adults might be caused by inherited CARD9 deficiency.	[Lanternier, Fanny; Barbati, Elisa; Levy, Romain; Liu, Luyan; Migaud, Melanie; Pedergnana, Vincent; Abel, Laurent; Picard, Capucine; Casanova, Jean-Laurent; Puel, Anne] INSERM, UMR 1163, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Lanternier, Fanny; Barbati, Elisa; Levy, Romain; Denis, Blandine; Liu, Luyan; Migaud, Melanie; Pedergnana, Vincent; Abel, Laurent; Picard, Capucine; Lortholary, Olivier; Casanova, Jean-Laurent; Puel, Anne] Univ Paris 05, Imagine Inst, F-75015 Paris, France; [Lanternier, Fanny; Denis, Blandine; Lortholary, Olivier] Hop Necker Enfants Malad, AP HP, Necker Pasteur Infect Dis Ctr, Imagine Inst, Paris, France; [Mandaviani, Seyed Alireza] NRITLD, Pediat Resp Dis Res Ctr, Tehran, Iran; [Darazam, Ilad Alavi; Mansouri, Davood] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Natl Res Inst TB & Lung Dis, Dept Clin Immunol & Allergy, Tehran, Iran; [Chaussade, Helene; Bernard, Louis] Bretonneau Hosp, Infect Dis Unit, Tours, France; [Koumar, Yatrika; Brunel, Anne-Sophie; Reynes, Jacques] Infect Dis Unit, Montpellier, France; [Martin, Sophie; Peeters, Julie; Chatzis, Olga; Van der Linden, Dimitri] UCL, St Luc Univ Hosp, Pediat Infect Dis Unit, Brussels, Belgium; [Vermylen, Christiane] UCL, St Luc Univ Hosp, Pediat Hematol Oncol Unit, Brussels, Belgium; [Nassogne, Marie-Cecile] UCL, St Luc Univ Hosp, Pediat Neurol Unit, Brussels, Belgium; [Loop, Michele; de Selys, Ariel; Vanclaire, Jean] St Jean Hosp, Pediat Neonatol Unit, Brussels, Belgium; [Desoubeaux, Guillaume] Bretonneau Hosp, Ctr Study Resp Dis, Parasitol Mycol Trop Med Unit, INSERM,U1100,Equipe 3,Sch Med, Tours, France; [Jouvion, Gregory; Chretien, Fabrice] Inst Pasteur, Human Histopathol & Anim Models, Infect & Epidemiol Dept, Paris, France; [Lortholary, Olivier] Inst Pasteur, Mol Mycol Unit, Natl Reference Ctr Invas Mycoses & Antifungals, Paris, France; [Chretien, Fabrice] Hop St Anne, Neuropathol Lab, F-75674 Paris, France; [Schaeffer, Alejandro A.] NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA; [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, NL-6525 ED Nijmegen, Netherlands; [De Bruycker, Jean J.] Hop St Justine, Univ Ctr, Immunol & Rheumatol Unit, Montreal, PQ H3T 1C5, Canada; [Amazrine, Noureddine] Dept Neurosurg, Tangier, Morocco; [Abel, Laurent; Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY 10021 USA; [Harrison, Tom] St Georges Univ London, Infect & Immun Res Inst, London, England; [Picard, Capucine] Hop Necker Enfants Malad, AP HP, Study Ctr Immunodeficiency, Paris, France; [Picard, Capucine; Casanova, Jean-Laurent] Hop Necker Enfants Malad, AP HP, Pediat Hematol Immunol Unit, Paris, France; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Shahid Beheshti University Medical Sciences; CHU Tours; Universite de Montpellier; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; Radboud University Nijmegen; Radboud University Nijmegen; Universite de Montreal; Rockefeller University; St Georges University London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute	Puel, A (corresponding author), Univ Paris 05, Sorbonne Paris Cite, Lab Human Genet Infect Dis, Necker Branch,INSERM,UMR 1163,Imagine Inst, 24 Blvd Montparnasse, F-75015 Paris, France.	anne.puel@inserm.fr	mansouri, davood/G-6471-2017; Schaffer, Alejandro/N-1222-2019; Migaud, Mélanie/H-8044-2017; Jouvion, Grégory/AAL-2620-2021; Netea, Mihai/N-5155-2014; mahdaviani, alireza/G-3256-2017; Puel, Anne/H-7305-2017; Casanova, Jean-Laurent/I-3418-2017; Schaffer, Alejandro A/F-2902-2012; DESOUBEAUX, Guillaume/J-5026-2015; Levy, Romain/AAM-6426-2020; Lanternier, Fanny/AAQ-2815-2021; Abel, Laurent/H-8888-2017; Darazam, Ilad Alavi/K-6593-2014; Chretien, fabrice B/D-4035-2018	mansouri, davood/0000-0002-0564-8282; Migaud, Mélanie/0000-0003-3062-1214; mahdaviani, alireza/0000-0001-6224-4797; Puel, Anne/0000-0003-2603-0323; DESOUBEAUX, Guillaume/0000-0001-7945-9890; Levy, Romain/0000-0002-6393-0198; Abel, Laurent/0000-0001-7016-6493; Darazam, Ilad Alavi/0000-0002-4440-335X; Chretien, fabrice B/0000-0002-2794-1383; Pedergnana, Vincent/0000-0002-7852-5339; Van der Linden, Dimitri/0000-0002-2696-4559; Casanova, Jean-Laurent/0000-0002-7782-4169; Nassogne, Marie-Cecile/0000-0001-6936-1611; Harrison, Thomas/0000-0003-3619-4348; DE BRUYCKER, JEAN JACQUES/0000-0001-6026-6861	Rockefeller University; INSERM; Paris Descartes University; St. Giles Foundation; l'Agence Nationale de la Recherche [11-BSV3-005-01]; Jeffrey Modal Foundation; French Government, Investissement d' Avenir program, Laboratoire d' Excellence "Integrative Biology of Emerging Infectious Diseases" [ANR-10-LABX-62-IBEID]; CMIT (French Faculties College of Infectious Diseases); NATIONAL LIBRARY OF MEDICINE [ZIALM000097] Funding Source: NIH RePORTER	Rockefeller University; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Paris Descartes University; St. Giles Foundation; l'Agence Nationale de la Recherche(French National Research Agency (ANR)); Jeffrey Modal Foundation; French Government, Investissement d' Avenir program, Laboratoire d' Excellence "Integrative Biology of Emerging Infectious Diseases"; CMIT (French Faculties College of Infectious Diseases); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Supported in part by the Rockefeller University, INSERM, Paris Descartes University, the St. Giles Foundation and l'Agence Nationale de la Recherche (grant GENCMCD no 11-BSV3-005-01 to A.P.), and a Translational Research grant from the Jeffrey Modal Foundation (to A.P.). This study also received funding from the French Government as part of the Investissement d' Avenir program, Laboratoire d' Excellence "Integrative Biology of Emerging Infectious Diseases" (grant no. ANR-10-LABX-62-IBEID). F.L. was supported by a grant from the CMIT (French Faculties College of Infectious Diseases) and INSERM.	Adderson EE, 1998, J PEDIATR SURG, V33, P1463, DOI 10.1016/S0022-3468(98)90475-4; Agus S, 2000, BRIT J NEUROSURG, V14, P59, DOI 10.1080/02688690042951; Akyuz M, 2002, ACTA NEUROCHIR, V144, P505, DOI 10.1007/s007010200074; Alcais A, 2010, ANN NY ACAD SCI, V1214, P18, DOI 10.1111/j.1749-6632.2010.05834.x; BELISLE LG, 1968, REV NEUROPSYCH INFAN, V16, P763; Benjamin DK, 2006, PEDIATRICS, V117, P84, DOI 10.1542/peds.2004-2292; BLACK JT, 1970, J NEUROL NEUROSUR PS, V33, P864, DOI 10.1136/jnnp.33.6.864; Boisson B, 2013, IMMUNITY, V39, P676, DOI 10.1016/j.immuni.2013.09.002; Borha A, 2009, NEUROCHIRURGIE, V55, P57, DOI 10.1016/j.neuchi.2008.06.001; Casado JL, 1998, AIDS PATIENT CARE ST, V12, P681, DOI 10.1089/apc.1998.12.681; Casanova JL, 2013, ANNU REV GENOM HUM G, V14, P215, DOI 10.1146/annurev-genom-091212-153448; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Choudhari YK, 2007, BRIT J HOSP MED, V68, P274, DOI 10.12968/hmed.2007.68.5.23337; Cimbaluk D, 2005, J CLIN GASTROENTEROL, V39, P795, DOI 10.1097/01.mcg.0000177237.82382.b8; CRAIG WM, 1949, ARCH NEURO PSYCHIATR, V62, P314, DOI 10.1001/archneurpsyc.1949.02310150061007; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Dorhoi A, 2010, J EXP MED, V207, P777, DOI 10.1084/jem.20090067; Drewniak A, 2013, BLOOD, V121, P2385, DOI 10.1182/blood-2012-08-450551; EDELSON RN, 1975, NEW YORK STATE J MED, V75, P900; EMDIN W, 1954, S Afr Med J, V28, P868; FINE JM, 1955, NEUROLOGY, V5, P438, DOI 10.1212/WNL.5.6.438; FLEISCHMANN J, 1986, AM J MED SCI, V291, P334, DOI 10.1097/00000441-198605000-00009; Gavino C, 2014, CLIN INFECT DIS, V59, P81, DOI 10.1093/cid/ciu215; George K, 2001, EUR J GASTROEN HEPAT, V13, P735, DOI 10.1097/00042737-200106000-00021; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; HALPERT B, 1946, JAMA-J AM MED ASSOC, V130, P932, DOI 10.1001/jama.1946.02870140024008; Hanci M, 1998, ZBL NEUROCHIR, V59, P129; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; HOLYST J, 1976, NEUROCHIRURGIA, V19, P126; Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426; IKEDA K, 1990, NEUROSURGERY, V26, P860, DOI 10.1227/00006123-199005000-00020; Jachiet M, 2014, JAMA DERMATOL; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P501, DOI 10.3109/02688699208995043; JANKE D, 1957, Arch Klin Exp Dermatol, V206, P608, DOI 10.1007/BF00479057; JAYAGOPAL S, 1992, CLIN INFECT DIS, V15, P555, DOI 10.1093/clind/15.3.555; KAUFFMAN CA, 1981, ARCH INTERN MED, V141, P1076, DOI 10.1001/archinte.141.8.1076; Kitagawa KH, 2008, J AM ACAD DERMATOL, V59, pS120, DOI 10.1016/j.jaad.2008.06.035; Kudo T, 2010, J PEDIATR GASTR NUTR, V51, P96, DOI 10.1097/MPG.0b013e31818de1ba; Lamagni TL, 2001, EPIDEMIOL INFECT, V126, P397, DOI 10.1017/S0950268801005507; Lanternier F, 2014, J INFECT DIS; Lanternier F, 2013, CURR OPIN PEDIATR, V25, P736, DOI 10.1097/MOP.0000000000000031; Lanternier F, 2013, NEW ENGL J MED, V369, P1704, DOI 10.1056/NEJMoa1208487; Lionakis MS, 2014, J INFECT DIS; LISCH S, 1994, DEUT MED WOCHENSCHR, V119, P13, DOI 10.1055/s-2008-1058655; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lortholary O, 2014, INTENS CARE MED, V40, P1303, DOI 10.1007/s00134-014-3408-3; Mason TBA, 1996, J CHILD NEUROL, V11, P336, DOI 10.1177/088307389601100413; Mathai Alka Mary, 2007, Indian J Pathol Microbiol, V50, P838; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; MORRIS AA, 1945, ARCH NEURO PSYCHIATR, V54, P361, DOI 10.1001/archneurpsyc.1945.02300110045006; NADORRA R L, 1987, Pediatric Pathology, V7, P245; NGUYEN MH, 1995, CLIN INFECT DIS, V21, P323, DOI 10.1093/clinids/21.2.323; O'Brien D, 2011, ACTA NEUROCHIR, V153, P1347, DOI 10.1007/s00701-011-0990-9; POPOW C, 1981, KLIN PADIATR, V193, P401, DOI 10.1055/s-2008-1034509; Praneenararat Surat, 2014, Case Rep Gastroenterol, V8, P199, DOI 10.1159/000363566; PRESCOTT RJ, 1992, J CLIN PATHOL, V45, P806, DOI 10.1136/jcp.45.9.806; Puel A, 2012, CURR OPIN ALLERGY CL, V12, P616, DOI 10.1097/ACI.0b013e328358cc0b; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Puel A, 2010, CURR OPIN IMMUNOL, V22, P467, DOI 10.1016/j.coi.2010.06.009; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Sokol H, 2013, GASTROENTEROLOGY, V145, P591, DOI 10.1053/j.gastro.2013.05.047; Vasylyk V U, 1992, Probl Tuberk, P62; VILELLA JM, 1985, PRESSE MED, V14, P980; VORREITH M, 1961, Cas Lek Cesk, V100, P966; Wang XW, 2014, J ALLERGY CLIN IMMUN, V133, P905, DOI 10.1016/j.jaci.2013.09.033; WHITE BE, 1972, NEW ENGL J MED, V286, P321; WIETHOLTER H, 1984, CLIN NEUROPATHOL, V3, P37; Zheng L, 1996, NEUROL SURG TOKYO, V24, P389; ZIMMERMAN SL, 1947, JAMA-J AM MED ASSOC, V135, P145, DOI 10.1001/jama.1947.02890030013004	70	129	132	0	65	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1558	U269		10.1016/j.jaci.2014.12.1930	http://dx.doi.org/10.1016/j.jaci.2014.12.1930			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25702837	Green Accepted			2022-12-18	WOS:000355933400019
J	Ballmer-Weber, BK; Fernandez-Rivas, M; Beyer, K; Defernez, M; Sperrin, M; Mackie, AR; Salt, LJ; Hourihane, JO; Asero, R; Belohlavkova, S; Kowalski, M; de Blay, F; Papadopoulos, NG; Clausen, M; Knulst, AC; Roberts, G; Popov, T; Sprikkelman, AB; Dubakiene, R; Vieths, S; van Ree, R; Crevel, R; Mills, ENC				Ballmer-Weber, Barbara K.; Fernandez-Rivas, Montserrat; Beyer, Kirsten; Defernez, Marianne; Sperrin, Matthew; Mackie, Alan R.; Salt, Louise J.; Hourihane, Jonathan O'B.; Asero, Riccardo; Belohlavkova, Simona; Kowalski, Marek; de Blay, Frederic; Papadopoulos, Nikolaos G.; Clausen, Michael; Knulst, Andre C.; Roberts, Graham; Popov, Ted; Sprikkelman, Aline B.; Dubakiene, Ruta; Vieths, Stefan; van Ree, Ronald; Crevel, Rene; Mills, E. N. Clare			How much is too much? Threshold dose distributions for 5 food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food; allergy; threshold; peanut; hazelnut; celeriac; fish; shrimp; EuroPrevall	DOUBLE-BLIND; EUROPEAN ACADEMY; PREVALENCE; PEANUT; CHALLENGES; CHILDREN; POPULATION; RISK	Background: Precautionary labeling is used to warn consumers of the presence of unintended allergens, but the lack of agreed allergen thresholds can result in confusion and risk taking by patients with food allergy. The lack of data on threshold doses below which subjects are unlikely to react is preventing the development of evidence-based allergen management strategies that are understood by clinician and patient alike. Objective: We sought to define threshold dose distributions for 5 major allergenic foods in the European population. Methods: Patients with food allergy were drawn from the EuroPrevall birth cohort, community surveys, and outpatient clinic studies and invited to undergo a food challenge. Low-dose, double-blind, placebo-controlled food challenges were undertaken with commercially available food ingredients (peanut, hazelnut, celery, fish, and shrimp) blinded into common matrices. Dose distributions were modeled by using interval-censoring survival analysis with 3 parametric approaches. Results: Of the 5 foods used for challenge, 4 produced similar dose distributions, with estimated doses eliciting reactions in 10% of the allergic population (ED10), ranging from 1.6 to 10.1 mg of protein for hazelnut, peanut, and celery with overlapping 95% CIs. ED10 values for fish were somewhat higher (27.3 mg of protein), although the CIs were wide and overlapping between fish and plant foods. Shrimp provided radically different dose distributions, with an ED10 value of 2.5 g of protein. Conclusion: This evidence base will contribute to the development of reference doses and action levels for allergens in foods below which only the most sensitive subjects might react.	[Ballmer-Weber, Barbara K.] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Fernandez-Rivas, Montserrat] IdISSC, Hosp Clin San Carlos, Dept Allergy, Madrid, Spain; [Beyer, Kirsten] Charite Univ Med Ctr, Dept Paediat Pneumol & Immunol, Berlin, Germany; [Defernez, Marianne; Mackie, Alan R.; Salt, Louise J.; Mills, E. N. Clare] Inst Food Res, Norwich NR4 7UA, Norfolk, England; [Sperrin, Matthew] Univ Manchester, Inst Populat Hlth, Manchester M1 7DN, Lancs, England; [Hourihane, Jonathan O'B.] Univ Coll Cork, Cork, Ireland; [Asero, Riccardo] Clin San Carlo, Ambulatorio Allergol, Milan, Italy; [Belohlavkova, Simona] Fac Hosp Bulovka, Dept Pediat, Prague, Czech Republic; [Kowalski, Marek] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [de Blay, Frederic] Univ Strasbourg, Federat Translat Med, Univ Hosp, Chest Dis Dept, Strasbourg, France; [Papadopoulos, Nikolaos G.] Univ Athens, Pediat Clin 2, Dept Allergy, GR-10679 Athens, Greece; [Clausen, Michael] Univ Hosp, Landspitali, Childrens Hosp Iceland, Reykjavik, Iceland; [Knulst, Andre C.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands; [Roberts, Graham] Univ Southampton, Fac Med, Human Dev & Hlth Acad Unit, Southampton SO9 5NH, Hants, England; [Popov, Ted] Med Univ, Clin Ctr Allergol, Alexandrovska Hosp, Sofia, Bulgaria; [Sprikkelman, Aline B.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Resp Med & Allergy, NL-1012 WX Amsterdam, Netherlands; [Dubakiene, Ruta] Vilnius Univ, Fac Med, Chest Clin Allergol & Radiol, Vilnius, Lithuania; [Vieths, Stefan] Paul Ehrlich Inst, Langen, Germany; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1012 WX Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands; [Crevel, Rene] Unilever Safety & Environm Assurance Ctr, Sharnbrook, Beds, England; [Mills, E. N. Clare] Univ Manchester, Manchester Inst Biotechnol, Manchester Acad Hlth Sci Ctr, Inst Inflammat & Repair, Manchester M1 7DN, Lancs, England	University of Zurich; University Zurich Hospital; Hospital Clinico San Carlos; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Manchester; University College Cork; Bulovka University Hospital; Medical University Lodz; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National & Kapodistrian University of Athens; Landspitali National University Hospital; Utrecht University; Utrecht University Medical Center; University of Southampton; Medical University Sofia; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Vilnius University; Paul Ehrlich Institute; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Unilever; University of Manchester	Mills, ENC (corresponding author), Univ Manchester, Manchester Inst Biotechnol, Manchester Acad Hlth Sci Ctr, Inst Inflammat & Repair, 131 Princess St, Manchester M1 7DN, Lancs, England.	clare.mills@manchester.ac.uk	Papadopoulos, Nikolaos/ABE-1774-2021; N.G., Papadopoulos/L-8670-2013; Mills, Clare/P-4261-2015; Popov, Todor/Q-9928-2016; Mackie, Alan/N-7780-2018	Papadopoulos, Nikolaos/0000-0002-4448-3468; N.G., Papadopoulos/0000-0002-4448-3468; Mills, Clare/0000-0001-7433-1740; Popov, Todor/0000-0001-5052-5866; Mackie, Alan/0000-0002-5681-0593; Knulst, Andre/0000-0002-1056-3179; Sperrin, Matthew/0000-0002-5351-9960; Roberts, Graham/0000-0003-2252-1248	European Union through the EuroPrevall project [FOOD-CT-2005-514000]; UK Food Standards Agency (FSA projects) [T07062, T07046]; Grida; MSD; Nutricia Advanced Medical Nutrition Netherlands; AstraZeneca Netherlands; TEVA Netherlands; GlaxoSmithKline Netherlands; UK Biological and Biotechnological Sciences Research Council through an Institute Strategic Programme Grant [BBS/E/F/00041800, BBS/E/F/00042204]; Biotechnology and Biological Sciences Research Council [BBS/E/F/00042204, BBS/E/F/00041800] Funding Source: researchfish; Medical Research Council [MC_PC_13042, MR/K006665/1] Funding Source: researchfish; MRC [MR/K006665/1] Funding Source: UKRI	European Union through the EuroPrevall project; UK Food Standards Agency (FSA projects); Grida; MSD; Nutricia Advanced Medical Nutrition Netherlands(Danone Nutricia); AstraZeneca Netherlands(AstraZeneca); TEVA Netherlands(Teva Pharmaceutical Industries); GlaxoSmithKline Netherlands(GlaxoSmithKline); UK Biological and Biotechnological Sciences Research Council through an Institute Strategic Programme Grant(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the European Union through the EuroPrevall project (FOOD-CT-2005-514000) and the UK Food Standards Agency (FSA projects T07062 and T07046). The Lithuanian birth cohort was supported by unrestricted grants from Grida and MSD and the Dutch birth cohort by unrestricted grants from Nutricia Advanced Medical Nutrition Netherlands, AstraZeneca Netherlands, TEVA Netherlands, and GlaxoSmithKline Netherlands. M.D., A.R.M., L.J.S., and E.N.C.M. were partly funded by the UK Biological and Biotechnological Sciences Research Council through an Institute Strategic Programme Grant to the Institute of Food Research (BBS/E/F/00041800, BBS/E/F/00042204).	Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Burney P, 2010, ALLERGY, V65, P1182, DOI 10.1111/j.1398-9995.2010.02346.x; Cochrane SA, 2012, ALLERGY, V67, P107, DOI 10.1111/j.1398-9995.2011.02715.x; Cornelisse-Vermaat JR, 2008, EUR J PUBLIC HEALTH, V18, P115, DOI 10.1093/eurpub/ckm032; Crevel RWR, 2008, ALLERGY, V63, P597, DOI 10.1111/j.1398-9995.2008.01636.x; Crevel RWR, 2007, FOOD CHEM TOXICOL, V45, P691, DOI 10.1016/j.fct.2006.09.005; EFSA (European Food Safety Authority), 2004, EFSA J, V2, P32, DOI [10.2903/j.efsa.2004.32, DOI 10.2903/J.EFSA.2004.32]; Eller E, 2012, ANN ALLERG ASTHMA IM, V108, P332, DOI 10.1016/j.anai.2012.03.010; Flokstra-de Blok BMJ, 2010, ALLERGY, V65, P1031, DOI 10.1111/j.1398-9995.2009.02304.x; Gendel SM, 2012, REGUL TOXICOL PHARM, V63, P279, DOI 10.1016/j.yrtph.2012.04.007; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Kummeling I, 2009, ALLERGY, V64, P1493, DOI 10.1111/j.1398-9995.2009.02046.x; Madsen CB, 2012, CLIN EXP ALLERGY, V42, P30, DOI 10.1111/j.1365-2222.2011.03868.x; Mills ENC, 2007, ALLERGY, V62, P717, DOI 10.1111/j.1398-9995.2007.01425.x; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osterballe M, 2005, PEDIAT ALLERG IMM-UK, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Rance F, 2005, CLIN EXP ALLERGY, V35, P167, DOI 10.1111/j.1365-2222.2005.02162.x; Robertson ON, 2013, FOOD ADDIT CONTAM A, V30, P1467, DOI 10.1080/19440049.2013.804953; Sakellariou A, 2010, ALLERGY, V65, P534, DOI 10.1111/j.1398-9995.2009.02209.x; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Steensma DP, 2003, MAYO CLIN PROC, V78, P221, DOI 10.4065/78.2.221; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; The R Development Core Team, R LANG ENV STAT COMP; Therneau TM., PACKAGE SURVIVAL ANA	34	129	133	1	60	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					964	971		10.1016/j.jaci.2014.10.047	http://dx.doi.org/10.1016/j.jaci.2014.10.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25589011				2022-12-18	WOS:000352238600018
J	Dretzke, J; Meadows, A; Novielli, N; Huissoon, A; Fry-Smith, A; Meads, C				Dretzke, Janine; Meadows, Angela; Novielli, Nicola; Huissoon, Aarnoud; Fry-Smith, Anne; Meads, Catherine			Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergic rhinitis; sublingual immunotherapy; subcutaneous immunotherapy; systematic review; meta-analysis; indirect comparison; meta-regression	POLLEN IMMUNOTHERAPY; CLINICAL-EFFICACY; DOUBLE-BLIND	Background: Severe allergic rhinitis uncontrolled by pharmacotherapy can adversely affect quality of life. Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) have demonstrated effectiveness in this patient group; however, it remains uncertain which route of administration is more effective. Objectives: We sought to update existing systematic reviews on the clinical effectiveness of SCIT and SLIT versus placebo, to undertake a systematic review of head-to-head trials, and to compare the relative effectiveness of SCIT and SLIT in an adjusted indirect comparison. Methods: Standard systematic review methods aimed at minimizing bias were used. Double-blind, randomized, placebo-controlled trials of SCIT or SLIT or trials of SCIT versus SLIT were included. Meta-analysis and indirect comparison metaanalysis with meta-regression were performed. Results: Updated meta-analyses confirmed statistically significant benefits for SCIT and SLIT compared with placebo in adults and, to a lesser extent, in children. Only 1 head-to-head trial met the inclusion criteria; both this and the indirect comparisons did not provide conclusive results in favor of either SCIT or SLIT based on symptom-medication or quality-of-life scores. There was a trend toward favoring SCIT for symptom and medication scores. Conclusions: Although there is clear evidence of effectiveness of both SCIT and SLIT, superiority of one mode of administration over the other could not be consistently demonstrated through indirect comparison, and further research is needed to establish the comparative effectiveness of SCIT versus SLIT.	[Dretzke, Janine; Meadows, Angela; Novielli, Nicola; Fry-Smith, Anne] Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England; [Huissoon, Aarnoud] Birmingham Heartlands Hosp, Dept Immunol, Birmingham, W Midlands, England; [Meads, Catherine] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; Brunel University	Dretzke, J (corresponding author), Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England.	j.dretzke@bham.ac.uk	Meadows, Angela/H-5872-2019	Meadows, Angela/0000-0002-6273-7564; Meads, Catherine/0000-0002-2368-0665; Novielli, Nicola/0000-0001-9314-7092	UK National Institute for Health Research Health Technology Assessment Programme [09/78/01]; National Institute for Health Research Health Technology Assessment Programme; Meda advisory board; GlaxoSmithKline; National Institute for Health Research [09/78/01] Funding Source: researchfish	UK National Institute for Health Research Health Technology Assessment Programme(National Institute for Health Research (NIHR)); National Institute for Health Research Health Technology Assessment Programme(National Institute for Health Research (NIHR)); Meda advisory board; GlaxoSmithKline(GlaxoSmithKline); National Institute for Health Research(National Institute for Health Research (NIHR))	This work formed part of a wider project commissioned and funded by the UK National Institute for Health Research Health Technology Assessment Programme as project no. 09/78/01.; Disclosure of potential conflict of interest: J. Dretzke, A. Meadows, N. Novielli, A. Fry-Smith, and C. Meads have received research support from the National Institute for Health Research Health Technology Assessment Programme. A. Huissoon has received consultancy fees from the Meda advisory board, has received lecture fees from and holds stock in GlaxoSmithKline, has received travel support from ALK-Abello, and ALK-Abello and Meda Pharmaceuticals have sponsored annual allergy training meetings that his department organizes for primary care physicians.	Allergy UK, NIGHT PAY EVERY DAY; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Cochrane Collaboration, 2008, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9780470712184; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Donegan S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011054; DuBuske LH, 2011, ALLERGY ASTHMA PROC, V32, P239, DOI 10.2500/aap.2011.32.3453; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Fiocchi A, 2011, ARCH DIS CHILDHOOD-E, V96, P91, DOI 10.1136/adc.2010.183095; Hrobjartsson A, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003974.pub2, DOI 10.1002/14651858.CD003974.PUB2]; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kuna P, 2011, J ALLERGY CLIN IMMUN, V127, P502, DOI 10.1016/j.jaci.2010.11.036; Malling HJ, 1998, ALLERGY, V53, P461; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; National Institute of Allergy and Infectious Diseases (NIAID), LONG TERM EFF SUBL G; Okuda Minoru, 2006, Arerugi, V55, P655; Pfaar O, 2011, IMMUNOL ALLERGY CLIN, V31, P289, DOI 10.1016/j.iac.2011.02.004; PRISMA, 2015, TRANSP REP SYST REV; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Schunemann HJ., 2008, COCHRANE HDB SYSTEMA, P359, DOI DOI 10.1002/9780470712184.CH12; Sterne JA, 2008, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch10, DOI 10.1002/9780470712184.CH10]; The Cochrane Collaboration, 2011, REV MAN REVMAN COMP; Vance GHS, 2011, CLIN EXP ALLERGY, V41, P1313, DOI 10.1111/j.1365-2222.2011.03803.x; Ventura MT, 2009, INT J IMMUNOPATH PH, V22, P403, DOI 10.1177/039463200902200217; Walker SM, 2011, CLIN EXP ALLERGY, V41, P1177, DOI 10.1111/j.1365-2222.2011.03794.x; White P, 1998, CLIN EXP ALLERGY, V28, P266	32	129	132	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1361	1366		10.1016/j.jaci.2013.02.013	http://dx.doi.org/10.1016/j.jaci.2013.02.013			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23557834				2022-12-18	WOS:000318912200013
J	Lee, HC; Headley, MB; Loo, YM; Berlin, A; Gale, M; Debley, JS; Lukacs, NW; Ziegler, SF				Lee, Hai-Chon; Headley, Mark B.; Loo, Yueh-Ming; Berlin, Aaron; Gale, Michael, Jr.; Debley, Jason S.; Lukacs, Nicholas W.; Ziegler, Steven F.			Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TSLP; RSV; asthma; epithelium; T(H)2	RIG-I; IMMUNE ENVIRONMENT; PEDIATRIC-AIRWAY; EXPRESSION; ASTHMA; INFLAMMATION; TSLP; INNATE; INTERFERON; CYTOKINE	Background: Respiratory viral infection, including respiratory syncytial virus (RSV) and rhinovirus, has been linked to respiratory disease in pediatric patients, including severe acute bronchiolitis and asthma exacerbation. Objective: The study examined the role of the epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) in the response to RSV infection. Methods: Infection of human airway epithelial cells was used to examine TSLP induction after RSV infection. Air-liquid interface cultures from healthy children and children with asthma were also tested for TSLP production after infection. Finally, a mouse model was used to directly test the role of TSLP signaling in the response to RSV infection. Results: Infection of airway epithelial cells with RSV led to the production of TSLP via activation of an innate signaling pathway that involved retinoic acid induced gene I, interferon promoter-stimulating factor 1, and nuclear factor-kappa B. Consistent with this observation, airway epithelial cells from asthmatic children a produced significantly greater levels of TSLP after RSV infection than cells from healthy children. In mouse models, RSV-induced TSLP expression was found to be critical for the development of immunopathology. Conclusion: These findings suggest that RSV can use an innate antiviral signaling pathway to drive a potentially nonproductive immune response and has important implications for the role of TSLP in viral immune responses in general. (J Allergy Clin Immunol 2012;130:1187-96.)	[Lee, Hai-Chon; Headley, Mark B.; Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA 98101 USA; [Headley, Mark B.; Loo, Yueh-Ming; Gale, Michael, Jr.; Ziegler, Steven F.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA; [Berlin, Aaron; Lukacs, Nicholas W.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; [Debley, Jason S.] Seattle Childrens Res Inst, Ctr Tissue & Cell Sci, Seattle, WA USA; [Debley, Jason S.] Univ Washington, Sch Med, Dept Pediat, Div Pulm Med, Seattle, WA 98195 USA	Benaroya Research Institute; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Ziegler, SF (corresponding author), Benaroya Res Inst, Program Immunol, 1201 9th Ave, Seattle, WA 98101 USA.	sziegler@benaroyaresearch.org	Lukacs, Nicholas W/ABH-5583-2020	Loo, Yueh-Ming/0000-0001-6294-7273; Gale, Michael/0000-0002-6332-7436; Headley, Mark/0000-0002-0924-9326	National Institutes of Health [AI068731, HL098067, AR055695, AR056113, HL102708, AI060389, AI083019, HL059178]; National Institutes of Health (NIH); NIH; American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL098067, R21HL102708, R01HL059178] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068731, R01AI060389, R56AI060389, U19AI083019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056113, R01AR055695] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma Immunology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the National Institutes of Health (grants AI068731, HL098067, AR055695, and AR056113 to S.F.Z.; grant HL102708 to S.F.Z. and J.S.D.; grants AI060389 and AI083019 to M.G. Jr; and grant HL059178 to N.W.L.).; Disclosure of potential conflict of interest: M. Headley, M. Gale, J. S. Debley, and N. W. Lukacs have received research support from the National Institutes of Health (NIH). S. F. Ziegler has received research support from the NIH, has received lecture fees from the American Academy of Allergy, Asthma & Immunology, and has received travel expenses from the Federation of Clinical Immunology Services. The rest of the authors declare that they have no relevant conflicts of interest.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Bendelja K, 2000, CLIN EXP IMMUNOL, V121, P332, DOI 10.1046/j.1365-2249.2000.01297.x; Bueno SM, 2008, INT IMMUNOPHARMACOL, V8, P1320, DOI 10.1016/j.intimp.2008.03.012; Calven J, 2012, J INNATE IMMUN, V4, P86, DOI 10.1159/000329131; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Chang J, 2002, NAT MED, V8, P54, DOI 10.1038/nm0102-54; Davies Donna E, 2009, Proc Am Thorac Soc, V6, P678, DOI 10.1513/pats.200907-067DP; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Erjefalt JS, 2010, CLIN RESPIR J, V4, P9, DOI 10.1111/j.1752-699X.2010.00191.x; Fontenot D, 2009, P NATL ACAD SCI USA, V106, P16776, DOI 10.1073/pnas.0907347106; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Groskreutz DJ, 2006, J IMMUNOL, V176, P1733, DOI 10.4049/jimmunol.176.3.1733; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Headley MB, 2009, J IMMUNOL, V182, P1641, DOI 10.4049/jimmunol.182.3.1641; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kassim SY, 2007, INFECT IMMUN, V75, P5640, DOI 10.1128/IAI.00799-07; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Keller BC, 2006, J VIROL, V80, P9424, DOI 10.1128/JVI.00768-06; Kristjansson S, 2005, J ALLERGY CLIN IMMUN, V116, P805, DOI 10.1016/j.jaci.2005.07.012; Lane C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-53; Lee HC, 2008, J IMMUNOL, V181, P5189, DOI 10.4049/jimmunol.181.8.5189; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Lindell DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021823; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07; Lukacs NW, 2006, AM J PATHOL, V169, P977, DOI 10.2353/ajpath.2006.051055; Lukacs NW, 2001, J IMMUNOL, V167, P1060, DOI 10.4049/jimmunol.167.2.1060; Miller AL, 2004, J INFECT DIS, V189, P1419, DOI 10.1086/382958; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Psarras Stelios, 2004, Paediatr Respir Rev, V5 Suppl A, pS179, DOI 10.1016/S1526-0542(04)90034-6; Qiao JO, 2011, IMMUNOL CELL BIOL, V89, P231, DOI 10.1038/icb.2010.85; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; Rudd BD, 2006, J IMMUNOL, V176, P1937, DOI 10.4049/jimmunol.176.3.1937; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Smit JJ, 2007, AM J PATHOL, V171, P1944, DOI 10.2353/ajpath.2007.070578; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stevens PT, 2008, CLIN EXP ALLERGY, V38, P1901, DOI 10.1111/j.1365-2222.2008.03093.x; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Tekkanat KK, 2001, J IMMUNOL, V166, P3542, DOI 10.4049/jimmunol.166.5.3542; Wennergren G, 2001, EUR RESPIR J, V18, P1044, DOI 10.1183/09031936.01.00254101; Wilkins C, 2010, CURR OPIN IMMUNOL, V22, P41, DOI 10.1016/j.coi.2009.12.003; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zhou BH, 2008, J IMMUNOL, V181, P6557, DOI 10.4049/jimmunol.181.9.6557; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	57	129	134	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1187	+		10.1016/j.jaci.2012.07.031	http://dx.doi.org/10.1016/j.jaci.2012.07.031			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22981788	Green Accepted			2022-12-18	WOS:000310571400021
J	Lucendo, AJ; Arias, A; De Rezende, LC; Yague-Compadre, JL; Mota-Huertas, T; Gonzalez-Castillo, S; Cuesta, RA; Tenias, JM; Bellon, T				Lucendo, Alfredo J.; Arias, Angel; De Rezende, Livia C.; Luis Yaguee-Compadre, Jose; Mota-Huertas, Teresa; Gonzalez-Castillo, Sonia; Cuesta, Ruben A.; Tenias, Jose M.; Bellon, Teresa			Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: A prospective study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; fibrosis; lamina propria; IL-5; TGF-beta 1; fibroblast growth factor 9; CCL18; fluticasone propionate	ACTIVATION-REGULATED CHEMOKINE; BASEMENT-MEMBRANE; TGF-BETA; PULMONARY; FIBROSIS; CCL18; LUNG; CHILDREN; ASTHMA; INFLAMMATION	Background: Recent research shows that both pediatric and adult patients with eosinophilic esophagitis (EoE) experience esophageal remodeling marked by increased collagen deposition in which TGF-beta plays an important role. However, limited data are available on the intensity and reversibility of fibrous remodeling in adults with EoE. Objective: We sought to analyze differences in collagen deposition in the lamina propria (LP) and profibrogenic cytokine gene expression along with other changes induced by prolonged treatment with fluticasone propionate in adults with EoE. Methods: Ten adults given consecutive diagnoses of EoE were studied prospectively. Deep esophageal biopsy specimens were obtained before and after 1 year of treatment with fluticasone propionate. Collagen deposition in the LP was assessed in tissue sections with the aid of the Masson trichrome technique. IL5, TGFB1, fibroblast growth factor 9 (FGF9), and CCL18 gene expression was quantified through real-time PCR. EoE results were compared among samples from 10 adult patients with gastroesophageal reflux disease and 10 control subjects with healthy esophagi. Results: Patients with EoE showed a significant increase in subepithelial collagen deposition; this correlated positively with eosinophil density in the LP and the patient's age. Prolonged steroid treatment induced a nonsignificant reduction in subepithelial fibrosis, which remained significantly higher than in control subjects. Profibrogenic cytokine gene expression also increased in patients with EoE, with IL5 (P < .001), FGF9 (P = 5.005), and CCL18 (P = .008) all significantly upregulated. After 1 year of treatment, a reduction was observed in gene expression; for CCL18 expression, this decrease was statistically significant (P < .001). Conclusions: Esophageal remodeling is associated with upregulated gene expression of profibrogenic cytokines in adults with EoE. Prolonged treatment with fluticasone propionate leads to a nonsignificant reduction in subepithelial collagen deposition accompanied by downregulation of profibrogenic cytokine gene expression, with that of CCL18 being especially significant. (J Allergy Clin Immunol 2011;128:1037-46.)	[Lucendo, Alfredo J.; De Rezende, Livia C.; Gonzalez-Castillo, Sonia] Hosp Gen Tomelloso, Dept Gastroenterol, Tomelloso 13700, Spain; [Arias, Angel; Tenias, Jose M.] Complejo Hosp La Mancha Ctr, Res Unit, Alcazar De San Juan, Spain; [Luis Yaguee-Compadre, Jose; Mota-Huertas, Teresa; Cuesta, Ruben A.] Complejo Hosp La Mancha Ctr, Dept Pathol, Alcazar De San Juan, Spain; [Bellon, Teresa] La Paz Hosp Res Inst IdiPAZ, Madrid, Spain		Lucendo, AJ (corresponding author), Hosp Gen Tomelloso, Dept Gastroenterol, Vereda Socuellamos S-N, Tomelloso 13700, Spain.	alucendo@vodafone.es	Tenias, Jose Maria/I-8755-2019; Bellón, Teresa/ABF-4916-2020; Lucendo, Alfredo J/C-1958-2009; Arias, Ángel J/E-5885-2016	Tenias, Jose Maria/0000-0002-8079-8491; Bellón, Teresa/0000-0002-0138-6879; Lucendo, Alfredo J/0000-0003-1183-1072; Arias, Ángel J/0000-0003-1006-0958	Castilla-La Mancha Health Research Foundation (Fundacion para la Investigacion Sanitaria de Castilla La Mancha or FISCAM) [AN-2008/21]; Association of Biomedical Research La Mancha Centro (Asociacion de Investigacion Biomedica La Mancha Centro)	Castilla-La Mancha Health Research Foundation (Fundacion para la Investigacion Sanitaria de Castilla La Mancha or FISCAM); Association of Biomedical Research La Mancha Centro (Asociacion de Investigacion Biomedica La Mancha Centro)	Supported by grants from the Castilla-La Mancha Health Research Foundation (Fundacion para la Investigacion Sanitaria de Castilla La Mancha or FISCAM, grant AN-2008/21) and from the Association of Biomedical Research La Mancha Centro (Asociacion de Investigacion Biomedica La Mancha Centro).	Abu-Sultaneh SMA, 2011, DIGEST DIS SCI, V56, P97, DOI 10.1007/s10620-010-1259-5; Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2008, CURR MOL MED, V8, P350, DOI 10.2174/156652408785161023; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Aceves SS, 2005, J ALLERGY CLIN IMMUN, V116, P705, DOI 10.1016/j.jaci.2005.05.011; Ahmad S, 2010, EUR J CLIN INVEST, V40, P1067, DOI 10.1111/j.1365-2362.2010.02353.x; Atamas SP, 2003, AM J RESP CELL MOL, V29, P743, DOI 10.1165/rcmb.2003-0078OC; Bellon T, 2011, NEPHROL DIAL TRANSPL; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384; De Nadai P, 2006, J IMMUNOL, V176, P6286, DOI 10.4049/jimmunol.176.10.6286; Faubion WA, 1998, J PEDIATR GASTR NUTR, V27, P90, DOI 10.1097/00005176-199807000-00016; Fromer L, 2010, SOUTH MED J, V103, P1038, DOI 10.1097/SMJ.0b013e3181ebec5c; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; Kin HB, 2009, CHEST, V135, P295, DOI 10.1378/chest.08-0962; Kwiatek MA, 2011, GASTROENTEROLOGY, V140, P82, DOI 10.1053/j.gastro.2010.09.037; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2007, ENDOSCOPY, V39, P765, DOI 10.1055/s-2007-966738; Lucendo AJ, 2008, AM J GASTROENTEROL, V103, P2184, DOI 10.1111/j.1572-0241.2008.01937.x; Lucendo AJ, 2010, EXPERT REV GASTROENT, V4, P141, DOI 10.1586/EGH.10.9; Luzina IG, 2006, J CELL PHYSIOL, V206, P221, DOI 10.1002/jcp.20452; Luzina IG, 2006, AM J RESP CELL MOL, V35, P298, DOI 10.1165/rcmb.2006-0033OC; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Mulder DJ, 2009, GUT, V58, P166, DOI 10.1136/gut.2008.157628; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC; Prasse A, 2007, ARTHRITIS RHEUM-US, V56, P1685, DOI 10.1002/art.22559; Schraufstatter I, 2004, AM J PHYSIOL-LUNG C, V286, pL494, DOI 10.1152/ajplung.00323.2002; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2010, GASTROINTEST ENDOSC, V18, P99; Straumann A, 2011, CLIN GASTROENTEROL H, V9, P400, DOI 10.1016/j.cgh.2011.01.017; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Ward C, 2004, CLIN EXP ALLERGY, V34, P1905, DOI 10.1111/j.1365-2222.2004.02121.x; Wimmer A, 2006, BLOOD, V108, P3722, DOI 10.1182/blood-2006-04-014399; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	41	129	132	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1037	1046		10.1016/j.jaci.2011.08.007	http://dx.doi.org/10.1016/j.jaci.2011.08.007			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21880354	Bronze			2022-12-18	WOS:000296578200017
J	Silverman, RA; Ito, K				Silverman, Robert A.; Ito, Kazuhiko			Age-related association of fine particles and ozone with severe acute asthma in New York City	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; ozone; PM(2.5); asthma; age; exacerbation; emergency; hospitalization; intensive care unit	EMERGENCY-DEPARTMENT VISITS; RESPIRATORY HOSPITAL ADMISSIONS; AMBIENT AIR-POLLUTION; LUNG-FUNCTION; SOCIOECONOMIC-STATUS; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; MEXICO-CITY; ROOM VISITS; LOS-ANGELES	Background: Ambient fine particles (particular matter <2.5 mu m diameter [PM(2.5)]) and ozone exacerbate respiratory conditions including asthma. There is little documentation determining whether children are more vulnerable to the effects of ambient pollution than adults, or whether pollution causes life-threatening episodes requiring intensive care unit (ICU) admission. Objective: We investigate the relationship between severe asthma morbidity and PM(2.5) and ozone in the warm season, and determine whether there is an age-related susceptibility to pollution. Methods: Daily time-series analysis of 6008 asthma ICU admissions and 69,375 general (non-ICU) asthma admissions in 4 age groups (<6, 6-18, 19-49, and 50+ years) in 74 New York City hospitals for the months April to August from 1999 to 2006. The regression model adjusted for temporal trends, weather, and day of the week. Risks were estimated for interquartile range increases in the a priori exposure time window of the average of 0-day and 1-day lagged pollutants. Results: Age was a significant effect modifier for hospitalizations, and children age 6 to 18 years consistently had the highest risk. Among children age 6 to 18 years', there was a 26% (95% CI, 10% to 44%) increased rate of ICU admissions and a 19% increased rate of general hospitalizations (95% CI, 12% to 27%) for each 12-mu g/m(3) increase in PM(2.5). For each 22-ppb increase in ozone, there was a 19% (95% CI, 1% to 40%) increased risk for ICU admissions and a 20% (95% CI, 11% to 29%) increased risk for general hospitalizations. Conclusion: Warm weather patterns of ozone and PM(2.5) disproportionately affect children with asthma and appear responsible for severe attacks that could have been avoided. (J Allergy Clin Immunol 2010;125:367-73.)	[Silverman, Robert A.] Long Isl Jewish Med Ctr, Dept Emergency Med, Queens, NY 11040 USA; [Silverman, Robert A.] Feinstein Inst Med Res, Manhasset, NY USA; [Ito, Kazuhiko] NYU Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY USA	Northwell Health; Northwell Health; New York University	Silverman, RA (corresponding author), Long Isl Jewish Med Ctr, Dept Emergency Med, Queens, NY 11040 USA.	rsilverm@lij.edu			NIH [NIEHS ES00260]; National Institutes of Health; AstraZeneca; MedImmune; MediciNova; Environmental Protection Agency; Health Effects Institute; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca); MedImmune(AstraZenecaMedimmune); MediciNova; Environmental Protection Agency(United States Environmental Protection Agency); Health Effects Institute; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	supported in part by NIH center grant NIEHS ES00260.; Disclosure of potential conflict of interest: R. A. Silverman has received research support from the National Institutes of Health, AstraZeneca, MedImmune, and MediciNova. K. Ito has received research support from the National Institutes of Health, the Environmental Protection Agency, and the Health Effects Institute.	*AM LUNG ASS, 2008, STAT AIR; [Anonymous], 2009, NATL AMBIENT AIR QUA; Avol E.L., 1998, RES REP HLTH EFF I, V82, P1; Babin SM, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-9; Brauer M, 1996, AM J RESP CRIT CARE, V154, P981, DOI 10.1164/ajrccm.154.4.8887595; Cassino C, 1999, AM J RESP CRIT CARE, V159, P1773, DOI 10.1164/ajrccm.159.6.9809042; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; DRECHSLERPARKS DM, 1987, EXP GERONTOL, V22, P91, DOI 10.1016/0531-5565(87)90044-1; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hazucha MJ, 2003, J APPL PHYSIOL, V95, P1917, DOI 10.1152/japplphysiol.00490.2003; Hoppe P, 2003, INT J HYG ENVIR HEAL, V206, P505, DOI 10.1078/1438-4639-00250; Jaffe DH, 2003, ENVIRON RES, V91, P21, DOI 10.1016/S0013-9351(02)00004-X; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; Ko FWS, 2007, CLIN EXP ALLERGY, V37, P1312, DOI 10.1111/j.1365-2222.2007.02791.x; Korrick SA, 1998, ENVIRON HEALTH PERSP, V106, P93, DOI 10.2307/3433784; LARSEN RI, 1991, J AIR WASTE MANAGE, V41, P455, DOI 10.1080/10473289.1991.10466858; Linn WS, 1996, J EXPO ANAL ENV EPID, V6, P449; McDonnell WF, 1997, AM J RESP CRIT CARE, V156, P715, DOI 10.1164/ajrccm.156.3.9611044; MCDONNELL WF, 1994, J APPL PHYSIOL, V76, P2776, DOI 10.1152/jappl.1994.76.6.2776; McDonnell WF, 1999, EUR RESPIR J, V14, P845, DOI 10.1034/j.1399-3003.1999.14d21.x; MCDONNELL WF, 1985, AM REV RESPIR DIS, V132, P875; Medina S, 1997, ENVIRON RES, V75, P73, DOI 10.1006/enrs.1997.3773; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; O'Connor GT, 2008, J ALLERGY CLIN IMMUN, V121, P1133, DOI 10.1016/j.jaci.2008.02.020; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Pendergraft TB, 2004, ANN ALLERG ASTHMA IM, V93, P29, DOI 10.1016/S1081-1206(10)61444-5; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; Romieu I, 1998, AM J RESP CRIT CARE, V158, P226, DOI 10.1164/ajrccm.158.1.9712053; Seal E, 1996, ARCH ENVIRON HEALTH, V51, P132, DOI 10.1080/00039896.1996.9936006; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Silverman RA, 2005, ARCH PEDIAT ADOL MED, V159, P818, DOI 10.1001/archpedi.159.9.818; SPIER CE, 1992, J EXPO ANAL ENV EPID, V2, P277; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654, DOI 10.1164/ajrccm.155.2.9032209; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798, DOI 10.1093/oxfordjournals.aje.a010280; WEISEL CP, 1995, ENVIRON HEALTH PERSP, V103, P97, DOI 10.2307/3432456; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Wilson AM, 2005, ENVIRON RES, V97, P312, DOI 10.1016/j.envres.2004.07.010	46	129	132	1	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					367	373		10.1016/j.jaci.2009.10.061	http://dx.doi.org/10.1016/j.jaci.2009.10.061			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159246				2022-12-18	WOS:000274764000013
J	Pfefferle, PI; Buchele, G; Blumer, N; Roponen, M; Ege, MJ; Krauss-Etschmann, S; Genuneit, J; Hyvarinen, A; Hirvonen, MR; Lauener, R; Pekkanen, J; Riedler, J; Dalphin, JC; Brunekeef, B; Braun-Fahrlander, C; von Mutius, E; Renz, H				Pfefferle, Petra Ina; Buechele, Gisela; Bluemer, Nicole; Roponen, Marjut; Ege, Markus Johannes; Krauss-Etschmann, Susanne; Genuneit, Jon; Hyvaerinen, Anne; Hirvonen, Maija-Riitta; Lauener, Roger; Pekkanen, Juha; Riedler, Josef; Dalphin, Jean Charles; Brunekeef, Bert; Braun-Fahrlaender, Charlotte; von Mutius, Erika; Renz, Harald		PASTURE Study Grp	Cord blood cytokines are modulated by maternal farming activities and consumption of farm dairy products during pregnancy: The PASTURE Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hygiene hypothesis; allergy protection farm; effect; cord blood cytokine pattern	IN-HOUSE DUST; AIRWAY INFLAMMATION; MONONUCLEAR-CELLS; ALLERGIC SENSITIZATION; INVERSE ASSOCIATION; GAMMA PRODUCTION; MURINE MODEL; MILK-FAT; EXPOSURE; ASTHMA	Background: Traditional farming represents a unique model situation to investigate the relationship of early-life farm-related exposure and allergy protection. Objectives: To investigate associations between maternal farm exposures and cytokine production in cord blood (CB) mononuclear cells in a prospective multinational birth cohort of 299 farm and 326 nonfarm children and their families. Methods: Supernatants from phorbol 12-myristate 13-acetate/ionomycin-stimulated CB mononuclear cells were assessed for the production of IFN-gamma, TNF-alpha, IL-5, IL-10, and IL-12. Results: Significantly higher levels of IFN-gamma and TNF-alpha in farm compared with nonfarm children were found, whereas IL-5, IL-10, and IL-12 levels did not differ between study groups. Maternal contact with different farm animal species and barns and consumption of farm-produced butter during pregnancy enhanced the production of proinflammatory CB cytokines, whereas maternal consumption of farm-produced yogurt resulted in significant lower levels of IFN-gamma and TNF-alpha in umbilical blood. Conclusion: Maternal exposure to farming activities and farm dairy products during pregnancy modulated cytokine production patterns of offspring at birth. (J Allergy Clin Immunol 2010;125:108-15.)	[Pfefferle, Petra Ina; Bluemer, Nicole; Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, D-35032 Marburg, Germany; [Buechele, Gisela; Genuneit, Jon] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [Lauener, Roger] Univ Zurich, Childrens Hosp, CH-8006 Zurich, Switzerland; [Roponen, Marjut; Hyvaerinen, Anne; Hirvonen, Maija-Riitta; Pekkanen, Juha] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Pekkanen, Juha] Univ Kuopio, FIN-70211 Kuopio, Finland; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Dalphin, Jean Charles] Univ Franche Comte, Res Unit, F-25030 Besancon, France; [Braun-Fahrlaender, Charlotte] Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; [Ege, Markus Johannes; Krauss-Etschmann, Susanne; von Mutius, Erika] Univ Childrens Hosp Munich, Munich, Germany; [Krauss-Etschmann, Susanne] Natl Res Ctr Environm & Hlth, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Brunekeef, Bert] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands	Philipps University Marburg; Ulm University; University Children's Hospital Zurich; University of Zurich; Finland National Institute for Health & Welfare; University of Eastern Finland; Universite de Franche-Comte; University of Basel; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Utrecht University	Renz, H (corresponding author), Univ Hosp Marburg, Dept Clin Chem & Mol Diagnost, Baldingerstr 1, D-35033 Marburg, Germany.	renzh@med.uni-marburg.de	Roponen, Marjut/C-2086-2017; Lauener, Roger P/O-8612-2016; Ege, Markus/C-1962-2012; Schaub, Bianca/B-9935-2019; Krauss-Etschmann, Susanne/H-5198-2018; riedler, josef/AAQ-4666-2020; Genuneit, Jon/I-9323-2012	Roponen, Marjut/0000-0002-4442-9090; Lauener, Roger P/0000-0002-8412-606X; Ege, Markus/0000-0001-6643-3923; Schaub, Bianca/0000-0003-1652-8873; Krauss-Etschmann, Susanne/0000-0001-5945-5702; Genuneit, Jon/0000-0001-5764-1528; piarroux, renaud/0000-0002-4151-4134; Reboux, Gabriel/0000-0002-7923-0858; Hyvarinen, Anne/0000-0002-2823-0866; von Mutius, Erika/0000-0002-8893-4515	European Union [QLK4-C7-2001-00250, FOOD-CT-2004-506378]; Deutsche Forschungsgemeinschaft; Kuhne Foundation; Finnish foundations; Academy of Finland	European Union(European Commission); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Kuhne Foundation; Finnish foundations; Academy of Finland(Academy of Finland)	Supported by the European Union (research grant QLK4-C7-2001-00250).; M. J. Ege received research support from grant EU FOOD-CT-2004-506378 and Deutsche Forschungsgemeinschaft. S. Krauss-Etschmann has served as an expert witness on the evaluation of health claims on probiotic products for European Food Safety Authorities. R. Lauener has received research support from the European Union and the Kuhne Foundation. J. Pekkanen has received research support from the European Union 7th Framework Programme, Finnish foundations, and the Academy of Finland. E. von Mutius has served as a consultant for GlaxoSmithKline, Union Chemique Beige (UCB), and ProtectImmun; has received research support from Airsonett; and is on the editorial board for the New England Journal of Medicine.	Argiles Josep M., 1997, Cytokine and Growth Factor Reviews, V8, P181, DOI 10.1016/S1359-6101(97)00012-9; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braun-Fahrlander C, 2000, PEDIATR ALLERGY IMMU, V11, P19, DOI 10.1034/j.1399-3038.2000.00505.x; Cross ML, 2001, INT IMMUNOPHARMACOL, V1, P891, DOI 10.1016/S1567-5769(01)00025-X; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Entrican G, 2002, J COMP PATHOL, V126, P79, DOI 10.1053/jcpa.2001.0539; Feleszko W, 2007, CLIN EXP ALLERGY, V37, P498, DOI 10.1111/j.1365-2222.2006.02629.x; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Furrie E, 2005, P NUTR SOC, V64, P465, DOI 10.1079/PNS2005466; Gehring U, 2008, ENVIRON INT, V34, P1132, DOI 10.1016/j.envint.2008.04.003; Gerhold K, 2006, J ALLERGY CLIN IMMUN, V118, P666, DOI 10.1016/j.jaci.2006.05.022; HUNT JS, 1990, PLACENTA, V11, P467, DOI 10.1016/S0143-4004(05)80192-4; JANDSZUS A, 2008, J NUTR, V138, P1336; Jeurink PV, 2008, CRYOBIOLOGY, V57, P91, DOI 10.1016/j.cryobiol.2008.06.002; Jeurink PV, 2008, INT IMMUNOPHARMACOL, V8, P1124, DOI 10.1016/j.intimp.2008.04.004; Kanwar RK, 2008, CLIN EXP ALLERGY, V38, P208, DOI 10.1111/j.1365-2222.2007.02868.x; Keski-Nisula L, 2004, EUR CYTOKINE NETW, V15, P347; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Kraft J, 2003, LIPIDS, V38, P657, DOI 10.1007/s11745-003-1111-z; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Malamitsi-Puchner A, 2005, EARLY HUM DEV, V81, P387, DOI 10.1016/j.earlhumdev.2004.10.017; Molloy EJ, 2004, AM J OBSTET GYNECOL, V190, P448, DOI 10.1016/j.ajog.2003.08.027; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Noverr MC, 2005, CLIN EXP ALLERGY, V35, P1511, DOI 10.1111/j.1365-2222.2005.02379.x; Nugent AP, 2005, EUR J CLIN NUTR, V59, P742, DOI 10.1038/sj.ejcn.1602132; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Pochard P, 2002, J ALLERGY CLIN IMMUN, V110, P617, DOI 10.1067/mai.2002.128528; Protonotariou E, 1999, EARLY HUM DEV, V56, P31, DOI 10.1016/S0378-3782(99)00029-8; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Saji F, 2000, J REPROD IMMUNOL, V47, P185, DOI 10.1016/S0165-0378(00)00064-4; Sarandakou A, 1998, MEDIAT INFLAMM, V7, P309, DOI 10.1080/09629359890811; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Toder V, 2003, J ASSIST REPROD GEN, V20, P73, DOI 10.1023/A:1021740108284; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567	44	129	130	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					108	115		10.1016/j.jaci.2009.09.019	http://dx.doi.org/10.1016/j.jaci.2009.09.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19969338				2022-12-18	WOS:000273660500012
J	Baker, MW; Grossman, WJ; Laessig, RH; Hoffman, GL; Brokopp, CD; Kurtycz, DF; Cogley, MF; Litsheim, TJ; Katcher, ML; Routes, JM				Baker, Mei W.; Grossman, William J.; Laessig, Ronald H.; Hoffman, Gary L.; Brokopp, Charles D.; Kurtycz, Daniel F.; Cogley, Michael F.; Litsheim, Thomas J.; Katcher, Murray L.; Routes, John M.			Development of a routine newborn screening protocol for severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dried blood spots; hematopoietic stem cell transplantation; newborn screening; real-time quantitative PCR; severe combined immunodeficiency; T-cell receptor excision circles		Background: Severe combined immunodeficiency ( SCID) is characterized by the absence of functional T cells and B cells. Without early diagnosis and treatment, infants with SCID die from severe infections within the first year of life. Objective: To determined the feasibility of detecting SCID in newborns by quantitating T-cell receptor excision circles (TRECs) from dried blood spots (DBSs) on newborn screening (NBS) cards. Methods: DNA was extracted from DBSs on deidentified NBS cards, and real-time quantitative PCR (RT-qPCR) was used to determine the number of TRECs. Positive controls consisted of DBS from a 1-week-old T-B-NK+ patient with SCID and whole blood specimens selectively depleted of naive T cells. Results: The mean and median numbers of TRECs from 5766 deidentified DBSs were 827 and 708, respectively, per 3.2-mm punch (similar to 3 mu L whole blood). Ten samples failed to amplify TRECs on initial analysis; all but 1 demonstrated normal TRECs and beta-actin amplification on retesting. No TRECs were detected in either the SCID or naive T-cell-depleted samples, despite the presence of normal levels of beta-actin. Conclusions: The use of RT-qPCR to quantitate TRECs from DNA extracted from newborn DBSs is a highly sensitive and specific screening test for SCID. This assay is currently being used in Wisconsin for routine screening infants for SCID. (J Allergy Clin Immunol 2009;124:522-7.)	[Baker, Mei W.; Laessig, Ronald H.; Hoffman, Gary L.; Brokopp, Charles D.; Kurtycz, Daniel F.; Cogley, Michael F.; Litsheim, Thomas J.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin State Lab Hyg, Madison, WI 53706 USA; [Baker, Mei W.; Katcher, Murray L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Grossman, William J.; Routes, John M.] Med Coll Wisconsin, Childrens Res Inst, Dept Pediat, Div Allergy Clin Immunol, Milwaukee, WI 53226 USA; [Katcher, Murray L.] Wisconsin Div Publ Hlth, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin	Baker, MW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin State Lab Hyg, 465 Henry Mall, Madison, WI 53706 USA.	mwbaker@wisc.edu	Routes, john/AAA-4833-2021	Routes, john/0000-0001-8378-3773	Jeffrey Modell Foundation; Children's Hospital of Wisconsin Foundation; Children's Research Foundation; Wisconsin State Laboratory of Hygiene	Jeffrey Modell Foundation; Children's Hospital of Wisconsin Foundation; Children's Research Foundation; Wisconsin State Laboratory of Hygiene	Supported by the Jeffrey Modell Foundation, the Children's Hospital of Wisconsin Foundation, the Children's Research Foundation, and the Wisconsin State Laboratory of Hygiene.	Abu al-Soud W, 2001, J CLIN MICROBIOL, V39, P485, DOI 10.1128/JCM.39.2.485-493.2001; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Lindegren Mary Lou, 2004, Morbidity and Mortality Weekly Report, V53, P1; LIPSTEIN EA, EVIDENCE REV SEVERE; McCabe LL, 2008, ANNU REV MED, V59, P163, DOI 10.1146/annurev.med.59.110106.132016; McGhee SA, 2005, J PEDIATR-US, V147, P603, DOI 10.1016/j.jpeds.2005.06.001; McGhee SA, 2005, MOL GENET METAB, V86, P427, DOI 10.1016/j.ymgme.2005.09.005; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; QUIE PG, 1996, IMMUNOLOGIC DISORDER; Verschuren MCM, 1997, J IMMUNOL, V158, P1208; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; Watson MS, 2006, GENET MED, V8, p1S, DOI 10.1097/01.gim.0000223891.82390.ad; Wilcken B, 2008, PATHOLOGY, V40, P104, DOI 10.1080/00313020701813743	16	129	136	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					522	527		10.1016/j.jaci.2009.04.007	http://dx.doi.org/10.1016/j.jaci.2009.04.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19482345				2022-12-18	WOS:000274315900018
J	Li, XM; Brown, L				Li, Xiu-Min; Brown, LaVerne			Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Complementary and alternative medicine; traditional Chinese herbal medicine; botanical drug; asthma; food allergy; T(H)1/T(H)1 balance	PEANUT-INDUCED ANAPHYLAXIS; PITUITARY-ADRENAL AXIS; FOOD ALLERGY; MURINE MODEL; INHALED CORTICOSTEROIDS; AIRWAY HYPERREACTIVITY; BIOACTIVE COMPOUNDS; HERBAL FORMULA-2; ADULT PATIENTS; CHILDREN	Background: Although corticosteroids and beta(2)-agonists are effective in managing asthma symptoms, a curative therapy for asthma is lacking. Traditional Chinese medicine (TCM), used in Asia for centuries, is beginning to play a role in Western health care as a complementary and alternative medicine modality. There is increasing scientific evidence supporting the use of TCM for asthma treatment. Objective: This review article discusses promising TCM interventions for asthma and explores their possible mechanisms of action. Methods: We first reviewed 5 clinical studies of antiasthma TCM herbal remedies published between 2005 and 2007. We then summarized possible mechanisms underlying their effects on the basis of data in the original articles, published abstracts, and available databases. Possible mechanisms include anti-inflammation, inhibition of airway smooth muscle contraction, and immunomodulation. Research on TCM herbal therapy for food allergy is rare, and we therefore focused on the effect and mechanism of action of food allergy herbal formula-2 on a marine model of peanut allergy and preliminary clinical study results. Conclusion: Evidence from clinical studies supports beneficial effects of TCM herbal therapy on asthma. A number of mechanisms may be responsible for efficacy of these agents. Strong preclinical study data suggest the potential efficacy of food allergy herbal formula-2 for food allergy. (J Allergy Clin Immunol 2009;123:297-306.)	[Li, Xiu-Min; Brown, LaVerne] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl,Pediat Box 1198, New York, NY 10029 USA.	xiu-min.li@mssm.edu	li, xiu/GXV-1745-2022		National Institutes of Health/National Center for Complementary and Alternative Medicine; Food Allergy Initiative,; Rothstein family; Cornfield Family Foundation;  [1P01 AT002644725-01];  [R01 AT001-14]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000114, P01AT002647] Funding Source: NIH RePORTER	National Institutes of Health/National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)NIH National Center for Complementary & Alternative Medicine); Food Allergy Initiative,; Rothstein family; Cornfield Family Foundation; ; ; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by the National Institutes of Health/National Center for Complementary and Alternative Medicine grant #1P01 AT002644725-01 and #R01 AT001-14 the Food Allergy Initiative, the Rothstein family, and the Cornfield Family Foundation.	Barrios RJ, 2006, ARCH PATHOL LAB MED, V130, P447; Bensky D, 1993, CHINESE HERBAL MED M; Bensky D, 1990, CHINESE HERBAL MED F; Bielory L, 2004, ALLERGY ASTHMA PROC, V25, P283; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bolleddula J, 2007, J ALLERGY CLIN IMMUN, V119, pS172, DOI 10.1016/j.jaci.2006.12.035; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busse P. J., 2004, Journal of Allergy and Clinical Immunology, V113, pS220, DOI 10.1016/j.jaci.2004.01.243; Chan CK, 2006, PEDIAT ALLERG IMM-UK, V17, P316, DOI 10.1111/j.1399-3038.2006.00406.x; Chang TT, 2006, IMMUNOPHARM IMMUNOT, V28, P683, DOI 10.1080/08923970601067409; Chang TT, 2006, PHYTOTHER RES, V20, P342, DOI 10.1002/ptr.1843; Chen ML, 2007, INT ARCH ALLERGY IMM, V143, P21, DOI 10.1159/000098222; Chu XP, 2007, J ETHNOPHARMACOL, V111, P490, DOI 10.1016/j.jep.2006.12.013; Conroy DM, 2001, RESP RES, V2, P150, DOI 10.1186/rr52; Efferth T, 2008, MOL CANCER THER, V7, P152, DOI 10.1158/1535-7163.MCT-07-0073; Ehrman TM, 2007, J CHEM INF MODEL, V47, P2316, DOI 10.1021/ci700155t; Ehrman TM, 2007, J CHEM INF MODEL, V47, P254, DOI 10.1021/ci600288m; Engler RJM, 2000, J ALLERGY CLIN IMMUN, V106, P627, DOI 10.1067/mai.2000.110504; Epstein MM, 2006, PHARMACOL THERAPEUT, V109, P107, DOI 10.1016/j.pharmthera.2005.06.006; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hassed Craig, 2005, Aust Fam Physician, V34, P573; Hoang BX, 2007, PHYTOTHER RES, V21, P554, DOI 10.1002/ptr.2107; Hsu CH, 2005, PEDIATR ALLERGY IMMU, V16, P76, DOI 10.1111/j.1399-3038.2005.00230.x; Huang K.C., 1998, PHARM CHINESE HERBS; Huang XD, 2004, J CHROMATOGR B, V812, P71, DOI 10.1016/j.jchromb.2004.06.046; Huntley A, 2000, THORAX, V55, P925, DOI 10.1136/thorax.55.11.925; JAYAPRAKASAM B, 2009, J AGR FOOD IN PRESS; Kattan JD, 2008, PHYTOTHER RES, V22, P651, DOI 10.1002/ptr.2357; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Ko J, 2005, J ALLERGY CLIN IMMUN, V115, pS34; Lazar MA, 2004, J CLIN INVEST, V113, P23, DOI 10.1172/JCI200420661; Li XM, 2007, J ALLERGY CLIN IMMUN, V120, P25, DOI 10.1016/j.jaci.2007.04.030; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P660, DOI 10.1067/mai.2000.110102; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Matsui S, 2006, INT IMMUNOPHARMACOL, V6, P369, DOI 10.1016/j.intimp.2005.08.025; Matsui S, 2004, INT IMMUNOPHARMACOL, V4, P1633, DOI 10.1016/j.intimp.2004.07.023; *NCCAM, 2008, WHOL MED SYST OV; Peirce A., 1999, AM PHARM ASS PRACTIC; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; QU C, 2006, J ALLERGY CLIN IMMUN, V115, pS204; Quan WY, 2008, PLANTA MED, V74, P168, DOI 10.1055/s-2008-1034285; Ray A, 2000, Curr Opin Investig Drugs, V1, P442; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sato E, 2002, INT ARCH ALLERGY IMM, V128, P12, DOI 10.1159/000059413; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Slader CA, 2006, RESPIROLOGY, V11, P373, DOI 10.1111/j.1440-1843.2006.00861.x; Sorkness CA, 1999, CLIN THER, V21, P353, DOI 10.1016/S0149-2918(00)88292-2; Srivastava KD, 2008, J ALLERGY CLIN IMMUN, V121, pS246, DOI 10.1016/j.jaci.2007.12.973; Srivastava KD, 2007, J ALLERGY CLIN IMMUN, V119, pS197, DOI 10.1016/j.jaci.2006.12.141; Srivastava KD, 2006, J ALLERGY CLIN IMMUN, V117, pS328, DOI 10.1016/j.jaci.2005.12.1292; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Szefler S, 2000, NEW ENGL J MED, V343, P1054; The State Pharmacopoeia Commission of P.R. China, 2005, PHARM PEOPL REP CHIN; US Food and Drug Administration, 2004, GUID IND BOT DRUG PR; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029; WHO, 1999, WHO MON SEL MED PLAN, V1, P183; Zhang H, 2007, J PHARMACEUT BIOMED, V43, P151, DOI 10.1016/j.jpba.2006.06.033; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5	63	129	137	1	40	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					297	306		10.1016/j.jaci.2008.12.026	http://dx.doi.org/10.1016/j.jaci.2008.12.026			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203653	Green Accepted			2022-12-18	WOS:000263495000002
J	Smits, HH; Hammad, H; van Nimwegen, M; Soullie, T; Willart, MA; Lievers, E; Kadouch, J; Kool, M; Kos-van Oosterhoud, J; Deelder, AM; Lambrecht, BN; Yazdanbakhsh, M				Smits, Hermehin H.; Hammad, Hamida; van Nimwegen, Menno; Soullie, Thomas; Willart, Monique A.; Lievers, Ellen; Kadouch, Jonathan; Kool, Mirjam; Kos-van Oosterhoud, Janneke; Deelder, Andre M.; Lambrecht, Bart N.; Yazdanbakhsh, Maria			Protective effect of Schistosoma mansoni infection on allergic airway inflammation depends on the intensity and chronicity of infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						helminth; allergy; immune suppression; IL-10; regulatory B cells; regulatory T cells	REGULATORY T-CELLS; HELMINTH INFECTION; CHRONIC DISEASE; B-CELLS; RESPONSES; MICE; CHILDREN; MODULATION; ANTIGEN; IL-10	Background: Population studies have suggested that chronic and intense helminth infections, in contrast to acute and mild helminth infections, might suppress allergic airway inflammation. Objective: We sought to address the question of how the chronicity and intensity of helminth infections affect allergic airway inflammation in a well-defined experimental model. Methods: C57/B16 mice were infected with Schistosoma mansoni, followed by sensitization and challenge with ovalbumin (OVA), and different stages and intensities of infection were studied. To this end, mice were analyzed at 8, 12, or 16 weeks, representing the acute, intermediate, or chronic phases of infection, respectively. Results: Lung lavage eosinophilia, peribronchial inflammation, and OVA-induced airway hyperresponsiveness were increased during acute infection but significantly decreased when infection progressed into chronicity. Decreases in lung lavage eosinophilia were parasite density-dependent. Similar levels of OVA-specific IgE were found during all phases of infection, whereas both OVA-specific and parasite-specific T(H)2 cytokine levels were significantly reduced during chronic infection. Inhibition of airway inflammation could be transferred to OVA-sensitized recipient mice by B cells and CD4(+) T cells from spleens of chronically, but not acutely, infected mice. This suppression was IL-10-dependent. Conclusion: During chronic, but not acute, helminth infections, suppressive mechanisms are induced that regulate immune reactions to inhaled allergens. These data confirm human epidemiologic observations in a well-controlled animal model. Clinical implications: Characterization of chronic helminth infection-induced regulatory mechanisms will help in the development of future therapeutics to treat or prevent allergic disease.	Leiden Univ, Med Ctr, Dept Parasitol, Ctr Infect Dis, NL-2333 ZA Leiden, Netherlands; Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	Smits, HH (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Ctr Infect Dis, P4-25,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	H.H.Smits@lumc.nl	Lambrecht, Bart N/K-2484-2014; Yazdanbakhsh, Maria/AAI-3996-2020; Smits, Hermelijn/V-4216-2018; Hammad, Hamida/J-9391-2015	Lambrecht, Bart N/0000-0003-4376-6834; Yazdanbakhsh, Maria/0000-0002-7666-1441; Smits, Hermelijn/0000-0001-9279-2890; Hammad, Hamida/0000-0003-3762-8603				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; Baumgart M, 2006, J IMMUNOL, V176, P5374, DOI 10.4049/jimmunol.176.9.5374; Buijs J, 1997, EUR RESPIR J, V10, P1467, DOI 10.1183/09031936.97.10071467; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Elias D, 2005, VACCINE, V23, P1326, DOI 10.1016/j.vaccine.2004.09.038; FANNING MM, 1981, J INFECT DIS, V144, P148, DOI 10.1093/infdis/144.2.148; Gonzalez-Quintela A, 2006, INT ARCH ALLERGY IMM, V139, P317, DOI 10.1159/000091603; Grogan JL, 1998, J INFECT DIS, V177, P1433, DOI 10.1086/517832; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; HENDERSON GS, 1993, AM J PATHOL, V142, P703; Hesse M, 2004, J IMMUNOL, V172, P3157, DOI 10.4049/jimmunol.172.5.3157; Jankovic D, 1998, J EXP MED, V187, P619, DOI 10.1084/jem.187.4.619; Kitagaki K, 2006, J IMMUNOL, V177, P1628, DOI 10.4049/jimmunol.177.3.1628; KULLBERG MC, 1992, J IMMUNOL, V148, P3264; Lima C., 2002, Clinical and Experimental Allergy, V32, P1659, DOI 10.1046/j.1365-2222.2002.01506.x; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Maizels RM, 2005, CURR OPIN IMMUNOL, V17, P656, DOI 10.1016/j.coi.2005.09.001; Mangan NE, 2006, J IMMUNOL, V176, P138, DOI 10.4049/jimmunol.176.1.138; Mangan NE, 2004, J IMMUNOL, V173, P6346, DOI 10.4049/jimmunol.173.10.6346; Negrao-Correa D, 2003, INFECT IMMUN, V71, P2607, DOI 10.1128/IAI.71.5.2607-2614.2003; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P640, DOI 10.1111/j.1365-2222.2006.02479.x; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Pearce EJ, 2004, IMMUNOL REV, V201, P117, DOI 10.1111/j.0105-2896.2004.00187.x; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269; Sadler CH, 2003, EUR J IMMUNOL, V33, P880, DOI 10.1002/eji.200323501; Satoguina J, 2002, MICROBES INFECT, V4, P1291, DOI 10.1016/S1286-4579(02)00014-X; Schopf L, 2005, INVEST OPHTH VIS SCI, V46, P2772, DOI 10.1167/iovs.04-0899; Taylor JJ, 2006, J IMMUNOL, V176, P5839, DOI 10.4049/jimmunol.176.10.5839; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Wang CC, 2001, CLIN EXP ALLERGY, V31, P495, DOI 10.1046/j.1365-2222.2001.01044.x; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x; Wynn TA, 1998, J IMMUNOL, V160, P4473; Yazdanbakhsh M, 2005, CURR OPIN ALLERGY CL, V5, P386, DOI 10.1097/01.all.0000182541.52971.eb	38	129	138	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					932	940		10.1016/j.jaci.2007.06.009	http://dx.doi.org/10.1016/j.jaci.2007.06.009			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17689595				2022-12-18	WOS:000250157700030
J	de Lange, EE; Altes, TA; Patrie, JT; Parmar, J; Brookeman, JR; Mugler, JP; Platts-Mills, TAE				de Lange, Eduard E.; Altes, Talissa A.; Patrie, James T.; Parmar, Jaywant; Brookeman, James R.; Mugler, John P., III; Platts-Mills, Thomas A. E.			The variability of regional airflow obstruction within the lungs of patients with asthma: Assessment with hyperpolarized helium-3 magnetic resonance imaging	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airflow obstruction; airway asthma; bronchial activity; hyperpolarized gases; hyperpolarized helium-3; pulmonary function; spirometry; magnetic resonance imaging; MRI; ventilation defect; ventilation; lung diseases	THIN-SECTION CT; EXERCISE CHALLENGE; METHACHOLINE; VENTILATION; VOLUME; GAS; MRI; HYPERREACTIVITY; CLOSURE; AIRWAYS	Background: It is unknown whether focal changes of airflow obstruction within the lungs of patients with asthma vary or are fixed in location with time or repeated bronchoconstriction. With hyperpolarized helium-3 magnetic resonance ((HHeMR)-He-3) imaging, the airspaces are depicted and focal areas of airflow obstruction are shown as "ventilation defects." Objective: To investigate the regional changes of airflow obstruction with time and repeated bronchoconstriction. Methods: (HHeMR)-He-3 and spirometry were performed before (pre) and immediately after (post) methacholine challenge in 10 young patients with asthma on 2 days that were 7-476 days (mean, 185.3 +/- 37.2 days) apart. Pair-wise image comparisons were performed to determine the change in location of ventilation defects within the lung and their change in size. Results: When comparing premethacholine versus premethacholine and postmetbacholine versus postmethacholine images of the 2 days, 41% +/- 10% and 69% +/- 5% (P = .017) of defects, respectively, were in the same location, and of those, 69% +/- 12 % and 43% +/- 5 % (P = .022), respectively, did not change size. Comparing premethacholine versus postmethacholine images, 58% +/- 9% of defects were in the same location on day I and 73% +/- 7% (P = .088) on day 2. On both days, the percent increase in defect number from premethacholine to postmethacholine was much greater than the percent decrease in spirometric values (P < .001). Conclusion: Many of the ventilation defects persisted or recurred in the same location with time or repeated bronchoconstriction, suggesting that the regional changes of airflow obstruction are relatively fixed within the lung. Clinical implications: The findings give new insight into the regional airflow variability within the lungs of patients with asthma.	Univ Virginia, Hlth Sci Syst, Dept Radiol, Div Asthma Allergy & Immunol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Hlth Evaluat Sci, Div Asthma Allergy & Immunol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Div Asthma Allergy & Immunol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	de Lange, EE (corresponding author), Univ Virginia, Hlth Sci Syst, Dept Radiol, Div Asthma Allergy & Immunol, HSC 800170, Charlottesville, VA 22908 USA.	delange@virginia.edu	Mugler, John/B-9432-2013	Mugler, John/0000-0002-4140-308X; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066479] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 66479] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; Arakawa H, 1998, AM J ROENTGENOL, V170, P1349, DOI 10.2214/ajr.170.5.9574614; Beigelman-Aubry C, 2002, RADIOLOGY, V223, P181, DOI 10.1148/radiol.2231010779; Cibella F, 2002, CHEST, V122, P1944, DOI 10.1378/chest.122.6.1944; Cirillo I, 2006, ANN ALLERG ASTHMA IM, V96, P692, DOI 10.1016/S1081-1206(10)61067-8; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; de Lange EE, 1999, RADIOLOGY, V210, P851, DOI 10.1148/radiology.210.3.r99fe08851; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Edgington E. S., 1995, RANDOMIZATION TESTS; ENGEL LA, 1976, J APPL PHYSIOL, V40, P411, DOI 10.1152/jappl.1976.40.3.411; FILUK RB, 1987, J APPL PHYSIOL, V63, P2223, DOI 10.1152/jappl.1987.63.6.2223; GAARE JD, 2004, P RSNA 90 SCI ASS AN, V3, P514; Goldin JG, 1998, RADIOLOGY, V208, P321, DOI 10.1148/radiology.208.2.9680554; Guenther D, 2000, NMR BIOMED, V13, P182, DOI 10.1002/1099-1492(200006)13:4<182::AID-NBM642>3.0.CO;2-N; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; King GG, 1997, AM J RESP CRIT CARE, V155, P682, DOI 10.1164/ajrccm.155.2.9032213; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MacFall JR, 1996, RADIOLOGY, V200, P553, DOI 10.1148/radiology.200.2.8685356; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; Miller LA, 2005, CLIN EXP ALLERGY, V35, P894, DOI 10.1111/j.1365-2222.2005.02271.x; *NAT ASTHM ED PREV, 1997, NIH PUBL; Park CS, 1997, RADIOLOGY, V203, P361, DOI 10.1148/radiology.203.2.9114089; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Tgavalekos NT, 2005, J APPL PHYSIOL, V99, P2388, DOI 10.1152/japplphysiol.00391.2005; van Beek EJR, 2004, J MAGN RESON IMAGING, V20, P540, DOI 10.1002/jmri.20154; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	27	129	129	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1072	1078		10.1016/j.jaci.2006.12.659	http://dx.doi.org/10.1016/j.jaci.2006.12.659			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17353032				2022-12-18	WOS:000246427200004
J	Kristjansson, S; Bjarnarson, SP; Wennergren, GE; Palsdottir, AH; Arnadottir, T; Haraidsson, A; Jonsdottir, I				Kristjansson, S; Bjarnarson, SP; Wennergren, GE; Palsdottir, AH; Arnadottir, T; Haraidsson, A; Jonsdottir, I			Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local T(H)2-like response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; infant; cytokines; chemokines; ECP	AIRWAY HYPERRESPONSIVENESS; TRACT INFECTION; GAMMA PRODUCTION; IFN-GAMMA; AGE 13; BRONCHIOLITIS; INFANTS; DISEASE; ASTHMA; NASAL	Background: Respiratory syncytial virus (RSV) infections during infancy are considered to be a risk factor for developing asthma and possibly allergic sensitization. Objective: The aim of this study was to investigate the cytokines, chemokines, and eosinophil cationic protein in the nasopharyngeal secretions of infants <= 7 months of age with RSV infections or other respiratory viral infections and healthy infants as controls. Groups were also analyzed according to age, <= 3 months and > 3 months, and the levels were compared within and between groups. Results: Thirty-nine infants with RSV, 9 with influenza or parainfluenza virus infections and 50 controls with no history of infections, were enrolled in the study. The RSV-infected infants had significantly higher levels of IL-4; macrophage inflammatory protein 1 beta, a chemoattractant for T cells; and eosinophil cationic protein in nasopharyngeal secretions compared with the control group. The levels of the T(H)2 cytokine IL-4 were significantly higher in RSV-infected infants : 3 months of age compared with RSV-infected infants > 3 months of age. In infants <= 3 months of age, infections with influenza or parainfluenza virus caused T(H)2-like responses similar to those produced by RSV. Conclusion: Infections with RSV as well as with influenza and parainfluenza virus during early infancy preferentially promote a T(H)2-like response in the nose with local production of IL-4, IL-5, and macrophage inflammatory protein 1 beta and infiltration and activation of eosinophils.	Landspitali Univ Hosp, Dept Pediat, Childrens Hosp Iceland, IS-101 Reykjavik, Iceland; Landspitali Univ Hosp, Dept Immunol, IS-101 Reykjavik, Iceland; Landspitali Univ Hosp, Dept Virol, IS-101 Reykjavik, Iceland; Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland; Gothenburg Univ, Queen Silvia Childrens Hosp, Dept Pediat, S-41124 Gothenburg, Sweden; Reykjavik Community Hlth Care, Reykjavik, Iceland	Landspitali National University Hospital; Landspitali National University Hospital; Landspitali National University Hospital; University of Iceland; Queen Silvia Children's Hospital; University of Gothenburg	Kristjansson, S (corresponding author), Landspitali Univ Hosp, Dept Pediat, Childrens Hosp Iceland, IS-101 Reykjavik, Iceland.	sig@landspitali.is		Bjarnarson, Stefania P/0000-0003-3823-6329; Haraldsson, Asgeir/0000-0001-5364-7877				AMBROSE RT, 1983, CLIN CHEM, V29, P256; Bendelja K, 2000, CLIN EXP IMMUNOL, V121, P332, DOI 10.1046/j.1365-2249.2000.01297.x; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; Bout L, 2002, INTENS CARE MED, V28, P616, DOI 10.1007/s00134-002-1256-z; COURT SDM, 1973, POSTGRAD MED J, V49, P771, DOI 10.1136/pgmj.49.577.771; Ehlenfield DR, 2000, PEDIATRICS, V105, P79, DOI 10.1542/peds.105.1.79; Fritz RS, 1999, J INFECT DIS, V180, P586, DOI 10.1086/314938; Garofalo R, 1994, Pediatr Allergy Immunol, V5, P111, DOI 10.1111/j.1399-3038.1994.tb00227.x; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; GRAHAM DE, 1990, AM REV RESPIR DIS, V142, P152, DOI 10.1164/ajrccm/142.1.152; Hall CB, 1999, J PEDIATR-US, V135, pS2; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Joshi P, 1998, J ALLERGY CLIN IMMUN, V102, P618, DOI 10.1016/S0091-6749(98)70278-7; LAMPRECHT CL, 1976, J INFECT DIS, V134, P211, DOI 10.1093/infdis/134.3.211; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; MOK JYQ, 1982, BRIT MED J, V285, P333, DOI 10.1136/bmj.285.6338.333; MORRIS JA, 1956, P SOC EXP BIOL MED, V92, P544, DOI 10.3181/00379727-92-22538; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; MURRAY M, 1992, ARCH DIS CHILD, V67, P482, DOI 10.1136/adc.67.4.482; Noah TL, 2002, CLIN IMMUNOL, V104, P86, DOI 10.1006/clim.2002.5248; Pala P, 2002, EUR RESPIR J, V20, P376, DOI 10.1183/09031936.02.00249902; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Renzi PM, 1997, J PEDIATR-US, V130, P584, DOI 10.1016/S0022-3476(97)70243-9; Roman M, 1997, AM J RESP CRIT CARE, V156, P190, DOI 10.1164/ajrccm.156.1.9611050; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; Schwarze J, 2000, CLIN CHEST MED, V21, P279, DOI 10.1016/S0272-5231(05)70266-5; Schwarze J, 1999, J IMMUNOL, V162, P2997; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Sheeran P, 1999, PEDIATR INFECT DIS J, V18, P115, DOI 10.1097/00006454-199902000-00007; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Soukup JM, 2003, CLIN IMMUNOL, V107, P178, DOI 10.1016/S1521-6616(03)00038-X; Spender LC, 1998, J GEN VIROL, V79, P1751, DOI 10.1099/0022-1317-79-7-1751; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Sznajer Y, 2004, J PEDIATR-US, V145, P115, DOI 10.1016/j.jpeds.2004.03.049; van Benten IJ, 2003, J MED VIROL, V71, P290, DOI 10.1002/jmv.10482; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; Wennergren G, 2001, EUR RESPIR J, V18, P1044, DOI 10.1183/09031936.01.00254101	39	129	130	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					805	811		10.1016/j.jaci.2005.07.012	http://dx.doi.org/10.1016/j.jaci.2005.07.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210054				2022-12-18	WOS:000235686600014
J	Hauswirth, AW; Natter, S; Ghannadan, M; Majlesi, Y; Schernthaner, GH; Sperr, WR; Buhring, HJ; Valenta, R; Valent, P				Hauswirth, AW; Natter, S; Ghannadan, M; Majlesi, Y; Schernthaner, GH; Sperr, WR; Buhring, HJ; Valenta, R; Valent, P			Recombinant allergens promote expression of CD203c on basophils in sensitized individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; allergy; recombinant allergens; diagnostic test; E-NPP3; CD203c	FC-EPSILON-RI; HISTAMINE-RELEASE; BLOOD BASOPHILS; CYCLOSPORINE-A; ANTIBODY 97A6; POLLEN; ACTIVATION; GRASS; IGE; DIAGNOSIS	Background: Traditionally, the diagnosis of type I allergies is based on clinical data, skin test results, and laboratory test results with allergen extracts. During the past few years, several attempts have been made to refine diagnostic assays in clinical allergy by introducing recombinant allergens and novel markers of IgE-dependent cell activation. Objectives: We have identified the ectoenzyme CD203c as a novel basophil antigen that is upregulated on IgE receptor cross-linkage. In this study A e applied CD203c and a panel of recombinant allergens to establish a novel basophil test that,allows for a reliable quantification of IgE-dependent responses at the effector cell level. Methods: Patients allergic to birch (Bet v, 1, n = 15; Bet v 2, n := 8) and grass (Phl p 1, n = 15; Phl p 2, n = 10; Phl p 5, n = 14) pollen allergens, as well as 10 nonallergic donors, were examined. Basophils were exposed to various concentrations of recombinant allergens for 15 minutes and then examined for expression of CD203c by means of flow cytometry. CD203c upregulation was correlated with the increase in CD63. Results: Exposure to recombinant allergens resulted in a dose-dependent increase in expression of CD203c on peripheral blood basophils in sensitized individuals, whereas no increase,was seen in healthy control subjects. The effects of the recombinant allergens on CD203c expression were also time dependent. There was a good correlation between allergen-induced upregulation of CD203c and upregulation of CD63 (R = 0.76). Conclusion: Flow cytometric quantitation of CD203c on blood basophils exposed to recombinant allergens is a useful approach to determine the allergic state in sensitized individuals and represents a basis for a sensitive novel allergy test.	Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria; Univ Vienna, Inst Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 2, Div Angiol, A-1090 Vienna, Austria; Univ Tubingen, Dept Internal Med 2, Div Hematol & Immunol, Tubingen, Germany	University of Vienna; University of Vienna; University of Vienna; Eberhard Karls University of Tubingen	Valent, P (corresponding author), Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Sperr, Mast/V-4767-2019; Valent, Peter/B-8533-2016	Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365; Sperr, Wolfgang/0000-0003-3288-8027; Schernthaner, Gerit-Holger/0000-0002-9587-1727				BALL T, 1994, J BIOL CHEM, V269, P28323; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Buhring HJ, 1999, BLOOD, V94, P2343; CIRILLO R, 1990, J IMMUNOL, V144, P3891; DATTWYLER R, 1985, ALLERGY, P599; GANE P, 1995, CYTOMETRY, V19, P361, DOI 10.1002/cyto.990190411; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Kay A.B., 1997, ALLERGY ALLERGIC DIS; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MODDERMAN PW, 1989, LEUKOCYTE TYPING, V4, P1042; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Paris-Kohler A, 2000, J ALLERGY CLIN IMMUN, V105, P339, DOI 10.1016/S0091-6749(00)90085-X; PELIKAN Z, 1983, ANN ALLERGY, V51, P395; Platz IJ, 2001, INT ARCH ALLERGY IMM, V126, P335, DOI 10.1159/000049531; RASANEN L, 1994, ALLERGY, V49, P342, DOI 10.1111/j.1398-9995.1994.tb02279.x; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; Sperr WR, 1997, INT ARCH ALLERGY IMM, V114, P68, DOI 10.1159/000237645; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; VALENTI JAM, 1995, ENCYC ENVIR, V7, P1; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4	33	129	139	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					102	109		10.1067/mai.2002.125257	http://dx.doi.org/10.1067/mai.2002.125257			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110828				2022-12-18	WOS:000176870300020
J	Geha, RS; Meltzer, EO				Geha, RS; Meltzer, EO			Desloratadine: A new, nonsedating. oral antihistamine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						desloratadine; antihistamine; seasonal allergic rhinitis; asthma; urticaria; anti-inflammatory; drug interactions; safety; congestion	ALLERGIC RHINITIS; P-GLYCOPROTEIN; COMPLICATIONS; EPIDEMIOLOGY; LORATADINE; PREVENT; CELLS	Desloratadine is a new, selective, H-1-receptor antagonist that also has anti-inflammatory activity. In vitro studies have shown that desloratadine inhibits the release or generation of multiple inflammatory mediators, including IL-4, IL-6, IL-8, IL-13, PGD(2), leukotriene C-4, tryptase, histamine, and the TNF-alpha -induced chemokine RANTES, Desloratadine also inhibits the induction of cell adhesion molecules, platelet-activating factor-induced eosinophil chemotaxis, TNF-alpha -induced eosinophil adhesion, and spontaneous and phorbol myristate acetate-induced superoxide generation in vitro. In animals desloratadine had no effect on the central nervous, cardiovascular. renal, or gastrointestinal systems. Desloratadine is rapidly absorbed, has dose-proportional pharmacokinetics, and has a half-life of 27 hours, The absorption of desloratadine is not affected by food, and the metabolism and elimination are not significantly affected by the subject's age, race, or sex, There are no clinically relevant interactions between desloratadine and erythromycin, ketoconazole, or grapefruit juice. Desloratadine is not a significant substrate of the P-glycoprotein transport system, Once daily administration of desloratadine rapidly reduces the nasal and nonnasal symptoms of seasonal allergic rhinitis, including congestion. In patients with seasonal allergic rhinitis and concomitant asthma, desloratadine treatment was also associated with significant reductions in total asthma symptom score and use of inhaled Pz-agonists, Use of desloratadine in patients with chronic idiopathic urticaria was associated with significant reductions in pruritus, number of hives, size of the largest hive, and interference with sleep and daily activities. Clinical experience in over 2300 patients has shown that the adverse event profile of desloratadine is similar to that of placebo; desloratadine has no clinically relevant effects on electrocardiographic parameters, does not impair wakefulness or psychomotor performance, and does not exacerbate the psychomotor impairment associated with alcohol use.	Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Harvard Univ, Sch Med, Boston, MA USA; Boston Childrens Hosp, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Geha, RS (corresponding author), Childrens Hosp, 300 Longwood Ave,Enders Bldg,Room 809, Boston, MA 02115 USA.							AFFRIME M, IN PRESS CLIN PHARMA; Aguawal DK, 2000, ALLERGY S, V55, P276; ANTHES JC, 2000, ALLERGY, V55, P277; BANFIELD C, 2000, ANN ALLERG ASTHMA IM, V86, P108; BANFIELD C, IN PRESS CLIN PHARMA; BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; Beckman DB, 1999, ALLERGY ASTHMA PROC, V20, P215, DOI 10.2500/108854199778339026; CAYEN M, 2000, ALLERGY S, V55, P282; Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866; DuBuske LM, 1999, CLIN THER, V21, P281, DOI 10.1016/S0149-2918(00)88286-7; Dykema KJ, 1998, GEOM FUNCT ANAL, V8, P1, DOI 10.1007/s000390050046; Genovese A, 1997, CLIN EXP ALLERGY, V27, P559, DOI 10.1111/j.1365-2222.1997.tb00745.x; Gonzalez MA, 1998, INT J CLIN PHARM TH, V36, P292; GUPTA S, IN PRESS CLIN PHARMA; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Kreutner W, 2000, ARZNEIMITTELFORSCH, V50, P441; Kreutner W, 2000, ARZNEIMITTEL-FORSCH, V50, pE345; Lippert U, 1995, Exp Dermatol, V4, P272, DOI 10.1111/j.1600-0625.1995.tb00257.x; LORBER R, 2001, IN PRESS NEW TRENDS; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Mann RD, 2000, BRIT MED J, V320, P1184, DOI 10.1136/bmj.320.7243.1184; *MED EC, 2000, PHYS DESK REF, P3147; *MED EC, 2000, PHYS DESK REF, P2404; Meltzer EO, 2001, CLIN DRUG INVEST, V21, P25, DOI 10.2165/00044011-200121010-00004; Rachelefsky GS, 1999, ANN ALLERG ASTHMA IM, V82, P296, DOI 10.1016/S1081-1206(10)62612-9; RATNER PH, 2000, ANN ALLERG ASTHMA IM, V86, P109; RIKKEN G, 2000, ALLERGY S, V55, P277; Ring J, 2001, INT J DERMATOL, V40, P72, DOI 10.1046/j.1365-4362.2001.00186.x; Scharf MB, 2000, ALLERGY S, V55, P280; SCHENKEL E, 2000, ANN ALLERG ASTHMA IM, V86, P110; Schoenwetter WF, 2000, ALLERGY ASTHMA PROC, V21, P1, DOI 10.2500/108854100778248971; SCHROEDER JT, IN PRESS CLIN EXP AL; SILVERMAN JA, 2000, METABOLIC DRUG INTER, P135; Tanigawara Y, 2000, THER DRUG MONIT, V22, P137, DOI 10.1097/00007691-200002000-00029; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; VIGNOLA AM, 1995, ALLERGY, V50, P200, DOI 10.1111/j.1398-9995.1995.tb01133.x; VUURMAN E, 2000, ALLERGY S, V55, P263; Yu DK, 1999, J CLIN PHARMACOL, V39, P1203, DOI 10.1177/00912709922012006	38	129	145	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					752	762		10.1067/mai.2001.114239	http://dx.doi.org/10.1067/mai.2001.114239			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295678				2022-12-18	WOS:000168190100040
J	Weiler, JM; Ryan, EJ				Weiler, JM; Ryan, EJ			Asthma in United States Olympic athletes who participated in the 1998 Olympic Winter Games	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; athletics; exercise-induced asthma; sports medicine; Olympics	CROSS-COUNTRY SKIERS; EXERCISE-INDUCED BRONCHOSPASM; PHYSICAL PERFORMANCE; FIGURE SKATERS; PREVALENCE; -15-DEGREES-C	Background: About one of every 5 athletes who participated in the 1996 Summer Olympic Games in Atlanta had a past history of asthma, had symptoms that suggested asthma, or took asthma medications. No previous study has determined the prevalence of asthma in all US athletes who participated in an Olympic Winter Games, Objectives: We sought to determine how many US athletes who participated in the 1998 Olympic Winter Games had a past history of asthma, had symptoms that suggested asthma, or indicated taking a medication used to treat asthma, Methods: We evaluated responses to questions that asked about allergic and respiratory diseases in the United States Olympic Committee Medical History Questionnaire that was completed by all 196 athletes who represented the United States at the 1998 Olympic Winter Games in Nagano, Japan, Results: Forty-three (21.9%) of the 196 athletes had a previous diagnosis of asthma, and 36 (18.4%) recorded use of an asthma medication at some time in the past. Forty-four (22.4%) reported use of an asthma medication, a diagnosis of asthma, or both (our basis for the diagnosis of asthma). Thirty-Four (17.4%) of the athletes were currently taking an asthma medication at the time that they completed the questionnaire or indicated that they took these medications on a permanent or semipermanent basis and were considered to have active asthma. Athletes who participated in Nordic combined, cross-country, and short track events had the highest prevalence of having been told that they had asthma or had taken an asthma medication in the past (60.7%) in contrast with only one (2.8%) of the 36 athletes who participated in bobsled, biathlon, luge, and ski jumping. Eighteen (24%) of 75 athletes who participated in alpine, long track, figure skating, snow boarding, and curling had a previous diagnosis of asthma or recorded use of an asthma medication. Conclusions: We conclude that asthma appeared to have been more common in athletes who participated in the 1998 Winter Games than in athletes who participated in either the 1996 or 1984 Summer Games. Clearly, asthma rates vary widely among sports. This suggests that the environment in which exercise is performed is important in leading to a decrease in the amount of exercise required to trigger asthma and perhaps in causing injury to the airways.	Univ Iowa, Iowa City, IA 52242 USA; US Olymp Comm, Colorado Springs, CO USA	University of Iowa	Weiler, JM (corresponding author), Univ Iowa, T307 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.							Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; KAELIN M, 1993, SCHWEIZ MED WSCHR, V123, P174; Kujala UM, 1996, THORAX, V51, P288, DOI 10.1136/thx.51.3.288; Larsson K, 1997, MED SCI SPORT EXER, V29, P1631, DOI 10.1097/00005768-199712000-00013; LARSSON K, 1993, BRIT MED J, V307, P1326, DOI 10.1136/bmj.307.6915.1326; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; RUPP NT, 1992, AM J DIS CHILD, V146, P941, DOI 10.1001/archpedi.1992.02160200063028; RUPP NT, 1993, ANN ALLERGY, V70, P339; Sandsund M, 1998, EUR J APPL PHYSIOL O, V77, P297, DOI 10.1007/s004210050337; Sue-Chu M, 1999, SCAND J MED SCI SPOR, V9, P48; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597, DOI 10.1164/ajrccm.158.2.9711012; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003	20	129	133	0	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					267	271		10.1067/mai.2000.108605	http://dx.doi.org/10.1067/mai.2000.108605			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932069				2022-12-18	WOS:000088708100008
J	Kline, JN; Krieg, AM; Waldschmidt, TJ; Ballas, ZK; Jain, V; Businga, TR				Kline, JN; Krieg, AM; Waldschmidt, TJ; Ballas, ZK; Jain, V; Businga, TR			CpG oligodeoxynucleotides do not require T-H1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; murine; CpG oligodeoxynucleotides; IFN-gamma; IL-12; T-H1	IFN-GAMMA PRODUCTION; BACTERIAL-DNA; IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES; MONOCLONAL-ANTIBODY; NK CELLS; MICE; EXPRESSION; MOTIFS; IL-12; INTERLEUKIN-12	Background: Oligodeoxynucleotides (ODNs) containing the dinucleotide CpG in a specific sequence contest (CpG-ODNs) have the ability to prevent the development of eosinophilic airway inflammation and bronchial hyperreactivity in a murine model of asthma. We have previously demonstrated that CpG-ODNs stimulate expression of the T-H1-inducing cytokines IFN-gamma and IL-12 in a murine model of asthma and that this stimulation is associated with the protection against asthmatic inflammation. Objective: The purpose of this study was to examine whether the protection conferred by CpG-ODNs in a schistosome egg-egg antigen murine model of asthma is dependent on the induction of IFN-gamma, IL-12, or both. Methods: C57BL/6 mice were sensitized to schistosome eggs in the presence or absence of CpG-ODNs or control ODNs and then stimulated with soluble egg antigen in the airway. The protection offered by CpG-ODNs in these mice was compared with the protection induced by CpG-ODNs in IL-12 and IFN-gamma knockout mice and in mice treated with anticytokine blocking antibodies. Double-knockout mice (IL-12/IFN-gamma) were also generated and used in these studies. Determinations included airway eosinophilic inflammation and branchial hyperreactivity to inhaled methacholine. Results: We found that CpG-ODNs confer protection against both airway eosinophilia and bronchial hyperreactivity in the absence of IFN-gamma or IL-12 or in the presence of both cytokines together However, in the absence of either IL-12 or IFN-gamma, mice require 10 times as much CpG-ODNs to be protected against the induction of airway eosinophilia. The T-H2 cytokines IL-4 and IL-5 were reduced in all of the CpG-treated mice, although less in the absence of IL-12 and IFN-gamma. Conclusion: These data indicate that CpG-ODNs prevent the generation of T-H2-like immune responses by multiple mechanisms, which involve, but do not require, IL-12 and IFN-gamma. A direct suppressive effect of CpG-ODNs on T-H2 responses is suggested by their reduction in IFN-gamma and IL-12 knockout mice.	Univ Iowa, Dept Med, Iowa City, IA USA; Univ Iowa, Dept Pathol, Iowa City, IA USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Kline, JN (corresponding author), C33GH UIHC, Iowa City, IA 52242 USA.		Krieg, Arthur M/K-8109-2019; Krieg, Art/R-6166-2019	Waldschmidt, Thomas/0000-0001-6147-6991; kline, joel/0000-0002-5523-8855; Knaack, Aaron/0000-0001-7712-1415; Ballas, Zuhair/0000-0001-5569-1230	NHLBI NIH HHS [HL02950, HL59324] Funding Source: Medline; NIEHS NIH HHS [ES05605] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059324, K08HL002950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bartholome EJ, 1999, J INTERF CYTOK RES, V19, P471, DOI 10.1089/107999099313910; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Chace JH, 1997, CLIN IMMUNOL IMMUNOP, V84, P185, DOI 10.1006/clin.1997.4380; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; Cowdery J, 1996, J IMMUNOL, V156, P4570; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hunter CA, 1997, IMMUNOL LETT, V59, P1, DOI 10.1016/S0165-2478(97)00091-6; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115, DOI 10.1159/000236947; Kline JN, 1998, J IMMUNOL, V160, P2555; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 1998, TRENDS MICROBIOL, V6, P23, DOI 10.1016/S0966-842X(97)01145-1; Li XM, 1996, J IMMUNOL, V157, P3216; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; McRae BL, 1997, EUR J IMMUNOL, V27, P2650, DOI 10.1002/eji.1830271026; McRae BL, 1998, J IMMUNOL, V160, P4298; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; National Asthma Education Prevention Program (National Heart Lung and Blood Institute), 1997, 2 NAT ASTHM ED PREV; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rosner B, 2011, FUNDAMENTALS BIOSTAT; SPITALNY GL, 1984, J EXP MED, V159, P1560, DOI 10.1084/jem.159.5.1560; Vieillard V, 1997, P NATL ACAD SCI USA, V94, P11595, DOI 10.1073/pnas.94.21.11595; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833; Wenner CA, 1996, J IMMUNOL, V156, P1442; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994; WYNN TA, 1995, J IMMUNOL, V154, P3999; Yi AK, 1996, J IMMUNOL, V157, P4918	29	129	137	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1258	1264		10.1016/S0091-6749(99)70022-9	http://dx.doi.org/10.1016/S0091-6749(99)70022-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589010	Bronze			2022-12-18	WOS:000084289200022
J	Peat, JK; Li, J				Peat, JK; Li, J			Reversing the trend: Reducing the prevalence of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						prevalence; risk factors; asthma; diet; allergens; breast-feeding; parental smoking	HOUSE-DUST MITE; SKIN-TEST REACTIVITY; DIETARY SALT INTAKE; NEW-SOUTH-WALES; CHILDHOOD ASTHMA; ATOPIC DISEASE; PARENTAL SMOKING; RISK FACTOR; RESPIRATORY SYMPTOMS; HAY-FEVER	Background: We urgently need to take steps towards reducing the prevalence of asthma in countries where the prevalence has become unacceptably high in recent years. Because we do not have any good information about causes of the increased prevalence, me cannot act directly to reverse the trend. Therefore we need to take an indirect approach and use known information of etiologic factors to try to reduce asthma in the next generation, while acknowledging that we may be dealing with different factors from those responsible for the increased prevalence. Any successful strategies will also help to ensure that developing countries do not attain such high rates of asthma in their children in coming years. Objective: This article summarizes the roles of the risk factors that identify "high-risk" children, that provide insights into mechanisms, or that have potential for primary prevention. The factors with the most potential for primary prevention are allergen exposure, parental smoking, breast-feeding, and dietary fatty acids. Conclusion: In other health models, information about risk factors has been used in successful public health interventions. It is disappointing that the important risk factors for asthma are well documented but that there have been few trials of primary prevention and no changes in public health policies.	Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Inst Resp Med, Sydney, NSW, Australia	University of Sydney; University of Sydney	Peat, JK (corresponding author), New Childrens Hosp, Clin Epidemiol Unit, Sydney, NSW 2145, Australia.							Austin JB, 1997, ARCH DIS CHILD, V76, P22, DOI 10.1136/adc.76.1.22; *AUSTR BUR STAT, 1995, RISK FACT, P8; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BISGAARD H, 1987, ACTA PAEDIATR SCAND, V76, P719, DOI 10.1111/j.1651-2227.1987.tb10555.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BRITTON J, 1994, THORAX, V49, P875, DOI 10.1136/thx.49.9.875; BRITTON JR, 1995, AM J RESP CRIT CARE, V151, P1383, DOI 10.1164/ajrccm.151.5.7735589; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; Burney P, 1996, EUR RESPIR J, V9, P687; BURNEY PGJ, 1997, ASTHMA, P35; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; BUSINCO L, 1983, ANN ALLERGY, V51, P296; Butland BK, 1997, THORAX, V52, P618, DOI 10.1136/thx.52.7.618; Calder PC, 1997, ANN NUTR METAB, V41, P203, DOI 10.1159/000177997; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; CHANYEUNG M, 1998, AM J RESP CRIT CARE, V157, pA12; Cook DG, 1997, THORAX, V52, P628, DOI 10.1136/thx.52.7.628; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Cook DG, 1998, THORAX, V53, P295, DOI 10.1136/thx.53.4.295; COOK DG, 1997, THORAX, V52; COOKSON WOC, 1998, AM J RESP CRIT CARE, V157, pA11; Couper D, 1998, CLIN EXP ALLERGY, V28, P715, DOI 10.1046/j.1365-2222.1998.00307.x; CUIJPERS CEJ, 1995, ENVIRON RES, V68, P11, DOI 10.1006/enrs.1995.1003; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218, DOI 10.1164/ajrccm.153.1.8542119; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Demissie K, 1996, THORAX, V51, P59, DOI 10.1136/thx.51.1.59; DEMISSIE K, 1997, CAN RESPIR J, V4, P91; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; FLOYD RL, 1993, ANNU REV PUBL HEALTH, V14, P379, DOI 10.1146/annurev.pu.14.050193.002115; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459, DOI 10.1046/j.1365-2222.1998.00255.x; GELLERBERNSTEIN G, 1987, ALLERGY, V42, P85, DOI 10.1111/j.1398-9995.1987.tb02364.x; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; GrummerStrawn LM, 1996, INT J EPIDEMIOL, V25, P94, DOI 10.1093/ije/25.1.94; GRUSKAY FL, 1982, CLIN PEDIATR, V21, P486, DOI 10.1177/000992288202100807; GUSTAFSSON D, 1992, ARCH DIS CHILD, V67, P1008, DOI 10.1136/adc.67.8.1008; Haslam C, 1997, J PUBLIC HEALTH MED, V19, P187, DOI 10.1093/oxfordjournals.pubmed.a024607; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hodge L, 1996, MED J AUSTRALIA, V164, P137, DOI 10.5694/j.1326-5377.1996.tb122010.x; HODGE L, 1994, AUST NZ J MED, V24, P727, DOI 10.1111/j.1445-5994.1994.tb01793.x; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834, DOI 10.1093/oxfordjournals.aje.a116745; Jarvis D, 1998, BRIT MED J, V316, P607, DOI 10.1136/bmj.316.7131.607; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Kemp TJ, 1996, BMJ-BRIT MED J, V313, P916, DOI 10.1136/bmj.313.7062.916; KHAW KT, 1994, LANCET, V343, P838, DOI 10.1016/S0140-6736(94)92031-1; KUN HY, 1993, MED J AUSTRALIA, V159, P312, DOI 10.5694/j.1326-5377.1993.tb137867.x; Lercher P, 1997, EUR RESPIR J, V10, P2502, DOI 10.1183/09031936.97.10112502; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; MARTIN CJ, 1987, BRIT MED J, V294, P1125, DOI 10.1136/bmj.294.6580.1125; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MCCONNOCHIE KM, 1986, PEDIATR PULM, V2, P260, DOI 10.1002/ppul.1950020503; Mellis C M, 1993, Pharmacoeconomics, V3, P205, DOI 10.2165/00019053-199303030-00004; MIDWINTER RE, 1987, ARCH DIS CHILD, V62, P965, DOI 10.1136/adc.62.9.965; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410, DOI 10.1164/ajrccm.157.2.9706033; Pabst HF, 1997, PEDIATR INFECT DIS J, V16, P991, DOI 10.1097/00006454-199710000-00017; Peat J K, 1996, Curr Opin Pulm Med, V2, P7; PEAT JK, 1992, EUR RESPIR J, V5, P921; PEAT JK, 1994, EUR RESPIR J, V7, P1805, DOI 10.1183/09031936.94.07101805; Peat JK, 1998, CLIN EXP ALLERGY, V28, P261; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PEAT JK, 1995, MED J AUSTRALIA, V163, P22, DOI 10.5694/j.1326-5377.1995.tb126083.x; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Piacentini GL, 1998, CLIN EXP ALLERGY, V28, P561, DOI 10.1046/j.1365-2222.1998.00260.x; PISTELLI R, 1993, EUR RESPIR J, V6, P517; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; Rasanen M, 1997, CLIN EXP ALLERGY, V27, P515, DOI 10.1111/j.1365-2222.1997.tb00739.x; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517, DOI 10.1007/BF00209530; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWARTZ J, 1994, EUR RESPIR J, V7, P1821, DOI 10.1183/09031936.94.07101821; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Strachan D, 1997, BRIT MED J, V314, P518, DOI 10.1136/bmj.314.7079.518; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; Strachan DP, 1997, THORAX, V52, P905, DOI 10.1136/thx.52.10.905; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; Sunyer Y, 1997, EUR RESPIR J, V10, P2490, DOI 10.1183/09031936.97.10112490; THIEN FCK, 1993, AM REV RESPIR DIS, V147, P1138, DOI 10.1164/ajrccm/147.5.1138; THIEN FCK, 1992, J ALLERGY CLIN IMMUN, V89, P829, DOI 10.1016/0091-6749(92)90438-8; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079, DOI 10.1164/ajrccm.157.4.9704140; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; VONMUTIUS E, 1998, AM J RESP CRIT CARE, V157, pA11; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Weiss ST, 1997, CIBA F SYMP, V206, P244; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Williamson IJ, 1997, THORAX, V52, P229, DOI 10.1136/thx.52.3.229; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804; Woodcock A, 1998, BRIT MED J, V316, P1075, DOI 10.1136/bmj.316.7137.1075; WOODWARD A, 1990, J EPIDEMIOL COMMUN H, V44, P224, DOI 10.1136/jech.44.3.224; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758, DOI 10.1001/archpedi.1995.02170200048006; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	114	129	136	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				1	10		10.1016/S0091-6749(99)70517-8	http://dx.doi.org/10.1016/S0091-6749(99)70517-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893177				2022-12-18	WOS:000078112300001
J	Johnson, M				Johnson, M			Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; BUDESONIDE; MODERATE; ASTHMA				Johnson, M (corresponding author), GLAXO WELLCOME RES & DEV LTD,INT MED AFFAIRS,STOCKLEY PK W,UXBRIDGE UB11 1BU,MIDDX,ENGLAND.							ABBINANTENISSEN JM, 1994, AM J RESP CRIT CARE, V149, pA869; AYRES JG, 1995, EUR RESPIR J, V8, P579; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; BRATTSAND R, 1992, NEW DRUGS ASTHMA, V2, P192; BRATTSAND R, 1994, DRUGS LUNG, P101; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; DERENDORF H, 1993, J CLIN PHARMACOL, V33, P115, DOI 10.1002/j.1552-4604.1993.tb03930.x; EDSBACKER S, 1985, EUR J CLIN PHARMACOL, V29, P477, DOI 10.1007/BF00613465; ENGLISH AF, 1994, AM J RESP CRIT CAR S, V149, pA212; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; HOGGER P, 1994, EUR RESP J S18, V7, pS382; Hogger P, 1993, EUR RESP J S17, V6, p584S; HOLLIDAY SM, 1994, DRUGS, V47, P318, DOI 10.2165/00003495-199447020-00007; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; MCDOWALL JE, 1995, J ALLERGY CLIN IMMUN, V95, P194; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; Rohdewald P., 1994, European Respiratory Journal, V7, p382S; ROHDEWALD P, 1985, AGENTS ACTIONS, V17, P34; SAREEN M, IN PRESS EUR RESPIR; VANDENBOSCH JMM, 1993, BIOPHARM DRUG DISPOS, V14, P455, DOI 10.1002/bdd.2510140511; WURTHWEIN G, 1992, PHARM ZTG WISS, V5, P2	25	129	132	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	2	S			169	176		10.1016/S0091-6749(96)80217-X	http://dx.doi.org/10.1016/S0091-6749(96)80217-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT805	8568148				2022-12-18	WOS:A1996TT80500004
J	NORDMAN, H; KESKINEN, H; TUPPURAINEN, M				NORDMAN, H; KESKINEN, H; TUPPURAINEN, M			FORMALDEHYDE ASTHMA - RARE OR OVERLOOKED	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NORDMAN, H (corresponding author), INST OCCUPAT HLTH,HAARTMANINKATU 1,SF-00290 HELSINKI 29,FINLAND.							AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; ADAMS WGF, 1975, BRIT J IND MED, V32, P72; Alanko K, 1977, Duodecim, V93, P306; ANDERSEN I, 1979, P INT CLIMATE S SB, V1; Andersen I., 1983, FORMALDEHYDE TOXICIT, P154; BERGER JM, 1981, LANCET, V1, P1264; BERGLUND E, 1963, ACTA MED SCAND, V173, P186; BIRATH G, 1963, ACTA MED SCAND, V173, P193; BLEJER HP, 1966, S1806 STAT CAL HLTH; BROOKS SM, 1977, SCAND J WORK ENV HEA, V3, P53, DOI 10.5271/sjweh.2790; BRYSON DD, 1981, LANCET, V1, P1263; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CRONIN E, 1982, CONTACT DERMATITIS, P788; EGLE JL, 1972, ARCH ENVIRON HEALTH, V25, P119, DOI 10.1080/00039896.1972.10666147; FRIGAS E, 1981, CHEST, V79, P706, DOI 10.1378/chest.79.6.706; Gamble J., 1983, FORMALDEHYDE TOXICIT, P175; GAMBLE JF, 1976, AM IND HYG ASSOC J, V37, P499, DOI 10.1080/0002889768507508; GANDEVIA B, 1970, MED J AUST S2, V57, P332; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARRIS DK, 1953, BRIT J IND MED, V10, P255; HENDRICK DJ, 1975, BRIT MED J, V1, P607, DOI 10.1136/bmj.1.5958.607; HENDRICK DJ, 1982, J OCCUP ENVIRON MED, V24, P893; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; INFANTE PF, 1981, LANCET, V2, P980; KERFOOT EJ, 1975, AM IND HYG ASSOC J, V36, P533, DOI 10.1080/0002889758507286; Laitinen L A, 1974, Scand J Respir Dis Suppl, V86, P1; MAGNUSSON B, 1970, ALLERGIC CONTACT DER; MORGAN WKC, 1981, LANCET, V2, P981; NIEMELA R, 1981, SCAND J WORK ENV HEA, V7, P95, DOI 10.5271/sjweh.2554; OLSEN JH, 1982, AM IND HYG ASSOC J, V43, P366, DOI 10.1080/15298668291409866; PARKES WR, 1982, OCCUPATIONAL LUNG DI, P415; PEPYS J, 1972, Clinical Allergy, V2, P189, DOI 10.1111/j.1365-2222.1972.tb01282.x; PEPYS J, 1982, J OCCUP ENVIRON MED, V24, P534; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PIRILA V, 1949, Ann Med Intern Fenn, V38, P38; Pirila V, 1975, Contact Dermatitis, V1, P48, DOI 10.1111/j.1600-0536.1975.tb05311.x; POPA V, 1965, DIS CHEST, V56, P395; RADAR J, 1974, THESIS WURZBURG U; ROTH WG, 1969, BERUFS-DERMATOSEN, V17, P263; SAKULA A, 1975, LANCET, V1, P816; SCHOENBERG JB, 1975, ARCH ENVIRON HEALTH, V30, P574, DOI 10.1080/00039896.1975.10666782; STANESCU D, 1972, M BRONCHODILATATION, P46; SWENBERG JA, 1980, CANCER RES, V40, P3398; TAYLOR AJN, 1981, OCCUPATIONAL LUNG DI, P143; WALLENSTEIN G, 1978, DEUT GESUNDHEITSWES, V33, P1119; 1980, JOINT NIOSH OSHA CUR, V34, P1; 1981, LANCET, V1, P926; [No title captured]; 1975, CHEST, V67, P383; 1974, HEW PUBLICATION NIOS, P75	50	129	133	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					91	99		10.1016/0091-6749(85)90018-1	http://dx.doi.org/10.1016/0091-6749(85)90018-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	3968333				2022-12-18	WOS:A1985ABF2600014
J	SPAULDING, HS; MANSFIELD, LE; STEIN, MR; SELLNER, JC; GREMILLION, DE				SPAULDING, HS; MANSFIELD, LE; STEIN, MR; SELLNER, JC; GREMILLION, DE			FURTHER INVESTIGATION OF THE ASSOCIATION BETWEEN GASTRO-ESOPHAGEAL REFLUX AND BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM BEAUMONT ARMY MED CTR,ALLERGY IMMUNOL SERV,EL PASO,TX 79920; FITZSIMMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO	William Beaumont Army Medical Center								BABB RR, 1970, AM J GASTROENTEROL, V53, P230; BANNISTER W, 1961, ANESTHESIOLOGY, V22, P440, DOI 10.1097/00000542-196105000-00017; BERNSTEIN A, 1980, BRIT J DIS CHEST, V74, P420, DOI 10.1016/S0007-0971(80)80033-7; BERNSTEIN A, 1981, BRIT J DIS CHEST, V75, P320; BRYNE J, 1961, AM J SURG, V101, P301; CHERNOW B, 1979, DIGEST DIS SCI, V24, P839, DOI 10.1007/BF01324899; DANUS O, 1976, J PEDIATR-US, V89, P220, DOI 10.1016/S0022-3476(76)80452-0; DARLING DB, 1978, RADIOLOGY, V127, P735, DOI 10.1148/127.3.735; DAVIS MV, 1972, NEW YORK STATE J MED, V72, P935; DEES SC, 1974, N C MED J, V35, P230; EULER AR, 1979, PEDIATRICS, V63, P47; FISHER AB, 1968, J CLIN INVEST, V47, P2045, DOI 10.1172/JCI105890; Friedland G W, 1973, Pediatr Radiol, V1, P156, DOI 10.1007/BF00974060; GHAED N, 1979, ANN ALLERGY, V42, P306; GOODALL RJR, 1981, THORAX, V36, P116, DOI 10.1136/thx.36.2.116; HORTON DJ, 1978, AM REV RESPIR DIS, V117, P1029; IVERSON LIG, 1973, AM J SURG, V126, P223, DOI 10.1016/S0002-9610(73)80156-4; JOLLEY SG, 1980, J PEDIATR-US, V96, P194, DOI 10.1016/S0022-3476(80)80801-8; KJELLEN G, 1981, EUR J RESPIR DIS, V1, P285; KLOTZ SD, 1971, ANN ALLERGY, V29, P325; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MAYS EE, 1976, JAMA-J AM MED ASSOC, V236, P2626, DOI 10.1001/jama.236.23.2626; MAYS EE, 1976, CHEST, V69, P512, DOI 10.1378/chest.69.4.512; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; OVERHOLT RH, 1966, NEW YORK STATE J MED, V66, P3030; PAINTAL AS, 1977, BRIT MED BULL, V33, P169, DOI 10.1093/oxfordjournals.bmb.a071418; Paulson D L, 1973, Am Surg, V39, P67; PEARSON JEG, 1971, THORAX, V26, P300, DOI 10.1136/thx.26.3.300; PELLEGRINI CA, 1979, SURGERY, V86, P110; REICH SB, 1977, J NUCL MED, V18, P1079; SMITH HLM, 1980, NEW ZEAL MED J, V92, P148; STERNLIEB CM, 1974, J AM GERIATR SOC, V22, P511, DOI 10.1111/j.1532-5415.1974.tb05839.x; [No title captured]	34	129	129	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					516	521		10.1016/0091-6749(82)90176-2	http://dx.doi.org/10.1016/0091-6749(82)90176-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076992				2022-12-18	WOS:A1982NT02500007
J	SZEFLER, SJ; ROSE, JQ; ELLIS, EF; SPECTOR, SL; GREEN, AW; JUSKO, WJ				SZEFLER, SJ; ROSE, JQ; ELLIS, EF; SPECTOR, SL; GREEN, AW; JUSKO, WJ			THE EFFECT OF TROLEANDOMYCIN ON METHYLPREDNISOLONE ELIMINATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,SCH MED,DEPT PEDIAT,BUFFALO,NY 14214; SUNY BUFFALO,SCH PHARM,DEPT PHARMACOL & THERAPEUT,BUFFALO,NY 14214; SUNY BUFFALO,SCH PHARM,DEPT PHARMACEUT,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Jusko, William J/G-4885-2015		NCRR NIH HHS [RR-05493] Funding Source: Medline; NIAID NIH HHS [AI-14198] Funding Source: Medline; PHS HHS [24211] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DJACZENKO W, 1977, CHEMOTHERAPY, V23, P167, DOI 10.1159/000221985; FOX JL, 1961, PENN MED J, V64, P634; Goldstein A, 1964, BIOSTATISTICS; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; LASSEN NA, 1979, TRACER KINETIC METHO, P76; MEIKLE AW, 1975, J CLIN ENDOCR METAB, V41, P717, DOI 10.1210/jcem-41-4-717; ONG KS, 1978, J ALLERGY CLIN IMMUN, V62, P115, DOI 10.1016/0091-6749(78)90088-X; ROBINSON MM, 1962, AM J MED SCI, V243, P502, DOI 10.1097/00000441-196204000-00012; ROSE JQ, 1979, J CHROMATOGR, V162, P273, DOI 10.1016/S0378-4347(00)81514-5; ROSE JQ, 1980, BIOPHARM DRUG DISPOS, V1, P98; SCHATZ M, 1979, AM REV RESPIR DIS, V119, P167; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; YEH KC, 1978, J PHARMACOKINET BIOP, V6, P79, DOI 10.1007/BF01066064	16	129	130	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					447	451		10.1016/0091-6749(80)90004-4	http://dx.doi.org/10.1016/0091-6749(80)90004-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	6968763				2022-12-18	WOS:A1980KV36300003
J	McNeil, MM; DeStefano, F				McNeil, Michael M.; DeStefano, Frank			Vaccine-associated hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Acute; delayed; hypersensitivity; immunologically mediated; mast cell; IgE mediated; T cell mediated; allergy; anaphylaxis; postvaccination; vaccine safety	EVENT REPORTING SYSTEM; INACTIVATED INFLUENZA VACCINE; INJECTION-SITE REACTIONS; OF-THE-LITERATURE; HYGIENE HYPOTHESIS; UNITED-STATES; SAFETY DATA; SEASONAL INFLUENZA; RUBELLA VACCINE; IMMUNIZATION PRACTICES	Vaccine-associated hypersensitivity reactions are not infrequent; however, serious acute-onset, presumably IgE-mediated or IgG and complement-mediated anaphylactic or serious delayed-onset T cell-mediated systemic reactions are considered extremely rare. Hypersensitivity can occur because of either the active vaccine component (antigen) or one of the other components. Postvaccination acute-onset hypersensitivity reactions include self-limited localized adverse events and, rarely, systemic reactions ranging from urticaria/angioedema to full-blown anaphylaxis with multisystem involvement. Risk of anaphylaxis after all vaccines is estimated to be 1.31 (95% CI, 0.90-1.84) per million vaccine doses, respectively. Serious hypersensitivity reactions after influenza vaccines are particularly important because of the large number of persons vaccinated annually. Influenza vaccines are unique in requiring annual changes in the vaccines' antigenic composition to match the predicted circulating influenza strains. Recently, novel influenza vaccine types were introduced in the United States (recombinant vaccines, some with higher antigen content and a new adjuvanted vaccine). Providers should be aware of changing recommendations on the basis of recent published evidence for persons with a history of egg allergy to receive annual influenza vaccination. Further research is needed to elucidate the pathophysiology and risk factors for reported vaccine-associated adverse events. Further research is also needed to determine whether repeated annual inactivated influenza vaccination, the number of vaccine antigens administered at the same time, and the current timing of routine infant vaccinations are optimal for overall population well-being.	[McNeil, Michael M.; DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, 1825 Century Ctr Blvd,MS D26, Atlanta, GA 30345 USA	Centers for Disease Control & Prevention - USA	McNeil, MM (corresponding author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1825 Century Ctr Blvd,MS D26, Atlanta, GA 30345 USA.	mmm2@cdc.gov		McNeil, Michael/0000-0003-0713-8312	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI), 2015, CAN IMM GUID CHAPT I; Arroabarren E, 2016, PEDIAT ALLERG IMM-UK, V27, P433, DOI 10.1111/pai.12548; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bektas A, 2017, J LEUKOCYTE BIOL, V102, P977, DOI 10.1189/jlb.3RI0716-335R; BENJAMIN CM, 1992, BMJ-BRIT MED J, V304, P1075, DOI 10.1136/bmj.304.6834.1075; Bergfors E, 2013, EUR J PEDIATR, V172, P171, DOI 10.1007/s00431-012-1841-2; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Brooks C, 2013, CURR OPIN ALLERGY CL, V13, P70, DOI 10.1097/ACI.0b013e32835ad0d2; Brotherton JML, 2008, CAN MED ASSOC J, V179, P525, DOI 10.1503/cmaj.080916; Byington CL, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-2550; Caubet JC, 2014, IMMUNOL ALLERGY CLIN, V34, P597, DOI 10.1016/j.iac.2014.04.004; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Cheng DR, 2015, VACCINE, V33, P1602, DOI 10.1016/j.vaccine.2015.02.008; Clark S, 2014, J ALLERGY CLIN IMMUN, V134, P1125, DOI 10.1016/j.jaci.2014.05.018; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cook IF, 2009, HUM VACCINES, V5, P441, DOI 10.4161/hv.8476; Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054; Cuhna JP, RXLIST FLUAD; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; DiMiceli L, 2006, VACCINE, V24, P703, DOI 10.1016/j.vaccine.2005.07.069; Dreskin SC, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0120-5; Echeverria-Zudaire LA, 2015, ALLERGOL IMMUNOPATH, V43, P304, DOI 10.1016/j.aller.2015.01.004; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; Erlewyn-Lajeunesse M, 2012, ARCH DIS CHILD, V97, P487, DOI 10.1136/archdischild-2011-301163; Erlewyn-Lajeunesse M, 2010, DRUG SAFETY, V33, P57, DOI 10.2165/11318970-000000000-00000; Glanz JM, 2011, ARCH PEDIAT ADOL MED, V165, P749, DOI 10.1001/archpediatrics.2011.112; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Grohskopf LA, 2016, MMWR-MORBID MORTAL W, V65, P691; Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1; Hox V, 2015, J ALLERGY CLIN IMMUN, V135, P729, DOI 10.1016/j.jaci.2014.11.003; Jaiganesh T, 2013, EUR J EMERG MED, V20, P10, DOI 10.1097/MEJ.0b013e328356f76e; Kattan JD, 2011, J ALLERGY CLIN IMMUN, V128, P215, DOI 10.1016/j.jaci.2011.04.046; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Kelso JM, 1999, J ALLERGY CLIN IMMUN, V103, P698, DOI 10.1016/S0091-6749(99)70245-9; Kelso JM, 2015, J ALLER CL IMM-PRACT, V3, P140, DOI 10.1016/j.jaip.2014.08.011; Kemp A, 2003, PEDIAT ALLERG IMM-UK, V14, P74, DOI 10.1034/j.1399-3038.2003.00017.x; Khalil M K, 2003, East Mediterr Health J, V9, P152; Kiraly N, 2016, ALLERGY, V71, P541, DOI 10.1111/all.12830; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Kroger AT, GEN BEST PRACTICE GU; Lauren CT, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2014-1690; Lefebvre CDS, 2015, HUM VACC IMMUNOTHER, V11, P2142, DOI 10.1080/21645515.2015.1052196; Leventhal JS, 2012, DERMATITIS, V23, P102, DOI 10.1097/DER.0b013e31825228cf; Lieberman P, 2015, ANN ALLERG ASTHMA IM, V115, P341, DOI 10.1016/j.anai.2015.07.019; McNeil MM, 2015, ALERGOL POL, V2, pT37, DOI 10.1016/j.jaci.2015.07.048; McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073; MILIAUSKAS JR, 1993, AM J SURG PATHOL, V17, P516, DOI 10.1097/00000478-199305000-00012; Nagao M, 2016, J ALLERGY CLIN IMMUN, V137, P861, DOI 10.1016/j.jaci.2015.08.001; Nichol KL, 1996, ARCH INTERN MED, V156, P1546, DOI 10.1001/archinte.156.14.1546; Nilsson L, 2017, PEDIAT ALLERG IMM-UK, V28, P628, DOI 10.1111/pai.12762; Nolan T, 2014, VACCINE, V32, P6146, DOI 10.1016/j.vaccine.2014.08.068; Orenstein WA, 2013, PUBLIC HEALTH REP, V128, P78; Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101; Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013; Pool V, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e71; Radonjic-Hoesli S, 2017, CLIN REV ALLERGY IMM; Reynolds LA, 2017, NAT REV IMMUNOL, V17, P518, DOI 10.1038/nri.2017.39; Robinson CL, 2017, MMWR-MORBID MORTAL W, V66, P134, DOI 10.15585/mmwr.mm6605e1; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rouleau I, 2014, VACCINE, V32, P3480, DOI 10.1016/j.vaccine.2014.04.059; Rouleau I, 2013, VACCINE, V31, P5989, DOI 10.1016/j.vaccine.2013.10.033; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Russell M, 2004, VACCINE, V23, P664, DOI 10.1016/j.vaccine.2004.06.042; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sargant N, 2015, EMERG MED J, V32, P83, DOI 10.1136/emermed-2014-203603; Schlaud M, 2017, VACCINE, V35, P5156, DOI 10.1016/j.vaccine.2017.07.111; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Simons FER, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0080-1; Simons FER, 2015, J ALLERGY CLIN IMMUN, V135, P1125, DOI 10.1016/j.jaci.2014.09.014; Stiemsma LT, 2015, IMMUNOTARGETS THER, V4, P143, DOI 10.2147/ITT.S61528; Stone CA, 2017, J ALLERGY CLIN IMMUN, V139, P1710, DOI 10.1016/j.jaci.2016.10.037; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Stratton K, 2001, ADVERSE EFFECTS VACC; Tavares F, 2011, VACCINE, V29, P6402, DOI 10.1016/j.vaccine.2011.04.026; Tsai TF, 2013, INFECT CHEMOTHER, V45, P159, DOI 10.3947/ic.2013.45.2.159; Verthelyi D, 2001, INT IMMUNOPHARMACOL, V1, P983, DOI 10.1016/S1567-5769(01)00044-3; Vesikari T, 2009, PEDIATR INFECT DIS J, V28, P563, DOI 10.1097/INF.0b013e31819d6394; Vogt T, 1998, CONTACT DERMATITIS, V38, P50, DOI 10.1111/j.1600-0536.1998.tb05644.x; Wolfe S, 2015, EPIDEMIOLOGY PREVENT; Woo EJ, 2015, CLIN INFECT DIS, V60, P777, DOI 10.1093/cid/ciu948; Yang LPH, 2013, DRUGS, V73, P1357, DOI 10.1007/s40265-013-0103-6; Zafack JG, 2017, J ALLER CL IMM-PRACT, V5, P718, DOI 10.1016/j.jaip.2016.09.048; Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1	84	128	130	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					463	472		10.1016/j.jaci.2017.12.971	http://dx.doi.org/10.1016/j.jaci.2017.12.971			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29413255	Bronze, Green Accepted			2022-12-18	WOS:000424410800001
J	Kelleher, MM; Dunn-Galvin, A; Gray, C; Murray, DM; Kiely, M; Kenny, L; McLean, WHI; Irvine, AD; Hourihane, JO				Kelleher, Maeve M.; Dunn-Galvin, Audrey; Gray, Claire; Murray, Deirdre M.; Kiely, Mairead; Kenny, Louise; McLean, W. H. Irwin; Irvine, Alan D.; Hourihane, Jonathan O'B			RETRACTED: Skin barrier impairment at birth predicts food allergy at 2 years of age (Retracted article. See vol. 147, pg. 1527, 2021)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Retracted Publication						Infant; skin barrier; transepidermal water loss; atopic dermatitis; food sensitization; food allergy; prediction	TRANSEPIDERMAL WATER-LOSS; ATOPIC-DERMATITIS; ORAL TOLERANCE; FILAGGRIN; CHILDREN; SENSITIZATION; PREVALENCE; EXPOSURE; MUTATIONS; TRENDS	Background: Transcutaneous exposure to food allergens can lead to food sensitization (FS)/food allergy (FA). We measured skin barrier function in early infancy and related it to the later development of FS/FA at age 2 years. Objective: We sought to examine the relationship between early life skin barrier function and FA in infancy. Methods: Infants in the Babies After Scope: Evaluating the Longitudinal Impact Using Neurological and Nutritional Endpoints (BASELINE) birth cohort had transepidermal water loss (TEWL) measured in the early newborn period and at 2 and 6 months of age. At age 2 years, infants had FS/FA screening with skin prick tests and oral food challenges. Results: One thousand nine hundred three infants were enrolled. One thousand three hundred fifty-five were retained to age 2 years, and 1260 underwent FS screening. FS was present in 6.27% (79/1260; 95% CI, 4.93% to 7.61%), and FA prevalence was 4.45% (56/1258; 95% CI, 3.38% to 5.74%). Egg was the most prevalent allergen (2.94%), followed by peanut (1.75%) and cow's milk (0.74%). Day 2 upper-quartile TEWL (>9 g(water)/m(2)/h) was a significant predictor of FA at age 2 years (odds ratio [OR], 4.1; 95% CI, 1.5-4.8). Seventy-five percent of children with FA at 2 years of age had day 2 TEWL in the upper quartile. Even in those without atopic dermatitis (AD), infants with upper-quartile day 2 TEWL were 3.5 times more likely to have FA at 2 years than infants in the lowest quartile (95% CI, 1.3-11.1; P = .04). Conclusion: Neonatal skin barrier dysfunction predicts FA at 2 years of age, supporting the concept of transcutaneous allergen sensitization, even in infants who do not have AD. TEWL could be used for stratifying infants in the first few days of life before development of AD or FA for targeted intervention studies to potentially alter the atopic march.	[Kelleher, Maeve M.; Dunn-Galvin, Audrey; Gray, Claire; Murray, Deirdre M.; Hourihane, Jonathan O'B] Natl Univ Ireland Univ Coll Cork, Paediat & Child Hlth, Cork, Ireland; [Kiely, Mairead] Natl Univ Ireland Univ Coll Cork, Sch Food & Nutr Sci, Vitamin Res Grp D, Cork, Ireland; [Murray, Deirdre M.; Irvine, Alan D.; Hourihane, Jonathan O'B] Natl Childrens Res Ctr, Dublin, Ireland; [Kenny, Louise] Natl Univ Ireland Univ Coll Cork, Irish Ctr Fetal & Neonatal Translat Res, Cork, Ireland; [Kenny, Louise] Cork Univ Matern Hosp, Cork, Ireland; [McLean, W. H. Irwin] Univ Dundee, Dermatol & Genet Med, Dundee, Scotland; [Irvine, Alan D.] Our Ladys Childrens Hosp, Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Med Clin, Dublin 2, Ireland	University College Cork; University College Cork; National Children's Research Centre (NCRC); Trinity College Dublin; University College Cork; University of Dundee; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin	Hourihane, JO (corresponding author), Cork Univ Hosp, Dept Paediat & Child Hlth, Cork, Ireland.	J.Hourihane@ucc.ie	Irvine, Alan D/A-3982-2008; Kiely, Mairead E/ABA-3235-2020; Kenny, Louise/X-6329-2019; Kenny, Louise C/G-1112-2011; Kiely, Mairead/I-8269-2019; DunnGalvin, Audrey/G-1741-2012	Irvine, Alan D/0000-0002-9048-2044; Kenny, Louise/0000-0002-9011-759X; Kenny, Louise C/0000-0002-9011-759X; Kiely, Mairead/0000-0003-0973-808X; Murray, Deirdre/0000-0002-2201-9912	Food Safety Agency, United Kingdom [TO7060]; Wellcome Trust [090066/B/09/Z, 092530/Z/10/Z]; National Children's Research Centre, Dublin, Ireland; Centre for Dermatology and Genetic Medicine, University of Dundee [098439/Z/12/Z]; MRC [G0700314] Funding Source: UKRI; Medical Research Council [G0700314] Funding Source: researchfish	Food Safety Agency, United Kingdom; Wellcome Trust(Wellcome TrustEuropean Commission); National Children's Research Centre, Dublin, Ireland; Centre for Dermatology and Genetic Medicine, University of Dundee; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the Food Safety Agency, United Kingdom (TO7060), and in part by grants from the Wellcome Trust (090066/B/09/Z and 092530/Z/10/Z to A.D.I. and W.H.I.M.). The BASELINE cohort is supported by the National Children's Research Centre, Dublin, Ireland. The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported a Wellcome Trust Strategic Award (098439/Z/12/Z to W.H.I.M.).	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; BAREL AO, 1995, SKIN PHARMACOL, V8, P186; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Budtz-Jorgensen E, 2007, ANN EPIDEMIOL, V17, P27, DOI 10.1016/j.annepidem.2006.05.007; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Duggan EM, 2012, PEDIAT ALLERG IMM-UK, V23, P464, DOI 10.1111/j.1399-3038.2012.01291.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Fluhr JW, 2005, BRIT J DERMATOL, V153, P125, DOI 10.1111/j.1365-2133.2005.06430.x; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Horimukai K, 2016, ALLERGOL INT, V65, P103, DOI 10.1016/j.alit.2015.09.004; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Kelleher M, 2014, J ALLERGY CLIN IMMUN, V135; Kelleher MM, 2013, PEDIATR DERMATOL, V30, P712, DOI 10.1111/pde.12106; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; O'Donovan SM, 2015, INT J EPIDEMIOL, V44, P764, DOI 10.1093/ije/dyu157; Prescott SL, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-21; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Schoemaker AA, 2015, ALLERGY, V70, P963, DOI 10.1111/all.12630; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	33	128	136	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1111	+		10.1016/j.jaci.2015.12.1312	http://dx.doi.org/10.1016/j.jaci.2015.12.1312			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26924469				2022-12-18	WOS:000373351200017
J	Suarez-Farinas, M; Ungar, B; Noda, S; Shroff, A; Mansouri, Y; Fuentes-Duculan, J; Czernik, A; Zheng, XZ; Estrada, YD; Xu, H; Peng, XY; Shemer, A; Krueger, JG; Lebwohl, MG; Guttman-Yassky, E				Suarez-Farinas, Mayte; Ungar, Benjamin; Noda, Shinji; Shroff, Anjali; Mansouri, Yasaman; Fuentes-Duculan, Judilyn; Czernik, Annette; Zheng, Xiuzhong; Estrada, Yeriel D.; Xu, Hui; Peng, Xiangyu; Shemer, Avner; Krueger, James G.; Lebwohl, Mark G.; Guttman-Yassky, Emma			Alopecia areata profiling shows T(H)1, T(H)2, and IL-23 cytokine activation without parallel T(H)17/T(H)22 skewing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alopecia areata; T cell; T(H)1; T(H)2; IL-23; hair keratin; atopic dermatitis	SEVERE ATOPIC-DERMATITIS; TO-SEVERE PSORIASIS; IN-VITRO; HAIR-FOLLICLES; COMORBIDITY PROFILES; COMBINATION THERAPY; SUSCEPTIBILITY LOCI; DENDRITIC CELLS; TH17 CELLS; SKIN	Background: Alopecia areata (AA) is a common T cell-mediated disorder with limited therapeutics. A molecular profile of cytokine pathways in AA tissues is lacking. Although studies have focused on T(H)1/IFN-gamma responses, several observations support a shared genetic background between AA and atopy. Objective: We sought to define the AA scalp transcriptome and associated biomarkers with comparisons with atopic dermatitis (AD) and psoriasis. Methods: We performed microarray and RT-PCR profiling of 27 lesional and 17 nonlesional scalp samples from patients with AA for comparison with normal scalp samples (n = 6). AA gene expression was also compared with samples from patients with lesional or nonlesional AD and those with psoriasis. A fold change of greater than 1.5 and a false discovery rate of less than 0.05 were used for differentially expressed genes (DEGs). Results: We established the AA transcriptomes (lesional vs nonlesional: 734 DEGs[297 upregulated and 437 downregulated]; lesional vs normal: 4230 DEGs [1980 upregulated and 2250 downregulated]), including many upregulated immune and downregulated hair keratin genes. Equally impressive as upregulation in T(H)1/interferon markers (IFNG and CXCL10/CXCL9) were those noted in T(H)2 (IL13, CCL18, CCL26, thymic stromal lymphopoietin, and periostin), T(H)9/IL-9, IL-23 (p40 and p19), and IL-16 mediators (all P < .05). There were no increases in T(H)17/T(H)22 markers. Hair keratin (KRT) expressions (ie, KRT86 and KRT85) were significantly suppressed in lesional skin. Greater scalp involvement (>25%) was associated with greater immune and keratin dysregulation and larger abnormalities in nonlesional scalp samples (ie, CXCL10 and KRT85). Conclusions: Our data associate the AA signature with T(H)2, T(H)1, IL-23, and IL-9/T(H)9 cytokine activation, suggesting consideration of anti-T(H)2, anti-T(H)1, and anti-IL-23 targeting strategies. Similar to psoriasis and AD, clinical trials with selective antagonists are required to dissect key pathogenic pathways.	[Suarez-Farinas, Mayte; Ungar, Benjamin; Shroff, Anjali; Mansouri, Yasaman; Czernik, Annette; Estrada, Yeriel D.; Xu, Hui; Peng, Xiangyu; Lebwohl, Mark G.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Suarez-Farinas, Mayte; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Immunol, New York, NY 10029 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA; [Suarez-Farinas, Mayte; Ungar, Benjamin; Noda, Shinji; Fuentes-Duculan, Judilyn; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA; [Shemer, Avner] Tel Hashomer, Dept Dermatol, Tel Aviv, Israel	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Lauschner, Flavia H/P-2457-2018	Ungar, Benjamin/0000-0003-0882-8163	National Center for Research Resources (NCRR), National Institutes of Health (NIH) [5UL1RR024143-02]; NIH Roadmap for Medical Research; Dermatology Foundation Physician Scientist Career Development Award; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation Physician Scientist Career Development Award; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	B.U., J.G.K., M.S.-F., and S.N. were supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y was supported by the Dermatology Foundation Physician Scientist Career Development Award.	Aghaei Shahin, 2014, ISRN Dermatol, V2014, P304370, DOI 10.1155/2014/304370; Alkhalifah A, 2013, DERMATOL CLIN, V31, P93, DOI 10.1016/j.det.2012.08.010; Alkhalifah A, 2011, DERMATOL THER, V24, P355, DOI 10.1111/j.1529-8019.2011.01419.x; Alkhalifah A, 2010, J AM ACAD DERMATOL, V62, P191, DOI 10.1016/j.jaad.2009.10.031; Alkhalifah A, 2010, J AM ACAD DERMATOL, V62, P177, DOI 10.1016/j.jaad.2009.10.032; Andrisani G, 2013, EUR REV MED PHARMACO, V17, P2831; Attia EAS, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/503587; Avitabile S, 2015, J DERMATOL, V42, P98, DOI 10.1111/1346-8138.12740; Bakry Ola Ahmed, 2014, Indian Dermatol Online J, V5, P122, DOI 10.4103/2229-5178.131076; Bao Lei, 2013, JAKSTAT, V2, pe24137, DOI 10.4161/jkst.24137; Barahmani N, 2010, CLIN EXP DERMATOL, V35, P409, DOI 10.1111/j.1365-2230.2009.03523.x; Barahmani N, 2009, J AM ACAD DERMATOL, V61, P581, DOI 10.1016/j.jaad.2009.04.031; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Betz RC, 2007, J INVEST DERMATOL, V127, P2539, DOI 10.1038/sj.jid.5700915; Betz RC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6966; Biran R, 2015, J DERMATOL SCI, V78, P11, DOI 10.1016/j.jdermsci.2015.01.004; Busa S, 2015, EXPERT OPIN DRUG SAF, V14, P979, DOI 10.1517/14740338.2015.1031743; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Chen C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017238; Chu SY, 2011, J AM ACAD DERMATOL, V65, P949, DOI 10.1016/j.jaad.2010.08.032; Coda AB, 2011, GENOMICS, V98, P431, DOI 10.1016/j.ygeno.2011.08.009; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Craiglow BG, 2014, J INVEST DERMATOL, V134, P2988, DOI 10.1038/jid.2014.260; Czarnowicki T, 2014, J ALLER CL IMM-PRACT, V2, P371, DOI 10.1016/j.jaip.2014.03.006; Durdu M, 2015, J AM ACAD DERMATOL, V72, P640, DOI 10.1016/j.jaad.2015.01.008; El Khoury J, 2013, INT J DERMATOL, V52, P1551, DOI 10.1111/ijd.12226; Finner AM, 2011, DERMATOL THER, V24, P348, DOI 10.1111/j.1529-8019.2011.01413.x; Fridman JS, 2011, J INVEST DERMATOL, V131, P1838, DOI 10.1038/jid.2011.140; Gilhar A, 2012, NEW ENGL J MED, V366, P1515, DOI 10.1056/NEJMra1103442; Giordano CN, 2013, EUR J DERMATOL, V23, P308, DOI 10.1684/ejd.2013.2042; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gregoriou S, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/928030; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012; Haider AS, 2008, J IMMUNOL, V180, P1913, DOI 10.4049/jimmunol.180.3.1913; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Harden JL, 2015, J ALLERGY CLIN IMMUN, V135, P553, DOI 10.1016/j.jaci.2014.05.046; Hirota R, 2002, J INTERF CYTOK RES, V22, P935, DOI 10.1089/10799900260286641; Hoffmann R, 1999, J INVEST DERM SYMP P, V4, P235, DOI 10.1038/sj.jidsp.5640218; Hordinsky Maria K, 2013, J Investig Dermatol Symp Proc, V16, pS13, DOI 10.1038/jidsymp.2013.4; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huang KP, 2013, JAMA DERMATOL, V149, P789, DOI 10.1001/jamadermatol.2013.3049; Hunt N, 2005, BRIT MED J, V331, P951, DOI 10.1136/bmj.331.7522.951; Inui S, 2013, J DERMATOL, V40, P881, DOI 10.1111/1346-8138.12273; Ito T, 2005, BRIT J DERMATOL, V152, P623, DOI 10.1111/j.1365-2133.2005.06453.x; Ito T, 2014, EXP DERMATOL, V23, P787, DOI 10.1111/exd.12489; Ito T, 2013, J DERMATOL SCI, V69, P140, DOI 10.1016/j.jdermsci.2012.12.003; Ito T, 2012, J DERMATOL, V39, P11, DOI 10.1111/j.1346-8138.2011.01476.x; Jagielska D, 2012, J INVEST DERMATOL, V132, P2192, DOI 10.1038/jid.2012.129; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kalkan G, 2013, GENE, V527, P565, DOI 10.1016/j.gene.2013.05.086; Kanda N, 2008, EUR J IMMUNOL, V38, P1287, DOI 10.1002/eji.200738051; Karimkhani C, 2015, BRIT J DERMATOL, V172, P1424, DOI 10.1111/bjd.13559; Kasumagic-Halilovic Emina, 2006, Acta Dermatovenerol Croat, V14, P149; Kasumagic-Halilovic Emina, 2010, Med Arh, V64, P212; Katagiri K, 2007, ARCH DERMATOL RES, V298, P397, DOI 10.1007/s00403-006-0700-2; Keren A, 2015, J DERMATOL SCI, V77, P74, DOI 10.1016/j.jdermsci.2014.11.009; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim BJ, 2008, J DERMATOL TREAT, V19, P216, DOI 10.1080/09546630701846095; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim CD, 2002, BIOCHEM BIOPH RES CO, V290, P1133, DOI 10.1006/bbrc.2001.6324; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Kumaresan M, 2010, Int J Trichology, V2, P63, DOI 10.4103/0974-7753.66920; Lee NR, 2014, ANN DERMATOL, V26, P722, DOI 10.5021/ad.2014.26.6.722; Lee S, 1998, BRIT J RHEUMATOL, V37, P1334; Lew BL, 2014, INT J DERMATOL, V53, P319, DOI 10.1111/ijd.12251; Luk NM, 2013, J EUR ACAD DERMATOL, V27, pe400, DOI 10.1111/jdv.12009; Madani S, 2000, J AM ACAD DERMATOL, V42, P549, DOI 10.1016/S0190-9622(00)90164-6; Malajian D, 2015, CYTOKINE, V73, P311, DOI 10.1016/j.cyto.2014.11.023; McElwee KJ, 2013, EXP DERMATOL, V22, P609, DOI 10.1111/exd.12209; McElwee KJ, 1996, BRIT J DERMATOL, V135, P211, DOI 10.1111/j.1365-2133.1996.tb01149.x; McElwee KJ, 2003, VET PATHOL, V40, P643, DOI 10.1354/vp.40-6-643; McPhee CG, 2012, J INVEST DERMATOL, V132, P1736, DOI 10.1038/jid.2012.17; Mohan GC, 2015, JAMA DERMATOL, V151, P522, DOI 10.1001/jamadermatol.2014.3324; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Ohmatsu H, 2014, CANCER IMMUNOL RES, V2, P890, DOI 10.1158/2326-6066.CIR-13-0199-T; Omori-Miyake M, 2014, J INVEST DERMATOL, V134, P1342, DOI 10.1038/jid.2013.503; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Park KY, 2013, ANN DERMATOL, V25, P12, DOI 10.5021/ad.2013.25.1.12; Philpott MP, 1996, BRIT J DERMATOL, V135, P942, DOI 10.1046/j.1365-2133.1996.d01-1099.x; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; PRICE VH, 1987, J AM ACAD DERMATOL, V16, P737, DOI 10.1016/S0190-9622(87)70096-6; Richmond J, 2014, J CELL PHYSIOL, V229, P139, DOI 10.1002/jcp.24441; Samrao A, 2012, ARCH DERMATOL, V148, P890, DOI 10.1001/archdermatol.2012.812; Schafer P, 2012, BIOCHEM PHARMACOL, V83, P1583, DOI 10.1016/j.bcp.2012.01.001; Schweizer J, 2007, EXP CELL RES, V313, P2010, DOI 10.1016/j.yexcr.2007.02.032; Seetharam KA, 2013, INDIAN J DERMATOL VE, V79, P563, DOI 10.4103/0378-6323.116725; Shimomura Y, 2005, J INVEST DERM SYMP P, V10, P230, DOI 10.1111/j.1087-0024.2005.10112.x; Shohat M, 2005, CLIN EXP DERMATOL, V30, P432, DOI 10.1111/j.1365-2230.2005.01817.x; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Subramanya RD, 2010, GENOMICS, V96, P146, DOI 10.1016/j.ygeno.2010.05.002; Tanemura A, 2013, DERMATOLOGY, V226, P333, DOI 10.1159/000350933; Tanyasiri K, 2005, J DERMATOL SCI, V37, P55, DOI 10.1016/j.jdermsci.2004.09.006; Tauber M, 2014, J AM ACAD DERMATOL, V70, P1146, DOI 10.1016/j.jaad.2014.03.005; Tembhre MK, 2013, BRIT J DERMATOL, V169, P543, DOI 10.1111/bjd.12396; Teraki Y, 1996, ACTA DERM-VENEREOL, V76, P421; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tojo G, 2013, DERMATOLOGY, V227, P78, DOI 10.1159/000353159; Whitmont Kaley J, 2003, Australas J Dermatol, V44, P106, DOI 10.1046/j.1440-0960.2003.00654.x; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645; Yamakoshi T, 2013, ACTA DERM-VENEREOL, V93, P575, DOI 10.2340/00015555-1613; Yang CC, 2013, ANN DERMATOL, V25, P471, DOI 10.5021/ad.2013.25.4.471; Yu M, 2008, EXP DERMATOL, V17, P12, DOI 10.1111/j.1600-0625.2007.00643.x; Zhang B, 2013, AUSTRALAS J DERMATOL, V54, P184, DOI 10.1111/ajd.12065; Zhang XT, 2015, ARCH DERMATOL RES, V307, P319, DOI 10.1007/s00403-015-1539-1	112	128	134	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1277	1287		10.1016/j.jaci.2015.06.032	http://dx.doi.org/10.1016/j.jaci.2015.06.032			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26316095				2022-12-18	WOS:000364787200017
J	Buters, J; Prank, M; Sofiev, M; Pusch, G; Albertini, R; Annesi-Maesano, I; Antunes, C; Behrendt, H; Berger, U; Brandao, R; Celenk, S; Galan, C; Grewling, L; Jackowiak, B; Kennedy, R; Rantio-Lehtimaki, A; Reese, G; Sauliene, I; Smith, M; Thibaudon, M; Weber, B; Cecchi, L				Buters, Jeroen; Prank, Marje; Sofiev, Mikhail; Pusch, Gudrun; Albertini, Roberto; Annesi-Maesano, Isabella; Antunes, Celia; Behrendt, Heidrun; Berger, Uwe; Brandao, Rui; Celenk, Sevcan; Galan, Carmen; Grewling, Lukasz; Jackowiak, Bogdan; Kennedy, Roy; Rantio-Lehtimaki, Auli; Reese, Gerald; Sauliene, Ingrida; Smith, Matt; Thibaudon, Michel; Weber, Bernhard; Cecchi, Lorenzo		HIALINE Working Grp	Variation of the group 5 grass pollen allergen content of airborne pollen in relation to geographic location and time in season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; grass; Phl p 5; Europe; PM10; PM2.5; exposure; allergy; basophil; modeling; SILAM; HIALINE	THUNDERSTORM-RELATED ASTHMA; BET V 1; BIRCH POLLEN; CREATE PROJECT; TIMOTHY GRASS; HAY-FEVER; RELEASE; IGE; STANDARDIZATION; SENSITIZATION	Background: Allergies to grass pollen are the number one cause of outdoor hay fever. The human immune system reacts with symptoms to allergen from pollen. Objective: We investigated the natural variability in release of the major group 5 allergen from grass pollen across Europe. Methods: Airborne pollen and allergens were simultaneously collected daily with a volumetric spore trap and a high-volume cascade impactor at 10 sites across Europe for 3 consecutive years. Group 5 allergen levels were determined with a Phl p 5-specific ELISA in 2 fractions of ambient air: particulate matter of greater than 10 mu m in diameter and particulate matter greater than 2.5 mu m and less than 10 mu m in diameter. Mediator release by ambient air was determined in Fc epsilon RI-humanized basophils. The origin of pollen was modeled and condensed to pollen potency maps. Results: On average, grass pollen released 2.3 pg of Phl p 5 per pollen. Allergen release per pollen (potency) varied substantially, ranging from less than 1 to 9 pg of Phl p 5 per pollen (5% to 95% percentile). The main variation was locally day to day. Average potency maps across Europe varied between years. Mediator release from basophilic granulocytes correlated better with allergen levels per cubic meter (r(2) = 0.80, P < .001) than with pollen grains per cubic meter (r(2) = 0.61, P < .001). In addition, pollen released different amounts of allergen in the non-pollenbearing fraction of ambient air, depending on humidity. Conclusion: Across Europe, the same amount of pollen released substantially different amounts of group 5 grass pollen allergen. This variation in allergen release is in addition to variations in pollen counts. Molecular aerobiology (ie, determining allergen in ambient air) might be a valuable addition to pollen counting.	[Buters, Jeroen; Pusch, Gudrun; Behrendt, Heidrun] Tech Univ Munich, Helmholtz Ctr Munich, ZAUM Ctr Allergy & Environm, D-80802 Munich, Germany; [Buters, Jeroen; Pusch, Gudrun; Behrendt, Heidrun] Christine Kuhne Ctr Allergy Res & Educ CK CARE, Kuhne Fdn, Munich, Germany; [Prank, Marje; Sofiev, Mikhail] Finnish Meteorol Inst, FIN-00101 Helsinki, Finland; [Albertini, Roberto] Univ Parma, Univ Hosp Parma, UO Med Immunol, Dept Clin & Expt Med,Lab Allergol, I-43100 Parma, Italy; [Annesi-Maesano, Isabella] INSERM, Inst Pierre Louis Epidemiol & Sante Publ, UMR S1136, EPAR Dept, F-75654 Paris 13, France; [Annesi-Maesano, Isabella] Univ Paris 06, Sorbonne Univ, EPAR Dept, UMR S 1136,Inst Pierre Louis Epidemiol & Sane Pub, Paris, France; [Antunes, Celia; Brandao, Rui] Univ Evora, ICAAM Inst Mediterranean Crop & Environm Sci, Evora, Portugal; [Antunes, Celia] Univ Coimbra, Ctr Neurosci & Cell Biol CNC, P-3000 Coimbra, Portugal; [Berger, Uwe; Smith, Matt] Med Univ Vienna, Dept Otorhinolaryngol, Res Unit Aerobiol & Pollen Informat, Vienna, Austria; [Celenk, Sevcan] Uludag Univ, Sci & Arts Fac, Dept Biol, Aerobiol Lab, Gorukle, Turkey; [Galan, Carmen] Univ Cordoba, Dept Bot Ecol & Plant Physiol, Cordoba, Spain; [Grewling, Lukasz; Jackowiak, Bogdan] Adam Mickiewicz Univ, Fac Biol, Lab Aeropalynol, Poznan, Poland; [Kennedy, Roy] Univ Worcester, Natl Pollen & Aerobiol Res Unit, Worcester, MA USA; [Rantio-Lehtimaki, Auli] Univ Turku, CERUT, Aerobiol Unit, Turku, Finland; [Reese, Gerald] Allergopharma GmbH & Co KG, Reinbek, Germany; [Sauliene, Ingrida] Siauliai Univ, Dept Environm Res, Shiauliai, Lithuania; [Thibaudon, Michel] Reseau Natl Surveillance Aerobiol, Brussieu, France; [Cecchi, Lorenzo] Univ Florence, Interdept Ctr Bioclimatol, I-50121 Florence, Italy	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Finnish Meteorological Institute; University of Parma; University Hospital of Parma; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Evora; Universidade de Coimbra; Medical University of Vienna; Uludag University; Universidad de Cordoba; Adam Mickiewicz University; University of Turku; Allergopharma; Siauliai University; University of Florence	Buters, J (corresponding author), Tech Univ Munich, Helmholtz Ctr Munich, ZAUM Ctr Allergy & Environm, Biedersteinerstr 29, D-80802 Munich, Germany.	buters@tum.de	Prank, Marje/AAZ-5209-2020; Albertini, Roberto/Q-1708-2015; Galan, Carmen Mrs/M-1377-2015; Buters, Jeroen T/G-5070-2011; Annesi-Maesano, Isabella/D-9173-2016; Smith, Matt R/C-3911-2014; Sofiev, Mikhail/F-7606-2016; Antunes, Célia/AGZ-1234-2022; Šaulienė, Ingrida/M-9325-2015; BUTERS, JEROEN/AAF-6949-2020; Sauliene, Ingrida/J-9320-2019; Çelenk, Sevcan/K-2981-2012	Prank, Marje/0000-0002-4280-8898; Albertini, Roberto/0000-0002-9569-0467; Galan, Carmen Mrs/0000-0002-6849-1219; Annesi-Maesano, Isabella/0000-0002-6340-9300; Smith, Matt R/0000-0002-4170-2960; Sofiev, Mikhail/0000-0001-9542-5746; Antunes, Célia/0000-0001-8906-1085; Šaulienė, Ingrida/0000-0003-0250-1127; Sauliene, Ingrida/0000-0003-0250-1127; Çelenk, Sevcan/0000-0003-4925-8902; Cecchi, Lorenzo/0000-0002-0658-2449; Buters, Jeroen/0000-0003-3581-5472; Jackowiak, Bogdan/0000-0003-1684-7380; Berger, Uwe E./0000-0002-9265-2131	European Union	European Union(European Commission)	This publication arises from HIALINE, a project that has received funding from the European Union in the framework of the Health Programme.	Abou Chakra OR, 2012, J PROTEOME RES, V11, P1208, DOI 10.1021/pr200923f; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Berger U, 2013, ALLERGY, V68, P963, DOI 10.1111/all.12181; Bergmann KC, 2013, ALLERGO J, V22, P471; Bienboire-Frosini C, 2012, VET J, V193, P162, DOI 10.1016/j.tvjl.2011.09.031; BROWN HM, 1973, ACTA ALLERGOL, V28, P132, DOI 10.1111/j.1398-9995.1973.tb01319.x; Bullimore A, 2011, WORLD ALLERGY ORGAN, V4, P140, DOI 10.1097/WOX.0b013e3182260bd2; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Buters JTM, 2010, ALLERGY, V65, P850, DOI 10.1111/j.1398-9995.2009.02286.x; Buters JTM, 2008, INT ARCH ALLERGY IMM, V145, P122, DOI 10.1159/000108137; Buters JTM, 2012, ATMOS ENVIRON, V55, P496, DOI 10.1016/j.atmosenv.2012.01.054; Caillaud DM, 2012, J ALLERGY CLIN IMMUN, V130, P812, DOI 10.1016/j.jaci.2012.04.034; Canova C, 2013, EUR RESPIR J, V42, P935, DOI 10.1183/09031936.00097412; Cecchi L, 2013, EUR RESPIR J, V42, P898, DOI 10.1183/09031936.00096413; Chapman MD, 2008, J ALLERGY CLIN IMMUN, V122, P882, DOI 10.1016/j.jaci.2008.07.030; D'Amato G, 2008, J ALLERGY CLIN IMMUN, V121, P537, DOI 10.1016/j.jaci.2007.10.046; de Weger L, 2012, ALLERGENIC POLLEN; DellaValle CT, 2012, EPIDEMIOLOGY, V23, P55, DOI 10.1097/EDE.0b013e31823b66b8; Demokritou P, 2002, J AEROSOL SCI, V33, P1111, DOI 10.1016/S0021-8502(02)00064-2; Duffort O, 2008, INT ARCH ALLERGY IMM, V145, P283, DOI 10.1159/000110887; European Aerosol Society, 2011, INT AEROBIOLOGY NEWS, V72, P1; Brito FF, 2010, J INVEST ALLERG CLIN, V20, P295; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; Frenguelli G, 2010, ANN ALLERG ASTHMA IM, V105, P223, DOI 10.1016/j.anai.2010.06.016; Galan C, 2013, ALLERGY, V68, P809, DOI 10.1111/all.12144; Gangl K, 2013, CLIN EXP ALLERGY, V43, P1202, DOI 10.1111/cea.12128; Gilles S, 2011, J ALLERGY CLIN IMMUN, V127, P454, DOI 10.1016/j.jaci.2010.12.1082; Haftenberger M, 2013, BUNDESGESUNDHEITSBLA, V56, P687, DOI 10.1007/s00103-012-1658-1; ICRP, 1994, HUM RESP TRACT MOD R; Jantunen J, 2012, AEROBIOLOGIA, V28, P169, DOI 10.1007/s10453-011-9221-3; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; King EM, 2013, J IMMUNOL METHODS, V387, P89, DOI 10.1016/j.jim.2012.09.015; Leon-Ruiz E, 2011, AEROBIOLOGIA, V27, P37, DOI 10.1007/s10453-010-9174-y; Livingston EH, 2004, J SURG RES, V118, P58, DOI 10.1016/j.jss.2004.02.003; Lorenz R.J., 1989, BIOMETRIE GRUNDBEGRI; Mitlehner W., 2013, ALLERGO J, V22, P244; Moverare R, 2006, J INVEST ALLERG CLIN, V16, P274; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pottering H, 2008, OFFICIAL J EUROPEAN, V152, P1; Prank M, 2013, AGR FOREST METEOROL, V182, P43, DOI 10.1016/j.agrformet.2013.08.003; Ramirez J, 1997, ALLERGY, V52, P806, DOI 10.1111/j.1398-9995.1997.tb02151.x; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Sofiev M, 2013, INT J BIOMETEOROL, V57, P45, DOI 10.1007/s00484-012-0532-z; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Taylor PE, 2004, CURR ALLERGY ASTHM R, V4, P409, DOI 10.1007/s11882-004-0092-3; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; van Oort E, 2005, INT ARCH ALLERGY IMM, V136, P113, DOI 10.1159/000083318; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; Vieths S, 2012, Pharmeur Bio Sci Notes, V2012, P118; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Zafred D, 2013, J ALLERGY CLIN IMMUN, V132, P696, DOI 10.1016/j.jaci.2013.03.021	55	128	129	1	55	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					87	U179		10.1016/j.jaci.2015.01.049	http://dx.doi.org/10.1016/j.jaci.2015.01.049			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25956508				2022-12-18	WOS:000357542200010
J	Peters, RL; Allen, KJ; Dharmage, SC; Koplin, JJ; Dang, T; Tilbrook, KP; Lowe, A; Tang, MLK; Gurrin, LC				Peters, Rachel L.; Allen, Katrina J.; Dharmage, Shyamali C.; Koplin, Jennifer J.; Thanh Dang; Tilbrook, Kate P.; Lowe, Adrian; Tang, Mimi L. K.; Gurrin, Lyle C.		HealthNuts Study	Natural history of peanut allergy and predictors of resolution in the first 4 years of life: A population-based assessment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; predictive value of tests; natural history; resolution; skin prick test; specific IgE	MEDIATED FOOD ALLERGY; SKIN-TEST REACTIVITY; IGE LEVELS; CHALLENGE OUTCOMES; EGG ALLERGY; PRICK TESTS; INFANTS; MILK; CHILDREN; TOLERANCE	Background: There are no prospectively collected data available on the natural history of peanut allergy in early childhood. Previous studies of predictors of tolerance development have been biased by failure to challenge high-risk children when IgE antibody levels are high, therefore potentially introducing bias to persistent allergy. Objectives: We sought to describe the natural history of peanut allergy between 1 and 4 years of age and develop thresholds for skin prick test (SPT) results and specific IgE (sIgE) levels measured at age 1 and 4 years that have 95% positive predictive value (PPV) or negative predictive value for the persistence or resolution of peanut allergy. Methods: One-year-old infants with challenge-confirmed peanut allergy (n = 156) from the population-based, longitudinal HealthNuts Study (n = 5276) were followed up at 4 years of age with repeat oral food challenges, SPTs, and sIgE measurements (n = 103). Challenges were undertaken in all peanut-sensitized children at 1 and 4 years of age, irrespective of risk profile. Results: Peanut allergy resolved in 22% (95% CI, 14% to 31%) of children by age 4 years. Decreasing wheal size predicted tolerance, and increasing wheal size was associated with persistence. Thresholds for SPT responses and sIgE levels at age 1 year with a 95% PPV for persistent peanut allergy are an SPT-induced response of 13 mm or greater and an sIgE level of 5.0 kU/L or greater. Thresholds for SPT and sIgE results at age 4 years with a 95% PPV for persistent peanut allergy are an SPT response of 8 mm or greater and an sIgE level of 2.1 kU/L or greater. Ara h 2, tree nut, and house dust mite sensitization; coexisting food allergies; eczema; and asthma were not predictive of persistent peanut allergy. Conclusion: These thresholds are the first to be generated from a unique data set in which all participants underwent oral food challenges at both diagnosis and follow-up, irrespective of SPT and sIgE results.	[Peters, Rachel L.; Allen, Katrina J.; Dharmage, Shyamali C.; Koplin, Jennifer J.; Thanh Dang; Tilbrook, Kate P.; Lowe, Adrian; Tang, Mimi L. K.; Gurrin, Lyle C.] Murdoch Childrens Res Inst, Populat Hlth, Parkville, Vic, Australia; [Peters, Rachel L.; Allen, Katrina J.; Tilbrook, Kate P.; Tang, Mimi L. K.] Univ Melbourne, Ctr Biostat & Epidemiol, Dept Paediat, Parkville, Vic 3052, Australia; [Dharmage, Shyamali C.; Lowe, Adrian; Gurrin, Lyle C.] Univ Melbourne, Ctr Biostat & Epidemiol, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3052, Australia; [Allen, Katrina J.; Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Allen, Katrina J.] Univ Manchester, Sch Inflammat & Repair, Manchester M13 9PL, Lancs, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Matheson, Melanie C/O-4721-2015; Tang, Mimi/ABD-8350-2020; Allen, Katrina/I-4361-2018; Dang, Thanh/AAK-1608-2021	Matheson, Melanie C/0000-0002-5822-3499; Tang, Mimi/0000-0002-3839-5293; Allen, Katrina/0000-0002-1921-4493; Dang, Thanh/0000-0003-2010-5582; Lowe, Adrian/0000-0002-4691-8162; Gurrin, Lyle/0000-0001-7052-1969; Peters, Rachel/0000-0002-2411-6628; Koplin, Jennifer/0000-0002-7576-5142	National Health and Medical Research Council (NHMRC) of Australia [1006215]; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC Centre for Food and Allergy Research [1041420]	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC Centre for Food and Allergy Research(National Health and Medical Research Council (NHMRC) of Australia)	Supported by funding from the National Health and Medical Research Council (NHMRC) of Australia (ID 1006215), the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, the Victorian Government's Operational Infrastructure Support Program, and the NHMRC Centre for Food and Allergy Research (ID 1041420). K.J.A. is a Viertel senior medical research fellow. R.L.P. is an Australian Postgraduate Award scholar. L.C.G., A.L., J.J.K., and S.C.D. hold NHMRC awards.	Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; ASCIA, 2013, AN SYDN AUSTR SOC CL; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Burks AW, 2014, ANN ALLERG ASTHMA IM, V112, P200, DOI 10.1016/j.anai.2014.01.008; Clark A, 2011, CLIN EXP ALLERGY, V41, P706, DOI 10.1111/j.1365-2222.2011.03697.x; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Johannsen H, 2011, CLIN EXP ALLERGY, V41, P994, DOI 10.1111/j.1365-2222.2011.03717.x; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Koplin JJ, 2014, ALLERGY, V69, P1639, DOI 10.1111/all.12487; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; Mudd K, 2009, J ALLERGY CLIN IMMUN, V124, P1115, DOI 10.1016/j.jaci.2009.08.023; Nolan RC, 2007, PEDIAT ALLERG IMM-UK, V18, P224, DOI 10.1111/j.1399-3038.2007.00519.x; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Peters RL, 2013, INT J ENV RES PUB HE, V10, P5039, DOI 10.3390/ijerph10105039; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473, DOI 10.1016/S1081-1206(10)62574-4; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Tan HTT, 2012, J ALLERGY CLIN IMMUN, V130, P1211, DOI 10.1016/j.jaci.2012.07.022; Umasunthar T., 2013, BJU International, V112, P1333, DOI 10.1111/cea.12211; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	35	128	129	2	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1257	U668		10.1016/j.jaci.2015.01.002	http://dx.doi.org/10.1016/j.jaci.2015.01.002			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25725989				2022-12-18	WOS:000353980700019
J	Kohler, J; Blank, S; Muller, S; Bantleon, F; Frick, M; Huss-Marp, J; Lidholm, J; Spillner, E; Jakob, T				Koehler, Julian; Blank, Simon; Mueller, Sabine; Bantleon, Frank; Frick, Marcel; Huss-Marp, Johannes; Lidholm, Jonas; Spillner, Edzard; Jakob, Thilo			Component resolution reveals additional major allergens in patients with honeybee venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Apis mellifera; cross-reactive carbohydrate determinant; Hymenoptera venom; insect venom allergy; honeybee venom allergy; recombinant allergen; Vespula vulgaris	RVES V 5; API M 1; REACTIVE CARBOHYDRATE DETERMINANTS; WASP VENOM; PHLEUM-PRATENSE; MELLIFERA VENOM; INSECT CELLS; MOLECULAR-CLONING; CROSS-REACTIVITY; DISTINGUISH BEE	Background: Detection of IgE to recombinant Hymenoptera venom allergens has been suggested to improve the diagnostic precision in Hymenoptera venom allergy. However, the frequency of sensitization to the only available recombinant honeybee venom (HBV) allergen, rApi m 1, in patients with HBVallergy is limited, suggesting that additional HBVallergens might be of relevance. Objective: We performed an analysis of sensitization profiles of patients with HBVallergy to a panel of HBV allergens. Methods: Diagnosis of HBV allergy (n = 144) was based on history, skin test results, and allergen-specific IgE levels to HBV. IgE reactivity to 6 HBV allergens devoid of cross-reactive carbohydrate determinants (CCD) was analyzed by ImmunoCAP. Results: IgE reactivity to rApim 1, rApim 2, rApim 3, nApim 4, rApi m 5, and rApi m 10 was detected in 72.2%, 47.9%, 50.0%, 22.9%, 58.3%, and 61.8% of the patients with HBV allergy, respectively. Positive results to at least 1 HBV allergen were detected in 94.4%. IgE reactivity to Api m 3, Api m 10, or both was detected in 68.0% and represented the only HBV allergen-specific IgE in 5% of the patients. Limited inhibition of IgE binding by therapeutic HBV and limited induction of Api m 3- and Api m 10-specific IgG(4) in patients obtaining immunotherapy supports recent reports on the underrepresentation of these allergens in therapeutic HBV preparations. Conclusion: Analysis of a panel of CCD-free HBV allergens improved diagnostic sensitivity compared with use of rApi m 1 alone, identified additional major allergens, and revealed sensitizations to allergens that have been reported to be absent or underrepresented in therapeutic HBV preparations.	[Koehler, Julian; Mueller, Sabine; Frick, Marcel; Huss-Marp, Johannes; Jakob, Thilo] Univ Freiburg, Med Ctr, Dept Dermatol, Allergy Res Grp, D-79104 Freiburg, Germany; [Blank, Simon; Bantleon, Frank; Spillner, Edzard] Univ Hamburg, Inst Biochem & Mol Biol, Hamburg, Germany; [Huss-Marp, Johannes] Thermo Fisher Sci, Freiburg, Germany; [Lidholm, Jonas] Thermo Fisher Sci, Uppsala, Sweden	University of Freiburg; University of Hamburg; Thermo Fisher Scientific; Thermo Fisher Scientific	Jakob, T (corresponding author), Univ Freiburg, Med Ctr, Dept Dermatol, Allergy Res Grp, Hauptstr 7, D-79104 Freiburg, Germany.	spillner@chemie.uni-hamburg.de; thilo.jakob@uniklinik-freiburg.de	Blank, Simon/M-7708-2013	Lidholm, Jonas/0000-0002-7779-3411; spillner, edzard/0000-0003-0999-5254	Allergopharma; Thermo Fisher; Birken; Cosmetic Europe	Allergopharma; Thermo Fisher; Birken; Cosmetic Europe	J. Huss-Marp is employed by and owns stock/stock options in Thermo Fisher Scientific. J. Lidholm is employed by Thermo Fisher. T. Jakob has been supported by one or more grants from, has received one or more consulting fees or honoraria from, and has received support for travel from Phadia/Thermo Fisher; has consultancy arrangements with Allergopharma, Novartis, and Jansen Cilag; has received one or more grants from or has one or more grants pending with Allergopharma, Thermo Fisher, Birken, and Cosmetic Europe; has received one or more payments for lecturing from or is on the speakers' bureau for Stallergenes, ALK Abello, Allergies Therapeutics, and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; ARBESMAN CE, 1976, CLIN ALLERGY, V6, P587, DOI 10.1111/j.1365-2222.1976.tb01945.x; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Blank S, 2012, CLIN EXP ALLERGY, V42, P976, DOI 10.1111/j.1365-2222.2012.03966.x; Blank S, 2011, ALLERGY, V66, P1322, DOI 10.1111/j.1398-9995.2011.02667.x; Blank S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062009; Blank S, 2011, PROTEIN PEPTIDE LETT, V18, P415, DOI 10.2174/092986611794653923; Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Eberlein B, 2012, J ALLERGY CLIN IMMUN, V130, P155, DOI 10.1016/j.jaci.2012.02.008; Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P460, DOI 10.1111/j.1365-2222.2004.01897.x; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V128, P248, DOI 10.1016/j.jaci.2011.02.020; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; Jakob T, 2012, J ALLERGY CLIN IMMUN, V130, P276, DOI 10.1016/j.jaci.2012.03.048; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Jin C, 2010, J ALLERGY CLIN IMMUN, V125, P184, DOI 10.1016/j.jaci.2009.08.037; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; Korosec P, 2012, J ALLERGY CLIN IMMUN, V129, P1406, DOI 10.1016/j.jaci.2011.12.975; Korosec P, 2011, J ALLERGY CLIN IMMUN, V128, P671, DOI 10.1016/j.jaci.2011.03.012; Michel Y, 2012, J INVEST ALLERG CLIN, V22, P476; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Moverare R, 2005, INT ARCH ALLERGY IMM, V136, P33, DOI 10.1159/000082582; Muller UR, 2005, CURR OPIN ALLERGY CL, V5, P343; Muller UR, 1988, INSEKTENSTICHALLERGI; Peiren N, 2006, FEBS LETT, V580, P4895, DOI 10.1016/j.febslet.2006.08.005; Seismann Henning, 2010, Clin Mol Allergy, V8, P7, DOI 10.1186/1476-7961-8-7; Seismann H, 2010, MOL IMMUNOL, V47, P799, DOI 10.1016/j.molimm.2009.10.005; Skov LK, 2006, ACTA CRYSTALLOGR D, V62, P595, DOI 10.1107/S0907444906010687; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691, DOI 10.1016/S0091-6749(98)70179-4; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P247, DOI 10.1016/j.jaci.2011.02.021; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Vos B, 2013, J ALLERGY CLIN IMMUN, V131, P1225, DOI 10.1016/j.jaci.2012.07.041	36	128	130	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1383	U627		10.1016/j.jaci.2013.10.060	http://dx.doi.org/10.1016/j.jaci.2013.10.060			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24440283	hybrid			2022-12-18	WOS:000335450700021
J	Jaakkola, MS; Quansah, R; Hugg, TT; Heikkinen, SAM; Jaakkola, JJK				Jaakkola, Maritta S.; Quansah, Reginald; Hugg, Timo T.; Heikkinen, Sirpa A. M.; Jaakkola, Jouni J. K.			Association of indoor dampness and molds with rhinitis risk: A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; mold; dampness; case-control; longitudinal; cross-sectional; meta-analysis	CHILDRENS RESPIRATORY HEALTH; ELEMENTARY-SCHOOL-CHILDREN; BUILDING-RELATED SYMPTOMS; ALLERGIC RHINITIS; HOME DAMPNESS; HOUSING CHARACTERISTICS; ENVIRONMENTAL-FACTORS; COLLEGE-STUDENTS; YOUNG-CHILDREN; FLOOR DUST	Background: A substantial proportion of the world's population is exposed to indoor dampness-related exposures. Since the 1990s, studies have assessed the relation between indoor dampness and mold and rhinitis, but the evidence has been inconclusive. No previous meta-analysis has been reported on this topic. Objective: We conducted a systematic review and meta-analysis of studies on the relations between indoor dampness and mold and the risk of different types of rhinitis and investigated whether these relations differ according to the type of exposure. Methods: A systematic search of the Ovid MEDLINE and EMBASE databases was conducted (1950 through August 2012), and reference lists of relevant articles were reviewed. Cross-sectional, case-control, and cohort studies in children or adults were selected according to a priori criteria and evaluated by 3 authors independently. Results: Thirty-one studies on rhinitis, allergic rhinitis (AR), or rhinoconjunctivitis were included. In meta-analyses the largest risk was observed in relation to mold odor (rhinitis: 2.18 [95% CI, 1.76-2.71]; AR: 1.87 [95% CI, 0.95-3.68]). The risk related to visible mold was also consistently increased (rhinitis: 1.82 [95% CI, 1.56-2.12]; AR: 1.51 [95% CI, 1.39-1.64]; rhinoconjunctivitis: 1.66 [95% CI, 1.27-2.18]). In addition, exposure to dampness was related to increased risk of all types of rhinitis. Conclusion: This meta-analysis provides new evidence that dampness and molds at home are determinants of rhinitis and its subcategories. The associations were strongest with mold odor, suggesting the importance of microbial causal agents. Our results provide evidence that justifies prevention and remediation of indoor dampness and mold problems, and such actions are likely to reduce rhinitis.	[Jaakkola, Maritta S.; Quansah, Reginald; Hugg, Timo T.; Heikkinen, Sirpa A. M.; Jaakkola, Jouni J. K.] Univ Oulu, Ctr Environm & Resp Hlth Res, FI-90014 Oulu, Finland; [Jaakkola, Maritta S.; Heikkinen, Sirpa A. M.] Univ Oulu, Resp Med Unit, Inst Clin Med, FI-90014 Oulu, Finland; [Hugg, Timo T.; Jaakkola, Jouni J. K.] Univ Oulu, Inst Hlth Sci, FI-90014 Oulu, Finland; [Jaakkola, Maritta S.; Heikkinen, Sirpa A. M.; Jaakkola, Jouni J. K.] Oulu Univ Hosp, Resp Med Unit, Dept Med, Oulu, Finland	University of Oulu; University of Oulu; University of Oulu; University of Oulu	Jaakkola, MS (corresponding author), Univ Oulu, Ctr Environm & Resp Hlth Res, FI-90014 Oulu, Finland.	maritta.jaakkola@oulu.fi	Hugg, Timo/P-5531-2018; Quansah, Reginald/AAZ-4015-2020; Jaakkola, Jouni J.K./G-4314-2012	Quansah, Reginald/0000-0002-7318-4192; Hugg, Timo/0000-0003-2558-1780; Jaakkola, Jouni/0000-0003-4168-4683; Jaakkola, Maritta S./0000-0003-1373-7784	Research Council for Health; Academy of Finland [129419, 138691]; Ministry of Social Affairs and Health of Finland [STM/1523/2012]; Finnish Lung Health Association	Research Council for Health; Academy of Finland(Academy of Finland); Ministry of Social Affairs and Health of Finland; Finnish Lung Health Association	Supported by the Research Council for Health, the Academy of Finland (grants no. 129419 [SALVE Research Program] and 138691), the Ministry of Social Affairs and Health of Finland (grant no. STM/1523/2012), and the Finnish Lung Health Association.	Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; Adhikari A, 2011, ANN OCCUP HYG, V55, P272, DOI 10.1093/annhyg/meq082; Antova T, 2008, J EPIDEMIOL COMMUN H, V62, P708, DOI 10.1136/jech.2007.065896; Austin JB, 1997, ARCH DIS CHILD, V76, P22, DOI 10.1136/adc.76.1.22; Bernstein JA, 2010, ALLERGY ASTHMA PROC, V31, P365, DOI 10.2500/aap.2010.31.3380; Biagini JM, 2006, PEDIAT ALLERG IMM-UK, V17, P278, DOI 10.1111/j.1399-3038.2006.00386.x; Borenstein M., 2011, INTRO METAANALYSIS; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BRUNEKREEF B, 1992, ALLERGY, V47, P498, DOI 10.1111/j.1398-9995.1992.tb00672.x; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; Bunyavanich S, 2010, ALLERGY, V65, P256, DOI 10.1111/j.1398-9995.2009.02159.x; Celtik C, 2011, ASIAN PAC J ALLERGY, V29, P42; Chen WY, 2003, ENVIRON RES, V93, P1, DOI 10.1016/S0013-9351(03)00070-7; Civelek E, 2011, PEDIATR PULM, V46, P166, DOI 10.1002/ppul.21346; Civelek E, 2010, AM J RHINOL ALLERGY, V24, P364, DOI 10.2500/ajra.2010.24.3484; Dangman Kenneth H, 2005, Conn Med, V69, P9; Dong GH, 2008, RESPIRATION, V76, P82, DOI 10.1159/000121370; Effat KG, 2009, J LARYNGOL OTOL, V123, P631, DOI 10.1017/S002221510800399X; Engvall K, 2001, INT J TUBERC LUNG D, V5, P468; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Galante D, 2006, MYCOSES, V49, P493, DOI 10.1111/j.1439-0507.2006.01273.x; Gelincik AA, 2005, INDOOR BUILT ENVIRON, V14, P427, DOI 10.1177/1420326X05058107; Hagerhed-Engman L, 2009, INDOOR AIR, V19, P184, DOI 10.1111/j.1600-0668.2008.00573.x; Hsu SP, 2009, INT J PEDIATR OTORHI, V73, P807, DOI 10.1016/j.ijporl.2009.02.023; Ibargoyen-Roteta N, 2007, J INVEST ALLERG CLIN, V17, P137; Immonen J, 2002, PEDIATR ALLERGY IMMU, V13, P125, DOI 10.1034/j.1399-3038.2002.01003.x; Jaakkola JJK, 2010, AM J EPIDEMIOL, V172, P451, DOI 10.1093/aje/kwq110; Jaakkola MS, 2004, ADV APPL MICROBIOL, V55, P309, DOI 10.1016/S0065-2164(04)55012-8; Jaakkola MS, 2011, ENV BURDEN DIS ASS I; Jedrychowski W, 1998, Int J Occup Med Environ Health, V11, P19; Karvala K, 2008, AM J RHINOL, V22, P457, DOI 10.2500/ajr.2008.22.3209; Keall MD, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-33; Kilpelainen M, 2001, THORAX, V56, P462, DOI 10.1136/thorax.56.6.462; Koskinen OM, 1999, INT J ENVIRON HEAL R, V9, P143, DOI 10.1080/09603129973281; Koskinen OM, 1999, EUR RESPIR J, V14, P1363, DOI 10.1183/09031936.99.14613639; Kuyucu S, 2006, PEDIAT ALLERG IMM-UK, V17, P269, DOI 10.1111/j.1399-3038.2006.00407.x; Larsson M, 2008, ACTA PAEDIATR, V97, P1210, DOI 10.1111/j.1651-2227.2008.00910.x; Li CS, 1996, ARCH ENVIRON HEALTH, V51, P42, DOI 10.1080/00039896.1996.9935992; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Meyer HW, 2005, INDOOR AIR, V15, P17, DOI 10.1111/j.1600-0668.2005.00356.x; Meyer HW, 2004, INDOOR AIR, V14, P65, DOI 10.1046/j.1600-0668.2003.00213.x; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nafstad P, 2005, INDOOR AIR, V15, P69, DOI 10.1111/j.1600-0668.2004.00310.x; Osborne M, 2006, PEDIAT ALLERG IMM-UK, V17, P450, DOI 10.1111/j.1399-3038.2006.00414.x; Ozdoganoglu T, 2012, THER ADV RESPIR DIS, V6, P11, DOI 10.1177/1753465811431975; Palmer TM, 2008, STATA J, V8, P242, DOI 10.1177/1536867X0800800206; Patovirta RL, 2004, INT J ENVIRON HEAL R, V14, P415, DOI 10.1080/09603120400012876; Pegas PN, 2011, REV PORT PNEUMOL, V17, P109, DOI 10.1016/j.rppneu.2011.01.004; Pirastu R, 2009, ENVIRON RES, V109, P59, DOI 10.1016/j.envres.2008.09.002; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; Quansah R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047526; Randriamanantany ZA, 2010, ALLERGY, V65, P368, DOI 10.1111/j.1398-9995.2009.02210.x; Simoni M, 2005, OCCUP ENVIRON MED, V62, P616, DOI 10.1136/oem.2004.018291; Simoni M, 2011, PEDIAT ALLERG IMM-UK, V22, P843, DOI 10.1111/j.1399-3038.2011.01208.x; Spengler JD, 2004, AM J PUBLIC HEALTH, V94, P657, DOI 10.2105/AJPH.94.4.657; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; StataCorp, 2019, STATA STAT SOFTWARE, V16; Stazi MA, 2002, PEDIAT ALLERG IMM-UK, V13, P105, DOI 10.1034/j.1399-3038.2002.00070.x; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sun Y, 2011, INDOOR AIR, V21, P277, DOI 10.1111/j.1600-0668.2010.00699.x; Sun Y, 2009, INDOOR AIR, V19, P174, DOI 10.1111/j.1600-0668.2008.00577.x; Sun YX, 2011, SCI TOTAL ENVIRON, V409, P4229, DOI 10.1016/j.scitotenv.2011.07.011; Tamay Z, 2007, INT J PEDIATR OTORHI, V71, P463, DOI 10.1016/j.ijporl.2006.11.013; Tham KW, 2007, PEDIAT ALLERG IMM-UK, V18, P418, DOI 10.1111/j.1399-3038.2007.00544.x; Tischer C, 2011, EUR RESPIR J, V37, P1050, DOI 10.1183/09031936.00091210; Vesper SJ, 2007, J EXPO SCI ENV EPID, V17, P88, DOI 10.1038/sj.jes.7500528; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Wells GA, NEWCASTLE OTTAWA SCA; World Health Organization (WHO) Europe, 2009, WHO GUID IND QUAL DA; Yang CY, 1997, ENVIRON RES, V75, P49, DOI 10.1006/enrs.1997.3774; Zacharasiewicz A, 2000, ALLERGY, V55, P945, DOI 10.1034/j.1398-9995.2000.00575.x; Zhang GC, 2005, PEDIAT ALLERG IMM-UK, V16, P587, DOI 10.1111/j.1399-3038.2005.00325.x	73	128	132	3	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1099	+		10.1016/j.jaci.2013.07.028	http://dx.doi.org/10.1016/j.jaci.2013.07.028			30	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24028857	Bronze			2022-12-18	WOS:000326235600009
J	Baraldo, S; Contoli, M; Bazzan, E; Turato, G; Padovani, A; Marku, B; Calabrese, F; Caramori, G; Ballarin, A; Snijders, D; Barbato, A; Saetta, M; Papi, A				Baraldo, Simonetta; Contoli, Marco; Bazzan, Erica; Turato, Graziella; Padovani, Anna; Marku, Brunilda; Calabrese, Fiorella; Caramori, Gaetano; Ballarin, Andrea; Snijders, Deborah; Barbato, Angelo; Saetta, Marina; Papi, Alberto			Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; viral infections; interferons; T(H)2 inflammation; epithelial damage	INVASIVE PNEUMOCOCCAL DISEASE; PLASMACYTOID DENDRITIC CELLS; RHINOVIRUS INFECTION; EPITHELIAL-CELLS; VIRAL-INFECTIONS; RISK-FACTOR; EARLY-LIFE; CHILDREN; EXPRESSION; EXACERBATIONS	Background: Impaired immune response to viral infections in atopic asthmatic patients has been recently reported and debated. Whether this condition is present in childhood and whether it is affected by atopy per se deserves further investigation. Objective: We sought to investigate airway interferon production in response to rhinovirus infection in children who are asthmatic, atopic, or both and its correlation with the airway inflammatory profile. Methods: Bronchial biopsy specimens and epithelial cells were obtained from 47 children (mean age, 5 +/- 0.5 years) undergoing bronchoscopy. The study population included asthmatic children who were either atopic or nonatopic, atopic children without asthma, and children without atopy or asthma. Rhinovirus type 16 induction of IFN-lambda and IFN-beta mRNA and protein levels was assessed in bronchial epithelial cell cultures. The immunoinflammatory profile was evaluated by means of immunohistochemistry in bronchial biopsy specimens. Results: Rhinovirus type 16-induced interferon production was significantly reduced in atopic asthmatic, nonatopic asthmatic, and atopic nonasthmatic children compared with that seen in nonatopic nonasthmatic children (all P < .05). Increased rhinovirus viral RNA levels paralleled this deficient interferon induction. Additionally, IFN-l and IFN-b induction correlated inversely with the airway T(H)2 immunopathologic profile (eosinophilia and IL-4 positivity: P < .05 and r = -0.38 and P < .05 and r = -0.58, respectively) and with epithelial damage (P < .05 and r = -0.55). Furthermore, total serum IgE levels correlated negatively with rhinovirus-induced IFN-l mRNA levels (P < .05 and r = -0.41) and positively with rhinovirus viral RNA levels (P < .05 and r = 0.44). Conclusions: Deficient interferon responses to rhinovirus infection are present in childhood in asthmatic subjects irrespective of their atopic status and in atopic patients without asthma. These findings suggest that deficient immune responses to viral infections are not limited to patients with atopic asthma but are present in those with other T(H)2-oriented conditions. (J Allergy Clin Immunol 2012;130:1307-14.)	[Papi, Alberto] Univ Ferrara, Resp Med & Res Ctr Asthma & COPD, Dept Clin & Expt Med, Sect Resp Dis, I-44121 Ferrara, Italy; [Baraldo, Simonetta; Bazzan, Erica; Turato, Graziella; Calabrese, Fiorella; Ballarin, Andrea; Saetta, Marina] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Sect Resp Dis, Padua, Italy; [Snijders, Deborah; Barbato, Angelo] Univ Padua, Dept Woman & Child Hlth, Padua, Italy	University of Ferrara; University of Padua; University of Padua	Papi, A (corresponding author), Univ Ferrara, Resp Med & Res Ctr Asthma & COPD, Dept Clin & Expt Med, Sect Resp Dis, Via Savonarola 9, I-44121 Ferrara, Italy.	ppa@unife.it	Caramori, Gaetano/AAS-8611-2020; Contoli, Marco/K-3947-2018; Papi, alberto/AAC-1888-2019; Bazzan, Erica/G-3123-2018; Baraldo, Simonetta/AAE-3862-2021; SNIJDERS, Deborah/N-6670-2015	Caramori, Gaetano/0000-0002-9807-327X; Contoli, Marco/0000-0002-2731-5809; Bazzan, Erica/0000-0003-2956-0880; Baraldo, Simonetta/0000-0001-8923-7511; PAPI, ALBERTO/0000-0002-6924-4500; Ballarin, Andrea/0000-0001-7560-9361; SAETTA, MARINA/0000-0002-1547-2102; TURATO, GRAZIELLA/0000-0003-1895-6388; SNIJDERS, Deborah/0000-0002-7118-0630	Chiesi Foundation (Parma, Italy); Fondazione Salvatore Maugeri (Pavia, Italy); University of Padova; University of Ferrara; Italian Ministry of University and Research; Italian Society of Pediatric Respiratory Diseases; Chiesi Farmaceutici; Boehringer Ingelheim; AstraZeneca; Merck Sharp Dohme; Takeda; GlaxoSmithKline	Chiesi Foundation (Parma, Italy)(Chiesi Pharmaceuticals Inc); Fondazione Salvatore Maugeri (Pavia, Italy); University of Padova; University of Ferrara; Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Italian Society of Pediatric Respiratory Diseases; Chiesi Farmaceutici(Chiesi Pharmaceuticals Inc); Boehringer Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca); Merck Sharp Dohme(Merck & Company); Takeda(Takeda Pharmaceutical Company Ltd); GlaxoSmithKline(GlaxoSmithKline)	The Section of Respiratory Diseases, Department of Clinical and Experimental Medicine, University of Ferrara, received unrestricted grants supportive for research activities from the Chiesi Foundation (Parma, Italy) and the Fondazione Salvatore Maugeri (Pavia, Italy).; Supported by the Universities of Padova and Ferrara, the Italian Ministry of University and Research, and the Italian Society of Pediatric Respiratory Diseases.; M. Contoli has received lecture fees from Chiesi Farmaceutici, Boehringer Ingelheim, and AstraZeneca and has received consulting fees from Merck Sharp & Dohme. M. Saetta has received lecture fees, consulting fees, and a grant for research from Takeda; has received lecture fees and a grant for research from Chiesi Farmaceutici; and has received lecture fees from GlaxoSmithKline and AstraZeneca. A. Papi is on the advisory board for and has received lecture fees, consulting fees, and grants for research from Chiesi Farmaceutici; has received lecture fees and consulting fees from GlaxoSmithKline; and has received lecture fees and grants for research from AstraZeneca, Boehringer Ingelheim, and Merck Sharp & Dome. The rest of the authors declare that they have no relevant conflicts of interest.	Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Bullens DMA, 2008, CLIN EXP ALLERGY, V38, P1459, DOI 10.1111/j.1365-2222.2008.03045.x; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Crimi E, 2001, J APPL PHYSIOL, V91, P1029, DOI 10.1152/jappl.2001.91.3.1029; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Global Initiative for Asthma (GINA), 2011, GLOB STRAT ASTHM MAN; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Juhn YJ, 2012, PRIM CARE RESP J, V21, P153, DOI 10.4104/pcrj.2011.00110; Jung JA, 2010, J ALLERGY CLIN IMMUN, V125, P217, DOI 10.1016/j.jaci.2009.10.045; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Midulla F, 2003, EUR RESPIR J, V22, P698, DOI 10.1183/09031936.02.00113202; Miller EK, 2012, AM J RESP CRIT CARE, V185, P508, DOI 10.1164/rccm.201108-1462OC; Miller EK, 2011, J ALLERGY CLIN IMMUN, V127, P883, DOI 10.1016/j.jaci.2010.11.041; Moriwaki A, 2011, BIOCHEM BIOPH RES CO, V404, P922, DOI 10.1016/j.bbrc.2010.12.082; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Pilishvili T, 2010, PEDIATRICS, V126, pE9, DOI 10.1542/peds.2009-2150; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sriram U, 2007, J IMMUNOL, V179, P6446, DOI 10.4049/jimmunol.179.10.6446; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Sumino K, 2012, J ALLERGY CLIN IMMUN, V129, P1267, DOI 10.1016/j.jaci.2012.02.033; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901	42	128	135	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1307	1314		10.1016/j.jaci.2012.08.005	http://dx.doi.org/10.1016/j.jaci.2012.08.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22981791	Green Submitted			2022-12-18	WOS:000311641100009
J	Bachert, C; van Steen, K; Zhang, N; Holtappels, G; Cattaert, T; Maus, B; Buhl, R; Taube, C; Korn, S; Kowalski, M; Bousquet, J; Howarth, P				Bachert, Claus; van Steen, Kristel; Zhang, Nan; Holtappels, Gabriele; Cattaert, Tom; Maus, Barbel; Buhl, Roland; Taube, Christian; Korn, Stephanie; Kowalski, Marek; Bousquet, Jean; Howarth, Peter			Specific IgE against Staphylococcus aureus enterotoxins: An independent risk factor for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma severity; hospitalizations; FEV1; IgE; Staphylococcus aureus; enterotoxins; superantigens	NASAL POLYPOSIS; T-CELLS; SENSITIZATION; SEVERITY; EXPOSURE; DISEASE; SERUM	Background: The role of IgE in patients with severe asthma is not fully understood. Objective: We sought to investigate whether IgE to Staphylococcus aureus enterotoxins might be relevant to disease severity in adult asthmatic patients. Methods: Specific IgE antibody concentrations in serum against enterotoxins, grass pollen (GP), and house dust mite allergens and total IgE levels were measured in adult cohorts of 69 control subjects, 152 patients with nonsevere asthma, and 166 patients with severe asthma. Severe asthma was defined as inadequately controlled disease despite high-dose inhaled corticosteroids plus at least 2 other controller therapies, including oral steroids. Results: Enterotoxin IgE positivity was significantly greater in patients with severe asthma (59.6%) than in healthy control subjects (13%, P < .001). Twenty-one percent of patients with severe asthma with enterotoxin IgE were considered nonatopic. Logistic regression analyses demonstrated significantly increased risks for enterotoxin IgE-positive subjects to have any asthma (OR, 7.25; 95% CI, 2.7-19.1) or severe asthma (OR, 11.09; 95% CI, 4.1-29.6) versus enterotoxin IgE-negative subjects. The presence of GP or house dust mite IgE antibodies was not associated with either significantly increased risk for asthma or severity. Oral steroid use and hospitalizations were significantly increased in patients with enterotoxin IgE and nonatopic asthma. GP IgE was associated with a higher FEV1 percent predicted value, and enterotoxin IgE was associated with a lower FEV1 percent predicted value. Conclusions: Staphylococcal enterotoxin IgE antibodies, but not IgE against inhalant allergens, are risk factors for asthma severity. We hypothesize that the presence of enterotoxin IgE in serum indicates the involvement of staphylococcal superantigens in the pathophysiology of patients with severe asthma. (J Allergy Clin Immunol 2012;130:376-81.)	[Bachert, Claus; Zhang, Nan; Holtappels, Gabriele] Ghent Univ Hosp, Upper Airway Res Lab URL, B-9000 Ghent, Belgium; [van Steen, Kristel; Cattaert, Tom; Maus, Barbel] Univ Liege, Inst Montefiore, Syst & Modelling Unit, B-4000 Liege, Belgium; [van Steen, Kristel; Cattaert, Tom; Maus, Barbel] Univ Liege, GIGA Res, B-4000 Liege, Belgium; [Buhl, Roland; Taube, Christian; Korn, Stephanie] Mainz Univ Hosp, Dept Pulm, Mainz, Germany; [van Steen, Kristel; Maus, Barbel] Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; [Kowalski, Marek] Med Univ Lodz, Dept Allergy Immunol & Rheumatol, Lodz, Poland; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean] INSERM 1080, Montpellier, France; [Howarth, Peter] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Howarth, Peter] Southampton Gen Hosp, Natl Inst Hlth, Resp Biomed Res Unit, Southampton, Hants, England; [Taube, Christian] Leiden Univ, Med Ctr, Dept Pulmonol, NL-2300 RA Leiden, Netherlands	Ghent University; Ghent University Hospital; University of Liege; University of Liege; University Hospital Mainz; Ghent University; Ghent University Hospital; Medical University Lodz; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Southampton; University of Southampton; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bachert, C (corresponding author), Ghent Univ Hosp, Upper Airway Res Lab URL, De Pintelaan 185, B-9000 Ghent, Belgium.	claus.bachert@ugent.be	Zhang, Nan/AAQ-3944-2020; Bousquet, Jean/O-4221-2019; Bachert, Claus/J-8825-2012	Van Steen, Kristel/0000-0001-9868-5033; Howarth, Peter/0000-0003-0619-7927	Flemish Scientific Research Board, FWO [A12/5-HB-KH3, G.0436.04]; Interuniversity Attraction Poles Programme (IUAP), Belgian state, Belgian Science Policy [P6/35]; UK Medical Research Council [G0800649]; Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN); Belgian Network BioMAGNet (Bioinformatics and Modelling: from Genomes to Networks); Interuniversity Attraction Poles Programme (Phase VI/4); IST Programme of the European Community under the PASCAL2 Network of Excellence [IST-2007-216886]; Medical Research Council [G0900453, G0400473, G0800649] Funding Source: researchfish; MRC [G0400473, G0900453, G0800649] Funding Source: UKRI	Flemish Scientific Research Board, FWO(FWO); Interuniversity Attraction Poles Programme (IUAP), Belgian state, Belgian Science Policy(Belgian Federal Science Policy Office); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN); Belgian Network BioMAGNet (Bioinformatics and Modelling: from Genomes to Networks); Interuniversity Attraction Poles Programme (Phase VI/4); IST Programme of the European Community under the PASCAL2 Network of Excellence; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by grants to C.B. from the Flemish Scientific Research Board, FWO, nos. A12/5-HB-KH3 and G.0436.04, and the Interuniversity Attraction Poles Programme (IUAP), Belgian state, Belgian Science Policy P6/35, and to P. H. from the UK Medical Research Council, G0800649 (Wessex Severe Asthma Cohort), and by the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN). T C. is a Postdoctoral Researcher of the Fonds de la Recherche Scientifique (FNRS). T.C. and K.S. acknowledge research support by the Belgian Network BioMAGNet (Bioinformatics and Modelling: from Genomes to Networks), funded by the Interuniversity Attraction Poles Programme (Phase VI/4), and by the IST Programme of the European Community under the PASCAL2 Network of Excellence (Pattern Analysis, Statistical Modelling and Computational Learning), IST-2007-216886.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Bachert C, 2003, J ALLERGY CLIN IMMUN, V111, P1131, DOI 10.1016/S0091-6749(03)70044-X; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Ben-Gal, 2007, ENCY STAT QUALITY RE; Blasius, 2006, MULTIPLE CORRES ANAL; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Hellings PW, 2006, CLIN EXP ALLERGY, V36, P1063, DOI 10.1111/j.1365-2222.2006.02527.x; Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3; Holgate S, 2008, EUR RESPIR J, V32, P1433, DOI 10.1183/09031936.00053108; Husson F., 2010, EXPLORATORY MULTIVAR, DOI DOI 10.1201/B10345; Huvenne W, 2010, ALLERGY, V65, P1013, DOI 10.1111/j.1398-9995.2009.02313.x; Huvenne W, 2010, CLIN EXP ALLERGY, V40, P1079, DOI 10.1111/j.1365-2222.2010.03464.x; Kowalski ML, 2010, ALLERGY, V6, P32; Mechtcheriakova D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025611; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Pastacaldi C, 2011, ALLERGY, V66, P549, DOI 10.1111/j.1398-9995.2010.02502.x; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Perez-Novo CA, 2004, INT ARCH ALLERGY IMM, V133, P255, DOI 10.1159/000076832; Semic-Jusufagic A, 2007, J ALLERGY CLIN IMMUN, V119, P930, DOI 10.1016/j.jaci.2006.12.639; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x	32	128	131	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					376	+		10.1016/j.jaci.2012.05.012	http://dx.doi.org/10.1016/j.jaci.2012.05.012			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22738677	Bronze			2022-12-18	WOS:000307002200016
J	Heederik, D; von Mutius, E				Heederik, Dick; von Mutius, Erika			Does diversity of environmental microbial exposure matter for the occurrence of allergy and asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Environmental exposure; farming exposure; microbial exposure; allergy; asthma; microbiome; protective effects	IN-HOUSE DUST; MYCOPLASMA-PNEUMONIAE INFECTION; CHILDHOOD ASTHMA; ENDOTOXIN EXPOSURE; RESPIRATORY HEALTH; BRONCHIAL HYPERRESPONSIVENESS; PROTECTIVE PROPERTIES; REDUCED DIVERSITY; TEMPERATE ZONES; MOLD COMPONENTS	This review describes the recent literature on microbial exposures and protective effects for asthma and atopy. Certain microorganism-associated molecular patterns have been identified as agents that might influence the development of the immune system, which in turn leads to protective effects for asthma and atopy. Endotoxins from gram-negative bacteria were the first agents associated with a reduced risk for asthma and atopy. In later studies, beta(1 -> 3)glucans, extracellular polysaccharides, and muramic acid from, respectively, molds and gram-positive bacteria were associated with a reduced risk of allergy and asthma separately in rural and urban populations. These results already suggested that not just one but several independent microbial signals from gram-negative and gram-positive bacteria, as well as molds, might play a role in explaining the protective effects. Recently, the diversity of microbial exposure has been associated with such a reduced risk in farmers' children. Surprisingly, the diversity of both fungal and bacterial exposure seemed to have protective effects. These results open new areas of research and create complex challenges. Methodological issues, such as environmental exposure characterization and assessment and elucidation of potential underlying mechanisms, are discussed because these aspects have a major influence on how microbial diversity can be studied in future studies in relation to protective effects for asthma and atopy. (J Allergy Clin Immunol 2012;130:44-50.)	[Heederik, Dick] Univ Utrecht, Div Environm Epidemiol, IRAS, NL-3508 TD Utrecht, Netherlands; [von Mutius, Erika] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany	Utrecht University; University of Munich	Heederik, D (corresponding author), Univ Utrecht, Div Environm Epidemiol, IRAS, POB 80198, NL-3508 TD Utrecht, Netherlands.	d.heederik@uu.nl		von Mutius, Erika/0000-0002-8893-4515; Heederik, Dick/0000-0002-4550-1437	European Commission; InfectoPharm; Airsonett AB	European Commission(European CommissionEuropean Commission Joint Research Centre); InfectoPharm; Airsonett AB	D. Heederik receives research support from the European Commission. E. von Mutius has consultant arrangements with Novartis, GlaxoSmithKline, ALK-Abello, and Protectimmune; receives speaker's fees from InfectoPharm; receives research support from Airsonett AB; is a member of the expert panel for the UK Research Excellence Framework; and is an Associate Editor of the Journal of Allergy and Clinical Immunology.	Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Amend AS, 2010, P NATL ACAD SCI USA, V107, P13748, DOI 10.1073/pnas.1000454107; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; ATTWOOD P, 1987, AM IND HYG ASSOC J, V48, P745, DOI 10.1080/15298668791385507; ATTWOOD P, 1986, ANN OCCUP HYG, V30, P201, DOI 10.1093/annhyg/30.2.201; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Bowers RM, 2011, ISME J, V5, P601, DOI 10.1038/ismej.2010.167; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brodie EL, 2007, P NATL ACAD SCI USA, V104, P299, DOI 10.1073/pnas.0608255104; Caporaso JG, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r50; Chu HW, 2003, CHEST, V123, p390S, DOI 10.1378/chest.123.3_suppl.390S; Chu HW, 2003, INFECT IMMUN, V71, P1520, DOI 10.1128/IAI.71.3.1520-1526.2003; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Debarry J, 2010, ALLERGY, V65, P690, DOI 10.1111/j.1398-9995.2009.02253.x; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Diggle SP, 2007, CHEM BIOL, V14, P87, DOI 10.1016/j.chembiol.2006.11.014; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Foxman B, 2008, INTERDISCIP PERSPECT; Foxman B, 2010, EPIDEMIOLOGY, V21, P757, DOI 10.1097/EDE.0b013e3181f4e1f9; Gehring U, 2008, CLIN EXP ALLERGY, V38, P1911, DOI 10.1111/j.1365-2222.2008.03087.x; Gehring U, 2007, EUR RESPIR J, V29, P1144, DOI 10.1183/09031936.00118806; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Giovannangelo M, 2007, INDOOR AIR, V17, P70, DOI 10.1111/j.1600-0668.2006.00461.x; Giovannangelo M, 2007, J EXPO SCI ENV EPID, V17, P134, DOI 10.1038/sj.jes.7500482; Hansen LT, 2000, J APPL MICROBIOL, V88, P1049, DOI 10.1046/j.1365-2672.2000.01074.x; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hirsch T, 1998, CLIN EXP ALLERGY, V28, P956, DOI 10.1046/j.1365-2222.1998.00340.x; Horick N, 2006, ENVIRON HEALTH PERSP, V114, P135, DOI 10.1289/ehp.7981; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Huang YJ, 2010, OMICS, V14, P9, DOI 10.1089/omi.2009.0100; Hugg T, 2008, EUR J EPIDEMIOL, V23, P123, DOI 10.1007/s10654-007-9217-z; Hugg TT, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-28; James AL, 2010, EUR RESPIR J, V35, P273, DOI 10.1183/09031936.00194308; Just N, 2011, ENVIRON RES, V111, P492, DOI 10.1016/j.envres.2011.01.009; Khajanchi BK, 2011, INFECT IMMUN, V79, P2646, DOI 10.1128/IAI.00096-11; Korf J, 2005, EUR J IMMUNOL, V35, P890, DOI 10.1002/eji.200425332; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; Lee L, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-27; Letourneau V, 2010, BIORESOURCE TECHNOL, V101, P4048, DOI 10.1016/j.biortech.2010.01.009; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Maier RM, 2010, APPL ENVIRON MICROB, V76, P2663, DOI 10.1128/AEM.01665-09; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Nehme B, 2009, APPL ENVIRON MICROB, V75, P5445, DOI 10.1128/AEM.00726-09; Normand AC, 2009, APPL ENVIRON MICROB, V75, P7617, DOI 10.1128/AEM.01414-09; Noss I, 2008, APPL ENVIRON MICROB, V74, P5621, DOI 10.1128/AEM.00619-08; Omland O, 2002, ANN AGR ENV MED, V9, P119; Pakarinen J, 2008, ENVIRON MICROBIOL, V10, P3317, DOI 10.1111/j.1462-2920.2008.01723.x; Palma AS, 2006, J BIOL CHEM, V281, P5771, DOI 10.1074/jbc.M511461200; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Pearce N, 2005, INT J EPIDEMIOL, V34, P1018, DOI 10.1093/ije/dyi115; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Roussel S, 2011, ENVIRON RES, V111, P744, DOI 10.1016/j.envres.2011.05.002; Samadi S, 2009, ANN OCCUP HYG, V53, P595, DOI 10.1093/annhyg/mep040; SCHENKER M, 1991, OCCUP MED, V6, P415; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Sjogren YM, 2009, CLIN EXP ALLERGY, V39, P518, DOI 10.1111/j.1365-2222.2008.03156.x; Smit LAM, 2010, INT ARCH ALLERGY IMM, V152, P151, DOI 10.1159/000265536; Sordillo JE, 2010, CLIN EXP ALLERGY, V40, P902, DOI 10.1111/j.1365-2222.2010.03509.x; Sordillo JE, 2011, ENVIRON HEALTH PERSP, V119, P189, DOI 10.1289/ehp.1002004; Stsepetove J, 2007, FEMS IMMUNOL MED MIC, V51, P260, DOI 10.1111/j.1574-695X.2007.00306.x; Taubel M, 2009, J ALLERGY CLIN IMMUN, V124, P834, DOI 10.1016/j.jaci.2009.07.045; Tavernier G, 2006, J ALLERGY CLIN IMMUN, V117, P656, DOI 10.1016/j.jaci.2005.12.1311; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Tischer C, 2011, EUR RESPIR J, V37, P1050, DOI 10.1183/09031936.00091210; Topp R, 2003, CLIN EXP ALLERGY, V33, P1659, DOI 10.1111/j.1365-2222.2003.01807.x; Tringe SG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001862; Tringe SG, 2008, CURR OPIN MICROBIOL, V11, P442, DOI 10.1016/j.mib.2008.09.011; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; VERHOEFF AP, 1992, ALLERGY, V47, P83, DOI 10.1111/j.1398-9995.1992.tb05093.x; Vineis P, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-54; Vogel K, 2008, J ALLERGY CLIN IMMUN, V122, P307, DOI 10.1016/j.jaci.2008.05.016; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; von Wintzingerode F, 1997, FEMS MICROBIOL REV, V21, P213; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Williams P, 2007, PHILOS T R SOC B, V362, P1119, DOI 10.1098/rstb.2007.2039	84	128	129	3	87	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					44	50		10.1016/j.jaci.2012.01.067	http://dx.doi.org/10.1016/j.jaci.2012.01.067			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22502794	Green Published			2022-12-18	WOS:000306644800006
J	Brand, S; Teich, R; Dicke, T; Harb, H; Yildirim, AO; Tost, J; Schneider-Stock, R; Waterland, RA; Bauer, UM; von Mutius, E; Garn, H; Pfefferle, PI; Renz, H				Brand, Stephanie; Teich, Rene; Dicke, Tanja; Harb, Hani; Yildirim, Ali O.; Tost, Joerg; Schneider-Stock, Regine; Waterland, Robert A.; Bauer, Uta-Maria; von Mutius, Erika; Garn, Holger; Pfefferle, Petra I.; Renz, Harald			Epigenetic regulation in murine offspring as a novel mechanism for transmaternal asthma protection induced by microbes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; epigenetics; histone acetylation; hygiene hypothesis; T cells	IFN-GAMMA PROMOTER; NAIVE T-CELLS; INTERFERON-GAMMA; DNA METHYLATION; GENE-EXPRESSION; AIRWAY HYPERRESPONSIVENESS; IGE PRODUCTION; EXPOSURE; ALLERGY; DIFFERENTIATION	Background: Bronchial asthma is a chronic inflammatory disease resulting from complex gene-environment interactions. Natural microbial exposure has been identified as an important environmental condition that provides asthma protection in a prenatal window of opportunity. Epigenetic regulation is an important mechanism by which environmental factors might interact with genes involved in allergy and asthma development. Objective: This study was designed to test whether epigenetic mechanisms might contribute to asthma protection conferred by early microbial exposure. Methods: Pregnant maternal mice were exposed to the farm-derived gram-negative bacterium Acinetobacter lwoffii F78. Epigenetic modifications in the offspring were analyzed in T(H)1- and T(H)2-relevant genes of CD4(+) T cells. Results: Prenatal administration of A lwoffii F78 prevented the development of an asthmatic phenotype in the progeny, and this effect was IFN-gamma dependent. Furthermore, the IFNG promoter of CD4(+) T cells in the offspring revealed a significant protection against loss of histone 4 (H4) acetylation, which was closely associated with IFN-gamma expression. Pharmacologic inhibition of H4 acetylation in the offspring abolished the asthma-protective phenotype. Regarding T(H)2-relevant genes only at the IL4 promoter, a decrease could be detected for H4 acetylation but not at the IL5 promoter or the intergenic T(H)2 regulatory region conserved noncoding sequence 1 (CNS1). Conclusion: These data support the hygiene concept and indicate that microbes operate by means of epigenetic mechanisms. This provides a new mechanism in the understanding of gene-environment interactions in the context of allergy protection. (J Allergy Clin Immunol 2011;128:618-25.)	[Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, Fac Med, D-35043 Marburg, Germany; [Bauer, Uta-Maria] Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35043 Marburg, Germany; [Teich, Rene] Helmholtz Ctr Infect Res, Braunschweig, Germany; [Yildirim, Ali O.] Helmholtz Ctr Munich, Inst Lung Biol & Dis, Comprehens Pneumol Ctr, Neuherberg, Germany; [Tost, Joerg] CEA Inst Genom, Ctr Natl Genotypage, Lab Epigenet, Evry, France; [Tost, Joerg] Fdn Jean Dausset CEPH, Lab Funct Gen, Paris, France; [Schneider-Stock, Regine] Univ Erlangen Nurnberg, Inst Pathol, D-8520 Erlangen, Germany; [Waterland, Robert A.] USDA, Childrens Nutr Res Ctr, Baylor Coll Med, Dept Pediat, Houston, TX USA; [Waterland, Robert A.] USDA, Childrens Nutr Res Ctr, Baylor Coll Med, Dept Mol & Human Genet, Houston, TX USA; [von Mutius, Erika] Univ Munich, Univ Childrens Hosp, Munich, Germany	Philipps University Marburg; Philipps University Marburg; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; CEA; UDICE-French Research Universities; Universite Paris Saclay; Foundation Jean Dausset-CEPH; University of Erlangen Nuremberg; Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine; United States Department of Agriculture (USDA); University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Renz, H (corresponding author), Univ Marburg, Dept Clin Chem & Mol Diagnost, Fac Med, Baldingerstr 1, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de	Schneider-Stock, Regine/H-8863-2012; Tost, Joerg/H-7129-2019; Harb, Hani/HGB-7333-2022; Harb, Hani/J-6517-2019	Tost, Joerg/0000-0002-2683-0817; Harb, Hani/0000-0001-8218-2538; Harb, Hani/0000-0001-8218-2538; von Mutius, Erika/0000-0002-8893-4515; Garn, Holger/0000-0002-5178-4023; Yildirim, Ali Onder/0000-0003-1969-480X	Deutsche Forschungsgemeinschaft [SFB/TR22]; Stiftung P.E. Kempkes, Marburg [10/07]; LOEWE excellence centre UGMLC (Universities of Giessen and the Marburg Lung Centre); Airsonett AB; German Research Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081557] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Stiftung P.E. Kempkes, Marburg; LOEWE excellence centre UGMLC (Universities of Giessen and the Marburg Lung Centre); Airsonett AB; German Research Foundation(German Research Foundation (DFG)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the Deutsche Forschungsgemeinschaft (SFB/TR22); Stiftung P.E. Kempkes, Marburg (10/07); and the LOEWE excellence centre UGMLC (Universities of Giessen and the Marburg Lung Centre).; Disclosure of potential conflict of interest: E. von Mutius has consulted for GlaxoSmithKline, Novartis, and Mundipharma and has received research support from Airsonett AB and the German Research Foundation. The rest of the authors have declared that they have no conflict of interest.	Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Chang SJ, 2007, NAT IMMUNOL, V8, P723, DOI 10.1038/ni1473; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Debarry J, 2010, ALLERGY, V65, P690, DOI 10.1111/j.1398-9995.2009.02253.x; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Dow SW, 1999, HUM GENE THER, V10, P1905, DOI 10.1089/10430349950017266; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hoymann Heinz Gerd, 2007, Journal of Pharmacological and Toxicological Methods, V55, P16, DOI 10.1016/j.vascn.2006.04.006; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Koya T, 2006, AM J RESP CELL MOL, V35, P147, DOI 10.1165/rcmb.2005-0394OC; LACK G, 1994, J IMMUNOL, V152, P2546; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mantelingu K, 2007, CHEM BIOL, V14, P645, DOI 10.1016/j.chembiol.2007.04.011; Martino DJ, 2010, ALLERGY, V65, P7, DOI 10.1111/j.1398-9995.2009.02186.x; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Schoenborn JR, 2007, NAT IMMUNOL, V8, P732, DOI 10.1038/ni1474; Stenvinkel P, 2007, J INTERN MED, V261, P488, DOI 10.1111/j.1365-2796.2007.01777.x; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Vercelli D, 2009, J ALLERGY CLIN IMMUN, V123, P26, DOI 10.1016/j.jaci.2008.11.031; Vogel K, 2008, J ALLERGY CLIN IMMUN, V122, P307, DOI 10.1016/j.jaci.2008.05.016; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; Wagner S, 2006, J BIOL CHEM, V281, P27242, DOI 10.1074/jbc.M605172200; Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; White GP, 2006, PEDIAT ALLERG IMM-UK, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487; Yang SR, 2008, AM J RESP CELL MOL, V38, P689, DOI 10.1165/rcmb.2007-0379OC; YOUNG HA, 1994, J IMMUNOL, V153, P3603	42	128	131	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					618	U279		10.1016/j.jaci.2011.04.035	http://dx.doi.org/10.1016/j.jaci.2011.04.035			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21680015				2022-12-18	WOS:000294283400022
J	Kang, EM; Marciano, BE; DeRavin, S; Zarember, KA; Holland, SM; Malech, HL				Kang, Elizabeth M.; Marciano, Betty E.; DeRavin, SukSee; Zarember, Kol A.; Holland, Steven M.; Malech, Harry L.			Chronic granulomatous disease: Overview and hematopoietic stem cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic granulomatous disease; infection; inflammation; autoimmune; allogeneic hematopoietic transplantation	BONE-MARROW-TRANSPLANTATION; UMBILICAL-CORD BLOOD; OF-THE-LITERATURE; FULMINANT MULCH PNEUMONITIS; VERSUS-HOST-DISEASE; UNRELATED-DONOR; NADPH OXIDASE; GENE-THERAPY; CLINICAL-FEATURES; MCLEOD PHENOTYPE	Chronic granulomatous disease (CGD) still causes significant morbidity and mortality. The difficulty in considering high-risk yet curative treatments, such as allogeneic bone marrow transplantation, lies in the unpredictable courses of both CGD and bone marrow transplantation in different patients. Some patients with CGD can have frequent infections, granulomatous or autoimmune disorders necessitating immunosuppressive therapy, or both but also experience long periods of relative good health. However, the risk of death is clearly higher in patients with CGD of all types, and the complications of CGD short of death can still cause significant morbidity. Therefore, with recent developments and improvements, bone marrow transplantation, previously considered an experimental or high-risk procedure, has emerged as an important option for patients with CGD. We will discuss the complications of CGD that result in significant morbidity and mortality, particularly the most common infections and autoimmune/inflammatory complications, as well as their typical management. We will then discuss the status of bone marrow transplantation. (J Allergy Clin Immunol 2011;127:1319-26.)	[Kang, Elizabeth M.; DeRavin, SukSee; Zarember, Kol A.; Malech, Harry L.] NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; [Marciano, Betty E.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kang, EM (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Room 6-3752,10 Ctr Dr, Bethesda, MD 20892 USA.	ekang@niaid.nih.gov		Malech, Harry/0000-0001-5874-5775; Zarember, Kol/0000-0002-9624-7096; De Ravin, Suk See/0000-0002-9800-774X	NIH; National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000989, ZIAAI000991, ZIAAI001151, ZIAAI000646, ZIAAI000645, ZIAAI000644, ZIAAI000155, ZIAAI000988] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Research Program of the NIH, the National Institute of Allergy and Infectious Diseases.	Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Ameratunga R, 2010, CLIN PEDIATR, V49, P1143, DOI 10.1177/0009922810370057; Arroyo A, 2002, J BIOL CHEM, V277, P49965, DOI 10.1074/jbc.M204513200; Barker JN, 2005, BLOOD, V105, P1343, DOI 10.1182/blood-2004-07-2717; BEAUTE J, 2010, PEDIAT INFECT DIS J; Bhattacharya A, 2003, BONE MARROW TRANSPL, V31, P403, DOI 10.1038/sj.bmt.1703863; Borge D. P., 2010, BLOOD, V116, P1329; Brechard S, 2008, J LEUKOCYTE BIOL, V84, P1223, DOI 10.1189/jlb.0807553; Brown KL, 2008, CLIN IMMUNOL, V129, P90, DOI 10.1016/j.clim.2008.06.005; Brunstein CG, 2010, BLOOD, V116, P4693, DOI 10.1182/blood-2010-05-285304; Chu R, 2010, BIOL BLOOD MARROW TR; Couriel DR, 2004, BIOL BLOOD MARROW TR, V10, P178, DOI 10.1016/j.bbmt.2003.10.006; Cowen EW, 2010, J AM ACAD DERMATOL, V62, P31, DOI 10.1016/j.jaad.2009.09.033; De Ravin SS, 2008, J ALLERGY CLIN IMMUN, V122, P1097, DOI 10.1016/j.jaci.2008.07.050; Del Giudice I, 2003, ANN HEMATOL, V82, P189, DOI 10.1007/s00277-002-0590-0; Diaconescu R, 2004, BLOOD, V104, P1550, DOI 10.1182/blood-2004-03-0804; Dorman SE, 2002, CLIN INFECT DIS, V35, P390, DOI 10.1086/341416; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Feld JJ, 2008, GASTROENTEROLOGY, V134, P1917, DOI 10.1053/j.gastro.2008.02.081; Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005; Fernandez-Boyanapalli R, 2010, J IMMUNOL, V185, P4030, DOI 10.4049/jimmunol.1001778; Fernandez-Boyanapalli RF, 2009, BLOOD, V113, P2047, DOI 10.1182/blood-2008-05-160564; Foster MH, 1998, MOL IMMUNOL, V35, P83, DOI 10.1016/S0161-5890(98)00018-2; Frasch SC, 2008, J BIOL CHEM, V283, P33736, DOI 10.1074/jbc.M807047200; Gallin JI, 2003, NEW ENGL J MED, V348, P2416, DOI 10.1056/NEJMoa021931; GALLIN JI, 1983, INFLAMMATION, V7, P227, DOI 10.1007/BF00917259; Goussetis E, 2010, BIOL BLOOD MARROW TR, V16, P344, DOI 10.1016/j.bbmt.2009.10.010; Greenberg DE, 2006, PLOS PATHOG, V2, P260, DOI [10.1371/journal.ppat.0020028, 10.1382/journal.ppat.0020028]; Grez M, 2011, MOL THER, V19, P28, DOI 10.1038/mt.2010.232; Gungor T, 2005, TRANSPLANTATION, V79, P1596, DOI 10.1097/01.TP.0000163466.73485.5E; GUNGOR T, 2010, 14 M EUR SOC IMM IST; Honig M, 2010, BONE MARROW TRANSPL, V45, P209, DOI 10.1038/bmt.2009.115; Horn B, 2009, BONE MARROW TRANSPL, V43, P469, DOI 10.1038/bmt.2008.339; Horwitz ME, 2001, NEW ENGL J MED, V344, P881, DOI 10.1056/NEJM200103223441203; Huang YF, 2009, FREE RADICAL BIO MED, V47, P932, DOI 10.1016/j.freeradbiomed.2009.06.037; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Jaing TH, 2010, INT J HEMATOL, V91, P670, DOI 10.1007/s12185-010-0537-5; Kang EM, 2010, BLOOD, V115, P783, DOI 10.1182/blood-2009-05-222760; Kang EM, 2011, BIOL BLOOD MARROW TR, V17, P1; Kansoy S, 2006, TURKISH J PEDIATR, V48, P253; Kikuta A, 2006, BONE MARROW TRANSPL, V38, P665, DOI 10.1038/sj.bmt.1705511; Klaudel-Dreszler MA, 2009, INT J HEMATOL, V90, P571, DOI 10.1007/s12185-009-0433-z; Kobayashi S, 2008, EUR J PEDIATR, V167, P1389, DOI 10.1007/s00431-008-0680-7; Kordes U, 2008, BONE MARROW TRANSPL, V42, P219, DOI 10.1038/bmt.2008.159; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Lekstrom-Himes JA, 2005, J IMMUNOL, V174, P411, DOI 10.4049/jimmunol.174.1.411; Lublin M, 2002, ANN SURG, V235, P383, DOI 10.1097/00000658-200203000-00010; Marciano BE, 2004, CLIN INFECT DIS, V39, P692, DOI 10.1086/422993; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Matute JD, 2009, BLOOD, V114, P3309, DOI 10.1182/blood-2009-07-231498; Messina CGM, 2002, FEBS LETT, V518, P107, DOI 10.1016/S0014-5793(02)02658-3; Miki M, 2009, PEDIATR INT, V51, P838, DOI 10.1111/j.1442-200X.2009.02931.x; Miller DD, 2010, ARCH DERMATOL, V146, P300, DOI 10.1001/archdermatol.2009.362; Mochizuki K, 2009, PEDIATR TRANSPLANT, V13, P384, DOI 10.1111/j.1399-3046.2008.00996.x; Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207; MOUY R, 1991, NEW ENGL J MED, V325, P1516; MOUY R, 1994, J PEDIATR-US, V125, P998, DOI 10.1016/S0022-3476(05)82023-2; Nakano T, 1999, J PEDIAT HEMATOL, V12, P264; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Ozyurek E, 2008, BONE MARROW TRANSPL, V42, P83, DOI 10.1038/bmt.2008.89; Parikh SH, 2007, PEDIATR BLOOD CANCER, V49, P982, DOI 10.1002/pbc.21365; Petrovic A, 2009, IMMUNOL RES, V44, P169, DOI 10.1007/s12026-009-8111-z; RAPPEPORT JM, 1982, J PEDIATR-US, V101, P952, DOI 10.1016/S0022-3476(82)80017-6; Reichenbach J, 2008, PEDIATRICS, V122, pE778, DOI 10.1542/peds.2008-0123; Reichenbach J, 2009, CLIN INFECT DIS, V49, P1703, DOI 10.1086/647945; Ringden O, 2007, BONE MARROW TRANSPL, V39, P383, DOI 10.1038/sj.bmt.1705602; SANCHEZORTEGA I, 2010, BONE MARROW TRANSPLA; Sastry J, 2006, PEDIATR BLOOD CANCER, V47, P327, DOI 10.1002/pbc.20865; Schuetz C, 2009, IMMUNOL RES, V44, P35, DOI 10.1007/s12026-008-8068-3; Schuetz C, 2007, EUR J PEDIATR, V166, P785, DOI 10.1007/s00431-006-0317-7; Segal BH, 2005, CLIN INFECT DIS, V40, P1684, DOI 10.1086/430068; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Segal BH, 2002, J LEUKOCYTE BIOL, V71, P410; Segal BH, 1998, MEDICINE, V77, P345, DOI 10.1097/00005792-199809000-00004; Segal BH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009631; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; Siddiqui S, 2007, CLIN INFECT DIS, V45, P673, DOI 10.1086/520985; Soncini E, 2008, BONE MARROW TRANSPL, V41, pS28; Soncini E, 2009, BRIT J HAEMATOL, V145, P73, DOI 10.1111/j.1365-2141.2009.07614.x; Sorror ML, 2004, BLOOD, V104, P961, DOI 10.1182/blood-2004-02-0545; Suzuki N, 2007, INT J HEMATOL, V85, P70, DOI 10.1532/IJH9706129; The International Chronic Granulomatous Disease Cooperative Study Group, 1991, N ENGL J MED, V324, P509; Uzel G, 2010, CLIN INFECT DIS, V51, P1429, DOI 10.1086/657308; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; Vinh DC, 2009, CLIN INFECT DIS, V49, P102, DOI 10.1086/599345; Vinh DC, 2009, EMERG INFECT DIS, V15, P1292, DOI 10.3201/eid1508.090251; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Yamamoto A, 2002, CLIN EXP IMMUNOL, V129, P479, DOI 10.1046/j.1365-2249.2002.01930.x; Yamazaki-Nakashimada MA, 2006, ANN ALLERG ASTHMA IM, V97, P257, DOI 10.1016/S1081-1206(10)60023-3; Yokoyama S, 2008, TRANSPLANTATION, V86, P367, DOI 10.1097/TP.0b013e31817c16eb	91	128	139	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1319	1326		10.1016/j.jaci.2011.03.028	http://dx.doi.org/10.1016/j.jaci.2011.03.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21497887	Bronze, Green Accepted			2022-12-18	WOS:000291048500001
J	Frew, AJ				Frew, Anthony J.			Allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; immunomodulation; rhinitis; asthma; T cell; B cell; IgE; IgG; sublingual	GRASS-POLLEN IMMUNOTHERAPY; LONG-TERM PREVENTION; HOUSE-DUST MITE; DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; CLINICAL-EFFICACY; CAT-DANDER; HAY-FEVER; AIRWAY INFLAMMATION; BRONCHIAL-ASTHMA	Specific immunotherapy (SIT) involves the administration of allergen extracts to achieve clinical tolerance of those allergens that cause symptoms in patients with allergic conditions. Immunotherapy is effective in patients with mild forms of allergic disease and also in those who do not respond well to standard drug therapy. Most SIT is given by means of injection, but there is increasing interest in performing SIT through the sublingual route. SIT remains the treatment of choice for patients with systemic allergic reactions to wasp and bee stings and should be considered as an option in patients with allergic rhinitis, asthma, or both. SIT can modify the course of allergic disease by reducing the risk of new allergic sensitizations and inhibiting the development of clinical asthma in children treated for allergic rhinitis. The precise mechanisms responsible for the beneficial effects of SIT remain a matter of research and debate. An effect on regulatory T cells seems most probable and is associated with switching of allergen-specific B cells toward IgG4 production. Few direct comparisons of SIT and drug therapy have been made. Existing data suggest that the effects of SIT take longer to develop, but once established, SIT achieves long-lasting relief of allergic symptoms, whereas the benefits of drugs only last as long as they are continued. (J Allergy Clin Immunol 2010;125:S306-13.)	Brighton Gen Hosp, Dept Resp Med, Brighton & Sussex Med Sch, Brighton BN2 3EW, E Sussex, England	Brighton and Sussex University Hospitals NHS Trust; Brighton General Hospital; University of Brighton; University of Sussex	Frew, AJ (corresponding author), Brighton Gen Hosp, Dept Resp Med, Brighton & Sussex Med Sch, Brighton BN2 3EW, E Sussex, England.	anthony.frew@bsuh.nhs.uk	Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392	Allergy Therapeutics, Ltd; ARTU biological NV	Allergy Therapeutics, Ltd; ARTU biological NV	A. J. Frew is on the Advisory Board for Allergopharma and Stallergenes; gives lectures for MSD, Schering-Plough, and Novartis; gives lectures and is on the Advisory Board for ALK-Abello, UK; has received research support from Allergy Therapeutics, Ltd, and ARTU biological NV; has provided expert witness testimony on the topic of antihistamine patents; is on the Executive Committee for the European Academy of Allergy and Clinical Immunology; and is a Council Member for the British Society for Allergy and Clinical Immunology.	Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alvarez-Cuesta E, 2007, ALLERGY, V62, P810, DOI 10.1111/j.1398-9995.2007.01365.x; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Bellinghausen I, 2001, INT ARCH ALLERGY IMM, V126, P97, DOI 10.1159/000049499; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V109, P743; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Fasler S, 1998, J ALLERGY CLIN IMMUN, V101, P521, DOI 10.1016/S0091-6749(98)70406-3; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Freeman J, 1914, LANCET, V1, P1178; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Graft DF, 2006, MED CLIN N AM, V90, P211, DOI 10.1016/j.mcna.2005.08.006; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; HORAK F, 1985, ARCH OTORHINOLARYNGO, V242, P242; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Jutel M, 2006, ALLERGY, V61, P796, DOI 10.1111/j.1398-9995.2006.01175.x; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kline JN, 1998, J IMMUNOL, V160, P2555; Lewith GT, 2002, BMJ-BRIT MED J, V324, P520, DOI 10.1136/bmj.324.7336.520; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; MAURO M, 2007, ALLERG IMMUNOL PARIS, V39, P119; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; OHEHIR RE, 1991, INT IMMUNOL, V3, P819, DOI 10.1093/intimm/3.8.819; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; REILLY DT, 1986, LANCET, V2, P881; Shaikh WA, 1997, CLIN EXP ALLERGY, V27, P1279; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; White P, 1998, CLIN EXP ALLERGY, V28, P266; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V126, P68, DOI 10.1159/000049496; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	59	128	137	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S306	S313		10.1016/j.jaci.2009.10.064	http://dx.doi.org/10.1016/j.jaci.2009.10.064			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176266				2022-12-18	WOS:000280170600028
J	Ege, MJ; Herzum, I; Buchele, G; Krauss-Etschmann, S; Lauener, RP; Roponen, M; Hyvarinen, A; Vuitton, DA; Riedler, J; Brunekreef, B; Dalphin, JC; Braun-Fahrlander, C; Pekkanen, J; Renz, H; von Mutius, E				Ege, Markus Johannes; Herzum, Ileana; Buechele, Gisela; Krauss-Etschmann, Susanne; Lauener, Roger P.; Roponen, Marjut; Hyvaerinen, Anne; Vuitton, Dominique A.; Riedler, Josef; Brunekreef, Bert; Dalphin, Jean-Charles; Braun-Fahrlaender, Charlotte; Pekkanen, Juha; Renz, Harald; von Mutius, Erika		Protection Against Allergy Study	Prenatal exposure to a farm environment modifies atopic sensitization at birth	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						prenatal exposure; atopic sensitization; cord blood; farming; microbial components	HOUSE-DUST; ALLERGIC DISEASES; EARLY-LIFE; ASTHMA; CHILDREN	Background: Previous cross-sectional surveys have suggested that maternal exposure to animal sheds during pregnancy exerted a protective effect on atopic sensitization in children lasting until school age. Objective: We sought to evaluate the effects of maternal exposure to animal sheds and other farm-related exposures during pregnancy on cord blood IgE levels in a prospective birth cohort. Methods: Pregnant women living in rural areas in Austria, Finland, France, Germany, and Switzerland were recruited in the third trimester of pregnancy. Information on maternal farm-related exposures, nutrition, and health during pregnancy was obtained by means of interviews. Specific IgE levels for food and common inhalant allergens were assessed in cord blood of 922 children and peripheral blood samples of their mothers. Results: Different sensitization patterns in cord blood of farm and nonfarm children were observed. In multivariable analysis consumption of boiled, but not unboiled, farm milk during pregnancy was positively associated with specific IgE to cow's milk independently from maternal IgE. In contrast, there was an inverse relationship between maternal exposure to animal sheds and cord blood IgE levels against seasonal allergens (adjusted odds ratio, 0.38; 95% CI, 0.21-0.70). This association was not confounded by maternal IgE levels. Maternal contact with hay enhanced the protective effect of exposure to animal sheds on IgE levels to grass pollen in cord blood.	[Ege, Markus Johannes; Krauss-Etschmann, Susanne; von Mutius, Erika] Univ Childrens Hosp, Munich, Germany; [Herzum, Ileana; Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; [Buechele, Gisela] Univ Ulm, Inst Epidemiol, Ulm, Germany; [Krauss-Etschmann, Susanne] HelmholtzZentrum Munchen German Res Ctr Environm, Munich, Germany; [Lauener, Roger P.] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Roponen, Marjut; Hyvaerinen, Anne; Pekkanen, Juha] Natl Publ Hlth Inst, Dept Environm Hlth, Kuopio, Finland; [Vuitton, Dominique A.] Univ Franche Comte, SERF Res Unit, F-25030 Besancon, France; [Riedler, Josef] Childrens Hosp, Schwarzach, Austria; [Brunekreef, Bert] Univ Med Ctr Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Dalphin, Jean-Charles] Univ Hosp, Dept Resp Dis, Besancon, France; [Braun-Fahrlaender, Charlotte] Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; [Pekkanen, Juha] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Philipps University Marburg; Ulm University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University Children's Hospital Zurich; University of Zurich; Finland National Institute for Health & Welfare; Universite de Franche-Comte; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Universite de Franche-Comte; CHU Besancon; University of Basel; University of Eastern Finland	Ege, MJ (corresponding author), Dr von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	markus.ege@med.uni-muenchen.de	Roponen, Marjut/C-2086-2017; riedler, josef/AAQ-4666-2020; Huttunen, Kati/D-8755-2012; Lauener, Roger P/O-8612-2016; Ege, Markus/C-1962-2012; Krauss-Etschmann, Susanne/H-5198-2018; Genuneit, Jon/I-9323-2012	Roponen, Marjut/0000-0002-4442-9090; Huttunen, Kati/0000-0002-4888-9203; Lauener, Roger P/0000-0002-8412-606X; Ege, Markus/0000-0001-6643-3923; Krauss-Etschmann, Susanne/0000-0001-5945-5702; Genuneit, Jon/0000-0001-5764-1528; Gehring, Ulrike/0000-0003-3612-5780; piarroux, renaud/0000-0002-4151-4134; Reboux, Gabriel/0000-0002-7923-0858; Virtanen, Suvi/0000-0001-8928-0878; brunekreef, bert/0000-0001-9908-0060; von Mutius, Erika/0000-0002-8893-4515; Hyvarinen, Anne/0000-0002-2823-0866	European Union [QLK4-CT-2001-00250]	European Union(European Commission)	Supported by the European Union (research grant QLK4-CT-2001-00250).	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Boyle RJ, 2006, ALLERGY, V61, P1423, DOI 10.1111/j.1398-9995.2006.01113.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763, DOI 10.1128/AEM.61.5.1763-1769.1995; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Hagendorens MM, 2004, PEDIAT ALLERG IMM-UK, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; Herzum I, 2005, CLIN CHEM LAB MED, V43, P963, DOI 10.1515/CCLM.2005.165; Holt P, 2004, CHEM IMMUNOL, V84, P102; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; Landau LI, 2006, PAEDIATR RESPIR REV, V7, pS251, DOI 10.1016/j.prrv.2006.04.186; Myatt L, 2006, J PHYSIOL-LONDON, V572, P25, DOI 10.1113/jphysiol.2006.104968; PFEFFERLE P, 2008, J ALLERGY C IN PRESS; Prescott SL, 2006, CURR ALLERGY ASTHM R, V6, P75, DOI 10.1007/s11882-006-0014-7; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Rytkonen J, 2002, PEDIATR ALLERGY IMMU, V13, P269, DOI 10.1034/j.1399-3038.2002.01028.x; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Warner JO, 2004, ARCH DIS CHILD, V89, P97, DOI 10.1136/adc.2002.013029	27	128	130	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					407	412		10.1016/j.jaci.2008.06.011	http://dx.doi.org/10.1016/j.jaci.2008.06.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18678343	Bronze			2022-12-18	WOS:000258426300030
J	Kato, A; Peters, A; Suh, L; Carter, R; Harris, KE; Chandra, R; Conley, D; Grammer, LC; Kern, R; Schleimer, RP				Kato, Atsushi; Peters, Anju; Suh, Lydia; Carter, Roderick; Harris, Kathleen E.; Chandra, Rakesh; Conley, David; Grammer, Leslie C.; Kern, Robert; Schleimer, Robert P.			Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic rhinosinusitis; nasal polyps; BAFF; IgA; B cells; eosinophils; epithelial cells	AIRWAY EPITHELIAL-CELLS; NECROSIS-FACTOR FAMILY; ABERRANT EXPRESSION; IGE PRODUCTION; CUTTING EDGE; IN-VIVO; BAFF; EOSINOPHILS; MUCOSA; INFLAMMATION	Background: The polypoid form of chronic rhinosinusitis (chronic rhinosinusitis with nasal polyps [CRSwNP]) is a highly prevalent disease that often requires surgical intervention for treatment. Nasal polyps contain large quantities of B lymphocytes and immunoglobulin as well as eosinophils. Objectives: The objective of this study was to investigate the expression of B cell-activating factor of the TNF family (BAFF), an important regulator of class-switch recombination and immunoglobulin production, in patients with chronic rhinosinusitis (CRS). Methods: We collected nasal tissue and nasal lavage fluid from patients with CRS and control subjects. We assayed mRNA for BAFF and B-lymphocyte markers, CD20 and transmembrane activator and calcium-modulator and cyclophilin ligand interactor, by using real-time PCR, and assayed BAFF protein by using ELISA and immunohistochemistry. Results: BAFF mRNA was significantly increased in nasal polyps from patients with CRSwNP (P<.001) compared with inferior turbinate tissue from patients with CRS or healthy subjects. BAFF protein was also elevated in polypoid tissue and nasal lavage from patients with CRSwNP. Immunohistochemistry showed considerable BAFF staining in mucosal epithelial cells in nasal polyps along with unidentified cells in the lamina propria. Expression of mRNA for BAFF in sinonasal tissue was significantly correlated with CD20 and transmembrane activator and CAML interactor in sinus tissue. IgA, an immunoglobulin isotype known to activate eosinophils, was also significantly elevated in the polypoid tissue. Conclusion: Overproduction of BAFF in nasal polyps may contribute to the pathogenesis of CRSwNP via the local induction of IgA and activation of eosinophils.	[Kato, Atsushi; Peters, Anju; Suh, Lydia; Carter, Roderick; Harris, Kathleen E.; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Chandra, Rakesh; Conley, David; Kern, Robert] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Otolaryngol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, 240 E Huron, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Grammer, Leslie/0000-0001-6860-2014; Kato, Atsushi/0000-0001-9144-3138	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R01HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL068546-24, R01 HL068546, R01 HL078860, R01 HL078860-03] Funding Source: Medline; NIAID NIH HHS [1R01 AI072570, R01 AI072570, R01 AI072570-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Beck LA, 1996, J ALLERGY CLIN IMMUN, V98, P766, DOI 10.1016/S0091-6749(96)70126-4; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Darce JR, 2007, J IMMUNOL, V178, P5612, DOI 10.4049/jimmunol.178.9.5612; Daridon C, 2007, ARTHRITIS RHEUM-US, V56, P1134, DOI 10.1002/art.22458; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Hamilos Daniel L, 2007, Clin Allergy Immunol, V20, P1; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; Homma T, 2004, AM J RESP CELL MOL, V31, P463, DOI 10.1165/rcmb.2004-0161OC; Huard B, 2004, INT IMMUNOL, V16, P467, DOI 10.1093/intimm/dxh043; JAHNSEN FL, 1995, AM J RESP CELL MOL, V12, P624, DOI 10.1165/ajrcmb.12.6.7539273; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kim J, 2005, AM J RESP CELL MOL, V33, P280, DOI 10.1165/rcmb.2004-0129OC; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; Lane AP, 2006, AM J RHINOL, V20, P138, DOI 10.1177/194589240602000203; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; Mackay F, 2007, CURR OPIN IMMUNOL, V19, P327, DOI 10.1016/j.coi.2007.04.008; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; Olze H, 2006, RHINOLOGY, V44, P145; Polzehl D, 2006, ALLERGY, V61, P1275, DOI 10.1111/j.1398-9995.2006.01132.x; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; SHATKIN JS, 1994, OTOLARYNG HEAD NECK, V111, P553, DOI 10.1016/S0194-5998(94)70520-8; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Simon HU, 1997, J IMMUNOL, V158, P3902; SMALL P, 1985, ANN ALLERGY, V55, P736; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Xu WF, 2007, NAT IMMUNOL, V8, P294, DOI 10.1038/ni1434; Yoshimoto K, 2006, INT IMMUNOL, V18, P1189, DOI 10.1093/intimm/dxl053; Zhang N, 2006, AM J RHINOL, V20, P445, DOI 10.2500/ajr.2006.20.2887	49	128	135	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1385	1392		10.1016/j.jaci.2008.03.002	http://dx.doi.org/10.1016/j.jaci.2008.03.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18410958	Green Accepted			2022-12-18	WOS:000256771700013
J	Wen, MC; Wei, CH; Hu, ZQ; Srivastava, K; Ko, J; Xi, ST; Mu, DZ; Du, JB; Li, MH; Wallenstein, S; Sampson, H; Kattan, M; Li, XM				Wen, MC; Wei, CH; Hu, ZQ; Srivastava, K; Ko, J; Xi, ST; Mu, DZ; Du, JB; Li, MH; Wallenstein, S; Sampson, H; Kattan, M; Li, XM			Efficacy and tolerability of antiasthma herbal medicine intervention in adult patients with moderate-severe allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; clinical trial; Chinese herbal medicine; prednisone; cortisol; T(H)1/T(H)2 balance	PITUITARY-ADRENAL AXIS; SERUM CORTISOL-LEVELS; CHILDREN; FLUTICASONE; SYSTEM; IGE; POPULATION	Background: Chinese herbal medicine has a long history of human use. A novel herbal formula, antiasthma herbal medicine intervention (ASHMI), has been shown to be an effective therapy in a murine model of allergic asthma. Objective: This study was undertaken to compare the efficacy, safety, and immunomodulatory effects of ASHMI treatment in patients with moderate-severe, persistent asthma with prednisone therapy. Methods: In a double-blind trial, 91 subjects underwent randomization. Forty-five subjects received oral ASHMI capsules and prednisone placebo tablets (ASHMI group) and 46 subjects received oral prednisone tablets and ASHMI placebo capsules (prednisone group) for 4 weeks. Spirometry measurements; symptom scores; side effects; and serum cortisol, cytokine, and IgE levels were evaluated before and after treatment. Results: Posttreatment lung function was significantly improved in both groups as shown by increased FEV1 and peak expiratory flow findings (P < .001). The improvement was slightly but significantly greater in the prednisone group (P < .05). Clinical symptom scores, use of beta(2)-bronchodilators, and serum IgE levels were reduced significantly, and to a similar degree in both groups (P < .001). T(H)2 cytokine levels were significantly reduced in both treated groups (P < .001) and were lower in the prednisone-treated group (P < .05). Serum IFN-gamma and cortisol levels were significantly decreased in the prednisone group (P < .001) but significantly increased in the ASHMI group (P < .001). No severe side effects were observed in either group. Conclusion: Antiasthma herbal medicine intervention appears to be a safe and effective alternative medicine for treating asthma. In contrast with prednisone, ASHMI had no adverse effect on adrenal function and had a beneficial effect on TO and T(H)2 balance.	Mt Sinai Sch Med, Weifang Asthma Hosp, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Community Med, New York, NY 10029 USA; Weifang Sch Med, Dept Immunol, Weifang, Peoples R China	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), Mt Sinai Sch Med, Weifang Asthma Hosp, 1 Gustave L Levy Pl, New York, NY 10029 USA.	wen637@hotmail.com; xiu-min.li@mssm.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001495] Funding Source: NIH RePORTER; NCCIH NIH HHS [AT001495-01A1] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ALEXANDER AG, 1994, THORAX, V49, P1231, DOI 10.1136/thx.49.12.1231; BACKER V, 1992, ALLERGY, V47, P484, DOI 10.1111/j.1398-9995.1992.tb00669.x; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BENSKY D, 1993, CHINESE HERBAL MED F, P466; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse P. J., 2004, Journal of Allergy and Clinical Immunology, V113, pS220, DOI 10.1016/j.jaci.2004.01.243; *CHIN RESP MED SCI, 2003, ASTHM ED MAN PROJ SC; Eid N, 2002, PEDIATRICS, V109, P217, DOI 10.1542/peds.109.2.217; Fei GH, 2004, ACTA PHARMACOL SIN, V25, P651; FONG HHS, 1999, WHO MONOGRAPHS SELEC, V1, P183; FRANKLIN HR, 1994, ANN ONCOL, V5, P113, DOI 10.1093/oxfordjournals.annonc.a058760; Gea-Banacloche Juan C, 2004, Crit Care Med, V32, pS578, DOI 10.1097/01.CCM.0000143020.27340.FF; Global Initiative for Asthma, 2002, GLOB STRAT ASTHM MAN; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Hope B E, 1993, Hawaii Med J, V52, P160; HU KM, 2000, SHANGHAI J TRADIT CH, V8, P39; JIN SL, 1995, J HARBIN MED SCH, V16, P81; Kauffmann F, 1999, AM J RESP CRIT CARE, V160, P1428, DOI 10.1164/ajrccm.160.4.16040_1; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Ko J, 2005, J ALLERGY CLIN IMMUN, V115, pS34; Landstra AM, 2002, AM J RESP CRIT CARE, V165, P708, DOI 10.1164/ajrccm.165.5.2102115; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Leonard P, 2002, MED CLIN N AM, V86, P1131, DOI 10.1016/S0025-7125(02)00037-8; LEYNAERT B, 2000, J ALLERGY CLIN IMMUN, V106, P201; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P660, DOI 10.1067/mai.2000.110102; Li XM, 2004, ANN ALLERG ASTHMA IM, V93, pS35, DOI 10.1016/S1081-1206(10)61485-8; Liu JP, 2003, AM J CHINESE MED, V31, P337, DOI 10.1142/S0192415X03001107; Massey D G, 1994, Hawaii Med J, V53, P350; Minzhi S., 2000, ADV COURSE BASKETBAL, Vfirst; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; Peirce A., 1999, AM PHARM ASS PRACTIC; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; SETTIPANE GA, 1978, J ALLERGY CLIN IMMUN, V62, P162, DOI 10.1016/0091-6749(78)90101-X; Sorkness CA, 1999, CLIN THER, V21, P353, DOI 10.1016/S0149-2918(00)88292-2; Srivastava K, 2004, J ALLERGY CLIN IMMUN, V113, P268, DOI 10.1016/j.jaci.2003.10.062; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; TANG A, 1999, ZHONG GUO SHIYONG NE, V39, P665; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Visser MJ, 2004, EUR RESPIR J, V24, P420, DOI 10.1183/09031936.04.00023904; WANG Q, 2000, CHIN J TUBERC RESP D, V23, P147; Yang M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-18; YU QH, 1999, IMMUNOHERBOLOGY TRAD, P54; ZHANG S, 1994, EOSINOPHIL COUNTING, P13; ZIEG G, 1994, J ALLERGY CLIN IMMUN, V94, P222, DOI 10.1016/0091-6749(94)90044-2; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5	45	128	132	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					517	524		10.1016/j.jaci.2005.05.029	http://dx.doi.org/10.1016/j.jaci.2005.05.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159618				2022-12-18	WOS:000235686500007
J	Valent, P; Sperr, WR; Schwartz, LB; Horny, HP				Valent, P; Sperr, WR; Schwartz, LB; Horny, HP			Diagnosis and classification of mast cell proliferative disorders: Delineation from immunologic diseases and non-mast cell hernatopoietic neoplasms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						mastocytosis; classification; criteria; c-kit; tryptase	AGGRESSIVE SYSTEMIC MASTOCYTOSIS; BLOOD MONONUCLEAR-CELLS; KINASE INHIBITOR STI571; PROTOONCOGENE C-KIT; BONE-MARROW; PERIPHERAL-BLOOD; SMOLDERING MASTOCYTOSIS; TRYPTASE LEVELS; HISTOPATHOLOGICAL ASPECTS; GENERALIZED MASTOCYTOSIS	In mast cell (MC) disorders (mastocytosis), clinical symptoms are caused by the release of chemical mediators from MCs, the pathologic infiltration of neoplastic MCs in tissues, or both. Cutaneous mastocytosis is a benign disease in which MC infiltration is confined to the skin. In pediatric cases cutaneous mastocytosis might regress spontaneously. Systemic mastocytosis (SM) is more frequently diagnosed in adults and is a persistent (clonal) disease of bone marrow-derived myelomastocytic progenitors. The somatic c-kit mutation D816V is found in the majority of such patients. The natural clinical course in SM is variable. Whereas most patients remain at the indolent stage for many years, some have aggressive SM (ASM) at diagnosis. Other patients have an associated clonal hematologic non-MC lineage disease (AHNMD). MC leukemia (MCL) is a rare disease variant characterized by circulating MCs and fatal disease progression. The diagnoses of ASM, SM-AHNMD, and MCL might be confused with a variety of endocrinologic, vascular, or immunologic disorders. It is therefore of particular importance to be aware of the possibility of an underlying (malignant) MC disease in patients with unexplained vascular instability, unexplained (anaphylactoid) shock, idiopathic Hushing, diarrhea, headache, and other symptoms that might be mediator related. An important diagnostic clue in such cases is an increased serum tryptase level. The current review provides an overview of mastocytosis and its subvariants and a practical guide that might help to delineate mastincytosis from unrelated systemic disorders.	Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria; Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA USA; Med Univ Lubeck, Inst Pathol, Lubeck, Germany	Medical University of Vienna; Virginia Commonwealth University; University of Lubeck	Valent, P (corresponding author), Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Wahringer Gurtel 18-20, Vienna, Austria.	peter.valent@akh-wien.ac.at	Test, PV/U-9451-2019; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016; Sperr, Mast/V-4767-2019; Test, Test/Y-7921-2019	Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Sperr, Wolfgang/0000-0003-3288-8027				AGIS H, 1993, J IMMUNOL, V151, P4221; Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Akin C, 2003, EXP HEMATOL, V31, P686, DOI 10.1016/S0301-472X(03)00112-7; Akin C, 2002, INT ARCH ALLERGY IMM, V127, P133, DOI 10.1159/000048184; Akin C, 2001, LEUKEMIA RES, V25, P635, DOI 10.1016/S0145-2126(01)00023-6; AKIN C, 2003, IN PRESS BLOOD; AUSTEN KF, 1992, NEW ENGL J MED, V326, P639, DOI 10.1056/NEJM199202273260912; Butterfield JH, 1998, BRIT J DERMATOL, V138, P489; Buttner C, 1998, J INVEST DERMATOL, V111, P1227, DOI 10.1046/j.1523-1747.1998.00414.x; CAPLAN RM, 1963, ARCH DERMATOL, V87, P146, DOI 10.1001/archderm.1963.01590140008002; Casassus P, 2002, BRIT J HAEMATOL, V119, P1090, DOI 10.1046/j.1365-2141.2002.03944.x; Castells M, 2002, INT ARCH ALLERGY IMM, V127, P147, DOI 10.1159/000048188; DALTON R, 1986, BRIT J HAEMATOL, V64, P397, DOI 10.1111/j.1365-2141.1986.tb04133.x; DELAPORTE E, 1995, BRIT J DERMATOL, V132, P479, DOI 10.1111/j.1365-2133.1995.tb08689.x; Escribano L, 2002, ANN HEMATOL, V81, P677, DOI 10.1007/s00277-002-0575-z; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Escribano L, 2002, LEUKEMIA RES, V26, P1043, DOI 10.1016/S0145-2126(02)00073-5; Escribano L, 2001, LEUKEMIA RES, V25, P563, DOI 10.1016/S0145-2126(01)00050-9; Feger F, 2002, INT ARCH ALLERGY IMM, V127, P110, DOI 10.1159/000048179; Fritsche-Polanz R, 2001, BRIT J HAEMATOL, V113, P357, DOI 10.1046/j.1365-2141.2001.02783.x; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Ghannadan M, 2002, INT ARCH ALLERGY IMM, V127, P299, DOI 10.1159/000057747; Guenther PP, 2001, J PEDIAT HEMATOL ONC, V23, P134, DOI 10.1097/00043426-200102000-00014; Hartmann K, 2002, INT ARCH ALLERGY IMM, V127, P143, DOI 10.1159/000048187; Hauswirth AW, 2002, LEUKEMIA RES, V26, P601, DOI 10.1016/S0145-2126(01)00172-2; Hauswirth AW, 2004, LEUKEMIA RES, V28, P249, DOI 10.1016/S0145-2126(03)00259-5; HOMY HP, 1990, BRIT J HAEMATOL, V76, P186; Horny HP, 1998, AM J SURG PATHOL, V22, P1132, DOI 10.1097/00000478-199809000-00013; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; HORNY HP, 1992, HISTOPATHOLOGY, V21, P439, DOI 10.1111/j.1365-2559.1992.tb00428.x; HORNY HP, 1992, CANCER-AM CANCER SOC, V70, P459, DOI 10.1002/1097-0142(19920715)70:2<459::AID-CNCR2820700214>3.0.CO;2-4; Horny HP, 2003, J CLIN PATHOL, V56, P575, DOI 10.1136/jcp.56.8.575; HORNY HP, 1989, CANCER-AM CANCER SOC, V63, P532, DOI 10.1002/1097-0142(19890201)63:3<532::AID-CNCR2820630322>3.0.CO;2-F; HORNY HP, 1986, J CLIN PATHOL, V39, P596, DOI 10.1136/jcp.39.6.596; Horny HP, 2002, INT ARCH ALLERGY IMM, V127, P115, DOI 10.1159/000048180; Jordan JH, 2002, LEUKEMIA LYMPHOMA, V43, P575, DOI 10.1080/10428190290012065; Jordan JH, 2001, LEUKEMIA RES, V25, P627, DOI 10.1016/S0145-2126(01)00019-4; Jordan JH, 2001, HUM PATHOL, V32, P545, DOI 10.1053/hupa.2001.24319; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; Kluin-Nelemans HC, 2003, BLOOD, V102, P4270, DOI 10.1182/blood-2003-05-1699; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; Kojima M, 1999, MODERN PATHOL, V12, P739; LAWRENCE JB, 1991, AM J MED, V91, P612, DOI 10.1016/0002-9343(91)90214-I; Li CY, 2001, LEUKEMIA RES, V25, P537, DOI 10.1016/S0145-2126(01)00029-7; Li WV, 1996, MODERN PATHOL, V9, P982; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS45, DOI 10.1111/1523-1747.ep12469022; Metcalfe DD, 1991, J INVEST DERMATOL, V96, p2S; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; PROKOCIMER M, 1981, AM J CLIN PATHOL, V75, P34; ROTTEM M, 1994, BLOOD, V84, P2489; Schernthaner GH, 2001, BLOOD, V98, P3784, DOI 10.1182/blood.V98.13.3784; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Schwartz LB, 2001, LEUKEMIA RES, V25, P553, DOI 10.1016/S0145-2126(01)00020-0; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Schwartz LB, 2002, CL ALLER IM, V16, P3; Shimizu Y, 2002, CLIN EXP ALLERGY, V32, P872, DOI 10.1046/j.1365-2222.2002.01373.x; SILLABER C, 1991, J IMMUNOL, V147, P4224; Sotlar K, 2000, J CLIN PATHOL-MOL PA, V53, P188, DOI 10.1136/mp.53.4.188; Sperr WR, 2002, INT ARCH ALLERGY IMM, V128, P136, DOI 10.1159/000059404; Sperr WR, 2001, LEUKEMIA RES, V25, P529, DOI 10.1016/S0145-2126(01)00041-8; Sperr WR, 2002, LEUKEMIA LYMPHOMA, V43, P1097, DOI 10.1080/10428190290021470; Sperr WR, 2001, BLOOD, V98, P2200, DOI 10.1182/blood.V98.7.2200; Sperr WR, 2000, LEUKEMIA LYMPHOMA, V37, P473, DOI 10.3109/10428190009058500; Tefferi A, 2004, CURR OPIN HEMATOL, V11, P58, DOI 10.1097/00062752-200401000-00009; Tefferi A, 2004, LEUKEMIA RES, V28, P223, DOI 10.1016/j.leukres.2003.09.004; Tefferi A, 2001, NEW ENGL J MED, V344, P307, DOI 10.1056/NEJM200101253440415; TRAVIS WD, 1988, MODERN PATHOL, V1, P4; TRAVIS WD, 1988, CANCER, V62, P965, DOI 10.1002/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M; TRAVIS WD, 1986, MAYO CLIN PROC, V61, P957, DOI 10.1016/S0025-6196(12)62636-6; Valent F, 2001, IMMUNOL REV, V179, P74, DOI 10.1034/j.1600-065X.2001.790108.x; Valent P, 1996, WIEN KLIN WOCHENSCHR, V108, P385; Valent P, 2003, BRIT J HAEMATOL, V122, P695, DOI 10.1046/j.1365-2141.2003.04575.x; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; VALENT P, 1992, BLOOD, V80, P2237; Valent P, 2003, HEMATOL ONCOL CLIN N, V17, P1227, DOI 10.1016/S0889-8588(03)00089-3; Valent P, 2003, LEUKEMIA RES, V27, P635, DOI 10.1016/S0145-2126(02)00168-6; VALENT P, 1994, IMMUNOL TODAY, V15, P111, DOI 10.1016/0167-5699(94)90153-8; VALENT P, 1991, Progress in Growth Factor Research, V3, P27, DOI 10.1016/0955-2235(91)90011-R; Valent P, 2002, INT ARCH ALLERGY IMM, V127, P137, DOI 10.1159/000048185; Valent P, 2001, LEUKEMIA RES, V25, P595, DOI 10.1016/S0145-2126(01)00040-6; VALENT P, 1989, BLOOD, V73, P1778; Valent P, 1999, INT ARCH ALLERGY IMM, V120, P1, DOI 10.1159/000024214; Valent P., 2001, TUMOURS HAEMATOPOIET, V1, P291; Valent Peter, 2002, Hematol J, V3, P90, DOI 10.1038/sj.thj.6200164; Weide R, 1996, ANN HEMATOL, V72, P41; WIMAZAL F, IN PRESS LEUK LYMPHO; Wolff K, 2001, LEUKEMIA RES, V25, P519, DOI 10.1016/S0145-2126(01)00044-3; Worobec AS, 1996, LEUKEMIA LYMPHOMA, V22, P501, DOI 10.3109/10428199609054789; Worobec AS, 2000, HEMATOL ONCOL CLIN N, V14, P659, DOI 10.1016/S0889-8588(05)70301-4; Xia HZ, 1997, J IMMUNOL, V159, P2911; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	102	128	130	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					3	11		10.1016/j.jaci.2004.02.045	http://dx.doi.org/10.1016/j.jaci.2004.02.045			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241337				2022-12-18	WOS:000222534300001
J	Green, BJ; Mitakakis, TZ; Tovey, ER				Green, BJ; Mitakakis, TZ; Tovey, ER			Allergen detection from 11 fungal species before and after germination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; fungi; germination; halogen; immunoassay	ASPERGILLUS-FUMIGATUS; ALTERNARIA-ALTERNATA; CLADOSPORIUM-HERBARUM; BINDING PROTEIN; IGE ANTIBODIES; MAJOR ALLERGEN; RISK-FACTOR; EXPRESSION; IDENTIFICATION; EXPOSURE	Background: Allergens dispersed by airborne fungal spores play an important but poorly understood role in the underlying cause and exacerbation of asthma. Previous studies suggest that spores of Alternaria and Aspergillus release greater quantities of allergen after germination than before germination. It is unknown whether this is true of other allergenic fungi. Objective: Our purpose was to investigate the release of allergen from a range of individual fungal-spores before and after germination. Methods: Allergen expression from spores of Alternaria alternata, Cladosporium herbarum, Aspergillius fumigatus, Botrytis cinerea, Epicoccum nigrum, Exserohilum rostralum, Penicillium chrysogenum, Stemphylium botryosum, Curvularia lunata, Trichoderma viride, and Bipolaris spicifera was examined by halogen immunoassays through the use of pooled serum IgE from patients allergic to fungus. Spores were deposited onto proteinbinding membranes direct, from culture. To germinate spores, samples were incubated in high humidity at room temperature for 48 hours. Ungerminated and germinated samples were then laminated with an adhesive film and immunostained by the halogen assay. The samples were examined by light microscopy, and positive counts (haloed particles) were expressed as percentages of total spores. Results: For 9 of 11 species, between 5.7% and 92% of spores released allergen before germination. Spores of Penicillium and Trichodemia did not release detectable allergen. After germination, all spores that germinated had allergen elution from their hyphae. Eight of I I species showed a significant increase (P <.05) in the percentage of spores eluting detectable allergen. Localization of allergen along the hyphae varied with species, such that some eluted allergen mainly from hyphal tips and septal junctions whereas others eluted allergen along the entire length. Conclusions: Increased elution of allergen after germination might be a common feature of many species of allergenic fungi. Although allergens from both spores and hyphae were recognized by human IgE, the extent to which human exposure occurs to allergens eluted from inhaled spores or from hyphae that germinate after deposition in the respiratory tract remains to be explored. The patterns of allergen expression might affect the clinical response to such exposure. (J Allergy Clin Immunol 2003;111:285-9.).	Univ Sydney, Fac Med, Woolcock Allergen Unit, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Woolcock Inst Med Res, Sydney, NSW, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Woolcock Institute of Medical Research	Green, BJ (corresponding author), Univ Sydney, Fac Med, Woolcock Allergen Unit, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				Achatz G, 1996, ADV EXP MED BIOL, V409, P157; AMITANI R, 1995, INFECT IMMUN, V63, P3266, DOI 10.1128/IAI.63.9.3266-3271.1995; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb02641.x; Bisht V, 2000, ALLERGY, V55, P274, DOI 10.1034/j.1398-9995.2000.00371.x; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Breitenbach M, 2002, CHEM IMMUNOL, V81, P48; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; Cody DT, 1997, LARYNGOSCOPE, V107, P1511, DOI 10.1097/00005537-199711000-00016; Crameri R, 2002, CHEM IMMUNOL, V81, P73; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; EINARSSON R, 1992, CLIN REV ALLERG, V10, P165; Gupta R, 1999, J ALLERGY CLIN IMMUN, V104, P857, DOI 10.1016/S0091-6749(99)70299-X; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; KARLSSONBORGA A, 1989, ANN ALLERGY, V63, P521; LAKE FR, 1991, AUST NZ J MED, V21, P871, DOI 10.1111/j.1445-5994.1991.tb01410.x; MIAKAKIS TZ, 2002, IN PRESS GRANA; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; NOBLE WC, 1963, J GEN MICROBIOL, V32, P397, DOI 10.1099/00221287-32-3-397; NOBLE WC, 1967, AIRBORNE MICROBES, P81; PARIS S, 1990, INT ARCH ALLER A IMM, V92, P1, DOI 10.1159/000235216; REIJULA KE, 1991, J ALLERGY CLIN IMMUN, V87, P683, DOI 10.1016/0091-6749(91)90389-6; Shen HD, 2001, CLIN EXP ALLERGY, V31, P295, DOI 10.1046/j.1365-2222.2001.01026.x; SPORIK RB, 1993, CLIN EXP ALLERGY, V23, P326, DOI 10.1111/j.1365-2222.1993.tb00330.x; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Tomee JFC, 2000, CLIN EXP ALLERGY, V30, P476, DOI 10.1046/j.1365-2222.2000.00796.x; Tovey E.R., 1989, Advances in the Biosciences, V74, P33; Tronchin G, 1997, INFECT IMMUN, V65, P9, DOI 10.1128/IAI.65.1.9-15.1997; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; Yang Z, 2000, THORAX, V55, P579, DOI 10.1136/thorax.55.7.579; ZHANG L, 1995, J IMMUNOL, V154, P710	36	128	135	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					285	289		10.1067/mai.2003.57	http://dx.doi.org/10.1067/mai.2003.57			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589346	Bronze			2022-12-18	WOS:000180942700010
J	Martin, RJ				Martin, RJ			Therapeutic significance of distal airway inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; distal airway inflammation; nocturnal asthma; inhaled corticosteroids; chlorofluorocarbon-based preparations; hydrofluoroalkane propellants	INHALED BECLOMETHASONE DIPROPIONATE; OBSTRUCTIVE PULMONARY-DISEASE; METERED-DOSE INHALER; LONG-TERM TREATMENT; NOCTURNAL ASTHMA; PSEUDOPHYSIOLOGIC EMPHYSEMA; EOSINOPHILIC INFLAMMATION; TRIAMCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; PERIPHERAL AIRWAYS	Inflammation In asthma is not merely confined to the large central airways but also extends to the small peripheral airways. Distal lung inflammation can be observed even In patients with asthma with mild disease and normal spirometric readings. Subjects with asymptomatic asthma can exhibit significant Increases In peripheral airway resistance, likely the result of distal lung inflammation. As determined from measurements of eosinophilic and other cellular infiltrates, the inflammatory response in the distal lung can exceed that in the large airways. Nocturnal asthma, a natural model of cyclic asthma worsening, is associated with an increase in nighttime distal lung inflammation, as evidenced by the accumulation of alveolar tissue eosinophils. Distal lung disease appears to Increase the risk of recurrent asthma exacerbation, whereas disease-related anatomic changes in the small airways of the distal lung are prominent in fatal asthma. The clinical significance of distal lung disease makes this region an important therapeutic target. Chlorofluorocarbon (CFC)-based preparations of inhaled corticosteroids used to treat airway inflammation produce aerosols of relatively large particle size (similar to4 mum); such aerosols have poor access to the distal lung. New formulations of Inhaled corticosteroids that use hydrofluoroalkane (HFA) propellants can have smaller particle sizes (similar to1 mum). Extrafine HFA aerosols have better access to the distal lung, with less oropharyngeal deposition. Imaging studies suggest that anti-inflammatory medication delivered as an extrafine aerosol produces beneficial changes in distal lung function. In one study, an HFA formulation of an inhaled corticosteroid reduced air trapping to a greater degree than a CFC formulation of the same corticosteroid. By extending the delivery of anti-inflammatory medication to the distal lung, the new HFA-based corticosteroids have the potential to treat asthma more effectively and at reduced steroid doses.	Natl Jewish Med & Res Ctr, Dept Med, Div Pulm, Denver, CO 80206 USA	National Jewish Health	Martin, RJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Div Pulm, 1400 Jackson St, Denver, CO 80206 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; ALMIND M, 1992, DAN MED BULL, V39, P561; Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Barnes NC, 2000, THORAX, V55, P478, DOI 10.1136/thorax.55.6.478; Berman AR, 1996, AM J RESP CRIT CARE, V154, P418, DOI 10.1164/ajrccm.154.2.8756816; BOGUNIEWICZ M, 2001, WORLD ASTHM M JUL 13; BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; CARROLL N, 1997, AM REV RESPIR DIS, V147, P405; Casale TB, 2001, CLIN DRUG INVEST, V21, P755, DOI 10.2165/00044011-200121110-00003; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P405, DOI 10.1016/S1081-1206(10)62922-5; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302, DOI 10.1002/j.1552-4604.1995.tb04064.x; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778, DOI 10.1164/ajrccm.162.5.2001037; Gelb AF, 1998, AM J RESP CRIT CARE, V158, P815, DOI 10.1164/ajrccm.158.3.9801045; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Goldin JG, 1998, RADIOLOGY, V208, P321, DOI 10.1148/radiology.208.2.9680554; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Howarth P, 1998, INT J CLIN PRACT, P15; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50, DOI 10.1164/ajrccm.161.1.9804053; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laurent F, 2000, EUR RADIOL, V10, P1404, DOI 10.1007/s003300000504; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; McNittGray MF, 1997, J COMPUT ASSIST TOMO, V21, P939, DOI 10.1097/00004728-199711000-00017; *NAT ASTHM ED PREV, 1997, NIH PUBL; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; PATEL P, 1990, AM REV RESPIR DIS, V141, P357, DOI 10.1164/ajrccm/141.2.357; PAVORD I, 1993, CLIN PHARMACOKINET, V25, P126, DOI 10.2165/00003088-199325020-00005; PEDERSEN S, 1994, EUR RESPIR REV, V17, P33; Pickering H, 2000, CLIN THER, V22, P1483, DOI 10.1016/S0149-2918(00)83046-5; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Richards J, 2001, J AEROSOL MED, V14, P197, DOI 10.1089/08942680152484126; Rohatagi S, 1996, J CLIN PHARMACOL, V36, P938, DOI 10.1002/j.1552-4604.1996.tb04761.x; Rohatagi S, 1995, J CLIN PHARMACOL, V35, P1187, DOI 10.1002/j.1552-4604.1995.tb04045.x; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; Selvadurai H, 2000, Paediatr Drugs, V2, P367, DOI 10.2165/00128072-200002050-00004; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Soria I, 1998, BIOPHARM DRUG DISPOS, V19, P297, DOI 10.1002/(SICI)1099-081X(199807)19:5<297::AID-BDD105>3.0.CO;2-I; Storms W, 2001, CLIN EXP ALLERGY, V31, P77, DOI 10.1046/j.1365-2222.2001.00969.x; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; TAKISHIMA T, 1988, TOHOKU J EXP MED, V156, P99, DOI 10.1620/tjem.156.99; Thien F, 2000, Aust Fam Physician, V29, P547; Thompson PJ, 1998, AM J RESP CRIT CARE, V157, pS199, DOI 10.1164/ajrccm.157.5.rsaa-7; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Villareal MS, 1996, ANN ALLERG ASTHMA IM, V76, P369, DOI 10.1016/S1081-1206(10)60040-3; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Wilson AM, 2001, CHEST, V119, P1021, DOI 10.1378/chest.119.4.1021; ZANEN P, 1995, INT J PHARM, V114, P111, DOI 10.1016/0378-5173(94)00224-S; 2000, RESP CARE, V45, P586	71	128	138	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2		S			S447	S460		10.1067/mai.2002.121409	http://dx.doi.org/10.1067/mai.2002.121409			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	529VQ	11842317				2022-12-18	WOS:000174322000001
J	Borish, L				Borish, L			IL-10: Evolving concepts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							T-CELL CLONES; CYTOKINE PRODUCTION; MICE; TH1		Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Borish, L (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; DELPRETE G, 1993, J IMMUNOL, V150, P353; DING L, 1993, J IMMUNOL, V151, P1224; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Gaglani B, 1997, ANN ALLERG ASTHMA IM, V79, P259, DOI 10.1016/S1081-1206(10)63012-8; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; WANIDWORANUN C, 1993, J IMMUNOL, V151, P6853; YSSEL H, 1992, J IMMUNOL, V149, P2378; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	12	128	130	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					293	297		10.1016/S0091-6749(98)70238-6	http://dx.doi.org/10.1016/S0091-6749(98)70238-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525442				2022-12-18	WOS:000072593900002
J	Werfel, SJ; Cooke, SK; Sampson, HA				Werfel, SJ; Cooke, SK; Sampson, HA			Clinical reactivity to beef in children allergic to cow's milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beef allergy; milk allergy; heat-labile proteins; heat-stabile proteins; immunoblot; BSA; EGG	FOOD HYPERSENSITIVITY; FISH HYPERSENSITIVITY; DOUBLE-BLIND; ALLERGENICITY; CHALLENGES	Background: Cow's milk is one of the most common food allergens in children. Limited Information is available on the prevalence of reactivity to a related food source, beef. The purposes of this study were to examine the prevalence of symptomatic sensitivity to beef in a selected pediatric population and to determine the frequency of concomitant reactivity to cow's milk and beef. Methods: Children referred for assessment of atopic dermatitis and possible food hypersensitivity were evaluated for symptomatic reactivity to beef by double-blind placebo-controlled food challenges (DBPCFCs) and subsequent open feedings of beef. Sodium dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), immunoblot, and immunodot blot analyses were performed with patients' sera on preparations of beef extracts subjected to different cooking conditions: raw (no heating), medium, and well-cooked. Results: Eleven of 335 children referred for evaluation of atopic dermatitis and possible food hypersensitivity were found to have symptomatic sensitivity to beef; eight were also sensitive to milk, as demonstrated in previous DBPCFCs. Eight patients reacted to beef during DBPCFC, and three tolerated beef in a DBPCFC and well-cooked beef in an open challenge but reacted to ingestion of less well-cooked beef. SDS-PAGE of raw beef revealed at least 24 protein fractions. Several protein bands in raw beef appeared to denature with heating. Bovine serum albumin and bovine gamma globulin were heat-labile in the beef extract, but six protein fractions persisted even after heating the beef extract for 2 hours at 85 degrees C. IgE from patients reacting to rare and well-cooked beef bound up to six of these heat-resistant fractions, but IgE from patients reacting only to rare beef failed to bind any of these fractions with one exception. in addition, patients reacting to rare and well-cooked beef had specific IgE to a 17.8 kd fraction, which was only weakly recognized by one patient reacting only to rare beef. Conclusions: Specific IgE antibodies to heat-labile beef proteins might explain why some patients can tolerate well-cooked beef but not medium-rare and rare beef. Patients reacting only to rare beef may not need to maintain a complete beef elimination diet.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NIAID NIH HHS [AI-24439] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDA H, 1990, Clinical and Experimental Allergy, V20, P28; BERNARD H, 1992, EUR J ALLERGY CLIN I, V47, P307; BERNHISELBROADB.J, 1990, PEDIATRICS, V87, P208; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; BLEUMINK E, 1968, INT ARCH ALLER A IMM, V34, P521, DOI 10.1159/000230147; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; EBBELING W, 1989, J ALLERGY CLIN IMMUN, V83, P238; FISHER AA, 1982, CONTACT DERMATITIS, V8, P425, DOI 10.1111/j.1600-0536.1982.tb04274.x; GARRETT JM, 1988, J DAIRY SCI, V71, P10, DOI 10.3168/jds.S0022-0302(88)79518-1; GOLDMAN AS, 1963, PEDIATRICS, V32, P425; HANSON LA, 1961, ACTA PAEDIATR, V50, P484, DOI 10.1111/j.1651-2227.1961.tb08203.x; HANSON LA, 1959, EXPERIENTIA, V15, P337; HEDBERG CW, 1987, NEW ENGL J MED, V316, P993, DOI 10.1056/NEJM198704163161605; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; HILL LW, 1964, PEDIATR CLIN N AM, V11, P17; HOFFMAN KM, 1995, J ALLERGY CLIN IMMUN, V95, P330; JENKINS HR, 1984, ARCH DIS CHILD, V59, P326, DOI 10.1136/adc.59.4.326; KARTE H, 1958, Z Kinderheilkd, V80, P530, DOI 10.1007/BF00438332; KELLA NK, 1988, BIOCHEM J, V255, P113, DOI 10.1042/bj2550113; Kinsella J E, 1989, Adv Food Nutr Res, V33, P343, DOI 10.1016/S1043-4526(08)60130-8; LINDEMAYR H, 1981, ALLERGY, V36, P471, DOI 10.1111/j.1398-9995.1981.tb01858.x; LOMBARD C, 1992, ALLERGY, V12, P47; LUZ AQ, 1964, AM J DIS CHILD, V108, P479, DOI 10.1001/archpedi.1964.02090010481006; MCCRORY WW, 1986, KIDNEY INT, V30, P592, DOI 10.1038/ki.1986.226; MCMEEKIN TL, 1987, PROTEINS, V2, pCH16; NAGPAL S, 1989, J ALLERGY CLIN IMMUN, V83, P26, DOI 10.1016/0091-6749(89)90474-0; OGLE KA, 1980, ANN ALLERGY, V44, P273; PERMYAKOV EA, 1988, BIOPHYS CHEM, V32, P37, DOI 10.1016/0301-4622(88)85031-2; READ NW, 1980, GASTROENTEROLOGY, V78, P264; ROULET D. L. A., 1961, Milchwissenschaft, V16, P415; STRESEMANN E, 1967, ACTA ALLERGOL, V22, P139, DOI 10.1111/j.1398-9995.1967.tb03206.x; TINKELMAN DG, 1984, ANN ALLERGY, V53, P243; US Bureau of the Census, 1991, STAT ABSTR US	37	128	131	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					293	300		10.1016/S0091-6749(97)70045-9	http://dx.doi.org/10.1016/S0091-6749(97)70045-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058683	hybrid			2022-12-18	WOS:A1997WM42200004
J	Martin, U; Bryden, K; Devoy, M; Howarth, P				Martin, U; Bryden, K; Devoy, M; Howarth, P			Increased levels of exhaled nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitric oxide; allergic rhinitis; inflammation	L-ARGININE; ASTHMA; INFLAMMATION; PATHWAY	Background: Allergic rhinitis is associated with nasal mucosal inflammation. Exhaled nitric oxide may by a useful marker of inflammation and has recently been shown to be increased in patients with asthma. Objective: The purpose of this study was to determine whether exhaled levels of nitric oxide are increased with nasal breathing in patients with seasonal allergic rhinitis compared with nonatopic individuals and whether there is an increase with oral breathing consistent with lower respiratory inflammation in the absence of clinical asthma. Methods: Nitric oxide levels in exhaled air were measured by chemiluminescence in 18 nonatopic volunteers and 32 patients with seasonal rhinitis. Measurements were made with both nasal and oral exhalation and orally after 10 seconds of breath-holding. The detection limit was 1 part per billion (ppb). Results: In control subjects nasal levels of nitric oxide in exhaled air (mean +/- SD, 24.7 +/- 9.2 ppb) were higher than those after oral exhalation (11.1 +/- 2.5 ppb, p < 0.0001). Breath-holding significantly increased levels of nitric oxide in exhaled air ina time-dependent manner. Levels of exhaled nitric oxide were significantly higher for all measurements in patients with seasonal rhinitis, with levels without breath-holding of 35.4 +/- 11.3 ppb (p < 0.001) in nasally exhaled air and 16.3 +/- 5.9 ppb (p < 0.001) in orally exhaled air. Nasal levels were significantly higher than oral levels in subjects with rhinitis (p < 0.0001). Conclusions: The results indicate that exhaled nitric oxide may be a useful marker for nasal inflammation in patients with seasonal rhinitis and suggest that generalized airway inflammation may be present, even without clinical asthma, in such patients.	SOUTHAMPTON GEN HOSP,CLIN PHARMACOL GRP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton				Howarth, Peter/0000-0003-0619-7927				ALVING K, 1993, EUR RESPIR J, V6, P1368; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUBOIS AB, 1994, AM J RESPIR CRIT C S, V149, pA40; GARNIER P, 1994, AM J RESP CRIT CARE, V149, pA198; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HOWARTH PH, 1991, INT ARCH ALLER A IMM, V94, P266, DOI 10.1159/000235379; HOWARTH PH, 1989, RESP MED, V83, P179, DOI 10.1016/S0954-6111(89)80029-0; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; MASSARO AF, 1994, AM J RESPIR CRIT C S, V149, pA198; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PERSSON MG, 1993, AM REV RESPIR DIS, V148, P1210, DOI 10.1164/ajrccm/148.5.1210	14	128	133	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					768	772		10.1016/S0091-6749(96)80154-0	http://dx.doi.org/10.1016/S0091-6749(96)80154-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613633				2022-12-18	WOS:A1996UA97500007
J	QUIRCE, S; CUEVAS, M; DIEZGOMEZ, ML; FERNANDEZRIVAS, M; HINOJOSA, M; GONZALEZ, R; LOSADA, E				QUIRCE, S; CUEVAS, M; DIEZGOMEZ, ML; FERNANDEZRIVAS, M; HINOJOSA, M; GONZALEZ, R; LOSADA, E			RESPIRATORY ALLERGY TO ASPERGILLUS-DERIVED ENZYMES IN BAKERS ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALPHA-AMYLASE; ASPERGILLUS; BAKERS ASTHMA; BRONCHIAL PROVOCATION TEST; CEREAL FLOUR; CELLULASE; ENZYMES; OCCUPATIONAL ASTHMA	OCCUPATIONAL ASTHMA; AMYLASE; INHALATION; CELLULASE; HISTAMINE; PAPAIN; SYSTEM; FLOUR	Baking and food industry workers are exposed to several powdered Aspergillus-derived enzymes with carbohydrate-cleaving activity that are commonly used to enhance baked products. We describe a retrospective study of sensitization to fungal alpha-amylase and cellulase on bakers. Five bakers in whom respiratory allergy symptoms developed when they were exposed to bread ''improvers'' that contained fungal alpha-amylase and cellulase were investigated by in vivo and in vitro tests. Type I hypersensitivity to these enzymes was demonstrated in the five patients by means of skin testing, histamine release test, positive reverse enzyme-immunoassay for specific IgE antibodies, and bronchial provocation test response to alpha-amylase or cellulase or both. Isolated immediate and dual responses to the bronchial challenge tests with these enzymes were observed. Immunoblot analysis with use of a pooled serum identified IgE-binding components in both enzymes. In the reverse-enzyme immunoassay-inhibition assays cross-reactivity between alpha-amylase and cellulase was not found, but some degree of cross-reactivity between alpha-amylase and A. oryzae, and between cellulase and A. niger was demonstrated. Four of the patients were also sensitized to cereal flour. Aspergillus-derived enzymes used as flour additives can elicit IgE-mediated respiratory allergy, and this fact has to be considered in the diagnosis and clinical management of bakers' asthma.	HOSP RAMON & CAJAL, DEPT ALLERGY & IMMUNOL, MADRID, SPAIN; ALERGIA & INMUNOL ABELLO SA, RES DEPT, MADRID, SPAIN	Hospital Universitario Ramon y Cajal			s, q/AAD-7171-2020					ARMENTIA A, 1990, ANN ALLERGY, V65, P265; BAUR X, 1988, RESPIRATION, V54, P70, DOI 10.1159/000195503; BAUR X, 1979, CLIN ALLERGY, V9, P75, DOI 10.1111/j.1365-2222.1979.tb01525.x; BAUR X, 1986, LANCET, V1, P43; BIRNBAUM J, 1988, REV MAL RESPIR, V5, P519; BLOCK G, 1983, CLIN ALLERGY, V13, P359, DOI 10.1111/j.1365-2222.1983.tb02610.x; CARMONA JGB, 1991, ALLERGY, V46, P274, DOI 10.1111/j.1398-9995.1991.tb00585.x; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V73, P574, DOI 10.1016/0091-6749(84)90513-X; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; FLINDT MLH, 1979, LANCET, V1, P1407; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRANKLAND AW, 1965, BRIT J IND MED, V22, P157; GALLEGUILLOS F, 1978, CLIN ALLERGY, V8, P21, DOI 10.1111/j.1365-2222.1978.tb00443.x; KLAUSTERMEYER WB, 1977, CLIN ALLERGY, V7, P227, DOI 10.1111/j.1365-2222.1977.tb01447.x; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; LINKO Y, 1986, CHEM PHYSICS BAKING; LOSADA E, 1986, J ALLERGY CLIN IMMUN, V77, P635, DOI 10.1016/0091-6749(86)90358-1; LOSADA E, 1992, J ALLERGY CLIN IMMUN, V89, P118, DOI 10.1016/S0091-6749(05)80048-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONEO I, 1983, INT ARCH ALLER A IMM, V71, P285, DOI 10.1159/000233406; MONEO I, 1980, ALLERGOL IMMUNOPAT S, V7, P311; PAUWELS R, 1978, LANCET, V1, P669; PEPYS J, 1969, LANCET, V1, P1181; RANSOM JH, 1981, J ALLERGY CLIN IMMUN, V67, P412, DOI 10.1016/0091-6749(81)90088-9; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALDIVIESO R, 1989, ANN ALLERGY, V63, P149; WIESSMANN KJ, 1985, EUR J RESPIR DIS, V66, P13; ZWEIMAN B, 1967, J ALLERGY, V39, P11, DOI 10.1016/0021-8707(67)90121-9	31	128	128	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				970	978		10.1016/0091-6749(92)90470-M	http://dx.doi.org/10.1016/0091-6749(92)90470-M			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1281180				2022-12-18	WOS:A1992KD19000014
J	PIPKORN, U; KARLSSON, G; ENERBACK, L				PIPKORN, U; KARLSSON, G; ENERBACK, L			THE CELLULAR-RESPONSE OF THE HUMAN ALLERGIC MUCOSA TO NATURAL ALLERGEN EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT PATHOL,S-41345 GOTHENBURG,SWEDEN; VASTRA FROLUNDA HOSP,DEPT EAR NOSE & THROAT,GOTHENBURG,SWEDEN; UNIV LUND HOSP,DEPT OTORHINOLARYNGOL,S-22185 LUND,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Lund University; Skane University Hospital								ALLENMARK S, 1985, ANAL BIOCHEM, V144, P98, DOI 10.1016/0003-2697(85)90089-2; ANDERSSON M, 1987, ALLERGY, V42, P631, DOI 10.1111/j.1398-9995.1987.tb00395.x; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BASCOM R, 1986, J ALLERGY CLIN IMMUN, V77, P246; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; COCKROFT DW, 1982, CLIN ALLERGY, V7, P503; DAHL R, 1987, PATHOPHYSIOLOGICAL A, P136; DAVIES RJ, 1985, ALLERGIC VASOMOTOR R, P65; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289, DOI 10.1159/000234152; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; ENERBACK L, 1986, MAST CELL DIFFERENTI, P1; Eyermann C. H., 1927, ANN OTO RHINOL LARYN, V36, P808; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; HASTIE R, 1979, LAB INVEST, V40, P554; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; JAMES MP, 1981, J INVEST DERMATOL, V78, P406; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; KAY AB, 1982, EUR J RESPIR DIS, V63, P9; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LINDER A, 1987, ALLERGY, V42, P126, DOI 10.1111/j.1398-9995.1987.tb02370.x; MACGLASHAN DW, 1980, J IMMUNOL, V124, P2519; MURRAY AB, 1971, ANN ALLERGY, V28, P142; MYGIND N, 1986, ESSENTIAL ALLERGY, P23; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; PIPKORN U, 1984, J IMMUNOL METHODS, V73, P133, DOI 10.1016/0022-1759(84)90038-3; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, INT ARCH ALLER A IMM, V84, P123, DOI 10.1159/000234410; PIPKORN U, 1983, ALLERRGY, V83, P125; SHULMAN ES, 1983, J IMMUNOL, V131, P1936; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; VORHORST R, 1961, ADV OTORHINOLARYNGOL, V10, P86; WHELAN CFA, 1980, J LARYNGOL OTOL, V84, P399	40	128	131	3	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1046	1054		10.1016/0091-6749(88)90143-1	http://dx.doi.org/10.1016/0091-6749(88)90143-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	2462580				2022-12-18	WOS:A1988R631100014
J	BARBEE, RA; HALONEN, M; KALTENBORN, W; LEBOWITZ, M; BURROWS, B				BARBEE, RA; HALONEN, M; KALTENBORN, W; LEBOWITZ, M; BURROWS, B			A LONGITUDINAL-STUDY OF SERUM IGE IN A COMMUNITY COHORT - CORRELATIONS WITH AGE, SEX, SMOKING, AND ATOPIC STATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BARBEE, RA (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,COLL MED,WESTEND RES LABS,DIV RESP SCI,TUCSON,AZ 85724, USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL 14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BAZARAL M, 1971, J IMMUNOL, V107, P794; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GRUNDBACHER FJ, 1985, J ALLERGY CLIN IMMUN, V75, P651, DOI 10.1016/0091-6749(85)90089-2; HALLGREN R, 1982, ACTA MED SCAND, V211, P269; HANNEUSE Y, 1978, CLIN ALLERGY, V8, P165, DOI 10.1111/j.1365-2222.1978.tb00461.x; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; RAWLE FC, 1983, CLIN ALLERGY, V13, P409, DOI 10.1111/j.1365-2222.1983.tb02616.x; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	28	128	131	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					919	927		10.1016/0091-6749(87)90241-7	http://dx.doi.org/10.1016/0091-6749(87)90241-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584747				2022-12-18	WOS:A1987H904400013
J	SOBOTKA, AK; FRANKLIN, RM; ADKINSON, NF; VALENTINE, M; BAER, H; LICHTENSTEIN, LM				SOBOTKA, AK; FRANKLIN, RM; ADKINSON, NF; VALENTINE, M; BAER, H; LICHTENSTEIN, LM			ALLERGY TO INSECT STINGS .2. PHOSPHOLIPASE-A - MAJOR ALLERGEN IN HONEYBEE VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218	Johns Hopkins University								ARBESMAN CE, 1966, J ALLERGY, V38, P1, DOI 10.1016/0021-8707(66)90067-0; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BENSON RL, 1930, J ALLERGY, V1, P105; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BUSSE W, 1974, J ALLERGY CLIN IMMUN, V53, P104; FRANKLIN R, 1975, J ALLERGY CLIN IMMUN, V55, P285, DOI 10.1016/0091-6749(75)90001-9; FRANKLIN RM, 1974, P SOC EXP BIOL MED, V147, P585, DOI 10.3181/00379727-147-38393; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; JAQUES R, 1954, BRIT J PHARM CHEMOTH, V9, P53, DOI 10.1111/j.1476-5381.1954.tb00816.x; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LANGLOIS C, 1966, J ALLERGY, V37, P359, DOI 10.1016/0021-8707(66)90135-3; LEVY DA, 1966, J IMMUNOL, V97, P203; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LOVELESS MH, 1962, J IMMUNOL, V89, P204; LUBKE K, 1971, EXPERIENTIA, V27, P765, DOI 10.1007/BF02136852; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NEWCOMB RW, 1967, J IMMUNOL, V99, P40; OCONNOR R, 1964, SCIENCE, V145, P1320, DOI 10.1126/science.145.3638.1320; REISMAN RE, 1974, J ALLERGY CLIN IMMUN, V53, P110, DOI 10.1016/0091-6749(74)90076-1; SCHRODER E, 1974, EXPERIENTIA, V27, P764; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SHIPOLINI RA, 1971, FEBS LETT, V17, P39, DOI 10.1016/0014-5793(71)80558-6; SHULMAN S, 1966, J ALLERGY, V37, P350, DOI 10.1016/0021-8707(66)90134-1; SHULMAN S, 1964, J ALLERGY, V35, P446, DOI 10.1016/0021-8707(64)90071-1; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; WIDE L, 1967, LANCET, V2, P1105	30	128	133	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	1					29	40		10.1016/0091-6749(76)90076-2	http://dx.doi.org/10.1016/0091-6749(76)90076-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BC141	54382				2022-12-18	WOS:A1976BC14100004
J	Silverberg, JI; Pinter, A; Pulka, G; Poulin, Y; Bouaziz, JD; Wollenberg, A; Murrell, DF; Alexis, A; Lindsey, L; Ahmad, F; Piketty, C; Clucas, A				Silverberg, Jonathan, I; Pinter, Andreas; Pulka, Grazyna; Poulin, Yves; Bouaziz, Jean-David; Wollenberg, Andreas; Murrell, Dedee F.; Alexis, Andrew; Lindsey, Lisa; Ahmad, Faiz; Piketty, Christophe; Clucas, Alan			Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; humanized mAb; anti-IL-31 receptor	ULCERATIVE-COLITIS; DOUBLE-BLIND; IL-31; CELLS; ANTIBODY; RECEPTOR; SKIN; ITCH	Background: Nemolizumab targets the IL-31 receptor a subunit involved in atopic dermatitis (AD) pathogenesis. Objective: We sought to evaluate a new dosing strategy of nemolizumab in patients with AD. Methods: We performed a 24-week, randomized, double-blind, multicenter study of nemolizumab (10, 30, and 90 mg) subcutaneous injections every 4 weeks versus placebo, with topical corticosteroids in adults with moderate-to-severe AD, severe pruritus, and inadequate control with topical treatment (n = 226). The Eczema Area and Severity Index (EASI), the peak pruritus (PP) numeric rating scale (NRS), and the Investigator's Global Assessment (IGA) were assessed. Standard safety assessments were performed. Results: Nemolizumab improved EASI, IGA, and/or NRS-itch scores, with the 30-mg dose being most effective. Nemolizumab (30 mg) reduced EASI scores versus placebo at week 24 (-68.8% vs -52.1%, P = .016); significant differences were observed by week 8 (P <=.01). With significant improvement (P = .028) as early as week 4, IGA 0/1 rates were higher for 30 mg of nemolizumab versus placebo at week 16 (33.3% vs 12.3%, P = .008) but not week 24 because of an increased placebo/topical corticosteroid effect (36.8% vs 21.1%, P = .06). PP-NRS scores were improved for 30 mg of nemolizumab versus placebo at week 16 (-68.6% vs -34.3%, P < .0001) and week 24 (-67.3% vs -35.8%, P < .0001), with a difference by week 1 (P < .001). NRS response rates (>= 4-point decrease) were greater for 30 mg of nemolizumab versus placebo at week 16 (P <= .001) and week 24 (P <= .01). Nemolizumab was safe and well tolerated. The most common adverse events were nasopharyngitis and upper respiratory tract infection. Conclusions: Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30 mg. Nemolizumab had an acceptable safety profile.	[Silverberg, Jonathan, I] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA; [Pinter, Andreas] Goethe Univ Frankfurt Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany; [Pulka, Grazyna] Jagiellonian Univ, Med Coll, Sch Med, Krakow, Poland; [Poulin, Yves] Univ Laval, Dept Med, Quebec City, PQ, Canada; [Bouaziz, Jean-David] Paris VII Sorbonne Paris Cite Univ, AP HP, Dept Dermatol, Paris, France; [Wollenberg, Andreas] Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergol, Munich, Germany; [Murrell, Dedee F.] Univ New South Wales, St George Clin Sch, Dept Dermatol, Sydney, NSW, Australia; [Alexis, Andrew] Icahn Sch Med, Dept Dermatol, Mt Sinai, NY USA; [Lindsey, Lisa; Ahmad, Faiz] Galderma Labs, Ft Worth, TX USA; [Piketty, Christophe] Galderma R&D, Lausanne, Switzerland	Northwestern University; Feinberg School of Medicine; Goethe University Frankfurt; Jagiellonian University; Collegium Medicum Jagiellonian University; Laval University; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; University of Munich; University of New South Wales Sydney; Icahn School of Medicine at Mount Sinai; Galderma R&D SNC	Silverberg, JI (corresponding author), 676 N St Clair St 1600, Chicago, IL 60611 USA.	jonathanisilverberg@gmail.com	Alexis, Andrew/AAY-4028-2021; silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805	Nestle Skin Health-Galderma RD	Nestle Skin Health-Galderma RD	The study was funded by Nestle Skin Health-Galderma R&D. The funders participated in the conception and design of the study, analysis and interpretation of the data, and drafting and critical revision of the report and provided approval to submit.	Armstrong AW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210517; Bagci IS, 2018, J ALLERGY CLIN IMMUN, V141, P858, DOI 10.1016/j.jaci.2017.10.045; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chrostowska-Plak D, 2013, J EUR ACAD DERMATOL, V27, pE239, DOI 10.1111/j.1468-3083.2012.04578.x; Feld M, 2016, J ALLERGY CLIN IMMUN, V138, P500, DOI 10.1016/j.jaci.2016.02.020; Fontenot E, 2013, MOL CANCER THER, V12, P685, DOI 10.1158/1535-7163.MCT-12-1066; Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7; Kabashima K, 2018, J ALLERGY CLIN IMMUN, V142, P1121, DOI 10.1016/j.jaci.2018.03.018; Kato A, 2014, J DERMATOL SCI, V74, P229, DOI 10.1016/j.jdermsci.2014.02.009; Meng JH, 2018, J ALLERGY CLIN IMMUN, V141, P1677, DOI 10.1016/j.jaci.2017.12.1002; Nemoto O, 2016, BRIT J DERMATOL, V174, P296, DOI 10.1111/bjd.14207; Nobbe S, 2012, ACTA DERM-VENEREOL, V92, P24, DOI 10.2340/00015555-1191; Ruzicka T, 2017, NEW ENGL J MED, V376, P826, DOI 10.1056/NEJMoa1606490; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Silverberg JI, 2018, ANN ALLERG ASTHMA IM, V121, P340, DOI 10.1016/j.anai.2018.07.006; Silverberg JI, 2017, ALLERGY ASTHMA PROC, V38, P243, DOI 10.2500/aap.2017.38.4054; Silverberg JI, 2015, J INVEST DERMATOL, V135, P56, DOI 10.1038/jid.2014.325; Singh B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161877; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Szegedi K, 2012, EXP DERMATOL, V21, P431, DOI 10.1111/j.1600-0625.2012.01487.x; Vermeire S, 2017, LANCET, V390, P135, DOI 10.1016/S0140-6736(17)30930-3; Vermeire S, 2014, LANCET, V384, P309, DOI 10.1016/S0140-6736(14)60661-9	23	127	129	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					173	182		10.1016/j.jaci.2019.08.013	http://dx.doi.org/10.1016/j.jaci.2019.08.013			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31449914	hybrid, Green Published			2022-12-18	WOS:000505590800024
J	Wu, WD; Jin, YF; Carlsten, C				Wu, Weidong; Jin, Yuefei; Carlsten, Chris			Inflammatory health effects of indoor and outdoor particulate matter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Air pollution; inflammation; particulate matter; wildfire; biomass	OBSTRUCTIVE PULMONARY-DISEASE; DIESEL EXHAUST PARTICLES; HOUSEHOLD AIR-POLLUTION; SHORT-TERM EXPOSURE; BIOMASS FUEL SMOKE; AMBIENT AIR; RESPIRATORY HEALTH; OXIDATIVE STRESS; RISK-FACTOR; HOSPITAL ADMISSIONS	Inflammation is a common and essential event in the pathogenesis of diverse diseases. Decades of research has converged on an understanding that all combustion-derived particulate matter (PM) is inflammatory to some extent in the lungs and also systemically, substantially explaining a significant portion of the massive cardiopulmonary disease burden associated with these exposures. In general, this means that efforts to do the following can all be beneficial: reduce particulates at the source, decrease the inflammatory potential of PM output, and, where PM inhalation is unavoidable, administer anti-inflammatory treatment. A range of research, including basic illumination of inflammatory pathways, assessment of disease burden in large cohorts, tailored treatment trials, and epidemiologic, animal, and in vitro studies, is highlighted in this review. However, meaningful translation of this research to decrease the burden of disease and deliver a clear and cohesive message to guide daily clinical practice remains rudimentary. Ongoing efforts to better understand substantial differences in the concentration and type of PM to which the global community is exposed and then distill how that influences inflammation promises to have real-world benefit. This review addresses this complex topic in 3 sections, including ambient PM (typically associated with ground-level transportation), wildfire-induced PM, and PM from indoor biomass burning. Recognizing the overlap between these domains, we also describe differences and suggest future directions to better inform clinical practice and public health.	[Wu, Weidong] Xinxiang Med Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Xinxiang, Peoples R China; [Jin, Yuefei] Zhengzhou Univ, Dept Epidemiol, Coll Publ Hlth, Zhengzhou, Henan, Peoples R China; [Carlsten, Chris] Univ British Columbia, Dept Med, Air Pollut Exposure Lab, Vancouver, BC, Canada; [Carlsten, Chris] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada	Xinxiang Medical University; Zhengzhou University; University of British Columbia; University of British Columbia	Carlsten, C (corresponding author), Vancouver Gen Hosp, Dept Med, 2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.	carlsten@mail.ubc.ca	Jin, Yuefei/AES-4089-2022; Jin, Yuefei/AAL-5163-2020		National Natural Science Foundation of China [81573112, 81373030]; Canada Research Chairs Program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Canada Research Chairs Program(Canada Research Chairs)	Supported by grants from the National Natural Science Foundation of China (81573112 and 81373030) and the Canada Research Chairs Program.	Adetona O, 2016, INHAL TOXICOL, V28, P95, DOI 10.3109/08958378.2016.1145771; Akagi SK, 2011, ATMOS CHEM PHYS, V11, P4039, DOI 10.5194/acp-11-4039-2011; Alman BL, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0146-8; [Anonymous], WHO BURD DIS HOUS AI; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067, DOI 10.1164/ajrccm.164.11.2102005; Balbi B, 2007, EUR RESPIR J, V30, P769, DOI 10.1183/09031936.00112306; Bayer-Oglesby L, 2005, ENVIRON HEALTH PERSP, V113, P1632, DOI 10.1289/ehp.8159; Bayram H, 1998, AM J RESP CELL MOL, V18, P441, DOI 10.1165/ajrcmb.18.3.2882; Borm PJA, 2006, PART FIBRE TOXICOL, V3, DOI 10.1186/1743-8977-3-11; Brauner EV, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-13; Brauner EV, 2009, INHAL TOXICOL, V21, P38, DOI [10.1080/08958370802304735, 10.1080/08958370802304735 ]; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Caravedo MA, 2016, INDOOR AIR, V26, P768, DOI 10.1111/ina.12259; Carlsten C, 2016, THORAX, V71, P35, DOI 10.1136/thoraxjnl-2015-207399; Chen BY, 2012, AM J EPIDEMIOL, V175, P764, DOI 10.1093/aje/kwr380; Chen L, 2016, AM J RESP CELL MOL, V55, P815, DOI 10.1165/rcmb.2016-0051OC; Cundale K, 2017, SOC SCI MED, V183, P1, DOI 10.1016/j.socscimed.2017.04.017; DEKONING HW, 1985, B WORLD HEALTH ORGAN, V63, P11; Delfino RJ, 2009, OCCUP ENVIRON MED, V66, P189, DOI 10.1136/oem.2008.041376; Delfino RJ, 2010, EPIDEMIOLOGY, V21, P892, DOI 10.1097/EDE.0b013e3181f20e6c; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.2307/3434265; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Diffey BL, 2011, BRIT J DERMATOL, V164, P848, DOI 10.1111/j.1365-2133.2010.10165.x; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; DUSSELDORP A, 1995, AM J RESP CRIT CARE, V152, P1932, DOI 10.1164/ajrccm.152.6.8520758; Dutta A, 2013, INT J HYG ENVIR HEAL, V216, P301, DOI 10.1016/j.ijheh.2012.05.005; Dutta A, 2012, SCI TOTAL ENVIRON, V438, P293, DOI 10.1016/j.scitotenv.2012.08.065; Dutta A, 2012, TOXICOL APPL PHARM, V261, P255, DOI 10.1016/j.taap.2012.04.004; Farmer SA, 2014, AM J PHYSIOL-HEART C, V307, pH467, DOI 10.1152/ajpheart.00235.2014; Finlay SE, 2012, PLOS CURR, V4; Flannigan M, 2013, FOREST ECOL MANAG, V294, P54, DOI 10.1016/j.foreco.2012.10.022; Franzi LM, 2011, TOXICOL APPL PHARM, V257, P182, DOI 10.1016/j.taap.2011.09.003; Fullerton DG, 2008, T ROY SOC TROP MED H, V102, P843, DOI 10.1016/j.trstmh.2008.05.028; Gan WQ, 2013, AM J RESP CRIT CARE, V187, P721, DOI 10.1164/rccm.201211-2004OC; Gan WQ, 2010, EPIDEMIOLOGY, V21, P642, DOI 10.1097/EDE.0b013e3181e89f19; Gaughan DM, 2008, J OCCUP ENVIRON MED, V50, P1019, DOI 10.1097/JOM.0b013e3181754161; Ghio AJ, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13597; Ghio AJ, 2012, OCCUP ENVIRON MED, V69, P170, DOI 10.1136/oem.2011.065276; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105, DOI 10.1164/ajrccm.155.6.9196122; Gong JC, 2014, ENVIRON SCI TECHNOL, V48, P5264, DOI 10.1021/es5006016; Guarnieri MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088455; Han YQ, 2016, SCI TOTAL ENVIRON, V565, P412, DOI 10.1016/j.scitotenv.2016.04.196; Hart JE, 2013, EPIDEMIOLOGY, V24, P734, DOI 10.1097/EDE.0b013e31829d5dae; Hejl AM, 2013, J OCCUP ENVIRON HYG, V10, P173, DOI 10.1080/15459624.2012.760064; Henderson SB, 2011, ENVIRON HEALTH PERSP, V119, P1266, DOI 10.1289/ehp.1002288; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; HJERMANN I, 1981, LANCET, V2, P1303; Ierodiakonou D, 2016, J ALLERGY CLIN IMMUN, V137, P390, DOI 10.1016/j.jaci.2015.05.028; Johnston F, 2011, ENVIRON RES, V111, P811, DOI 10.1016/j.envres.2011.05.007; Karr CJ, 2009, AM J RESP CRIT CARE, V180, P995, DOI 10.1164/rccm.200901-0117OC; Kramer MM, 2017, TRANSL RES, V182, P49, DOI 10.1016/j.trsl.2016.11.001; Krimmer D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083938; Langrish JP, 2012, J INTERN MED, V272, P224, DOI 10.1111/j.1365-2796.2012.02566.x; Lee A, 2015, ANN GLOB HEALTH, V81, P368, DOI 10.1016/j.aogh.2015.08.006; Lee JT, 2007, SCI TOTAL ENVIRON, V385, P28, DOI 10.1016/j.scitotenv.2007.07.005; Li N, 2008, FREE RADICAL BIO MED, V44, P1689, DOI 10.1016/j.freeradbiomed.2008.01.028; Li Yanli, 2012, Reviews on Environmental Health, V27, P133, DOI 10.1515/reveh-2012-0012; Liu JC, 2015, ENVIRON RES, V136, P120, DOI 10.1016/j.envres.2014.10.015; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; Mannucci PM, 2015, INTERN EMERG MED, V10, P657, DOI 10.1007/s11739-015-1276-7; Manuel J, 2003, ENVIRON HEALTH PERSP, V111, pA28, DOI 10.1289/ehp.111-a28; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McDonald E, 2002, CHEST, V122, P1535, DOI 10.1378/chest.122.5.1535; Mishra V, 2003, ENVIRON HEALTH PERSP, V111, P71, DOI 10.1289/ehp.5559; Morgan G, 2010, EPIDEMIOLOGY, V21, P47, DOI 10.1097/EDE.0b013e3181c15d5a; Mortimer K, 2017, LANCET, V389, P167, DOI 10.1016/S0140-6736(16)32507-7; Mortimer K, 2012, CHEST, V142, P1308, DOI 10.1378/chest.12-1596; Muala A, 2015, PART FIBRE TOXICOL, V12, DOI 10.1186/s12989-015-0111-7; Mutlu GM, 2007, J CLIN INVEST, V117, P2952, DOI 10.1172/JCI30639; Myatt TA, 2011, J OCCUP ENVIRON MED, V53, P1110, DOI 10.1097/JOM.0b013e3182337605; Naeher LP, 2007, INHAL TOXICOL, V19, P67, DOI 10.1080/08958370600985875; Nemmar A, 2011, BRIT J PHARMACOL, V164, P1871, DOI 10.1111/j.1476-5381.2011.01442.x; Nemmar A, 2009, TOXICOLOGY, V263, P84, DOI 10.1016/j.tox.2009.06.017; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161, DOI 10.1164/ajrccm.162.1.9908092; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Olloquequi J, 2016, INNATE IMMUN-LONDON, V22, P373, DOI 10.1177/1753425916650272; Padkao T, 2013, PHAYAO RES C U PHAYA; Pavese G, 2014, ADV METEOROL, V2014, DOI 10.1155/2014/529850; Pena MSB, 2017, INDOOR AIR, V27, P737, DOI 10.1111/ina.12362; Peters A, 2001, CIRCULATION, V103, P2810; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; Rappold AG, 2011, ENVIRON HEALTH PERSP, V119, P1415, DOI 10.1289/ehp.1003206; Reid CE, 2016, ENVIRON HEALTH PERSP, V124, P1334, DOI 10.1289/ehp.1409277; REISMAN RE, 1990, J ALLERGY CLIN IMMUN, V85, P1050, DOI 10.1016/0091-6749(90)90050-E; Robinson RK, 2017, J ALLERGY CLIN IMMUN; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118, DOI 10.1164/ajrccm/147.1.118; Romieu I, 2009, AM J RESP CRIT CARE, V180, P649, DOI 10.1164/rccm.200810-1556OC; Rylance J, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0803-7; Rylance J, 2015, AM J RESP CELL MOL, V52, P584, DOI 10.1165/rcmb.2014-0188OC; Saha H, 2016, J APPL TOXICOL, V36, P969, DOI 10.1002/jat.3275; Salin JT, 2017, ENVIRON RES, V154, P234, DOI 10.1016/j.envres.2017.01.015; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083; Sava F, 2013, AM J RESP CRIT CARE, V188, P759, DOI 10.1164/rccm.201302-0330LE; Schikowski T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-152; Schins RPF, 2004, TOXICOL APPL PHARM, V195, P1, DOI 10.1016/j.taap.2003.10.002; Sehlstedt M, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-21; Simoni M, 2015, J THORAC DIS, V7, P34, DOI 10.3978/j.issn.2072-1439.2014.12.10; Subramanian M, 2014, NATURE, V509, P548, DOI 10.1038/509548a; Sussan TE, 2014, AM J RESP CELL MOL, V50, P538, DOI 10.1165/rcmb.2013-0201OC; Suwa T, 2002, J AM COLL CARDIOL, V39, P935, DOI 10.1016/S0735-1097(02)01715-1; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; Swiston JR, 2008, EUR RESPIR J, V32, P129, DOI 10.1183/09031936.00097707; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213, DOI 10.1164/ajrccm.161.4.9904084; Tanaka T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-766; United States Environment Protection Agency, NAAQS TABL; Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538; van Berlo Damien, 2012, Exp Suppl, V101, P165, DOI 10.1007/978-3-7643-8340-4_7; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826, DOI 10.1164/ajrccm.164.5.2010160; Viegi G, 1999, INT J TUBERC LUNG D, V3, P1034; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Wegesser TC, 2010, INHAL TOXICOL, V22, P561, DOI 10.3109/08958370903571849; Wegesser TC, 2009, ENVIRON HEALTH PERSP, V117, P893, DOI 10.1289/ehp.0800166; Wong LSN, 2011, TOXICOL IN VITRO, V25, P1895, DOI 10.1016/j.tiv.2011.06.001; Wu SW, 2016, ENVIRON INT, V94, P76, DOI 10.1016/j.envint.2016.05.004; Yang IA, 2008, THORAX, V63, P555, DOI 10.1136/thx.2007.079426; Yao JY, 2016, J EXPO SCI ENV EPID, V26, P233, DOI 10.1038/jes.2014.67; Youssouf H, 2014, INT J ENV RES PUB HE, V11, P11772, DOI 10.3390/ijerph111111772; Zanobetti A, 2001, AM J RESP CRIT CARE, V164, P831, DOI 10.1164/ajrccm.164.5.2012039; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961; Zhang X, 2016, FREE RADICAL BIO MED, V96, P385, DOI 10.1016/j.freeradbiomed.2016.04.202; Zhuang XG, 2014, AEROSOL AIR QUAL RES, V14, P338, DOI 10.4209/aaqr.2012.11.0316	121	127	133	8	60	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					833	844		10.1016/j.jaci.2017.12.981	http://dx.doi.org/10.1016/j.jaci.2017.12.981			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29519450				2022-12-18	WOS:000426974800001
J	Morita, H; Moro, K; Koyasu, S				Morita, Hideaki; Moro, Kazuyo; Koyasu, Shigeo			Innate lymphoid cells in allergic and nonallergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate lymphoid cell; asthma; viral infection; obesity; atopic dermatitis; psoriasis; eosinophilic gastrointestinal disorder; inflammatory bowel disease	THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR GATA3; NATURAL HELPER-CELLS; MUCOSAL IL-22 PRODUCTION; TYPE-2 IMMUNE-RESPONSE; MAST-CELLS; ATOPIC-DERMATITIS; T-CELL; EOSINOPHILIC ESOPHAGITIS; EPITHELIAL-CELLS	In the last decade, the full picture of the role of innate lymphoid cells (ILCs) has been gradually revealed. ILCs are classified into 3 groups based on their transcription factors and cytokine production patterns, which mirror helper T-cell subsets. Unlike T cells and B cells, ILCs do not have antigen receptors. They promptly respond to multiple tissue-derived factors, such as cytokines and alarmins, and produce multiple proinflammatory and immunoregulatory cytokines. It has been reported that ILC-derived cytokines are important for the induction and regulation of inflammation. Accumulating evidence suggests that ILCs play substantial roles in protection against infection and the pathogenesis of inflammatory diseases, such as allergic diseases and autoimmune diseases. Different ILC subsets localize in distinct tissue/organ niches and receive tissue-derived signals on different types of inflammation, which allows them to acquire diverse phenotypes with specialized effector capacities. In this review we highlight the roles of ILCs in a variety of organs, such as the airway, skin, and gastrointestinal tract, in the context of allergic and nonallergic inflammation.	[Morita, Hideaki] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Morita, Hideaki] Christine Kuhne Ctr, Allergy Res & Educ, Davos, Switzerland; [Moro, Kazuyo] RIKEN, Ctr Integrat Med Sci, Lab Innate Immune Syst, Yokohama, Kanagawa, Japan; [Koyasu, Shigeo] RIKEN, Ctr Integrat Med Sci, Lab Immune Cell Syst, Yokohama, Kanagawa, Japan; [Moro, Kazuyo] Yokohama City Univ, Grad Sch Med Life Sci, Dept Med Life Sci, Div Immunobiol, Yokohama, Kanagawa, Japan; [Koyasu, Shigeo] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan	Swiss Institute of Allergy & Asthma Research; University of Zurich; RIKEN; RIKEN; Yokohama City University; Keio University	Koyasu, S (corresponding author), RIKEN, Ctr Integrat Med Sci, Lab Immune Cell Syst, Yokohama, Kanagawa, Japan.	shigeo.koyasu@riken.jp	Morita, Hideaki/S-2214-2016; Morita, Hideaki/ADL-2008-2022; Koyasu, Shigeo/J-5583-2015	Morita, Hideaki/0000-0003-0928-8322; Koyasu, Shigeo/0000-0001-9585-3038; Moro, Kazuyo/0000-0002-7377-1303	Grants-in-Aid for Scientific Research [26293110] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bishop JL, 2014, MUCOSAL IMMUNOL, V7, P405, DOI 10.1038/mi.2013.60; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Bowcock AM, 2005, NAT REV IMMUNOL, V5, P699, DOI 10.1038/nri1689; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Cella M, 2010, P NATL ACAD SCI USA, V107, P10961, DOI 10.1073/pnas.1005641107; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cherrier M, 2012, J EXP MED, V209, P729, DOI 10.1084/jem.20111594; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Cianferoni A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0558-5; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; Crellin NK, 2010, IMMUNITY, V33, P752, DOI 10.1016/j.immuni.2010.10.012; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Dyring-Andersen B, 2014, BRIT J DERMATOL, V170, P609, DOI 10.1111/bjd.12658; Eken A, 2014, MUCOSAL IMMUNOL, V7, P143, DOI 10.1038/mi.2013.33; Everaere L, 2016, J ALLERGY CLIN IMMUN; Fuchs A, 2013, IMMUNITY, V38, P769, DOI 10.1016/j.immuni.2013.02.010; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Gordon SM, 2012, IMMUNITY, V36, P55, DOI 10.1016/j.immuni.2011.11.016; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Halim TYF, 2016, NAT IMMUNOL, V17, P57, DOI 10.1038/ni.3294; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Julia V, 2015, NAT REV IMMUNOL, V15, P308, DOI 10.1038/nri3830; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim CJ, 2012, MUCOSAL IMMUNOL, V5, P670, DOI 10.1038/mi.2012.72; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Lee HC, 2012, J ALLERGY CLIN IMMUN, V130, P1187, DOI 10.1016/j.jaci.2012.07.031; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Li Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11394; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Liu T, 2015, RESP MED, V109, P1391, DOI 10.1016/j.rmed.2015.09.016; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Mchedlidze T, 2016, MUCOSAL IMMUNOL; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; MILNE J, 1975, BRIT J IND MED, V32, P302; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Mizoguchi A, 2012, INFLAMM BOWEL DIS, V18, P1777, DOI 10.1002/ibd.22929; Mizuno S, 2014, INFLAMM BOWEL DIS, V20, P1426, DOI 10.1097/MIB.0000000000000105; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Morita H, 2016, SEMIN IMMUNOPATHOL, V38, P623, DOI 10.1007/s00281-016-0566-0; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mortha A, 2014, SCIENCE, V343, P1477, DOI 10.1126/science.1249288; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Oboki Keisuke, 2010, Allergology International, V59, P143, DOI 10.2332/allergolint.10-RAI-0186; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Otsuka A, 2016, SEMIN IMMUNOPATHOL, V38, P563, DOI 10.1007/s00281-016-0570-4; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Pelly V. S., 2016, MUCOSAL IMMUNOL; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Powell N, 2012, IMMUNITY, V37, P674, DOI 10.1016/j.immuni.2012.09.008; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Rovedatti L, 2009, GUT, V58, P1629, DOI 10.1136/gut.2009.182170; Sakuraba A, 2009, GASTROENTEROLOGY, V137, P1736, DOI 10.1053/j.gastro.2009.07.049; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Satoh-Takayama N, 2010, J EXP MED, V207, P273, DOI 10.1084/jem.20092029; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; Serafini N, 2014, J EXP MED, V211, P199, DOI 10.1084/jem.20131038; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shoda T, 2016, J ALLERGY CLIN IMMUN, V138, P299, DOI 10.1016/j.jaci.2015.11.042; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Simon D, 2015, ALLERGY, V70, P443, DOI 10.1111/all.12570; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Sonnenberg GF, 2011, IMMUNITY, V34, P122, DOI 10.1016/j.immuni.2010.12.009; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Stier MT, 2016, J ALLERGY CLIN IMMUN, V138, P814, DOI 10.1016/j.jaci.2016.01.050; Takai Toshiro, 2011, Allergology International, V60, P25, DOI 10.2332/allergolint.10-RAI-0273; Takayama T, 2010, GASTROENTEROLOGY, V139, P882, DOI 10.1053/j.gastro.2010.05.040; Tamari M, 2013, ALLERGOL INT, V62, P21, DOI 10.2332/allergolint.13-RAI-0539; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Trautmann A, 2001, J INVEST DERMATOL, V117, P927, DOI 10.1046/j.0022-202x.2001.01474.x; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Vonarbourg C, 2010, IMMUNITY, V33, P736, DOI 10.1016/j.immuni.2010.10.017; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yagi RJ, 2014, IMMUNITY, V40, P378, DOI 10.1016/j.immuni.2014.01.012; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC	133	127	132	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1253	1264		10.1016/j.jaci.2016.09.011	http://dx.doi.org/10.1016/j.jaci.2016.09.011			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27817797	hybrid, Green Accepted			2022-12-18	WOS:000389542700002
J	Santos, AF; Du Toit, G; Douiri, A; Radulovic, S; Stephens, A; Turcanu, V; Lack, G				Santos, Alexandra F.; Du Toit, George; Douiri, Abdel; Radulovic, Suzana; Stephens, Alick; Turcanu, Victor; Lack, Gideon			Distinct parameters of the basophil activation test reflect the severity and threshold of allergic reactions to peanut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophil activation test; peanut; peanut allergy; threshold; severity; sensitivity; CD63; CD203c; CD-sens; double-blind; placebo-controlled food challenge	FOOD CHALLENGES; DOUBLE-BLIND; EUROPEAN ACADEMY; ORAL IMMUNOTHERAPY; ANAPHYLAXIS; IGE; MILK; SENSITIZATION; IMMUNOLOGY; BIOMARKERS	Background: The management of peanut allergy relies on allergen avoidance and epinephrine autoinjector for rescue treatment in patients at risk of anaphylaxis. Biomarkers of severity and threshold of allergic reactions to peanut could significantly improve the care for patients with peanut allergy. Objective: We sought to assess the utility of the basophil activation test (BAT) to predict the severity and threshold of reactivity to peanut during oral food challenges (OFCs). Methods: The severity of the allergic reaction and the threshold dose during OFCs to peanut were determined. Skin prick tests, measurements of specific IgE to peanut and its components, and BATs to peanut were performed on the day of the challenge. Results: Of the 124 children submitted to OFCs to peanut, 52 (median age, 5 years) reacted with clinical symptoms that ranged from mild oral symptoms to anaphylaxis. Severe reactions occurred in 41% of cases, and 57% reacted to 0.1 g or less of peanut protein. The ratio of the percentage of CD63 1 basophils after stimulation with peanut and after stimulation with anti-IgE (CD63 peanut/anti-IgE) was independently associated with severity (P 5.001), whereas the basophil allergen threshold sensitivity CD-sens (1/EC50 3 100, where EC50 is half maximal effective concentration) value was independently associated with the threshold (P 5.020) of allergic reactions to peanut during OFCs. Patients with CD63 peanut/anti-IgE levels of 1.3 or greater had an increased risk of severe reactions (relative risk, 3.4; 95% CI, 1.8-6.2). Patients with a CD-sens value of 84 or greater had an increased risk of reacting to 0.1 g or less of peanut protein (relative risk, 1.9; 95% CI, 1.3-2.8). Conclusions: Basophil reactivity is associated with severity and basophil sensitivity is associated with the threshold of allergic reactions to peanut. CD63 peanut/anti-IgEandCD-sens values can be used to estimate the severity and threshold of allergic reactions during OFCs.	[Santos, Alexandra F.; Du Toit, George; Radulovic, Suzana; Stephens, Alick; Turcanu, Victor; Lack, Gideon] Kings Coll London, Div Asthma Allergy & Lung Biol, Dept Pediat Allergy, London WC2R 2LS, England; [Santos, Alexandra F.; Du Toit, George; Radulovic, Suzana; Stephens, Alick; Turcanu, Victor; Lack, Gideon] MRC & Asthma UK Ctr Allerg Mech Asthma, London, England; [Santos, Alexandra F.] Coimbra Univ Hosp, Immunoallergol Dept, Coimbra, Portugal; [Santos, Alexandra F.] Gulbenkian Programme Adv Med Educ, Lisbon, Portugal; [Douiri, Abdel] Kings Coll London, Sch Med, Dept Publ Hlth Sci, London WC2R 2LS, England; [Douiri, Abdel] Guys & St Thomas NHS Fdn Trust, Biomed Res Ctr, NIHR, London, England	University of London; King's College London; University of London; King's College London; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Lack, G (corresponding author), St Thomas Hosp, Dept Pediat Allergy, 2nd Floor,Stairwell B,SouthWing, London SE1 7EH, England.	gideon.lack@kcl.ac.uk		Douiri, Abdel/0000-0002-4354-4433; Santos, Alexandra/0000-0002-7805-1436; Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021	Medical Research Council [G0902018]; MRC [G0902018] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council (G0902018), Goldman Sachs Gives, and the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's& St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. The clinical trials unit is supported by the National Peanut Board, Atlanta, Ga. The Programme for Advanced Medical Education is sponsored by Fundacao Calouste Gulbenkian, Fundac, ~ ao Champalimaud, Ministerio da Saude and Fundacao para a Ciencia e a Tecnologia, Portugal.	Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Eller E, 2013, ALLERGY, V68, P190, DOI 10.1111/all.12075; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Glaumann S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053465; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Johansson SGO, 2005, ALLERGY, V60, P1192, DOI 10.1111/j.1398-9995.2005.00870.x; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Marrs T, 2013, J ALLERGY CLIN IMMUN, V132, P502, DOI 10.1016/j.jaci.2013.04.040; Mudd K, 2009, J ALLERGY CLIN IMMUN, V124, P1115, DOI 10.1016/j.jaci.2009.08.023; Mueller H L, 1966, J Asthma Res, V3, P331; Muraro A, 2014, ALLERGY, V69, P1026, DOI 10.1111/all.12437; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Patil SU, 2012, CLIN EXP IMMUNOL, V167, P59, DOI 10.1111/j.1365-2249.2011.04503.x; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rubio A, 2011, ALLERGY, V66, P92, DOI 10.1111/j.1398-9995.2010.02432.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Shreffler WG, 2006, CURR OPIN ALLERGY CL, V6, P226, DOI 10.1097/01.all.0000225165.83144.2f; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Ta Von, 2011, Br J Med Med Res, V1, P410; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; van der Zee T, 2011, J ALLERGY CLIN IMMUN, V128, P1031, DOI 10.1016/j.jaci.2011.07.050; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235	39	127	130	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					179	186		10.1016/j.jaci.2014.09.001	http://dx.doi.org/10.1016/j.jaci.2014.09.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25567046	Green Published, hybrid			2022-12-18	WOS:000347298200022
J	Venkataraman, D; Soto-Ramirez, N; Kurukulaaratchy, RJ; Holloway, JW; Karmaus, W; Ewart, SL; Arshad, SH; Erlewyn-Lajeunesse, M				Venkataraman, Devasmitha; Soto-Ramirez, Nelis; Kurukulaaratchy, Ramesh J.; Holloway, John W.; Karmaus, Wilfried; Ewart, Susan L.; Arshad, S. Hasan; Erlewyn-Lajeunesse, Mich			Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; filaggrin; FLG-LOF; food allergen sensitization; path analysis; prediction; eczema	ATOPIC-DERMATITIS; FUNCTION VARIANTS; SKIN BARRIER; RISK-FACTOR; HAY-FEVER; SENSITIZATION; GENE; ECZEMA; ONSET; DISORDERS	Background: Filaggrin is an epidermal protein that has a role in skin barrier function. Filaggrin loss-of-function (FLG-LOF) mutations are a significant risk factor for eczema and atopy, but their association with food allergy (FA) is less clear. Objective: We explored the longitudinal relationship between 3 common FLG-LOF mutations and FA using the Isle of Wight birth cohort. Methods: FA diagnosis was based on recognized allergic reactions within 4 hours after exposure to known food allergens. Food allergen sensitization (FAS) was identified by using skin prick tests conducted between 1 and 18 years of age to a range of food allergens. Three FLG mutations were genotyped in 1150 (79%) of 1456 children. The temporal relationships between FA, FAS, and eczema in children with FLG mutations were explored by using path analysis with total, direct, and indirect effect models. Results: There was a significant total effect of FLG-LOF mutations on the risk of FA in later childhood at the ages of 10 (odds ratio, 31.46; 95% CI, 2.86 to >100) and 18 (odds ratio, 4.25; 95% CI, 1.55-11.61) years. Path analysis showed that there was no direct effect of FLG-LOF mutations on FA at any age; however, an indirect effect was found on FA at all ages through eczema and FAS in the earlier years. Conclusion: FLG-LOF mutations are associated with FA in older children through eczema and FAS during early childhood. Our results highlight a biologically plausible pathway, which suggests that skin barrier function is important in the development and persistence of FA.	[Venkataraman, Devasmitha] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Venkataraman, Devasmitha] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Soto-Ramirez, Nelis; Karmaus, Wilfried] Univ Memphis, Sch Publ Hlth, Div Epidemiol Biostat & Environm Hlth, Memphis, TN 38152 USA; [Kurukulaaratchy, Ramesh J.; Arshad, S. Hasan] David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Isle Of Wight, England; [Kurukulaaratchy, Ramesh J.; Arshad, S. Hasan; Erlewyn-Lajeunesse, Mich] Southampton Univ Hosp, NHS Fdn Trust, Southampton, Hants, England; [Holloway, John W.; Arshad, S. Hasan; Erlewyn-Lajeunesse, Mich] Univ Southampton, Southampton SO9 5NH, Hants, England; [Holloway, John W.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Ewart, Susan L.] Michigan State Univ, Coll Vet Med, E Lansing, MI 48824 USA	University of Southampton; James Cook University Hospital; University of Memphis; University of Southampton; University of Southampton; University of Southampton; Michigan State University	Arshad, SH (corresponding author), David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Isle Of Wight, England.	S.H.Arshad@soton.ac.uk	Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Kurukulaaratchy, Ramesh/0000-0002-1588-2400; Erlewyn-Lajeunesse, Michel/0000-0003-1982-1397	National Institutes of Health [R01-HL082925, R01-AI061471, R01-AI091905]; National Asthma Campaign, UK [364]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061471, R01AI091905] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Asthma Campaign, UK; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health project grants R01-HL082925, R01-AI061471, and R01-AI091905. The 10-year follow-up of this study was funded by the National Asthma Campaign, UK (grant no. 364).	Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hanifin JM, 2009, J INVEST DERMATOL, V129, P320, DOI 10.1038/jid.2008.252; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lleras C., 2005, PATH ANAL ENCY SOCIA, V3; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; Muthen L., 2017, STAT ANAL LATENT VAR, V8th; Niggemann B, 2010, ALLERGY, V65, P2, DOI 10.1111/j.1398-9995.2009.02170.x; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Roberts G, 2012, CLIN EXP ALLERGY, V42, P1501, DOI 10.1111/j.1365-2222.2012.04074.x; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Wood HF., 2000, COMMITTEE TOXICITY C; Ziyab AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032721	31	127	131	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					876	U483		10.1016/j.jaci.2014.07.033	http://dx.doi.org/10.1016/j.jaci.2014.07.033			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25174864	Green Accepted			2022-12-18	WOS:000343155700014
J	Hirota, JA; Hirota, SA; Warner, SM; Stefanowicz, D; Shaheen, F; Beck, PL; MacDonald, JA; Hackett, TL; Sin, DD; Van Eeden, S; Knight, DA				Hirota, Jeremy A.; Hirota, Simon A.; Warner, Stephanie M.; Stefanowicz, Dorota; Shaheen, Furquan; Beck, Paul L.; MacDonald, Justin A.; Hackett, Tillie-Louise; Sin, Don D.; Van Eeden, Stephan; Knight, Darryl A.			The airway epithelium nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome is activated by urban particulate matter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome; particulate matter with mean diameter less than 10 mu m; IL-1 beta; mouse; human; oxidative stress; dendritic cell	DENDRITIC CELLS; OXIDATIVE STRESS; NLRP3 INFLAMMASOME; NALP3 INFLAMMASOME; CUTTING EDGE; POLLUTION; EXPOSURE; RELEASE; LUNG; EXPRESSION	Background: The airway epithelium is the first line of defense against inhaled insults and therefore must be capable of coordinating appropriate inflammatory and immune responses. Objective: We sought to test the hypothesis that the nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inflammasome, an intracellular danger-sensing complex, plays a critical role in airway epithelium-mediated immune responses to urban particulate matter (PM) exposure. Methods: In this study we (1) identified NLRP3 and caspase-1 expression in human airway epithelium bronchus and primary cells, (2) characterized NLRP3 inflammasome-mediated IL-1 beta production from human airway epithelium in response to PM, and (3) performed in vivo PM exposure experiments with wildtype and Nlrp3(-/-) mice. Results: Our results demonstrate that human airway epithelium contains a functional NLRP3 inflammasome that responds to PM exposure with caspase-1 cleavage and production of IL-1 beta. Exposure of Nlrp3(-/-) and wild-type mice to PM in vivo demonstrates NLRP3-dependent production of IL-1 beta in the lung, airway neutrophilia, and increases in CD11c(+hi)/MHC class II+hi cell numbers in intrathoracic lymph nodes. Conclusion: Our study is the first to characterize airway epithelial NLRP3 inflammasome-mediated immune responses to PM exposure, which might have implications in patients with asthma and other lung diseases. (J Allergy Clin Immunol 2012; 129:1116-25.)	[Hirota, Jeremy A.] Univ British Columbia, UBC James Hogg Res Ctr, St Pauls Hosp, Inst Heart & Lung Hlth, Vancouver, BC V6Z 1Y6, Canada; [Hirota, Jeremy A.; Warner, Stephanie M.; Stefanowicz, Dorota; Shaheen, Furquan; Hackett, Tillie-Louise; Sin, Don D.; Van Eeden, Stephan; Knight, Darryl A.] Univ British Columbia, St Pauls Hosp, Inst Heart Lung Hlth, Vancouver, BC V6Z 1Y6, Canada; [Hirota, Jeremy A.; Hackett, Tillie-Louise; Knight, Darryl A.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Div Resp Med, Vancouver, BC V6Z 1Y6, Canada; [Sin, Don D.; Van Eeden, Stephan] Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC V6Z 1Y6, Canada; [MacDonald, Justin A.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Hirota, Simon A.; Beck, Paul L.] Univ Calgary, Gastrointestinal Res Grp, Calgary, AB, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of British Columbia; University of Calgary; University of Calgary	Hirota, JA (corresponding author), Univ British Columbia, UBC James Hogg Res Ctr, St Pauls Hosp, Inst Heart & Lung Hlth, Rm 166,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	Jeremy.Hirota@hli.ubc.ca	Sin, Don/AAC-2219-2021	MacDonald, Justin/0000-0002-9238-8473	CIHR; IMPACT strategic training; AllerGen NCE; CIHR/Canadian Lung Association/GSK; MSFHR; Alberta Health Innovates	CIHR(Canadian Institutes of Health Research (CIHR)); IMPACT strategic training; AllerGen NCE; CIHR/Canadian Lung Association/GSK(Canadian Institutes of Health Research (CIHR)GlaxoSmithKline); MSFHR(Michael Smith Foundation for Health Research); Alberta Health Innovates	J.A.H. is a recipient of CIHR, IMPACT strategic training, and AllerGen NCE postdoctoral training fellowships. D.S. is the Canada Research Chair in Chronic Obstructive Pulmonary Disease and a Michael Smith Foundation for Health Research (MSFHR) Senior Scholar. T.-L.H. is a recipient of a CIHR/Canadian Lung Association/GSK, IMPACT strategic training, and MSFHR postdoctoral fellowship. S.V. is a senior scholar with the MSFHR and CIHR/GSK professor in Chronic Obstructive Pulmonary Disease. D.A.K. is the Canada Research Chair in Airway Disease and an MSFHR career investigator.; S.A. Hirota receives research support from the Canadian Institutes for Health Research and Alberta Health Innovates. The rest of the authors declare that they have no relevant conflicts of interest.	Abdul-Sater AA, 2009, J BIOL CHEM, V284, P26789, DOI 10.1074/jbc.M109.026823; Becker S, 2005, ENVIRON HEALTH PERSP, V113, P1032, DOI 10.1289/ehp.7996; Bleck B, 2008, J CLIN IMMUNOL, V28, P147, DOI 10.1007/s10875-007-9149-0; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Bruske I, 2010, INHAL TOXICOL, V22, P245, DOI 10.3109/08958370903207274; Chen LC, 2009, INHAL TOXICOL, V21, P1, DOI [10.1080/08958370802105405, 10.1080/08958370802105405 ]; Couillin I, 2009, J IMMUNOL, V183, P8195, DOI 10.4049/jimmunol.0803154; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Donaldson K, 2000, Respir Res, V1, P12, DOI 10.1186/rr5; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Fujii T, 2002, AM J RESP CELL MOL, V27, P34, DOI 10.1165/ajrcmb.27.1.4787; Fujii T, 2001, AM J RESP CELL MOL, V25, P265, DOI 10.1165/ajrcmb.25.3.4445; Grabarek Jerzy, 2002, Hum Cell, V15, P1, DOI 10.1111/j.1749-0774.2002.tb00094.x; Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749, DOI 10.1289/ehp.02110749; Hackett TL, 2008, STEM CELLS, V26, P2576, DOI 10.1634/stemcells.2008-0171; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hirota JA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-120; Ishii H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-87; Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010; Kadiiska MB, 1997, CHEM RES TOXICOL, V10, P1104, DOI 10.1021/tx970049r; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6; Kido T, 2011, AM J RESP CELL MOL, V44, P197, DOI 10.1165/rcmb.2009-0427OC; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Li HF, 2009, J IMMUNOL, V183, P1528, DOI 10.4049/jimmunol.0901080; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li N, 2008, FREE RADICAL BIO MED, V44, P1689, DOI 10.1016/j.freeradbiomed.2008.01.028; Li N, 2010, AM J PHYSIOL-LUNG C, V299, pL374, DOI 10.1152/ajplung.00115.2010; Li N, 2009, ENVIRON HEALTH PERSP, V117, P1116, DOI 10.1289/ehp.0800319; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Omara FO, 2000, J TOXICOL ENV HEAL A, V59, P67, DOI 10.1080/009841000156989; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Pope CA, 2009, NEW ENGL J MED, V360, P376, DOI 10.1056/NEJMsa0805646; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Sousa AR, 1996, AM J RESP CRIT CARE, V154, P1061, DOI 10.1164/ajrccm.154.4.8887608; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Vincent R, 1997, AM J PATHOL, V151, P1563; Vincent R, 1997, FUND APPL TOXICOL, V39, P18, DOI 10.1006/faat.1997.2336; von Garnier C, 2005, J IMMUNOL, V175, P1609, DOI 10.4049/jimmunol.175.3.1609; Watanabe H, 2007, J INVEST DERMATOL, V127, P1956, DOI 10.1038/sj.jid.5700819; Wen LP, 1997, AM J PHYSIOL-LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921; Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	56	127	145	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1116	U599		10.1016/j.jaci.2011.11.033	http://dx.doi.org/10.1016/j.jaci.2011.11.033			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22227418	Bronze			2022-12-18	WOS:000302144600028
J	Thomas, B; Rutman, A; Hirst, RA; Haldar, P; Wardlaw, AJ; Bankart, J; Brightling, CE; O'Callaghan, C				Thomas, Biju; Rutman, Andrew; Hirst, Robert A.; Haldar, Pranab; Wardlaw, Andrew J.; Bankart, John; Brightling, Christopher E.; O'Callaghan, Christopher			Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ciliated epithelium; ciliary beat frequency; ciliary beat pattern; ciliary disorientation; ciliary dyskinesia; refractory asthma; severe asthma	MUCOCILIARY CLEARANCE; BEAT PATTERN; MUCUS; EXACERBATIONS; DYSKINESIA; MECHANISM; DIAGNOSIS; POLARITY; ADULTS; SPUTUM	Background: Epithelial dysfunction has been implicated in asthma pathophysiology, but no studies have directly assessed ciliary function in asthma. Objective: To study the ciliary function and epithelial ultrastructure of patients with asthma and healthy controls. Methods: We studied ciliary beat frequency and beat pattern by using digital high-speed video imaging and ultrastructure by transmission electron microscopy of bronchial epithelial strips from 7 subjects with mild, 7 with moderate, and 19 with severe asthma and 9 healthy controls. Results: The median (interquartile range) ciliary beat frequency was decreased in moderate (6.5 [4.4-8.5] Hz) and severe asthma (6.7 [6.1-7.6] Hz) compared with controls (10.5 [9.7-11.8] Hz; P < .01). Dyskinesia and immotility indices were higher in severe asthma (65% [43%-75%]; 6.3% [1%-9.5%], respectively) compared with controls (4% [0%-6.7%; 0%, respectively; P < .01). These abnormalities were related to disease severity (ciliary beat frequency, r(s) = -0.68; dyskinesia index, r(s) = 0.86; immotility index, r(s) = 0.65; P < .0001). The ultrastructure of the epithelium was abnormal in severe asthma with a reduction in ciliated cells, an increase in dead cells, and ciliary disorientation compared with all other groups (P < .05). Compared with patients with mild asthma and healthy controls, patients with severe asthma showed increased ciliary depletion, microtubular defects, mitochondrial damage, and cytoplasmic blebbing (P < .01). All of these changes were related to disease severity. Conclusion: Ciliary dysfunction and ultrastructural abnormalities are closely related to asthma severity. Ciliary dysfunction is a feature of moderate to severe asthma, and profound ultrastructural abnormalities are restricted to severe disease. Whether these changes contribute to the development of severe asthma phenotype remains to be determined. (J Allergy Clin Immunol 2010;126:722-9.)	[O'Callaghan, Christopher] Univ Leicester, Leicester Royal Infirm, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester LE2 7LX, Leics, England	University of Leicester	O'Callaghan, C (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Infect Immun & Inflammat, Inst Lung Hlth, POB 65, Leicester LE2 7LX, Leics, England.	ajb64@le.ac.uk	Hirst, Robert/AAD-1649-2022	brightling, chris/0000-0002-9345-4903; Wardlaw, Andrew/0000-0001-6583-0791; Hirst, Robert Anthony/0000-0003-1989-1790; Haldar, Pranabashis/0000-0002-1572-5421	Wellcome Trust; Asthma UK; GlaxoSmithKline; Pfizer; AstraZeneca; MedImmune	Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); AstraZeneca(AstraZeneca); MedImmune(AstraZenecaMedimmune)	C.E.B. obtained support from the Wellcome Trust, Asthma UK, and GlaxoSmithKline, which funded this study in part. Ciliary function analysis and electron microscopy analysis were performed in C.O.'s laboratory and were not supported by these sources.; Disclosure of potential conflict of interest: A. J. Wardlaw serves on advisory boards for GlaxoSmithKline and receives research support from GlaxoSmithKline, Pfizer, and AstraZeneca. C. E. Brightling serves on advisory boards for GlaxoSmithKline, AstraZeneca, MedImmune, Roche, and Aerovance; receives honoraria from Novartis; and receives research support from GlaxoSmithKline, AstraZeneca, and MedImmune. The rest of the authors have declared that they have no conflict of interest.	Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; BATEMAN JRM, 1983, THORAX, V38, P463, DOI 10.1136/thx.38.6.463; Bloodgood RA, 2010, J CELL SCI, V123, P505, DOI 10.1242/jcs.066308; BOISVIEUXULRICH E, 1991, BIOL CELL, V72, P3, DOI 10.1016/0248-4900(91)90072-U; Bush A, 1998, EUR RESPIR J, V12, P982, DOI 10.1183/09031936.98.12040982; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chilvers MA, 2000, THORAX, V55, P314, DOI 10.1136/thorax.55.4.314; Chilvers MA, 2003, J ALLERGY CLIN IMMUN, V112, P518, DOI 10.1067/mai.2003.1701; Chilvers MA, 2001, EUR RESPIR J, V18, P965, DOI 10.1183/09031936.01.00093001; Danahay H, 2002, AM J PHYSIOL-LUNG C, V282, pL226, DOI 10.1152/ajplung.00311.2001; Del Donno M, 2000, CHEST, V118, P1142, DOI 10.1378/chest.118.4.1142; DULFANO MJ, 1982, THORAX, V37, P646, DOI 10.1136/thx.37.9.646; GINA, 2008, GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; GREENSTONE M, 1988, Q J MED, V67, P405; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Hasani A, 2003, RESP MED, V97, P667, DOI 10.1053/rmed.2003.1498; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P848, DOI 10.1164/arrd.1987.135.4.848; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; Holgate Stephen T, 2008, Allergol Int, V57, P1, DOI 10.2332/allergolint.R-07-154; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Honeybourne D, 2001, THORAX, V56, pI1; IP MSM, 1992, EUR RESPIR J, V5, P418; Joki S, 1996, PULM PHARMACOL THER, V9, P231, DOI 10.1006/pulp.1996.0029; Juniper E, 1994, HISTAMINE METHACHOLI; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; MESSINA MS, 1991, AM REV RESPIR DIS, V143, P993, DOI 10.1164/ajrccm/143.5_Pt_1.993; Mitchell B, 2007, NATURE, V447, P97, DOI 10.1038/nature05771; MONTEFORT S, 1993, RESP MED, V87, P9, DOI 10.1016/0954-6111(93)90118-J; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Partridge MR, 2007, EUR RESPIR REV, V16, P67, DOI 10.1183/09059180.00010402; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rogers DF, 2004, CURR OPIN PHARMACOL, V4, P241, DOI 10.1016/j.coph.2004.01.011; RUTMAN A, 1993, THORAX, V48, P770, DOI 10.1136/thx.48.7.770; SEYBOLD ZV, 1990, J APPL PHYSIOL, V68, P1421, DOI 10.1152/jappl.1990.68.4.1421; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; SMALLMAN LA, 1984, LANCET, V1, P965; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; TSANG KWT, 1994, EUR RESPIR J, V7, P1746, DOI 10.1183/09031936.94.07101746; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; YATES GT, 1980, BIORHEOLOGY, V17, P151	45	127	130	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					722	U85		10.1016/j.jaci.2010.05.046	http://dx.doi.org/10.1016/j.jaci.2010.05.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20673980				2022-12-18	WOS:000282510000005
J	Janson, SL; McGrath, KW; Covington, JK; Cheng, SC; Boushey, HA				Janson, Susan L.; McGrath, Kelly Wong; Covington, Jack K.; Cheng, Su-Chun; Boushey, Homer A.			Individualized asthma self-management improves medication adherence and markers of asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; self-management; adherence; asthma control	PEAK EXPIRATORY FLOW; QUALITY-OF-LIFE; ADULT ASTHMA; INHALED CORTICOSTEROIDS; EDUCATION-PROGRAM; RANDOMIZED TRIAL; EFFICACY; OUTCOMES; NURSE	Background: Adherence to inhaled anti-inflammatory therapy and self-management skills are essential parts of the asthma treatment plan to improve asthma control and prevent exacerbations. Whether self-management education improves long-term medication adherence is less clear. Objective: A 24-week prospective, randomized controlled trial was performed to study the effect of self-management education on long-term adherence to inhaled corticosteroid (ICS) therapy and markers of asthma control. Methods: After stabilization on ICS medication during a run-in phase, 95 adults with moderate-to-severe asthma were recruited from a large metropolitan community, and 84 were randomized to individualized self-management education, including self-monitoring of symptoms and peak flow or usual care with self-monitoring alone. The key components of the 30-minute intervention were asthma information, assessment, and correction of inhaler technique; an individualized action plan based on self-monitoring data; and environmental control strategies for relevant allergen and irritant exposures. The intervention was personalized based on pulmonary function, allergen skin test reactivity, and inhaler technique and reinforced at 2-week intervals. Results: Participants randomized to the self-management intervention maintained consistently higher ICS adherence levels and showed a 9-fold greater odds of more than 60% adherence to the prescribed dose compared with control subjects at the end of the intervention (P = .02) and maintained a 3-fold greater odds of higher than 60% adherence at the end of the study. Perceived control of asthma improved (P = .006), nighttime awakenings decreased (P = .03), and inhaled beta-agonist use decreased (P = .01) in intervention participants compared with control subjects. Conclusion: Our results show that individualized asthma self-management education attenuates the usual decrease in medication adherence and improves clinical markers of asthma control. (J Allergy Clin Immunol 2009;123:840-6.)	[Janson, Susan L.; McGrath, Kelly Wong; Covington, Jack K.] Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA 94143 USA; [Janson, Susan L.; Boushey, Homer A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Cheng, Su-Chun] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Janson, SL (corresponding author), Univ Calif San Francisco, Dept Community Hlth Syst, 2 Koret Way,5th Floor,N505, San Francisco, CA 94143 USA.	Susan.Janson@nursing.ucsf.edu		Wong McGrath, Kelly/0000-0001-6542-4611	National Institutes of Health [R01HL64586]; GlaxoSmithKline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064586] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a grant from the National Institutes of Health (National Institutes of Health/National Heart, Lung, and Blood Institute R01HL64586) and unrestricted donations from GlaxoSmithKline (Donation of Flovent Inhalation Aerosol).	BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; Bonner S, 2002, J ASTHMA, V39, P167, DOI 10.1081/JAS-120002198; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Cote J, 1997, AM J RESP CRIT CARE, V155, P1509, DOI 10.1164/ajrccm.155.5.9154850; Couturaud F, 2002, J ASTHMA, V39, P493, DOI 10.1081/JAS-120004913; De Smet BD, 2006, ANN PHARMACOTHER, V40, P414, DOI 10.1345/aph.1G475; Gallefoss F, 1999, AM J RESP CRIT CARE, V160, P2000, DOI 10.1164/ajrccm.160.6.9901028; GIBSON PG, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001117; Gillissen A, 2007, J PHYSIOL PHARMACOL, V58, P205; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; Janson S, 2001, HEART LUNG, V30, P39, DOI 10.1067/mhl.2001.110290; Janson SL, 2003, AM J MED, V115, P620, DOI 10.1016/j.amjmed.2003.07.008; JANSONBJERKLIE S, 1993, RES NURS HEALTH, V16, P241, DOI 10.1002/nur.4770160403; JANSONBJERKLIE S, 1988, HEART LUNG, V17, P543; Katz PP, 2002, ANN ALLERG ASTHMA IM, V89, P251, DOI 10.1016/S1081-1206(10)61951-5; Kochanek Kenneth D., 2004, NATL VITAL STAT REPO, V53, P1; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; Kotses H, 1996, J ASTHMA, V33, P113, DOI 10.3109/02770909609054539; LETHBRIDGECEJKU M, 2002, VITAL HLTH STAT, V10, P1; Lopez-Vina A, 2000, RESP MED, V94, P760, DOI 10.1053/rmed.2000.0815; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Morice AH, 2001, RESP MED, V95, P851, DOI 10.1053/rmed.2001.1166; *NAEPP, 2002, NAEPP EXP PAN REP GU; *NAT HEART LUNG BL, 2007, NAEPP EXP PAN REP GU; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-1291OC; Popa V, 2001, AM J RESP CRIT CARE, V163, P292, DOI 10.1164/ajrccm.163.1.16310b; Powell H, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004107; Ryan P, 2002, J NURS SCHOLARSHIP, V34, P331, DOI 10.1111/j.1547-5069.2002.00331.x; Schaffer Susan D, 2004, Clin Nurs Res, V13, P69, DOI 10.1177/1054773803259300; Simmons MS, 1998, J ALLERGY CLIN IMMUN, V102, P409, DOI 10.1016/S0091-6749(98)70128-9; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5	36	127	129	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					840	846		10.1016/j.jaci.2009.01.053	http://dx.doi.org/10.1016/j.jaci.2009.01.053			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348923	Green Accepted			2022-12-18	WOS:000265058600009
J	Komata, T; Soderstrom, L; Borres, MP; Tachimoto, H; Ebisawa, M				Komata, Takatsugu; Soderstrom, Lars; Borres, Magnus P.; Tachimoto, Hiroshi; Ebisawa, Motohiro			The predictive relationship of food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOGLOBULIN-E LEVELS; ALLERGY		Sagamihara Natl Hosp, Dept Pediat, Kanagawa, Japan; Jikei Univ, Sch Med, Dept Pediat, Tokyo, Japan; Phadia AB, Uppsala, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden; Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan	Jikei University; Thermo Fisher Scientific; Phadia; University of Gothenburg	Komata, T (corresponding author), Sagamihara Natl Hosp, Dept Pediat, Kanagawa, Japan.	m-ebisawa@sagamihara-hosp.gr.jp		Soderstrom, Lars/0000-0002-6474-6501; Ebisawa, Motohiro/0000-0003-4117-558X				Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Ikematsu Kaori, 2006, Arerugi, V55, P533; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708	8	127	137	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1272	1274		10.1016/j.jaci.2007.01.038	http://dx.doi.org/10.1016/j.jaci.2007.01.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17337292				2022-12-18	WOS:000246427200034
J	Eddleston, J; Herschbach, J; Wagelie-Steffen, AL; Christiansen, SC; Zuraw, BL				Eddleston, Jane; Herschbach, Jack; Wagelie-Steffen, Amy L.; Christiansen, Sandra C.; Zuraw, Bruce L.			The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoid-induced leucine zipper; cytokines; inflammation; epithelial cell; corticosteroid; nuclear factor kappa B	NF-KAPPA-B; TRANSCRIPTION FACTOR; AIRWAY INFLAMMATION; ASTHMA; ACTIVATION; INHIBITION; EXPRESSION; GILZ; HYPERRESPONSIVENESS; INTERLEUKIN-8	Background: Nuclear factor kappa B (NF-kappa B) plays a key role in the pathogenesis of asthma, being linked to the production of inflammatory cytokines that drive inflammation. A recently described anti-inflammatory protein, glucocorticoid-induced leucine zipper (GILZ), interferes with NF-kappa B-mediated gene transcription in T cells and macrophages. Objective: We sought to analyze the regulation of GILZ expression in airway epithelial cells and determine whether GILZ mediates part of the anti-inflammatory effect of corticosteroids. Methods: GILZ expression was assessed by means of PCR and immunoblotting in human epithelial cells at baseline and after stimulation with dexamethasone or cytokines (IL-1 beta, TNF-alpha, and IFN-gamma). The effect of GILZ on LPS-, IL-1 beta-, and polyinosinic:polycytidylic acid-induced NF-kappa B activation was assessed in BEAS-2B cells overexpressing GILZ. The requirement for GILZ in the inhibitory action of dexamethasone was assessed by knocking down GILZ expression by means of small interfering RNA (siRNA) technology. Results: GILZ is constitutively expressed by human airway epithelial cells, and its levels are increased by dexamethasone and decreased by inflammatory cytokines. Overexpression of GILZ in BEAS-2B cells significantly inhibited the ability of IL-1 beta, LPS, and polyinosinic:polycytidylic acid to activate NF-kappa B, whereas knockdown of GILZ inhibited the ability of dexamethasone to suppress IL-1 beta-induced chemokine expression. Conclusion: This study demonstrates the expression of GILZ in human airway epithelial cells, its induction by dexamethasone, its suppression by inflammatory cytokines, and its role in mediating the anti-inflammatory effects of dexamethasone. Clinical implications: Therapeutic upregulation of GILZ may be a novel strategy for the treatment of asthma.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Med Res Fdn, La Jolla, CA USA; Kaiser Permanente, Dept Allergy, San Diego, CA USA	University of California System; University of California San Diego; Veterans Medical Research Foundation; Kaiser Permanente	Eddleston, J (corresponding author), Univ Calif San Diego, Dept Med, Mail Drop 0732,9500 Gilman Dr, La Jolla, CA 92093 USA.	jeddleston@vapop.ucsd.edu		Zuraw, Bruce/0000-0003-0640-6768	NIAID NIH HHS [AI50498] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050498] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adcock Ian M, 2004, Proc Am Thorac Soc, V1, P247, DOI 10.1513/pats.200402-001MS; ADCOCK IM, 1995, AM J PHYSIOL, V268, P331; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BECKER S, 1994, AM J PHYSIOL, V266, P278; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Chen LY, 2003, AM J PHYSIOL-LUNG C, V284, pL607, DOI 10.1152/ajplung.00116.2002; Christiansen SC, 2002, J IMMUNOL, V169, P2054, DOI 10.4049/jimmunol.169.4.2054; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; Cohen N, 2006, BLOOD, V107, P2037, DOI 10.1182/blood-2005-07-2760; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; DAMADIO F, 1997, IMMUNITY, V7, P803; Donovan CE, 1999, J IMMUNOL, V163, P6827; Eddleston J, 2002, J IMMUNOL, V169, P6445, DOI 10.4049/jimmunol.169.11.6445; Edwards MR, 2005, PULM PHARMACOL THER, V18, P337, DOI 10.1016/j.pupt.2004.12.015; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Poynter ME, 2004, J IMMUNOL, V173, P7003, DOI 10.4049/jimmunol.173.11.7003; Sandlow JI, 2000, POSTGRAD MED, V107, P235, DOI 10.3810/pgm.2000.02.902; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Schwiebert LA, 1996, J ALLERGY CLIN IMMUN, V97, P143, DOI 10.1016/S0091-6749(96)80214-4; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16; VANDERSAAG PT, 1996, EUR RESPIR J, V22, P146; Wilson SJ, 2001, AM J RESP CRIT CARE, V164, P1047, DOI 10.1164/ajrccm.164.6.2010045; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	33	127	132	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					115	122		10.1016/j.jaci.2006.08.027	http://dx.doi.org/10.1016/j.jaci.2006.08.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208592				2022-12-18	WOS:000243622200017
J	Johnston, NW; Johnston, SL; Norman, GR; Dai, J; Sears, MR				Johnston, NW; Johnston, SL; Norman, GR; Dai, J; Sears, MR			The September epidemic of asthma hospitalization: School children as disease vectors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma exacerbations; school return; rhinovirus; hospitalization; transmission of infection; asthma control	RESPIRATORY-INFECTIONS; RHINOVIRUS INFECTIONS; INDUSTRIAL POPULATION; EMERGENCY-DEPARTMENT; ADMISSIONS; ILLNESS; AEROALLERGENS; COMMUNITY; CANADA; VISITS	Background: Viral infections are associated with the majority of asthma exacerbations in children and adults. Increased asthma hospitalization rates of children and adults, particularly in the early fall, have been observed to follow school vacations. Objective: We sought to determine the sequence of timing of September asthma hospitalization epidemics in children and adults and to determine whether school-age children are the primary source of transmission of agents that cause them. Methods: By using Canadian asthma hospital admission data from 1990 to 2002, we examined geographic variation in the timing of fall asthma epidemics and applied mathematical modeling to estimate their exact timing and magnitude in school-age children, preschool children, and adults, and relation to school return. Results: The September asthma hospitalization epidemic peak occurred in school-age children each year on average 17.7 (95% Cl, 16.8-18.5) days after Labor Day. Similar epidemics of lesser magnitude were observed in preschool children peaking 1.7 (95% CI, 0.9-2.5; P <.001) days later, and in adults 6.3 (95% Cl, 4.7-7.9; P <.001) days later than in school-age children. The epidemics peaked 4.2 (95% CI, 1.2-7.1; P <.001) days earlier in school-age children in northernmost compared with southernmost latitudes. Conclusion: September epidemics of asthma hospitalizations in Canada have a precise relationship to school return after the summer vacation. It may be speculated that school-age children transmit the agents responsible for the epidemic to adults. Measures to improve asthma control and reduce transmission of infections should he directed at children with asthma before school return.	St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Natl Heart & Lung Inst, Imperial Coll London, Dept Resp Med, London, England	McMaster University; McMaster University; Imperial College London	Johnston, NW (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	njohnsto@sympatico.ca	Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; *CAN I HLTH INF, 2002, DISHC ABSTR DAT DAT; COME JM, 2002, LANCET, V359, P831; Crighton EJ, 2001, BMC HEALTH SERV RES, V1, DOI 10.1186/1472-6963-1-7; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; GANY BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563; Gern JE, 1999, CLIN MICROBIOL REV, V12, P9, DOI 10.1128/CMR.12.1.9; Gern JE, 2002, AM J MED, V112, p19S; GREEN RM, 2002, BMJ-BRIT MED J, V324, P1126; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; Harju T, 1997, EUR J PEDIATR, V156, P436, DOI 10.1007/s004310050632; HENDLEY JO, 1969, AM J EPIDEMIOL, V89, P184, DOI 10.1093/oxfordjournals.aje.a120928; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON NW, 2002, AM J RESP CRIT CARE, V165, pA489; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kimes D, 2004, ENVIRON RES, V94, P7, DOI 10.1016/S0013-9351(03)00046-X; LONGINI IM, 1984, INT J EPIDEMIOL, V13, P99, DOI 10.1093/ije/13.1.99; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; Monteil MA, 2000, J ASTHMA, V37, P677, DOI 10.3109/02770900009087306; Monto AS, 2002, AM J MED, V112, p4S; POTTER PC, 1984, S AFR MED J, V66, P397; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Silverman RA, 2005, ARCH PEDIAT ADOL MED, V159, P818, DOI 10.1001/archpedi.159.9.818; *STAT CAN SPEC SUR, NAT LONG SURV CHILDR; STRACHAN D, 1999, COLLATION COMP DATA; Taskinen T, 1999, ACTA PAEDIATR, V88, P1373, DOI 10.1080/080352599750030112; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33, DOI 10.1111/j.1746-1561.2002.tb06509.x; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323	34	127	130	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					557	562		10.1016/j.jaci.2005.11.034	http://dx.doi.org/10.1016/j.jaci.2005.11.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522453				2022-12-18	WOS:000236263100009
J	Clark, S; Long, AA; Gaeta, TJ; Camargo, CA				Clark, S; Long, AA; Gaeta, TJ; Camargo, CA			Multicenter study of emergency department visits for insect sting allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						insect sting allergy; emergency department; epinephrine; referral to allergist	UNITED-STATES; ANAPHYLAXIS; EPIDEMIOLOGY; HYPERSENSITIVITY; HYMENOPTERA; MANAGEMENT; SENSITIVITY; POPULATION; SEVERITY; DISEASE	Background: An earlier study of food-related anaphylaxis in the emergency department (ED) suggested low concordance with national guidelines for anaphylaxis management. Objective: To extend these findings, we performed a chart review study to describe current ED management of insect sting allergy. Methods: The Multicenter Airway Research Collaboration performed a chart review study in 15 North American EDs. Investigators reviewed 617 charts of patients with insect sting allergy. Patients were identified by using International Classification of Diseases, 9th Revision, codes 989.5 (toxic effect of venom), 995.0 (other anaphylactic shock), and 995.3 (allergy, unspecified). Results: The cohort was 42% female and 61% white, with a mean age of 36 +/- 19 years. In this cohort, 58% had local reactions, 11% had mild systemic reactions, and 31% had anaphylactic reactions, as defined by multisystem organ involvement or hypotension. Among patients with systemic reactions (mild or anaphylaxis), most (75%) were stung within 6 hours of ED arrival. While in the ED, 69% of systemic reaction patients received antihistamines, 50% systemic corticosteroids, and 12% epinephrine. Almost all systemic reaction patients (95%) were discharged to home. At ED discharge, 27% (95% CI, 22% to 33%) of systemic reaction patients received a prescription for self-injectable epinephrine. Only 20% (95% CI, 15% to 26%) had documentation of referral to an allergist. Conclusions: Although guidelines suggest specific approaches for the emergency management of insect sting allergy, concordance with these guidelines appears low in patients with a severe insect sting reaction.	Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Rheumatol Allergy & Immunol, Boston, MA 02114 USA; New York Methodist Hosp, Dept Emergency Med, Brooklyn, NY USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Clark, S (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	sclark3@partners.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI052338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007069] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52338] Funding Source: Medline; NIEHS NIH HHS [T32 ES07069] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; *CACI, 2000, SOURC ZIP COD DEM; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; GAETA TJ, 2001, ACAD EMERG MED, V8, P449; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; HERBERT FA, 1982, ANN ALLERGY, V48, P12; *HLTH CAN, 1996, FED CAUS DAT STAT CA; Hosmer DW, 1989, APPL LOGISTIC REGRES; Jerrard DA, 1996, AM J EMERG MED, V14, P429, DOI 10.1016/S0735-6757(96)90067-4; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; Matasar MJ, 2003, CURR ALLERGY ASTHM R, V3, P30, DOI 10.1007/s11882-003-0007-8; McDougle Leon, 1995, Journal of Emergency Medicine, V13, P9, DOI 10.1016/0736-4679(94)00105-7; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; O'Brien J, 2000, EMERG MED PRACT, V2, P1; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SCHWARTZ HJ, 1995, ALLERGY PROC, V16, P247, DOI 10.2500/108854195778702639; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P118, DOI 10.1016/j.jaci.2004.03.056; *STATA, 1985, STATA REF MAN; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859, DOI 10.1093/qjmed/89.11.859; VALENTINE MD, 1992, JAMA-J AM MED ASSOC, V268, P2830, DOI 10.1001/jama.268.20.2830; YOCUM MW, 1996, MED PRACTICING PHYS	30	127	130	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					643	649		10.1016/j.jaci.2005.06.026	http://dx.doi.org/10.1016/j.jaci.2005.06.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159637				2022-12-18	WOS:000235686500027
J	Reisinger, J; Horak, F; Pauli, G; van Hage, M; Cromwell, O; Konig, F; Valenta, R; Niederberger, V				Reisinger, J; Horak, F; Pauli, G; van Hage, M; Cromwell, O; Konig, F; Valenta, R; Niederberger, V			Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen-specific immunotherapy; IgG antibodies; genetically modified allergens; nasal provocation	BIRCH POLLEN ALLERGEN; BET V 1; FRAGMENTS; DERIVATIVES; RESPONSES; FUTURE; TRIMER; TEARS	Background: We have performed a double-blind, placebo-controlled injection immunotherapy study with genetically modified derivatives of the major birch pollen allergen, Bet v 1 (Bet v 1-trimer, Bet v 1-fragments). Objective: To investigate whether vaccination with genetically modified allergens induces allergen-specific antibodies in nasal secretions and to study whether these antibodies affect nasal allergen sensitivity. Methods: A randomly picked subgroup of patients (n = 23; placebo, n = 10; trimer, n = 10; fragments, n = 3) was subjected to an extensive analysis of serum samples and nasal lavage fluids and to nasal provocation testing. Bet v 1-specific IgG(1-4) and IgA antibodies were determined in serum samples obtained before and after vaccination, after the birch pollen season, and 1 year after start of vaccination as well as in nasal lavage fluids obtained after the birch pollen season and 1 year after start of vaccination by ELISA. Nasal sensitivity to natural, birch pollen-derived Bet v 1 was determined by active anterior rhinomanometry after the birch pollen season and 1 year after start of vaccination. Results: Vaccination with genetically modified Bet v 1 derivatives, but not with placebo, induced Bet v 1-specific IgG(1), IgG(2), and IgG(4), and low IgA antibodies in serum, which also appeared in nasal secretions, but no IgG(3) antibodies. The levels of therapy-induced Bet v 1-specific IgG4 antibodies in nasal secretions were significantly (P < .05) associated with reduced nasal sensitivity to natural, birch pollen-derived Bet v 1 as objectively determined by controlled nasal provocation experiments. Conclusion: Our data demonstrate that vaccination with genetically modified allergens induces IgG antibody responses against the corresponding natural allergen not only in serum but also in mucosal fluids, where they may protect against allergen-induced inflammation.	Univ Vienna, AKH, Vienna Gen Hosp, Dept Otorhinolaryngol, A-1090 Vienna, Austria; Vienna Gen Hosp, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Med Stat, Vienna, Austria; Karolinska Hosp & Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; Hop Univ Strasbourg, Serv Pneumol, Strasbourg, France; Allergopharma Joachim Ganzer KG, Reinbek, Germany	University of Vienna; University of Vienna; Karolinska Institutet; Karolinska University Hospital; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Allergopharma	Niederberger, V (corresponding author), Univ Vienna, AKH, Vienna Gen Hosp, Dept Otorhinolaryngol, Waehringer Guertel 18, A-1090 Vienna, Austria.	Niederberger@meduniwien.ac.at	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Valenta, Rudolf/0000-0001-5944-3365; Konig, Franz/0000-0002-6893-3304				Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; CLINTON PM, 1989, INT ARCH ALLER A IMM, V89, P43, DOI 10.1159/000234921; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; Drew AC, 2004, J IMMUNOL, V173, P5872, DOI 10.4049/jimmunol.173.9.5872; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128, DOI 10.1159/000237525; Ferreira F, 2002, INT ARCH ALLERGY IMM, V128, P171, DOI 10.1159/000064249; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; HoffmannSommergruber K, 1996, CLIN EXP ALLERGY, V26, P79, DOI 10.1111/j.1365-2222.1996.tb00059.x; Mahler V, 2004, CLIN EXP ALLERGY, V34, P115, DOI 10.1111/j.1365-2222.2004.01857.x; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Singh MB, 1999, INT ARCH ALLERGY IMM, V119, P75, DOI 10.1159/000024181; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969, DOI 10.1016/S0091-6749(99)70077-1; Vrtala S, 2000, J IMMUNOL, V165, P6653, DOI 10.4049/jimmunol.165.11.6653; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Vrtala S, 2004, METHODS, V32, P313, DOI 10.1016/j.ymeth.2003.08.016; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0	26	127	133	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					347	354		10.1016/j.jaci.2005.04.003	http://dx.doi.org/10.1016/j.jaci.2005.04.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083789				2022-12-18	WOS:000235686400017
J	Hamilton, RG; Adkinson, NF				Hamilton, RG; Adkinson, NF			In vitro assays for the diagnosis of IgE-mediated disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IgE antibody; diagnosis; serologic assays; basophil; histamine; sulfidoleukotriene; CD63; CD203c; allergy	BASOPHIL HISTAMINE-RELEASE; ALLERGEN-SPECIFIC IGE; RADIOALLERGOSORBENT TEST; CLINICAL-EVALUATION; CD63 EXPRESSION; ACTIVATION TEST; ANTIBODIES; CHILDREN; RAST; INTERLEUKIN-3	Advances in technology have provided new laboratory tools for the quantitation of allergen-specific IgE antibodies in serum and on the surface of basophils. This review examines the evolution from qualitative IgE antibody assays of the late 1960s to the present-day, third-generation, automated and quantitative allergen-specific IgE assays. The latest technology trend is toward microarrays in which crude or purified native and recombinant allergens can be spotted in microdot arrays on silica chips to permit extensive panels of specific IgE measurements to be performed with small quantities of serum. Although these technologies hold promise, their diagnostic performance requires further assessment once their technical details have been optimized. Potential abuses of this newer IgE antibody technology include the use of allergosorbent specificities (eg, especially food and drugs) that lack validation, application of IgE antibody measurements in the diagnosis of non-IgE-dependent disorders (eg, aspirin sensitivity), and modification of IgE antibody assays to measure food-specific IgG antibody for which there is no clinical indication. Basophil mediator release assays have evolved to include flow cytometric methods that can quantitatively detect the presence of cell surface-bound allergen-specific IgE antibodies. Assays for histamine and leukotriene C-4 released after in vitro basophil activation are now more accurate and standardized. Current analytic methods for IgE antibodies provide more quantitative and reproducible measurements of IgE than ever before, although still with less sensitivity that traditional skin testing. The current challenge is to translate the quantitative IgE antibody results into a more accurate diagnosis of allergic disease.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA	Johns Hopkins University	Hamilton, RG (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							ADKINSON NF, 1980, J ALLERGY CLIN IMMUN, V65, P1, DOI 10.1016/0091-6749(80)90169-4; ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; ADKINSON NF, 1983, ALLERGY PRINCIPLES P, pCH3; BARINAGA M, 1991, SCIENCE, V253, P1489, DOI 10.1126/science.1896858; BENNICH H, 1969, J IMMUNOL, V102, P826; Bernstein DI, 2003, J ALLERGY CLIN IMMUN, V111, P610, DOI 10.1067/mai.2003.164; Bochner BS, 1997, METHODS, V13, P61, DOI 10.1006/meth.1997.0497; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Boumiza R, 2003, CLIN EXP ALLERGY, V33, P259, DOI 10.1046/j.1365-2222.2003.01594.x; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Butler J. E., 1991, IMMUNOCHEMISTRY SOLI; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; *COLL AM PATH SE D, 2004, ALL PROF SURV PART S; Cozon G, 1999, Allergol Immunopathol (Madr), V27, P182; Crockard AD, 2001, CLIN EXP ALLERGY, V31, P345, DOI 10.1046/j.1365-2222.2001.01043.x; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; Demoly P, 1999, ALLERGY, V54, P500, DOI 10.1034/j.1398-9995.1999.00020.x; Demoly P, 2003, ALLERGY, V58, P553, DOI 10.1034/j.1398-9995.2003.00253.x; DEWECK AL, 1993, ACI NEWS, V1, P9; Ebo DG, 2004, CLIN EXP ALLERGY, V34, P332, DOI 10.1111/j.1365-2222.2004.01891.x; Ebo DG, 2002, ALLERGY, V57, P706, DOI 10.1034/j.1398-9995.2002.23553.x; Eigenmann PA, 2000, PEDIATR ALLERGY IMMU, V11, P95, DOI 10.1034/j.1399-3038.2000.00071.x; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; GRIESE M, 1990, ANN ALLERGY, V65, P46; Hamilton RG, 2003, J ALLERGY CLIN IMMUN, V111, P1414, DOI 10.1067/mai.2003.1520; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V86, P353, DOI 10.1016/S1081-1206(10)62477-5; HAMILTON RG, 2003, J ALLERGY CLIN IMM S, V11, pS174; HAMILTON RG, 2004, IN PRESS CURR OPIN A; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Iwamoto I, 1990, Arerugi, V39, P1374; Jahn-Schmid B, 2003, CLIN EXP ALLERGY, V33, P1443, DOI 10.1046/j.1365-2222.2003.01784.x; Kim TE, 2002, EXP MOL MED, V34, P152, DOI 10.1038/emm.2002.22; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; Li TM, 2004, ANN CLIN LAB SCI, V34, P67; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; Malkin R, 1998, ENVIRON RES, V76, P85, DOI 10.1006/enrs.1997.3800; Maly FE, 1997, J INVEST ALLERG CLIN, V7, P217; MATSSON P, 1997, EVALUATION METHODS A; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Miadonna A, 1996, ALLERGY, V51, P525; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; NALEBUFF DJ, 1979, CONT ED FAM PHYSICIA, V10, P64; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; NOLTE H, 1993, ALLERGY PROC, V14, P251, DOI 10.2500/108854193778812017; OSTERGAARD PA, 1990, ALLERGY, V45, P231, DOI 10.1111/j.1398-9995.1990.tb00488.x; OWNBY DR, 1994, EUR J CLIN CHEM CLIN, V32, P631; Paganelli R, 1998, ALLERGY, V53, P763; PERRICK D, 1991, J ALLERGY CLIN IMMUN, V87, P98, DOI 10.1016/0091-6749(91)90218-D; Platz IJ, 2001, INT ARCH ALLERGY IMM, V126, P335, DOI 10.1159/000049531; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; Soderstrom L, 2003, ALLERGY, V58, P921, DOI 10.1034/j.1398-9995.2003.00227.x; VAUTRIN DAM, 1993, ANN ALLERGY, V71, P107; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; WIDE L, 1967, LANCET, V2, P1105; WILLIAMS PB, 1992, ANN ALLERGY, V69, P48; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; Williams PB, 2003, ANN ALLERG ASTHMA IM, V91, P26; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041	64	127	135	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					213	225		10.1016/j.jaci.2004.06.046	http://dx.doi.org/10.1016/j.jaci.2004.06.046			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316492				2022-12-18	WOS:000223405600001
J	Weber, RW				Weber, RW			Patterns of pollen cross-allergenicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergen; cross-reactivity; immunotherapy; pollen; taxonomy; protein	SHORT RAGWEED POLLEN; BERMUDA GRASS-POLLEN; GROUP-I ALLERGENS; PLANTAIN PLANTAGO-LANCEOLATA; DIFFERENT DECIDUOUS TREES; GROUP-V ALLERGENS; OLE-E-I; MAJOR ALLERGEN; BIRCH-POLLEN; MONOCLONAL-ANTIBODIES	Knowledge of patterns of pollen cross-reactivity is crucial for diagnostics and especially for formulation of immunotherapy vaccines in times of diminishing availability of pollen extract constituents. As phylogenetic relationships have become better clarified, it becomes apparent that cross-reactivity does reflect taxonomy in the very great majority of cases. Contradictory observations of unexpected cross-reactivity between unrelated plants, sometimes remarkably distant ones, require explanation. There are many proteins, presumably performing vital functions, that are tightly preserved throughout the evolutionary tree from plants to animals, such as profilins, lipid transfer proteins, and pathogenesis-related proteins. These might function as panallergens. The small differences that exist between these ubiquitous proteins explain why these are frequently minor allergens not reacting in the majority of allergic sera. This review summarizes cross-reactivity studies with both crude pollen extracts and purified or recombinant allergenic proteins. The patterns of cross-allergenicity that emerge should be helpful in guiding both diagnostic and therapeutic decisions.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Weber, RW (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Alisi C, 2001, ALLERGY, V56, P978, DOI 10.1034/j.1398-9995.2001.00125.x; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Asturias JA, 1997, CLIN EXP ALLERGY, V27, P1307, DOI 10.1111/j.1365-2222.1997.tb01176.x; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; BALDO BA, 1982, INT ARCH ALLER A IMM, V68, P295, DOI 10.1159/000233117; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; Barderas R, 2002, INT ARCH ALLERGY IMM, V127, P47, DOI 10.1159/000048168; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNTON HS, 1924, JAMA-J AM MED ASSOC, V82, P1434; BOND JF, 1991, J IMMUNOL, V146, P3380; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BRANDYS J, 1993, PLANTA MED, V59, P221, DOI 10.1055/s-2006-959656; Brown A, 1927, J IMMUNOL, V13, P73; Calabozo B., 2002, Clinical and Experimental Allergy, V32, P1628, DOI 10.1046/j.1365-2222.2002.01530.x; Chang Z. N., 1994, Journal of Biomedical Science, V1, P93, DOI 10.1007/BF02257982; CORNFORD CA, 1990, INT ARCH ALLER A IMM, V93, P41, DOI 10.1159/000235277; COULTER KM, 1987, MOL IMMUNOL, V24, P1207, DOI 10.1016/0161-5890(87)90167-2; CROMWELL H. W., 1933, JOUR ALLERGY, V4, P347, DOI 10.1016/S0021-8707(33)90023-4; DELAHOZ F, 1990, MOL IMMUNOL, V27, P651, DOI 10.1016/0161-5890(90)90008-N; Di Felice G, 2001, INT ARCH ALLERGY IMM, V125, P280, DOI 10.1159/000053828; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V79, P489, DOI 10.1016/0091-6749(87)90367-8; FAHLBUSCH B, 1993, CLIN EXP ALLERGY, V23, P51, DOI 10.1111/j.1365-2222.1993.tb02484.x; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; FERNANDEZ C, 1993, J ALLERGY CLIN IMMUN, V92, P660, DOI 10.1016/0091-6749(93)90008-4; Focke M, 1998, INT ARCH ALLERGY IMM, V117, P105, DOI 10.1159/000023996; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P110, DOI 10.1016/0091-6749(80)90194-3; GONZALEZ RM, 1987, ANN ALLERGY, V59, P149; Grobe K, 1999, EUR J BIOCHEM, V263, P33, DOI 10.1046/j.1432-1327.1999.00462.x; Hayek B, 1998, J IMMUNOL, V161, P7031; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; HOLGATE ST, 1988, CLIN ALLERGY, V18, P549, DOI 10.1111/j.1365-2222.1988.tb02906.x; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; Judd W.S., 1999, PLANT SYSTEMATICS PH; KALVERAM KJ, 1978, INT ARCH ALLER A IMM, V57, P549, DOI 10.1159/000232151; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; KATELARIS C, 1982, ALLERGY, V37, P21, DOI 10.1111/j.1398-9995.1982.tb04113.x; Katial RK, 1997, ANN ALLERG ASTHMA IM, V79, P340, DOI 10.1016/S1081-1206(10)63025-6; KERNERMAN SM, 1992, ANN ALLERGY, V69, P493; Kimura T, 1969, Arerugi, V18, P1005; KRILIS S, 1983, J ALLERGY CLIN IMMUN, V71, P261, DOI 10.1016/0091-6749(83)90079-9; KUO MC, 1993, MOL IMMUNOL, V30, P1077, DOI 10.1016/0161-5890(93)90154-4; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Ledesma A, 2002, CLIN EXP ALLERGY, V32, P1476, DOI 10.1046/j.1365-2745.2002.01493.x; LEE YS, 1979, AM J BOT, V66, P245, DOI 10.2307/2442600; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; LOWENSTEIN H, 1980, ALLERGY, V35, P198, DOI 10.1111/j.1398-9995.1980.tb01743.x; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521, DOI 10.1159/000229739; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MARTINOROZCO E, 1994, INT ARCH ALLERGY IMM, V104, P160, DOI 10.1159/000236725; MATTHEWS PA, 1988, MOL IMMUNOL, V25, P63, DOI 10.1016/0161-5890(88)90091-0; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; Midoro-Horiuti T, 1999, J ALLERGY CLIN IMMUN, V104, P613, DOI 10.1016/S0091-6749(99)70332-5; MOORE MARJORIE B., 1931, JOUR ALLERGY, V2, P85, DOI 10.1016/S0021-8707(31)90023-3; Muller WD, 1996, INT ARCH ALLERGY IMM, V109, P352, DOI 10.1159/000237262; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 2002, CLIN EXP ALLERGY, V32, P933, DOI 10.1046/j.1365-2222.2002.01369.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 1999, FASEB J, V13, P843, DOI 10.1096/fasebj.13.8.843; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; OBISPO TM, 1993, CLIN EXP ALLERGY, V23, P311, DOI 10.1111/j.1365-2222.1993.tb00328.x; PAULL BR, 1979, J ALLERGY CLIN IMMUN, V64, P539, DOI 10.1016/0091-6749(79)90065-4; PETERSEN A, 1993, J ALLERGY CLIN IMMUN, V92, P789, DOI 10.1016/0091-6749(93)90055-K; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PRINCE HOMER E., 1939, JOUR ALLERGY, V10, P537, DOI 10.1016/S0021-8707(39)90248-0; RACKEMANN FM, 1936, J ALLERGY, V7, P319; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROEBBER M, 1982, J IMMUNOL, V129, P120; ROEBBER M, 1983, J IMMUNOL, V131, P706; Schwietz LA, 2000, ANN ALLERG ASTHMA IM, V84, P87, DOI 10.1016/S1081-1206(10)62746-9; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SELLERS ED, 1931, J ALLERGY, V3, P166; SERAFINI UMBERTO, 1957, ACTA ALLERGOL, V11, P3, DOI 10.1111/j.1398-9995.1957.tb03005.x; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; SHEN HD, 1988, INT ARCH ALLER A IMM, V85, P167, DOI 10.1159/000234497; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; Smith PM, 1997, INT ARCH ALLERGY IMM, V114, P265, DOI 10.1159/000237678; SOLOMON WR, 1969, J ALLERGY, V44, P25, DOI 10.1016/0021-8707(69)90045-8; SPAIN WC, 1930, J ALLERGY, V1, P209; SRIRAMARAO P, 1993, INT ARCH ALLERGY IMM, V100, P79, DOI 10.1159/000236391; STULL ARTHUR, 1932, JOUR ALLERGY, V3, P120, DOI 10.1016/S0021-8707(32)90371-2; SUZUKI S, 1975, INT ARCH ALLER A IMM, V48, P800, DOI 10.1159/000231368; Tinghino R, 2002, J ALLERGY CLIN IMMUN, V109, P314, DOI 10.1067/mai.2002.121528; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; TUFT L, 1937, J ALLERGY, V8, P464; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; Vallverdu A, 1998, J ALLERGY CLIN IMMUN, V101, P363, DOI 10.1016/S0091-6749(98)70249-0; VANREE R, 1994, ALLERGY, V49, P254; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; Wahl R, 1996, J ALLERGY CLIN IMMUN, V98, P99, DOI 10.1016/S0091-6749(96)70231-2; Weber RW, 2001, CLIN REV ALLERG IMMU, V21, P153, DOI 10.1385/CRIAI:21:2-3:153; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; WEBER RW, 1981, ANN ALLERGY, V46, P208; WEDNER HJ, 1987, INT ARCH ALLER A IMM, V84, P116; Welch J, 2000, CLIN EXP ALLERGY, V30, P370, DOI 10.1046/j.1365-2222.2000.00763.x; WODEHOUSE ROGER P., 1957, ANN ALLERGY, V15, P527; Wopfner N, 2002, BIOL CHEM, V383, P1779, DOI 10.1515/BC.2002.199; WURTZEN PA, 1995, ALLERGY, V50, P489, DOI 10.1111/j.1398-9995.1995.tb01184.x; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X; YOO TJ, 1975, ANN ALLERGY, V34, P87; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; ZETTERST.O, 1972, ACTA ALLERGOL, V27, P15, DOI 10.1111/j.1398-9995.1972.tb01638.x; ZHU XJ, 1995, J IMMUNOL, V155, P5064	112	127	135	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					229	239		10.1067/mai.2003.1683	http://dx.doi.org/10.1067/mai.2003.1683			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897724	Bronze			2022-12-18	WOS:000184650600001
J	Kepley, CL; Youssef, L; Andrews, RP; Wilson, BS; Oliver, JM				Kepley, CL; Youssef, L; Andrews, RP; Wilson, BS; Oliver, JM			Syk deficiency in nonreleaser basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; signal transduction; nonreleaser; tyrosine kinase; Lyn; Syk; human	FC-EPSILON-RI; SIGNAL-TRANSDUCTION; CROSS-LINKING; MAST-CELLS; TYROSINE; RECEPTOR; RELEASE	Background: Peripheral blood basophils from 10% to 20% of donors fail to degranulate in response to cross-linking the high-affinity IgE receptor Fc epsilon RI, The molecular mechanisms underlying the nonreleaser phenotype have not been established, Objectives: Our aim was to compare the expression of Fc epsilon RI-associated protein tyrosine kinases between nonreleaser and releaser basophils, Methods: With use of Western blotting we investigated Syk and Lyn protein levels in highly purified basophils from 3 anti-IgE nonreleasers and 2 releasers, Results: We identified 3 healthy nonatopic donors whose nonreleaser basophils express Fc epsilon RI normally but fail to express protein for the tyrosine kinase Syk, which is implicated in the initiation of Fc epsilon RI-mediated secretion. Protein levels for the tyrosine kinase Lyn are somewhat reduced but not absent in nonreleaser basophils, Levels of Lyn and Syk protein are similar in B cells,eosinophils, and neutrophils from releaser and nonreleaser donors. During these studies one nonreleaser "converted" into a releaser with concomitant basophil Syk expression. Conclusion: The absence of detectable Syk could explain the nonreleaser phenotype of basophils from some donors.	Univ New Mexico, Hlth Sci Ctr, Sch Med, Dept Pathol,Canc Res Facil, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Kepley, CL (corresponding author), Univ New Mexico, Hlth Sci Ctr, Sch Med, Dept Pathol,Canc Res Facil, Room 203A, Albuquerque, NM 87131 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL56384] Funding Source: Medline; NIGMS NIH HHS [R01 GM49814] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beaven MA, 1996, CURR OPIN IMMUNOL, V8, P766, DOI 10.1016/S0952-7915(96)80002-1; HOOK WA, 1991, J IMMUNOL, V147, P2670; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; KEPLEY C, 1994, J IMMUNOL METHODS, V175, P1, DOI 10.1016/0022-1759(94)90326-3; Kepley CL, 1998, J ALLERGY CLIN IMMUN, V102, P304, DOI 10.1016/S0091-6749(98)70100-9; KNOL EF, 1992, J ALLERGY CLIN IMMUN, V90, P92, DOI 10.1016/S0091-6749(06)80015-1; KUSTER H, 1992, J BIOL CHEM, V267, P12782; MACGLASHAN DW, 1995, CHEM IMMUNOL, V61, P88; Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Peters JD, 1996, J BIOL CHEM, V271, P4755; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; Yamaguchi M, 1996, J ALLERGY CLIN IMMUN, V97, P1279, DOI 10.1016/S0091-6749(96)70196-3; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	15	127	138	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				279	284		10.1016/S0091-6749(99)70367-2	http://dx.doi.org/10.1016/S0091-6749(99)70367-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452745	Green Published			2022-12-18	WOS:000082364800016
J	Lynch, NR; Hagel, IA; Palenque, ME; Di Prisco, MC; Escudero, JE; Corao, LA; Sandia, JA; Ferreira, LJ; Botto, C; Perez, M; Le Souef, PN				Lynch, NR; Hagel, IA; Palenque, ME; Di Prisco, MC; Escudero, JE; Corao, LA; Sandia, JA; Ferreira, LJ; Botto, C; Perez, M; Le Souef, PN			Relationship between helminthic infection and IgE response in atopic and nonatopic children in a tropical environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergic disease; IgE; helminthic parasites; Ascaris lumbricoides	PAPUA-NEW-GUINEA; ALLERGIC REACTIVITY; SLUM CHILDREN; ASTHMA; HIGHLANDS; IMMUNITY; PARASITES; MORBIDITY	Background: Although IgE antibody is clearly involved in allergic reactions to environmental allergens, this immunoglobulin is an important component of host-protective immune responses against the helminthic parasites that are endemic in the majority of the world population. However, these infections not only stimulate the production of antiparasite IgE antibody but can nonspecifically induce polyclonal IgE synthesis that results in highly elevated total serum IgE levels. Such polyclonal stimulation can diminish specific IgE antibody responses and cause saturation of mast cell Fee receptors, thus inhibiting allergic reactivity. This may represent a mechanism of immune evasion by the parasite. Objective: Because an atopic disposition is generally recognized to be associated with elevated IgE synthesis against environmental allergens, the aim of this study was to evaluate the influence of atopy on the antiparasite response. To this end, we examined two groups of Venezuelan children in whom the intestinal helminth Ascaris lumbricoides is endemic but that differ greatly in their level of atopy. One group was from an island population (Coche Island) that has a very strong atopic background and in which the prevalence of allergic disease is extremely high. The other was a group of nonatopic children belonging to a mainland population (Barrio Los Erases) that is of comparable socioeconomic level and has an exposure to helminthic infection similar to that of the island group but a relatively low expression of allergic diseases. Results: Although the living conditions and the prevalence of Ascaris infection of the two groups were comparable, the intensity of the parasitic infection was considerably higher in the nonatopic mainland children (geometric mean values of eggs per gram of feces: Barrio Los Erases, 7621; Coche Island, 1435; p < 0.001). In addition, their total serum IgE levels were significantly more elevated than in the atopic island group (geometric mean: Barrio Los Erasos, 2172; Coche Island, 941 IU/ml; p < 0.001). In contrast, the specific anti-Ascaris response was much stronger in the atopic children (geometric mean: Barrio Los Erasos, 0.30; Coche Island, 0.91 PRU/ml; p < 0.001), which resulted in the ratio of specific to total IgE being nine times higher than in the nonatopic mainland subjects. These differences were maintained even when the children were matched on the basis of infection intensity, thus indicating that the atopic children have an intrinsic propensity to favor specific over polyclonal IgE responses to the parasite. Conclusions: The children with a strong atopic background demonstrated IgE responses concordant with an enhanced protective response against helminthic parasites and had significantly lower intensities of infection than their nonatopic counterparts. These observations support the concept that the atopic state has conferred a selective evolutionary advantage that could compensate for its involvement in allergic disease.	Cent Univ Venezuela, Inst Biomed, Caracas 1010, Venezuela; FONDENE Edo, Clin Expt Asma, Nueva Esparta, Venezuela; Hosp Miguel Perez Carreno, Caracas, Venezuela; Hosp Ninos JM Los Rios, Caracas, Venezuela; Cent Univ Venezuela, Inst Trop Med, Caracas, Venezuela; Univ Western Australia, Fac Med, Dept Paediat, Perth, WA 6009, Australia	University of Central Venezuela; University of Central Venezuela; University of Western Australia	Lynch, NR (corresponding author), Cent Univ Venezuela, Inst Biomed, Aptdo 4043, Caracas 1010, Venezuela.		Lynch, Natalie/GSI-7336-2022; Le Souef, Peter N/H-5256-2014	Le Souef, Peter/0000-0003-0930-1654; Hagel, Isabel/0000-0003-4464-1830				AALBERSE RC, 1991, EUR RESPIR J, V4, pS78; Allen JE, 1996, INT ARCH ALLERGY IMM, V109, P3, DOI 10.1159/000237225; ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; Bell RG, 1996, IMMUNOL CELL BIOL, V74, P337, DOI 10.1038/icb.1996.60; Brown H.W., 1975, BASIC CLIN PARASITOL; BUNDY DAP, 1992, PARASITOLOGY, V104, pS105, DOI 10.1017/S0031182000075284; Butterworth AE, 1996, AM J TROP MED HYG, V55, P109, DOI 10.4269/ajtmh.1996.55.109; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; FINKELMAN FD, 1991, IMMUNOPARASITOL TOD, pA62, DOI 10.1016/S0167-5699(05)80018-0; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; GROVE DI, 1975, MED J AUSTRALIA, V1, P336, DOI 10.5694/j.1326-5377.1975.tb111423.x; Hagan P, 1996, AM J TROP MED HYG, V55, P116, DOI 10.4269/ajtmh.1996.55.116; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; HAGEL I, 1993, INT ARCH ALLERGY IMM, V101, P209, DOI 10.1159/000236521; HAGEL I, 1993, CLIN EXP IMMUNOL, V94, P80, DOI 10.1111/j.1365-2249.1993.tb05981.x; HAGEL I, 1993, T ROY SOC TROP MED H, V87, P16, DOI 10.1016/0035-9203(93)90401-B; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; ISTURIZ G, 1987, NEUMOS, V5, P35; JARRETT EEE, 1982, PROG ALLERGY, V31, P178; Lynch N. R., 1992, Allergy and immunity to helminths: common mechanisms or divergent pathways., P51; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; LYNCH NR, 1993, J INVEST ALLERG CLIN, V3, P96; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; LYNCH NR, 1984, J ALLERGY CLIN IMMUN, V73, P229, DOI 10.1016/S0091-6749(84)80012-3; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; LYNCH NR, 1983, INT ARCH ALLER A IMM, V72, P369, DOI 10.1159/000234899; LYNCH NR, 1984, CLIN ALLERGY, V14, P233, DOI 10.1111/j.1365-2222.1984.tb02202.x; LYNCH NR, 1987, ALLERGOL IMMUNOPATH, V15, P19; LYNCH NR, 1987, BAILLIERE CLIN TROP, V2, P573; MANTLE J, 1974, CLIN ALLERGY, V4, P161, DOI 10.1111/j.1365-2222.1974.tb01373.x; Mendez-Castellano H., 1986, VENEZUELAN ARCH CHIL, V49, P93; Miller HRP, 1996, VET IMMUNOL IMMUNOP, V54, P331, DOI 10.1016/S0165-2427(96)05696-6; MOQBEL R, 1990, CLIN EXP ALLERGY, V20, P611, DOI 10.1111/j.1365-2222.1990.tb02699.x; PRITCHARD DI, 1993, PARASITE IMMUNOL, V15, P5, DOI 10.1111/j.1365-3024.1993.tb00566.x; PRITCHARD DI, 1994, J INVEST ALLERG CLIN, V4, P238; Ruffilli A, 1997, ALLERGY, V52, P256, DOI 10.1111/j.1398-9995.1997.tb00990.x; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TURNER KJ, 1986, J ALLERGY CLIN IMMUN, V77, P558, DOI 10.1016/0091-6749(86)90345-3; WOOLCOCK AJ, 1989, EUR RESPIR J, V2, P822; WOOLHOUSE MEJ, 1993, PARASITE IMMUNOL, V15, P583	41	127	136	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				217	221		10.1016/S0091-6749(98)70386-0	http://dx.doi.org/10.1016/S0091-6749(98)70386-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500755	Bronze			2022-12-18	WOS:000072244800011
J	HOFFMAN, DR				HOFFMAN, DR			ALLERGENS IN HYMENOPTERA VENOM .25. THE AMINO-ACID-SEQUENCES OF ANTIGEN 5 MOLECULES AND THE STRUCTURAL BASIS OF ANTIGENIC CROSS-REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGEN; ANTIGEN-5; CROSS-REACTIVITY; FIRE ANT; HORNET; SEQUENCE; VENOM; VESPID; WASP; YELLOW JACKET	YELLOW JACKET; PROTEIN ALLERGENS; HORNET	The complete amino acid sequences have been determined by solid-phase protein sequencing for eight different vespid venom antigen 5 molecules. These include five species of yellow jackets, Vespula squamosa, V. flavopilosa, V. germanica, V. pensylvanica and V. vidua, representing all three species groups; two variants from the European hornet, Vespa crabro; and a species of paper wasp, Polistes fuscatus, from a second subgenus. The new sequences were compared with the seven previously published sequences from yellow jackets, hornets, and wasps, and to that of Solenopsis invicta 3 allergen from imported fire ant venom. These comparisons provided structural evidence to support the observed high degree of cross-reactivity among the antigens of the common group of yellow jackets and among those of the two common North American subgenera of paper wasps studied. The antigen 5 of V. squamosa and of V. vidua were significantly different from those of the vulgaris group. Common features that could generate immunologic cross-reactivity were seen among the antigen 5 molecules of hornets of both genera and among those of yellow jackets, hornets, and paper wasps. The imported fire ant allergen has only minimal conserved areas in common with the vespid allergens, which explains the lack of observed IgE cross-reactivity. These results provide the structural basis for the cross-reactivity patterns observed in clinical practice and suggest that the commercial extracts of yellow jacket and paper wasp could be prepared with fewer carefully selected species.			HOFFMAN, DR (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27858, USA.							ABE T, 1987, BIOCHEMISTRY-US, V21, P1693; AKRE RD, 1981, US DEP AGR AGR HDB, V552; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; HIGGINS JA, 1992, J ALLERGY CLIN IMMUN, V90, P749, DOI 10.1016/0091-6749(92)90098-M; HOFFMAN D R, 1990, Journal of Allergy and Clinical Immunology, V85, P211; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1982, ANN ALLERGY, V48, P82; HOFFMAN DR, 1981, ANN ALLERGY, V47, P23; HOFFMAN DR, 1987, INT ARCH ALLER A IMM, V84, P25, DOI 10.1159/000234394; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P606, DOI 10.1016/0091-6749(85)90037-5; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P187; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; HOFFMAN DR, 1981, ANN ALLERGY, V48, P78; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1987, MOL IMMUNOL, V24, P857, DOI 10.1016/0161-5890(87)90188-X; LU G, 1993, J IMMUNOL, V150, P2823; MARSH DG, 1988, IMMUNOLOGICAL DISEAS, P981; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; ROEBBER M, 1985, J IMMUNOL, V135, P3062; SOLDATOVA L, 1993, J ALLERGY CLIN IMMUN, V91, P283; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TUICHIBAEV MU, 1984, BIOORG KHIM+, V10, P318; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985	31	127	142	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					707	716		10.1016/0091-6749(93)90014-7	http://dx.doi.org/10.1016/0091-6749(93)90014-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227862				2022-12-18	WOS:A1993MG98200012
J	MAZER, BD; GELFAND, EW				MAZER, BD; GELFAND, EW			AN OPEN-LABEL STUDY OF HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN IN SEVERE CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IDIOPATHIC THROMBOCYTOPENIC PURPURA; GAMMA-GLOBULIN THERAPY; T-CELL SUBSETS; SYNTHESIS INVITRO; BRONCHIAL-ASTHMA; DEPENDENT ASTHMA; GOLD SALT; METHOTREXATE; REVERSAL; IGG	Eight pediatric patients with severe steroid-dependent asthma were enrolled in an open-label trial of high-dose intravenous immunoglobulin (IVIG) in an attempt to decrease their steroid requirements. Monthly therapy with high-dose IVIG resulted in a threefold decrease in both maintenance oral corticosteroid dose and in extra oral corticosteroids needed for control of exacerbations of asthma. This was accompanied by significant improvements in peak expiratory flow rates and in symptom-score rating. An immunomodulatory effect of IVIG was suggested by the changes in immediate skin test reactivity. Seven of the eight patients demonstrated one or more reactions to a panel of allergens before therapy. During the course of the trial, there was a progressive diminution in skin test reactivity with a 100-fold reduction in sensitivity at the completion of 6 months of therapy. In this preliminary study, the reduction in steroid requirements, improvement in symptoms and peak flow measurements, and diminution in immediate skin test reactivity support a potential role for IVIG in the treatment of severe steroid-dependent asthma. A larger, randomized trial now appears warranted.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206; RAYMOND & BEVERLY SACKLER FDN,DENVER,CO	National Jewish Health					NIAID NIH HHS [AI-26490] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUCKLEY RH, 1987, JAMA-J AM MED ASSOC, V258, P2841; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COOK L, 1988, J CLIN IMMUNOL, V8, P23, DOI 10.1007/BF00915153; DAMMACCO F, 1986, BRIT J HAEMATOL, V62, P125, DOI 10.1111/j.1365-2141.1986.tb02908.x; DURANDY A, 1981, J CLIN INVEST, V67, P867, DOI 10.1172/JCI110104; ELLIS E, 1988, ALLERGY PRINCIPLES P, V2, P1037; HOLLMAN A, 1988, PEDIATRICS, V81, P452; IMBACH P, 1983, BLUT, V46, P117, DOI 10.1007/BF00320269; IMBACH P, 1986, CLIN USE INTRAVENOUS, P177; IMHOLZ B, 1988, BLUT, V56, P63, DOI 10.1007/BF00633464; LAMMERT J, 1989, J ALLERGY CLIN IMMUN, V83, P272; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; MAZER BD, 1989, CLIN IMMUNOL IMMUNOP, V53, P156; MCGUIRE WA, 1987, NEW ENGL J MED, V317, P1004, DOI 10.1056/NEJM198710153171606; MORRIS HG, 1978, ADV ASTHMA ALLERGY, V5, P19; MORRIS HG, 1988, CHEST, V88, P133; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P3417; ROIFMAN CM, 1987, JAMA-J AM MED ASSOC, V258, P513, DOI 10.1001/jama.1987.03400040111034; ROSSI F, 1986, CLIN USE INTRAVENOUS, P421; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; TSUBAKIO T, 1983, CLIN EXP IMMUNOL, V53, P697	24	127	129	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					976	983		10.1016/0091-6749(91)90420-S	http://dx.doi.org/10.1016/0091-6749(91)90420-S			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	2026848				2022-12-18	WOS:A1991FM09500010
J	FOGH, K; HERLIN, T; KRAGBALLE, K				FOGH, K; HERLIN, T; KRAGBALLE, K			EICOSANOIDS IN SKIN OF PATIENTS WITH ATOPIC-DERMATITIS - PROSTAGLANDIN-E2 AND LEUKOTRIENE-B4 ARE PRESENT IN BIOLOGICALLY-ACTIVE CONCENTRATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FOGH, K (corresponding author), AARHUS UNIV,MARSELISBORG HOSP,DEPT DERMATOL,DK-8000 AARHUS C,DENMARK.							ARCHER CB, 1987, PROSTAGLANDINS, V33, P799, DOI 10.1016/0090-6980(87)90108-0; BARR RM, 1984, BRIT J DERMATOL, V111, P23, DOI 10.1111/j.1365-2133.1984.tb04012.x; BJORK J, 1982, INFLAMMATION, V6, P189, DOI 10.1007/BF00916243; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BRAIN S, 1984, J INVEST DERMATOL, V83, P70, DOI 10.1111/1523-1747.ep12261712; CAMP R, 1984, J INVEST DERMATOL, V82, P202, DOI 10.1111/1523-1747.ep12259945; CUNNINGHAM FM, 1987, PROSTAGLANDINS, V34, P71, DOI 10.1016/0090-6980(87)90264-4; CZARNETZKI BM, 1986, PROSTAGLANDINS, V31, P851, DOI 10.1016/0090-6980(86)90018-3; DOWD PM, 1987, ARCH DERMATOL RES, V279, P427, DOI 10.1007/BF00412586; FOGH K, 1987, ARCH DERMATOL RES, V279, P504, DOI 10.1007/BF00413280; FOGH K, 1988, J INVEST DERMATOL, V91, P401; HANIFIN JM, 1984, PATHOPHYSIOLOGY DERM, P135; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JOHNSON HH, 1960, J INVEST DERMATOL, V34, P237, DOI 10.1038/jid.1960.38; JUHLIN L, 1967, ACTA DERM-VENEREOL, V47, P383; Parker C W, 1986, Adv Prostaglandin Thromboxane Leukot Res, V16, P113; PAYAN DG, 1981, J CLIN IMMUNOL, V1, P266, DOI 10.1007/BF00915147; RUZICKA T, 1987, J INVEST DERMATOL, V88, P120, DOI 10.1111/1523-1747.ep12525265; RUZICKA T, 1986, J INVEST DERMATOL, V86, P105, DOI 10.1111/1523-1747.ep12284061; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TERNOWITZ T, 1988, Skin Pharmacology, V1, P93; TERNOWITZ T, 1987, ACTA PATH MICRO IM C, V95, P47; VANDERHOEK JY, 1980, J BIOL CHEM, V255, P64; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0	24	127	131	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				450	455		10.1016/0091-6749(89)90132-2	http://dx.doi.org/10.1016/0091-6749(89)90132-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2537352				2022-12-18	WOS:A1989T448900013
J	MCBRIDE, P; BRADLEY, D; KALINER, M				MCBRIDE, P; BRADLEY, D; KALINER, M			EVALUATION OF A RADIOIMMUNOASSAY FOR HISTAMINE MEASUREMENT IN BIOLOGIC FLUIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		Atack C, 1977, Acta Physiol Scand Suppl, V451, P1; BROWN MJ, 1980, ANAL BIOCH, V109, P147; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; DAVIS TP, 1978, CLIN CHEM, V24, P1317; DELAAGE MA, 1988, IMMUNOANALYSIS HISTA; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; ENDO Y, 1978, ANAL BIOCHEM, V89, P235, DOI 10.1016/0003-2697(78)90746-7; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; GUESDON JL, 1986, J IMMUNOL METHODS, V87, P69, DOI 10.1016/0022-1759(86)90345-5; GUILLOUX L, 1981, CLIN CHIM ACTA, V116, P269, DOI 10.1016/0009-8981(81)90046-2; HAYDIK IB, 1983, J ALLERGY CLIN IMMUN, V71, P152, DOI 10.1016/0091-6749(83)90380-9; HORAKOVA Z, 1977, CLIN CHIM ACTA, V79, P447, DOI 10.1016/0009-8981(77)90441-7; HUFF JA, 1966, J LAB CLIN MED, V67, P1044; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KHANDELWAL JK, 1982, AGENTS ACTIONS, V12, P583, DOI 10.1007/BF01965064; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; MCBRIDE P, IN PRESS J ALLERGY C; MINE K, 1986, ANAL BIOCHEM, V152, P127, DOI 10.1016/0003-2697(86)90130-2; MITA H, 1984, AGENTS ACTIONS, V14, P574, DOI 10.1007/BF01978889; MOREL AM, 1984, Patent No. 8405783; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; PERINI F, 1979, ANAL BIOCHEM, V94, P431, DOI 10.1016/0003-2697(79)90386-5; PEYRET L M, 1986, Journal of Immunological Methods, V90, P39, DOI 10.1016/0022-1759(86)90380-7; ROBERT JC, 1983, J CHROMATOGR, V273, P275, DOI 10.1016/S0378-4347(00)80949-4; ROBERTS LJ, 1985, J CHROMATOGR, V338, P41, DOI 10.1016/0378-4347(85)80068-2; ROSENBAUM RC, 1984, J NUCL MED, V25, P859; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Shore PA, 1971, METHODS BIOCH ANAL S, P89, DOI [10.1002/9780470110409.ch3, DOI 10.1002/9780470110409.CH3]; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WOLDEMUSSIE E, 1984, NER ALLERGY P, V5, P300	36	127	129	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					638	646		10.1016/0091-6749(88)90977-3	http://dx.doi.org/10.1016/0091-6749(88)90977-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171005				2022-12-18	WOS:A1988Q639900017
J	ADINOFF, AD; TELLEZ, P; CLARK, RAF				ADINOFF, AD; TELLEZ, P; CLARK, RAF			ATOPIC-DERMATITIS AND AEROALLERGEN CONTACT SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206	National Jewish Health; National Jewish Health								ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; BRONSWIJK JEM, 1971, RES POPUL ECOL, V13, P67; CAZORT A. G., 1936, Southern, M. J., V29, P1022; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; DAHL MV, 1978, ARCH DERMATOL, V114, P544, DOI 10.1001/archderm.114.4.544; Feinberg SM, 1939, ARCH DERMATOL SYPH, V40, P200, DOI 10.1001/archderm.1939.01490020027004; GLODE MP, 1986, PEDIATR INFECT DIS J, V5, P644, DOI 10.1097/00006454-198611000-00009; HANIFIN JM, 1977, ARCH DERMATOL, V113, P1383, DOI 10.1001/archderm.113.10.1383; HILL LW, 1937, J ALLERGY, V9, P37; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; JONES HE, 1975, BRIT J DERMATOL, V92, P17; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; MARGHESCU S, 1985, ACTA DERM-VENEREOL S, V114, P113; MITCHELL EB, 1982, LANCET, V1, P127; MOYER DB, 1985, ANN ALLERGY, V55, P680; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NADCHATRAM M, 1981, ANN ALLERGY, V46, P197; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OLOUGHLIN S, 1977, ARCH DERMATOL, V113, P309; Peck SM, 1933, AM J DIS CHILD, V46, P1308, DOI 10.1001/archpedi.1933.01960070074005; RASMUSSEN JE, 1983, ALLERGY PRINCIPLES P, P1297; REITAMO S, 1986, BRIT J DERMATOL, V114, P303, DOI 10.1111/j.1365-2133.1986.tb02821.x; ROWE AH, 1946, ARCH DERMATOL SYPH, V53, P437, DOI 10.1001/archderm.1946.01510340003001; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; TUFT L, 1949, J INVEST DERMATOL, V12, P211, DOI 10.1038/jid.1949.33; TUFT L, 1952, J ALLERGY, V23, P528, DOI 10.1016/0021-8707(52)90040-3; UEHARA M, 1977, ARCH DERMATOL, V113, P1226, DOI 10.1001/archderm.113.9.1226; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102	29	127	128	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					736	742		10.1016/0091-6749(88)91047-0	http://dx.doi.org/10.1016/0091-6749(88)91047-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356851				2022-12-18	WOS:A1988N065000016
J	BUTLER, JM; CHAN, SC; STEVENS, S; HANIFIN, JM				BUTLER, JM; CHAN, SC; STEVENS, S; HANIFIN, JM			INCREASED LEUKOCYTE HISTAMINE-RELEASE WITH ELEVATED CYCLIC AMP-PHOSPHODIESTERASE ACTIVITY IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALM P E, 1982, Life Sciences, V30, P213, DOI 10.1016/0024-3205(82)90501-X; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BUBLITZ C, 1973, BIOCHEM BIOPH RES CO, V52, P173, DOI 10.1016/0006-291X(73)90970-4; CHAN SC, 1982, J CYCLIC NUCL PROT, V8, P211; CONROY MC, 1977, J IMMUNOL, V118, P1317; EARP HS, 1978, ANNU REV PHARMACOL, V18, P431, DOI 10.1146/annurev.pa.18.040178.002243; FREDHOLM BB, 1979, ACTA PHARMACOL TOX, V45, P336; GILBERT HS, 1975, BLOOD, V46, P279; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; HOLGATE ST, 1980, P NATL ACAD SCI-BIOL, V77, P6800, DOI 10.1073/pnas.77.11.6800; ISHIZAKA T, 1981, P NATL ACAD SCI-BIOL, V78, P6812, DOI 10.1073/pnas.78.11.6812; ISHIZAKA T, 1973, MECHANISMS ALLERGY, P221; JOHNSON HH, 1960, J INVEST DERMATOL, V34, P237, DOI 10.1038/jid.1960.38; JUHLIN L, 1967, ACTA DERM-VENEREOL, V42, P218; KALINER M, 1974, J IMMUNOL, V112, P664; KALINER M, 1974, BIOCHEM PHARMACOL, V23, P763, DOI 10.1016/0006-2952(74)90206-8; KALINER M, 1974, CYCLIC AMP CELL GROW, P163; KAPLAN HJ, 1978, ARCH DERMATOL, V114, P60; LEBEL B, 1980, ACTA DERM-VENEREOL, V92, P57; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MIKHAIL GR, 1976, J INVEST DERMATOL, V67, P305; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; RING J, 1979, BRIT J DERMATOL, V100, P521, DOI 10.1111/j.1365-2133.1979.tb05577.x; RING J, 1979, INT ARCH ALLER A IMM, V58, P322, DOI 10.1159/000232208; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SIRAGANIAN RP, 1975, J IMMUNOL, V114, P886; SOBOTKA AK, 1978, IMMUNOL REV, V41, P171, DOI 10.1111/j.1600-065X.1978.tb01464.x; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; SULLIVAN TJ, 1975, J IMMUNOL, V115, P278; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; THUESON DO, 1979, J IMMUNOL, V123, P626; WELLS JN, 1981, MOL CELL ENDOCRINOL, V23, P1, DOI 10.1016/0303-7207(81)90112-X; WINSLOW CM, 1982, FED PROC, V41, P22	35	127	128	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					490	497		10.1016/0091-6749(83)90467-0	http://dx.doi.org/10.1016/0091-6749(83)90467-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6188771				2022-12-18	WOS:A1983QQ74200010
J	CHAPMAN, MD; ROWNTREE, S; MITCHELL, EB; DEFUENMAJOR, MCD; PLATTSMILLS, TAE				CHAPMAN, MD; ROWNTREE, S; MITCHELL, EB; DEFUENMAJOR, MCD; PLATTSMILLS, TAE			QUANTITATIVE ASSESSMENTS OF IGG AND IGE ANTIBODIES TO INHALANT ALLERGENS IN PATIENTS WITH ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CLIN RES CTR,DIV IMMUNOL,HARROW HA1 3UJ,MIDDX,ENGLAND					Chapman, Martin/0000-0002-0845-3632				AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; BARNETSON RS, 1981, CLIN EXP IMMUNOL, V46, P54; BLACK PL, 1976, IMMUNOGENETICS, V3, P349, DOI 10.1007/BF01576967; BUCKLEY RH, 1979, CELLULAR MOL CLIN AS, P513; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CLENDENNING WE, 1973, J INVEST DERMATOL, V61, P233, DOI 10.1111/1523-1747.ep12676481; DAHL MGC, 1981, IMMUNOLOGICAL CLIN A, P179; DIAMOND H E, 1957, N Y State J Med, V57, P754; DVORAK HF, 1976, J INVEST DERMATOL, V67, P391, DOI 10.1111/1523-1747.ep12514713; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; HILL LW, 1937, J ALLERGY, V9, P37; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; JOHNSON P, 1965, EUR POLYM J, V1, P63; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KEMENY DM, 1982, INT ARCH ALLER A IMM, V68, P268, DOI 10.1159/000233110; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; MITCHELL EB, 1982, LANCET, V1, P127; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; NAGEL JE, 1979, J ALLERGY CLIN IMMUN, V63, P308, DOI 10.1016/0091-6749(79)90124-6; NEWMANTAYLOR A, 1977, LANCET, V2, P847; NORINS AL, 1971, PEDIATR CLIN N AM, V18, P801; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OHMAN S, 1974, ACTA DERM-VENEREOL, V54, P283; OLOUGHLIN S, 1977, ARCH DERMATOL, V113, P309; PLATTSMILLS TAE, 1981, J ALLERGY CLIN IMMUN, V67, P129, DOI 10.1016/0091-6749(81)90008-7; PLATTSMILLS TAE, 1975, J IMMUNOL, V114, P1058; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; RAJKA G, 1975, MAJOR PROBLEMS DERMA, V3, P77; RASMUSSEN JE, 1978, ATOPIC DERMATITIS AL, P1039; ROST AG, 1929, ARCH DERMATOL SYPHIL, V155, P297; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SCHELLENBERG RR, 1976, J IMMUNOL, V117, P355; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SOLOMON LM, 1978, IMMUNOLOGICAL DISEAS, V2, P958; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TUFT L, 1949, J INVEST DERMATOL, V12, P211, DOI 10.1038/jid.1949.33; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7	41	127	128	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					27	33		10.1016/0091-6749(83)90048-9	http://dx.doi.org/10.1016/0091-6749(83)90048-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6853930				2022-12-18	WOS:A1983QZ19800003
J	Yosipovitch, G; Rosen, JD; Hashimoto, T				Yosipovitch, Gil; Rosen, Jordan Daniel; Hashimoto, Takashi			Itch: From mechanism to (novel) therapeutic approaches	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Itch; pruritus; treatment; mechanism; pathophysiology; management	GASTRIN-RELEASING-PEPTIDE; HISTAMINE-INDUCED ITCH; QUALITY-OF-LIFE; ATOPIC-DERMATITIS; CHRONIC PRURITUS; SPINAL-CORD; NERVE-FIBERS; LYSOPHOSPHATIDIC ACID; CRISABOROLE OINTMENT; NA(V)1.7 INHIBITORS	Itch is a common sensory experience that is prevalent in patients with inflammatory skin diseases, as well as in those with systemic and neuropathic conditions. In patients with these conditions, itch is often severe and significantly affects quality of life. Itch is encoded by 2 major neuronal pathways: histaminergic (in acute itch) and nonhistaminergic (in chronic itch). In the majority of cases, crosstalk existing between keratinocytes, the immune system, and nonhistaminergic sensory nerves is responsible for the pathophysiology of chronic itch. This review provides an overview of the current understanding of the molecular, neural, and immune mechanisms of itch: beginning in the skin, proceeding to the spinal cord, and eventually ascending to the brain, where itch is processed. A growing understanding of the mechanisms of chronic itch is expanding, as is our pipeline of more targeted topical and systemic therapies. Our therapeutic armamentarium for treating chronic itch has expanded in the last 5 years, with developments of topical and systemic treatments targeting the neural and immune systems.	Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Coral Gables, FL 33124 USA; Univ Miami, Miller Sch Med, Miami Itch Ctr, Coral Gables, FL 33124 USA	University of Miami; University of Miami	Yosipovitch, G (corresponding author), 1600 NW 10th Ave,RMSB 2067B, Miami, FL 33136 USA.	gyosipovitch@med.miami.edu	Hashimoto, Takashi/N-5419-2017	Hashimoto, Takashi/0000-0001-6779-5598				Akiyama T, 2012, NEUROSCIENCE, V226, P305, DOI 10.1016/j.neuroscience.2012.09.019; Akiyama T, 2015, HANDB EXP PHARMACOL, V226, P219, DOI 10.1007/978-3-662-44605-8_13; Andersen HH, 2017, CLIN EXP DERMATOL, V42, P596, DOI 10.1111/ced.13114; Andersen HH, 2018, EXP DERMATOL, V27, P258, DOI 10.1111/exd.13508; Andersen HH, 2017, ACTA DERM-VENEREOL, V97, P63, DOI 10.2340/00015555-2447; Andersen HH, 2018, PAIN, V159, P1185, DOI 10.1097/j.pain.0000000000001220; Andoh T, 2018, NEUROSCI LETT, V672, P84, DOI 10.1016/j.neulet.2018.02.034; Arnold P, 2008, CLIN J PAIN, V24, P116, DOI 10.1097/AJP.0b013e318159f94a; Bae BG, 2012, ACTA DERM-VENEREOL, V92, P57, DOI 10.2340/00015555-1189; Bilir KA, 2018, CLIN EXP DERMATOL, V43, P553, DOI 10.1111/ced.13398; bin Saif GA, 2012, BRIT J DERMATOL, V166, P981, DOI 10.1111/j.1365-2133.2012.10826.x; Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871; Boozalis E, 2018, J DERMATOL TREAT, P1; Bordon Y, 2017, NAT REV IMMUNOL, V17, P591, DOI 10.1038/nri.2017.114; Bourane S, 2015, SCIENCE, V350, P550, DOI 10.1126/science.aac8653; Cao LF, 2017, NEUROREPORT, V28, P518, DOI 10.1097/WNR.0000000000000779; Catterall WA., 2011, PHARM BASIS THERAPEU, V12th ed, P565; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cedeno-Laurent F, 2015, CLIN IMMUNOL, V158, P1, DOI 10.1016/j.clim.2015.02.014; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chida Y, 2007, INT ARCH ALLERGY IMM, V144, P1, DOI 10.1159/000101940; Davidson S, 2012, J NEUROPHYSIOL, V108, P1711, DOI 10.1152/jn.00206.2012; Dawn AG, 2006, J AM ACAD DERMATOL, V54, P527, DOI 10.1016/j.jaad.2005.12.010; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Desbordes G, 2015, NEUROIMAGE-CLIN, V7, P213, DOI 10.1016/j.nicl.2014.12.002; Devigili G, 2014, PAIN, V155, P1702, DOI 10.1016/j.pain.2014.05.006; Dunford PJ, 2007, J ALLERGY CLIN IMMUN, V119, P176, DOI 10.1016/j.jaci.2006.08.034; Durham PL, 2004, HEADACHE, V44, P35, DOI 10.1111/j.1526-4610.2004.04007.x; Eberlein B, 2008, J EUR ACAD DERMATOL, V22, P73, DOI 10.1111/j.1468-3083.2007.02351.x; Elmariah SB, 2011, SEMIN CUTAN MED SURG, V30, P118, DOI 10.1016/j.sder.2011.04.008; Feng J, 2018, SCIENCE, V360, P530, DOI 10.1126/science.aar5703; Fukuoka M, 2013, PAIN, V154, P897, DOI 10.1016/j.pain.2013.02.021; Fukuyama T, 2017, J ALLERGY CLIN IMMUN, V140, P306, DOI 10.1016/j.jaci.2016.12.960; Gazerani P, 2018, TOXINS, V10, DOI 10.3390/toxins10040143; Gibson RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100610; Gotoh Y, 2011, NEUROPHARMACOLOGY, V61, P825, DOI 10.1016/j.neuropharm.2011.05.030; Gottlieb A, 2010, J AM ACAD DERMATOL, V63, P580, DOI 10.1016/j.jaad.2009.09.049; Graceffa RF, 2017, J MED CHEM, V60, P5990, DOI 10.1021/acs.jmedchem.6b01850; Griffiths CEM, 2015, LANCET, V386, P541, DOI 10.1016/S0140-6736(15)60125-8; Gutierrez-Mecinas M, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-79; HAGERMARK O, 1977, J INVEST DERMATOL, V69, P527, DOI 10.1111/1523-1747.ep12687966; HAGERMARK O, 1977, ACTA DERM-VENEREOL, V57, P37; Hashimoto T, 2015, BRIT J DERMATOL, V173, P1334, DOI 10.1111/bjd.13992; Hashimoto T, 2018, EXP DERMATOL; He A, 2017, J DERMATOL TREAT, V28, P338, DOI 10.1080/09546634.2016.1243787; Hesselink JMK, 2017, J PAIN RES, V10, P635, DOI 10.2147/JPR.S131434; Heyer Gisela, 1997, Journal of Dermatology (Tokyo), V24, P621; Hidaka T, 2017, NAT IMMUNOL, V18, P64, DOI 10.1038/ni.3614; Hundley JL, 2004, J AM ACAD DERMATOL, V50, P889, DOI 10.1016/j.jaad.2004.01.045; Iannetti GD, 2005, P NATL ACAD SCI USA, V102, P18195, DOI 10.1073/pnas.0506624102; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Ishiuji Y, 2009, BRIT J DERMATOL, V161, P1072, DOI 10.1111/j.1365-2133.2009.09308.x; Jaiswal D, 2016, CAN J KIDNEY HLTH DI, V3; Kabashima K, 2018, J ALLERGY CLIN IMMUN, V142, P1121, DOI 10.1016/j.jaci.2018.03.018; Kamo A, 2011, J DERMATOL SCI, V62, P91, DOI 10.1016/j.jdermsci.2011.01.004; Kaul I, 2018, BURNS, V44, P414, DOI 10.1016/j.burns.2017.07.018; Kawahara K, 2015, BBA-MOL CELL BIOL L, V1851, P414, DOI 10.1016/j.bbalip.2014.07.008; Kim DW, 2015, TOXINS, V7, P2435, DOI 10.3390/toxins7072435; Kimball AB, 2016, J AM ACAD DERMATOL, V75, P1156, DOI 10.1016/j.jaad.2016.07.034; Kittaka H, 2017, ALLERGOL INT, V66, P22, DOI 10.1016/j.alit.2016.10.003; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kouwenhoven TA, 2017, J AM ACAD DERMATOL, V77, P1068, DOI 10.1016/j.jaad.2017.08.025; Kremer AE, 2012, HEPATOLOGY, V56, P1391, DOI 10.1002/hep.25748; Kremer AE, 2010, GASTROENTEROLOGY, V139, P1008, DOI 10.1053/j.gastro.2010.05.009; Krueger J, 2016, J ALLERGY CLIN IMMUN, V137, P1079, DOI 10.1016/j.jaci.2015.12.1318; Kumagai H, 2012, AM J NEPHROL, V36, P175, DOI 10.1159/000341268; Kuraishi Y, 2015, HANDB EXP PHARMACOL, V226, P207, DOI 10.1007/978-3-662-44605-8_12; Lee HG, 2017, J AM ACAD DERMATOL, V76, P760, DOI 10.1016/j.jaad.2016.10.030; Lee JH, 2014, CELL, V157, P1393, DOI 10.1016/j.cell.2014.03.064; Leslie TA, 2015, HANDB EXP PHARMACOL, V226, P337, DOI 10.1007/978-3-662-44605-8_18; Liu BY, 2016, P NATL ACAD SCI USA, V113, pE7572, DOI 10.1073/pnas.1606608113; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; Liu T, 2016, PAIN, V157, P806, DOI 10.1097/j.pain.0000000000000439; Ludbrook VJ, 2016, BRIT J DERMATOL, V174, P985, DOI 10.1111/bjd.14399; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Massaro AM, 2005, ANN PHARMACOTHER, V39, P77, DOI 10.1345/aph.1E242; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Meng J, 2016, CURR RES TRANSL MED, V64, P203, DOI 10.1016/j.retram.2016.08.006; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; Mishra SK, 2013, SCIENCE, V340, P968, DOI 10.1126/science.1233765; Mochizuki H, 2003, PAIN, V105, P339, DOI 10.1016/S0304-3959(03)00249-5; Mochizuki H, 2017, ALLERGOL INT, V66, P14, DOI 10.1016/j.alit.2016.08.013; Mochizuki H, 2015, J INVEST DERMATOL, V135, P2814, DOI 10.1038/jid.2015.223; Mochizuki H, 2015, CLIN NEUROPHYSIOL, V126, P1650, DOI 10.1016/j.clinph.2014.11.019; Mochizuki H, 2015, J DERMATOL, V42, P761, DOI 10.1111/1346-8138.12956; Mochizuki H, 2014, J NEUROPHYSIOL, V111, P488, DOI 10.1152/jn.00374.2013; Mu D, 2017, SCIENCE, V357, P695, DOI 10.1126/science.aaf4918; Murota H, 2017, ALLERGOL INT, V66, P8, DOI 10.1016/j.alit.2016.10.005; Murota H, 2012, J ALLERGY CLIN IMMUN, V130, P671, DOI 10.1016/j.jaci.2012.05.027; Nakagawa H, 2018, J DERMATOL, V45, P701, DOI 10.1111/1346-8138.14322; Napadow V, 2014, CEREB CORTEX, V24, P873, DOI 10.1093/cercor/bhs363; Nattkemper LA, 2018, J INVEST DERMATOL, V138, P1311, DOI 10.1016/j.jid.2017.12.029; Nattkemper LA, 2016, ACTA DERM-VENEREOL, V96, P894, DOI 10.2340/00015555-2417; Nattkemper LA, 2013, J INVEST DERMATOL, V133, P2489, DOI 10.1038/jid.2013.166; Phan NQ, 2012, ACTA DERM-VENEREOL, V92, P555, DOI 10.2340/00015555-1353; Nishihara M, 2013, PAIN PHYSICIAN, V16, pE547; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; O'Donoghue Michael, 2005, Dermatol Ther, V18, P333; O'Neill JL, 2011, ACTA DERM-VENEREOL, V91, P537, DOI 10.2340/00015555-1126; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P5; Palkar R, 2018, J INVEST DERMATOL, V138, P1391, DOI 10.1016/j.jid.2017.12.025; Paller AS, 2016, J AM ACAD DERMATOL, V75, P494, DOI 10.1016/j.jaad.2016.05.046; Papoiu ADP, 2015, J INVEST DERMATOL, V135, P560, DOI 10.1038/jid.2014.398; Papoiu ADP, 2014, J NEUROPHYSIOL, V112, P1729, DOI 10.1152/jn.00827.2013; Papoiu ADP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082389; Papoiu ADP, 2013, ACTA DERM-VENEREOL, V93, P520, DOI 10.2340/00015555-1564; Papoiu ADP, 2012, NEUROIMAGE, V59, P3611, DOI 10.1016/j.neuroimage.2011.10.099; Papoiu ADP, 2010, EXPERT OPIN PHARMACO, V11, P1359, DOI 10.1517/14656566.2010.481670; Papp KA, 2016, BRIT J DERMATOL, V174, P1266, DOI 10.1111/bjd.14403; Park Bomi, 2013, J Lifestyle Med, V3, P91; Patel T, 2007, J AM ACAD DERMATOL, V57, P873, DOI 10.1016/j.jaad.2007.04.008; Pereira MP, 2018, J EUR ACAD DERMATOL, V32, P1059, DOI 10.1111/jdv.14570; Pereira U, 2010, BRIT J DERMATOL, V163, P70, DOI 10.1111/j.1365-2133.2010.09757.x; Phan NQ, 2010, J DTSCH DERMATOL GES, V8, P88, DOI [10.1111/j.1610-0387.2009.07213_supp.x, 10.1111/j.1610-0387.2009.07213.x]; Pongcharoen P, 2016, EUR J PAIN, V20, P24, DOI 10.1002/ejp.766; Poterucha TJ, 2013, J AM ACAD DERMATOL, V69, P320, DOI 10.1016/j.jaad.2013.03.013; Reich K, 2018, J EUR ACAD DERMATOL, V32, P397, DOI 10.1111/jdv.14738; Roblin D, 2015, ACTA DERM-VENEREOL, V95, P542, DOI 10.2340/00015555-2047; Roecker AJ, 2017, BIOORG MED CHEM LETT, V27, P2087, DOI 10.1016/j.bmcl.2017.03.085; Rosa AC, 2013, BRIT J PHARMACOL, V170, P38, DOI 10.1111/bph.12266; Rosen JD, 2018, DERMATOL CLIN, V36, P213, DOI 10.1016/j.det.2018.02.005; Ross SE, 2010, NEURON, V65, P886, DOI 10.1016/j.neuron.2010.02.025; Rukwied RR, 2013, J INVEST DERMATOL, V133, P268, DOI 10.1038/jid.2012.242; Sawynok J., 2014, ANESTH ANALG; Schmelz M, 2001, NEWS PHYSIOL SCI, V16, P33; Schmelz M, 1997, J NEUROSCI, V17, P8003; Schut C, 2016, ACTA DERM-VENEREOL, V96, DOI 10.2340/00015555-2177; Sekine R, 2012, EXP DERMATOL, V21, P201, DOI 10.1111/j.1600-0625.2011.01433.x; Selescu T, 2013, CHEM SENSES, V38, P563, DOI 10.1093/chemse/bjt027; Shim WS, 2007, J NEUROSCI, V27, P2331, DOI 10.1523/JNEUROSCI.4643-06.2007; Shimizu K, 2015, AM J PATHOL, V185, P3003, DOI 10.1016/j.ajpath.2015.07.015; Shiratori-Hayashi M, 2015, NAT MED, V21, P927, DOI 10.1038/nm.3912; Simonsen E, 2017, AM J KIDNEY DIS, V70, P638, DOI 10.1053/j.ajkd.2017.05.018; Skoff AM, 2006, EXP NEUROL, V197, P430, DOI 10.1016/j.expneurol.2005.10.006; Sobell JM, 2016, ACTA DERM-VENEREOL, V96, P514, DOI 10.2340/00015555-2360; Sola-Ortigosa J, 2012, J DERMATOL TREAT, V23, P203, DOI 10.3109/09546634.2010.519376; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sousa-Valente J, 2014, BRIT J PHARMACOL, V171, P2508, DOI 10.1111/bph.12532; Stander S, 2018, ACTA DERM-VENEREOL, V98, P340, DOI 10.2340/00015555-2856; Stander S, 2006, HAUTARZT, V57, P801, DOI 10.1007/s00105-006-1180-1; Stander S, 2005, J DERMATOL SCI, V38, P177, DOI 10.1016/j.jdermsci.2005.01.007; Stander S, 2003, ARCH DERMATOL, V139, P1463, DOI 10.1001/archderm.139.11.1463; Stander Sonja, 2006, Ther Clin Risk Manag, V2, P213; Steinhoff M, 2012, J ALLERGY CLIN IMMUN, V130, P1015, DOI 10.1016/j.jaci.2012.08.006; Storan ER, 2015, HANDB EXP PHARMACOL, V226, P163, DOI 10.1007/978-3-662-44605-8_9; Strober B, 2016, INT J DERMATOL, V55, P401, DOI 10.1111/ijd.13236; Stull C, 2016, AM J CLIN DERMATOL, V17, P617, DOI 10.1007/s40257-016-0213-5; Stull C, 2016, EXPERT OPIN PHARMACO, V17, P671, DOI 10.1517/14656566.2016.1127355; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Sun YG, 2007, NATURE, V448, P700, DOI 10.1038/nature06029; Sun Y, 2016, AUTOIMMUN REV, V15, P795, DOI 10.1016/j.autrev.2016.03.019; Tey HL, 2011, BRIT J DERMATOL, V165, P5, DOI 10.1111/j.1365-2133.2011.10217.x; Therene C, 2018, J INVEST DERMATOL, V138, P38, DOI 10.1016/j.jid.2017.05.039; Tominaga M, 2007, J INVEST DERMATOL, V127, P2228, DOI 10.1038/sj.jid.5700942; Tominaga M, 2014, J DERMATOL, V41, P205, DOI 10.1111/1346-8138.12317; Toth BI, 2014, BRIT J PHARMACOL, V171, P2568, DOI 10.1111/bph.12569; Valenzuela F, 2016, J EUR ACAD DERMATOL, V30, P1753, DOI 10.1111/jdv.13702; Velasco M, 2017, NEUROPHARMACOLOGY, V113, P608, DOI 10.1016/j.neuropharm.2016.04.002; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Wang FP, 2018, J DERMATOL SCI, V90, P190, DOI 10.1016/j.jdermsci.2018.01.016; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789; Wollina U, 2007, AM J CLIN DERMATOL, V8, P157, DOI 10.2165/00128071-200708030-00003; Yagi M, 2018, J GASTROENTEROL, V53, P1151, DOI 10.1007/s00535-018-1465-z; Yoshimura M, 2006, J PHARMACOL SCI, V101, P107, DOI 10.1254/jphs.CRJ06008X; Yosipovitch G, 2007, BRIT J DERMATOL, V156, P629, DOI 10.1111/j.1365-2133.2006.07711.x; Yosipovitch G, 1996, J AM ACAD DERMATOL, V35, P118, DOI 10.1016/S0190-9622(96)90524-1; Yosipovitch G, 2018, J EUR ACAD DERMATOL, V32, P1403, DOI 10.1111/jdv.15187; Yosipovitch G, 2008, J INVEST DERMATOL, V128, P1806, DOI 10.1038/jid.2008.3; Yosipovitch G, 2007, PAIN, V131, P4, DOI 10.1016/j.pain.2007.04.017; Yosipovitch G, 2018, ACTA DERM-VENEREOL, V98, P484, DOI 10.2340/00015555-2893; Yosipovitch G, 2018, J AM ACAD DERMATOL, V78, P882, DOI 10.1016/j.jaad.2018.02.030; Yosipovitch G, 2015, HANDB EXP PHARMACOL, V226, P57, DOI 10.1007/978-3-662-44605-8_4; Yosipovitch G, 2013, NEW ENGL J MED, V368, P1625, DOI 10.1056/NEJMcp1208814; Zachariae R, 2012, ACTA DERM-VENEREOL, V92, P508, DOI 10.2340/00015555-1221; Zhao ZQ, 2014, NEURON, V84, P821, DOI 10.1016/j.neuron.2014.10.003	178	126	130	4	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1375	1391		10.1016/j.jaci.2018.09.005	http://dx.doi.org/10.1016/j.jaci.2018.09.005			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30409247	Bronze			2022-12-18	WOS:000449429800001
J	Maurer, M; Metz, M; Brehler, R; Hillen, U; Jakob, T; Mahler, V; Pfohler, C; Staubach, P; Treudler, R; Wedi, B; Magerl, M				Maurer, Marcus; Metz, Martin; Brehler, Randolf; Hillen, Uwe; Jakob, Thilo; Mahler, Vera; Pfohler, Claudia; Staubach, Petra; Treudler, Regina; Wedi, Bettina; Magerl, Markus			Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IgE; physical urticaria; therapy; symptomatic dermographism; cholinergic urticaria	DELAYED PRESSURE URTICARIA; REFRACTORY SOLAR URTICARIA; CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA; CHRONIC IDIOPATHIC URTICARIA; ANTIIMMUNOGLOBULIN-E THERAPY; COLD CONTACT URTICARIA; CHOLINERGIC URTICARIA; PHYSICAL URTICARIA; HISTAMINE-RELEASE; VISIBLE-LIGHT	Background: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in patients with chronic inducible urticarias (CIndUs), which are frequently H-1-antihistamine resistant. Objective: From the current published literature, we aimed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. Methods: We performed a PubMed search to identify evidence on omalizumab use in the following 9 CIndU subtypes: symptomatic dermographism, cold urticaria, delayed-pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria, and aquagenic urticaria. Results: Forty-three trials, case studies, case reports, and analyses were identified. Our review indicates that omalizumab has substantial benefits in patients with various CIndUs. The evidence is strongest for symptomatic dermographism, cold urticaria, and solar urticaria. Little/no evidence was available on vibratory angioedema and aquagenic and contact urticaria. Our review supports rapid onset of action demonstrated through early symptom control in most cases, sometimes within 24 hours. Many patients gained complete/partial symptom relief and substantially improved quality of life. Adverse events were generally low, with omalizumab being well tolerated by most patients, including children. Conclusions: A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU. More data from randomized controlled studies are warranted.	[Maurer, Marcus; Metz, Martin; Magerl, Markus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany; [Brehler, Randolf] Univ Klinikum Munster, Klin Hautkrankheiten, Munster, Germany; [Hillen, Uwe] Vivantes Klinikum Berlin Neukolln, Klin Dermatol & Venerol, Berlin, Germany; [Jakob, Thilo] Justus Liebig Univ Giessen, Univ Med Ctr Giessen UKGM, Dept Dermatol & Allergol, Giessen, Germany; [Mahler, Vera] Friedrich Alexander Univ Erlangen Nuremberg, Dept Dermatol, Erlangen, Germany; [Pfohler, Claudia] Saarland Univ, Med Sch, Dept Dermatol, Homburg, Germany; [Staubach, Petra] Univ Med Mainz, Hautklin, Mainz, Germany; [Staubach, Petra] Univ Med Mainz, Poliklin, Mainz, Germany; [Treudler, Regina] Univ Med Ctr, Dept Dermatol Venereol & Allergol, Leipzig Interdisciplinary Allergy Ctr LICA, Leipzig, Germany; [Wedi, Bettina] Hannover Med Sch, Klin Dermatol Allergol & Venerol, Hannover, Germany; [Mahler, Vera] Paul Ehrlich Inst, Langen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster; VIivantes Klinikum Neukolln; Justus Liebig University Giessen; University Hospital of Giessen & Marburg; University of Erlangen Nuremberg; Universitatsklinikum des Saarlandes; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Leipzig University; Hannover Medical School; Paul Ehrlich Institute	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Wedi, Bettina/ABE-3636-2021; Magerl, Markus/ABI-5335-2020; Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Wedi, Bettina/0000-0002-9868-6308; Magerl, Markus/0000-0001-9218-5468; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X	Urticaria Network e.V.	Urticaria Network e.V.	We thank Gillian Brodie for editorial help with the preparation of this review. Gillian's help was made possible by the support of the Urticaria Network e.V. (www.urtikaria.net), which we gratefully acknowledge.	Abajian M, 2016, ACTA DERM-VENEREOL, V96, P56, DOI 10.2340/00015555-2150; Marin JCA, 2015, J INVEST ALLERG CLIN, V25, P303; Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Arasi S, 2015, PEDIAT ALLERG IMM-UK, V26, P583, DOI 10.1111/pai.12413; Aubin F, 2016, J AM ACAD DERMATOL, V74, P574, DOI 10.1016/j.jaad.2015.11.021; Baliu-Pique C, 2016, J EUR ACAD DERMATOL, V30, P704, DOI 10.1111/jdv.13001; BARLOW RJ, 1993, J AM ACAD DERMATOL, V29, P954, DOI 10.1016/0190-9622(93)70273-V; Bindslev-Jensen C, 2010, ALLERGY, V65, P138, DOI 10.1111/j.1398-9995.2009.02188.x; Botto NC, 2008, J AM ACAD DERMATOL, V59, P909, DOI 10.1016/j.jaad.2008.08.020; Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Brandes K, 1970, Z Allgemeinmed, V46, P1219; British Association of Dermatologists, 2016, SOL URT PAT INF LEAF; Brodska P, 2012, CASE REP DERMATOL, V4, P275, DOI 10.1159/000346284; Bruning JH, 2016, J DTSCH DERMATOL GES, V14, P936, DOI 10.1111/ddg.13017; Bullerkotte U, 2010, ALLERGY, V65, P931, DOI 10.1111/j.1398-9995.2009.02268.x; Carballada F, 2013, J INVEST ALLERG CLIN, V23, P519; Casale TB, 2015, J ALLER CL IMM-PRACT, V3, P743, DOI 10.1016/j.jaip.2015.04.015; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Combalia A, 2017, ACTAS DERMO-SIFILOGR, V108, P593, DOI [10.1016/j.ad.2016.11.0150001, 10.1016/j.ad.2016.11.015]; de Dios-Velazquez A, 2016, ANN ALLERG ASTHMA IM, V116, P260, DOI 10.1016/j.anai.2015.12.023; DELORE P, 1956, J Med Lyon, V37, P497; Duchini G, 2011, PHOTODERMATOL PHOTO, V27, P336, DOI 10.1111/j.1600-0781.2011.00624.x; Ferrer M, 2011, J ALLERGY CLIN IMMUN, V127, P1300, DOI 10.1016/j.jaci.2010.12.1085; Geller M, 2016, ANN ALLERG ASTHMA IM, V116, P81, DOI 10.1016/j.anai.2015.10.009; Gericke J, 2017, J ALLERGY CLIN IMMUN, V139, P1059, DOI 10.1016/j.jaci.2016.07.047; Ghazanfar MN, 2016, BRIT J DERMATOL, V175, P404, DOI 10.1111/bjd.14540; Gimenez-Arnau A, 2010, EUR J DERMATOL, V20, P552, DOI 10.1684/ejd.2010.1049; Groffik A, 2011, ALLERGY, V66, P303, DOI 10.1111/j.1398-9995.2010.02472.x; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Guzelbey O, 2008, ALLERGY, V63, P1563, DOI 10.1111/j.1398-9995.2008.01879.x; Harris JM, 2016, J ALLERGY CLIN IMMUN, V138, P1730, DOI 10.1016/j.jaci.2016.06.023; Hochhaus G, 2003, CURR MED RES OPIN, V19, P491, DOI 10.1185/030079903125002171; JACQUES P, 1992, J ALLERGY CLIN IMMUN, V89, P1139, DOI 10.1016/0091-6749(92)90297-F; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; Kasperska-Zajac A, 2016, INT J IMMUNOPATH PH, V29, P320, DOI 10.1177/0394632015623795; Kitsioulis NA, 2016, PEDIAT ALLERG IMM-UK, V27, P752, DOI 10.1111/pai.12609; Koch K, 2016, J ALLERGY CLIN IMMUN, V138, P1483, DOI 10.1016/j.jaci.2016.05.026; Kolkhir P, 2017, J ALLERGY CLIN IMMUN, V139, P1772, DOI 10.1016/j.jaci.2016.08.050; KontouFili K, 1997, ALLERGY, V52, P504, DOI 10.1111/j.1398-9995.1997.tb02593.x; Kowalzick L, 2017, HAUTARZT, V68, P492, DOI 10.1007/s00105-016-3913-0; Krause K, 2010, ALLERGY, V65, P1494, DOI 10.1111/j.1398-9995.2010.02409.x; Kutlu A, 2015, CHINESE MED J-PEKING, V128, P1559, DOI 10.4103/0366-6999.157703; Le Moing A, 2013, J AM ACAD DERMATOL, V69, DOI 10.1016/j.jaad.2012.10.026; Levi A, 2015, PEDIAT ALLERG IMM-UK, V26, P588, DOI 10.1111/pai.12441; Magerl M, 2016, ALLERGY, V71, P780, DOI 10.1111/all.12884; Maurer M, 2017, FITZPATRICKS DERMATO; Maurer M, 2017, J ALLERGY CLIN IMMUN; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; Mazarakis A, 2014, INT J CARDIOL, V176, pE52, DOI 10.1016/j.ijcard.2014.07.040; Metz M, 2008, ALLERGY, V63, P247, DOI 10.1111/j.1398-9995.2007.01591.x; Metz M, 2017, J ALLERGY CLIN IMMUN; Metz M, 2017, THERANOSTICS, V7, P1266, DOI 10.7150/thno.18304; Metz M, 2014, JAMA DERMATOL, V150, P288, DOI 10.1001/jamadermatol.2013.8705; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; Metz M, 2011, INT ARCH ALLERGY IMM, V154, P177, DOI 10.1159/000320233; Mihic LL, 2008, COLLEGIUM ANTROPOL, V32, P153; Moncourier M, 2016, PHOTODERMATOL PHOTO, V32, P314, DOI 10.1111/phpp.12271; Muller S, 2016, J EUR ACAD DERMATOL, V30, P524, DOI 10.1111/jdv.12922; Muller S, 2016, ACTA DERM-VENEREOL, V96, P416, DOI 10.2340/00015555-2224; MURPHY GM, 1987, BRIT J DERMATOL, V116, P801, DOI 10.1111/j.1365-2133.1987.tb04898.x; Nam YH, 2012, ALLERGY ASTHMA IMMUN, V4, P357, DOI 10.4168/aair.2012.4.6.357; Netchiporouk E, 2015, PEDIAT ALLERG IMM-UK, V26, P585, DOI 10.1111/pai.12407; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; Otto HF, 2009, ALLERGY ASTHMA PROC, V30, P333, DOI 10.2500/aap.2009.30.3237; Quintero OP, 2017, J ALLER CL IMM-PRACT, V5, P179, DOI 10.1016/j.jaip.2016.07.016; Poon E, 1999, BRIT J DERMATOL, V140, P667; Pressler A, 2013, CLIN EXP DERMATOL, V38, P151, DOI 10.1111/j.1365-2230.2012.04430.x; Rodriguez-Rodriguez M, 2014, ALLERGOL IMMUNOPATH, V42, P78, DOI 10.1016/j.aller.2012.11.001; Rorie A, 2016, J ALLER CL IMM-PRACT, V4, P547, DOI 10.1016/j.jaip.2015.12.017; Sabroe RA, 2010, CLIN EXP DERMATOL, V35, pe127, DOI 10.1111/j.1365-2230.2009.03748.x; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Saini SS, 2015, J INVEST DERMATOL, V135, P925, DOI [10.1038/jid.2014.512, 10.1038/jid.2014.306]; Sanchez J, 2017, J ALLER CL IMM-PRACT, V5, P464, DOI 10.1016/j.jaip.2016.09.029; Sanchez-Borges M, 2017, J EUR ACAD DERMATOL, V31, P964, DOI 10.1111/jdv.14221; Schoepke N, 2015, J EUR ACAD DERMATOL, V29, P708, DOI 10.1111/jdv.12661; Shindo H, 2012, ARCH DERMATOL RES, V304, P647, DOI 10.1007/s00403-012-1236-2; Siebenhaar F, 2007, CLIN EXP DERMATOL, V32, P241, DOI 10.1111/j.1365-2230.2007.02376.x; SIGAL C, 1964, CAN MED ASSOC J, V91, P609; Staubach P, 2016, ALLERGY, V71, P1135, DOI 10.1111/all.12870; Sussman G, 2014, ANN ALLERG ASTHMA IM, V112, P170, DOI 10.1016/j.anai.2013.12.005; Tannert LK, 2012, DERMATOLOGY, V224, P101, DOI 10.1159/000336572; Terrani I, 2016, CLIN EXP DERMATOL, V41, P890, DOI 10.1111/ced.12951; dos Santos RV, 2014, BRIT J DERMATOL, V170, P469, DOI 10.1111/bjd.12628; Vietri J, 2015, ANN ALLERG ASTHMA IM, V115, P306, DOI 10.1016/j.anai.2015.06.030; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P490, DOI 10.1016/j.jaci.2009.11.007; Wallengren J, 2007, ACTA DERM-VENEREOL, V87, P493, DOI 10.2340/00015555-0306; Weldon D, 2014, ALLERGY ASTHMA PROC, V35, P4, DOI 10.2500/aap.2014.35.3713; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x; Zuberbier T, 2007, ACTA DERM-VENEREOL, V87, P196, DOI 10.2340/00015555-0240; Zuberbier T, 2015, EXPERT REV CLIN IMMU, V11, P171, DOI 10.1586/1744666X.2015.993971	95	126	138	9	49	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					638	649		10.1016/j.jaci.2017.06.032	http://dx.doi.org/10.1016/j.jaci.2017.06.032			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28751232	Bronze			2022-12-18	WOS:000424410800021
J	Rivas, MN; Burton, OT; Oettgen, HC; Chatila, T				Rivas, Magali Noval; Burton, Oliver T.; Oettgen, Hans C.; Chatila, Talal			IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; food allergy; IL-4; IL-13; IL-33; group 2 innate lymphoid cells; innate lymphoid cells; nuocytes; mast cells; regulatory T cells; oral tolerance	TRANSCRIPTION FACTOR GATA3; RECEPTOR; PATHOGENESIS; ANAPHYLAXIS; INDUCTION; CYTOKINES; INSIGHTS; IMMUNITY; PROTEIN; POTENT	Background: Food allergy is a major health issue, but its pathogenesis remains obscure. Group 2 innate lymphoid cells (ILC2s) promote allergic inflammation. However their role in food allergy is largely unknown. Objective: We sought to investigate the role of ILC2s in food allergy. Methods: Food allergy-prone mice with a gain-of-function mutation in the IL-4 receptor a chain (Il4raF709) were orally sensitized with food allergens, and the ILC2 compartment was analyzed. The requirement for ILC2s in food allergy was investigated by using Il4raF709, IL-33 receptor-deficient (Il1rl1(-/-)), IL-13-deficient (Il13(-/-)), and IL-4-deficient (Il4(-/-)) mice and by adoptive transfer of in vitro-expanded ILC2s. Direct effects of ILC2s on regulatory T (Treg) cells and mast cells were analyzed in coculture experiments. Treg cell control of ILC2s was assessed in vitro and in vivo. Results: Il4raF709 mice with food allergy exhibit increased numbers of ILC2s. IL-4 secretion by ILC2s contributes to the allergic response by reducing allergen-specific Treg cell and activating mast cell counts. IL-33 receptor deficiency in Il4raF709 Il1rl1(-/-) mice protects against allergen sensitization and anaphylaxis while reducing ILC2 induction. Adoptive transfer of wild-type and Il13(-/-) but not Il4(-/-) ILC2s restored sensitization in Il4raF709 Il1rl1(-/-) mice. Treg cells suppress ILC2s in vitro and in vivo. Conclusion: IL-4 production by IL-33-stimulated ILC2s blocks the generation of allergen-specific Treg cells and favors food allergy. Strategies to block ILC2 activation or the IL-33/IL-33 receptor pathway can lead to innovative therapies in the treatment of food allergy.	[Rivas, Magali Noval; Burton, Oliver T.; Oettgen, Hans C.; Chatila, Talal] Boston Childrens Hosp, Div Immunol, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA; [Rivas, Magali Noval; Burton, Oliver T.; Oettgen, Hans C.; Chatila, Talal] Harvard Med Sch, Dept Pediat, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA; [Rivas, Magali Noval] Cedars Sinai Med Ctr, Dept Pediat, Div Pediat Infect Dis & Immunol, Infect & Immunol Dis Res Ctr, Los Angeles, CA 90048 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Cedars Sinai Medical Center	Chatila, T (corresponding author), Boston Childrens Hosp, Div Immunol, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA.; Chatila, T (corresponding author), Harvard Med Sch, Dept Pediat, Karp Family Bldg,Rm 10-214,1 Blackfan St, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Noval Rivas, Magali/R-4987-2016	Noval Rivas, Magali/0000-0001-5570-8928; Burton, Oliver/0000-0003-3884-7373; Oettgen, Hans/0000-0003-1199-1391; Chatila, Talal/0000-0001-7439-2762	National Institutes of Health/National Institute of Allergy and Infectious Diseases [5R01AI065617, 1R56AI117983-01, 1R01AI119918-01, 5T32AI007512-28, 1K01DK106303-01]; Rao Chakravorti Family Fund; Bunning Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007512, R01AI065617, R01AI119918, R56AI117983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK106303] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Rao Chakravorti Family Fund; Bunning Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases grants 5R01AI065617 and 1R56AI117983-01 (to T.C.), 1R01AI119918-01 (to H.C.O.), 5T32AI007512-28 (to O.T.B.) and 1K01DK106303-01 and (to O.T.B.), by the Rao Chakravorti Family Fund (to H.C.O.), and by the Bunning Foundation (to H.C.O. and T.C.).	Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Haribhai D, 2011, IMMUNITY, V35, P109, DOI 10.1016/j.immuni.2011.03.029; Haribhai D, 2009, J IMMUNOL, V182, P3461, DOI 10.4049/jimmunol.0802535; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Li JN, 2013, J ALLERGY CLIN IMMUN, V131, P442, DOI 10.1016/j.jaci.2012.10.011; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mosconi I, 2013, MUCOSAL IMMUNOL, V6, P1157, DOI 10.1038/mi.2013.12; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oczypok EA, 2015, J ALLERGY CLIN IMMUN, V136, P747, DOI 10.1016/j.jaci.2015.03.011; Palmer G, 2011, NAT REV RHEUMATOL, V7, P321, DOI 10.1038/nrrheum.2011.53; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rivas MN, 2012, J CLIN INVEST, V122, P1933, DOI 10.1172/JCI40591; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Saenz SA, 2013, J EXP MED, V210, P1823, DOI 10.1084/jem.20122332; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Spencer SP, 2014, SCIENCE, V343, P432, DOI 10.1126/science.1247606; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tachdjian R, 2010, J ALLERGY CLIN IMMUN, V125, P1128, DOI 10.1016/j.jaci.2010.01.054; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208	55	126	129	2	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					801	+		10.1016/j.jaci.2016.02.030	http://dx.doi.org/10.1016/j.jaci.2016.02.030			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27177780	Green Accepted, Bronze			2022-12-18	WOS:000385496000016
J	Green, PHR; Lebwohl, B; Greywoode, R				Green, Peter H. R.; Lebwohl, Benjamin; Greywoode, Ruby			Celiac disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Celiac disease; gluten intolerance; food allergy	TISSUE TRANSGLUTAMINASE; INCREASING PREVALENCE; CLINICAL PRESENTATION; LARAZOTIDE ACETATE; GLUTEN SENSITIVITY; ADULT-POPULATION; DOUBLE-BLIND; RISK; CHILDREN; DIAGNOSIS	This review will focus on the pathogenesis, clinical manifestations, diagnosis, and management of celiac disease (CD). Given an increasing awareness of gluten-related disorders, medical professionals of all varieties are encountering patients with a diagnosis of CD or who are thought to have food intolerance to gluten. The prevalence of CD among the general population is estimated to be 1% in Western nations, and there is growing evidence for underdiagnosis of the disease, especially in non-Western nations that were traditionally believed to be unaffected. The development of serologic markers specific to CD has revolutionized the ability both to diagnose and monitor patients with the disease. Additionally, understanding of the clinical presentations of CD has undergone a major shift over the past half century. Although it is well understood that CD develops in genetically predisposed subjects exposed to gluten, the extent of other environmental factors in the pathogenesis of the disease is an area of continued research. Currently, the main therapeutic intervention for CD is a gluten-free diet; however, novel nondietary agents are under active investigation. Future areas of research should also help us understand the relationship of CD to other gluten-related disorders.	[Green, Peter H. R.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10027 USA; Columbia Univ, Med Ctr, Celiac Dis Ctr, New York, NY 10027 USA	Columbia University; Columbia University	Green, PHR (corresponding author), Celiac Dis Ctr, 180 Ft Washington Ave, New York, NY 10032 USA.	pg11@columbia.edu						Akobeng AK, 2008, ALIMENT PHARM THER, V27, P1044, DOI 10.1111/j.1365-2036.2008.03669.x; Akobeng AK, 2006, ARCH DIS CHILD, V91, P39, DOI 10.1136/adc.2005.082016; Al-Hussaini A, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-180; Alessio MG, 2012, J PEDIATR GASTR NUTR, V55, P44, DOI 10.1097/MPG.0b013e3182470249; Armentia A, 2002, CLIN EXP ALLERGY, V32, P1216, DOI 10.1046/j.1365-2745.2002.01456.x; Ascher H, 1997, ARCH DIS CHILD, V76, P113, DOI 10.1136/adc.76.2.113; Bagdi E, 1999, BLOOD, V94, P260, DOI 10.1182/blood.V94.1.260.413k40_260_264; Bardella MT, 2005, SCAND J GASTROENTERO, V40, P15, DOI 10.1080/00365520410008169; Biesiekierski JR, 2013, GASTROENTEROLOGY, V145, P320, DOI 10.1053/j.gastro.2013.04.051; Brant A, 2007, CURR OPIN ALLERGY CL, V7, P152, DOI 10.1097/ACI.0b013e328042ba77; Brown GJ, 2011, GASTROENTEROLOGY, V140, pS437; Byass P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022774; Collado MC, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-232; Catassi C, 1999, LANCET, V354, P647, DOI 10.1016/S0140-6736(99)02609-4; Catassi C, 2013, NUTRIENTS, V5, P3839, DOI 10.3390/nu5103839; Collado MC, 2009, J CLIN PATHOL, V62, P264, DOI 10.1136/jcp.2008.061366; Constantin C, 2005, INT ARCH ALLERGY IMM, V138, P257, DOI 10.1159/000088727; Cosnes J, 2008, CLIN GASTROENTEROL H, V6, P753, DOI 10.1016/j.cgh.2007.12.022; Perez LC, 2012, EUR J INTERN MED, V23, P9, DOI 10.1016/j.ejim.2011.08.030; Crowe SE, 2014, GASTROENTEROLOGY, V146, P1594, DOI 10.1053/j.gastro.2014.04.027; Daveson AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017366; DeGaetani M, 2013, AM J GASTROENTEROL, V108, P647, DOI 10.1038/ajg.2013.45; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Digiacomo DV, 2013, SCAND J GASTROENTERO, V48, P921, DOI 10.3109/00365521.2013.809598; Dixit R, 2014, DIGEST DIS SCI, V59, P1509, DOI 10.1007/s10620-014-3025-6; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fasano A, 2012, NEW ENGL J MED, V367, P2419, DOI 10.1056/NEJMcp1113994; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Food and Drug Administration, FOOD LAB GLUT FREE L; GOLFETTO Lisléia, 2014, Arq. Gastroenterol., V51, P139, DOI 10.1590/S0004-28032014000200013; Gomez JC, 2001, AM J GASTROENTEROL, V96, P2700, DOI 10.1111/j.1572-0241.2001.04124.x; Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600; Green PHR, 2003, AM J MED, V115, P191, DOI 10.1016/S0002-9343(03)00302-4; Green PHR, 2001, AM J GASTROENTEROL, V96, P126, DOI 10.1111/j.1572-0241.2001.03462.x; Green PHR, 2003, LANCET, V362, P383, DOI 10.1016/S0140-6736(03)14027-5; Harper JW, 2007, AM J HEMATOL, V82, P996, DOI 10.1002/ajh.20996; HOLM S, 1992, ACTA PAEDIATR, V81, P585, DOI 10.1111/j.1651-2227.1992.tb12305.x; Hornell A, 2013, FOOD NUTR RES, V57, DOI 10.3402/fnr.v57i0.20823; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Husby S, 2014, RISK MANAGEMENT FOOD, V7, P129; Inomata N, 2009, CURR OPIN ALLERGY CL, V9, P238, DOI 10.1097/ACI.0b013e32832aa5bc; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914, DOI 10.1093/ajcn/75.5.914; James JM, 1997, J ALLERGY CLIN IMMUN, V99, P239, DOI 10.1016/S0091-6749(97)70103-9; Kearney J, 2010, PHILOS T R SOC B, V365, P2793, DOI 10.1098/rstb.2010.0149; Kelly CP, 2013, ALIMENT PHARM THER, V37, P252, DOI 10.1111/apt.12147; Korponay-Szabo IR, 2003, GUT, V52, P1567, DOI 10.1136/gut.52.11.1567; Krishnareddy S, 2014, AM J CLIN DERMATOL, V15, P51, DOI 10.1007/s40257-013-0051-7; Lahdeaho ML, 2014, GASTROENTEROLOGY, V146, P1649, DOI 10.1053/j.gastro.2014.02.031; Laurin P, 2004, SCAND J GASTROENTERO, V39, P946, DOI 10.1080/00365520410003380; Lebwohl B, 2014, CLIN GASTROENTEROL H, V12, P632, DOI 10.1016/j.cgh.2013.10.031; Lebwohl B, 2013, ANN INTERN MED, V159, P169, DOI 10.7326/0003-4819-159-3-201308060-00006; Lebwohl B, 2013, ARCH DIS CHILD, V98, P48, DOI 10.1136/archdischild-2012-302360; Lee AR, 2007, J HUM NUTR DIET, V20, P423, DOI 10.1111/j.1365-277X.2007.00763.x; Leffler DA, 2012, AM J GASTROENTEROL, V107, P1554, DOI 10.1038/ajg.2012.211; Leonard MM, 2014, CLIN EXP GASTROENTER, V7, P25, DOI 10.2147/CEG.S54567; Lionetti E, 2014, NEW ENGL J MED, V371, P1295, DOI 10.1056/NEJMoa1400697; Lohi S, 2007, ALIMENT PHARM THERAP, V26, P1217, DOI 10.1111/j.1365-2036.2007.03502.x; Ludvigsson JF, 2013, GUT, V62, P43, DOI 10.1136/gutjnl-2011-301346; Makharia GK, 2014, J GASTROEN HEPATOL, V29, P666, DOI 10.1111/jgh.12514; Malamut G, 2014, EXPERT REV GASTROENT, V8, P323, DOI 10.1586/17474124.2014.887438; Marild K, 2013, J PEDIATR-US, V163, P237, DOI 10.1016/j.jpeds.2012.12.087; Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116; Mention JJ, 2003, GASTROENTEROLOGY, V125, P730, DOI 10.1016/S0016-5085(03)01047-3; Meyer D, 2001, AM J GASTROENTEROL, V96, P112; Morita Eishin, 2009, Allergology International, V58, P493, DOI 10.2332/allergolint.09-RAI-0125; Mustalahti K, 2010, ANN MED, V42, P587, DOI 10.3109/07853890.2010.505931; Nadal I, 2007, J MED MICROBIOL, V56, P1669, DOI 10.1099/jmm.0.47410-0; Nijeboer P, 2013, J GASTROINTEST LIVER, V22, P435; Olivares M, 2014, BRIT J NUTR, V112, P30, DOI 10.1017/S0007114514000609; Palosuo K, 2003, CURR OPIN ALLERGY CL, V3, P205, DOI [10.1097/00130832-200306000-00009, 10.1097/01.all.0000072717.82112.cc]; Pozo-Rubio T, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/654143; Rampertab SD, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.08.044; Ravikumara M, 2007, J PEDIATR GASTR NUTR, V45, P497, DOI 10.1097/MPG.0b013e31812e5710; Ravikumara M, 2006, ARCH DIS CHILD, V91, P969, DOI 10.1136/adc.2006.094045; Reilly NR, 2011, J PEDIATR GASTR NUTR, V53, P528, DOI 10.1097/MPG.0b013e3182276d5e; Riddle MS, 2013, DIGEST DIS SCI, V58, P3242, DOI 10.1007/s10620-013-2733-7; Roberts SE, 2009, ALIMENT PHARM THER, V29, P222, DOI 10.1111/j.1365-2036.2008.03871.x; Rodrigo L, 2009, EXPERT OPIN INV DRUG, V18, P1865, DOI 10.1517/13543780903369333; Roma E, 2009, DIGESTION, V80, P185, DOI 10.1159/000227275; Rubio-Tapia A, 2012, AM J GASTROENTEROL, V107, P1538, DOI 10.1038/ajg.2012.219; Rubio-Tapia A, 2012, MAYO CLIN PROC, V87, P732, DOI 10.1016/j.mayocp.2012.06.003; Rubio-Tapia A, 2010, GUT, V59, P547, DOI 10.1136/gut.2009.195131; Rubio-Tapia A, 2009, GASTROENTEROLOGY, V137, P88, DOI 10.1053/j.gastro.2009.03.059; Sandberg-Bennich S, 2002, ACTA PAEDIATR, V91, P30, DOI 10.1080/080352502753457905; Sapone A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-13; Schuppan D, 2009, GASTROENTEROLOGY, V137, P1912, DOI 10.1053/j.gastro.2009.09.008; Shahbazkhani B, 2003, EUR J GASTROEN HEPAT, V15, P475, DOI 10.1097/01.meg.0000059118.41030.96; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Singh J, 2011, J HUM NUTR DIET, V24, P479, DOI 10.1111/j.1365-277X.2011.01160.x; Singh P, 2015, J CLIN GASTROENTEROL, V49, P212, DOI 10.1097/MCG.0000000000000105; Smith C M, 2000, Pediatr Diabetes, V1, P199, DOI 10.1046/j.1399543X.2000.010405.x; Sollid LM, 2005, CLIN GASTROENTEROL H, V3, P843, DOI 10.1016/S1542-3565(05)00532-X; Sood Ajit, 2003, Indian J Gastroenterol, V22, P124; Stene LC, 2006, AM J GASTROENTEROL, V101, P2333, DOI 10.1111/j.1572-0241.2006.00741.x; Tack GJ, 2013, WORLD J GASTROENTERO, V19, P5837, DOI 10.3748/wjg.v19.i35.5837; Tanpowpong P, 2014, PUBLIC HEALTH NUTR, V17, P823, DOI 10.1017/S1368980013003510; Tavakkoli A, 2014, DIGEST DIS SCI, V59, P1255, DOI 10.1007/s10620-013-2981-6; Taylor TB, 2015, J INVEST DERMATOL, V135, P623, DOI 10.1038/jid.2014.368; Tonutti E, 2014, AUTOIMMUN REV, V13, P472, DOI 10.1016/j.autrev.2014.01.043; Troncone R, 2011, J INTERN MED, V269, P582, DOI 10.1111/j.1365-2796.2011.02385.x; Vriezinga SL, 2014, NEW ENGL J MED, V371, P1304, DOI 10.1056/NEJMoa1404172; Welander A, 2010, PEDIATRICS, V125, pE530, DOI 10.1542/peds.2009-1200; West J, 2003, GUT, V52, P960, DOI 10.1136/gut.52.7.960; Whyte LA, 2013, ARCH DIS CHILD, V98, P405, DOI 10.1136/archdischild-2012-303113; Zevit N, 2014, J PEDIATR GASTR NUTR, V59, pS13, DOI 10.1097/01.mpg.0000450396.76521.b0	105	126	135	2	82	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1099	1106		10.1016/j.jaci.2015.01.044	http://dx.doi.org/10.1016/j.jaci.2015.01.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25956012				2022-12-18	WOS:000353980700001
J	Lao-Araya, M; Steveling, E; Scadding, GW; Durham, SR; Shamji, MH				Lao-Araya, Mongkol; Steveling, Esther; Scadding, Guy W.; Durham, Stephen R.; Shamji, Mohamed H.			Seasonal increases in peripheral innatelymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INNATE LYMPHOID-CELLS; ALLERGIC RHINITIS		[Lao-Araya, Mongkol] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Leukocyte Biol, London, England; MRC & Asthma UK Ctr Allerg Mech Asthma, London, England	Imperial College London; University of London; King's College London	Lao-Araya, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Leukocyte Biol, London, England.	m.shamji@imperial.ac.uk	Shamji, Mohamed/AAU-8811-2020; Shamji, Mohamed/AAD-1788-2019	Shamji, Mohamed/0000-0003-3425-3463; Lao-araya, Mongkol/0000-0002-6679-4152	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015416] Funding Source: NIH RePORTER; NIAID NIH HHS [N01 AI15416] Funding Source: Medline; Wellcome Trust [097881/Z/11/Z] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365	9	126	131	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1193	1195		10.1016/j.jaci.2014.07.029	http://dx.doi.org/10.1016/j.jaci.2014.07.029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25212194				2022-12-18	WOS:000344938900027
J	Rebane, A; Runnel, T; Aab, A; Maslovskaja, J; Ruckert, B; Zimmermann, M; Plaas, M; Kaner, J; Treis, A; Pihlap, M; Haljasorg, U; Hermann, H; Nagy, N; Kemeny, L; Erm, T; Kingo, K; Li, M; Boldin, MP; Akdis, CA				Rebane, Ana; Runnel, Toomas; Aab, Alar; Maslovskaja, Julia; Rueckert, Beate; Zimmermann, Maya; Plaas, Mario; Kaener, Jaanika; Treis, Angela; Pihlap, Maire; Haljasorg, Uku; Hermann, Helen; Nagy, Nikoletta; Kemeny, Lajos; Erm, Triin; Kingo, Kuelli; Li, Mei; Boldin, Mark P.; Akdis, Cezmi A.			MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; noncoding RNA; atopic eczema; gene therapy	NF-KAPPA-B; THYMIC STROMAL LYMPHOPOIETIN; T-CELL; IFN-GAMMA; EPITHELIAL-CELLS; ECZEMATOUS DERMATITIS; SIGNALING PROTEINS; GENE-EXPRESSION; ACTIVATION; APOPTOSIS	Background: Chronic skin inflammation in atopic dermatitis (AD) is associated with elevated expression of proinflammatory genes and activation of innate immune responses in keratinocytes. microRNAs (miRNAs) are short, single-stranded RNA molecules that silence genes via the degradation of target mRNAs or inhibition of translation. Objective: The aim of this study was to investigate the role of miR-146a in skin inflammation in AD. Methods: RNA and protein expression was analyzed using miRNA and mRNA arrays, RT-quantitative PCR, Western blotting, and immunonohistochemistry. Transfection of miR-146a precursors and inhibitors into human primary keratinocytes, luciferase assays, and MC903-dependent mouse model of AD were used to study miR-146a function. Results: We show that miR-146a expression is increased in keratinocytes and chronic lesional skin of patients with AD. miR-146a inhibited the expression of numerous proinflammatory factors, including IFN-gamma-inducible and AD-associated genes CCL5, CCL8, and ubiquitin D (UBD) in human primary keratinocytes stimulated with IFN-gamma, TNF-alpha, or IL-1 beta. In a mouse model of AD, miR-146a-deficient mice developed stronger inflammation characterized by increased accumulation of infiltrating cells in the dermis, elevated expression of IFN-gamma, CCL5, CCL8, and UBD in the skin, and IFN-gamma, IL-1 beta, and UBD in draining lymph nodes. Both tissue culture and in vivo experiments in mice demonstrated that miR-146a-mediated suppression in allergic skin inflammation partially occurs through direct targeting of upstream nuclear factor kappa B signal transducers caspase recruitment domain-containing protein 10 and IL-1 receptor-associated kinase 1. In addition, human CCL5 was determined as a novel, direct target of miR-146a. Conclusion: Our data demonstrate that miR-146a controls nuclear factor kappa B-dependent inflammatory responses in keratinocytes and chronic skin inflammation in AD.	[Rebane, Ana; Runnel, Toomas; Aab, Alar; Maslovskaja, Julia; Rueckert, Beate; Zimmermann, Maya; Kaener, Jaanika; Treis, Angela; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Rebane, Ana; Aab, Alar; Maslovskaja, Julia; Kaener, Jaanika; Pihlap, Maire; Haljasorg, Uku; Hermann, Helen] Univ Tartu, Inst Biomed & Translat Med, EE-50411 Tartu, Estonia; [Runnel, Toomas] Univ Tartu, Inst Mol & Cellular Biol, EE-50411 Tartu, Estonia; [Plaas, Mario] Univ Tartu, Transgen Technol Core Lab, EE-50411 Tartu, Estonia; [Nagy, Nikoletta; Kemeny, Lajos] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary; [Nagy, Nikoletta; Kemeny, Lajos] Hungarian Acad Sci, Dermatol Res Grp, Szeged, Hungary; [Erm, Triin] Tartu Univ Hosp, Dept Pathol, Tartu, Estonia; [Kingo, Kuelli] Univ Tartu, Dept Dermatol & Venereol, EE-50411 Tartu, Estonia; [Kingo, Kuelli] Tartu Univ Hosp, Dermatol Clin, Tartu, Estonia; [Li, Mei] Univ Strasbourg, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; [Boldin, Mark P.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA 91010 USA	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Tartu; University of Tartu; University of Tartu; Szeged University; Hungarian Academy of Sciences; University of Tartu; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; City of Hope; Beckman Research Institute of City of Hope	Rebane, A (corresponding author), Univ Tartu, Inst Biomed & Translat Med, Ravila 19, EE-50411 Tartu, Estonia.	ana.rebane@ut.ee	Kemeny, Lajos/ABF-1339-2021; Akdis, Cezmi/AAV-4844-2020; Nagy, Nikoletta/AAJ-6631-2020; Aab, Alar/AAF-7859-2021; Kärner, Jaanika/Q-5989-2017; Vaher, Helen/ABA-4471-2021; Kingo, Külli/H-3603-2012; Rebane, Ana/D-4279-2013; Haljasorg, Uku/Q-6147-2017; Aab, Alar/G-8177-2017	Kemeny, Lajos/0000-0002-2119-9501; Akdis, Cezmi/0000-0001-8020-019X; Nagy, Nikoletta/0000-0001-8576-7953; Kärner, Jaanika/0000-0002-3548-5023; Rebane, Ana/0000-0001-6051-1361; Kingo, Kulli/0000-0001-6301-9612; Haljasorg, Uku/0000-0002-1541-6020; Vaher, Helen/0000-0002-8845-0326; Aab, Alar/0000-0001-7661-0284; Li, Mei/0000-0003-4225-6699; Boldin, Mark/0000-0003-4593-0669	Swiss National Science Foundation [32-132899, 32-112306]; Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland (CK-CARE), Swiss-Polish contribution; Estonian Science Foundation [ESF8350, ESF7437]; European Union [SARMP12219T]; Estonian Research Council [IUT2-2, PUT214, PUT177]; SCIEX Program NMS-CH; SCIEX Program ESTBIOREG; European Regional Fund with Archimedes Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland (CK-CARE), Swiss-Polish contribution; Estonian Science Foundation; European Union(European Commission); Estonian Research Council(Estonian Research Council); SCIEX Program NMS-CH; SCIEX Program ESTBIOREG; European Regional Fund with Archimedes Foundation	This work was supported by the Swiss National Science Foundation (grant no. 32-132899 and grant no. 32-112306), the Christine Kuhne-Center for Allergy Research and Education, Davos, Switzerland (CK-CARE), Swiss-Polish contribution, the Estonian Science Foundation (grant no. ESF8350 and grant no. ESF7437), European Regional Fund with Archimedes Foundation, European Union structural assistance grant (grant no. SARMP12219T), institutional research grant (grant no. IUT2-2), and personal research grants (grant no. PUT214 and grant no. PUT177) from the Estonian Research Council. A. Rebane was supported by fellowships from the SCIEX Program NMS-CH and ESTBIOREG.	Ahn J, 2013, EMBO MOL MED, V5, P1602, DOI 10.1002/emmm.201302647; Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Bai BX, 2005, J DERMATOL SCI, V39, P189, DOI 10.1016/j.jdermsci.2005.06.003; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boldin MP, 2012, IMMUNOL REV, V246, P205, DOI 10.1111/j.1600-065X.2011.01089.x; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Canaan A, 2006, MOL CELL BIOL, V26, P5180, DOI 10.1128/MCB.00966-05; Classen A, 2011, EXP DERMATOL, V20, P48, DOI 10.1111/j.1600-0625.2010.01174.x; Crone SG, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-71; Curtale G, 2013, P NATL ACAD SCI USA, V110, P11499, DOI 10.1073/pnas.1219852110; Djuranovic S, 2011, SCIENCE, V331, P550, DOI 10.1126/science.1191138; Etzrodt M, 2012, CELL REPORTS, V1, P317, DOI 10.1016/j.celrep.2012.02.009; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1010/J.JACL2011.05.016; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gong PF, 2010, J AM SOC NEPHROL, V21, P316, DOI 10.1681/ASN.2009050479; Grabiner BC, 2007, GENE DEV, V21, P984, DOI 10.1101/gad.1502507; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hener P, 2011, J INVEST DERMATOL, V131, P2324, DOI 10.1038/jid.2011.208; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Lu TX, 2013, J ALLERGY CLIN IMMUN, V132, P3, DOI 10.1016/j.jaci.2013.04.039; Mahanivong C, 2008, ONCOGENE, V27, P1273, DOI 10.1038/sj.onc.1210746; Makeyev EV, 2008, SCIENCE, V319, P1789, DOI 10.1126/science.1152326; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; Medoff BD, 2009, AM J RESP CELL MOL, V40, P286, DOI 10.1165/rcmb.2008-0129OC; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Rebane A, 2012, J ALLERGY CLIN IMMUN, V129, P1297, DOI 10.1016/j.jaci.2012.02.020; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tanaka K, 2006, INT J IMMUNOGENET, V33, P423, DOI 10.1111/j.1744-313X.2006.00635.x; Tang YJ, 2009, ARTHRITIS RHEUM-US, V60, P1065, DOI 10.1002/art.24436; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J INVEST DERMATOL, V117, P927, DOI 10.1046/j.0022-202x.2001.01474.x; Watanabe N, 2004, NAT IMMUNOL, V5, P426, DOI 10.1038/ni1048; Xu N, 2011, J INVEST DERMATOL, V131, P1521, DOI 10.1038/jid.2011.55; Yang LL, 2012, J EXP MED, V209, P1655, DOI 10.1084/jem.20112218; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, P200, DOI 10.1016/j.jaci.2010.11.005	64	126	132	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					836	U443		10.1016/j.jaci.2014.05.022	http://dx.doi.org/10.1016/j.jaci.2014.05.022			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24996260	Bronze			2022-12-18	WOS:000343155700009
J	Lee, JJ; Jacobsen, EA; Ochkur, SI; McGarry, MP; Condjella, RM; Doyle, AD; Luo, HJ; Zellner, KR; Protheroe, CA; Willetts, L; LeSuer, WE; Colbert, DC; Helmers, RA; Lacy, P; Moqbel, R; Lee, NA				Lee, James J.; Jacobsen, Elizabeth A.; Ochkur, Sergei I.; McGarry, Michael P.; Condjella, Rachel M.; Doyle, Alfred D.; Luo, Huijun; Zellner, Katie R.; Protheroe, Cheryl A.; Willetts, Lian; LeSuer, William E.; Colbert, Dana C.; Helmers, Richard A.; Lacy, Paige; Moqbel, Redwan; Lee, Nancy A.			Human versus mouse eosinophils: "That which we call an eosinophil, by any other name would stain as red"	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; mouse; human; rodent; primate; hematology	MAJOR BASIC-PROTEIN; ANTIGEN-PRESENTING CELLS; AIRWAY MUCOSAL EOSINOPHILS; PLATELET-ACTIVATING-FACTOR; TOLL-LIKE RECEPTORS; ALLERGIC INFLAMMATION; MOLECULAR-CLONING; BONE-MARROW; RIBONUCLEASE GENES; CATIONIC PROTEIN	The respective life histories of human subjects and mice are well defined and describe a unique story of evolutionary conservation extending from sequence identity within the genome to the underpinnings of biochemical, cellular, and physiologic pathways. As a consequence, the hematopoietic lineages of both species are invariantly maintained, each with identifiable eosinophils. This canonical presence nonetheless does not preclude disparities between human and mouse eosinophils, their effector functions, or both. Indeed, many books and reviews dogmatically highlight differences, providing a rationale to discount the use of mouse models of human eosinophilic diseases. We suggest that this perspective is parochial and ignores the wealth of available studies and the consensus of the literature that overwhelming similarities (and not differences) exist between human and mouse eosinophils. The goal of this review is to summarize this literature and in some cases provide experimental details comparing and contrasting eosinophils and eosinophil effector functions in human subjects versus mice. In particular, our review will provide a summation and an easy-to-use reference guide to important studies demonstrating that although differences exist, more often than not, their consequences are unknown and do not necessarily reflect inherent disparities in eosinophil function but instead species-specific variations. The conclusion from this overview is that despite nominal differences, the vast similarities between human and mouse eosinophils provide important insights as to their roles in health and disease and, in turn, demonstrate the unique utility of mouse-based studies with an expectation of valid extrapolation to the understanding and treatment of patients. (J Allergy Clin Immunol 2012;130:572-84.)	[Lee, James J.; Jacobsen, Elizabeth A.; Ochkur, Sergei I.; McGarry, Michael P.; Doyle, Alfred D.; Luo, Huijun; Willetts, Lian] Mayo Clin Arizona, Dept Biochem & Mol Biol, Div Pulm Med, Scottsdale, AZ 85259 USA; [Condjella, Rachel M.; Zellner, Katie R.; Protheroe, Cheryl A.; LeSuer, William E.; Colbert, Dana C.; Lee, Nancy A.] Mayo Clin Arizona, Dept Biochem & Mol Biol, Div Hematol Oncol, Scottsdale, AZ 85259 USA; [Helmers, Richard A.] Mayo Clin Arizona, Dept Crit Care Med, Div Pulm Med, Scottsdale, AZ 85259 USA; [Willetts, Lian; Lacy, Paige] Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB, Canada; [Moqbel, Redwan] Univ Manitoba, Dept Immunol, Winnipeg, MB R3T 2N2, Canada	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; University of Alberta; University of Manitoba	Lee, JJ (corresponding author), Mayo Clin Arizona, Dept Biochem & Mol Biol, Div Pulm Med, Mayo Clin Collaborat Res Bldg,2 206,13400 E Shea, Scottsdale, AZ 85259 USA.	jjlee@mayo.edu	Lacy, Paige/A-6021-2010	Lacy, Paige/0000-0001-8885-6011; Jacobsen, Elizabeth A./0000-0003-2956-753X	Mayo Foundation; United States National Institutes of Health [HL058723, HL065228, RR0109709]; American Heart Association [05556392, 0855703, 11SDG7510043]; Canadian Institutes of Health Research [MOP89748]; Lung Association of Alberta; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL058723, R01HL065228, R01HL058723, R01HL060793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR061567] Funding Source: NIH RePORTER	Mayo Foundation; United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Lung Association of Alberta; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Mayo Foundation and grants from the United States National Institutes of Health (to N.A.L. [HL058723] and J.J.L. [HL065228 and RR0109709]), the American Heart Association (to N.A.L. [05556392], J.J.L. [0855703], and E.A.J. [11SDG7510043]), the Canadian Institutes of Health Research (to R.M. [MOP89748]), and the Lung Association of Alberta (to L.W.).	ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Ackerman SJ, 2002, J BIOL CHEM, V277, P14859, DOI 10.1074/jbc.M200221200; ACKERMAN SJ, 1983, J EXP MED, V158, P946, DOI 10.1084/jem.158.3.946; Ackerman SJ, 2007, IMMUNOL ALLERGY CLIN, V27, P357, DOI 10.1016/j.iac.2007.07.004; Akuthota P, 2008, CLIN EXP ALLERGY, V38, P1254, DOI 10.1111/j.1365-2222.2008.03037.x; Akuthota P, 2010, CURR OPIN ALLERGY CL, V10, P14, DOI 10.1097/ACI.0b013e328334f693; BARKER RL, 1991, J CLIN INVEST, V88, P798, DOI 10.1172/JCI115379; Berro AI, 2004, J IMMUNOL, V173, P2174, DOI 10.4049/jimmunol.173.3.2174; Bink K, 2001, HISTOCHEM CELL BIOL, V115, P293; Blanchard C, 2009, ADV IMMUNOL, V101, P81, DOI 10.1016/S0065-2776(08)01003-1; Bloom JW, 2004, APOPTOSIS, V9, P97, DOI 10.1023/B:APPT.0000012126.06126.c4; Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033; Chauhan S, 2003, J STEROID BIOCHEM, V84, P441, DOI 10.1016/S0960-0760(03)00065-7; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Christie PE, 2002, CL ALLER IM, V16, P233; Church DM, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000112; Clark K, 2004, J LEUKOCYTE BIOL, V75, P1001, DOI 10.1189/jlb.0803391; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Cormier SA, 2001, MAMM GENOME, V12, P352, DOI 10.1007/s003350020007; Cormier SA, 2002, AM J RESP CELL MOL, V27, P678, DOI 10.1165/rcmb.4882; Correale J, 2004, NEUROLOGY, V63, P2363, DOI 10.1212/01.WNL.0000148481.80152.BF; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Das AM, 1999, CLIN EXP IMMUNOL, V117, P223, DOI 10.1046/j.1365-2249.1999.00978.x; de Jong M, 2010, J NUCL MED, V51, P501, DOI 10.2967/jnumed.109.065706; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Denzler KL, 2001, J IMMUNOL, V167, P1672, DOI 10.4049/jimmunol.167.3.1672; DVORAK AM, 1994, J HISTOCHEM CYTOCHEM, V42, P1443, DOI 10.1177/42.11.7930526; DVORAK AM, 1994, HISTOL HISTOPATHOL, V9, P339; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Dyer KD, 2010, J IMMUNOL, V184, P6327, DOI 10.4049/jimmunol.0904043; EGESTEN A, 1986, J HISTOCHEM CYTOCHEM, V34, P1399, DOI 10.1177/34.11.3772075; Ehrlich P, 1879, ARCH ANAT PHYSL, V3, P571; Erjefalt JS, 1998, J ALLERGY CLIN IMMUN, V102, P286, DOI 10.1016/S0091-6749(98)70098-3; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074, DOI 10.1164/ajrccm.161.6.9906085; Evsikov AV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-r84; FILLEY WV, 1982, LANCET, V2, P11; Foster EL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022029; Geijsen N, 2001, CYTOKINE GROWTH F R, V12, P19, DOI 10.1016/S1359-6101(00)00019-8; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Giemsa G, 1902, ZENTRALBLBAKTERIOL, V31, P429; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; Goldman M, 2001, TRENDS IMMUNOL, V22, P247, DOI 10.1016/S1471-4906(01)01893-2; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gouon-Evans V, 2000, DEVELOPMENT, V127, P2269; Grant GE, 2009, PROSTAG OTH LIPID M, V89, P98, DOI 10.1016/j.prostaglandins.2009.05.002; Greiff L, 1998, ALLERGY, V53, P200, DOI 10.1111/j.1398-9995.1998.tb03871.x; Hevko JM, 2001, J PHARMACOL EXP THER, V296, P293; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Horton MA, 1996, J LEUKOCYTE BIOL, V60, P285, DOI 10.1002/jlb.60.2.285; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; Iwasaki H, 2005, J EXP MED, V201, P1891, DOI 10.1084/jem.20050548; Jacobsen EA, 2012, BLOOD IN PRESS; Jacobsen EA, 2011, J IMMUNOL, V187, P6059, DOI 10.4049/jimmunol.1102299; Jampilek J, 2006, CURR MED CHEM, V13, P117, DOI 10.2174/092986706775197935; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; KARARLI TT, 1995, BIOPHARM DRUG DISPOS, V16, P351, DOI 10.1002/bdd.2510160502; Kim HJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011439; Kita H, 2011, IMMUNOL REV, V242, P161, DOI 10.1111/j.1600-065X.2011.01026.x; Kubach J, 2007, BLOOD, V110, P1550, DOI 10.1182/blood-2007-01-069229; Kvarnhammar AM, 2012, IMMUNOLOGY, V136, P11, DOI 10.1111/j.1365-2567.2012.03556.x; Lacy P, 2000, CHEM IMMUNOL, V76, P134; Lacy P, 2001, CURR OPIN ALLERGY CL, V1, P79, DOI 10.1097/01.all.0000010989.39379.49; LARSON KA, 1995, J IMMUNOL, V155, P3002; Larson KA, 1996, P NATL ACAD SCI USA, V93, P12370, DOI 10.1073/pnas.93.22.12370; Lee JJ, 2010, CLIN EXP ALLERGY, V40, P563, DOI 10.1111/j.1365-2222.2010.03484.x; Lee J.J., 2012, EOSINOPHILS HLTH DIS; Lee JB, 2004, IMMUNOL INVEST, V33, P27, DOI 10.1081/IMM-120027682; Lee JJ, 2005, CLIN EXP ALLERGY, V35, P986, DOI 10.1111/j.1365-2222.2005.02302.x; LEIFERMAN KM, 1989, ALLERGY, V44, P20, DOI 10.1111/j.1398-9995.1989.tb02450.x; Letuve S, 2001, J LEUKOCYTE BIOL, V70, P767; LI MS, 1995, BIOCHEM J, V305, P921, DOI 10.1042/bj3050921; Logan MR, 2006, ALLERGY, V61, P777, DOI 10.1111/j.1398-9995.2006.01089.x; Logan MR, 2002, J ALLERGY CLIN IMMUN, V109, P299, DOI 10.1067/mai.2002.121453; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; Macias MP, 2000, J LEUKOCYTE BIOL, V67, P567, DOI 10.1002/jlb.67.4.567; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352, DOI 10.1165/ajrcmb.24.3.4357; Masterson JC, 2011, CURR OPIN GASTROEN, V27, P515, DOI 10.1097/MOG.0b013e32834b314c; Matsuwaki Y, 2011, INT ARCH ALLERGY IMM, V155, P123, DOI 10.1159/000327498; McGarry MP, 2009, MOUSE HEMATOLOGY; McGarry MP, 2012, EOSINOPHILS HLTH DIS; MCKENNA MG, 1969, ANN NY ACAD SCI, V167, P217, DOI 10.1111/j.1749-6632.1969.tb20446.x; McNagny K, 2002, J EXP MED, V195, pf43, DOI 10.1084/jem.20020636; Melo RCN, 2005, TRAFFIC, V6, P1047, DOI 10.1111/j.1600-0854.2005.00344.x; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; MILLER F, 1966, J CELL BIOL, V31, P349, DOI 10.1083/jcb.31.2.349; Moqbel R, 2000, CHEM IMMUNOL, V78, P189; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; Mori Y, 2009, J EXP MED, V206, P183, DOI 10.1084/jem.20081756; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; Nakajima T, 2001, BLOOD, V98, P1127, DOI 10.1182/blood.V98.4.1127; Neves JS, 2008, P NATL ACAD SCI USA, V105, P18478, DOI 10.1073/pnas.0804547105; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Ochkur SI, 2007, J IMMUNOL, V178, P7879, DOI 10.4049/jimmunol.178.12.7879; Ochkur SI, 2012, J IMMUNOL METHODS, V375, P138, DOI 10.1016/j.jim.2011.10.002; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Percopo CM, 2009, J IMMUNOL, V183, P604, DOI 10.4049/jimmunol.0802270; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P465; Persson CGA, 1997, THORAX, V52, P569, DOI 10.1136/thx.52.6.569; Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; POWELL WS, 1995, J IMMUNOL, V154, P4123; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; Raap U, 2008, EXP DERMATOL, V17, P731, DOI 10.1111/j.1600-0625.2008.00741.x; Radinger M, 2009, PHARMACOL THERAPEUT, V121, P174, DOI 10.1016/j.pharmthera.2008.10.008; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Romanovski DL, 1891, QUESTION PARASITOLOG; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; Rosenthal N, 2007, NAT CELL BIOL, V9, P993, DOI 10.1038/ncb437; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Shamri R, 2012, FASEB J, V26, P2084, DOI 10.1096/fj.11-200246; Shamri R, 2011, CELL TISSUE RES, V343, P57, DOI 10.1007/s00441-010-1049-6; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shi HZ, 2004, ALLERGY, V59, P428, DOI 10.1046/j.1398-9995.2003.00405.x; Spencer LA, 2010, IMMUNOL CELL BIOL, V88, P250, DOI 10.1038/icb.2009.115; Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058; Stanley AC, 2010, PHYSIOLOGY, V25, P218, DOI 10.1152/physiol.00017.2010; Stelts D, 1998, AM J RESP CELL MOL, V18, P463, DOI 10.1165/ajrcmb.18.4.2957; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; Throsby M, 2000, J IMMUNOL, V165, P1965, DOI 10.4049/jimmunol.165.4.1965; Timmons BC, 2009, J IMMUNOL, V182, P2700, DOI 10.4049/jimmunol.0803138; Tokoyoda K, 2010, NAT REV IMMUNOL, V10, P193, DOI 10.1038/nri2727; Tong JK, 2006, J EXP MED, V203, P1173, DOI 10.1084/jem.20051680; Tseng YK, 2004, ANN TROP MED PARASIT, V98, P831, DOI 10.1179/000349804X3199; Tulic MK, 2009, AM J PATHOL, V175, P2043, DOI 10.2353/ajpath.2009.090015; Uhm TG, 2012, ALLERGY ASTHMA IMMUN, V4, P68, DOI 10.4168/aair.2012.4.2.68; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; WAGNER JM, 1994, PLACENTA, V15, P625, DOI 10.1016/S0143-4004(05)80409-6; Walsh GM, 2003, J ENDOCRINOL, V178, P37, DOI 10.1677/joe.0.1780037; Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WELLER PF, 1980, P NATL ACAD SCI-BIOL, V77, P7440, DOI 10.1073/pnas.77.12.7440; WELLER PF, 1993, J IMMUNOL, V150, P2554; Wen T, 2012, J IMMUNOL, V188, P1075, DOI 10.4049/jimmunol.1102222; Wenzel S, 2006, AM J RESP CRIT CARE, V174, P1173, DOI 10.1164/rccm.2609002; Wenzel SE, 2009, NEW ENGL J MED, V360, P1026, DOI 10.1056/NEJMe0900334; Willetts L, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-116; Wong CK, 2007, AM J RESP CELL MOL, V37, P85, DOI 10.1165/rcmb.2006-0457OC; Wright JH, 1902, J MED RES, V7, P138; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x	158	126	127	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					572	584		10.1016/j.jaci.2012.07.025	http://dx.doi.org/10.1016/j.jaci.2012.07.025			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22935586	Green Accepted			2022-12-18	WOS:000308463500002
J	Bauer, RN; Diaz-Sanchez, D; Jaspers, I				Bauer, Rebecca N.; Diaz-Sanchez, David; Jaspers, Ilona			Effects of air pollutants on innate immunity: The role of Toll-like receptors and nucleotide-binding oligomerization domain-like receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor; NOD-like receptor; pattern recognition receptor; inflammasome; cigarette smoke; particulate matter; ozone; diesel exhaust; nanoparticles; air pollutant; innate immunity; host defense; pathogen-associated molecular pattern; danger-associated molecular pattern; lung; airway	PATTERN-RECOGNITION RECEPTORS; PLASMACYTOID DENDRITIC CELLS; DIESEL EXHAUST PARTICLES; EPITHELIAL-CELLS; NLRP3 INFLAMMASOME; NALP3 INFLAMMASOME; OZONE EXPOSURE; LUNG HYPERPERMEABILITY; PULMONARY INFLAMMATION; HOSPITAL ADMISSIONS	Interactions between exposure to ambient air pollutants and respiratory pathogens have been shown to modify respiratory immune responses. Emerging data suggest key roles for Toll-like receptor (TLR) and nucleotide-binding oligomerization domain-like receptor (NLR) signaling in pathogen-induced immune responses. Similarly, immune responses elicited by exposure to air pollutants are mediated by specific TLR- and NLR-dependent mechanisms. This review article will summarize current knowledge about how air pollutants modify TLR-and NLR-dependent signaling and host defense responses in the lung. (J Allergy Clin Immunol 2012; 129: 14-24.)	[Bauer, Rebecca N.; Jaspers, Ilona] Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27515 USA; [Jaspers, Ilona] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA; [Jaspers, Ilona] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Diaz-Sanchez, David] US EPA, Natl Hlth & Environm Effects, Res Lab, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency	Jaspers, I (corresponding author), 104 Mason Farm Rd, Chapel Hill, NC 27599 USA.	ilona_japsers@med.unc.edu	Jaspers, Ilona/AAZ-5035-2020		National Institute of Environmental Health Sciences (NIEHS); Howard Hughes Medical Institute (HHMI); NIEHS/National Institutes of Health (NIH); National Heart, Lung, and Blood Institute/NIH; Flight Attendant Medical Research Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007126, R01ES013611] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Howard Hughes Medical Institute (HHMI)(Howard Hughes Medical Institute); NIEHS/National Institutes of Health (NIH); National Heart, Lung, and Blood Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Flight Attendant Medical Research Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	R. N. Bauer has received research support from the National Institute of Environmental Health Sciences (NIEHS) Toxicology Training Grant and the Howard Hughes Medical Institute (HHMI) Translational Medicine Training Grant. D. Diaz-Sanchez declares that he has no relevant conflicts of interest. I. Jaspers has received research support from the NIEHS/National Institutes of Health (NIH); the National Heart, Lung, and Blood Institute/NIH; and the Flight Attendant Medical Research Institute.	Ahmad S, 2005, FREE RADICAL BIO MED, V39, P213, DOI 10.1016/j.freeradbiomed.2005.03.009; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; American Lung Association, STAT AIR 2011; Armstrong L, 2004, AM J RESP CELL MOL, V31, P241, DOI 10.1165/rcmb.2004-0078OC; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; Babelova A, 2009, J BIOL CHEM, V284, P24035, DOI 10.1074/jbc.M109.014266; Bauer AK, 2011, ENVIRON HEALTH PERSP, V119, P1091, DOI 10.1289/ehp.1003326; Becker S, 2005, TOXICOL APPL PHARM, V203, P45, DOI 10.1016/j.taap.2004.07.007; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Bloomberg GR, 2011, CURR OPIN ALLERGY CL, V11, P144, DOI 10.1097/ACI.0b013e3283445950; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Card JW, 2008, AM J PHYSIOL-LUNG C, V295, pL400, DOI 10.1152/ajplung.00041.2008; Castro SM, 2011, TOXICOL IN VITRO, V25, P1106, DOI 10.1016/j.tiv.2011.03.011; Chaudhuri N, 2010, AM J PHYSIOL-LUNG C, V299, pL263, DOI 10.1152/ajplung.00297.2009; Ciencewicki J, 2006, AM J PHYSIOL-LUNG C, V290, pL1154, DOI 10.1152/ajplung.00318.2005; Corr SC, 2009, J INNATE IMMUN, V1, P350, DOI 10.1159/000200774; Cottey L, 2010, THORAX, V65, pA21, DOI 10.1136/thx.2010.150912.42; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034; Di Virgilio Francesco, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P85; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Doz E, 2008, J IMMUNOL, V180, P1169, DOI 10.4049/jimmunol.180.2.1169; Dye JA, 1999, AM J PHYSIOL-LUNG C, V277, pL498, DOI 10.1152/ajplung.1999.277.3.L498; Eltom S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024097; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; Garantziotis S, 2010, AM J RESP CRIT CARE, V181, P666, DOI 10.1164/rccm.200903-0381OC; Garantziotis S, 2009, J BIOL CHEM, V284, P11309, DOI 10.1074/jbc.M802400200; Goulaouic S, 2008, J IMMUNOTOXICOL, V5, P337, DOI 10.1080/15476910802371016; Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hernandez ML, 2010, J ALLERGY CLIN IMMUN, V126, P537, DOI 10.1016/j.jaci.2010.06.043; Hollingsworth John W, 2007, Proc Am Thorac Soc, V4, P240, DOI 10.1513/pats.200701-023AW; Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC; Hopke Philip K, 2006, Clin Occup Environ Med, V5, P747; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Huttunen R, 2011, J INTERN MED, V269, P258, DOI 10.1111/j.1365-2796.2010.02332.x; Inoue K, 2006, ARCH TOXICOL, V80, P275, DOI 10.1007/s00204-005-0040-6; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jiang DH, 2006, CELL RES, V16, P693, DOI 10.1038/sj.cr.7310085; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851; Kaplan Charlotte, 2010, Reviews on Environmental Health, V25, P221; Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020; Kim CS, 2011, AM J RESP CRIT CARE, V183, P1215, DOI 10.1164/rccm.201011-1813OC; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620, DOI 10.1165/ajrcmb.22.5.3912; Kleeberger SR, 2001, AM J PHYSIOL-LUNG C, V280, pL326, DOI 10.1152/ajplung.2001.280.2.L326; Kum-Nji P, 2006, PEDIATRICS, V117, P1745, DOI 10.1542/peds.2005-1886; Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272; Lafferty EI, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-57; Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Li XY, 1998, AM J RESP CRIT CARE, V157, P1027, DOI 10.1164/ajrccm.157.4.9605080; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Migliaretti G, 2005, INT ARCH OCC ENV HEA, V78, P164, DOI 10.1007/s00420-004-0569-3; Mikerov AN, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-24; MORRIS K, 1990, AM J DIS CHILD, V144, P105, DOI 10.1001/archpedi.1990.02150250117047; Mortaz E, 2010, EUR RESPIR J, V36, P1143, DOI 10.1183/09031936.00062209; Mortaz E, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-47; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Pace E, 2008, IMMUNOLOGY, V124, P401, DOI 10.1111/j.1365-2567.2007.02788.x; Peden D, 2010, J ALLERGY CLIN IMMUN, V125, pS150, DOI 10.1016/j.jaci.2009.10.073; Peden DB, 2011, IMMUNOL REV, V242, P91, DOI 10.1111/j.1600-065X.2011.01035.x; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Reisetter AC, 2011, J BIOL CHEM, V286, P21844, DOI 10.1074/jbc.M111.238519; Sarir H, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-12; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Shoenfelt J, 2009, J LEUKOCYTE BIOL, V86, P303, DOI 10.1189/jlb.1008587; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54, DOI 10.1080/00039899809605689; Strachan DP, 1997, THORAX, V52, P905, DOI 10.1136/thx.52.10.905; Sun HL, 2006, AM J EMERG MED, V24, P709, DOI 10.1016/j.ajem.2006.03.006; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; United States Environmental Protection Agency, AIR QUAL TRENDS; Watters TM, 2007, IMMUNOL CELL BIOL, V85, P411, DOI 10.1038/sj.icb.7100095; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; Williams MA, 2007, J ALLERGY CLIN IMMUN, V119, P488, DOI 10.1016/j.jaci.2006.10.022; Yamawaki H, 2006, CIRC J, V70, P129, DOI 10.1253/circj.70.129; Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107; Yazdi AS, 2010, J CLIN IMMUNOL, V30, P623, DOI 10.1007/s10875-010-9437-y; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	87	126	127	4	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					14	26		10.1016/j.jaci.2011.11.004	http://dx.doi.org/10.1016/j.jaci.2011.11.004			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22196521	Green Accepted, Green Published			2022-12-18	WOS:000298634000003
J	Gupta, J; Grube, E; Ericksen, MB; Stevenson, MD; Lucky, AW; Sheth, AP; Assa'ad, AH; Hershey, GKK				Gupta, Jayanta; Grube, Emilie; Ericksen, Mark B.; Stevenson, Michelle D.; Lucky, Anne W.; Sheth, Anita P.; Assa'ad, Amal H.; Hershey, Gurjit K. Khurana			Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; transepidermal water loss; objective SCORAD; African American; white	TRANSEPIDERMAL WATER-LOSS; SODIUM LAURYL SULFATE; STRATUM-CORNEUM; UNINVOLVED SKIN; FILAGGRIN GENE; SUSCEPTIBILITY; MUTATIONS; PH; CAPACITANCE; PREDISPOSE	Background: Recent genetic evidence supports that an underlying defect in skin barrier function contributes to the pathogenesis of atopic dermatitis (AD). The integrity of the skin barrier can be assessed objectively by measuring transepidermal water loss (TEWL). Previous investigations of TEWL as a biomarker of skin barrier function have been limited by small sample size, and studies including African American subjects are lacking. Objective: We sought to determine whether children with AD have inherently altered skin barrier function by comparing TEWL as a measure of skin barrier function in African American and white children with AD with that in control subjects without AD. Methods: TEWL was measured on nonlesional normal-appearing skin at 4 sites (the volar forearm, dorsal arm, lower leg, and cheek) in (1) children with AD (cases), (2) children with asthma or allergic rhinitis but without AD (allergic control subjects), and (3) nonatopic control subjects. AD severity was assessed by using the objective SCORAD index. Results: TEWL was increased in children with AD compared with that seen in both control groups at most of the anatomic sites tested (P < .05). TEWL also correlated with objective SCORAD score. The presence of allergic sensitization or other allergic conditions did not affect TEWL among children with AD. TEWL was higher in white than in African American children. Conclusion: Skin barrier function as assessed by TEWL is intrinsically compromised in children with AD but not in children with other allergic conditions. The magnitude of skin barrier dysfunction correlates with AD disease severity.	[Gupta, Jayanta; Ericksen, Mark B.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Med Ctr, Inst Personalized & Predict Med, Dept Pediat, Cincinnati, OH 45229 USA; [Gupta, Jayanta] Cincinnati Childrens Hosp, Med Ctr, Div Epidemiol & Biostat, Dept Environm Hlth, Cincinnati, OH USA; [Grube, Emilie; Ericksen, Mark B.; Assa'ad, Amal H.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Lucky, Anne W.; Sheth, Anita P.] Cincinnati Childrens Hosp, Med Ctr, Div Pediat Dermatol, Cincinnati, OH USA; [Stevenson, Michelle D.] Cincinnati Childrens Hosp, Med Ctr, Div Emergency Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Inst Personalized & Predict Med, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchme.org	Lucky, Anne W/ABH-1415-2021	Stevenson, Michelle/0000-0002-3583-4481; Khurana Hershey, Gurjit/0000-0001-6663-977X	NICHD NIH HHS [T32 HD43005] Funding Source: Medline; NIEHS NIH HHS [T32 ES10957] Funding Source: Medline; PHS HHS [U19A170235-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD043005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGNER T, 1991, ACTA DERM-VENEREOL, V71, P296; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Basketter DA, 1998, CONTACT DERMATITIS, V38, P253, DOI 10.1111/j.1600-0536.1998.tb05738.x; BERARDESCA E, 1990, ACTA DERM-VENEREOL, V70, P400; BERARDESCA E, 1991, DERMATOLOGICA, V182, P89, DOI 10.1159/000247752; Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Choi SJ, 2003, J KOREAN MED SCI, V18, P93, DOI 10.3346/jkms.2003.18.1.93; Conti A, 1996, DERMATOLOGY, V192, P317, DOI 10.1159/000246402; Eberlein-Konig B, 2000, ACTA DERM-VENEREOL, V80, P188; Elias P M, 1999, Am J Contact Dermat, V10, P119, DOI 10.1016/S1046-199X(99)90054-4; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hatano Y, 2005, J INVEST DERMATOL, V124, P786, DOI 10.1111/j.0022-202X.2005.23651.x; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Jakasa I, 2006, BRIT J DERMATOL, V155, P104, DOI 10.1111/j.1365-2133.2006.07319.x; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Lee SH, 2006, YONSEI MED J, V47, P293, DOI 10.3349/ymj.2006.47.3.293; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Loffler H, 1999, CONTACT DERMATITIS, V40, P239, DOI 10.1111/j.1600-0536.1999.tb06056.x; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Matsui K, 2002, CLIN EXP ALLERGY, V32, P783, DOI 10.1046/j.1365-2222.2002.01357.x; Nicander I, 2004, SKIN RES TECHNOL, V10, P178, DOI 10.1111/j.1600-0846.2004.00065.x; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; PINNAGODA J, 1990, CONTACT DERMATITIS, V22, P164, DOI 10.1111/j.1600-0536.1990.tb01553.x; REINERTSON RP, 1959, J INVEST DERMATOL, V32, P49, DOI 10.1038/jid.1959.11; Schachner L, 1983, Pediatr Dermatol, V1, P157, DOI 10.1111/j.1525-1470.1983.tb01108.x; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Singh J, 2000, FOOD CHEM TOXICOL, V38, P717, DOI 10.1016/S0278-6915(00)00058-2; TUPKER RA, 1990, BRIT J DERMATOL, V123, P199, DOI 10.1111/j.1365-2133.1990.tb01847.x; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; WERNER Y, 1986, ACTA DERM-VENEREOL, V66, P281; Wesley NO, 2003, AM J CLIN DERMATOL, V4, P843, DOI 10.2165/00128071-200304120-00004	40	126	129	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					725	730		10.1016/j.jaci.2007.12.1161	http://dx.doi.org/10.1016/j.jaci.2007.12.1161			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18249438	Bronze			2022-12-18	WOS:000253918900029
J	Bousquet, J; Flahault, A; Vandenplas, O; Ameille, J; Duron, JJ; Pecquet, C; Chevrie, K; Annesi-Maesano, I				Bousquet, Jean; Flahault, Antoine; Vandenplas, Olivier; Ameille, Jacques; Duron, Jean-Jacques; Pecquet, Corine; Chevrie, Karine; Annesi-Maesano, Isabella			Natural rubber latex allergy among health care workers: A systematic review of the evidence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						latex allergy; health care workers; IgE; skin test; exposure-response relationship; meta-analysis	APPRENTICES STARTING EXPOSURE; OPERATING-ROOM NURSES; IN-HOSPITAL PERSONNEL; POWDER-FREE GLOVES; IGE ANTIBODIES; DENTAL STUDENTS; BLOOD-DONORS; OCCUPATIONAL EPIDEMIOLOGY; RESPIRATORY SYMPTOMS; NURSING STAFF	Background: Natural rubber latex is a recognized allergen, but a recent meta-analysis failed to find any association between latex exposure and allergy in health care workers (HCWs). Objectives: A meta-analysis was carried out under the auspices of the French National Regulatory Authority to assess the allergic risk induced by latex gloves in HCWs. Methods: The risk of work-related exposure to latex for the development of latex allergy was assessed. Prevalence and incidence rates of latex sensitization or allergy were compared in HCWs and in the general population. Exposure-response relationships were assessed in HCWs. Results: Latex allergy was found in 4.32% (range, 4.01% to 4.63%) of HCWs and in 1.37% (range, 0.43% to 2.31%) of the general population. Latex-positive skin prick test responses ranged from 2.1% to 3.7% in the general population and from 6.9% to 7.8% for the HCWs. HCWs exposed to latex showed an increased risk of hand dermatitis (odds ratio [OR], 2.46; 95% CI, 2.11-2.86), asthma or wheezing (OR, 1.55; 95% CI, 1.15-2.08), rhinoconjunctivitis (OR, 2.73; 95% CI, 1.97-3.81), and at least one generic symptom (OR, 1.27; 95% CI, 1.09-1.47). Sensitization to latex was significantly associated with asthma and rhinoconjunctivitis. By contrast, exposure to latex was not associated with a significantly increased risk of positive skin prick test responses to latex (OR, 1.47; 95% CI, 0.94-2.30). Conclusion: HCWs have an increased risk of sensitization and allergic symptoms to latex. Clinical implications: Prevention of latex allergy in HCWs is needed.	Univ Hosp, Clin Malad Resp, INSERM, U454,Hop Arnaud Villeneuve, F-34295 Montpellier 5, France; Univ Paris 06, INSERM, U707, Med Sch St Antoine, Paris, France; Clin Univ UCL Montgodinne, Serv Pneumol, Yvoir, France; Hop Raymond Poincare, Assistance Publ Hop Paris, Unit Occupat Hlth, Paris, France; CHU Pitie Salpetriere, Serv Chirurg Digest & Gen, Paris, France; Hop Tenon, Ctr Allergol, F-75970 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Bousquet, J (corresponding author), Univ Hosp, Clin Malad Resp, INSERM, U454,Hop Arnaud Villeneuve, F-34295 Montpellier 5, France.	jean.bousquet@wanadoo.fr	Annesi-Maesano, Isabella/D-9173-2016; Bousquet, Jean/O-4221-2019	Annesi-Maesano, Isabella/0000-0002-6340-9300; 				Ahmed DDF, 2003, IMMUNOL ALLERGY CLIN, V23, P205, DOI 10.1016/S0889-8561(02)00079-6; Aichane A, 1997, REV MAL RESPIR, V14, P451; AKASAWA A, 1993, INT ARCH ALLERGY IMM, V101, P177, DOI 10.1159/000236516; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Amin A, 1998, INT DENT J, V48, P77, DOI 10.1111/j.1875-595X.1998.tb00464.x; Archambault S, 2001, J ALLERGY CLIN IMMUN, V107, P921; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; Baur X, 2003, J ALLERGY CLIN IMMUN, V111, P652, DOI 10.1067/mai.2003.109; BEAUDOUIN E, 1990, REV FR ALLERGOL, V30, P157, DOI 10.1016/S0335-7457(05)80230-8; Bernstein DI, 2003, ANN ALLERG ASTHMA IM, V90, P209, DOI 10.1016/S1081-1206(10)62143-6; BLETTNER M, 1990, STAT MED, V9, P1339, DOI 10.1002/sim.4780091111; Bollinger ME, 2002, ANN ALLERG ASTHMA IM, V88, P560, DOI 10.1016/S1081-1206(10)61886-8; BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; Charous BL, 2002, J ALLERGY CLIN IMMUN, V109, P31, DOI 10.1067/mai.2002.120953; Chen YH, 2002, J FORMOS MED ASSOC, V101, P622; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; CORMIO L, 1993, CLIN EXP ALLERGY, V23, P618, DOI 10.1111/j.1365-2222.1993.tb00903.x; de Groot H, 1998, CONTACT DERMATITIS, V38, P159; Di Lorenzo G, 2002, J INVEST ALLERG CLIN, V12, P114; Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Douglas R, 1997, AUST NZ J MED, V27, P165, DOI 10.1111/j.1445-5994.1997.tb00933.x; Fein JA, 1996, PEDIATR EMERG CARE, V12, P6, DOI 10.1097/00006565-199602000-00002; Filon FL, 2001, INT ARCH OCC ENV HEA, V74, P219, DOI 10.1007/s004200000208; Galobardes B, 2001, DERMATOLOGY, V203, P226, DOI 10.1159/000051754; Garabrant DH, 2002, J ALLERGY CLIN IMMUN, V110, pS82, DOI 10.1067/mai.2002.124967; Garabrant DH, 2001, AM J EPIDEMIOL, V153, P515, DOI 10.1093/aje/153.6.515; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Grzybowski M, 2002, ANN EMERG MED, V40, P411, DOI 10.1067/mem.2002.128144; Hack ME, 2001, ANAESTH INTENS CARE, V29, P43, DOI 10.1177/0310057X0102900108; HADJILIADIS D, 1995, J ALLERGY CLIN IMMUN, V96, P431, DOI 10.1016/S0091-6749(95)70067-6; Hamann CP, 1998, J AM DENT ASSOC, V129, P43, DOI 10.14219/jada.archive.1998.0021; Hamilton RG, 2000, J ALLERGY CLIN IMMUN, V105, P839, DOI 10.1067/mai.2000.105224; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; Harmanci E, 2000, J INVEST ALLERG CLIN, V10, P162; Holter G, 2002, DERMATOLOGY, V205, P28, DOI 10.1159/000063146; Hunt LW, 2002, J ALLERGY CLIN IMMUN, V110, pS96, DOI 10.1067/mai.2002.125442; Jackson EM, 2000, J EMERG MED, V18, P241, DOI 10.1016/S0736-4679(99)00202-4; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51, DOI 10.1016/S1081-1206(10)63406-0; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41, DOI 10.1016/S1081-1206(10)63370-4; Kim KT, 1999, ALLERGY ASTHMA PROC, V20, P387, DOI 10.2500/108854199778251780; Konrad C, 1997, ANESTH ANALG, V84, P629, DOI 10.1097/00000539-199703000-00031; KUJALA VM, 1995, AM J IND MED, V28, P89, DOI 10.1002/ajim.4700280108; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Levy Y, 2000, ISRAEL MED ASSOC J, V2, P154; Li CY, 1999, OCCUP MED-OXFORD, V49, P225, DOI 10.1093/occmed/49.4.225; Lindberg M, 2000, CONTACT DERMATITIS, V43, P4, DOI 10.1034/j.1600-0536.2000.043001004.x; Liss GM, 2001, AM J IND MED, V40, P347, DOI 10.1002/ajim.1108; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Lonnroth EC, 1998, SWED DENT J, V22, P23; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252, DOI 10.1016/S1081-1206(10)62966-3; McElvenny DM, 2004, OCCUP MED-OXFORD, V54, P336, DOI 10.1093/occmed/kqh049; Merrett TG, 1999, CLIN EXP ALLERGY, V29, P1572; Mizutari Kumiko, 1995, Journal of Dermatology (Tokyo), V22, P19; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nettis E, 2002, CLIN EXP ALLERGY, V32, P441, DOI 10.1046/j.1365-2222.2002.01308.x; Nielsen PS, 2000, ANN ALLERG ASTHMA IM, V85, P489, DOI 10.1016/S1081-1206(10)62577-X; Nolte H, 2002, ANN ALLERG ASTHMA IM, V89, P452, DOI 10.1016/S1081-1206(10)62080-7; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; Page EH, 2000, J OCCUP ENVIRON MED, V42, P613, DOI 10.1097/00043764-200006000-00010; Palczynski C, 2000, ALLERGY, V55, P34, DOI 10.1034/j.1398-9995.2000.00037.x; Porri F, 1997, CLIN EXP ALLERGY, V27, P413; Potter PC, 2001, SAMJ S AFR MED J, V91, P760; Rueff F, 2001, ALLERGY, V56, P889, DOI 10.1034/j.1398-9995.2001.00021.x; Ryan M, 2001, Health Technol Assess, V5, P1; Saary MJ, 2002, J ALLERGY CLIN IMMUN, V109, P131, DOI 10.1067/mai.2002.120557; Safadi GS, 1996, ANN ALLERG ASTHMA IM, V77, P39, DOI 10.1016/S1081-1206(10)63477-1; Safadi GS, 1996, J AM DENT ASSOC, V127, P83, DOI 10.14219/jada.archive.1996.0034; SALKIE ML, 1993, ARCH PATHOL LAB MED, V117, P897; Saxon A, 2000, ANN ALLERG ASTHMA IM, V84, P199, DOI 10.1016/S1081-1206(10)62756-1; Schmid K, 2002, CONTACT DERMATITIS, V47, P103, DOI 10.1034/j.1600-0536.2002.470209.x; Sener O, 2000, J INVEST ALLERG CLIN, V10, P30; Shahnaz M, 1999, Med J Malaysia, V54, P26; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; Tarlo S M, 2001, Curr Opin Pulm Med, V7, P27, DOI 10.1097/00063198-200101000-00005; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Verna N, 2003, ANN CLIN LAB SCI, V33, P184; Vila L, 1999, J INVEST ALLERG CLIN, V9, P356; Vyas A, 2000, OCCUP ENVIRON MED, V57, P752, DOI 10.1136/oem.57.11.752; Watts DN, 1998, AM J IND MED, V34, P359, DOI 10.1002/(SICI)1097-0274(199810)34:4<359::AID-AJIM9>3.0.CO;2-N; WRANGSJO K, 1994, CONTACT DERMATITIS, V30, P139, DOI 10.1111/j.1600-0536.1994.tb00694.x; YASSIN MS, 1994, ANN ALLERGY, V72, P245; Zaza S, 1994, AORN J, V60, P806, DOI 10.1016/S0001-2092(07)63329-8	89	126	138	2	27	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					447	454		10.1016/j.jaci.2006.03.048	http://dx.doi.org/10.1016/j.jaci.2006.03.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890771				2022-12-18	WOS:000239877700022
J	Gupta, RS; Carrion-Carire, V; Weiss, KB				Gupta, RS; Carrion-Carire, V; Weiss, KB			The widening black/white gap in asthma hospitalizations and mortality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; disparities; hospitalizations; mortality	HEALTH-INSURANCE; EMERGENCY-DEPARTMENT; ETHNIC DISPARITIES; CHILDHOOD ASTHMA; PRIMARY-CARE; CHILDREN; GUIDELINES; REDUCTION; OUTCOMES; TRENDS	Background: Large racial differences in asthma morbidity and mortality have prompted research on new interventions, public awareness, and health policy efforts in the past decade. Objective: We sought to characterize recent trends in US asthma hospitalization and mortality for black and white children and adults during the period from 1980 through 2002. Methods: We conducted a successive representative national cohort study of US residents ages 5 to 34 years using data from the National Hospital Discharge Survey and the US vital statistics system. Outcome measures included black/white (B/W) asthma hospitalization and mortality rates, rate ratios, and rate differences. Results: For asthma hospitalizations from 1980 through 2002, children ages 5 to 18 years had a 50% increase in the B/W rate ratio, and the rate difference increased from 22.8 to 28.3 hospitalizations per 10,000 population. For young adults ages 19 to 34 years, the B/W rate ratio increased from 2.3 to 2.8, and the rate difference decreased front 9.6 to 7.9 hospitalizations per 10,000 population. For asthma mortality front 1980 through 2001, children ages 5 to 19 years had a large increase in the B/W rate ratio from 4.5 to 5.6 and in the rate difference from 5.6 to 8.1 deaths per 1,000,000 population. There did not appear to be a significant change in the B/W differences for adults ages 20 to 34 years. Conclusions: For children, there have been notable increases in asthma B/W differences in hospitalizations and mortality since 1980, whereas for adults the increase has been smaller. National efforts to improve asthma care over the past decade do not appear to have reduced this B/W gap. When treating children with asthma, it is important to consider the racial-ethnic factors that might lead to avoidable hospitalizations and premature mortality.	Inst Healthcare Studies, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL USA; Childrens Mem Hosp, Smith Child Hlth Res Program, Chicago, IL USA; Vet Affairs Edward Hines Jr Hosp, US Dept Vet Affairs, Midwest Ctr Hlth Serv & Policy Res, Hines, IL USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Gupta, RS (corresponding author), Inst Healthcare Studies, 339 E Chicago Ave,Room 712, Chicago, IL 60611 USA.	r-gupta@northwestern.edu	Dalla Zuanna, Teresa/G-3133-2015		AHRQ HHS [T32HS00078-07] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000078] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Adams K., 2003, PRIORITY AREAS NATL; *AG HEALTHC RES QU, 2004, PUBL AG HEALTHC RES; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Benson V, 1998, VITAL HLTH STAT 10, P1; Boudreaux ED, 2003, CHEST, V124, P803, DOI 10.1378/chest.124.3.803; Cabana Michael D, 2002, Paediatr Respir Rev, V3, P52, DOI 10.1053/prrv.2002.0182; *CDCP, 2002, DEATHS FIN DAT 2000; Cloutier MM, 2005, J PEDIATR-US, V146, P591, DOI 10.1016/j.jpeds.2004.12.017; Dougherty D, 2005, MED CARE, V43, P58; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562, DOI 10.1001/archpedi.156.6.562; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; Grant EN, 1999, J ALLERGY CLIN IMMUN, V104, pS1, DOI 10.1016/S0091-6749(99)70268-X; Green SL, 1998, AM J RESP CRIT CARE, V158, P1487, DOI 10.1164/ajrccm.158.5.9707099; GREINEDER DK, 1995, ARCH PEDIAT ADOL MED, V149, P415, DOI 10.1001/archpedi.1995.02170160069010; Homer CJ, 1996, PEDIATRICS, V98, P18; Jones JA, 2001, PATIENT EDUC COUNS, V42, P67, DOI 10.1016/S0738-3991(00)00102-6; Krishnan JA, 2001, ARCH INTERN MED, V161, P1660, DOI 10.1001/archinte.161.13.1660; Lara M, 2002, PEDIATRICS, V109, P919, DOI 10.1542/peds.109.5.919; Lave JR, 1998, JAMA-J AM MED ASSOC, V279, P1820, DOI 10.1001/jama.279.22.1820; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Lozano P, 2004, ARCH PEDIAT ADOL MED, V158, P875, DOI 10.1001/archpedi.158.9.875; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Mansour ME, 2000, PEDIATRICS, V106, P512, DOI 10.1542/peds.106.3.512; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; Martinez FD, 2002, PEDIATRICS, V109, P362; *NAT COOP INN CIT, 1996, STUD RED ASTHM SEV C; *NAT CTR HLTH STAT, 1998, GUID STAT IMPL ICD 1; *NAT CTR HLTH STAT, 1979, US PHS PUBL; *NAT HEART LUNG BL, 1991, EXP PAN MAN ASTHM EX; Nelson A, 2002, J NATL MED ASSOC, V94, P666; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; Ortega AN, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e1; *R WOOD JOHNS FDN, 2005, NAT LOC PROGR GRANTS; Shone LP, 2005, PEDIATRICS, V115, pE697, DOI 10.1542/peds.2004-1726; SIMMONS WR, 1970, US PHS PUBL, V1000; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; Velsor-Friedrich Barbara, 2005, J Pediatr Health Care, V19, P163, DOI 10.1016/j.pedhc.2004.12.002; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; 2004, MMWR MORB MORTAL WKL, V53, P145	41	126	127	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					351	358		10.1016/j.jaci.2005.11.047	http://dx.doi.org/10.1016/j.jaci.2005.11.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461136	Bronze			2022-12-18	WOS:000235687300018
J	Logan, MR; Odemuyiwa, SO; Moqbel, R				Logan, MR; Odemuyiwa, SO; Moqbel, R			Understanding exocytosis in immune and inflammatory cells: The molecular basis of mediator secretion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						botulinum; eosinophils; exocytosis; munc18; neutrophils; SNARE; tetanus; Rab	PROTEIN-KINASE-C; RECOMBINANT HUMAN INTERLEUKIN-5; STIMULATED GLUT4 TRANSLOCATION; SNARE PROTEINS; REGULATED SECRETION; MEMBRANE-PROTEIN; MAST-CELLS; PIECEMEAL DEGRANULATION; PLATELET EXOCYTOSIS; COMPOUND EXOCYTOSIS	Inflammatory cells secrete proteins from intracellular vesicles or granules by a process referred to either as exocytosis or as degranulation, which is common to all cell types. Exocytosis is a precise term that describes the process of granule or vesicular fusion with the plasma membrane and is accompanied by release of granule/vesicle contents to the cell exterior. This process is of particular significance with respect to tissue damage and remodeling in inflammatory diseases, inasmuch as these changes are the consequences of inflammatory cell activation and mediator elaboration. Despite its unifying importance to all inflammatory cell types, little is known about the precise molecular and intracellular mechanisms that regulate mobilization of secretory granules/vesicles and, ultimately, secretion of mediators from immune and inflammatory cells. This article reviews the mechanisms and molecules currently implicated at distal stages of exocytosis from eosinophils, neutrophils, mast cells, platelets, and macrophages. Conserved molecules identified among inflammatory cell types indicate a convergence of pathways leading to mediator secretion. The identification of essential molecules in the cascade of events leading to exocytosis is critical in the search for novel therapeutic targets aimed at modulating mediator secretion from these cell types.	Univ Alberta, Heritage Med Res Ctr 550A, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta	Moqbel, R (corresponding author), Univ Alberta, Heritage Med Res Ctr 550A, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada.	redwan.moqbel@ualberta.ca	Odemuyiwa, Solomon O/C-9177-2018	Odemuyiwa, Solomon Olawole (Wole)/0000-0003-3993-9878				Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Allen LAH, 2002, J LEUKOCYTE BIOL, V72, P217; ALVAREZ DT, 1990, J GEN PHYSIOL, V95, P397, DOI DOI 10.1085/JGP.95.3.397; Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Bandeira-Melo C, 2000, J IMMUNOL METHODS, V244, P105, DOI 10.1016/S0022-1759(00)00264-7; Baram D, 1998, J IMMUNOL, V161, P5120; Baram D, 1999, J EXP MED, V189, P1649, DOI 10.1084/jem.189.10.1649; BATES ME, 1993, J IMMUNOL, V150, P4486; Bernstein AM, 1999, BLOOD, V93, P571, DOI 10.1182/blood.V93.2.571.402k05_571_579; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; BRENNER S, 1974, GENETICS, V77, P71; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Coco S, 1999, J NEUROSCI, V19, P9803; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; Crivellato E, 2002, J ANAT, V201, P507, DOI 10.1046/j.1469-7580.2002.00116.x; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; de Wit H, 1999, MOL BIOL CELL, V10, P4163, DOI 10.1091/mbc.10.12.4163; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; DVORAK AM, 1992, AM J PATHOL, V140, P795; DVORAK AM, 1991, AM J PATHOL, V138, P69; Dvorak AM, 1997, INT ARCH ALLERGY IMM, V114, P1, DOI 10.1159/000237635; DVORAK AM, 1991, MEGAKARYOCYTES PLATE, P237; Erjefalt JS, 1998, J ALLERGY CLIN IMMUN, V102, P286, DOI 10.1016/S0091-6749(98)70098-3; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304, DOI 10.1164/ajrccm.160.1.9809048; Evans DJ, 1999, AM J PHYSIOL-LUNG C, V277, pL233, DOI 10.1152/ajplung.1999.277.2.L233; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Feng D, 2002, BLOOD, V99, P4006, DOI 10.1182/blood.V99.11.4006; Feng D, 2001, J HISTOCHEM CYTOCHEM, V49, P293, DOI 10.1177/002215540104900303; Fitzgerald ML, 1999, BIOCHEM J, V342, P353, DOI 10.1042/0264-6021:3420353; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; GLOGAU RG, 2002, CLIN J PAIN S, V18, pS1951; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Hackam DJ, 1996, J IMMUNOL, V156, P4377; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Hepp R, 2002, FEBS LETT, V532, P52, DOI 10.1016/S0014-5793(02)03629-3; Hibi T, 2000, BIOCHEM BIOPH RES CO, V271, P36, DOI 10.1006/bbrc.2000.2591; HIDE I, 1993, J CELL BIOL, V123, P585, DOI 10.1083/jcb.123.3.585; Hoffmann HJ, 2001, BIOCHEM BIOPH RES CO, V282, P194, DOI 10.1006/bbrc.2001.4499; HOUNG AK, 2003, J BIOL CHEM, P20; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KANKAANRANTA H, 1995, BIOCHEM PHARMACOL, V50, P197, DOI 10.1016/0006-2952(95)00126-K; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; Kawasaki F, 1998, J NEUROSCI, V18, P10241; Kent JD, 1996, J IMMUNOL, V157, P4641; Khan AH, 2001, J BIOL CHEM, V276, P4063, DOI 10.1074/jbc.M007419200; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KROEGEL C, 1989, J IMMUNOL, V142, P3518; Lacy P, 1999, BLOOD, V94, P23, DOI 10.1182/blood.V94.1.23.413k13_23_32; Lacy P, 2001, J ALLERGY CLIN IMMUN, V107, P671, DOI 10.1067/mai.2001.113562; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Li L, 2001, J BIOL CHEM, V276, P5265, DOI 10.1074/jbc.M003883200; Lindmark IM, 2002, BBA-MOL CELL RES, V1590, P159, DOI 10.1016/S0167-4889(02)00209-4; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Loder E, 2002, CLIN J PAIN, V18, pS169, DOI 10.1097/00002508-200211001-00009; Logan MR, 2002, J ALLERGY CLIN IMMUN, V109, P299, DOI 10.1067/mai.2002.121453; Logan MR, 2003, J ALLERGY CLIN IMMUN, V111, P923, DOI 10.1067/mai.2003.1573; Lollike K, 2002, J LEUKOCYTE BIOL, V71, P973; Lonart G, 2002, TRENDS NEUROSCI, V25, P329, DOI 10.1016/S0166-2236(02)02193-8; Lyubchenko TA, 2003, J PHYSIOL-LONDON, V547, P835, DOI 10.1113/jphysiol.2002.033522; Marti-Verdeaux S, 2003, J CELL SCI, V116, P325, DOI 10.1242/jcs.00216; Martin-Martin B, 1999, J LEUKOCYTE BIOL, V65, P397, DOI 10.1002/jlb.65.3.397; Martin-Martin B, 2000, BLOOD, V96, P2574; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Misura KMS, 2001, J BIOL CHEM, V276, P13273, DOI 10.1074/jbc.M009636200; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; MOLLARD GF, 1997, J CELL BIOL, V137, P1511; Mollinedo F, 2003, J IMMUNOL, V170, P1034, DOI 10.4049/jimmunol.170.2.1034; Moqbel R, 1999, CLIN EXP ALLERGY, V29, P1017; MORGENSTERN E, 1995, EUR J CELL BIOL, V68, P183; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Nabokina S, 1997, BIOCHEM BIOPH RES CO, V239, P592, DOI 10.1006/bbrc.1997.7515; Naucler C, 2002, J LEUKOCYTE BIOL, V71, P701; Noll T, 1997, BIOL SIGNAL, V6, P1; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; O'Brien CF, 2002, CLIN J PAIN, V18, pS182, DOI 10.1097/00002508-200211001-00011; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Pagan JK, 2003, CURR BIOL, V13, P156, DOI 10.1016/S0960-9822(03)00006-X; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Polgar J, 2002, BLOOD, V100, P1081, DOI 10.1182/blood.V100.3.1081; Pombo I, 2001, J BIOL CHEM, V276, P42893, DOI 10.1074/jbc.M103527200; Quetglas S, 2002, EMBO J, V21, P3970, DOI 10.1093/emboj/cdf404; RAO M, 1997, J IMMUNOL, V159, P2815; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Scales SJ, 2000, NATURE, V407, P144, DOI 10.1038/35025176; SCEPEK S, 1994, PARASITOL TODAY, V10, P276, DOI 10.1016/0169-4758(94)90146-5; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; SMOLEN JE, 1990, BIOCHIM BIOPHYS ACTA, V1052, P133, DOI 10.1016/0167-4889(90)90068-O; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takizawa T, 2002, J ALLERGY CLIN IMMUN, V110, P241, DOI 10.1067/mai.2002.126303; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tasaka K, 1994, J Physiol Pharmacol, V45, P479; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; Turton K, 2002, TRENDS BIOCHEM SCI, V27, P552, DOI 10.1016/S0968-0004(02)02177-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; Valdez AC, 1999, J CELL SCI, V112, P845; Verges M, 1999, P NATL ACAD SCI USA, V96, P10146, DOI 10.1073/pnas.96.18.10146; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	136	126	135	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					923	932		10.1067/mai.2003.1573	http://dx.doi.org/10.1067/mai.2003.1573			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743551				2022-12-18	WOS:000182904500002
J	Moneo, I; Caballero, ML; Gomez, F; Ortega, E; Alonso, MJ				Moneo, I; Caballero, ML; Gomez, F; Ortega, E; Alonso, MJ			Isolation and characterization of a major allergen from the fish parasite Anisakis simplex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; parasite; IgE; IgG4; Anisakis simplex; immunoblotting	NEMATODE ASCARIS-SUUM; ACUTE URTICARIA; ABA-1 ALLERGEN; BINDING; ANTIBODIES; INFECTIONS; RESPONSES	Background: Ingestion of raw or undercooked fish can lead to infection of human subjects by the fish parasite Anisakis simplex, a disease known as anisakiasis or anisakidosis, Patients sensitized to this fish parasite show high levels of total and specific IgE. Cross-reactions seem to explain the fact that specific IgE antibodies are also found in a high number of normal subjects, as reported in other parasitoses. Objective: We sought to purify and characterize a major IgE-binding protein From the parasite. Methods: A protein was purified from the crude parasite extract by means of ethanol precipitation and reversed-phase HPLC. Its clinical relevance was tested on 20 parasite-positive sera by using IgE and IgG4 immunoblotting, A monospecific human serum was used to study its localization in the parasite body. Results: A 24-kd protein was purified, to which only 45% of the sera had specific IgG4, but 85% of sera had specific IgE, The protein was present only in the excretory gland, as shown by immunohistochemistry. N-terminal amino acid sequence (17 residues) showed no homology to previously described proteins. Conclusion: A simplex contains a potent allergen in the excretory gland. This major parasite allergen, named Ani s 1, could have important clinical relevance, as shown by the high number of positive sera in the specific IgE immunoblotting.	Inst Salud Carlos III, Ctr Invest Clin, Madrid 28029, Spain; Hosp Ramon & Cajal, E-28034 Madrid, Spain	Instituto de Salud Carlos III; Hospital Universitario Ramon y Cajal	Moneo, I (corresponding author), Inst Salud Carlos III, Ctr Invest Clin, Sinesio Delgado 10, Madrid 28029, Spain.		Gómez-Aguado, Fernando/E-8784-2013; Alonso, Maria Jose/K-3893-2014	Gómez-Aguado, Fernando/0000-0002-3926-4930; 				AKAO N, 1990, J HELMINTHOL, V64, P310, DOI 10.1017/S0022149X00012359; Allen JE, 1996, INT ARCH ALLERGY IMM, V109, P3, DOI 10.1159/000237225; Alonso A, 1999, ALLERGY, V54, P517, DOI 10.1034/j.1398-9995.1999.00046.x; Anibarro B, 1998, J ALLERGY CLIN IMMUN, V102, P331, DOI 10.1016/S0091-6749(98)70108-3; Anibarro PC, 1997, CONTACT DERMATITIS, V37, P247, DOI 10.1111/j.1600-0536.1997.tb02453.x; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buendia E, 1997, ALLERGY, V52, P481, DOI 10.1111/j.1398-9995.1997.tb02590.x; CHRISTIE JF, 1993, CLIN EXP IMMUNOL, V92, P125, DOI 10.1111/j.1365-2249.1993.tb05958.x; Cuende E, 1998, CLIN EXP RHEUMATOL, V16, P303; DelPozo MD, 1997, ALLERGY, V52, P576; delPozo MD, 1996, J ALLERGY CLIN IMMUN, V97, P977, DOI 10.1016/S0091-6749(96)80073-X; deNoya BA, 1996, EPIDEMIOL INFECT, V116, P323, DOI 10.1017/S095026880005264X; GARATE T, 1990, AM J TROP MED HYG, V42, P140, DOI 10.4269/ajtmh.1990.42.140; Garcia M, 1997, J ALLERGY CLIN IMMUN, V99, P497, DOI 10.1016/S0091-6749(97)70076-9; Gomez B, 1998, ALLERGY, V53, P1148, DOI 10.1111/j.1398-9995.1998.tb03834.x; Guillen-Bueno R, 1999, DIGESTION, V60, P268, DOI 10.1159/000007668; Iglesias R, 1996, PARASITOL RES, V82, P378, DOI 10.1007/s004360050131; Ishikura H, 1993, Prog Clin Parasitol, V3, P43; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; LEE H, 1973, J PARASITOL, V59, P289, DOI 10.2307/3278820; Moneo I, 1997, ALLERGY, V52, P565, DOI 10.1111/j.1398-9995.1997.tb02601.x; MONEO I, 1995, OCCUP MED-OXFORD, V45, P151, DOI 10.1093/occmed/45.3.151; Montoro A, 1997, ALLERGY, V52, P985, DOI 10.1111/j.1398-9995.1997.tb02418.x; Pascual CY, 1997, ALLERGY, V52, P514, DOI 10.1111/j.1398-9995.1997.tb02594.x; RAMOS RG, 1994, J HELMINTHOL, V68, P305, DOI 10.1017/S0022149X0000153X; RUITENBE.EJ, 1971, J PARASITOL, V57, P1149, DOI 10.2307/3277888; Silva MLS, 1996, AM J TROP MED HYG, V54, P146, DOI 10.4269/ajtmh.1996.54.146	29	126	134	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				177	182		10.1067/mai.2000.106732	http://dx.doi.org/10.1067/mai.2000.106732			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887322				2022-12-18	WOS:000088393300024
J	Passalacqua, G; Albano, M; Riccio, A; Fregonese, L; Puccinelli, P; Parmiani, S; Canonica, GW				Passalacqua, G; Albano, M; Riccio, A; Fregonese, L; Puccinelli, P; Parmiani, S; Canonica, GW			Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sublingual-swallow immunotherapy; allergic inflammation; allergen specific nasal challenge; intercellular adhesion molecule-1	HOUSE-DUST MITE; POLLEN EXTRACT; ALLERGIC INFLAMMATION; RHINITIS; ASTHMA; CELLS; RHINOCONJUNCTIVITIS; EFFICACY	Background: The local (noninjection) routes of immunotherapy are presently regarded as viable therapeutic options for respiratory allergy, and their mechanisms of action are currently undergoing investigation, Objective: We evaluated the clinical efficacy of a preseasonal rush sublingual-swallow immunotherapy and its effects on allergic inflammation in patients with seasonal rhinoconjunctivitis caused by Parietaria species. Methods: Thirty patients with Parietaria species-induced rhinoconjunctivitis (13 with mild intermittent asthma) Here randomly assigned sublingual-swallow immunotherapy or placebo in a Nh preseasonal course, we assessed the seasonal symptom-drug intake score by diary card and the inflammatory infiltration and the intercellular adhesion molecule 1 expression on nasal epithelium after specific allergenic challenge before and after treatment, Results: The investigated immunotherapy was well tolerated, and no side effects Here recorded, A significant reduction of the symptom score (P = .016) and drug intake score (P = .008) after immunotherapy was observed only in the active group. A decrease of the cumulative score was observed also in the placebo group (P = .046), but the significance Has clearly higher (P = .006) in the active group. In the active group a reduction of neutrophils (P = .001). eosinophils (P = .01), and intercellular adhesion molecule 1 expression (P = .01) after specific nasal challenge was also detected, Conclusion: The present results suggest that this sublingual-swallow immunotherapy administered through a rush schedule is clinically effective and safe and that it decreases the immune-mediated inflammatory responses to the allergen.	Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Ospiate Bollate, ALK Abello Grp, Milan, Italy	University of Genoa; ALK-Abello AS	Canonica, GW (corresponding author), Univ Genoa, Dept Internal Med, Pad Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.		canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557; RICCIO, ANNA MARIA/0000-0001-8392-533X				Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bousquet J, 1998, ALLERGY S, V53, P20; CARREIRA J, 1984, CLIN ALLERGY, V14, P503, DOI 10.1111/j.1365-2222.1984.tb02236.x; CARREIRA LM, 1994, NEW DEV IN VITRO MET; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; Ciprandi G, 1998, ASTHMA AND ALLERGIC DISEASES, P309; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DIRIENZO V, 1999, IN PRESS ALLERGY; FELIZIANI V, 1995, ALLERGOL IMMUNOPATH, V23, P173; Giannarini L, 1998, CLIN EXP ALLERGY, V28, P404; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MALLING HJ, 1993, ALLERGY, V48, P9; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x	25	126	130	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					964	968		10.1016/S0091-6749(99)70076-X	http://dx.doi.org/10.1016/S0091-6749(99)70076-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550740				2022-12-18	WOS:000083778400018
J	Yawn, BP; Yunginger, JW; Wollan, PC; Reed, CE; Silverstein, MD; Harris, AG				Yawn, BP; Yunginger, JW; Wollan, PC; Reed, CE; Silverstein, MD; Harris, AG			Allergic rhinitis in Rochester, Minnesota residents with asthma: Frequency and impact on health care charges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; rhinitis; costs; charge data; population based	CHRONIC SINUS DISEASE; UNITED-STATES; HAY-FEVER; CHILDREN; EPIDEMIOLOGY; PREVALENCE; HISTORY; SEVERITY; PATIENT; ECZEMA	Background: Asthma is a common and costly condition. Concomitant asthma and allergic rhinitis (AR) have been shown to increase the medication costs for people with asthma. No studies have compared medical care costs of those with and without concomitant BE. Objectives: We sought to determine the prevalence and incremental medical care costs of concomitant AR. Methods: For each member of a population-based asthma cohort, we used all their medical charts within Olmsted County to record age at first diagnosis of asthma; the presence and age of any diagnosis of AR; and the total, ambulatory, and respiratory care-related costs of medical care. Costs mere compared for age- and ser-specific strata of people with asthma who did and did not have AR. Results: AR was most commonly diagnosed in people whose asthma was diagnosed before age 25 (prevalence of 59%) and uncommonly diagnosed in anyone after age 40 (prevalence <15%). Yearly medical care charges were on average 46% higher for those with asthma and concomitant AR than for persons with asthma alone, controlling for age and sex We were unable to assess the impact of treatment of AR on medical care charges. Conclusions: Physicians should consider the diagnosis of AR (prevalence >50%) in all symptomatic children and young adults with asthma Further evaluation is necessary to evaluate the ability of treatment to decrease the incremental costs of AR in persons with asthma.	Olmsted Med Ctr, Dept Res, Rochester, MN 55904 USA; Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Allergy Immunol Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Allerg Dis Div, Rochester, MN 55905 USA; Med Univ S Carolina, Sect Hlth Care Res, Charleston, SC 29425 USA; Schering Plough Corp, Phase Res Unit 4, Kenilworth, NJ 07033 USA	Olmsted Medical Center; Mayo Clinic; Mayo Clinic; Mayo Clinic; Medical University of South Carolina; Merck & Company; Schering Plough Corporation	Yawn, BP (corresponding author), Olmsted Med Ctr, Dept Res, 210 9th St SE, Rochester, MN 55904 USA.			Harris, Alan/0000-0002-6618-2092				BARANIUK JN, 1996, J RESP DIS S, V17, pS11; BENNINGER MS, 1992, AM J RHINOL, V6, P37, DOI 10.2500/105065892781874829; BENSON V, 1993, VITAL HLTH STAT, V10; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; CORREN J, 1991, American Review of Respiratory Disease, V143, pA37; DRUCE HM, 1993, ALLERGY PRINCIPLES P, P1433; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; Goh DYT, 1996, ARCH DIS CHILD, V74, P131, DOI 10.1136/adc.74.2.131; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; Halpern G M, 1995, Allergol Immunopathol (Madr), V23, P171; HOGG RV, 1993, P0ROBABILITY STAT IN; *ISAAC COORD COMM, 1992, MAN INT STUD ASTHM A; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Naclerio R, 1997, JAMA-J AM MED ASSOC, V278, P1842, DOI 10.1001/jama.278.22.1842; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; POYSA L, 1991, ALLERGY, V46, P161, DOI 10.1111/j.1398-9995.1991.tb00564.x; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; ROSS RN, 1996, AM J MANAG CARE, V2, P285; Rossoff LJ, 1997, AM J MANAG CARE, V3, pS6; SETTIPANE GA, 1986, OTOLARYNG HEAD NECK, V94, P470, DOI 10.1177/019459988609400411; Slavin Raymond G., 1994, P549; SMITH JM, 1988, ALLERGY PRINCIPLES P, P881; STOMS W, 1997, J ALLERGY CLIN IMM S, V99, pS820; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; Weeke E R, 1992, Rhinol Suppl, V13, P5; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILSON TL, 1997, CPI DETAILED REPORT; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	35	126	129	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				54	59		10.1016/S0091-6749(99)70525-7	http://dx.doi.org/10.1016/S0091-6749(99)70525-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893185				2022-12-18	WOS:000078112300009
J	Baraniuk, JN				Baraniuk, JN			Pathogenesis of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; mast cell; inflammatory response; eosinophils; adhesion molecules	HUMAN NASAL-MUCOSA; MAST-CELLS; NEUROGENIC INFLAMMATION; ADHESION MOLECULES; PATHO-PHYSIOLOGY; EPITHELIAL-CELLS; ATOPIC SUBJECTS; MESSENGER-RNA; B-CELL; EOSINOPHILS	Allergic rhinitis is an increasing problem for which new and exciting therapies are being developed. These can be understood through an appreciation of the newer concepts of pathogenesis of allergic rhinitis. Allergen induces Th2 lymphocyte proliferation in persons with allergies with the release of their characteristic combination of cytokines including IL-3, IL-4, IL-5, IL-9, IL-10, and IL-13. These substances promote IgE and mast cell production. Mucosal mast cells that produce IL-4, IL-5, IL-6, and tryptase proliferate in the allergic epithelium. Inflammatory mediators and cytokines upregulate endothelial cell adhesion markers, such as vascular cell adhesion molecule-1. Chemoattractants, including eotaxin, IL-5, and RANTES, lead to characteristic infiltration by eosinophils, basophils, Th2 lymphocytes, and mast cells in chronic allergic rhinitis. As our understanding of the basic pathophysiologic features of allergic rhinitis continues to increase, the development of new diagnostic and treatment strategies may allow more effective modulation of the immune system, the atopic disease process, and the associated morbidity.	GEORGETOWN UNIV,DEPT MED,WASHINGTON,DC 20007	Georgetown University				Baraniuk, James Nicholas/0000-0002-1866-4177				ALTMAN LC, 1993, J ALLERGY CLIN IMMUN, V92, P527, DOI 10.1016/0091-6749(93)90077-S; BARANIUK JN, 1992, AM J RHINOL, V6, P145, DOI 10.2500/105065892781874649; Baraniuk JN, 1996, J ALLERGY CLIN IMMUN, V97, P141, DOI 10.1016/S0091-6749(96)80213-2; BARANIUK JN, 1996, IMMUNOPHARMACOLOGY R, P575; BARANIUK JN, 1994, CLIN EXP ALLERGY, V14, P724; BAROODY FM, 1992, J ALLERGY CLIN IMMUN, V90, P373, DOI 10.1016/S0091-6749(05)80017-X; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P406, DOI 10.1111/j.1365-2222.1995.tb01071.x; BRADDING P, 1995, J IMMUNOL, V155, P297; CALDERON MA, 1994, J ALLERGY CLIN IMMUN, V93, P635, DOI 10.1016/S0091-6749(94)70075-3; De Graaf-In't Veld C., 1995, Clinical and Experimental Allergy, V25, P966, DOI 10.1111/j.1365-2222.1995.tb00399.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282, DOI 10.1159/000237003; ERJEFALT I, 1991, CLIN EXP ALLERGY, V21, P217, DOI 10.1111/j.1365-2222.1991.tb00833.x; Fajac I, 1995, ALLERGY, V50, P970, DOI 10.1111/j.1398-9995.1995.tb02509.x; FEATHER IH, 1995, ASTHMA RHINITIS, P347; Fischer A, 1996, AM J RESP CRIT CARE, V154, P209, DOI 10.1164/ajrccm.154.1.8680682; Furukawa K, 1996, AM J RESP CELL MOL, V14, P248, DOI 10.1165/ajrcmb.14.3.8845175; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GOSSET P, 1993, J ALLERGY CLIN IMMUN, V92, P878, DOI 10.1016/0091-6749(93)90066-O; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; HOLM AF, 1995, ALLERGY, V50, P204, DOI 10.1111/j.1398-9995.1995.tb01134.x; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; Iriyoshi N, 1996, CLIN EXP ALLERGY, V26, P379, DOI 10.1111/j.1365-2222.1996.tb00553.x; JAMES DG, 1995, CLIN EXP ALLERGY, V25, P389, DOI 10.1111/j.1365-2222.1995.tb01067.x; JOOS GF, 1995, THORAX, V50, P217, DOI 10.1136/thx.50.3.217; JULUISSON S, 1995, ALLERGY, V50, P15; KAWABORI S, 1995, CLIN EXP ALLERGY, V25, P173, DOI 10.1111/j.1365-2222.1995.tb01023.x; KENNEY JS, 1994, J ALLERGY CLIN IMMUN, V93, P1060, DOI 10.1016/S0091-6749(94)70055-9; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; MASUDA S, 1990, Practica Otologica Kyoto, V83, P1855; MCDONALD DM, 1987, AM REV RESPIR DIS, V136, pS65, DOI 10.1164/ajrccm/136.6_Pt_2.S65; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MOSSIMAN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95; MULLOL J, 1992, J APPL PHYSIOL, V73, P2069, DOI 10.1152/jappl.1992.73.5.2069; MULLOL J, 1993, AM J RESP CELL MOL, V8, P393, DOI 10.1165/ajrcmb/8.4.393; NACLERIO RM, 1994, J ALLERGY CLIN IMMUN, V94, P1303, DOI 10.1016/0091-6749(94)90346-8; Nonaka M, 1996, AM J RESP CRIT CARE, V153, P1675, DOI 10.1164/ajrccm.153.5.8630619; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; OKAYAMA M, 1992, J ALLERGY CLIN IMMUN, V89, P1144, DOI 10.1016/0091-6749(92)90298-G; OKAYAMA M, 1995, J ALLERGY CLIN IMMUN, V95, P96, DOI 10.1016/S0091-6749(95)70157-5; Pawankar RU, 1996, AM J RESP CRIT CARE, V153, P1655, DOI 10.1164/ajrccm.153.5.8630617; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2049, DOI 10.1164/ajrccm.152.6.8520775; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; Riccio MM, 1996, J ALLERGY CLIN IMMUN, V97, P1252, DOI 10.1016/S0091-6749(96)70193-8; Sanico A. M., 1996, Journal of Allergy and Clinical Immunology, V97, P430, DOI 10.1016/S0091-6749(96)81210-3; SCHOU C, 1995, CLIN EXP ALLERGY, V25, P10, DOI 10.1111/j.1365-2222.1995.tb00997.x; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SIMONS E, 1996, HISTAMINE H1 ANTAGON; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; STJARNE P, 1991, ACTA PHYSIOL SCAND, V141, P335, DOI 10.1111/j.1748-1716.1991.tb09089.x; SVENSSON C, 1995, CLIN EXP ALLERGY, V25, P942, DOI 10.1111/j.1365-2222.1995.tb00396.x; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; TERADA N, 1994, J ALLERGY CLIN IMMUN, V94, P629, DOI 10.1016/0091-6749(94)90140-6; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P782, DOI 10.1016/0091-6749(88)90932-3; VALENT P, 1994, J ALLERGY CLIN IMMUN, V94, P1177, DOI 10.1016/0091-6749(94)90329-8; WARDLAW AJ, 1994, J ALLERGY CLIN IMMUN, V94, P1163, DOI 10.1016/0091-6749(94)90327-1; WHITE MV, 1993, J ALLERGY CLIN IMMUN, V92, P278, DOI 10.1016/0091-6749(93)90171-B	69	126	135	1	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					S763	S772		10.1016/S0091-6749(97)70125-8	http://dx.doi.org/10.1016/S0091-6749(97)70125-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042069	hybrid			2022-12-18	WOS:A1997WH83100037
J	Quiralte, J; Blanco, C; Castillo, R; Delgado, J; Carrillo, T				Quiralte, J; Blanco, C; Castillo, R; Delgado, J; Carrillo, T			Intolerance to nonsteroidal antiinflammatory drugs: Results of controlled drug challenges in 98 patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nonsteroidal antiinflammatory drugs; controlled oral challenge; atopy; angioedema; other adverse reactions	ASPIRIN-SENSITIVE ASTHMA; ANTI-INFLAMMATORY DRUGS; ADVERSE REACTIONS; ORAL CHALLENGE; ASSOCIATION; POPULATION	Background: Controlled oral challenge is the only definitive way to detect the different clinical manifestations of intolerance to nonsteroidal inflammatory drugs (NSAIDs). Objective: This study was carried out to describe the clinical manifestations of drug challenges in a population with histories of intolerance to NSAIDs. Methods: Two-hundred forty subjects were included in a single-blind, placebo-controlled drug challenge protocol. Results: Eighty patients exhibited a positive response to drug challenge: 52 had isolated periorbital angioedema, 13 had cutaneous rashes eight had bronchial asthmas (7 with associated periorbital angioedema), three had nasoocular reactions, and four had systemic anaphylaxis. In another 18 patients who were referred for treatment because of a reaction suggesting systemic anaphylaxis, the implicated drug was not given, but tolerance to other NSAIDs was found. The mean age of patients with isolated periorbital angioedema was significantly lower (p < 0.001) than that of the other group of NSAID reactors. A significant increase (p < 0.001) in atopy was found among patients with isolated periorbital angioedema (100%) in comparison with other patients with NSAID intolerance (45.6%). NSAID cross-reactivity was a common finding, but cross-reactivity was not found in two cases of periorbital angioedema, one case of urticaria, one case of bronchial asthma, and 18 cases of systemic anaphylaxis. Conclusion: In atopic subjects, isolated periorbital angioedema constitutes that most frequent manifestation of NSAID intolerance. Such patients are younger than other NSAID reactors and commonly have intolerance to several NSAIDs.			Quiralte, J (corresponding author), HOSP UNIV NUESTRA SENORA DEL PINO,SECC ALERGIA,C ANGEL GUIMERA 93,LAS PALMAS 35005,SPAIN.		Blanco, Carlos/B-3895-2012; IBIS, ALERGICAS/C-1733-2016	Blanco, Carlos/0000-0002-2893-6594; 				BLANCA M, 1989, ANN ALLERGY, V62, P295; CARMONA MJ, 1992, J ALLERGY CLIN IMMUN, V90, P873, DOI 10.1016/0091-6749(92)90459-F; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; CHRISTIE PE, 1992, CLIN EXP ALLERGY, V22, P171, DOI 10.1111/j.1365-2222.1992.tb03069.x; CZERNIAWSKAMYSIK G, 1981, ALLERGY, V36, P381, DOI 10.1111/j.1398-9995.1981.tb01842.x; GARCIA-RAMOS ALONSO E, 1992, Journal of Investigational Allergology and Clinical Immunology, V2, P19; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; KATZ Y, 1993, ALLERGY, V48, P366, DOI 10.1111/j.1398-9995.1993.tb02407.x; KRISHNAMOORTHY R, 1993, GENETICS ASTHMA, P225; LEE TH, 1993, AM REV RESPIR DIS, V148, P1442, DOI 10.1164/ajrccm/148.6_Pt_1.1442; LEUNG R, 1992, CLIN EXP ALLERGY, V22, P831, DOI 10.1111/j.1365-2222.1992.tb02827.x; LYMPANY PA, 1993, J ALLERGY CLIN IMMUN, V92, P114, DOI 10.1016/0091-6749(93)90045-H; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MULLARKEY MF, 1986, AM REV RESPIR DIS, V133, P261; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STEVENSON DD, 1993, ANN ALLERGY, V71, P417; SZCZEKLIK A, 1987, ANN ALLERGY, V59, P113; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1983, ALLERGIC REACTIONS D, P286; WARIN RP, 1976, BRIT J DERMATOL, V94, P401, DOI 10.1111/j.1365-2133.1976.tb06117.x; WELTMAN JK, 1978, ALLERGY, V34, P273	25	126	126	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					678	685		10.1016/S0091-6749(96)70102-1	http://dx.doi.org/10.1016/S0091-6749(96)70102-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828546	Bronze			2022-12-18	WOS:A1996VJ42800025
J	Horie, S; Gleich, GJ; Kita, H				Horie, S; Gleich, GJ; Kita, H			Cytokines directly induce degranulation and superoxide production from human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; cytokine; degranulation; superoxide production	COLONY-STIMULATING FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; PLATELET-ACTIVATING-FACTOR; MAJOR BASIC-PROTEIN; TRACHEAL EPITHELIUM; ANTIGEN CHALLENGE; ENDOTHELIAL-CELLS; MAST-CELL; INTERLEUKIN-5; ASTHMA	Background: Cytokines are implicated in allergic diseases and can modulate effector functions of eosinophils stimulated by another agonist. However, little is known about the capacity of cytokines to directly trigger eosinophil degranulation. Objectives: We attempted to determine whether cytokines can directly induce degranulation and superoxide production from eosinophils. Methods: Eosinophils from normal donors were incubated with various cytokines in albumin coated tissue culture plates for 4 hours. To quantitate degranulation, the amounts of eosinophil-derived neurotoxin in supernatants were measured by radioimmunoassay. In addition, superoxide production was measure by superoxide dismutase-inhibitable reduction of cytochrome c. Results: IL-5, IL-3, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and RANTES all induced eosinophil degranulation. Granulocyte-macrophage colony-stimulating factor was the most potent and induced eosinophil-derived neurotoxin release comparable to that induced by secretory IgA beads, one of the most potent secretagogues for eosinophils. In addition, IL-5 and tumor necrosis factor-alpha were synergistic in their induction of eosinophil degranulation. In contrast, IL-1, IL-8, interferon-gamma, and macrophage inflammatory protein-1 alpha did not induce degranulation. finally, IL-5, IL-3, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha, but not RANTES, also induced superoxide production from eosinophils. Conclusions: Certain cytokines directly induce eosinophil degranulation and superoxide production in vitro. Therefore these cytokines may be important in the release of toxic granule proteins from eosinophils in allergic diseases.	MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034486, R37AI015231, R01AI015231, R01AI034486, R56AI034486, U19AI034577, U01AI034577] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34577, AI 15231, AI 34486] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ALAM R, 1993, J IMMUNOL, V150, P3442; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BUSSE W, 1989, J ALLERGY CLIN IMMUN, V83, P400, DOI 10.1016/0091-6749(89)90125-5; BUTTERFIELD JH, 1992, BLOOD, V79, P688; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; EBISAWA M, 1992, J IMMUNOL, V149, P4021; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1980, LAB INVEST, V42, P35; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GLEICH GJ, 1994, SAMTERS IMMUNOLOGICA, P205; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HANSEL TT, 1992, J IMMUNOL, V149, P2130; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HORIE S, 1994, J IMMUNOL, V152, P5457; Kita H, 1996, J IMMUNOL, V156, P1174; KITA H, 1992, J IMMUNOL, V149, P629; KITA H, 1991, J IMMUNOL, V147, P3466; KITA H, IN PRESS AM J RESP C; KROEGEL C, 1989, J IMMUNOL, V142, P3518; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; OHKAWARA Y, 1992, AM J RESP CELL MOL, V7, P385, DOI 10.1165/ajrcmb/7.4.385; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PISANI CV, 1991, BLOOD, V78, P1538, DOI 10.1182/blood.V78.6.1538.1538; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; VONWICHERT P, 1993, AM REV RESPIR DIS, V147, P148, DOI 10.1164/ajrccm/147.1.148; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; WALLEN N, 1991, J IMMUNOL, V147, P3490; WALSH GM, 1991, J IMMUNOL, V146, P3419; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; ZORATTI EM, 1991, J ALLERGY CLIN IMMUN, V88, P749, DOI 10.1016/0091-6749(91)90182-N	50	126	129	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					371	381		10.1016/S0091-6749(96)70161-6	http://dx.doi.org/10.1016/S0091-6749(96)70161-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757214				2022-12-18	WOS:A1996VC99500016
J	Hsieh, LS; Moos, M; Lin, Y				Hsieh, LS; Moos, M; Lin, Y			Characterization of apple 18 and 31 kd allergens by microsequencing and evaluation of their content during storage and ripening	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apple allergens; food allergy; Bet v 1; IgE-reactive proteins; disease resistance proteins	BIRCH BETULA-VERRUCOSA; CROSS-REACTIVITY; IGE ANTIBODIES; POLLEN; PROTEINS; ETHYLENE; CARROT; FRUITS	Patients with tree pollinosis frequently report allergic reactions after ingestion of apples. The severity of apple allergy has been related to the variety of apples and their degree of maturity. To generate a serum pool that is representative of various IgE-binding patterns of apple-allergic sera, serum samples from 34 patients allergic to tree pollens were screened. Only 24 serum samples reacted to the apple extract. Pooled serum was used to identify allergens in apples. An efficient and consistent extraction method for apple fruits was used to compare the immunoreactivities of extracts of different varieties (McIntosh, Red Delicious, Granny Smith, and Golden Delicious) of freshly picked and store-purchased apples. We found that Golden Delicious apples had the greatest amount of 18 kd allergen, which has been reported to be a potent IgE-binding apple allergen. Store-purchased apples contained higher concentrations of the 18 kd allergen than freshly picked apples. In our study only 37.5% of sera reacted to the 18 kd protein, whereas 75% of the sera reacted to a 31 kd allergen. Other immunoreactive bands in apple extracts included proteins of 50, 38, 16, 14, and 13 kd. The amino-terminal amino acid sequences of the two major allergens, 18 kd and 31 kd, were determined. These sequences shared approximately 50% identity with disease resistance proteins of various plants or Bet v 1 in birch tree pollens. The appearance of various allergens was also investigated in mature apples during storage. The amount of 18 kd allergen increased significantly when apples were stored at 4 degrees C. However, under controlled atmospheric conditions in which oxygen- and carbon dioxide-induced ripening were regulated, the amount of 18 kd allergen remained unaffected. Because ripening and maturation were not associated with increases in 18 kd allergen content, the observed changes might be induced by factors related to disease resistance.	US FDA,CTR BIOL EVALUAT & RES,DIV ALLERGY PROD & PARASITOL,IMMUNOBIOCHEM LAB,BETHESDA,MD; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,DEV BIOL LAB,BETHESDA,MD	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)			Moos, Malcolm C/F-3673-2011	Moos, Malcolm C/0000-0002-9575-9938				BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BREITENEDER H, 1988, INT ARCH ALLER A IMM, V87, P19, DOI 10.1159/000234643; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; DREBORG S, 1988, ANN ALLERGY, V61, P41; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ERIKSSON NE, 1982, ALLERGY, V37, P473; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; HALMEPURO L, 1985, ALLERGY, V40, P264, DOI 10.1111/j.1398-9995.1985.tb00231.x; KANELLIS AK, 1989, PLANT PHYSIOL, V90, P251, DOI 10.1104/pp.90.1.251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; MOOS M, 1988, J BIOL CHEM, V263, P6005; STINTZI A, 1993, BIOCHIMIE, V75, P687, DOI 10.1016/0300-9084(93)90100-7; TEMPST P, 1991, CHROMAT ANAL, V183, P290; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, INT ARCH ALLER A IMM, V94, P368, DOI 10.1159/000235406; VIETHS S, 1994, ALLERGY, V49, P262, DOI 10.1111/j.1398-9995.1994.tb02659.x; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; WADEE AA, 1990, J ALLERGY CLIN IMMUN, V85, P801, DOI 10.1016/0091-6749(90)90202-F; WALTER MH, 1990, MOL GEN GENET, V222, P253; YANG SF, 1980, HORTSCIENCE, V15, P238	24	126	129	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				960	970		10.1016/S0091-6749(95)70234-2	http://dx.doi.org/10.1016/S0091-6749(95)70234-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543755	Bronze			2022-12-18	WOS:A1995TN12400014
J	HANANIA, NA; CHAPMAN, KR; STURTRIDGE, WC; SZALAI, JP; KESTEN, S				HANANIA, NA; CHAPMAN, KR; STURTRIDGE, WC; SZALAI, JP; KESTEN, S			DOSE-RELATED DECREASE IN BONE-DENSITY AMONG ASTHMATIC-PATIENTS TREATED WITH INHALED CORTICOSTEROIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; INHALED CORTICOSTEROIDS; BONE DENSITY; ADRENAL GLAND	ADRENAL AXIS SUPPRESSION; BECLOMETHASONE DIPROPIONATE; PROXIMAL FEMUR; LUMBAR SPINE; BUDESONIDE; FRACTURES; THERAPY; TURNOVER; SAFETY; MASS	Background: Inhaled corticosteroids are being prescribed more commonly and in higher doses than previously in the management of asthma. Although these topically active compounds have less potential for systemic impact than oral steroids, biochemical markers suggest that they are not devoid of systemic side effects. We conducted this study to investigate the effect of commonly prescribed doses of inhaled steroids on bone density. Methods: We studied 36 patients with asthma. Those in group A (n = 18) had been taking inhaled beclomethasone dipropionate or budesonide in a dosage of 800 mu g or more per day for at least 1 year. Those in group B (n = 18) had used only bronchodilator therapy. Adrenal function was assessed by morning serum cortisol level and by short adrenocortictropic hormone stimulation test. Bone turnover was assessed by measurement of serum osteocalcin, alkaline phosphatase, and urinary pyridinium cross-links. Bone mineral density was measured by dual-energy x-ray absorptiometry with a Hologic QDR-1000 densitometer (Holologic Inc, Waltham, Mass). Results: Group A, mean age (SD) = 36.6 (8.4) years, had used inhaled corticosteroids at a mean dose of 1323 mu g/day (range, 800 to 2000 mu/day) for a medium duration of 24 months. Group B, mean ag (SD) = 33.4 (8.1) years, had not been taking any form of steroid. Four patients from group A had suppressed morning serum cortisol; three of these had abnormal adrenocorticotropic hormone stimulation test results. All patients in group B had normal baseline adrenal function and an appropriate response to adrenocorticotropic hormone. Mean serum osteocalcin level in group A was significantly lower than that in group B (8.8 vs 14.2 ng/ml, p = 0.0003). Bone density measurements showed parallel changes: in group A the mean Z score (SD) of the femoral neck was -0.78 (1.02), significantly below predicted normal values (p = 0.0025). Mean Z scores of the lumbar spine and of femoral Ward's triangle were not significantly reduced. In group B the mean Z scores of the lumbar spine, femoral neck, and femoral Ward's triangle were all within normal limits. In group A the dose duration of inhaled corticosteroid therapy corrected for body mass index correlated negatively with bone density and adrenal function measurements. Conclusion: We conclude that the regular use of conventional doses of inhaled corticosteroids by patients with asthma can suppress adrenal function and decrease bone density in a dose-related fashion.	UNIV TORONTO,TORONTO HOSP,CTR ASTHMA,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO HOSP,MED PHYS LAB,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,TORONTO,ON M5T 2S8,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center			Hanania, Nicola A/C-5875-2016; YAMAMOTO, MASAHIRO/F-9094-2011	Hanania, Nicola A/0000-0003-3087-9530; YAMAMOTO, MASAHIRO/0000-0003-3859-0125; Kesten, Steven/0000-0002-5522-7910				ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; BARNES NC, 1993, RESP MED, V87, P27, DOI 10.1016/S0954-6111(05)80254-9; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BRAILLON P, 1989, PRESSE MED, V18, P1062; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; BROWN PH, 1991, RESP MED, V85, P501, DOI 10.1016/S0954-6111(06)80268-4; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; CONNETT G, 1991, LANCET, V338, P634, DOI 10.1016/0140-6736(91)90646-7; COPHEN J, 1988, STATISTICAL POWER AN, P75; CROMPTON GK, 1987, BRIT MED J, V294, P123, DOI 10.1136/bmj.294.6564.123-a; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; GARFINKEL SK, 1992, AM REV RESPIR DIS, V145, P741, DOI 10.1164/ajrccm/145.4_Pt_1.741; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; GENNARI C, 1985, BONE MINERAL RES ANN, V3, P213; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KESTEN S, 1993, J ALLERGY CLIN IMMUN, V92, P499, DOI 10.1016/0091-6749(93)90073-O; KRUSZYNSKA YT, 1987, THORAX, V42, P881, DOI 10.1136/thx.42.11.881; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; LUENGO M, 1991, EUR RESPIR J S, V14, pS342; MAK VHF, 1992, EUR RESPIR J, V5, P1068; MAKRIDES L, 1985, CLIN SCI, V69, P197, DOI 10.1042/cs0690197; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; PRATT DA, 1992, ANAL BIOCHEM, V207, P168, DOI 10.1016/0003-2697(92)90519-D; PRICE PA, 1980, P NATL ACAD SCI-BIOL, V77, P2234, DOI 10.1073/pnas.77.4.2234; REID DM, 1986, BMJ-BRIT MED J, V293, P1463, DOI 10.1136/bmj.293.6560.1463; REID DM, 1990, OSTEOPOROSIS, P99; REID IR, 1992, OSTEOPOROSIS INT, V2, P103, DOI 10.1007/BF01623844; ROBBINS SP, 1991, EUR J CLIN INVEST, V21, P310; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; STEAD R J, 1990, Thorax, V45, P792; TEELUCKSINGH S, 1991, LANCET, V38, P60; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; WARD MJ, 1993, RESP MED, V87, P33, DOI 10.1016/S0954-6111(05)80255-0; WOLFF AH, 1991, ANN ALLERGY, V67, P117; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; 1987, AM REV RESPIR DIS, V136, P225; 1992, EUR RESPIR J, V5, P601	44	126	129	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				571	579		10.1016/S0091-6749(95)70254-7	http://dx.doi.org/10.1016/S0091-6749(95)70254-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499672				2022-12-18	WOS:A1995TG52800001
J	JUNIPER, EF; KLINE, PA; VANZIELEGHEM, MA; HARGREAVE, FE				JUNIPER, EF; KLINE, PA; VANZIELEGHEM, MA; HARGREAVE, FE			REDUCTION OF BUDESONIDE AFTER A YEAR OF INCREASED USE - A RANDOMIZED CONTROLLED TRIAL TO EVALUATE WHETHER IMPROVEMENTS IN AIRWAY RESPONSIVENESS AND CLINICAL ASTHMA ARE MAINTAINED	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHIAL HYPERREACTIVITY; HISTAMINE	We have demonstrated recently that 1 year of regular inhaled budesonide use can produce substantial improvements in airway responsiveness accompanied by significant improvements in clinical asthma severity. The present study was designed to evaluate whether these improvements are maintained when the dose of budesonide is reduced. At the end of the original study, 28 subjects with asthma, who had been in the active-treatment arm of the study were randomized either to continue taking the dose of budesonide taken in the original study or to have the dose reduced. Airway responsiveness to methacholine, bronchodilator requirements, symptoms, and spirometry were assessed after 6 weeks and 3 months. During the 3 months, no subject experienced an asthma exacerbation, and there was no evidence of change in airway responsiveness in subjects who had their steroids reduced (provocative concentration causing a 20% drop in FEV1: initial, 2.03 mg/ml; final, 1.91 mg/ml), and this change was not different from change in subjects maintained with a higher dose (initial, 3.02 mg/ml; final, 3.12 mg/ml) (p = 0.39). Similarly, there was no evidence of any change in bronchodilator requirements (p = 0.89). However, after 3 months of reduced steroid use, there was a small decline in spirometry (FEV1 percent predicted: initial, 84.4%; final, 81.5%), and this change was significantly different from change in subjects in whom steroids were not reduced (initial, 90.2%; final, 90.2%) (p = 0.002). At 3 months, symptoms (predominantly sputum production) were also beginning to redevelop in the reduced budesonide group (p = 0.056). The results suggest that, when inhaled steroids are reduced after prolonged treatment, improvements in airway responsiveness can be maintained for at least 3 months and that a deterioration in spirometry and symptoms may precede an increase in responsiveness.	ST JOSEPHS HOSP,FIRESTONE REG CHEST & ALLERGY UNIT,HAMILTON L8N 1Y4,ONTARIO,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA; ASTRA PHARMA,MISSISSAUGA,ONTARIO,CANADA	McGill University; McMaster University; McMaster University	JUNIPER, EF (corresponding author), MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,1200 MAIN ST,HAMILTON L8N 3Z5,ONTARIO,CANADA.							GOMEZ E, 1988, BRIT MED J, V296, P1572, DOI 10.1136/bmj.296.6636.1572-a; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, IN PRESS EUR RESPIR; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; PERRSON CGA, 1986, LANCET, V2, P1126; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; WOOLCOCK AJ, 1989, J ALLERGY CLIN IMMUN, V84, P975, DOI 10.1016/0091-6749(89)90397-7; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x	14	126	126	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					483	489		10.1016/0091-6749(91)90006-A	http://dx.doi.org/10.1016/0091-6749(91)90006-A			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993808				2022-12-18	WOS:A1991EX98700005
J	POLLART, SM; MULLINS, DE; VAILES, LD; HAYDEN, ML; PLATTSMILLS, TAE; SUTHERLAND, WM; CHAPMAN, MD				POLLART, SM; MULLINS, DE; VAILES, LD; HAYDEN, ML; PLATTSMILLS, TAE; SUTHERLAND, WM; CHAPMAN, MD			IDENTIFICATION, QUANTITATION, AND PURIFICATION OF COCKROACH ALLERGENS USING MONOCLONAL-ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FEL-D-I; BRONCHIAL-ASTHMA; RAST ANALYSES; HOUSE DUST; HYPERSENSITIVITY; CHILDREN; ANTIGENS; EXTRACTS; BINDING	A panel of murine IgG monoclonal antibodies (MAbs) was raised against German cockroach (CR) (Blattella germanica) extract and selectively screened to identify MAb directed against allergen(s) recognized by IgE antibodies. Sera from 28 CR-allergic patients were used as sources of IgE antibodies to detect allergens "presented" by the MAb. Four clones (10A6, 3G12, 8F4, and 1D4) produced MAb to allergen(s) that bound IgE antibodies. Quantitative radioimmunoassays were used to compare levels of the MAb-defined allergens in CR extracts. MAb 10A6 reacted with a cross-reacting allergen that was detected in 9/14 CR species, including Blattella, Periplaneta, Blatta, Leucophea, and Supella spp, at concentrations of 100 to 10,000 U/ml. In contrast, MAb 3G12, 8F4, and 1D4 were Blattella specific. The allergen defined by MAb 8F4 was purified by MAb affinity chromatography and size-exclusion by high-performance liquid chromatography. It is a 36 kd heat-sensitive protein, isoelectric point, 5.2 to 5.4. Allergen 10A6 was partially purified by isoelectric focusing and high-performance liquid chromatography. It is a heat-stable, acidic protein (isoelectric point 3.15). Based on comparison of their properties with properties of previously described CR allergens, the allergens defined by MAb 10A6 and 8F4 have been provisionally designated Blattella germanica allergen I (Bla g I) and Blattella germanica allergen II (Bla g II), respectively. Assays of six commercial CR skin test extracts demonstrated a 200-fold difference in Bla g I levels (4.7 to 1085 U/ml) and only two extracts that contained detectable Bla g II (248 and 324 U/ml). The results demonstrate that MAb can be used to identify and define CR allergens and that the strategy of the use of MAb as a first step in allergen analysis and purification can be very effective, especially for poorly characterized allergen extracts.	UNIV VIRGINIA, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT ANAT, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT CELL BIOL, CHARLOTTESVILLE, VA 22908 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT ENTOMOL, BLACKSBURG, VA 24061 USA	University of Virginia; University of Virginia; University of Virginia; Virginia Polytechnic Institute & State University				Chapman, Martin/0000-0002-0845-3632	NCRR NIH HHS [2-303-RR03174] Funding Source: Medline; NIAID NIH HHS [AI-24687, AI-20565] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S03RR003174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024687, R01AI020565, R37AI020565] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CHOOVIVATHANAVANICH P, 1970, LANCET, V2, P1362; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; FRASER BN, 1979, S AFR MED J, V55, P637; FROMER JM, 1980, J ALLERGY CLIN IMMUN, V65, P203; HULETT AC, 1979, ANN ALLERGY, V42, P160; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1989, ANN ALLERGY, V63, P207; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; MENDOZA J, 1970, ANN ALLERGY, V28, P159; MENON P, IN PRESS ANN ALLERGY; MORRIS EC, 1986, J ALLERGY CLIN IMMUN, V77, P206; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULANER FA, 1970, PEDIATRICS, V45, P465; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STEINBERG DR, 1987, J ALLERGY CLIN IMMUN, V80, P586, DOI 10.1016/0091-6749(87)90012-1; THONG Y H, 1976, SMJ Singapore Medical Journal, V17, P90; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VAILES L, 1990, Journal of Allergy and Clinical Immunology, V85, P171; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1	35	126	127	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					511	521		10.1016/0091-6749(91)90010-L	http://dx.doi.org/10.1016/0091-6749(91)90010-L			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993811	Bronze			2022-12-18	WOS:A1991EX98700009
J	WRIGHT, DN; NELSON, RP; LEDFORD, DK; FERNANDEZCALDAS, E; TRUDEAU, WL; LOCKEY, RF				WRIGHT, DN; NELSON, RP; LEDFORD, DK; FERNANDEZCALDAS, E; TRUDEAU, WL; LOCKEY, RF			SERUM IGE AND HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JAMES A HALEY VET ADM MED CTR,TAMPA,FL 33612	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	WRIGHT, DN (corresponding author), UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,13000 BRUCE B DOWNS BLVD,TAMPA,FL 33612, USA.							AMMANN AJ, 1983, CLIN IMMUNOL IMMUNOP, V27, P315, DOI 10.1016/0090-1229(83)90084-3; BECKER W, 1969, IMMUNOCHEMISTRY, V6, P539, DOI 10.1016/0019-2791(69)90193-1; BLUMBERG RS, 1987, J INFECT DIS, V155, P877, DOI 10.1093/infdis/155.5.877; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; CARINI C, 1988, P NATL ACAD SCI USA, V85, P9214, DOI 10.1073/pnas.85.23.9214; COFFMAN RL, 1989, HOSP PRAC, V24, P55; FIFIELD R, 1987, ANN CLIN BIOCHEM, V24, P232, DOI 10.1177/000456328702400302; FLING JA, 1988, J ALLERGY CLIN IMMUN, V82, P965, DOI 10.1016/0091-6749(88)90132-7; GEHA RS, 1987, INT ARCH ALLER A IMM, V82, P39; GRIECO MH, 1989, J ALLERGY CLIN IMMUN, V84, P1, DOI 10.1016/0091-6749(89)90170-X; HOFFMAN RA, 1980, P NATL ACAD SCI USA, V77, P491; HOLGARTHSCOTT RS, 1969, CLIN EXP IMMUNOL, V5, P619; ISHIZAKA K, 1987, FUNDAMENTALS IMMUNOL, P193; JOHANSSON SG, 1968, LANCET, V1, P1118; KEYSTONE JS, 1980, CAN MED ASSOC J, V123, P512; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LIN RY, 1988, ANN ALLERGY, V61, P269; LOWENSTEIN W, 1988, 4TH P INT AIDS C STO, P188; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MURRAY HW, 1985, NEW ENGL J MED, V313, P1504, DOI 10.1056/NEJM198512123132403; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; NICHOLSON JKA, 1984, J CLIN INVEST, V73, P191, DOI 10.1172/JCI111190; ODONNELL CR, 1988, CHEST, V94, P945, DOI 10.1378/chest.94.5.945; PAHWA SG, 1984, ANN INTERN MED, V101, P757, DOI 10.7326/0003-4819-101-6-757; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PETITHORY JC, 1987, LANCET, V1, P921; PHILLIPS SC, 1981, NEW ENGL J MED, V305, P603, DOI 10.1056/NEJM198109103051102; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; RING J, 1986, ACTA DERM-VENEREOL, V66, P530; ROGERS MF, 1983, ANN INTERN MED, V99, P151, DOI 10.7326/0003-4819-99-2-151; ROSENBERG EB, 1970, NEW ENGL J MED, V283, P1148, DOI 10.1056/NEJM197011192832107; ROSENBERG EB, 1971, ANN INTERN MED, V75, P575, DOI 10.7326/0003-4819-75-4-575; SAMPLE S, 1989, J ALLERGY CLINIMMUNO, V89, P190; SAXON A, 1988, J ALLERGY CLIN IMMUN, V81, P796, DOI 10.1016/0091-6749(88)90934-7; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SNEDECOR GW, 1967, STATISTICAL METHODS, P111; SPENCE JT, 1976, ELEMENTARY STATISTIC, P157; YARCHOAN R, 1986, J CLIN INVEST, V78, P439, DOI 10.1172/JCI112595; 1986, JAMA-J AM MED ASSOC, V256, P20	40	126	127	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					445	452		10.1016/0091-6749(90)90154-V	http://dx.doi.org/10.1016/0091-6749(90)90154-V			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2303648	Bronze			2022-12-18	WOS:A1990CP51100005
J	Stier, MT; Bloodworth, MH; Toki, S; Newcomb, DC; Goleniewska, K; Boyd, KL; Quitalig, M; Hotard, AL; Moore, ML; Hartert, TV; Zhou, BH; McKenzie, AN; Peebles, RS				Stier, Matthew T.; Bloodworth, Melissa H.; Toki, Shinji; Newcomb, Dawn C.; Goleniewska, Kasia; Boyd, Kelli L.; Quitalig, Marc; Hotard, Anne L.; Moore, Martin L.; Hartert, Tina V.; Zhou, Baohua; McKenzie, Andrew N.; Peebles, R. Stokes, Jr.			Respiratory syncytial virus infection activates IL-13-producing group 2 innate lymphoid cells through thymic stromal lymphopoietin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cells; IL-13; IL-33; thymic stromal lymphopoietin; respiratory syncytial virus; type 2 immunity (T(H)2)	AIRWAY EPITHELIAL-CELLS; ALLERGIC INFLAMMATION; CYTOKINE PRODUCTION; LUNG INFLAMMATION; T-LYMPHOCYTES; HYPERRESPONSIVENESS; DEXAMETHASONE; IL-33; IL-25; TSLP	Background: Respiratory syncytial virus (RSV) is a major health care burden with a particularly high worldwide morbidity and mortality rate among infants. Data suggest that severe RSV-associated illness is in part caused by immunopathology associated with a robust type 2 response. Objective: We sought to determine the capacity of RSV infection to stimulate group 2 innate lymphoid cells (ILC2s) and the associated mechanism in a murine model. Methods: Wild-type (WT) BALB/c, thymic stromal lymphopoietin receptor (TSLPR) knockout (KO), or WT mice receiving an anti-TSLP neutralizing antibody were infected with the RSV strain 01/2-20. During the first 4 to 6 days of infection, lungs were collected for evaluation of viral load, protein concentration, airway mucus, airway reactivity, or ILC2 numbers. Results were confirmed with 2 additional RSV clinical isolates, 12/11-19 and 12/12-6, with known human pathogenic potential. Results: RSV induced a 3-fold increase in the number of IL-13-producing ILC2s at day 4 after infection, with a concurrent increase in total lung IL-13 levels. Both thymic stromal lymphopoietin (TSLP) and IL-33 levels were increased 12 hours after infection. TSLPR KO mice did not mount an IL-13 producing ILC2 response to RSV infection. Additionally, neutralization of TSLP significantly attenuated the RSV-induced IL-13-producing ILC2 response. TSLPR KO mice displayed reduced lung IL-13 protein levels, decreased airway mucus and reactivity, attenuated weight loss, and similar viral loads as WT mice. Both 12/11-19 and 12/12-6 similarly induced IL-13 producing ILC2s through a TSLP-dependent mechanism. Conclusion: These data demonstrate that multiple pathogenic strains of RSV induce IL-13-producing ILC2 proliferation and activation througha TSLP-dependent mechanism in a murine model and suggest the potential therapeutic targeting of TSLP during severe RSV infection.	[Stier, Matthew T.; Bloodworth, Melissa H.; Newcomb, Dawn C.; Boyd, Kelli L.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Toki, Shinji; Newcomb, Dawn C.; Goleniewska, Kasia; Quitalig, Marc; Hartert, Tina V.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA; [Hotard, Anne L.; Moore, Martin L.] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA; [Hotard, Anne L.; Moore, Martin L.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Zhou, Baohua] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [McKenzie, Andrew N.] Univ Cambridge, MRC Lab Mol Biol, Cambridge CB2 1TN, England	Vanderbilt University; Vanderbilt University; Emory University; Children's Healthcare of Atlanta (CHOA); Indiana University System; Indiana University Bloomington; MRC Laboratory Molecular Biology; University of Cambridge	Peebles, RS (corresponding author), Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, T-1218 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	stokes.peebles@vanderbilt.edu			National Institutes of Health (NIH) [R01 AI 111820]; United States Department of Veterans Affairs [2I01BX000624]; NIH [U19 AI 095227-02, R01 HL 090664-04, T32 GM07347-Vanderbilt MSTP, F30 AI114262, R01 AI085046, K24 AI77930]; Medical Research Council [MC_U105178805] Funding Source: researchfish; MRC [MC_U105178805] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122554, R01HL090664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F30AI114262, K24AI077930, R01AI085046, R21AI121420, U19AI070489, F30AI118376, U19AI095227, R01AI054660, R01AI111820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000624] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	Supported by National Institutes of Health (NIH) grant R01 AI 111820 (to R.S.P.), United States Department of Veterans Affairs 2I01BX000624 (to R.S.P.), NIH U19 AI 095227-02 (to R.S.P.), NIH R01 HL 090664-04 (to R.S.P.), NIH T32 GM07347-Vanderbilt MSTP, NIH F30 AI114262 (to M.T.S.), NIH R01 AI085046 (to B.Z.), and NIH K24 AI77930 (to T.V.H.).	Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Brady MT, 2014, PEDIATRICS, V134, P415, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Carroll KN, 2008, IMMUNOL ALLERGY CLIN, V28, P539, DOI 10.1016/j.iac.2008.03.001; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Collins PL, 2008, J VIROL, V82, P2040, DOI 10.1128/JVI.01625-07; Corneli HM, 2007, NEW ENGL J MED, V357, P331, DOI 10.1056/NEJMoa071255; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Dulek DE, 2014, J VIROL, V88, P9655, DOI 10.1128/JVI.03299-13; Feltes TF, 2003, J PEDIATR-US, V143, P532, DOI 10.1067/S0022-3476(03)00454-2; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gorski SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003615; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Halsey NA, 1996, PEDIATRICS, V97, P137; Han JY, 2012, J ALLERGY CLIN IMMUN, V130, P1175, DOI 10.1016/j.jaci.2012.08.033; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Johnson JE, 2007, MODERN PATHOL, V20, P108, DOI 10.1038/modpathol.3800725; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Klassen TP, 1997, J PEDIATR-US, V130, P191, DOI 10.1016/S0022-3476(97)70342-1; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Larkin EK, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0040-0; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/00006454-200207000-00005; Lee HC, 2012, J ALLERGY CLIN IMMUN, V130, P1187, DOI 10.1016/j.jaci.2012.07.031; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mosconi I, 2013, MUCOSAL IMMUNOL, V6, P1157, DOI 10.1038/mi.2013.12; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Peebles RS, 1999, J MED VIROL, V57, P186, DOI 10.1002/(SICI)1096-9071(199902)57:2<186::AID-JMV17>3.0.CO;2-Q; Peebles RS, 2001, J MED VIROL, V63, P178, DOI 10.1002/1096-9071(20000201)63:2<178::AID-JMV1013>3.3.CO;2-F; Petersen BC, 2014, J LEUKOCYTE BIOL, V95, P809, DOI 10.1189/jlb.0913482; Plint AC, 2009, NEW ENGL J MED, V360, P2079, DOI 10.1056/NEJMoa0900544; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Saravia J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005217; Shiraki Y, 2006, J MED MICROBIOL, V55, P1175, DOI 10.1099/jmm.0.46632-0; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Stokes KL, 2011, J VIROL, V85, P5782, DOI 10.1128/JVI.01693-10; Tripp RA, 2000, CYTOKINE, V12, P801, DOI 10.1006/cyto.1999.0615; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yu X, 2014, MUCOSAL IMMUNOL, V7, P730, DOI 10.1038/mi.2013.92; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	61	125	128	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					814	+		10.1016/j.jaci.2016.01.050	http://dx.doi.org/10.1016/j.jaci.2016.01.050			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27156176	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000385496000018
J	Feld, M; Garcia, R; Buddenkotte, J; Katayama, S; Lewis, K; Muirhead, G; Hevezi, P; Plesser, K; Schrumpf, H; Krjutskov, K; Sergeeva, O; Muller, HW; Tsoka, S; Kere, J; Dillon, SR; Steinhoff, M; Homey, B				Feld, Micha; Garcia, Richard; Buddenkotte, Joerg; Katayama, Shintaro; Lewis, Katherine; Muirhead, Gareth; Hevezi, Peter; Plesser, Kristin; Schrumpf, Holger; Krjutskov, Kaarel; Sergeeva, Olga; Mueller, Hans Werner; Tsoka, Sophia; Kere, Juha; Dillon, Stacey R.; Steinhoff, Martin; Homey, Bernhard			The pruritus- and T(H)2-associated cytokine IL-31 promotes growth of sensory nerves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-31; IL-31 receptor alpha; dorsal root ganglia; atopic dermatitis; nerve growth; cutaneous hyperinnervation	ATOPIC-DERMATITIS; NEURITE OUTGROWTH; T-CELLS; SKIN; INTERLEUKIN-31; ITCH; NEURONS; STAT3; PHOSPHORYLATION; NEUROPEPTIDES	Background: Pruritus is a cardinal symptom of atopic dermatitis, and an increased cutaneous sensory network is thought to contribute to pruritus. Although the immune cell-IL-31-neuron axis has been implicated in severe pruritus during atopic skin inflammation, IL-31's neuropoietic potential remains elusive. Objective: We sought to analyze the IL-31-related transcriptome in sensory neurons and to investigate whether IL-31 promotes sensory nerve fiber outgrowth. Methods: In vitro primary sensory neuron culture systems were subjected to whole-transcriptome sequencing, ingenuity pathway analysis, immunofluorescence, and nerve elongation, as well as branching assays after IL-31 stimulation. In vivo we investigated the cutaneous sensory neuronal network in wild-type, Il31-transgenic, and IL-31 pump-equipped mice. Results: Transgenic Il31 overexpression and subcutaneously delivered IL-31 induced an increase in the cutaneous nerve fiber density in lesional skin in vivo. Transcriptional profiling of IL-31-activated dorsal root ganglia neurons revealed enrichment for genes promoting nervous system development and neuronal outgrowth and negatively regulating cell death. Moreover, the growth cones of primary small-diameter dorsal root ganglia neurons showed abundant IL-31 receptor a expression. Indeed, IL-31 selectively promoted nerve fiber extension only in small-diameter neurons. Signal transducer and activator of transcription 3 phosphorylation mediated IL-31-induced neuronal outgrowth, and pharmacologic inhibition of signal transducer and activator of transcription 3 completely abolished this effect. In contrast, transient receptor potential cation channel vanilloid subtype 1 channels were dispensable for IL-31-induced neuronal sprouting. Conclusions: The pruritus-and TH2-associated novel cytokine IL-31 induces a distinct transcriptional program in sensory neurons, leading to nerve elongation and branching both in vitro and in vivo. This finding might help us understand the clinical observation that patients with atopic dermatitis experience increased sensitivity to minimal stimuli inducing sustained itch.	[Feld, Micha; Buddenkotte, Joerg; Plesser, Kristin; Schrumpf, Holger; Steinhoff, Martin; Homey, Bernhard] Univ Hosp Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany; [Garcia, Richard; Lewis, Katherine; Dillon, Stacey R.] ZymoGenetics, Seattle, WA USA; [Katayama, Shintaro; Krjutskov, Kaarel; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Muirhead, Gareth; Tsoka, Sophia] Kings Coll London, Dept Informat, London, England; [Hevezi, Peter] Univ Calif Irvine, Physiol & Biophys, Irvine, CA USA; [Sergeeva, Olga] Univ Dusseldorf, Dept Neurophysiol, Dusseldorf, Germany; [Mueller, Hans Werner] Heinrich Heine Univ, Mol Neurobiol Lab, Neurol, Dusseldorf, Germany; [Steinhoff, Martin] Dept Dermatol, Dublin, Ireland; [Steinhoff, Martin] UCD Charles Inst Translat Dermatol, Dublin, Ireland	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Zymogenet Inc.; Karolinska Institutet; University of London; King's College London; University of California System; University of California Irvine; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Homey, B (corresponding author), Univ Hosp Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	bernhard.homey@uni-duesseldorf.de	Kere, Juha/A-9179-2008; Katayama, Shintaro/F-2958-2010; Sergeeva, Olga/AAE-1869-2019; Kere, Juha/AAX-9117-2021	Kere, Juha/0000-0003-1974-0271; Katayama, Shintaro/0000-0001-7581-5157; Kere, Juha/0000-0003-1974-0271; Tsoka, Sophia/0000-0001-8403-1282; Steinhoff, Martin/0000-0002-7090-2187	Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) [b2014069]; European Union's Seventh Framework Programme FP7 [261366]; SFI IvP award; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR059402-01A1, AR059402]; Toray Japan; Skin and Cancer Hospital Charity Dublin; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059402] Funding Source: NIH RePORTER	Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX); European Union's Seventh Framework Programme FP7; SFI IvP award; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Toray Japan(Toray Industries, Inc.); Skin and Cancer Hospital Charity Dublin; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Michaela Fastrich for expert technical assistance. The computations were performed with resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project b2014069.; Supported by the European Union's Seventh Framework Programme FP7/2007-2013 under grant agreement no. 261366 (to B.H.), the SFI IvP award, National Institutes of Health (AR059402-01A1)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01 (AR059402), Toray Japan, and the Skin and Cancer Hospital Charity Dublin (to M.S.).	Bareyre FM, 2011, P NATL ACAD SCI USA, V108, P6282, DOI 10.1073/pnas.1015239108; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Cevikbas F, 2007, CURR OPIN ALLERGY CL, V7, P365, DOI 10.1097/ACI.0b013e3282a644d2; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Christie KJ, 2013, NEUROSCIENCE, V240, P310, DOI 10.1016/j.neuroscience.2013.02.059; Cornelissen C, 2012, EUR J CELL BIOL, V91, P552, DOI 10.1016/j.ejcb.2011.07.006; Deister C, 2006, J NEURAL ENG, V3, P172, DOI 10.1088/1741-2560/3/2/011; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Dou YC, 2006, ARCH DERMATOL RES, V298, P31, DOI 10.1007/s00403-006-0657-1; Emtestam L, 2012, ARCH DERMATOL RES, V304, P781, DOI 10.1007/s00403-012-1246-0; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Gallagher D, 2007, J NEUROSCI, V27, P9664, DOI 10.1523/JNEUROSCI.0608-07.2007; Gallo G, 2004, J NEUROBIOL, V58, P92, DOI 10.1002/neu.10282; Goswami C, 2010, J CELL SCI, V123, P2044, DOI 10.1242/jcs.065144; Grimstad O, 2009, EXP DERMATOL, V18, P35, DOI 10.1111/j.1600-0625.2008.00766.x; Guo W, 2007, DEV BIOL, V306, P457, DOI 10.1016/j.ydbio.2007.03.019; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hartmann K, 2013, J ALLERGY CLIN IMMUN, V132, P232, DOI 10.1016/j.jaci.2012.11.008; Hawro T, 2014, ALLERGY, V69, P113, DOI 10.1111/all.12316; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Islam S, 2012, NAT PROTOC, V7, P813, DOI 10.1038/nprot.2012.022; Jarvikallio A, 2003, ARCH DERMATOL RES, V295, P2, DOI 10.1007/s00403-002-0378-z; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kasutani K, 2014, BRIT J PHARMACOL, V171, P5049, DOI 10.1111/bph.12823; Kato A, 2014, J DERMATOL SCI, V74, P229, DOI 10.1016/j.jdermsci.2014.02.009; Kivioja T, 2012, NAT METHODS, V9, P72, DOI [10.1038/NMETH.1778, 10.1038/nmeth.1778]; Lei Z, 2008, ALLERGY, V63, P327, DOI 10.1111/j.1398-9995.2007.01566.x; Li Y, 2005, NATURE, V434, P894, DOI 10.1038/nature03477; Liu HX, 2014, NEUROSCI LETT, V569, P110, DOI 10.1016/j.neulet.2014.03.071; Liu WL, 2015, PEDIATR RES, V77, P20, DOI 10.1038/pr.2014.151; Moidunny S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-198; Murota H, 2014, ACTA DERM-VENEREOL, V94, P78, DOI 10.2340/00015555-1648; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; Nemoto O, 2015, EUR AC DERM VEN M IS; Oh MH, 2013, J IMMUNOL, V191, P5371, DOI 10.4049/jimmunol.1300300; Park K, 2012, J LEUKOCYTE BIOL, V91, P245, DOI 10.1189/jlb.0111020; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; PINCELLI C, 1990, BRIT J DERMATOL, V122, P745, DOI 10.1111/j.1365-2133.1990.tb06261.x; Quarta S, 2014, J NEUROSCI, V34, P13222, DOI 10.1523/JNEUROSCI.1209-13.2014; Saijilafu, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3690; Segal RA, 2014, COLD SPRING HARB PER, V6; Selvaraj BT, 2012, J CELL BIOL, V199, P437, DOI 10.1083/jcb.201203109; Shimada T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/564534; Slaets H, 2014, MOL NEUROBIOL, V50, P1142, DOI 10.1007/s12035-014-8795-5; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stott B, 2013, J ALLERGY CLIN IMMUN, V132, P446, DOI 10.1016/j.jaci.2013.03.050; Tominaga M, 2008, BRIT J DERMATOL, V158, P842, DOI 10.1111/j.1365-2133.2007.08410.x; Tominaga M, 2014, J DERMATOL, V41, P205, DOI 10.1111/1346-8138.12317; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Urashima R, 1998, VIRCHOWS ARCH, V432, P363, DOI 10.1007/s004280050179	50	125	130	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					500	+		10.1016/j.jaci.2016.02.020	http://dx.doi.org/10.1016/j.jaci.2016.02.020			33	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27212086	Bronze			2022-12-18	WOS:000380835800021
J	Burks, AW; Wood, RA; Jones, SM; Sicherer, SH; Fleischer, DM; Scurlock, AM; Vickery, BP; Liu, AH; Henning, AK; Lindblad, R; Dawson, P; Plaut, M; Sampson, HA				Burks, A. Wesley; Wood, Robert A.; Jones, Stacie M.; Sicherer, Scott H.; Fleischer, David M.; Scurlock, Amy M.; Vickery, Brian P.; Liu, Andrew H.; Henning, Alice K.; Lindblad, Robert; Dawson, Peter; Plaut, Marshall; Sampson, Hugh A.		Consortium Food Allergy Res CoFAR	Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; sublingual immunotherapy; desensitization; food allergy; follow-up	ORAL IMMUNOTHERAPY; ANAPHYLACTIC REACTIONS; FOOD ALLERGY; DOUBLE-BLIND; KIWI FRUIT; FATALITIES; EFFICACY; READY	Background: We previously reported the initial results of the first multicenter, randomized, double-blind, placebo-controlled clinical trial of peanut sublingual immunotherapy (SLIT), observing a favorable safety profile associated with modest clinical and immunologic effects in the first year. Objective: We sought to provide long-term (3-year) clinical and immunologic outcomes for our peanut SLIT trial. Key end points were (1) percentage of responders at 2 years (ie, could consume 5 g of peanut powder or a 10-fold increase from baseline), (2) percentage reaching desensitization at 3 years, (3) percentage attaining sustained unresponsiveness after 3 years, (4) immunologic end points, and (5) assessment of safety parameters. Methods: Response to treatment was evaluated in 40 subjects aged 12 to 40 years by performing a 10-g peanut powder oral food challenge after 2 and 3 years of daily peanut SLIT therapy. At 3 years, SLIT was discontinued for 8 weeks, followed by another 10-g oral food challenge and an open feeding of peanut butter to assess sustained unresponsiveness. Results: Approximately 98% of the 18,165 doses were tolerated without adverse reactions beyond the oropharynx, with no severe symptoms or uses of epinephrine. A high rate (> 50%) discontinued therapy. By study's end, 4 (10.8%) of 37 SLITtreated participants were fully desensitized to 10 g of peanut powder, and all 4 achieved sustained unresponsiveness. Responders at 2 years showed a significant decrease in peanutspecific basophil activation and skin prick test titration compared with nonresponders. Conclusions: Peanut SLIT induced a modest level of desensitization, decreased immunologic activity over 3 years in responders, and had an excellent long-term safety profile. However, most patients discontinued therapy by the end of year 3, and only 10.8% of subjects achieved sustained unresponsiveness.	[Burks, A. Wesley; Vickery, Brian P.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Jones, Stacie M.; Scurlock, Amy M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.; Scurlock, Amy M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Sicherer, Scott H.; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Fleischer, David M.] Univ Colorado, Denver Sch Med, Dept Pediat, Denver, CO 80202 USA; [Fleischer, David M.] Childrens Hosp Colorado, Denver, CO USA; [Liu, Andrew H.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Henning, Alice K.; Lindblad, Robert; Dawson, Peter] EMMES Corp, Rockville, MD USA; [Plaut, Marshall] NIAID, NIH, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Icahn School of Medicine at Mount Sinai; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; National Jewish Health; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Burks, AW (corresponding author), Dept Pediat, 260 Macnider Bldg,Box 7220, Chapel Hill, NC 27599 USA.	wburks@email.unc.edu		Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; National Center for Research Resources (NCRR)/NIH [UL1 RR025780]; NIH/National Center for Advancing Translational Sciences [UL1 TR000154]; NCRR [UL1 TR000067, UL1 TR000039, UL 1 RR024128, UL1 RR 025005]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128, UL1RR025005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI077932, U19AI066738, R01AI068074, UM1AI109565, U01AI066560] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR)/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/National Center for Advancing Translational Sciences; NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants U19AI066738 and U01AI066560. The project was also supported by grant no. UL1 RR025780 from the National Center for Research Resources (NCRR)/NIH and grant no. UL1 TR000154 from the NIH/National Center for Advancing Translational Sciences (National Jewish) and grant nos. UL1 TR000067 (Mount Sinai), UL1 TR000039 (Arkansas), UL 1 RR024128 (North Carolina), and UL1 RR 025005 (Johns Hopkins) from the NCRR. The article's contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH.	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Boyce JA, 2011, J AM ACAD DERMATOL, V64, P175, DOI [10.1016/j.jaad.2010.11.020, 10.1016/j.nutres.2011.01.001]; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Greenhawt MJ, 2013, ALLERGY ASTHMA PROC, V34, P197, DOI 10.2500/aap.2013.34.3661; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2014, J CLIN INVEST, V124, P1880, DOI 10.1172/JCI72061; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kerzl R, 2007, J ALLERGY CLIN IMMUN, V119, P507, DOI 10.1016/j.jaci.2006.09.041; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Pleskovic N, 2014, CURR OPIN ALLERGY CL, V14, P582, DOI 10.1097/ACI.0000000000000112; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sun JQ, 2014, ALLERGY ASTHMA PROC, V35, P171, DOI 10.2500/aap.2014.35.3730; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007	27	125	125	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1240	U648		10.1016/j.jaci.2014.12.1917	http://dx.doi.org/10.1016/j.jaci.2014.12.1917			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25656999	Green Accepted, Green Submitted			2022-12-18	WOS:000353980700017
J	Baiz, N; Dargent-Molina, P; Wark, JD; Souberbielle, JC; Annesi-Maesano, I				Baiz, Nour; Dargent-Molina, Patricia; Wark, John D.; Souberbielle, Jean-Claude; Annesi-Maesano, Isabella		Eden Mother-Child Cohort Study Grp	Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; 25-hydroxyvitamin D; cord blood; allergic diseases; wheezing; atopic dermatitis; mother-child cohort	VITAMIN-D STATUS; NUTRITION EXAMINATION SURVEY; REGULATORY T-CELLS; D DEFICIENCY; WORLDWIDE VARIATIONS; D SUPPLEMENTATION; ASTHMA SYMPTOMS; NATIONAL-HEALTH; MATERNAL INTAKE; PREGNANCY	Background: There is increasing evidence of the effect of maternal vitamin D intake during pregnancy on the risk of asthma and allergic outcomes in offspring. However, studies on the relationship between cord levels of 25-hydroxyvitamin D (25 [OH]D) and asthma and allergic diseases are very few. Objective: Our aim was to investigate the associations between cord serum25(OH)D levels and asthma, wheezing, allergic rhinitis, and atopic dermatitis in the offspring from birth to 5 years. Methods: Cord blood samples were collected at birth and analyzed for 25(OH)D levels in 239 newborns from the Etude des Determinants pre et post natals du developpement et de la sante de l'Enfant (EDEN) birth cohort. The children were followed up until age 5 years by using International Study of Asthma and Allergies in Childhood-based symptom questionnaires. Results: The median cord serum level of 25(OH)D was 17.8 ng/mL (interquartile range, 15.1 ng/mL). By using multivariable-adjusted logistic regression models, a significant inverse association was observed between cord serum 25(OH) D levels and risk of transient early wheezing and early-and late-onset atopic dermatitis, as well as atopic dermatitis, by the ages of 1, 2, 3, and 5 years. We found no association between cord serum 25(OH) D levels and asthma and allergic rhinitis at age 5 years. Conclusions: Cord serum 25(OH) D levels were inversely associated with the risk of transient early wheezing and atopic dermatitis by the age of 5 years, but no association was found with asthma and allergic rhinitis.	[Baiz, Nour; Annesi-Maesano, Isabella] INSERM, Epidemiol Allerg & Resp Dis EPAR Dept, F-75571 Paris 12, France; [Baiz, Nour; Annesi-Maesano, Isabella] Univ Paris 06, UPMC, Med Sch St Antoine, Paris, France; [Dargent-Molina, Patricia] INSERM, UMR S953, Villejuif, France; [Dargent-Molina, Patricia] Univ Paris 06, UMR S953, Paris, France; [Wark, John D.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic, Australia; [Souberbielle, Jean-Claude] Univ Paris 05, Hop Necker Enfants Malades, AP HP, Physiol Lab, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Royal Melbourne Hospital; University of Melbourne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Baiz, N (corresponding author), INSERM, EPAR UMR S 707, 27 Rue Chaligny, F-75571 Paris 12, France.	baiz@u707.jussieu.fr	Heude, Barbara/G-3095-2016; Dargent-Molina, Patricia/N-3887-2017; Annesi-Maesano, Isabella/D-9173-2016; de Lauzon-Guillain, Blandine/P-4659-2016	Heude, Barbara/0000-0002-1565-1629; Dargent-Molina, Patricia/0000-0001-8596-6899; Annesi-Maesano, Isabella/0000-0002-6340-9300; de Lauzon-Guillain, Blandine/0000-0001-5887-8842; BAIZ, Nour/0000-0001-6165-3935	French Agency for Environment Security; Fondation pour la Recherche Medicale (FRM); French Ministry of Research: IFR program; French National Institute for Health Education (INPES); National Agency for Research; French Ministry of Health: Perinatality Program; French National Institute for Population Health Surveillance (INVS); INSERM Nutrition Research Program Paris-Sud University; Nestle; Mutuelle Generale de L'education Nationale (MGEN); French agency for Environment Security (AFFSET); French Ministry of Research; INSERM Nutrition Research program; French Ministry of Health; French Speaking Association for the Study of Diabetes and Metabolism (Alfediam); National Agency for Research (ANR)	French Agency for Environment Security; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); French Ministry of Research: IFR program(Ministry of Research, France); French National Institute for Health Education (INPES)(Institut National de la Sante et de la Recherche Medicale (Inserm)); National Agency for Research(French National Research Agency (ANR)); French Ministry of Health: Perinatality Program; French National Institute for Population Health Surveillance (INVS); INSERM Nutrition Research Program Paris-Sud University; Nestle(Nestle SA); Mutuelle Generale de L'education Nationale (MGEN); French agency for Environment Security (AFFSET)(French National Research Agency (ANR)); French Ministry of Research(Ministry of Research, FranceEuropean Commission); INSERM Nutrition Research program(Institut National de la Sante et de la Recherche Medicale (Inserm)); French Ministry of Health; French Speaking Association for the Study of Diabetes and Metabolism (Alfediam); National Agency for Research (ANR)(French National Research Agency (ANR))	N. Baiz has received grants from the French Agency for Environment Security, Fondation pour la Recherche Medicale (FRM), the French Ministry of Research: IFR program, the French National Institute for Health Education (INPES), the National Agency for Research, the French Ministry of Health: Perinatality Program, the French National Institute for Population Health Surveillance (INVS), INSERM Nutrition Research Program Paris-Sud University, Nestle, Mutuelle Generale de L'education Nationale (MGEN), and the French Speaking Association for the study of Diabetes and Metabolism (Alfediam). P. Dargent-Molina, J. D. Wark, J.-C. Souberbielle, and I. Annesi-Maesano have received grants from the French agency for Environment Security (AFFSET), Fondation pour la Recherche Medicale (FRM), the French Ministry of Research, INSERM Nutrition Research program, the French Ministry of Health, the French National Institute for Population Health Surveillance (INVS), the French National Institute for Health Education (INPES), Nestle, Mutuelle Generale de l'Education Nationale (MGEN), the French Speaking Association for the Study of Diabetes and Metabolism (Alfediam), and the National Agency for Research (ANR).	Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716; Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Agosti M, 2003, ACTA PAEDIATR, V92, P44; Agrawal R, 2011, CURR PROBL DERMATOL, V41, P112, DOI 10.1159/000323305; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Annesi-Maesano I, 2002, PEDIATR RES, V52, P3, DOI 10.1023/01.PDR/0000017228.29635.EF; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BIKLE DD, 1989, ENDOCRINOLOGY, V124, P655, DOI 10.1210/endo-124-2-655; Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2; Bozzetto S, 2012, ALLERGY, V67, P10, DOI 10.1111/j.1398-9995.2011.02711.x; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; Camargo CA, 2006, J ALLERGY CLIN IMMUN, V117, P721, DOI 10.1016/j.jaci.2006.01.024; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Dror DK, 2011, J AM DIET ASSOC, V111, P111, DOI 10.1016/j.jada.2010.10.002; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Fukuoka M, 1998, BRIT J DERMATOL, V138, P63; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Gillman MW, 2005, NEW ENGL J MED, V353, P1848, DOI 10.1056/NEJMe058187; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; HADDAD JG, 1976, J CLIN ENDOCR METAB, V42, P284, DOI 10.1210/jcem-42-2-284; Hewison M, 2012, CLIN ENDOCRINOL, V76, P315, DOI 10.1111/j.1365-2265.2011.04261.x; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Kim DH, 2008, AM J CARDIOL, V102, P1540, DOI 10.1016/j.amjcard.2008.06.067; Kinder BW, 2011, EXPERT REV CLIN IMMU, V7, P255, DOI [10.1586/eci.11.12, 10.1586/ECI.11.12]; Komine M, 1999, ARCH DERMATOL RES, V291, P500, DOI 10.1007/s004030050444; Lange NE, 2009, EXPERT REV CLIN IMMU, V5, P693, DOI 10.1586/ECI.09.53; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Mak G, 2011, CURR OPIN PULM MED, V17, P1, DOI 10.1097/MCP.0b013e3283411440; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Mulligan ML, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.09.002; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Neto HJC, 2007, PEDIAT ALLERG IMM-UK, V18, P86, DOI 10.1111/j.1399-3038.2006.00488.x; Oren E, 2008, J ALLERGY CLIN IMMUN, V121, P533, DOI 10.1016/j.jaci.2007.11.005; Ozfirat Z, 2010, POSTGRAD MED J, V86, P18, DOI 10.1136/pgmj.2009.078626; Patel SP, 2012, J EPIDEMIOL COMMUN H, V66, P809, DOI 10.1136/jech.2011.133777; Robison R, 2010, CURR OPIN ALLERGY CL, V10, P139, DOI 10.1097/ACI.0b013e32833667a8; RUDZKI E, 1994, DERMATOLOGY, V189, P41, DOI 10.1159/000246781; Salle BL, 2000, AM J CLIN NUTR, V71, p1317S, DOI 10.1093/ajcn/71.5.1317s; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; Thandrayen K, 2010, ENDOCRIN METAB CLIN, V39, P303, DOI 10.1016/j.ecl.2010.02.006; Tong SL, 2001, ANN EPIDEMIOL, V11, P38, DOI 10.1016/S1047-2797(00)00176-9; Trump DL, 2010, CANCER J, V16, P1, DOI 10.1097/PPO.0b013e3181c51ee6; Tsiaras WG, 2011, ACTA DERM-VENEREOL, V91, P115, DOI 10.2340/00015555-0980; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Wright CY, 2007, PHOTOCHEM PHOTOBIOL, V83, P749, DOI 10.1562/2006-08-22-RA-1010; Zhang Jian-Zhong, 1994, Journal of Dermatological Science, V7, P24, DOI 10.1016/0923-1811(94)90018-3	59	125	132	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					147	153		10.1016/j.jaci.2013.05.017	http://dx.doi.org/10.1016/j.jaci.2013.05.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23810764	Green Submitted			2022-12-18	WOS:000329105700020
J	Bae, JM; Choi, YY; Park, CO; Chung, KY; Lee, KH				Bae, Jung Min; Choi, Yoon Young; Park, Chang Ook; Chung, Kee Yang; Lee, Kwang Hoon			Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergen-specific immunotherapy; atopic dermatitis; meta-analysis; subcutaneous immunotherapy; sublingual immunotherapy; systematic review	DOUBLE-BLIND; DERMATOPHAGOIDES-PTERONYSSINUS; SUBLINGUAL IMMUNOTHERAPY; HYPOSENSITIZATION; CHILDREN; GUIDELINES; THERAPY; ECZEMA	Background: Allergen-specific immunotherapy (allergen-SIT) is the only treatment directed at the cause of IgE-mediated allergic diseases. However, there is controversy over the use of SIT for patients with atopic dermatitis. Objective: We performed a systematic review and meta-analysis to assess the efficacy of SIT for patients with atopic dermatitis. Methods: We performed manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, CINAHL, Web of Science, and Cochrane databases (through December 10, 2012) for randomized controlled trials that compared SIT with placebo for patients with atopic dermatitis. The outcome of interest was a dichotomous variable, in terms of treatment success; a meta-analysis was performed by using a random-effects analysis. Subgroup analyses were carried out to evaluate the effects of long-term treatment (more than 1 year), SIT for severe atopic dermatitis, SIT for children, and subcutaneous and sublingual administration of immunotherapy. Results: We analyzed 8 randomized controlled trials that comprised a total of 385 subjects. We found that SIT has a significant positive effect on atopic dermatitis (odds ratio [OR], 5.35; 95% CI, 1.61-17.77; number needed to treat, 3; 95% CI, 2-9). SIT also showed significant efficacy in long-term treatment (OR, 6.42; 95% CI, 1.50-27.52) for patients with severe atopic dermatitis (OR, 3.13; 95% CI, 1.31-7.48), and when administered subcutaneously (OR, 4.27; 95% CI, 1.36-13.39). Conclusions: A meta-analysis provides moderate-level evidence for the efficacy of SIT against atopic dermatitis. However, these findings are based on an analysis of a small number of randomized controlled trials, with considerable heterogeneity among trials.	[Bae, Jung Min; Park, Chang Ook; Chung, Kee Yang; Lee, Kwang Hoon] Yonsei Univ, Coll Med, Severance Hosp, Dept Dermatol, Seoul 120752, South Korea; [Bae, Jung Min; Park, Chang Ook; Chung, Kee Yang; Lee, Kwang Hoon] Yonsei Univ, Coll Med, Cutaneous Biol Res Inst, Seoul 120752, South Korea; [Choi, Yoon Young] Yonsei Univ, Coll Med, Severance Hosp, Dept Surg, Seoul 120752, South Korea; [Lee, Kwang Hoon] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, KH (corresponding author), Yonsei Univ, Coll Med, Dept Dermatol, 50 Yonsei Ro, Seoul 120752, South Korea.	kwanglee@yuhs.ac		Chung, Kee Yang/0000-0003-3257-0297; Park, Chang Ook/0000-0003-3856-1201; Bae, Jung Min/0000-0001-5975-8519; Choi, Yoon Young/0000-0002-2179-7851	Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [A111718]	Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea	This study was supported by grants of the Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (grant no. A111718).	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Bonness S, 2007, CURR OPIN ALLERGY CL, V7, P382, DOI 10.1097/ACI.0b013e3282a643c3; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Compalati E, 2012, CURR OPIN ALLERGY CL, V12, P427, DOI 10.1097/ACI.0b013e328354e540; Darsow U, 2011, CURR ALLERGY ASTHM R, V11, P277, DOI 10.1007/s11882-011-0194-7; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Durham SR, 2011, J ALLERGY CLIN IMMUN, V127, P3, DOI 10.1016/j.jaci.2010.11.032; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Galli E, 1994, Allergol Immunopathol (Madr), V22, P18; Glanville JM, 2006, J MED LIBR ASSOC, V94, P130; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Higgins J, 2008, COCHRANE HDB SYSTEMA, P187, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; KAUFMAN HS, 1974, ANN ALLERGY, V32, P321; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; Madonini E, 2011, EUR ANN ALLERGY CLIN, V43, P103; Mastrandrea F, 2004, AM J CLIN DERMATOL, V5, P281, DOI 10.2165/00128071-200405050-00001; Matricardi PM, 2011, J ALLERGY CLIN IMMUN, V128, P791, DOI 10.1016/j.jaci.2011.03.049; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Noon L, 1911, LANCET, V1, P1572; Novak N, 2009, ALLERGY, V64, P265, DOI 10.1111/j.1398-9995.2008.01922.x; Novak N, 2007, CURR OPIN ALLERGY CL, V7, P542, DOI 10.1097/ACI.0b013e3282f1d66c; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P925, DOI 10.1016/j.jaci.2012.08.004; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Plotz SG, 2010, EXPERT OPIN EMERG DR, V15, P249, DOI 10.1517/14728211003792518; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1045, DOI 10.1111/j.1468-3083.2012.04635.x; Silny W, 2006, ALLERGOLOGIE, V29, P171; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; WARNER JO, 1978, LANCET, V2, P912; Wollenberg A, 2012, ANN DERMATOL, V24, P253, DOI 10.5021/ad.2012.24.3.253	36	125	131	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					110	117		10.1016/j.jaci.2013.02.044	http://dx.doi.org/10.1016/j.jaci.2013.02.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23647790	Bronze			2022-12-18	WOS:000321052300015
J	Donohue, KM; Miller, RL; Perzanowski, MS; Just, AC; Hoepner, LA; Arunajadai, S; Canfield, S; Resnick, D; Calafat, AM; Perera, FP; Whyatt, RM				Donohue, Kathleen M.; Miller, Rachel L.; Perzanowski, Matthew S.; Just, Allan C.; Hoepner, Lori A.; Arunajadai, Srikesh; Canfield, Stephen; Resnick, David; Calafat, Antonia M.; Perera, Frederica P.; Whyatt, Robin M.			Prenatal and postnatal bisphenol A exposure and asthma development among inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bisphenol A; asthma; wheeze; children; exhaled nitric oxide; IgE; cohort study	ISAAC VIDEO QUESTIONNAIRE; EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; PRESCHOOL-CHILDREN; BIRTH COHORT; DAY-CARE; T-CELLS; WHEEZE; PREGNANCY; DESIGN	Background: Bisphenol A (BPA) is used widely to manufacture food container linings. Mouse models suggest exposure to BPA might increase allergic inflammation. Objectives: We hypothesized that BPA exposure, as assessed based on urinary BPA concentrations, would be associated with increased odds of wheeze and asthma and increased fraction of exhaled nitric oxide (FENO) values in children. Methods: The Columbia Center for Children's Environmental Health recruited pregnant women for a prospective birth cohort study (n = 568). Mothers during the third trimester and children at ages 3, 5, and 7 years provided spot urine samples. Total urinary BPA concentrations were measured by using online solid-phase extraction, high-performance liquid chromatography, isotope-dilution tandem mass spectrometry. Wheeze in the last 12 months was measured by using questionnaires at ages 5, 6, and 7 years. Asthma was determined by a physician once between ages 5 and 12 years. FENO values were measured at ages 7 to 11 years. Results: Prenatal urinary BPA concentrations were associated inversely with wheeze at age 5 years (odds ratio [OR], 0.7; 95% CI, 0.5-0.9; P = .02). Urinary BPA concentrations at age 3 years were associated positively with wheeze at ages 5 years (OR, 1.4; 95% CI, 1.1-1.8; P = .02) and 6 years (OR, 1.4; 95% CI, 1.0-1.9; P = .03). BPA concentrations at age 7 years were associated with wheeze at age 7 years (OR, 1.4; 95% CI, 1.0-1.9; P = .04) and FENO values (beta = 0.1; 95% CI, 0.02-0.2; P = .02). BPA concentrations at ages 3, 5, and 7 years were associated with asthma (OR, 1.5 [95% CI, 1.1-2.0], P = .005; OR, 1.4 [95% CI, 1.0-1.9], P = .03; and OR, 1.5 [95% CI, 1.0-2.1], P = .04, respectively). Conclusions: This is the first report of an association between postnatal urinary BPA concentrations and asthma in children. (J Allergy Clin Immunol 2013;131:736-42.)	[Donohue, Kathleen M.; Miller, Rachel L.; Canfield, Stephen] Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care, New York, NY 10032 USA; [Miller, Rachel L.; Resnick, David] Columbia Univ Coll Phys & Surg, Div Pediat Allergy & Immunol, New York, NY 10032 USA; [Donohue, Kathleen M.; Miller, Rachel L.; Perzanowski, Matthew S.; Just, Allan C.; Hoepner, Lori A.; Perera, Frederica P.; Whyatt, Robin M.] Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY USA; [Miller, Rachel L.; Perzanowski, Matthew S.; Just, Allan C.; Hoepner, Lori A.; Perera, Frederica P.; Whyatt, Robin M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA; [Arunajadai, Srikesh] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA; [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Centers for Disease Control & Prevention - USA	Donohue, KM (corresponding author), Columbia Univ, Div Gen Med, 622 West 168th St,PH9E Rm 105K, New York, NY 10032 USA.	Kd2128@columbia.edu	Calafat, Antonia/B-8076-2012; Calafat, Antonia/N-1183-2019; Calafat, Antonia/GOP-1115-2022	Calafat, Antonia/0000-0002-9796-7482; Hoepner, Lori/0000-0002-4404-8140; Just, Allan/0000-0003-4312-5957	National Institute of Environmental Health Sciences [RC2ES018784, R01ES014393, P30ES009089, R01ES08977, PO1ES09600, R01ES013163]; US Environmental Protection Agency [R827027, RD832141, RD834509]; John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; Educational Foundation of America; Millstream Fund; New York Community Trust; NIH; US Environmental Protection Agency (EPA); National Institute of Environmental Health Sciences; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, P01ES009600, R01ES014393, R01ES013163, RC2ES018784, R01ES008977] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency(United States Environmental Protection Agency); John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; Educational Foundation of America; Millstream Fund; New York Community Trust; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency (EPA)(United States Environmental Protection Agency); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Environmental Health Sciences (RC2ES018784, R01ES014393, P30ES009089, R01ES08977, R01ES013163, and PO1ES09600), the US Environmental Protection Agency (R827027, RD832141, and RD834509), the John and Wendy Neu Family Foundation, the Blanchette Hooker Rockefeller Fund, New York Community Trust, the Educational Foundation of America, and the Millstream Fund. The findings expressed in this article are the opinions of the authors and do not necessarily reflect the official opinion of the Centers for Disease Control and Prevention.; K. M. Donohue has received research and travel support from the National Institutes of Health (NIH), is employed by Columbia University, and has received travel support from the Alpha-1 Foundation. R. L. Miller has received research support from the NIH and the US Environmental Protection Agency (EPA). M.S. Perzanowski has received research support from the NIH and has received travel support from Indoor Biotechnology. L. A. Hoepner has received research support from the National Institute of Environmental Health Sciences. S. Canfield has received research support from the NIH and EPA and has received travel support from the NIH. D. Resnick has received research support from the NIH. R. M. Whyatt has received research and travel support from the NIH and is employed by Columbia University. The rest of the authors declare that they have no relevant conflicts of interest.	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bjorksten B, 2011, ALLERGOL IMMUNOPATH, V39, P318, DOI 10.1016/j.aller.2011.02.005; Braun JM, 2012, ENVIRON HEALTH PERSP, V120, P739, DOI 10.1289/ehp.1104139; Braun JM, 2011, ENVIRON HEALTH PERSP, V119, P131, DOI 10.1289/ehp.1002366; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Caudill SP, 2008, STAT MED, V27, P4094, DOI 10.1002/sim.3222; Civelek E, 2011, PEDIATR PULM, V46, P166, DOI 10.1002/ppul.21346; Clayton EMR, 2011, ENVIRON HEALTH PERSP, V119, P390, DOI 10.1289/ehp.1002883; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Fuso L, 2000, RESP MED, V94, P397, DOI 10.1053/rmed.1999.0747; Hannu T, 2009, INT ARCH ALLERGY IMM, V148, P41, DOI 10.1159/000151504; Jeffery PK, 1998, AM J RESP CRIT CARE, V157, pS174, DOI 10.1164/ajrccm.157.5.rsaa-1; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Kwak Eun Soo, 2009, Open Allergy J, V2, P45; Lai CKW, 1997, CLIN EXP ALLERGY, V27, P540, DOI 10.1046/j.1365-2222.1997.520869.x; Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Lovinsky-Desir S, 2012, CURR ALLERGY ASTHM R, V12, P211, DOI 10.1007/s11882-012-0257-4; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Matsumoto J, 2002, ENVIRON HEALTH PERSP, V110, P193, DOI 10.1289/ehp.02110193; Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259; Mitchell H, 1997, PEDIATR PULM, V24, P237; Morgan MK, 2011, ENVIRON SCI TECHNOL, V45, P5309, DOI 10.1021/es200537u; Nepomnaschy PA, 2009, ENVIRON RES, V109, P734, DOI 10.1016/j.envres.2009.04.004; Nishikawa M, 2010, ENVIRON HEALTH PERSP, V118, P1196, DOI 10.1289/ehp.0901575; Ohshima Y, 2007, PEDIATR RES, V62, P60, DOI 10.1203/PDR.0b013e3180674dae; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Rastogi D, 2007, J CLIN INVEST, V117, P1637, DOI 10.1172/JCI29466; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; Richardson DB, 2003, AM J EPIDEMIOL, V157, P355, DOI 10.1093/aje/kwf217; Rosa MJ, 2011, PEDIATR PULM, V46, P83, DOI 10.1002/ppul.21328; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Roy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038448; Sawai C, 2003, ENVIRON HEALTH PERSP, V111, P1883, DOI 10.1289/ehp.6359; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Spanier AJ, 2012, ENVIRON HEALTH PERSP, V120, P916, DOI 10.1289/ehp.1104175; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Tian XL, 2003, INT ARCH ALLERGY IMM, V132, P240, DOI 10.1159/000074305; Ublagger E, 2005, CLIN EXP ALLERGY, V35, P1033, DOI 10.1111/j.1365-2222.2005.02308.x; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; vonMutius E, 1996, PEDIATR ALLERGY IMMU, V7, P54; Whyatt RM, 2003, ENVIRON HEALTH PERSP, V111, P749, DOI 10.1289/ehp.5768; Wilson NK, 2007, ENVIRON RES, V103, P9, DOI 10.1016/j.envres.2006.04.006; Wilson NK, 2003, J EXPO ANAL ENV EPID, V13, P187, DOI 10.1038/sj.jea.7500270; Wolff MS, 2007, ENVIRON HEALTH PERSP, V115, P116, DOI 10.1289/ehp.9488; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Ye XY, 2011, ENVIRON HEALTH PERSP, V119, P983, DOI 10.1289/ehp.1002701; Zalko D, 2003, ENVIRON HEALTH PERSP, V111, P309, DOI 10.1289/ehp.5603; Zalko D, 2011, CHEMOSPHERE, V82, P424, DOI 10.1016/j.chemosphere.2010.09.058; 1999, CONTROL CLIN TRIALS, V20, P91	57	125	129	0	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					736	+		10.1016/j.jaci.2012.12.1573	http://dx.doi.org/10.1016/j.jaci.2012.12.1573			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23452902	Green Submitted, Green Accepted			2022-12-18	WOS:000315587800015
J	Stepensky, P; Keller, B; Buchta, M; Kienzler, AK; Elpeleg, O; Somech, R; Cohen, S; Shachar, I; Miosge, LA; Schlesier, M; Fuchs, I; Enders, A; Eibel, H; Grimbacher, B; Warnatz, K				Stepensky, Polina; Keller, Baerbel; Buchta, Mary; Kienzler, Anne-Kathrin; Elpeleg, Orly; Somech, Raz; Cohen, Sivan; Shachar, Idit; Miosge, Lisa A.; Schlesier, Michael; Fuchs, Ilka; Enders, Anselm; Eibel, Hermann; Grimbacher, Bodo; Warnatz, Klaus			Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CARD11; human; combined immunodeficiency; hypogammaglobulinemia; profound combined immunodeficiency disorder; transitional B cell; nuclear factor kappa B; B cell-activating factor receptor; inducible T-cell costimulator; germinal center	NF-KAPPA-B; T-CELL; DIFFERENTIAL REQUIREMENT; ICOS DEFICIENCY; RECEPTOR; CARMA1; ACTIVATION; LYMPHOCYTE; MUTATION; PROLIFERATION	Background: Profound combined immunodeficiency can present with normal numbers of T and B cells, and therefore the functional defect of the cellular and humoral immune response is often not recognized until the first severe clinical manifestation. Here we report a patient of consanguineous descent presenting at 13 months of age with hypogammaglobulinemia, Pneumocystis jirovecii pneumonia, and a suggestive family history. Objective: We sought to identify the genetic alteration in a patient with combined immunodeficiency and characterize human caspase recruitment domain family, member 11 (CARD11), deficiency. Methods: Molecular, immunologic, and functional assays were performed. Results: The immunologic characterization revealed only subtle changes in the T-cell and natural killer cell compartment, whereas B-cell differentiation, although normal in number, was distinctively blocked at the transitional stage. Genetic evaluation revealed a homozygous deletion of exon 21 in CARD11 as the underlying defect. This deletion abrogated protein expression and activation of the canonical nuclear factor kappa B (NF-kappa B) pathway in lymphocytes after antigen receptor or phorbol 12-myristate 13-acetate stimulation, whereas CD40 signaling in B cells was preserved. The abrogated activation of the canonical NF-kappa B pathway was associated with severely impaired upregulation of inducible T-cell costimulator, OX40, cytokine production, proliferation of T cells, and B cell-activating factor receptor expression on B cells. Conclusion: Thus in patients with CARD11 deficiency, the combination of impaired activation and especially upregulation of inducible T-cell costimulator on T cells, together with severely disturbed peripheral B-cell differentiation, apparently leads to a defective T-cell/B-cell cooperation and probably germinal center formation and clinically results in severe immunodeficiency. This report discloses the crucial and nonredundant role of canonical NF-kappa B activation and specifically CARD11 in the antigen-specific immune response in human subjects. (J Allergy Clin Immunol 2013;131:477-85.)	Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel; [Keller, Baerbel; Buchta, Mary; Kienzler, Anne-Kathrin; Schlesier, Michael; Fuchs, Ilka; Eibel, Hermann; Grimbacher, Bodo; Warnatz, Klaus] Univ Med Ctr Freiburg, CCI, D-79106 Freiburg, Germany; [Keller, Baerbel; Buchta, Mary; Kienzler, Anne-Kathrin; Schlesier, Michael; Fuchs, Ilka; Eibel, Hermann; Grimbacher, Bodo; Warnatz, Klaus] Univ Freiburg, Freiburg, Germany; [Elpeleg, Orly] Hebrew Univ Jerusalem, Med Ctr, Monique & Jacques Roboh Dept Genet Res, Jerusalem, Israel; [Somech, Raz] Chaim Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Jeffrey Modell Fdn JMF Ctr, Dept Pediat, IL-52621 Tel Hashomer, Israel; [Somech, Raz] Chaim Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Jeffrey Modell Fdn JMF Ctr, Serv Immunol, IL-52621 Tel Hashomer, Israel; [Somech, Raz] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Cohen, Sivan; Shachar, Idit] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Miosge, Lisa A.] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol, Canberra, ACT 2601, Australia; [Schlesier, Michael] Univ Med Ctr Freiburg, Div Rheumatol & Clin Immunol, D-79106 Freiburg, Germany; [Enders, Anselm] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol, Ramaciotti Immunizat Genom Lab, Canberra, ACT 2601, Australia	Hebrew University of Jerusalem; Hadassah University Medical Center; University of Freiburg; University of Freiburg; Hebrew University of Jerusalem; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Australian National University; John Curtin School of Medical Research; University of Freiburg; Australian National University; John Curtin School of Medical Research	Warnatz, K (corresponding author), Univ Med Ctr Freiburg, CCI, Breisacher Str 117, D-79106 Freiburg, Germany.	klaus.warnatz@uniklinik-freiburg.de	Enders, Anselm/B-1165-2011; Warnatz, Klaus/AAD-3464-2022	Enders, Anselm/0000-0001-5933-6463; Miosge, Lisa/0000-0001-8317-3377; Kienzler, Anne-Kathrin/0000-0002-3082-9210	Deutsche Forschungsgemeinschaft [SFB 620]; Federal Ministry of Education and Research [BMBF 01 EO0803]; Dahlia Greidinger Cancer Research Fund; Clive and Vera Ramaciotti Foundation; NHMRC [APP1035858]; Bundesministerium fur Bildung und Forschung (BMBF); Federal Ministry of Education and Research; BMBF; Baxter; GlaxoSmithKline; CSL Behring; Pfizer	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Dahlia Greidinger Cancer Research Fund; Clive and Vera Ramaciotti Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); BMBF(Federal Ministry of Education & Research (BMBF)); Baxter; GlaxoSmithKline(GlaxoSmithKline); CSL Behring; Pfizer(Pfizer)	Supported by Deutsche Forschungsgemeinschaft Grant SFB 620 (to K. W.) and by the Federal Ministry of Education and Research (BMBF 01 EO0803, to K. W., H. E., and B. G.). P. S. was supported by a Dahlia Greidinger Cancer Research Fund. A. E. was supported by a Major Initiative Award from the Clive and Vera Ramaciotti Foundation and a Career Development Fellowship from the NHMRC (APP1035858).; B. Keller has received grants from Bundesministerium fur Bildung und Forschung (BMBF). B. Grimbacher has received grants from the Federal Ministry of Education and Research. K. Warnatz has received grants from BMBF and Baxter, and has received payment for lectures, including service on speakers' bureaus, from Baxter, GlaxoSmithKline, CSL Behring, and Pfizer. I. Fuchs has received grants from BMBF. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; ARNAIZVILLENA A, 1992, NEW ENGL J MED, V327, P529, DOI 10.1056/NEJM199208203270805; Barnes MJ, 2009, PLOS BIOL, V7, P513, DOI 10.1371/journal.pbio.1000051; Bossaller L, 2006, J IMMUNOL, V177, P4927, DOI 10.4049/jimmunol.177.7.4927; Caruana G, 2002, INT J DEV BIOL, V46, P511; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227; Edvardson S, 2012, ANN NEUROL, V71, P569, DOI 10.1002/ana.23524; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; ELDER ME, 1995, CELL IMMUNOL, V165, P110, DOI 10.1006/cimm.1995.1193; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Foerster C, 2010, J IMMUNOL, V184, P7305, DOI 10.4049/jimmunol.1000434; Fu LC, 2006, BLOOD, V107, P4540, DOI 10.1182/blood-2005-10-4042; Gigliotti Francis, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010203; Gross O, 2008, BLOOD, V112, P2421, DOI 10.1182/blood-2007-11-123513; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hara H, 2008, J IMMUNOL, V181, P918, DOI 10.4049/jimmunol.181.2.918; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Lee AJ, 2010, J BIOL CHEM, V285, P15696, DOI 10.1074/jbc.M109.095190; Lev A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030494; Li FY, 2011, NATURE, V475, P471, DOI 10.1038/nature10246; Linka RM, 2012, LEUKEMIA, V26, P963, DOI 10.1038/leu.2011.371; Malarkannan S, 2007, J IMMUNOL, V179, P3752, DOI 10.4049/jimmunol.179.6.3752; Malek TR, 2010, IMMUNITY, V33, P153, DOI 10.1016/j.immuni.2010.08.004; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Medoff BD, 2006, J IMMUNOL, V176, P7272, DOI 10.4049/jimmunol.176.12.7272; Medoff BD, 2009, EUR J IMMUNOL, V39, P78, DOI 10.1002/eji.200838734; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Sasaki Y, 2006, IMMUNITY, V24, P729, DOI 10.1016/j.immuni.2006.04.005; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Tampella G, 2011, J INVEST ALLERG CLIN, V21, P348; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Tusche MW, 2009, J EXP MED, V206, P2671, DOI 10.1084/jem.20091802; van der Burg M, 2011, EUR J PEDIATR, V170, P561, DOI 10.1007/s00431-011-1452-3; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Warnatz K, 2006, BLOOD, V107, P3045, DOI 10.1182/blood-2005-07-2955; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963	41	125	130	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					477	+		10.1016/j.jaci.2012.11.050	http://dx.doi.org/10.1016/j.jaci.2012.11.050			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374270	Green Submitted, Bronze			2022-12-18	WOS:000314661500027
J	Limb, SL; Starke, PR; Lee, CE; Chowdhury, BA				Limb, Susan L.; Starke, Peter R.; Lee, Charles E.; Chowdhury, Badrul A.			Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; omalizumab	ALLERGIC REACTIONS; IMMUNOTHERAPY; EMERGENCY	Background: Risk of anaphylaxis is included in the prescribing information for omalizumab, but the nature of these reactions merits further elaboration. Objective: To describe cases of anaphylaxis associated with omalizumab administration in patients with asthma. Methods: We reviewed spontaneous postmarketing adverse event reports submitted to the US Food and Drug Administration's Adverse Event Reporting System database and to the manufacturers of omalizumab and cases published in the literature through December 2006. Diagnostic criteria for anaphylaxis outlined by the National Institute of Allergy and Infectious Diseases and the Food Allergy and Anaphylaxis Network were used to screen cases. Results: One-hundred twenty-four cases of anaphylaxis associated with omalizumab administration in patients with asthma were identified. Many cases had a delayed onset of symptoms beyond 2 hours after dose administration. Many cases were also characterized by a protracted progression, with individual signs and symptoms of anaphylaxis staggered over hours. Review of the case reports did not reveal any predictive risk factors for the delayed onset or protracted progression of anaphylaxis. Conclusion: Omalizumab-induced anaphylaxis may be characterized by a delayed onset and a protracted progression of symptoms. Clinical implications: The unusual timing of anaphylaxis in these cases challenges our understanding of anaphylaxis. A delayed onset of symptoms and protracted progression of anaphylaxis should be taken into account when administering omalizumab.	[Limb, Susan L.; Starke, Peter R.; Lee, Charles E.; Chowdhury, Badrul A.] US FDA, Div Pulm & Allergy Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA	US Food & Drug Administration (FDA)	Limb, SL (corresponding author), US FDA, Div Pulm & Allergy Prod, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave,Bldg 22,Room 3323, Silver Spring, MD 20993 USA.	susan.limb@fda.hhs.gov						Bousquet PJ, 2007, ALLERGY, V62, P872, DOI 10.1111/j.1398-9995.2007.01463.x; Brady WJ, 1997, ACAD EMERG MED, V4, P193, DOI 10.1111/j.1553-2712.1997.tb03739.x; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Cheifetz A, 2005, MT SINAI J MED, V72, P250; Chipps B, 2006, ANN ALLERG ASTHMA IM, V97, P267, DOI 10.1016/S1081-1206(10)60027-0; Dreyfus DH, 2006, ANN ALLERG ASTHMA IM, V96, P624, DOI 10.1016/S1081-1206(10)63560-0; *GEN INC, 2007, XOL OM FULL PRESCR I; *GEN INC, 2000, HERC TRAST FULL PRES; Ghaffari G, 2006, J ALLERGY CLIN IMMUN, V117, pS309, DOI 10.1016/j.jaci.2005.12.1221; Green TD, 2006, J PEDIATR-US, V149, P733, DOI 10.1016/j.jpeds.2006.06.048; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; Inomata N, 2005, ANN ALLERG ASTHMA IM, V94, P402, DOI 10.1016/S1081-1206(10)60995-7; MATLOFF SM, 1993, ALLERGY PROC, V14, P347, DOI 10.2500/108854193778774001; *NOV PHARM CORP, 2005, SIM BAS FULL PRESCR; Oyefara BI, 2007, ALLERGY ASTHMA PROC, V28, P64, DOI 10.2500/aap.2007.28.2951; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; *ROCH PHARM, 2005, ZEN DACL FULL PRESCR; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SHIBASAKI M, 1989, ANN ALLERGY, V63, P421; SPIEGEL RJ, 1980, MED PEDIATR ONCOL, V8, P123, DOI 10.1002/mpo.2950080204; *US FDA, 2007, OM HEALTHC PROF SHEE; US Food and Drug Administration, 2003, 1039760 BLA STN US F; *WYETH PHARM INC, 2007, MYL GEMT OZ INJ FULL	23	125	135	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1378	1381		10.1016/j.jaci.2007.09.022	http://dx.doi.org/10.1016/j.jaci.2007.09.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17936893	Bronze			2022-12-18	WOS:000251653800020
J	Foroughi, S; Foster, B; Kim, N; Bernardino, LB; Scott, LM; Hamilton, RG; Metcalfe, DD; Mannon, PJ; Prussin, C				Foroughi, Shabnam; Foster, Barbara; Kim, NaYoung; Bernardino, Leigh B.; Scott, Linda M.; Hamilton, Robert G.; Metcalfe, Dean D.; Mannon, Peter J.; Prussin, Calman			Anti-IgE treatment of eosinophil-associated gastrointestinal disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; eosinophilic gostroenteritis; eosinophilic esophagitis; omalizumab; IgE; food allergy; basophil	EPSILON-RI EXPRESSION; BASOPHIL ACTIVATION; ALLERGIC-ASTHMA; SERUM IGE; F-RI; OMALIZUMAB; ESOPHAGITIS; THERAPY; INFLAMMATION; HISTAMINE	Background: Eosinophil-associated gastrointestinal disorders (EGIDs) are commonly associated with atopy and are being recognized with increasing frequency. Current therapy for EGIDs is inadequate. Objective: We sought to determine the efficacy of anti-IgE therapy in EGIDs and investigate the role of IgE in disease pathogenesis. Methods: Nine subjects with EGIDs received omalizumab every 2 weeks for 16 weeks while other therapy was held constant. Blood absolute eosinophil counts, tissue eosinophil counts, symptom scores, and free IgE levels were serially measured. Allergen skin testing and flow cytometry for basophil activation and Fc epsilon RI were determined at baseline and at week 16. Results: Omalizumab was associated with a decrease in absolute eosinophil count at both the week 16 (34%, P =.004) and combined weeks 12 to 16 (42%, P =.012) time points. Tissue eosinophils decreased in the duodenum (59%) and gastric antrum (69%) but did not reach statistical significance (P =.074 and .098, respectively). Esophageal eosinophil counts remained unchanged. Basophil and dendritic cell Fc epsilon RI expression and free IgE levels were all significantly decreased (P <.005). Omalizumab increased the concentration of allergen required to trigger half-maximal basophil activation by 170-fold. Allergen skin test wheal and erythema responses decreased by 78% and 82%, respectively. Symptom scores were decreased at both the midstudy (63%) and end of study (70%) time points (P <.005 for both). Conclusion: These results demonstrate that IgE-mediated processes contribute to the generation of eosinophilic inflammation in EGIDs and suggest that anti-IgE therapy might be effective in these disorders. Clinical implications: Anti-IgE might be a potential therapy for EGIDs.	NIH, Bethesda, MD 20892 USA; Natl Inst Allergy & Infect Dis, Natl Inst Hlth, Lab Allerg Dis, Bethesda, MD USA; Natl Inst Allergy & Infect Dis, Natl Inst Hlth, Host Def Lab, Bethesda, MD USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Prussin, C (corresponding author), NIH, Bldg 10,Room 11C205, Bethesda, MD 20892 USA.	cprussin@niaid.nih.gov		Prussin, Calman/0000-0002-3917-3326	Intramural NIH HHS [Z01 AI000761-10, Z01 AI000761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000903, Z01AI000761] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Hamilton RG, 2005, J IMMUNOL METHODS, V303, P81, DOI 10.1016/j.jim.2005.06.008; Hochhaus G, 2003, CURR MED RES OPIN, V19, P491, DOI 10.1185/030079903125002171; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Konikoff MR, 2006, CLIN GASTROENTEROL H, V4, P1328, DOI 10.1016/j.cgh.2006.08.013; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1111/j.1572-0241.2003.07390.x; Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Shreffler WG, 2006, CURR OPIN ALLERGY CL, V6, P226, DOI 10.1097/01.all.0000225165.83144.2f; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Vasagar K, 2006, CLIN EXP ALLERGY, V36, P770, DOI 10.1111/j.1365-2222.2006.02494.x; Yoshida EM, 1999, CAN J GASTROENTEROL, V13, P65, DOI 10.1155/1999/506915	21	125	142	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					594	601		10.1016/j.jaci.2007.06.015	http://dx.doi.org/10.1016/j.jaci.2007.06.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17765756	Green Accepted			2022-12-18	WOS:000249505400018
J	Jahn-Schmid, B; Radakovics, A; Luttkopf, D; Scheurer, S; Vieths, S; Ebner, C; Bohle, B				Jahn-Schmid, B; Radakovics, A; Luttkopf, D; Scheurer, S; Vieths, S; Ebner, C; Bohle, B			Bet v 1(142-156) is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollen allergy; food allergy; oral allergy syndrome; PR-10; Bet v 1; T-cell cross-reactiviry	BET V 1; IGE-BINDING PROPERTIES; 4 RECOMBINANT ISOFORMS; HAZEL POLLEN; BET-V-1; HYPERSENSITIVITY; CLONING; CLONES; LEVEL; CLASSIFICATION	Background: Individuals with birch pollen allergy frequently experience hypersensitivity reactions to certain foods, primarily because of IgE antibodies specific for the major birch pollen allergen Bet v 1 that cross-react with homologous food allergens. Objective: We sought to characterize the major T-cell epitopes of Bet v I and to investigate their involvement in the cellular cross-reactivity with homologous food allergens. Methods: T-cell epitope mapping of Bet v 1 was performed by testing Bet v I-specific T-cell lines derived from 57 individuals with birch pollen allergy, with overlapping peptides representing the entire allergen. T-cell lines and T-cell clones were stimulated with Bet v 1-related major allergens from apple (Mal d 1), cherry (Pru av 1), hazelnut (Cor a 1), celery (Api g 1), carrot (Dan c 1), and soybean (Gly m 4) and with peptides deduced from the C-terminal amino acid sequences of these molecules. Results: Bet v 1(142-156), positioned in the highly conserved C-terminal region of Bet v 1, was identified as the major T-cell epitope recognized by 61% of individuals. Most T lymphocytes specific for Bet v 1(142-156) were activated by one or more homologous food proteins or the respective peptides, as indicated by proliferation and cytokine production. Conclusion: The major T-cell epitope of Bet v 1, Bet v 1(142-156), plays an important role in the cellular cross-reactivity between this respiratory allergen and related food allergens. Thus T lymphocytes specific for Bet v 1(142-156) might be activated by various Bet v 1-related food allergens in vivo, even out of the pollen season.	Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, A-1090 Vienna, Austria; Allergieambulatorium Reumannpl, Vienna, Austria; Paul Ehrlich Inst, D-6070 Langen, Germany	Medical University of Vienna; Paul Ehrlich Institute	Bohle, B (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X; Bohle, Barbara/0000-0002-5105-7985				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Asero R, 1997, ALLERGY, V52, P560, DOI 10.1111/j.1398-9995.1997.tb02600.x; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Bohle B, 1998, J IMMUNOL, V160, P2022; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Breuer K, 2004, ALLERGY, V59, P988, DOI 10.1111/j.1398-9995.2004.00493.x; Bullens DMA, 2004, CLIN EXP ALLERGY, V34, P879, DOI 10.1111/j.1365-2222.2004.01955.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Ferreira F, 1996, ADV EXP MED BIOL, V409, P127; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Mirza O, 2000, J IMMUNOL, V165, P331, DOI 10.4049/jimmunol.165.1.331; Nakamura Y, 2001, ALLERGY, V56, P385, DOI 10.1034/j.1398-9995.2001.056005385.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Sparholt SH, 1997, CLIN EXP ALLERGY, V27, P932; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	40	125	132	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					213	219		10.1016/j.jaci.2005.04.019	http://dx.doi.org/10.1016/j.jaci.2005.04.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990797	Bronze			2022-12-18	WOS:000235686300032
J	Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Friedman, W; Zeldin, DC				Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Friedman, W; Zeldin, DC			Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: Results from the National Survey of Lead and Allergens in Housing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; asthma; cat allergen; Can f 1; dog allergen; epidemiology; Fel d 1; survey	DUST MITE; D-I; COCKROACH ALLERGENS; DOMESTIC ALLERGENS; PUBLIC PLACES; PARTICLE-SIZE; RISK-FACTORS; LOS-ALAMOS; NEW-MEXICO; F I	Background: Exposures to dog and cat allergens are believed to play important roles in the etiology of asthma; however, the levels of these allergens have never been assessed in a representative sample of US homes. Objective: The objective of this study was to estimate and characterize exposures to Can f 1 (dog allergen) and Fell d 1 (cat allergen) in US homes. Methods: Data were obtained from the National Survey of Lead and Allergens in Housing, a nationally representative survey of 831 US homes. Vacuumed-collected dust samples from the bed, bedroom floor, living room floor, and living room sofa were analyzed for concentrations of Can f 1 and Fel d 1 (micrograms of allergen per gram of dust). Results: Although a dog or cat had lived in only 49.1% of homes in the previous 6 months, Can f 1 and Fel d 1 were detected in 100% and 99.9% of homes, respectively. Averaged over the sampled sites, geometric mean concentrations (mug/g) were 4.69 for Can f 1 and 4.73 for Fel d 1. Among homes with an indoor dog and cat, respectively, geometric mean concentrations were 69 for Can f 1 and 200 for Fel d 1. Among homes without the indoor pet, geometric mean concentrations were above 1.0. The independent predictors of elevated concentrations in homes without pets were all demographic variables that were also linked to a higher prevalence of pet ownership. Conclusions: Can f 1 and Fel d 1 are universally present in US homes. Levels that have been associated with an increased risk of allergic sensitization were found even in homes without pets. Because of the transportability of these allergens on clothing, elevated levels in homes without pets, particularly among demographic groups in which pet ownership is more prevalent, implicate the community as an important source of these pet allergens.	NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Constella Grp Inc, Durham, NC USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; US Dept Housing & Urban Dev, Off Healthy Homes & Lead Hazard Control, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Harvard T.H. Chan School of Public Health	Zeldin, DC (corresponding author), NIEHS, NIH, POB 12233,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.		Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025043, Z01ES025043, Z01ES025044, ZIAES025041, Z01ES025041] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Burge H, 1993, INDOOR ALLERGENS ASS; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; EGGLESTON PA, 1992, ALLERGY PROC, V13, P289, DOI 10.2500/108854192778816942; ENBERG RN, 1993, ANN ALLERGY, V70, P471; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Jacobs DE, 2002, ENVIRON HEALTH PERSP, V110, pA599, DOI 10.1289/ehp.021100599; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Partti-Pellinen K, 2000, ALLERGY, V55, P65, DOI 10.1034/j.1398-9995.2000.00226.x; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Plaschke P, 1999, ALLERGY, V54, P843, DOI 10.1034/j.1398-9995.1999.00162.x; PLATTSMILLS TA, 1997, J ALLERGY CLIN IMM S, V100, P2; PLATTSMILLS TAE, 1995, INT ARCH ALLERGY IMM, V107, P301, DOI 10.1159/000237008; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1	32	125	130	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					111	117		10.1016/j.jaci.2004.04.036	http://dx.doi.org/10.1016/j.jaci.2004.04.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241352				2022-12-18	WOS:000222534300016
J	Wenzel, SE; Balzar, S; Cundall, M; Chu, HW				Wenzel, SE; Balzar, S; Cundall, M; Chu, HW			Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: Association with asthma severity, neutrophilic inflammation, and wound repair	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pathology; matrix metalloproteinase; newtrophils	INDUCED AIRWAY INFLAMMATION; TISSUE INHIBITOR; BRONCHOALVEOLAR LAVAGE; COLLAGEN DEPOSITION; BRONCHIAL BIOPSIES; MURINE MODEL; SPUTUM; MATRIX-METALLOPROTEINASE-9; EXPRESSION; LOCALIZATION	Background: Asthma likely involves an active injury and repair process, including components such as neutrophils and matrix metalloproteinase 9 (MMP-9). Although MMP-9 is increased in lavage fluid and sputum in patients with asthma, controversy exists as to the role of tissue MMP-9. Objective: The purpose of this study was to determine whether increases in submucosal cellular MMP-9, matrix MMP-9 (subepithelial basement membrane [SBM]), or both would be associated with severe asthma, neutrophilic inflammation, and wound repair. Methods: Immunohistochemical staining and analyses of MMP-9, inflammatory cells, transforming growth factor beta, and collagen I were performed in endobronchial biopsy specimens, bronchoalveolar lavage fluid, or both from 38 patients with severe asthma and compared with results in 10 patients with mild asthma, 8 patients with moderate asthma, and 10 healthy control subjects. Results: A significantly greater proportion of patients with severe asthma demonstrated MMP-9 staining of the SBM than control subjects (P =.02). Bronchoalveolar lavage MMP-9 levels were also increased in patients with severe asthma (P =.0004). The numbers of submucosal neutrophils and macrophages, but not eosinophils, were significantly higher in asthmatic individuals with MMP-9 staining of the SBM (P = .004 and P = .01, respectively). However, the presence of SBM MNIP-9 was associated with a high correlation between lavage and tissue eosinophils (r = 0.58, P = .009). Although the SBM thickness did not differ between groups, higher numbers of transforming growth factor beta-positive cells were seen in subjects with SKIM MMP-9 staining. Pulmonary function was significantly lower in those asthmatic subjects with SBM staining. Conclusions: These results suggest that localized tissue MMP9 might play an important role in wound repair and cell trafficking. (J Allergy Clin Immunol 2003;111:1345-52.).	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wenzel, SE (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; CHU HW, 1995, CLIN EXP IMMUNOL, V100, P319; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; Dahlen B, 1999, THORAX, V54, P590, DOI 10.1136/thx.54.7.590; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1111/j.1365-2222.1997.tb01211.x; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Kumagai K, 1999, J IMMUNOL, V162, P4212; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; Ravanti L, 2000, INT J MOL MED, V6, P391; Raza S L, 2000, Adv Dermatol, V16, P185; Tanaka H, 2000, J ALLERGY CLIN IMMUN, V105, P900, DOI 10.1067/mai.2000.105316; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046	23	125	135	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1345	1352		10.1067/mai.2003.1464	http://dx.doi.org/10.1067/mai.2003.1464			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789238	Bronze			2022-12-18	WOS:000183424700026
J	Sheikh, A; Smeeth, L; Hubbard, R				Sheikh, A; Smeeth, L; Hubbard, R			There is no evidence of an inverse relationship between T(H)2-mediated atopy and T(H)1-mediated autoimmune disorders: Lack of support for the hygiene hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adult; allergic rhinitis; allergy; asthma atopy; autoimmune; T cell	DECREASED PREVALENCE; DIABETES-MELLITUS; TYPE-1; DISEASE; ASTHMA; RISK; ASSOCIATION; PARASITES; CHILDREN; AGE	Background: The findings of an inverse relationship between T(H)1- and T(H)2-mediated disorders would provide strong empiric support to the hygiene hypothesis. Objective: We sought to investigate the relationship between T(H)2-mediated atopic allergy and T(H)1-mediated autoimmune conditions in a nationally representative population. Methods: We used logistic regression to analyze adult data from the Third National Health and Nutrition Examination Survey. Data on allergic and autoimmune disease history were available for 20,050 subjects, and data on atopy were available for a subsample of 7304 subjects. Atopy was defined by one or more positive skin prick test responses (wheal of greater than or equal to3 mm) to 10 common aeroallergens. Allergic disease was defined by patient reports of physician-diagnosed asthma, hay fever, or both. T(H)1-mediated autoimmune disease was defined by patient reports of physician-diagnosed type 1 diabetes mellitus, thyroid disorders, and/or rheumatoid arthritis. Results: Adjusted for age and sex and taking into account the complex survey design, there was no relationship between atopy and a history of autoimmune disorders (adjusted odds ratio, 1.01; 95% CI, 0.61-1.67; P = .97). In contrast, physician diagnosis of allergic disorders was associated with a significant increased risk of physician-diagnosed autoimmune disorders (adjusted odds ratio, 1.67; 95% CI, 1.35-2.07; P < .001). Conclusion: We found no evidence of an inverse relationship between atopy and patient reports of physician-diagnosed common autoimmune disorders in the adult American population. Contrary to our initial hypothesis, reports of physician-diagnosed common allergic disorders are positively associated with reports of physician-diagnosed autoimmune disorders, with this possibly being caused by ascertainment bias. These findings suggest that the T(H)1/T(H)2 paradigm might be an oversimplification.	St George Hosp, Sch Med, Primary Care Epidemiol Unit, Dept Publ Hlth Sci, London SW17 0RE, England; Univ Nottingham, Dept Epidemiol, Nottingham NG7 2RD, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol, London WC1E 7HT, England	St Georges University London; University of Nottingham; University of London; London School of Hygiene & Tropical Medicine	Sheikh, A (corresponding author), St George Hosp, Sch Med, Primary Care Epidemiol Unit, Dept Publ Hlth Sci, Cranmer Terrace, London SW17 0RE, England.		Sheikh, Aziz/D-2818-2009; Smeeth, Liam/X-5862-2018	Sheikh, Aziz/0000-0001-7022-3056; Smeeth, Liam/0000-0002-9168-6022				Allanore Y, 1998, LANCET, V351, P497, DOI 10.1016/S0140-6736(05)78684-0; [Anonymous], 1994, Vital Health Stat 2, P1; FREW AJ, 1997, ALLERGY ALLERGIC DIS, P1007; Gavin JR, 1997, DIABETES CARE, V20, P1183; Green A, 2000, LANCET, V355, P873; Holt PG, 2000, LANCET, V356, P1699, DOI 10.1016/S0140-6736(00)03198-6; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; JARVIS D, 1997, ALLERGY ALLERGIC DIS, P1208; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Marrack P, 2001, NAT MED, V7, P899, DOI 10.1038/90935; McKinney PA, 2000, DIABETIC MED, V17, P236, DOI 10.1046/j.1464-5491.2000.00220.x; *NAT CTR HLTH STAT, 1996, AN REP GUIID 3 NAT; National Center for Health Statistics, 2001, 3 NAT HLTH NUTR EX S; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Olesen AB, 2001, LANCET, V357, P1749, DOI 10.1016/S0140-6736(00)04896-0; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Rao A, 2000, BRIT MED BULL, V56, P969, DOI 10.1258/0007142001903634; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; *STAT CORP, 2001, INT STATA 6 0 WIND 9; Stene LC, 2001, BRIT MED J, V323, P369, DOI 10.1136/bmj.323.7309.369; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tedeschi A, 2001, LANCET, V357, P1622, DOI 10.1016/S0140-6736(00)04764-4; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Warner JA, 2000, BRIT MED BULL, V56, P883, DOI 10.1258/0007142001903571	28	125	131	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					131	135		10.1067/mai.2003.8	http://dx.doi.org/10.1067/mai.2003.8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532108				2022-12-18	WOS:000180465500020
J	Van Sambeek, R; Stevenson, DD; Baldasaro, M; Lam, BK; Zhao, JL; Yoshida, S; Yandora, C; Drazen, JM; Penrose, JF				Van Sambeek, R; Stevenson, DD; Baldasaro, M; Lam, BK; Zhao, JL; Yoshida, S; Yandora, C; Drazen, JM; Penrose, JF			5 ' Flanking region polymorphism of the gene encoding leukotriene C-4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-intolerant asthma; cysteinyl leukotrienes; leukotriene C-4 synthase; polymorphism	RECEPTOR ANTAGONIST MK-0679; SENSITIVE ASTHMATICS; ARACHIDONIC-ACID; 5-LIPOXYGENASE; EXCRETION; TRANSFERASE; ASSOCIATION; LEUKOCYTES; SEVERITY; PROTEIN	Background: Approximately 10% of patients with asthma have a distinct clinical entity in which their symptoms are exacerbated by aspirin and most other nonsteroidal anti-inflammatory agents. These individuals typically have significant basal overproduction of cysteinyl leukotrienes, and within their biosynthetic pathway, the terminal enzyme, leukotriene C-4 synthase (LTC4S), is significantly overexpressed. A single nucleotide polymorphism consisting of an adenine (A) to cytosine (C) transversion -444 nucleotides upstream of the ATG translation start site in the LTC4S gene has been associated with a relative risk of 3.89 for the aspirin-intolerant phenotype in Polish patients. Objective: These studies were undertaken to further investigate the functional effect of this allele in LTC4S gene expression and subsequently to determine whether an association between the presence of this polymorphism and aspirin-intolerant asthma existed within patients of the United States. Methods: Functionality of the C-444 allele was assessed by using promoter-reporter constructs and transient transfection assays in the THP-1 monocytic cell Line. Genotyping was performed on 137 unaffected control subjects, 33 patients with aspirin-tolerant asthma, and 61 patients with aspirin-intolerant asthma from the United States. Results: Promoter-reporter constructs containing the C-444 allele revealed no significant upregulatory or downregulatory effects in the transcription of the LTC4S gene. The LTC4S genotype distribution was consistent with the Hardy-Weinberg equilibrium in patients with aspirin-tolerant asthma and unaffected control subjects but not in patients with aspirin-intolerant asthma; however, the distributions were not significantly different among the phenotype groups. Conclusions: Our data demonstrate that the C-444 allele in the LTC4S gene is not statistically different among patients with the aspirin-intolerant asthmatic phenotype, patients with the aspirin-tolerant asthmatic phenotype, and unaffected control subjects in the United States. This finding, along with the lack of functionality of this polymorphism, suggest that it is not related to a specific asthma phenotype and may represent a population-stratified polymorphism within patients of eastern European descent.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Scripps Clin, Div Clin Immunol & Allergy, La Jolla, CA 92037 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Scripps Research Institute; Scripps Research Institute	Penrose, JF (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Room 626C,1 Jimmy Fund Way, Boston, MA 02115 USA.				NCRR NIH HHS [MO1RR00633] Funding Source: Medline; NHLBI NIH HHS [K08-HL03208-05] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003208] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; BACH MK, 1984, ARCH BIOCHEM BIOPHYS, V230, P455, DOI 10.1016/0003-9861(84)90426-0; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN B, 1993, THORAX, V48, P1205, DOI 10.1136/thx.48.12.1205; Hijazi Z, 1998, CLIN GENET, V53, P149; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; KNAPP HR, 1992, J LAB CLIN MED, V119, P48; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LAM BK, 1989, J BIOL CHEM, V264, P12885; LEE CW, 1983, IMMUNOLOGY, V48, P27; Penrose JF, 1998, LUNG BIOL HEALTH DIS, V120, P33; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; SODERSTROM M, 1992, BIOCHEM BIOPH RES CO, V189, P1043, DOI 10.1016/0006-291X(92)92309-L; Stafforini DM, 1999, J CLIN INVEST, V103, P989, DOI 10.1172/JCI5574; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; Szczeklik A, 1997, ALLERGY, V52, P613, DOI 10.1111/j.1398-9995.1997.tb01039.x; TORNHAMRE S, 1996, EUR J BIOCHEM, V243, P513; Weir B., 1996, GENETIC DATA ANAL	24	125	126	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				72	76		10.1067/mai.2000.107603	http://dx.doi.org/10.1067/mai.2000.107603			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887308				2022-12-18	WOS:000088393300010
J	Scalabrin, DMF; Bavbek, S; Perzanowski, MS; Wilson, BB; Platts-Mills, TAE; Wheatley, LM				Scalabrin, DMF; Bavbek, S; Perzanowski, MS; Wilson, BB; Platts-Mills, TAE; Wheatley, LM			Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: A comparison with asthmatic and nonasthmatic control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; dust mite; fungi; specific IgE anti-bodies; Malassezia furfur; Alternaria alternata	PITYROSPORUM-OVALE; CANDIDA-ALBICANS; STAPHYLOCOCCUS-AUREUS; ANTIBODIES; SKIN; SENSITIZATION; ORBICULARE; CHILDREN	Background: Although allergens have been implicated as aggravating factors in atopic dermatitis (AD), there is little epidemiologic data on the significance of specific IgE. Objective: We sought to compare sensitization to dust mite and fungi between patients with AD and asthmatic and nonasthmatic control subjects. Methods: Total IgE and specific IgE to Dermatophagoides pteronyssinus, Alternaria alternata, Aspergillus fumigatus, Candida albicans, Malassezia furfur, and Trichophyton rubrum were measured in 73 patients with moderate to severe AD. Total IgE and IgE specific for D pteronyssinus, A alternata, and M furfur were also measured in sera from 156 asthmatic and 212 nonasthmatic control subjects. Results: Positive correlations were found between total IgE and IgE antibodies specific for each of the antigens, IgE specific for M furfur was observed more frequently in adults compared with children with AD (P < .01), AD sera had higher levels of total IgE and a higher prevalence of positive sera to D pteronyssinus (95% vs 42% and 17% for subjects with AD, asthmatic subjects, and nonasthmatic subjects, respectively), M furfur (53% vs 1% and 0.5%), and A alternata (49% vs 29% and 18%). Among the sera from subjects allergic to mites, the contribution of IgE specific for D pteronyssinus to the total IgE levels was similar regardless of the clinical status. Conclusions: Our results demonstrate that moderate-to-severe AD is strongly associated with sensitization to dust mite and M furfur (odds ratios, 45.6 and 132 vs pooled control sera). These results suggest that both environmental allergens and colonizing fungi contribute to the severity of disease, which is consistent with the view that mite avoidance and antifungal treatment can be beneficial in the treatment of these patients.	Univ Virginia, Hlth Sci Ctr, Asthma & Aller Dis Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Dermatol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Hlth Sci Ctr, Asthma & Aller Dis Ctr, Dept Internal Med, Box 225, Charlottesville, VA 22908 USA.		Bavbek, Sevim/AAP-9944-2020	Bavbek, Sevim/0000-0002-7884-0830; Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI01416, AI20565, AI30840] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001416, R37AI020565, R01AI020565, R01AI030840] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROBERG A, 1992, ACTA DERM-VENEREOL, V72, P187; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CLARK RAF, 1989, J AM ACAD DERMATOL, V21, P863, DOI 10.1016/S0190-9622(89)70269-3; CLARK RAF, 1989, CLIN IMMUNOL IMMUNOP, V53, pS132, DOI 10.1016/0090-1229(89)90078-0; CLEMMENSEN OJ, 1983, SEMIN DERMATOL, V2, P26; DOEKES G, 1993, ALLERGY, V48, P394, DOI 10.1111/j.1398-9995.1993.tb00736.x; FAERGEMANN J, 1980, ACTA DERM-VENEREOL, V60, P531; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; ISHIGURO A, 1992, INFECT IMMUN, V60, P1550, DOI 10.1128/IAI.60.4.1550-1557.1992; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P44, DOI 10.1016/S0091-6749(05)80039-9; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; Kolmer HL, 1996, J ALLERGY CLIN IMMUN, V98, P702, DOI 10.1016/S0091-6749(96)70106-9; LESTER MR, 1995, J IMMUNOL, V154, P6174; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; MILES RM, 1983, J ALLERGY CLIN IMMUN, V71, P36, DOI 10.1016/0091-6749(83)90544-4; MITCHELL EB, 1982, LANCET, V1, P127; NORDVALL SL, 1992, CLIN EXP ALLERGY, V22, P756, DOI 10.1111/j.1365-2222.1992.tb02815.x; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROBERTS SOB, 1969, BRIT J DERMATOL, V81, P264, DOI 10.1111/j.1365-2133.1969.tb13978.x; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; SAVOLAINEN J, 1993, CLIN EXP ALLERGY, V23, P332, DOI 10.1111/j.1365-2222.1993.tb00331.x; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TUFT L, 1950, J ALLERGY, V21, P181, DOI 10.1016/0021-8707(50)90125-0; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WESSELS MW, 1991, BRIT J DERMATOL, V125, P227, DOI 10.1111/j.1365-2133.1991.tb14745.x; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1	31	125	131	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1273	1279		10.1016/S0091-6749(99)70024-2	http://dx.doi.org/10.1016/S0091-6749(99)70024-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589012				2022-12-18	WOS:000084289200024
J	Leung, PSC; Chen, YC; Gershwin, ME; Wong, H; Kwan, HS; Chu, KH				Leung, PSC; Chen, YC; Gershwin, ME; Wong, H; Kwan, HS; Chu, KH			Identification and molecular characterization of Charybdis feriatus tropomyosin, the major crab allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						crab allergen; cDNA; Cha f 1; tropomyosin	HYPERSENSITIVITY REACTIONS; NUCLEOTIDE-SEQUENCE; SHRIMP ALLERGEN; CRUSTACEA; REACTIVITY; CLONING; PEN	Background: Crab sensitivity is one of the most common seafood allergies, However, to date, there has been no report on the molecular characterization of crab allergens and no comparative analysis with other seafood allergens. Objective: This study was undertaken to clone, identify, and determine the primary structure of a major IgE-reactive molecule in crab. Methods: We constructed an expression cDNA library from a common crab, Charybdis feriatus. This library was then screened with the use of sera from subjects with a well-documented history of type I hypersensitivity reactions upon ingestion of crab. An IgE-reactive clone was chosen and subcloned into plasmids for nucleotide sequence determination and expression in Escherichia coli. Results: We identified a 1-kb cDNA designated as Cha f 1. Expression of Cha f 1 produces a 34-kd recombinant protein reactive to the IgE antibodies from patients with crab allergies but not from control subjects. Cha f 1 has an opening reading frame of 261 amino acids and demonstrates marked homology to the shrimp tropomyosin Met e 1. Absorption of allergic sera with Cha f I removes IgE reactivity to crab extract. Moreover, absorption of allergic sera with recombinant shrimp Met e 1 tropomyosin removes IgE reactivity to Cha f 1. Conclusions: This 31-kd protein, designated as Cha f 1, is the first identified major allergen of crab. Nucleotide and amino acid comparison shows that this protein is the crab tropomyosin. The molecular basis of shrimp and crab allergy is readily demonstrated at the nucleotide and amino acid level.	Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, 1 Shields Ave,TB 192, Davis, CA 95616 USA; Chinese Univ Hong Kong, Dept Biol, Shatin, Peoples R China	University of California System; University of California Davis; Chinese University of Hong Kong	Leung, PSC (corresponding author), Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, 1 Shields Ave,TB 192, Davis, CA 95616 USA.		Kwan, Hoi Shan/F-3048-2010; Chu, Ka Hou/B-8010-2011	Chu, Ka Hou/0000-0001-8107-5415; Kwan, Hoi Shan/0000-0002-7943-2513	NIDDK NIH HHS [DK 35747] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASI GS, 1986, J BIOL CHEM, V261, P817; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; Daniels S E, 1996, Methods Mol Biol, V65, P155; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; DAUL CB, 1993, CLIN REV ALLERG, V11, P201; DAUL CB, 1993, J ALLERGY CLIN IMMUN, V91, P341; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; HANKE PD, 1986, GENE, V45, P211, DOI 10.1016/0378-1119(86)90256-8; HEFLE SL, 1995, J ALLERGY CLIN IMMUN, V95, P332; HENRIKSEN O, 1994, NAT CTR RES RESOURCE, V18, P10; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; HORTON JH, 1994, PCR METH APPL, V3, P359; LEHRER SB, 1986, ANN ALLERGY, V57, P267; Leung P.S.C., 1998, FRONT BIOSCI, P306, DOI DOI 10.2741/A243; Leung PSC, 1998, MOL MAR BIOL BIOTECH, V7, P12; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LEUNG PSC, 1995, HEPATOLOGY, V22, P505, DOI 10.1016/0270-9139(95)90572-3; MANITIS T, 1982, MOL CLONING LAB MANU; MARSH DG, 1988, INT ARCH ALLER A IMM, V85, P194; MORGAN JE, 1989, CLIN EXP ALLERGY, V19, P431, DOI 10.1111/j.1365-2222.1989.tb02410.x; Mykles DL, 1998, J MUSCLE RES CELL M, V19, P105, DOI 10.1023/A:1005352410725; NAGPAL S, 1989, J ALLERGY CLIN IMMUN, V83, P26, DOI 10.1016/0091-6749(89)90474-0; NAGPAL S, 1987, J IMMUNOL, V138, P4169; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240, DOI 10.1159/000237558; RUIZOPAZO N, 1985, NATURE, V315, P67, DOI 10.1038/315067a0; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9; WEE PC, 1995, B ZOOL S, V1, P128	31	125	153	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					847	852		10.1016/S0091-6749(98)70027-2	http://dx.doi.org/10.1016/S0091-6749(98)70027-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819304				2022-12-18	WOS:000077033400021
J	Toru, H; Pawankar, R; Ra, C; Yata, J; Nakahata, T				Toru, H; Pawankar, R; Ra, C; Yata, J; Nakahata, T			Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: Enhanced IL-13 production by IL-4-primed human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4; IL-13; Fc epsilon RI alpha chain; SCF; LFA-1; ICAM-1; HMC-1; KU812F; allergy; IgE	HUMAN B-CELLS; MESSENGER-RNA EXPRESSION; TUMOR-NECROSIS-FACTOR; FC-EPSILON-RI; SIGNAL-TRANSDUCTION; INTERLEUKIN-13 RECEPTOR; MEDIATED ACTIVATION; NASAL-MUCOSA; ALPHA CHAIN; IFN-GAMMA	Background: Mast cells play a central role not only in the early phase of the allergic reaction, but also participate in the late phase of the allergic reaction through the allergen and IgE-dependent release of multifunctional cytokines, Objective: Using the recently established culture system for human mast cells, we examined the expression of a variety of cytokines in cord blood-derived human cultured mast cells (HCMCs) in response to different stimuli. Methods: HCMCs were grown from cord blood mononuclear cells in the presence of stem cell factor and IL-6 for 10 weeks. Cytokine mRNA expression in HCMCs by the different stimuli was examined by RT-PCR. Then taking 2 important cytokines, IL-13 and IL-4, that share several functional properties and play important roles in allergic diseases, we examined protein as well as mRNA expression of both cytokines in HCMCs. Results: HCMCs did not express either IL-13 or IL-4 spontaneously, Stimulation with PMA + A23187 induced the expression of IL-4 protein, as well as IL-13 protein, in their cytoplasm, although IL-4 secreted in the supernatant was below detectable levels in contrast to a significant amount of IL-13, Stimulation of HCMCs by cross-linking of the high-affinity IgE receptor (Fc epsilon RI) induced the expression of IL-13 mRNA and protein, but not IL-4, Although we previously found that IL-4 upregulates Fc epsilon RI expression on HCMCs, when HCMCs were first cultured in the presence of IL-4 and then activated through Fc epsilon RI cross-linking, remarkable increase was found in IL-13 production. Furthermore, although IL-4 was still undetectable at protein level, IL-4 mRNA expression was induced in the IL-4-primed HCMCs stimulating Fc epsilon RI cross-linking. In addition, we examined the effects of these cytokines on the surface molecule expression in HCMCs. Although IL-4 remarkably upregulated lymphocyte function-associated antigen-1, intercellular adhesion molecule-1, and Fc epsilon RI expression and downregulated c-kit expression in HCMCs, IL-13 did not. Conclusions: Our observation that HCMCs produce IL-13 on cross-linking of Fc epsilon RI, which was enhanced by IL-4 priming, supports an important role of mast cells in amplification of allergic reaction and further suggests one of the mechanisms enhancing mast cell function in the microenvironment.	Tokyo Med & Dent Univ, Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 113, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Nippon Med Sch, Dept Otorhinolaryngol, Tokyo 113, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Oncol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Juntendo University; Nippon Medical School; University of Tokyo	Toru, H (corresponding author), Tokyo Med & Dent Univ, Sch Med, Dept Pediat, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.							Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; Banks EMS, 1996, CYTOKINE, V8, P190, DOI 10.1006/cyto.1996.0027; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DURAND B, 1994, BLOOD, V84, P3667, DOI 10.1182/blood.V84.11.3667.bloodjournal84113667; DVORAK AM, 1993, MAST CELL HLTH DIS, P1; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Gupta AA, 1996, J IMMUNOL, V157, P2123; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; IRANI AMA, 1992, BLOOD, V80, P3009; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; Jaffe JS, 1996, AM J RESP CELL MOL, V15, P473, DOI 10.1165/ajrcmb.15.4.8879181; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MITUI H, 1993, P NATL ACAD SCI USA, V90, P735; MOLLER A, 1993, J IMMUNOL, V151, P3261; NAKAHATA T, 1995, BIOLOGICAL AND MOLECULAR ASPECTS OF MAST CELL AND BASOPHIL DIFFERENTIATION AND FUNCTION, P13; NILSSON G, 1994, SCAND J IMMUNOL, V39, P489, DOI 10.1111/j.1365-3083.1994.tb03404.x; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; SILLABER C, 1993, EXP HEMATOL, V21, P1271; SMITH TJ, 1994, EUR J IMMUNOL, V24, P822, DOI 10.1002/eji.1830240408; STEFFEN M, 1989, IMMUNOLOGY, V66, P445; STEM AS, 1990, P NATL ACAD SCI USA, V87, P6808; Toru H, 1997, BLOOD, V89, P3296, DOI 10.1182/blood.V89.9.3296; Toru H, 1998, BLOOD, V91, P187, DOI 10.1182/blood.V91.1.187.187_187_195; Toru H, 1996, INT IMMUNOL, V8, P1367; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Xia HZ, 1997, J IMMUNOL, V159, P2911; YANAGIHARA Y, 1994, J CLIN INVEST, V94, P2162, DOI 10.1172/JCI117574; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	54	125	127	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					491	502		10.1016/S0091-6749(98)70140-X	http://dx.doi.org/10.1016/S0091-6749(98)70140-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768593				2022-12-18	WOS:000076212800026
J	Niederberger, V; Laffer, S; Froschl, R; Kraft, D; Rumpold, H; Kapiotis, S; Valenta, R; Spitzauer, S				Niederberger, V; Laffer, S; Froschl, R; Kraft, D; Rumpold, H; Kapiotis, S; Valenta, R; Spitzauer, S			IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant pollen allergens; Phl p 1; Phl p 2; Phl p 5; profilin; Bet v 2; IgE cross-reactivity; immunoabsorption; grass pollen allergy	HIGH-LEVEL EXPRESSION; PRATENSE POLLEN; ESCHERICHIA-COLI; MAJOR ALLERGEN; CDNA CLONING; IMMUNOLOGICAL CHARACTERIZATION; BINDING CAPACITY; PROFILIN; PURIFICATION; PROTEINS	Background: Pollen from different grass species are some of the most potent elicitors of Type I allergy worldwide. The characterization of antigenic structures and IgE epitopes common to different grass species is relevant to define reagents for diagnosis and specific therapy of grass pollen allergy. Objective: The purpose of this study was to estimate the percentage of IgE directed to common, cross-reactive, or both types of epitopes shared by recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) and natural pollen extracts from nine different monocots (Anthoxanthum odoratum, Avena sativa, Cynodon dactylon, Lolium perenne, Phragmites australis, Poa pratensis, Secale cereale, Triticum sativum, Zea mays) by using sera from different populations. Methods: Natural pollen extracts from nine different monocot species were characterized regarding their allergen contents by using specific antibodies and by IgE immunoblot inhibition with recombinant allergens. The percentage of grass pollen-specific IgE that was preabsorbed with a combination of recombinant timothy grass pollen allergens (Phl p 1, Phl p 2, and Phl p 5) and recombinant birch profilin (Bet v 2) was determined by ELISA in sera from 193 European, American, and Asian subjects. Results: IgE to recombinant pollen allergens accounted for a mean 59% of grass pollen-specific IgE. A lower inhibition of IgE binding to certain natural extracts (C. dactylon and Z. mays) could be attributed to the absence of immunologically detectable group 5 and group 2 allergens in these species. Conclusion: We define four recombinant pollen allergens that account for a substantial proportion of grass pollen-specific IgE. The recombinant pollen allergens characterized may represent candidates not only for diagnosis but also for patient-tailored immunotherapy of grass pollen allergy.	Univ Vienna, AKH, Inst Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Vienna, AKH, Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria	University of Vienna; University of Vienna	Valenta, R (corresponding author), Univ Vienna, AKH, Inst Gen & Expt Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.			Valenta, Rudolf/0000-0001-5944-3365				ANSARI AA, 1989, BIOCHEMISTRY-US, V28, P8665, DOI 10.1021/bi00447a058; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; FAHLBUSCH B, 1993, CLIN EXP ALLERGY, V23, P51, DOI 10.1111/j.1365-2222.1993.tb02484.x; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; IPSEN H, 1988, ALLERGY, V43, P370, DOI 10.1111/j.1398-9995.1988.tb00431.x; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; MATTHIESEN F, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P189; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; PETERSEN A, 1995, INT ARCH ALLERGY IMM, V108, P55, DOI 10.1159/000237118; SIDOLI A, 1993, J BIOL CHEM, V268, P21819; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; Valenta R, 1996, ADV EXP MED BIOL, V409, P185; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1989, J ALLERGY CLIN IMMUN, V83, P144, DOI 10.1016/0091-6749(89)90489-2; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1996, BIOCHEM BIOPH RES CO, V226, P42, DOI 10.1006/bbrc.1996.1309	34	125	133	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				258	264		10.1016/S0091-6749(98)70391-4	http://dx.doi.org/10.1016/S0091-6749(98)70391-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500760				2022-12-18	WOS:000072244800016
J	Schappi, GF; Suphioglu, C; Taylor, PE; Knox, RB				Schappi, GF; Suphioglu, C; Taylor, PE; Knox, RB			Concentrations of the major birch tree allergen Bet v 1 in pollen and respirable fine particles in the atmosphere	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bet v 1; birch pollen; respirable fine particles; birch pollen equivalents; allergen; asthma	VERRUCOSA; ANTIGENS	Background: Birch tree pollen allergens are an important cause of early spring hay fever and allergic asthma. Pollen counts provide a guide for individuals with birch pollen allergy. However, birch pollen, because of its size, has a low probability of entering the lower airways to trigger asthma, Yet birch pollen allergens are known to be associated with respirable particles present in the atmosphere. Objective: We sought to determine the concentration of major allergen Bet v 1 in birch pollen and respirable particles in the atmosphere during the birch pollen season. Methods: We used a two-site monoclonal antibody-based assay (ELISA) to quantitate Bet v 1 in pollen extracts and high-volume air sampler filters collecting particles larger and smaller than 7.2 mu m. Results: Bet v 1 (0.006 ng) is detectable per birch pollen grain, of which 0.004 ng is present in aqueous extracts (13.9% of soluble proteins), Atmospheric Bet v 1 concentrations are correlated with birch pollen counts, Heavy rainfall tended to wash out pollen and particles, indicated by a mean daily Bet v 1 concentration of 0.12 ng/m(3) (20 pollen equivalents), but light rainfall produced a dramatic increase in allergen-loaded respirable particles with Bet vl concentrations of 1.2 ng/m(3) (200 pollen equivalents). Conclusion: These results highlight the different environmental risk factors for hay fever and allergic asthma in patients sensitized to Bet v 1. Light rainfall causes an increase in respirable particles; hence, this is an important risk factor for asthma.	UNIV MELBOURNE,SCH BOT,POLLEN & ALLERGEN RES GRP,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne								Bates D V, 1966, Health Phys, V12, P173; Ekebom A, 1996, GRANA, V35, P113, DOI 10.1080/00173139609429481; GROTE M, 1991, J HISTOCHEM CYTOCHEM, V39, P1395, DOI 10.1177/39.10.1940310; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JENSEN J, 1989, ALLERGY, V44, P52, DOI 10.1111/j.1398-9995.1989.tb00446.x; JILEK A, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P39; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Ong E. K., 1995, Aerobiologia, V11, P51, DOI 10.1007/BF02136145; Pehkonen E, 1995, GRANA, V34, P350, DOI 10.1080/00173139509429070; PEHKONEN E, 1994, ALLERGY, V49, P472, DOI 10.1111/j.1398-9995.1994.tb00842.x; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; Schappi GF, 1996, INT ARCH ALLERGY IMM, V110, P364, DOI 10.1159/000237329; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006	15	125	126	0	17	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					656	661		10.1016/S0091-6749(97)70170-2	http://dx.doi.org/10.1016/S0091-6749(97)70170-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389296				2022-12-18	WOS:A1997YG20200013
J	Weller, PF				Weller, PF			Human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							RECRUITMENT		HARVARD UNIV, SCH MED,BETH ISRAEL MED CTR,DEPT MED, DIV INFECT DIS, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Weller, PF (corresponding author), HARVARD UNIV, SCH MED,BETH ISRAEL MED CTR,DEPT MED, DIV ALLERGY & INFLAMMAT, DANA 617, BOSTON, MA 02215 USA.				NHLBI NIH HHS [HL56386] Funding Source: Medline; NIAID NIH HHS [AI22571, AI20241] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022571, R01AI020241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOZZA PT, 1997, IN PRESS J EXP MED; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; MOQBEL R, 1994, ANN NY ACAD SCI, V725, P223, DOI 10.1111/j.1749-6632.1994.tb39805.x; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; SEDGWICK JB, 1995, J ALLERGY CLIN IMMUN, V96, P375, DOI 10.1016/S0091-6749(95)70057-9; Weller PF, 1996, EUR RESPIR J, V9, pS109	8	125	130	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					283	287		10.1016/S0091-6749(97)70237-9	http://dx.doi.org/10.1016/S0091-6749(97)70237-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314336				2022-12-18	WOS:A1997XX47900001
J	Yeang, HY; Cheong, KF; Sunderasan, E; Hamzah, S; Chew, NP; Hamid, S; Hamilton, RG; Cardosa, MJ				Yeang, HY; Cheong, KF; Sunderasan, E; Hamzah, S; Chew, NP; Hamid, S; Hamilton, RG; Cardosa, MJ			The 14.6 kd rubber elongation factor (Hev b 1) and 24 kd (Hev b 3) rubber particle proteins are recognized by IgE from patients with spina bifida and latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; latex allergy; spina bifida; monoclonal antibodies; immunogold labeling; rubber particle; rubber particle protein; Hev b 1; Hev b 3; USM/RC2	BRASILIENSIS; CHILDREN; ANTIBODY; CLONING	Two major water-insoluble proteins are located on the surface of rubber particles in Hevea brasiliensis latex. A 14.6 kd protein (Hev b 1), found mainly on large rubber particles (>350 nm in diameter), and a 24 kd protein (Hev b 3), found mainly on small rubber particles (average diameter, 70 nm), are recognized by IgE from patients with spina bifida and latex allergy. Although Hev b 1 (also called the rubber elongation factor [REF]) has previously been reported as a major latex allergen, this conclusion has been disputed on the basis of results from other studies. The allergenicity of Hev b 1 is verified in this study by testing the recombinant protein generated from its gene. Because allergenicity is confined to patients with spina bifida and not observed in adults sensitive to latex, it is not a major latex allergen. The identification of Hev b 3 as another allergen originating from rubber particles is confirmed by immunogold labeling and electron microscopy. Observations with the monoclonal antibody USM/RC2 developed against Hev b 3 show that the protein has a tendency to fragment into several polypeptides of lower molecular weight (from 24 kd to about 5 kd) when stored at -20 degrees C. There is also indication of protein aggregation from the appearance of proteins with molecular weights greater than 24 kd. Fragmentation of Hev b 3 is induced immediately on he addition of latex B-serum, which is normally compartmentalized in the lutoids in fresh latex. In the preparation of ammoniated latex (used for the manufacture of latex products), the lutoids ar ruptured, and the released B-serum reacts with Hev b 3 on the rubber particles to give rise to an array of low molecular weight polypeptides that are allergenic to patients with spina bifida.	VENTURE TECHNOL,GEORGE TOWN,MALAYSIA; JOHNS HOPKINS UNIV,SCH MED,REFERENCE LAB DERMATOL ALLERGY & CLIN IMMUNOL,BALTIMORE,MD; UNIV SAINS MALAYSIA,SCH PHARMACEUT SCI,GEORGE TOWN,MALAYSIA	Johns Hopkins University; Universiti Sains Malaysia	Yeang, HY (corresponding author), RUBBER RES INST MALAYSIA,DIV BIOTECHNOL & STRATEG RES,POB 10150,KUALA LUMPUR 50908,MALAYSIA.		Elumalai, Sunderasan/U-6110-2018; Cardosa, Mary Jane/A-3611-2009	Elumalai, Sunderasan/0000-0003-2442-6754; 				ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1994, J LAB CLIN MED, V123, P712; ATTANYAKA DPSTG, 1991, PLANT MOL BIOL, V16, P1079, DOI 10.1007/BF00016080; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cornish K., 1993, Journal of Natural Rubber Research, V8, P275; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; CZUPPON AB, 1993, CHEST S, V104, P1595; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; FRIDAY GA, 1993, J ALLERGY CLIN IMMUN, V91, P271; GOYVAERTS E, 1991, PLANT PHYSIOL, V97, P317, DOI 10.1104/pp.97.1.317; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; Hasma H, 1992, J NAT RUBBER RES, V7, P102; HSIA RCH, 1958, T I RUBBER IND, V34, P267; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V92, P638, DOI 10.1016/0091-6749(93)90005-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCULLOUGH J, 1994, LAT S 63 ANN M ROYAL; MOIR GFJ, 1959, NATURE, V184, P1926; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PRESCOTT A, 1987, PLANT MOL BIOL REP, V4, P219, DOI DOI 10.1007/BF02675414; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; Sunderasan E., 1994, Journal of Natural Rubber Research, V9, P127; TATA SJ, 1980, J RUBBER RES I MALAY, V28, P77; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; YEANG H Y, 1988, Journal of Natural Rubber Research, V3, P115; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3	31	125	136	0	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					628	639		10.1016/S0091-6749(96)70097-0	http://dx.doi.org/10.1016/S0091-6749(96)70097-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828541	hybrid			2022-12-18	WOS:A1996VJ42800020
J	Golden, DBK; Kwiterovich, KA; KageySobotka, A; Valentine, MD; Lichtenstein, LM				Golden, DBK; Kwiterovich, KA; KageySobotka, A; Valentine, MD; Lichtenstein, LM			Discontinuing venom immunotherapy: Outcome after five years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hymenoptera; venom; insect sting; anaphylaxis; immunotherapy	INSECT STING ALLERGY; NATURAL-HISTORY; FOLLOW-UP; ANAPHYLAXIS; SENSITIVITY; CHALLENGE; SEVERITY; SYMPTOMS; SERUM	Background: The clinical and immunologic consequences of discontinuing venom immunotherapy are not well-defined. To determine which patients can safely stop treatment, we accepted all volunteers who had completed at least 5 years of maintenance venom immunotherapy regardless of the severity of the historical sting reaction, the persistence of venom skin test sensitivity, or any other variable. Methods: Sting challenge was performed every 1 to 2 years after therapy was stopped; and venom-specific skin tests were performed, and IgE antibody levels were measured. Results: Systemic symptoms occurred after challenge in eight of 270 stings (3%), in seven en of 74 patients (10%); only two reactions were clinically significant. Venom skin test results became negative in 28% after 5 years of venom immunotherapy (at the time of discontinuation) and were negative in 56% to 67% of patients after 2 to 4 years without venom immunotherapy. There was a parallel decrease in the venom-specific IgE antibody levels. Challenge stings did not prevent the progressive decline in sensitivity, nor did they increase the risk of sting reaction even after two sequential stings 1 month apart. Conclusions: Venom immunotherapy can be safely discontinued after 5 years of maintenance therapy in virtually all patients, with the possible exception of those in whom the level of venom sensitivity has not declined during therapy. Venom sensitivity decreases with time even after venom therapy is stopped, Insect stings do not cause re-sensitization, and there was no increased risk from sequential stings. There appears to be a late-onset, non-IgG-mediated mechanism for long-term suppression of allergic sensitivity by prolonged high-dose venom immunotherapy.			Golden, DBK (corresponding author), JOHNS HOPKINS UNIV, CTR ASTHMA & ALLERGY, 5501 HOPKINS BAYVIEW CIRCLE, BALTIMORE, MD 21224 USA.				NCRR NIH HHS [RR00722] Funding Source: Medline; NIAID NIH HHS [AI08270, AI20136] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136, R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V89, P291; GOLDEN DBK, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90330-5; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; GOLDEN DBK, 1988, IMMUNOLOGIC DISEASES, P1173; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4	22	125	127	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					579	587		10.1016/S0091-6749(96)70302-0	http://dx.doi.org/10.1016/S0091-6749(96)70302-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621842	hybrid			2022-12-18	WOS:A1996TW08700002
J	HILL, DJ; CAMERON, DJS; FRANCIS, DEM; GONZALEZANDAYA, AM; HOSKING, CS				HILL, DJ; CAMERON, DJS; FRANCIS, DEM; GONZALEZANDAYA, AM; HOSKING, CS			CHALLENGE CONFIRMATION OF LATE-ONSET REACTIONS TO EXTENSIVELY HYDROLYZED FORMULAS IN INFANTS WITH MULTIPLE FOOD PROTEIN INTOLERANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPERSENSITIVITY; EXTENSIVELY HYDROLYZED FORMULAS; MULTIPLE FOOD PROTEIN INTOLERANCE; INFANCY	COWS MILK ALLERGY; 1ST 3 YEARS; CLINICAL MANIFESTATIONS; CHILDHOOD; CHILDREN; LIFE	Background: Many infants with cow's milk protein intolerance have adverse reactions to soy, casein and whey hydrolysate formula and to other foods. The recent development of Neocate, a hypoallergenic, nutritionally complete infant formula composed of individual amino acids and other nutrients, has enabled these infants to be stabilized. Objective: We observed the effect of food challenges in infants with reported hypersensitivity to hypoallergenic formulas. Methods: Eighteen infants (median age, 7 1/2 months) were given Neocate formula for 2 months and then underwent a 7-day double-blind placebo-controlled challenge with the formula previously best tolerated. Results: In 12 of the 18 infants irritability, vomiting diarrhea, and/or eczema flares developed during the formula challenge. In two patients symptoms developed immediately, but in the remainder adverse reactions evolved within 7 days (range 4 to 7 days). Adverse reactions were to soy formula (six patients), whey hydrolysate (two), and casein hydrolysate (four). When infants were 12 months of age, parents reported adverse reactions after the ingestion of other low allergen foods (median, six; from a panel of 10 such foods). Conclusion: A group of infants with late-onset adverse reactions to soy, extensively hydrolyzed casein, and whey formulas and to other foods has been identified. Neocate formula proved to be an effective substitute formula for these patients.	ROYAL CHILDRENS HOSP,DEPT ALLERGY,MELBOURNE,VIC,AUSTRALIA; ST TOMAS UNIV HOSP,MANILA,PHILIPPINES	Royal Children's Hospital Melbourne; University of Santo Tomas								AAS K, 1973, INT ARCH ALLER A IMM, V45, P56; BARR RG, 1988, ARCH DIS CHILD, V63, P380, DOI 10.1136/adc.63.4.380; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BUSINCO L, 1989, ANN ALLERGY, V62, P333; BUSINCO L, 1992, J PEDIATR S, V22, P21; FIRER MA, 1987, INT ARCH ALLER A IMM, V84, P173, DOI 10.1159/000234419; HIDE DW, 1993, CLIN EXP ALLERGY, V23, P79, DOI 10.1111/j.1365-2222.1993.tb00302.x; HILL DJ, 1993, ALLERGY, V48, P75, DOI 10.1111/j.1398-9995.1993.tb00689.x; HILL DJ, 1984, CLIN REV ALLERG, V2, P125; HILL DJ, 1992, J PEDIATR-US, V121, P755, DOI 10.1016/S0022-3476(05)81911-0; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HILL DJ, 1982, CLIN ALLERGY, V12, P313, DOI 10.1111/j.1365-2222.1982.tb02533.x; HILL DJ, 1989, J PEDIATR-US, V114, P761, DOI 10.1016/S0022-3476(89)80133-7; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; HILL DJ, 1992, CLIN EXP ALLERGY, V23, P124; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; IACONO G, 1993, J PEDIATR GASTR NUTR, V16, P472, DOI 10.1097/00005176-199305000-00023; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V92, P909, DOI 10.1016/0091-6749(93)90069-R; SAMPSON HA, 1993, MAST CELL INVOLVEMEN, P609; SAYLOR JD, 1991, J PEDIATR-US, V118, P71, DOI 10.1016/S0022-3476(05)81848-7; SUOMALAINEN H, 1990, PEDIATR ALLERGY IMMU, V5, P20	24	125	127	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					386	394		10.1016/S0091-6749(95)70058-7	http://dx.doi.org/10.1016/S0091-6749(95)70058-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560641				2022-12-18	WOS:A1995RU66000011
J	FERGUSON, AC; WHITELAW, M; BROWN, H				FERGUSON, AC; WHITELAW, M; BROWN, H			CORRELATION OF BRONCHIAL EOSINOPHIL AND MAST-CELL ACTIVATION WITH BRONCHIAL HYPERRESPONSIVENESS IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; EOSINOPHIL; MAST CELLS; BRONCHIAL HYPERRESPONSIVENESS; EOSINOPHIL CATIONIC PROTEIN; MAST CELL TRYPTASE	BRONCHOALVEOLAR LAVAGE; NONASTHMATIC SUBJECTS; RELEASE; HISTAMINE; ALLERGEN; TRYPTASE; INFLAMMATION; PROTEINS; FLUID	Bronchial hyperresponsiveness in asthma has been associated with increased numbers of eosinophils and mast cells in the bronchial airway. It is unclear if these cells are important in the pathogenesis of hyperresponsiveness, and the role of mast cells has been discounted because they are effectively stabilized by beta-adrenergic drugs. Because the pathogenesis of asthma in children may be different from that in adults, and to find out if cellular activation is associated with bronchial reactivity, we studied 17 children with mild to moderately severe chronic asthma who had been treated with intermittent bronchodilator therapy and compared their bronchial responsiveness to histamine with the levels of eosinophil cationic protein and mast cell tryptase in broncholavage fluid. The number of eosinophils in lavage fluid was correlated with histamine responsiveness (r = -0.444, p < 0.05) but not with levels of cationic protein (r = 0.33, p = NS). Bronchial responsiveness to histamine was highly correlated with mast cell tryptase (r = -0.714, p < 0.005), but there was no correlation with eosinophil cationic protein (r = -0.355, p = NS). We conclude that in children with chronic asthma mast cells as well as eosinophils contribute to bronchial hyperresponsiveness. Activated mast cells may play a primary role, possibly by tryptase-induced upregulation of bronchial smooth muscle tone.	UNIV BRITISH COLUMBIA,DEPT PEDIAT,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia				Ferguson, Alexander C./0000-0002-3143-5619				AGIUS RM, 1986, MAST CELL DIFFERENTI, P277; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHERNIACK RM, 1990, AM REV RESPIR DIS, V141, pS67; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DIXON WJ, 1969, INTRO STATISTICAL AN, P193; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; FLINT KC, 1985, CLIN SCI, V68, P427, DOI 10.1042/cs0680427; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GOLD WM, 1991, AM REV RESPIR DIS, V143, pS61, DOI 10.1164/ajrccm/143.3_Pt_2.S61; HOWARTH P, 1990, American Review of Respiratory Disease, V141, pA500; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KELLY C, 1988, THORAX, V43, P684, DOI 10.1136/thx.43.9.684; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LAM S, 1991, J ALLERGY CLIN IMMUN, V87, P842, DOI 10.1016/0091-6749(91)90131-7; MALO JL, 1990, ASTHMA INFLAMMATORY, P71; MURRAY AB, 1983, PEDIATRICS, V71, P418; OREHEK J, 1980, AIRWAY REACTIVITY, P201; PAGE CP, 1991, LANCET, V337, P717, DOI 10.1016/0140-6736(91)90289-2; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9, DOI 10.1164/ajrccm/141.1.9; SCHWARTZ LB, 1990, NEUTRAL PROTEASES MA, V27, P90; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	29	125	126	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				609	613		10.1016/0091-6749(92)90133-M	http://dx.doi.org/10.1016/0091-6749(92)90133-M			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1357019				2022-12-18	WOS:A1992JT99500006
J	SLATER, JE; CHHABRA, SK				SLATER, JE; CHHABRA, SK			LATEX ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; RUBBER; IMMEDIATE HYPERSENSITIVITY; RAST	CONTACT URTICARIA; RUBBER; GLOVES; HYPERSENSITIVITY; ANAPHYLAXIS	Previous studies have demonstrated that some children with spina bifida have IgE to proteins in natural rubber. In this study we compare different sources of latex antigen and identify possible antigenic peptides by radioimmunoblotting technique. Sera were collected from 26 children with spina bifida, tested by RAST with ammoniated latex extract (AL), and frozen until use. Extracts were prepared from ammoniated and nonammoniated latex, and the proteins were separated by electrophoresis on a 15% sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylene difluoride (PVDF). Strips of PVDF were then incubated with individual sera and I-125-labeled rabbit antihuman IgE before development by autoradiography; 18/26 sera were Al RAST positive; 0/8 AL RAST-negative patients had any binding to the latex proteins on PVDF. Sera from all patients were tested in a RAST with a nonammoniated latex extract (NAL), and the results were comparable to the AL RAST. Liquid-phase AL and NAL were comparable in their ability to inhibit the binding of patient's IgE to solid-phase AL and NAL. Sera from 14 RAST-positive patients were tested by immunoblotting with separated, reduced, and nonreduced AL and NAL. All 14 sera demonstrated IgE binding to a 14 kd peptide, which was more pronounced in reduced NAL. These results suggest that the 14 kd peptide in NAL is a major antigen in rubber allergy but that AL is an acceptable antigen source for in vitro diagnostic studies.	CHILDRENS RES INST,CTR CANC & TRANSPLANTAT BIOL,WASHINGTON,DC; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT PEDIAT,WASHINGTON,DC 20052	George Washington University	SLATER, JE (corresponding author), CHILDRENS NATL MED CTR,DEPT ALLERGY & IMMUNOL,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.				NIAID NIH HHS [AI 29428-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCHER BL, 1960, BIOCHEM J, V75, P236, DOI 10.1042/bj0750236; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P443; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; RODRIGUEZ A, 1988, J BIOL CHEM, V263, P4047; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; STCYR DR, 1982, ENCY CHEM TECHNOLOGY, P468; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG SCG, 1985, OPHTHALMOLOGY, V92, P728; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V; WALUJONO K, 1975, P INT RUBBER C KUALA, P518	20	125	128	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					673	678		10.1016/0091-6749(92)90373-A	http://dx.doi.org/10.1016/0091-6749(92)90373-A			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545088				2022-12-18	WOS:A1992HJ34000005
J	TOOGOOD, JH				TOOGOOD, JH			RISK OF ANAPHYLAXIS IN PATIENTS RECEIVING BETA-BLOCKER DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											TOOGOOD, JH (corresponding author), VICTORIA HOSP,ALLERGY CLIN,375 S ST,LONDON N6A 4G5,ONTARIO,CANADA.							ASSEM ESK, 1974, CLIN ALLERGY, V4, P185, DOI 10.1111/j.1365-2222.1974.tb01375.x; ASSEM ESK, 1971, BRIT J PHARMACOL, V42, P620, DOI 10.1111/j.1476-5381.1971.tb07146.x; AWAI LE, 1984, ANN ALLERGY, V53, P48; BARRETTBEE K, 1978, BIOCHEM BIOPH RES CO, V84, P998, DOI 10.1016/0006-291X(78)91682-0; BENOWITZ NL, 1983, CLIN MANAGEMENT POIS, P846; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134, DOI 10.7326/0003-4819-104-1-134_1; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; BOURNE HR, 1972, J IMMUNOL, V108, P695; BUSSE WW, 1985, CHEST, V87, pS44, DOI 10.1378/chest.87.1_Supplement.44S; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; CASS E, 1979, CAN MED ASSOC J, V120, P1261; Committee on the Safety of Medicines (CSM) in Great Britain, 1986, BR MED J, V293, P948; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; DUNN TL, 1986, AM REV RESPIR DIS, V133, P264; FRANKISH C, 1985, CLIN INVEST MED, V8, pA42; FREELY J, 1981, NEW ENGL J MED, V304, P692; FRISHMAN WH, 1983, CIRCULATION, V67, P111; HAMILTON G, 1985, CAN MED ASSOC J, V133, P122; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; HANSTEN PD, 1979, DRUG INTERACTIONS CL, P13; HIATT WR, 1985, CLIN PHARMACOL THER, V37, P2, DOI 10.1038/clpt.1985.2; HOVMARK A, 1981, ALLERGY, V36, P391, DOI 10.1111/j.1398-9995.1981.tb01844.x; INGALL M, 1984, JAMA-J AM MED ASSOC, V251, P1432, DOI 10.1001/jama.1984.03340350026019; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V69, P331; JONES B, 1980, LANCET, V1, P1031; KAAD PH, 1982, CLIN ALLERGY, V12, P317, DOI 10.1111/j.1365-2222.1982.tb02534.x; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KOSINSKI EJ, 1971, NEW ENGL J MED, V285, P1325; KROGH CME, 1986, COMPENDIUM PHARM SPE; LEIER CV, 1986, ANN INTERN MED, V104, P198; LEMANSKE RF, 1985, ALLERGY, P199; LENNARD MS, 1986, CLIN PHARMACOKINET, V11, P1, DOI 10.2165/00003088-198611010-00001; LEWIS RV, 1985, BRIT J CLIN PHARMACO, V19, P329, DOI 10.1111/j.1365-2125.1985.tb02651.x; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P395, DOI 10.1016/0091-6749(76)90120-2; MCLAREN EH, 1976, BRIT MED J, V2, P283, DOI 10.1136/bmj.2.6030.283-a; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MILLER RR, 1975, NEW ENGL J MED, V293, P416, DOI 10.1056/NEJM197508282930902; MJORNDAL TO, 1983, J ALLERGY CLIN IMMUN, V71, P62, DOI 10.1016/0091-6749(83)90548-1; MYERS MG, 1977, CHEST, V71, P24, DOI 10.1378/chest.71.1.24; NELSON BL, 1986, ANN ALLERGY, V56, P331; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; NISAM MR, 1978, J APPL PHYSIOL, V44, P455, DOI 10.1152/jappl.1978.44.3.455; NORMAN PS, 1987, J ALLERGY CLIN IMMUN, V79, P572, DOI 10.1016/S0091-6749(87)80150-1; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OSTERGAARD PA, 1986, ALLERGY, V41, P588; PARMLEY WW, 1971, NEW ENGL J MED, V285, P801, DOI 10.1056/NEJM197109302851414; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929; WALLIN JD, 1985, CHEST, V88, P801, DOI 10.1378/chest.88.6.801; WARD DE, 1976, BRIT MED J, V2, P151, DOI 10.1136/bmj.2.6028.151; WASSERMAN SI, 1986, J ALLERGY CLIN IMMUN, V77, P663, DOI 10.1016/0091-6749(86)90405-7; WILCOX PG, 1986, CLIN PHARMACOL THER, V39, P29, DOI 10.1038/clpt.1986.5; YOUNG C, 1986, J ALLERGY CLIN IMMUN, V77, P225; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65	60	125	129	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					1	5		10.1016/0091-6749(88)90212-6	http://dx.doi.org/10.1016/0091-6749(88)90212-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	2892872				2022-12-18	WOS:A1988M027400001
J	GOLDEN, DBK; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM				GOLDEN, DBK; KAGEYSOBOTKA, A; VALENTINE, MD; LICHTENSTEIN, LM			DOSE DEPENDENCE OF HYMENOPTERA VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOLDEN, DBK (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.							BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; FRANKLIN W, 1967, JAMA-J AM MED ASSOC, V201, P95; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P247, DOI 10.1016/0091-6749(77)90158-0; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SOBOTKA AK, 1978, J ALLERGY CLIN IMMUN, V61, P136, DOI 10.1016/0091-6749(78)90263-4	12	125	126	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					370	374		10.1016/0091-6749(81)90082-8	http://dx.doi.org/10.1016/0091-6749(81)90082-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	7229226				2022-12-18	WOS:A1981LQ56300007
J	KANG, B				KANG, B			STUDY ON COCKROACH ANTIGEN AS A PROBABLE CAUSATIVE AGENT IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUSH MED COLL,SCH MED,DEPT MED,CHICAGO,IL 60612; MT SINAI HOSP,MED CTR,CHICAGO,IL 60608	Rush University								BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1970, ANN ALLERGY, V28, P420; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; COLLDAHL H, 1967, ACTA ALLERGOL      S, V8, P149; COLLDAHL H, 1967, ACTA ALLERGOL S, V8, P7; COX JSG, 1970, DISODIUM CROMOGLYCAT, pCH2; GREEN AA, 1962, NEW SCI, V16, P74; KANG B, 1975, CLIN RES, V23, pA348; KOLOTKIN BM, 1974, J ALLERGY CLIN IMMUN, V53, P288, DOI 10.1016/0091-6749(74)90108-0; MCALLEN MK, 1970, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.5708.501; PEPYS J, 1975, NEW ENGL J MED, V293, P758; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROTH LM, 1951, MISCELLANEOUS SMITHS, V134, P10; RYO UY, 1971, J ALLERGY, V47, P96; SHEFFIELD GJ, 1967, SO MED J, V60, P852; UY CG, 1973, ANN ALLERGY, V31, P407; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7	21	125	125	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					357	365		10.1016/0091-6749(76)90115-9	http://dx.doi.org/10.1016/0091-6749(76)90115-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	965615				2022-12-18	WOS:A1976CD45400001
J	Sampson, HA; O'Mahony, L; Burks, AW; Plaut, M; Lack, G; Akdis, CA				Sampson, Hugh A.; O'Mahony, Liam; Burks, A. Wesley; Plaut, Marshall; Lack, Gideon; Akdis, Cezmi A.			Mechanisms of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; sensitization; tolerance; desensitization; sustained unresponsiveness; remission; allergen immunotherapy; microbiota	REGULATORY T-CELLS; THYMIC STROMAL LYMPHOPOIETIN; PEANUT ORAL IMMUNOTHERAPY; B-CELLS; BARRIER INTEGRITY; AMERICAN ACADEMY; IMMUNE TOLERANCE; PROMOTES; MICROBIOME; BASOPHIL	Although oral tolerance is the normal physiologic response to ingested antigens, a breakdown in this process appears to have occurred in the past 2 decades, leading to an increasing prevalence of sensitization to food allergens. Over the past decade, basic research has intensified in an attempt to better understand the mechanisms leading to sensitization and disease versus desensitization and short- and long-term tolerance. In this review we assess various factors that can influence tissue and immune responses to food antigens, the current understanding of immune tolerance development, the role of the gastrointestinal microbiota, and current knowledge regarding immunologic mechanisms involved in desensitization and sustained unresponsiveness, although perhaps the latter is more appropriately termed remission.	[Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol,Kravis Childrens Hosp, New York, NY 10029 USA; [O'Mahony, Liam; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Plaut, Marshall] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Lack, Gideon] Kings Coll London, Dept Paediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [Lack, Gideon] St Thomas NHS Fdn Trust, London, England	Icahn School of Medicine at Mount Sinai; Swiss Institute of Allergy & Asthma Research; University of Zurich; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of London; King's College London	Sampson, HA (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Akdis, Cezmi/AAV-4844-2020; O'Mahony, Liam/AAG-5838-2019	Akdis, Cezmi/0000-0001-8020-019X; O'Mahony, Liam/0000-0003-4705-3583; Lack, Gideon/0000-0001-7350-4021	National Institute of Allergy and Infectious Diseases [AI-44236]; NIH AITC Review Panel; Allertein; American Society for Microbiology; Elsevier; FARE; World Allergy Organization; Adept Field Solutions; Aimmune Therapeutics, Inc; Astellas Pharma Global Development, Inc; Biomerica, Inc; Evelo Biosciences, Inc/Epiva Biosciences, Inc; First Manhattan Co; Genentech; GLG Research, Inc; Insys Therapeutics; Intrommune Therapeutics; PPD Development, LP; Regeneron Pharmceuticals, Inc; Sanofi US Services; SRA International; Stallergenes; UKKO, Inc; Valeant Pharmaceuticals North America, LLC; National Institutes of Health; Wallace Research Foundation; National Institutes of Allergy and Infectious Diseases [NO1-AI-15416, UM1AI109565]; Food Allergy Research and Education (FARE); MRC & Asthma UK Centre; UK Department of Health through the National Institute for Health Research; National Peanut Board; Osem; Actellion; European Union project Medall; Allergopharma; Swiss National Science Foundation; Christine Kuhne Center for Allergy Research and Education; European Union project Predicta; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI109565] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH AITC Review Panel(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Allertein; American Society for Microbiology; Elsevier; FARE; World Allergy Organization; Adept Field Solutions; Aimmune Therapeutics, Inc; Astellas Pharma Global Development, Inc; Biomerica, Inc; Evelo Biosciences, Inc/Epiva Biosciences, Inc; First Manhattan Co; Genentech(Roche HoldingGenentech); GLG Research, Inc; Insys Therapeutics; Intrommune Therapeutics; PPD Development, LP; Regeneron Pharmceuticals, Inc; Sanofi US Services; SRA International; Stallergenes; UKKO, Inc; Valeant Pharmaceuticals North America, LLC; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wallace Research Foundation; National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Research and Education (FARE); MRC & Asthma UK Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health through the National Institute for Health Research; National Peanut Board; Osem; Actellion; European Union project Medall; Allergopharma; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education; European Union project Predicta; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	H. A. Sampson has received grants from the National Institute of Allergy and Infectious Diseases (AI-44236, CoFar, ITN); has consultant arrangements with Allertein Therapeutics, LLC, Hycor, and UCB; is Chief Scientific Officer of DBV Technologies; has received royalties from UpToDate; and has stock/stock options with DBV Technologies. A. W. Burks reports personal fees from NIH AITC Review Panel, Allertein, American Society for Microbiology, Elsevier, FARE, World Allergy Organization, Adept Field Solutions, Aimmune Therapeutics, Inc, Astellas Pharma Global Development, Inc, Biomerica, Inc, Evelo Biosciences, Inc/Epiva Biosciences, Inc, First Manhattan Co, Genentech, GLG Research, Inc, Insys Therapeutics, Intrommune Therapeutics, PPD Development, LP, Regeneron Pharmceuticals, Inc, Sanofi US Services, SRA International, Stallergenes, UKKO, Inc, and Valeant Pharmaceuticals North America, LLC and reports grants from Food Allergy Research and Education (FARE), National Institutes of Health, and Wallace Research Foundation. G. Lack has received grants from the National Institutes of Allergy and Infectious Diseases (NO1-AI-15416 [contract] and UM1AI109565 [grant]), Food Allergy Research and Education (FARE), MRC & Asthma UK Centre, UK Department of Health through the National Institute for Health Research, the National Peanut Board, and Osem; and has consultant arrangements and stock/stock options with DBV Technologies. C. A. Akdis has received grants from Actellion, the European Union projects Medall and Predicta, Allergopharma, the Swiss National Science Foundation, and the Christine Kuhne Center for Allergy Research and Education. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Ather JL, 2015, CLIN EXP ALLERGY, V45, P1245, DOI 10.1111/cea.12491; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Barcik W, 2016, DRUG DISCOV TODAY DI, V17, P71; Barcik W, 2016, J ALLERGY CLIN IMMUN, V138, P1491, DOI 10.1016/j.jaci.2016.05.049; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Bogh KL, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0110-2; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2017, J ALLERGY CLIN IMMUN; Butto LF, 2017, J ALLERGY CLIN IMMUN, V139, P1092, DOI 10.1016/j.jaci.2017.02.010; Chen CC, 2017, J ALLERGY CLIN IMMUN, V140, P1351, DOI 10.1016/j.jaci.2017.01.015; Clay CD, 2017, J ALLERGY CLIN IMMUN; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Duan S, 2016, J ALLERGY CLIN IMMUN, V138, P1725, DOI 10.1016/j.jaci.2016.05.037; Ebbo M, 2017, NAT REV IMMUNOL, V17, P665, DOI 10.1038/nri.2017.86; Ferstl R, 2014, J ALLERGY CLIN IMMUN, V134, P744, DOI 10.1016/j.jaci.2014.04.034; Frei R, 2015, CURR OPIN GASTROEN, V31, P153, DOI 10.1097/MOG.0000000000000151; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Gensollen T, 2017, J ALLERGY CLIN IMMUN, V139, P1084, DOI 10.1016/j.jaci.2017.02.011; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Hornby S, 2016, SKIN RES TECHNOL, V22, P196, DOI 10.1111/srt.12250; Hua X, 2016, EBIOMEDICINE, V3, P172, DOI 10.1016/j.ebiom.2015.11.038; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Hussain M, 2018, J ALLERGY CLIN IMMUN, V141, P223, DOI 10.1016/j.jaci.2017.02.035; Janzi M, 2009, CLIN IMMUNOL, V133, P78, DOI 10.1016/j.clim.2009.05.014; Jimenez-Saiz R., 2017, J ALLERGY CLIN IMMUN; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Khodoun MV, 2018, J ALLERGY CLIN IMMUN, V141, P171, DOI 10.1016/j.jaci.2017.02.046; Kim AR, 2016, SCI REP-UK, V6, DOI 10.1038/srep19685; Kim KS, 2016, SCIENCE, V351, P858, DOI 10.1126/science.aac5560; Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936; Kucuksezer UC, 2015, WORLD ALLERGY ORGAN, pA257; Kucuksezer UC, 2013, J ALLERGY CLIN IMMUN, V131, P875, DOI 10.1016/j.jaci.2012.10.051; Loxham M, 2017, J ALLERGY CLIN IMMUN, V139, P1736, DOI 10.1016/j.jaci.2017.04.005; Lyons A, 2010, CLIN EXP ALLERGY, V40, P811, DOI 10.1111/j.1365-2222.2009.03437.x; Mortha A, 2014, SCIENCE, V343, P1477, DOI 10.1126/science.1249288; Mu QH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00598; Muehling L. M., 2017, J ALLERGY CLIN IMMUN; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Plunkett CH, 2017, J IMMUNOL, V198, P581, DOI 10.4049/jimmunol.1601266; Prince BT, 2017, J ALLERGY CLIN IMMUN, V140, P1194, DOI 10.1016/j.jaci.2017.04.039; Reboldi A, 2016, SCIENCE, V352, DOI 10.1126/science.aaf4822; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Schiavi E, 2015, CURR OPIN GASTROEN, V31, P98, DOI 10.1097/MOG.0000000000000155; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Smit JJ, 2016, DRUG DISCOV TODAY DI, V17, P63; Smith PK, 2017, J ALLERGY CLIN IMMUN, V139, P429, DOI 10.1016/j.jaci.2016.05.040; Smolinska S, 2017, GASTROENTEROL CLIN N, V46, P19, DOI 10.1016/j.gtc.2016.09.004; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Sugita K, 2015, EXP DERMATOL, V24, P554, DOI 10.1111/exd.12711; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Tordesillas L, 2017, J ALLERGY CLIN IMMUN, V139, P189, DOI 10.1016/j.jaci.2016.03.057; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wang S, 2017, CELL, V171, P201, DOI 10.1016/j.cell.2017.07.027; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Werfel T, 2015, J ALLERGY CLIN IMMUN, V136, P96, DOI 10.1016/j.jaci.2015.04.015; Xian M, 2016, J ALLERGY CLIN IMMUN, V138, P890, DOI 10.1016/j.jaci.2016.07.003; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111	75	124	134	11	63	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					11	19		10.1016/j.jaci.2017.11.005	http://dx.doi.org/10.1016/j.jaci.2017.11.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	29307410	Bronze			2022-12-18	WOS:000419312200002
J	Gericke, J; Metz, M; Ohanyan, T; Weller, K; Altrichter, S; Skov, PS; Falkencrone, S; Brand, J; Kromminga, A; Hawro, T; Church, MK; Maurer, M				Gericke, Janine; Metz, Martin; Ohanyan, Tatevik; Weller, Karsten; Altrichter, Sabine; Skov, Per Stahl; Falkencrone, Sidsel; Brand, Janko; Kromminga, Arno; Hawro, Tomasz; Church, Martin K.; Maurer, Marcus			Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SKIN-TEST		[Gericke, Janine; Metz, Martin; Ohanyan, Tatevik; Weller, Karsten; Altrichter, Sabine; Hawro, Tomasz; Church, Martin K.; Maurer, Marcus] Charite, Dept Dermatol Venerol & Allergy, Allergie Ctr Charite, Berlin, Germany; [Skov, Per Stahl] Univ Hosp Southern Denmark, Dept Dermatol, Odense, Denmark; [Skov, Per Stahl; Falkencrone, Sidsel] RefLab ApS, Copenhagen, Denmark; [Skov, Per Stahl] Natl Univ Copenhagen, Inst Immunol, Copenhagen, Denmark; [Brand, Janko] BioTeZ Berlin Buch GmbH, Berlin, Germany; [Kromminga, Arno] IPM Biotech GmbH, Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Southern Denmark; Odense University Hospital; University of Copenhagen	Maurer, M (corresponding author), Charite, Dept Dermatol Venerol & Allergy, Allergie Ctr Charite, Berlin, Germany.	marcus.maurer@charite.de	Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313; Altrichter, Sabine/0000-0001-9955-385X; Hawro, Tomasz/0000-0001-9990-1332	Novartis Pharma GmbH; Medixiline; Index Venture Management Jersey Ltd; Sanofi; Nerre; LORA Group; Jenapharm; Novartis; Charite; Bayer; MarDi; Dr. R. Pfleger; Urtimed; Klinikzentrum Bad Sulza; GlaxoKline; DDG; ADF; Universitat Munster; Roche; Arztekammer Berlin; BVDD; Mediengruppe Oberfranken; Moxie GmbH; Rahel-Hirsch-Stipend; RefLab ApS; Uriach; Genentech; Moxie	Novartis Pharma GmbH; Medixiline; Index Venture Management Jersey Ltd; Sanofi(Sanofi-Aventis); Nerre; LORA Group; Jenapharm; Novartis(Novartis); Charite; Bayer(Bayer AG); MarDi; Dr. R. Pfleger; Urtimed; Klinikzentrum Bad Sulza; GlaxoKline; DDG; ADF; Universitat Munster; Roche(Roche Holding); Arztekammer Berlin; BVDD; Mediengruppe Oberfranken; Moxie GmbH; Rahel-Hirsch-Stipend; RefLab ApS; Uriach; Genentech(Roche HoldingGenentech); Moxie	J. Gericke's institution has received grants from Novartis Pharma GmbH. M. Metz has received consultancy fees from Medixiline, Index Venture Management Jersey Ltd, Sanofi, Nerre, LORA Group, Jenapharm, and Novartis; payment for lectures from Novartis, Charite, Bayer, MarDi, Dr. R. Pfleger, Urtimed, Klinikzentrum Bad Sulza, GlaxoKline, DDG, ADF, Jenapharm, Universitat Munster, Roche, Arztekammer Berlin, and BVDD; and payment for manuscript preparation from Mediengruppe Oberfranken, Jenapharm, and Moxie GmbH. K. Weller has received consultancy fees, grants, and payment for lectures from Novartis. S. Altrichter is employed by Charite-Universitatsmedizin Berlin and has received grants from Rahel-Hirsch-Stipend. P. S. Skov has received consultancy fees from RefLab ApS. S. Falkencrone is employed by RefLab ApS. A. Kromminga is employed by and has received stock options from IPM Biotech GmbH. M. K. Church has received grants or honorarium and support for travel from Novartis for the work under consideration for publication. M. Maurer has received board membership, consultancy fees, expert testimony fees, and grants from Uriach, Novartis, Genentech, and Moxie and payment for lectures from Uriach and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; Konstantinou GN, 2009, ALLERGY, V64, P1256, DOI 10.1111/j.1398-9995.2009.02132.x; Meno-Tetang GML, 2005, BASIC CLIN PHARMACOL, V96, P182, DOI 10.1111/j.1742-7843.2005.pto960307.x; Metz M, 2014, ALLERGY, V69, P87; Platzer MH, 2005, ALLERGY, V60, P1152, DOI 10.1111/j.1398-9995.2005.00841.x; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	8	124	132	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1059	1061		10.1016/j.jaci.2016.07.047	http://dx.doi.org/10.1016/j.jaci.2016.07.047			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27838346	Bronze			2022-12-18	WOS:000397295800047
J	Higgins, E; Al Shehri, T; McAleer, MA; Conlon, N; Feighery, C; Lilic, D; Irvine, AD				Higgins, Eleanor; Al Shehri, Tariq; McAleer, Maeve A.; Conlon, Niall; Feighery, Conleth; Lilic, Desa; Irvine, Alan D.			Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IL-17 IMMUNITY		[Higgins, Eleanor; Conlon, Niall; Feighery, Conleth; Irvine, Alan D.] St James Hosp, Dublin 8, Ireland; [Al Shehri, Tariq; Lilic, Desa] Newcastle Univ, Primary Immunodeficiency Grp, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [McAleer, Maeve A.; Irvine, Alan D.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland	Trinity College Dublin; Newcastle University - UK; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Trinity College Dublin	Higgins, E (corresponding author), St James Hosp, Dublin 8, Ireland.	desa.lilic@newcastle.ac.uk; irvinea@tcd.ie	Irvine, Alan D/A-3982-2008	Irvine, Alan D/0000-0002-9048-2044				Harrison C, 2012, NEW ENGL J MED, V366, P787, DOI 10.1056/NEJMoa1110556; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Ng WF, 2010, J ALLERGY CLIN IMMUN, V126, P1006, DOI 10.1016/j.jaci.2010.08.027; Puel A, 2012, CURR OPIN ALLERGY CL, V12, P616, DOI 10.1097/ACI.0b013e328358cc0b; Romberg N, 2013, J ALLERGY CLIN IMMUN, V131, P1691, DOI 10.1016/j.jaci.2013.01.004; Sharfe N, 2014, J ALLERGY CLIN IMMUN, V133, P807, DOI 10.1016/j.jaci.2013.09.032; Soltesz B, 2013, J MED GENET, V50, P567, DOI 10.1136/jmedgenet-2013-101570; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645	11	124	128	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					551	U356		10.1016/j.jaci.2014.12.1867	http://dx.doi.org/10.1016/j.jaci.2014.12.1867			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25662309	Bronze			2022-12-18	WOS:000349372300030
J	Commins, SP; James, HR; Stevens, W; Pochan, SL; Land, MH; King, C; Mozzicato, S; Platts-Mills, TAE				Commins, Scott P.; James, Hayley R.; Stevens, Whitney; Pochan, Shawna L.; Land, Michael H.; King, Carol; Mozzicato, Susan; Platts-Mills, Thomas A. E.			Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; alpha-gal; basophil; mammalian meat; food allergy	MAST-CELL ACTIVATION; ALPHA-GAL EPITOPE; INDUCED ANAPHYLAXIS; HUMAN BASOPHILS; UP-REGULATION; CARBOHYDRATE; EXPRESSION; FOOD; ANTIBODIES; CETUXIMAB	Background: In 2009, we reported a novel form of delayed anaphylaxis to red meat related to serum IgE antibodies to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal). Although patients were remarkably consistent in their description of a 3-to 6-hour delay between eating mammalian meat and the appearance of symptoms, this delay has not been demonstrated under observed studies. Objectives: We sought to formally document the time course of clinical symptoms after the ingestion of mammalian meat in subjects with IgE to alpha-gal and to monitor ex vivo for the appearance of markers of an allergic reaction. Methods: Open food challenges were performed with mammalian meat in 12 subjects with a history of severe urticarial reactions 3 to 6 hours after eating beef, pork, or lamb, as well as in 13 control subjects. Blood samples were taken hourly during each challenge. Results: Ten of 12 subjects with IgE to alpha-gal had clinical evidence of a reaction during the food challenge (vs none of the control subjects, P <. 001). The reactions occurred 3 to 7 hours after the initial ingestion of mammalian meat and ranged from urticaria to anaphylaxis. Tryptase levels were positive in 3 challenges. Basophil activation, as measured by increased expression of CD63, correlated with the appearance of clinical symptoms. Conclusion: The results presented provide clear evidence of an IgE-mediated food allergy that occurs several hours after ingestion of the inciting allergen. Moreover, here we report that in vivo basophil activation during a food challenge occurs in the same time frame as clinical symptoms and likely reflects the appearance of the antigen in the bloodstream.	[Commins, Scott P.; James, Hayley R.; Stevens, Whitney; Pochan, Shawna L.; King, Carol; Mozzicato, Susan; Platts-Mills, Thomas A. E.] Univ Virginia, Dept Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; [Land, Michael H.] Duke Univ, Duke Asthma Allergy & Airway Ctr, Durham, NC USA	University of Virginia; Duke University	Commins, SP (corresponding author), Univ Virginia, Div Allergy, POB 801355, Charlottesville, VA 22908 USA.	scottcommins@virginia.edu		Land, Michael/0000-0001-8016-5419; Platts-Mills, Thomas/0000-0002-1263-329X	National Institutes of Health [K08 AI085190, R01 AI-20565, R21 AI087985]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, K08AI085190, R21AI087985, T32AI007496] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants K08 AI085190 (to S. P. C.), R01 AI-20565 (to T. A. E. P.-M.), and R21 AI087985 (to S.P.C. and T.A.E.P.-M.).	Bruhns P, 2005, CURR OPIN IMMUNOL, V17, P662, DOI 10.1016/j.coi.2005.09.012; Caponetto P, 2013, J ALLER CL IMM-PRACT, V1, P302, DOI 10.1016/j.jaip.2013.01.007; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cianferoni A, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-14; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V124, P652, DOI 10.1016/j.jaci.2009.08.026; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; de Weck AL, 2004, J INVEST ALLERG CLIN, V14, P253; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; Gober LM, 2007, J ALLERGY CLIN IMMUN, V119, P1181, DOI 10.1016/j.jaci.2007.01.008; GONEN B, 1987, BIOCHIM BIOPHYS ACTA, V917, P418, DOI 10.1016/0005-2760(87)90121-4; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Jacquenet S, 2009, J ALLERGY CLIN IMMUN, V124, P603, DOI 10.1016/j.jaci.2009.06.014; Jappe U, 2012, HAUTARZT, V63, P299, DOI 10.1007/s00105-011-2266-y; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Kennedy JL, 2013, PEDIATRICS, V131, pE1545, DOI 10.1542/peds.2012-2585; Koike C, 2007, P NATL ACAD SCI USA, V104, P559, DOI 10.1073/pnas.0610012104; Lemon-Mule H, 2008, CURR ALLERGY ASTHM R, V8, P201, DOI 10.1007/s11882-008-0034-6; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; Oole-Groen CJ, 2013, ALLERGOL IMMUNOPATHO; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Platz IJ, 2001, INT ARCH ALLERGY IMM, V126, P335, DOI 10.1159/000049531; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; Rydberg L, 1996, XENOTRANSPLANTATION, V3, P340, DOI 10.1111/j.1399-3089.1996.tb00156.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Sekiya K, 2012, J INVEST ALLERG CLIN, V22, P446; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; Strokan V, 1998, TRANSPLANTATION, V66, P1495, DOI 10.1097/00007890-199812150-00013; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; van Erp FC, 2013, PEDIAT ALLERG IMM-UK, V24, P596, DOI 10.1111/pai.12107; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; VIRGOLINI I, 1995, ARTERIOSCL THROM VAS, V15, P17, DOI 10.1161/01.ATV.15.1.17	42	124	126	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					108	+		10.1016/j.jaci.2014.01.024	http://dx.doi.org/10.1016/j.jaci.2014.01.024			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24656556	Green Accepted			2022-12-18	WOS:000338930300015
J	Jones, CP; Gregory, LG; Causton, B; Campbell, GA; Lloyd, CM				Jones, Carla P.; Gregory, Lisa G.; Causton, Benjamin; Campbell, Gaynor A.; Lloyd, Clare M.			Activin A and TGF-beta promote T(H)9 cell-mediated pulmonary allergic pathology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Activin A; T(H)9 cells; IL-9; asthma; allergy; mast cells; house dust mite; TGF-beta	GROWTH-FACTOR-BETA; REGULATORY T-CELLS; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTOR; IL-9 EXPRESSION; TRANSGENIC MICE; INTERLEUKIN 9; ASTHMA; INFLAMMATION	Background: IL-9-secreting (T(H)9) T cells are thought to represent a distinct T-cell subset. However, evidence for their functionality in disease is uncertain. Objective: To define a functional phenotype for T(H)9-driven pathology in vivo. Methods: We used fluorescence-activated cell sorting to identify circulating T(H)9 cells in atopic and nonatopic subjects. In mice we utilized a model of allergic airways disease induced by house dust mite to determine T(H)9 cell function in vivo and the role of activin A in T(H)9 generation. Results: Allergic patients have elevated T(H)9 cell numbers in comparison to nonatopic donors, which correlates with elevated IgE levels. In a murine model, allergen challenge with house dust mite leads to rapid T(H)9 differentiation and proliferation, with much faster kinetics than for T(H)2 cell differentiation, resulting in the specific recruitment and activation of mast cells. The TGF-beta superfamily member activin A replicates the function of TGF-beta 1 in driving the in vitro generation of T(H)9 cells. Importantly, the in vivo inhibition of T(H)9 differentiation induced by allergen was achieved only when activin A and TGF-beta were blocked in conjunction but not alone, resulting in reduced airway hyperreactivity and collagen deposition. Conversely, adoptive transfer of T(H)9 cells results in enhanced pathology. Conclusion: Our data identify a distinct functional role for T(H)9 cells and outline a novel pathway for their generation in vitro and in vivo. Functionally, T(H)9 cells promote allergic responses resulting in enhanced pathology mediated by the specific recruitment and activation of mast cells in the lungs. (J Allergy Clin Immunol 2012;129:1000-10.)	[Jones, Carla P.; Gregory, Lisa G.; Causton, Benjamin; Campbell, Gaynor A.; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Fac Med, Natl Heart & Lung Inst, London SW7 2AZ, England	Imperial College London	Lloyd, CM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Fac Med, Natl Heart & Lung Inst, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk		Jones, Carla P/0000-0002-4329-3267; Gregory, Lisa/0000-0003-2199-5417; Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust [057704, 085851/Z/08/Z]; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by the Wellcome Trust (grant nos. 057704 and 085851/Z/08/Z).	Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Angkasekwinai P, 2010, NAT IMMUNOL, V11, P250, DOI 10.1038/ni.1846; Carotta S, 2010, IMMUNOL REV, V238, P63, DOI 10.1111/j.1600-065X.2010.00955.x; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Fawaz LM, 2007, J ALLERGY CLIN IMMUN, V120, P1208, DOI 10.1016/j.jaci.2007.08.022; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Funaba M, 2003, J BIOL CHEM, V278, P52032, DOI 10.1074/jbc.M306991200; Gregory LG, 2010, AM J RESP CRIT CARE, V182, P143, DOI 10.1164/rccm.200905-0725OC; Huber S, 2011, CRIT REV IMMUNOL, V31, P53; Huber S, 2009, J IMMUNOL, V182, P4633, DOI 10.4049/jimmunol.0803143; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Karagiannidis C, 2006, J ALLERGY CLIN IMMUN, V117, P111, DOI 10.1016/j.jaci.2005.09.017; Kariyawasam HH, 2009, J ALLERGY CLIN IMMUN, V124, P454, DOI 10.1016/j.jaci.2009.06.022; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Matsuzawa S, 2003, J IMMUNOL, V170, P3461, DOI 10.4049/jimmunol.170.7.3461; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Neill DR, 2010, IMMUNOL CELL BIOL, V88, P502, DOI 10.1038/icb.2010.43; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Noelle RJ, 2010, NAT REV IMMUNOL, V10, P683, DOI 10.1038/nri2848; Nowak EC, 2009, CELL CYCLE, V8, P3798, DOI 10.4161/cc.8.23.10069; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; Soroosh P, 2009, IMMUNOLOGY, V127, P450, DOI 10.1111/j.1365-2567.2009.03114.x; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Tan CY, 2010, J IMMUNOL, V185, P6795, DOI 10.4049/jimmunol.1001676; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659	33	124	135	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1000	U512		10.1016/j.jaci.2011.12.965	http://dx.doi.org/10.1016/j.jaci.2011.12.965			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22277204	Green Accepted			2022-12-18	WOS:000302144600015
J	O'Regan, GM; Sandilands, A; McLean, WHI; Irvine, AD				O'Regan, Grainne M.; Sandilands, Aileen; McLean, W. H. Irwin; Irvine, Alan D.			Filaggrin in atopic dermatitis (Reprinted from J Allergy Clin Immunol vol 122, pg 689-93, 2008)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Reprint						atopic dermatitis; barrier function; cornified cell envelope; eczema; epidermal differentiation complex; filaggrin; ichthyosis vulgaris; natural moisturizing factor; pH; proteases; Staphylococcus aureus	OF-FUNCTION MUTATIONS; GENE; BARRIER; ECZEMA; PREDISPOSE; POPULATION; VARIANTS; ASTHMA; RISK	The recent identification of loss-of-function mutations in the structural protein filaggrin as a widely replicated major risk factor for eczema sheds new light on disease mechanisms in eczema, a disease that had heretofore largely been considered to have a primarily immunologic etiopathogenesis. The filaggrin gene (FLG) mutation findings are consistent with a recently proposed unifying hypothesis that offers a mechanistic understanding of eczema pathogenesis synthesizing a heritable epithelial barrier defect and resultant diminished epidermal defense mechanisms to allergens and microbes, followed by polarized T(H)2 lymphocyte responses with resultant chronic inflammation, including autoimmune mechanisms. Although compelling evidence from genetic studies on FLG implicates perturbed barrier function as a key player in the pathogenesis of eczema in many patients, much is still unknown about the sequence of biologic, physicochemical, and aberrant regulatory events that constitute the transition from an inherited barrier defect to clinical manifestations of inflammatory eczematous lesions and susceptibility to related atopic disorders. The exact contribution of FLG to the wider atopic story, factors modifying FLG expression, and the role of other barrier proteins remain to be delineated. In this review we highlight recent advances in our understanding of the FLG genetics in the cause of eczema and related complex diseases. (Reprinted from J Allergy Clin Immunol 2008; 122: 689-93.)	[O'Regan, Grainne M.; Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin 12, Ireland; [Sandilands, Aileen; McLean, W. H. Irwin] Epithelial Genet Grp, Div Mol Med, Dundee, Scotland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland	National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; University of Dundee; Trinity College Dublin	Irvine, AD (corresponding author), Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin 12, Ireland.	irvinea@tcd.ie	McLean, William HI/C-6352-2009; Irvine, Alan D/A-3982-2008	Irvine, Alan D/0000-0002-9048-2044; McLean, William Henry Irwin/0000-0001-5539-5757	MRC [G0700314] Funding Source: UKRI; Medical Research Council [G0700314] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McLean WHI, 2008, J ALLERGY CLIN IMMUN, V121, P1294, DOI 10.1016/j.jaci.2008.02.039; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Sevilla LM, 2007, J CELL BIOL, V179, P1599, DOI 10.1083/jcb.200706187; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stemmler S, 2007, J INVEST DERMATOL, V127, P722, DOI 10.1038/sj.jid.5700579; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014	26	124	127	0	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3		2			R2	R6		10.1016/j.jaci.2009.07.013	http://dx.doi.org/10.1016/j.jaci.2009.07.013			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553NC	19720209				2022-12-18	WOS:000274372800002
J	Gern, JE; Brooks, GD; Meyer, P; Chang, A; Shen, KL; Evans, MD; Tisler, C; DaSilva, D; Roberg, KA; Mikus, LD; Rosenthal, LA; Kirk, CJ; Shult, PA; Bhattacharya, A; Li, ZH; Gangnon, R; Lemanske, RF				Gern, JE; Brooks, GD; Meyer, P; Chang, A; Shen, KL; Evans, MD; Tisler, C; DaSilva, D; Roberg, KA; Mikus, LD; Rosenthal, LA; Kirk, CJ; Shult, PA; Bhattacharya, A; Li, ZH; Gangnon, R; Lemanske, RF			Bidirectional interactions between viral respiratory illnesses and cytokine responses in the first year of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; rhinoviruses; wheezing; IL-13; cytokines; viral infections; bronchiolitis; IFN-gamma; atopy; birth cohort	SYNCYTIAL VIRUS BRONCHIOLITIS; GAMMA PRODUCTION; 1ST YEAR; INFECTIONS; ASTHMA; IL-13; ATOPY; INTERLEUKIN-13; SENSITIZATION; CHILDREN	Background: Viral infections are the major cause of acute wheezing illnesses in childhood. Variations in immunologic responses at birth may be determinants of the risk of acquiring these illnesses. Objectives: To determine the immunologic risk factors for virus-induced wheezing in high-risk infants. Methods: The study involves 285 children with a parental history of asthma and/or respiratory allergies. Mononuclear cells obtained at birth (umbilical cord blood) and at 1 year of age were incubated with phytohemagglutinin, respiratory syncytial virus, or rhinovirus, and supernatants were analyzed for IL-5, IL-10, IL-13, and IFN-gamma. Nasal secretions obtained at well child visits and during respiratory illnesses were analyzed for common respiratory viruses. Results: Respiratory syncytial virus-induced wheezing was associated with reduced phytohemagglutinin-induced IL-13 responses (medians, 213 vs 304 mu g/mL; P = .026) from cord blood cells, and similar trends were found for wheezing in general. Furthermore, median IL-13 responses diminished by 28% in nonwheezing children by age 1 year, versus only 3% in wheezing children (P = .013). Children with >= 2 episodes of wheezing had lower phytohemagglutinin-induced IFN-gamma responses and were less likely to have rhinovirus-induced IFN-gamma responses at birth (P < .05). Finally, children with measurable cord blood IFN responses to respiratory syncytial virus were less likely to wheeze in their first year (odds ratio, 0.43 [0.23, 0.79]). Conclusion: In children with a family history of allergies and/or asthma, mononuclear cell phytohemagglutinin-induced IL-13 and virus-induced IFN-gamma responses at birth are indicative of the risk for wheezing in the first year of life.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Beijing Childrens Hosp, Beijing, Peoples R China; Wisconsin State Lab Hyg, Madison, WI USA; Univ Buenos Aires, Buenos Aires, DF, Argentina	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Capital Medical University; University of Buenos Aires	Gern, JE (corresponding author), Univ Wisconsin Hosp, K4-918 CSC,600 Highland Ave, Madison, WI 53792 USA.		Rosenthal, Louis/A-8868-2008	Gangnon, Ronald/0000-0003-2587-6714; Evans, Michael/0000-0001-7449-3993	NCRR NIH HHS [5M01 RR03186-18] Funding Source: Medline; NHLBI NIH HHS [R01HL61879-01, P01HL70831-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P01HL070831] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bogdan C, 1997, J IMMUNOL, V159, P4506; Bont L, 2000, AM J RESP CRIT CARE, V161, P1518, DOI 10.1164/ajrccm.161.5.9904078; Choi EH, 2002, J INFECT DIS, V186, P1207, DOI 10.1086/344310; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Gern JE, 2002, PEDIAT ALLERG IMM-UK, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Haeberle HA, 2002, J INFECT DIS, V186, P1199, DOI 10.1086/344644; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Holt PG, 2002, EUR RESPIR J, V19, P538, DOI 10.1183/09031936.02.00229302; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Hull J, 2003, J INFECT DIS, V188, P904, DOI 10.1086/377587; Krishnan S, 2004, VIRAL IMMUNOL, V17, P220, DOI 10.1089/0882824041310612; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lahti M, 2002, PEDIATR RES, V51, P696, DOI [10.1203/00006450-200206000-00006, 10.1023/01.PDR.0000015911.65104.93]; Legg JP, 2002, ARCH DIS CHILD, V86, P431, DOI 10.1136/adc.86.6.431; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Miles E A, 1994, Pediatr Allergy Immunol, V5, P202, DOI 10.1111/j.1399-3038.1994.tb00240.x; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Shay DK, 2001, J INFECT DIS, V183, P16, DOI 10.1086/317655; Sorkness RL, 2002, J ALLERGY CLIN IMMUN, V110, P607, DOI 10.1067/mai.2002.128241; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142	33	124	125	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					72	78		10.1016/j.jaci.2005.10.002	http://dx.doi.org/10.1016/j.jaci.2005.10.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387587				2022-12-18	WOS:000235687100012
J	Contopoulos-Ioannidis, DG; Manoli, EN; Ioannidis, JPA				Contopoulos-Ioannidis, DG; Manoli, EN; Ioannidis, JPA			Meta-analysis of the association of beta 2-adrenergic receptor polymorphisms with asthma phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta 2-adrenergic receptor; asthma; polymorphism; nocturnal asthma; bronchial hyperresponsiveness	BETA(2)-ADRENERGIC RECEPTOR; BRONCHIAL HYPERRESPONSIVENESS; GENETIC POLYMORPHISMS; AIRWAY RESPONSIVENESS; BETA(2) ADRENOCEPTOR; NOCTURNAL ASTHMA; LUNG-FUNCTION; HAPLOTYPES; CHILDREN; POPULATION	Background: Two common polymorphisms of the beta 2-adrenergic receptor gene (Arg16Gly and Gln27Glu) have been extensively studied for their possible association with asthma-related phenotypes, but the results of individual studies have been inconclusive. Objective: We aimed to integrate quantitatively the available evidence on the association of the Arg16Gly and the Gln27Gu polymorphisms with asthma, nocturnal asthma, asthma severity, and bronchial hyperresponsiveness. Methods: Meta-analysis of case-control and cohort studies using random effects models. Results: A total of 28 studies were included in the meta-analysis. The summary estimates suggested that neither the Gly16 nor the Glu27 allele contributes to asthma susceptibility overall (odds ratio [OR], 1.01; 95% CI, 0.90-1.13; and OR, 0.95; 95% CI, 0.83-1.09, respectively) or to bronchial hyperresponsiveness (OR, 0.90; 95% CI, 0.77-1.05; and OR, 1.07; 95% CI, 0.94-1.22, respectively). There was a strong association of Glyl 6 with nocturnal asthma (OR, 2.20; 95% CI, 1.56-3.11) and a less strong association with severe or moderate rather than milder asthma (OR, 1.42; 95% CI, 1.04-1.94). No such effects were seen for the Glu27 allele (OR, 1.02; 95% CI, 0.74-1.40; and OR, 0.82; 95% CI, 0.59-1.14, respectively). Moreover, there was evidence that Gly16 homozygotes had a much higher risk for nocturnal asthma (OR, 5.15; 95% CI, 2.44-10.84) and asthma severity (OR, 2.84; 95% CI, 1.62-4.96) than the Arg16 homozygotes. Conclusion: The Gly16 allele of the beta 2-adrenergic receptor gene predisposes to nocturnal asthma, and this may also explain the association with asthma severity. Neither polymorphism modulates the risk for bronchial hyperresponsiveness or mild asthma.	Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA; Univ Ioannina, Sch Med, Dept Pediat, GR-45110 Ioannina, Greece; Biomed Res Inst, Fdn Res & Technol Hellas, Ioannina, Greece; Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Dept Med,New England Med Ctr, Boston, MA 02111 USA	University of Ioannina; George Washington University; University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Tufts Medical Center; Tufts University	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011					BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Binaei S, 2003, CHEST, V123, p375S, DOI 10.1016/S0012-3692(15)35221-1; Calhoun WJ, 2003, CHEST, V123, p399S, DOI 10.1378/chest.123.3_suppl.399S; Carey VJ, 1996, AM J RESP CRIT CARE, V153, P356, DOI 10.1164/ajrccm.153.1.8542143; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; Dai Lu-ming, 2004, Sichuan Da Xue Xue Bao Yi Xue Ban, V35, P32; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Fenech A, 2002, BRIT J CLIN PHARMACO, V53, P3, DOI 10.1046/j.0306-5251.2001.01509.x; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Fowler SJ, 2000, AM J RESP CRIT CARE, V162, P1318, DOI 10.1164/ajrccm.162.4.9912103; Fu Jin, 2002, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V19, P41; Gao Guangkai, 2000, Zhonghua Jiehe He Huxi Zazhi, V23, P93; Gao Jin-ming, 2002, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V24, P626; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Holloway JW, 2000, CLIN EXP ALLERGY, V30, P1097; Hopes E, 1998, BRIT MED J, V316, P664, DOI 10.1136/bmj.316.7132.664; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Johnatty SE, 2002, BRIT J PHARMACOL, V137, P1213, DOI 10.1038/sj.bjp.0704935; Kim SH, 2002, J ALLERGY CLIN IMMUN, V109, P630, DOI 10.1067/mai.2002.122842; Kotani Y, 1999, J ASTHMA, V36, P583, DOI 10.3109/02770909909087295; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Liggett SB, 2000, PHARMACOLOGY, V61, P167, DOI 10.1159/000028397; Lin YC, 2003, J ASTHMA, V40, P265, DOI 10.1081/JAS-120018323; Lipworth BJ, 1999, CHEST, V115, P324, DOI 10.1378/chest.115.2.324; Litonjua AA, 2004, CHEST, V126, P66, DOI 10.1378/chest.126.1.66; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P861, DOI 10.1164/ajrccm.165.7.2109096; Petitti D, 1994, METAANALYSIS DECISIO; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Santillan AA, 2003, J ALLERGY CLIN IMMUN, V112, P1095, DOI 10.1016/j.jaci.2003.09.029; Sato R, 2000, Hokkaido Igaku Zasshi, V75, P81; Shachor J, 2003, ISRAEL MED ASSOC J, V5, P821; Strauch E, 2001, PEDIATR PULM, V31, P44, DOI 10.1002/1099-0496(200101)31:1<44::AID-PPUL1006>3.0.CO;2-2; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Turner SW, 2004, CLIN EXP ALLERGY, V34, P1043, DOI 10.1111/j.1365-2222.2004.02001.x; Ulbrecht M, 2000, AM J RESP CRIT CARE, V161, P469, DOI 10.1164/ajrccm.161.2.9902072; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404, DOI 10.1164/ajrccm.163.6.2001101; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035; Winterton DL, 2001, ANN ALLERG ASTHMA IM, V86, P232, DOI 10.1016/S1081-1206(10)62697-X; Xie HG, 1999, PHARMACOGENETICS, V9, P511	51	124	132	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					963	972		10.1016/j.jaci.2004.12.1119	http://dx.doi.org/10.1016/j.jaci.2004.12.1119			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867853				2022-12-18	WOS:000229055100011
J	Zanconato, S; Carraro, S; Corradi, M; Alinovi, R; Pasquale, MF; Piacentini, G; Zacchello, F; Baraldi, E				Zanconato, S; Carraro, S; Corradi, M; Alinovi, R; Pasquale, MF; Piacentini, G; Zacchello, F; Baraldi, E			Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; exhaled breath condensate; cysteinylleukotrienes; 8-isoprostane; exhaled nitric oxide; oxidative stress	NITRIC-OXIDE; AIRWAY INFLAMMATION; DIFFICULT ASTHMA; DISEASE SEVERITY; SPUTUM; PROSTAGLANDINS; ISOPROSTANES; COLLECTION; SYMPTOMS; STRESS	Background: Cysteinyl-leukotrienes (cys-LTs) and 8-isoprostane are biomarkers of airway inflammation and oxidative stress. Objective: The aim of this study was to evaluate cys-LT and 8-isoprostane levels in exhaled breath condensate (EBC) of children with different degrees of asthma severity. Methods: EBC was collected from 14 steroid-naive children with mild persistent asthma, 13 children with stable mild-to-moderate persistent asthma treated with inhaled corticosteroids (ICS), 9 ICS-treated children with unstable asthma, and 19 healthy children. Results: In the three groups of asthmatic children, EBC concentrations of cys-LTs and 8-isoprostane were significantly higher than in control children (steroid-naive asthmatic children: cys-LTs median, 10.8 pg/mL, P < .001, 8-isoprostane, 16.2 pg/mL, P < .001; ICS-treated stable asthmatic children: cys-LTs , 12.7 pg/mL, P < .001, 8-isoprostane, 18.1 pg/mL, P < .001; children with unstable asthma: cys-LTs, 106.0 pg/mL, P < .01, 8-isoprostane, 29.7 pg/mL, P < .01; control children: cys-LTs,, 4.3 pg/mL, 8-isoprostane, 3.5 pg/mL). Cys-LT levels were higher in children with unstable asthma than in the other two asthmatic groups (P < .05). FENO levels were significantly higher in steroid-naive and in children with unstable asthma compared with ICS-treated children with stable asthma (P < .01). Conclusions: Our study shows that EBC cys-LTs and 8-iso-prostane concentrations are higher in asthmatic children than in healthy control children, with scattered values in patients with unstable asthma. These findings suggest that EBC eicosanoid measurement may have useful clinical implications for investigating phenotype differences among asthmatic patients.	Univ Padua, Dept Pediat, I-35128 Padua, Italy; Univ Parma, Lab Ind Toxicol, Dept Clin Med Nephrol & Hlth Sci, Parma, Italy; Univ Verona, Dept Pediat, I-37100 Verona, Italy	University of Padua; University of Parma; University of Verona	Baraldi, E (corresponding author), Univ Padua, Dept Pediat, Via Giustiniani 3, I-35128 Padua, Italy.		baraldi, eugenio/AAC-5233-2022	corradi, massimo/0000-0002-2808-4184; BARALDI, EUGENIO/0000-0002-1829-3652				Baraldi E, 2003, THORAX, V58, P505, DOI 10.1136/thorax.58.6.505; Baraldi E, 2003, ARCH DIS CHILD, V88, P358, DOI 10.1136/adc.88.4.358; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Biernacki WA, 2003, THORAX, V58, P294, DOI 10.1136/thorax.58.4.294; Bisgaard H, 2001, PEDIATRICS, V107, P381, DOI 10.1542/peds.107.2.381; Corradi M, 2003, AM J RESP CRIT CARE, V167, P395, DOI 10.1164/rccm.200206-507OC; Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203-233OC; Dworski R, 1999, AM J RESP CRIT CARE, V160, P1947, DOI 10.1164/ajrccm.160.6.9903064; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Frew AJ, 2002, J ALLERGY CLIN IMMUN, V109, P210, DOI 10.1067/mai.2002.121950; Gaston B, 2003, AM J RESP CRIT CARE, V167, P292, DOI 10.1164/rccm.2211005; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273, DOI 10.1164/ajrccm.162.4.9912064; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067, DOI 10.1152/ajplung.2001.280.6.L1067; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Montuschi P, 2003, THORAX, V58, P585, DOI 10.1136/thorax.58.7.585; Montuschi P, 2002, J ALLERGY CLIN IMMUN, V109, P615, DOI 10.1067/mai.2002.122461; Mutlu GM, 2001, AM J RESP CRIT CARE, V164, P731, DOI 10.1164/ajrccm.164.5.2101032; *NAT ASTHM ED PREV, 1997, NIH PUBL; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; Payne DNR, 2001, THORAX, V56, P345, DOI 10.1136/thorax.56.5.345; PEERS SH, 1990, AM REV RESPIR DIS, V141, pS18; Romagnoli M, 2002, EUR RESPIR J, V20, P1370, DOI 10.1183/09031936.02.00029202; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; Vass G, 2003, AM J RESP CRIT CARE, V167, P850, DOI 10.1164/rccm.200207-716BC; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; Wood LG, 2000, LIPIDS, V35, P967, DOI 10.1007/s11745-000-0607-x	33	124	132	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					257	263		10.1016/j.jaci.2003.10.046	http://dx.doi.org/10.1016/j.jaci.2003.10.046			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767439				2022-12-18	WOS:000188885700012
J	Linneberg, A; Ostergaard, C; Tvede, M; Andersen, LP; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T				Linneberg, A; Ostergaard, C; Tvede, M; Andersen, LP; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T			IgG antibodies against microorganisms and atopic disease in Danish adults: The Copenhagen Allergy Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; atopy; Campylobacter jejuni; Clostridium difficile; Helicobacter pylori; hepatitis A virus; respiratory hypersensitivity; Toxoplasma gondii	HEPATITIS-A; INTESTINAL MICROFLORA; HELICOBACTER-PYLORI; HAY-FEVER; PREVALENCE; INFECTION; HYGIENE; ASTHMA; POPULATION; EXPOSURE	Background: Seropositivity to food-borne and orofecal microorganisms (hepatitis A virus, Helicobacter pylori, and Toxoplasma gondii), which are considered to be markers of poor hygiene, has been reported to be associated with a lower prevalence of atopy. In contrast, colonization of the gut with Clostridium difficile, a potential intestinal bacterial pathogen, in early childhood may be associated with a higher prevalence of atopy. Objective: The objective of this study was to investigate the association between atopy and exposure to 2 groups of food-borne and orofecal microorganisms: (1) markers of a poor hygiene and (2) intestinal bacterial pathogens. Methods: A cross-sectional population-based study of 15- to 69-year-olds living in Copenhagen, Denmark, was carried out in 1990 to 1991. Atopy was defined as a positive test result for specific IgE to at least 1 of 6 inhalant allergens. Exposure to microorganisms was assessed as IgG seropositivity to microorganisms. Results: Seropositivity to 2 or 3 markers of poor hygiene (hepatitis A virus, H pylori, and T gondii) was associated with a lower prevalence of atopy (adjusted odds ratio, 0.5; 95% CI, 0.3 to 0.8). In contrast, seropositivity to 2 or 3 intestinal bacterial pathogens (C difficile, Campylobacter jejuni, and Yersinia enterocolitica) was associated with a higher prevalence of atopy (adjusted odds ratio, 1.7; 95% Cl, 1.2 to 2.6). Conclusion: Exposure to markers of poor hygiene was associated with a lower prevalence of atopy, whereas exposure to intestinal bacterial pathogens was associated with a higher prevalence of atopy. These findings raise the hypothesis that different groups of food-borne and orofecal microorganisms may have different effects on the risk of atopy.	Glostrup Univ Hosp, Ctr Prevent Med, DK-2600 Glostrup, Denmark; Statens Serum Inst, Dept Res & Dev, DK-2300 Copenhagen, Denmark; Natl Univ Hosp, Dept Clin Microbiol, Rigshosp, Copenhagen, Denmark; Gentofte Univ Hosp, Dept Dermatol, Copenhagen, Denmark; Frederiksberg Univ Hosp, Dept Internal Med B, DK-2000 Copenhagen, Denmark; Gentofte Univ Hosp, Dept Resp Med Y, Copenhagen, Denmark	University of Copenhagen; Statens Serum Institut; Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital	Linneberg, A (corresponding author), Glostrup Univ Hosp, Ctr Prevent Med, 57 Ndr Ringvej,Entrance 8,7th Floor, DK-2600 Glostrup, Denmark.		Jørgensen, Torben/Z-1335-2018	Linneberg, Allan/0000-0002-0994-0184; Jorgensen, Torben/0000-0001-9453-2830; Madsen, Flemming/0000-0002-9911-0175				ANDERSEN LP, 1991, P 5 INT WORKSH CAMP; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; BOUSQUET J, 1908, J ALLERGY CLIN IMMUN, V108, P147; BRIEM H, 1991, SCAND J INFECT DIS, V23, P135, DOI 10.3109/00365549109023390; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P252; Crane J, 2002, ALLERGY, V57, P663, DOI 10.1034/j.1398-9995.2002.25004.x; FORSGREN M, 1991, LANCET, V337, P1413, DOI 10.1016/0140-6736(91)93095-Q; Gdalevich M, 1998, EPIDEMIOL INFECT, V121, P477, DOI 10.1017/S0950268898001198; JOHANSEN HK, 1995, CLIN DIAGN LAB IMMUN, V2, P149, DOI 10.1128/CDLI.2.2.149-155.1995; Joussemet M, 1999, GASTROEN CLIN BIOL, V23, P447; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Klingler PJ, 2000, DIGEST DIS, V18, P147, DOI 10.1159/000051388; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; NIELSEN NH, 1993, ALLERGY, V48, P319, DOI 10.1111/j.1398-9995.1993.tb02400.x; NOGUCHI A, 1991, J INFECTION, V23, P255, DOI 10.1016/0163-4453(91)92828-S; PEREZTRALLERO E, 1994, SCAND J INFECT DIS, V26, P133, DOI 10.3109/00365549409011775; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strid MA, 2001, CLIN DIAGN LAB IMMUN, V8, P314, DOI 10.1128/CDLI.8.2.314-319.2001; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; WALKER J, 1992, EPIDEMIOL INFECT, V108, P99, DOI 10.1017/S0950268800049542; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x	34	124	126	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					847	853		10.1067/mai.2003.1335	http://dx.doi.org/10.1067/mai.2003.1335			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704368	Bronze			2022-12-18	WOS:000182258500028
J	Elberink, JNGO; de Monchy, JGR; van der Heide, S; Guyatt, GH; Dubois, AEJ				Elberink, JNGO; de Monchy, JGR; van der Heide, S; Guyatt, GH; Dubois, AEJ			Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						venom immunotherapy; EpiPen; quality of life; Hymenoptera allergy; insect allergy; yellow jacket allergy; number needed to treat; minimal important difference; Vespid Allergy Quality-of-Life Questionnaire	HYPERSENSITIVITY; TRIALS; SAFETY; STINGS	Background: Venom immunotherapy (VIT) is effective in preventing anaphylactic reactions after insect stings. The effect of VIT on health-related quality of life (HRQL) was studied to evaluate whether this treatment is of importance to patients. Objective: We compared HRQL outcomes measured with a disease-specific instrument (Vespid Allergy Quality-of-Life Questionnaire [VQLQ]) in patients allergic to yellow jacket venom treated with VIT or with an adrenalin self-administration device (EpiPen) in an open-label, randomized, controlled trial. Methods: Consenting patients were block randomized to either VIT or EpiPen. Patients received uniform, standardized information, which specified the risk of their condition and the risks and benefits of both treatment options. HRQL measures took place before and after 1 year of treatment with VIT or EpiPen. Results: Seventy-four patients agreed to be randomized, of whom 36 received VIT and 38 an EpiPen. The mean change in VQLQ score in the group randomized to VIT was 1.07 (95% CI, 0.68-1.46), and this improvement was statistically significant (P <.0001) compared with that seen in the group randomized to the EpiPen, in which this change was -0.43 (95% CI, -0.71 to -0.16). These differences Acre seen in both men and women, persons with more or less general anxiety, and those stung recently and those stung more than a year before their outpatient department visit. The overall proportion of patients receiving benefit from VIT is 0.72, generating a number needed to treat of 1.4. Conclusions: VIT results in a clinically important improvement in HRQL in patients allergic to yellow jacket venom in;all subgroups studied. Of every 3 patients treated with VIT, 2 patients experience an important improvement in their quality of life.	Univ Groningen Hosp, Dept Allergol, NL-9700 RB Groningen, Netherlands; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada	University of Groningen; McMaster University	Elberink, JNGO (corresponding author), Univ Groningen Hosp, Dept Allergol, POB 30-001, NL-9700 RB Groningen, Netherlands.							Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; Elberink JNGO, 1999, J ALLERGY CLIN IMMUN, V103, pS182; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; GOLDEN DBK, 1985, ALLERGY; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MOSBECH H, 1983, ALLERGY, V38, P195, DOI 10.1111/j.1398-9995.1983.tb01606.x; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1995, AM ACAD ALLERGY MONO, P129; Prahlow JA, 1998, AM J FOREN MED PATH, V19, P137, DOI 10.1097/00000433-199806000-00007; REISMAN RE, 1994, J ALLERGY CLIN IMMUN, V94, P651, DOI 10.1016/0091-6749(94)90167-8; RUBENSTEIN HS, 1982, LANCET, V1, P496; Spielberger C.D., 1970, STAI MANUAL; Van Cauwenberge P, 2000, CLIN EXP ALLERGY, V30, P891; van der Linden P W, 1993, Ned Tijdschr Geneeskd, V137, P2194; YUNGINGER JW, 1998, ALLERGY PRINCIPLES P, P1063	20	124	126	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					174	182		10.1067/mai.2002.125827	http://dx.doi.org/10.1067/mai.2002.125827			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110838				2022-12-18	WOS:000176870300030
J	Fujisawa, T; Fujisawa, R; Kato, Y; Nakayama, T; Morita, A; Katsumata, H; Nishimori, H; Iguchi, K; Kamiya, H; Gray, PW; Chantry, D; Suzuki, R; Yoshie, O				Fujisawa, T; Fujisawa, R; Kato, Y; Nakayama, T; Morita, A; Katsumata, H; Nishimori, H; Iguchi, K; Kamiya, H; Gray, PW; Chantry, D; Suzuki, R; Yoshie, O			Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; chemokine; chemokine receptor; platelet; T(H)2 eosinophil	T-CELLS; RECEPTOR; EXPRESSION; EOTAXIN; BLOOD; MDC; RANTES; SDF-1; TARC	Background: T(H)2 cells and eosinophils selectively express CC chemokine receptor 4 and CCR3, respectively, and their chemokine ligands are likely to play important roles in the pathogenesis of atopic dermatitis (AD). Objective: The purpose of this study was to demonstrate the presence of thymus and activation-regulated chemokine (TARC) in platelets and its release during clotting and to evaluate the circulating levels of TARC, macrophage-derived chemokine (MDC), and eotaxin in control subjects and patients with AD. Methods: We compared plasma and serum contents of TARC, MDC, and eotaxin. We measured TARC contents in platelet lysates. We analyzed the correlation of plasma levels of TARC, MDC, and eotaxin with various clinicolaboratory parameters in patients with AD. Results: Serum contents of TARC rapidly, increased during clotting, whereas those or MDC and eotaxin increased only slightly. We demonstrated that platelets contained TARC, and its levels were dramatically elevated in patients with AD. Platelets also released TARC on stimulation with thrombin. We therefore evaluated circulating levels of these chemokines in control subjects and patients with AD by using plasma samples. Plasma TARC levels were significantly increased in patients with AD (P <.0001) and showed significant correlations with severity scoring of atopic dermatitis (SCORAD) index (r = 0.665, P <.00001), serum lactate dehydrogenese levels (r = 0.696, P= .00001), cosinophil counts (r = 0.381, P = .007), and platelet counts (r = 0.562, P <.0001). Similarly, plasma MDC levels were significantly increased in patients with AD (P <.0001) and showed significant correlations with SCORAD index (r = 0.727, P <.0001), serum lactate dehydrogenese levels (r = 0.861, P <.0001), eosinophil counts (r = 0.505, P = .005), and platelet counts (r = 0.370, P = .01). On treatment, plasma TARC and MDC levels were dramatically decreased in accordance with improved SCORAD scores (P = .0012 and P = .0007, respectively). On the other hand, plasma eotaxin levels did not show any significant increase or correlation with any of the clinical parameters in patients with AD. Conclusion: Platelets from patients with AD contain high levels of TARC. Thus platelets might play an important role in AD pathogenesis by releasing T(H)2-attracting TARC on activation. Furthermore, circulating levels of TARC and MDC, but not those of eotaxin, correlate well with the disease activity of AD.	Natl Mie Hosp, Dept Pediat & Allergy, Tsu, Mie 5140125, Japan; Kinki Univ, Sch Med, Dept Microbiol, Osaka 589, Japan; Shionogi Inst Med Sci, Osaka, Japan; ICOS Corp, Bothell, WA USA	Kindai University (Kinki University); Shionogi & Company Limited; Icos Corporation	Fujisawa, T (corresponding author), Natl Mie Hosp, Dept Pediat & Allergy, 357 Osato Kubota, Tsu, Mie 5140125, Japan.			Yoshie, Osamu/0000-0003-4353-5809				Abi-Younes S, 2001, THROMB RES, V101, P279, DOI 10.1016/S0049-3848(00)00402-3; Andrew DP, 2001, J IMMUNOL, V166, P103, DOI 10.4049/jimmunol.166.1.103; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; Brandt E, 2000, J LEUKOCYTE BIOL, V67, P471, DOI 10.1002/jlb.67.4.471; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; CELLA G, 1981, NEW ENGL J MED, V305, P892; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587, DOI 10.1164/ajrccm/142.3.587; COYLE AJ, 1990, BRIT J PHARMACOL, V101, P31, DOI 10.1111/j.1476-5381.1990.tb12084.x; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V106, P507; Galli G, 2000, EUR J IMMUNOL, V30, P204, DOI 10.1002/1521-4141(200001)30:1<204::AID-IMMU204>3.0.CO;2-G; Gear ARL, 2001, BLOOD, V97, P937, DOI 10.1182/blood.V97.4.937; Gluck Joanna, 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P367; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hasegawa S, 1999, BLOOD, V93, P2543, DOI 10.1182/blood.V93.8.2543.408k14_2543_2551; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hossny E, 2001, ALLERGY, V56, P996, DOI 10.1034/j.1398-9995.2001.00169.x; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KLINGER MHF, 1995, INT ARCH ALLERGY IMM, V107, P541, DOI 10.1159/000237097; Kowalska MA, 2000, BLOOD, V96, P50, DOI 10.1182/blood.V96.1.50.013k40_50_57; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; LUPINETTI MD, 1989, AM REV RESPIR DIS, V140, P932, DOI 10.1164/ajrccm/140.4.932; Morita A, 1999, J IMMUNOL METHODS, V226, P159, DOI 10.1016/S0022-1759(99)00066-6; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Nakatani T, 2001, J ALLERGY CLIN IMMUN, V107, P353, DOI 10.1067/mai.2001.112601; Nomiyama H, 2001, INT IMMUNOL, V13, P1021, DOI 10.1093/intimm/13.8.1021; PAGE CP, 1988, TRENDS PHARMACOL SCI, V9, P66, DOI 10.1016/0165-6147(88)90120-4; POWER CA, 1994, GENE, V151, P333, DOI 10.1016/0378-1119(94)90682-3; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Suttitanamongkol S, 2001, FEBS LETT, V490, P84, DOI 10.1016/S0014-5793(00)02413-3; Taha RA, 2000, J ALLERGY CLIN IMMUN, V105, P1002, DOI 10.1067/mai.2000.106483; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9	35	124	129	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					139	146		10.1067/mai.2002.126079	http://dx.doi.org/10.1067/mai.2002.126079			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110833				2022-12-18	WOS:000176870300025
J	Ray, NF; Baraniuk, JN; Thamer, M; Rinehart, CS; Gergen, PJ; Kaliner, M; Josephs, S; Pung, YH				Ray, NF; Baraniuk, JN; Thamer, M; Rinehart, CS; Gergen, PJ; Kaliner, M; Josephs, S; Pung, YH			Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinoconjunctivitis; allergic rhinitis; allergic conjunctivitis; cost of illness; health economics	COST-EFFECTIVENESS; UNITED-STATES; RHINITIS; ASTHMA; RISK; RESPONSIVENESS; IMMUNIZATION; SINUSITIS; CHILDREN	Background: Previous estimates of the national economic burden of allergic rhinoconjunctivitis (AR/AC) have relied on data analyses in which AR/AC was the primary International Classification of Diseases-ninth revision-Clinical Modification (ICD-9-CM)-coded diagnosis, These studies ignore the costs when AR/AC was a secondary diagnosis to other disorders such as asthma and sinusitis, Objective: We sought to determine the national direct cost of illness for AR/AC. Methods: An expert panel used the Delphi technique to estimate the proportion of visits coded by other primary ICD-9-CM diagnoses in which AR/AC was a significant secondary comorbid condition. The costs of this proportion,were deemed to be "attributable" to AR/AC and were added to the costs when allergic rhinitis and allergic conjunctivitis were the primary diagnoses. Results: The cost when AR/AC was the primary diagnosis was $1.9 billion (in 1996 dollars). The cost when AR/AC was a secondary diagnosis was estimated at $4.0 billion, giving an estimate of $5.9 billion for the overall direct medical expenditures attributable to AR/AC, Outpatient services (63%, $3.7 billion), medications (25%, $1.5 billion), and inpatient services (12%, $0.7 billion) accounted for the expenditures. Children 12 years and younger accounted for $2.3 billion (38.0%). Conclusion: Upper airway allergy is an expensive disease process because of its readily apparent manifestations as AR/AC and its contribution to other airway disorders.	Med Technol & Practice Patterns Inst, Washington, DC USA; Georgetown Univ, Sch Med, Washington, DC USA; US Dept HHS, Agcy Hlth Care Policy & Res, Rockville, MD 20852 USA; Washington Hosp Ctr, Inst Allergy & Asthma, Washington, DC 20010 USA	Georgetown University; Agency for Healthcare Research & Quality; MedStar Washington Hospital Center	Ray, NF (corresponding author), Medicare Payment Advisory Commiss, 1730 K St NW,Suite 800, Washington, DC 20006 USA.			Baraniuk, James Nicholas/0000-0002-1866-4177				ADAMS PF, 1995, VITAL HLTH STAT 10, V193, P94; AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; CAMPOSTRINI S, 1993, AM J PUBLIC HEALTH, V83, P1139, DOI 10.2105/AJPH.83.8.1139; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; Fireman P, 1997, ALLERGY ASTHMA PROC, V18, P135, DOI 10.2500/108854197778984428; GORDON JF, 1964, P2982 RAND CORP; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; KALINER M, 1992, JAMA-J AM MED ASSOC, V268, P2807, DOI 10.1001/jama.268.20.2807; KARLSSON G, 1994, ACTA OTO-LARYNGOL, P26; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LESLIE PJ, 1992, DIABETIC MED, V9, P379, DOI 10.1111/j.1464-5491.1992.tb01801.x; Linstone H. A., 1975, DELPHI METHOD; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; MARTIN JP, 1970, TECH FORECASTING, V3, P293; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; Melton LJ, 1997, J BONE MINER RES, V12, P16, DOI 10.1359/jbmr.1997.12.1.16; Newton DA, 1996, PRIMARY CARE, V23, P701, DOI 10.1016/S0095-4543(05)70358-4; ODDONE EZ, 1994, MED DECIS MAKING, V14, P19, DOI 10.1177/0272989X9401400103; ONORATO IM, 1989, MED DECIS MAKING, V9, P76, DOI 10.1177/0272989X8900900202; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; *US BUR CENS, CURR POP REP PPL21; *US BUR CENS, CURR POP REP P25, V1095; *US BUR LAB STAT, 1997, CONS PRIC IND HOSP R; *US DEP HHS, 1994, ICD9CM INT CLASS DIS; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Westley CR, 1997, ALLERGY ASTHMA PROC, V18, P15, DOI 10.2500/108854197778612835	34	124	125	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				401	407		10.1016/S0091-6749(99)70463-X	http://dx.doi.org/10.1016/S0091-6749(99)70463-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069872				2022-12-18	WOS:000079175700007
J	Sorensen, RU; Leiva, LE; Javier, FC; Sacerdote, DM; Bradford, N; Butler, B; Giangrosso, PA; Moore, C				Sorensen, RU; Leiva, LE; Javier, FC; Sacerdote, DM; Bradford, N; Butler, B; Giangrosso, PA; Moore, C			Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						S pneumoniae; pneumococcal polysaccharide vaccine; antibody; aged	PNEUMOCOCCAL ANTIBODY-TITERS; RESPIRATORY-TRACT INFECTIONS; OTITIS-MEDIA; POLYSACCHARIDE ANTIGENS; IGG SUBCLASS; CHILDREN; PENICILLIN; INFANTS; COLONIZATION; SERUM	Background: A deficient antibody response to polysaccharide antigens is determined by measuring the response to the 23-valent pneumococcal polysaccharide vaccine. However, the diagnosis of this specific antibody deficiency is hampered by the lack of sufficient data and standardized testing of the response to pneumococcal polysaccharides. Methods: All patients evaluated in our allergy/immunology clinic for recurrent respiratory infections between 1995 and 1997 without immunoglobulin, IgG subclass, or other known primary or secondary immunodeficiency were included in this analysis,IgG antipneumococcal serotypes 1, 3, 4, 6B, 9V, 14, 18C, 19F, and 23F were determined by a modified ELISA protocol. An adequate IgG antibody response to an individual serotype was arbitrarily defined as a postimmunization antibody titer of 1.3 mu g/ml or greater or at least four times the baseline value. Results: A total of 113 patients fulfilling the criteria for inclusion in this analysis were divided into five age groups. The geometric means for preimmunization and postimmunization pneumococcal antibody titers for all serotypes increased with age. For postimmunization antibody concentrations, there was a sharp increase in the specific antibody concentrations in adults in comparison with all pediatric age groups ranging in age from 7 months to 16 years. Similarly, the number of serotypes to which there was an adequate response also increased with age. Conclusion: We conclude that the definition of what constitutes an adequate response to pneumococcal immunization needs further definition. It is clear, however, that age has an important influence on the intensity of the response to most pneumococcal polysaccharides. Correlation studies between antibody concentrations in different IgG subclasses, functional studies, and protection studies against mucosal and invasive pneumococcal infections are in progress, and these should contribute to a refined definition of a normal response. The availability of a standardized method for the measurement of IgG antibodies against relevant pneumococcal serotypes is an important step toward this goal.	Louisiana State Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, New Orleans, LA 70112 USA; Childrens Hosp New Orleans, New Orleans, LA USA	Louisiana State University System; Children's Hospital of New Orleans	Sorensen, RU (corresponding author), Louisiana State Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, 1542 Tulane Ave, New Orleans, LA 70112 USA.							AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; AUSTRIAN R, 1977, JOHNS HOPKINS MED J, V141, P104; BAKER CJ, 1980, NEW ENGL J MED, V303, P173, DOI 10.1056/NEJM198007243030401; BARRETT DJ, 1984, PEDIATR RES, V18, P1067, DOI 10.1203/00006450-198411000-00001; BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005; Boken DJ, 1996, PEDIATR INFECT DIS J, V15, P667, DOI 10.1097/00006454-199608000-00006; BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; EPSTEIN MM, 1995, ANN ALLERG ASTHMA IM, V75, P125; FREIJD A, 1984, CLIN EXP IMMUNOL, V56, P233; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; Go ES, 1996, J ALLERGY CLIN IMMUN, V98, P205, DOI 10.1016/S0091-6749(96)70244-0; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; GROSS S, 1992, J PEDIATR-US, V121, P516, DOI 10.1016/S0022-3476(05)81137-0; HAMMARSTROM L, 1986, MONOGR ALLERGY, V19, P241; Hidalgo H, 1996, ANN ALLERG ASTHMA IM, V76, P341, DOI 10.1016/S1081-1206(10)60035-X; KNUTSEN AP, 1989, J ALLERGY CLIN IMMUN, V84, P640, DOI 10.1016/0091-6749(89)90203-0; KOSKELA M, 1987, PEDIATR INFECT DIS J, V6, P519, DOI 10.1097/00006454-198706000-00006; LAHOOD N, 1993, ANN ALLERGY, V70, P289; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LAWRENCE EM, 1983, AM J DIS CHILD, V137, P846, DOI 10.1001/archpedi.1983.02140350024007; PATON JC, 1986, AM J DIS CHILD, V140, P135, DOI 10.1001/archpedi.1986.02140160053031; QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590, DOI 10.1128/CDLI.2.5.590-597.1995; RUUSKANEN O, 1994, PEDIATR INFECT DIS J, V13, pS23, DOI 10.1097/00006454-199401001-00006; SANDERS LAM, 1995, PEDIATR RES, V37, P812, DOI 10.1203/00006450-199506000-00023; SANDERS LAM, 1993, J ALLERGY CLIN IMMUN, V91, P110, DOI 10.1016/0091-6749(93)90303-W; SNIADACK DH, 1995, PEDIATR INFECT DIS J, V14, P503, DOI 10.1097/00006454-199506000-00007; SORENSEN RU, 1994, PEDIATR CLIN N AM, V41, P691; Sorensen RU, 1996, PEDIATR PULM, V22, P167, DOI 10.1002/(SICI)1099-0496(199609)22:3<167::AID-PPUL5>3.0.CO;2-M; ZENNI MK, 1995, J PEDIATR-US, V127, P533, DOI 10.1016/S0022-3476(95)70108-7; ZORA JA, 1993, ANN ALLERGY, V70, P283	32	124	127	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					215	221		10.1016/S0091-6749(98)70089-2	http://dx.doi.org/10.1016/S0091-6749(98)70089-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723664				2022-12-18	WOS:000075537100012
J	Pastorello, EA; Conti, A; Pravettoni, V; Farioli, L; Rivolta, F; Ansaloni, R; Ispano, M; Incorvaia, C; Giuffrida, MG; Ortolani, C				Pastorello, EA; Conti, A; Pravettoni, V; Farioli, L; Rivolta, F; Ansaloni, R; Ispano, M; Incorvaia, C; Giuffrida, MG; Ortolani, C			Identification of actinidin as the major allergen of kiwi fruit	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; Actinidia chinensis; actinidin	CROSS-REACTIVITY; CATHEPSIN-H; PURIFICATION	Background: Allergic reactions to fruits and vegetables are among the most frequent food allergies in adults. Kiwi fruit (Actinidia chinensis) is commonly involved, causing local mucosal, systemic, or both types of symptoms by an IgE-mediated mechanism. In a previous study on 30 patients allergic to kiwi, we identified a major allergen of 30 kd against which all sera tested clearly reacted. Other allergens were detected at 12, 24, and 28 kd. Objective: The aim of this study was to fully characterize the major kiwi fruit allergen of 30 kd. Methods: Allergens were separated and purified by high-performance liquid chromatography with anion-exchange columns. The purity of the single proteins was checked by sodium dodecylsulfate-polyacrylamide gel electrophoresis, and their allergenicity was checked by immunoblotting with a pool of sera from patients allergic to kiwi. The allergens were characterized by isoelectrofocusing and amino acid sequencing, and periodic acid-Schiff stain was used to detect glycoproteins. Results: Proteins of 30, 28, 24, and 17 kd were purified by high-performance liquid chromatography. IgE binding indicated the 30 kd protein, which shelved an isoelectric point of 3.5, as the major allergen of kiwi. Determination of its partial amino acid sequence and comparison with the Swiss Protein Bank shelved that this was actinidin, the main protein component of kiwi. The 24 and 28 kd proteins had the same N-terminal sequence, which did not correspond to any known protein. The 17 kd protein had a blocked N-terminal sequence. Conclusions: These results demonstrate that the major allergen of kiwi fruit, Act c 1, is actinidin, a proteolytic enzyme belonging to the class of thiol-proteases, Two other allergens of 24 and 28 kd appear identical on amino acid sequencing.	Osped Maggiore, IRCCS, Dept Gen Med, I-20122 Milan, Italy; Niguarda Ca Granada Hosp, Div Bizzozzero, Milan, Italy; Natl Res Council, Torino, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico	Pastorello, EA (corresponding author), Osped Maggiore, IRCCS, Dept Gen Med, Via F Sforza 35,Pad Granelli, I-20122 Milan, Italy.		Giuffrida, Maria Gabriella/AAY-6314-2020; PASTORELLO, ELIDE ANNA/E-3897-2017	Giuffrida, Maria Gabriella/0000-0002-1297-2558; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				AAS K, 1973, CLIN ALLERGY, V9, P3327; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BURKS AW, 1994, J ALLERGY CLIN IMMUN, V93, P743, DOI 10.1016/0091-6749(94)90254-2; CAME A, 1978, J BIOCH, V173, P73; FAHLBUSCH B, 1995, INT ARCH ALLERGY IMM, V108, P119, DOI 10.1159/000237128; FALLIERS CJ, 1983, J ASTHMA, V20, P193, DOI 10.3109/02770908309114944; FINE AJ, 1981, J ALLERGY CLIN IMMUN, V68, P235, DOI 10.1016/0091-6749(81)90189-5; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P523, DOI 10.1080/00021369.1978.10863014; JOHANSSON E, 1991, CLIN EXP ALLERGY, V21, P511, DOI 10.1111/j.1365-2222.1991.tb01693.x; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; PEARS CJ, 1985, NUCLEIC ACIDS RES, V13, P8853, DOI 10.1093/nar/13.24.8853; ROGERS JC, 1985, P NATL ACAD SCI USA, V82, P6512, DOI 10.1073/pnas.82.19.6512; SOJI H, 1996, BIOSCI BIOTECH BIOCH, V60, P621; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Warburg O., 1942, BIOCHEM Z, V310, P384	21	124	127	0	16	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				531	537		10.1016/S0091-6749(98)70360-4	http://dx.doi.org/10.1016/S0091-6749(98)70360-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564807				2022-12-18	WOS:000073113500016
J	CIPRANDI, G; BUSCAGLIA, S; PESCE, G; PASSALACQUA, G; RIHOUX, JP; BAGNASCO, M; CANONICA, GW				CIPRANDI, G; BUSCAGLIA, S; PESCE, G; PASSALACQUA, G; RIHOUX, JP; BAGNASCO, M; CANONICA, GW			CETIRIZINE REDUCES INFLAMMATORY CELL RECRUITMENT AND ICAM-1 (OR CD54) EXPRESSION ON CONJUNCTIVAL EPITHELIUM IN BOTH EARLY-PHASE AND LATE-PHASE REACTIONS AFTER ALLERGEN-SPECIFIC CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC INFLAMMATION; ADHESION MOLECULES; ICAM-1/CD54 ANTIALLERGIC DRUGS; CETIRIZINE; ALLERGIC CONJUNCTIVITIS	PROVOCATION TEST; ADHESION MOLECULES; PHARMACOLOGICAL PROPERTIES; EOSINOPHIL RECRUITMENT; MEDIATOR RELEASE; ORAL CETIRIZINE; OCULAR ALLERGY; ASTHMA; HISTAMINE; RHINITIS	Background: Allergen-specific conjunctival challenge (ASCC) is a safe and reproducible experimental model of allergic conjunctivitis and a useful tool in the evaluation of effectiveness and possible mechanisms of action of drugs commonly used in the treatment of allergic diseases. Objective: The protective effect of cetirizine on inflammatory changes after ASCC was assessed in 12 patients with rhinoconjunctivitis caused by Parietaria judaica in a double-blind study. Methods: After a screening ASCC was performed patients were randomized into two treatment groups; each patient was given cetirizine (oral tablets) 10 mg twice daily, or matching placebo for 3% days in off-pollen season. Clinical evaluation (itching, hyperemia, lacrimation, and swelling of eyelids) and cytologic assessment (number of inflammatory cells in conjunctival scraping and evaluation of intercellular adhesion molecule-1 (ICAM-1)/CD54 expression on epithelial cells) were performed at baseline 30 minutes (i.e., early-phase reaction [EPR]), 6 hours, and 24 hours (i.e., late-phase reaction [LPR]) after ASCC, before and after treatment. Results: The EPR clinical events and the EPR total number of inflammatory cells were significantly reduced by cetirizine compared with placebo. The LPR clinical events and inflammatory cell recruitment were reduced by cetirizine in a similar manner. Both eosinophil and neutrophil numbers were decreased by active drug in EPR and LPR. Furthermore, ICAM-1/CD54 expression was significantly reduced by cetirizine in both the EPR and LPR compared with placebo. Conclusions: This study shows that cetirizine has a protective effect on clinical and cellular EPR and LPR events (including ICAM-1/CD54 expression on epithelium) induced by ASCC.	UNIV GENOA,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SERV,DLML,I-16132 GENOA,ITALY; UNION CHEM BELGIQUE SOC ACT,PHARMACEUT SECTOR,BRAINE LALLEUD,BELGIUM	University of Genoa			canonica, giorgio walter/ABF-2037-2020; Ciprandi, Giorgio/G-7462-2012	canonica, giorgio walter/0000-0001-8467-2557; Ciprandi, Giorgio/0000-0001-7016-8421; Pesce, Giampaola/0000-0002-6294-9110				AICHANE A, 1993, J ALLERGY CLIN IMMUN, V92, P49, DOI 10.1016/0091-6749(93)90036-F; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BONINI S, 1990, J ALLERGY CLIN IMMUN, V86, P869, DOI 10.1016/S0091-6749(05)80148-4; BROIDE DH, 1988, J ALLERGY CLIN IMMUN, V81, P176, DOI 10.1016/0091-6749(88)90268-0; CALDERON E, 1992, J ALLERGY CLIN IMMUN, V90, P852, DOI 10.1016/0091-6749(92)90112-F; CAMPOLIRICHARDS DM, 1990, DRUGS, V40, P762, DOI 10.2165/00003495-199040050-00009; CANONICA GW, 1992, ANN ALLERGY, V68, P251; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CIPRANDI G, 1993, ALLERGY, V48, P421, DOI 10.1111/j.1398-9995.1993.tb00740.x; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P1227, DOI 10.1016/0091-6749(93)90327-C; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CIPRANDI G, 1993, INT ARCH ALLERGY IMM, V100, P185, DOI 10.1159/000236407; CIPRANDI G, 1992, ALLERGY, V47, P309, DOI 10.1111/j.1398-9995.1992.tb02059.x; CIPRANDI G, 1994, IN PRESS AM J RESPIR; DEVOS C, 1989, INT ARCH ALLER A IMM, V88, P212, DOI 10.1159/000234789; DURHAM SR, 1991, CLIN EXP ALLERGY, V21, P3, DOI 10.1111/j.1365-2222.1991.tb00797.x; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FRIEDLAENDER MH, 1991, ANN ALLERGY, V67, P5; GONG H, 1990, J ALLERGY CLIN IMMUN, V85, P632, DOI 10.1016/0091-6749(90)90104-C; HANSEL TT, 1992, CLIN EXP ALLERGY, V22, P345, DOI 10.1111/j.1365-2222.1992.tb03096.x; JUHLIN L, 1986, BRIT J DERMATOL, V119, P67; KREUTNER W, 1987, ALLERGY, V42, P57, DOI 10.1111/j.1398-9995.1987.tb02188.x; KVALE D, 1992, SCAND J IMMUNOL, V35, P669, DOI 10.1111/j.1365-3083.1992.tb02973.x; KYANAUNG U, 1992, J ALLERGY CLIN IMMUN, V90, P270, DOI 10.1016/0091-6749(92)90083-E; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; MAKGOBA MW, 1989, IMMUNOL TODAY, V10, P417, DOI 10.1016/0167-5699(89)90039-X; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; MICHEL L, 1987, J ALLERGY CLIN IMMUN, V2, P82; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; RIMMER SJ, 1990, CLIN EXP ALLERGY, V20, P3, DOI 10.1111/j.1365-2222.1990.tb02456.x; SCHOENEICH M, 1990, CLIN EXP ALLERGY, V20, P171, DOI 10.1111/j.1365-2222.1990.tb02663.x; SIMONS FER, 1993, ALLERGY PRINCIPLES P, P856; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TASHKIN DP, 1987, ANN ALLERGY, V59, P49; VANEPPS DE, 1987, ANN ALLERGY, V59, P13	40	124	127	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					612	621		10.1016/S0091-6749(95)70324-1	http://dx.doi.org/10.1016/S0091-6749(95)70324-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7531732				2022-12-18	WOS:A1995QH69700014
J	HURD, SZ				HURD, SZ			WORKSHOP SUMMARY AND GUIDELINES - INVESTIGATIVE USE OF BRONCHOSCOPY, LAVAGE, AND BRONCHIAL BIOPSIES IN ASTHMA AND OTHER AIRWAY DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							BRONCHOALVEOLAR LAVAGE; MAST-CELLS; MILD ASTHMA; ALLERGEN CHALLENGE; ANTIGEN CHALLENGE; MEDIATOR RELEASE; INFLAMMATION; EXERCISE; BRONCHOCONSTRICTION; PROSTAGLANDIN-D2				HURD, SZ (corresponding author), NHLBI,DLD,WESTWOOD BLDG,ROOM 6A-15,BETHESDA,MD 20892, USA.							ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ALAM R, 1990, AM REV RESPIR DIS, V141, P668; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FORESI A, 1990, CHEST, V98, P528, DOI 10.1378/chest.98.3.528; GILBERT IA, 1990, AM REV RESPIR DIS, V142, P826, DOI 10.1164/ajrccm/142.4.826; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641, DOI 10.1164/ajrccm/137.3.641; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MCFADDEN ER, 1985, J CLIN INVEST, V76, P1007, DOI 10.1172/JCI112052; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MIADONNA A, 1990, J ALLERGY CLIN IMMUN, V85, P906, DOI 10.1016/0091-6749(90)90076-G; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73, DOI 10.1164/ajrccm/142.1.73; RANKIN JA, 1987, J ALLERGY CLIN IMMUN, V79, P371, DOI 10.1016/0091-6749(87)90158-8; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WOOD RE, 1988, J PEDIATR-US, V112, P1, DOI 10.1016/S0022-3476(88)80109-4; 1985, J ALLERGY CLIN IMMUN, V76, P145; 1990, AM REV RESPIR DIS, V142, P481	40	124	125	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					808	814						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955640				2022-12-18	WOS:A1991GQ45200017
J	ONORATO, J; MERLAND, N; TERRAL, C; MICHEL, FB; BOUSQUET, J				ONORATO, J; MERLAND, N; TERRAL, C; MICHEL, FB; BOUSQUET, J			PLACEBO-CONTROLLED DOUBLE-BLIND FOOD CHALLENGE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RES CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019					AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; ATHERTON DJ, 1982, CLIN IMMUNOL ALLERGY, V2, P78; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BALDO BA, 1982, PROG ALLERGY, V30, P1; BARNETSON RS, 1981, CLIN EXP IMMUNOL, V46, P54; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; BOUSQUET J, 1986, REV FR ALLERGOL; BOUSQUET J, 1982, MED HYG, V40, P2887; DANNAEUS A, 1977, CLIN ALLERGY, V7, P109, DOI 10.1111/j.1365-2222.1977.tb01431.x; DANNAEUS A, 1981, CLIN EXP IMMUNOL, V11, P539; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; ERIKSSON NE, 1983, ALLERGY, V38, P353, DOI 10.1111/j.1398-9995.1983.tb04130.x; GANDERTON MA, 1978, BRIT MED J, V1, P1624; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; Lessof M. H., 1983, Clinical reactions to food, P103; MAY CD, 1976, J ALLERGY CLIN IMMUN, V57, P62; MAY CD, 1983, ALLERGY PRINCIPLES P, P1159; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; MONERETVAUTRIN DA, 1983, IMMUNOPATHOLOGIE ALL; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; PEPYS J, 1975, BR J HOSP MED, V14, P912; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SPECTOR SL, 1982, PROVOCATIVE CHALLENG, P97; WRAITH DG, 1982, CLIN IMMUNOL ALLERGY, V2, P101; 1962, AM REV RESPIR DIS, V85, P762; 1984, J ROY COLL PHYSICIAN, V18, P83; 1984, ADVERSE REACTIONS FO	40	124	124	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1139	1146		10.1016/0091-6749(86)90263-0	http://dx.doi.org/10.1016/0091-6749(86)90263-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3097108				2022-12-18	WOS:A1986F302600009
J	ELIAS, J; BOSS, E; KAPLAN, AP				ELIAS, J; BOSS, E; KAPLAN, AP			STUDIES OF THE CELLULAR INFILTRATE OF CHRONIC IDIOPATHIC URTICARIA - PROMINENCE OF LYMPHOCYTES-T, MONOCYTES, AND MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,STONY BROOK,NY 11794; SUNY STONY BROOK,HLTH SCI CTR,DEPT PATHOL,HISTOPATHOL SECT,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P149; CENTER DM, 1983, J ALLERGY CLIN IMMUN, V71, P29, DOI 10.1016/0091-6749(83)90543-2; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; ELIAS JM, 1982, AM J CLIN PATHOL, V77, P611; ELIAS JM, 1982, PRINCIPLES TECHNIQUE, P325; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAPLAN AP, 1985, CLIN RES, V33, pA594; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1985, ALLERGY, P431; LEDER LD, 1964, KLIN WOCHENSCHR, V42, P553, DOI 10.1007/BF01486688; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LIU MC, 1986, J IMMUNOL, V136, P2588; MATHEWS KP, 1983, J ALLERGY CLIN IMMUN, V72, P1, DOI 10.1016/0091-6749(83)90042-8; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; MONROE EW, 1981, J INVEST DERMATOL, V76, P103, DOI 10.1111/1523-1747.ep12525403; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; PINKARD RM, 1980, J ALLERGY CLIN INVES, V65, P196; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SOTER NA, 1977, NEW ENGL J MED, V296, P1440, DOI 10.1056/NEJM197706232962505; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626; WARNER JA, 1986, J IMMUNOL, V136, P2583	31	124	124	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				914	918		10.1016/0091-6749(86)90240-X	http://dx.doi.org/10.1016/0091-6749(86)90240-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3491100				2022-12-18	WOS:A1986E971300015
J	FRIEDMAN, R; ACKERMAN, M; WALD, E; CASSELBRANT, M; FRIDAY, G; FIREMAN, P				FRIEDMAN, R; ACKERMAN, M; WALD, E; CASSELBRANT, M; FRIDAY, G; FIREMAN, P			ASTHMA AND BACTERIAL SINUSITIS IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,SCH MED,DEPT PEDIAT & OTOLARYNGOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00084] Funding Source: Medline; NIAID NIH HHS [IR01AI19262] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BULLEN SS, 1932, J ALLERGY, V4, P402; CAFFEY J, 1978, SURGICAL RADIOLOGY; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; Maresh MM, 1940, AM J DIS CHILD, V60, P841, DOI 10.1001/archpedi.1940.02000040060005; PHIPATAN.CS, 1974, ARCH OTOLARYNGOL, V100, P109; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P302; SHOPFNER CE, 1973, AM J ROENTGENOL, V118, P176, DOI 10.2214/ajr.118.1.176; SLAVIN R G, 1982, Journal of Allergy and Clinical Immunology, V69, P102; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; Sluder G, 1919, J AMER MED ASSOC, V73, P589, DOI 10.1001/jama.1919.02610340021006; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302	14	124	125	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					185	189		10.1016/0091-6749(84)90284-7	http://dx.doi.org/10.1016/0091-6749(84)90284-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6747140	Bronze			2022-12-18	WOS:A1984TE22600012
J	BARBEE, RA; BROWN, WG; KALTENBORN, W; HALONEN, M				BARBEE, RA; BROWN, WG; KALTENBORN, W; HALONEN, M			ALLERGEN SKIN-TEST REACTIVITY IN A COMMUNITY POPULATION-SAMPLE - CORRELATION WITH AGE, HISTAMINE SKIN REACTIONS, AND TOTAL SERUM IMMUNOGLOBULIN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BARBEE, RA (corresponding author), UNIV ARIZONA, COLL MED, DIV RESP SCI, TUCSON, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL 14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLSTEDT S, 1974, CLIN ALLERGY, V4, P131, DOI 10.1111/j.1365-2222.1974.tb01370.x; Alexander HL, 1931, ANN INTERN MED, V5, P52, DOI 10.7326/0003-4819-5-1-52; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BECKER WG, 1978, J ALLERGY CLIN IMMUN, V61, P177, DOI 10.1016/0091-6749(78)90401-3; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BUCKLEY CE, 1970, J IMMUNOL, V105, P964; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; de Vries K, 1968, Bronches, V18, P439; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V59, P377, DOI 10.1016/0091-6749(77)90022-7; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; Nye L, 1975, Clin Allergy, V5, P13; Pearson RSB, 1937, Q J MED, V6, P165; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; SINGHAL SK, 1978, FED PROC, V37, P1245; van der Lende R, 1973, Rev Inst Hyg Mines (Hasselt), V28, P186; WARREN CPW, 1974, CAN MED ASSOC J, V110, P425	26	124	126	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					15	19		10.1016/0091-6749(81)90117-2	http://dx.doi.org/10.1016/0091-6749(81)90117-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	7240595				2022-12-18	WOS:A1981LY10100003
J	SETTIPANE, GA; BOYD, GK; NEWSTEAD, GJ				SETTIPANE, GA; BOYD, GK; NEWSTEAD, GJ			FREQUENCY OF HYMENOPTERA ALLERGY IN AN ATOPIC AND NORMAL POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ABRISHAMI MA, 1971, ACTA ALLERGOL, V26, P117; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; REMINGTON JS, 1964, J CLIN INVEST, V43, P1613, DOI 10.1172/JCI105037; SALVAGGIO J, 1966, J ALLERGY, V38, P31, DOI 10.1016/0021-8707(66)90070-0; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SAMTER M, 1947, P SOC EXP BIOL MED, V65, P140; SCHWARTZ HJ, 1968, J ALLERGY, V42, P169, DOI 10.1016/0021-8707(68)90090-7; SCHWARTZ HJ, 1970, J ALLERGY, V45, P87; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SETTIPANE GA, 1965, J ALLERGY, V36, P92, DOI 10.1016/0021-8707(65)90036-5	12	124	125	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	3					146	+		10.1016/0091-6749(72)90045-0	http://dx.doi.org/10.1016/0091-6749(72)90045-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N4708	5050325				2022-12-18	WOS:A1972N470800003
J	Dicker, AJ; Crichton, ML; Pumphrey, EG; Cassidy, AJ; Suarez-Cuartin, G; Sibila, O; Furrie, E; Fong, CJ; Ibrahim, W; Brady, G; Einarsson, GG; Elborn, JS; Schembri, S; Marshall, SE; Palmer, CNA; Chalmers, JD				Dicker, Alison J.; Crichton, Megan L.; Pumphrey, Eleanor G.; Cassidy, Andrew J.; Suarez-Cuartin, Guillermo; Sibila, Oriol; Furrie, Elizabeth; Fong, Christopher J.; Ibrahim, Wasyla; Brady, Gill; Einarsson, Gisli G.; Elborn, J. Stuart; Schembri, Stuart; Marshall, Sara E.; Palmer, Colin N. A.; Chalmers, James D.			Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neutrophils; phagocytosis; chronic obstructive pulmonary; disease; Haemophilus species; exacerbations	APOPTOTIC CELLS; NET FORMATION; COPD; EXACERBATIONS; SURVIVAL; ACTIVATION; CLEARANCE; ELASTASE; RELEASE	Background: Neutrophil extracellular traps (NETs) have been observed in the airway in patients with chronic obstructive pulmonary disease (COPD), but their clinical and pathophysiologic implications have not been defined. Objective: We sought to determine whether NETs are associated with disease severity in patients with COPD and how they are associated with microbiota composition and airway neutrophil function. Methods: NET protein complexes (DNA-elastase and histone-elastase complexes), cell-free DNA, and neutrophil biomarkers were quantified in soluble sputum and serum from patients with COPD during periods of disease stability and during exacerbations and compared with clinical measures of disease severity and the sputum microbiome. Peripheral blood and airway neutrophil function were evaluated by means of flow cytometry ex vivo and experimentally after stimulation of NET formation. Results: Sputum NET complexes were associated with the severity of COPD evaluated by using the composite Global Initiative for Obstructive Lung Disease scale (P < .0001). This relationship was due to modest correlations between NET complexes and FEV1, symptoms evaluated by using the COPD assessment test, and higher levels of NET complexes in patients with frequent exacerbations (P = .002). Microbiota composition was heterogeneous, but there was a correlation between NET complexes and both microbiota diversity (P = .009) and dominance of Haemophilus species operational taxonomic units (P = .01). Ex vivo airway neutrophil phagocytosis of bacteria was reduced in patients with increased sputum NET complexes. Consistent results were observed regardless of the method of quantifying sputum NETs. Failure of phagocytosis could be induced experimentally by incubating healthy control neutrophils with soluble sputum from patients with COPD. Conclusion: NET formation is increased in patients with severe COPD and associated with more frequent exacerbations and a loss of microbiota diversity.	[Dicker, Alison J.; Crichton, Megan L.; Pumphrey, Eleanor G.; Cassidy, Andrew J.; Furrie, Elizabeth; Fong, Christopher J.; Ibrahim, Wasyla; Brady, Gill; Schembri, Stuart; Palmer, Colin N. A.; Chalmers, James D.] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland; [Suarez-Cuartin, Guillermo; Sibila, Oriol] Hosp Santa Creu & Sant Pau, Inst Invest Biomed IIB St Pau, Resp Dept, Barcelona, Spain; [Einarsson, Gisli G.; Elborn, J. Stuart] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Infect & Immun, Belfast, Antrim, North Ireland; [Elborn, J. Stuart] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Marshall, Sara E.] Univ Dundee, Sch Med, Div Mol & Clin Med, London, England; [Marshall, Sara E.] Wellcome Trust Res Labs, London, England	University of Dundee; Hospital of Santa Creu i Sant Pau; Queens University Belfast; Imperial College London; University of Dundee	Chalmers, JD (corresponding author), Univ Dundee, Div Mol & Clin Med, Dundee DD1 9SY, Scotland.	jchalmers@dundee.ac.uk	Sibila, Oriol/T-4366-2017; Suarez-Cuartin, Guillermo/AAA-8105-2019; Palmer, Colin NA/C-7053-2008	Sibila, Oriol/0000-0002-4833-6713; Suarez-Cuartin, Guillermo/0000-0003-2320-6047; Palmer, Colin NA/0000-0002-6415-6560; Einarsson, Gisli/0000-0003-1353-950X; Chalmers, James/0000-0001-5514-7868; Dicker, Alison/0000-0002-4791-3259	Chief Scientist Office, Scotland [ETM/262]; Wellcome Trust; Chief Scientist Office [ETM/262] Funding Source: researchfish	Chief Scientist Office, Scotland; Wellcome Trust(Wellcome TrustEuropean Commission); Chief Scientist Office	Supported by the Chief Scientist Office, Scotland (grant no. ETM/262). J.D.C. acknowledges fellowship support from the Wellcome Trust. S.E.M. is an employee of the Wellcome Trust.	Agusti A, 2013, EUR RESPIR J, V42, P636, DOI 10.1183/09031936.00195212; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303; Celli BR, 2015, AM J RESP CRIT CARE, V191, P831, DOI 10.1164/rccm.201501-0044ST; Dickson RP, 2013, EXPERT REV RESP MED, V7, P245, DOI [10.1586/ERS.13.24, 10.1586/ers.13.24]; Donnelly LE, 2012, CHEST, V141, P1055, DOI 10.1378/chest.11-2348; Dworski R, 2011, J ALLERGY CLIN IMMUN, V127, P1260, DOI 10.1016/j.jaci.2010.12.1103; Farnworth SL, 2008, AM J PATHOL, V172, P395, DOI 10.2353/ajpath.2008.070870; Flynn RW, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0141-y; Grabcanovic-Musija F, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0221-7; Gray RD, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-12; Greenwood H, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-332; Haslett C, 1999, AM J RESP CRIT CARE, V160, pS5, DOI 10.1164/ajrccm.160.supplement_1.4; Hoenderdos K, 2013, AM J RESP CELL MOL, V48, P531, DOI 10.1165/rcmb.2012-0492TR; Jiang SN, 2014, J IMMUNOL, V192, P4795, DOI 10.4049/jimmunol.1302764; Juneau RA, 2015, INFECT IMMUN, V83, P239, DOI 10.1128/IAI.02390-14; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Knight JS, 2015, ANN RHEUM DIS, V74, P2199, DOI 10.1136/annrheumdis-2014-205365; Lange P, 2015, NEW ENGL J MED, V373, P111, DOI 10.1056/NEJMoa1411532; Leidy NK, 2011, AM J RESP CRIT CARE, V183, P323, DOI 10.1164/rccm.201005-0762OC; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Menegazzi R, 2012, BLOOD, V119, P1214, DOI 10.1182/blood-2011-07-364604; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC; Obermayer A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097784; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2016, THORAX, V71, P118, DOI 10.1136/thoraxjnl-2015-207021; Pedersen F, 2015, RESP MED, V109, P1360, DOI 10.1016/j.rmed.2015.08.008; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Richens TR, 2009, AM J RESP CRIT CARE, V179, P1011, DOI 10.1164/rccm.200807-1148OC; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Sayah DM, 2015, AM J RESP CRIT CARE, V191, P455, DOI 10.1164/rccm.201406-1086OC; Short PM, 2015, LUNG, V193, P487, DOI 10.1007/s00408-015-9724-8; Speizer FE, 2015, NEW ENGL J MED, V373, P185, DOI 10.1056/NEJMe1503888; Willemse BWM, 2005, EUR RESPIR J, V26, P835, DOI 10.1183/09031936.05.00108904; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Zabieglo K, 2015, J LEUKOCYTE BIOL, V98, P99, DOI 10.1189/jlb.4AB1114-543R	43	123	132	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					117	127		10.1016/j.jaci.2017.04.022	http://dx.doi.org/10.1016/j.jaci.2017.04.022			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28506850	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000419312200018
J	du Toit, G; Tsakok, T; Lack, S; Lack, G				du Toit, George; Tsakok, Teresa; Lack, Simon; Lack, Gideon			Prevention of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; atopic dermatitis; peanut allergy; cow's milk allergy; egg allergy; oral food challenge; specific IgE	EARLY PEANUT INTRODUCTION; ATOPIC-DERMATITIS; HIGH-RISK; VITAMIN-D; CONSENSUS COMMUNICATION; 1ST YEAR; POPULATION COHORT; STRATUM-CORNEUM; MATERNAL INTAKE; SKIN BARRIER	The past few decades have witnessed an increase in the prevalence of IgE-mediated food allergy (FA). For prevention strategies to be effective, we need to understand the causative factors underpinning this rise. Genetic factors are clearly important in the development of FA, but given the dramatic increase in prevalence over a short period of human evolution, it is unlikely that FA arises through germline genetic changes alone. Aplausible hypothesis is that 1 or more environmental exposures, or lack thereof, induce epigenetic changes that result in interruption of the default immunologic state of tolerance. Strategies for the prevention of FA might include primary prevention, which seeks to prevent the onset of IgE sensitization; secondary prevention, which seeks to interrupt the development of FA in IgE-sensitized children; and tertiary prevention, which seeks to reduce the expression of end-organ allergic disease in children with established FA. This review emphasizes the prevention of IgE-mediated FA through dietary manipulation, among other strategies; in particular, we focus on recent interventional studies in this field.	[du Toit, George; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, MRC, Kings Hlth Partners, Kings Coll London, Westminster Bridge Rd, London SE1 7EH, England; [du Toit, George; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, Asthma UK Ctr Allerg Mech Asthma, Westminster Bridge Rd, London SE1 7EH, England; [du Toit, George; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, Dept Paediat Allergy, Westminster Bridge Rd, London SE1 7EH, England; [Tsakok, Teresa] Guys & St Thomas NHS Fdn Trust, Kings Coll London, Westminster Bridge Rd, London SE1 7EH, England; [Tsakok, Teresa] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, Westminster Bridge Rd, London SE1 7EH, England; [Lack, Simon] Univ London Imperial Coll Sci Technol & Med, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Westminster Bridge Rd, London SE1 7EH, England.	gideon.lack@kcl.ac.uk		Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Food Allergy Research & Education (FARE); Medical Research Council; Asthma UK Centre; UK Department of Health through NIH Research; National Peanut Board (NPB); UK Food Standards Agency (FSA)	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Food Allergy Research & Education (FARE); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK Centre; UK Department of Health through NIH Research; National Peanut Board (NPB); UK Food Standards Agency (FSA)	G. du Toit has received grants from the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Food Allergy Research & Education (FARE), the Medical Research Council and Asthma UK Centre, and the UK Department of Health through NIH Research and has equity holding in FoodMaestro. G. Lack has received grants from the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), Food Allergy Research & Education (FARE), the Medical Research Council and Asthma UK Centre, the UK Department of Health through NIH Research, the National Peanut Board (NPB), the UK Food Standards Agency (FSA), and the Medical Research Council, and has equity holding in DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest.	Almqvist C, 2007, J ALLERGY CLIN IMMUN, V119, P1438, DOI 10.1016/j.jaci.2007.01.046; Anandan C, 2009, ALLERGY, V64, P840, DOI 10.1111/j.1398-9995.2009.02042.x; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Bellach J, 2015, EARLY INTRO HENS EGG; Boralevi F, 2008, ALLERGY, V63, P205, DOI 10.1111/j.1398-9995.2007.01556.x; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; du Toit G, 2016, N ENGL J MED; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Eller E, 2010, PEDIAT ALLERG IMM-UK, V21, P307, DOI 10.1111/j.1399-3038.2009.00914.x; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; Fleischer DM, 2016, PEDIATR DERMATOL, V33, P102, DOI 10.1111/pde.12685; Fleischer DM, 2015, J ALLERGY CLIN IMMUN, V136, P258, DOI 10.1016/j.jaci.2015.06.001; Fleischer DM, 2015, ANN ALLERG ASTHMA IM, V115, P87, DOI 10.1016/j.anai.2015.06.001; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; GERRARD JW, 1986, ANN ALLERGY, V56, P351; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Heinrich J, 2001, EUR RESPIR J, V17, P395, DOI 10.1183/09031936.01.17303950; Hong XM, 2009, CURR OPIN PEDIATR, V21, P770, DOI 10.1097/MOP.0b013e32833252dc; Horimukai K, 2014, J ALLERGY CLIN IMMUN, V134, P824, DOI 10.1016/j.jaci.2014.07.060; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jelding-Dannemand E, 2015, J ALLERGY CLIN IMMUN, V136, P1302, DOI 10.1016/j.jaci.2015.02.023; Joseph CL, 2016, ANN ALLERGY ASTHMA I; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000133.pub3; Kramer MS, 2004, ADV EXP MED BIOL, V554, P63; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; Lichtenstein P, 1997, ALLERGY, V52, P1079, DOI 10.1111/j.1398-9995.1997.tb00179.x; LILJA G, 1988, CLIN ALLERGY, V18, P131, DOI 10.1111/j.1365-2222.1988.tb02852.x; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Lodge CJ, 2015, ACTA PAEDIATR, V104, P38, DOI 10.1111/apa.13132; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Molloy J, 2015, MINI-REV MED CHEM, V15, P944, DOI 10.2174/1389557515666150519111328; Mullins RJ, 2010, PEDIAT ALLERG IMM-UK, V21, pE413, DOI 10.1111/j.1399-3038.2009.00962.x; Mullins RJ, 2011, PEDIAT ALLERG IMM-UK, V22, P583, DOI 10.1111/j.1399-3038.2011.01151.x; Munns C, 2006, MED J AUSTRALIA, V185, P268, DOI 10.5694/j.1326-5377.2006.tb00558.x; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nikolovski J, 2008, J INVEST DERMATOL, V128, P1728, DOI 10.1038/sj.jid.5701239; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Osborn DA, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003664; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Palmer DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e184; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Panjari M, 2016, CLIN EXP ALLERGY; Paton J, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/675724; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Perkin MR, 2016, NEW ENGL J MED, V375; Peters RL, 2015, CLIN EXP ALLERGY, V45, P953, DOI 10.1111/cea.12478; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V104, P413, DOI 10.1016/j.anai.2010.01.022; SAARINEN UM, 1980, LANCET, V1, P166; Sabounchi S, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0533-1; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P453, DOI 10.1016/j.jaci.2012.05.006; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Shaheen SO, 2004, EUR RESPIR J, V24, P292, DOI 10.1183/09031936.04.00117803; Sheehan WJ, 2012, J ALLERGY CLIN IMMUN, V129, pAB236, DOI 10.1016/j.jaci.2011.12.166; Sherriff A, 2002, ARCH DIS CHILD, V87, P26, DOI 10.1136/adc.87.1.26; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P492, DOI 10.1016/j.jaci.2013.12.1041; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200425196; Umasunthar T, 2013, CLIN EXP ALLERGY, V43, P1333, DOI 10.1111/cea.12211; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; Vassallo MF, 2010, ALLERGY, V65, P1492, DOI 10.1111/j.1398-9995.2010.02384.x; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Walkner M, 2015, PEDIATR CLIN N AM, V62, P1453, DOI 10.1016/j.pcl.2015.07.003; Wawro N, 2014, BMC PEDIATR, V14, DOI 10.1186/s12887-014-0286-3; Wegienka G, 2015, J ALLERGY CLIN IMMUN, V136, P1309, DOI 10.1016/j.jaci.2015.04.017; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V107, P566, DOI 10.1159/000237100; Wjst Matthias, 2005, Clin Mol Allergy, V3, P7, DOI 10.1186/1476-7961-3-7; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	104	123	129	0	42	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					998	1010		10.1016/j.jaci.2016.02.005	http://dx.doi.org/10.1016/j.jaci.2016.02.005			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	27059727	hybrid, Green Published			2022-12-18	WOS:000373351200004
J	Durrani, SR; Viswanathan, RK; Busse, WW				Durrani, Sheharyar R.; Viswanathan, Ravi K.; Busse, William W.			What effect does asthma treatment have on airway remodeling? Current perspectives	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; asthma treatment; remodeling; corticosteroids; inflammation; anti-IgE; omalizumab; anti-TNF-alpha; golimumab; anti-IL-5; mepolizumab	SUBEPITHELIAL COLLAGEN DEPOSITION; BRONCHIAL MUCOSAL BIOPSIES; NECROSIS-FACTOR-ALPHA; BASEMENT-MEMBRANE; INHALED CORTICOSTEROIDS; SMOOTH-MUSCLE; TIOTROPIUM BROMIDE; GROWTH-FACTOR; FLUTICASONE PROPIONATE; SEVERE EXACERBATIONS	Airway remodeling, or structural changes of the airway wall arising from injury and repair, plays an important role in the pathophysiology of asthma. Remodeling is characterized as structural changes involving the composition, content, and organization of many of the cellular and molecular constituents of the bronchial wall. These structural changes can include epithelial injury, subepithelial thickening/fibrosis, airway smooth muscle hyperplasia, goblet cell hypertrophy and hyperplasia, and angiogenesis. Historically, these changes are considered a consequence of long-standing airway inflammation. Recent infant and child studies, however, suggest that remodeling occurs in parallel with inflammation in asthmatic subjects. Despite advancements in the recognition of key cellular and molecular mechanisms involved in remodeling, there remains a paucity of information about which treatments or interactions are most likely to regulate these processes. Furthermore, it is unclear as to when is the best time to initiate treatments to modify remodeling, which components to target, and how best to monitor interventions on remodeling. Indeed, inhaled corticosteroids, which are generally considered to have limited influence on remodeling, have been shown to be beneficial in studies in which the dose and duration of treatment were increased and prolonged, respectively. Moreover, several studies have identified the need to identify novel asthma indices and phenotypes that correlate with remodeling and, as a consequence, might specifically respond to new therapies, such as anti-IgE, anti-IL-5, and anti-TNF-alpha mAbs. Our review will evaluate the development of remodeling in asthmatic subjects and the effects of treatment on these processes. (J Allergy Clin Immunol 2011;128:439-48.)	[Durrani, Sheharyar R.; Viswanathan, Ravi K.; Busse, William W.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Sect Allergy Pulm & Crit Care Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Sect Allergy Pulm & Crit Care Med, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Bai TR, 2000, AM J RESP CRIT CARE, V162, P663, DOI 10.1164/ajrccm.162.2.9907151; Baluk P, 2009, J CLIN INVEST, V119, P2954, DOI 10.1172/JCI37626; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bos IST, 2007, EUR RESPIR J, V30, P653, DOI 10.1183/09031936.00004907; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; BRAMLEY AM, 1994, EUR RESPIR J, V7, P337, DOI 10.1183/09031936.94.07020337; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Burgess JK, 2006, J ALLERGY CLIN IMMUN, V118, P649, DOI 10.1016/j.jaci.2006.05.019; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207-710OC; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Kluijver J, 2005, CLIN EXP ALLERGY, V35, P1361, DOI 10.1111/j.1365-2222.2005.02334.x; Detoraki A, 2010, ALLERGY, V65, P946, DOI 10.1111/j.1398-9995.2010.02372.x; Diamant Z, 2009, EXPERT REV CLIN IMMU, V5, P639, DOI [10.1586/eci.09.62, 10.1586/ECI.09.62]; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; ERJEFALT JS, 1995, THORAX, V50, P785, DOI 10.1136/thx.50.7.785; Fahy JV, 2006, J ALLERGY CLIN IMMUN, V117, P1230, DOI 10.1016/j.jaci.2006.01.046; Feltis BN, 2007, THORAX, V62, P314, DOI 10.1136/thx.2006.069229; Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778, DOI 10.1164/ajrccm.162.5.2001037; Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Halwani R, 2010, CURR OPIN PHARMACOL, V10, P236, DOI 10.1016/j.coph.2010.06.004; Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501-088OC; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 2004, CLIN REV ALLERG IMMU, V27, P59, DOI 10.1385/CRIAI:27:1:059; Hoshino M, 1998, CLIN EXP ALLERGY, V28, P568; Hoshino M, 2001, CLIN EXP ALLERGY, V31, P722, DOI 10.1046/j.1365-2222.2001.01071.x; Huang YC, 2005, ANN ALLERG ASTHMA IM, V95, P443, DOI 10.1016/S1081-1206(10)61170-2; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; James A, 2005, CLIN EXP ALLERGY, V35, P703, DOI 10.1111/j.1365-2222.2005.02270.x; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Kelly MM, 2010, J ALLERGY CLIN IMMUN, V125, P349, DOI 10.1016/j.jaci.2009.09.011; Kung YC, 2011, RESP PHYSIOL NEUROBI, V175, P349, DOI 10.1016/j.resp.2010.12.013; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAURSEN LC, 1988, ALLERGY, V43, P284, DOI 10.1111/j.1398-9995.1988.tb00901.x; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Leung SY, 2005, J ALLERGY CLIN IMMUN, V115, P989, DOI 10.1016/j.jaci.2005.01.036; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Mauad T, 2007, J ALLERGY CLIN IMMUN, V120, P997, DOI 10.1016/j.jaci.2007.06.031; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Milanese M, 2001, J APPL PHYSIOL, V91, P1035, DOI 10.1152/jappl.2001.91.3.1035; Minoguchi K, 2002, CHEST, V121, P732, DOI 10.1378/chest.121.3.732; Murphy DM, 2010, CHEST, V137, P1417, DOI 10.1378/chest.09-1895; Muz MH, 2006, EXP MOL MED, V38, P109, DOI 10.1038/emm.2006.14; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Ohta S, 2010, CLIN EXP ALLERGY, V40, P1266, DOI 10.1111/j.1365-2222.2010.03478.x; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; Pare PD, 2007, CAN J PHYSIOL PHARM, V85, P653, DOI 10.1139/Y07-051; Pavord ID, 2009, J ALLERGY CLIN IMMUN, V123, P1083, DOI 10.1016/j.jaci.2009.02.034; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Rhee CK, 2011, INT ARCH ALLERGY IMM, V155, P243, DOI 10.1159/000321261; ROCHE WR, 1989, LANCET, V1, P520; Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Royce SG, 2009, ANN ALLERG ASTHMA IM, V102, P238, DOI 10.1016/S1081-1206(10)60087-7; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Shale DJ, 2004, EUR RESPIR J, V23, P797, DOI 10.1183/09031936.0.00018404; Shiba K, 2002, CHEST, V122, P1622, DOI 10.1378/chest.122.5.1622; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Sumi Yuki, 2007, Allergol Int, V56, P341, DOI 10.2332/allergolint.R-07-153; Todorova L, 2009, RESP MED, V103, P1755, DOI 10.1016/j.rmed.2009.03.018; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Vanacker NJ, 2002, EUR RESPIR J, V20, P873, DOI 10.1183/09031936.02.02562001; Vanacker NJ, 2002, CLIN EXP ALLERGY, V32, P914, DOI 10.1046/j.1365-2222.2002.01394.x; Vanacker NJ, 2001, AM J RESP CRIT CARE, V163, P674, DOI 10.1164/ajrccm.163.3.2004160; Wadsworth SJ, 2006, J CLIN IMMUNOL, V26, P376, DOI 10.1007/s10875-006-9029-z; Wang K, 2011, ACTA PHARMACOL SIN, V32, P126, DOI 10.1038/aps.2010.170; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Ward C, 2001, AM J RESP CRIT CARE, V164, P1718, DOI 10.1164/ajrccm.164.9.2102039; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; White SR, 2002, CHEST, V122, p278S, DOI 10.1378/chest.122.6_suppl.278S; Zietkowski Z, 2010, RESPIRATION, V80, P534, DOI 10.1159/000317137	99	123	128	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					439	448		10.1016/j.jaci.2011.06.002	http://dx.doi.org/10.1016/j.jaci.2011.06.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21752441	Bronze			2022-12-18	WOS:000294283400001
J	Busse, PJ; Mathur, SK				Busse, Paula J.; Mathur, Sameer K.			Age-related changes in immune function: Effect on airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; aging; elderly; immune function; immunosenescence	REGULATORY T-CELLS; COMMUNITY POPULATION-SAMPLE; HUMAN PERIPHERAL-BLOOD; NATURAL-KILLER-CELLS; SKIN-TEST REACTIVITY; CD28 EXPRESSION; TOTAL IGE; ALVEOLAR MACROPHAGES; GENERAL-POPULATION; ELDERLY-PATIENTS	Immunosenescence is defined as changes in the innate and adaptive immune response associated with increased age. The clinical consequences of immunosenescence include increased susceptibility to infection, malignancy and autoimmunity, decreased response to vaccination, and impaired wound healing. However, there are several immune alterations that might facilitate persistence of asthma into late adulthood or development of asthma after the age of 50 to 60 years. Asthma in older patients is not uncommon, and this is a growing population as the average lifespan increases. Specific innate changes that might affect severity of asthma in older patients or be involved in the development of late-onset asthma include impaired mucociliary clearance and changes in airway neutrophil, eosinophil, and mast cell numbers and function. Additionally, age-related altered antigen presentation and decreased specific antibody responses might increase the risk of respiratory tract infections. Respiratory tract infections exacerbate asthma in older patients and possibly play a role in the pathogenesis of late-onset asthma. Furthermore, cytokine profiles might be modified with aging, with some investigators suggesting a trend toward T(H)2 cytokine expression. This review examines specific innate and adaptive immune responses affected by aging that might affect the inflammatory response in older adults with asthma. (J Allergy Clin Immunol 2010;126:690-9.)	[Busse, Paula J.] Mt Sinai Sch Med, Dept Med, Div Clin Immunol, New York, NY 10029 USA; [Mathur, Sameer K.] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton VA Hosp, Dept Med,Sect Allergy Pulm & Crit Care, Madison, WI USA	Icahn School of Medicine at Mount Sinai; University of Wisconsin System; University of Wisconsin Madison	Busse, PJ (corresponding author), Mt Sinai Sch Med, Dept Med, Div Clin Immunol, 1425 Madison Ave,Room 11-20, New York, NY 10029 USA.	paula.busse@mssm.edu			National Institutes of Health; American Academy of Allergy, Asthma Immunology; John A. Hartford Foundation; American Academy of Allergy, Asthma & Immunology/T. Franklin Williams Scholars Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL088594] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma Immunology; John A. Hartford Foundation; American Academy of Allergy, Asthma & Immunology/T. Franklin Williams Scholars Program; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Disclosure of potential conflict of interest: P.J. Busse has received research support from the National Institutes of Health and the American Academy of Allergy, Asthma & Immunology. S.K. Mathur has received research support from the American Academy of Allergy, Asthma & Immunology/T. Franklin Williams Scholars Program and the John A. Hartford Foundation and is vice chair of the American Academy of Allergy, Asthma & Immunology's Asthma and Allergic Diseases in the Elderly Committee.	Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912; ANNEMA JT, 1995, EUR RESPIR J, V8, P62, DOI 10.1183/09031936.95.08010062; Ariano R, 1998, J INVEST ALLERG CLIN, V8, P35; ARRANZ E, 1992, GUT, V33, P882, DOI 10.1136/gut.33.7.882; Atsuta R, 1999, INT ARCH ALLERGY IMM, V120, P76, DOI 10.1159/000053600; Bacharier LB, 2003, PEDIATRICS, V112, pE85, DOI 10.1542/peds.112.2.e85; BANERJEE DK, 1987, BRIT J DIS CHEST, V81, P23, DOI 10.1016/0007-0971(87)90104-5; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; Bellia V, 2007, CHEST, V132, P1175, DOI 10.1378/chest.06-2824; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336, DOI 10.1164/ajrccm/143.2.336; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; Bryl E, 2001, J IMMUNOL, V167, P3231, DOI 10.4049/jimmunol.167.6.3231; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; Busse PJ, 2007, CLIN EXP ALLERGY, V37, P1392, DOI 10.1111/j.1365-2222.2007.02775.x; BUSSE PJ, 2010, J ASTHMA; Butcher SK, 2001, J LEUKOCYTE BIOL, V70, P881; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; Chiu BC, 2007, MECH AGEING DEV, V128, P618, DOI 10.1016/j.mad.2007.09.002; Chiu WK, 2006, J IMMUNOL, V177, P7802, DOI 10.4049/jimmunol.177.11.7802; Clise-Dwyer K, 2007, J IMMUNOL, V178, P1321, DOI 10.4049/jimmunol.178.3.1321; Creticos P, 2002, ANN ALLERG ASTHMA IM, V88, P401, DOI 10.1016/S1081-1206(10)62372-1; Culley FJ, 2009, IMMUNOLOGY, V128, P151, DOI 10.1111/j.1365-2567.2009.03167.x; Dailey RW, 2001, CELL IMMUNOL, V214, P99, DOI 10.1006/cimm.2001.1894; Dejaco C, 2006, EXP GERONTOL, V41, P339, DOI 10.1016/j.exger.2006.01.008; DelaRosa O, 2002, EXP GERONTOL, V37, P213, DOI 10.1016/S0531-5565(01)00186-3; Di Lorenzo G, 2008, RESP MED, V102, P232, DOI 10.1016/j.rmed.2007.09.007; Diette GB, 2002, ARCH INTERN MED, V162, P1123, DOI 10.1001/archinte.162.10.1123; DORIA G, 1978, IMMUNOLOGY, V35, P601; Eaton SM, 2008, J IMMUNOL, V181, P4825, DOI 10.4049/jimmunol.181.7.4825; Eaton SM, 2004, J EXP MED, V200, P1613, DOI 10.1084/jem.20041395; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; FARINATI F, 1993, GERONTOLOGY, V39, P146; FERGUSON FG, 1995, J GERONTOL A-BIOL, V50, pB378, DOI 10.1093/gerona/50A.6.B378; Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; Fletcher JM, 2005, J IMMUNOL, V175, P8218, DOI 10.4049/jimmunol.175.12.8218; Flores KG, 1999, J CLIN INVEST, V104, P1031, DOI 10.1172/JCI7558; Fortin CF, 2006, J LEUKOCYTE BIOL, V79, P1061, DOI 10.1189/jlb.0805481; Fortin CF, 2007, FEBS LETT, V581, P1173, DOI 10.1016/j.febslet.2007.02.029; FRANCESCHI C, 1995, IMMUNOL TODAY, V16, P12, DOI 10.1016/0167-5699(95)80064-6; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Fulop T, 1997, MECH AGEING DEV, V96, P15, DOI 10.1016/S0047-6374(96)01881-7; Gagliano N, 2007, DIGEST DIS, V25, P118, DOI 10.1159/000099475; Gangemi S, 2005, EXP GERONTOL, V40, P612, DOI 10.1016/j.exger.2005.04.004; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x; Hale JS, 2006, P NATL ACAD SCI USA, V103, P8447, DOI 10.1073/pnas.0601040103; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hartert TV, 2002, ANN ALLERG ASTHMA IM, V89, P467, DOI 10.1016/S1081-1206(10)62083-2; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Haynes L, 2003, P NATL ACAD SCI USA, V100, P15053, DOI 10.1073/pnas.2433717100; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; High KP, 2007, BIOGERONTOLOGY, V8, P583, DOI 10.1007/s10522-007-9106-6; Ho JC, 2001, AM J RESP CRIT CARE, V163, P983, DOI 10.1164/ajrccm.163.4.9909121; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Huss K, 2001, ANN ALLERG ASTHMA IM, V86, P524, DOI 10.1016/S1081-1206(10)62900-6; Hwang KA, 2009, MECH AGEING DEV, V130, P509, DOI 10.1016/j.mad.2009.06.003; Ito Y, 2007, EXP GERONTOL, V42, P789, DOI 10.1016/j.exger.2007.04.008; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Jing Y, 2007, EXP GERONTOL, V42, P719, DOI 10.1016/j.exger.2007.01.009; Johnson SA, 2002, J IMMUNOL, V168, P5014, DOI 10.4049/jimmunol.168.10.5014; Kang IS, 2004, J IMMUNOL, V173, P673, DOI 10.4049/jimmunol.173.1.673; Kapasi ZF, 2002, EUR J IMMUNOL, V32, P1567, DOI 10.1002/1521-4141(200206)32:6<1567::AID-IMMU1567>3.0.CO;2-P; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kearley J, 2008, J ALLERGY CLIN IMMUN, V122, P617, DOI 10.1016/j.jaci.2008.05.048; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984; Kim YK, 2002, CLIN EXP ALLERGY, V32, P1706, DOI 10.1046/j.1365-2222.2002.01524.x; King MJ, 2004, ALLERGY ASTHMA PROC, V25, P321; Kong KF, 2008, J VIROL, V82, P7613, DOI 10.1128/JVI.00618-08; Korenblat PE, 2000, ANN ALLERG ASTHMA IM, V84, P217, DOI 10.1016/S1081-1206(10)62759-7; Korn T, 2007, SEMIN IMMUNOL, V19, P362, DOI 10.1016/j.smim.2007.10.007; Lages CS, 2008, J IMMUNOL, V181, P1835, DOI 10.4049/jimmunol.181.3.1835; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23, DOI 10.1164/ajrccm.156.1.9608072; Malik A, 2004, ALLERGY ASTHMA PROC, V25, P169; Mancuso P, 2001, MECH AGEING DEV, V122, P1899, DOI 10.1016/S0047-6374(01)00322-0; Mathur SK, 2008, CHEST, V133, P412, DOI 10.1378/chest.07-2114; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; McKenna RW, 2001, BLOOD, V98, P2498, DOI 10.1182/blood.V98.8.2498; Meyer KC, 1999, THORAX, V54, P697, DOI 10.1136/thx.54.8.697; Meyer KC, 1998, MECH AGEING DEV, V104, P169, DOI 10.1016/S0047-6374(98)00065-7; MILLER C, 1995, J IMMUNOL, V155, P3377; Miller SJ, 2007, AM J PHYSIOL-HEART C, V293, pH2634, DOI 10.1152/ajpheart.00397.2007; Mitsunobu F, 1998, J ASTHMA, V35, P367, DOI 10.3109/02770909809075670; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MONTAGNA W, 1990, BRIT J DERMATOL, V122, P61, DOI 10.1111/j.1365-2133.1990.tb16127.x; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; *NAT ASTHM ED PREV, 1996, NIH PUBL; Naylor K, 2005, J IMMUNOL, V174, P7446, DOI 10.4049/jimmunol.174.11.7446; Nguyen M, 2005, J IMMUNOL, V175, P5701, DOI 10.4049/jimmunol.175.9.5701; Nyenhuis Sharmilee M, 2010, Immun Ageing, V7, P8, DOI 10.1186/1742-4933-7-8; Nyenhuis SM, 2010, J ALLERGY CLIN IMMUN, V125, P1163, DOI 10.1016/j.jaci.2010.02.015; Oda N, 2005, AM J RESP CRIT CARE, V171, P12, DOI 10.1164/rccm.200406-778OC; Ogata K, 1997, CLIN IMMUNOL IMMUNOP, V84, P269, DOI 10.1006/clin.1997.4401; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Parameswaran K, 1999, J ASTHMA, V36, P613, DOI 10.3109/02770909909087299; Pascual G, 2007, J VASC RES, V44, P192, DOI 10.1159/000100375; Peralbo E, 2006, BIOGERONTOLOGY, V7, P483, DOI 10.1007/s10522-006-9063-5; Plackett TP, 2004, J LEUKOCYTE BIOL, V76, P291, DOI 10.1189/jlb.1103592; Reed CE, 2006, J ALLERGY CLIN IMMUN, V118, P543, DOI 10.1016/j.jaci.2006.06.020; Reed CE, 2010, J ALLERGY CLIN IMMUN, V126, P681, DOI 10.1016/j.jaci.2010.05.035; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Russo M, 2001, AM J RESP CELL MOL, V24, P518, DOI 10.1165/ajrcmb.24.5.4320; Sandmand M, 2002, CLIN EXP IMMUNOL, V127, P107, DOI 10.1046/j.1365-2249.2002.01736.x; Sin DD, 2001, CHEST, V119, P720, DOI 10.1378/chest.119.3.720; Sin DD, 2001, EUR RESPIR J, V17, P380, DOI 10.1183/09031936.01.17303800; Stout-Delgado HW, 2009, CELL HOST MICROBE, V6, P446, DOI 10.1016/j.chom.2009.09.011; Svartengren M, 2005, EUR RESPIR J, V26, P609, DOI 10.1183/09031936.05.00002105; Tasat DR, 2003, AGING CELL, V2, P159, DOI 10.1046/j.1474-9728.2003.00051.x; Tesar BM, 2009, AM J TRANSPLANT, V9, P54, DOI 10.1111/j.1600-6143.2008.02458.x; Thomas SY, 2010, J ALLERGY CLIN IMMUN, V125, P980, DOI 10.1016/j.jaci.2010.01.032; Timm JA, 1999, J IMMUNOL, V162, P711; Topp MS, 2003, J EXP MED, V198, P947, DOI 10.1084/jem.20021288; TORTORELLA C, 1993, MECH AGEING DEV, V69, P53, DOI 10.1016/0047-6374(93)90071-X; Tsaknaridis L, 2003, J NEUROSCI RES, V74, P296, DOI 10.1002/jnr.10766; Tsukamoto H, 2009, P NATL ACAD SCI USA, V106, P18333, DOI 10.1073/pnas.0910139106; Turygin V V, 2005, Neurosci Behav Physiol, V35, P909, DOI 10.1007/s11055-005-0144-8; Umetsu DT, 2010, J ALLERGY CLIN IMMUN, V125, P975, DOI 10.1016/j.jaci.2010.02.006; Valenzuela HF, 2002, CLIN IMMUNOL, V105, P117, DOI 10.1006/clim.2002.5271; van Duin D, 2007, J IMMUNOL, V178, P970, DOI 10.4049/jimmunol.178.2.970; Vargas PA, 2004, J ALLERGY CLIN IMMUN, V114, P499, DOI 10.1016/j.jaci.2004.05.025; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Yager EJ, 2008, J EXP MED, V205, P711, DOI 10.1084/jem.20071140; Yang YH, 2008, J IMMUNOL, V180, P3775, DOI 10.4049/jimmunol.180.6.3775; Yen CJ, 2000, J BIOMED SCI, V7, P317; Zureik M, 2002, RESPIRATION, V69, P223, DOI 10.1159/000063624	133	123	126	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					690	699		10.1016/j.jaci.2010.08.011	http://dx.doi.org/10.1016/j.jaci.2010.08.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920759	Green Accepted			2022-12-18	WOS:000282510000002
J	Wang, J; Godbold, JH; Sampson, HA				Wang, Julie; Godbold, James H.; Sampson, Hugh A.			Correlation of serum allergy (IgE) tests performed by different assay systems	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; IgE; ImmunoCAP; Turbo-MP; Immulite; food allergy	FOOD ALLERGY; PEANUT ALLERGY; EGG ALLERGY; ACCURACY; CHALLENGES; ANTIBODIES; RESOLUTION; PRECISION; CHILDREN	Background: In vitro testing is commonly used to diagnose and manage allergies. Clinical reactivity has been correlated with food-specific IgE levels by using the ImmunoCAP (Phadia, Uppsala, Sweden). Objective: To determine whether IgE levels derived from different assays are equivalent to those measured by ImmunoCAP. Methods: Fifty patients from the Mount Sinai Pediatric Allergy practice were prospectively enrolled. For each deidentified sample, specific IgE levels were measured to egg, milk, peanut, cat, birch, and Dermatophagoides farinae at different laboratories, each using a different assay system (Phadia ImmunoCAP, Agilent Turbo-MP, and Siemens Immulite 2000). Results were analyzed to determine whether IgE measurements were equivalent. Food allergen-specific IgE levels were correlated with clinical data and around empirically determined thresholds that predict probability of clinical disease in 50% or 95% of subjects. Results: Variable degrees of agreement existed among the 3 assays. Immulite 2000 overestimated all specific IgE levels compared with ImmunoCAP. Turbo-MP overestimated for egg but underestimated for birch and D farinae. Differences for milk, peanut, and cat were observed, without a trend toward overestimation or underestimation. Furthermore, several values for the food allergens were discrepant around the 50 % and 95 % positive predictive values for clinical reactivity. Conclusion: Discrepancies in specific IgE values from 3 different assays can potentially lead to altered management and treatment. The predictive values for clinical reactivity associated with food-specific IgE levels determined by ImmunoCAP should not be applied to results from other assays.	[Wang, Julie; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Godbold, James H.] Mt Sinai Sch Med, Dept Commun & Prevent Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Wang, J (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	Julie.wang@mssm.edu						Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Eigenmann PA, 2005, CLIN EXP ALLERGY, V35, P247, DOI 10.1111/j.1365-2222.2005.02183.x; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; MATSSON P, 2007, ILA20A2 CLSI; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Szeinbach SL, 2001, ANN ALLERG ASTHMA IM, V86, P373, DOI 10.1016/S1081-1206(10)62481-7; Vignati G, 2003, Eur Ann Allergy Clin Immunol, V35, P285; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219; Wood RA, 2003, PEDIATRICS, V111, P1631; Wood RA, 2007, ANN ALLERG ASTHMA IM, V99, P34, DOI 10.1016/S1081-1206(10)60618-7	18	123	127	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1219	1224		10.1016/j.jaci.2007.12.1150	http://dx.doi.org/10.1016/j.jaci.2007.12.1150			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18243289				2022-12-18	WOS:000255961700022
J	Williams, LK; Joseph, CL; Peterson, EL; Wells, K; Wang, M; Chowdhry, VK; Walsh, M; Campbell, J; Rand, CS; Apter, AJ; Lanfear, DE; Tunceli, K; Pladevall, M				Williams, L. Keoki; Joseph, Christine L.; Peterson, Edward L.; Wells, Karen; Wang, Mingqun; Chowdhry, Vimal K.; Walsh, Matthew; Campbell, Janis; Rand, Cynthia S.; Apter, Andrea J.; Lanfear, David E.; Tunceli, Kaan; Pladevall, Manel			Patients with asthma who do not fill their inhaled corticosteroids: A study of primary nonadherence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary nonadherence; inhaled corticosteroids; asthma race-ethnicity; controller medication	PHARMACY RECORDS; LOW-INCOME; ADHERENCE; MEDICATION; OUTCOMES; ADULTS; CARE; GUIDELINES; MANAGEMENT; STEROIDS	Background: Adherence to inhaled corticosteroids (ICSs) is known to be poor among patients with asthma; however, little is known about patients who do not fill their ICS prescriptions (ie, primary nonadherence). Objective: To estimate rates of primary nonadherence and to explore associated factors. Methods: The study population was members of a large health maintenance organization in southeast Michigan who met the following criteria: age 5 to 56 years; previous diagnosis of asthma; at least I electronic prescription for an ICS between February 17, 2005, and June 1, 2006; and at least 3 months follow-tip after the ICS prescription. Adherence was estimated by using electronic prescription information and pharmacy claims data. Multivariable stepwise analysis was used to identify factors associated with primary nonadherence compared with adherent patients. Results: One thousand sixty-four patients met the study criteria and bad calculable adherence. Of these patients, 82 (8%) never filled their ICS prescription. Stepwise regression identified the following factors to be associated with an increased likelihood of primary nonadherence: younger age, female sex, African American race-ethnicity, and lower rescue medication use. Factors associated with primary nonadherence differed between race-ethnic groups. Conclusion: Primary nonadherence was associated with lower baseline rescue medication use, which may reflect lower perceived need for ICS therapy in patients with milder asthma. Rates of primary nonadherence and the factors which influenced this outcome differed by race-ethnicity. Clinical implications: Understanding patient characteristics associated with primary nonadherence may be important for disease management, because many patients with asthma do not fill their ICS prescriptions.	Henry Ford Hosp, Dept Internal Med, Detroit, MI 48202 USA; Henry Ford Hosp, Ctr Hlth Serv Res, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Hlth Alliance Plan, Detroit, MI USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Johns Hopkins University; University of Pennsylvania	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,3A CHSR, Detroit, MI 48202 USA.	kwillia5@hfhs.org			NHLBI NIH HHS [R01HL079055] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079055] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RJ, 2003, J ALLERGY CLIN IMMUN, V112, P445, DOI 10.1067/mai.2003.1625; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; Bronstein J M, 2000, J Healthc Qual, V22, P13; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Cabana MD, 2001, ARCH PEDIAT ADOL MED, V155, P1057, DOI 10.1001/archpedi.155.9.1057; Charles H, 2003, J NATL MED ASSOC, V95, P17; Choo PW, 1999, MED CARE, V37, P846, DOI 10.1097/00005650-199909000-00002; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Crim C, 2000, CHEST, V118, p62S, DOI 10.1378/chest.118.2_suppl.62S; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DiMatteo MR, 2002, MED CARE, V40, P794, DOI 10.1097/01.MLR.0000024612.61915.2D; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; Horne R, 2002, PSYCHOL HEALTH, V17, P17, DOI 10.1080/08870440290001502; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Lindberg M, 2001, INT J QUAL HEALTH C, V13, P375, DOI 10.1093/intqhc/13.5.375; O'Malley AS, 2004, PREV MED, V38, P777, DOI 10.1016/j.ypmed.2004.01.018; Pladevall M, 2004, DIABETES CARE, V27, P2800, DOI 10.2337/diacare.27.12.2800; Riekert KA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e214; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schectman JM, 2002, DIABETES CARE, V25, P1015, DOI 10.2337/diacare.25.6.1015; Schroeder K, 2004, J CLIN EPIDEMIOL, V57, P2, DOI 10.1016/j.jclinepi.2003.07.002; SCHUR CL, 2004, ISSUE BRIEF COMMONW, V716, P1; SHEA S, 1992, AM J PUBLIC HEALTH, V82, P1607, DOI 10.2105/AJPH.82.12.1607; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; Watts R W, 1997, Aust Fam Physician, V26 Suppl 1, pS4; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028	31	123	127	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1153	1159		10.1016/j.jaci.2007.08.020	http://dx.doi.org/10.1016/j.jaci.2007.08.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	231TZ	17936894				2022-12-18	WOS:000250973400026
J	Zhang, L; Radigan, L; Salzer, U; Behrens, TW; Grimbacher, B; Diaz, G; Bussel, J; Cunningham-Rundles, C				Zhang, Li; Radigan, Lin; Salzer, Ulrich; Behrens, Timothy W.; Grimbacher, Bodo; Diaz, George; Bussel, James; Cunningham-Rundles, Charlotte			Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: Clinical and immunologic outcomes in heterozygotes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						common variable immune deficiency; TACI; B cell; IgG; IgA; immune thrombocytopenia purpura; splenectomy	SELECTIVE IGA DEFICIENCY; B-CELLS; T-CELLS; TACI; APRIL; RECEPTOR; BLYS; IDENTIFICATION; BINDING; BAFF	Background: Mutations in the gene coding for transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) have been identified in common variable immunodeficiency (CVID). Mutations coincided with immunodeficiency in families, suggesting dominant inheritance. Objective: Because most subjects with CVID have no immunodeficient family members and heterozygous mutations predominate, the role of TACI mutations in sporadic CVID is unclear. Methods: TACI was sequenced from the genomic DNA of 176 subjects with CVID and family members. B cells of subjects with or without mutations were examined for binding to the ligand, a proliferation inducing ligand (APRIL), and for proliferation and immunoglobulin production after ligand stimulation. Data analysis was performed to assess the clinical relevance of TACI mutations. Results: Heterozygous TACI mutations were found in 13 subjects (7.3%). Six with mutations (46%) had episodes of autoimmune thrombocytopenia, in contrast with 12% of 163 subjects without mutations; splenomegaly and splenectomy were significantly increased (P =.012; P =.001.) B cells of some had impaired binding of APRIL and on culture with this ligand were defective in proliferation and immunoglobulin production; however, this was not different from B cells of subjects without mutations. Eight first-degree relatives from 5 families had the same mutations but were not immune-deficient, and their B cells produced normal amounts of IgG and IgA after APRIL stimulation. Conclusion: Mutations in TACI significantly predispose to autoimmunity and lymphoid hyperplasia in CVID, but additional genetic or environmental factors are required to induce immune deficiency. Clinical implications: Additional causes of this common immune deficiency syndrome remain to be determined.	Mt Sinai Med Ctr, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, Pediat & Immunobiol Ctr, New York, NY 10029 USA; Univ Freiburg, Sch Med, Div Rheumatol & Clin Immunol, Freiburg, Germany; UCL, Royal Free Hosp, Dept Immunol & Mol Pathol, London WC1E 6BT, England; Cornell Univ, Weil Med Sch, Dept Pediat, New York, NY USA; Genentech Inc, San Francisco, CA 94080 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Freiburg; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cornell University; Roche Holding; Genentech	Cunningham-Rundles, C (corresponding author), Mt Sinai Med Ctr, Dept Pediat, 1425 Madison Ave, New York, NY 10029 USA.	Charlotte.Cunningham-Rundles@MSSM.edu	Diaz, George/AAF-6199-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI030070, R21AI101093, R18AI048693, P01AI061093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043274] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI101093, AI 101093, P01 AI061093, N01AI30070, AI-48693, P01 AI061093-01, P01 AI061093-020002, P01 AI061093-019001, U19 AI0167152, P01 AI061093-07, AI-467320, R18 AI048693] Funding Source: Medline; NIAMS NIH HHS [R01 AR043274, AR043274] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agematsu K, 2002, CLIN IMMUNOL, V103, P34, DOI 10.1006/clim.2001.5197; Bischof D, 2006, BLOOD, V107, P3235, DOI 10.1182/blood-2005-01-0256; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Chapel H, 2003, CLIN EXP IMMUNOL, V132, P9, DOI 10.1046/j.1365-2249.2003.02110.x; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Cunningham-Rundles C, 2001, Curr Allergy Asthma Rep, V1, P421, DOI 10.1007/s11882-001-0027-1; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; FISCHER MB, 1994, BLOOD, V84, P4234, DOI 10.1182/blood.V84.12.4234.bloodjournal84124234; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; Goldacker S, 2005, CURR OPIN ALLERGY CL, V5, P504, DOI 10.1097/01.all.0000191888.97397.b3; Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Kondratenko I, 1997, CLIN EXP IMMUNOL, V108, P9, DOI 10.1046/j.1365-2249.1997.d01-993.x; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; NORTH ME, 1989, CLIN EXP IMMUNOL, V76, P19; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; PANHAMMARSTROM Q, 2007, IN PRESS NAT GENET; Sakurai D, 2007, BLOOD, V109, P2961, DOI 10.1182/blood-2006-08-041772; Sakurai D, 2007, EUR J IMMUNOL, V37, P110, DOI 10.1002/eji.200636623; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2006, CURR OPIN RHEUMATOL, V18, P377, DOI 10.1097/01.bor.0000231906.12172.6e; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Wallweber HJA, 2004, J MOL BIOL, V343, P283, DOI 10.1016/j.jmb.2004.08.040; Worth A, 2006, BRIT J HAEMATOL, V133, P124, DOI 10.1111/j.1365-2141.2006.05993.x; Yan MH, 2000, NAT IMMUNOL, V1, P37, DOI 10.1038/76889; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790	34	123	125	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1178	1185		10.1016/j.jaci.2007.10.001	http://dx.doi.org/10.1016/j.jaci.2007.10.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17983875	Green Accepted, Bronze			2022-12-18	WOS:000250973400030
J	Simon, D; Simon, HU				Simon, Dagmar; Simon, Hans-Uwe			Eosinophilic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; classification; eosinophilia; eosinophils; eosinophilic disorders; infection; IL-5; leukemia; lymphoma; hypereosinophilic syndrome; tumors	COLONY-STIMULATING FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; VERSUS-HOST-DISEASE; HYPER-IGE SYNDROME; PERIPHERAL-BLOOD; T-CELLS; HYPEREOSINOPHILIC SYNDROME; CHROMOSOME-TRANSLOCATION; LYMPHOCYTIC-LEUKEMIA; MONOCLONAL-ANTIBODY	Eosinophilic inflammatory responses occur in association with multiple disorders. Although the initial cause and the affected organs vary among the different eosinophilic disorders, there are only 2 major pathways that mediate eosinophilia: (1) cytokine-mediated increased differentiation and survival of eosinophils (extrinsic eosinophilic disorders), and (2) mutation-mediated clonal expansion of eosinophils (intrinsic eosinophilic disorders). Independent from the original trigger, the most common cause of eosinophilia is the increased generation of IL-5-producing T cells. In some cases, tumor cells are the source of eosinophil hematopoietins. The intrinsic eosinophilic disorders are characterized by mutations in pluripotent or multipotent hematopoietic stem cells leading to chronic myeloid leukemias with eosinophils as part of the clone. Here, we propose a new classification of eosinophilic disorders on the basis of these obvious pathogenic differences between the 2 groups of patients. We then discuss many known eosinophilic disorders, which can be further subdivided by differences in T-cell activation mechanisms, origin of the cytokine-producing tumor cell, or potency of the mutated stem cell. Interestingly, many subgroups of patients originally thought to have the idiopathic hypereosinophilic syndrome can be integrated in this classification.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bern, Dept Dermatol, Inselspital, CH-3010 Bern, Switzerland; Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Aleman K, 2001, EUR J PEDIATR, V160, P718, DOI 10.1007/s004310100816; Ansarin Habib, 2006, Dermatol Online J, V12, P19; Bain BJ, 2003, BRIT J HAEMATOL, V122, P173, DOI 10.1046/j.1365-2141.2003.04458.x; Bain BJ, 2004, AM J HEMATOL, V77, P82, DOI 10.1002/ajh.20088; Bain BJ, 2001, WHO CLASSIFICATION T, P29; Basara N, 2002, BLOOD, V100, P3055, DOI 10.1182/blood-2002-04-1118; Becker Y, 2006, VIRUS GENES, V33, P235, DOI 10.1007/s11262-006-0064-x; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; Bonnekoh B, 2002, J CANCER RES CLIN, V128, P161, DOI 10.1007/s00432-001-0313-2; BORISH L, 1993, J ALLERGY CLIN IMMUN, V92, P123, DOI 10.1016/0091-6749(93)90046-I; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse WW, 1997, J ALLERGY CLIN IMMUN, V100, P147, DOI 10.1016/S0091-6749(97)70216-1; BUTTERFIELD JH, 1992, BLOOD, V79, P688; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; Casagrande BF, 2006, J INVEST DERMATOL, V126, P2414, DOI 10.1038/sj.jid.5700431; Cay A, 2006, CAN J GASTROENTEROL, V20, P361, DOI 10.1155/2006/386918; Chan Joanna L, 2004, J Drugs Dermatol, V3, P315; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; COX D, 1995, ARTHRITIS RHEUM, V38, P939, DOI 10.1002/art.1780380709; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DICKER RM, 1990, ANN INTERN MED, V112, P957, DOI 10.7326/0003-4819-112-12-957; Ehrlich P., 1879, ARCH ANAT PHYSL, V3, P166; Eriksson MO, 1998, BRIT J DERMATOL, V138, P390; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fridlender ZG, 2003, AM J MED SCI, V326, P98, DOI 10.1097/00000441-200308000-00008; Geisinger KR, 1998, AM J CLIN PATHOL, V109, P294, DOI 10.1093/ajcp/109.3.294; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gotlib J, 2006, BEST PRACT RES CL HA, V19, P535, DOI 10.1016/j.beha.2005.07.013; Gouon-Evans V, 2000, DEVELOPMENT, V127, P2269; GRANTER SR, 1994, JAMA-J AM MED ASSOC, V272, P1283, DOI 10.1001/jama.272.16.1283; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; GRUSS HJ, 1994, CRIT REV ONCOGENESIS, V5, P473, DOI 10.1615/CritRevOncog.v5.i5.30; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Heufelder AE, 1996, J CLIN ENDOCR METAB, V81, P977, DOI 10.1210/jc.81.3.977; HILL SM, 1990, ARCH DIS CHILD, V65, P132, DOI 10.1136/adc.65.1.132; HOGAN TF, 1987, J CLIN ONCOL, V5, P382, DOI 10.1200/JCO.1987.5.3.382; Horie S, 1996, LANCET, V348, P166, DOI 10.1016/S0140-6736(96)00145-6; Imai Y, 1996, BRIT J HAEMATOL, V95, P710, DOI 10.1046/j.1365-2141.1996.d01-1961.x; Ionescu MA, 2005, J AM ACAD DERMATOL, V52, P32, DOI 10.1016/j.jaad.2004.03.003; Jacobsohn DA, 2004, TRANSPLANTATION, V77, P1096, DOI 10.1097/01.TP.0000118409.92769.FA; Jaggi P, 2005, PEDIATR INFECT DIS J, V24, P1020, DOI 10.1097/01.inf.0000183775.69035.33; JANIN A, 1994, ANN INTERN MED, V120, P993, DOI 10.7326/0003-4819-120-12-199406150-00004; JEDERLINIC PJ, 1988, MEDICINE, V67, P154, DOI 10.1097/00005792-198805000-00002; Jezior D, 2003, TRANSPLANT P, V35, P2182, DOI 10.1016/S0041-1345(03)00776-0; Kargili AE, 2004, RHEUMATOL INT, V24, P321, DOI 10.1007/s00296-004-0469-6; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Keung YK, 2002, CANCER GENET CYTOGEN, V138, P139, DOI 10.1016/S0165-4608(02)00609-X; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Laman JD, 2003, TRENDS IMMUNOL, V24, P190, DOI 10.1016/S1471-4906(03)00063-2; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEHRER RI, 1989, J IMMUNOL, V142, P4428; LOWE D, 1981, J CLIN PATHOL, V34, P1343, DOI 10.1136/jcp.34.12.1343; MA SK, 1995, BRIT J HAEMATOL, V90, P216, DOI 10.1111/j.1365-2141.1995.tb03405.x; MacDonald SM, 2001, P NATL ACAD SCI USA, V98, P10829, DOI 10.1073/pnas.201191498; MCMASTER MT, 1992, J IMMUNOL, V148, P1699; MEEKER TC, 1990, BLOOD, V76, P285; Meleg-Smith S, 2005, TRANSPLANTATION, V79, P444, DOI 10.1097/01.TP.0000147318.48620.44; Meningaud JP, 2007, J ORAL MAXIL SURG, V65, P134, DOI 10.1016/j.joms.2005.10.043; Nagai Y, 2001, ENDOCR J, V48, P311, DOI 10.1507/endocrj.48.311; Nagano T, 1999, J CLIN IMMUNOL, V19, P422, DOI 10.1023/A:1020511002025; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Osgood EE, 1939, ARCH INTERN MED, V64, P105, DOI 10.1001/archinte.1939.00190010115010; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; Papi Alberto, 2006, Proc Am Thorac Soc, V3, P245, DOI 10.1513/pats.200512-125SF; Pichler WJ, 2002, CURR OPIN ALLERGY CL, V2, P301, DOI 10.1097/00130832-200208000-00003; Pichler WJ, 2005, TOXICOLOGY, V209, P95, DOI 10.1016/j.tox.2004.12.014; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Plotz SG, 2001, BLOOD, V97, P235, DOI 10.1182/blood.V97.1.235; Rasi A, 2004, INT J DERMATOL, V43, P588, DOI 10.1111/j.1365-4632.2004.02155.x; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263; RIGAUPEREZ JG, 1984, AM J EPIDEMIOL, V119, P250, DOI 10.1093/oxfordjournals.aje.a113744; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; Robertson SA, 1996, J REPROD FERTIL, V107, P265, DOI 10.1530/jrf.0.1070265; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Roujeau JC, 2005, TOXICOLOGY, V209, P123, DOI 10.1016/j.tox.2004.12.022; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Sasama Jan, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P2, DOI 10.1097/00020840-200502000-00003; Schaffer JV, 2006, SEMIN CUTAN MED SURG, V25, P190, DOI 10.1016/j.sder.2006.09.001; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; SILBERSTEIN DS, 1989, J IMMUNOL, V142, P2162; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Simon HU, 2007, J ALLERGY CLIN IMMUN, V119, P246, DOI 10.1016/j.jaci.2006.08.025; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 1997, EUR J IMMUNOL, V27, P3536, DOI 10.1002/eji.1830271256; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; Simon HU, 2001, INT ARCH ALLERGY IMM, V124, P242, DOI 10.1159/000053723; Simon HU, 1997, J IMMUNOL, V158, P3902; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SPIERS ASD, 1977, SCAND J HAEMATOL, V18, P25; Steensma DP, 2003, LEUKEMIA RES, V27, P95, DOI 10.1016/S0145-2126(02)00098-X; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2004, ALLERGY, V59, P15, DOI 10.1046/j.1398-9995.2003.00382.x; STURROCK RF, 1983, T ROY SOC TROP MED H, V77, P363, DOI 10.1016/0035-9203(83)90166-9; TONOOKA T, 1984, MED PEDIATR ONCOL, V12, P33, DOI 10.1002/mpo.2950120109; Vassina EM, 2006, EUR J IMMUNOL, V36, P1975, DOI 10.1002/eji.200635943; Viallard JF, 2001, J RHEUMATOL, V28, P75; Wakugawa M, 2000, BRIT J DERMATOL, V143, P112, DOI 10.1046/j.1365-2133.2000.03599.x; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WHITTAKER SJ, 1993, BRIT J DERMATOL, V128, P483, DOI 10.1111/j.1365-2133.1993.tb00223.x; Wolf R, 2005, CLIN DERMATOL, V23, P311, DOI 10.1016/j.clindermatol.2005.02.001; Wolff D, 2004, EUR J HAEMATOL, V72, P145, DOI 10.1046/j.0902-4441.2003.00181.x; WOOD C, 1986, AM J DERMATOPATH, V8, P186, DOI 10.1097/00000372-198606000-00002; Yamazaki K, 1996, AM J GASTROENTEROL, V91, P516; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356; YOUSEM SA, 1992, HUM PATHOL, V23, P1172, DOI 10.1016/0046-8177(92)90036-3; Zhang N, 2005, RHINOLOGY, V43, P162	121	123	135	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1291	1300		10.1016/j.jaci.2007.02.010	http://dx.doi.org/10.1016/j.jaci.2007.02.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17399779				2022-12-18	WOS:000247232800001
J	von Berg, A; Koletzko, S; Filipiak-Pittroff, B; Laubereau, B; Grubl, A; Wichmann, HE; Bauer, CP; Reinhardt, D; Berdel, D				von Berg, Andrea; Koletzko, Sibylle; Filipiak-Pittroff, Birgit; Laubereau, Birgit; Gruebl, Armin; Wichmann, Heinz-Erich; Bauer, Carl-Peter; Reinhardt, Dietrich; Berdel, Dietrich			Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: Three-year results of the German Infant Nutritional Intervention Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birth cohort; randomized trial; cow's milk formula; hydrolyzed formula; breast-feeding; prevention; atopic dermatitis asthma	FOOD-ALLERGEN AVOIDANCE; PRIMARY PREVENTION	Background: Recommendations for primary prevention of allergic diseases in high-risk children include feeding with hydrolyzed formulas if breast-feeding is insufficient. Objective: The primary objective of the German Infant Nutritional Intervention study was to investigate the allergy preventive effect of 3 hydrolyzed formulas compared with cow's milk formula in the first 3 years of life in a randomized, double-blind trial. Methods: Between 1995 and 1998, 2252 newborns with atopic heredity were allocated to a group receiving cow's milk formula, partially or extensively hydrolyzed whey formula, or extensively hydrolyzed casein formula as a milk substitute for the first 4 months if breast-feeding was insufficient. Main outcome parameters were allergic manifestations, atopic dermatitis (AD), and asthma. Results: After 3 years, 396 of 2252 children (17.6%) had dropped out. Breast-fed infants without formula feeding during the intervention (n = 889) were considered separately. A significant reduction of the incidence of AD was achieved with the extensively hydrolyzed casein formula in the intention-to-treat (ITT; n = 1363) and per protocol (PP; n = 904) analyses (ITT: population odds ratio [95% CI], 0.67 [0.45-0.99]; PP: adjusted odds ratio [ORadj], 0.53 [0.32-0.88]), and with the partially hydrolyzed whey formula in the PP analysis (ITT: population odds ratio, 0.76 [0.52-1.11]; PP:O-adj, 0.60 [0.37-0.97]). None of the formulas reduced the incidence of asthma. Conclusion: The risk for AD, but not for asthma, can be reduced with certain cow's milk hydrolyzates in high-risk infants when breast-feeding is insufficient. Clinical implications: Early nutritional intervention in high-risk children has significant influence on the incidence of AD, but not of asthma.	Marien Hosp Wesel, Dept Paediat, D-46483 Wesel, Germany; Univ Munich, Dept Paediat, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Tech Univ Munich, Dept Paediat, D-8000 Munich, Germany; Landesversicherungsanstalt Oberbayern, Munich, Germany	St. Marien Hospital; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	von Berg, A (corresponding author), Marien Hosp Wesel, Dept Paediat, Pastor Janssenstr 8-38, D-46483 Wesel, Germany.	vonberg@marien-hospital-wesel.de	Wichmann, Heinz Erich/AAA-5695-2022					Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Baker SS, 2000, PEDIATRICS, V106, P346; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Fritsche R, 1998, NUTR RES, V18, P1335, DOI 10.1016/S0271-5317(98)00112-2; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Heine RG, 2004, J PEDIATR-US, V144, P564, DOI 10.1016/j.jpeds.2004.03.001; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; Osborn DA, 2003, COCHRANE DB SYST REV, V4; Rosendal A, 2000, J DAIRY SCI, V83, P2200, DOI 10.3168/jds.S0022-0302(00)75103-4; RUGO E, 1992, CLIN EXP ALLERGY, V22, P635, DOI 10.1111/j.1365-2222.1992.tb00180.x; Schoetzau A, 2002, ARCH DIS CHILD, V86, P180, DOI 10.1136/adc.86.3.180; Schoetzau A, 2001, EUR J PEDIATR, V160, P323, DOI 10.1007/PL00008442; Soderhall C, 2005, J ALLERGY CLIN IMMUN, V116, P220, DOI 10.1016/j.jaci.2005.03.002; Szajewska H, 2004, ACTA PAEDIATR, V93, P1159, DOI 10.1080/08035250410026554; Szajewska H, 2001, J PEDIATR GASTR NUTR, V32, P303, DOI 10.1097/00005176-200103000-00013; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; VANBERESTEIJN ECH, 1995, J ALLERGY CLIN IMMUN, V96, P365, DOI 10.1016/S0091-6749(95)70056-0; vanBeresteijn ECH, 1996, DIABETES CARE, V19, P1364, DOI 10.2337/diacare.19.12.1364; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/BF02029362; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Zeiger RS, 2003, PEDIATRICS, V111, P1662; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	28	123	128	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					718	725		10.1016/j.jaci.2006.11.017	http://dx.doi.org/10.1016/j.jaci.2006.11.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17240440				2022-12-18	WOS:000244925000027
J	Gurish, MF; Boyce, JA				Gurish, MF; Boyce, JA			Mast cells: Ontogeny, homing, and recruitment of a unique innate effector cell	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; basophils; progenitors; homing; recruitment	RAT GASTROINTESTINAL MUCOSA; BONE-MARROW; TRICHINELLA-SPIRALIS; MICE; PROGENITORS; IDENTIFICATION; PRECURSORS; INFECTION; DIFFERENTIATION; ULTRASTRUCTURE	Mast cells (MCs) are found principally in peripheral tissues yet are of bone marrow origin. Recent studies in mice trace the MC lineage from the common myeloid progenitor through the granulocyte-macrophage progenitor in the bone marrow to a committed MC progenitor (MCP). Additionally, at least in the mouse, a bipotent basophil-MC progenitor has been identified in the spleen, suggesting a physiologic role for this organ in MC development. MCPs are especially abundant in the mouse intestine, likely ensuring the capacity for a rapid expansion of MCs in the intestinal epithelium during the effector response to helminth infection and perhaps providing a pool of committed cells capable of redistribution to other tissues. Migration of MCPs to the intestine is constitutive and controlled by a chemokine receptor 2 and alpha 4 beta 7 integrins expressed on the MCPs, with the latter integrin interacting with endothelial vascular cell adhesion molecule 1 and mucosal addressin cell adhesion molecule 1. In contrast, normal mouse lung tissue contains few MCPs and MCs, and these cellular reservoirs are not affected by the lack of alpha chemokine receptor 2 or alpha 4 beta 7 integrin. Nonetheless, robust recruitment of MCPs to the lung occurs during experimentally induced allergic pulmonary inflammation and requires alpha 4 beta 7 and alpha 4 beta 1 integrins interacting with vascular cell adhesion molecule 1 but not with mucosal addressin cell adhesion molecule 1. Thus although MCs are present in all organs, the pathways responsible for the trafficking of MCPs from the circulation are organ specific and include both constitutive and inducible systems, ensuring both resident MCs and the potential for incremental recruitment in accord with the requirements of the immune response. These findings in mice await confirmation in human subjects.	Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University	Gurish, MF (corresponding author), Rm 616,Smith Res Bldg,1 Jimmy Fund Way, Boston, MA 02115 USA.	mgurish@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048802, U01AI031599, R56AI052353, R01AI052353, U19AI031599] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 036110] Funding Source: Medline; NIAID NIH HHS [AI 48802, AI 031599, AI 052353] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abonia JP, 2005, BLOOD, V105, P4308, DOI 10.1182/blood-2004-09-3578; Arinobu Y, 2005, P NATL ACAD SCI USA, V102, P18105, DOI 10.1073/pnas.0509148102; Artis D, 2000, EUR J IMMUNOL, V30, P1656, DOI 10.1002/1521-4141(200006)30:6&lt;1656::AID-IMMU1656&gt;3.0.CO;2-Z; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Boyce JA, 2001, SAMTERS IMMUNOLOGIC, P253; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; CRAPPER RM, 1983, J IMMUNOL, V131, P923; Ehrlich P, 1879, ARCH ANAT PHYSL, V3, P571; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Gurish MF, 2001, J EXP MED, V194, P1243, DOI 10.1084/jem.194.9.1243; GUYGRAND D, 1984, J EXP MED, V160, P12, DOI 10.1084/jem.160.1.12; Ikeda RK, 2003, J IMMUNOL, V171, P4860, DOI 10.4049/jimmunol.171.9.4860; IRANI AMA, 1987, J IMMUNOL, V138, P4381; Jamur MC, 2005, BLOOD, V105, P4282, DOI 10.1182/blood-2004-02-0756; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1983, RADIAT RES, V93, P147, DOI 10.2307/3575950; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Mwamtemi HH, 2001, J IMMUNOL, V166, P4672, DOI 10.4049/jimmunol.166.7.4672; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Pennock JL, 2004, BLOOD, V103, P2655, DOI 10.1182/blood-2003-09-3146; ROBINSON DS, 1993, SPRINGER SEMIN IMMUN, V15, P17; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; ROTTEM M, 1993, J IMMUNOL, V151, P4950; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; SONODA S, 1986, J IMMUNOL, V137, P1319; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; Yuan Q, 1998, J IMMUNOL, V161, P5143	37	123	131	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1285	1291		10.1016/j.jaci.2006.04.017	http://dx.doi.org/10.1016/j.jaci.2006.04.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750988				2022-12-18	WOS:000238332300013
J	Hoarau, C; Lagaraine, C; Martin, L; Velge-Roussel, F; Lebranchu, Y				Hoarau, C; Lagaraine, C; Martin, L; Velge-Roussel, F; Lebranchu, Y			Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bifidobacterium breve; dendritic cells; maturation; cell survival; tolerance; Bcl-2 protein family; Toll-like receptor 2; IL-10; IL-12; allergy	CD4(+) T-CELLS; LACTOBACILLUS-RHAMNOSUS; PROTEIN-KINASE; CUTTING EDGE; IN-VITRO; INDUCTION; BACTERIA; MODULATION; PROBIOTICS; RESPONSES	Background: Commensal gut bacteria are essential for the development and maintenance of the gut's immune system. Some bacteria strains, such as Lactobacillus and Bifidobacterium species, have been reported to provide protection from allergic and inflammatory bowel diseases. However, the interactions between these commensal bacteria and the immune system are largely unknown. Objective: We studied the effects of a supernatant from the culture of B breve C50 (BbC50) on the maturation, activation, and survival of human dendritic cells (DCs). Methods: DCs were differentiated from human monocytes with IL-4 and GM-CSF for 5 days and cultured with BbC50 supernatant (BbC50(SN)) or LPS for 2 days. Results: BbC50(SN) induced DC maturation, with increase in CD83, CD86, and HLA-DR expression. We also showed, for the first time,, that BbC50(SN) prolonged DC survival, with high IL-10 and low IL-12 production compared with that seen in LPS-DCs. Moreover, BbC50(SN) inhibited the effects of LPS on DCs, both in terms of IL-12 production and in terms of survival. The prolonged DC survival was independent of IL-10 production and nuclear factor kappa B pathway but was associated with an upregulation of Bcl-x(L) and Phospho-Bad. Finally, BbC50(SN) induced activation of Toll-like receptor 2 (TLR2)-transfected cells in contrast to TLR4-, TLR7-, and TLR9-transfected cells. Conclusion: The supernatant of B breve C50 can induce DC maturation and prolonged DC survival through TLR2, with high IL-10 production. These properties might correspond to a regulatory DC profile, which could limit the excessive T(H)1 response and control the excessive T(H)2 polarization observed in atopic newborns.	Univ Tours, IFR 135, UFR Med Tours, F-37032 Tours, France; Univ Tours, UFR Sci Pharmaceut, F-37032 Tours, France	Universite de Tours; Universite de Tours	Lebranchu, Y (corresponding author), Univ Tours, IFR 135, UFR Med Tours, JE 2448,10 Bd Tonnelle, F-37032 Tours, France.	cdg@med.univ-tours.fr						Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Braat H, 2004, AM J CLIN NUTR, V80, P1618, DOI 10.1093/ajcn/80.6.1618; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; Colino J, 2003, J IMMUNOL, V171, P2354, DOI 10.4049/jimmunol.171.5.2354; Cruchet S, 2003, NUTRITION, V19, P716, DOI 10.1016/S0899-9007(03)00109-6; Dillon S, 2004, J IMMUNOL, V172, P4733, DOI 10.4049/jimmunol.172.8.4733; Guarner F, 1998, INT J FOOD MICROBIOL, V39, P237, DOI 10.1016/S0168-1605(97)00136-0; Guslandi M, 2000, DIGEST DIS SCI, V45, P1462, DOI 10.1023/A:1005588911207; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Hou WS, 2004, NAT IMMUNOL, V5, P583, DOI 10.1038/ni1071; Isolauri E, 2001, AM J CLIN NUTR, V73, p444S, DOI 10.1093/ajcn/73.2.444s; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Lagaraine C, 2005, INT IMMUNOL, V17, P351, DOI 10.1093/intimm/dxh215; Lammers KM, 2003, FEMS IMMUNOL MED MIC, V38, P165, DOI 10.1016/S0928-8244(03)00144-5; Lievin V, 2000, GUT, V47, P646, DOI 10.1136/gut.47.5.646; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Menard S, 2004, GUT, V53, P821, DOI 10.1136/gut.2003.026252; Moser M, 2004, NAT IMMUNOL, V5, P559, DOI 10.1038/ni0604-559; O'Garra A, 2003, IMMUNOL LETT, V85, P135, DOI 10.1016/S0165-2478(02)00239-0; Park Y, 2002, J IMMUNOL, V168, P5, DOI 10.4049/jimmunol.168.1.5; Qi H, 2003, INFECT IMMUN, V71, P3337, DOI 10.1128/IAI.71.6.3337-3342.2003; Re F, 2004, J IMMUNOL, V173, P7548, DOI 10.4049/jimmunol.173.12.7548; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rembacken BJ, 1999, LANCET, V354, P635, DOI 10.1016/S0140-6736(98)06343-0; Roller M, 2004, J NUTR, V134, P153, DOI 10.1093/jn/134.1.153; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Schultz M, 2003, J DAIRY RES, V70, P165, DOI 10.1017/S0022029903006034; Shornikova AV, 1997, J PEDIATR GASTR NUTR, V24, P399, DOI 10.1097/00005176-199704000-00008; Smits HH, 2005, TRENDS IMMUNOL, V26, P123, DOI 10.1016/j.it.2005.01.002; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Takeda K, 2004, J DERMATOL SCI, V34, P73, DOI 10.1016/j.jdermsci.2003.10.002; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	35	123	139	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					696	702		10.1016/j.jaci.2005.10.043	http://dx.doi.org/10.1016/j.jaci.2005.10.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522473				2022-12-18	WOS:000236263100029
J	Notarangelo, L; Casanova, JL; Fischer, A; Puck, J; Rosen, F; Seger, R; Geha, R				Notarangelo, L; Casanova, JL; Fischer, A; Puck, J; Rosen, F; Seger, R; Geha, R		Int Union Immunological Soc Primar	Primary immunodeficiency diseases: An update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary immunodeficiency diseases; T cells; B cells; phagocytes; complement; immune dysregulation syndromes; innate immunity	CLASSIFICATION	Although relatively rare, primary immune deficiency diseases (PIDs) provide an excellent window into the functioning of the immune system. In the late 1960s, observations on these diseases, with their associated infections and genetics, bisected the immune system into Immoral immunity and cell-mediated immunity. These diseases also represent a challenge in their diagnosis and treatment. Beginning in 1970, a unified nomenclature for the then-known primary immunodeficiency diseases was created by a committee convened by the World Health Organization. Since then, and later under the aegis of the International Union of Immunological Societies, an international committee of experts has met every 2 to 3 years to update the classification of PIDs. During the past 15 years, the molecular basis of more than 100 PIDs has been elucidated. This update results from the latest meeting of this committee in Sintra, Portugal, June 2003, which followed 2(1)/(2) days of scientific discussions.	Univ Brescia Spedali Civili, Dept Pediat, Brescia, Italy; Hop Necker Enfants Malad, Paris, France; NIH, Bethesda, MD USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA USA; Univ Kinderklin, Zurich, Switzerland; Harvard Univ, Sch Med, Dept Pediat, Boston, MA USA	Hospital Spedali Civili Brescia; University of Brescia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University Children's Hospital Zurich; Harvard University; Harvard Medical School	Geha, R (corresponding author), Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016; Casanova, Jean-Laurent/I-3418-2017	Notarangelo, Luigi D/0000-0002-8335-0262; Casanova, Jean-Laurent/0000-0002-7782-4169	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000010, Z01HG000116] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chapel H, 2003, CLIN EXP IMMUNOL, V132, P9, DOI 10.1046/j.1365-2249.2003.02110.x; COOPER MD, 1973, NEW ENGL J MED, V288, P966, DOI 10.1056/NEJM197305032881814; FUDENBERG H, 1971, PEDIATRICS, V47, P927; FUDENBERG HH, 1970, NEW ENGL J MED, V283, P656, DOI 10.1056/NEJM197009172831211	4	123	135	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					677	687		10.1016/j.jaci.2004.06.044	http://dx.doi.org/10.1016/j.jaci.2004.06.044			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356576				2022-12-18	WOS:000223799600032
J	Perry, TT; Conover-Walker, MK; Pomes, A; Chapman, MD; Wood, RA				Perry, TT; Conover-Walker, MK; Pomes, A; Chapman, MD; Wood, RA			Distribution of peanut allergen in the environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut allergen	TREE-NUT-ALLERGY; ANAPHYLACTIC REACTIONS; FOOD; CHILDREN; CAT; SCHOOLS	Background: Patients with peanut allergy can have serious reactions to very small quantities of peanut allergen and often go to extreme measures to avoid potential contact with this allergen. Objective: The purpose of this study was to detect peanut allergen under various environmental conditons and examine the effectiveness of cleaning agents for allergen removal. Methods: A monoclonal-based ELISA for Arachis hypogaea allergen 1 (Ara h 1; range of detection, 30-2000 ng/mL) was used to assess peanut contamination on cafeteria tables and other surfaces in schools, the presence of residual peanut protein after using various cleaning products on bands and tabletops, and airborne peanut allergen during the consumption of several forms of peanut. Results: After hand washing with liquid soap, bar soap, or commercial wipes, Ara h 1 was undetectable. Plain water and antibacterial hand sanitizer left detectable Ara h 1 on 3 of 12 and 6 of 12 hands, respectively. Common household cleaning agents removed peanut allergen from tabletops, except dish-washing liquid, which left Ara h 1 on 4 of 12 tables. Of the 6 area preschools and schools evaluated, Ara h 1 was found on 1 of 13 water fountains, 0 of 22 desks, and 0 of 36 cafeteria tables. Airborne Ara h 1 was undetectable in simulated real-life situations when participants consumed peanut butter, shelled peanuts, and unshelled peanuts. Conclusion: The major peanut allergen, Ara h 1, is relatively easily cleaned from hands and tabletops with common cleaning agents and does not appear to be widely distributed in preschools and schools. We were not able to detect airborne allergen in many simulated environments.	Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; INDOOR Biotechnol, Charlottesville, VA USA	Johns Hopkins University; INDOOR Biotechnologies	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, 600 N Wolfe,CMSC 1102, Baltimore, MD 21287 USA.	rwood@jhmi.edu	Pomés, Anna/H-7010-2019	Pomés, Anna/0000-0002-8729-1829; Chapman, Martin/0000-0002-0845-3632				Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1987, PEDIATRICS, V79, P683; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790, DOI 10.1001/archpedi.155.7.790; Pomes A, 2004, J FOOD PROTECT, V67, P793, DOI 10.4315/0362-028X-67.4.793; Pomes A, 2003, J ALLERGY CLIN IMMUN, V111, P640, DOI 10.1067/mai.2003.118; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x	17	123	124	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					973	976		10.1016/j.jaci.2004.02.035	http://dx.doi.org/10.1016/j.jaci.2004.02.035			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131582				2022-12-18	WOS:000221269000022
J	Palosuo, K; Varjonen, E; Nurkkala, J; Kalkkinen, N; Harvima, R; Reunala, T; Alenius, H				Palosuo, K; Varjonen, E; Nurkkala, J; Kalkkinen, N; Harvima, R; Reunala, T; Alenius, H			Transglutaminase-mediated cross-linking of a peptic fraction of omega-5 gliadin enhances IgE reactivity in wheat-dependent, exercise-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; exercise; gliadin; lgE; transglutaminases; wheat hvpersensitivity	TISSUE TRANSGLUTAMINASE; CELIAC-DISEASE; IMMUNE-SYSTEM; GTP-BINDING; BLOOD-FLOW; FOOD; INTERLEUKIN-6; ASPIRIN; CELLS; PERMEABILITY	Background: Patients with wheat-dependent, exercise-induced anaphylaxis (WDEIA) experience recurrent anaphylactic reactions when exercising after ingestion of wheat products. We have identified omega-5 gliadin (Tri a 19) as a major allergen in WDEIA, but the role of exercise in eliciting the symptoms remains obscure. Objective: The aim was to examine whether tissue transglutaminase (tTG)-mediated cross-linking could be involved in modulating the IgE-binding ability and in vivo reactivity of digested omega-5 gliadin peptides in WDEIA. Methods: Purified omega-5 gliadin was digested with pepsin or with pepsin and trypsin and treated with tTG. The binding of IgE antibodies in pooled sera from 10 patients with WDEIA was studied by means of immunoblotting before and after tTG treatment of the digested peptides. The peptides derived from pepsin digestion were separated by means of gel-filtration chromatography, and IgE reactivity of 4 different peptide fractions was studied by immunoblotting before and after tTG treatment. The fraction showing the greatest degree of crosslinking by tTG was further studied by means of IgE ELISA, ELISA inhibition, and skin prick testing. Results: The IgE-binding ability of omega-5 gliadin was retained after pepsin and pepsin-trypsin digestion. tTG treatment of the whole peptic digest formed large peptide complexes, with molecular weights ranging from 40 to greater than 200 kd. These cross-linked aggregates bound IgE antibodies in immunoblotting more intensely than untreated, pepsin-digested, or pepsin-trypsin-digested omega-5 gliadin. A gel-filtration fraction of the whole peptic digest corresponding to the highest peak of the chromatogram and showing the greatest degree of tTG-mediated cross-linking showed an increase in serum IgE reactivity in ELISA after tTG treatment, as well as a shift of reactivity to cross-linked complexes. In the 20 patients with WDEIA, the mean skin prick test wheal elicited by this tTG-treated peptic fraction was 77% larger (P < .001) than that elicited by the untreated peptic fraction and 56% larger (P < .01) than that elicited by intact w-5 gliadin. Conclusions: omega-5 Gliadin-derived peptides are cross-linked by tTG, which causes a marked increase in IgE binding both in vitro and in vivo. Activation of tTG during exercise in the intestinal mucosa of patients with WDEIA could lead to the formation of large allergen complexes capable of eliciting anaphylactic reactions. (J Allergy Clin Immunol 2003;111:1386-92.).	Finnish Inst Occupat Hlth, Lab Immunotoxicol, Helsinki, Finland; Univ Helsinki, Dept Dermatol, Helsinki, Finland; Hosp Skin & Allerg Dis, Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Helsinki, Finland; Univ Kuopio, Dept Dermatol, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, SF-70210 Kuopio, Finland; Tampere Univ, Dept Dermatol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	Finnish Institute of Occupational Health; University of Helsinki; University of Helsinki; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University; Tampere University Hospital	Palosuo, K (corresponding author), Finnish Inst Occupat Hlth, Lab Immunotoxicol, Topeliuksenkatu 41B, Helsinki, Finland.		Kalkkinen, Nisse EJ/B-3923-2010	Alenius, Harri/0000-0003-0106-8923				Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Aihara M, 2002, BRIT J DERMATOL, V146, P466, DOI 10.1046/j.1365-2133.2002.04601.x; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Cooper CE, 2002, BIOCHEM SOC T, V30, P280, DOI 10.1042/BST0300280; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; Di Venere A, 2000, J BIOL CHEM, V275, P3915, DOI 10.1074/jbc.275.6.3915; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; FUKUTOMI O, 1992, ANN ALLERGY, V68, P438; Guinnepain MT, 1996, ANN ALLERG ASTHMA IM, V77, P491, DOI 10.1016/S1081-1206(10)63357-1; Harada S, 2001, BRIT J DERMATOL, V145, P336, DOI 10.1046/j.1365-2133.2001.04329.x; HOFFMANGOETZ L, 1994, IMMUNOL TODAY, V15, P382, DOI 10.1016/0167-5699(94)90177-5; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Johnson TS, 1998, BIOCHEM J, V331, P105, DOI 10.1042/bj3310105; KASARDA DD, 1983, BIOCHIM BIOPHYS ACTA, V747, P138, DOI 10.1016/0167-4838(83)90132-2; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; KIVITY S, 1988, J ALLERGY CLIN IMMUN, V81, P1155, DOI 10.1016/0091-6749(88)90884-6; KORNER G, 1993, FEBS LETT, V330, P41, DOI 10.1016/0014-5793(93)80915-H; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; Lambert GP, 2001, J APPL PHYSIOL, V90, P2075, DOI 10.1152/jappl.2001.90.6.2075; LEHTA M, 2002, CLIN EXP ALLERGY, V33, P90; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281, DOI 10.1152/ajpgi.1997.272.2.G281; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Morita E, 2001, BRIT J DERMATOL, V145, P182, DOI 10.1046/j.1365-2133.2001.04314.x; Osada T, 1999, J APPL PHYSIOL, V86, P709, DOI 10.1152/jappl.1999.86.2.709; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; Otte JA, 2001, J APPL PHYSIOL, V91, P866, DOI 10.1152/jappl.2001.91.2.866; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2001, CLIN EXP ALLERGY, V31, P466, DOI 10.1046/j.1365-2222.2001.01023.x; Pals KL, 1997, J APPL PHYSIOL, V82, P571, DOI 10.1152/jappl.1997.82.2.571; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; QAMAR MI, 1987, GUT, V28, P583, DOI 10.1136/gut.28.5.583; Romano A, 2001, INT ARCH ALLERGY IMM, V125, P264, DOI 10.1159/000053825; Shadick NA, 1999, J ALLERGY CLIN IMMUN, V104, P123, DOI 10.1016/S0091-6749(99)70123-5; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; SUTO N, 1993, J BIOL CHEM, V268, P7469; Varjonen E, 1997, CLIN EXP ALLERGY, V27, P162, DOI 10.1046/j.1365-2222.1997.d01-481.x; Vider J, 2001, Pathophysiology, V7, P263; WOJNAR RJ, 1980, J ALLERGY CLIN IMMUN, V66, P37, DOI 10.1016/0091-6749(80)90136-0	45	123	129	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1386	1392		10.1067/mai.2003.1498	http://dx.doi.org/10.1067/mai.2003.1498			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789243				2022-12-18	WOS:000183424700031
J	Colilla, S; Nicolae, D; Pluzhnikov, A; Blumenthal, MN; Beaty, TH; Bleecker, ER; Lange, EM; Rich, SS; Meyers, DA; Ober, C; Cox, NJ				Colilla, S; Nicolae, D; Pluzhnikov, A; Blumenthal, MN; Beaty, TH; Bleecker, ER; Lange, EM; Rich, SS; Meyers, DA; Ober, C; Cox, NJ		Collaborative Study Genetics Asthm	Evidence for gene-environment interactions in a linkage study of asthma and smoking exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; genetics; linkage; smoking; gene-environment interaction; environmental tobacco smoke; genetic epidemiology	GENOME-WIDE SEARCH; TOBACCO-SMOKE; RISK-FACTORS; CHILDHOOD; CHILDREN; HOUSEHOLD; MARKERS; SCREEN; CHROMOSOME-5; ASSOCIATION	Background: Asthma, a common and chronic disease of the airways, has a multifactorial cause involving both genetic and environmental factors. As a result, mapping genes that influence asthma susceptibility has been challenging. Objective: This study tests the hypothesis that inclusion of exposure to environmental tobacco smoke (ETS), a potential risk factor for asthma, would improve the ability to map genes for asthma. Methods: By using 144 white families from the Collaborative Study for the Genetics of Asthma, environmental information about exposure to ETS during infancy was incorporated into a genome-wide multipoint linkage analysis. Statistical significance of observed gene-environment interactions was assessed by means of simulation. Results: Three regions with nominal evidence for linkage when stratified on the basis of ETS exposure were identified (P < .01) and showed a significant increase from the baseline lod score (1p at 97 cM, D1S1669-D1S1665; 5q at 135 cM, D5S1505-D5S816; and 9q at 106 cM, D9S910; all P < .05). In addition, 2 other regions, although not meeting nominal significance after stratification on the basis of ETS exposure, showed a significant increase from baseline lod score when ETS was taken into account (1q at 240 cM, D1S549; 17p at 3 cM, D17S1308; all P < .01). Conclusion: These results illustrate how evidence for linkage of asthma can depend on exposure to an environmental factor, such as ETS. Future linkage analyses should include information on suspected environmental factors for asthma to help target new candidate susceptibility genes for asthma.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA	University of Chicago; University of Chicago; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Cox, NJ (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,Room 507, Chicago, IL 60637 USA.			Rich, Stephen/0000-0003-3872-7793; Nicolae, Dan/0000-0002-0918-4630	NCRR NIH HHS [RR 00400, RR 00055] Funding Source: Medline; NHLBI NIH HHS [HL 49609, HL 49602, HL 49596, HL 49612, HL 58977] Funding Source: Medline; NIDDK NIH HHS [DK 55889] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000400] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049602, U01HL049596, R01HL049609, U01HL049612, U01HL058977, U01HL049609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055889] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Barnes KC, 1999, CLIN EXP ALLERGY, V29, P47; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Ehrlich R, 2001, J ASTHMA, V38, P239, DOI 10.1081/JAS-100000111; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681, DOI 10.1164/ajrccm.154.3.8810605; Gauderman WJ, 2001, HUM HERED, V52, P34, DOI 10.1159/000053352; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Goddard KAB, 2001, AM J HUM GENET, V68, P1197, DOI 10.1086/320103; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Greenwood CMT, 1997, GENET EPIDEMIOL, V14, P635; Greenwood CMT, 1999, AM J HUM GENET, V64, P871, DOI 10.1086/302288; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Jordaan ER, 1999, ARCH ENVIRON HEALTH, V54, P319, DOI 10.1080/00039899909602494; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Larsson ML, 2001, CHEST, V120, P711, DOI 10.1378/chest.120.3.711; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097, DOI 10.1164/ajrccm.162.6.2004178; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36, DOI 10.1001/archpedi.155.1.36; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martin LJ, 2002, GENET EPIDEMIOL, V22, P105, DOI 10.1002/gepi.0135; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2000, CLIN CHEST MED, V21, P245, DOI 10.1016/S0272-5231(05)70264-1; Olson JM, 1999, AM J HUM GENET, V65, P1760, DOI 10.1086/302662; Palmer LJ, 2001, CLIN EXP ALLERGY, V31, P152; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404, DOI 10.1164/ajrccm.163.6.2001101; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	42	123	125	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					840	846		10.1067/mai.2003.170	http://dx.doi.org/10.1067/mai.2003.170			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704367	Bronze			2022-12-18	WOS:000182258500027
J	Bayram, H; Sapsford, RJ; Abdelaziz, MM; Khair, OA				Bayram, H; Sapsford, RJ; Abdelaziz, MM; Khair, OA			Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic asthma; ozone; nitrogen dioxide; bronchial epithelial cells; cytokines; soluble intercellular adhesion molecule 1	INFLAMMATORY MEDIATORS; INHALED ALLERGEN; AIR-POLLUTION; IN-VITRO; RESPONSES; CYTOKINES	Background: Although studies have suggested that ozone (O-3) and nitrogen dioxide (NO2) may play a role in the pathogenesis of asthma, the underlying mechanisms are not clear. Objective: We aimed to investigate the effects of O-3 and NO2 on the release of IL-8, GM-CSF, RANTES, and soluble intercellular adhesion molecule 1 (sICAM-1) from human bronchial epithelial cells (HBF,Cs) of nonatopic nonasthmatic subjects (nonasthmatic subjects) and atopic subjects with mild asthma (asthmatic subjects) in vitro. Methods: We cultured HBECs from bronchial biopsy specimens of nonasthmatic and asthmatic subjects; exposed these for 6 hours to air, 10 to 100 ppb O-3, or 100 to 400 ppb NO2; and analyzed the release of IL-8, GM-CSF, RANTES, and sICAM-1 after 24 hours' incubation. Results: There was no significant difference between the constitutive release of IL-8, GM-CSF; and sICAM-1 from HBECs of asthmatic and nonasthmatic subjects, RANTES was detected only in HBECs derived from asthmatic subjects. Exposure of HBECs of asthmatic subjects to both 50 to 100 ppb O-3 and 200 to 400 ppb NO2 significantly increased the release of IL-8, GM-CSF, RANTES, and sICAM-1 from these cells after 24 hours of incubation. However, 50 to 100 ppb O-3 and 200 to 400 ppb NO2 led to a significant increase in release of only IL-8 and sICAM-1 from HBECs of nonasthmatic subjects after 24 hours' incubation. A comparison between the pollutant-induced release of mediators demonstrated that 100 ppb O-3. induced release of GM-CSF and sICAM-1 was significantly greater in HBECs of asthmatic subjects (medians, 0.59 and 27.4 pg/mug cellular protein, respectively) than in HBECs of nonasthmatic subjects (medians, 0.27 and 14.4 pg/mug cellular protein, respectively; P<.02). Conclusion: These results suggest that O-3 and NO2 may modulate airway diseases, such as asthma, by increasing the release of inflammatory mediators from bronchial epithelial cells and that the cells of asthmatic subjects may be more susceptible to the adverse effects of these pollutants.	Univ Dicle, Sch Med, Dept Resp Med, TR-21280 Diyarbakir, Turkey; St Bartholomews & Royal London Sch Med & Dent, Acad Resp Med Dept, London, England; Royal Liverpool Univ Hosp, Dept Resp Med, Liverpool, Merseyside, England; City Hosp NHS Trust, Birmingham, W Midlands, England	Dicle University; University of London; Queen Mary University London; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Bayram, H (corresponding author), Univ Dicle, Sch Med, Dept Resp Med, TR-21280 Diyarbakir, Turkey.		Bayram, Hasan/ABE-5094-2021	Bayram, Hasan/0000-0002-5236-766X				Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Balmes J R, 1997, Res Rep Health Eff Inst, P1; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; Bayram H, 1999, J ALLERGY CLIN IMMUN, V104, P93, DOI 10.1016/S0091-6749(99)70119-3; Bloemen PGM, 1997, CLIN EXP ALLERGY, V27, P128; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Calderon MA, 1997, J ALLERGY CLIN IMMUN, V99, P65, DOI 10.1016/S0091-6749(97)70302-6; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1990, RESP MED, V84, P303, DOI 10.1016/S0954-6111(08)80058-3; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DEVLIN RB, 1994, AM J PHYSIOL, V266, pL612, DOI 10.1152/ajplung.1994.266.6.L612; Devlin RB, 1999, INHAL TOXICOL, V11, P89, DOI 10.1080/089583799197195; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72, DOI 10.1165/ajrcmb/4.1.72; Gormand F, 1995, PULM PHARMACOL, V8, P107, DOI 10.1006/pulp.1995.1013; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; JORRES R, 1995, EUR RESPIR J, V8, P416, DOI 10.1183/09031936.95.08030416; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Peden DB, 1997, J ALLERGY CLIN IMMUN, V100, P802, DOI 10.1016/S0091-6749(97)70277-X; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144; RUSZNAK C, 1996, EUR RESPIR J, V9, P2296; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24, DOI 10.1164/ajrccm.154.1.8680687; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKAHASHI N, 1994, AM J RESP CRIT CARE, V150, P704, DOI 10.1164/ajrccm.150.3.7916246; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Wang JH, 1997, EUR RESPIR J, V10, P834	28	123	132	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					287	294		10.1067/mai.2001.111141	http://dx.doi.org/10.1067/mai.2001.111141			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174195				2022-12-18	WOS:000167071400015
J	Altman, LC; Munk, Z; Seltzer, J; Noonan, N; Shingo, S; Zhang, J; Reiss, TF				Altman, LC; Munk, Z; Seltzer, J; Noonan, N; Shingo, S; Zhang, J; Reiss, TF		Montelukast Asthma Study Grp	A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cysteinyl leukotriene receptor antagonist; montelukast	QUALITY-OF-LIFE; LUNG-FUNCTION; ASTHMA; POTENT; BRONCHODILATION; QUESTIONNAIRE; AIRWAYS; THERAPY	Background: The cysteinyl leukotrienes are important mediators of bronchial asthma. The clinical effect of montelukast, a potent cysteinyl leukotriene-receptor antagonist, was investigated in a randomized, placebo-controlled, multicenter, parallel-group, dose-ranging study. Methods: After a 3-week, single-blind, placebo run-in period, 343 asthmatic patients (FEV1 40% to 80% of the predicted value with an improvement in FEV1 of at least 15% [absolute value] after receiving inhaled beta-agonists on at least two occasions) were randomly assigned to one of sir treatment groups: placebo; 10, 100, or 200 mg once daily montelukast in the evening; or 10 or 50 mg twice daily montelukast for a 6-week, double-blind treatment period followed by a 1-week placebo washout period. All patients used inhaled, short-acting beta-agonists as needed. Results: All montelukast doses caused similar and significant differences compared with placebo in asthma control endpoints. The least-square mean difference between pooled montelukast groups and placebo in the percentage change from baseline in morning FEV1 (10.30%; 95% CI: 5.56 to 15.04), as-needed beta-agonist use (-0.98 puffs; 95% CI: -1.53 to -0.44), morning peak expiratory flow rate (18.80 L/min; 95% CI: 8.62 to 28.98), physicians' and patients' global evaluations, and asthma-specific quality-of-life scores were all significant (p less than or equal to 0.050). The incidence of adverse experiences was not dose related and was similar between placebo and montelukast treatment. Conclusion: Montelukast caused a significant improvement in chronic asthma at an oral, once daily evening dose as low as 10 mg.	Merck Res Labs, Rahway, NJ 07065 USA; Univ Washington, Seattle, WA 98195 USA; Breco Res, Houston, TX USA; Clin Res Inst, San Diego, CA USA	Merck & Company; University of Washington; University of Washington Seattle	Reiss, TF (corresponding author), Merck Res Labs, POB 2000,RY 33-648, Rahway, NJ 07065 USA.							BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DeLepeleire I, 1997, CLIN PHARMACOL THER, V61, P83, DOI 10.1016/S0009-9236(97)90184-3; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; IMPENS N, 1993, AM REV RESPIR DIS, V147, P1442, DOI 10.1164/ajrccm/147.6_Pt_1.1442; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Santanello NC, 1997, EUR RESPIR J, V10, P646; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V83, P528, DOI 10.1016/0091-6749(89)90034-1; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666; *US DEP HHS, 1995, US DEP HHS PUBL; *US DEP HHS, 1992, US DEP HHS PUBL; WICKREMASINGHE RG, 1993, PROSTAG LEUKOTR ESS, V48, P123, DOI 10.1016/0952-3278(93)90099-I; WOODWARD DF, 1983, PROSTAGLANDINS, V25, P131, DOI 10.1016/0090-6980(83)90142-9	24	123	125	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					50	56		10.1016/S0091-6749(98)70054-5	http://dx.doi.org/10.1016/S0091-6749(98)70054-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679847				2022-12-18	WOS:000074909500009
J	Bagnasco, M; Mariani, G; Passalacqua, G; Motta, C; Bartolomei, M; Falagiani, P; Mistrello, G; Canonica, GW				Bagnasco, M; Mariani, G; Passalacqua, G; Motta, C; Bartolomei, M; Falagiani, P; Mistrello, G; Canonica, GW			Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral immunotherapy; sublingual immunotherapy; local nasal immunotherapy; iodine 123; radiolabeling; Par j 1	LOCAL NASAL IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ORAL IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; POLLEN; RHINITIS; RESPONSES; EXTRACT; EFFICACY	Background and objective: The clinical effectiveness of noninjectable routes for specific immunotherapy has been demonstrated in many studies, but no data are available on the kinetics of allergens administered by these routes. Therefore we studied the kinetics of the radiolabeled purified major Parietaria judaica allergen (Par j 1) after sublingual, oral, and intranasal administration to healthy human beings. Methods: After tracer administration (10 to 12.5 mu g of Par j 1 labeled with iodine 123) to nonallergic volunteers, scintigraphic images were recorded at various times. Blood samples were also obtained at serial intervals to evaluate the absorption and distribution of radioactivity in plasma and to identify circulating radioactive species by molecular exclusion gel chromatography. Results: When the sublingual route was used, no circulating radioactivity was detected until the tracer was kept under the tongue. The labeled allergen was rapidly degraded and absorbed in the gastrointestinal tract after swallowing. Plasma radioactivity peaked at about 1.5 to 3 hours and was mostly represented by free radioiodine and small radiolabeled peptides. Some activity not caused by free I-123 remained associated with the oral mucose up to 18 to 20 hours after administration. When the oral route was used, the results were similar to those observed after swallowing the sublingually administered allergen but without any persistence of the tracer in the mouth. When the intranasal route was used, the pattern of plasma radioactivity mimicked that of the sublingual and oral routes, viith absorption of activity from the radiolabeled allergen occurring in the gastrointestinal tract after transport to the pharynx by mucociliary clearance. A relevant fraction of the tracer was retained on the nasal mucosa up to 48 hours after administration. Conclusion: The data in this study provide the first experimental basis for exploring the in vivo kinetics of allergen administered through noninjectable routes for specific immunotherapy in human beings.	UNIV GENOA, DEPT INTERNAL MED, ALLERGY & CLIN IMMUNOL SERV, I-16132 GENOA, ITALY; UNIV GENOA, DEPT INTERNAL MED, NUCL MED SERV, I-16126 GENOA, ITALY; LAB FARMACEUT LOFARMA, MILAN, ITALY	University of Genoa; University of Genoa			canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557; Mariani, Giuliano/0000-0002-1900-4488				ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P948; BUCKLE FG, 1975, J ALLERGY CLIN IMMUN, V55, P213, DOI 10.1016/0091-6749(75)90139-6; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P141, DOI 10.1111/j.1365-2222.1995.tb01019.x; EINARSSON R, 1988, ALLERGY, V43, P469, DOI 10.1111/j.1398-9995.1988.tb00921.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEORGITIS JW, 1986, INT ARCH ALLER A IMM, V81, P170, DOI 10.1159/000234127; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; Holt PG, 1989, CLIN EXP ALLERGY, V19, P55; LENG X, 1990, ANN ALLERGY, V64, P27; LITWIN A, 1996, IN PRESS ANN ALLERGY; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MALLING HJ, 1993, ALLERGY, V48, P9; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MISTRELLO G, 1991, ALLERGY, V46, P52, DOI 10.1111/j.1398-9995.1991.tb00543.x; MISTRELLO G, 1994, IMMUNOL LETT, V40, P31, DOI 10.1016/0165-2478(94)90202-X; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SWARBRICK ET, 1979, GUT, V20, P121, DOI 10.1136/gut.20.2.121; Tari M G, 1994, Allergol Immunopathol (Madr), V22, P209; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633	31	123	131	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					122	129		10.1016/S0091-6749(97)70203-3	http://dx.doi.org/10.1016/S0091-6749(97)70203-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257796				2022-12-18	WOS:A1997XP42800018
J	Leung, R; Ho, P; Lam, CWK; Lai, CKW				Leung, R; Ho, P; Lam, CWK; Lai, CKW			Sensitization to inhaled allergens as a risk factor for asthma and allergic diseases in Chinese population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; rhinitis; eczema; atopy; allergy; epidemiology; Chinese; skin test; house dust mite; cockroach; indoor allergen	RESPIRATORY SYMPTOMS; NITROGEN-DIOXIDE; PREVALENCE; EXPOSURE; ATOPY; SCHOOLCHILDREN; CHILDREN; MITE; CHILDHOOD; SEVERITY	Background: Allergen sensitization is associated with asthma and allergic disease in children, but such a relationship has not been confirmed in Chinese populations, Objective: The objective of this study was to evaluate the effects of allergen sensitization and family history of atopy on asthma and allergic disease in Chinese schoolchildren from three southeast Asian populations, Methods: Written questionnaires on respiratory and allergic symptoms were completed by parents of children of secondary-school age (age range 12 to 18 years) in Hong Kong (n = 1062), Kota Kinabalu in eastern Malaysia (n = 409), and San Bu in southern China (n = 737). A subsample of school-children underwent skin prick testing to common inhalant allergens (Hung Kong 471 children, Kota Kinabalu 321, San Bu 647). Results: The prevalence of asthma and allergic disease in schoolchildren was highest in song Kong, intermediate in Kota Kinabalu, and lowest in San Bu. However, the overall rate of atopic sensitization was similar in the three populations (49% to 63%). House dust mite and cockroach were the two most common allergens causing sensitization and these gave rise to more than 95% of the positive skill test results in all three populations. By regression analysis, mite allergy was associated with rhinitis and asthma in all three populations, and a family history of asthma, rhinitis, or eczema was strongly associated with respective symptoms in the subjects, After adjusting for age, sea, atopic status, and family history of allergic disease, the place of residence remained a significant independent factor fur asthma (odds ratio [OR] = 1.0 for song Kong, 0.57 for I(ota Kinabalu, 0.15 for San Bu, p < 0.001), rhinitis (OR = 1.0 for Hong Kong, 0.59 for Kota Kinabalu, 0.15 for San Bu, p < 0.001), or eczema (OR = 1.0 for Hong Kong, 0.35 for Kota Kjnabalu, 1.01 for San Bu, p < 0.001). Conclusion: Sensitization to indoor allergens was a significant risk factor for asthma and allergic disease, and familial clustering of disease was common in the region, However, the marked difference in disease prevalence in the three southeast Asian populations of Chinese schoolchildren cannot be explained by atopic sensitization and family history alone, and the place of residence was an independent risk factor for asthma and allergies, which suggests an important environmental role in disease pathogenesis.	CHINESE UNIV HONG KONG, DEPT CHEM PATHOL, PRINCE WALES HOSP, SHATIN, HONG KONG; DEPT HLTH, HONG KONG, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital	Leung, R (corresponding author), CHINESE UNIV HONG KONG, DEPT MED, PRINCE WALES HOSP, SHATIN, HONG KONG.		Leung, Roland/ABB-5798-2021					ABRAMSON M, 1992, AUST NZ J MED, V22, P358, DOI 10.1111/j.1445-5994.1992.tb02148.x; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; *EUR COMM RESP HLT, 1996, EUR RESPIR J, V9, P987; FLYNN MGL, 1994, AM J RESP CRIT CARE, V150, P415, DOI 10.1164/ajrccm.150.2.8049824; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Lai CKW, 1996, CLIN EXP ALLERGY, V26, P5, DOI 10.1111/j.1365-2222.1996.tb00050.x; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; LEUNG R, 1994, EUR RESPIR J, V7, P2046; LEUNG R, 1997, IN PRESS HONG KONG M; LEUNG RC, 1994, MED J AUSTRALIA, V161, P418, DOI 10.5694/j.1326-5377.1994.tb127522.x; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Omenaas E, 1996, EUR RESPIR J, V9, P919, DOI 10.1183/09031936.96.09050919; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; SAMET JM, 1978, AM J EPIDEMIOL, V108, P435, DOI 10.1093/oxfordjournals.aje.a112642; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794, DOI 10.1111/j.1365-2222.1996.tb00610.x; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; VRIGMOED LLP, 1995, P 6 ANN M AUSTR SOC, P16; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; ZHONG NS, 1990, THORAX, V45, P860, DOI 10.1136/thx.45.11.860	31	123	129	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					594	599		10.1016/S0091-6749(97)70018-6	http://dx.doi.org/10.1016/S0091-6749(97)70018-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155823	Bronze			2022-12-18	WOS:A1997WY60000004
J	ELOVIC, A; WONG, DTW; WELLER, PF; MATOSSIAN, K; GALLI, SJ				ELOVIC, A; WONG, DTW; WELLER, PF; MATOSSIAN, K; GALLI, SJ			EXPRESSION OF TRANSFORMING GROWTH FACTORS-ALPHA AND BETA(1) MESSENGER-RNA AND PRODUCT BY EOSINOPHILS IN NASAL POLYPS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NASAL POLYPS; EOSINOPHILS; TGF-ALPHA; TGF-BETA(1); MESSENGER-RNA; CYTOKINES	FACTOR-BETA-1	Nasal polyps are thought to develop as a manifestation of a chronic inflammatory process involving the upper airways. The eosinophil characteristically represents a prominent component of the inflammatory cell infiltrate of these lesions. However, the major clinical problem associated with nasal polyps, nasal obstruction, reflects the proliferation of die stromal and epithelial elements, which constitute the bulk of these lesions. We recently reported that blood eosinophils of patients with hypereosinophilia can produce the cytokines transforming growth factors-alpha (TGF-alpha) and beta(1) (TGF-beta(1)). These cytokines have many biologic activities, which include the regulation of epithelial proliferation, the promotion of extracellular matrix formation, and the induction of angiogenesis. We therefore used in situ hybridization to determine whether the eosinophils that infiltrate nasal polyps express TGF-alpha and/or TGF-beta(1) messenger RNA and used immunohistochemistry to determine whether these eosinophils also express TGF-alpha and TGF-beta(1) proteins. We found that eosinophils represented a major source of both transforming growth factors in each case of nasal polyposis examined and that in most cases the majority of all eosinophils expressed both TGF-alpha and TGF-beta(1). These results suggest that production of TGF-alpha and TGF-beta(1) by the infiltrating eosinophils may contribute to some of the pathologic changes observed in nasal polyposis, such as thickening of the epithelial basement membrane, stromal fibrosis, angiogenesis, and epithelial and glandular hyperplasia.	HARVARD UNIV,SCH DENT MED,DEPT ORAL MED & DIAGNOST SCI,DIV ORAL PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010335, R01DE008680, R29DE008680] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22674] Funding Source: Medline; NIDCR NIH HHS [DE-10335, DE-08680] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; MCCRONE EL, 1988, J IMMUNOL METHODS, V114, P79, DOI 10.1016/0022-1759(88)90157-3; NAEIM F, 1978, SURGICAL PATHOLOGY, P311; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; RIBMAN J, 1991, P NATL ACAD SCI USA, V88, P6805; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WLADISLAVOSKYWASERMAN P, 1984, CLIN ALLERGY, V14, P241, DOI 10.1111/j.1365-2222.1984.tb02203.x; WONG DTW, 1991, BLOOD, V78, P2702; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673	12	123	131	2	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					864	869		10.1016/0091-6749(94)90379-4	http://dx.doi.org/10.1016/0091-6749(94)90379-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182229				2022-12-18	WOS:A1994NL91900010
J	HEDLIN, G; GRAFFLONNEVIG, V; HEILBORN, H; LILJA, G; NORRLIND, K; PEGELOW, K; SUNDIN, B; LOWENSTEIN, H				HEDLIN, G; GRAFFLONNEVIG, V; HEILBORN, H; LILJA, G; NORRLIND, K; PEGELOW, K; SUNDIN, B; LOWENSTEIN, H			IMMUNOTHERAPY WITH CAT-DANDER AND DOG-DANDER EXTRACTS .5. EFFECTS OF 3 YEARS OF TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DOUBLE-BLIND PLACEBO; BRONCHIAL HYPERRESPONSIVENESS; ASTHMATIC-CHILDREN; RESPONSES; ALLERGY; CHILDHOOD; HISTAMINE; FAILURE; INVIVO; TRIAL	The effect of a 3-year course of cat or dog immunotherapy (IT) was evaluated in 32 patients with a history of asthma on exposure to cat or dog. Twenty-one subjects (14 children and seven adults) received cat IT and 11 subjects (six children and five adults) received dog IT. Bronchial challenges with allergen and histamine were performed once a year. Specific IgE, IgGl, and IgG4 were measured, and skin prick tests were done in connection with the challenges. Allergen sensitivity decreased significantly in both treated groups (p < 0.001 and p < 0.05 in the cat-allergen and dog-allergen treated groups, respectively). Bronchial hyperreactivity measured by the provocative concentration of histamine causing a 20% decrease in peak expiratory flow in the cat-allergen treated patients (p < 0.001) but not in the dog-allergen treated patients. Skin sensitivity decreased in both groups (p < 0.01 and p < 0.05), whereas specific IgE increased initially but dropped to the pretreatment level during the second year. Specific IgG1 and IgG4 increased during the first and second year in the cat-allergen treated group (p < 0.01 and p < 0.001), whereas only IgG4 increased in the dog-allergen treated group (p < 0.01). Five cat-allergen treated children and one of the adults who completed 3 years of therapy had mild systemic reactions. We conclude that cat IT ameliorated bronchial allergen sensitivity and bronchial hyperreactivity and resulted in an adequate antibody response. Dog IT was less efficacious but led to attenuation of bronchial allergen sensitivity.			HEDLIN, G (corresponding author), HUDDINGE HOSP,DEPT PEDIAT,S-14186 HUDDINGE,SWEDEN.							AAS K, 1978, ALLERGY, V3, P130; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; CHOUQUET PH, 1987, PRESSE MED, V16, P126; CLOUGH JB, 1989, CLIN REV ALLERG, V7, P257; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KJELLMAN B, 1986, ALLERGY, V41, P351, DOI 10.1111/j.1398-9995.1986.tb00312.x; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; MURRAY AB, 1985, ANN ALLERGY, V54, P541; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SCHWARTZ B, 1986, J ALLERGY CLIN IMMUN, V77, P330; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3	22	123	132	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					955	964		10.1016/0091-6749(91)90417-M	http://dx.doi.org/10.1016/0091-6749(91)90417-M			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	2026846				2022-12-18	WOS:A1991FM09500007
J	ATKINS, FM; STEINBERG, SS; METCALFE, DD				ATKINS, FM; STEINBERG, SS; METCALFE, DD			EVALUATION OF IMMEDIATE ADVERSE REACTIONS TO FOODS IN ADULT PATIENTS .1. CORRELATION OF DEMOGRAPHIC, LABORATORY, AND PRICK SKIN-TEST DATA WITH RESPONSE TO CONTROLLED ORAL FOOD CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ATKINS, FM (corresponding author), NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11C-209,BETHESDA,MD 20205, USA.							ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P297	8	123	123	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					348	355		10.1016/0091-6749(85)90071-5	http://dx.doi.org/10.1016/0091-6749(85)90071-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3973309				2022-12-18	WOS:A1985AEB4600005
J	HOPP, RJ; BEWTRA, AK; NAIR, NM; TOWNLEY, RG				HOPP, RJ; BEWTRA, AK; NAIR, NM; TOWNLEY, RG			SPECIFICITY AND SENSITIVITY OF METHACHOLINE INHALATION CHALLENGE IN NORMAL AND ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT MED,CTR ALLERG DIS,OMAHA,NE 68178	Creighton University								ALPER B, 1982, AM REV RESPIR DIS, V125, P73; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P45; FEINSTEIN AR, 1975, CLIN PHARMACOL THER, V17, P104; FERRIS BG, 1962, AM REV RESPIR DIS, V86, P165; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HELSING KJ, 1979, AM REV RESPIR DIS, V120, P1221; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; SHAPIRO GG, 1982, J ALLERGY CLIN IMMUN, V69, P365, DOI 10.1016/0091-6749(82)90147-6; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; 1971, 1ST P NAT HEART LUNG	16	123	125	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	2					154	158		10.1016/0091-6749(84)90279-3	http://dx.doi.org/10.1016/0091-6749(84)90279-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE226	6747136				2022-12-18	WOS:A1984TE22600007
J	STEVENSON, DD; SIMON, RA; MATHISON, DA				STEVENSON, DD; SIMON, RA; MATHISON, DA			ASPIRIN-SENSITIVE ASTHMA - TOLERANCE TO ASPIRIN AFTER POSITIVE ORAL ASPIRIN CHALLENGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,RES INST,DEPT CLIN RES,LA JOLLA,CA 92037	Scripps Research Institute								ARROYAVE CM, 1977, CLIN ALLERGY, V7, P173, DOI 10.1111/j.1365-2222.1977.tb01439.x; BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; Cooke RA, 1919, J AMER MED ASSOC, V73, P759, DOI 10.1001/jama.1919.02610360029008; HARNETT JC, 1978, ALLERGY PRINCIPLES P, P1002; JAKSCHIK B, 1976, CLIN RES, V24, pA575; MARTELLI NA, 1977, THORAX, V32, P684, DOI 10.1136/thx.32.6.684; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SCZEKLIK, 1975, BRIT MED J, V1, P67; SIMON RA, 1979, NOV INT C ALL JER; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; VANE JR, 1976, J ALLERGY CLIN IMMUN, V58, P691, DOI 10.1016/0091-6749(76)90181-0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	17	123	124	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					82	88		10.1016/0091-6749(80)90143-8	http://dx.doi.org/10.1016/0091-6749(80)90143-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	7381126				2022-12-18	WOS:A1980JZ54100013
J	METZGER, WJ; TURNER, E; PATTERSON, R				METZGER, WJ; TURNER, E; PATTERSON, R			SAFETY OF IMMUNOTHERAPY DURING PREGNANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, SCH MED, DEPT INTERNAL MED, ALLERGY & IMMUNOL SECT, CHICAGO, IL 60611 USA	Northwestern University								CHESTER S W, 1950, Ann Allergy, V8, P772; Cooke RA, 1922, J IMMUNOL, V7, P119; DERBES VJ, 1946, AM J MED, V1, P367, DOI 10.1016/0002-9343(46)90055-1; FRANCIS NATHAN, 1941, JOUR ALLERGY, V12, P559, DOI 10.1016/S0021-8707(41)90203-4; Freeman J, 1911, LANCET, V2, P814; GILL TJ, 1971, SCIENCE, V172, P1346, DOI 10.1126/science.172.3990.1346; JENSEN KLAUS, 1953, ACTA ALLERGOL, V6, P44, DOI 10.1111/j.1398-9995.1953.tb03468.x; KAPLAN MA, 1952, ANN ALLERGY, V10, P82; KAUFMAN HS, 1976, ANN ALLERGY, V37, P410; KISTNER RW, 1971, GYNECOLOGY PRINCIPLE, P500; Lieberman P, 1974, Adv Intern Med, V19, P391; MAIETTA A L, 1955, Ann Allergy, V13, P516; MINTZ S, 1976, BRONCHIAL ASTHMA MEC, P971; Negrini A C, 1970, Folia Allergol (Roma), V17, P181; Noon L, 1911, LANCET, V1, P1572; PATTERSON R, 1972, ALLERGIC DISEASES DI, P295; PATTERSON R, 1972, ALLERGIC DISEASE DIA, P286; PRITCHARD JA, 1971, WILLIAMS OBSTETRICS, P494; PRITCHARD JA, 1976, WILLIAMS OBSTETRICS, P551; SCHAEFER G, 1961, AM J OBSTET GYNECOL, V82, P182, DOI 10.1016/S0002-9378(16)36114-2; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P121; SIEGEL S, 1965, MEDICAL SURGICAL GYN, P170; SMITH JM, 1974, MED CLIN N AM, V58, P3; SOOTHILL JF, 1976, CLIN ALLERGY, V6, P305, DOI 10.1111/j.1365-2222.1976.tb01911.x; SPEERT H, 1966, TXB OBSTETRICS GYNEC, P579; WARKANY J, 1961, NEW ENGL J MED, V265, P993, DOI 10.1056/NEJM196111162652007; 1972, VITAL STATISTICS REP	27	123	125	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	4					268	272		10.1016/0091-6749(78)90202-6	http://dx.doi.org/10.1016/0091-6749(78)90202-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EV080	632475	Bronze			2022-12-18	WOS:A1978EV08000027
J	GLEICH, GJ; JACOB, GL; YUNGINGER, JW; HENDERSON, LL				GLEICH, GJ; JACOB, GL; YUNGINGER, JW; HENDERSON, LL			MEASUREMENT OF ABSOLUTE LEVELS OF IGE ANTIBODIES IN PATIENTS WITH RAGWEED HAY-FEVER - EFFECT OF IMMUNOTHERAPY ON SEASONAL-CHANGES AND RELATIONSHIP TO IGG ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ALLERG DIS RES LAB,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT PEDIAT,ALLEG DIS RES LAB,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic								COX DR, 1958, PLANNING EXPT, P49; DIXON WJ, 1969, INTRO STATISTICAL AN, P150; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P83; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; GLEICH GJ, 1975, CLIN ALLERGY, V1, P79; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; HENDERSON LL, 1973, J ALLERGY CLIN IMMUN, V52, P352, DOI 10.1016/0091-6749(73)90094-8; LEIFERMAN KM, 1975, J ALLERGY CLIN IMMUN, V56, P481, DOI 10.1016/0091-6749(75)90066-4; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; MAY CD, 1972, J ALLERGY CLIN IMMUN, V50, P99, DOI 10.1016/0091-6749(72)90005-X; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; OGAWA M, 1971, AM J MED, V51, P193, DOI 10.1016/0002-9343(71)90238-5; PRUZANSKY JJ, 1968, J AMER MED ASSOC, V203, P805, DOI 10.1001/jama.203.9.805; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZEISS CR, 1973, J IMMUNOL, V110, P414	34	123	123	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	3					188	198		10.1016/0091-6749(77)90123-3	http://dx.doi.org/10.1016/0091-6749(77)90123-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DU852	893877	Bronze			2022-12-18	WOS:A1977DU85200007
J	JOHNSON, EE; IRONS, JS; PATTERSON, R; ROBERTS, M				JOHNSON, EE; IRONS, JS; PATTERSON, R; ROBERTS, M			SERUM-IGE CONCENTRATION IN ATOPIC-DERMATITIS - RELATIONSHIP TO SEVERITY OF DISEASE AND PRESENCE OF ATOPIC RESPIRATORY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV, MCGAW MED CTR,DEPT MED,SECT ALLERGY IMMUNOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University								AARONSON DW, 1972, ALLERGIC DISEASES DI; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GUREVITCH AW, 1973, ARCH DERMATOL, V107, P712, DOI 10.1001/archderm.107.5.712; JOHANSSON SGO, 1972, PROGR CLINICAL IMMUN, V1; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OGAWA M, 1970, CLIN RES, V2, P350; OHMAN S, 1971, EXCERPTA MEDICA  235, P36; SPARKS DB, 1972, ALLERGIC DISEASES DI; TENNENBAUM JI, 1972, ALLERGIC DISEASES DI	11	123	123	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	2					94	99		10.1016/0091-6749(74)90037-2	http://dx.doi.org/10.1016/0091-6749(74)90037-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T7816	4854265				2022-12-18	WOS:A1974T781600004
J	Rigas, D; Lewis, G; Aron, JL; Wang, BW; Banie, H; Sankaranarayanan, I; Galle-Treger, L; Maazi, H; Lo, R; Freeman, GJ; Sharpe, AH; Soroosh, P; Akbari, O				Rigas, Diamanda; Lewis, Gavin; Aron, Jennifer L.; Wang, Bowen; Banie, Homayon; Sankaranarayanan, Ishwarya; Galle-Treger, Lauriane; Maazi, Hadi; Lo, Richard; Freeman, Gordon J.; Sharpe, Arlene H.; Soroosh, Pejman; Akbari, Omid			Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 2 innate lymphoid cells; regulatory T cells; IL-5; IL-13; asthma; airway hyperreactivity; inducible T-cell costimulator; inducible T-cell costimulator ligand	ALLERGIC INFLAMMATION; INDUCTION; ICOS; TOLERANCE; HOMEOSTASIS	Background: Atopic diseases, including asthma, exacerbate type 2 immune responses and involve a number of immune cell types, including regulatory T (Treg) cells and the emerging type 2 innate lymphoid cells (ILC2s). Although ILC2s are potent producers of type 2 cytokines, the regulation of ILC2 activation and function is not well understood. Objective: In the present study, for the first time, we evaluate how Treg cells interact with pulmonary ILC2s and control their function. Methods: ILC2s and Treg cells were evaluated by using in vitro suppression assays, cell-contact assays, and gene expression panels. Also, human ILC2s and Treg cells were adoptively transferred into NOD SCID gamma C-deficient mice, which were given isotype or anti-inducible T-cell costimulator ligand (ICOSL) antibodies and then challenged with IL-33 and assessed for airway hyperreactivity. Results: We show that induced Treg cells, but not natural Treg cells, effectively suppress the production of the ILC2-driven proinflammatory cytokines IL-5 and IL-13 both in vitro and in vivo. Mechanistically, our data reveal the necessity of inducible T-cell costimulator (ICOS)-ICOS ligand cell contact for Treg cell-mediated ILC2 suppression alongside the suppressive cytokines TGF-beta and IL-10. Using a translational approach, we then demonstrate that human induced Treg cells suppress syngeneic human ILC2s through ICOSL to control airway inflammation in a humanized ILC2 mouse model. Conclusion: These findings suggest that peripheral expansion of induced Treg cells can serve as a promising therapeutic target against ILC2-dependent asthma.	[Rigas, Diamanda; Lewis, Gavin; Aron, Jennifer L.; Wang, Bowen; Sankaranarayanan, Ishwarya; Galle-Treger, Lauriane; Maazi, Hadi; Lo, Richard; Akbari, Omid] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Norris Res Tower,Rm 5505,1450 Biggy St, Los Angeles, CA 90033 USA; [Lewis, Gavin; Banie, Homayon; Soroosh, Pejman] Janssen Res & Dev, San Diego, CA USA; [Freeman, Gordon J.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med, Dept Med Oncol, Boston, MA USA; [Sharpe, Arlene H.] Harvard Med Sch, Dept Microbiol & Immunol, Boston, MA USA	University of Southern California; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Akbari, O (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Norris Res Tower,Rm 5505,1450 Biggy St, Los Angeles, CA 90033 USA.	akbari@usc.edu	Soroosh, Pejman/AAD-8386-2021; Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Maazi, Hadi/0000-0002-8979-3769	National Institutes of Health Public Health Service [R01ES 021801, R01ES025786, R21AI109059, R21 ES 024707]; NIAID [P01 AI 056299]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066020, P01AI056299, R21AI132084, R21AI109059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES025786, P30ES007048, R01ES021801, R21ES024707] Funding Source: NIH RePORTER	National Institutes of Health Public Health Service(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The studies described in this article were financially supported by National Institutes of Health Public Health Service grants R01ES 021801, R01ES025786, R21AI109059 and R21 ES 024707 (to O.A.) and NIAID P01 AI 056299 (to G.F. and A.S.).	Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akbari O, 2008, J IMMUNOL, V180, P5448, DOI 10.4049/jimmunol.180.8.5448; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Andersson J, 2008, J EXP MED, V205, P1975, DOI 10.1084/jem.20080308; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Collison LW, 2009, J IMMUNOL, V182, P6121, DOI 10.4049/jimmunol.0803646; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, P3; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang H, 2013, J IMMUNOL, V191, P1136, DOI 10.4049/jimmunol.1201899; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Kerzerho J, 2013, J ALLERGY CLIN IMMUN, V131, P1048, DOI 10.1016/j.jaci.2012.09.027; Kornete M, 2012, J IMMUNOL, V188, P1064, DOI 10.4049/jimmunol.1101303; Maazi H, 2015, IMMUNITY, V42, P538, DOI 10.1016/j.immuni.2015.02.007; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Rezende RM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9726; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Schreiber TH, 2010, J CLIN INVEST, V120, P3629, DOI 10.1172/JCI42933; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Tjota MY, 2013, J CLIN INVEST, V123, P2287, DOI 10.1172/JCI63802; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Xu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040314; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	39	122	123	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1468	+		10.1016/j.jaci.2016.08.034	http://dx.doi.org/10.1016/j.jaci.2016.08.034			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27717665	Bronze, Green Accepted			2022-12-18	WOS:000400465300007
J	von Mutius, E				von Mutius, Erika			The microbial environment and its influence on asthma prevention in early life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; asthma; environment; children; epidemiology	FARM MILK CONSUMPTION; EXHALED NITRIC-OXIDE; SCHOOL-AGE-CHILDREN; CHILDHOOD ASTHMA; ALLERGIC SENSITIZATION; HAY-FEVER; HOUSE-DUST; BACTERIAL-COLONIZATION; ATOPIC SENSITIZATION; INVERSE ASSOCIATION	There is accumulating evidence to suggest that the environmental microbiome plays a significant role in asthma development. The very low prevalence of asthma in populations highly exposed to microbial environments (farm children and Amish populations) highlights its preventive potential. This microbial diversity might be necessary to instruct a well-adapted immune response and regulated inflammatory responses to other inhaled and ingested environmental elements, such as allergens, particles, and viruses. Like the internal gut microbiome, which is increasingly recognized as an important instructor of immune maturation, the external environmental microbiome might shape immune responses on the skin, airway mucosal surfaces, and potentially also the gut early in life. The diversity of the external microbial world will ensure that of the many maladapted pathways leading to asthma development, most, if not all, will be counterbalanced. Likewise, important contributors to asthma, such as allergen sensitization and allergic manifestations early in life, are being suppressed. Thus the facets of innate immunity targeted by microbes and their compounds and metabolites might be the master switch to asthma and allergy protection, which has been found in environments rich in microbial exposures.	[von Mutius, Erika] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat, Lindwurmstr 4, D-80337 Munich, Germany	University of Munich	von Mutius, E (corresponding author), Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat, Lindwurmstr 4, D-80337 Munich, Germany.	erika.von.mutius@med.lmu.de		von Mutius, Erika/0000-0002-8893-4515	FrieslandCampina	FrieslandCampina	E. von Mutius has served as an Associate Editor for the Journal of Allergy and Clinical Immunology; is on the editorial board for the New England Journal of Medicine; has consultant arrangements with GlaxoSmithKline, Novartis, ALK-Abello, Astellas Pharma Europe, and Vifor Pharma; has provided expert testimony on behalf of the European Research Council, the UK Research Excellence Framework, and AUKCAR; and has received grants from FrieslandCampina.	Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barberan A, 2015, P BIOL SCI, V7, P282; Barberan A, 2015, P NATL ACAD SCI USA, V112, P5756, DOI 10.1073/pnas.1420815112; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brick T, 2016, J ALLERGY CLIN IMMUN; Bringolf-Isler B, 2013, J ALLERGY CLIN IMMUN, V132, P743, DOI 10.1016/j.jaci.2013.03.042; Cardenas PA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046803; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Chen CM, 2008, INT J HYG ENVIR HEAL, V211, P337, DOI 10.1016/j.ijheh.2007.05.007; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; DeMarco ML, 2011, MOL IMMUNOL, V49, P124, DOI 10.1016/j.molimm.2011.08.003; Douwes J, 2007, ALLERGY, V62, P1158, DOI 10.1111/j.1398-9995.2007.01490.x; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ege MJ, 2008, ALLERGY, V63, P1505, DOI 10.1111/j.1398-9995.2008.01793.x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Frei R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091097; Fuchs O, 2012, J ALLERGY CLIN IMMUN, V130, P382, DOI 10.1016/j.jaci.2012.04.049; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fyhrquist N, 2014, J ALLERGY CLIN IMMUN, V134, P1301, DOI 10.1016/j.jaci.2014.07.059; Gehring U, 2008, ENVIRON INT, V34, P1132, DOI 10.1016/j.envint.2008.04.003; Genuneit J, 2013, PEDIAT ALLERG IMM-UK, V24, P293, DOI 10.1111/pai.12053; Giovannangelo M, 2007, INDOOR AIR, V17, P70, DOI 10.1111/j.1600-0668.2006.00461.x; Gozdz J, 2015, AM THOR SOC INT C DE; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Hagner S, 2013, ALLERGY, V68, P322, DOI 10.1111/all.12094; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Holbreich M, 2012, J ALLERGY CLIN IMMUN, V129, P1671, DOI 10.1016/j.jaci.2012.03.016; Horak F, 2002, CLIN EXP ALLERGY, V32, P1155, DOI 10.1046/j.1365-2745.2002.01448.x; Hrusch CL, 2015, AM THOR SOC INT C DE; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kanchongkittiphon W, 2015, ENVIRON HEALTH PERSP, V123, P6, DOI [10.1289/ehp.1307922, 10.1289/ehp.123-A6]; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; Kettleson EM, 2015, ENVIRON RES, V138, P130, DOI 10.1016/j.envres.2015.02.003; Kirchner B, 2015, J ALLERGY CLIN IMMUN; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lampi J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007350; Legatzki A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0466-0; Lluis A, 2014, J ALLERGY CLIN IMMUN, V133, P551, DOI 10.1016/j.jaci.2013.06.034; Loss G, 2015, J ALLERGY CLIN IMMUN, V135, P56, DOI 10.1016/j.jaci.2014.08.044; Loss G, 2012, J ALLERGY CLIN IMMUN, V130, P523, DOI 10.1016/j.jaci.2012.05.049; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Loss GJ, 2015, AM J RESP CRIT CARE; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Maier RM, 2010, APPL ENVIRON MICROB, V76, P2663, DOI 10.1128/AEM.01665-09; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Mendy A, 2011, J ASTHMA, V48, P685, DOI 10.3109/02770903.2011.594140; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC; Normand AC, 2011, OCCUP ENVIRON MED, V68, P849, DOI 10.1136/oem.2010.061879; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Parks CG, 2008, LUPUS, V17, P711, DOI 10.1177/0961203308089436; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Peters M, 2010, J ALLERGY CLIN IMMUN, V126, P648, DOI 10.1016/j.jaci.2010.05.011; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Quansah R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047526; Radon K, 2005, DIABETES, V54, P3212, DOI 10.2337/diabetes.54.11.3212; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Radon K, 2007, PEDIATRICS, V120, P354, DOI 10.1542/peds.2006-3624; Radon K, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-73; Rappe MS, 2003, ANNU REV MICROBIOL, V57, P369, DOI 10.1146/annurev.micro.57.030502.090759; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Roduit C, 2011, J ALLERGY CLIN IMMUN, V127, P179, DOI 10.1016/j.jaci.2010.10.010; Rompa S, 2014, EUR RESP S58, V44; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schaub B, 2015, CURR OPIN IMMUNOL, V36, P88, DOI 10.1016/j.coi.2015.07.004; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Singer F, 2013, ALLERGY, V68, P531, DOI 10.1111/all.12127; Sozanska B, 2007, ALLERGY, V62, P394, DOI 10.1111/j.1398-9995.2007.01346.x; Sozanska B, 2014, J ALLERGY CLIN IMMUN, V133, P1347, DOI 10.1016/j.jaci.2013.10.035; Steinmeyer S, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0524-2; Stocklin L, 2013, INT J PUBLIC HEALTH, V58, P355, DOI 10.1007/s00038-012-0410-9; Thorne PS, 2015, AM J RESP CRIT CARE, V192, P1287, DOI 10.1164/rccm.201502-0251OC; Timm S, 2014, EUR J EPIDEMIOL, V29, P429, DOI 10.1007/s10654-014-9922-3; Tischer C, 2015, EUR RESPIR J, V45, P328, DOI 10.1183/09031936.00060214; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Tse K, 2008, SEMIN IMMUNOPATHOL, V30, P53, DOI 10.1007/s00281-007-0098-8; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Ursell LK, 2012, J ALLERGY CLIN IMMUN, V129, P1204, DOI 10.1016/j.jaci.2012.03.010; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Viinanen A, 2007, ALLERGY, V62, P272, DOI 10.1111/j.1398-9995.2007.01279.x; Vissing NH, 2013, AM J RESP CRIT CARE, V188, P1246, DOI 10.1164/rccm.201302-0215OC; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000; Zekveld C, 2006, EUR RESPIR J, V28, P82, DOI 10.1183/09031936.06.00021305	111	122	124	1	59	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					680	689		10.1016/j.jaci.2015.12.1301	http://dx.doi.org/10.1016/j.jaci.2015.12.1301			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26806048	Bronze			2022-12-18	WOS:000371897500003
J	Khattri, S; Shemer, A; Rozenblit, M; Dhingra, N; Czarnowicki, T; Finney, R; Gilleaudeau, P; Sullivan-Whalen, M; Zheng, XZ; Xu, H; Cardinale, I; Strong, CD; Gonzalez, J; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E				Khattri, Saakshi; Shemer, Avner; Rozenblit, Mariya; Dhingra, Nikhil; Czarnowicki, Tali; Finney, Robert; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Zheng, Xiuzhong; Xu, Hui; Cardinale, Irma; Strong, Cristina de Guzman; Gonzalez, Juana; Suarez-Farinas, Mayte; Krueger, Jim G.; Guttman-Yassky, Emma			Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; cyclosporine; T cell; immune; epidermal abnormalities; S100 proteins	TH2 CYTOKINES; T-CELLS; THERAPEUTIC RESPONSE; A MICROEMULSION; EXPRESSION; SKIN; DISEASE; KERATINOCYTES; INHIBITION; BARRIER	Background: Atopic dermatitis (AD) is the most common inflammatory disease. Evolving disease models link changes in epidermal growth and differentiation to T(H)2/T(H)22 cytokine activation. However, these models have not been tested by in vivo suppression of T-cell cytokines. Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe disease, but its mechanism in AD skin lesions has not been studied. Objective: We sought to establish the ability of a systemic immunosuppressant to modulate immune and epidermal alterations that form the pathogenic disease phenotype and to correlate changes with clinical improvement. Methods: CsA's effects on AD skin pathology were evaluated by using gene expression and immunohistochemistry studies in baseline, week 2, and week 12 lesional and nonlesional biopsy specimens from 19 patients treated with 5 mg/kg/d CsA for 12 weeks. Results: After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in SCORAD scores. Clinical improvements were associated with significant gene expression changes in lesional but also nonlesional skin, particularly reductions in levels of T(H)2-, T(H)22-, and some T(H)17-related molecules (ie, IL-13, IL-22, CCL17, S100As, and elafin/peptidase inhibitor 3), and modulation of epidermal hyperplasia and differentiation measures. Conclusions: This is the first study that establishes a relationship between cytokine activation and molecular epidermal alterations, as well as correlations between disease biomarkers in the skin and clinical improvement. The reversal of the molecular phenotype with CsA and the associated biomarkers can serve as a reference for the successful modulation of tissue inflammation with specific immune antagonists in future studies, contributing to the understanding of the specific cytokines involved in epidermal pathology.	[Khattri, Saakshi; Rozenblit, Mariya; Dhingra, Nikhil; Czarnowicki, Tali; Finney, Robert; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Zheng, Xiuzhong; Xu, Hui; Cardinale, Irma; Gonzalez, Juana; Suarez-Farinas, Mayte; Krueger, Jim G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10065 USA; [Rozenblit, Mariya; Czarnowicki, Tali; Suarez-Farinas, Mayte; Krueger, Jim G.] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY USA; [Shemer, Avner] Dept Dermatol, Tel Aviv, Israel; [Rozenblit, Mariya; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA; [Dhingra, Nikhil] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Finney, Robert] Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol, Philadelphia, PA 19107 USA; [Strong, Cristina de Guzman] Washington Univ, Sch Med, Dept Internal Med, Div Dermatol,Ctr Pharmacogen, St Louis, MO 63130 USA	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai; Columbia University; Jefferson University; Washington University (WUSTL)	Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Icahn Sch Med, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	eguttman@rockefeller.edu	de Guzman Strong, Cristina/AAA-7270-2019; Suarez-Farinas, Mayte/I-3558-2012	de Guzman Strong, Cristina/0000-0001-8540-9611; Suarez-Farinas, Mayte/0000-0001-8712-3553; Rozenblit, Mariya/0000-0002-8874-6688	National Center for Research Resources (NCRR) of the National Institutes of Health (NIH) [5UL1RR024143-02]; NIH Roadmap for Medical Research; Dermatology Foundation; Rockefeller University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation; Rockefeller University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	J.G.K., M.S.-F., M. R., T. C., and N.D. were supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y was supported by the Dermatology Foundation Physician Scientist Career Development Award and a CTSA grant from Rockefeller University.	Aizu T, 2008, J DERMATOL SCI, V51, P45, DOI 10.1016/j.jdermsci.2008.01.006; Baumgrass R, 2010, J ALLERGY CLIN IMMUN, V126, P183, DOI 10.1016/j.jaci.2010.04.032; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Brandt C, 2009, ALLERGY, V64, P1588, DOI 10.1111/j.1398-9995.2009.02054.x; Bunikowski R, 2001, PEDIAT ALLERG IMM-UK, V12, P216, DOI 10.1034/j.1399-3038.2001.012004216.x; Bunikowski R, 2001, INT ARCH ALLERGY IMM, V125, P344, DOI 10.1159/000053836; Bussmann C, 2009, J DTSCH DERMATOL GES, V7, P205, DOI 10.1111/j.1610-0387.2008.06834.x; Chamlin SL, 2010, IMMUNOL ALLERGY CLIN, V30, P281, DOI 10.1016/j.iac.2010.05.004; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Farrell AM, 2001, BRIT J DERMATOL, V144, P24, DOI 10.1046/j.1365-2133.2001.03948.x; FARTASCH M, 1992, ACTA DERM-VENEREOL, P26; Furukawa H, 2004, J DERMATOL SCI, V35, P35, DOI 10.1016/j.jdermsci.2004.02.008; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; GRANLUND H, 1995, BRIT J DERMATOL, V132, P106, DOI 10.1111/j.1365-2133.1995.tb08633.x; Granlund H, 1998, ACTA DERM-VENEREOL, V78, P40; Guttman-Yassky E, 2013, EXPERT OPIN BIOL TH, V13, P549, DOI 10.1517/14712598.2013.758708; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Haider AS, 2008, J IMMUNOL, V180, P1913, DOI 10.4049/jimmunol.180.3.1913; Hibino M, 2011, ARCH DERMATOL RES, V303, P481, DOI 10.1007/s00403-010-1099-3; Hijnen DJ, 2007, J EUR ACAD DERMATOL, V21, P85, DOI 10.1111/j.1468-3083.2006.01877.x; Hijnen D, 2009, J ALLERGY CLIN IMMUN, V124, P856, DOI 10.1016/j.jaci.2009.07.056; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Kashyap T, 2012, J BIOL CHEM, V287, P32440, DOI 10.1074/jbc.M112.385245; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kim BE, 2012, ALLERGY ASTHMA IMMUN, V4, P12, DOI 10.4168/aair.2012.4.1.12; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Liao SC, 2004, J IMMUNOL, V173, P6712, DOI 10.4049/jimmunol.173.11.6712; MUNRO CS, 1991, BRIT J DERMATOL, V124, P43; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Otsuka A, 2011, EUR J DERMATOL, V21, P816, DOI 10.1684/ejd.2011.1470; Reich A, 2013, INT J MOL SCI, V14, P8456, DOI 10.3390/ijms14048456; Rudloff I, 2012, J BIOL CHEM, V287, P4531, DOI 10.1074/jbc.M111.286492; Sehra S, 2010, J IMMUNOL, V184, P3186, DOI 10.4049/jimmunol.0901860; Shemer A, 2013, J ALLERGY CLIN IMMUN, V131, P577, DOI 10.1016/j.jaci.2012.11.010; Smit NPM, 2008, J INVEST DERMATOL, V128, P1686, DOI 10.1038/sj.jid.5701244; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Tajima K, 2003, IMMUNOLOGY, V108, P321, DOI 10.1046/j.1365-2567.2003.01585.x; Takei-Taniguchi R, 2012, J DERMATOL, V39, P625, DOI 10.1111/j.1346-8138.2011.01462.x; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tsuda K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031465; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683	49	122	128	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1626	1634		10.1016/j.jaci.2014.03.003	http://dx.doi.org/10.1016/j.jaci.2014.03.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24786238	Bronze, Green Accepted			2022-12-18	WOS:000336672500015
J	Ortega, VE; Meyers, DA				Ortega, Victor E.; Meyers, Deborah A.			Pharmacogenetics: Implications of race and ethnicity on defining genetic profiles for personalized medicine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genes; pharmacogenetics; response heterogeneity; single nucleotide polymorphism; admixture mapping; ethnic group	SINGLE-NUCLEOTIDE POLYMORPHISMS; HUMAN BETA(2)-ADRENERGIC RECEPTOR; ACTING BETA-AGONISTS; PUERTO-RICAN; LUNG-FUNCTION; SEVERE ASTHMA; AFRICAN-AMERICANS; MEXICAN-AMERICAN; RARE ALLELES; ASSOCIATION	Pharmacogenetics is being used to develop personalized therapies specific to subjects from different ethnic or racial groups. To date, pharmacogenetic studies have been primarily performed in trial cohorts consisting of non-Hispanic white subjects of European descent. A "bottleneck" or collapse of genetic diversity associated with the first human colonization of Europe during the Upper Paleolithic period, followed by the recent mixing of African, European, and Native American ancestries, has resulted in different ethnic groups with varying degrees of genetic diversity. Differences in genetic ancestry might introduce genetic variation, which has the potential to alter the therapeutic efficacy of commonly used asthma therapies, such as beta(2)-adrenergic receptor agonists (beta-agonists). Pharmacogenetic studies of admixed ethnic groups have been limited to small candidate gene association studies, of which the best example is the gene coding for the receptor target of beta-agonist therapy, the beta(2)-adrenergic receptor (ADRB2). Large consortium-based sequencing studies are using next-generation whole-genome sequencing to provide a diverse genome map of different admixed populations, which can be used for future pharmacogenetic studies. These studies will include candidate gene studies, genome-wide association studies, and whole-genome admixture-based approaches that account for ancestral genetic structure, complex haplotypes, gene-gene interactions, and rare variants to detect and replicate novel pharmacogenetic loci.	[Ortega, Victor E.; Meyers, Deborah A.] Wake Forest Sch Med, Ctr Genom & Personalized Med, Winston Salem, NC 27157 USA	Wake Forest University	Meyers, DA (corresponding author), Wake Forest Sch Med, Ctr Genom & Personalized Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dmeyers@wakehealth.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109164, U10HL098103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR013700] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10 HL098103, U10 HL109164] Funding Source: Medline; NINR NIH HHS [R01 NR013700] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298; Ambrose HJ, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-37; Anderson HR, 2005, BRIT MED J, V330, P117, DOI 10.1136/bmj.38316.729907.8F; Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0; Bleecker ER, 2006, J ALLERGY CLIN IMMUN, V118, P809, DOI 10.1016/j.jaci.2006.06.036; Bleecker ER, 2010, AM J RESP CRIT CARE, V181, P676, DOI [10.1164/rccm.200809-1511OC, 10.1164/200809-1511OC]; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Bruse S, 2011, AM J RESP CRIT CARE, V184, P1254, DOI 10.1164/rccm.201103-0568OC; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Cho SH, 2005, CLIN EXP ALLERGY, V35, P1162, DOI 10.1111/j.1365-2222.2005.02319.x; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Choudhry S, 2006, AM J RESP CRIT CARE, V174, P1086, DOI [10.1164/RCCM.200605-596OC, 10.1164/rccm.200605-596OC]; Choudhry S, 2010, PHARMACOGENET GENOM, V20, P351, DOI 10.1097/FPC.0b013e328337f992; Chowdhury BA, 2011, NEW ENGL J MED, V364, P2473, DOI 10.1056/NEJMp1104375; Cohen JC, 2006, P NATL ACAD SCI USA, V103, P1810, DOI 10.1073/pnas.0508483103; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Dahlin A, 2012, PHARMACOGENOMICS, V13, P1387, DOI [10.2217/pgs.12.126, 10.2217/PGS.12.126]; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Duan QL, 2011, AM J RESP CRIT CARE, V183, P449, DOI 10.1164/rccm.201005-0758OC; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Exome Variant Server, 2013, NHLBI GO EX SEQ PROJ; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; Green SA, 2001, EUR J PHARMACOL, V421, P141, DOI 10.1016/S0014-2999(01)01049-4; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Harpending H, 2000, ANNU REV GENOM HUM G, V1, P361, DOI 10.1146/annurev.genom.1.1.361; Hawkins GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/rccm.200509-1405OC; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; Himes BE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002824; Himes BE, 2009, PHARMACOGENOMICS, V10, P1393, DOI 10.2217/PGS.09.93; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Irizarry K, 2000, NAT GENET, V26, P233, DOI 10.1038/79981; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Keinan A, 2012, SCIENCE, V336, P740, DOI 10.1126/science.1217283; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Lee DKC, 2004, BRIT J CLIN PHARMACO, V57, P68, DOI 10.1046/j.1365-2125.2003.01955.x; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Liggett SB, 2008, NAT MED, V14, P510, DOI 10.1038/nm1750; Liggett SB, 2006, P NATL ACAD SCI USA, V103, P11288, DOI 10.1073/pnas.0509937103; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; Marth G, 2003, P NATL ACAD SCI USA, V100, P376, DOI 10.1073/pnas.222673099; McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032; Meyer LR, 2013, NUCLEIC ACIDS RES, V41, pD64, DOI 10.1093/nar/gks1048; Montana G, 2004, AM J HUM GENET, V75, P771, DOI 10.1086/425281; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morris AP, 2010, GENET EPIDEMIOL, V34, P188, DOI 10.1002/gepi.20450; Naqvi M, 2007, J ASTHMA, V44, P639, DOI 10.1080/02770900701554441; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Ni Chroinin M, 2005, COCHRANE DB SYST REV, V4; Ortega VE, 2007, IMMUNOL ALLERGY CLIN, V27, P665, DOI 10.1016/j.iac.2007.09.007; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Peters SP, 2008, ALLERGY ASTHMA PROC, V29, P499, DOI 10.2500/aap.2008.29.3147; Roberts L, 2011, SCIENCE, V333, P540, DOI 10.1126/science.333.6042.540; Rose D, 2006, AM J PUBLIC HEALTH, V96, P880, DOI 10.2105/AJPH.2004.050039; Rumpel JA, 2012, J ALLERGY CLIN IMMUN, V130, P1302, DOI 10.1016/j.jaci.2012.09.001; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Sankar P, 2007, AM J MED GENET A, V143A, P961, DOI 10.1002/ajmg.a.31575; Sears MR, 2009, EUR RESPIR J, V33, P21, DOI 10.1183/09031936.00145006; Sherry ST, 1997, GENETICS, V147, P1977; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; Sunyaev SR, 2000, TRENDS GENET, V16, P335, DOI 10.1016/S0168-9525(00)02058-8; Tandon A, 2011, GENET EPIDEMIOL, V35, P80, DOI 10.1002/gepi.20550; Tang H, 2005, AM J HUM GENET, V76, P268, DOI 10.1086/427888; Tantisira KG, 2012, AM J RESP CRIT CARE, V185, P1286, DOI 10.1164/rccm.201111-2061OC; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Tantisira KG, 2009, PHARMACOGENET GENOM, V19, P244, DOI 10.1097/FPC.0b013e328326e0b1; Tantisira KG, 2005, HUM MOL GENET, V14, P1671, DOI 10.1093/hmg/ddi175; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Telleria JJ, 2008, RESP MED, V102, P857, DOI 10.1016/j.rmed.2008.01.011; Thomsen M, 2012, EUR RESPIR J, V39, P558, DOI 10.1183/09031936.00023511; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P622, DOI 10.1016/j.jaci.2012.03.045; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Tsuji S, 2010, HUM MOL GENET, V19, pR65, DOI 10.1093/hmg/ddq162; US Food and Drug Administration, 2011, FDA DRUG SAF COMM FD; VESELL ES, 1989, PHARMACOL THERAPEUT, V41, P535, DOI 10.1016/0163-7258(89)90130-7; Vonk JM, 2010, PHARMACOGENET GENOM, V20, P179, DOI 10.1097/FPC.0b013e328336c7fd; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Wechsler ME, 2011, AM J RESP CRIT CARE, V184, P1247, DOI 10.1164/rccm.201103-0514OC; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029; Zhu XF, 2008, ADV GENET, V60, P547, DOI 10.1016/S0065-2660(07)00419-1	100	122	125	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					16	26		10.1016/j.jaci.2013.10.040	http://dx.doi.org/10.1016/j.jaci.2013.10.040			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369795	Green Accepted			2022-12-18	WOS:000329105700002
J	Zuraw, BL; Bernstein, JA; Lang, DM; Craig, T; Dreyfus, D; Hsieh, F; Khan, D; Sheikh, J; Weldon, D; Bernstein, DI; Blessing-Moore, J; Cox, L; Nicklas, RA; Oppenheimer, J; Portnoy, JM; Randolph, CR; Schuller, DE; Spector, SL; Tilles, SA; Wallace, D				Zuraw, Bruce L.; Bernstein, Jonathan A.; Lang, David M.; Craig, Timothy; Dreyfus, David; Hsieh, Fred; Khan, David; Sheikh, Javed; Weldon, David; Bernstein, David I.; Blessing-Moore, Joann; Cox, Linda; Nicklas, Richard A.; Oppenheimer, John; Portnoy, Jay M.; Randolph, Christopher R.; Schuller, Diane E.; Spector, Sheldon L.; Tilles, Stephen A.; Wallace, Dana			A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Angiotensin-converting enzyme inhibitor; acquired C1 inhibitor deficiency; angioedema; angiotensin receptor blocker; bradykinin; C1 inhibitor deficiency; hereditary angioedema	HUMAN C1-INHIBITOR CONCENTRATE; MOLECULAR-WEIGHT KININOGEN; 1ST COMPLEMENT COMPONENT; FRESH-FROZEN PLASMA; ANGIONEUROTIC-EDEMA; RECEPTOR ANTAGONIST; INTERNATIONAL CONSENSUS; VASCULAR-PERMEABILITY; REPLACEMENT THERAPY; DANAZOL PROPHYLAXIS	These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the JTFPP, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. The Joint Task Force on Practice Parameters understands that the cost of diagnostic tests and therapeutic agents is an important concern that might appropriately influence the work-up and treatment chosen for a given patient. The JTFPP recognizes that the emphasis of our primary recommendations regarding a medication might vary, for example, depending on third-party payer issues and product patent expiration dates. However, because the cost of a given test or agent is so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not consider cost when formulating practice parameter recommendations. In some instances the cost benefit of an intervention is considered relevant, and commentary might be provided. These parameters are not designed for use by pharmaceutical companies in drug promotion. The Joint Task Force is committed to ensuring that the practice parameters are based on the best scientific evidence that is free of commercial bias. To this end, the parameter development process includes multiple layers of rigorous review. These layers include the Workgroup convened to draft the parameter, the Task Force Reviewers, and peer review by members of each sponsoring society. Although the Task Force has the final responsibility for the content of the documents submitted for publication, each reviewer comment will be discussed, and reviewers will receive written responses to comments when appropriate. To preserve the greatest transparency regarding potential conflicts of interest, all members of the Joint Task Force and the Practice Parameters Workgroups will complete a standard potential conflict of interest disclosure form, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of a Workgroup chairperson, the Joint Task Force will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter workgroups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias.	[Zuraw, Bruce L.] Joint Council Allergy Asthma & Immunol, Palatine, IL 60067 USA		Zuraw, BL (corresponding author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St 304, Palatine, IL 60067 USA.		Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870; Bernstein, Jonathan/0000-0002-3476-1196; Zuraw, Bruce/0000-0003-0640-6768	Shire; National Institutes of Health (NIH); Department of Defense (DOD); Veterans' Administration; Dyax; CSL Behring; ViroPharma; Pharming; Novartis; Genentech/Novartis; Merck; Forrest; Genentech; Biota; GlaxoSmithKline; Grifols; TEVA; Vietnam Education Foundation; Howard Hughes Medical Institute; Vanberg Family Foundation; NIH/National Institute of Mental Health; Pfizer; Meda; ARRAY; Cephalon; MedImmune; Stallergenes; Circassia; BCBS TEC; Southeastern Allergy, Asthma, Immunology Association; AstraZeneca; Boehringer Ingelheim; Amgen; Mylan; Sanofi; Astellas; Amphastar; Sunovion; Rigel	Shire; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (DOD)(United States Department of Defense); Veterans' Administration(US Department of Veterans Affairs); Dyax; CSL Behring; ViroPharma; Pharming; Novartis(Novartis); Genentech/Novartis(Roche HoldingGenentech); Merck(Merck & Company); Forrest; Genentech(Roche HoldingGenentech); Biota; GlaxoSmithKline(GlaxoSmithKline); Grifols; TEVA(Teva Pharmaceutical Industries); Vietnam Education Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Vanberg Family Foundation; NIH/National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Pfizer(Pfizer); Meda; ARRAY; Cephalon; MedImmune(AstraZenecaMedimmune); Stallergenes; Circassia; BCBS TEC; Southeastern Allergy, Asthma, Immunology Association; AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Amgen(Amgen); Mylan; Sanofi; Astellas(Astellas Pharmaceuticals); Amphastar; Sunovion; Rigel	Disclosure of potential conflict of interest: B. L. Zuraw has received research support from Shire, the National Institutes of Health (NIH), the Department of Defense (DOD), and the Veterans' Administration; is the chair of the medical advisory board for the Hereditary Angioedema Association, and has consultant arrangements with CSL Behring, Dyax, Isis, and Biocryst. J. A. Bernstein is a partner in the Bernstein Allergy Group and a member of Bernstein Clinical Research; has received research support from Dyax, Shire, CSL Behring, ViroPharma, Pharming, and Novartis; is on the Board of Directors for the American Academy of Allergy, Asthma & Immunology (AAAAI), is a fellow of the American College of Allergy, Asthma & Immunology (ACAAI), is Chairman of Allergists for Israel, and is on the advisory board for the Hereditary Angioedema Association; is Editor in Chief of the Journal of Asthma; serves on the Editorial Boards for the Journal of Allergy and Clinical Immunology, the Annals of Allergy, Allergy Proceedings, and the Journal of Angioedema; and is the Editor of the Joint Task Force Guidelines on Urticaria and Angioedema. D. M. Lang serves on the Board of Directors for the AAAAI; is a member of the Pulmonary and Critical Care Steering Committee of the National Quality Forum; is a speaker for Genentech/Novartis, GlaxoSmithKline, and Merck; is a consultant for GlaxoSmithKline, Merck, and Aerocrine; and has received research support from Genentech/Novartis and Merck. T. Craig is an interest section leader for the AAAAI, is a board member for the ACAAI, the American Lung Association-Pennsylvania, and the Joint Council of Allergy, Asthma and Immunology; has consultant arrangements with CSL Behring, Dyax, Viropharma, and Shire; has provided expert testimony in cases related to anaphylaxis; has received grants from Viropharma, CSL Behring, Shire, Dyax, Pharming, Forrest, Genentech, Biota, GlaxoSmithKline, and Grifols; has received payment for lectures from Viropharma, CSL Behring, Dyax, Merck, Novartis, Genentech, and TEVA; and has received payment for development of educational presentations from the Vietnam Education Foundation. F. Hsieh has received a research grant from the Howard Hughes Medical Institute. D. Khan has speaker arrangements with Genentech, Merck, Baxter, and Viropharma; has received research support from the Vanberg Family Foundation and the NIH/National Institute of Mental Health; is the Allied Health Chair for the ACAAI, and is a member of the Joint Task Force on Practice Parameters for the Joint Council of Allergy, Asthma, and Immunology. J. Sheikh has consultant arrangements with CSL Behring; has consulted in cases related to allergy/immunology medical malpractice; is a member of the ACAAI; is on the Executive Board for the Massachusetts Allergy Society; and is on the Executive Board and is CME Director for the New England Society of Allergy. D. Weldon has provided expert testimony on behalf of the Texas Allergy, Asthma, and Immunology Society; is on the Board of Regents for the ACAAI; and is chair of the Practice Standards Committee for the Texas Allergy, Asthma, and Immunology Society. D. I Bernstein has received research support from TEVA, Genentech, Pfizer, Merck, Meda, GlaxoSmithKline, ARRAY, Cephalon, and MedImmune and has provided legal consultation services or expert witness testimony in cases related to anaphylaxis, contact dermatitis, and occupational asthma. J.; Blessing-Moore is a speaker for Meda, Alcon, Teva, Sunovion, Genentech/Novartis, Merck and AstraZeneca; receives research support from Meda; and is a committee member of the American Thoracic Society, the American College of Chest Physicians, the ACAAI, and the AAAAI. L. Cox has received consulting fees from Stallergenes, has received travel support from the AAAAI, has received fees for participation in review activities from Circassia and Novartis, has received payment for writing or reviewing the manuscript from BCBS TEC, is a member of the American Board of Allergy and Immunology, has consultant arrangements with the US Food and Drug Administration Allergenic Products Advisory Committee, has provided expert testimony in cases related to chronic cinguteria, and has received payment for lectures from the Southeastern Allergy, Asthma, Immunology Association. R. A. Nicklas is a committee chair and fellow for the ACAAI. J. Oppenheimer has received research support from AstraZeneca, GlaxoSmithKline, Merck, Boehringer Ingelheim, Novartis, and MedImmune; has provided legal consultation services or expert witness testimony for the defense in a malpractice case; is Chairman of the American Board of Allergy and Immunology; and has consultant arrangements with GlaxoSmithKline, Mylan, Novartis, and Sunovion. J. M. Portnoy is a speaker for Thermo Fisher and Mylan and has consultant arrangements with Thermo Fisher and Sanofi. C. R. Randolph is a speaker for GlaxoSmithKline, TEVA, Viropharma, Merck, and Dey; has received research grants from GlaxoSmithKline, Merck, Amgen, and Genentech/Novartis; has provided an advertisement for Pharmaxis; and has consultant arrangements with AstraZeneca and Meda. S. L. Spector has stock in GlaxoSmithKline and Merck; has consultant arrangements with Hycor; has received research support from AstraZeneca, GlaxoSmithKline, Amgen, Genentech, Novartis, TEVA, Mylan, Sanofi, and Boehringer Ingelheim; and is a speaker/moderator for the ACAAI. S. A. Tilles has consultant arrangements with SRXA, Sunovion, and Hyrox; has received research support from Astellas, Amphastar, MedImmune, Cephalon, Genentech, Merck, TEVA, Sunovion, Boehringer Ingelheim, Novartis, Array, Rigel, and AstraZeneca; is Associate Editor of AllergyWatch, Annals of Allergy, and the Joint Task Force for Practice Parameters; and is on the Executive Committee for the Seattle Food Allergy Consortium. D. Wallace is a speaker for the ACAAI, TEVA, and Mylan; is an advisor for Sanofi and Sunovion; is on the executive committee for the ACAAI; and is on the Board of Directors for the World Allergy Organization. The rest of the editors, contributors, and reviewers declare that they have no relevant conflicts of interest.	Adam A, 2002, LANCET, V359, P2088, DOI 10.1016/S0140-6736(02)08914-6; AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; ALSENZ J, 1989, J CLIN INVEST, V83, P1794, DOI 10.1172/JCI114084; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; Bas M, 2010, ANN EMERG MED, V56, P278, DOI 10.1016/j.annemergmed.2010.03.032; Beavers CJ, 2011, ANN PHARMACOTHER, V45, P520, DOI 10.1345/aph.1P630; Beinrohr L, 2007, J BIOL CHEM, V282, P21100, DOI 10.1074/jbc.M700841200; Bernstein JA, 2010, EXPERT REV CLIN IMMU, V6, P29, DOI 10.1586/ECI.09.60; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; Blais C, 1999, IMMUNOPHARMACOLOGY, V43, P293, DOI 10.1016/S0162-3109(99)00133-2; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2006, BRIT J DERMATOL, V154, P542, DOI 10.1111/j.1365-2133.2005.07048.x; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bork K, 2008, ANN ALLERG ASTHMA IM, V100, P153, DOI 10.1016/S1081-1206(10)60424-3; Bork K, 2007, AM J MED, V120, P987, DOI 10.1016/j.amjmed.2007.08.021; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Bork K, 2006, IMMUNOL ALLERGY CLIN, V26, P709, DOI 10.1016/j.iac.2006.09.003; Bork K, 2011, ORAL SURG ORAL MED O, V112, P58, DOI 10.1016/j.tripleo.2011.02.034; Bork K, 2009, BLOOD COAGUL FIBRIN, V20, P325, DOI 10.1097/MBC.0b013e32832811f8; Bouillet L, 2007, BRIT J DERMATOL, V156, P1063, DOI 10.1111/j.1365-2133.2007.07778.x; Bouillet Laurence, 2010, Allergy Asthma Clin Immunol, V6, P17, DOI 10.1186/1710-1492-6-17; Bouillet L, 2009, ANN ALLERG ASTHMA IM, V103, P448, DOI 10.1016/S1081-1206(10)60369-9; Bouillet L, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.034; Bowen T, 2008, ANN ALLERG ASTHMA IM, V100, pS30, DOI 10.1016/S1081-1206(10)60584-4; Boxer M, 1996, J ALLERGY CLIN IMMUN, V98, P471, DOI 10.1016/S0091-6749(96)70176-8; Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; Byrd JB, 2006, IMMUNOL ALLERGY CLIN, V26, P725, DOI 10.1016/j.iac.2006.08.001; Caballero T, 2012, J ALLERGY CLIN IMMUN, V129, P308, DOI 10.1016/j.jaci.2011.11.025; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; Campbell DJ, 2005, CIRCULATION, V111, P315, DOI 10.1161/01.CIR.0000153269.07762.3B; Campbell DJ, 2003, HYPERTENSION, V41, P383, DOI 10.1161/01.HYP.0000054215.71691.16; CARTER PE, 1991, EUR J BIOCHEM, V197, P301, DOI 10.1111/j.1432-1033.1991.tb15911.x; Carugati A, 2001, MOL IMMUNOL, V38, P161, DOI 10.1016/S0161-5890(01)00040-2; CHAPPATTE O, 1988, BRIT J OBSTET GYNAEC, V95, P938, DOI 10.1111/j.1471-0528.1988.tb06585.x; Cicardi M, 2003, MEDICINE, V82, P274, DOI 10.1097/00005792-200307000-00006; Cicardi M, 2004, ARCH INTERN MED, V164, P910, DOI 10.1001/archinte.164.8.910; Cicardi M, 1996, CLIN EXP IMMUNOL, V106, P475, DOI 10.1046/j.1365-2249.1996.d01-866.x; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; Cicardi M, 2012, ALLERGY, V67, P147, DOI 10.1111/j.1398-9995.2011.02751.x; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; Cicardi Marco, 2010, Allergy Asthma Clin Immunol, V6, P14, DOI 10.1186/1710-1492-6-14; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Craig TJ, 2008, ALLERGY ASTHMA PROC, V29, P225, DOI 10.2500/aap.2008.29.3107; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; Cronin JA, 2012, ANN ALLERG ASTHMA IM, V108, P61, DOI 10.1016/j.anai.2011.09.020; Cupido C, 2007, SAMJ S AFR MED J, V97, P244; CURD JG, 1982, MOL IMMUNOL, V19, P1365, DOI 10.1016/0161-5890(82)90035-9; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; Czaller I, 2010, EUR J OBSTET GYN R B, V152, P44, DOI 10.1016/j.ejogrb.2010.05.008; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAVIS AE, 1986, P NATL ACAD SCI USA, V83, P3161, DOI 10.1073/pnas.83.10.3161; Davis AE, 2006, IMMUNOL ALLERGY CLIN, V26, P633, DOI 10.1016/j.iac.2006.08.003; De Serres J, 2003, TRANSFUS APHER SCI, V29, P247, DOI 10.1016/j.transci.2003.08.006; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1985, J CLIN INVEST, V75, P124, DOI 10.1172/JCI111664; DONALDSON VH, 1992, J LAB CLIN MED, V119, P330; DONALDSON VH, 1972, NEW ENGL J MED, V286, P835, DOI 10.1056/NEJM197204132861510; DONALDSON VH, 1992, J LAB CLIN MED, V119, P397; Drouet C, 2008, J ALLERGY CLIN IMMUN, V121, P429, DOI 10.1016/j.jaci.2007.10.048; Duan QL, 2009, J ALLERGY CLIN IMMUN, V123, P906, DOI 10.1016/j.jaci.2008.12.010; Farkas H, 2007, J ALLERGY CLIN IMMUN, V120, P941, DOI 10.1016/j.jaci.2007.06.026; Farkas H, 2007, PEDIATRICS, V120, pE713, DOI 10.1542/peds.2006-3303; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FRANGI D, 1992, FEBS LETT, V301, P34, DOI 10.1016/0014-5793(92)80204-T; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; FRANK MM, 1979, ARTHRITIS RHEUM, V22, P1295, DOI 10.1002/art.1780221118; Gallitelli M, 2012, AM J EMERG MED, V30, DOI 10.1016/j.ajem.2011.09.014; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Gosswein T, 2008, CYTOGENET GENOME RES, V121, P181, DOI 10.1159/000138883; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Gompels MM, 2002, J CLIN PATHOL, V55, P145, DOI 10.1136/jcp.55.2.145; Guyatt GH, 2008, BRIT MED J, V336, P1170, DOI 10.1136/bmj.39504.506319.80; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Haymore BR, 2008, ANN ALLERG ASTHMA IM, V101, P495, DOI 10.1016/S1081-1206(10)60288-8; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; JACKSON J, 1989, J CLIN INVEST, V83, P698, DOI 10.1172/JCI113934; JAFFE CJ, 1975, J ALLERGY CLIN IMMUN, V55, P386, DOI 10.1016/0091-6749(75)90077-9; JASON DR, 1992, J FORENSIC SCI, V37, P1418; Kalaria SS, 2011, ANN ALLERG ASTHMA IM, V107, pA107; Keleman Z, 2010, CLIN IMMUNOL, V134, P354, DOI 10.1016/j.clim.2009.11.002; Kreuz W, 2012, TRANSFUSION, V52, P100, DOI 10.1111/j.1537-2995.2011.03240.x; Kreuz W, 2009, TRANSFUSION, V49, P1987, DOI 10.1111/j.1537-2995.2009.02230.x; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; LAMMLE B, 1988, THROMB HAEMOSTASIS, V59, P151; Levi M, 2006, J ALLERGY CLIN IMMUN, V117, P904, DOI 10.1016/j.jaci.2006.01.002; Levi M, 2006, AM J MED, V119, pE3, DOI 10.1016/j.amjmed.2005.09.018; Lomas DA, 2005, BIOCHEM SOC T, V33, P321, DOI 10.1042/BST0330321; Lumry WR, 2011, ANN ALLERG ASTHMA IM, V107, P529, DOI 10.1016/j.anai.2011.08.015; Lunn ML, 2010, ANN ALLERG ASTHMA IM, V104, P211, DOI 10.1016/j.anai.2009.12.004; MOLINA C, 1977, CLIN ALLERGY, V7, P127, DOI 10.1111/j.1365-2222.1977.tb01433.x; Monnier N, 2006, MOL IMMUNOL, V43, P2161, DOI 10.1016/j.molimm.2006.01.006; Nielsen EW, 1996, J INTERN MED, V239, P119, DOI 10.1046/j.1365-2796.1996.418764000.x; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Pappalardo E, 2003, IMMUNOL LETT, V86, P271, DOI 10.1016/S0165-2478(03)00029-4; Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471; Pappalardo E, 2008, MOL IMMUNOL, V45, P3536, DOI 10.1016/j.molimm.2008.05.007; PARAD RB, 1990, P NATL ACAD SCI USA, V87, P6786, DOI 10.1073/pnas.87.17.6786; Prematta M, 2007, ANN ALLERG ASTHMA IM, V98, P383, DOI 10.1016/S1081-1206(10)60886-1; Prematta MJ, 2009, ALLERGY ASTHMA PROC, V30, P506, DOI 10.2500/aap.2009.30.3279; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498, DOI 10.1016/S1081-1206(10)61121-0; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; ROSEN FS, 1969, NEW ENGL J MED, V280, P1356, DOI 10.1056/NEJM196906122802414; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; Schmidt PW, 2010, J AM ACAD DERMATOL, V63, P913, DOI 10.1016/j.jaad.2010.03.023; SCHREIBER AD, 1976, BLOOD, V48, P567; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P855, DOI 10.1016/S0091-6749(87)80277-4; SHEPHERD GM, 1990, AM J MED, V88, P446, DOI 10.1016/0002-9343(90)90514-E; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; SKRIVER K, 1989, J BIOL CHEM, V264, P3066; Sloane DE, 2007, J ALLERGY CLIN IMMUN, V120, P654, DOI 10.1016/j.jaci.2007.06.037; Szeplaki G, 2005, J ALLERGY CLIN IMMUN, V115, P864, DOI 10.1016/j.jaci.2004.12.1130; Tilles SA, 2011, ANN ALLERG ASTHMA IM, V106, P264, DOI 10.1016/j.anai.2011.01.025; TOSI M, 1986, GENE, V42, P265, DOI 10.1016/0378-1119(86)90230-1; Tourangeau LM, 2012, INT ARCH ALLERGY IMM, V157, P417, DOI 10.1159/000329635; ULMER JL, 1992, ANN PHARMACOTHER, V26, P1245, DOI 10.1177/106002809202601012; Verpy E, 1996, AM J HUM GENET, V59, P308; VERPY E, 1995, J CLIN INVEST, V95, P350, DOI 10.1172/JCI117663; Visy B, 2007, HELICOBACTER, V12, P251, DOI 10.1111/j.1523-5378.2007.00501.x; Vitrat-Hincky V, 2010, ALLERGY, V65, P1331, DOI 10.1111/j.1398-9995.2010.02368.x; Wagenaar-Bos IGA, 2008, J IMMUNOL METHODS, V338, P14, DOI 10.1016/j.jim.2008.06.004; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; White WB, 2010, J CLIN HYPERTENS, V12, P765, DOI 10.1111/j.1751-7176.2010.00352.x; Zanichelli A, 2011, INTERN EMERG MED, V6, P279, DOI 10.1007/s11739-010-0431-4; Zingale LC, 2006, CAN MED ASSOC J, V175, P1065, DOI 10.1503/cmaj.060535; Zingale LC, 2006, IMMUNOL ALLERGY CLIN, V26, P669, DOI 10.1016/j.iac.2006.08.002; Zuraw BL, 2000, J ALLERGY CLIN IMMUN, V105, P541, DOI 10.1067/mai.2000.104780; ZURAW BL, 1986, J ALLERGY CLIN IMMUN, V78, P1115, DOI 10.1016/0091-6749(86)90259-9; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610; Zuraw B, 2010, J ALLERGY CLIN IMMUN, V126, P821, DOI 10.1016/j.jaci.2010.07.021; Zuraw B, 2010, NAT REV DRUG DISCOV, V9, P189, DOI 10.1038/nrd3125; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977; Zuraw BL, 2008, EXPERT OPIN INV DRUG, V17, P697, DOI [10.1517/13543784.17.5.697, 10.1517/13543784.17.5.697 ]; Zuraw BL, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2012.02.020; Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538	144	122	124	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1491	+		10.1016/j.jaci.2013.03.034	http://dx.doi.org/10.1016/j.jaci.2013.03.034			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23726531	Bronze			2022-12-18	WOS:000320532800004
J	Tan, BK; Li, QZ; Suh, L; Kato, A; Conley, DB; Chandra, RK; Zhou, JC; Norton, J; Carter, R; Hinchcliff, M; Harris, K; Peters, A; Grammer, LC; Kern, RC; Mohan, C; Schleimer, RP				Tan, Bruce K.; Li, Quan-Zhen; Suh, Lydia; Kato, Atsushi; Conley, David B.; Chandra, Rakesh K.; Zhou, Jinchun; Norton, James; Carter, Roderick; Hinchcliff, Monique; Harris, Kathleen; Peters, Anju; Grammer, Leslie C.; Kern, Robert C.; Mohan, Chandra; Schleimer, Robert P.			Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; sinusitis; nasal polyps; autoimmunity; autoantibodies; biomarker	INFLAMMATORY-BOWEL-DISEASE; ACTIVE LUPUS NEPHRITIS; CELL-ACTIVATING FACTOR; STAPHYLOCOCCUS-AUREUS; SEROLOGIC MARKERS; DNA ANTIBODIES; TNF FAMILY; AUTOIMMUNITY; PATHOGENESIS; RECEPTOR	Background: Chronic rhinosinusitis (CRS) with nasal polyps is an inflammatory condition of the nasal passage and paranasal sinuses characterized by T(H)2-biased inflammation with increased levels of B-cell activating factor of the TNF family (BAFF), B lymphocytes, and immunoglobulins. Because high levels of BAFF are associated with autoimmune diseases, we assessed for evidence of autoimmunity in patients with CRS. Objectives: The objective of this study was to investigate the presence of autoantibodies in sinonasal tissue from patients with CRS. Methods: Standardized nasal tissue specimens were collected from patients with CRS and control subjects and assayed for immunoglobulin production, autoantibody levels, tissue distribution of immunoglobulins, and binding potential of antibodies in nasal tissue with a multiplexed autoantibody microarray, ELISA, and immunofluorescence. Results: Increased levels of several specific autoantibodies were found in nasal polyp tissue in comparison with levels seen in control tissue and inflamed tissue from patients with CRS without nasal polyps (P < .05). In particular, nuclear-targeted autoantibodies, such as anti-dsDNA IgG and IgA antibodies, were found at increased levels in nasal polyps (P < .05) and particularly in nasal polyps from patients requiring revision surgery for recurrence. Direct immunofluorescence staining demonstrated diffuse epithelial and subepithelial deposition of IgG and increased numbers of IgA-secreting plasma cells not seen in control nasal tissue. Conclusions: Autoantibodies, particularly those against nuclear antigens, are present at locally increased levels in nasal polyps. The presence of autoantibodies suggests that the microenvironment of a nasal polyp promotes the expansion of self-reactive B-cell clones. Although the pathogenicity of these antibodies remains to be elucidated, the presence of increased anti-dsDNA antibody levels is associated with a clinically more aggressive form of CRS with nasal polyps requiring repeated surgery. (J Allergy Clin Immunol 2011;128:1198-206.)	[Tan, Bruce K.; Conley, David B.; Chandra, Rakesh K.; Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA; [Suh, Lydia; Kato, Atsushi; Norton, James; Carter, Roderick; Harris, Kathleen; Peters, Anju; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Hinchcliff, Monique] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA; [Li, Quan-Zhen; Zhou, Jinchun; Mohan, Chandra] Univ Texas SW, Div Rheumatol, Dallas, TX USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas	Tan, BK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, 676 N St Clair,Suite 1325, Chicago, IL 60611 USA.	btan@nmff.org	Mohan, Chandra/GPX-8233-2022	Chandra, Rakesh/0000-0002-3612-0026; Grammer, Leslie/0000-0001-6860-2014; Hinchcliff, Monique/0000-0002-8652-9890; Kato, Atsushi/0000-0001-9144-3138	National Institutes of Health [R01 HL068546, R01 HL078860, R01 AI072570]; Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R01HL068546, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by National Institutes of Health grants R01 HL068546, R01 HL078860, and R01 AI072570 and the Ernest S. Bazley Trust.	ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Albu S, 2004, Acta Otorhinolaryngol Belg, V58, P79; Bachert Claus, 2007, Clin Allergy Immunol, V20, P163; BASS RM, 1974, ARCH OTOLARYNGOL, V99, P446; Bendouah Z, 2006, OTOLARYNG HEAD NECK, V134, P991, DOI 10.1016/j.otohns.2006.03.001; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; BERNSTEIN KA, 1994, CLIN EXP IMMUNOL, V98, P60; Bosello S, 2008, J RHEUMATOL, V35, P1256; Bossuyt X, 2006, CLIN CHEM, V52, P171, DOI 10.1373/clinchem.2005.058560; Brandtzaeg P, 2006, ADV EXP MED BIOL, V579, P149; Chandra RK, 2011, AM J OTOLARYNG, V32, P388, DOI 10.1016/j.amjoto.2010.07.013; Conley DB, 2006, AM J RHINOL, V20, P534, DOI 10.2500/ajr.2006.20.2941; Conley DB, 2006, AM J RHINOL, V20, P451, DOI 10.2500/ajr.2006.20.2880; Deshmukh US, 2006, AUTOIMMUN REV, V5, P414, DOI 10.1016/j.autrev.2005.10.010; Dorner T, 2009, NAT REV RHEUMATOL, V5, P433, DOI 10.1038/nrrheum.2009.141; Fauchais AL, 2010, AUTOIMMUN REV, V9, P595, DOI 10.1016/j.autrev.2010.05.004; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Huvenne W, 2009, CURR ALLERGY ASTHM R, V9, P213, DOI 10.1007/s11882-009-0031-4; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; KISHIMOTO T, 1992, J AUTOIMMUN, V5, P123, DOI 10.1016/0896-8411(92)90027-N; Kowal C, 2006, P NATL ACAD SCI USA, V103, P19854, DOI 10.1073/pnas.0608397104; Larsen K, 1997, EUR ARCH OTO-RHINO-L, V254, pS85, DOI 10.1007/BF02439732; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; Malm L, 1997, ACTA OTO-LARYNGOL, V117, P465, DOI 10.3109/00016489709113422; Patadia M, 2010, AM J RHINOL ALLERGY, V24, P11, DOI 10.2500/ajra.2010.24.3386; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Radtke MJ, 2008, J ALLERGY CLIN IMMUN, V121, pS72, DOI 10.1016/j.jaci.2007.12.288; Rekvig OP, 2003, ARTHRITIS RHEUM-US, V48, P300, DOI 10.1002/art.10739; Sabirov A, 2008, LARYNGOSCOPE, V118, P4, DOI 10.1097/MLG.0b013e3181567a7a; Singh S, 2010, J CLIN LAB ANAL, V24, P44, DOI 10.1002/jcla.20365; Smeenk RJT, 2000, RHEUMATOLOGY, V39, P581, DOI 10.1093/rheumatology/39.6.581; Suenaga R, 1996, J RHEUMATOL, V23, P279; SUENAGA R, 1993, CLIN EXP IMMUNOL, V94, P418; Tan BK, 2010, CURR OPIN OTOLARYNGO, V18, P21, DOI 10.1097/MOO.0b013e3283350053; Thomas Mike, 2008, Prim Care Respir J, V17, P79, DOI 10.3132/pcrj.2008.00029; Thorn M, 2010, CELL IMMUNOL, V261, P9, DOI 10.1016/j.cellimm.2009.10.004; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Van Ghelue M, 2003, J AUTOIMMUN, V20, P171, DOI 10.1016/S0896-8411(02)00110-5; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI200114235; Yoshida T, 2010, IMMUNOL REV, V237, P117, DOI 10.1111/j.1600-065X.2010.00938.x; Young Yuki, 2006, Curr Gastroenterol Rep, V8, P470, DOI 10.1007/s11894-006-0037-1; Zaravinos A, 2009, J MED VIROL, V81, P1613, DOI 10.1002/jmv.21534; Zhen QL, 2005, J CLIN INVEST, V115, P3428, DOI 10.1172/JCI23587	48	122	123	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1198	U516		10.1016/j.jaci.2011.08.037	http://dx.doi.org/10.1016/j.jaci.2011.08.037			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21996343	Green Accepted			2022-12-18	WOS:000298342700007
J	van der Aar, AMG; Sibiryak, DS; Bakdash, G; van Capel, TMM; van der Kleij, HPM; Opstelten, DJE; Teunissen, MBM; Kapsenberg, ML; de Jong, EC				van der Aar, Angelic M. G.; Sibiryak, Darya S.; Bakdash, Ghaith; van Capel, Toni M. M.; van der Kleij, Hanneke P. M.; Opstelten, Dirk-Jan E.; Teunissen, Marcel B. M.; Kapsenberg, Martien L.; de Jong, Esther C.			Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Skin; Langerhans cells; dendritic cells; regulatory T cells; vitamin D3; forkhead box protein 3; IL-10; TGF-beta	D-RECEPTOR LIGANDS; TGF-BETA; 1,25-DIHYDROXYVITAMIN D-3; IN-VITRO; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; ALLERGEN IMMUNOTHERAPY; RETINOIC-ACID; DIFFERENTIATION; EXPRESSION; MATURATION	Background: The vitamin D metabolite 1,25(OH) 2D3 (VitD3) is a potent immunosuppressive drug and, among others, is used for topical treatment of psoriasis. A proposed mechanism of VitD3-mediated suppression is priming of dendritic cells (DCs) to induce regulatory T (Treg) cells. Objective: Currently, there is confusion about the phenotype of VitD3-induced Treg cells and the DC-derived molecules driving their development. We investigated Treg cell induction after VitD3 priming of 2 distinct skin DC subsets: Langerhans cells (LCs) and dermal dendritic cells (DDCs). Methods: LCs and DDCs primed with VitD3 were cocultured with allogeneic naive T cells. The phenotype and function of the DCs and induced T cells were analyzed. Results: Both VitD3-primed DC subtypes induced T cells with regulatory activity. Unexpectedly, whereas the Treg cell populations generated by VitD3-primed LCs were CD25(hi) CD127(lo) forkhead box protein 3 (Foxp3)-positive cells, which meet the criteria of classical inducible Treg cells, the T cells developing in response to VitD3-primed DDCs were Foxp3(-) T(R)1 cells expressing IL-10. Inhibition experiments revealed that LC-derived TGF-beta is a key factor in the induction of Foxp3 1 Treg cells, whereas DDC-derived IL-10 is important for the induction of IL-10(+) T(R)1 cells. Conclusion: Thus we report the novel finding that distinct but closely related DC subsets are differentially programmed by VitD3 to support development of either TGF-beta-dependent Foxp3(+) Treg cells or IL-10-dependent IL-10(+) Treg cells. (J Allergy Clin Immunol 2011;127:1532-40.)	[van der Aar, Angelic M. G.; Sibiryak, Darya S.; Bakdash, Ghaith; van Capel, Toni M. M.; Kapsenberg, Martien L.; de Jong, Esther C.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; [van der Aar, Angelic M. G.; Teunissen, Marcel B. M.] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands; [van der Kleij, Hanneke P. M.; Opstelten, Dirk-Jan E.] HAL Allergy BV, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; HAL Allergy Group	de Jong, EC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, L3-105,Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	e.c.dejong@amc.uva.nl	Teunissen, Marcel BM/D-6512-2012		HAL Allergy B.V.; Dutch Asthma Foundation (NAF); Dutch Asthma Foundation	HAL Allergy B.V.; Dutch Asthma Foundation (NAF); Dutch Asthma Foundation	D.S.S. and T. M. M. C. were financially supported by HAL Allergy B.V. and G. B. by the Dutch Asthma Foundation (NAF).; G. Bakdash and E. C. de Jong receive research support from the Dutch Asthma Foundation. H. P. M. van der Kleij and D. E. Opstelten are employed by HAL Allergy. The rest of the authors have declared that they have no conflict of interest.	Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; ADORINI L, 2007, FUTURE DRUGS, V3, P477; Adorini Luciano, 2002, Curr Opin Investig Drugs, V3, P1458; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Anderson AE, 2009, J LEUKOCYTE BIOL, V85, P243, DOI 10.1189/jlb.0608374; Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008; Berer A, 2000, EXP HEMATOL, V28, P575, DOI 10.1016/S0301-472X(00)00143-0; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Enioutina EY, 2007, VACCINE, V25, P1236, DOI 10.1016/j.vaccine.2006.10.008; Fuss IJ, 2002, J IMMUNOL, V168, P900, DOI 10.4049/jimmunol.168.2.900; Ghoreishi M, 2009, J IMMUNOL, V182, P6071, DOI 10.4049/jimmunol.0804064; Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945; Griffin MD, 2001, P NATL ACAD SCI USA, V98, P6800, DOI 10.1073/pnas.121172198; Griffin MD, 2000, BIOCHEM BIOPH RES CO, V270, P701, DOI 10.1006/bbrc.2000.2490; Jonuleit H, 2003, J IMMUNOL, V171, P6323, DOI 10.4049/jimmunol.171.12.6323; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Penna G, 2005, BLOOD, V106, P3490, DOI 10.1182/blood-2005-05-2044; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Penna G, 2007, J IMMUNOL, V178, P145, DOI 10.4049/jimmunol.178.1.145; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Strobl H, 1999, MICROBES INFECT, V1, P1283, DOI 10.1016/S1286-4579(99)00256-7; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Taher YA, 2008, J IMMUNOL, V180, P5211, DOI 10.4049/jimmunol.180.8.5211; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; van der Aar AMG, 2007, J IMMUNOL, V178, P1986, DOI 10.4049/jimmunol.178.4.1986; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Yamazaki S, 2009, J DERMATOL SCI, V54, P69, DOI 10.1016/j.jdermsci.2009.02.001; Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007	37	122	129	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1532	U334		10.1016/j.jaci.2011.01.068	http://dx.doi.org/10.1016/j.jaci.2011.01.068			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21497886				2022-12-18	WOS:000291048500033
J	Ford, LS; Taylor, SL; Pacenza, R; Niemann, LM; Lambrecht, DM; Sicherer, SH				Ford, Lara S.; Taylor, Steve L.; Pacenza, Robert; Niemann, Lynn M.; Lambrecht, Debra M.; Sicherer, Scott H.			Food allergen advisory labeling and product contamination with egg, milk, and peanut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ford, Lara S.; Sicherer, Scott H.] Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY 10029 USA; [Taylor, Steve L.; Niemann, Lynn M.; Lambrecht, Debra M.] Univ Nebraska, Dept Food Sci & Technol, Food Allergy Res & Resource Program, Lincoln, NE 68583 USA; [Pacenza, Robert] Food Allergy Initiat, New York, NY USA	Icahn School of Medicine at Mount Sinai; University of Nebraska System; University of Nebraska Lincoln	Ford, LS (corresponding author), Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY 10029 USA.	lara.ford@mssm.edu	Taylor, Steve L./V-1341-2019					Crotty MP, 2010, J ALLERGY CLIN IMMUN, V125, P935, DOI 10.1016/j.jaci.2009.12.003; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Pieretti MM, 2009, J ALLERGY CLIN IMMUN, V124, P337, DOI 10.1016/j.jaci.2009.05.032; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013	5	122	123	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					384	385		10.1016/j.jaci.2010.05.034	http://dx.doi.org/10.1016/j.jaci.2010.05.034			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621349				2022-12-18	WOS:000281203800025
J	Hol, J; van Leer, EHG; Schuurman, BEEE; de Ruiter, LF; Samsom, JN; Hop, W; Neijens, HJ; de Jongste, JC; Nieuwenhuis, EES				Hol, Jeroen; van Leer, Eduard H. G.; Schuurman, Beatrix E. E. Elink; de Ruiter, Lilian F.; Samsom, Janneke N.; Hop, Wim; Neijens, Herman J.; de Jongste, Johan C.; Nieuwenhuis, Edward E. S.		Cow's Milk Allergy Modified Elimin	The acquisition of tolerance toward cow's milk through probiotic supplementation: A randomized, controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; probiotics; tolerance; infants; atopic eczema/dermatitis syndrome; flow cytometry	ATOPIC ECZEMA/DERMATITIS SYNDROME; CLINICAL-COURSE; DOUBLE-BLIND; INTESTINAL MICROFLORA; LACTOBACILLUS STRAINS; LYMPHOCYTE SUBSETS; HAY-FEVER; CHILDREN; DERMATITIS; LIFE	Background: Cow's milk allergy (CMA) is the most frequently diagnosed food allergy in infancy. In general, patients have a good prognosis because the majority acquire tolerance within the first years. Interventions have been proposed to accelerate tolerance and reduce morbidity. Probiotic supplementation could be effective through modulation of the immune system. Objective: We sought to determine whether supplementation with a combination of probiotics (Lactobacillus casei CRL431 and Bifidobacterium lactis Bb-12) accelerates tolerance to cow's milk (CM) in infants with CMA. Methods: We performed a double-blind, randomized, placebo-controlled trial in 119 infants with CMA. Infants received CRL431 and Bb-12 supplemented to their standard treatment of extensively hydrolyzed formula for 12 months. Primary outcome was clinical tolerance to CM at 6 and 12 months of treatment. Furthermore, we analyzed T- and B-lymphocyte subsets (CD3(+), CD3(+)CD4(+), CD3(+)CD8(+), and CD20(+)) in peripheral blood at randomization and at 12 months with flow cytometry and examined the presence of viable probiotic strains in fecal samples. Results: The cumulative percentage of tolerance to CM at 6 and 12 months was similar in both groups: 56 (77%) in the probiotics group versus 54 (81%) in the placebo group. Infants in the placebo group had higher percentages of CD3(+) and CD3(+)CD4(+) lymphocytes compared with those seen in probiotic-treated infants. Probiotic intake was confirmed because probiotics were isolated from feces more often in treated infants than in the placebo group. Conclusion: Supplementation of CRL431 and Bb-12 to extensively hydrolyzed formula does not accelerate CM tolerance in infants with CMA.	[Hol, Jeroen; Schuurman, Beatrix E. E. Elink; Neijens, Herman J.; de Jongste, Johan C.] Sophia Childrens Univ Hosp, Erasmus Univ Med Ctr, Dept Pediat Resp Med, Rotterdam, Netherlands; [Hol, Jeroen; de Ruiter, Lilian F.; Samsom, Janneke N.; Nieuwenhuis, Edward E. S.] Sophia Childrens Univ Hosp, Erasmus Univ Med Ctr, Dept Pediat Gastroenterol & Nutr, Rotterdam, Netherlands; [Hop, Wim] Sophia Childrens Univ Hosp, Erasmus Univ Med Ctr, Dept Med Stat, Rotterdam, Netherlands; [van Leer, Eduard H. G.] Groene Hart Ziekenhuis, Dept Pediat, Gouda, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital	Nieuwenhuis, EES (corresponding author), Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Gastroenterol, Pediat Lab, POB 2060, NL-3000 CB Rotterdam, Netherlands.	e.nieuwenhuis@erasmusmc.nl	Samsom, Janneke/C-5304-2013	Vaessen-Verberne, Anna/0000-0002-2272-8815; Versteegh, Florens G.A./0000-0003-4773-5592				Bauer M, 2001, J IMMUNOL, V166, P5000, DOI 10.4049/jimmunol.166.8.5000; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Brouwer ML, 2006, CLIN EXP ALLERGY, V36, P899, DOI 10.1111/j.1365-2222.2006.02513.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Food and Agriculture Organization of the United Nations World Health Organization, 2006, PROB FOOD HLTH NUTR; Fukushima Y, 1998, INT J FOOD MICROBIOL, V42, P39, DOI 10.1016/S0168-1605(98)00056-7; Gaon D, 2002, MEDICINA-BUENOS AIRE, V62, P159; Gonzalez SN, 1995, BIOTHERAPY, V8, P129, DOI 10.1007/BF01878496; Guerin-Danan C, 1998, AM J CLIN NUTR, V67, P111, DOI 10.1093/ajcn/67.1.111; Host A, 1994, Pediatr Allergy Immunol, V5, P1; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Jarvinen KM, 2002, PEDIAT ALLERG IMM-UK, V13, P243, DOI 10.1034/j.1399-3038.2002.00087.x; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Peluso I, 2007, INFECT IMMUN, V75, P1730, DOI 10.1128/IAI.01172-06; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Pessi T, 1998, J NUTR, V128, P2313, DOI 10.1093/jn/128.12.2313; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; Rosenfeldt V, 2004, J PEDIATR-US, V145, P612, DOI 10.1016/j.jpeds.2004.06.068; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Saarinen KM, 2000, CLIN EXP ALLERGY, V30, P400, DOI 10.1046/j.1365-2222.2000.00732.x; Saavedra JM, 2004, AM J CLIN NUTR, V79, P261; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sistek D, 2006, CLIN EXP ALLERGY, V36, P629, DOI 10.1111/j.1365-2222.2006.02485.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strobel S, 1996, ANN NY ACAD SCI, V778, P88, DOI 10.1111/j.1749-6632.1996.tb21118.x; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Upton MN, 2000, BMJ-BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; van Belkum A, 2007, FEMS IMMUNOL MED MIC, V50, P281, DOI 10.1111/j.1574-695X.2007.00290.x; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063; Viljanen M, 2005, J ALLERGY CLIN IMMUN, V115, P1254, DOI 10.1016/j.jaci.2005.03.047; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Viljanen M, 2005, PEDIAT ALLERG IMM-UK, V16, P65, DOI 10.1111/j.1399-3038.2005.00224.x; Wang MF, 2004, PEDIAT ALLERG IMM-UK, V15, P152, DOI 10.1111/j.1399-3038.2004.00156.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673	46	122	130	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1448	1454		10.1016/j.jaci.2008.03.018	http://dx.doi.org/10.1016/j.jaci.2008.03.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18436293				2022-12-18	WOS:000256771700022
J	Allam, JP; Peng, WM; Appel, T; Wenghoefer, M; Niederhagen, B; Bieber, T; Berg, S; Novak, N				Allam, Jean-Pierre; Peng, Wen-Ming; Appel, Torsten; Wenghoefer, Matthias; Niederhagen, Bernd; Bieber, Thomas; Berg, Stefaan; Novak, Natalija			Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; Toll-like receptors; Langerhans cells; immunotherapy; tolerance; mucosa	FC-EPSILON-RI; MATURE DENDRITIC CELLS; REGULATORY T-CELLS; SUBLINGUAL IMMUNOTHERAPY; SEMI-MATURE; TLR4; LPS; RECOGNITION; ENGAGEMENT; EXPRESSION	Background: Despite high bacterial colonization, acute infections are rare in the oral mucosa, implicating tolerogenic predominance. Bacterial antigens like LPSs are recognized by innate immunity receptors such as Toll-like receptor 4 (TLR4), associated with LPS receptor (CD14). Objectives: Toll-like receptor 4 agonist monosphoryl lipid A has been successfully used as adjuvant in subcutaneous immunotherapy, suggesting reinforcement of allergen-specific tolerance. Recently sublingual immunotherapy (SLIT) has been shown to be an effective alternative to subcutaneous immunotherapy. We observed CD14 expression on human oral Langerhans cells (oLCs), representing a major target of SLIT. However, not much is known about TLR4 expression and its effect on oLCs. Methods: Cell suspensions were obtained by trypsinization of human oral mucosa and analyzed by flow cytometry, RT-PCR, cytometric bead arrays, ELISA, and mixed lymphocyte reactions. Results: We could show that oLCs express TLR4, and its ligation by monosphoryl lipid A upregulated expression of coinhibitory molecules B7-H1 and B7-H3 while surface expression of costimulatory molecule CD86 was concomitantly decreased. Furthermore, TLR4 ligation on oLCs increased their release of the anti-inflammatory cytokine IL-10 and decreased their stimulatory capacity toward T cells. Moreover, TLR4-ligation on oLCs induced IL-10, TGF-beta 1, Forkhead box protein 3, IFN-gamma, and IL-2 production in T cells. Conclusion: In view of these data, TLR4-ligation on oLCs might not only play a role in pathogen recognition for efficient immunity but also contribute to the tolerogenic state predominating in the oral cavity.	[Allam, Jean-Pierre; Peng, Wen-Ming; Bieber, Thomas; Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, D-53105 Bonn, Germany; [Appel, Torsten; Wenghoefer, Matthias; Niederhagen, Bernd] Univ Bonn, Dept Oral & Maxillofacial Surg, D-53105 Bonn, Germany; [Berg, Stefaan] Radboud Univ Nijmegen, Dept Oral & Maxillofacial Surg, Nijmegen, Netherlands	University of Bonn; University of Bonn; Radboud University Nijmegen	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de	Bergé, S.J./H-8011-2014; Peng, Wenming/GSD-3650-2022; Peng, PD Dr. rer. nat. Wenming/E-3708-2017	Peng, PD Dr. rer. nat. Wenming/0000-0003-0012-7389				Akdis CA, 2006, ALLERGY, V61, P11, DOI 10.1111/j.1398-9995.2006.01159.x; Allam JP, 2006, ALLERGY, V61, P166, DOI 10.1111/j.1398-9995.2005.00965.x; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; De Trez C, 2005, J IMMUNOL, V175, P839, DOI 10.4049/jimmunol.175.2.839; Drachenberg K J, 2003, Allergol Immunopathol (Madr), V31, P270; Fan W, 2005, BIOCHEM BIOPH RES CO, V337, P840, DOI 10.1016/j.bbrc.2005.09.123; Francis JN, 2004, CURR OPIN ALLERGY CL, V4, P543, DOI 10.1097/00130832-200412000-00012; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Ismaili J, 2002, J IMMUNOL, V168, P926, DOI 10.4049/jimmunol.168.2.926; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Nakajima T, 2005, J DENT RES, V84, P639, DOI 10.1177/154405910508400711; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2004, ALLERGY, V59, P5, DOI 10.1046/j.1398-9995.2003.00337.x; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Novak N, 2006, IMMUNOL ALLERGY CLIN, V26, P307, DOI 10.1016/j.iac.2006.02.010; Okemoto K, 2006, J IMMUNOL, V176, P1203, DOI 10.4049/jimmunol.176.2.1203; Paster BJ, 2006, PERIODONTOL 2000, V42, P80, DOI 10.1111/j.1600-0757.2006.00174.x; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Reife RA, 2006, CELL MICROBIOL, V8, P857, DOI 10.1111/j.1462-5822.2005.00672.x; Sato K, 2002, CELL IMMUNOL, V215, P186, DOI 10.1016/S0008-8749(02)00021-7; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Thompson BS, 2005, J LEUKOCYTE BIOL, V78, P1273, DOI 10.1189/jlb.0305172; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; van der Aar AMG, 2007, J IMMUNOL, V178, P1986, DOI 10.4049/jimmunol.178.4.1986; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xu JF, 2006, CELL MOL IMMUNOL, V3, P235; Zheng Y, 2004, J IMMUNOL, V172, P2778, DOI 10.4049/jimmunol.172.5.2778	33	122	131	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					368	374		10.1016/j.jaci.2007.09.045	http://dx.doi.org/10.1016/j.jaci.2007.09.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18036651	Bronze			2022-12-18	WOS:000253337800014
J	Belloni, B; Ziai, M; Lim, A; Lemercier, B; Sbornik, M; Weidinger, S; Andres, C; Schnopp, C; Ring, J; Hein, R; Ollert, M; Mempel, M				Belloni, Benedetta; Ziai, Mahzad; Lim, Annick; Lemercier, Brigitte; Sbornik, Martin; Weidinger, Stephan; Andres, Christian; Schnopp, Christina; Ring, Johannes; Hein, Ruediger; Ollert, Markus; Mempel, Martin			Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACTIVATION-REGULATED CHEMOKINE; DERMATITIS; OMALIZUMAB; THYMUS		Tech Univ Munich, Dept Dermatol & Allergy, D-8000 Munich, Germany; Inst Pasteur, INSERM, U668, F-75724 Paris, France; Tech Univ Munich, Clin Res Div Mol & Clin Allergotoxicol, D-8000 Munich, Germany; Tech Univ Munich, GSF Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy, D-8000 Munich, Germany; Unite Rech & Expertise Immunite Antivirale Biothe, Paris, France	Technical University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich	Belloni, B (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, D-8000 Munich, Germany.	m.mempel@lrz.tum.de	Weidinger, Stephan/C-8461-2011; Ring, Johannes/GLN-4341-2022	Weidinger, Stephan/0000-0003-3944-252X; Ring, Johannes/0000-0001-8236-3152; Ollert, Markus W./0000-0002-8055-0103				Deniz VM, 2005, CLIN REV ALLERG IMMU, V29, P31; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Karnowski A, 2006, EUR J IMMUNOL, V36, P1917, DOI 10.1002/eji.200535495; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Lim A, 2002, J IMMUNOL METHODS, V261, P177, DOI 10.1016/S0022-1759(02)00004-2; Lim A, 2007, J ALLERGY CLIN IMMUN, V120, P696, DOI 10.1016/j.jaci.2007.05.035; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723	9	122	127	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1223	1225		10.1016/j.jaci.2007.08.060	http://dx.doi.org/10.1016/j.jaci.2007.08.060			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17936892				2022-12-18	WOS:000250973400039
J	Puxeddu, I; Ribatti, D; Crivellato, E; Levi-Schaffer, F				Puxeddu, I; Ribatti, D; Crivellato, E; Levi-Schaffer, F			Mast cells and eosinophils: A novel link between inflammation and angiogenesis in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; eosinophils; allergy; angiogenesis; tissue remodeling; asthma; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; ASTHMATIC AIRWAYS; BRONCHIAL-MUCOSA; EXPRESSION; HYPERRESPONSIVENESS; VASCULARITY	Mast cells and eosinophils are the key cells in the early and late stages of allergic inflammation. There is increasing evidence that angiogenesis plays an important role both in the development of inflammation and in the pathophysiology of tissue remodeling during allergic disorders. In this review we provide recent data showing a link between allergy and angiogenesis and some possible mechanisms through which vascular endothelial growth factor and the immune system can interact. We discuss the multifaceted roles of mast cells and eosinophils in tissue remodeling and angiogenesis during allergic diseases and whether these cells can be both source and target cells for proangiogenic mediators.	Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Jerusalem, Israel; Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy; Univ Udine, Sch Med, Dept Med & Morphol Res, Anat Sect, I-33100 Udine, Italy	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Universita degli Studi di Bari Aldo Moro; University of Udine	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	fls@cc.huji.ac.il	Puxeddu, Ilaria/AAB-3263-2019	Levi-Schaffer, Francesca/0000-0003-0620-2810				Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Feistritzer C, 2004, AM J RESP CELL MOL, V30, P729, DOI 10.1165/rcmb.2003-0314OC; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Groneberg DA, 2005, ALLERGY, V60, P90, DOI 10.1111/j.1398-9995.2004.00628.x; GRUBER BL, 1995, BLOOD, V86, P2488; Horiuchi T, 1997, AM J RESP CELL MOL, V17, P70, DOI 10.1165/ajrcmb.17.1.2796; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levi-Schaffer F, 2001, CLIN EXP ALLERGY, V31, P521, DOI 10.1046/j.1365-2222.2001.01041.x; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Munitz A, 2004, ALLERGY, V59, P268, DOI 10.1111/j.1398-9995.2003.00442.x; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; Puxeddu A, 2005, INT J BIOCHEM CELL B, V37, P628, DOI 10.1016/j.biocel.2004.09.001; Puxeddu I, 2003, INT J BIOCHEM CELL B, V35, P1601, DOI 10.1016/S1357-2725(03)00208-5; Redington AE, 2001, J ALLERGY CLIN IMMUN, V107, P384, DOI 10.1067/mai.2001.112268; Ribatti D, 2001, CLIN EXP ALLERGY, V31, P602, DOI 10.1046/j.1365-2222.2001.00986.x; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SVENSSON C, 1995, CLIN EXP ALLERGY, V25, P942, DOI 10.1111/j.1365-2222.1995.tb00396.x; Temkin V, 2004, J ALLERGY CLIN IMMUN, V113, P703, DOI 10.1016/j.jaci.2003.11.038	26	122	129	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					531	536		10.1016/j.jaci.2005.06.007	http://dx.doi.org/10.1016/j.jaci.2005.06.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159620	Bronze			2022-12-18	WOS:000235686500010
J	Heinzmann, A; Ahlert, I; Kurz, T; Berner, R; Deichmann, KA				Heinzmann, A; Ahlert, I; Kurz, T; Berner, R; Deichmann, KA			Association study suggests opposite effects of polymorphisms within IL8 on bronchial asthma and respiratory syncytial virus bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; bronchiolitis; IL-8; bronchial asthma	JUVENILE RHEUMATOID-ARTHRITIS; PERIPHERAL-BLOOD; INTERLEUKIN-8 IL-8; INFLAMMATION; CYTOKINES; DISEASES; CELLS; GENE; HYPERRESPONSIVENESS; ALLERGY	Background: IL-8 is a strong inductor of inflammation. Accordingly, it plays a pivotal role in acute inflammatory responses during respiratory syncytial virus (RSV) infections and in chronic inflammatory diseases such as bronchial asthma and juvenile idiopathic arthritis. Recently, 2 studies have found association of the polymorphism -251A of IL8 with RSV bronchiolitis. Furthermore, epidemiologic studies have demonstrated an increased risk for the development of asthma after RSV bronchiolitis, and a common genetic background for the 2 diseases is currently being discussed. Objective: This study investigated whether IL-8 is in association with asthma and/or arthritis and whether the results can confirm a common genetic background of RSV bronchiolitis and asthma. Methods: The polymorphisms -A251T, C781T, C1633T, and A2767T within IL8 were genotyped in the following 4 populations: children with asthma, atopic children, children with juvenile idiopathic arthritis, and control subjects. Statistical analysis made use of the Armitage trend test and the software program Arlequine. Results: Association of all polymorphisms was found with asthma (P = .008 to P = .03). Surprisingly -251T was associated with asthma, which is the opposite allele as described in association with RSV bronchiolitis. Furthermore, all polymorphisms were significantly more common in children with arthritis than in asthmatic children (P = .006 to P = .02). No association was seen with the diagnosis of arthritis per se or with atopy. Conclusion: This is the first study to describe association of IL-8 with asthma and a significant inverse distribution of the polymorphisms in juvenile idiopathic arthritis. In addition, the results of this study might suggest that RSV bronchiolitis and bronchial asthma have at least some different genetic factors.	Univ Freiburg, Childrens Hosp, D-76106 Freiburg, Germany	University of Freiburg	Heinzmann, A (corresponding author), Univ Freiburg, Childrens Hosp, Mathildenstr 1, D-76106 Freiburg, Germany.	heinzmann@kikli.ukl.uni-freiburg.de	Berner, Reinhard/P-7351-2017	Berner, Reinhard/0000-0002-6216-9173	NHLBI NIH HHS [R01 HL66533-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066533] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Bont L, 1999, EUR RESPIR J, V14, P144, DOI 10.1034/j.1399-3003.1999.14a24.x; Cheon H, 2002, CLIN EXP IMMUNOL, V127, P547, DOI 10.1046/j.1365-2249.2002.01785.x; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; De Benedetti F, 1999, J RHEUMATOL, V26, P425; Fujimura M, 1998, EUR RESPIR J, V11, P306, DOI 10.1183/09031936.98.11020306; Gu J, 2002, RHEUMATOLOGY, V41, P759, DOI 10.1093/rheumatology/41.7.759; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Heinzmann A, 2003, J ALLERGY CLIN IMMUN, V112, P735, DOI 10.1016/S0091-6749(03)01887-6; HIORT O, 1994, HUM MOL GENET, V3, P1163, DOI 10.1093/hmg/3.7.1163; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; KIMATA H, 1995, BLOOD, V85, P3191, DOI 10.1182/blood.V85.11.3191.bloodjournal85113191; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kurashima K, 1996, J LEUKOCYTE BIOL, V59, P313, DOI 10.1002/jlb.59.3.313; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Lisignoli G, 2002, CYTOKINE, V20, P231, DOI 10.1006/cyto.2002.2006; MANGGE H, 1995, ARTHRITIS RHEUM, V38, P211, DOI 10.1002/art.1780380209; Mangge H, 1999, J INTERF CYTOK RES, V19, P1005, DOI 10.1089/107999099313217; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Ozen S, 1997, CLIN RHEUMATOL, V16, P173, DOI 10.1007/BF02247847; Petty Ross E., 1998, Journal of Rheumatology, V25, P1991; Sanger F, 1992, Biotechnology, V24, P104; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Striz I, 1999, INFLAMMATION, V23, P545, DOI 10.1023/A:1020242523697; XIU Q, 1995, CLIN EXP ALLERGY, V25, P51, DOI 10.1111/j.1365-2222.1995.tb01002.x; Xu JF, 2002, HUM GENET, V111, P573, DOI 10.1007/s00439-002-0819-y	33	122	130	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					671	676		10.1016/j.jaci.2004.06.038	http://dx.doi.org/10.1016/j.jaci.2004.06.038			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356575				2022-12-18	WOS:000223799600031
J	Boyce, JA				Boyce, JA			Mast cells: Beyond IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						mast cells; IL-4; cysteinyl leukotrienes; cysteinyl leukotriene 1 receptor; uridine diphosphate	LEUKOTRIENE C-4 SYNTHASE; ASPIRIN-INTOLERANT ASTHMA; ACUTE SEPTIC PERITONITIS; HUMAN-LUNG; RECEPTOR ANTAGONIST; BACTERIAL CLEARANCE; CYTOKINE PRODUCTION; MULTIPLE-SCLEROSIS; RECOMBINANT HUMAN; PERIPHERAL-BLOOD	Mast cells, historically known for their involvement in type I hypersensitivity, also serve critical protective and homeostatic functions. They directly recognize the products of bacterial infection through several surface receptor proteins, releasing proteases, cytokines, and eicosanoid mediators that recruit neutrophils, limit the spread of bacterial infection, and facilitate subsequent tissue repair. In vitro studies suggest that the spectrum of microbes capable of initiating mast cell activation is broad and extends to common respiratory viruses, mycoplasma, and even products of tissue injury, such as nucleotides. T(H)2-polarized inflammation elicits a reactive hyperplasia of mast cells at the involved mucosal surfaces in both mice and human subjects. Several recombinant T(H)2 cytokines (IL-3, IL-4, IL-5, and IL-9) act synergistically with stem cell factor to facilitate proliferation of nontransformed human mast cells in vitro. IL-4 induces the expression of critical inflammation-associated genes by human mast cells, such as those encoding leukotriene C-4 synthase, FcepsilonRI, and several cytokines. Consequently, priming with IL-4 not only amplifies classical FcepsilonRI-dependent mast cell activation but also dramatically alters the product profile of mast cells activated by innate signals and by chemical mediators of inflammation. Strikingly, IL-4 induces an activation response by mast cells to cysteinyl leukotrienes, which act through a receptor shared with uridine diphosphate to induce cytokine generation without exocytosis. It is possible that alterations in mast cell phenotype by the T(H)2 milieu of allergy permits otherwise trivial infections or homeostatic chemical signals to initiate harmful inflammatory cascades and sustain tissue pathology. Drug development must take these nonclassical mast cell activation pathways into account without compromising the beneficial and protective functions of mast cells.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Boyce, JA (corresponding author), Harvard Univ, Sch Med, Div Rheumatol Allergy & Immunol, Smith Res Bldg,Room 626,1 Jimmy Fund Way, Boston, MA 02199 USA.				NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI48802, AI31599, AI52353] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048802, U01AI031599, R56AI052353, U19AI031599, R01AI052353] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Algermissen B, 1999, EXP DERMATOL, V8, P193, DOI 10.1111/j.1600-0625.1999.tb00370.x; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; Amin K, 2001, J ALLERGY CLIN IMMUN, V107, P249, DOI 10.1067/mai.2001.112266; Anderson DF, 1997, CLIN EXP ALLERGY, V27, P1060, DOI 10.1111/j.1365-2222.1997.tb01258.x; Arbustini E, 1997, G Ital Cardiol, V27, P209; Bidri M, 1997, PARASITE IMMUNOL, V19, P475, DOI 10.1046/j.1365-3024.1997.d01-153.x; Bischoff SC, 2001, INT ARCH ALLERGY IMM, V124, P151, DOI 10.1159/000053695; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Blair RJ, 1997, J CLIN INVEST, V99, P2691, DOI 10.1172/JCI119458; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown JK, 2002, AM J PHYSIOL-LUNG C, V282, pL197, DOI 10.1152/ajplung.2002.282.2.L197; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Cairns JA, 1996, J IMMUNOL, V156, P275; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAHLEN SE, 2001, CLIN EXP ALLERGY REV, V2, P137; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; FOX CC, 1985, J IMMUNOL, V135, P483; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; Garbuzenko E, 2002, CLIN EXP ALLERGY, V32, P237, DOI 10.1046/j.1365-2222.2002.01293.x; Gebhardt T, 2002, EUR J IMMUNOL, V32, P2308, DOI 10.1002/1521-4141(200208)32:8<2308::AID-IMMU2308>3.0.CO;2-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gommerman JL, 2000, J IMMUNOL, V165, P6915, DOI 10.4049/jimmunol.165.12.6915; GotisGraham I, 1997, ARTHRITIS RHEUM, V40, P479, DOI 10.1002/art.1780400314; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; Gurish MF, 2001, J EXP MED, V194, P1243, DOI 10.1084/jem.194.9.1243; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Hara M, 2002, J EXP MED, V195, P375, DOI 10.1084/jem.20002036; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hoek KL, 2002, J ALLERGY CLIN IMMUN, V109, P470, DOI 10.1067/mai.2002.121951; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Ibrahim MZM, 1996, J NEUROIMMUNOL, V70, P131, DOI 10.1016/S0165-5728(96)00102-6; IRANI AMA, 1992, BLOOD, V80, P3009; IRANI AMA, 1987, J IMMUNOL, V138, P4381; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kirshenbaum AS, 1998, EXP HEMATOL, V26, P245; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; Kobayashi H, 1998, CLIN EXP ALLERGY, V28, P1219, DOI 10.1046/j.1365-2222.1998.00377.x; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; LEE DO, 1984, PROG PHYS GEOG, V8, P1, DOI 10.1177/030913338400800101; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; Lorentz A, 2002, BLOOD, V99, P966, DOI 10.1182/blood.V99.3.966; Lynch KR, 1999, NATURE, V399, P789; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MADDEN KB, 1991, J IMMUNOL, V147, P1387; Maier R, 1997, BIOCHEM BIOPH RES CO, V237, P297, DOI 10.1006/bbrc.1997.7135; Malaviya R, 2000, J LEUKOCYTE BIOL, V67, P841, DOI 10.1002/jlb.67.6.841; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MASSEY WA, 1991, J IMMUNOL, V147, P1621; Matsunaga Y, 1999, AM J GASTROENTEROL, V94, P1923; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; MENCIAHUERTA JM, 1983, J IMMUNOL, V130, P1885; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; NILSSON G, 1994, J IMMUNOL, V153, P3717; Noguchi E, 2002, CLIN EXP ALLERGY, V32, P93, DOI 10.1046/j.0022-0477.2001.01261.x; Noli C, 2001, VET DERMATOL, V12, P303, DOI 10.1046/j.0959-4493.2001.00272.x; Ochi H, 2000, P NATL ACAD SCI USA, V97, P10509, DOI 10.1073/pnas.180318697; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OKAYAMA Y, 1995, J IMMUNOL, V155, P1796; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; PESCI A, 1993, CHEST, V103, P989, DOI 10.1378/chest.103.4.989; PETERS SP, 1984, J IMMUNOL, V132, P1972; RAULF M, 1985, IMMUNOLOGY, V55, P135; ROTTEM M, 1994, BLOOD, V84, P2489; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Toru H, 1996, INT IMMUNOL, V8, P1367; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Warny M, 2001, J BIOL CHEM, V276, P26051, DOI 10.1074/jbc.M102568200; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; Woolley DE, 2000, ARTHRITIS RES, V2, P65, DOI 10.1186/ar70; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777	111	122	127	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					24	33		10.1067/mai.2003.60	http://dx.doi.org/10.1067/mai.2003.60			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532090				2022-12-18	WOS:000180465500003
J	Kawaguchi, M; Kokubu, F; Kuga, H; Matsukura, S; Hoshino, H; Ieki, K; Imai, T; Adachi, M; Huang, SK				Kawaguchi, M; Kokubu, F; Kuga, H; Matsukura, S; Hoshino, H; Ieki, K; Imai, T; Adachi, M; Huang, SK			Modulation of bronchial epithelial cells by IL-17	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adhesion molecule; bronchial epithelial cell; ERK1/2; interleukin-8; interleukin-6; interleukin-17	HUMAN KERATINOCYTES; INTERFERON-GAMMA; GENE-EXPRESSION; TNF-ALPHA; IN-VITRO; KAPPA-B; INTERLEUKIN-17; ACTIVATION; LYMPHOCYTES; CYTOKINES	Background: The induction of epithelial cytokines/chemokines is crucial in the migration of leukocytes, and its regulatory mechanisms remain incompletely defined. Objective: To determine the role of IL-17, a CD4(+) T cell-derived cytokine, in modulation of primary bronchial epithelial cells, the expression of IL-6, IL-8, and intercellular adhesion molecule 1 (ICAM-1) and the potential involvement of mitogen-activated protein (MAP) kinases in IL-17-mediated signaling were examined. Methods: The levels of gene expression and protein production for IL-6 and IL-8 in IL-17-treated cells, in the presence or absence of MAP kinase inhibitors, were analyzed by RT-PCR and ELISA, respectively, and activation of MAP kinases was determined by Western blot analyses. Results: We showed first that IL-17 induced time-dependent expression of IL-6 and IL-8 but not of the chemokines eotaxin and RANTES. In addition, IL-17 induced activation of extracellular signal-regulated kinase 1/2 but not of p38 or JNK kinases. A selective MAP kinase kinase inhibitor, PD98059, inhibited IL-17-induced IL-6 and IL-8. A combination of IL-17 and each of the cytokines IL-4, IL-13, and IFN-gamma further enhanced IL-8 expression. IL-17 alone did not induce ICAM-1 expression and showed no effect on IL-4- or IL-13-induced ICAM-1 expression. In contrast, a combination of IL-17 and IFN-gamma augmented IL-6 and ICAM-1 expression. Conclusion: These findings suggest that IL-17, alone or in combination with other cytokines, modulates airway inflammation via-in part-the expression of epithelial IL-6, IL-8, and ICAM-1.	Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA; Showa Univ, Sch Med, Dept Internal Med 1, Tokyo 142, Japan	Johns Hopkins University; Showa University	Huang, SK (corresponding author), Johns Hopkins Univ, Ctr Asthma & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Huang, Shau-Ku/F-5509-2010					Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Attur MG, 1997, ARTHRITIS RHEUM, V40, P1050, DOI 10.1002/art.1780400609; Cai XY, 1998, IMMUNOL LETT, V62, P51, DOI 10.1016/S0165-2478(98)00027-3; Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Laan M, 2001, BRIT J PHARMACOL, V133, P200, DOI 10.1038/sj.bjp.0704063; Laan M, 1999, J IMMUNOL, V162, P2347; Linden A, 2000, EUR RESPIR J, V15, P973, DOI 10.1034/j.1399-3003.2000.15e28.x; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Molet S, 1999, J ALLERGY CLIN IMMUN, V103, pS107; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; YOO ZB, 1995, J IMMUNOL, V155, P5483	22	122	128	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					804	809		10.1067/mai.2001.119027	http://dx.doi.org/10.1067/mai.2001.119027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692108	Bronze			2022-12-18	WOS:000172523800023
J	Custovic, A; Hallam, CL; Simpson, BM; Craven, M; Simpson, A; Woodcock, A				Custovic, A; Hallam, CL; Simpson, BM; Craven, M; Simpson, A; Woodcock, A		Natl Asthma Campaign Manchester As	Decreased prevalence of sensitization to cats with high exposure to cat allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; asthma; allergic disease; cat; dog; dust mite; allergens; exposure	ASTHMA; ENVIRONMENT; CHILDREN; RISK	We investigated the relationship between current exposure to cat allergen and sensitization to cats. A questionnaire was administered and skin prick testing and home visits for collection of dust samples (Fel d 1; ELISA) were performed in 2502 adults (mean age, 31.8 years; age range, 18-58 years; 1251 women). The results for Fel d 1 in relation to sensitization to cats were analyzed for 10 deciles of cat allergen exposure (cut points [mug/g]: 0.05, 0.34, 0.48, 0.72, 1.13, 1.92, 7.2, 44, 151). The prevalence of sensitization to cat was significantly decreased in the lowest and the highest exposure groups. In the multivariate regression analysis (age, sex, socioeconomic status, and current smoking being adjusted for), the risk of sensitization to cats was significantly increased with medium exposure to Fel d 1 (3rd centile, OR 2.3, 95% CI 1.2-4.4, P = .01; 4th centile, OR 2.1, 95% CI 1.1-4.0, P = .03; 5th centile, OR 2.2, 95% CI 1.2-4.3, P = .04, 6th centile, OR 2.5, 95% CI 1.3-4.9, P = .005). These results indicate that the prevalence of sensitization to cat is decreased in the lowest and highest cat allergen exposure groups.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Custovic, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Simpson, Angela/0000-0003-2733-6666; Woodcock, Ashley/0000-0002-5428-8578				Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; MILLS TAE, 2001, LANCET, V357, P752; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; Wickens K, 1999, PEDIAT ALLERG IMM-UK, V10, P199, DOI 10.1034/j.1399-3038.1999.00033.x	10	122	123	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					537	539						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590378				2022-12-18	WOS:000171760300011
J	Linneberg, A; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T				Linneberg, A; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T			Increasing prevalence of specific IgE to aeroallergens in an adult population: Two cross-sectional surveys 8 years apart - The Copenhagen Allergy Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adult; epidemiology; prevalence; respiratory hypersensitivity; specific IgE positivity; specific IgE stability	SKIN-TEST REACTIVITY; CHANGING PREVALENCE; DANISH POPULATION; HAY-FEVER; RHINITIS; ASTHMA; CHILDREN; ANTIBODIES; DIAGNOSIS; SYMPTOMS	Background: There is evidence that the prevalence of respiratory allergy has increased in children in many countries. However, this evidence is largely based on questionnaire data, and little is known about similar trends in adults. Objective: We investigated whether the prevalence of specific IgE to aeroallergens had increased in an adult general population over an 8-year period. Methods: Two cross-sectional surveys were carried out in 1990 and 1998, A mailed screening questionnaire on respiratory symptoms sent to random samples of 15- to 41-year-old subjects living in Copenhagen (Denmark) preceded both surveys. Random samples of responders were invited to a health examination, including assessment of specific IgE to 6 common aeroallergens. Totals of 312 (74.6% of the invited subjects) and 482 (53.4% of the invited subjects) subjects were examined in 1990 and 1998, respectively, Analyses of serum samples from both surveys were performed in 1999, Results: The prevalence of specific IgE to at least one allergen increased significantly from 1990 to 1998 (26.5% vs 33.9%; odds ratio adjusted for sex, age, and season of examination, 1.63; 95% confidence interval, 1.15-2.32; P = .006), This increase remained unexplained after adjustment for changes in questionnaire variables on lifestyle and home environment, The clinical significance of this increase was underlined by a corresponding increase in the prevalence of allergic rhinitis symptoms associated with specific IgE positivity, Conclusion: We found that the prevalence of specific IgE positivity to aeroallergens increased in an adult Danish general population from 1990 and 1998.	Glostrup Hosp, Ctr Prevent Med, Dept Internal Med M, DK-2600 Glostrup, Denmark; Gentofte Hosp, Dept Dermatol, Gentofte, Denmark; Frederiksberg Hosp, Dept Internal Med B, Frederiksberg, Denmark; Bispebjerg Hosp, Clin Unit Prevent Med & Hlth Promot, Bispebjerg, Denmark; Univ Copenhagen, Rigshosp, Dept Resp Med, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; Rigshospitalet; University of Copenhagen	Linneberg, A (corresponding author), Glostrup Hosp, Ctr Prevent Med, Dept Internal Med M, 57 Ndr Ringvej,Entrance 8,7th Floor, DK-2600 Glostrup, Denmark.		Jørgensen, Torben/Z-1335-2018	Linneberg, Allan/0000-0002-0994-0184; Jorgensen, Torben/0000-0001-9453-2830; Madsen, Flemming/0000-0002-9911-0175				Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Crobach MJJS, 1998, SCAND J PRIM HEALTH, V16, P30; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Henderson CE, 1998, J IMMUNOL METHODS, V213, P99, DOI 10.1016/S0022-1759(98)00014-3; Johansen N., 1998, Allergy (Copenhagen), V53, P193; Linneberg A, 1999, ALLERGY, V54, P1194, DOI 10.1034/j.1398-9995.1999.00180.x; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; Mygind N, 1996, PEDIATR ALLERGY IMMU, V7, P57, DOI 10.1111/j.1399-3038.1996.tb00397.x; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; NIELSEN NH, 1994, ALLERGY, V49, P86, DOI 10.1111/j.1398-9995.1994.tb00805.x; Paganelli R, 1998, ALLERGY, V53, P763; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45	20	122	125	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					247	252		10.1067/mai.2000.108312	http://dx.doi.org/10.1067/mai.2000.108312			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932066				2022-12-18	WOS:000088708100005
J	Yunginger, JW; Ahlstedt, S; Eggleston, PA; Homburger, HA; Nelson, HS; Ownby, DR; Platts-Mills, TAE; Sampson, HA; Sicherer, SH; Weinstein, AM; Williams, PB; Wood, RA; Zeiger, RS				Yunginger, JW; Ahlstedt, S; Eggleston, PA; Homburger, HA; Nelson, HS; Ownby, DR; Platts-Mills, TAE; Sampson, HA; Sicherer, SH; Weinstein, AM; Williams, PB; Wood, RA; Zeiger, RS			Quantitative IgE antibody assays in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE antibody; quantitative immunoassay; allergic disease	SKIN-TEST REACTIVITY; HIGH-RISK CHILDREN; ATOPIC-DERMATITIS; PERFORMANCE-CHARACTERISTICS; FOOD ALLERGENS; EGG ALLERGY; FOLLOW-UP; SENSITIZATION; DIAGNOSIS; ASTHMA	During the past several years, immunoassays for specific IgE antibodies have been refined to permit reporting results in mass units. Thus quantitative immunoassays for IgE antibodies may be an adjunct to skin tests. In cases of food allergy among children with atopic dermatitis, cutoff values for IgE antibody concentrations to egg, milk, peanut, and fish have been derived to provide 95% positive and 90% negative predictive values. Food-specific IgE antibody determinations can also be used to predict which food allergies are resolving spontaneously. Elevated egg-specific IgE antibody levels in infancy are associated with significantly increased risk for development of inhalant allergies later in childhood. In cases of inhalant allergy, specific IgE antibody levels correlate closely with results of inhalation challenge studies in cat-sensitive persons. Also, mite-specific IgE antibody levels correlate significantly with the mite allergen contents of reservoir dust in the homes of mite-sensitive persons. Immunoassays for quantitation of specific IgE antibodies may be used to document allergen sensitization over time and to evaluate the risk of reaction on allergen exposure. However, immunoassays and skin tests are not entirely interchangeable, and neither will replace the other in appropriate circumstances.	Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Gothenburg, Dept Clin Immunol, Gothenburg, Sweden; Pharmacia & Upjohn Diagnost, Kalamazoo, MI USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Med Coll Georgia, Sect Allergy Immunol, Augusta, GA 30912 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Div Asthma Allergy & Immunol, Charlottesville, VA USA; Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY USA; Georgetown Univ, Sch Med, Washington, DC USA; Univ Missouri Kansas City, Sch Med, IBT Reference Lab, Lenexa, KS USA; So Calif Permanente Med Grp, Dept Allergy, San Diego, CA 92120 USA	Mayo Clinic; Mayo Clinic; University of Gothenburg; Pfizer; Johns Hopkins University; National Jewish Health; University System of Georgia; Augusta University; University of Virginia; Icahn School of Medicine at Mount Sinai; Georgetown University; University of Missouri System; University of Missouri Kansas City; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	Yunginger, JW (corresponding author), Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, 406 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.			Zeiger, Robert/0000-0001-5788-5063; Platts-Mills, Thomas/0000-0002-1263-329X				ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; AGATA H, 1993, J ALLERGY CLIN IMMUN, V91, P668, DOI 10.1016/0091-6749(93)90273-I; Bernardini R, 1999, CLIN EXP ALLERGY, V29, P681; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BONER AL, 1993, CLIN EXP ALLERGY, V23, P1021, DOI 10.1111/j.1365-2222.1993.tb00294.x; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; Brunnee T, 1996, CLIN EXP ALLERGY, V26, P1420; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Chanez P, 1996, ALLERGY, V51, P850; COSTONGS GMPJ, 1995, EUR J CLIN CHEM CLIN, V33, P295; CRESPO JF, 1994, ALLERGY PROC, V15, P73, DOI 10.2500/108854194778703099; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; DANTZLER BS, 1980, ANN ALLERGY, V45, P213; DELOVINFOSSE S, 1994, ALLERGY, V49, P64, DOI 10.1111/j.1398-9995.1994.tb00776.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, pS52; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; KELSO JM, 1991, ANN ALLERGY, V67, P511; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; LEIMGRUBER A, 1993, ALLERGY, V48, P415, DOI 10.1111/j.1398-9995.1993.tb00739.x; LIAPPIS N, 1996, CLIN LAB, V42, P707; LILJA G, 1991, PEDIATR ALLERGY IMMU, V2, P6; LINDQVIST A, 1995, P 16 EUR C ALL CLIN, P195; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153, DOI 10.1016/S0091-6749(98)70409-9; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Paganelli R, 1998, ALLERGY, V53, P763; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; PETERMAN JH, 1991, IMMUNOCHEMISTRY SOLI, P47; *PHS, REV CRIT ASS ALL SPE, P1; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sanz ML, 1996, J INVEST ALLERG CLIN, V6, P89; SENSI LG, 1994, CLIN EXP ALLERGY, V24, P377, DOI 10.1111/j.1365-2222.1994.tb00250.x; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; STRUCKEY MS, 1985, J ALLERGY CLIN IMMUN, V75, P373; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; 1992, FED REG 405, V57, P7002	49	122	130	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1077	1084		10.1067/mai.2000.107041	http://dx.doi.org/10.1067/mai.2000.107041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856139				2022-12-18	WOS:000087781800006
J	Finn, AF; Kaplan, AF; Fretwell, R; Qu, R; Long, J				Finn, AF; Kaplan, AF; Fretwell, R; Qu, R; Long, J			A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antihistamine; fexofenadine HCl; chronic idiopathic urticaria; pruritus; wheals	SEASONAL ALLERGIC RHINITIS; AUTOANTIBODIES; HYDROCHLORIDE; RELEASE; SAFETY; LIFE; SKIN	Background: Symptoms of chronic idiopathic urticaria (CIU) include relentless itching and painful wheals, which can be physically and psychologically debilitating. Half of all patients with urticaria have angioedema, which is often disfiguring. Objective: To evaluate the safety and efficacy of fexofenadine HCl for the treatment of CIU symptoms, Methods: In this 4-week, multicenter, placebo-controlled study, 439 patients with moderate to severe pruritus and urticaria received 1 of 4 oral doses of fexofenadine HCl (20, 60, 120, or 240 mg twice a day) or placebo. Patients reflectively assessed (over the previous 12 hours) the severity of pruritus, the number of wheals, and the interference with sleep (7 AM) and normal activities (7 PM) due to urticaria, Efficacy measures included a change from baseline of daily mean pruritus score (MPS), daily mean number of wheals (MNW) score, daily mean total symptom score (MTSS) (ie, the sum of the wheal and pruritus scores), and mean interference with sleep and daily activities due to urticaria, Results: All 4 doses of fexofenadine were statistically superior to placebo (P less than or equal to .0338) for MPS, MNW score, and MTSS, Patients receiving fexofenadine HCl also experienced significantly less interference with sleep and daily activities than patients receiving placebo (P less than or equal to .0001). Efficacy results were similar in the 60-, 120-, and 240-mg groups and were quantitatively better than those in the 20-mg group. Adverse events were mild and occurred with similar incidence in all treatment groups, Conclusions: Fexofenadine HCl is web tolerated and is statistically superior to placebo in reducing signs and symptoms of CIU and in ameliorating interference with sleep and daily activities due to urticaria, Doses of 60 mg twice a day or greater are most effective.	Allergy & Asthma Ctr Charleston PA, Natl Urticaria Res & Treatment Ctr, Charleston, SC USA; Hoechst Marion Roussel, Kansas City, MO USA		Finn, AF (corresponding author), 9165 Univ Blvd, Charleston, SC 29406 USA.							Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; BADOUX A, 1994, ANN ALLERGY, V72, P229; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443, DOI 10.1016/S1081-1206(10)63041-4; Black Anne Kobza, 1997, Keio Journal of Medicine, V46, P37; Bronsky EA, 1998, ALLERGY ASTHMA PROC, V19, P135, DOI 10.2500/108854198778604112; CHARLESWORTH EN, 1995, IMMUNOL ALLERGY CLIN, V15, P641; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Fox RW, 1995, ALLERGY PROC, V16, P289, DOI 10.2500/108854195778667837; Greaves Malcom W., 1996, Journal of Dermatology (Tokyo), V23, P735; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; Greaves MW, 1998, BRIT MED J, V316, P1147, DOI 10.1136/bmj.316.7138.1147; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Leung DYM, 1997, JAMA-J AM MED ASSOC, V278, P1914; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; ODonnell BF, 1997, BRIT J DERMATOL, V136, P197; Paul E, 1998, J DERMATOL TREAT, V9, P143, DOI 10.3109/09546639809160545; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Pratt CM, 1999, AM J CARDIOL, V83, P1451, DOI 10.1016/S0002-9149(99)00124-1; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Sabroe RA, 1999, J ALLERGY CLIN IMMUN, V103, P484, DOI 10.1016/S0091-6749(99)70475-6; Simons FER, 1997, ANN ALLERG ASTHMA IM, V79, P530, DOI 10.1016/S1081-1206(10)63061-X; SOTER NA, 1990, J ALLERGY CLIN IMMUN, V86, P1009, DOI 10.1016/S0091-6749(05)80245-3; Thompson A, 1999, ANN ALLERG ASTHMA IM, V82, P122	26	122	124	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1071	1078		10.1016/S0091-6749(99)70091-6	http://dx.doi.org/10.1016/S0091-6749(99)70091-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550755				2022-12-18	WOS:000083778400033
J	KLEIN, JS; YOCUM, MW				KLEIN, JS; YOCUM, MW			UNDERREPORTING OF ANAPHYLAXIS IN A COMMUNITY EMERGENCY ROOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											KLEIN, JS (corresponding author), MAYO CLIN & MAYO FDN,DIV ALLERG DIS,ROCHESTER,MN 55905, USA.							HUTCHESON PS, 1990, ANN ALLERGY, V64, P306; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; SETTIPANE GA, 1978, CLIN ALLERGY, V8, P259, DOI 10.1111/j.1365-2222.1978.tb03222.x; SORENSEN HT, 1989, ALLERGY, V44, P288, DOI 10.1111/j.1398-9995.1989.tb01071.x	4	122	124	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					637	638		10.1016/S0091-6749(95)70329-2	http://dx.doi.org/10.1016/S0091-6749(95)70329-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852677				2022-12-18	WOS:A1995QH69700019
J	MACGLASHAN, DW				MACGLASHAN, DW			RELEASABILITY OF HUMAN BASOPHILS - CELLULAR-SENSITIVITY AND MAXIMAL HISTAMINE-RELEASE ARE INDEPENDENT VARIABLES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HUMAN BASOPHILS; IGE; IGE RECEPTORS; HISTAMINE RELEASE; RELEASABILITY	ALLERGIC RHINITIS; ANTIGEN-BINDING; LEUKEMIA-CELLS; SERUM IGE; DESENSITIZATION; ASTHMA; HETEROGENEITY; LEUKOCYTES; RECEPTORS; INVITRO	Within the atopic and nonatopic population, basophils display a wide variation in the extent of histamine release when challenged with an optimal concentration of polyclonal anti-IgE antibody. We have tested the hypothesis that the maximum percent histamine release obtainable with this stimulus is an indicator of basophil sensitivity. We have defined basophil sensitivity, in the context of IgE-mediated releae, as the number of cell-surface IgE molecules required to obtain a half-maximal IgE-mediated response, and we have examined this parameter in the basophils of 39 donors. Sensitizing basophils with various densities of antigen-specific IgE, and measuring histamine release at these measured densities, allowed a determination of basophil sensitivity in 38 of the donors. Basophil sensitivities ranged from 300 to 40,000 molecules per basophil (point of 50% maximal response), although most donors fell in the 800 to 8000 range, with 1900 molecules per basophil as the median response. The maximal response, after challenge with an optimal concentration of either polyclonal or monoclonal anti-IgE antibody, ranged from 8% to 94% (median, 50%). There was no correlation between basophil sensitivity and the maximum histamine release obtained by a challenge with anti-IgE antibody. Therefore two independent variables appeared to control the IgE-mediated response in basophils, similar to the parameters of efficacy and potency in drug studies. In the IgE-mediated response one parameter is the maximum histamine release obtainable through IgE-mediated mechanisms, and the second parameter is basophil sensitivity as defined above. As a byproduct of these studies, we also found that the density of unoccupied high-affinity receptors for IgE antibody was uncorrelated with the total receptor density (range, 4200 to 572,000 receptors per basophil). Indeed, the density of unoccupied receptors was remarkably constant across this large range of total receptor densities.			MACGLASHAN, DW (corresponding author), JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,UNIT OFF 3A62,BALTIMORE,MD 21224, USA.							Adkinson NF, 1980, MEASUREMENT TOTAL SE; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108, DOI 10.1164/ajrccm/142.5.1108; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CONROY MC, 1977, J IMMUNOL, V118, P1317; FEWTRELL C, 1980, J IMMUNOL, V125, P701; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FLINT KC, 1986, RESPIRATION, V2, P31; GILBERT HS, 1975, BLOOD, V46, P279; ISERSKY C, 1979, J IMMUNOL, V122, P1926; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACGLASHAN D, 1983, J IMMUNOL, V130, P2337; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MACGLASHAN D, 1987, J IMMUNOL, V139, P501; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1980, J IMMUNOL, V124, P2519; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MARONE G, 1989, LIFE SCI, V45, P1745, DOI 10.1016/0024-3205(89)90513-4; MARONE G, 1986, J ALLERGY CLIN IMMUN, V77, P377, DOI 10.1016/S0091-6749(86)80121-X; MARONE G, 1986, J INVEST DERMATOL, V87, P19, DOI 10.1111/1523-1747.ep12523520; MARONE G, 1986, J IMMUNOL, V137, P358; MAY C D, 1973, Clinical Allergy, V3, P319, DOI 10.1111/j.1365-2222.1973.tb01340.x; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SUN LK, 1991, J IMMUNOL, V146, P199	32	122	125	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					605	615		10.1016/0091-6749(93)90266-I	http://dx.doi.org/10.1016/0091-6749(93)90266-I			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	7679683				2022-12-18	WOS:A1993KN54800008
J	ILIOPOULOS, O; PROUD, D; ADKINSON, NF; CRETICOS, PS; NORMAN, PS; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM				ILIOPOULOS, O; PROUD, D; ADKINSON, NF; CRETICOS, PS; NORMAN, PS; KAGEYSOBOTKA, A; LICHTENSTEIN, LM; NACLERIO, RM			EFFECTS OF IMMUNOTHERAPY ON THE EARLY, LATE, AND RECHALLENGE NASAL REACTION TO PROVOCATION WITH ALLERGEN - CHANGES IN INFLAMMATORY MEDIATORS AND CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RAGWEED HAY-FEVER; IMMUNOGLOBULIN-E; LATE-PHASE; CHALLENGE; ANTIGEN; ANTIBODIES; HISTAMINE; IGG; HYPOSENSITIZATION; RESPONSIVENESS	We investigated the effects of immunotherapy (IT) on the early (ER), late (LPR), and rechallenge reactions (RCRs) to nasal challenge with antigen as well as on the cutaneous ER and LPR to intradermal skin challenge. Our expectation was that IT would have a preferential effect on the LPR, and our aim was to understand the mechanism. Twenty-one ragweed hay fever-sensitive subjects were treated with a moderate dose of antigen extract (maintenance dose of 1.94-mu-g of antigen E (Amb a I)) during a period of 8 months (total dose equivalent to 24-mu-g of antigen E), and 20 matched subjects received placebo injections in a double-blind manner. Both groups underwent identical nasal challenges and intradermal skin tests with ragweed-antigen extract both before (1985) and during (1986) IT. Symptom and medication diaries, recorded during seasonal exposure, and changes in specific serum IgE and IgG antibodies confirmed the efficacy of the administered IT dose. Between-group analysis revealed that IT significantly reduced the levels of histamine, TAME-esterase activity, and kinins, as well as symptoms of rhinorrhea and congestion generated during the ER to nasal challenge. Within-group paired analysis demonstrated ER, LPR, and RCR mediators and symptoms also to be reduced by IT. Surprisingly, the placebo-treated group demonstrated an increase in the ER. There was no decrease of the LPR without an antecedent decrease of the ER. IT did not clearly change the late cellular inflammatory response. In the case of skin challenge, IT significantly reduced the cutaneous ER. The reduction of the cutaneous LPR was more pronounced. We speculate that moderate-dose IT ameliorates seasonal symptoms of allergic rhinitis by reducing the ER, LPR, and RCR to antigen challenge but does not preferentially reduce the nasal LPR.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000320] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32272] Funding Source: Medline; NIAID NIH HHS [AI 08270] Funding Source: Medline; NIDCD NIH HHS [DC 00320] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V79, P253; IMANARI T, 1986, DHEW NIH76791 PUBL, P205; KUNA P, 1988, J ALLERGY CLIN IMMUN, V81, P291, DOI 10.1016/0091-6749(88)90728-2; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; NORMAN PS, 1966, CLINICAL PHARMACOLOG, V2, P639; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; Siegel S., 1956, NONPARAMETRIC STAT B; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1	27	122	123	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					855	866		10.1016/0091-6749(91)90134-A	http://dx.doi.org/10.1016/0091-6749(91)90134-A			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013680				2022-12-18	WOS:A1991FG05900016
J	FREW, AJ; KAY, AB				FREW, AJ; KAY, AB			EOSINOPHILS AND LYMPHOCYTES-T IN LATE-PHASE ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL HEART & LUNG INST, DEPT ALLERGY & CLIN IMMUNOL, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND	Imperial College London			Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCHER CB, 1985, BRIT J DERMATOL, V113, P133, DOI 10.1111/j.1365-2133.1985.tb15642.x; BACHELET CM, 1988, INT ARCH ALLER A IMM, V87, P225, DOI 10.1159/000234677; BERNSTEIN IL, 1987, J ALLERGY CLIN IMMUN, V79, P320, DOI 10.1016/0091-6749(87)90148-5; BOS JD, 1987, J INVEST DERMATOL, V88, P569, DOI 10.1111/1523-1747.ep12470172; CAMPBELL DA, 1985, AM REV RESPIR DIS, V132, P1300; CAPRON M, 1981, J IMMUNOL, V126, P2087; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOR PJ, 1983, J ALLERGY CLIN IMMUN, V71, P363, DOI 10.1016/0091-6749(83)90063-5; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; FERRO TJ, 1987, AM REV RESPIR DIS, V135, P682; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FREW AJ, 1988, J IMMUNOL, V141, P4158; FREW AJ, 1988, J ALLERGY CLIN IMMUN, V81, P1117, DOI 10.1016/0091-6749(88)90878-0; FREW AJ, IN PRESS AM REV RESP; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; HIRSCHBERG H, 1982, IMMUNOL REV, V66, P57, DOI 10.1111/j.1600-065X.1982.tb00434.x; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JOSEPH M, 1986, EUR J IMMUNOL, V16, P306, DOI 10.1002/eji.1830160318; JOUVINMARCHE E, 1984, FED PROC, V43, P1924; KAPSENBERG ML, 1986, J INVEST DERMATOL, V87, P148; KERN P, 1987, BRIT J HAEMATOL, V66, P165, DOI 10.1111/j.1365-2141.1987.tb01294.x; KURIHARA K, 1988, FASEB J, V2, pA1449; LAPIERRE LA, 1988, J EXP MED, V167, P794, DOI 10.1084/jem.167.3.794; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; MARTIN TR, 1987, J CLIN INVEST, V80, P1114, DOI 10.1172/JCI113168; MELEWICZ FM, 1980, J IMMUNOL, V125, P1026; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MIOSSEC P, 1986, J IMMUNOL, V137, P2848; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; NUMAO T, 1989, J ALLERGY CLIN IMMUN, V83, P298; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PRINZ JC, 1988, J ALLERGY CLIN IMMUN, V81, P304, DOI 10.1016/0091-6749(88)90780-4; RAGHAVACHAR A, 1987, J IMMUNOL, V139, P3753; RAMESH KS, 1985, CELL IMMUNOL, V92, P366, DOI 10.1016/0008-8749(85)90018-8; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WALSH GM, 1989, FAEB J, V3, P1330; WALSH LJ, 1987, CLIN EXP IMMUNOL, V70, P379; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; ZWEIMAN B, 1988, CLIN ALLERGY, V18, P419, DOI 10.1111/j.1365-2222.1988.tb02892.x	58	122	124	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					533	539		10.1016/0091-6749(90)90090-Q	http://dx.doi.org/10.1016/0091-6749(90)90090-Q			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2179364				2022-12-18	WOS:A1990CU66800001
J	LOWHAGEN, O; RAK, S				LOWHAGEN, O; RAK, S			MODIFICATION OF BRONCHIAL HYPERREACTIVITY AFTER TREATMENT WITH SODIUM CROMOGLYCATE DURING POLLEN SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LOWHAGEN, O (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT MED 1,ASTHMA & ALLERGY RES CTR,S-41345 GOTHENBURG,SWEDEN.							ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRESLIN FJ, 1980, AM REV RESPIR DIS, V122, P11; BURGE PS, 1982, EUR J RESPIR DIS, V63, P91; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; DAVIES RJ, 1982, PHARMACOL THERAPEUT, V17, P279, DOI 10.1016/0163-7258(82)90018-3; DICKSON W, 1979, MAST CELL ITS ROLE H, P343; DICKSON W, 1970, DISODIUM CROMOGLYCAT, P105; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FABBRI LM, 1983, ANN ALLERGY, V50, P195; FANTA CH, 1981, AM REV RESPIR DIS, V123, P161; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HEGARDT B, 1980, ALLERGY, V35, P113, DOI 10.1111/j.1398-9995.1980.tb01725.x; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; KAUFFMAN HF, 1983, CLIN ALLERGY, V13, P219, DOI 10.1111/j.1365-2222.1983.tb02591.x; KOETER GH, 1982, ALLERGY, V37, P587, DOI 10.1111/j.1398-9995.1982.tb02344.x; LEE TH, 1983, LANCET, V1, P520; LOWHAGEN O, 1980, ALLERGY, V35, P521, DOI 10.1111/j.1398-9995.1980.tb01799.x; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P446; LOWHAGEN O, J ALLERGY CLIN IMMUN; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; PEGELOW KO, 1974, ACTA ALLERGOL, V29, P365, DOI 10.1111/j.1398-9995.1974.tb01472.x; ROSENTHAL R R, 1980, American Review of Respiratory Disease, V121, P90; RYO UY, 1971, J ALLERGY, V47, P96; TAN WC, 1982, THORAX, V37, P671, DOI 10.1136/thx.37.9.671; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; WOOLCOCK AJ, 1979, MAST CELL ITS ROLE H, P271	35	122	123	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	4					460	467		10.1016/S0091-6749(85)80018-X	http://dx.doi.org/10.1016/S0091-6749(85)80018-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AFY44	3920301				2022-12-18	WOS:A1985AFY4400005
J	SIRAGANIAN, RP; BRODSKY, MJ				SIRAGANIAN, RP; BRODSKY, MJ			AUTOMATED HISTAMINE ANALYSIS FOR INVITRO ALLERGY TESTING .1. METHOD UTILIZING ALLERGEN-INDUCED HISTAMINE-RELEASE FROM WHOLE-BLOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIDR,CLIN IMMUNOL SECT,MICROBIOL & IMMUNOL LAB,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BAER H, 1974, MED CLIN N AM, V58, P85, DOI 10.1016/S0025-7125(16)32179-4; BEAVEN MA, 1971, J PHARMACOL EXP THER, V176, P52; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; GARDEN JW, 1966, J APPL PHYSIOL, V21, P631, DOI 10.1152/jappl.1966.21.2.631; HAZELETT JR, 1974, J PHARMACEUTICAL SCI, V63, P701; Katz G, 1941, J AMER MED ASSOC, V117, P1782, DOI 10.1001/jama.1941.02820470030008; LEVY DA, 1966, J IMMUNOL, V97, P203; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1967, J ALLERGY, V40, P160, DOI 10.1016/0021-8707(67)90005-6; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; MAY CD, 1971, J ALLERGY CLIN IMMUN, V48, P313, DOI 10.1016/0091-6749(71)90033-9; MAY CD, 1972, J ALLERGY CLIN IMMUN, V49, P54, DOI 10.1016/0091-6749(72)90123-6; NOAH JW, 1955, J ALLERGY, V26, P385, DOI 10.1016/0021-8707(55)90029-0; NOAH JW, 1954, J ALLERGY, V25, P210, DOI 10.1016/0021-8707(54)90180-X; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PARROT JL, 1962, P SOC EXP BIOL MED, V109, P459; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SIRAGANIAN RP, 1975, CLIN IMMUNOL IMMUNOP, V4, P59, DOI 10.1016/0090-1229(75)90040-9; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; VANARSDEL PP, 1958, J ALLERGY, V29, P429, DOI 10.1016/0021-8707(58)90084-4; WIDE L, 1967, LANCET, V2, P1105	28	122	123	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					525	540		10.1016/0091-6749(76)90003-8	http://dx.doi.org/10.1016/0091-6749(76)90003-8			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	58879				2022-12-18	WOS:A1976BV05400003
J	Forbes, LR; Vogel, TP; Cooper, MA; Castro-Wagner, J; Schussler, E; Weinacht, KG; Plant, AS; Su, HC; Allenspach, EJ; Slatter, M; Abinun, M; Lilic, D; Cunningham-Rundles, C; Eckstein, O; Olbrich, P; Guillerman, RP; Patel, NC; Demirdag, YY; Zerbe, C; Freeman, AF; Holland, SM; Szabolcs, P; Gennery, A; Torgerson, TR; Milner, JD; Leiding, JW				Forbes, Lisa R.; Vogel, Tiphanie P.; Cooper, Megan A.; Castro-Wagner, Johana; Schussler, Edith; Weinacht, Katja G.; Plant, Ashley S.; Su, Helen C.; Allenspach, Eric J.; Slatter, Mary; Abinun, Mario; Lilic, Desa; Cunningham-Rundles, Charlotte; Eckstein, Olive; Olbrich, Peter; Guillerman, R. Paul; Patel, Niraj C.; Demirdag, Yesim Y.; Zerbe, Christa; Freeman, Alexandra F.; Holland, Steven M.; Szabolcs, Paul; Gennery, Andrew; Torgerson, Troy R.; Milner, Joshua D.; Leiding, Jennifer W.			Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RUXOLITINIB		[Forbes, Lisa R.; Vogel, Tiphanie P.] Baylor Coll Med, Dept Pediat, Div Allergy Immunol & Rheumatol, Houston, TX 77030 USA; [Forbes, Lisa R.; Vogel, Tiphanie P.] Texas Childrens Hosp, Ctr Human Immunobiol, Houston, TX 77030 USA; [Cooper, Megan A.] Washington Univ, Dept Pediat, Div Rheumatol, St Louis, MO 63130 USA; [Castro-Wagner, Johana; Leiding, Jennifer W.] Univ S Florida, Dept Pediat, Div Allergy & Immunol, St Petersburg, FL USA; [Schussler, Edith; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Inst Immunol, Div Allergy & Immunol, New York, NY 10029 USA; [Schussler, Edith; Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Inst Immunol, Dept Med & Pediat, New York, NY 10029 USA; [Weinacht, Katja G.] Stanford Sch Med, Dept Pediat, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA USA; [Plant, Ashley S.] Childrens Hosp Orange Cty, Dept Pediat Oncol, Orange, CA 92668 USA; [Su, Helen C.; Zerbe, Christa; Freeman, Alexandra F.; Holland, Steven M.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Allenspach, Eric J.; Torgerson, Troy R.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA; [Allenspach, Eric J.; Torgerson, Troy R.] Seattle Childrens Hosp, Seattle, WA USA; [Slatter, Mary; Abinun, Mario; Lilic, Desa; Gennery, Andrew] Newcastle Upon Tyne Hosp NHS Fdn, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Slatter, Mary; Abinun, Mario; Lilic, Desa; Gennery, Andrew] Newcastle Upon Tyne Univ, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Eckstein, Olive] Texas Childrens Canc Ctr, Dept Hematol & Oncol, Houston, TX USA; [Olbrich, Peter; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Olbrich, Peter] Univ Hosp Virgen del Rocio, Inst Biomed Seville IBiS, Dept Pediat Infect Dis & Immunopathol, Seville, Spain; [Guillerman, R. Paul] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Guillerman, R. Paul] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Patel, Niraj C.] Atrium Hlth, Levine Childrens Hosp, Dept Pediat, Sect Infect Dis & Immunol, Charlotte, NC USA; [Demirdag, Yesim Y.] Columbia Univ, Coll Phys & Surg, New York Presbyterian Morgan Stanley Childrens Ho, Dept Pediat,Div Pediat Allergy & Immunol, New York, NY USA; [Szabolcs, Paul] Univ Pittsburgh, Div Blood & Marrow Transplantat & Cellular Therap, Pittsburgh, PA USA; [Leiding, Jennifer W.] Johns Hopkins All Childrens Hosp, Canc & Blood Disorders Inst, St Petersburg, FL USA; [Schussler, Edith] Weill Cornell Med, Div Pulm Allergy & Immunol, New York, NY USA	Baylor College of Medicine; Baylor College of Medicine; Washington University (WUSTL); State University System of Florida; University of South Florida; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Stanford University; Childrens Hospital of Orange County; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle; Seattle Children's Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Texas Children's Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Baylor College of Medicine; Baylor College of Medicine; Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Cornell University	Forbes, LR (corresponding author), Baylor Coll Med, Dept Pediat, Div Allergy Immunol & Rheumatol, Houston, TX 77030 USA.; Forbes, LR (corresponding author), Texas Childrens Hosp, Ctr Human Immunobiol, Houston, TX 77030 USA.	lisa.forbes@bcm.edu; jleiding@health.usf.edu	Olbrich, Peter/AAV-3601-2021; Plant, Ashley/GVS-9394-2022; Eckstein, Olive S./T-8873-2019	Olbrich, Peter/0000-0001-9853-7903; Cooper, Megan/0000-0002-5696-172X	Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001247, ZIAAI000646, ZIAAI000647, ZIAAI001183, ZIAAI001059] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.	Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Leiding JW, 2018, J ALLERGY CLIN IMMUN, V141, P704, DOI 10.1016/j.jaci.2017.03.049; Loh ML, 2015, PEDIATR BLOOD CANCER, V62, P1717, DOI 10.1002/pbc.25575; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Vargas-Hernandez A, 2018, J ALLERGY CLIN IMMUN, V141, P2142, DOI 10.1016/j.jaci.2017.08.040; Verstovsek S, 2014, CANCER-AM CANCER SOC, V120, P513, DOI 10.1002/cncr.28441; Weinacht KG, 2017, J ALLERGY CLIN IMMUN, V139, P1629, DOI 10.1016/j.jaci.2016.11.022	9	121	126	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1665	1669		10.1016/j.jaci.2018.07.020	http://dx.doi.org/10.1016/j.jaci.2018.07.020			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30092289	Green Accepted, Bronze			2022-12-18	WOS:000449429800037
J	Molina-Infante, J; Arias, A; Alcedo, J; Garcia-Romero, R; Casabona-Frances, S; Prieto-Garcia, A; Modolell, I; Gonzalez-Cordero, PL; Perez-Martinez, I; Martin-Lorente, JL; Guarner-Argente, C; Masiques, ML; Vila-Miravet, V; Garcia-Puig, R; Savarino, E; Sanchez-Vegazo, CT; Santander, C; Lucendo, AJ				Molina-Infante, Javier; Arias, Angel; Alcedo, Javier; Garcia-Romero, Ruth; Casabona-Frances, Sergio; Prieto-Garcia, Alicia; Modolell, Ines; Gonzalez-Cordero, Pedro L.; Perez-Martinez, Isabel; Luis Martin-Lorente, Jose; Guarner-Argente, Carlos; Masiques, Maria L.; Vila-Miravet, Victor; Garcia-Puig, Roger; Savarino, Edoardo; Teruel Sanchez-Vegazo, Carlos; Santander, Cecilio; Lucendo, Alfredo J.			Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; diet; milk; wheat; six-food elimination	PROTON PUMP INHIBITOR; HISTOLOGIC REMISSION; FOOD TRIGGERS; METAANALYSIS; EFFICACY; CHILDREN; DISEASE; INFLAMMATION; VALIDATION; SYMPTOMS	Background: Numerous dietary restrictions and endoscopies limit the implementation of empiric elimination diets in patients with eosinophilic esophagitis (EoE). Milk and wheat/gluten are the most common food triggers. Objective: We sought to assess the effectiveness of a step-up dietary strategy for EoE. Methods: We performed a prospective study conducted in 14 centers. Patients underwent a 6-week 2-food-group elimination diet (TFGED; milk and gluten-containing cereals). Remission was defined by symptom improvement and less than 15 eosinophils/high-power field. Nonresponders were gradually offered a 4-food-group elimination diet (FFGED; TFGED plus egg and legumes) and a 6-food-group elimination diet (SFGED; FFGED plus nuts and fish/seafood). In responders eliminated food groups were reintroduced individually, followed by endoscopy. Results: One hundred thirty patients (25 pediatric patients) were enrolled, with 97 completing all phases of the study. ATFGED achieved EoE remission in 56 (43%) patients, with no differences between ages. Food triggers in TFGED responders were milk (52%), gluten-containing grains (16%), and both (28%). EoE induced only by milk was present in 18% and 33% of adults and children, respectively. Remission rates with FFGEDs and SFGEDs were 60% and 79%, with increasing food triggers, especially after an SFGED. Overall, 55 (91.6%) of 60 of the TFGED/FFGED responders had 1 or 2 food triggers. Compared with the initial SFGED, a step-up strategy reduced endoscopic procedures and diagnostic process time by 20%. Conclusions: A TFGED diet achieves EoE remission in 43% of children and adults. A step-up approach results in early identification of a majority of responders to an empiric diet with few food triggers, avoiding unnecessary dietary restrictions, saving endoscopies, and shortening the diagnostic process.	[Molina-Infante, Javier; Gonzalez-Cordero, Pedro L.] Hosp Univ San Pedro De Alcantara, Dept Gastroenterol, Avda Pablo Naranjo S-N, Caceres 10003, Spain; [Molina-Infante, Javier; Arias, Angel; Santander, Cecilio; Lucendo, Alfredo J.] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain; [Arias, Angel] Hosp Gen Mancha Ctr, Res Unit, Ciudad Real, Spain; [Alcedo, Javier] Hosp Univ Miguel Servet, Dept Gastroenterol, Zaragoza, Spain; [Garcia-Romero, Ruth] Hosp Univ Miguel Servet, Dept Pediat, Zaragoza, Spain; [Casabona-Frances, Sergio; Santander, Cecilio] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa, Dept Gastroenterol, Madrid, Spain; [Prieto-Garcia, Alicia] Hosp Gen Univ Gregorio Maranon, Dept Allergy, Madrid, Spain; [Modolell, Ines] Consorci Sanitari Terrassa, Dept Gastroenterol, Barcelona, Spain; [Perez-Martinez, Isabel] Hosp Univ Cent Asturias, Dept Gastroenterol, Oviedo, Spain; [Luis Martin-Lorente, Jose] Hosp Univ Burgos, Dept Gastroenterol, Burgos, Spain; [Guarner-Argente, Carlos] Hosp Santa Crue & St Pau, Dept Gastroenterol, Barcelona, Spain; [Masiques, Maria L.] Hosp Gen Granollers, Dept Pediat, Barcelona, Spain; [Vila-Miravet, Victor] Hosp St Joan Deu, Dept Pediat, Barcelona, Spain; [Garcia-Puig, Roger] Hosp Univ Mutua Terrassa, Dept Pediat, Barcelona, Spain; [Savarino, Edoardo] Univ Padua, Div Gastroenterol, Dept Surg Oncol & Gastroenterol, Padua, Italy; [Teruel Sanchez-Vegazo, Carlos] Hosp Univ Ramon y Cajal, Dept Gastroenterol, Madrid, Spain; [Lucendo, Alfredo J.] Hosp Gen Tomelloso, Dept Gastroenterol, Vereda Socuellamos S-N, Tomelloso 13700, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Miguel Servet University Hospital; Miguel Servet University Hospital; General University Gregorio Maranon Hospital; Central University Hospital Asturias; University of Barcelona; Hospital Universitario Mutua Terrassa; University of Padua; Hospital Universitario Ramon y Cajal	Molina-Infante, J (corresponding author), Hosp Univ San Pedro De Alcantara, Dept Gastroenterol, Avda Pablo Naranjo S-N, Caceres 10003, Spain.; Lucendo, AJ (corresponding author), Hosp Gen Tomelloso, Dept Gastroenterol, Vereda Socuellamos S-N, Tomelloso 13700, Spain.	xavi_molina@hotmail.com; ajlucendo@hotmail.com		Savarino, Edoardo/0000-0002-3187-2894; Guarner-Argente, Carlos/0000-0002-8180-1488; Perez-Martinez, Isabel/0000-0002-2535-1929; Santander Vaquero, Cecilio/0000-0001-5492-2535; Prieto-Garcia, Alicia/0000-0003-3915-1941	Norgine	Norgine	E. Savarino has consultant arrangements with Abbvie, MSD, Takeda, Malesci, and Sofar. C. T. Sanchez-Vegazo has received payment for lectures from Norgine and has received travel support from Norgine, Bama-Geve, and Allergan. The rest of the authors declare that they have no relevant conflicts of interest.	Aceves SS, 2009, ANN ALLERG ASTHMA IM, V103, P401, DOI 10.1016/S1081-1206(10)60359-6; Arias A, 2016, ALIMENT PHARM THER, V43, P3, DOI 10.1111/apt.13441; Arias A, 2014, GASTROENTEROLOGY, V146, P1639, DOI 10.1053/j.gastro.2014.02.006; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Franciosi JP, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-126; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kliewer KL, 2016, J ALLERGY CLIN IMMUN, V137, P1011, DOI 10.1016/j.jaci.2015.10.040; Kruszewski PG, 2016, DIS ESOPHAGUS, V29, P377, DOI 10.1111/dote.12339; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2016, CLIN GASTROENTEROL H, V14, P13, DOI 10.1016/j.cgh.2015.07.041; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Molina-Infante J, 2016, ALIMENT PHARM THER, V44, P904, DOI 10.1111/apt.13742; Molina-Infante J, 2014, J ALLERGY CLIN IMMUN, V134, P1093, DOI 10.1016/j.jaci.2014.07.023; Molina-Infante J, 2012, J ALLERGY CLIN IMMUN, V130, P1200, DOI 10.1016/j.jaci.2012.06.027; Murali AR, 2016, J GASTROEN HEPATOL, V31, P1111, DOI 10.1111/jgh.13281; Philpott H, 2016, ALIMENT PHARM THER, V44, P223, DOI 10.1111/apt.13676; Philpott H, 2016, ALIMENT PHARM THER, V43, P985, DOI 10.1111/apt.13576; Rodriguez-Sanchez J, 2014, ALLERGY, V69, P936, DOI 10.1111/all.12420; Safroneeva E, 2016, GASTROENTEROLOGY, V150, P581, DOI 10.1053/j.gastro.2015.11.004; Schoepfer AM, 2014, GASTROENTEROLOGY, V147, P1255, DOI 10.1053/j.gastro.2014.08.028; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; STRAUMANN A, 1994, SCHWEIZ MED WSCHR, V124, P1419; van Rhijn BD, 2015, J ALLERGY CLIN IMMUN, V136, P1095, DOI 10.1016/j.jaci.2015.02.038; Wolf WA, 2014, CLIN GASTROENTEROL H, V12, P1272, DOI 10.1016/j.cgh.2013.12.034	30	121	123	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1365	1372		10.1016/j.jaci.2017.08.038	http://dx.doi.org/10.1016/j.jaci.2017.08.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29074457	Bronze			2022-12-18	WOS:000429197800022
J	Hinks, TSC; Brown, T; Lau, LCK; Rupani, H; Barber, C; Elliott, S; Ward, JA; Ono, J; Ohta, S; Izuhara, K; Djukanovic, R; Kurukulaaratchy, RJ; Chauhan, A; Howarth, PH				Hinks, Timothy S. C.; Brown, Tom; Lau, Laurie C. K.; Rupani, Hitasha; Barber, Clair; Elliott, Scott; Ward, Jon A.; Ono, Junya; Ohta, Shoichiro; Izuhara, Kenji; Djukanovic, Ratko; Kurukulaaratchy, Ramesh J.; Chauhan, Anoop; Howarth, Peter H.			Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cytokines; eosinophils; neutrophils; phenotype; endotype; heterogeneity; matrix metalloproteinase; chitinase 3-like protein 1; topological data analysis	OBSTRUCTIVE PULMONARY-DISEASE; CLUSTER-ANALYSIS; LUNG; IDENTIFICATION; EXPRESSION; QUESTIONNAIRE; CONTRIBUTES; COLLAGENASE; PHENOTYPES; INSIGHTS	Background: Disease heterogeneity in patients with severe asthma and its relationship to inflammatory mechanisms remain poorly understood. Objective: We aimed to identify and replicate clinicopathologic endotypes based on analysis of blood and sputum parameters in asthmatic patients. Methods: One hundred ninety-four asthmatic patients and 21 control subjects recruited from 2 separate centers underwent detailed clinical assessment, sputum induction, and phlebotomy. One hundred three clinical, physiologic, and inflammatory parameters were analyzed by using topological data analysis and Bayesian network analysis. Results: Severe asthma was associated with anxiety and depression, obesity, sinonasal symptoms, decreased quality of life, and inflammatory changes, including increased sputum chitinase 3-like protein 1 (YKL-40) and matrix metalloproteinase (MMP) 1, 3, 8, and 12 levels. Topological data analysis identified 6 clinicopathobiologic clusters replicated in both geographic cohorts: young, mild paucigranulocytic; older, sinonasal disease; obese, high MMP levels; steroid resistant T(H)2 mediated, eosinophilic; mixed granulocytic with severe obstruction; and neutrophilic, low periostin levels, severe obstruction. Sputum IL-5 levels were increased in patients with severe particularly eosinophilic forms, whereas IL-13 was suppressed and IL-17 levels did not differ between clusters. Bayesian network analysis separated clinical features from intricately connected inflammatory pathways. YKL-40 levels strongly correlated with neutrophilic asthma and levels of myeloperoxidase, IL-8, IL-6, and IL-6 soluble receptor. MMP1, MMP3, MMP8, and MMP12 levels were associated with severe asthma and were correlated positively with sputum IL-5 levels but negatively with IL-13 levels. Conclusion: In 2 distinct cohorts we have identified and replicated 6 clinicopathobiologic clusters based on blood and induced sputum measures. Our data underline a disconnect between clinical features and underlying inflammation, suggest IL-5 production is relatively steroid insensitive, and highlight the expression of YKL-40 in patients with neutrophilic inflammation and the expression of MMPs in patients with severe asthma.	[Hinks, Timothy S. C.; Lau, Laurie C. K.; Rupani, Hitasha; Ward, Jon A.; Djukanovic, Ratko; Howarth, Peter H.] Univ Southampton, Sir Henry Wellcome Labs, Southampton Univ Hosp, Fac Med,Clin & Expt Sci, Southampton SO16 6YD, Hants, England; [Hinks, Timothy S. C.; Lau, Laurie C. K.; Rupani, Hitasha; Barber, Clair; Ward, Jon A.; Djukanovic, Ratko; Howarth, Peter H.] Southampton Univ Hosp, NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Brown, Tom; Elliott, Scott; Chauhan, Anoop] Portsmouth Hosp NHS Trust, Portsmouth, Hants, England; [Ono, Junya] Shino Test Corp, Sagamihara, Kanagawa, Japan; [Ohta, Shoichiro] Saga Med Sch, Dept Lab Med, Saga, Japan; [Izuhara, Kenji] Saga Med Sch, Dept Biomol Sci, Saga, Japan; [Kurukulaaratchy, Ramesh J.] Southampton Gen Hosp, Dept Resp Med, Southampton, Hants, England	University of Southampton; University of Southampton; Portsmouth Hospitals NHS Trust; Shino Test Corporation; Saga University; Saga University; University of Southampton	Hinks, TSC (corresponding author), Univ Southampton, Sir Henry Wellcome Labs, Southampton Univ Hosp, Fac Med,Clin & Expt Sci, Southampton SO16 6YD, Hants, England.	t.hinks@soton.ac.uk		Kurukulaaratchy, Ramesh/0000-0002-1588-2400; Djukanovic, Ratko/0000-0001-6039-5612; Howarth, Peter/0000-0003-0619-7927; Ward, Jon/0000-0002-9278-0002; Barber, Clair Gillian Mary/0000-0001-5335-5129	Medical Research Council [G0800649]; Wellcome Trust [088365/z/09/z]; Academy of Medical Sciences; National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit; NIHR; MRC [G0800649] Funding Source: UKRI; Academy of Medical Sciences (AMS) [AMS-SGCL11-Hinks] Funding Source: researchfish; National Institute for Health Research [ACF-2006-26-005, NF-SI-0514-10085] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Academy of Medical Sciences(Academy of Medical Sciences (AMS)); National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the Medical Research Council (G0800649). T.S.C.H. was supported by a Wellcome Trust Clinical Research Fellowship (088365/z/09/z) and by the Academy of Medical Sciences. Infrastructure support was funded by the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit. We acknowledge the support of the NIHR through the Primary Care Research Network and through an Academic Clinical Fellowship (to T.S.C.H.).	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bafadhel M, 2012, RESPIRATION, V83, P36, DOI 10.1159/000330667; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Carlsson G, 2009, B AM MATH SOC, V46, P255, DOI 10.1090/S0273-0979-09-01249-X; Chaudhuri R, 2012, J ALLERGY CLIN IMMUN, V129, P655, DOI 10.1016/j.jaci.2011.12.996; Chen WG, 2008, J ALLERGY CLIN IMMUN, V122, P625, DOI 10.1016/j.jaci.2008.06.022; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1038/bjc.2014.639, 10.1161/CIRCULATIONAHA.114.014508, 10.1186/s12916-014-0241-z, 10.1002/bjs.9736, 10.7326/M14-0698, 10.1016/j.jclinepi.2014.11.010, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025]; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Fingleton J, 2015, J ALLERGY CLIN IMMUN, V136, P601, DOI 10.1016/j.jaci.2015.01.013; Gomez JL, 2015, J ALLERGY CLIN IMMUN, V136, P51, DOI 10.1016/j.jaci.2014.11.027; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kang MJ, 2015, AM J RESP CELL MOL, V53, P863, DOI 10.1165/rcmb.2014-0366OC; KITA H, 1995, J IMMUNOL, V154, P4749; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; Monteseirin J, 2007, J IMMUNOL, V179, P2634, DOI 10.4049/jimmunol.179.4.2634; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mukhopadhyay S, 2010, J ALLERGY CLIN IMMUN, V126, P70, DOI 10.1016/j.jaci.2010.03.027; Newby C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102987; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Otsuka K, 2012, RESPIRATION, V83, P507, DOI 10.1159/000330840; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Shapiro SD, 2000, AM J RESP CELL MOL, V22, P4, DOI 10.1165/ajrcmb.22.1.f173; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Tang H, 2013, J IMMUNOL, V190, P438, DOI 10.4049/jimmunol.1201827; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	121	123	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					61	75		10.1016/j.jaci.2015.11.020	http://dx.doi.org/10.1016/j.jaci.2015.11.020			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26851968	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000379659100007
J	Sassi, A; Lazaroski, S; Wu, G; Haslam, SM; Fliegauf, M; Mellouli, F; Patiroglu, T; Unal, E; Ozdemir, MA; Jouhadi, Z; Khadir, K; Ben-Khemis, L; Ben-Ali, M; Ben-Mustapha, I; Borchani, L; Pfeifer, D; Jakob, T; Khemiri, M; Asplund, AC; Gustafsson, MO; Lundin, KE; Falk-Sorqvist, E; Moens, LN; Gungor, HE; Engelhardt, KR; Dziadzio, M; Stauss, H; Fleckenstein, B; Meier, R; Prayitno, K; Maul-Pavicic, A; Schaffer, S; Rakhmanov, M; Henneke, P; Kraus, H; Eibel, H; Kolsch, U; Nadifi, S; Nilsson, M; Bejaoui, M; Schaffer, AA; Smith, CIE; Dell, A; Barbouche, MR; Grimbacher, B				Sassi, Atfa; Lazaroski, Sandra; Wu, Gang; Haslam, Stuart M.; Fliegauf, Manfred; Mellouli, Fethi; Patiroglu, Turkan; Unal, Ekrem; Ozdemir, Mehmet Akif; Jouhadi, Zineb; Khadir, Khadija; Ben-Khemis, Leila; Ben-Ali, Meriem; Ben-Mustapha, Imen; Borchani, Lamia H.; Pfeifer, Dietmar; Jakob, Thilo; Khemiri, Monia; Asplund, A. Charlotta; Gustafsson, Manuela O.; Lundin, Karin E.; Falk-Soerqvist, Elin; Moens, Lotte N.; Gungor, Hatice Eke; Engelhardt, Karin R.; Dziadzio, Magdalena; Stauss, Hans; Fleckenstein, Bernhard; Meier, Rebecca; Prayitno, Khairunnadiya; Maul-Pavicic, Andrea; Schaffer, Sandra; Rakhmanov, Mirzokhid; Henneke, Philipp; Kraus, Helene; Eibel, Hermann; Koelsch, Uwe; Nadifi, Sellama; Nilsson, Mats; Bejaoui, Mohamed; Schaeffer, Alejandro A.; Smith, C. I. Edvard; Dell, Anne; Barbouche, Mohamed-Ridha; Grimbacher, Bodo			Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hyper-IgE syndrome; glycosylation; Staphylococcus aureus; signal transducer and activator of transcription 3; dedicator of cytokinesis 8; phosphoglucomutase 3	CONGENITAL DISORDERS; GLYCOSYLATION; DEFICIENCY; MUTASE; DOCK8; IDENTIFICATION; CLONING; DESIGN; PROBES; STAT3	Background: Recurrent bacterial and fungal infections, eczema, and increased serum IgE levels characterize patients with the hyper-IgE syndrome (HIES). Known genetic causes for HIES are mutations in signal transducer and activator of transcription 3 (STAT3) and dedicator of cytokinesis 8 (DOCK8), which are involved in signal transduction pathways. However, glycosylation defects have not been described in patients with HIES. One crucial enzyme in the glycosylation pathway is phosphoglucomutase 3 (PGM3), which catalyzes a key step in the synthesis of uridine diphosphate N-acetylglucosamine, which is required for the biosynthesis of N-glycans. Objective: We sought to elucidate the genetic cause in patients with HIES who do not carry mutations in STAT3 or DOCK8. Methods: After establishing a linkage interval by means of SNPchip genotyping and homozygosity mapping in 2 families with HIES from Tunisia, mutational analysis was performed with selector-based, high-throughput sequencing. Protein expression was analyzed by means of Western blotting, and glycosylation was profiled by using mass spectrometry. Results: Mutational analysis of candidate genes in an 11.9-Mb linkage region on chromosome 6 shared by 2 multiplex families identified 2 homozygous mutations in PGM3 that segregated with disease status and followed recessive inheritance. The mutations predict amino acid changes in PGM3 (p. Glu340del and p. Leu83Ser). A third homozygous mutation (p. Asp502Tyr) and the p. Leu83Ser variant were identified in 2 other affected families, respectively. These hypomorphic mutations have an effect on the biosynthetic reactions involving uridine diphosphate N-acetylglucosamine. Glycomic analysis revealed an aberrant glycosylation pattern in leukocytes demonstrated by a reduced level of tri-antennary and tetra-antennary N-glycans. T-cell proliferation and differentiation were impaired in patients. Most patients had developmental delay, and many had psychomotor retardation. Conclusion: Impairment of PGM3 function leads to a novel primary (inborn) error of development and immunity because biallelic hypomorphic mutations are associated with impaired glycosylation and a hyper-IgE-like phenotype.	[Sassi, Atfa; Ben-Khemis, Leila; Ben-Ali, Meriem; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha] Pasteur Inst Tunis, Lab Immunopathol Vaccinol & Mol Genet, Tunis, Tunisia; [Sassi, Atfa; Ben-Khemis, Leila; Ben-Ali, Meriem; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha] Univ Tunis El Manar, Tunis, Tunisia; [Lazaroski, Sandra; Fliegauf, Manfred; Meier, Rebecca; Prayitno, Khairunnadiya; Maul-Pavicic, Andrea; Schaffer, Sandra; Rakhmanov, Mirzokhid; Henneke, Philipp; Kraus, Helene; Eibel, Hermann; Grimbacher, Bodo] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, D-79108 Freiburg, Germany; [Pfeifer, Dietmar; Smith, C. I. Edvard] Univ Med Ctr Freiburg, Dept Med Specialt Hematol Oncol & Stem Cell Trans, D-79108 Freiburg, Germany; [Jakob, Thilo] Univ Med Ctr Freiburg, Dept Dermatol, Allergy Res Grp, D-79108 Freiburg, Germany; [Wu, Gang; Haslam, Stuart M.; Dell, Anne] Univ London Imperial Coll Sci Technol & Med, Dept Life Sci, London SW7 2AZ, England; [Mellouli, Fethi; Bejaoui, Mohamed] Bone Marrow Transplantat Ctr, Dept Pediat, Tunis, Tunisia; [Patiroglu, Turkan; Unal, Ekrem; Ozdemir, Mehmet Akif] Erciyes Univ, Fac Med, Dept Pediat, Div Pediat Hematol & Oncol, Kayseri, Turkey; [Patiroglu, Turkan; Gungor, Hatice Eke] Erciyes Univ, Fac Med, Dept Pediat, Div Pediat Immunol, Kayseri, Turkey; [Jouhadi, Zineb; Khadir, Khadija] Hassan II Univ, CHU IBN ROCHD, Dept Pediat Infect Dis, Casablanca, Morocco; [Nadifi, Sellama] Hassan II Univ, Dept Genet, Casablanca, Morocco; [Borchani, Lamia H.] Inst Pasteur Tunis, Lab Venoms & Therapeut Mol, Tunis, Tunisia; [Khemiri, Monia] Childrens Hosp Tunis, Pediat Dept A, Tunis, Tunisia; [Asplund, A. Charlotta; Gustafsson, Manuela O.; Lundin, Karin E.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Clin Res Ctr, Dept Lab Med, Huddinge, Sweden; [Falk-Soerqvist, Elin; Moens, Lotte N.; Nilsson, Mats] Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden; [Engelhardt, Karin R.; Dziadzio, Magdalena; Stauss, Hans; Grimbacher, Bodo] UCL, Royal Free Hosp, Inst Immun & Transplantat, London WC1E 6BT, England; [Fleckenstein, Bernhard] Univ Erlangen Nurnberg, Inst Virol, D-91054 Erlangen, Germany; [Koelsch, Uwe] Campus Virchow Klinikum, Div Immunol, Lab Berlin, Berlin, Germany; [Koelsch, Uwe] Campus Virchow Klinikum, Charite, Inst Med Immunol, Berlin, Germany; [Schaeffer, Alejandro A.] NIH, Natl Ctr Biotechnol Informat, US Dept HHS, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Universite de Tunis-El-Manar; University of Freiburg; University of Freiburg; University of Freiburg; Imperial College London; Universite de Tunis-El-Manar; Centre Nationale de Greffe de la Moelle Osseuse; Erciyes University; Erciyes University; Hassan II University of Casablanca; Ibn Rochd University Hospital Center of Casablanca; Hassan II University of Casablanca; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Universite de Tunis-El-Manar; Hopital d'Enfants; Karolinska Institutet; Karolinska University Hospital; Uppsala University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA	Grimbacher, B (corresponding author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Engesserstr 4, D-79108 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de	Schaffer, Alejandro/N-1222-2019; Schaffer, Alejandro A/F-2902-2012; Unal, Ekrem/A-5099-2019; Rakhmanov, Mirzokhid/P-8351-2019; bejaoui, mohamed/K-2679-2016; Rakhmanov, Mirzokhid/GMW-5383-2022	Unal, Ekrem/0000-0002-2691-4826; Wu, Gang/0000-0002-4283-9213; gustafsson, manuela/0000-0002-0268-9476; Sellama, NADIFI/0000-0002-4272-1506; SMITH, C. I. Edvard/0000-0003-1907-3392; Dell, Anne/0000-0003-1380-2347	German Federal Ministry of Education and Research [BMBF 01 EO 0803]; Intramural Research Program of the National Library of Medicine-National Institutes of Health; Tunisian Ministry for Higher Education and Research; Swedish Medical Research Council; Swedish Cancer Society; Stockholm County Council [ALF]; European Community's 6th and 7th Framework Programs FP7/2007-2013 [Health-F5-2008-223292]; Biotechnology and Biological Sciences Research Council [BBF0083091, BB/K016164/1]; BBSRC [BB/K016164/1] Funding Source: UKRI; NATIONAL LIBRARY OF MEDICINE [ZIALM000097] Funding Source: NIH RePORTER	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Intramural Research Program of the National Library of Medicine-National Institutes of Health; Tunisian Ministry for Higher Education and Research; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Cancer Society(Swedish Cancer Society); Stockholm County Council(Stockholm County Council); European Community's 6th and 7th Framework Programs FP7/2007-2013; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Supported by the German Federal Ministry of Education and Research (BMBF 01 EO 0803). The research was supported in part by the Intramural Research Program of the National Library of Medicine-National Institutes of Health. Parts of the study were supported by the Tunisian Ministry for Higher Education and Research, the Swedish Medical Research Council, the Swedish Cancer Society and the Stockholm County Council ( research grant ALF), and the European Community's 6th and 7th Framework Programs FP7/2007-2013 under grant agreement Health-F5-2008-223292 (Euro-Gene-Scan). This work was also supported by the Biotechnology and Biological Sciences Research Council (BBF0083091 and BB/K016164/1 to A. D. and S. M. H). G. W. is grateful for a Sun Hung Kai Properties Kwoks' Foundation-Imperial College PhD Scholarship.	Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; AYED K, 1987, ANN PEDIATR-PARIS, V34, P645; Babovic-Vuksanovic D, 2007, MOL DIAGN THER, V11, P303, DOI 10.1007/BF03256251; Babu P, 2009, GLYCOCONJUGATE J, V26, P975, DOI 10.1007/s10719-008-9146-4; Boztug K, 2009, NEW ENGL J MED, V360, P32, DOI 10.1056/NEJMoa0805051; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Ceroni A, 2008, J PROTEOME RES, V7, P1650, DOI 10.1021/pr7008252; Chou Janice Yang, 2001, Current Molecular Medicine (Hilversum), V1, P25; Cormier-Daire V, 2000, J MED GENET, V37, P875, DOI 10.1136/jmg.37.11.875; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dennis JW, 2009, CELL, V139, P1229, DOI 10.1016/j.cell.2009.12.008; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Etzioni A, 2002, AM J MED GENET, V110, P131, DOI 10.1002/ajmg.10423; FUKUDA MN, 1992, BRIT J HAEMATOL, V82, P745, DOI 10.1111/j.1365-2141.1992.tb06953.x; Gazit Y, 2010, J CLIN IMMUNOL, V30, P308, DOI 10.1007/s10875-009-9354-0; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Greig KT, 2007, MOL CELL BIOL, V27, P5849, DOI 10.1128/MCB.00802-07; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Grubenmann CE, 2004, HUM MOL GENET, V13, P535, DOI 10.1093/hmg/ddh050; Ha S, 2011, GLYCOBIOLOGY, V21, P1087, DOI 10.1093/glycob/cwr047; Hayee B, 2011, GLYCOBIOLOGY, V21, P914, DOI 10.1093/glycob/cwr023; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; HOPKINSON DA, 1968, ANN HUM GENET, V31, P359, DOI 10.1111/j.1469-1809.1968.tb00567.x; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; Jaeken J, 2007, ANNU REV GENOM HUM G, V8, P261, DOI 10.1146/annurev.genom.8.080706.092327; Jaeken J, 2009, BBA-MOL BASIS DIS, V1792, P825, DOI 10.1016/j.bbadis.2009.08.005; Johansson H, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1005; Kenzel S, 2012, J IMMUNOL, V189, P4582, DOI 10.4049/jimmunol.1200205; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Li CY, 2000, GENE, V242, P97, DOI 10.1016/S0378-1119(99)00543-0; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/88289; Marodi L, 2007, NAT REV IMMUNOL, V7, P851, DOI 10.1038/nri2195; Metin A, 2012, PEDIATR TRANSPLANT, V16, P398, DOI 10.1111/j.1399-3046.2011.01641.x; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Mio T, 2000, BBA-GENE STRUCT EXPR, V1492, P369, DOI 10.1016/S0167-4781(00)00120-2; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Pang H, 2002, ANN HUM GENET, V66, P139, DOI 10.1017/S0003480002001033; Perez B, 2013, J INHERIT METAB DIS, V36, P535, DOI 10.1007/s10545-012-9525-7; Rabinovich GA, 2012, ANN NY ACAD SCI, V1253, P1, DOI 10.1111/j.1749-6632.2012.06492.x; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Schachter H, 2009, BBA-MOL BASIS DIS, V1792, P925, DOI 10.1016/j.bbadis.2008.11.002; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Stenberg J, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-229; Stenberg J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni071; Stenberg J, 2009, BIOINFORMATICS, V25, P666, DOI 10.1093/bioinformatics/btp001; Vogt G, 2005, NAT GENET, V37, P692, DOI 10.1038/ng1581; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, P1400, DOI 10.1016/j.jaci.2014.02.013	53	121	127	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1410	U681		10.1016/j.jaci.2014.02.025	http://dx.doi.org/10.1016/j.jaci.2014.02.025			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24698316	Green Accepted			2022-12-18	WOS:000335450700024
J	von Berg, A; Filipiak-Pittroff, B; Kramer, U; Hoffmann, B; Link, E; Beckmann, C; Hoffmann, U; Reinhardt, D; Grubl, A; Heinrich, J; Wichmann, HE; Bauer, CP; Koletzko, S; Berdel, D				von Berg, Andrea; Filipiak-Pittroff, Birgit; Kraemer, Ursula; Hoffmann, Barbara; Link, Elke; Beckmann, Christina; Hoffmann, Ute; Reinhardt, Dietrich; Gruebl, Armin; Heinrich, Joachim; Wichmann, H. -Erich; Bauer, Carl-P.; Koletzko, Sibylle; Berdel, Dietrich		GINIplus Study Grp	Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birth cohort; double-blind randomized trial; nutritional intervention; cow's milk protein hydrolysate infant formulas; long-term allergy prevention	HYDROLYZED FORMULAS; DIETARY PREVENTION; FOOD ALLERGY; CHILDREN; CHILDHOOD; DISEASE; ASTHMA; LIFE; RECOMMENDATIONS; AVOIDANCE	Background: The long-term effect of nutritional intervention with hydrolysate infant formulas on allergic manifestations in high-risk children is uncertain. Objective: We sought to investigate the effect of hydrolysate infant formulas on allergic phenotypes in children with family history of allergies at school age. Methods: We analyzed data from participants of the prospective German Infant Nutritional Intervention study after 10 years of follow-up. At birth, children were randomly assigned to receive, for the first 4 months, one of 4 blinded formulas as breast milk substitute, if necessary: partially hydrolyzed whey formula (pHF-W), extensively hydrolyzed whey formula (eHF-W), extensively hydrolyzed casein formula (eHF-C), or standard cow's milk formula. Outcomes were parent-reported, physician-diagnosed allergic diseases. Log-binomial regression models were used for statistical analysis. Results: The relative risk for the cumulative incidence of any allergic disease in the intention-to-treat analysis (n = 2252) was 0.87 (95% CI, 0.77-0.99) for pHF-W, 0.94 (95% CI, 0.83-1.07) for eHF-W, and 0.83 (95% CI, 0.72-0.95) for eHF-C compared with standard cow's milk formula. The corresponding figures for atopic eczema/dermatits (AD) were 0.82 (95% CI, 0.68-1.00), 0.91 (95% CI, 0.76-1.10), and 0.72 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis (n = 988) effects were stronger. The period prevalence of AD at 7 to 10 years was significantly reduced with eHF-C in this analysis, but there was no preventive effect on asthma or allergic rhinitis. Conclusion: The significant preventive effect on the cumulative incidence of allergic diseases, particularly AD, with pHF-W and eHF-C persisted until 10 years without rebound, whereas eHF-W showed no significant risk reduction. There is insufficient evidence of ongoing preventive activity at 7 to 10 years of age.	[von Berg, Andrea; Filipiak-Pittroff, Birgit; Beckmann, Christina; Berdel, Dietrich] Marien Hosp Wesel, Dept Pediat, Res Inst, Wesel, Germany; [Filipiak-Pittroff, Birgit; Reinhardt, Dietrich; Koletzko, Sibylle] Univ Munich, Dr V Hauner Childrens Hosp, Munich, Germany; [Kraemer, Ursula; Hoffmann, Barbara; Link, Elke] Univ Dusseldorf, IUF Leibniz Res Inst Environm Med, Dusseldorf, Germany; [Hoffmann, Barbara] Univ Dusseldorf, Fac Med, D-40225 Dusseldorf, Germany; [Hoffmann, Ute; Heinrich, Joachim; Wichmann, H. -Erich] Helmholtz Zentrum Munich, Inst Epidemiol 1, German Res Ctr Environm Hlth GmbH, Neuherberg, Germany; [Hoffmann, Ute; Gruebl, Armin; Bauer, Carl-P.] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Hoffmann, Ute; Gruebl, Armin; Bauer, Carl-P.] LVA Oberbayern, Munich, Germany; [Wichmann, H. -Erich] Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany	St. Marien Hospital; University of Munich; Heinrich Heine University Dusseldorf; Leibniz Institut fur Umweltmedizinische Forschung (IUF); Heinrich Heine University Dusseldorf; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich	von Berg, A (corresponding author), Marien Hosp Wesel, Dept Pediat, Pastor Janssen Str 8-38, Wesel, Germany.	andrea.vonberg@prohomine.de	Heinrich, Joachim/N-1720-2013; Wichmann, Heinz Erich/AAA-5695-2022	Heinrich, Joachim/0000-0002-9620-1629; 	Federal Ministry for Education, Science, Research and Technology [01 EE 9401-4]; Federal Ministry for Environment (IUF) [FKZ 20462296]; Nestle; Mead Johnson; Aerocrine; AstraZeneca; Novartis; Deutsche Atemwegsliga; Gesellschaft fur Padiatrische Allergologie; Lions Club; Federal Ministry of the Environment; German Science Foundation (DFG); European Union; Germany Ministry of Education and Research; Phadia; Euroimmune; MSD; Danone; Hipp	Federal Ministry for Education, Science, Research and Technology; Federal Ministry for Environment (IUF); Nestle(Nestle SA); Mead Johnson; Aerocrine; AstraZeneca(AstraZeneca); Novartis(Novartis); Deutsche Atemwegsliga; Gesellschaft fur Padiatrische Allergologie; Lions Club; Federal Ministry of the Environment; German Science Foundation (DFG)(German Research Foundation (DFG)); European Union(European Commission); Germany Ministry of Education and Research; Phadia(Phadia); Euroimmune; MSD; Danone(Danone Nutricia); Hipp	The German Infant Nutritional Intervention (GINI) study was funded for 3 years by grants from the Federal Ministry for Education, Science, Research and Technology (grant no. 01 EE 9401-4). Milupa, Nestle, Mead Johnson, and Nutricia provided the blinded study formulas for the participating children for the first 4 to 6 months. The 3, 6 and 10-year follow-up examinations of the GINI study were covered from the respective budgets of the initial 4 study centers (Wesel, LMU Munich, TU Munich, and Helmholtz Zentrum Munich [former GSF]), and from 6 years onward, was additionally partly funded by the Federal Ministry for Environment (IUF, FKZ 20462296). Some projects not directly related to the intervention effect of the hydrolysates (eg, effect of cesarean section, and effect of solid food introduction) were partly supported by Nestle, Mead Johnson, Numico, Pharmacia, and Stiftung Kindergesundheit in cooperation with European Studies (eg, Enrieco).; Disclosure of potential conflict of interest: A. von Berg has received speakers' fees from Nestle, Mead Johnson, Aerocrine, AstraZeneca, Novartis, and was on the Board and has received travel support from Airsonett. The Research Institute at the Marien-Hospital has received honoraria from the industry for the performance of studies (Airsonett, Aerocrine, ALK-Abello, Astellas, Allergopharma, AstraZeneca, Boehringer, GlaxoSmithKline, Grasax, Leti, MSD, Nestle, Ndd, Novartis, Stallergenes), and has received research support from Deutsche Atemwegsliga, Gesellschaft fur Padiatrische Allergologie, and the Lions Club. U. Kramer has received research support from the Federal Ministry of the Environment and the German Science Foundation (DFG). J. Heinrich has received research support from the European Union and the Germany Ministry of Education and Research. C.-P. Bauer has received speakers' fees from Nestle. S. Koletzko has received research support from Phadia, Mead Johnson, and Nestle; has received speakers' fees from Euroimmune, MSD, Danone, Nestle, and Hipp; and is on the advisory board for Danone, Nestle, and Mead Johnson. D. Berdel has received reimbursement for travel expenses to GINI meetings from his institute. The rest of the authors declare that they have no relevant conflicts of interest.	Alexander DD, 2010, JPGN, V50, P356; American Academy of Pediatrics Committee on Nutrition, 2000, PEDIATRICS, V106, P236; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Brand PLP, 2007, PEDIAT ALLERG IMM-UK, V18, P475, DOI 10.1111/j.1399-3038.2007.00541.x; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Dahmen G, 2004, METHOD INFORM MED, V43, P451; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Food and Drug Administration, 100 WHEY PROT PART H; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Koletzko S, 2012, J ALLERGY CLIN IMMUN, V129, P262, DOI 10.1016/j.jaci.2011.08.038; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Mertens J, 2012, PEDIAT ALLERG IMM-UK, V23, P597, DOI 10.1111/j.1399-3038.2012.01304.x; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; Osborn DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003664.pub3; Schoetzau A, 2002, ARCH DIS CHILD, V86, P180, DOI 10.1136/adc.86.3.180; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Szajewska H, 2010, CURR MED RES OPIN, V26, P423, DOI 10.1185/03007990903510317; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/BF02029362; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Zeiger RS, 2003, PEDIATRICS, V111, P1662	36	121	128	0	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1565	+		10.1016/j.jaci.2013.01.006	http://dx.doi.org/10.1016/j.jaci.2013.01.006			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23506844				2022-12-18	WOS:000320532800015
J	Dullaers, M; De Bruyne, R; Ramadani, F; Gould, HJ; Gevaert, P; Lambrecht, BN				Dullaers, Melissa; De Bruyne, Ruth; Ramadani, Faruk; Gould, Hannah J.; Gevaert, Philippe; Lambrecht, Bart N.			The who, where, and when of IgE in allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; atopic asthma; allergic rhinitis; memory B cells; plasma cells	CLASS SWITCH RECOMBINATION; GERMLINE GENE TRANSCRIPTS; EPSILON-HEAVY-CHAIN; NERVE GROWTH-FACTOR; NASAL B-CELLS; DENDRITIC CELLS; PLASMA-CELLS; PERIPHERAL-BLOOD; SOMATIC HYPERMUTATION; DEPENDENT MECHANISM	Allergic asthma and allergic rhinitis/conjunctivitis are characterized by a T(H)2-dominated immune response associated with increased serum IgE levels in response to inhaled allergens. Because IgE is a key player in the induction and maintenance of allergic inflammation, it represents a prime target for therapeutic intervention. However, our understanding of IgE biology remains fragmentary. This article puts together our current knowledge on IgE in allergic airway diseases with a special focus on the identity of IgE-secreting cells ("who''), their location ("where''), and the circumstances in which they are induced ("when''). We further consider the therapeutic implications of the insights gained. (J Allergy Clin Immunol 2012; 129: 635-45.)	[Dullaers, Melissa; Lambrecht, Bart N.] Univ Hosp Ghent, Lab Immunoregulat & Mucosal Immunol, Dept Pulm Med, Ghent, Belgium; [De Bruyne, Ruth] Univ Hosp Ghent, Dept Paediat Gastroenterol & Hepatol, Ghent, Belgium; [Ramadani, Faruk; Gould, Hannah J.] Kings Coll London, Randall Div Cell & Mol Biophys, London, England; [Ramadani, Faruk; Gould, Hannah J.] Kings Coll London, MRC, London, England; [Ramadani, Faruk; Gould, Hannah J.] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Gevaert, Philippe] Univ Ghent, Upper Airways Res Lab, Dept Otorhinolaryngol, Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; University of London; King's College London; University of London; King's College London; University of London; King's College London; Ghent University	Dullaers, M (corresponding author), De Pintelaan 185,Blok B, B-9000 Ghent, Belgium.	melissa.dullaers@ugent.be	Ramadani, Faruk/HHM-9664-2022; Lambrecht, Bart N/K-2484-2014; De Bruyne, Ruth/S-9144-2019; Gevaert, Philippe/AAP-1892-2020; Gevaert, Philippe/ABA-4588-2021	Ramadani, Faruk/0000-0001-8228-4868; Lambrecht, Bart N/0000-0003-4376-6834; De Bruyne, Ruth/0000-0002-5623-3300; Gevaert, Philippe/0000-0002-1629-8468; Dullaers, Melissa/0000-0003-0223-230X; Gould, Hannah/0000-0003-0411-688X	Wellcome Trust; Medical Research Council; Biotechnology and Biological Sciences Research Council; MRC [G1100090, G0400106, G0501494] Funding Source: UKRI; Medical Research Council [G1000758, G0501494, G1100090, G1000758B, G0400106] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	H. J. Gould has received research support from the Wellcome Trust, the Medical Research Council, and the Biotechnology and Biological Sciences Research Council. The rest of the authors declare that they have no relevant conflicts of interest.	Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Abbas AK, 2005, CELLULAR MOL IMMUNOL; Abram M, 2009, J IMMUNOL, V182, P4705, DOI 10.4049/jimmunol.0802814; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; Auci Dominick L., 1992, Regional Immunology, V4, P216; Avila PC, 2007, ANNU REV MED, V58, P185, DOI 10.1146/annurev.med.58.061705.145252; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Bellou A, 1997, ANN ALLERG ASTHMA IM, V78, P513, DOI 10.1016/S1081-1206(10)63240-1; Brightbill HD, 2010, J CLIN INVEST, V120, P2218, DOI 10.1172/JCI40141; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; Chen JB, 2010, J IMMUNOL, V184, P1748, DOI 10.4049/jimmunol.0902437; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Dahlke I, 2006, J ALLERGY CLIN IMMUN, V117, P1477, DOI 10.1016/j.jaci.2005.12.1359; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DHANJAL MK, 1992, J ALLERGY CLIN IMMUN, V89, P895, DOI 10.1016/0091-6749(92)90446-9; DiazSanchez D, 1997, ALLERGY, V52, P52; DONOHOE PJ, 1995, J ALLERGY CLIN IMMUN, V95, P587, DOI 10.1016/S0091-6749(95)70321-7; Dullaers M, 2009, IMMUNITY, V30, P120, DOI 10.1016/j.immuni.2008.11.008; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURKIN HG, 1989, J IMMUNOL, V143, P1777; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003; Feichtner S, 2008, J IMMUNOL, V180, P5499, DOI 10.4049/jimmunol.180.8.5499; Felices M, 2009, P NATL ACAD SCI USA, V106, P8308, DOI 10.1073/pnas.0808459106; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; GANZER U, 1988, ORL J OTO-RHINO-LARY, V50, P257, DOI 10.1159/000276000; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gould HJ, 2006, TRENDS IMMUNOL, V27, P446, DOI 10.1016/j.it.2006.08.007; Hahn C, 2006, J ALLERGY CLIN IMMUN, V117, P787, DOI 10.1016/j.jaci.2005.12.1339; Hakonarson H, 1999, J ALLERGY CLIN IMMUN, V104, P575, DOI 10.1016/S0091-6749(99)70326-X; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Horst A, 2002, CLIN EXP IMMUNOL, V130, P370, DOI 10.1046/j.1365-2249.2002.02025.x; HUGGINS KG, 1975, LANCET, V2, P148; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Janeway C., 2005, IMMUNOBIOLOGY; Jungsuwadee P, 2004, INT ARCH ALLERGY IMM, V133, P40, DOI 10.1159/000075252; Karagiannis SN, 2001, IMMUNOLOGY, V103, P319, DOI 10.1046/j.1365-2567.2001.01238.x; Karnowski A, 2006, EUR J IMMUNOL, V36, P1917, DOI 10.1002/eji.200535495; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kelly KA, 2007, IMMUNOLOGY, V120, P345, DOI 10.1111/j.1365-2567.2006.02509.x; KING CL, 1991, J IMMUNOL, V146, P1478; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Luger E, 2001, EUR J IMMUNOL, V31, P2319, DOI 10.1002/1521-4141(200108)31:8<2319::AID-IMMU2319>3.0.CO;2-T; Luger EO, 2009, J ALLERGY CLIN IMMUN, V124, P819, DOI 10.1016/j.jaci.2009.06.047; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; Manz RA, 2002, CURR OPIN IMMUNOL, V14, P517, DOI 10.1016/S0952-7915(02)00356-4; MAURER D, 1995, J INVEST DERMATOL, V104, P707, DOI 10.1111/1523-1747.ep12606958; Maurer D, 1996, J IMMUNOL, V157, P607; Maurer D, 1998, J IMMUNOL, V161, P2731; McCoy KD, 2006, IMMUNITY, V24, P329, DOI 10.1016/j.immuni.2006.01.013; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; MCMENAMIN C, 1992, IMMUNOLOGY, V77, P592; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Mitre E, 2006, J ALLERGY CLIN IMMUN, V117, P939, DOI 10.1016/j.jaci.2005.12.1341; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; Payet-Jamroz M, 2001, J IMMUNOL, V166, P4863, DOI 10.4049/jimmunol.166.8.4863; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Peng Z, 2007, CLIN EXP ALLERGY, V37, P1040, DOI 10.1111/j.1365-2222.2007.02741.x; Perkins C, 2006, J ALLERGY CLIN IMMUN, V118, P410, DOI 10.1016/j.jaci.2006.06.004; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Quarcoo D, 2004, CLIN EXP ALLERGY, V34, P1146, DOI 10.1111/j.1365-2222.2004.01993.x; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Riechelmann H, 2005, ALLERGY, V60, P1418, DOI 10.1111/j.1398-9995.2005.00902.x; Scanlon KM, 2011, INT ARCH ALLERGY IMM, V156, P51, DOI 10.1159/000322178; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Snow RE, 1998, EUR J IMMUNOL, V28, P3354, DOI 10.1002/(SICI)1521-4141(199810)28:10<3354::AID-IMMU3354>3.0.CO;2-Z; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; STEIN LD, 1986, EUR J IMMUNOL, V16, P1167, DOI 10.1002/eji.1830160922; STEINBERGER P, 1995, J ALLERGY CLIN IMMUN, V96, P209, DOI 10.1016/S0091-6749(95)70010-2; Takahama H, 1997, CELL IMMUNOL, V176, P34, DOI 10.1006/cimm.1996.1065; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Tanabe T, 2008, CLIN EXP ALLERGY, V38, P122, DOI 10.1111/j.1365-2222.2007.02871.x; Tran TH, 2010, NAT IMMUNOL, V11, P148, DOI 10.1038/ni.1829; Tu Y, 2005, GASTROENTEROLOGY, V129, P928, DOI 10.1053/j.gastro.2005.06.014; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Wang C H, 1998, Front Biosci, V3, pA58; Yamauchi Kohei, 2007, Allergol Int, V56, P321, DOI 10.2332/allergolint.R-07-151; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339; Zotos D, 2010, J EXP MED, V207, P365, DOI 10.1084/jem.20091777	103	121	132	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					635	645		10.1016/j.jaci.2011.10.029	http://dx.doi.org/10.1016/j.jaci.2011.10.029			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22168998				2022-12-18	WOS:000301189300006
J	Vocanson, M; Rozieres, A; Hennino, A; Poyet, G; Gaillard, V; Renaudineau, S; Achachi, A; Benetiere, J; Kaiserlian, D; Dubois, B; Nicolas, JF				Vocanson, Marc; Rozieres, Aurore; Hennino, Anca; Poyet, Gaelle; Gaillard, Vincent; Renaudineau, Sarah; Achachi, Amine; Benetiere, Josette; Kaiserlian, Dominique; Dubois, Bertrand; Nicolas, Jean-Francxois			Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of T(H)17/T(H)1 and regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; ICOS; antigen-specificity; T(H)17/T(H)1 features; skin inflammation; allergic contact dermatitis; haptens	PLASMACYTOID DENDRITIC CELLS; ALLERGIC CONTACT-DERMATITIS; NONALLERGIC INDIVIDUALS; IMMUNE TOLERANCE; EFFECTOR-CELLS; IN-VIVO; RESPONSES; INFLAMMATION; CD8(+); HYPERSENSITIVITY	Background: CD4(+)CD25(+) regulatory T (Treg) cells are involved in the downmodulation of numerous immune responses to pathogens, tumors, or allergens. Objective: In this study, we further characterized the nature of Treg cells that control skin inflammatory reactions to haptens. Methods: In a model of contact hypersensitivity to 2,4-dinitrofluorobenzene, we have investigated the phenotype, the specificity, and the origin of Treg cells that modulate the priming of effector CD8(+) T cells responsible for the development of the pathology. Results: 2,4-Dinitrofluorobenzene immunization induced a population of CD4(+)CD25(+) Treg cells that controlled CD8(+) T-cell effector responses in a hapten-specific manner in vivo. High levels of inducible costimulator (ICOS) expression defined a population of CD4(+)CD25(+)FoxP3(+) (forkhead box protein 3) Treg cells that presented superior suppressive activity. Importantly, ICOS+ Treg cells were distinguishable from all other FoxP3(+) Treg cells by the expression of IL-10, IL-17, and IFN-gamma. Hapten-specific Treg cells proliferating in response to their cognate antigen in vivo predominantly displayed a CD25(+) FoxP3(+) ICOS+ phenotype. By using reporter mice, we showed that ICOS+ Treg cells derived from the expansion of natural CD4(+)FoxP3(+) Treg cells rather than generation of adaptive Treg cells. Furthermore, the generation of ICOS+ Treg cells depended on innate cells rather than the effector CD8(+) T-cell population. Conclusion: Taken together, our data show that a population of CD4(+)CD25(+) FoxP3(+) T cells upregulates ICOS on in vivo sensitization and specifically suppresses hapten-reactive CD8(+) T cells both in vivo and in vitro. (J Allergy Clin Immunol 2010;126:280-9.)	[Nicolas, Jean-Francxois] INSERM, U851, IFR 128, F-69365 Lyon 07, France; [Vocanson, Marc; Rozieres, Aurore; Poyet, Gaelle; Gaillard, Vincent; Benetiere, Josette; Nicolas, Jean-Francxois] Univ Lyon 1, Fac Med Lyon Sud, F-69365 Lyon, France; [Vocanson, Marc; Rozieres, Aurore; Hennino, Anca; Poyet, Gaelle; Gaillard, Vincent; Renaudineau, Sarah; Achachi, Amine; Benetiere, Josette; Kaiserlian, Dominique; Dubois, Bertrand; Nicolas, Jean-Francxois] Univ Lyon 1, IFR128, F-69365 Lyon, France; [Nicolas, Jean-Francxois] Hosp Civils Lyon, Serv Allergol & Immunol Clin, Ctr Hosp Lyon Sud, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Nicolas, JF (corresponding author), INSERM, U851, IFR 128, 21 Av Tony Garnier, F-69365 Lyon 07, France.	jean-francois.nicolas@chu-lyon.fr	ROZIERES, Aurore/M-4447-2014; KAISERLIAN, Dominique/G-3325-2013; Nicolas, Jean-François/AAW-9289-2020; Dubois, Bertrand/D-4446-2013; Vocanson, Marc/G-5431-2017; Hennino, Ana/I-5837-2014	ROZIERES, Aurore/0000-0003-0293-4002; KAISERLIAN, Dominique/0000-0001-6252-4916; Dubois, Bertrand/0000-0002-7859-4975; Vocanson, Marc/0000-0002-0181-8862; NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X; Hennino, Ana/0000-0002-2619-8559	Universite Claude Bernard Lyon1; INSERM	Universite Claude Bernard Lyon1; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Supported by institutional grants from Universite Claude Bernard Lyon1 and INSERM.	Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; BERG DJ, 1995, J EXP MED, V182, P99, DOI 10.1084/jem.182.1.99; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; Cavani A, 2003, J IMMUNOL, V171, P5760, DOI 10.4049/jimmunol.171.11.5760; Cavani A, 1998, J INVEST DERMATOL, V111, P621, DOI 10.1046/j.1523-1747.1998.00334.x; Cavani A, 2008, CURR OPIN ALLERGY CL, V8, P294, DOI 10.1097/ACI.0b013e3283079ea4; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; GARRIGUE JL, 1994, CONTACT DERMATITIS, V30, P231, DOI 10.1111/j.1600-0536.1994.tb00650.x; Gotsman I, 2006, CIRCULATION, V114, P2047, DOI 10.1161/CIRCULATIONAHA.106.633263; Guo J, 2001, J IMMUNOL, V166, P5578, DOI 10.4049/jimmunol.166.9.5578; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; Ito T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Kish DD, 2005, J LEUKOCYTE BIOL, V78, P725, DOI 10.1189/jlb.0205069; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106; Krasteva M, 1998, J IMMUNOL, V160, P1181; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; Miyamoto K, 2005, J IMMUNOL, V175, P7341, DOI 10.4049/jimmunol.175.11.7341; Nosbaum A, 2009, ANN DERMATOL VENER, V136, P630, DOI 10.1016/j.annder.2009.06.019; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Sperling AI, 2001, NAT IMMUNOL, V2, P573, DOI 10.1038/89709; Szymczak-Workman AL, 2009, J IMMUNOL, V182, P5188, DOI 10.4049/jimmunol.0803123; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Vocanson M, 2006, J INVEST DERMATOL, V126, P815, DOI 10.1038/sj.jid.5700174; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhou K, 2009, J DIGEST DIS, V10, P7, DOI 10.1111/j.1751-2980.2008.00356.x; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zhou XY, 2009, CURR OPIN IMMUNOL, V21, P281, DOI 10.1016/j.coi.2009.05.007	35	121	124	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					280	U27		10.1016/j.jaci.2010.05.022	http://dx.doi.org/10.1016/j.jaci.2010.05.022			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624644	Bronze			2022-12-18	WOS:000281203800013
J	Fitzpatrick, AM; Higgins, M; Holguin, F; Brown, LAS; Teague, WG				Fitzpatrick, Anne M.; Higgins, Melinda; Holguin, Fernando; Brown, Lou Ann S.; Teague, W. Gerald		Natl Inst Hlth; Natl Heart Lung Blood Inst Severe	The molecular phenotype of severe asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; macrophage; children; cytokine; chemokine; inflammation	RELATIVE CORTICOSTEROID INSENSITIVITY; ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; DIFFICULT ASTHMA; CELL; PHAGOCYTOSIS; ACTIVATION; SAFETY; VALUES; AGE	Background: Although the clinical attributes of severe asthma in children have been well described, the differentiating features of the lower airway inflammatory response are less understood. Objectives: We sought to discriminate severe from moderate asthma in children by applying linear discriminant analysis, a supervised method of high-dimensional data reduction, to cytokines and chemokines measured in the bronchoalveolar lavage (BAL) fluid and alveolar macrophage (AM) lysate. Methods: Bronchoalveolar lavage fluid was available from 53 children with asthma (severe asthma, n = 31) undergoing bronchoscopy for clinical indications and 30 nonsmoking adults. Twenty-three cytokines and chemokines were measured by using head-based multiplex assays. Linear discriminant analyses of the BAL fluid and AM analytes were performed to develop predictive models of severe asthma in children. Results: Although univariate analysis of single analytes did not differentiate severe from moderate asthma in children, linear discriminant analyses allowed for near complete separation of the moderate and severe asthmatic groups. Significant correlations were also noted between several of the AM and BAL analytes measured. In the BAL fluid, IL-13 and IL-6 differentiated subjects with asthma from controls, whereas growth-related oncogene (CXCL1), RANTES (CCL5), IL-12, IFN-gamma, and IL-10 best characterized severe versus moderate asthma in children. In the AM lysate, IL-6 was the strongest discriminator of all the groups. Conclusion: Severe asthma in children is characterized by a distinct airway molecular phenotype that does not have a clear T(H)1 or T(H)2 pattern. Improved classification of children with severe asthma may assist with the development of targeted therapeutics for this group of children who are difficult to treat. (J Allergy Clin Immunol 2010;125:851-7.)	[Fitzpatrick, Anne M.; Holguin, Fernando; Brown, Lou Ann S.; Teague, W. Gerald] Emory Univ, Sch Med, Atlanta, GA USA; [Higgins, Melinda] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA	Emory University; Emory University	Fitzpatrick, AM (corresponding author), 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu	Higgins, Melinda K/B-6459-2013	Higgins, Melinda K/0000-0001-6579-5885; Fitzpatrick, Anne/0000-0002-2933-5926	NIH/NINR [KO1 NR010548]; NIH/NCRR [K12 RR017643]; NIH/NHLBI [SARP RO1 HL69170]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010548, K01NR010584] Funding Source: NIH RePORTER	NIH/NINR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Supported by NIH/NINR KO1 NR010548, NIH/NCRR K12 RR017643, and NIH/NHLBI SARP RO1 HL69170.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; Fisher RA, 1936, ANN EUGENIC, V7, P179, DOI 10.1111/j.1469-1809.1936.tb02137.x; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2008, J ALLERGY CLIN IMMUN, V121, P1372, DOI 10.1016/j.jaci.2008.03.008; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Fulkerson PC, 2006, AM J PATHOL, V169, P2117, DOI 10.2353/ajpath.2006.060617; Gibson PG, 1999, PEDIATR PULM, V28, P261, DOI 10.1002/(SICI)1099-0496(199910)28:4<261::AID-PPUL5>3.0.CO;2-I; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Hand D. J, 1981, WILEY SERIES PROBABI; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hauk PJ, 2008, PEDIATR PULM, V43, P916, DOI 10.1002/ppul.20880; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Lex C, 2005, PEDIATR PULM, V39, P318, DOI 10.1002/ppul.20159; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; *NAT HEART LUNG BL, 2002, NAT I HLTH PUBL; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769, DOI 10.1164/ajrccm.161.3.9809071; Payne D, 2001, ARCH DIS CHILD, V84, P423, DOI 10.1136/adc.84.5.423; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Peters-Golden M, 2004, AM J RESP CELL MOL, V31, P3, DOI 10.1165/rcmb.f279; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00	32	121	123	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					851	857		10.1016/j.jaci.2010.01.048	http://dx.doi.org/10.1016/j.jaci.2010.01.048			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371397	Green Accepted			2022-12-18	WOS:000276787900010
J	Tieu, DD; Kern, RC; Schleimer, RP				Tieu, David D.; Kern, Robert C.; Schleimer, Robert P.			Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; S100; epithelium; barrier hypothesis; inflammation	UBIQUITOUS AIRBORNE FUNGI; TOLL-LIKE RECEPTORS; NASAL POLYPS; PSORIASIN S100A7; CALPROTECTIN EXPRESSION; ANTIMICROBIAL PEPTIDE; ATOPIC-DERMATITIS; ESCHERICHIA-COLI; IMMUNE-RESPONSE; POTENTIAL ROLE	Chronic rhinosinusitis (CRS) is characterized by a chronic symptomatic inflammation of the nasal and paranasal sinus mucosae and is one of the most frequently reported chronic diseases in the United States, with an estimated prevalence of greater than 10% of the general population. Although the pathogenesis of CRS remains poorly understood, there is evidence for a role of bacteria and fungi, as well as the presence of a robust adaptive immune response in the upper airways and sinuses. Recent studies of CRS, as well as several other diseases in the skin and respiratory epithelium, have uncovered evidence that deficiencies in epithelial immune barrier function might compromise the interaction between the host and external immune stimuli. Recent studies suggest the hypothesis that reduced expression of antimicrobial S100 proteins, particularly psoriasin and calprotectin, might lead to increased susceptibility to bacterial and fungal colonization in patients with CRS. The main emphasis of this review will be to highlight the current literature that suggests that a defect in the expression of a broad set of epithelially derived genes might lead to barrier compromise and subsequently a dysfunctional host immune response to environmental agents in patients with CRS. (J Allergy Clin Immunol 2009;124:37-42.)	[Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Tieu, David D.; Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, 240 E Huron,Room M-318,McGaw Pavil, Chicago, IL 60611 USA.	rpschleimer@northwestem.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL078860-04, R01 HL078860] Funding Source: Medline; NIAID NIH HHS [R01 AI072570, R01 AI072570-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abtin A, 2008, FASEB J, V22, P2168, DOI 10.1096/fj.07-104117; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Avila PC, 2008, ALLERGY ALLERGIC DIS, P366; Benninger MS, 1997, OTOLARYNG HEAD NECK, V117, pS41, DOI 10.1016/S0194-5998(97)70006-8; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; Bryborn M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-118; Champaiboon C, 2009, J BIOL CHEM, V284, P7078, DOI 10.1074/jbc.M806605200; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Claeys S, 2003, ALLERGY, V58, P748, DOI 10.1034/j.1398-9995.2003.00180.x; Commins S, 2008, J ALLERGY CLIN IMMUN, V121, P1108, DOI 10.1016/j.jaci.2008.02.026; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Dejima K, 2006, ARCH OTOLARYNGOL, V132, P1352, DOI 10.1001/archotol.132.12.1352; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Glaser R, 2009, J INVEST DERMATOL, V129, P641, DOI 10.1038/jid.2008.268; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Lee KC, 2007, J INVEST DERMATOL, V127, P945, DOI 10.1038/sj.jid.5700663; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Meyer JE, 2008, MUCOSAL IMMUNOL, V1, P239, DOI 10.1038/mi.2008.3; Michalek M, 2009, DEV COMP IMMUNOL, V33, P740, DOI 10.1016/j.dci.2008.12.005; Nisapakultorn K, 2001, INFECT IMMUN, V69, P4242, DOI 10.1128/IAI.69.7.4242-4247.2001; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Pitzurra L, 2004, INFECT IMMUN, V72, P7275, DOI 10.1128/IAI.72.12.7275-7281.2004; Ponikau JU, 2006, CLIN REV ALLERG IMMU, V30, P187, DOI 10.1385/CRIAI:30:3:187; Richer SL, 2008, AM J RHINOL, V22, P228, DOI 10.2500/ajr.2008.22.3162; Ross KF, 2001, INFECT IMMUN, V69, P3248, DOI 10.1128/IAI.69.5.3248-3254.2001; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schnekenburger J, 2008, J CELL PHYSIOL, V216, P558, DOI 10.1002/jcp.21433; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Vandal K, 2003, J IMMUNOL, V171, P2602, DOI 10.4049/jimmunol.171.5.2602; VanderMeer J, 2004, ARCH OTOLARYNGOL, V130, P1374, DOI 10.1001/archotol.130.12.1374; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wang Cheng-shuo, 2003, Zhonghua Er Bi Yan Hou Ke Za Zhi, V38, P243; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503	45	121	128	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					37	42		10.1016/j.jaci.2009.04.045	http://dx.doi.org/10.1016/j.jaci.2009.04.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19560577	Green Accepted			2022-12-18	WOS:000267909700003
